0	Torsade	B-Disease	S-Chemical
1	de	I-Disease	O
2	pointes	E-Disease	O
3	ventricular	B-Disease	O
4	tachycardia	E-Disease	E-Disease
5	during	O	O
6	low	O	O
7	dose	O	O
8	intermittent	O	O
9	dobutamine	S-Chemical	S-Chemical
10	treatment	O	O
11	in	O	O
12	a	O	O
13	patient	O	O
14	with	O	O
15	dilated	B-Disease	O
16	cardiomyopathy	E-Disease	S-Disease
17	and	O	O
18	congestive	B-Disease	O
19	heart	I-Disease	B-Disease
20	failure	E-Disease	E-Disease
21	.	O	O

0	The	O	O
1	authors	O	O
2	describe	O	O
3	the	O	O
4	case	O	O
5	of	O	O
6	a	O	O
7	56	O	O
8	-	O	O
9	year	O	O
10	-	O	O
11	old	O	O
12	woman	O	O
13	with	O	O
14	chronic	O	S-Disease
15	,	O	O
16	severe	O	O
17	heart	B-Disease	B-Disease
18	failure	E-Disease	E-Disease
19	secondary	O	O
20	to	O	O
21	dilated	B-Disease	B-Disease
22	cardiomyopathy	E-Disease	B-Disease
23	and	O	O
24	absence	O	O
25	of	O	O
26	significant	O	O
27	ventricular	B-Disease	B-Disease
28	arrhythmias	E-Disease	E-Disease
29	who	O	O
30	developed	O	O
31	QT	B-Disease	O
32	prolongation	E-Disease	O
33	and	O	O
34	torsade	B-Disease	O
35	de	I-Disease	O
36	pointes	E-Disease	O
37	ventricular	B-Disease	O
38	tachycardia	E-Disease	S-Disease
39	during	O	O
40	one	O	O
41	cycle	O	O
42	of	O	O
43	intermittent	O	O
44	low	O	O
45	dose	O	O
46	(	O	O
47	2	O	O
48	.	O	O
49	5	O	O
50	mcg	O	O
51	/	O	O
52	kg	O	O
53	per	O	O
54	min	O	O
55	)	O	O
56	dobutamine	S-Chemical	S-Chemical
57	.	O	O

0	This	O	O
1	report	O	O
2	of	O	O
3	torsade	B-Disease	S-Chemical
4	de	I-Disease	O
5	pointes	E-Disease	O
6	ventricular	B-Disease	B-Disease
7	tachycardia	E-Disease	E-Disease
8	during	O	O
9	intermittent	O	O
10	dobutamine	S-Chemical	S-Disease
11	supports	O	O
12	the	O	O
13	hypothesis	O	O
14	that	O	O
15	unpredictable	O	O
16	fatal	O	O
17	arrhythmias	S-Disease	S-Disease
18	may	O	O
19	occur	O	O
20	even	O	O
21	with	O	O
22	low	O	O
23	doses	O	O
24	and	O	O
25	in	O	O
26	patients	O	O
27	with	O	O
28	no	O	O
29	history	O	O
30	of	O	O
31	significant	O	O
32	rhythm	O	O
33	disturbances	O	S-Disease
34	.	O	O

0	The	O	O
1	mechanisms	O	O
2	of	O	O
3	proarrhythmic	O	O
4	effects	O	O
5	of	O	O
6	Dubutamine	S-Chemical	S-Chemical
7	are	O	O
8	discussed	O	O
9	.	O	O

0	Positive	O	O
1	skin	O	O
2	tests	O	O
3	in	O	O
4	late	O	O
5	reactions	O	O
6	to	O	O
7	radiographic	O	O
8	contrast	B-Chemical	O
9	media	E-Chemical	O
10	.	O	O

0	In	O	O
1	the	O	O
2	last	O	O
3	few	O	O
4	years	O	O
5	delayed	O	O
6	reactions	O	O
7	several	O	O
8	hours	O	O
9	after	O	O
10	the	O	O
11	injection	O	O
12	of	O	O
13	radiographic	O	O
14	and	O	O
15	contrast	B-Chemical	O
16	materials	E-Chemical	O
17	(	O	O
18	PRC	S-Chemical	S-Disease
19	)	O	O
20	have	O	O
21	been	O	O
22	described	O	O
23	with	O	O
24	increasing	O	O
25	frequency	O	O
26	.	O	O

0	The	O	O
1	authors	O	O
2	report	O	O
3	two	O	O
4	observations	O	O
5	on	O	O
6	patients	O	O
7	with	O	O
8	delayed	O	O
9	reactions	O	O
10	in	O	O
11	whom	O	O
12	intradermoreactions	O	O
13	(	O	O
14	IDR	O	S-Chemical
15	)	O	O
16	and	O	O
17	patch	O	O
18	tests	O	O
19	to	O	O
20	a	O	O
21	series	O	O
22	of	O	O
23	ionic	O	S-Disease
24	and	O	O
25	non	O	O
26	ionic	O	S-Disease
27	PRC	S-Chemical	O
28	were	O	O
29	studied	O	O
30	.	O	O

0	After	O	O
1	angiography	O	O
2	by	O	O
3	the	O	O
4	venous	O	O
5	route	O	O
6	in	O	O
7	patient	O	O
8	n	O	O
9	degree	O	O
10	1	O	O
11	a	O	O
12	biphasic	O	S-Disease
13	reaction	O	O
14	with	O	O
15	an	O	O
16	immediate	O	O
17	reaction	O	O
18	(	O	O
19	dyspnea	S-Disease	S-Disease
20	,	O	O
21	loss	B-Disease	O
22	of	I-Disease	I-Disease
23	consciousness	E-Disease	S-Disease
24	)	O	O
25	and	O	O
26	delayed	O	O
27	macro	B-Disease	B-Disease
28	-	I-Disease	O
29	papular	I-Disease	O
30	rash	E-Disease	E-Disease
31	appeared	O	O
32	,	O	O
33	whilst	O	O
34	patient	O	O
35	n	O	O
36	degree	O	O
37	2	O	O
38	developed	O	O
39	a	O	O
40	generalised	O	O
41	sensation	O	O
42	of	O	O
43	heat	O	O
44	,	O	O
45	persistent	O	O
46	pain	S-Disease	S-Disease
47	at	O	O
48	the	O	O
49	site	O	O
50	of	O	O
51	injection	O	O
52	immediately	O	O
53	and	O	O
54	a	O	O
55	generalised	O	O
56	macro	O	S-Disease
57	-	O	O
58	papular	O	S-Disease
59	reaction	O	E-Disease
60	after	O	O
61	24	O	O
62	hours	O	O
63	.	O	O

0	The	O	O
1	skin	O	O
2	tests	O	O
3	revealed	O	O
4	positive	O	O
5	delayed	O	O
6	reactions	O	O
7	of	O	O
8	24	O	O
9	hours	O	O
10	and	O	O
11	48	O	O
12	hours	O	O
13	by	O	O
14	IDR	O	S-Chemical
15	and	O	O
16	patch	O	O
17	tests	O	O
18	to	O	O
19	only	O	O
20	some	O	O
21	PRC	S-Chemical	O
22	with	O	O
23	common	O	O
24	chains	O	O
25	in	O	O
26	their	O	O
27	structures	O	O
28	.	O	O

0	The	O	O
1	positive	O	O
2	skin	O	O
3	tests	O	O
4	are	O	O
5	in	O	O
6	favour	O	O
7	of	O	O
8	immunological	O	O
9	reactions	O	E-Disease
10	and	O	O
11	may	O	O
12	help	O	O
13	in	O	O
14	diagnosis	O	O
15	of	O	O
16	allergy	S-Disease	S-Disease
17	in	O	O
18	the	O	O
19	patients	O	O
20	.	O	O

0	Risk	O	O
1	of	O	O
2	transient	O	O
3	hyperammonemic	B-Disease	S-Disease
4	encephalopathy	E-Disease	S-Disease
5	in	O	O
6	cancer	S-Disease	S-Disease
7	patients	O	O
8	who	O	O
9	received	O	O
10	continuous	O	O
11	infusion	O	O
12	of	O	O
13	5	B-Chemical	S-Chemical
14	-	I-Chemical	I-Chemical
15	fluorouracil	E-Chemical	S-Chemical
16	with	O	O
17	the	O	O
18	complication	O	O
19	of	O	O
20	dehydration	S-Disease	O
21	and	O	O
22	infection	S-Disease	S-Disease
23	.	O	O

0	From	O	O
1	1986	O	O
2	to	O	O
3	1998	O	O
4	,	O	O
5	29	O	O
6	cancer	S-Disease	S-Disease
7	patients	O	O
8	who	O	O
9	had	O	O
10	32	O	O
11	episodes	O	O
12	of	O	O
13	transient	O	O
14	hyperammonemic	B-Disease	S-Disease
15	encephalopathy	E-Disease	S-Disease
16	related	O	O
17	to	O	O
18	continuous	O	O
19	infusion	O	O
20	of	O	O
21	5	B-Chemical	B-Chemical
22	-	I-Chemical	I-Chemical
23	fluorouracil	E-Chemical	S-Chemical
24	(	O	O
25	5	B-Chemical	O
26	-	I-Chemical	I-Chemical
27	FU	E-Chemical	E-Chemical
28	)	O	O
29	were	O	O
30	identified	O	O
31	.	O	O

0	None	O	O
1	of	O	O
2	the	O	O
3	patients	O	O
4	had	O	O
5	decompensated	O	O
6	liver	B-Disease	B-Disease
7	disease	E-Disease	E-Disease
8	.	O	O

0	Onset	O	O
1	of	O	O
2	hyperammonemic	B-Disease	S-Disease
3	encephalopathy	E-Disease	S-Disease
4	varied	O	O
5	from	O	O
6	0	O	O
7	.	O	O
8	5	O	O
9	to	O	O
10	5	O	O
11	days	O	O
12	(	O	O
13	mean	O	O
14	:	O	O
15	2	O	O
16	.	O	O
17	6	O	O
18	+	O	O
19	/	O	O
20	-	O	O
21	1	O	O
22	.	O	O
23	3	O	O
24	days	O	O
25	)	O	O
26	after	O	O
27	the	O	O
28	initiation	O	O
29	of	O	O
30	chemotherapy	O	O
31	.	O	O

0	Plasma	O	O
1	ammonium	S-Chemical	E-Chemical
2	level	O	O
3	ranged	O	O
4	from	O	O
5	248	O	O
6	to	O	O
7	2387	O	O
8	microg	O	O
9	%	O	O
10	(	O	O
11	mean	O	O
12	:	O	O
13	626	O	O
14	+	O	O
15	/	O	O
16	-	O	O
17	431	O	O
18	microg	O	O
19	%	O	O
20	)	O	O
21	.	O	O

0	Among	O	O
1	the	O	O
2	32	O	O
3	episodes	O	O
4	,	O	O
5	26	O	O
6	(	O	O
7	81	O	O
8	%	O	O
9	)	O	O
10	had	O	O
11	various	O	O
12	degrees	O	O
13	of	O	O
14	azotemia	S-Disease	S-Disease
15	,	O	O
16	18	O	O
17	(	O	O
18	56	O	O
19	%	O	O
20	)	O	O
21	occurred	O	O
22	during	O	O
23	bacterial	B-Disease	B-Disease
24	infections	E-Disease	E-Disease
25	and	O	O
26	14	O	O
27	(	O	O
28	44	O	O
29	%	O	O
30	)	O	O
31	without	O	O
32	infection	S-Disease	S-Disease
33	occurred	O	O
34	during	O	O
35	periods	O	O
36	of	O	O
37	dehydration	S-Disease	O
38	.	O	O

0	Higher	O	O
1	plasma	O	O
2	ammonium	S-Chemical	S-Chemical
3	levels	O	O
4	and	O	O
5	more	O	O
6	rapid	O	O
7	onset	O	O
8	of	O	O
9	hyperammonemia	S-Disease	S-Disease
10	were	O	O
11	seen	O	O
12	in	O	O
13	18	O	O
14	patients	O	O
15	with	O	O
16	bacterial	B-Disease	B-Disease
17	infections	E-Disease	E-Disease
18	(	O	O
19	p	O	O
20	=	O	O
21	0	O	O
22	.	O	O
23	003	O	O
24	and	O	O
25	0	O	O
26	.	O	O
27	0006	O	O
28	,	O	O
29	respectively	O	O
30	)	O	O
31	and	O	O
32	in	O	O
33	nine	O	O
34	patients	O	O
35	receiving	O	O
36	high	O	O
37	daily	O	O
38	doses	O	O
39	(	O	O
40	2600	O	O
41	or	O	O
42	1800	O	O
43	mg	O	O
44	/	O	O
45	m2	O	O
46	)	O	O
47	of	O	O
48	5	B-Chemical	O
49	-	I-Chemical	O
50	FU	E-Chemical	O
51	(	O	O
52	p	O	O
53	=	O	O
54	0	O	O
55	.	O	O
56	0001	O	O
57	and	O	O
58	<	O	O
59	0	O	O
60	.	O	O
61	0001	O	O
62	,	O	O
63	respectively	O	O
64	)	O	O
65	.	O	O

0	In	O	O
1	25	O	O
2	out	O	O
3	of	O	O
4	32	O	O
5	episodes	O	O
6	(	O	O
7	78	O	O
8	%	O	O
9	)	O	O
10	,	O	O
11	plasma	O	O
12	ammonium	S-Chemical	S-Disease
13	levels	O	O
14	and	O	O
15	mental	O	O
16	status	O	O
17	returned	O	O
18	to	O	O
19	normal	O	O
20	within	O	O
21	2	O	O
22	days	O	O
23	after	O	O
24	adequate	O	O
25	management	O	O
26	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	hyperammonemic	B-Disease	S-Disease
4	encephalopathy	E-Disease	S-Disease
5	can	O	O
6	occur	O	O
7	in	O	O
8	patients	O	O
9	receiving	O	O
10	continuous	O	O
11	infusion	O	O
12	of	O	O
13	5	B-Chemical	S-Disease
14	-	I-Chemical	O
15	FU	E-Chemical	S-Disease
16	.	O	O

0	Azotemia	S-Disease	S-Disease
1	,	O	O
2	body	O	O
3	fluid	O	I-Disease
4	insufficiency	O	O
5	and	O	O
6	bacterial	B-Disease	B-Disease
7	infections	E-Disease	E-Disease
8	were	O	O
9	frequently	O	O
10	found	O	O
11	in	O	O
12	these	O	O
13	patients	O	O
14	.	O	O

0	It	O	O
1	is	O	O
2	therefore	O	O
3	important	O	O
4	to	O	O
5	recognize	O	O
6	this	O	O
7	condition	O	O
8	in	O	O
9	patients	O	O
10	receiving	O	O
11	continuous	O	O
12	infusion	O	O
13	of	O	O
14	5	B-Chemical	O
15	-	I-Chemical	O
16	FU	E-Chemical	O
17	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	quinine	S-Chemical	S-Chemical
4	and	O	O
5	4	B-Chemical	S-Chemical
6	-	I-Chemical	I-Chemical
7	aminopyridine	E-Chemical	S-Chemical
8	on	O	O
9	conditioned	O	O
10	place	O	O
11	preference	O	O
12	and	O	O
13	changes	O	O
14	in	O	O
15	motor	O	B-Disease
16	activity	O	E-Disease
17	induced	O	O
18	by	O	O
19	morphine	S-Chemical	S-Chemical
20	in	O	O
21	rats	O	O
22	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	two	O	O
4	unselective	O	O
5	potassium	S-Chemical	O
6	(	O	O
7	K	S-Chemical	O
8	(	O	O
9	+	O	O
10	)	O	O
11	-	O	O
12	)	O	O
13	channel	O	O
14	blockers	O	O
15	,	O	O
16	quinine	S-Chemical	S-Chemical
17	(	O	O
18	12	O	O
19	.	O	O
20	5	O	O
21	,	O	O
22	25	O	O
23	and	O	O
24	50	O	O
25	mg	O	O
26	/	O	O
27	kg	O	O
28	)	O	O
29	and	O	O
30	4	B-Chemical	O
31	-	I-Chemical	O
32	aminopyridine	E-Chemical	S-Disease
33	(	O	O
34	1	O	O
35	and	O	O
36	2	O	O
37	mg	O	O
38	/	O	O
39	kg	O	O
40	)	O	O
41	,	O	O
42	on	O	O
43	conditioned	O	O
44	place	O	O
45	preference	O	O
46	and	O	O
47	biphasic	O	S-Disease
48	changes	O	O
49	in	O	O
50	motor	O	B-Disease
51	activity	O	E-Disease
52	induced	O	O
53	by	O	O
54	morphine	S-Chemical	S-Disease
55	(	O	O
56	10	O	O
57	mg	O	O
58	/	O	O
59	kg	O	O
60	)	O	O
61	were	O	O
62	tested	O	O
63	in	O	O
64	Wistar	O	O
65	rats	O	O
66	.	O	O

0	Quinine	S-Chemical	S-Chemical
1	is	O	O
2	known	O	O
3	to	O	O
4	block	O	O
5	voltage	O	O
6	-	O	O
7	,	O	O
8	calcium	S-Chemical	S-Chemical
9	-	O	O
10	and	O	O
11	ATP	S-Chemical	S-Chemical
12	-	O	O
13	sensitive	O	O
14	K	S-Chemical	B-Chemical
15	(	O	E-Chemical
16	+	O	O
17	)	O	O
18	-	O	O
19	channels	O	O
20	while	O	O
21	4	B-Chemical	S-Chemical
22	-	I-Chemical	I-Chemical
23	aminopyridine	E-Chemical	S-Chemical
24	is	O	O
25	known	O	O
26	to	O	O
27	block	O	O
28	voltage	O	O
29	-	O	O
30	sensitive	O	O
31	K	S-Chemical	B-Chemical
32	(	O	E-Chemical
33	+	O	O
34	)	O	O
35	-	O	O
36	channels	O	O
37	.	O	O

0	In	O	O
1	the	O	O
2	counterbalanced	O	O
3	method	O	O
4	,	O	O
5	quinine	S-Chemical	S-Chemical
6	attenuated	O	O
7	morphine	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	place	O	O
11	preference	O	O
12	,	O	O
13	whereas	O	O
14	4	B-Chemical	S-Chemical
15	-	I-Chemical	I-Chemical
16	aminopyridine	E-Chemical	S-Chemical
17	was	O	O
18	ineffective	O	O
19	.	O	O

0	In	O	O
1	the	O	O
2	motor	O	O
3	activity	O	O
4	test	O	O
5	measured	O	O
6	with	O	O
7	an	O	O
8	Animex	O	S-Chemical
9	-	O	O
10	activity	O	O
11	meter	O	O
12	neither	O	O
13	of	O	O
14	the	O	O
15	K	S-Chemical	S-Chemical
16	(	O	O
17	+	O	O
18	)	O	O
19	-	O	O
20	channel	O	O
21	blockers	O	O
22	affected	O	O
23	morphine	S-Chemical	S-Chemical
24	-	O	O
25	induced	O	O
26	hypoactivity	S-Disease	S-Disease
27	,	O	O
28	but	O	O
29	both	O	O
30	K	S-Chemical	S-Chemical
31	(	O	O
32	+	O	O
33	)	O	O
34	-	O	O
35	channel	O	O
36	blockers	O	O
37	prevented	O	O
38	morphine	S-Chemical	S-Disease
39	-	O	O
40	induced	O	O
41	secondary	O	O
42	hyperactivity	S-Disease	S-Disease
43	.	O	O

0	These	O	O
1	results	O	O
2	suggest	O	O
3	the	O	O
4	involvement	O	O
5	of	O	O
6	quinine	S-Chemical	S-Chemical
7	-	O	O
8	sensitive	O	O
9	but	O	O
10	not	O	O
11	4	B-Chemical	O
12	-	I-Chemical	O
13	aminopyridine	E-Chemical	S-Chemical
14	-	O	O
15	sensitive	O	O
16	K	S-Chemical	O
17	(	O	I-Chemical
18	+	O	O
19	)	O	O
20	-	O	O
21	channels	O	O
22	in	O	O
23	morphine	S-Chemical	S-Chemical
24	reward	O	O
25	.	O	O

0	It	O	O
1	is	O	O
2	also	O	O
3	suggested	O	O
4	that	O	O
5	the	O	O
6	blockade	O	O
7	of	O	O
8	K	S-Chemical	B-Chemical
9	(	O	O
10	+	O	O
11	)	O	O
12	-	O	O
13	channels	O	O
14	sensitive	O	O
15	to	O	O
16	these	O	O
17	blockers	O	O
18	is	O	O
19	not	O	O
20	sufficient	O	O
21	to	O	O
22	prevent	O	O
23	morphine	S-Chemical	S-Chemical
24	-	O	O
25	induced	O	O
26	hypoactivity	S-Disease	S-Disease
27	whereas	O	O
28	morphine	S-Chemical	S-Chemical
29	-	O	O
30	induced	O	O
31	hyperactivity	S-Disease	S-Disease
32	seems	O	O
33	to	O	O
34	be	O	O
35	connected	O	O
36	to	O	O
37	both	O	O
38	quinine	S-Chemical	S-Chemical
39	-	O	O
40	and	O	O
41	4	B-Chemical	O
42	-	I-Chemical	O
43	aminopyridine	E-Chemical	O
44	-	O	O
45	sensitive	O	O
46	K	S-Chemical	B-Chemical
47	(	O	O
48	+	O	O
49	)	O	O
50	-	O	O
51	channels	O	O
52	.	O	O

0	Nociceptin	S-Chemical	B-Chemical
1	/	O	I-Disease
2	orphanin	B-Chemical	E-Chemical
3	FQ	E-Chemical	E-Chemical
4	and	O	O
5	nocistatin	S-Chemical	S-Chemical
6	on	O	O
7	learning	B-Disease	O
8	and	I-Disease	O
9	memory	I-Disease	O
10	impairment	E-Disease	O
11	induced	O	O
12	by	O	O
13	scopolamine	S-Chemical	S-Chemical
14	in	O	O
15	mice	O	O
16	.	O	O

0	Nociceptin	S-Chemical	S-Chemical
1	,	O	O
2	also	O	O
3	known	O	O
4	as	O	O
5	orphanin	B-Chemical	B-Chemical
6	FQ	E-Chemical	E-Chemical
7	,	O	O
8	is	O	O
9	an	O	O
10	endogenous	O	O
11	ligand	O	O
12	for	O	O
13	the	O	O
14	orphan	O	O
15	opioid	O	B-Disease
16	receptor	O	I-Disease
17	-	O	O
18	like	O	O
19	receptor	O	O
20	1	O	O
21	(	O	O
22	ORL1	O	S-Chemical
23	)	O	O
24	and	O	O
25	involves	O	O
26	in	O	O
27	various	O	O
28	functions	O	O
29	in	O	O
30	the	O	O
31	central	O	O
32	nervous	O	I-Disease
33	system	O	E-Disease
34	(	O	O
35	CNS	O	S-Chemical
36	)	O	O
37	.	O	O

0	On	O	O
1	the	O	O
2	other	O	O
3	hand	O	O
4	,	O	O
5	nocistatin	S-Chemical	S-Chemical
6	is	O	O
7	recently	O	O
8	isolated	O	O
9	from	O	O
10	the	O	O
11	same	O	O
12	precursor	O	O
13	as	O	O
14	nociceptin	S-Chemical	S-Chemical
15	and	O	O
16	blocks	O	O
17	nociceptin	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	allodynia	S-Disease	S-Disease
21	and	O	O
22	hyperalgesia	S-Disease	S-Disease
23	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	was	O	O
4	designed	O	O
5	to	O	O
6	investigate	O	O
7	whether	O	O
8	nociceptin	S-Chemical	B-Chemical
9	/	O	I-Chemical
10	orphanin	B-Chemical	E-Chemical
11	FQ	E-Chemical	S-Disease
12	and	O	O
13	nocistatin	S-Chemical	S-Disease
14	could	O	O
15	modulate	O	O
16	impairment	B-Disease	O
17	of	I-Disease	O
18	learning	I-Disease	O
19	and	I-Disease	O
20	memory	E-Disease	O
21	induced	O	O
22	by	O	O
23	scopolamine	S-Chemical	S-Chemical
24	,	O	O
25	a	O	O
26	muscarinic	O	S-Disease
27	cholinergic	O	B-Disease
28	receptor	O	O
29	antagonist	O	O
30	,	O	O
31	using	O	O
32	spontaneous	O	O
33	alternation	O	O
34	of	O	O
35	Y	O	O
36	-	O	O
37	maze	O	O
38	and	O	O
39	step	O	O
40	-	O	O
41	down	O	O
42	type	O	O
43	passive	O	O
44	avoidance	O	O
45	tasks	O	O
46	in	O	O
47	mice	O	O
48	.	O	O

0	While	O	O
1	nocistatin	S-Chemical	O
2	(	O	O
3	0	O	O
4	.	O	O
5	5	O	O
6	-	O	O
7	5	O	O
8	.	O	O
9	0	O	O
10	nmol	O	O
11	mouse	O	O
12	-	O	O
13	1	O	O
14	,	O	O
15	i	O	O
16	.	O	O
17	c	O	O
18	.	O	O
19	v	O	O
20	.	O	O
21	)	O	O
22	administered	O	O
23	30	O	O
24	min	O	O
25	before	O	O
26	spontaneous	O	O
27	alternation	O	O
28	performance	O	O
29	or	O	O
30	the	O	O
31	training	O	O
32	session	O	O
33	of	O	O
34	the	O	O
35	passive	O	O
36	avoidance	O	O
37	task	O	O
38	,	O	O
39	had	O	O
40	no	O	O
41	effect	O	O
42	on	O	O
43	spontaneous	O	O
44	alternation	O	O
45	or	O	O
46	passive	O	O
47	avoidance	O	O
48	behaviours	O	O
49	,	O	O
50	a	O	O
51	lower	O	O
52	per	O	O
53	cent	O	O
54	alternation	O	O
55	and	O	O
56	shorter	O	O
57	median	O	O
58	step	O	O
59	-	O	O
60	down	O	O
61	latency	O	O
62	in	O	O
63	the	O	O
64	retention	O	O
65	test	O	O
66	were	O	O
67	obtained	O	O
68	in	O	O
69	nociceptin	S-Chemical	S-Chemical
70	(	O	O
71	1	O	O
72	.	O	O
73	5	O	O
74	and	O	O
75	/	O	O
76	or	O	O
77	5	O	O
78	.	O	O
79	0	O	O
80	nmol	O	S-Disease
81	mouse	O	O
82	-	O	O
83	1	O	O
84	,	O	O
85	i	O	O
86	.	O	O
87	c	O	O
88	.	O	O
89	v	O	O
90	.	O	O
91	)	O	O
92	-	O	O
93	treated	O	O
94	normal	O	O
95	mice	O	O
96	.	O	O

0	Administration	O	O
1	of	O	O
2	nocistatin	S-Chemical	S-Chemical
3	(	O	O
4	1	O	O
5	.	O	O
6	5	O	O
7	and	O	O
8	/	O	O
9	or	O	O
10	5	O	O
11	.	O	O
12	0	O	O
13	nmol	O	O
14	mouse	O	O
15	-	O	O
16	1	O	O
17	,	O	O
18	i	O	O
19	.	O	O
20	c	O	O
21	.	O	O
22	v	O	O
23	.	O	O
24	)	O	O
25	30	O	O
26	min	O	O
27	before	O	O
28	spontaneous	O	O
29	alternation	O	O
30	performance	O	O
31	or	O	O
32	the	O	O
33	training	O	O
34	session	O	O
35	of	O	O
36	the	O	O
37	passive	O	O
38	avoidance	O	O
39	task	O	O
40	,	O	O
41	attenuated	O	O
42	the	O	O
43	scopolamine	S-Chemical	O
44	-	O	O
45	induced	O	O
46	impairment	O	O
47	of	O	O
48	spontaneous	O	O
49	alternation	O	O
50	and	O	O
51	passive	O	O
52	avoidance	O	O
53	behaviours	O	O
54	.	O	O

0	These	O	O
1	results	O	O
2	indicated	O	O
3	that	O	O
4	nocistatin	S-Chemical	S-Chemical
5	,	O	O
6	a	O	O
7	new	O	O
8	biologically	O	O
9	active	O	O
10	peptide	O	O
11	,	O	O
12	ameliorates	O	O
13	impairments	O	O
14	of	O	O
15	spontaneous	O	O
16	alternation	O	O
17	and	O	O
18	passive	O	O
19	avoidance	O	O
20	induced	O	O
21	by	O	O
22	scopolamine	S-Chemical	S-Chemical
23	,	O	O
24	and	O	O
25	suggested	O	O
26	that	O	O
27	these	O	O
28	peptides	O	O
29	play	O	O
30	opposite	O	O
31	roles	O	O
32	in	O	O
33	learning	O	O
34	and	O	O
35	memory	O	O
36	.	O	O

0	Meloxicam	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	liver	B-Disease	B-Disease
4	toxicity	E-Disease	E-Disease
5	.	O	O

0	We	O	O
1	report	O	O
2	the	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	female	O	O
7	patient	O	O
8	with	O	O
9	rheumatoid	B-Disease	B-Disease
10	arthritis	E-Disease	E-Disease
11	who	O	O
12	developed	O	O
13	acute	O	B-Disease
14	cytolytic	O	B-Disease
15	hepatitis	S-Disease	E-Disease
16	due	O	O
17	to	O	O
18	meloxicam	S-Chemical	S-Disease
19	.	O	O

0	Recently	O	O
1	introduced	O	O
2	in	O	O
3	Belgium	O	O
4	,	O	O
5	meloxicam	S-Chemical	S-Chemical
6	is	O	O
7	the	O	O
8	first	O	O
9	nonsteroidal	O	O
10	antiinflammatory	O	O
11	drug	O	O
12	with	O	O
13	selective	O	O
14	action	O	O
15	on	O	O
16	the	O	O
17	inducible	O	O
18	form	O	O
19	of	O	O
20	cyclooxygenase	O	S-Chemical
21	2	O	O
22	.	O	O

0	The	O	O
1	acute	O	O
2	cytolytic	O	S-Disease
3	hepatitis	S-Disease	S-Disease
4	occurred	O	O
5	rapidly	O	O
6	after	O	O
7	meloxicam	S-Chemical	S-Chemical
8	administration	O	O
9	and	O	O
10	was	O	O
11	associated	O	O
12	with	O	O
13	the	O	O
14	development	O	O
15	of	O	O
16	antinuclear	O	O
17	antibodies	O	O
18	suggesting	O	O
19	a	O	O
20	hypersensitivity	S-Disease	O
21	mechanism	O	O
22	.	O	O

0	This	O	O
1	first	O	O
2	case	O	O
3	of	O	O
4	meloxicam	S-Chemical	S-Chemical
5	related	O	O
6	liver	B-Disease	B-Disease
7	toxicity	E-Disease	E-Disease
8	demonstrates	O	O
9	the	O	O
10	potential	O	O
11	of	O	O
12	this	O	O
13	drug	O	O
14	to	O	O
15	induce	O	O
16	hepatic	B-Disease	B-Disease
17	damage	E-Disease	E-Disease
18	.	O	O

0	Induction	O	O
1	of	O	O
2	apoptosis	O	S-Disease
3	by	O	O
4	remoxipride	S-Chemical	O
5	metabolites	O	O
6	in	O	O
7	HL60	O	S-Disease
8	and	O	O
9	CD34	O	B-Disease
10	+	O	O
11	/	O	O
12	CD19	O	O
13	-	O	O
14	human	O	O
15	bone	O	I-Disease
16	marrow	O	I-Disease
17	progenitor	O	O
18	cells	O	O
19	:	O	O
20	potential	O	O
21	relevance	O	O
22	to	O	O
23	remoxipride	S-Chemical	O
24	-	O	O
25	induced	O	O
26	aplastic	B-Disease	S-Disease
27	anemia	E-Disease	O
28	.	O	O

0	The	O	O
1	antipsychotic	O	O
2	agent	O	O
3	,	O	O
4	remoxipride	S-Chemical	O
5	[	O	O
6	(	B-Chemical	O
7	S	I-Chemical	O
8	)	I-Chemical	O
9	-	I-Chemical	I-Chemical
10	(	I-Chemical	O
11	-	I-Chemical	I-Chemical
12	)	I-Chemical	O
13	-	I-Chemical	I-Chemical
14	3	I-Chemical	O
15	-	I-Chemical	I-Chemical
16	bromo	I-Chemical	O
17	-	I-Chemical	I-Chemical
18	N	I-Chemical	O
19	-	I-Chemical	O
20	[	I-Chemical	O
21	(	I-Chemical	O
22	1	I-Chemical	O
23	-	I-Chemical	I-Chemical
24	ethyl	I-Chemical	E-Chemical
25	-	I-Chemical	I-Chemical
26	2	I-Chemical	O
27	-	I-Chemical	I-Chemical
28	pyrrolidinyl	I-Chemical	S-Chemical
29	)	I-Chemical	O
30	methyl	I-Chemical	S-Chemical
31	]	I-Chemical	O
32	-	I-Chemical	O
33	2	I-Chemical	O
34	,	I-Chemical	O
35	6	I-Chemical	O
36	-	I-Chemical	O
37	dimethoxybenz	I-Chemical	O
38	amide	E-Chemical	O
39	]	O	O
40	has	O	O
41	been	O	O
42	associated	O	O
43	with	O	O
44	acquired	O	O
45	aplastic	B-Disease	O
46	anemia	E-Disease	O
47	.	O	O

0	We	O	O
1	have	O	O
2	examined	O	O
3	the	O	O
4	ability	O	O
5	of	O	O
6	remoxipride	S-Chemical	S-Disease
7	,	O	O
8	three	O	O
9	pyrrolidine	S-Chemical	S-Chemical
10	ring	O	O
11	metabolites	O	O
12	and	O	O
13	five	O	O
14	aromatic	O	O
15	ring	O	O
16	metabolites	O	O
17	of	O	O
18	the	O	O
19	parent	O	O
20	compound	O	O
21	to	O	O
22	induce	O	O
23	apoptosis	O	S-Disease
24	in	O	O
25	HL60	O	O
26	cells	O	O
27	and	O	O
28	human	O	O
29	bone	O	I-Disease
30	marrow	O	I-Disease
31	progenitor	O	O
32	(	O	O
33	HBMP	O	O
34	)	O	O
35	cells	O	O
36	.	O	O

0	Apoptosis	O	S-Disease
1	was	O	O
2	assessed	O	O
3	by	O	O
4	fluorescence	O	O
5	microscopy	O	O
6	in	O	O
7	Hoechst	B-Chemical	B-Chemical
8	33342	E-Chemical	E-Chemical
9	-	O	O
10	and	O	O
11	propidium	B-Chemical	S-Chemical
12	iodide	E-Chemical	E-Chemical
13	stained	O	O
14	cell	O	O
15	samples	O	O
16	.	O	O

0	The	O	O
1	catechol	S-Chemical	S-Disease
2	and	O	O
3	hydroquinone	S-Chemical	S-Disease
4	metabolites	O	O
5	,	O	O
6	NCQ436	S-Chemical	B-Chemical
7	and	O	O
8	NCQ344	S-Chemical	S-Chemical
9	,	O	O
10	induced	O	O
11	apoptosis	O	S-Disease
12	in	O	O
13	HL60	O	S-Disease
14	and	O	O
15	HBMP	O	O
16	cells	O	O
17	in	O	O
18	a	O	O
19	time	O	O
20	-	O	O
21	and	O	O
22	concentration	O	O
23	dependent	O	O
24	manner	O	O
25	,	O	O
26	while	O	O
27	the	O	O
28	phenols	S-Chemical	S-Disease
29	,	O	O
30	NCR181	O	B-Chemical
31	,	O	O
32	FLA873	O	B-Chemical
33	,	O	O
34	and	O	O
35	FLA797	S-Chemical	B-Chemical
36	,	O	O
37	and	O	O
38	the	O	O
39	derivatives	O	O
40	formed	O	O
41	by	O	O
42	oxidation	O	O
43	of	O	O
44	the	O	O
45	pyrrolidine	S-Chemical	S-Chemical
46	ring	O	O
47	,	O	O
48	FLA838	O	B-Chemical
49	,	O	O
50	NCM001	O	S-Chemical
51	,	O	O
52	and	O	O
53	NCL118	O	B-Chemical
54	,	O	O
55	had	O	O
56	no	O	O
57	effect	O	O
58	.	O	O

0	No	O	O
1	necrosis	S-Disease	O
2	was	O	O
3	observed	O	O
4	in	O	O
5	cells	O	O
6	treated	O	O
7	with	O	O
8	NCQ436	S-Chemical	S-Chemical
9	but	O	O
10	NCQ344	S-Chemical	S-Chemical
11	had	O	O
12	a	O	O
13	biphasic	O	O
14	effect	O	O
15	in	O	O
16	both	O	O
17	cell	O	O
18	types	O	O
19	,	O	O
20	inducing	O	O
21	apoptosis	O	S-Disease
22	at	O	O
23	lower	O	O
24	concentrations	O	O
25	and	O	O
26	necrosis	S-Disease	S-Disease
27	at	O	O
28	higher	O	O
29	concentrations	O	O
30	.	O	O

0	These	O	O
1	data	O	O
2	show	O	O
3	that	O	O
4	the	O	O
5	catechol	S-Chemical	S-Chemical
6	and	O	O
7	hydroquinone	S-Chemical	S-Chemical
8	metabolites	O	O
9	of	O	O
10	remoxipride	S-Chemical	S-Chemical
11	have	O	O
12	direct	O	O
13	toxic	O	O
14	effects	O	O
15	in	O	O
16	HL60	O	S-Disease
17	and	O	O
18	HBMP	O	S-Disease
19	cells	O	O
20	,	O	O
21	leading	O	O
22	to	O	O
23	apoptosis	O	S-Disease
24	,	O	O
25	while	O	O
26	the	O	O
27	phenol	S-Chemical	S-Chemical
28	metabolites	O	O
29	were	O	O
30	inactive	O	O
31	.	O	O

0	Similarly	O	O
1	,	O	O
2	benzene	S-Chemical	S-Chemical
3	-	O	O
4	derived	O	O
5	catechol	S-Chemical	S-Chemical
6	and	O	O
7	hydroquinone	S-Chemical	S-Disease
8	,	O	O
9	but	O	O
10	not	O	O
11	phenol	S-Chemical	S-Chemical
12	,	O	O
13	induce	O	O
14	apoptosis	O	S-Disease
15	in	O	O
16	HBMP	O	S-Disease
17	cells	O	O
18	[	O	O
19	Moran	O	S-Chemical
20	et	O	O
21	al	O	O
22	.	O	O
23	,	O	O
24	Mol	O	S-Chemical
25	.	O	O
26	Pharmacol	O	S-Chemical
27	.	O	O
28	,	O	O
29	50	O	O
30	(	O	O
31	1996	O	O
32	)	O	O
33	610	O	O
34	-	O	O
35	615	O	O
36	]	O	O
37	.	O	O

0	We	O	O
1	propose	O	O
2	that	O	O
3	remoxipride	S-Chemical	S-Disease
4	and	O	O
5	benzene	S-Chemical	S-Chemical
6	may	O	O
7	induce	O	O
8	aplastic	B-Disease	O
9	anemia	E-Disease	S-Disease
10	via	O	O
11	production	O	O
12	of	O	O
13	similar	O	O
14	reactive	O	O
15	metabolites	O	O
16	and	O	O
17	that	O	O
18	the	O	O
19	ability	O	O
20	of	O	O
21	NCQ436	S-Chemical	B-Chemical
22	and	O	O
23	NCQ344	S-Chemical	B-Chemical
24	to	O	O
25	induce	O	O
26	apoptosis	O	O
27	in	O	O
28	HBMP	O	O
29	cells	O	O
30	may	O	O
31	contribute	O	O
32	to	O	O
33	the	O	O
34	mechanism	O	O
35	underlying	O	O
36	acquired	O	O
37	aplastic	B-Disease	O
38	anemia	E-Disease	O
39	that	O	O
40	has	O	O
41	been	O	O
42	associated	O	O
43	with	O	O
44	remoxipride	S-Chemical	O
45	.	O	O

0	Synthesis	O	O
1	and	O	O
2	preliminary	O	O
3	pharmacological	O	O
4	investigations	O	O
5	of	O	O
6	1	B-Chemical	O
7	-	I-Chemical	O
8	(	I-Chemical	O
9	1	I-Chemical	O
10	,	I-Chemical	O
11	2	I-Chemical	O
12	-	I-Chemical	O
13	dihydro	I-Chemical	S-Chemical
14	-	I-Chemical	O
15	2	I-Chemical	I-Chemical
16	-	I-Chemical	I-Chemical
17	acenaphthylenyl	I-Chemical	E-Chemical
18	)	I-Chemical	O
19	piperazine	E-Chemical	S-Chemical
20	derivatives	O	O
21	as	O	O
22	potential	O	O
23	atypical	O	O
24	antipsychotic	O	O
25	agents	O	O
26	in	O	O
27	mice	O	O
28	.	O	O

0	The	O	O
1	synthesis	O	O
2	and	O	O
3	preliminary	O	O
4	pharmacological	O	O
5	evaluation	O	O
6	of	O	O
7	a	O	O
8	series	O	O
9	of	O	O
10	potential	O	O
11	atypical	O	O
12	antipsychotic	O	O
13	agents	O	O
14	based	O	O
15	on	O	O
16	the	O	O
17	structure	O	O
18	of	O	O
19	1	B-Chemical	B-Chemical
20	-	I-Chemical	I-Chemical
21	(	I-Chemical	O
22	1	I-Chemical	O
23	,	I-Chemical	O
24	2	I-Chemical	O
25	-	I-Chemical	I-Chemical
26	dihydro	I-Chemical	E-Chemical
27	-	I-Chemical	I-Chemical
28	2	I-Chemical	I-Chemical
29	-	I-Chemical	I-Chemical
30	acenaphthylenyl	I-Chemical	S-Chemical
31	)	I-Chemical	O
32	piperazine	E-Chemical	S-Chemical
33	(	O	O
34	7	O	O
35	)	O	O
36	is	O	O
37	described	O	O
38	.	O	O

0	Compound	O	O
1	7e	O	O
2	,	O	O
3	5	B-Chemical	O
4	-	I-Chemical	I-Chemical
5	{	I-Chemical	O
6	2	I-Chemical	O
7	-	I-Chemical	I-Chemical
8	[	I-Chemical	O
9	4	I-Chemical	O
10	-	I-Chemical	I-Chemical
11	(	I-Chemical	O
12	1	I-Chemical	O
13	,	I-Chemical	O
14	2	I-Chemical	O
15	-	I-Chemical	I-Chemical
16	dihydro	I-Chemical	S-Chemical
17	-	I-Chemical	O
18	2	I-Chemical	I-Chemical
19	-	I-Chemical	O
20	acenaphthylenyl	I-Chemical	S-Chemical
21	)	I-Chemical	O
22	piperazinyl	I-Chemical	S-Chemical
23	]	I-Chemical	O
24	ethyl	I-Chemical	S-Chemical
25	}	I-Chemical	O
26	-	I-Chemical	O
27	2	I-Chemical	O
28	,	I-Chemical	O
29	3	I-Chemical	O
30	-	I-Chemical	O
31	dihy	I-Chemical	O
32	dro	I-Chemical	E-Chemical
33	-	I-Chemical	I-Chemical
34	1H	I-Chemical	E-Chemical
35	-	I-Chemical	I-Chemical
36	indol	I-Chemical	O
37	-	I-Chemical	O
38	2	I-Chemical	O
39	-	I-Chemical	O
40	one	E-Chemical	O
41	,	O	O
42	from	O	O
43	this	O	O
44	series	O	O
45	showed	O	O
46	significant	O	O
47	affinities	O	O
48	at	O	O
49	the	O	O
50	5	O	O
51	-	O	I-Chemical
52	HT1A	O	O
53	and	O	O
54	5	O	O
55	-	O	O
56	HT2A	O	O
57	receptors	O	O
58	and	O	O
59	moderate	O	O
60	affinity	O	O
61	at	O	O
62	the	O	O
63	D2	O	B-Chemical
64	receptor	O	O
65	.	O	O

0	7e	O	S-Chemical
1	exhibits	O	O
2	a	O	O
3	high	O	O
4	reversal	O	O
5	of	O	O
6	catalepsy	S-Disease	S-Disease
7	induced	O	O
8	by	O	O
9	haloperidol	S-Chemical	S-Chemical
10	indicating	O	O
11	its	O	O
12	atypical	O	O
13	antipsychotic	O	O
14	nature	O	O
15	.	O	O

0	Sub	O	O
1	-	O	O
2	chronic	O	O
3	inhibition	O	O
4	of	O	O
5	nitric	B-Chemical	S-Chemical
6	-	I-Chemical	I-Disease
7	oxide	E-Chemical	E-Chemical
8	synthesis	O	O
9	modifies	O	O
10	haloperidol	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	catalepsy	S-Disease	S-Disease
14	and	O	O
15	the	O	O
16	number	O	O
17	of	O	O
18	NADPH	S-Chemical	S-Chemical
19	-	O	O
20	diaphorase	O	S-Disease
21	neurons	O	O
22	in	O	O
23	mice	O	O
24	.	O	O

0	RATIONALE	O	O
1	:	O	O
2	NG	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	nitro	I-Chemical	E-Chemical
5	-	I-Chemical	I-Chemical
6	L	I-Chemical	E-Chemical
7	-	I-Chemical	I-Chemical
8	arginine	E-Chemical	E-Chemical
9	(	O	O
10	L	B-Chemical	B-Chemical
11	-	I-Chemical	I-Chemical
12	NOARG	E-Chemical	E-Chemical
13	)	O	O
14	,	O	O
15	an	O	O
16	inhibitor	O	O
17	of	O	O
18	nitric	B-Chemical	S-Chemical
19	-	I-Chemical	O
20	oxide	E-Chemical	E-Chemical
21	synthase	O	O
22	(	O	O
23	NOS	O	O
24	)	O	O
25	,	O	O
26	induces	O	O
27	catalepsy	S-Disease	O
28	in	O	O
29	mice	O	O
30	.	O	O

0	This	O	O
1	effect	O	O
2	undergoes	O	O
3	rapid	O	O
4	tolerance	O	O
5	,	O	O
6	showing	O	O
7	a	O	O
8	significant	O	O
9	decrease	O	O
10	after	O	O
11	2	O	O
12	days	O	O
13	of	O	O
14	sub	O	O
15	-	O	O
16	chronic	O	O
17	L	B-Chemical	B-Chemical
18	-	I-Chemical	I-Chemical
19	NOARG	E-Chemical	E-Chemical
20	treatment	O	O
21	.	O	O

0	Nitric	B-Chemical	S-Chemical
1	oxide	E-Chemical	E-Chemical
2	(	O	O
3	NO	S-Chemical	S-Chemical
4	)	O	O
5	has	O	O
6	been	O	O
7	shown	O	O
8	to	O	O
9	influence	O	O
10	dopaminergic	O	O
11	neurotransmission	O	S-Disease
12	in	O	O
13	the	O	O
14	striatum	O	S-Disease
15	.	O	O

0	Neuroleptic	O	O
1	drugs	O	O
2	such	O	O
3	as	O	O
4	haloperidol	S-Chemical	S-Chemical
5	,	O	O
6	which	O	O
7	block	O	O
8	dopamine	S-Chemical	O
9	receptors	O	O
10	,	O	O
11	also	O	O
12	cause	O	O
13	catalepsy	S-Disease	S-Disease
14	in	O	O
15	rodents	O	O
16	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	To	O	O
3	investigate	O	O
4	the	O	O
5	effects	O	O
6	of	O	O
7	subchronic	O	O
8	L	B-Chemical	B-Chemical
9	-	I-Chemical	I-Chemical
10	NOARG	E-Chemical	E-Chemical
11	treatment	O	O
12	in	O	O
13	haloperidol	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	catalepsy	S-Disease	S-Disease
17	and	O	O
18	the	O	O
19	number	O	O
20	of	O	O
21	NOS	O	O
22	neurons	O	O
23	in	O	O
24	areas	O	O
25	related	O	O
26	to	O	O
27	motor	O	O
28	control	O	O
29	.	O	O

0	METHODS	O	O
1	:	O	O
2	Male	O	O
3	albino	O	O
4	Swiss	O	O
5	mice	O	O
6	were	O	O
7	treated	O	O
8	sub	O	O
9	-	O	O
10	chronically	O	O
11	(	O	O
12	twice	O	O
13	a	O	O
14	day	O	O
15	for	O	O
16	4	O	O
17	days	O	O
18	)	O	O
19	with	O	O
20	L	B-Chemical	B-Chemical
21	-	I-Chemical	I-Chemical
22	NOARG	E-Chemical	E-Chemical
23	(	O	O
24	40	O	O
25	mg	O	O
26	/	O	O
27	kg	O	O
28	i	O	O
29	.	O	O
30	p	O	O
31	.	O	O
32	)	O	O
33	or	O	O
34	haloperidol	S-Chemical	S-Chemical
35	(	O	O
36	1	O	O
37	mg	O	O
38	/	O	O
39	kg	O	O
40	i	O	O
41	.	O	O
42	p	O	O
43	.	O	O
44	)	O	O
45	.	O	O

0	Catalepsy	S-Disease	O
1	was	O	O
2	evaluated	O	O
3	at	O	O
4	the	O	O
5	beginning	O	O
6	and	O	O
7	the	O	O
8	end	O	O
9	of	O	O
10	the	O	O
11	treatments	O	O
12	.	O	O

0	Reduced	O	O
1	nicotinamide	B-Chemical	S-Chemical
2	adenine	I-Chemical	O
3	dinucleotide	I-Chemical	E-Chemical
4	phosphate	E-Chemical	S-Disease
5	-	O	O
6	diaphorase	O	S-Disease
7	(	O	O
8	NADPH	S-Chemical	S-Chemical
9	-	O	O
10	d	O	O
11	)	O	O
12	histochemistry	O	O
13	was	O	O
14	also	O	O
15	employed	O	O
16	to	O	O
17	visualize	O	O
18	NOS	O	S-Disease
19	as	O	O
20	an	O	O
21	index	O	O
22	of	O	O
23	enzyme	O	O
24	expression	O	O
25	in	O	O
26	mice	O	O
27	brain	O	O
28	regions	O	O
29	related	O	O
30	to	O	O
31	motor	O	O
32	control	O	O
33	.	O	O

0	RESULTS	O	O
1	:	O	O
2	L	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	NOARG	E-Chemical	E-Chemical
5	sub	O	O
6	-	O	O
7	chronic	O	S-Disease
8	administration	O	O
9	produced	O	O
10	tolerance	O	O
11	of	O	O
12	L	B-Chemical	B-Chemical
13	-	I-Chemical	I-Chemical
14	NOARG	E-Chemical	E-Chemical
15	and	O	O
16	of	O	O
17	haloperidol	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	catalepsy	S-Disease	S-Disease
21	.	O	O

0	It	O	O
1	also	O	O
2	induced	O	O
3	an	O	O
4	increase	O	O
5	in	O	O
6	the	O	O
7	number	O	O
8	of	O	O
9	NADPH	S-Chemical	B-Chemical
10	-	O	I-Chemical
11	d	O	E-Chemical
12	-	O	I-Chemical
13	positive	O	O
14	cells	O	O
15	in	O	O
16	the	O	O
17	dorsal	O	O
18	part	O	O
19	of	O	O
20	the	O	O
21	caudate	O	O
22	and	O	O
23	accumbens	O	O
24	nuclei	O	O
25	compared	O	O
26	with	O	O
27	haloperidol	S-Chemical	S-Chemical
28	and	O	O
29	in	O	O
30	the	O	O
31	pedunculopontine	O	O
32	tegmental	O	O
33	nucleus	O	O
34	compared	O	O
35	with	O	O
36	saline	O	S-Chemical
37	.	O	O

0	In	O	O
1	contrast	O	O
2	,	O	O
3	there	O	O
4	was	O	O
5	a	O	O
6	decrease	O	O
7	in	O	O
8	NADPH	S-Chemical	S-Disease
9	-	O	O
10	d	O	O
11	neuron	O	S-Disease
12	number	O	O
13	in	O	O
14	the	O	O
15	substantia	O	O
16	nigra	O	O
17	,	O	O
18	pars	O	S-Disease
19	compacta	O	S-Disease
20	in	O	O
21	both	O	O
22	haloperidol	S-Chemical	S-Chemical
23	-	O	O
24	treated	O	O
25	and	O	O
26	L	B-Chemical	B-Chemical
27	-	I-Chemical	I-Chemical
28	NOARG	E-Chemical	E-Chemical
29	-	O	O
30	treated	O	O
31	animals	O	O
32	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	results	O	O
4	give	O	O
5	further	O	O
6	support	O	O
7	to	O	O
8	the	O	O
9	hypothesis	O	O
10	that	O	O
11	NO	S-Chemical	S-Chemical
12	plays	O	O
13	a	O	O
14	role	O	O
15	in	O	O
16	motor	O	O
17	behavior	O	I-Disease
18	control	O	O
19	and	O	O
20	suggest	O	O
21	that	O	O
22	it	O	O
23	may	O	O
24	take	O	O
25	part	O	O
26	in	O	O
27	the	O	O
28	synaptic	O	O
29	changes	O	O
30	produced	O	O
31	by	O	O
32	antipsychotic	O	O
33	treatment	O	O
34	.	O	O

0	Prolonged	O	O
1	left	B-Disease	O
2	ventricular	I-Disease	B-Disease
3	dysfunction	E-Disease	E-Disease
4	occurs	O	O
5	in	O	O
6	patients	O	O
7	with	O	O
8	coronary	B-Disease	B-Disease
9	artery	I-Disease	I-Disease
10	disease	E-Disease	E-Disease
11	after	O	O
12	both	O	O
13	dobutamine	S-Chemical	S-Chemical
14	and	O	O
15	exercise	O	O
16	induced	O	O
17	myocardial	B-Disease	B-Disease
18	ischaemia	E-Disease	E-Disease
19	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	determine	O	O
4	whether	O	O
5	pharmacological	O	O
6	stress	O	O
7	leads	O	O
8	to	O	O
9	prolonged	O	O
10	but	O	O
11	reversible	O	O
12	left	B-Disease	B-Disease
13	ventricular	I-Disease	I-Disease
14	dysfunction	E-Disease	E-Disease
15	in	O	O
16	patients	O	O
17	with	O	O
18	coronary	B-Disease	B-Disease
19	artery	I-Disease	I-Disease
20	disease	E-Disease	E-Disease
21	,	O	O
22	similar	O	O
23	to	O	O
24	that	O	O
25	seen	O	O
26	after	O	O
27	exercise	O	O
28	.	O	O

0	DESIGN	O	O
1	:	O	O
2	A	O	O
3	randomised	O	O
4	crossover	O	O
5	study	O	O
6	of	O	O
7	recovery	O	O
8	time	O	O
9	of	O	O
10	systolic	O	S-Disease
11	and	O	O
12	diastolic	O	B-Disease
13	left	O	I-Disease
14	ventricular	O	I-Disease
15	function	O	E-Disease
16	after	O	O
17	exercise	O	O
18	and	O	O
19	dobutamine	S-Chemical	S-Chemical
20	induced	O	O
21	ischaemia	S-Disease	S-Disease
22	.	O	O

0	SUBJECTS	O	O
1	:	O	O
2	10	O	O
3	patients	O	O
4	with	O	O
5	stable	B-Disease	O
6	angina	E-Disease	S-Disease
7	,	O	O
8	angiographically	O	O
9	proven	O	O
10	coronary	B-Disease	B-Disease
11	artery	I-Disease	I-Disease
12	disease	E-Disease	E-Disease
13	,	O	O
14	and	O	O
15	normal	O	O
16	left	O	B-Disease
17	ventricular	O	I-Disease
18	function	O	E-Disease
19	.	O	O

0	INTERVENTIONS	O	O
1	:	O	O
2	Treadmill	O	O
3	exercise	O	O
4	and	O	O
5	dobutamine	S-Chemical	S-Chemical
6	stress	O	E-Disease
7	were	O	O
8	performed	O	O
9	on	O	O
10	different	O	O
11	days	O	O
12	.	O	O

0	There	O	O
1	was	O	O
2	no	O	O
3	difference	O	O
4	in	O	O
5	the	O	O
6	maximum	O	O
7	double	O	O
8	product	O	O
9	(	O	O
10	p	O	O
11	=	O	O
12	0	O	O
13	.	O	O
14	53	O	O
15	)	O	O
16	or	O	O
17	ST	O	B-Disease
18	depression	S-Disease	E-Disease
19	(	O	O
20	p	O	O
21	=	O	O
22	0	O	O
23	.	O	O
24	63	O	O
25	)	O	O
26	with	O	O
27	either	O	O
28	form	O	O
29	of	O	O
30	stress	O	O
31	.	O	O

0	After	O	O
1	exercise	O	O
2	,	O	O
3	ejection	O	O
4	fraction	O	O
5	was	O	O
6	reduced	O	O
7	at	O	O
8	15	O	O
9	and	O	O
10	30	O	O
11	minutes	O	O
12	compared	O	O
13	with	O	O
14	baseline	O	O
15	(	O	O
16	mean	O	O
17	(	O	O
18	SEM	O	S-Disease
19	)	O	O
20	,	O	O
21	-	O	O
22	5	O	O
23	.	O	O
24	6	O	O
25	(	O	O
26	1	O	O
27	.	O	O
28	5	O	O
29	)	O	O
30	%	O	O
31	,	O	O
32	p	O	O
33	<	O	O
34	0	O	O
35	.	O	O
36	05	O	O
37	;	O	O
38	and	O	O
39	-	O	O
40	6	O	O
41	.	O	O
42	1	O	O
43	(	O	O
44	2	O	O
45	.	O	O
46	2	O	O
47	)	O	O
48	%	O	O
49	,	O	O
50	p	O	O
51	<	O	O
52	0	O	O
53	.	O	O
54	01	O	O
55	)	O	O
56	,	O	O
57	and	O	O
58	at	O	O
59	30	O	O
60	and	O	O
61	45	O	O
62	minutes	O	O
63	after	O	O
64	dobutamine	S-Chemical	S-Chemical
65	(	O	O
66	-	O	O
67	10	O	O
68	.	O	O
69	8	O	O
70	(	O	O
71	1	O	O
72	.	O	O
73	8	O	O
74	)	O	O
75	%	O	O
76	and	O	O
77	-	O	O
78	5	O	O
79	.	O	O
80	5	O	O
81	(	O	O
82	1	O	O
83	.	O	O
84	8	O	O
85	)	O	O
86	%	O	O
87	,	O	O
88	both	O	O
89	p	O	O
90	<	O	O
91	0	O	O
92	.	O	O
93	01	O	O
94	)	O	O
95	.	O	O

0	Regional	O	O
1	analysis	O	O
2	showed	O	O
3	a	O	O
4	reduction	O	O
5	in	O	O
6	the	O	O
7	worst	O	O
8	affected	O	O
9	segment	O	O
10	15	O	O
11	and	O	O
12	30	O	O
13	minutes	O	O
14	after	O	O
15	exercise	O	O
16	(	O	O
17	-	O	O
18	27	O	O
19	.	O	O
20	9	O	O
21	(	O	O
22	7	O	O
23	.	O	O
24	2	O	O
25	)	O	O
26	%	O	O
27	and	O	O
28	-	O	O
29	28	O	O
30	.	O	O
31	6	O	O
32	(	O	O
33	5	O	O
34	.	O	O
35	7	O	O
36	)	O	O
37	%	O	O
38	,	O	O
39	both	O	O
40	p	O	O
41	<	O	O
42	0	O	O
43	.	O	O
44	01	O	O
45	)	O	O
46	,	O	O
47	and	O	O
48	at	O	O
49	30	O	O
50	minutes	O	O
51	after	O	O
52	dobutamine	S-Chemical	S-Chemical
53	(	O	O
54	-	O	O
55	32	O	O
56	(	O	O
57	5	O	O
58	.	O	O
59	3	O	O
60	)	O	O
61	%	O	O
62	,	O	O
63	p	O	O
64	<	O	O
65	0	O	O
66	.	O	O
67	01	O	O
68	)	O	O
69	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	In	O	O
3	patients	O	O
4	with	O	O
5	coronary	B-Disease	B-Disease
6	artery	I-Disease	I-Disease
7	disease	E-Disease	E-Disease
8	,	O	O
9	dobutamine	S-Chemical	S-Chemical
10	induced	O	O
11	ischaemia	S-Disease	S-Disease
12	results	O	O
13	in	O	O
14	prolonged	O	O
15	reversible	O	O
16	left	B-Disease	B-Disease
17	ventricular	I-Disease	I-Disease
18	dysfunction	E-Disease	E-Disease
19	,	O	O
20	presumed	O	O
21	to	O	O
22	be	O	O
23	myocardial	B-Disease	B-Disease
24	stunning	E-Disease	E-Disease
25	,	O	O
26	similar	O	O
27	to	O	O
28	that	O	O
29	seen	O	O
30	after	O	O
31	exercise	O	O
32	.	O	O

0	Dobutamine	S-Chemical	S-Chemical
1	induced	O	O
2	ischaemia	S-Disease	S-Disease
3	could	O	O
4	therefore	O	O
5	be	O	O
6	used	O	O
7	to	O	O
8	study	O	O
9	the	O	O
10	pathophysiology	O	O
11	of	O	O
12	this	O	O
13	phenomenon	O	O
14	further	O	O
15	in	O	O
16	patients	O	O
17	with	O	O
18	coronary	B-Disease	B-Disease
19	artery	I-Disease	I-Disease
20	disease	E-Disease	E-Disease
21	.	O	O

0	Anorexigens	O	O
1	and	O	O
2	pulmonary	B-Disease	B-Disease
3	hypertension	E-Disease	E-Disease
4	in	O	O
5	the	O	O
6	United	O	O
7	States	O	O
8	:	O	O
9	results	O	O
10	from	O	O
11	the	O	O
12	surveillance	O	O
13	of	O	O
14	North	O	B-Disease
15	American	O	I-Disease
16	pulmonary	B-Disease	B-Disease
17	hypertension	E-Disease	E-Disease
18	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	The	O	O
3	use	O	O
4	of	O	O
5	appetite	O	B-Disease
6	suppressants	O	E-Disease
7	in	O	O
8	Europe	O	S-Chemical
9	has	O	O
10	been	O	O
11	associated	O	O
12	with	O	O
13	the	O	O
14	development	O	O
15	of	O	O
16	primary	B-Disease	O
17	pulmonary	I-Disease	B-Disease
18	hypertension	E-Disease	E-Disease
19	(	O	O
20	PPH	S-Disease	S-Chemical
21	)	O	O
22	.	O	O

0	Recently	O	O
1	,	O	O
2	fenfluramine	S-Chemical	S-Chemical
3	appetite	O	B-Disease
4	suppressants	O	E-Disease
5	became	O	O
6	widely	O	O
7	used	O	O
8	in	O	O
9	the	O	O
10	United	O	O
11	States	O	O
12	but	O	O
13	were	O	O
14	withdrawn	O	O
15	in	O	O
16	September	O	O
17	1997	O	O
18	because	O	O
19	of	O	O
20	concerns	O	O
21	over	O	O
22	adverse	O	O
23	effects	O	O
24	.	O	O

0	MATERIALS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	We	O	O
5	conducted	O	O
6	a	O	O
7	prospective	O	O
8	surveillance	O	O
9	study	O	O
10	on	O	O
11	patients	O	O
12	diagnosed	O	O
13	with	O	O
14	pulmonary	B-Disease	B-Disease
15	hypertension	E-Disease	E-Disease
16	at	O	O
17	12	O	O
18	large	O	O
19	referral	O	O
20	centers	O	O
21	in	O	O
22	North	O	O
23	America	O	O
24	.	O	O

0	Data	O	O
1	collected	O	O
2	on	O	O
3	patients	O	O
4	seen	O	O
5	from	O	O
6	September	O	O
7	1	O	O
8	,	O	O
9	1996	O	O
10	,	O	O
11	to	O	O
12	December	O	O
13	31	O	O
14	,	O	O
15	1997	O	O
16	,	O	O
17	included	O	O
18	the	O	O
19	cause	O	O
20	of	O	O
21	the	O	O
22	pulmonary	B-Disease	B-Disease
23	hypertension	E-Disease	E-Disease
24	and	O	O
25	its	O	O
26	severity	O	O
27	.	O	O

0	Patients	O	O
1	with	O	O
2	no	O	O
3	identifiable	O	O
4	cause	O	O
5	of	O	O
6	pulmonary	B-Disease	B-Disease
7	hypertension	E-Disease	E-Disease
8	were	O	O
9	classed	O	O
10	as	O	O
11	PPH	S-Disease	S-Chemical
12	.	O	O

0	A	O	O
1	history	O	O
2	of	O	O
3	drug	O	O
4	exposure	O	O
5	also	O	O
6	was	O	O
7	taken	O	O
8	with	O	O
9	special	O	O
10	attention	O	O
11	on	O	O
12	the	O	O
13	use	O	O
14	of	O	O
15	antidepressants	O	O
16	,	O	O
17	anorexigens	O	S-Disease
18	,	O	O
19	and	O	O
20	amphetamines	S-Chemical	S-Chemical
21	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Five	O	O
3	hundred	O	O
4	seventy	O	O
5	-	O	O
6	nine	O	O
7	patients	O	O
8	were	O	O
9	studied	O	O
10	,	O	O
11	205	O	O
12	with	O	O
13	PPH	S-Disease	S-Chemical
14	and	O	O
15	374	O	O
16	with	O	O
17	pulmonary	B-Disease	B-Disease
18	hypertension	E-Disease	E-Disease
19	from	O	O
20	other	O	O
21	causes	O	O
22	(	O	O
23	secondary	O	O
24	pulmonary	B-Disease	B-Disease
25	hypertension	E-Disease	E-Disease
26	[	O	O
27	SPH	O	S-Disease
28	]	O	O
29	)	O	O
30	.	O	O

0	However	O	O
1	,	O	O
2	of	O	O
3	the	O	O
4	medications	O	O
5	surveyed	O	O
6	,	O	O
7	only	O	O
8	the	O	O
9	fenfluramines	S-Chemical	S-Chemical
10	had	O	O
11	a	O	O
12	significant	O	O
13	preferential	O	O
14	association	O	O
15	with	O	O
16	PPH	S-Disease	S-Chemical
17	as	O	O
18	compared	O	O
19	with	O	O
20	SPH	O	S-Disease
21	(	O	O
22	adjusted	O	O
23	odds	O	O
24	ratio	O	O
25	for	O	O
26	use	O	O
27	>	O	O
28	6	O	O
29	months	O	O
30	,	O	O
31	7	O	O
32	.	O	O
33	5	O	O
34	;	O	O
35	95	O	O
36	%	O	O
37	confidence	O	O
38	interval	O	O
39	,	O	O
40	1	O	O
41	.	O	O
42	7	O	O
43	to	O	O
44	32	O	O
45	.	O	O
46	4	O	O
47	)	O	O
48	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	The	O	O
3	magnitude	O	O
4	of	O	O
5	the	O	O
6	association	O	O
7	with	O	O
8	PPH	S-Disease	S-Chemical
9	,	O	O
10	the	O	O
11	increase	O	O
12	of	O	O
13	association	O	O
14	with	O	O
15	increasing	O	O
16	duration	O	O
17	of	O	O
18	use	O	O
19	,	O	O
20	and	O	O
21	the	O	O
22	specificity	O	O
23	for	O	O
24	fenfluramines	S-Chemical	S-Chemical
25	are	O	O
26	consistent	O	O
27	with	O	O
28	previous	O	O
29	studies	O	O
30	indicating	O	O
31	that	O	O
32	fenfluramines	S-Chemical	S-Chemical
33	are	O	O
34	causally	O	O
35	related	O	O
36	to	O	O
37	PPH	S-Disease	S-Chemical
38	.	O	O

0	The	O	O
1	high	O	O
2	prevalence	O	O
3	of	O	O
4	anorexigen	O	S-Chemical
5	use	O	O
6	in	O	O
7	patients	O	O
8	with	O	O
9	SPH	O	S-Disease
10	also	O	O
11	raises	O	O
12	the	O	O
13	possibility	O	O
14	that	O	O
15	these	O	O
16	drugs	O	O
17	precipitate	O	O
18	pulmonary	B-Disease	B-Disease
19	hypertension	E-Disease	E-Disease
20	in	O	O
21	patients	O	O
22	with	O	O
23	underlying	O	O
24	conditions	O	O
25	associated	O	O
26	with	O	O
27	SPH	O	S-Chemical
28	.	O	O

0	Clinical	O	O
1	aspects	O	O
2	of	O	O
3	heparin	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	thrombocytopenia	S-Disease	S-Disease
7	and	O	O
8	thrombosis	S-Disease	S-Disease
9	and	O	O
10	other	O	O
11	side	O	O
12	effects	O	O
13	of	O	O
14	heparin	S-Chemical	S-Chemical
15	therapy	O	O
16	.	O	O

0	Heparin	S-Chemical	S-Chemical
1	,	O	O
2	first	O	O
3	used	O	O
4	to	O	O
5	prevent	O	O
6	the	O	O
7	clotting	O	S-Disease
8	of	O	O
9	blood	O	O
10	in	O	O
11	vitro	O	O
12	,	O	O
13	has	O	O
14	been	O	O
15	clinically	O	O
16	used	O	O
17	to	O	O
18	treat	O	O
19	thrombosis	S-Disease	S-Disease
20	for	O	O
21	more	O	O
22	than	O	O
23	50	O	O
24	years	O	O
25	.	O	O

0	Although	O	O
1	several	O	O
2	new	O	O
3	anticoagulant	O	O
4	drugs	O	O
5	are	O	O
6	in	O	O
7	development	O	O
8	,	O	O
9	heparin	S-Chemical	S-Chemical
10	remains	O	O
11	the	O	O
12	anticoagulant	O	O
13	of	O	O
14	choice	O	O
15	to	O	O
16	treat	O	O
17	acute	O	B-Disease
18	thrombotic	S-Disease	E-Disease
19	episodes	O	O
20	.	O	O

0	The	O	O
1	clinical	O	O
2	effects	O	O
3	of	O	O
4	heparin	S-Chemical	S-Chemical
5	are	O	O
6	meritorious	O	O
7	,	O	O
8	but	O	O
9	side	O	O
10	effects	O	O
11	do	O	O
12	exist	O	O
13	.	O	O

0	Bleeding	S-Disease	O
1	is	O	O
2	the	O	O
3	primary	O	O
4	untoward	O	O
5	effect	O	O
6	of	O	O
7	heparin	S-Chemical	S-Chemical
8	.	O	O

0	Major	O	O
1	bleeding	S-Disease	O
2	is	O	O
3	of	O	O
4	primary	O	O
5	concern	O	O
6	in	O	O
7	patients	O	O
8	receiving	O	O
9	heparin	S-Chemical	S-Chemical
10	therapy	O	O
11	.	O	O

0	However	O	O
1	,	O	O
2	additional	O	O
3	important	O	O
4	untoward	O	O
5	effects	O	O
6	of	O	O
7	heparin	S-Chemical	S-Chemical
8	therapy	O	O
9	include	O	O
10	heparin	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	thrombocytopenia	S-Disease	S-Disease
14	,	O	O
15	heparin	S-Chemical	S-Chemical
16	-	O	O
17	associated	O	O
18	osteoporosis	S-Disease	S-Disease
19	,	O	O
20	eosinophilia	S-Disease	S-Disease
21	,	O	O
22	skin	B-Disease	B-Disease
23	reactions	E-Disease	E-Disease
24	,	O	O
25	allergic	B-Disease	B-Disease
26	reactions	E-Disease	E-Disease
27	other	O	O
28	than	O	O
29	thrombocytopenia	S-Disease	S-Disease
30	,	O	O
31	alopecia	S-Disease	S-Disease
32	,	O	O
33	transaminasemia	O	S-Disease
34	,	O	O
35	hyperkalemia	S-Disease	S-Disease
36	,	O	O
37	hypoaldosteronism	S-Disease	S-Disease
38	,	O	O
39	and	O	O
40	priapism	S-Disease	S-Disease
41	.	O	O

0	These	O	O
1	side	O	O
2	effects	O	O
3	are	O	O
4	relatively	O	O
5	rare	O	O
6	in	O	O
7	a	O	O
8	given	O	O
9	individual	O	O
10	,	O	O
11	but	O	O
12	given	O	O
13	the	O	O
14	extremely	O	O
15	widespread	O	O
16	use	O	O
17	of	O	O
18	heparin	S-Chemical	S-Chemical
19	,	O	O
20	some	O	O
21	are	O	O
22	quite	O	O
23	common	O	O
24	,	O	O
25	particularly	O	O
26	HITT	S-Disease	O
27	and	O	O
28	osteoporosis	S-Disease	S-Disease
29	.	O	O

0	Although	O	O
1	reasonable	O	O
2	incidences	O	O
3	of	O	O
4	many	O	O
5	of	O	O
6	these	O	O
7	side	O	O
8	effects	O	O
9	can	O	O
10	be	O	O
11	"	O	O
12	softly	O	O
13	"	O	O
14	deduced	O	O
15	from	O	O
16	current	O	O
17	reports	O	O
18	dealing	O	O
19	with	O	O
20	unfractionated	O	O
21	heparin	S-Chemical	S-Chemical
22	,	O	O
23	at	O	O
24	present	O	O
25	the	O	O
26	incidences	O	O
27	of	O	O
28	these	O	O
29	side	O	O
30	effects	O	O
31	with	O	O
32	newer	O	O
33	low	O	O
34	molecular	O	O
35	weight	O	O
36	heparins	S-Chemical	S-Chemical
37	appear	O	O
38	to	O	O
39	be	O	O
40	much	O	O
41	less	O	O
42	common	O	O
43	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	bilateral	O	O
4	optic	B-Disease	B-Disease
5	neuropathy	E-Disease	E-Disease
6	in	O	O
7	a	O	O
8	patient	O	O
9	on	O	O
10	tacrolimus	S-Chemical	S-Chemical
11	(	O	O
12	FK506	S-Chemical	S-Chemical
13	)	O	O
14	therapy	O	O
15	after	O	O
16	liver	O	B-Disease
17	transplantation	O	E-Disease
18	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	To	O	O
3	report	O	O
4	a	O	O
5	case	O	O
6	of	O	O
7	bilateral	O	O
8	optic	B-Disease	B-Disease
9	neuropathy	E-Disease	E-Disease
10	in	O	O
11	a	O	O
12	patient	O	O
13	receiving	O	O
14	tacrolimus	S-Chemical	S-Chemical
15	(	O	O
16	FK	B-Chemical	B-Chemical
17	506	E-Chemical	E-Chemical
18	,	O	O
19	Prograf	O	S-Chemical
20	;	O	O
21	Fujisawa	O	I-Chemical
22	USA	O	I-Disease
23	,	O	S-Chemical
24	Inc	O	O
25	,	O	O
26	Deerfield	O	S-Chemical
27	,	O	O
28	Illinois	O	S-Chemical
29	)	O	O
30	for	O	O
31	immunosuppression	O	O
32	after	O	O
33	orthotropic	O	O
34	liver	O	B-Disease
35	transplantation	O	E-Disease
36	.	O	O

0	In	O	O
1	a	O	O
2	58	O	O
3	-	O	O
4	year	O	O
5	-	O	O
6	old	O	O
7	man	O	O
8	receiving	O	O
9	tacrolimus	S-Chemical	S-Chemical
10	after	O	O
11	orthotropic	O	O
12	liver	O	B-Disease
13	transplantation	O	E-Disease
14	,	O	O
15	serial	O	O
16	neuro	O	S-Disease
17	-	O	O
18	ophthalmologic	O	S-Disease
19	examinations	O	O
20	and	O	O
21	laboratory	O	O
22	studies	O	O
23	were	O	O
24	performed	O	O
25	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	patient	O	O
4	had	O	O
5	episodic	O	O
6	deterioration	O	O
7	of	O	O
8	vision	O	S-Disease
9	in	O	O
10	both	O	O
11	eyes	O	O
12	,	O	O
13	with	O	O
14	clinical	O	O
15	features	O	O
16	resembling	O	O
17	ischemic	B-Disease	O
18	optic	I-Disease	B-Disease
19	neuropathies	E-Disease	E-Disease
20	.	O	O

0	Deterioration	B-Disease	O
1	of	I-Disease	O
2	vision	E-Disease	S-Disease
3	occurred	O	O
4	despite	O	O
5	discontinuation	O	O
6	of	O	O
7	the	O	O
8	tacrolimus	S-Chemical	S-Chemical
9	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Tacrolimus	S-Chemical	S-Chemical
3	and	O	O
4	other	O	O
5	immunosuppressive	O	S-Disease
6	agents	O	O
7	may	O	O
8	be	O	O
9	associated	O	O
10	with	O	O
11	optic	B-Disease	B-Disease
12	nerve	I-Disease	I-Disease
13	toxicity	E-Disease	E-Disease
14	.	O	O

0	Hypercalcemia	S-Disease	S-Disease
1	,	O	O
2	arrhythmia	S-Disease	S-Disease
3	,	O	O
4	and	O	O
5	mood	O	S-Disease
6	stabilizers	O	O
7	.	O	O

0	Recent	O	O
1	findings	O	O
2	in	O	O
3	a	O	O
4	bipolar	S-Disease	S-Disease
5	patient	O	O
6	receiving	O	O
7	maintenance	O	O
8	lithium	S-Chemical	E-Chemical
9	therapy	O	O
10	who	O	O
11	developed	O	O
12	hypercalcemia	S-Disease	S-Disease
13	and	O	O
14	severe	O	O
15	bradyarrhythmia	S-Disease	S-Disease
16	prompted	O	O
17	the	O	O
18	authors	O	O
19	to	O	O
20	conduct	O	O
21	a	O	O
22	retrospective	O	O
23	study	O	O
24	of	O	O
25	bipolar	S-Disease	S-Disease
26	patients	O	O
27	with	O	O
28	lithium	S-Chemical	S-Chemical
29	-	O	O
30	associated	O	O
31	hypercalcemia	S-Disease	S-Disease
32	.	O	O

0	A	O	O
1	printout	O	O
2	of	O	O
3	all	O	O
4	cases	O	O
5	of	O	O
6	hypercalcemia	S-Disease	S-Disease
7	that	O	O
8	presented	O	O
9	during	O	O
10	a	O	O
11	1	O	O
12	-	O	O
13	year	O	O
14	period	O	O
15	was	O	O
16	generated	O	O
17	.	O	O

0	After	O	O
1	eliminating	O	O
2	spurious	O	O
3	hypercalcemias	S-Disease	S-Disease
4	or	O	O
5	those	O	O
6	associated	O	O
7	with	O	O
8	intravenous	O	O
9	fluids	O	O
10	,	O	O
11	the	O	O
12	authors	O	O
13	identified	O	O
14	18	O	O
15	non	O	O
16	-	O	O
17	lithium	S-Chemical	S-Disease
18	-	O	O
19	treated	O	O
20	patients	O	O
21	with	O	O
22	hypercalcemias	S-Disease	S-Disease
23	related	O	O
24	to	O	O
25	malignancies	S-Disease	S-Disease
26	and	O	O
27	other	O	O
28	medical	O	O
29	conditions	O	O
30	(	O	O
31	group	O	O
32	A	O	O
33	)	O	O
34	and	O	O
35	12	O	O
36	patients	O	O
37	with	O	O
38	lithium	S-Chemical	S-Disease
39	-	O	O
40	associated	O	O
41	hypercalcemia	S-Disease	S-Disease
42	(	O	O
43	group	O	O
44	B	O	O
45	)	O	O
46	.	O	O

0	Thus	O	O
1	,	O	O
2	two	O	O
3	control	O	O
4	groups	O	O
5	were	O	O
6	generated	O	O
7	:	O	O
8	group	O	O
9	C1	O	O
10	,	O	O
11	which	O	O
12	included	O	O
13	age	O	O
14	-	O	O
15	and	O	O
16	sex	O	O
17	-	O	O
18	comparable	O	O
19	lithium	S-Chemical	S-Disease
20	-	O	O
21	treated	O	O
22	bipolar	S-Disease	S-Disease
23	normocalcemic	O	S-Disease
24	patients	O	O
25	,	O	O
26	and	O	O
27	group	O	O
28	C2	O	O
29	,	O	O
30	which	O	O
31	included	O	O
32	bipolar	S-Disease	O
33	normocalcemic	O	O
34	patients	O	O
35	treated	O	O
36	with	O	O
37	anticonvulsant	O	O
38	mood	O	S-Disease
39	stabilizers	O	O
40	.	O	O

0	Patients	O	O
1	with	O	O
2	hypercalcemia	S-Disease	S-Disease
3	resulting	O	O
4	from	O	O
5	medical	O	O
6	diseases	O	E-Disease
7	and	O	O
8	bipolar	S-Disease	S-Disease
9	patients	O	O
10	with	O	O
11	lithium	S-Chemical	S-Chemical
12	-	O	O
13	associated	O	O
14	hypercalcemia	S-Disease	S-Disease
15	had	O	O
16	significantly	O	O
17	higher	O	O
18	frequencies	O	O
19	of	O	O
20	conduction	O	B-Disease
21	defects	O	E-Disease
22	.	O	O

0	Attenuation	O	O
1	of	O	O
2	nephrotoxicity	S-Disease	S-Disease
3	by	O	O
4	a	O	O
5	novel	O	O
6	lipid	O	S-Disease
7	nanosphere	O	O
8	(	O	O
9	NS	O	B-Chemical
10	-	O	E-Chemical
11	718	O	E-Chemical
12	)	O	O
13	incorporating	O	O
14	amphotericin	B-Chemical	S-Chemical
15	B	E-Chemical	S-Disease
16	.	O	O

0	NS	O	B-Chemical
1	-	O	E-Chemical
2	718	O	E-Chemical
3	,	O	O
4	a	O	O
5	lipid	O	S-Disease
6	nanosphere	O	O
7	incorporating	O	O
8	amphotericin	B-Chemical	S-Chemical
9	B	E-Chemical	S-Disease
10	,	O	O
11	is	O	O
12	effective	O	O
13	against	O	O
14	pathogenic	O	O
15	fungi	O	S-Disease
16	and	O	O
17	has	O	O
18	low	O	O
19	toxicity	S-Disease	S-Disease
20	.	O	O

0	We	O	O
1	compared	O	O
2	the	O	O
3	toxicity	S-Disease	S-Disease
4	of	O	O
5	NS	O	B-Chemical
6	-	O	E-Chemical
7	718	O	E-Chemical
8	with	O	O
9	that	O	O
10	of	O	O
11	Fungizone	S-Chemical	S-Chemical
12	(	O	O
13	amphotericin	B-Chemical	S-Chemical
14	B	I-Chemical	O
15	-	I-Chemical	O
16	sodium	I-Chemical	I-Disease
17	deoxycholate	E-Chemical	S-Disease
18	;	O	O
19	D	B-Chemical	B-Chemical
20	-	I-Chemical	I-Chemical
21	AmB	E-Chemical	E-Chemical
22	)	O	O
23	in	O	O
24	vitro	O	O
25	using	O	O
26	renal	O	O
27	cell	O	O
28	cultures	O	O
29	and	O	O
30	in	O	O
31	vivo	O	O
32	by	O	O
33	biochemical	O	O
34	analysis	O	O
35	,	O	O
36	histopathological	O	O
37	study	O	O
38	of	O	O
39	the	O	O
40	kidney	O	O
41	and	O	O
42	pharmacokinetic	O	O
43	study	O	O
44	of	O	O
45	amphotericin	B-Chemical	B-Chemical
46	B	E-Chemical	E-Chemical
47	following	O	O
48	intravenous	O	O
49	infusion	O	O
50	of	O	O
51	the	O	O
52	formulation	O	O
53	in	O	O
54	rats	O	O
55	.	O	O

0	Incubation	O	O
1	with	O	O
2	NS	O	B-Chemical
3	-	O	E-Chemical
4	718	O	E-Chemical
5	resulted	O	O
6	in	O	O
7	significantly	O	O
8	less	O	O
9	damage	O	O
10	of	O	O
11	cultured	O	O
12	human	O	O
13	renal	O	I-Disease
14	proximal	O	I-Disease
15	tubular	O	B-Disease
16	epithelial	O	E-Disease
17	cells	O	O
18	compared	O	O
19	with	O	O
20	D	B-Chemical	B-Chemical
21	-	I-Chemical	I-Chemical
22	AmB	E-Chemical	E-Chemical
23	.	O	O

0	Serum	O	O
1	blood	O	O
2	urea	S-Chemical	E-Disease
3	and	O	O
4	creatinine	S-Chemical	S-Chemical
5	concentrations	O	O
6	increased	O	O
7	significantly	O	O
8	in	O	O
9	rats	O	O
10	given	O	O
11	an	O	O
12	iv	O	O
13	infusion	O	O
14	of	O	O
15	D	B-Chemical	B-Chemical
16	-	I-Chemical	I-Chemical
17	AmB	E-Chemical	E-Chemical
18	3	O	O
19	mg	O	O
20	/	O	O
21	kg	O	O
22	but	O	O
23	not	O	O
24	in	O	O
25	those	O	O
26	given	O	O
27	the	O	O
28	same	O	O
29	dose	O	O
30	of	O	O
31	NS	O	S-Chemical
32	-	O	O
33	718	O	O
34	.	O	O

0	Histopathological	O	O
1	examination	O	O
2	of	O	O
3	the	O	O
4	kidney	O	O
5	showed	O	O
6	tubular	B-Disease	B-Disease
7	necrosis	E-Disease	E-Disease
8	in	O	O
9	D	B-Chemical	B-Chemical
10	-	I-Chemical	I-Chemical
11	AmB	E-Chemical	E-Chemical
12	-	O	O
13	treated	O	O
14	rats	O	O
15	but	O	O
16	no	O	O
17	change	O	O
18	in	O	O
19	NS	O	B-Chemical
20	-	O	I-Chemical
21	718	O	E-Chemical
22	-	O	O
23	treated	O	O
24	rats	O	O
25	.	O	O

0	Amphotericin	B-Chemical	S-Chemical
1	B	E-Chemical	O
2	concentrations	O	O
3	in	O	O
4	the	O	O
5	kidney	O	O
6	in	O	O
7	NS	O	O
8	-	O	O
9	718	O	O
10	-	O	O
11	treated	O	O
12	rats	O	O
13	were	O	O
14	higher	O	O
15	than	O	O
16	those	O	O
17	in	O	O
18	D	B-Chemical	B-Chemical
19	-	I-Chemical	I-Chemical
20	AmB	E-Chemical	E-Chemical
21	-	O	O
22	treated	O	O
23	rats	O	O
24	.	O	O

0	Our	O	O
1	in	O	O
2	vitro	O	O
3	and	O	O
4	in	O	O
5	vivo	O	O
6	results	O	O
7	suggest	O	O
8	that	O	O
9	incorporation	O	O
10	of	O	O
11	amphotericin	B-Chemical	S-Chemical
12	B	E-Chemical	S-Disease
13	into	O	O
14	lipid	O	S-Disease
15	nanospheres	O	O
16	of	O	O
17	NS	O	B-Chemical
18	-	O	I-Chemical
19	718	O	E-Chemical
20	attenuates	O	O
21	the	O	O
22	nephrotoxicity	S-Disease	O
23	of	O	O
24	amphotericin	B-Chemical	S-Chemical
25	B	E-Chemical	S-Disease
26	.	O	O

0	Patterns	O	O
1	of	O	O
2	sulfadiazine	S-Chemical	S-Chemical
3	acute	B-Disease	B-Disease
4	nephrotoxicity	E-Disease	E-Disease
5	.	O	O

0	Sulfadiazine	S-Chemical	S-Chemical
1	acute	B-Disease	B-Disease
2	nephrotoxicity	E-Disease	E-Disease
3	is	O	O
4	reviving	O	O
5	specially	O	O
6	because	O	O
7	of	O	O
8	its	O	O
9	use	O	O
10	in	O	O
11	toxoplasmosis	S-Disease	S-Disease
12	in	O	O
13	HIV	O	B-Disease
14	-	O	I-Disease
15	positive	O	E-Disease
16	patients	O	O
17	.	O	O

0	Under	O	O
1	treatment	O	O
2	with	O	O
3	sulfadiazine	S-Chemical	S-Chemical
4	they	O	O
5	developed	O	O
6	oliguria	S-Disease	S-Chemical
7	,	O	O
8	abdominal	B-Disease	B-Disease
9	pain	E-Disease	E-Disease
10	,	O	O
11	renal	B-Disease	B-Disease
12	failure	E-Disease	E-Disease
13	and	O	O
14	showed	O	O
15	multiple	O	O
16	radiolucent	O	B-Disease
17	renal	B-Disease	I-Disease
18	calculi	E-Disease	E-Disease
19	in	O	O
20	echography	O	O
21	.	O	O

0	A	O	O
1	nephrostomy	O	O
2	tube	O	O
3	had	O	O
4	to	O	O
5	be	O	O
6	placed	O	O
7	in	O	O
8	one	O	O
9	of	O	O
10	the	O	O
11	patients	O	O
12	for	O	O
13	ureteral	B-Disease	S-Disease
14	lithiasis	E-Disease	S-Disease
15	in	O	O
16	a	O	O
17	single	O	O
18	functional	O	O
19	kidney	O	O
20	.	O	O

0	Treatment	O	O
1	with	O	O
2	sulfadiazine	S-Chemical	S-Chemical
3	requires	O	O
4	exquisite	O	O
5	control	O	O
6	of	O	O
7	renal	O	B-Disease
8	function	O	E-Disease
9	,	O	O
10	an	O	O
11	increase	O	O
12	in	O	O
13	water	O	O
14	ingestion	O	O
15	and	O	O
16	possibly	O	O
17	the	O	O
18	alcalinization	O	O
19	of	O	O
20	the	O	O
21	urine	O	O
22	.	O	O

0	Downbeat	B-Disease	O
1	nystagmus	E-Disease	S-Disease
2	associated	O	O
3	with	O	O
4	intravenous	O	O
5	patient	O	O
6	-	O	O
7	controlled	O	O
8	administration	O	O
9	of	O	O
10	morphine	S-Chemical	S-Chemical
11	.	O	O

0	IMPLICATIONS	O	O
1	:	O	O
2	This	O	O
3	case	O	O
4	documents	O	O
5	a	O	O
6	patient	O	O
7	who	O	O
8	developed	O	O
9	dizziness	S-Disease	O
10	with	O	O
11	downbeating	B-Disease	O
12	nystagmus	E-Disease	S-Disease
13	while	O	O
14	receiving	O	O
15	a	O	O
16	relatively	O	O
17	large	O	O
18	dose	O	O
19	of	O	O
20	IV	O	O
21	patient	O	O
22	-	O	O
23	controlled	O	O
24	analgesia	O	S-Disease
25	morphine	S-Chemical	S-Disease
26	.	O	O

0	Although	O	O
1	there	O	O
2	have	O	O
3	been	O	O
4	case	O	O
5	reports	O	O
6	of	O	O
7	epidural	O	S-Disease
8	morphine	S-Chemical	E-Disease
9	with	O	O
10	these	O	O
11	symptoms	O	O
12	and	O	O
13	signs	O	O
14	,	O	O
15	this	O	O
16	has	O	O
17	not	O	O
18	been	O	O
19	previously	O	O
20	documented	O	O
21	with	O	O
22	IV	O	O
23	or	O	O
24	patient	O	O
25	-	O	O
26	controlled	O	O
27	analgesia	O	O
28	morphine	S-Chemical	S-Disease
29	.	O	O

0	Hemodynamic	O	O
1	and	O	O
2	antiadrenergic	O	O
3	effects	O	O
4	of	O	O
5	dronedarone	S-Chemical	S-Chemical
6	and	O	O
7	amiodarone	S-Chemical	S-Chemical
8	in	O	O
9	animals	O	O
10	with	O	O
11	a	O	O
12	healed	O	O
13	myocardial	B-Disease	B-Disease
14	infarction	E-Disease	E-Disease
15	.	O	O

0	The	O	O
1	hemodynamic	O	O
2	and	O	O
3	antiadrenergic	O	O
4	effects	O	O
5	of	O	O
6	dronedarone	S-Chemical	S-Chemical
7	,	O	O
8	a	O	O
9	noniodinated	O	O
10	compound	O	O
11	structurally	O	O
12	related	O	O
13	to	O	O
14	amiodarone	S-Chemical	S-Chemical
15	,	O	O
16	were	O	O
17	compared	O	O
18	with	O	O
19	those	O	O
20	of	O	O
21	amiodarone	S-Chemical	S-Chemical
22	after	O	O
23	prolonged	O	O
24	oral	O	O
25	administration	O	O
26	,	O	O
27	both	O	O
28	at	O	O
29	rest	O	O
30	and	O	O
31	during	O	O
32	sympathetic	O	O
33	stimulation	O	O
34	in	O	O
35	conscious	O	O
36	dogs	O	O
37	with	O	O
38	a	O	O
39	healed	O	O
40	myocardial	B-Disease	S-Disease
41	infarction	E-Disease	E-Disease
42	.	O	O

0	All	O	O
1	dogs	O	O
2	(	O	O
3	n	O	O
4	=	O	O
5	6	O	O
6	)	O	O
7	randomly	O	O
8	received	O	O
9	orally	O	O
10	dronedarone	S-Chemical	S-Chemical
11	(	O	O
12	10	O	O
13	and	O	O
14	30	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	)	O	O
19	,	O	O
20	amiodarone	S-Chemical	S-Chemical
21	(	O	O
22	10	O	O
23	and	O	O
24	30	O	O
25	mg	O	O
26	/	O	O
27	kg	O	O
28	)	O	O
29	,	O	O
30	and	O	O
31	placebo	O	O
32	twice	O	O
33	daily	O	O
34	for	O	O
35	7	O	O
36	days	O	O
37	,	O	O
38	with	O	O
39	a	O	O
40	3	O	O
41	-	O	O
42	week	O	O
43	washout	O	O
44	between	O	O
45	consecutive	O	O
46	treatments	O	O
47	.	O	O

0	Heart	O	O
1	rate	O	O
2	(	O	O
3	HR	O	O
4	)	O	O
5	,	O	O
6	mean	O	O
7	arterial	O	O
8	pressure	O	O
9	(	O	O
10	MBP	O	S-Chemical
11	)	O	O
12	,	O	O
13	positive	O	O
14	rate	O	O
15	of	O	O
16	increase	O	O
17	of	O	O
18	left	O	O
19	ventricular	O	I-Disease
20	pressure	O	O
21	(	O	O
22	+	O	O
23	LVdP	O	O
24	/	O	O
25	dt	O	O
26	)	O	O
27	,	O	O
28	echocardiographically	O	O
29	assessed	O	O
30	left	O	O
31	ventricular	O	O
32	ejection	O	O
33	fraction	O	O
34	(	O	O
35	LVEF	O	O
36	)	O	O
37	,	O	O
38	and	O	O
39	fractional	O	O
40	shortening	O	O
41	(	O	O
42	FS	O	S-Disease
43	)	O	O
44	,	O	O
45	as	O	O
46	well	O	O
47	as	O	O
48	chronotropic	O	S-Disease
49	response	O	O
50	to	O	O
51	isoproterenol	S-Chemical	S-Chemical
52	and	O	O
53	exercise	O	S-Disease
54	-	O	O
55	induced	O	O
56	sympathetic	O	S-Disease
57	stimulation	O	O
58	were	O	O
59	evaluated	O	O
60	under	O	O
61	baseline	O	O
62	and	O	O
63	posttreatment	O	O
64	conditions	O	O
65	.	O	O

0	Resting	O	O
1	values	O	O
2	of	O	O
3	LVEF	O	S-Disease
4	,	O	O
5	FS	O	S-Disease
6	,	O	O
7	+	O	O
8	LVdP	O	O
9	/	O	O
10	dt	O	O
11	,	O	O
12	and	O	O
13	MBP	O	S-Disease
14	remained	O	O
15	unchanged	O	O
16	whatever	O	O
17	the	O	O
18	drug	O	O
19	and	O	O
20	the	O	O
21	dosing	O	O
22	regimen	O	O
23	,	O	O
24	whereas	O	O
25	resting	O	O
26	HR	O	O
27	was	O	O
28	significantly	O	O
29	and	O	O
30	dose	O	O
31	-	O	O
32	dependently	O	O
33	lowered	O	O
34	after	O	O
35	dronedarone	S-Chemical	S-Disease
36	and	O	O
37	to	O	O
38	a	O	O
39	lesser	O	O
40	extent	O	O
41	after	O	O
42	amiodarone	S-Chemical	S-Chemical
43	.	O	O

0	Both	O	O
1	dronedarone	S-Chemical	S-Chemical
2	and	O	O
3	amiodarone	S-Chemical	S-Chemical
4	significantly	O	O
5	reduced	O	O
6	the	O	O
7	exercise	O	S-Disease
8	-	O	O
9	induced	O	O
10	tachycardia	S-Disease	S-Disease
11	and	O	O
12	,	O	O
13	at	O	O
14	the	O	O
15	highest	O	O
16	dose	O	O
17	,	O	O
18	decreased	O	O
19	the	O	O
20	isoproterenol	S-Chemical	S-Chemical
21	-	O	O
22	induced	O	O
23	tachycardia	S-Disease	S-Disease
24	.	O	O

0	Thus	O	O
1	,	O	O
2	dronedarone	S-Chemical	S-Chemical
3	and	O	O
4	amiodarone	S-Chemical	S-Chemical
5	displayed	O	O
6	a	O	O
7	similar	O	O
8	level	O	O
9	of	O	O
10	antiadrenergic	O	O
11	effect	O	O
12	and	O	O
13	did	O	O
14	not	O	O
15	impair	O	O
16	the	O	O
17	resting	O	O
18	left	O	O
19	ventricular	O	B-Disease
20	function	O	E-Disease
21	.	O	O

0	Consequently	O	O
1	,	O	O
2	dronedarone	S-Chemical	S-Chemical
3	might	O	O
4	be	O	O
5	particularly	O	O
6	suitable	O	O
7	for	O	O
8	the	O	O
9	treatment	O	O
10	and	O	O
11	prevention	O	O
12	of	O	O
13	various	O	O
14	clinical	O	O
15	arrhythmias	S-Disease	S-Disease
16	,	O	O
17	without	O	O
18	compromising	O	O
19	the	O	O
20	left	O	B-Disease
21	ventricular	O	B-Disease
22	function	O	E-Disease
23	.	O	O

0	Phase	O	O
1	2	O	O
2	trial	O	O
3	of	O	O
4	liposomal	O	S-Chemical
5	doxorubicin	S-Chemical	E-Chemical
6	(	O	O
7	40	O	O
8	mg	O	O
9	/	O	O
10	m	O	O
11	(	O	O
12	2	O	O
13	)	O	O
14	)	O	O
15	in	O	O
16	platinum	S-Chemical	O
17	/	O	O
18	paclitaxel	S-Chemical	O
19	-	O	O
20	refractory	O	O
21	ovarian	B-Disease	O
22	and	I-Disease	O
23	fallopian	I-Disease	B-Disease
24	tube	I-Disease	O
25	cancers	E-Disease	S-Disease
26	and	O	O
27	primary	O	O
28	carcinoma	B-Disease	S-Disease
29	of	I-Disease	O
30	the	I-Disease	O
31	peritoneum	E-Disease	S-Disease
32	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Several	O	O
3	studies	O	O
4	have	O	O
5	demonstrated	O	O
6	liposomal	O	S-Chemical
7	doxorubicin	S-Chemical	S-Chemical
8	(	O	O
9	Doxil	S-Chemical	S-Chemical
10	)	O	O
11	to	O	O
12	be	O	O
13	an	O	O
14	active	O	O
15	antineoplastic	O	O
16	agent	O	O
17	in	O	O
18	platinum	S-Chemical	B-Disease
19	-	O	O
20	resistant	O	O
21	ovarian	B-Disease	B-Disease
22	cancer	E-Disease	E-Disease
23	,	O	O
24	with	O	O
25	dose	O	O
26	limiting	O	O
27	toxicity	S-Disease	S-Disease
28	of	O	O
29	the	O	O
30	standard	O	O
31	dosing	O	O
32	regimen	O	O
33	(	O	O
34	50	O	O
35	mg	O	O
36	/	O	O
37	m	O	O
38	(	O	O
39	2	O	O
40	)	O	O
41	q	O	O
42	4	O	O
43	weeks	O	O
44	)	O	O
45	being	O	O
46	severe	O	O
47	erythrodysesthesia	S-Disease	S-Disease
48	(	O	O
49	"	O	O
50	hand	B-Disease	B-Disease
51	-	I-Disease	I-Disease
52	foot	I-Disease	I-Disease
53	syndrome	E-Disease	S-Disease
54	"	O	O
55	)	O	O
56	and	O	O
57	stomatitis	S-Disease	S-Disease
58	.	O	O

0	We	O	O
1	wished	O	O
2	to	O	O
3	develop	O	O
4	a	O	O
5	more	O	O
6	tolerable	O	O
7	liposomal	O	S-Disease
8	doxorubicin	S-Chemical	S-Chemical
9	treatment	O	O
10	regimen	O	O
11	and	O	O
12	document	O	O
13	its	O	O
14	level	O	O
15	of	O	O
16	activity	O	O
17	in	O	O
18	a	O	O
19	well	O	O
20	-	O	O
21	defined	O	O
22	patient	O	O
23	population	O	O
24	with	O	O
25	platinum	S-Chemical	B-Disease
26	/	O	O
27	paclitaxel	S-Chemical	O
28	-	O	O
29	refractory	O	O
30	disease	O	S-Disease
31	.	O	O

0	METHODS	O	O
1	AND	O	O
2	MATERIALS	O	O
3	:	O	O
4	Patients	O	O
5	with	O	O
6	ovarian	B-Disease	O
7	or	I-Disease	O
8	fallopian	I-Disease	B-Disease
9	tube	I-Disease	I-Disease
10	cancers	E-Disease	E-Disease
11	or	O	O
12	primary	O	O
13	peritoneal	B-Disease	O
14	carcinoma	E-Disease	S-Disease
15	with	O	O
16	platinum	S-Chemical	B-Chemical
17	/	O	O
18	paclitaxel	S-Chemical	O
19	-	O	O
20	refractory	O	O
21	disease	O	S-Disease
22	(	O	O
23	stable	O	O
24	or	O	O
25	progressive	O	O
26	disease	O	S-Disease
27	following	O	O
28	treatment	O	O
29	with	O	O
30	these	O	O
31	agents	O	O
32	or	O	O
33	previous	O	O
34	objective	O	O
35	response	O	O
36	<	O	O
37	3	O	O
38	months	O	O
39	in	O	O
40	duration	O	O
41	)	O	O
42	were	O	O
43	treated	O	O
44	with	O	O
45	liposomal	O	B-Chemical
46	doxorubicin	S-Chemical	E-Chemical
47	at	O	O
48	a	O	O
49	dose	O	O
50	of	O	O
51	40	O	O
52	mg	O	O
53	/	O	O
54	m	O	O
55	(	O	O
56	2	O	O
57	)	O	O
58	q	O	O
59	4	O	O
60	weeks	O	O
61	.	O	O

0	Six	O	O
1	(	O	O
2	12	O	O
3	%	O	O
4	)	O	O
5	and	O	O
6	4	O	O
7	(	O	O
8	8	O	O
9	%	O	O
10	)	O	O
11	patients	O	O
12	experienced	O	O
13	grade	O	O
14	2	O	O
15	hand	B-Disease	B-Disease
16	-	I-Disease	O
17	foot	I-Disease	I-Disease
18	syndrome	E-Disease	E-Disease
19	and	O	O
20	stomatitis	S-Disease	S-Disease
21	,	O	O
22	respectively	O	O
23	(	O	O
24	no	O	O
25	episodes	O	O
26	of	O	O
27	grade	O	O
28	3	O	O
29	)	O	O
30	.	O	O

0	One	O	O
1	patient	O	O
2	developed	O	O
3	grade	O	O
4	3	O	O
5	diarrhea	S-Disease	S-Disease
6	requiring	O	O
7	hospitalization	O	O
8	for	O	O
9	hydration	O	S-Disease
10	.	O	O

0	The	O	O
1	median	O	O
2	number	O	O
3	of	O	O
4	courses	O	O
5	of	O	O
6	liposomal	O	S-Disease
7	doxorubicin	S-Chemical	E-Chemical
8	administered	O	O
9	on	O	O
10	this	O	O
11	protocol	O	O
12	was	O	O
13	2	O	O
14	(	O	O
15	range	O	O
16	:	O	O
17	1	O	O
18	-	O	O
19	12	O	O
20	)	O	O
21	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	This	O	O
3	modified	O	O
4	liposomal	O	S-Disease
5	doxorubicin	S-Chemical	S-Chemical
6	regimen	O	O
7	results	O	O
8	in	O	O
9	less	O	O
10	toxicity	S-Disease	S-Disease
11	(	O	O
12	stomatitis	S-Disease	S-Disease
13	,	O	O
14	hand	B-Disease	B-Disease
15	-	I-Disease	I-Disease
16	foot	I-Disease	I-Disease
17	syndrome	E-Disease	E-Disease
18	)	O	O
19	than	O	O
20	the	O	O
21	standard	O	O
22	FDA	O	O
23	-	O	O
24	approved	O	O
25	dose	O	O
26	schedule	O	O
27	.	O	O

0	Definite	O	O
1	,	O	O
2	although	O	O
3	limited	O	O
4	,	O	O
5	antineoplastic	O	O
6	activity	O	E-Disease
7	is	O	O
8	observed	O	O
9	in	O	O
10	patients	O	O
11	with	O	O
12	well	O	O
13	-	O	O
14	defined	O	O
15	platinum	S-Chemical	B-Disease
16	-	O	O
17	and	O	O
18	paclitaxel	S-Chemical	S-Disease
19	-	O	O
20	refractory	O	O
21	ovarian	B-Disease	B-Disease
22	cancer	E-Disease	E-Disease
23	.	O	O

0	Efficacy	O	O
1	of	O	O
2	olanzapine	S-Chemical	S-Chemical
3	in	O	O
4	acute	O	O
5	bipolar	B-Disease	B-Disease
6	mania	E-Disease	E-Disease
7	:	O	O
8	a	O	O
9	double	O	O
10	-	O	O
11	blind	O	O
12	,	O	O
13	placebo	O	O
14	-	O	O
15	controlled	O	O
16	study	O	O
17	.	O	O

0	The	O	O
1	Olanzipine	S-Chemical	S-Chemical
2	HGGW	O	O
3	Study	O	O
4	Group	O	O
5	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	We	O	O
3	compared	O	O
4	the	O	O
5	efficacy	O	O
6	and	O	O
7	safety	O	O
8	of	O	O
9	olanzapine	S-Chemical	S-Chemical
10	vs	O	O
11	placebo	O	S-Disease
12	for	O	O
13	the	O	O
14	treatment	O	O
15	of	O	O
16	acute	O	B-Disease
17	bipolar	B-Disease	B-Disease
18	mania	E-Disease	E-Disease
19	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	115	O	O
4	patients	O	O
5	with	O	O
6	a	O	O
7	DSM	O	S-Disease
8	-	O	I-Disease
9	IV	O	O
10	diagnosis	O	O
11	of	O	O
12	bipolar	B-Disease	B-Disease
13	disorder	E-Disease	E-Disease
14	,	O	O
15	manic	S-Disease	O
16	or	O	O
17	mixed	O	O
18	,	O	O
19	were	O	O
20	randomized	O	O
21	to	O	O
22	olanzapine	S-Chemical	S-Chemical
23	,	O	O
24	5	O	O
25	to	O	O
26	20	O	O
27	mg	O	O
28	/	O	O
29	d	O	O
30	(	O	O
31	n	O	O
32	=	O	O
33	55	O	O
34	)	O	O
35	,	O	O
36	or	O	O
37	placebo	O	S-Disease
38	(	O	O
39	n	O	O
40	=	O	O
41	60	O	O
42	)	O	O
43	.	O	O

0	The	O	O
1	primary	O	O
2	efficacy	O	O
3	measure	O	O
4	was	O	O
5	the	O	O
6	Young	O	O
7	-	O	O
8	Mania	S-Disease	O
9	Rating	O	O
10	Scale	O	O
11	(	O	O
12	Y	O	O
13	-	O	O
14	MRS	O	S-Disease
15	)	O	O
16	total	O	O
17	score	O	O
18	.	O	O

0	Safety	O	O
1	was	O	O
2	assessed	O	O
3	using	O	O
4	adverse	O	O
5	events	O	O
6	,	O	O
7	Extrapyramidal	B-Disease	O
8	Symptom	E-Disease	O
9	(	O	O
10	EPS	S-Disease	O
11	)	O	O
12	rating	O	O
13	scales	O	O
14	,	O	O
15	laboratory	O	O
16	values	O	O
17	,	O	O
18	electrocardiograms	O	O
19	,	O	O
20	vital	O	O
21	signs	O	O
22	,	O	O
23	and	O	O
24	weight	O	O
25	change	O	O
26	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Olanzapine	S-Chemical	S-Chemical
3	-	O	O
4	treated	O	O
5	patients	O	O
6	demonstrated	O	O
7	a	O	O
8	statistically	O	O
9	significant	O	O
10	greater	O	O
11	mean	O	O
12	(	O	O
13	+	O	O
14	/	O	O
15	-	O	O
16	SD	O	O
17	)	O	O
18	improvement	O	O
19	in	O	O
20	Y	O	O
21	-	O	O
22	MRS	O	S-Disease
23	total	O	O
24	score	O	O
25	than	O	O
26	placebo	O	O
27	-	O	O
28	treated	O	O
29	patients	O	O
30	(	O	O
31	-	O	O
32	14	O	O
33	.	O	O
34	8	O	O
35	+	O	O
36	/	O	O
37	-	O	O
38	12	O	O
39	.	O	O
40	5	O	O
41	and	O	O
42	-	O	O
43	8	O	O
44	.	O	O
45	1	O	O
46	+	O	O
47	/	O	O
48	-	O	O
49	12	O	O
50	.	O	O
51	7	O	O
52	,	O	O
53	respectively	O	O
54	;	O	O
55	P	O	O
56	<	O	O
57	.	O	O
58	001	O	O
59	)	O	O
60	,	O	O
61	which	O	O
62	was	O	O
63	evident	O	O
64	at	O	O
65	the	O	O
66	first	O	O
67	postbaseline	O	O
68	observation	O	O
69	1	O	O
70	week	O	O
71	after	O	O
72	randomization	O	O
73	and	O	O
74	was	O	O
75	maintained	O	O
76	throughout	O	O
77	the	O	O
78	study	O	O
79	(	O	O
80	last	O	O
81	observation	O	O
82	carried	O	O
83	forward	O	O
84	)	O	O
85	.	O	O

0	Olanzapine	S-Chemical	S-Chemical
1	-	O	O
2	treated	O	O
3	patients	O	O
4	demonstrated	O	O
5	a	O	O
6	higher	O	O
7	rate	O	O
8	of	O	O
9	response	O	O
10	(	O	O
11	65	O	O
12	%	O	O
13	vs	O	O
14	43	O	O
15	%	O	O
16	,	O	O
17	respectively	O	O
18	;	O	O
19	P	O	S-Disease
20	=	O	O
21	.	O	O
22	02	O	O
23	)	O	O
24	and	O	O
25	euthymia	O	O
26	(	O	O
27	61	O	O
28	%	O	O
29	vs	O	O
30	36	O	O
31	%	O	O
32	,	O	O
33	respectively	O	O
34	;	O	O
35	P	O	O
36	=	O	O
37	.	O	O
38	01	O	O
39	)	O	O
40	than	O	O
41	placebo	O	S-Disease
42	-	O	O
43	treated	O	O
44	patients	O	O
45	.	O	O

0	There	O	O
1	were	O	O
2	no	O	O
3	statistically	O	O
4	significant	O	O
5	differences	O	O
6	in	O	O
7	EPSs	S-Disease	O
8	between	O	O
9	groups	O	O
10	.	O	O

0	However	O	O
1	,	O	O
2	olanzapine	S-Chemical	S-Chemical
3	-	O	O
4	treated	O	O
5	patients	O	O
6	had	O	O
7	a	O	O
8	statistically	O	O
9	significant	O	O
10	greater	O	O
11	mean	O	O
12	(	O	O
13	+	O	O
14	/	O	O
15	-	O	O
16	SD	O	O
17	)	O	O
18	weight	B-Disease	O
19	gain	E-Disease	O
20	than	O	O
21	placebo	O	S-Disease
22	-	O	O
23	treated	O	O
24	patients	O	O
25	(	O	O
26	2	O	O
27	.	O	O
28	1	O	O
29	+	O	O
30	/	O	O
31	-	O	O
32	2	O	O
33	.	O	O
34	8	O	O
35	vs	O	O
36	0	O	O
37	.	O	O
38	45	O	O
39	+	O	O
40	/	O	O
41	-	O	O
42	2	O	O
43	.	O	O
44	3	O	O
45	kg	O	O
46	,	O	O
47	respectively	O	O
48	)	O	O
49	and	O	O
50	also	O	O
51	experienced	O	O
52	more	O	O
53	treatment	O	O
54	-	O	O
55	emergent	O	O
56	somnolence	S-Disease	S-Disease
57	(	O	O
58	21	O	O
59	patients	O	O
60	[	O	O
61	38	O	O
62	.	O	O
63	2	O	O
64	%	O	O
65	]	O	O
66	vs	O	O
67	5	O	O
68	[	O	O
69	8	O	O
70	.	O	O
71	3	O	O
72	%	O	O
73	]	O	O
74	,	O	O
75	respectively	O	O
76	)	O	O
77	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Olanzapine	S-Chemical	S-Chemical
3	demonstrated	O	O
4	greater	O	O
5	efficacy	O	O
6	than	O	O
7	placebo	O	S-Chemical
8	in	O	O
9	the	O	O
10	treatment	O	O
11	of	O	O
12	acute	O	B-Disease
13	bipolar	B-Disease	B-Disease
14	mania	E-Disease	E-Disease
15	and	O	O
16	was	O	O
17	generally	O	O
18	well	O	O
19	tolerated	O	O
20	.	O	O

0	The	O	O
1	effect	O	O
2	of	O	O
3	pupil	B-Disease	B-Disease
4	dilation	E-Disease	E-Disease
5	with	O	O
6	tropicamide	S-Chemical	S-Chemical
7	on	O	O
8	vision	O	O
9	and	O	O
10	driving	O	O
11	simulator	O	O
12	performance	O	O
13	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	To	O	O
3	assess	O	O
4	the	O	O
5	effect	O	O
6	of	O	O
7	pupil	B-Disease	B-Disease
8	dilation	E-Disease	E-Disease
9	on	O	O
10	vision	O	S-Disease
11	and	O	O
12	driving	O	O
13	ability	O	O
14	.	O	O

0	METHODS	O	O
1	:	O	O
2	A	O	O
3	series	O	O
4	of	O	O
5	tests	O	O
6	on	O	O
7	various	O	O
8	parameters	O	O
9	of	O	O
10	visual	O	O
11	function	O	E-Disease
12	and	O	O
13	driving	O	O
14	simulator	O	O
15	performance	O	O
16	were	O	O
17	performed	O	O
18	on	O	O
19	12	O	O
20	healthy	O	O
21	drivers	O	O
22	,	O	O
23	before	O	O
24	and	O	O
25	after	O	O
26	pupil	B-Disease	O
27	dilation	E-Disease	E-Disease
28	using	O	O
29	guttae	O	B-Chemical
30	tropicamide	S-Chemical	E-Chemical
31	1	O	O
32	%	O	O
33	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Pupillary	B-Disease	B-Disease
3	dilation	E-Disease	E-Disease
4	resulted	O	O
5	in	O	O
6	a	O	O
7	statistically	O	O
8	significant	O	O
9	deterioration	O	O
10	in	O	O
11	CT	O	O
12	and	O	O
13	HCVA	O	S-Disease
14	only	O	O
15	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Pupillary	B-Disease	B-Disease
3	dilation	E-Disease	E-Disease
4	may	O	O
5	lead	O	O
6	to	O	O
7	a	O	O
8	decrease	O	O
9	in	O	O
10	vision	O	O
11	and	O	O
12	daylight	O	O
13	driving	O	O
14	performance	O	O
15	in	O	O
16	young	O	O
17	people	O	O
18	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	isotretinoin	B-Disease	S-Chemical
4	embryopathy	E-Disease	O
5	with	O	O
6	bilateral	O	O
7	anotia	S-Disease	S-Disease
8	and	O	O
9	Taussig	B-Disease	S-Chemical
10	-	I-Disease	O
11	Bing	I-Disease	S-Chemical
12	malformation	E-Disease	O
13	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	newborn	O	O
4	infant	O	O
5	with	O	O
6	multiple	O	O
7	congenital	O	O
8	anomalies	O	O
9	(	O	O
10	anotia	S-Disease	S-Disease
11	and	O	O
12	Taussig	B-Disease	S-Chemical
13	-	I-Disease	I-Disease
14	Bing	I-Disease	E-Chemical
15	malformation	E-Disease	O
16	)	O	O
17	due	O	O
18	to	O	O
19	exposure	O	O
20	to	O	O
21	isotretinoin	S-Chemical	S-Chemical
22	within	O	O
23	the	O	O
24	first	O	O
25	trimester	O	O
26	.	O	O

0	In	O	O
1	this	O	O
2	paper	O	O
3	we	O	O
4	aim	O	O
5	to	O	O
6	draw	O	O
7	to	O	O
8	the	O	O
9	fact	O	O
10	that	O	O
11	caution	O	O
12	is	O	O
13	needed	O	O
14	when	O	O
15	prescribing	O	O
16	vitamin	B-Chemical	O
17	A	E-Chemical	E-Disease
18	-	O	O
19	containing	O	O
20	drugs	O	O
21	to	O	O
22	women	O	O
23	of	O	O
24	childbearing	O	O
25	years	O	O
26	.	O	O

0	Effect	O	O
1	of	O	O
2	methoxamine	S-Chemical	S-Chemical
3	on	O	O
4	maximum	O	O
5	urethral	O	S-Disease
6	pressure	O	O
7	in	O	O
8	women	O	O
9	with	O	O
10	genuine	O	O
11	stress	B-Disease	O
12	incontinence	E-Disease	O
13	:	O	O
14	a	O	O
15	placebo	O	S-Disease
16	-	O	O
17	controlled	O	O
18	,	O	O
19	double	O	O
20	-	O	O
21	blind	O	O
22	crossover	O	O
23	study	O	O
24	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	the	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	evaluate	O	O
8	the	O	O
9	potential	O	O
10	role	O	O
11	for	O	O
12	a	O	O
13	selective	O	O
14	alpha1	O	B-Disease
15	-	O	O
16	adrenoceptor	O	E-Chemical
17	agonist	O	O
18	in	O	O
19	the	O	O
20	treatment	O	O
21	of	O	O
22	urinary	B-Disease	B-Disease
23	stress	I-Disease	I-Disease
24	incontinence	E-Disease	E-Disease
25	.	O	O

0	Half	O	O
1	log	O	O
2	incremental	O	O
3	doses	O	O
4	of	O	O
5	intravenous	O	O
6	methoxamine	S-Chemical	S-Chemical
7	or	O	O
8	placebo	O	S-Disease
9	(	O	O
10	saline	O	S-Chemical
11	)	O	O
12	were	O	O
13	administered	O	O
14	to	O	O
15	a	O	O
16	group	O	O
17	of	O	O
18	women	O	O
19	with	O	O
20	genuine	O	O
21	stress	B-Disease	S-Disease
22	incontinence	E-Disease	O
23	while	O	O
24	measuring	O	O
25	maximum	O	O
26	urethral	O	S-Disease
27	pressure	O	O
28	(	O	O
29	MUP	O	S-Chemical
30	)	O	O
31	,	O	O
32	blood	O	O
33	pressure	O	O
34	,	O	O
35	heart	O	O
36	rate	O	O
37	,	O	O
38	and	O	O
39	symptomatic	O	O
40	side	O	O
41	effects	O	O
42	.	O	O

0	Methoxamine	S-Chemical	S-Chemical
1	evoked	O	O
2	non	O	O
3	-	O	O
4	significant	O	O
5	increases	O	O
6	in	O	O
7	MUP	O	S-Disease
8	and	O	O
9	diastolic	O	B-Disease
10	blood	O	I-Disease
11	pressure	O	E-Disease
12	but	O	O
13	caused	O	O
14	a	B-Disease	O
15	significant	I-Disease	O
16	rise	I-Disease	O
17	in	I-Disease	O
18	systolic	I-Disease	B-Disease
19	blood	I-Disease	I-Disease
20	pressure	E-Disease	E-Disease
21	and	O	O
22	significant	O	O
23	fall	O	O
24	in	O	O
25	heart	O	S-Disease
26	rate	O	O
27	at	O	O
28	maximum	O	O
29	dosage	O	O
30	.	O	O

0	Systemic	O	O
1	side	O	O
2	effects	O	O
3	including	O	O
4	piloerection	O	S-Disease
5	,	O	O
6	headache	S-Disease	S-Disease
7	,	O	O
8	and	O	O
9	cold	O	S-Disease
10	extremities	O	O
11	were	O	O
12	experienced	O	O
13	in	O	O
14	all	O	O
15	subjects	O	O
16	.	O	O

0	The	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	the	O	O
5	clinical	O	O
6	usefulness	O	O
7	of	O	O
8	direct	O	O
9	,	O	O
10	peripherally	O	O
11	acting	O	O
12	sub	O	O
13	-	O	O
14	type	O	O
15	-	O	O
16	selective	O	O
17	alpha1	O	B-Chemical
18	-	O	O
19	adrenoceptor	O	E-Chemical
20	agonists	O	O
21	in	O	O
22	the	O	O
23	medical	O	O
24	treatment	O	O
25	of	O	O
26	stress	B-Disease	B-Disease
27	incontinence	E-Disease	O
28	may	O	O
29	be	O	O
30	limited	O	O
31	by	O	O
32	associated	O	O
33	piloerection	O	O
34	and	O	O
35	cardiovascular	O	O
36	side	O	O
37	effects	O	O
38	.	O	O

0	Hyperglycemic	S-Disease	O
1	effect	O	O
2	of	O	O
3	amino	S-Chemical	S-Disease
4	compounds	O	O
5	structurally	O	O
6	related	O	O
7	to	O	O
8	caproate	S-Chemical	S-Chemical
9	in	O	O
10	rats	O	O
11	.	O	O

0	The	O	O
1	chronic	O	O
2	feeding	O	O
3	of	O	O
4	small	O	O
5	amounts	O	O
6	(	O	O
7	0	O	O
8	.	O	O
9	3	O	O
10	-	O	O
11	3	O	O
12	%	O	O
13	of	O	O
14	diet	O	O
15	weight	O	O
16	)	O	O
17	of	O	O
18	certain	O	O
19	amino	S-Chemical	O
20	derivatives	O	O
21	of	O	O
22	caproate	S-Chemical	S-Chemical
23	resulted	O	O
24	in	O	O
25	hyperglycemia	S-Disease	S-Disease
26	,	O	O
27	an	O	O
28	elevated	O	O
29	glucose	S-Chemical	B-Disease
30	tolerance	O	E-Disease
31	curve	O	O
32	and	O	O
33	,	O	O
34	occasionally	O	O
35	,	O	O
36	glucosuria	S-Disease	S-Chemical
37	.	O	O

0	Effective	O	O
1	compounds	O	O
2	included	O	O
3	norleucine	S-Chemical	S-Chemical
4	,	O	O
5	norvaline	S-Chemical	S-Chemical
6	,	O	O
7	glutamate	S-Chemical	S-Chemical
8	,	O	O
9	epsilon	B-Chemical	S-Chemical
10	-	I-Chemical	O
11	aminocaproate	E-Chemical	S-Chemical
12	,	O	O
13	methionine	S-Chemical	S-Chemical
14	,	O	O
15	and	O	O
16	leucine	S-Chemical	S-Chemical
17	.	O	O

0	Toleration	O	O
1	of	O	O
2	high	O	O
3	doses	O	O
4	of	O	O
5	angiotensin	B-Chemical	O
6	-	I-Chemical	O
7	converting	I-Chemical	O
8	enzyme	I-Chemical	O
9	inhibitors	E-Chemical	O
10	in	O	O
11	patients	O	O
12	with	O	O
13	chronic	O	B-Disease
14	heart	B-Disease	I-Disease
15	failure	E-Disease	E-Disease
16	:	O	O
17	results	O	O
18	from	O	O
19	the	O	O
20	ATLAS	O	S-Disease
21	trial	O	O
22	.	O	O

0	The	O	O
1	Assessment	O	O
2	of	O	O
3	Treatment	O	O
4	with	O	O
5	Lisinopril	S-Chemical	S-Chemical
6	and	O	O
7	Survival	O	S-Disease
8	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Treatment	O	O
3	with	O	O
4	angiotensin	B-Chemical	O
5	-	I-Chemical	O
6	converting	I-Chemical	O
7	enzyme	I-Chemical	O
8	(	I-Chemical	O
9	ACE	I-Chemical	S-Chemical
10	)	I-Chemical	O
11	inhibitors	E-Chemical	O
12	reduces	O	O
13	mortality	O	O
14	and	O	O
15	morbidity	O	O
16	in	O	O
17	patients	O	O
18	with	O	O
19	chronic	O	B-Disease
20	heart	B-Disease	I-Disease
21	failure	E-Disease	E-Disease
22	(	O	O
23	CHF	S-Disease	S-Chemical
24	)	O	O
25	,	O	O
26	but	O	O
27	most	O	O
28	affected	O	O
29	patients	O	O
30	are	O	O
31	not	O	O
32	receiving	O	O
33	these	O	O
34	agents	O	O
35	or	O	O
36	are	O	O
37	being	O	O
38	treated	O	O
39	with	O	O
40	doses	O	O
41	lower	O	O
42	than	O	O
43	those	O	O
44	found	O	O
45	to	O	O
46	be	O	O
47	efficacious	O	O
48	in	O	O
49	trials	O	O
50	,	O	O
51	primarily	O	O
52	because	O	O
53	of	O	O
54	concerns	O	O
55	about	O	O
56	the	O	O
57	safety	O	O
58	and	O	O
59	tolerability	O	O
60	of	O	O
61	these	O	O
62	agents	O	O
63	,	O	O
64	especially	O	O
65	at	O	O
66	the	O	O
67	recommended	O	O
68	doses	O	O
69	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	examines	O	O
4	the	O	O
5	safety	O	O
6	and	O	O
7	tolerability	O	O
8	of	O	O
9	high	O	O
10	-	O	O
11	compared	O	O
12	with	O	O
13	low	O	O
14	-	O	O
15	dose	O	O
16	lisinopril	S-Chemical	S-Chemical
17	in	O	O
18	CHF	S-Disease	S-Disease
19	.	O	O

0	METHODS	O	O
1	:	O	O
2	The	O	O
3	Assessment	O	O
4	of	O	O
5	Lisinopril	S-Chemical	S-Chemical
6	and	O	O
7	Survival	O	O
8	study	O	O
9	was	O	O
10	a	O	O
11	multicenter	O	O
12	,	O	O
13	randomized	O	O
14	,	O	O
15	double	O	O
16	-	O	O
17	blind	O	O
18	trial	O	O
19	in	O	O
20	which	O	O
21	patients	O	O
22	with	O	O
23	or	O	O
24	without	O	O
25	previous	O	O
26	ACE	B-Chemical	S-Chemical
27	inhibitor	E-Chemical	O
28	treatment	O	O
29	were	O	O
30	stabilized	O	O
31	receiving	O	O
32	medium	O	O
33	-	O	O
34	dose	O	O
35	lisinopril	S-Chemical	S-Chemical
36	(	O	O
37	12	O	O
38	.	O	O
39	5	O	O
40	or	O	O
41	15	O	O
42	.	O	O
43	0	O	O
44	mg	O	O
45	once	O	O
46	daily	O	O
47	[	O	O
48	OD	O	S-Chemical
49	]	O	O
50	)	O	O
51	for	O	O
52	2	O	O
53	to	O	O
54	4	O	O
55	weeks	O	O
56	and	O	O
57	then	O	O
58	randomized	O	O
59	to	O	O
60	high	O	O
61	-	O	O
62	(	O	O
63	35	O	O
64	.	O	O
65	0	O	O
66	or	O	O
67	32	O	O
68	.	O	O
69	5	O	O
70	mg	O	O
71	OD	O	S-Chemical
72	)	O	O
73	or	O	O
74	low	O	O
75	-	O	O
76	dose	O	O
77	(	O	O
78	5	O	O
79	.	O	O
80	0	O	O
81	or	O	O
82	2	O	O
83	.	O	O
84	5	O	O
85	mg	O	O
86	OD	O	S-Chemical
87	)	O	O
88	groups	O	O
89	.	O	O

0	Patients	O	O
1	with	O	O
2	New	O	B-Disease
3	York	O	I-Disease
4	Heart	O	I-Disease
5	Association	O	E-Disease
6	classes	O	O
7	II	O	O
8	to	O	O
9	IV	O	O
10	CHF	S-Disease	S-Disease
11	and	O	O
12	left	O	O
13	ventricular	O	B-Disease
14	ejection	O	E-Disease
15	fractions	O	O
16	of	O	O
17	no	O	O
18	greater	O	O
19	than	O	O
20	0	O	O
21	.	O	O
22	30	O	O
23	(	O	O
24	n	O	O
25	=	O	O
26	3164	O	O
27	)	O	O
28	were	O	O
29	randomized	O	O
30	and	O	O
31	followed	O	O
32	up	O	O
33	for	O	O
34	a	O	O
35	median	O	O
36	of	O	O
37	46	O	O
38	months	O	O
39	.	O	O

0	We	O	O
1	examined	O	O
2	the	O	O
3	occurrence	O	O
4	of	O	O
5	adverse	O	O
6	events	O	O
7	and	O	O
8	the	O	O
9	need	O	O
10	for	O	O
11	discontinuation	O	O
12	and	O	O
13	dose	O	O
14	reduction	O	O
15	during	O	O
16	treatment	O	O
17	,	O	O
18	with	O	O
19	a	O	O
20	focus	O	O
21	on	O	O
22	hypotension	S-Disease	S-Disease
23	and	O	O
24	renal	B-Disease	B-Disease
25	dysfunction	E-Disease	E-Disease
26	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Of	O	O
3	405	O	O
4	patients	O	O
5	not	O	O
6	previously	O	O
7	receiving	O	O
8	an	O	O
9	ACE	B-Chemical	S-Chemical
10	inhibitor	E-Chemical	O
11	,	O	O
12	doses	O	O
13	in	O	O
14	only	O	O
15	4	O	O
16	.	O	O
17	2	O	O
18	%	O	O
19	could	O	O
20	not	O	O
21	be	O	O
22	titrated	O	O
23	to	O	O
24	the	O	O
25	medium	O	O
26	doses	O	O
27	required	O	O
28	for	O	O
29	randomization	O	O
30	because	O	O
31	of	O	O
32	symptoms	O	O
33	possibly	O	O
34	related	O	O
35	to	O	O
36	hypotension	S-Disease	S-Disease
37	(	O	O
38	2	O	O
39	.	O	O
40	0	O	O
41	%	O	O
42	)	O	O
43	or	O	O
44	because	O	O
45	of	O	O
46	renal	B-Disease	B-Disease
47	dysfunction	E-Disease	E-Disease
48	or	O	O
49	hyperkalemia	S-Disease	S-Disease
50	(	O	O
51	2	O	O
52	.	O	O
53	3	O	O
54	%	O	O
55	)	O	O
56	.	O	O

0	Subgroups	O	O
1	presumed	O	O
2	to	O	O
3	be	O	O
4	at	O	O
5	higher	O	O
6	risk	O	O
7	for	O	O
8	ACE	B-Chemical	S-Chemical
9	inhibitor	E-Chemical	O
10	intolerance	O	O
11	(	O	O
12	blood	O	O
13	pressure	O	O
14	,	O	O
15	<	O	O
16	120	O	O
17	mm	O	O
18	Hg	O	O
19	;	O	O
20	creatinine	S-Chemical	S-Chemical
21	,	O	O
22	>	O	O
23	or	O	O
24	=	O	O
25	132	O	O
26	.	O	O
27	6	O	O
28	micromol	O	O
29	/	O	O
30	L	O	O
31	[	O	O
32	>	O	O
33	or	O	O
34	=	O	O
35	1	O	O
36	.	O	O
37	5	O	O
38	mg	O	O
39	/	O	O
40	dL	O	O
41	]	O	O
42	;	O	O
43	age	O	O
44	,	O	O
45	>	O	O
46	or	O	O
47	=	O	O
48	70	O	O
49	years	O	O
50	;	O	O
51	and	O	O
52	patients	O	O
53	with	O	O
54	diabetes	S-Disease	S-Disease
55	)	O	O
56	generally	O	O
57	tolerated	O	O
58	the	O	O
59	high	O	O
60	-	O	O
61	dose	O	O
62	strategy	O	O
63	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	These	O	O
3	findings	O	O
4	demonstrate	O	O
5	that	O	O
6	ACE	B-Chemical	S-Chemical
7	inhibitor	E-Chemical	O
8	therapy	O	O
9	in	O	O
10	most	O	O
11	patients	O	O
12	with	O	O
13	CHF	S-Disease	S-Chemical
14	can	O	O
15	be	O	O
16	successfully	O	O
17	titrated	O	O
18	to	O	O
19	and	O	O
20	maintained	O	O
21	at	O	O
22	high	O	O
23	doses	O	O
24	,	O	O
25	and	O	O
26	that	O	O
27	more	O	O
28	aggressive	O	O
29	use	O	O
30	of	O	O
31	these	O	O
32	agents	O	O
33	is	O	O
34	warranted	O	O
35	.	O	O

0	Cocaine	S-Chemical	S-Chemical
1	,	O	O
2	ethanol	S-Chemical	O
3	,	O	O
4	and	O	O
5	cocaethylene	S-Chemical	S-Chemical
6	cardiotoxity	S-Disease	E-Chemical
7	in	O	O
8	an	O	O
9	animal	O	O
10	model	O	O
11	of	O	O
12	cocaine	B-Disease	S-Disease
13	and	I-Disease	O
14	ethanol	I-Disease	S-Disease
15	abuse	E-Disease	O
16	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	Simultaneous	O	O
3	abuse	B-Disease	O
4	of	I-Disease	O
5	cocaine	I-Disease	S-Chemical
6	and	I-Disease	O
7	ethanol	E-Disease	S-Disease
8	affects	O	O
9	12	O	O
10	million	O	O
11	Americans	O	O
12	annually	O	O
13	.	O	O

0	Their	O	O
1	combined	O	O
2	cardiac	B-Disease	B-Disease
3	toxicity	E-Disease	E-Disease
4	may	O	O
5	be	O	O
6	due	O	O
7	to	O	O
8	independent	O	O
9	effects	O	O
10	of	O	O
11	each	O	O
12	drug	O	O
13	;	O	O
14	however	O	O
15	,	O	O
16	they	O	O
17	may	O	O
18	also	O	O
19	be	O	O
20	due	O	O
21	to	O	O
22	cocaethylene	S-Chemical	S-Chemical
23	(	O	O
24	CE	S-Chemical	S-Disease
25	)	O	O
26	,	O	O
27	a	O	O
28	cocaine	S-Chemical	S-Chemical
29	metabolite	O	O
30	formed	O	O
31	only	O	O
32	in	O	O
33	the	O	O
34	presence	O	O
35	of	O	O
36	ethanol	S-Chemical	O
37	.	O	O

0	The	O	O
1	purpose	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	delineate	O	O
8	the	O	O
9	role	O	O
10	of	O	O
11	CE	S-Chemical	S-Chemical
12	in	O	O
13	the	O	O
14	combined	O	O
15	cardiotoxicity	S-Disease	S-Disease
16	of	O	O
17	cocaine	S-Chemical	S-Chemical
18	and	O	O
19	ethanol	S-Chemical	S-Disease
20	in	O	O
21	a	O	O
22	model	O	O
23	simulating	O	O
24	their	O	O
25	abuse	O	O
26	.	O	O

0	METHODS	O	O
1	:	O	O
2	Twenty	O	O
3	-	O	O
4	three	O	O
5	dogs	O	O
6	were	O	O
7	randomized	O	O
8	to	O	O
9	receive	O	O
10	either	O	O
11	1	O	O
12	)	O	O
13	three	O	O
14	intravenous	O	O
15	(	O	O
16	IV	O	O
17	)	O	O
18	boluses	O	O
19	of	O	O
20	cocaine	S-Chemical	S-Chemical
21	7	O	O
22	.	O	O
23	5	O	O
24	mg	O	O
25	/	O	O
26	kg	O	O
27	with	O	O
28	ethanol	S-Chemical	O
29	(	O	O
30	1	O	O
31	g	O	O
32	/	O	O
33	kg	O	O
34	)	O	O
35	as	O	O
36	an	O	O
37	IV	O	O
38	infusion	O	O
39	(	O	O
40	C	O	S-Disease
41	+	O	O
42	E	O	O
43	,	O	O
44	n	O	O
45	=	O	O
46	8	O	O
47	)	O	O
48	,	O	O
49	2	O	O
50	)	O	O
51	three	O	O
52	cocaine	S-Chemical	S-Chemical
53	boluses	O	O
54	only	O	O
55	(	O	O
56	C	O	S-Chemical
57	,	O	O
58	n	O	O
59	=	O	O
60	6	O	O
61	)	O	O
62	,	O	O
63	3	O	O
64	)	O	O
65	ethanol	S-Chemical	O
66	infusion	O	O
67	only	O	O
68	(	O	O
69	E	O	O
70	,	O	O
71	n	O	O
72	=	O	O
73	5	O	O
74	)	O	O
75	,	O	O
76	or	O	O
77	4	O	O
78	)	O	O
79	placebo	O	S-Disease
80	boluses	O	S-Disease
81	and	O	O
82	infusion	O	O
83	(	O	O
84	n	O	O
85	=	O	O
86	4	O	O
87	)	O	O
88	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Two	O	O
3	of	O	O
4	eight	O	O
5	dogs	O	O
6	in	O	O
7	the	O	O
8	C	O	S-Chemical
9	+	O	O
10	E	O	O
11	group	O	O
12	experienced	O	O
13	cardiovascular	B-Disease	B-Disease
14	collapse	E-Disease	E-Disease
15	.	O	O

0	The	O	O
1	most	O	O
2	dramatic	O	O
3	hemodynamic	O	O
4	changes	O	O
5	occurred	O	O
6	after	O	O
7	each	O	O
8	cocaine	S-Chemical	S-Chemical
9	bolus	O	E-Chemical
10	in	O	O
11	the	O	O
12	C	O	O
13	+	O	O
14	E	O	O
15	and	O	O
16	C	O	O
17	only	O	O
18	groups	O	O
19	;	O	O
20	however	O	O
21	,	O	O
22	persistent	O	O
23	hemodynamic	O	O
24	changes	O	O
25	occurred	O	O
26	in	O	O
27	the	O	O
28	C	O	O
29	+	O	O
30	E	O	O
31	group	O	O
32	.	O	O

0	Peak	O	O
1	CE	S-Chemical	S-Disease
2	levels	O	O
3	were	O	O
4	associated	O	O
5	with	O	O
6	a	O	O
7	45	O	O
8	%	O	O
9	(	O	O
10	SD	O	O
11	+	O	O
12	/	O	O
13	-	O	O
14	22	O	O
15	%	O	O
16	,	O	O
17	95	O	O
18	%	O	O
19	CI	O	S-Chemical
20	=	O	O
21	22	O	O
22	%	O	O
23	to	O	O
24	69	O	O
25	%	O	O
26	)	O	O
27	decrease	B-Disease	O
28	in	I-Disease	O
29	cardiac	I-Disease	B-Disease
30	output	E-Disease	E-Disease
31	(	O	O
32	p	O	O
33	<	O	O
34	0	O	O
35	.	O	O
36	05	O	O
37	)	O	O
38	,	O	O
39	a	O	O
40	56	O	O
41	%	O	O
42	(	O	O
43	SD	O	O
44	+	O	O
45	/	O	O
46	-	O	O
47	23	O	O
48	%	O	O
49	,	O	O
50	95	O	O
51	%	O	O
52	CI	O	S-Disease
53	=	O	O
54	32	O	O
55	%	O	O
56	to	O	O
57	80	O	O
58	%	O	O
59	)	O	O
60	decrease	O	O
61	in	O	O
62	dP	O	O
63	/	O	O
64	dt	O	O
65	(	O	O
66	max	O	O
67	)	O	O
68	(	O	O
69	p	O	O
70	<	O	O
71	.	O	O
72	006	O	O
73	)	O	O
74	,	O	O
75	and	O	O
76	a	O	O
77	23	O	O
78	%	O	O
79	(	O	O
80	SD	O	O
81	+	O	O
82	/	O	O
83	-	O	O
84	15	O	O
85	%	O	O
86	,	O	O
87	95	O	O
88	%	O	O
89	CI	O	S-Chemical
90	=	O	O
91	7	O	O
92	%	O	O
93	to	O	O
94	49	O	O
95	%	O	O
96	)	O	O
97	decrease	O	O
98	in	O	O
99	SVO	O	S-Disease
100	(	O	O
101	2	O	O
102	)	O	O
103	(	O	O
104	p	O	O
105	<	O	O
106	0	O	O
107	.	O	O
108	025	O	O
109	)	O	O
110	.	O	O

0	Ventricular	B-Disease	O
1	arrhythmias	E-Disease	S-Disease
2	were	O	O
3	primarily	O	O
4	observed	O	O
5	in	O	O
6	the	O	O
7	C	O	O
8	+	O	O
9	E	O	O
10	group	O	O
11	,	O	O
12	in	O	O
13	which	O	O
14	four	O	O
15	of	O	O
16	eight	O	O
17	dogs	O	O
18	experienced	O	O
19	ventricular	B-Disease	B-Disease
20	tachycardia	E-Disease	E-Disease
21	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Cocaine	S-Chemical	S-Chemical
3	and	O	O
4	ethanol	S-Chemical	S-Disease
5	in	O	O
6	combination	O	O
7	were	O	O
8	more	O	O
9	toxic	O	O
10	than	O	O
11	either	O	O
12	substance	O	O
13	alone	O	O
14	.	O	O

0	Co	O	O
1	-	O	O
2	administration	O	O
3	resulted	O	O
4	in	O	O
5	prolonged	O	O
6	cardiac	B-Disease	B-Disease
7	toxicity	E-Disease	E-Disease
8	and	O	O
9	was	O	O
10	dysrhythmogenic	O	S-Disease
11	.	O	O

0	Peak	O	O
1	serum	O	O
2	cocaethylene	S-Chemical	S-Chemical
3	concentrations	O	O
4	were	O	O
5	associated	O	O
6	with	O	O
7	prolonged	O	O
8	myocardial	B-Disease	B-Disease
9	depression	E-Disease	E-Disease
10	.	O	O

0	Worsening	O	O
1	of	O	O
2	Parkinsonism	S-Disease	S-Disease
3	after	O	O
4	the	O	O
5	use	O	O
6	of	O	O
7	veralipride	S-Chemical	S-Chemical
8	for	O	O
9	treatment	O	O
10	of	O	O
11	menopause	O	S-Disease
12	:	O	O
13	case	O	O
14	report	O	O
15	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	female	O	O
4	patient	O	O
5	with	O	O
6	stable	O	O
7	Parkinson	B-Disease	B-Disease
8	'	I-Disease	I-Disease
9	s	I-Disease	I-Disease
10	disease	E-Disease	E-Disease
11	who	O	O
12	has	O	O
13	shown	O	O
14	a	O	O
15	marked	O	O
16	worsening	O	O
17	of	O	O
18	her	O	O
19	motor	O	B-Disease
20	functions	O	E-Disease
21	following	O	O
22	therapy	O	O
23	of	O	O
24	menopause	O	S-Disease
25	related	O	O
26	symptoms	O	O
27	with	O	O
28	veralipride	S-Chemical	S-Chemical
29	,	O	O
30	as	O	O
31	well	O	O
32	as	O	O
33	the	O	O
34	improvement	O	O
35	of	O	O
36	her	O	O
37	symptoms	O	O
38	back	O	O
39	to	O	O
40	baseline	O	O
41	after	O	O
42	discontinuation	O	O
43	of	O	O
44	the	O	O
45	drug	O	O
46	.	O	O

0	We	O	O
1	emphasize	O	O
2	the	O	O
3	anti	O	O
4	-	O	O
5	dopaminergic	O	S-Disease
6	effect	O	O
7	of	O	O
8	veralipride	S-Chemical	S-Chemical
9	.	O	O

0	Viracept	S-Chemical	O
1	and	O	O
2	irregular	B-Disease	O
3	heartbeat	E-Disease	O
4	warning	O	O
5	.	O	O

0	A	O	O
1	group	O	O
2	of	O	O
3	doctors	O	O
4	in	O	O
5	Boston	O	O
6	warn	O	O
7	that	O	O
8	the	O	O
9	protease	O	O
10	inhibitor	O	O
11	Viracept	S-Chemical	S-Chemical
12	may	O	O
13	cause	O	O
14	an	O	O
15	irregular	B-Disease	O
16	heart	I-Disease	B-Disease
17	beat	E-Disease	E-Disease
18	,	O	O
19	known	O	O
20	as	O	O
21	bradycardia	S-Disease	S-Disease
22	,	O	O
23	in	O	O
24	people	O	O
25	with	O	O
26	HIV	O	S-Chemical
27	.	O	O

0	Bradycardia	S-Disease	S-Disease
1	occurred	O	O
2	in	O	O
3	a	O	O
4	45	O	O
5	-	O	O
6	year	O	O
7	-	O	O
8	old	O	O
9	male	O	O
10	patient	O	O
11	who	O	O
12	was	O	O
13	Viracept	S-Chemical	S-Chemical
14	in	O	O
15	combination	O	O
16	with	O	O
17	other	O	O
18	anti	O	O
19	-	O	I-Disease
20	HIV	O	E-Disease
21	drugs	O	O
22	.	O	O

0	Frequency	O	O
1	of	O	O
2	appearance	O	O
3	of	O	O
4	myeloperoxidase	O	S-Chemical
5	-	O	O
6	antineutrophil	O	O
7	cytoplasmic	O	E-Chemical
8	antibody	O	O
9	(	O	O
10	MPO	O	S-Chemical
11	-	O	I-Disease
12	ANCA	O	E-Chemical
13	)	O	O
14	in	O	O
15	Graves	B-Disease	B-Disease
16	'	I-Disease	I-Disease
17	disease	E-Disease	E-Disease
18	patients	O	O
19	treated	O	O
20	with	O	O
21	propylthiouracil	S-Chemical	S-Chemical
22	and	O	O
23	the	O	O
24	relationship	O	O
25	between	O	O
26	MPO	O	S-Chemical
27	-	O	I-Disease
28	ANCA	O	E-Chemical
29	and	O	O
30	clinical	O	O
31	manifestations	O	O
32	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	Myeloperoxidase	O	S-Chemical
3	antineutrophil	O	O
4	cytoplasmic	O	I-Disease
5	antibody	O	O
6	(	O	O
7	MPO	O	S-Chemical
8	-	O	I-Disease
9	ANCA	O	E-Chemical
10	)	O	E-Disease
11	-	O	O
12	positive	O	O
13	vasculitis	S-Disease	S-Disease
14	has	O	O
15	been	O	O
16	reported	O	O
17	in	O	O
18	patients	O	O
19	with	O	O
20	Graves	B-Disease	B-Disease
21	'	I-Disease	I-Disease
22	disease	E-Disease	E-Disease
23	who	O	O
24	were	O	O
25	treated	O	O
26	with	O	O
27	propylthiouracil	S-Chemical	S-Chemical
28	(	O	O
29	PTU	S-Chemical	S-Disease
30	)	O	O
31	.	O	O

0	The	O	O
1	appearance	O	O
2	of	O	O
3	MPO	O	B-Chemical
4	-	O	I-Chemical
5	ANCA	O	E-Chemical
6	in	O	O
7	these	O	O
8	cases	O	O
9	was	O	O
10	suspected	O	O
11	of	O	O
12	being	O	O
13	related	O	O
14	to	O	O
15	PTU	S-Chemical	S-Disease
16	because	O	O
17	the	O	O
18	titres	O	S-Disease
19	of	O	O
20	MPO	O	S-Chemical
21	-	O	I-Disease
22	ANCA	O	E-Chemical
23	decreased	O	O
24	when	O	O
25	PTU	S-Chemical	S-Chemical
26	was	O	O
27	stopped	O	O
28	.	O	O

0	Nevertheless	O	O
1	,	O	O
2	there	O	O
3	have	O	O
4	been	O	O
5	no	O	O
6	studies	O	O
7	on	O	O
8	the	O	O
9	temporal	O	O
10	relationship	O	O
11	between	O	O
12	the	O	O
13	appearance	O	O
14	of	O	O
15	MPO	O	B-Chemical
16	-	O	I-Disease
17	ANCA	O	E-Chemical
18	and	O	O
19	vasculitis	S-Disease	S-Disease
20	during	O	O
21	PTU	S-Chemical	S-Disease
22	therapy	O	O
23	,	O	O
24	or	O	O
25	on	O	O
26	the	O	O
27	incidence	O	O
28	of	O	O
29	MPO	O	B-Chemical
30	-	O	I-Disease
31	ANCA	O	E-Chemical
32	in	O	O
33	untreated	O	O
34	Graves	B-Disease	B-Disease
35	'	I-Disease	I-Disease
36	disease	E-Disease	E-Disease
37	patients	O	O
38	.	O	O

0	Therefore	O	O
1	,	O	O
2	we	O	O
3	sought	O	O
4	to	O	O
5	address	O	O
6	these	O	O
7	parameters	O	O
8	in	O	O
9	patients	O	O
10	with	O	O
11	Graves	B-Disease	B-Disease
12	'	I-Disease	I-Disease
13	disease	E-Disease	E-Disease
14	.	O	O

0	PATIENTS	O	O
1	:	O	O
2	We	O	O
3	investigated	O	O
4	102	O	O
5	untreated	O	O
6	patients	O	O
7	with	O	O
8	hyperthyroidism	S-Disease	S-Disease
9	due	O	O
10	to	O	O
11	Graves	B-Disease	B-Disease
12	'	I-Disease	I-Disease
13	disease	E-Disease	E-Disease
14	for	O	O
15	the	O	O
16	presence	O	O
17	of	O	O
18	MPO	O	B-Chemical
19	-	O	I-Disease
20	ANCA	O	E-Chemical
21	,	O	O
22	and	O	O
23	for	O	O
24	the	O	O
25	development	O	O
26	vasculitis	S-Disease	S-Disease
27	after	O	O
28	starting	O	O
29	PTU	S-Chemical	S-Disease
30	therapy	O	O
31	.	O	O

0	Twenty	O	O
1	-	O	O
2	nine	O	O
3	of	O	O
4	them	O	O
5	were	O	O
6	later	O	O
7	excluded	O	O
8	because	O	O
9	of	O	O
10	adverse	O	O
11	effects	O	O
12	of	O	O
13	PTU	S-Chemical	S-Chemical
14	or	O	O
15	because	O	O
16	the	O	O
17	observation	O	O
18	period	O	O
19	was	O	O
20	less	O	O
21	than	O	O
22	3	O	O
23	months	O	O
24	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Before	O	O
3	treatment	O	O
4	,	O	O
5	the	O	O
6	MPO	O	S-Chemical
7	-	O	I-Disease
8	ANCA	O	E-Chemical
9	titres	O	E-Disease
10	of	O	O
11	all	O	O
12	102	O	O
13	untreated	O	O
14	Graves	B-Disease	B-Disease
15	'	I-Disease	I-Disease
16	disease	E-Disease	E-Disease
17	patients	O	O
18	were	O	O
19	within	O	O
20	the	O	O
21	reference	O	O
22	range	O	O
23	(	O	O
24	below	O	O
25	10	O	O
26	U	O	O
27	/	O	O
28	ml	O	O
29	)	O	O
30	.	O	O

0	Three	O	O
1	(	O	O
2	4	O	O
3	.	O	O
4	1	O	O
5	%	O	O
6	)	O	O
7	of	O	O
8	the	O	O
9	73	O	O
10	patients	O	O
11	were	O	O
12	positive	O	O
13	for	O	O
14	MPO	O	B-Chemical
15	-	O	I-Disease
16	ANCA	O	E-Chemical
17	at	O	O
18	13	O	O
19	,	O	O
20	16	O	O
21	and	O	O
22	17	O	O
23	months	O	O
24	,	O	O
25	respectively	O	O
26	,	O	O
27	after	O	O
28	the	O	O
29	start	O	O
30	of	O	O
31	PTU	S-Chemical	S-Disease
32	therapy	O	O
33	.	O	O

0	In	O	O
1	two	O	O
2	of	O	O
3	them	O	O
4	,	O	O
5	the	O	O
6	MPO	O	S-Chemical
7	-	O	I-Disease
8	ANCA	O	E-Chemical
9	titres	O	O
10	transiently	O	O
11	increased	O	O
12	to	O	O
13	12	O	O
14	.	O	O
15	8	O	O
16	and	O	O
17	15	O	O
18	.	O	O
19	0	O	O
20	U	O	O
21	/	O	O
22	ml	O	O
23	,	O	O
24	respectively	O	O
25	,	O	O
26	despite	O	O
27	continued	O	O
28	PTU	S-Chemical	S-Disease
29	therapy	O	O
30	,	O	O
31	but	O	O
32	no	O	O
33	vasculitic	B-Disease	S-Disease
34	disorders	E-Disease	S-Disease
35	developed	O	O
36	.	O	O

0	In	O	O
1	the	O	O
2	third	O	O
3	patient	O	O
4	,	O	O
5	the	O	O
6	MPO	O	B-Chemical
7	-	O	I-Chemical
8	ANCA	O	I-Disease
9	titre	O	S-Disease
10	increased	O	O
11	to	O	O
12	204	O	O
13	U	O	O
14	/	O	O
15	ml	O	O
16	and	O	O
17	she	O	O
18	developed	O	O
19	a	O	O
20	higher	O	O
21	fever	S-Disease	S-Disease
22	,	O	O
23	oral	B-Disease	O
24	ulcers	E-Disease	S-Disease
25	and	O	O
26	polyarthralgia	S-Disease	S-Disease
27	,	O	O
28	but	O	O
29	the	O	O
30	symptoms	O	O
31	resolved	O	O
32	2	O	O
33	weeks	O	O
34	after	O	O
35	stopping	O	O
36	PTU	S-Chemical	S-Disease
37	therapy	O	O
38	,	O	O
39	and	O	O
40	the	O	O
41	MPO	O	B-Chemical
42	-	O	I-Chemical
43	ANCA	O	E-Chemical
44	titre	O	S-Disease
45	decreased	O	O
46	to	O	O
47	20	O	O
48	.	O	O
49	7	O	O
50	U	O	O
51	/	O	O
52	ml	O	O
53	by	O	O
54	4	O	O
55	months	O	O
56	after	O	O
57	discontinuing	O	O
58	PTU	S-Chemical	S-Disease
59	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	PTU	S-Chemical	S-Disease
3	therapy	O	O
4	may	O	O
5	be	O	O
6	related	O	O
7	to	O	O
8	the	O	O
9	appearance	O	O
10	of	O	O
11	MPO	O	B-Chemical
12	-	O	I-Disease
13	ANCA	O	E-Chemical
14	,	O	O
15	but	O	O
16	MPO	O	S-Chemical
17	-	O	I-Disease
18	ANCA	O	E-Chemical
19	does	O	O
20	not	O	O
21	appear	O	O
22	to	O	O
23	be	O	O
24	closely	O	O
25	related	O	O
26	to	O	O
27	vasculitis	S-Disease	S-Disease
28	.	O	O

0	Prevalence	O	O
1	of	O	O
2	heart	B-Disease	B-Disease
3	disease	E-Disease	E-Disease
4	in	O	O
5	asymptomatic	O	O
6	chronic	O	B-Disease
7	cocaine	S-Chemical	E-Disease
8	users	O	O
9	.	O	O

0	To	O	O
1	determine	O	O
2	the	O	O
3	prevalence	O	O
4	of	O	O
5	heart	B-Disease	B-Disease
6	disease	E-Disease	E-Disease
7	in	O	O
8	outpatient	O	O
9	young	O	O
10	asymptomatic	O	O
11	chronic	O	B-Disease
12	cocaine	S-Chemical	E-Disease
13	users	O	O
14	,	O	O
15	35	O	O
16	cocaine	S-Chemical	S-Disease
17	users	O	O
18	and	O	O
19	32	O	O
20	age	O	O
21	-	O	O
22	matched	O	O
23	controls	O	O
24	underwent	O	O
25	resting	O	O
26	and	O	O
27	exercise	O	O
28	electrocardiography	O	O
29	(	O	O
30	ECG	O	S-Chemical
31	)	O	O
32	and	O	O
33	Doppler	O	S-Disease
34	echocardiography	O	O
35	.	O	O

0	Findings	O	O
1	consistent	O	O
2	with	O	O
3	coronary	B-Disease	B-Disease
4	artery	I-Disease	I-Disease
5	disease	E-Disease	E-Disease
6	were	O	O
7	detected	O	O
8	in	O	O
9	12	O	O
10	(	O	O
11	34	O	O
12	%	O	O
13	)	O	O
14	patients	O	O
15	and	O	O
16	3	O	O
17	(	O	O
18	9	O	O
19	%	O	O
20	)	O	O
21	controls	O	O
22	(	O	O
23	p	O	O
24	=	O	O
25	0	O	O
26	.	O	O
27	01	O	O
28	)	O	O
29	.	O	O

0	Finally	O	O
1	,	O	O
2	resting	O	O
3	and	O	O
4	peak	O	O
5	exercise	O	O
6	abnormal	B-Disease	O
7	left	I-Disease	O
8	ventricular	I-Disease	B-Disease
9	filling	E-Disease	E-Disease
10	was	O	O
11	detected	O	O
12	in	O	O
13	38	O	O
14	and	O	O
15	35	O	O
16	%	O	O
17	of	O	O
18	patients	O	O
19	as	O	O
20	compared	O	O
21	to	O	O
22	19	O	O
23	and	O	O
24	9	O	O
25	%	O	O
26	of	O	O
27	controls	O	O
28	,	O	O
29	respectively	O	O
30	(	O	O
31	p	O	O
32	=	O	O
33	0	O	O
34	.	O	O
35	11	O	O
36	and	O	O
37	0	O	O
38	.	O	O
39	02	O	O
40	,	O	O
41	respectively	O	O
42	)	O	O
43	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	coronary	B-Disease	B-Disease
4	artery	I-Disease	I-Disease
5	or	I-Disease	O
6	myocardial	I-Disease	B-Disease
7	disease	E-Disease	E-Disease
8	is	O	O
9	common	O	O
10	(	O	O
11	38	O	O
12	%	O	O
13	)	O	O
14	in	O	O
15	young	O	O
16	asymptomatic	O	O
17	chronic	O	B-Disease
18	cocaine	S-Chemical	I-Disease
19	users	O	O
20	.	O	O

0	Cardioprotective	O	O
1	effects	O	O
2	of	O	O
3	Picrorrhiza	O	B-Chemical
4	kurroa	O	E-Chemical
5	against	O	O
6	isoproterenol	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	myocardial	O	B-Disease
10	stress	O	E-Disease
11	in	O	O
12	rats	O	O
13	.	O	O

0	The	O	O
1	cardioprotective	O	O
2	effect	O	O
3	of	O	O
4	the	O	O
5	ethanol	S-Chemical	O
6	extract	O	O
7	of	O	O
8	Picrorrhiza	O	S-Chemical
9	kurroa	O	I-Disease
10	rhizomes	O	E-Chemical
11	and	O	O
12	roots	O	O
13	(	O	O
14	PK	O	S-Disease
15	)	O	O
16	on	O	O
17	isoproterenol	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	myocardial	B-Disease	S-Disease
21	infarction	E-Disease	O
22	in	O	O
23	rats	O	O
24	with	O	O
25	respect	O	O
26	to	O	O
27	lipid	O	B-Disease
28	metabolism	O	E-Disease
29	in	O	O
30	serum	O	O
31	and	O	O
32	heart	O	O
33	tissue	O	O
34	has	O	O
35	been	O	O
36	investigated	O	O
37	.	O	O

0	Oral	O	O
1	pre	O	O
2	-	O	O
3	treatment	O	O
4	with	O	O
5	PK	O	S-Chemical
6	(	O	O
7	80	O	O
8	mg	O	O
9	kg	O	O
10	(	O	O
11	-	O	O
12	1	O	O
13	)	O	O
14	day	O	O
15	(	O	O
16	-	O	O
17	1	O	O
18	)	O	O
19	for	O	O
20	15	O	O
21	days	O	O
22	)	O	O
23	significantly	O	O
24	prevented	O	O
25	the	O	O
26	isoproterenol	S-Chemical	S-Chemical
27	-	O	O
28	induced	O	O
29	myocardial	B-Disease	B-Disease
30	infarction	E-Disease	E-Disease
31	and	O	O
32	maintained	O	O
33	the	O	O
34	rats	O	O
35	at	O	O
36	near	O	O
37	normal	O	O
38	status	O	O
39	.	O	O

0	Phase	O	O
1	2	O	O
2	early	O	O
3	afterdepolarization	O	O
4	as	O	O
5	a	O	O
6	trigger	O	O
7	of	O	O
8	polymorphic	O	O
9	ventricular	B-Disease	O
10	tachycardia	E-Disease	E-Disease
11	in	O	O
12	acquired	O	O
13	long	B-Disease	O
14	-	I-Disease	O
15	QT	I-Disease	O
16	syndrome	E-Disease	O
17	:	O	O
18	direct	O	O
19	evidence	O	O
20	from	O	O
21	intracellular	O	O
22	recordings	O	O
23	in	O	O
24	the	O	O
25	intact	O	O
26	left	O	O
27	ventricular	O	B-Disease
28	wall	O	E-Disease
29	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	This	O	O
3	study	O	O
4	examined	O	O
5	the	O	O
6	role	O	O
7	of	O	O
8	phase	O	O
9	2	O	O
10	early	O	O
11	afterdepolarization	O	O
12	(	O	O
13	EAD	O	S-Disease
14	)	O	O
15	in	O	O
16	producing	O	O
17	a	O	O
18	trigger	O	O
19	to	O	O
20	initiate	O	O
21	torsade	B-Disease	O
22	de	I-Disease	O
23	pointes	E-Disease	O
24	(	O	O
25	TdP	S-Disease	S-Chemical
26	)	O	O
27	with	O	O
28	QT	B-Disease	O
29	prolongation	E-Disease	O
30	induced	O	O
31	by	O	O
32	dl	O	S-Chemical
33	-	O	I-Chemical
34	sotalol	S-Chemical	S-Chemical
35	and	O	O
36	azimilide	S-Chemical	S-Chemical
37	.	O	O

0	The	O	O
1	contribution	O	O
2	of	O	O
3	transmural	O	O
4	dispersion	O	O
5	of	O	O
6	repolarization	O	O
7	(	O	O
8	TDR	O	S-Chemical
9	)	O	O
10	to	O	O
11	transmural	O	O
12	propagation	O	O
13	of	O	O
14	EAD	O	S-Chemical
15	and	O	O
16	the	O	O
17	maintenance	O	O
18	of	O	O
19	TdP	S-Disease	S-Chemical
20	was	O	O
21	also	O	O
22	evaluated	O	O
23	.	O	O

0	dl	O	S-Chemical
1	-	O	O
2	Sotalol	S-Chemical	S-Chemical
3	preferentially	O	O
4	prolonged	O	O
5	action	O	O
6	potential	O	O
7	duration	O	O
8	(	O	O
9	APD	O	O
10	)	O	O
11	in	O	O
12	M	O	O
13	cells	O	O
14	dose	O	O
15	-	O	O
16	dependently	O	O
17	(	O	O
18	1	O	O
19	to	O	O
20	100	O	O
21	micromol	O	O
22	/	O	O
23	L	O	O
24	)	O	O
25	,	O	O
26	leading	O	O
27	to	O	O
28	QT	B-Disease	O
29	prolongation	E-Disease	O
30	and	O	O
31	an	O	O
32	increase	O	O
33	in	O	O
34	TDR	O	S-Chemical
35	.	O	O

0	Azimilide	S-Chemical	S-Chemical
1	,	O	O
2	however	O	O
3	,	O	O
4	significantly	O	O
5	prolonged	O	O
6	APD	O	O
7	and	O	O
8	QT	O	O
9	interval	O	O
10	at	O	O
11	concentrations	O	O
12	from	O	O
13	0	O	O
14	.	O	O
15	1	O	O
16	to	O	O
17	10	O	O
18	micromol	O	O
19	/	O	O
20	L	O	O
21	but	O	O
22	shortened	O	O
23	them	O	O
24	at	O	O
25	30	O	O
26	micromol	O	O
27	/	O	O
28	L	O	O
29	.	O	O

0	Unlike	O	O
1	dl	O	S-Chemical
2	-	O	O
3	sotalol	S-Chemical	S-Chemical
4	,	O	O
5	azimilide	S-Chemical	S-Chemical
6	(	O	O
7	>	O	O
8	3	O	O
9	micromol	O	O
10	/	O	O
11	L	O	O
12	)	O	O
13	increased	O	O
14	epicardial	O	S-Disease
15	APD	O	S-Disease
16	markedly	O	O
17	,	O	O
18	causing	O	O
19	a	O	O
20	diminished	O	O
21	TDR	O	S-Disease
22	.	O	O

0	Although	O	O
1	both	O	O
2	dl	O	S-Chemical
3	-	O	O
4	sotalol	S-Chemical	S-Chemical
5	and	O	O
6	azimilide	S-Chemical	S-Chemical
7	rarely	O	O
8	induced	O	O
9	EADs	O	S-Disease
10	in	O	O
11	canine	O	B-Disease
12	left	O	E-Disease
13	ventricles	O	E-Disease
14	,	O	O
15	they	O	O
16	produced	O	O
17	frequent	O	O
18	EADs	O	S-Disease
19	in	O	O
20	rabbits	O	O
21	,	O	O
22	in	O	O
23	which	O	O
24	more	O	O
25	pronounced	O	O
26	QT	B-Disease	O
27	prolongation	E-Disease	O
28	was	O	O
29	seen	O	O
30	.	O	O

0	An	O	O
1	increase	O	O
2	in	O	O
3	TDR	O	S-Disease
4	by	O	O
5	dl	O	S-Chemical
6	-	O	O
7	sotalol	S-Chemical	S-Chemical
8	facilitated	O	O
9	transmural	O	O
10	propagation	O	O
11	of	O	O
12	EADs	O	S-Disease
13	that	O	O
14	initiated	O	O
15	multiple	O	O
16	episodes	O	O
17	of	O	O
18	spontaneous	O	O
19	TdP	S-Disease	S-Chemical
20	in	O	O
21	3	O	O
22	of	O	O
23	6	O	O
24	rabbit	O	O
25	left	O	O
26	ventricles	O	O
27	.	O	O

0	Of	O	O
1	note	O	O
2	,	O	O
3	although	O	O
4	azimilide	S-Chemical	S-Chemical
5	(	O	O
6	3	O	O
7	to	O	O
8	10	O	O
9	micromol	O	O
10	/	O	O
11	L	O	O
12	)	O	O
13	increased	O	O
14	APD	O	S-Disease
15	more	O	O
16	than	O	O
17	dl	O	S-Chemical
18	-	O	O
19	sotalol	S-Chemical	S-Chemical
20	,	O	O
21	its	O	O
22	EADs	O	S-Disease
23	often	O	O
24	failed	O	O
25	to	O	O
26	propagate	O	O
27	transmurally	O	O
28	,	O	O
29	probably	O	O
30	because	O	O
31	of	O	O
32	a	O	O
33	diminished	O	O
34	TDR	O	S-Chemical
35	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	This	O	O
3	study	O	O
4	provides	O	O
5	the	O	O
6	first	O	O
7	direct	O	O
8	evidence	O	O
9	from	O	O
10	intracellular	O	O
11	action	O	O
12	potential	O	O
13	recordings	O	O
14	that	O	O
15	phase	O	O
16	2	O	O
17	EAD	O	S-Disease
18	can	O	O
19	be	O	O
20	generated	O	O
21	from	O	O
22	intact	O	O
23	ventricular	O	O
24	wall	O	O
25	and	O	O
26	produce	O	O
27	a	O	O
28	trigger	O	O
29	to	O	O
30	initiate	O	O
31	the	O	O
32	onset	O	O
33	of	O	O
34	TdP	S-Disease	S-Chemical
35	under	O	O
36	QT	B-Disease	O
37	prolongation	E-Disease	O
38	.	O	O

0	A	O	O
1	pilot	O	O
2	study	O	O
3	to	O	O
4	assess	O	O
5	the	O	O
6	safety	O	O
7	of	O	O
8	dobutamine	S-Chemical	S-Chemical
9	stress	O	O
10	echocardiography	O	O
11	in	O	O
12	the	O	O
13	emergency	O	O
14	department	O	O
15	evaluation	O	O
16	of	O	O
17	cocaine	S-Chemical	S-Chemical
18	-	O	O
19	associated	O	O
20	chest	B-Disease	B-Disease
21	pain	E-Disease	E-Disease
22	.	O	O

0	STUDY	O	O
1	OBJECTIVE	O	O
2	:	O	O
3	Chest	B-Disease	O
4	pain	E-Disease	S-Disease
5	in	O	O
6	the	O	O
7	setting	O	O
8	of	O	O
9	cocaine	S-Chemical	S-Chemical
10	use	O	O
11	poses	O	O
12	a	O	O
13	diagnostic	O	O
14	dilemma	O	O
15	.	O	O

0	Dobutamine	S-Chemical	S-Chemical
1	stress	O	O
2	echocardiography	O	O
3	(	O	O
4	DSE	O	S-Chemical
5	)	O	O
6	is	O	O
7	a	O	O
8	widely	O	O
9	available	O	O
10	and	O	O
11	sensitive	O	O
12	test	O	O
13	for	O	O
14	evaluating	O	O
15	cardiac	O	B-Disease
16	ischemia	S-Disease	E-Disease
17	.	O	O

0	Because	O	O
1	of	O	O
2	the	O	O
3	theoretical	O	O
4	concern	O	O
5	regarding	O	O
6	administration	O	O
7	of	O	O
8	dobutamine	S-Chemical	S-Chemical
9	in	O	O
10	the	O	O
11	setting	O	O
12	of	O	O
13	cocaine	S-Chemical	S-Chemical
14	use	O	O
15	,	O	O
16	we	O	O
17	conducted	O	O
18	a	O	O
19	pilot	O	O
20	study	O	O
21	to	O	O
22	assess	O	O
23	the	O	O
24	safety	O	O
25	of	O	O
26	DSE	O	S-Chemical
27	in	O	O
28	emergency	O	O
29	department	O	O
30	patients	O	O
31	with	O	O
32	cocaine	S-Chemical	S-Chemical
33	-	O	O
34	associated	O	O
35	chest	B-Disease	B-Disease
36	pain	E-Disease	E-Disease
37	.	O	O

0	Patients	O	O
1	were	O	O
2	eligible	O	O
3	for	O	O
4	DSE	O	S-Chemical
5	if	O	O
6	they	O	O
7	had	O	O
8	used	O	O
9	cocaine	S-Chemical	S-Chemical
10	within	O	O
11	24	O	O
12	hours	O	O
13	preceding	O	O
14	the	O	O
15	onset	O	O
16	of	O	O
17	chest	B-Disease	B-Disease
18	pain	E-Disease	E-Disease
19	and	O	O
20	had	O	O
21	a	O	O
22	normal	O	O
23	ECG	O	S-Chemical
24	and	O	O
25	tropinin	O	B-Disease
26	I	O	E-Disease
27	level	O	O
28	.	O	O

0	Patients	O	O
1	exhibiting	O	O
2	signs	O	O
3	of	O	O
4	continuing	O	O
5	cocaine	S-Chemical	S-Chemical
6	toxicity	S-Disease	E-Disease
7	were	O	O
8	excluded	O	O
9	from	O	O
10	the	O	O
11	study	O	O
12	.	O	O

0	Two	O	O
1	patients	O	O
2	had	O	O
3	inadequate	O	O
4	resting	O	O
5	images	O	O
6	,	O	O
7	one	O	O
8	DSE	O	S-Chemical
9	was	O	O
10	terminated	O	O
11	because	O	O
12	of	O	O
13	inferior	O	O
14	hypokinesis	S-Disease	S-Disease
15	,	O	O
16	another	O	O
17	DSE	O	S-Chemical
18	was	O	O
19	terminated	O	O
20	because	O	O
21	of	O	O
22	a	O	O
23	rate	O	O
24	-	O	O
25	related	O	O
26	atrial	O	B-Disease
27	conduction	O	E-Disease
28	deficit	O	E-Disease
29	,	O	O
30	and	O	O
31	1	O	O
32	patient	O	O
33	did	O	O
34	not	O	O
35	reach	O	O
36	the	O	O
37	target	O	O
38	heart	O	O
39	rate	O	O
40	.	O	O

0	None	O	O
1	of	O	O
2	the	O	O
3	patients	O	O
4	experienced	O	O
5	signs	O	O
6	of	O	O
7	exaggerated	O	O
8	adrenergic	O	O
9	response	O	O
10	,	O	O
11	which	O	O
12	was	O	O
13	defined	O	O
14	as	O	O
15	a	O	O
16	systolic	O	O
17	blood	O	O
18	pressure	O	O
19	of	O	O
20	greater	O	O
21	than	O	O
22	200	O	O
23	mm	O	O
24	Hg	O	O
25	or	O	O
26	the	O	O
27	occurrence	O	O
28	of	O	O
29	tachydysrhythmias	S-Disease	S-Disease
30	(	O	O
31	excluding	O	O
32	sinus	B-Disease	B-Disease
33	tachycardia	E-Disease	E-Disease
34	)	O	O
35	.	O	O

0	Further	O	O
1	suggesting	O	O
2	lack	O	O
3	of	O	O
4	exaggerated	O	O
5	adrenergic	O	O
6	response	O	O
7	,	O	O
8	13	O	O
9	(	O	O
10	65	O	O
11	%	O	O
12	)	O	O
13	of	O	O
14	20	O	O
15	patients	O	O
16	required	O	O
17	supplemental	O	O
18	atropine	S-Chemical	S-Disease
19	to	O	O
20	reach	O	O
21	their	O	O
22	target	O	O
23	heart	O	S-Disease
24	rates	O	O
25	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	No	O	O
3	exaggerated	O	O
4	adrenergic	O	O
5	response	O	O
6	was	O	O
7	detected	O	O
8	when	O	O
9	dobutamine	S-Chemical	S-Chemical
10	was	O	O
11	administered	O	O
12	to	O	O
13	patients	O	O
14	with	O	O
15	cocaine	S-Chemical	S-Chemical
16	-	O	O
17	related	O	O
18	chest	B-Disease	B-Disease
19	pain	E-Disease	E-Disease
20	.	O	O

0	Prenatal	O	O
1	cocaine	S-Chemical	S-Chemical
2	exposure	O	O
3	and	O	O
4	cranial	O	O
5	sonographic	O	E-Disease
6	findings	O	O
7	in	O	O
8	preterm	B-Disease	O
9	infants	E-Disease	O
10	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	Prenatal	O	O
3	cocaine	S-Chemical	S-Chemical
4	exposure	O	O
5	has	O	O
6	been	O	O
7	linked	O	O
8	with	O	O
9	subependymal	O	O
10	hemorrhage	S-Disease	O
11	and	O	O
12	the	O	O
13	formation	O	O
14	of	O	O
15	cysts	S-Disease	S-Disease
16	that	O	O
17	are	O	O
18	detectable	O	O
19	on	O	O
20	cranial	O	S-Disease
21	sonography	O	E-Disease
22	in	O	O
23	neonates	O	O
24	born	O	O
25	at	O	O
26	term	O	O
27	.	O	O

0	We	O	O
1	sought	O	O
2	to	O	O
3	determine	O	O
4	if	O	O
5	prenatal	O	O
6	cocaine	S-Chemical	S-Chemical
7	exposure	O	O
8	increases	O	O
9	the	O	O
10	incidence	O	O
11	of	O	O
12	subependymal	B-Disease	O
13	cysts	E-Disease	S-Disease
14	in	O	O
15	preterm	B-Disease	O
16	infants	E-Disease	O
17	.	O	O

0	METHODS	O	O
1	:	O	O
2	We	O	O
3	retrospectively	O	O
4	reviewed	O	O
5	the	O	O
6	medical	O	O
7	records	O	O
8	and	O	O
9	cranial	O	O
10	sonograms	O	O
11	obtained	O	O
12	during	O	O
13	a	O	O
14	1	O	O
15	-	O	O
16	year	O	O
17	period	O	O
18	on	O	O
19	122	O	O
20	premature	B-Disease	O
21	(	I-Disease	O
22	<	I-Disease	O
23	36	I-Disease	O
24	weeks	I-Disease	O
25	of	I-Disease	O
26	gestation	I-Disease	O
27	)	I-Disease	O
28	infants	E-Disease	O
29	.	O	O

0	Infants	O	O
1	were	O	O
2	categorized	O	O
3	into	O	O
4	1	O	O
5	of	O	O
6	2	O	O
7	groups	O	O
8	:	O	O
9	those	O	O
10	exposed	O	O
11	to	O	O
12	cocaine	S-Chemical	S-Chemical
13	and	O	O
14	those	O	O
15	not	O	O
16	exposed	O	O
17	to	O	O
18	cocaine	S-Chemical	S-Chemical
19	.	O	O

0	Infants	O	O
1	were	O	O
2	assigned	O	O
3	to	O	O
4	the	O	O
5	cocaine	S-Chemical	S-Chemical
6	-	O	O
7	exposed	O	O
8	group	O	O
9	if	O	O
10	there	O	O
11	was	O	O
12	a	O	O
13	maternal	O	O
14	history	O	O
15	of	O	O
16	cocaine	B-Disease	S-Chemical
17	abuse	E-Disease	E-Disease
18	during	O	O
19	pregnancy	O	O
20	or	O	O
21	if	O	O
22	maternal	O	O
23	or	O	O
24	neonatal	O	O
25	urine	O	O
26	toxicology	O	E-Disease
27	results	O	O
28	were	O	O
29	positive	O	O
30	at	O	O
31	the	O	O
32	time	O	O
33	of	O	O
34	delivery	O	O
35	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	subependymal	B-Disease	O
4	cysts	E-Disease	S-Disease
5	in	O	O
6	the	O	O
7	117	O	O
8	remaining	O	O
9	infants	O	O
10	was	O	O
11	14	O	O
12	%	O	O
13	(	O	O
14	16	O	O
15	of	O	O
16	117	O	O
17	)	O	O
18	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	subependymal	B-Disease	O
4	cysts	E-Disease	S-Disease
5	in	O	O
6	infants	O	O
7	exposed	O	O
8	to	O	O
9	cocaine	S-Chemical	S-Chemical
10	prenatally	O	O
11	was	O	O
12	44	O	O
13	%	O	O
14	(	O	O
15	8	O	O
16	of	O	O
17	18	O	O
18	)	O	O
19	compared	O	O
20	with	O	O
21	8	O	O
22	%	O	O
23	(	O	O
24	8	O	O
25	of	O	O
26	99	O	O
27	)	O	O
28	in	O	O
29	the	O	O
30	unexposed	O	O
31	group	O	O
32	(	O	O
33	p	O	O
34	<	O	O
35	0	O	O
36	.	O	O
37	01	O	O
38	)	O	O
39	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	We	O	O
3	found	O	O
4	an	O	O
5	increased	O	O
6	incidence	O	O
7	of	O	O
8	subependymal	B-Disease	O
9	cyst	E-Disease	S-Disease
10	formation	O	E-Disease
11	in	O	O
12	preterm	B-Disease	O
13	infants	E-Disease	O
14	who	O	O
15	were	O	O
16	exposed	O	O
17	to	O	O
18	cocaine	S-Chemical	S-Chemical
19	prenatally	O	O
20	.	O	O

0	Thalidomide	S-Chemical	S-Chemical
1	neuropathy	S-Disease	E-Chemical
2	in	O	O
3	patients	O	O
4	treated	O	O
5	for	O	O
6	metastatic	O	B-Disease
7	prostate	B-Disease	I-Disease
8	cancer	E-Disease	E-Disease
9	.	O	O

0	We	O	O
1	prospectively	O	O
2	evaluated	O	O
3	thalidomide	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	neuropathy	S-Disease	S-Disease
7	using	O	O
8	electrodiagnostic	O	O
9	studies	O	O
10	.	O	O

0	Sixty	O	O
1	-	O	O
2	seven	O	O
3	men	O	O
4	with	O	O
5	metastatic	O	O
6	androgen	S-Chemical	I-Disease
7	-	O	O
8	independent	O	O
9	prostate	B-Disease	B-Disease
10	cancer	E-Disease	E-Disease
11	in	O	O
12	an	O	O
13	open	O	O
14	-	O	O
15	label	O	O
16	trial	O	O
17	of	O	O
18	oral	O	O
19	thalidomide	S-Chemical	S-Disease
20	underwent	O	O
21	neurologic	O	O
22	examinations	O	O
23	and	O	O
24	nerve	O	B-Disease
25	conduction	O	E-Disease
26	studies	O	O
27	(	O	O
28	NCS	O	S-Disease
29	)	O	O
30	prior	O	O
31	to	O	O
32	and	O	O
33	at	O	O
34	3	O	O
35	-	O	O
36	month	O	O
37	intervals	O	O
38	during	O	O
39	treatment	O	O
40	.	O	O

0	Thalidomide	S-Chemical	S-Chemical
1	was	O	O
2	discontinued	O	O
3	in	O	O
4	55	O	O
5	patients	O	O
6	for	O	O
7	lack	O	O
8	of	O	O
9	therapeutic	O	O
10	response	O	O
11	.	O	O

0	Of	O	O
1	67	O	O
2	patients	O	O
3	initially	O	O
4	enrolled	O	O
5	,	O	O
6	24	O	O
7	remained	O	O
8	on	O	O
9	thalidomide	S-Chemical	S-Chemical
10	for	O	O
11	3	O	O
12	months	O	O
13	,	O	O
14	8	O	O
15	remained	O	O
16	at	O	O
17	6	O	O
18	months	O	O
19	,	O	O
20	and	O	O
21	3	O	O
22	remained	O	O
23	at	O	O
24	9	O	O
25	months	O	O
26	.	O	O

0	Six	O	O
1	patients	O	O
2	developed	O	O
3	neuropathy	S-Disease	S-Disease
4	.	O	O

0	Neuropathy	S-Disease	S-Disease
1	may	O	O
2	thus	O	O
3	be	O	O
4	a	O	O
5	common	O	O
6	complication	O	O
7	of	O	O
8	thalidomide	S-Chemical	S-Chemical
9	in	O	O
10	older	O	O
11	patients	O	O
12	.	O	O

0	The	O	O
1	SNAP	O	S-Disease
2	index	O	O
3	can	O	O
4	be	O	O
5	used	O	O
6	to	O	O
7	monitor	O	O
8	peripheral	B-Disease	B-Disease
9	neuropathy	E-Disease	E-Disease
10	,	O	O
11	but	O	O
12	not	O	O
13	for	O	O
14	early	O	O
15	detection	O	O
16	.	O	O

0	Overexpression	O	O
1	of	O	O
2	copper	S-Chemical	S-Chemical
3	/	O	O
4	zinc	S-Chemical	I-Chemical
5	-	O	O
6	superoxide	S-Chemical	E-Chemical
7	dismutase	O	O
8	protects	O	O
9	from	O	O
10	kanamycin	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	hearing	B-Disease	B-Disease
14	loss	E-Disease	E-Disease
15	.	O	O

0	The	O	O
1	participation	O	O
2	of	O	O
3	reactive	O	O
4	oxygen	S-Chemical	I-Disease
5	species	O	O
6	in	O	O
7	aminoglycoside	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	ototoxicity	S-Disease	S-Chemical
11	has	O	O
12	been	O	O
13	deduced	O	O
14	from	O	O
15	observations	O	O
16	that	O	O
17	aminoglycoside	S-Chemical	S-Chemical
18	-	O	O
19	iron	S-Chemical	E-Chemical
20	complexes	O	O
21	catalyze	O	O
22	the	O	O
23	formation	O	O
24	of	O	O
25	superoxide	S-Chemical	O
26	radicals	O	O
27	in	O	O
28	vitro	O	O
29	and	O	O
30	that	O	O
31	antioxidants	O	O
32	attenuate	O	O
33	ototoxicity	S-Disease	S-Chemical
34	in	O	O
35	vivo	O	O
36	.	O	O

0	We	O	O
1	therefore	O	O
2	hypothesized	O	O
3	that	O	O
4	overexpression	O	O
5	of	O	O
6	Cu	S-Chemical	B-Chemical
7	/	O	I-Chemical
8	Zn	S-Chemical	E-Chemical
9	-	O	O
10	superoxide	S-Chemical	E-Chemical
11	dismutase	O	O
12	(	O	O
13	h	O	B-Chemical
14	-	O	I-Chemical
15	SOD1	O	E-Chemical
16	)	O	O
17	should	O	O
18	protect	O	O
19	transgenic	O	O
20	mice	O	O
21	from	O	O
22	ototoxicity	S-Disease	S-Chemical
23	.	O	O

0	Transgenic	O	O
1	and	O	O
2	nontransgenic	O	O
3	littermates	O	O
4	received	O	O
5	kanamycin	S-Chemical	S-Chemical
6	(	O	O
7	400	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	body	O	O
12	weight	O	O
13	/	O	O
14	day	O	O
15	)	O	O
16	for	O	O
17	10	O	O
18	days	O	O
19	beginning	O	O
20	on	O	O
21	day	O	O
22	10	O	O
23	after	O	O
24	birth	O	O
25	.	O	O

0	In	O	O
1	nontransgenic	O	O
2	animals	O	O
3	,	O	O
4	the	O	O
5	threshold	O	O
6	in	O	O
7	the	O	O
8	kanamycin	S-Chemical	S-Chemical
9	-	O	O
10	treated	O	O
11	group	O	O
12	was	O	O
13	45	O	O
14	-	O	O
15	50	O	O
16	dB	O	O
17	higher	O	O
18	than	O	O
19	in	O	O
20	saline	O	S-Chemical
21	-	O	O
22	injected	O	O
23	controls	O	O
24	.	O	O

0	In	O	O
1	the	O	O
2	transgenic	O	O
3	group	O	O
4	,	O	O
5	kanamycin	S-Chemical	S-Chemical
6	increased	O	O
7	the	O	O
8	threshold	O	O
9	by	O	O
10	only	O	O
11	15	O	O
12	dB	O	O
13	over	O	O
14	the	O	O
15	respective	O	O
16	controls	O	O
17	.	O	O

0	The	O	O
1	protection	O	O
2	by	O	O
3	overexpression	O	O
4	of	O	O
5	superoxide	S-Chemical	S-Chemical
6	dismutase	O	S-Disease
7	supports	O	O
8	the	O	O
9	hypothesis	O	O
10	that	O	O
11	oxidant	O	O
12	stress	O	O
13	plays	O	O
14	a	O	O
15	significant	O	O
16	role	O	O
17	in	O	O
18	aminoglycoside	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	ototoxicity	S-Disease	S-Chemical
22	.	O	O

0	Fatty	B-Disease	O
1	liver	E-Disease	O
2	induced	O	O
3	by	O	O
4	tetracycline	S-Chemical	S-Chemical
5	in	O	O
6	the	O	O
7	rat	O	O
8	.	O	O

0	Dose	O	O
1	-	O	O
2	response	O	O
3	relationships	O	O
4	,	O	O
5	biochemical	O	O
6	mechanisms	O	O
7	,	O	O
8	and	O	O
9	sex	O	O
10	differences	O	O
11	in	O	O
12	the	O	O
13	experimental	O	O
14	fatty	B-Disease	B-Disease
15	liver	E-Disease	E-Disease
16	induced	O	O
17	by	O	O
18	tetracycline	S-Chemical	S-Chemical
19	were	O	O
20	studied	O	O
21	in	O	O
22	the	O	O
23	intact	O	O
24	rat	O	O
25	and	O	O
26	with	O	O
27	the	O	O
28	isolated	O	O
29	perfused	O	O
30	rat	O	O
31	liver	O	O
32	in	O	O
33	vitro	O	O
34	.	O	O

0	In	O	O
1	the	O	O
2	intact	O	O
3	male	O	O
4	and	O	O
5	female	O	O
6	rat	O	O
7	,	O	O
8	no	O	O
9	direct	O	O
10	relationship	O	O
11	was	O	O
12	observed	O	O
13	between	O	O
14	dose	O	O
15	of	O	O
16	tetracycline	S-Chemical	S-Chemical
17	and	O	O
18	hepatic	O	S-Chemical
19	accumulation	O	O
20	of	O	O
21	triglyceride	S-Chemical	S-Chemical
22	.	O	O

0	With	O	O
1	provision	O	O
2	of	O	O
3	adequate	O	O
4	oleic	B-Chemical	S-Chemical
5	acid	E-Chemical	O
6	as	O	O
7	a	O	O
8	substrate	O	O
9	for	O	O
10	the	O	O
11	isolated	O	O
12	perfused	O	O
13	liver	O	O
14	,	O	O
15	a	O	O
16	direct	O	O
17	relationship	O	O
18	was	O	O
19	observed	O	O
20	between	O	O
21	dose	O	O
22	of	O	O
23	tetracycline	S-Chemical	S-Chemical
24	and	O	O
25	both	O	O
26	accumulation	O	O
27	of	O	O
28	triglyceride	S-Chemical	S-Chemical
29	in	O	O
30	the	O	O
31	liver	O	O
32	and	O	O
33	depression	S-Disease	O
34	of	O	O
35	output	O	O
36	of	O	O
37	triglyceride	S-Chemical	S-Chemical
38	by	O	O
39	livers	O	O
40	from	O	O
41	male	O	O
42	and	O	O
43	female	O	O
44	rats	O	O
45	.	O	O

0	Marked	O	O
1	differences	O	O
2	were	O	O
3	observed	O	O
4	between	O	O
5	female	O	O
6	and	O	O
7	male	O	O
8	rats	O	O
9	with	O	O
10	regard	O	O
11	to	O	O
12	base	O	O
13	line	O	O
14	(	O	O
15	control	O	O
16	)	O	O
17	hepatic	O	S-Disease
18	concentration	O	O
19	of	O	O
20	triglyceride	S-Chemical	S-Chemical
21	and	O	O
22	output	O	O
23	of	O	O
24	triglyceride	S-Chemical	S-Chemical
25	.	O	O

0	Accumulation	O	O
1	of	O	O
2	hepatic	O	S-Chemical
3	triglyceride	S-Chemical	E-Chemical
4	,	O	O
5	as	O	O
6	a	O	O
7	per	O	O
8	cent	O	O
9	of	O	O
10	control	O	O
11	values	O	O
12	,	O	O
13	in	O	O
14	response	O	O
15	to	O	O
16	graded	O	O
17	doses	O	O
18	of	O	O
19	tetracycline	S-Chemical	S-Chemical
20	,	O	O
21	did	O	O
22	not	O	O
23	differ	O	O
24	significantly	O	O
25	between	O	O
26	male	O	O
27	,	O	O
28	female	O	O
29	and	O	O
30	pregnant	O	O
31	rat	O	O
32	livers	O	O
33	.	O	O

0	However	O	O
1	,	O	O
2	livers	O	O
3	from	O	O
4	female	O	O
5	,	O	O
6	and	O	O
7	especially	O	O
8	pregnant	O	O
9	female	O	O
10	rats	O	O
11	,	O	O
12	were	O	O
13	strikingly	O	O
14	resistant	O	O
15	to	O	O
16	the	O	O
17	effects	O	O
18	of	O	O
19	tetracycline	S-Chemical	S-Chemical
20	on	O	O
21	depression	S-Disease	S-Disease
22	of	O	O
23	output	O	O
24	of	O	O
25	triglyceride	S-Chemical	S-Chemical
26	under	O	O
27	these	O	O
28	experimental	O	O
29	conditions	O	O
30	.	O	O

0	These	O	O
1	differences	O	O
2	between	O	O
3	the	O	O
4	sexes	O	O
5	could	O	O
6	not	O	O
7	be	O	O
8	related	O	O
9	to	O	O
10	altered	O	O
11	disposition	O	S-Disease
12	of	O	O
13	tetracycline	S-Chemical	S-Chemical
14	or	O	O
15	altered	O	O
16	uptake	O	O
17	of	O	O
18	oleic	B-Chemical	S-Chemical
19	acid	E-Chemical	E-Disease
20	.	O	O

0	Depressed	O	O
1	hepatic	O	S-Disease
2	secretion	O	O
3	of	O	O
4	triglyceride	S-Chemical	S-Chemical
5	accounted	O	O
6	only	O	O
7	for	O	O
8	30	O	O
9	to	O	O
10	50	O	O
11	%	O	O
12	of	O	O
13	accumulated	O	O
14	hepatic	O	S-Disease
15	triglyceride	S-Chemical	S-Disease
16	,	O	O
17	indicating	O	O
18	that	O	O
19	additional	O	O
20	mechanisms	O	O
21	must	O	O
22	be	O	O
23	involved	O	O
24	in	O	O
25	the	O	O
26	production	O	O
27	of	O	O
28	the	O	O
29	triglyceride	S-Chemical	S-Chemical
30	-	O	O
31	rich	O	O
32	fatty	B-Disease	B-Disease
33	liver	E-Disease	E-Disease
34	in	O	O
35	response	O	O
36	to	O	O
37	tetracycline	S-Chemical	S-Chemical
38	.	O	O

0	Prednisone	S-Chemical	S-Chemical
1	induces	O	O
2	anxiety	S-Disease	S-Disease
3	and	O	O
4	glial	O	O
5	cerebral	O	B-Disease
6	changes	O	E-Disease
7	in	O	O
8	rats	O	O
9	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	assess	O	O
4	whether	O	O
5	prednisone	S-Chemical	S-Disease
6	(	O	O
7	PDN	S-Chemical	S-Chemical
8	)	O	O
9	produces	O	O
10	anxiety	S-Disease	S-Disease
11	and	O	O
12	/	O	O
13	or	O	O
14	cerebral	O	B-Disease
15	glial	O	I-Disease
16	changes	O	E-Disease
17	in	O	O
18	rats	O	O
19	.	O	O

0	The	O	O
1	moderate	O	O
2	-	O	O
3	dose	O	O
4	group	O	O
5	received	O	O
6	5	O	O
7	mg	O	O
8	/	O	O
9	kg	O	O
10	/	O	O
11	day	O	O
12	PDN	S-Chemical	S-Chemical
13	released	O	O
14	from	O	O
15	a	O	O
16	subcutaneous	O	O
17	implant	O	O
18	.	O	O

0	In	O	O
1	the	O	O
2	high	O	O
3	-	O	O
4	dose	O	O
5	group	O	O
6	,	O	O
7	implants	O	O
8	containing	O	O
9	PDN	S-Chemical	S-Chemical
10	equivalent	O	O
11	to	O	O
12	60	O	O
13	mg	O	O
14	/	O	O
15	kg	O	O
16	/	O	O
17	day	O	O
18	were	O	O
19	applied	O	O
20	.	O	O

0	In	O	O
1	the	O	O
2	control	O	O
3	group	O	O
4	implants	O	O
5	contained	O	O
6	no	O	O
7	PDN	S-Chemical	S-Chemical
8	.	O	O

0	Anxiety	S-Disease	O
1	was	O	O
2	assessed	O	O
3	using	O	O
4	an	O	O
5	open	O	O
6	field	O	O
7	and	O	O
8	elevated	O	O
9	plus	O	O
10	-	O	O
11	maze	O	O
12	devices	O	O
13	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Anxiety	S-Disease	O
3	was	O	O
4	documented	O	O
5	in	O	O
6	both	O	O
7	groups	O	O
8	of	O	O
9	PDN	S-Chemical	S-Chemical
10	treated	O	O
11	rats	O	O
12	compared	O	O
13	with	O	O
14	controls	O	O
15	.	O	O

0	The	O	O
1	magnitude	O	O
2	of	O	O
3	transformation	O	O
4	of	O	O
5	the	O	O
6	microglia	O	O
7	assessed	O	O
8	by	O	O
9	the	O	O
10	number	O	O
11	of	O	O
12	intersections	O	O
13	was	O	O
14	significantly	O	O
15	higher	O	O
16	in	O	O
17	the	O	O
18	PDN	S-Chemical	S-Disease
19	groups	O	O
20	than	O	O
21	in	O	O
22	controls	O	O
23	in	O	O
24	the	O	O
25	prefrontal	O	O
26	cortex	O	O
27	(	O	O
28	moderate	O	O
29	-	O	O
30	dose	O	O
31	,	O	O
32	24	O	O
33	.	O	O
34	1	O	O
35	;	O	O
36	high	O	O
37	-	O	O
38	dose	O	O
39	,	O	O
40	23	O	O
41	.	O	O
42	6	O	O
43	;	O	O
44	controls	O	O
45	18	O	O
46	.	O	O
47	7	O	O
48	;	O	O
49	p	O	O
50	<	O	O
51	0	O	O
52	.	O	O
53	01	O	O
54	)	O	O
55	and	O	O
56	striatum	O	O
57	(	O	O
58	moderate	O	O
59	-	O	O
60	dose	O	O
61	25	O	O
62	.	O	O
63	6	O	O
64	;	O	O
65	high	O	O
66	-	O	O
67	dose	O	O
68	26	O	O
69	.	O	O
70	3	O	O
71	;	O	O
72	controls	O	O
73	18	O	O
74	.	O	O
75	9	O	O
76	;	O	O
77	p	O	O
78	<	O	O
79	0	O	O
80	.	O	O
81	01	O	O
82	)	O	O
83	,	O	O
84	but	O	O
85	not	O	O
86	in	O	O
87	hippocampus	O	S-Disease
88	.	O	O

0	The	O	O
1	number	O	O
2	of	O	O
3	stained	O	O
4	microglia	O	O
5	cells	O	O
6	was	O	O
7	significantly	O	O
8	higher	O	O
9	in	O	O
10	the	O	O
11	PDN	S-Chemical	S-Chemical
12	treated	O	O
13	groups	O	O
14	in	O	O
15	the	O	O
16	prefrontal	O	O
17	cortex	O	O
18	than	O	O
19	in	O	O
20	controls	O	O
21	(	O	O
22	moderate	O	O
23	-	O	O
24	dose	O	O
25	,	O	O
26	29	O	O
27	.	O	O
28	1	O	O
29	;	O	O
30	high	O	O
31	-	O	O
32	dose	O	O
33	,	O	O
34	28	O	O
35	.	O	O
36	4	O	O
37	;	O	O
38	control	O	O
39	,	O	O
40	17	O	O
41	.	O	O
42	7	O	O
43	cells	O	O
44	per	O	O
45	field	O	O
46	;	O	O
47	p	O	O
48	<	O	O
49	0	O	O
50	.	O	O
51	01	O	O
52	)	O	O
53	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Subacute	O	O
3	exposure	O	O
4	to	O	O
5	PDN	S-Chemical	S-Chemical
6	induced	O	O
7	anxiety	S-Disease	S-Disease
8	and	O	O
9	reactivity	O	O
10	of	O	O
11	microglia	O	O
12	.	O	O

0	The	O	O
1	relevance	O	O
2	of	O	O
3	these	O	O
4	features	O	O
5	for	O	O
6	patients	O	O
7	using	O	O
8	PDN	S-Chemical	S-Chemical
9	remains	O	O
10	to	O	O
11	be	O	O
12	elucidated	O	O
13	.	O	O

0	Phase	O	O
1	II	O	O
2	study	O	O
3	of	O	O
4	carboplatin	S-Chemical	S-Chemical
5	and	O	O
6	liposomal	O	B-Disease
7	doxorubicin	S-Chemical	E-Chemical
8	in	O	O
9	patients	O	O
10	with	O	O
11	recurrent	O	O
12	squamous	B-Disease	B-Disease
13	cell	I-Disease	I-Disease
14	carcinoma	I-Disease	I-Disease
15	of	I-Disease	O
16	the	I-Disease	O
17	cervix	E-Disease	S-Chemical
18	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	The	O	O
3	activity	O	O
4	of	O	O
5	the	O	O
6	combination	O	O
7	of	O	O
8	carboplatin	S-Chemical	S-Chemical
9	and	O	O
10	liposomal	O	B-Chemical
11	doxorubicin	S-Chemical	E-Chemical
12	was	O	O
13	tested	O	O
14	in	O	O
15	a	O	O
16	Phase	O	O
17	II	O	O
18	study	O	O
19	of	O	O
20	patients	O	O
21	with	O	O
22	recurrent	O	O
23	cervical	B-Disease	B-Disease
24	carcinoma	E-Disease	E-Disease
25	.	O	O

0	METHODS	O	O
1	:	O	O
2	The	O	O
3	combination	O	O
4	of	O	O
5	carboplatin	S-Chemical	S-Chemical
6	(	O	O
7	area	O	O
8	under	O	O
9	the	O	O
10	concentration	O	O
11	curve	O	O
12	[	O	O
13	AUC	O	O
14	]	O	O
15	,	O	O
16	5	O	O
17	)	O	O
18	and	O	O
19	liposomal	O	S-Disease
20	doxorubicin	S-Chemical	S-Chemical
21	(	O	O
22	Doxil	S-Chemical	S-Chemical
23	;	O	O
24	starting	O	O
25	dose	O	O
26	,	O	O
27	40	O	O
28	mg	O	O
29	/	O	O
30	m	O	O
31	(	O	O
32	2	O	O
33	)	O	O
34	)	O	O
35	was	O	O
36	administered	O	O
37	intravenously	O	O
38	every	O	O
39	28	O	O
40	days	O	O
41	to	O	O
42	37	O	O
43	patients	O	O
44	with	O	O
45	recurrent	O	O
46	squamous	B-Disease	B-Disease
47	cell	I-Disease	I-Disease
48	cervical	I-Disease	I-Disease
49	carcinoma	E-Disease	I-Disease
50	to	O	O
51	determine	O	O
52	antitumor	O	O
53	activity	O	S-Disease
54	and	O	O
55	toxicity	S-Disease	S-Disease
56	profile	O	O
57	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Twenty	O	O
3	-	O	O
4	nine	O	O
5	patients	O	O
6	were	O	O
7	assessable	O	O
8	for	O	O
9	response	O	O
10	,	O	O
11	and	O	O
12	35	O	O
13	patients	O	O
14	were	O	O
15	assessable	O	O
16	for	O	O
17	toxicity	S-Disease	S-Disease
18	.	O	O

0	The	O	O
1	main	O	O
2	toxic	O	O
3	effect	O	O
4	was	O	O
5	myelosuppression	S-Disease	S-Disease
6	,	O	O
7	with	O	O
8	Grade	O	O
9	3	O	O
10	and	O	O
11	4	O	O
12	neutropenia	S-Disease	S-Disease
13	in	O	O
14	16	O	O
15	patients	O	O
16	,	O	O
17	anemia	S-Disease	O
18	in	O	O
19	12	O	O
20	patients	O	O
21	,	O	O
22	thrombocytopenia	S-Disease	S-Disease
23	in	O	O
24	11	O	O
25	patients	O	O
26	,	O	O
27	and	O	O
28	neutropenic	B-Disease	S-Disease
29	fever	E-Disease	S-Disease
30	in	O	O
31	3	O	O
32	patients	O	O
33	.	O	O

0	Four	O	O
1	patients	O	O
2	had	O	O
3	five	O	O
4	infusion	O	O
5	-	O	O
6	related	O	O
7	reactions	O	O
8	during	O	O
9	the	O	O
10	infusion	O	O
11	of	O	O
12	liposomal	O	B-Chemical
13	doxorubicin	S-Chemical	E-Chemical
14	,	O	O
15	leading	O	O
16	to	O	O
17	treatment	O	O
18	discontinuation	O	O
19	in	O	O
20	three	O	O
21	patients	O	O
22	.	O	O

0	Grade	O	O
1	>	O	O
2	or	O	O
3	=	O	O
4	2	O	O
5	nonhematologic	O	O
6	toxicity	S-Disease	S-Disease
7	included	O	O
8	nausea	S-Disease	S-Disease
9	in	O	O
10	17	O	O
11	patients	O	O
12	,	O	O
13	emesis	S-Disease	S-Disease
14	in	O	O
15	14	O	O
16	patients	O	O
17	,	O	O
18	fatigue	S-Disease	S-Disease
19	in	O	O
20	9	O	O
21	patients	O	O
22	,	O	O
23	mucositis	S-Disease	S-Disease
24	and	O	O
25	/	O	O
26	or	O	O
27	stomatitis	S-Disease	S-Disease
28	in	O	O
29	8	O	O
30	patients	O	O
31	,	O	O
32	constipation	S-Disease	O
33	in	O	O
34	6	O	O
35	patients	O	O
36	,	O	O
37	weight	B-Disease	B-Disease
38	loss	E-Disease	E-Disease
39	in	O	O
40	5	O	O
41	patients	O	O
42	,	O	O
43	hand	B-Disease	B-Disease
44	-	I-Disease	O
45	foot	I-Disease	B-Disease
46	syndrome	E-Disease	E-Disease
47	in	O	O
48	2	O	O
49	patients	O	O
50	,	O	O
51	and	O	O
52	skin	B-Disease	B-Disease
53	reactions	E-Disease	E-Disease
54	in	O	O
55	3	O	O
56	patients	O	O
57	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	combination	O	O
4	of	O	O
5	carboplatin	S-Chemical	S-Chemical
6	and	O	O
7	liposomal	O	S-Chemical
8	doxorubicin	S-Chemical	S-Chemical
9	has	O	O
10	modest	O	O
11	activity	O	O
12	in	O	O
13	patients	O	O
14	with	O	O
15	recurrent	O	O
16	cervical	B-Disease	B-Disease
17	carcinoma	E-Disease	I-Disease
18	.	O	O

0	Antimicrobial	O	O
1	-	O	O
2	induced	O	O
3	mania	S-Disease	S-Disease
4	(	O	O
5	antibiomania	S-Disease	O
6	)	O	O
7	:	O	O
8	a	O	O
9	review	O	O
10	of	O	O
11	spontaneous	O	O
12	reports	O	O
13	.	O	O

0	The	O	O
1	authors	O	O
2	reviewed	O	O
3	reported	O	O
4	cases	O	O
5	of	O	O
6	antibiotic	O	O
7	-	O	O
8	induced	O	O
9	manic	S-Disease	S-Disease
10	episodes	O	O
11	by	O	O
12	means	O	O
13	of	O	O
14	a	O	O
15	MEDLINE	O	S-Disease
16	and	O	O
17	PsychLit	O	S-Chemical
18	search	O	O
19	for	O	O
20	reports	O	O
21	of	O	O
22	antibiotic	O	O
23	-	O	O
24	induced	O	O
25	mania	S-Disease	S-Disease
26	.	O	O

0	Twenty	O	O
1	-	O	O
2	one	O	O
3	reports	O	O
4	of	O	O
5	antimicrobial	O	O
6	-	O	O
7	induced	O	O
8	mania	S-Disease	S-Disease
9	were	O	O
10	found	O	O
11	in	O	O
12	the	O	O
13	literature	O	O
14	.	O	O

0	There	O	O
1	were	O	O
2	6	O	O
3	cases	O	O
4	implicating	O	O
5	clarithromycin	S-Chemical	S-Chemical
6	,	O	O
7	13	O	O
8	implicating	O	O
9	isoniazid	S-Chemical	S-Chemical
10	,	O	O
11	and	O	O
12	1	O	O
13	case	O	O
14	each	O	O
15	implicating	O	O
16	erythromycin	S-Chemical	S-Chemical
17	and	O	O
18	amoxicillin	S-Chemical	S-Chemical
19	.	O	O

0	Of	O	O
1	these	O	O
2	,	O	O
3	clarithromycin	S-Chemical	S-Chemical
4	was	O	O
5	implicated	O	O
6	in	O	O
7	23	O	O
8	(	O	O
9	27	O	O
10	.	O	O
11	6	O	O
12	%	O	O
13	)	O	O
14	cases	O	O
15	,	O	O
16	ciprofloxacin	S-Chemical	S-Chemical
17	in	O	O
18	12	O	O
19	(	O	O
20	14	O	O
21	.	O	O
22	4	O	O
23	%	O	O
24	)	O	O
25	cases	O	O
26	,	O	O
27	and	O	O
28	ofloxacin	S-Chemical	S-Chemical
29	in	O	O
30	10	O	O
31	(	O	O
32	12	O	O
33	%	O	O
34	)	O	O
35	cases	O	O
36	.	O	O

0	Cotrimoxazole	S-Chemical	S-Chemical
1	,	O	O
2	metronidazole	S-Chemical	S-Chemical
3	,	O	O
4	and	O	O
5	erythromycin	S-Chemical	S-Chemical
6	were	O	O
7	involved	O	O
8	in	O	O
9	15	O	O
10	reported	O	O
11	manic	S-Disease	S-Disease
12	episodes	O	O
13	.	O	O

0	Cases	O	O
1	reported	O	O
2	by	O	O
3	the	O	O
4	FDA	O	S-Disease
5	showed	O	O
6	clarithromycin	S-Chemical	S-Chemical
7	and	O	O
8	ciprofloxacin	S-Chemical	S-Chemical
9	to	O	O
10	be	O	O
11	the	O	O
12	most	O	O
13	frequently	O	O
14	associated	O	O
15	with	O	O
16	the	O	O
17	development	O	O
18	of	O	O
19	mania	S-Disease	S-Disease
20	.	O	O

0	Patients	O	O
1	have	O	O
2	an	O	O
3	increased	O	O
4	risk	O	O
5	of	O	O
6	developing	O	O
7	mania	S-Disease	S-Disease
8	while	O	O
9	being	O	O
10	treated	O	O
11	with	O	O
12	antimicrobials	O	O
13	.	O	O

0	Further	O	O
1	research	O	O
2	clearly	O	O
3	is	O	O
4	required	O	O
5	to	O	O
6	determine	O	O
7	the	O	O
8	incidence	O	O
9	of	O	O
10	antimicrobial	O	O
11	-	O	O
12	induced	O	O
13	mania	S-Disease	S-Disease
14	,	O	O
15	the	O	O
16	relative	O	O
17	risk	O	O
18	factors	O	O
19	of	O	O
20	developing	O	O
21	an	O	O
22	antimicrobial	O	O
23	-	O	O
24	induced	O	O
25	manic	S-Disease	S-Disease
26	episode	O	E-Disease
27	among	O	O
28	various	O	O
29	demographic	O	O
30	populations	O	O
31	,	O	O
32	and	O	O
33	the	O	O
34	incidence	O	O
35	of	O	O
36	patients	O	O
37	who	O	O
38	continue	O	O
39	to	O	O
40	have	O	O
41	persistent	O	O
42	affective	O	B-Disease
43	disorders	O	E-Disease
44	once	O	O
45	the	O	O
46	initial	O	O
47	episode	O	O
48	,	O	O
49	which	O	O
50	occurs	O	O
51	while	O	O
52	the	O	O
53	patient	O	O
54	is	O	O
55	taking	O	O
56	antibiotics	O	O
57	,	O	O
58	subsides	O	O
59	.	O	O

0	The	O	O
1	authors	O	O
2	elected	O	O
3	to	O	O
4	name	O	O
5	this	O	O
6	syndrome	O	S-Disease
7	"	O	O
8	antibiomania	S-Disease	O
9	.	O	O
10	"	O	O

0	Levodopa	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	ocular	B-Disease	B-Disease
4	dyskinesias	E-Disease	E-Disease
5	in	O	O
6	Parkinson	B-Disease	B-Disease
7	'	I-Disease	I-Disease
8	s	I-Disease	I-Disease
9	disease	E-Disease	E-Disease
10	.	O	O

0	Levodopa	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	ocular	B-Disease	B-Disease
4	dyskinesias	E-Disease	E-Disease
5	are	O	O
6	very	O	O
7	uncommon	O	O
8	.	O	O

0	Usually	O	O
1	they	O	O
2	occur	O	O
3	simultaneously	O	O
4	with	O	O
5	limb	O	O
6	peak	O	O
7	-	O	O
8	dose	O	O
9	choreatic	B-Disease	S-Disease
10	dyskinesias	E-Disease	E-Disease
11	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	a	O	O
4	patient	O	O
5	with	O	O
6	leftward	O	O
7	and	O	O
8	upward	O	O
9	deviations	O	O
10	of	O	O
11	gaze	O	O
12	during	O	O
13	the	O	O
14	peak	O	O
15	effect	O	O
16	of	O	O
17	levodopa	S-Chemical	S-Chemical
18	,	O	O
19	and	O	O
20	hypothesize	O	O
21	that	O	O
22	a	O	O
23	severe	O	O
24	dopaminergic	O	O
25	denervation	O	O
26	in	O	O
27	the	O	O
28	caudate	O	S-Disease
29	nucleus	O	O
30	is	O	O
31	needed	O	O
32	for	O	O
33	the	O	O
34	appearance	O	O
35	of	O	O
36	these	O	O
37	levodopa	S-Chemical	S-Chemical
38	-	O	O
39	induce	O	O
40	ocular	B-Disease	B-Disease
41	dyskinesias	E-Disease	E-Disease
42	.	O	O

0	A	O	O
1	comparison	O	O
2	of	O	O
3	glyceryl	B-Chemical	B-Chemical
4	trinitrate	E-Chemical	E-Chemical
5	with	O	O
6	diclofenac	S-Chemical	S-Chemical
7	for	O	O
8	the	O	O
9	treatment	O	O
10	of	O	O
11	primary	O	O
12	dysmenorrhea	S-Disease	E-Disease
13	:	O	O
14	an	O	O
15	open	O	O
16	,	O	O
17	randomized	O	O
18	,	O	O
19	cross	O	O
20	-	O	O
21	over	O	O
22	trial	O	O
23	.	O	O

0	Primary	O	O
1	dysmenorrhea	S-Disease	S-Disease
2	is	O	O
3	a	O	O
4	syndrome	O	O
5	characterized	O	O
6	by	O	O
7	painful	O	S-Disease
8	uterine	O	B-Disease
9	contractility	O	E-Disease
10	caused	O	O
11	by	O	O
12	a	O	O
13	hypersecretion	O	S-Disease
14	of	O	O
15	endometrial	O	B-Disease
16	prostaglandins	S-Chemical	E-Disease
17	;	O	O
18	non	O	O
19	-	O	O
20	steroidal	O	S-Chemical
21	anti	O	O
22	-	O	O
23	inflammatory	O	S-Disease
24	drugs	O	O
25	are	O	O
26	the	O	O
27	first	O	O
28	choice	O	O
29	for	O	O
30	its	O	O
31	treatment	O	O
32	.	O	O

0	However	O	O
1	,	O	O
2	in	O	O
3	vivo	O	O
4	and	O	O
5	in	O	O
6	vitro	O	O
7	studies	O	O
8	have	O	O
9	demonstrated	O	O
10	that	O	O
11	myometrial	O	S-Disease
12	cells	O	O
13	are	O	O
14	also	O	O
15	targets	O	O
16	of	O	O
17	the	O	O
18	relaxant	O	O
19	effects	O	O
20	of	O	O
21	nitric	B-Chemical	S-Chemical
22	oxide	E-Chemical	E-Chemical
23	(	O	O
24	NO	S-Chemical	S-Chemical
25	)	O	O
26	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	the	O	O
4	present	O	O
5	study	O	O
6	was	O	O
7	to	O	O
8	determine	O	O
9	the	O	O
10	efficacy	O	O
11	of	O	O
12	glyceryl	B-Chemical	B-Chemical
13	trinitrate	E-Chemical	E-Chemical
14	(	O	O
15	GTN	S-Chemical	S-Chemical
16	)	O	O
17	,	O	O
18	an	O	O
19	NO	S-Chemical	S-Chemical
20	donor	O	O
21	,	O	O
22	in	O	O
23	the	O	O
24	resolution	O	O
25	of	O	O
26	primary	O	O
27	dysmenorrhea	S-Disease	S-Disease
28	in	O	O
29	comparison	O	O
30	with	O	O
31	diclofenac	S-Chemical	S-Chemical
32	(	O	O
33	DCF	S-Chemical	S-Chemical
34	)	O	O
35	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	24	O	O
4	patients	O	O
5	with	O	O
6	the	O	O
7	diagnosis	O	O
8	of	O	O
9	severe	O	O
10	primary	O	O
11	dysmenorrhea	S-Disease	E-Disease
12	were	O	O
13	studied	O	O
14	during	O	O
15	two	O	O
16	consecutive	O	O
17	menstrual	O	O
18	cycles	O	O
19	.	O	O

0	In	O	O
1	an	O	O
2	open	O	O
3	,	O	O
4	cross	O	O
5	-	O	O
6	over	O	O
7	,	O	O
8	controlled	O	O
9	design	O	O
10	,	O	O
11	patients	O	O
12	were	O	O
13	randomized	O	O
14	to	O	O
15	receive	O	O
16	either	O	O
17	DCF	S-Chemical	S-Disease
18	per	O	O
19	os	O	S-Disease
20	or	O	O
21	GTN	S-Chemical	S-Chemical
22	patches	O	O
23	the	O	O
24	first	O	O
25	days	O	O
26	of	O	O
27	menses	O	O
28	,	O	O
29	when	O	O
30	menstrual	O	O
31	cramps	O	E-Disease
32	became	O	O
33	unendurable	O	O
34	.	O	O

0	Patients	O	O
1	received	O	O
2	up	O	O
3	to	O	O
4	3	O	O
5	doses	O	O
6	/	O	O
7	day	O	O
8	of	O	O
9	50	O	O
10	mg	O	O
11	DCF	S-Chemical	S-Disease
12	or	O	O
13	2	O	O
14	.	O	O
15	5	O	O
16	mg	O	O
17	/	O	O
18	24	O	O
19	h	O	O
20	transdermal	O	O
21	GTN	S-Chemical	S-Chemical
22	for	O	O
23	the	O	O
24	first	O	O
25	3	O	O
26	days	O	O
27	of	O	O
28	the	O	O
29	cycle	O	O
30	,	O	O
31	according	O	O
32	to	O	O
33	their	O	O
34	needs	O	O
35	.	O	O

0	The	O	O
1	difference	O	O
2	in	O	O
3	pain	S-Disease	S-Disease
4	intensity	O	O
5	score	O	O
6	(	O	O
7	DPI	O	S-Chemical
8	)	O	O
9	was	O	O
10	the	O	O
11	main	O	O
12	outcome	O	O
13	variable	O	O
14	.	O	O

0	Both	O	O
1	treatments	O	O
2	significantly	O	O
3	reduced	O	O
4	DPI	O	S-Chemical
5	by	O	O
6	the	O	O
7	30th	O	O
8	minute	O	O
9	(	O	O
10	GTN	S-Chemical	S-Chemical
11	,	O	O
12	-	O	O
13	12	O	O
14	.	O	O
15	8	O	O
16	+	O	O
17	/	O	O
18	-	O	O
19	17	O	O
20	.	O	O
21	9	O	O
22	;	O	O
23	DCF	S-Chemical	S-Disease
24	,	O	O
25	-	O	O
26	18	O	O
27	.	O	O
28	9	O	O
29	+	O	O
30	/	O	O
31	-	O	O
32	16	O	O
33	.	O	O
34	6	O	O
35	)	O	O
36	.	O	O

0	However	O	O
1	,	O	O
2	DCF	S-Chemical	S-Chemical
3	continued	O	O
4	to	O	O
5	be	O	O
6	effective	O	O
7	in	O	O
8	reducing	O	O
9	pelvic	B-Disease	O
10	pain	E-Disease	E-Disease
11	for	O	O
12	two	O	O
13	hours	O	O
14	,	O	O
15	whereas	O	O
16	GTN	S-Chemical	S-Chemical
17	scores	O	O
18	remained	O	O
19	more	O	O
20	or	O	O
21	less	O	O
22	stable	O	O
23	after	O	O
24	30	O	O
25	min	O	O
26	and	O	O
27	significantly	O	O
28	higher	O	O
29	than	O	O
30	those	O	O
31	for	O	O
32	DFC	O	S-Disease
33	(	O	O
34	after	O	O
35	one	O	O
36	hour	O	O
37	:	O	O
38	GTN	S-Chemical	S-Chemical
39	,	O	O
40	-	O	O
41	12	O	O
42	.	O	O
43	8	O	O
44	+	O	O
45	/	O	O
46	-	O	O
47	17	O	O
48	.	O	O
49	9	O	O
50	;	O	O
51	DFC	O	S-Disease
52	,	O	O
53	-	O	O
54	18	O	O
55	.	O	O
56	9	O	O
57	+	O	O
58	/	O	O
59	-	O	O
60	16	O	O
61	.	O	O
62	6	O	O
63	and	O	O
64	after	O	O
65	two	O	O
66	hours	O	O
67	:	O	O
68	GTN	S-Chemical	S-Chemical
69	,	O	O
70	-	O	O
71	23	O	O
72	.	O	O
73	7	O	O
74	+	O	O
75	/	O	O
76	-	O	O
77	20	O	O
78	.	O	O
79	5	O	O
80	;	O	O
81	DFC	O	S-Chemical
82	,	O	O
83	-	O	O
84	59	O	O
85	.	O	O
86	7	O	O
87	+	O	O
88	/	O	O
89	-	O	O
90	17	O	O
91	.	O	O
92	9	O	O
93	,	O	O
94	p	O	O
95	=	O	O
96	0	O	O
97	.	O	O
98	0001	O	O
99	)	O	O
100	.	O	O

0	Low	B-Disease	O
1	back	I-Disease	O
2	pain	E-Disease	S-Disease
3	was	O	O
4	also	O	O
5	relieved	O	O
6	by	O	O
7	both	O	O
8	drugs	O	O
9	.	O	O

0	Headache	S-Disease	S-Disease
1	was	O	O
2	significantly	O	O
3	increased	O	O
4	by	O	O
5	GTN	S-Chemical	S-Chemical
6	but	O	O
7	not	O	O
8	by	O	O
9	DCF	S-Chemical	S-Chemical
10	.	O	O

0	Eight	O	O
1	patients	O	O
2	stopped	O	O
3	using	O	O
4	GTN	S-Chemical	S-Chemical
5	because	O	O
6	headache	S-Disease	S-Disease
7	-	O	O
8	-	O	O
9	attributed	O	O
10	to	O	O
11	its	O	O
12	use	O	O
13	-	O	O
14	-	O	O
15	became	O	O
16	intolerable	O	O
17	.	O	O

0	These	O	O
1	findings	O	O
2	indicate	O	O
3	that	O	O
4	GTN	S-Chemical	S-Chemical
5	has	O	O
6	a	O	O
7	reduced	O	O
8	efficacy	O	O
9	and	O	O
10	tolerability	O	O
11	by	O	O
12	comparison	O	O
13	with	O	O
14	DCF	S-Chemical	S-Chemical
15	in	O	O
16	the	O	O
17	treatment	O	O
18	of	O	O
19	primary	O	O
20	dysmenorrhea	S-Disease	S-Disease
21	.	O	O

0	Temocapril	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	long	O	O
4	-	O	O
5	acting	O	O
6	non	O	O
7	-	O	O
8	SH	O	O
9	group	O	O
10	angiotensin	S-Chemical	O
11	converting	O	O
12	enzyme	O	O
13	inhibitor	O	O
14	,	O	O
15	modulates	O	O
16	glomerular	B-Disease	B-Disease
17	injury	E-Disease	E-Disease
18	in	O	O
19	chronic	O	B-Disease
20	puromycin	B-Chemical	I-Disease
21	aminonucleoside	E-Chemical	S-Disease
22	nephrosis	S-Disease	S-Disease
23	.	O	O

0	The	O	O
1	purpose	O	O
2	of	O	O
3	the	O	O
4	present	O	O
5	study	O	O
6	was	O	O
7	to	O	O
8	determine	O	O
9	whether	O	O
10	chronic	O	O
11	administration	O	O
12	of	O	O
13	temocapril	S-Chemical	S-Chemical
14	,	O	O
15	a	O	O
16	long	O	O
17	-	O	O
18	acting	O	O
19	non	O	O
20	-	O	O
21	SH	O	O
22	group	O	O
23	angiotensin	S-Chemical	O
24	converting	O	O
25	enzyme	O	O
26	(	O	O
27	ACE	O	S-Chemical
28	)	O	O
29	inhibitor	O	O
30	,	O	O
31	reduced	O	O
32	proteinuria	S-Disease	S-Disease
33	,	O	O
34	inhibited	O	O
35	glomerular	O	B-Disease
36	hypertrophy	S-Disease	E-Disease
37	and	O	O
38	prevented	O	O
39	glomerulosclerosis	S-Disease	B-Chemical
40	in	O	O
41	chronic	O	B-Disease
42	puromycin	B-Chemical	I-Disease
43	aminonucleoside	E-Chemical	E-Chemical
44	(	O	O
45	PAN	S-Chemical	S-Disease
46	)	O	E-Chemical
47	-	O	O
48	induced	O	O
49	nephrotic	S-Disease	S-Disease
50	rats	O	O
51	.	O	O

0	Nephrosis	S-Disease	S-Disease
1	was	O	O
2	induced	O	O
3	by	O	O
4	injection	O	O
5	of	O	O
6	PAN	S-Chemical	S-Chemical
7	(	O	O
8	15mg	O	O
9	/	O	O
10	100g	O	O
11	body	O	O
12	weight	O	O
13	)	O	O
14	in	O	O
15	male	O	O
16	Sprague	O	O
17	-	O	O
18	Dawley	O	O
19	(	O	O
20	SD	O	O
21	)	O	O
22	rats	O	O
23	.	O	O

0	Four	O	O
1	groups	O	O
2	were	O	O
3	used	O	O
4	,	O	O
5	i	O	O
6	)	O	O
7	the	O	O
8	PAN	S-Chemical	S-Chemical
9	group	O	O
10	(	O	O
11	14	O	O
12	)	O	O
13	,	O	O
14	ii	O	O
15	)	O	O
16	PAN	S-Chemical	B-Chemical
17	/	O	I-Chemical
18	temocapril	S-Chemical	E-Chemical
19	(	O	O
20	13	O	O
21	)	O	O
22	,	O	O
23	iii	O	O
24	)	O	O
25	temocapril	S-Chemical	S-Chemical
26	(	O	O
27	14	O	O
28	)	O	O
29	and	O	O
30	iv	O	O
31	)	O	O
32	untreated	O	O
33	controls	O	O
34	(	O	O
35	15	O	O
36	)	O	O
37	.	O	O

0	Temocapril	S-Chemical	S-Chemical
1	(	O	O
2	8	O	O
3	mg	O	O
4	/	O	O
5	kg	O	O
6	/	O	O
7	day	O	O
8	)	O	O
9	was	O	O
10	administered	O	O
11	to	O	O
12	the	O	O
13	rats	O	O
14	which	O	O
15	were	O	O
16	killed	O	O
17	at	O	O
18	weeks	O	O
19	4	O	O
20	,	O	O
21	14	O	O
22	or	O	O
23	20	O	O
24	.	O	O

0	Systolic	O	O
1	BP	O	S-Disease
2	in	O	O
3	the	O	O
4	PAN	S-Chemical	S-Disease
5	group	O	O
6	was	O	O
7	significantly	O	O
8	high	O	O
9	at	O	O
10	4	O	O
11	,	O	O
12	14	O	O
13	and	O	O
14	20	O	O
15	weeks	O	O
16	,	O	O
17	but	O	O
18	was	O	O
19	normal	O	O
20	in	O	O
21	the	O	O
22	PAN	S-Chemical	B-Chemical
23	/	O	I-Chemical
24	temocapril	S-Chemical	E-Chemical
25	group	O	O
26	.	O	O

0	Urinary	O	O
1	protein	O	O
2	excretion	O	O
3	in	O	O
4	the	O	O
5	PAN	S-Chemical	S-Chemical
6	group	O	O
7	increased	O	O
8	significantly	O	O
9	,	O	O
10	peaking	O	O
11	at	O	O
12	8	O	O
13	days	O	O
14	,	O	O
15	then	O	O
16	decreased	O	O
17	at	O	O
18	4	O	O
19	weeks	O	O
20	,	O	O
21	but	O	O
22	rose	O	O
23	again	O	O
24	significantly	O	O
25	at	O	O
26	14	O	O
27	and	O	O
28	20	O	O
29	weeks	O	O
30	.	O	O

0	Temocapril	S-Chemical	S-Chemical
1	did	O	O
2	not	O	O
3	attenuate	O	O
4	proteinuria	S-Disease	S-Disease
5	at	O	O
6	8	O	O
7	days	O	O
8	,	O	O
9	but	O	O
10	it	O	O
11	did	O	O
12	markedly	O	O
13	lower	O	O
14	it	O	O
15	from	O	O
16	weeks	O	O
17	4	O	O
18	to	O	O
19	20	O	O
20	.	O	O

0	The	O	O
1	glomerulosclerosis	S-Disease	S-Disease
2	index	O	O
3	(	O	O
4	GSI	O	S-Chemical
5	)	O	O
6	was	O	O
7	6	O	O
8	.	O	O
9	21	O	O
10	%	O	O
11	at	O	O
12	4	O	O
13	weeks	O	O
14	and	O	O
15	respectively	O	O
16	25	O	O
17	.	O	O
18	35	O	O
19	%	O	O
20	and	O	O
21	30	O	O
22	.	O	O
23	49	O	O
24	%	O	O
25	at	O	O
26	14	O	O
27	and	O	O
28	20	O	O
29	weeks	O	O
30	in	O	O
31	the	O	O
32	PAN	S-Chemical	S-Chemical
33	group	O	O
34	.	O	O

0	The	O	O
1	ratio	O	O
2	of	O	O
3	glomerular	O	O
4	tuft	O	O
5	area	O	O
6	to	O	O
7	the	O	O
8	area	O	O
9	of	O	O
10	Bowman	O	S-Disease
11	'	O	O
12	s	O	O
13	capsules	O	O
14	(	O	O
15	GT	O	S-Chemical
16	/	O	O
17	BC	O	O
18	)	O	O
19	in	O	O
20	the	O	O
21	PAN	S-Chemical	S-Chemical
22	group	O	O
23	was	O	O
24	significantly	O	O
25	increased	O	O
26	,	O	O
27	but	O	O
28	it	O	O
29	was	O	O
30	significantly	O	O
31	lower	O	O
32	in	O	O
33	the	O	O
34	PAN	S-Chemical	B-Chemical
35	/	O	I-Chemical
36	temocapril	S-Chemical	E-Chemical
37	group	O	O
38	.	O	O

0	It	O	O
1	appears	O	O
2	that	O	O
3	temocapril	S-Chemical	S-Chemical
4	was	O	O
5	effective	O	O
6	in	O	O
7	retarding	O	O
8	renal	O	B-Disease
9	progression	O	E-Disease
10	and	O	O
11	protected	O	O
12	renal	O	B-Disease
13	function	O	E-Disease
14	in	O	O
15	PAN	S-Chemical	B-Disease
16	neprotic	S-Disease	E-Disease
17	rats	O	O
18	.	O	O

0	Pulmonary	B-Disease	O
1	hypertension	E-Disease	S-Disease
2	after	O	O
3	ibuprofen	S-Chemical	S-Chemical
4	prophylaxis	O	S-Disease
5	in	O	O
6	very	O	O
7	preterm	O	O
8	infants	O	O
9	.	O	O

0	We	O	O
1	report	O	O
2	three	O	O
3	cases	O	O
4	of	O	O
5	severe	O	O
6	hypoxaemia	S-Disease	S-Disease
7	after	O	O
8	ibuprofen	S-Chemical	S-Chemical
9	administration	O	O
10	during	O	O
11	a	O	O
12	randomised	O	O
13	controlled	O	O
14	trial	O	O
15	of	O	O
16	prophylactic	O	O
17	treatment	O	O
18	of	O	O
19	patent	B-Disease	B-Disease
20	ductus	I-Disease	I-Disease
21	arteriosus	E-Disease	E-Disease
22	with	O	O
23	ibuprofen	S-Chemical	S-Chemical
24	in	O	O
25	premature	O	O
26	infants	O	O
27	born	O	O
28	at	O	O
29	less	O	O
30	than	O	O
31	28	O	O
32	weeks	O	O
33	of	O	O
34	gestation	O	O
35	.	O	O

0	Hypoxaemia	S-Disease	S-Disease
1	resolved	O	O
2	quickly	O	O
3	on	O	O
4	inhaled	O	O
5	nitric	B-Chemical	O
6	oxide	E-Chemical	O
7	therapy	O	O
8	.	O	O

0	We	O	O
1	suggest	O	O
2	that	O	O
3	investigators	O	O
4	involved	O	O
5	in	O	O
6	similar	O	O
7	trials	O	O
8	pay	O	O
9	close	O	O
10	attention	O	O
11	to	O	O
12	pulmonary	O	B-Disease
13	pressure	O	E-Disease
14	if	O	O
15	hypoxaemia	S-Disease	S-Disease
16	occurs	O	O
17	after	O	O
18	prophylactic	O	O
19	administration	O	O
20	of	O	O
21	ibuprofen	S-Chemical	S-Chemical
22	.	O	O

0	Hyponatremia	S-Disease	O
1	and	O	O
2	syndrome	B-Disease	O
3	of	I-Disease	O
4	inappropriate	I-Disease	O
5	anti	I-Disease	O
6	-	I-Disease	O
7	diuretic	I-Disease	B-Disease
8	hormone	E-Disease	E-Disease
9	reported	O	O
10	with	O	O
11	the	O	O
12	use	O	O
13	of	O	O
14	Vincristine	S-Chemical	S-Chemical
15	:	O	O
16	an	O	O
17	over	O	O
18	-	O	O
19	representation	O	O
20	of	O	O
21	Asians	O	S-Chemical
22	?	O	O

0	PURPOSE	O	O
1	:	O	O
2	This	O	O
3	retrospective	O	O
4	study	O	O
5	used	O	O
6	a	O	O
7	pharmaceutical	O	O
8	company	O	O
9	'	O	O
10	s	O	O
11	global	O	O
12	safety	O	O
13	database	O	O
14	to	O	O
15	determine	O	O
16	the	O	O
17	reporting	O	O
18	rate	O	O
19	of	O	O
20	hyponatremia	S-Disease	S-Disease
21	and	O	O
22	/	O	O
23	or	O	O
24	syndrome	B-Disease	O
25	of	I-Disease	O
26	inappropriate	I-Disease	O
27	secretion	I-Disease	S-Disease
28	of	I-Disease	O
29	anti	I-Disease	O
30	-	I-Disease	O
31	diuretic	I-Disease	S-Chemical
32	hormone	E-Disease	S-Disease
33	(	O	O
34	SIADH	S-Disease	S-Chemical
35	)	O	O
36	among	O	O
37	vincristine	S-Chemical	S-Disease
38	-	O	O
39	treated	O	O
40	patients	O	O
41	and	O	O
42	to	O	O
43	explore	O	O
44	the	O	O
45	possibility	O	O
46	of	O	O
47	at	O	O
48	-	O	O
49	risk	O	O
50	population	O	O
51	subgroups	O	O
52	.	O	O

0	METHOD	O	O
1	:	O	O
2	We	O	O
3	searched	O	O
4	the	O	O
5	Eli	O	S-Chemical
6	Lilly	O	I-Disease
7	and	O	S-Disease
8	Company	O	S-Chemical
9	'	O	O
10	s	O	O
11	computerized	O	O
12	adverse	O	O
13	event	O	O
14	database	O	O
15	for	O	O
16	all	O	O
17	reported	O	O
18	cases	O	O
19	of	O	O
20	hyponatremia	S-Disease	S-Disease
21	and	O	O
22	/	O	O
23	or	O	O
24	SIADH	S-Disease	S-Chemical
25	as	O	O
26	of	O	O
27	1	O	O
28	November	O	O
29	1999	O	O
30	that	O	O
31	had	O	O
32	been	O	O
33	reported	O	O
34	during	O	O
35	the	O	O
36	use	O	O
37	of	O	O
38	vincristine	S-Chemical	S-Chemical
39	.	O	O

0	RESULTS	O	O
1	:	O	O
2	A	O	O
3	total	O	O
4	of	O	O
5	76	O	O
6	cases	O	O
7	of	O	O
8	hyponatremia	S-Disease	S-Disease
9	and	O	O
10	/	O	O
11	or	O	O
12	SIADH	S-Disease	S-Chemical
13	associated	O	O
14	with	O	O
15	vincristine	S-Chemical	S-Chemical
16	use	O	O
17	were	O	O
18	identified	O	O
19	.	O	O

0	Approximately	O	O
1	75	O	O
2	%	O	O
3	of	O	O
4	the	O	O
5	patients	O	O
6	were	O	O
7	receiving	O	O
8	treatment	O	O
9	for	O	O
10	leukemia	S-Disease	S-Disease
11	or	O	O
12	lymphoma	S-Disease	S-Disease
13	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Our	O	O
3	data	O	O
4	suggest	O	O
5	that	O	O
6	Asian	O	S-Chemical
7	patients	O	O
8	may	O	O
9	be	O	O
10	at	O	O
11	increased	O	O
12	risk	O	O
13	of	O	O
14	hyponatremia	S-Disease	S-Disease
15	and	O	O
16	/	O	O
17	or	O	O
18	SIADH	S-Disease	S-Chemical
19	associated	O	O
20	with	O	O
21	vincristine	S-Chemical	S-Chemical
22	use	O	O
23	.	O	O

0	Although	O	O
1	the	O	O
2	overall	O	O
3	reported	O	O
4	rate	O	O
5	of	O	O
6	SIADH	S-Disease	S-Chemical
7	associated	O	O
8	with	O	O
9	vincristine	S-Chemical	S-Chemical
10	is	O	O
11	very	O	O
12	low	O	O
13	,	O	O
14	physicians	O	O
15	caring	O	O
16	for	O	O
17	Asian	O	B-Disease
18	oncology	O	O
19	patients	O	O
20	should	O	O
21	be	O	O
22	aware	O	O
23	of	O	O
24	this	O	O
25	potential	O	O
26	serious	O	O
27	but	O	O
28	reversible	O	O
29	adverse	O	O
30	event	O	O
31	.	O	O

0	Delayed	O	O
1	toxicity	S-Disease	S-Disease
2	of	O	O
3	cyclophosphamide	S-Chemical	S-Chemical
4	on	O	O
5	the	O	O
6	bladder	O	O
7	of	O	O
8	DBA	O	B-Chemical
9	/	O	I-Disease
10	2	O	E-Chemical
11	and	O	O
12	C57BL	O	S-Chemical
13	/	O	O
14	6	O	O
15	female	O	O
16	mouse	O	O
17	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	describes	O	O
4	the	O	O
5	delayed	O	O
6	development	O	O
7	of	O	O
8	a	O	O
9	severe	O	O
10	bladder	O	B-Disease
11	pathology	O	E-Disease
12	in	O	O
13	a	O	O
14	susceptible	O	O
15	strain	O	O
16	of	O	O
17	mice	O	O
18	(	O	O
19	DBA	O	S-Chemical
20	/	O	E-Chemical
21	2	O	E-Disease
22	)	O	O
23	but	O	O
24	not	O	O
25	in	O	O
26	a	O	O
27	resistant	O	O
28	strain	O	O
29	(	O	O
30	C57BL	O	B-Chemical
31	/	O	O
32	6	O	O
33	)	O	O
34	when	O	O
35	both	O	O
36	were	O	O
37	treated	O	O
38	with	O	O
39	a	O	O
40	single	O	O
41	300	O	O
42	mg	O	O
43	/	O	O
44	kg	O	O
45	dose	O	O
46	of	O	O
47	cyclophosphamide	S-Chemical	S-Chemical
48	(	O	O
49	CY	S-Chemical	S-Chemical
50	)	O	O
51	.	O	O

0	Inbred	O	O
1	DBA	O	B-Chemical
2	/	O	I-Chemical
3	2	O	E-Chemical
4	and	O	O
5	C57BL	O	B-Chemical
6	/	O	O
7	6	O	O
8	female	O	O
9	mice	O	O
10	were	O	O
11	injected	O	O
12	with	O	O
13	CY	S-Chemical	S-Chemical
14	,	O	O
15	and	O	O
16	the	O	O
17	effect	O	O
18	of	O	O
19	the	O	O
20	drug	O	O
21	on	O	O
22	the	O	O
23	bladder	O	O
24	was	O	O
25	assessed	O	O
26	during	O	O
27	100	O	O
28	days	O	O
29	by	O	O
30	light	O	O
31	microscopy	O	O
32	using	O	O
33	different	O	O
34	staining	O	O
35	procedures	O	O
36	,	O	O
37	and	O	O
38	after	O	O
39	30	O	O
40	days	O	O
41	by	O	O
42	conventional	O	O
43	electron	O	O
44	microscopy	O	O
45	.	O	O

0	Early	O	O
1	CY	S-Chemical	B-Disease
2	toxicity	S-Disease	S-Disease
3	caused	O	O
4	a	O	O
5	typical	O	O
6	haemorrhagic	S-Disease	B-Disease
7	cystitis	S-Disease	S-Disease
8	in	O	O
9	both	O	O
10	strains	O	O
11	that	O	O
12	was	O	O
13	completely	O	O
14	repaired	O	O
15	in	O	O
16	about	O	O
17	7	O	O
18	-	O	O
19	10	O	O
20	days	O	O
21	.	O	O

0	After	O	O
1	30	O	O
2	days	O	O
3	of	O	O
4	CY	S-Chemical	S-Chemical
5	injection	O	O
6	ulcerous	O	O
7	and	O	O
8	non	O	O
9	-	O	O
10	ulcerous	O	O
11	forms	O	O
12	of	O	O
13	chronic	O	B-Disease
14	cystitis	S-Disease	E-Disease
15	appeared	O	O
16	in	O	O
17	86	O	O
18	%	O	O
19	of	O	O
20	DBA	O	B-Chemical
21	/	O	I-Disease
22	2	O	E-Disease
23	mice	O	O
24	but	O	O
25	only	O	O
26	in	O	O
27	4	O	O
28	%	O	O
29	of	O	O
30	C57BL	O	B-Chemical
31	/	O	O
32	6	O	O
33	mice	O	O
34	.	O	O

0	Delayed	O	O
1	cystitis	S-Disease	S-Disease
2	was	O	O
3	characterized	O	O
4	by	O	O
5	infiltration	O	O
6	and	O	O
7	transepithelial	O	O
8	passage	O	O
9	into	O	O
10	the	O	O
11	lumen	O	S-Disease
12	of	O	O
13	inflammatory	O	B-Disease
14	cells	O	O
15	and	O	O
16	by	O	O
17	frequent	O	O
18	exfoliation	O	O
19	of	O	O
20	the	O	O
21	urothelium	O	S-Disease
22	.	O	O

0	Delayed	O	O
1	cystitis	S-Disease	S-Disease
2	still	O	O
3	persisted	O	O
4	in	O	O
5	DBA	O	S-Chemical
6	/	O	O
7	2	O	O
8	mice	O	O
9	100	O	O
10	days	O	O
11	after	O	O
12	treatment	O	O
13	.	O	O

0	These	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	delayed	O	O
5	toxicity	S-Disease	S-Disease
6	of	O	O
7	CY	S-Chemical	S-Chemical
8	in	O	O
9	female	O	O
10	DBA	O	B-Chemical
11	/	O	E-Chemical
12	2	O	E-Disease
13	mice	O	O
14	causes	O	O
15	a	O	O
16	bladder	O	B-Disease
17	pathology	O	E-Disease
18	that	O	O
19	is	O	O
20	not	O	O
21	observed	O	O
22	in	O	O
23	C57BL	O	B-Chemical
24	/	O	O
25	6	O	O
26	mice	O	O
27	.	O	O

0	This	O	O
1	pathology	O	O
2	resembles	O	O
3	interstitial	B-Disease	O
4	cystitis	E-Disease	S-Disease
5	in	O	O
6	humans	O	O
7	and	O	O
8	could	O	O
9	perhaps	O	O
10	be	O	O
11	used	O	O
12	as	O	O
13	an	O	O
14	animal	O	O
15	model	O	O
16	for	O	O
17	studies	O	O
18	on	O	O
19	the	O	O
20	disease	O	S-Disease
21	.	O	O

0	High	O	O
1	-	O	O
2	dose	O	O
3	5	B-Chemical	O
4	-	I-Chemical	I-Chemical
5	fluorouracil	E-Chemical	E-Chemical
6	/	O	I-Chemical
7	folinic	B-Chemical	E-Chemical
8	acid	E-Chemical	E-Disease
9	in	O	O
10	combination	O	O
11	with	O	O
12	three	O	O
13	-	O	O
14	weekly	O	O
15	mitomycin	B-Chemical	B-Chemical
16	C	E-Chemical	E-Chemical
17	in	O	O
18	the	O	O
19	treatment	O	O
20	of	O	O
21	advanced	O	O
22	gastric	B-Disease	B-Disease
23	cancer	E-Disease	E-Disease
24	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	The	O	O
3	24	O	O
4	-	O	O
5	hour	O	O
6	continuous	O	O
7	infusion	O	O
8	of	O	O
9	5	B-Chemical	B-Chemical
10	-	I-Chemical	I-Chemical
11	fluorouracil	E-Chemical	S-Chemical
12	(	O	O
13	5	B-Chemical	O
14	-	I-Chemical	O
15	FU	E-Chemical	O
16	)	O	O
17	and	O	O
18	folinic	B-Chemical	S-Chemical
19	acid	E-Chemical	O
20	(	O	O
21	FA	S-Chemical	S-Disease
22	)	O	O
23	as	O	O
24	part	O	O
25	of	O	O
26	several	O	O
27	new	O	O
28	multidrug	O	O
29	chemotherapy	O	O
30	regimens	O	O
31	in	O	O
32	advanced	O	O
33	gastric	B-Disease	B-Disease
34	cancer	E-Disease	E-Disease
35	(	O	O
36	AGC	S-Disease	S-Chemical
37	)	O	O
38	has	O	O
39	shown	O	O
40	to	O	O
41	be	O	O
42	effective	O	O
43	,	O	O
44	with	O	O
45	low	O	O
46	toxicity	S-Disease	S-Disease
47	.	O	O

0	In	O	O
1	a	O	O
2	previous	O	O
3	phase	O	O
4	II	O	O
5	study	O	O
6	with	O	O
7	3	O	O
8	-	O	O
9	weekly	O	O
10	bolus	O	O
11	5	B-Chemical	O
12	-	I-Chemical	O
13	FU	E-Chemical	O
14	,	O	O
15	FA	S-Chemical	S-Disease
16	and	O	O
17	mitomycin	B-Chemical	B-Chemical
18	C	E-Chemical	E-Chemical
19	(	O	O
20	MMC	S-Chemical	S-Disease
21	)	O	O
22	we	O	O
23	found	O	O
24	a	O	O
25	low	O	O
26	toxicity	S-Disease	S-Disease
27	rate	O	O
28	and	O	O
29	response	O	O
30	rates	O	O
31	comparable	O	O
32	to	O	O
33	those	O	O
34	of	O	O
35	regimens	O	O
36	such	O	O
37	as	O	O
38	ELF	O	S-Chemical
39	,	O	O
40	FAM	O	S-Disease
41	or	O	O
42	FAMTX	O	S-Chemical
43	,	O	O
44	and	O	O
45	a	O	O
46	promising	O	O
47	median	O	O
48	overall	O	O
49	survival	O	O
50	.	O	O

0	In	O	O
1	order	O	O
2	to	O	O
3	improve	O	O
4	this	O	O
5	MMC	S-Chemical	S-Disease
6	-	O	O
7	dependent	O	O
8	schedule	O	O
9	we	O	O
10	initiated	O	O
11	a	O	O
12	phase	O	O
13	II	O	O
14	study	O	O
15	with	O	O
16	high	O	O
17	-	O	O
18	dose	O	O
19	5	B-Chemical	O
20	-	I-Chemical	O
21	FU	E-Chemical	O
22	/	O	O
23	FA	S-Chemical	O
24	and	O	O
25	3	O	O
26	-	O	O
27	weekly	O	O
28	bolus	O	O
29	MMC	S-Chemical	S-Disease
30	.	O	O

0	PATIENTS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	From	O	O
5	February	O	O
6	,	O	O
7	1998	O	O
8	to	O	O
9	September	O	O
10	,	O	O
11	2000	O	O
12	we	O	O
13	recruited	O	O
14	33	O	O
15	patients	O	O
16	with	O	O
17	AGC	S-Disease	S-Disease
18	to	O	O
19	receive	O	O
20	weekly	O	O
21	24	O	O
22	-	O	O
23	hour	O	O
24	5	B-Chemical	O
25	-	I-Chemical	O
26	FU	E-Chemical	O
27	2	O	O
28	,	O	O
29	600	O	O
30	mg	O	O
31	/	O	O
32	m	O	O
33	(	O	O
34	2	O	O
35	)	O	O
36	preceded	O	O
37	by	O	O
38	2	O	O
39	-	O	O
40	hour	O	O
41	FA	S-Chemical	O
42	500	O	O
43	mg	O	O
44	/	O	O
45	m	O	O
46	(	O	O
47	2	O	O
48	)	O	O
49	for	O	O
50	6	O	O
51	weeks	O	O
52	,	O	O
53	followed	O	O
54	by	O	O
55	a	O	O
56	2	O	O
57	-	O	O
58	week	O	O
59	rest	O	O
60	period	O	O
61	.	O	O

0	Bolus	O	S-Chemical
1	MMC	S-Chemical	O
2	10	O	O
3	mg	O	O
4	/	O	O
5	m	O	O
6	(	O	O
7	2	O	O
8	)	O	O
9	was	O	O
10	added	O	O
11	in	O	O
12	3	O	O
13	-	O	O
14	weekly	O	O
15	intervals	O	O
16	.	O	O

0	18	O	O
1	patients	O	O
2	had	O	O
3	a	O	O
4	primary	O	O
5	AGC	S-Disease	S-Chemical
6	,	O	O
7	and	O	O
8	15	O	O
9	showed	O	O
10	a	O	O
11	relapsed	O	O
12	AGC	S-Disease	S-Chemical
13	.	O	O

0	The	O	O
1	worst	O	O
2	toxicities	S-Disease	O
3	(	O	O
4	%	O	O
5	)	O	O
6	observed	O	O
7	were	O	O
8	(	O	O
9	CTC	O	S-Disease
10	-	O	O
11	NCI	O	S-Disease
12	1	O	O
13	/	O	O
14	2	O	O
15	/	O	O
16	3	O	O
17	)	O	O
18	:	O	O
19	leukopenia	S-Disease	S-Disease
20	45	O	O
21	.	O	O
22	5	O	O
23	/	O	O
24	18	O	O
25	.	O	O
26	2	O	O
27	/	O	O
28	6	O	O
29	.	O	O
30	1	O	O
31	,	O	O
32	thrombocytopenia	S-Disease	S-Disease
33	33	O	O
34	.	O	O
35	3	O	O
36	/	O	O
37	9	O	O
38	.	O	O
39	1	O	O
40	/	O	O
41	6	O	O
42	.	O	O
43	1	O	O
44	,	O	O
45	vomitus	S-Disease	S-Disease
46	24	O	O
47	.	O	O
48	2	O	O
49	/	O	O
50	9	O	O
51	.	O	O
52	1	O	O
53	/	O	O
54	0	O	O
55	,	O	O
56	diarrhea	S-Disease	S-Disease
57	36	O	O
58	.	O	O
59	4	O	O
60	/	O	O
61	6	O	O
62	.	O	O
63	1	O	O
64	/	O	O
65	3	O	O
66	.	O	O
67	0	O	O
68	,	O	O
69	stomatitis	S-Disease	S-Disease
70	18	O	O
71	.	O	O
72	2	O	O
73	/	O	O
74	9	O	O
75	.	O	O
76	1	O	O
77	/	O	O
78	0	O	O
79	,	O	O
80	hand	B-Disease	B-Disease
81	-	I-Disease	O
82	foot	I-Disease	I-Disease
83	syndrome	E-Disease	S-Disease
84	12	O	O
85	.	O	O
86	1	O	O
87	/	O	O
88	0	O	O
89	/	O	O
90	0	O	O
91	.	O	O

0	Two	O	O
1	patients	O	O
2	developed	O	O
3	hemolytic	B-Disease	O
4	-	I-Disease	O
5	uremic	I-Disease	B-Disease
6	syndrome	E-Disease	E-Disease
7	(	O	O
8	HUS	S-Disease	S-Disease
9	)	O	O
10	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	High	O	O
3	-	O	O
4	dose	O	O
5	5	B-Chemical	O
6	-	I-Chemical	O
7	FU	E-Chemical	O
8	/	O	O
9	FA	S-Chemical	O
10	/	O	O
11	MMC	S-Chemical	O
12	is	O	O
13	an	O	O
14	effective	O	O
15	and	O	O
16	well	O	O
17	-	O	O
18	tolerated	O	O
19	outpatient	O	O
20	regimen	O	O
21	for	O	O
22	AGC	S-Disease	S-Chemical
23	(	O	O
24	objective	O	O
25	response	O	O
26	rate	O	O
27	54	O	O
28	.	O	O
29	6	O	O
30	%	O	O
31	)	O	O
32	.	O	O

0	It	O	O
1	may	O	O
2	serve	O	O
3	as	O	O
4	an	O	O
5	alternative	O	O
6	to	O	O
7	cisplatin	S-Chemical	S-Chemical
8	-	O	O
9	containing	O	O
10	regimens	O	O
11	;	O	O
12	however	O	O
13	,	O	O
14	it	O	O
15	has	O	O
16	to	O	O
17	be	O	O
18	considered	O	O
19	that	O	O
20	possibly	O	O
21	HUS	S-Disease	S-Disease
22	may	O	O
23	occur	O	O
24	.	O	O

0	Persistent	O	O
1	sterile	O	O
2	leukocyturia	S-Disease	S-Disease
3	is	O	O
4	associated	O	O
5	with	O	O
6	impaired	B-Disease	B-Disease
7	renal	I-Disease	I-Disease
8	function	E-Disease	E-Disease
9	in	O	O
10	human	B-Disease	B-Disease
11	immunodeficiency	I-Disease	I-Disease
12	virus	I-Disease	E-Disease
13	type	I-Disease	I-Disease
14	1	I-Disease	E-Disease
15	-	I-Disease	I-Disease
16	infected	E-Disease	E-Disease
17	children	O	O
18	treated	O	O
19	with	O	O
20	indinavir	S-Chemical	S-Disease
21	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Prolonged	O	O
3	administration	O	O
4	of	O	O
5	indinavir	S-Chemical	S-Chemical
6	is	O	O
7	associated	O	O
8	with	O	O
9	the	O	O
10	occurrence	O	O
11	of	O	O
12	a	O	O
13	variety	O	O
14	of	O	O
15	renal	O	B-Disease
16	complications	O	E-Disease
17	in	O	O
18	adults	O	O
19	.	O	O

0	DESIGN	O	O
1	:	O	O
2	A	O	O
3	prospective	O	O
4	study	O	O
5	to	O	O
6	monitor	O	O
7	indinavir	S-Chemical	O
8	-	O	O
9	related	O	O
10	nephrotoxicity	S-Disease	S-Disease
11	in	O	O
12	a	O	O
13	cohort	O	O
14	of	O	O
15	30	O	O
16	human	B-Disease	B-Disease
17	immunodeficiency	I-Disease	I-Disease
18	virus	I-Disease	E-Disease
19	type	I-Disease	B-Disease
20	1	I-Disease	E-Disease
21	-	I-Disease	O
22	infected	E-Disease	O
23	children	O	O
24	treated	O	O
25	with	O	O
26	indinavir	S-Chemical	S-Chemical
27	.	O	O

0	METHODS	O	O
1	:	O	O
2	Urinary	O	O
3	pH	O	O
4	,	O	O
5	albumin	O	S-Chemical
6	,	O	O
7	creatinine	S-Chemical	S-Chemical
8	,	O	O
9	the	O	O
10	presence	O	O
11	of	O	O
12	erythrocytes	O	S-Disease
13	,	O	O
14	leukocytes	O	S-Disease
15	,	O	O
16	bacteria	O	O
17	and	O	O
18	crystals	O	O
19	,	O	O
20	and	O	O
21	culture	O	O
22	were	O	O
23	analyzed	O	O
24	every	O	O
25	3	O	O
26	months	O	O
27	for	O	O
28	96	O	O
29	weeks	O	O
30	.	O	O

0	Serum	O	O
1	creatinine	S-Chemical	S-Chemical
2	levels	O	O
3	were	O	O
4	routinely	O	O
5	determined	O	O
6	at	O	O
7	the	O	O
8	same	O	O
9	time	O	O
10	points	O	O
11	.	O	O

0	Steady	O	O
1	-	O	O
2	state	O	O
3	pharmacokinetics	O	O
4	of	O	O
5	indinavir	S-Chemical	S-Chemical
6	were	O	O
7	done	O	O
8	at	O	O
9	week	O	O
10	4	O	O
11	after	O	O
12	the	O	O
13	initiation	O	O
14	of	O	O
15	indinavir	S-Chemical	S-Chemical
16	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	cumulative	O	O
4	incidence	O	O
5	of	O	O
6	persistent	O	O
7	sterile	O	O
8	leukocyturia	S-Disease	S-Disease
9	(	O	O
10	>	O	O
11	or	O	O
12	=	O	O
13	75	O	O
14	cells	O	O
15	/	O	O
16	micro	O	O
17	L	O	O
18	in	O	O
19	at	O	O
20	least	O	O
21	2	O	O
22	consecutive	O	O
23	visits	O	O
24	)	O	O
25	after	O	O
26	96	O	O
27	weeks	O	O
28	was	O	O
29	53	O	O
30	%	O	O
31	.	O	O

0	Persistent	O	O
1	sterile	O	O
2	leukocyturia	S-Disease	S-Disease
3	was	O	O
4	frequently	O	O
5	associated	O	O
6	with	O	O
7	a	O	O
8	mild	O	O
9	increase	O	O
10	in	O	O
11	the	O	O
12	urine	O	O
13	albumin	O	S-Chemical
14	/	O	O
15	creatinine	S-Chemical	S-Chemical
16	ratio	O	O
17	and	O	O
18	by	O	O
19	microscopic	O	O
20	hematuria	S-Disease	O
21	.	O	O

0	The	O	O
1	cumulative	O	O
2	incidence	O	O
3	of	O	O
4	serum	O	O
5	creatinine	S-Chemical	S-Chemical
6	levels	O	O
7	>	O	O
8	50	O	O
9	%	O	O
10	above	O	O
11	normal	O	O
12	was	O	O
13	33	O	O
14	%	O	O
15	after	O	O
16	96	O	O
17	weeks	O	O
18	.	O	O

0	Children	O	O
1	with	O	O
2	persistent	O	O
3	sterile	O	S-Disease
4	leukocyturia	S-Disease	S-Disease
5	more	O	O
6	frequently	O	O
7	had	O	O
8	serum	O	O
9	creatinine	S-Chemical	S-Chemical
10	levels	O	O
11	of	O	O
12	50	O	O
13	%	O	O
14	above	O	O
15	normal	O	O
16	than	O	O
17	those	O	O
18	children	O	O
19	without	O	O
20	persistent	O	O
21	sterile	O	O
22	leukocyturia	S-Disease	S-Disease
23	.	O	O

0	In	O	O
1	children	O	O
2	younger	O	O
3	than	O	O
4	5	O	O
5	.	O	O
6	6	O	O
7	years	O	O
8	,	O	O
9	persistent	O	O
10	sterile	O	O
11	leukocyturia	S-Disease	S-Disease
12	was	O	O
13	significantly	O	O
14	more	O	O
15	frequent	O	O
16	than	O	O
17	in	O	O
18	older	O	O
19	children	O	O
20	.	O	O

0	A	O	O
1	higher	O	O
2	cumulative	O	O
3	incidence	O	O
4	of	O	O
5	persistent	O	O
6	leukocyturia	S-Disease	S-Disease
7	was	O	O
8	found	O	O
9	in	O	O
10	children	O	O
11	with	O	O
12	an	O	O
13	area	O	O
14	under	O	O
15	the	O	O
16	curve	O	O
17	>	O	O
18	19	O	O
19	mg	O	O
20	/	O	O
21	L	O	O
22	x	O	O
23	h	O	O
24	or	O	O
25	a	O	O
26	peak	O	O
27	serum	O	O
28	level	O	O
29	of	O	O
30	indinavir	S-Chemical	S-Chemical
31	>	O	O
32	12	O	O
33	mg	O	O
34	/	O	O
35	L	O	O
36	.	O	O

0	In	O	O
1	4	O	O
2	children	O	O
3	,	O	O
4	indinavir	S-Chemical	S-Chemical
5	was	O	O
6	discontinued	O	O
7	because	O	O
8	of	O	O
9	nephrotoxicity	S-Disease	S-Disease
10	.	O	O

0	Subsequently	O	O
1	,	O	O
2	the	O	O
3	serum	O	O
4	creatinine	S-Chemical	S-Chemical
5	levels	O	O
6	decreased	O	O
7	,	O	O
8	the	O	O
9	urine	O	O
10	albumin	O	S-Chemical
11	/	O	O
12	creatinine	S-Chemical	S-Chemical
13	ratios	O	O
14	returned	O	O
15	to	O	O
16	zero	O	O
17	,	O	O
18	and	O	O
19	the	O	O
20	leukocyturia	S-Disease	S-Disease
21	disappeared	O	O
22	within	O	O
23	3	O	O
24	months	O	O
25	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Children	O	O
3	treated	O	O
4	with	O	O
5	indinavir	S-Chemical	S-Chemical
6	have	O	O
7	a	O	O
8	high	O	O
9	cumulative	O	O
10	incidence	O	O
11	of	O	O
12	persistent	O	O
13	sterile	O	B-Disease
14	leukocyturia	S-Disease	E-Disease
15	.	O	O

0	Children	O	O
1	with	O	O
2	persistent	O	O
3	sterile	O	S-Disease
4	leukocyturia	S-Disease	S-Disease
5	more	O	O
6	frequently	O	O
7	had	O	O
8	an	O	O
9	increase	O	O
10	in	O	O
11	serum	O	O
12	creatinine	S-Chemical	S-Chemical
13	levels	O	O
14	of	O	O
15	>	O	O
16	50	O	O
17	%	O	O
18	above	O	O
19	normal	O	O
20	.	O	O

0	The	O	O
1	impairment	B-Disease	O
2	of	I-Disease	O
3	the	I-Disease	O
4	renal	I-Disease	B-Disease
5	function	E-Disease	E-Disease
6	in	O	O
7	these	O	O
8	children	O	O
9	occurred	O	O
10	in	O	O
11	the	O	O
12	absence	O	O
13	of	O	O
14	clinical	O	O
15	symptoms	O	O
16	of	O	O
17	nephrolithiasis	S-Disease	S-Disease
18	.	O	O

0	Indinavir	S-Chemical	S-Chemical
1	-	O	O
2	associated	O	O
3	nephrotoxicity	S-Disease	S-Disease
4	must	O	O
5	be	O	O
6	monitored	O	O
7	closely	O	O
8	,	O	O
9	especially	O	O
10	in	O	O
11	children	O	O
12	with	O	O
13	risk	O	O
14	factors	O	O
15	such	O	O
16	as	O	O
17	persistent	O	O
18	sterile	O	O
19	leukocyturia	S-Disease	S-Disease
20	,	O	O
21	age	O	O
22	<	O	O
23	5	O	O
24	.	O	O
25	6	O	O
26	years	O	O
27	,	O	O
28	an	O	O
29	area	O	O
30	under	O	O
31	the	O	O
32	curve	O	O
33	of	O	O
34	indinavir	S-Chemical	S-Chemical
35	>	O	O
36	19	O	O
37	mg	O	O
38	/	O	O
39	L	O	O
40	x	O	O
41	h	O	O
42	,	O	O
43	and	O	O
44	a	O	O
45	C	O	O
46	(	O	O
47	max	O	O
48	)	O	O
49	>	O	O
50	12	O	O
51	mg	O	O
52	/	O	O
53	L	O	O
54	.	O	O

0	Utility	O	O
1	of	O	O
2	troponin	O	B-Chemical
3	I	O	E-Chemical
4	in	O	O
5	patients	O	O
6	with	O	O
7	cocaine	S-Chemical	S-Chemical
8	-	O	O
9	associated	O	O
10	chest	B-Disease	B-Disease
11	pain	E-Disease	E-Disease
12	.	O	O

0	Baseline	O	O
1	electrocardiogram	O	O
2	abnormalities	O	O
3	and	O	O
4	market	O	O
5	elevations	O	O
6	not	O	O
7	associated	O	O
8	with	O	O
9	myocardial	B-Disease	B-Disease
10	necrosis	E-Disease	I-Disease
11	make	O	O
12	accurate	O	O
13	diagnosis	O	O
14	of	O	O
15	myocardial	B-Disease	B-Disease
16	infarction	E-Disease	E-Disease
17	(	O	O
18	MI	S-Disease	S-Disease
19	)	O	O
20	difficult	O	O
21	in	O	O
22	patients	O	O
23	with	O	O
24	cocaine	S-Chemical	S-Chemical
25	-	O	O
26	associated	O	O
27	chest	B-Disease	B-Disease
28	pain	E-Disease	E-Disease
29	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	assess	O	O
4	outcomes	O	O
5	based	O	O
6	on	O	O
7	troponin	O	S-Chemical
8	positivity	O	E-Chemical
9	in	O	O
10	patients	O	O
11	with	O	O
12	cocaine	S-Chemical	B-Disease
13	chest	B-Disease	I-Disease
14	pain	E-Disease	E-Disease
15	admitted	O	O
16	for	O	O
17	exclusion	O	O
18	of	O	O
19	MI	S-Disease	S-Chemical
20	.	O	O

0	METHODS	O	O
1	:	O	O
2	Outcomes	O	O
3	were	O	O
4	examined	O	O
5	in	O	O
6	patients	O	O
7	admitted	O	O
8	for	O	O
9	possible	O	O
10	MI	S-Disease	S-Disease
11	after	O	O
12	cocaine	S-Chemical	S-Chemical
13	use	O	O
14	.	O	O

0	All	O	O
1	patients	O	O
2	underwent	O	O
3	a	O	O
4	rapid	O	O
5	rule	O	O
6	-	O	O
7	in	O	O
8	protocol	O	O
9	that	O	O
10	included	O	O
11	serial	O	O
12	sampling	O	O
13	of	O	O
14	creatine	S-Chemical	B-Disease
15	kinase	O	E-Disease
16	(	O	O
17	CK	O	S-Chemical
18	)	O	O
19	,	O	O
20	CK	O	B-Chemical
21	-	O	I-Disease
22	MB	O	E-Disease
23	,	O	O
24	and	O	O
25	cardiac	O	B-Disease
26	troponin	O	I-Disease
27	I	O	E-Disease
28	(	O	O
29	cTnI	O	S-Chemical
30	)	O	O
31	over	O	O
32	eight	O	O
33	hours	O	O
34	.	O	O

0	Outcomes	O	O
1	included	O	O
2	CK	O	B-Chemical
3	-	O	O
4	MB	O	O
5	MI	S-Disease	S-Disease
6	(	O	O
7	CK	O	S-Chemical
8	-	O	O
9	MB	O	O
10	>	O	O
11	or	O	O
12	=	O	O
13	8	O	O
14	ng	O	O
15	/	O	O
16	mL	O	O
17	with	O	O
18	a	O	O
19	relative	O	O
20	index	O	O
21	[	O	O
22	(	O	O
23	CK	O	S-Chemical
24	-	O	O
25	MB	O	O
26	x	O	O
27	100	O	O
28	)	O	O
29	/	O	O
30	total	O	O
31	CK	O	S-Disease
32	]	O	O
33	>	O	O
34	or	O	O
35	=	O	O
36	4	O	O
37	,	O	O
38	cardiac	B-Disease	B-Disease
39	death	E-Disease	E-Disease
40	,	O	O
41	and	O	O
42	significant	O	O
43	coronary	B-Disease	B-Disease
44	disease	E-Disease	E-Disease
45	(	O	O
46	>	O	O
47	or	O	O
48	=	O	O
49	50	O	O
50	%	O	O
51	)	O	O
52	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Of	O	O
3	the	O	O
4	246	O	O
5	admitted	O	O
6	patients	O	O
7	,	O	O
8	34	O	O
9	(	O	O
10	14	O	O
11	%	O	O
12	)	O	O
13	met	O	O
14	CK	O	B-Disease
15	-	O	I-Disease
16	MB	O	E-Disease
17	criteria	O	O
18	for	O	O
19	MI	S-Disease	S-Disease
20	and	O	O
21	38	O	O
22	(	O	O
23	16	O	O
24	%	O	O
25	)	O	O
26	had	O	O
27	cTnI	O	S-Disease
28	elevations	O	O
29	.	O	O

0	Three	O	O
1	of	O	O
2	the	O	O
3	four	O	O
4	patients	O	O
5	without	O	O
6	significant	O	O
7	disease	O	S-Disease
8	who	O	O
9	had	O	O
10	cTnI	O	S-Disease
11	elevations	O	O
12	met	O	O
13	CK	O	S-Chemical
14	-	O	O
15	MB	O	O
16	criteria	O	O
17	for	O	O
18	MI	S-Disease	S-Disease
19	,	O	O
20	and	O	O
21	the	O	O
22	other	O	O
23	had	O	O
24	a	O	O
25	peak	O	O
26	CK	O	S-Chemical
27	-	O	I-Disease
28	MB	O	E-Disease
29	level	O	O
30	of	O	O
31	13	O	O
32	ng	O	O
33	/	O	O
34	mL	O	O
35	.	O	O

0	Sensitivities	O	O
1	,	O	O
2	specificities	O	O
3	,	O	O
4	and	O	O
5	positive	O	O
6	and	O	O
7	negative	O	O
8	likelihood	O	O
9	ratios	O	O
10	for	O	O
11	predicting	O	O
12	cardiac	B-Disease	B-Disease
13	death	E-Disease	E-Disease
14	or	O	O
15	significant	O	O
16	disease	O	S-Disease
17	were	O	O
18	high	O	O
19	for	O	O
20	both	O	O
21	CK	O	B-Disease
22	-	O	I-Disease
23	MB	O	I-Disease
24	MI	S-Disease	E-Disease
25	and	O	O
26	cTnI	O	S-Chemical
27	and	O	O
28	were	O	O
29	not	O	O
30	significantly	O	O
31	different	O	O
32	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Most	O	O
3	patients	O	O
4	with	O	O
5	cTnI	O	S-Chemical
6	elevations	O	O
7	meet	O	O
8	CK	O	S-Chemical
9	-	O	O
10	MB	O	E-Disease
11	criteria	O	O
12	for	O	O
13	MI	S-Disease	S-Disease
14	,	O	O
15	as	O	O
16	well	O	O
17	as	O	O
18	have	O	O
19	a	O	O
20	high	O	O
21	incidence	O	O
22	of	O	O
23	underlying	O	O
24	significant	O	O
25	disease	O	S-Disease
26	.	O	O

0	Troponin	O	S-Chemical
1	appears	O	O
2	to	O	O
3	have	O	O
4	an	O	O
5	equivalent	O	O
6	diagnostic	O	O
7	accuracy	O	O
8	compared	O	O
9	with	O	O
10	CK	O	B-Chemical
11	-	O	I-Chemical
12	MB	O	E-Disease
13	for	O	O
14	diagnosing	O	O
15	necrosis	S-Disease	S-Disease
16	in	O	O
17	patients	O	O
18	with	O	O
19	cocaine	S-Chemical	S-Chemical
20	-	O	O
21	associated	O	O
22	chest	B-Disease	B-Disease
23	pain	E-Disease	E-Disease
24	and	O	O
25	suspected	O	O
26	MI	S-Disease	S-Disease
27	.	O	O

0	Acute	O	O
1	interstitial	B-Disease	O
2	nephritis	E-Disease	S-Disease
3	due	O	O
4	to	O	O
5	nicergoline	S-Chemical	S-Chemical
6	(	O	O
7	Sermion	S-Chemical	S-Chemical
8	)	O	O
9	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	acute	O	O
6	interstitial	B-Disease	O
7	nephritis	E-Disease	E-Disease
8	(	O	O
9	AIN	S-Disease	S-Chemical
10	)	O	O
11	due	O	O
12	to	O	O
13	nicergoline	S-Chemical	S-Chemical
14	(	O	O
15	Sermion	S-Chemical	S-Chemical
16	)	O	O
17	.	O	O

0	A	O	O
1	50	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	patient	O	O
7	admitted	O	O
8	to	O	O
9	our	O	O
10	hospital	O	O
11	for	O	O
12	fever	S-Disease	S-Disease
13	and	O	O
14	acute	B-Disease	B-Disease
15	renal	I-Disease	I-Disease
16	failure	E-Disease	E-Disease
17	.	O	O

0	Before	O	O
1	admission	O	O
2	,	O	O
3	he	O	O
4	had	O	O
5	been	O	O
6	taking	O	O
7	nicergoline	S-Chemical	S-Chemical
8	and	O	O
9	bendazac	B-Chemical	B-Chemical
10	lysine	E-Chemical	E-Chemical
11	due	O	O
12	to	O	O
13	retinal	B-Disease	B-Disease
14	vein	I-Disease	I-Disease
15	occlusion	E-Disease	E-Disease
16	at	O	O
17	ophthalmologic	O	S-Disease
18	department	O	O
19	.	O	O

0	Thereafter	O	O
1	,	O	O
2	he	O	O
3	experienced	O	O
4	intermittent	O	O
5	fever	S-Disease	S-Disease
6	and	O	O
7	skin	B-Disease	O
8	rash	E-Disease	O
9	.	O	O

0	On	O	O
1	admission	O	O
2	,	O	O
3	clinical	O	O
4	symptoms	O	O
5	(	O	O
6	i	O	O
7	.	O	O
8	e	O	O
9	.	O	O
10	arthralgia	S-Disease	S-Disease
11	and	O	O
12	fever	S-Disease	S-Disease
13	)	O	O
14	and	O	O
15	laboratory	O	O
16	findings	O	O
17	(	O	O
18	i	O	O
19	.	O	O
20	e	O	O
21	.	O	O
22	eosinophilia	S-Disease	S-Disease
23	and	O	O
24	renal	B-Disease	B-Disease
25	failure	E-Disease	E-Disease
26	)	O	O
27	suggested	O	O
28	AIN	S-Disease	S-Chemical
29	,	O	O
30	and	O	O
31	which	O	O
32	was	O	O
33	confirmed	O	O
34	by	O	O
35	pathologic	O	O
36	findings	O	O
37	on	O	O
38	renal	O	S-Disease
39	biopsy	O	O
40	.	O	O

0	A	O	O
1	lymphocyte	O	O
2	transformation	O	O
3	test	O	O
4	demonstrated	O	O
5	a	O	O
6	positive	O	O
7	result	O	O
8	against	O	O
9	nicergoline	S-Chemical	S-Chemical
10	.	O	O

0	Treatment	O	O
1	was	O	O
2	consisted	O	O
3	of	O	O
4	withdrawal	O	O
5	of	O	O
6	nicergoline	S-Chemical	S-Chemical
7	and	O	O
8	intravenous	O	O
9	methylprednisolone	S-Chemical	S-Chemical
10	,	O	O
11	and	O	O
12	his	O	O
13	renal	O	B-Disease
14	function	O	E-Disease
15	was	O	O
16	completely	O	O
17	recovered	O	O
18	.	O	O

0	To	O	O
1	our	O	O
2	knowledge	O	O
3	,	O	O
4	this	O	O
5	is	O	O
6	the	O	O
7	first	O	O
8	report	O	O
9	of	O	O
10	nicergoline	S-Chemical	S-Disease
11	-	O	O
12	associated	O	O
13	AIN	S-Disease	S-Disease
14	.	O	O

0	Neuroleptic	B-Disease	B-Disease
1	malignant	I-Disease	I-Disease
2	syndrome	E-Disease	E-Disease
3	complicated	O	O
4	by	O	O
5	massive	O	O
6	intestinal	O	B-Disease
7	bleeding	S-Disease	E-Disease
8	in	O	O
9	a	O	O
10	patient	O	O
11	with	O	O
12	chronic	B-Disease	B-Disease
13	renal	I-Disease	I-Disease
14	failure	E-Disease	E-Disease
15	.	O	O

0	A	O	O
1	patient	O	O
2	with	O	O
3	chronic	B-Disease	B-Disease
4	renal	I-Disease	I-Disease
5	failure	E-Disease	E-Disease
6	(	O	O
7	CRF	S-Disease	S-Disease
8	)	O	O
9	developed	O	O
10	neuroleptic	B-Disease	B-Disease
11	malignant	I-Disease	I-Disease
12	syndrome	E-Disease	E-Disease
13	(	O	O
14	NMS	S-Disease	S-Disease
15	)	O	O
16	after	O	O
17	administration	O	O
18	of	O	O
19	risperidone	S-Chemical	S-Chemical
20	and	O	O
21	levomepromazine	S-Chemical	S-Chemical
22	.	O	O

0	In	O	O
1	addition	O	O
2	to	O	O
3	the	O	O
4	typical	O	O
5	symptoms	O	O
6	of	O	O
7	NMS	S-Disease	S-Disease
8	,	O	O
9	massive	O	O
10	intestinal	O	O
11	bleeding	S-Disease	E-Disease
12	was	O	O
13	observed	O	O
14	during	O	O
15	the	O	O
16	episode	O	O
17	.	O	O

0	This	O	O
1	report	O	O
2	suggests	O	O
3	that	O	O
4	NMS	S-Disease	S-Chemical
5	in	O	O
6	a	O	O
7	patient	O	O
8	with	O	O
9	CRF	S-Disease	S-Disease
10	may	O	O
11	be	O	O
12	complicated	O	O
13	by	O	O
14	intestinal	O	O
15	bleeding	S-Disease	E-Disease
16	and	O	O
17	needs	O	O
18	special	O	O
19	caution	O	O
20	for	O	O
21	this	O	O
22	complication	O	O
23	.	O	O

0	Adrenaline	S-Chemical	O
1	-	O	O
2	induced	O	O
3	hypertension	S-Disease	S-Disease
4	was	O	O
5	used	O	O
6	to	O	O
7	destroy	O	O
8	the	O	O
9	BBB	O	S-Disease
10	,	O	O
11	which	O	O
12	was	O	O
13	evaluated	O	O
14	using	O	O
15	triphenyltetrazolium	S-Chemical	S-Chemical
16	(	O	O
17	TTC	S-Chemical	S-Disease
18	)	O	O
19	staining	O	O
20	of	O	O
21	the	O	O
22	brain	O	O
23	slices	O	O
24	just	O	O
25	after	O	O
26	giving	O	O
27	adrenaline	S-Chemical	O
28	for	O	O
29	30	O	O
30	s	O	O
31	.	O	O

0	In	O	O
1	normal	O	O
2	rats	O	O
3	,	O	O
4	the	O	O
5	whole	O	O
6	brain	O	O
7	sections	O	O
8	exhibited	O	O
9	complete	O	O
10	staining	O	O
11	with	O	O
12	TTC	S-Chemical	S-Chemical
13	.	O	O

0	After	O	O
1	adrenaline	S-Chemical	O
2	infusion	O	O
3	for	O	O
4	30	O	O
5	s	O	O
6	,	O	O
7	there	O	O
8	were	O	O
9	large	O	O
10	unstained	O	O
11	areas	O	O
12	in	O	O
13	the	O	O
14	left	O	O
15	brain	O	O
16	in	O	O
17	right	O	O
18	-	O	O
19	pawed	O	O
20	animals	O	O
21	,	O	O
22	and	O	O
23	vice	O	O
24	versa	O	O
25	in	O	O
26	left	O	O
27	-	O	O
28	pawed	O	O
29	animals	O	O
30	.	O	O

0	Similar	O	O
1	results	O	O
2	were	O	O
3	obtained	O	O
4	in	O	O
5	seizure	S-Disease	S-Disease
6	-	O	O
7	induced	O	O
8	breakdown	O	O
9	of	O	O
10	BBB	O	S-Disease
11	.	O	O

0	Carvedilol	S-Chemical	S-Chemical
1	protects	O	O
2	against	O	O
3	doxorubicin	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	mitochondrial	O	B-Disease
7	cardiomyopathy	S-Disease	E-Disease
8	.	O	O

0	Several	O	O
1	cytopathic	O	S-Chemical
2	mechanisms	O	O
3	have	O	O
4	been	O	O
5	suggested	O	O
6	to	O	O
7	mediate	O	O
8	the	O	O
9	dose	O	O
10	-	O	O
11	limiting	O	O
12	cumulative	O	O
13	and	O	O
14	irreversible	O	O
15	cardiomyopathy	S-Disease	S-Disease
16	caused	O	O
17	by	O	O
18	doxorubicin	S-Chemical	S-Chemical
19	.	O	O

0	Recent	O	O
1	evidence	O	O
2	indicates	O	O
3	that	O	O
4	oxidative	O	O
5	stress	O	O
6	and	O	O
7	mitochondrial	B-Disease	B-Disease
8	dysfunction	E-Disease	E-Disease
9	are	O	O
10	key	O	O
11	factors	O	O
12	in	O	O
13	the	O	O
14	pathogenic	O	O
15	process	O	O
16	.	O	O

0	The	O	O
1	objective	O	O
2	of	O	O
3	this	O	O
4	investigation	O	O
5	was	O	O
6	to	O	O
7	test	O	O
8	the	O	O
9	hypothesis	O	O
10	that	O	O
11	carvedilol	S-Chemical	S-Chemical
12	,	O	O
13	a	O	O
14	nonselective	O	O
15	beta	O	O
16	-	O	O
17	adrenergic	O	O
18	receptor	O	O
19	antagonist	O	O
20	with	O	O
21	potent	O	O
22	antioxidant	O	O
23	properties	O	O
24	,	O	O
25	protects	O	O
26	against	O	O
27	the	O	O
28	cardiac	O	S-Disease
29	and	O	O
30	hepatic	O	S-Disease
31	mitochondrial	O	O
32	bioenergetic	O	O
33	dysfunction	O	O
34	associated	O	O
35	with	O	O
36	subchronic	O	O
37	doxorubicin	S-Chemical	S-Chemical
38	toxicity	S-Disease	S-Disease
39	.	O	O

0	Heart	O	O
1	and	O	O
2	liver	O	O
3	mitochondria	O	E-Disease
4	were	O	O
5	isolated	O	O
6	from	O	O
7	rats	O	O
8	treated	O	O
9	for	O	O
10	7	O	O
11	weeks	O	O
12	with	O	O
13	doxorubicin	S-Chemical	S-Chemical
14	(	O	O
15	2	O	O
16	mg	O	O
17	/	O	O
18	kg	O	O
19	sc	O	O
20	/	O	O
21	week	O	O
22	)	O	O
23	,	O	O
24	carvedilol	S-Chemical	S-Chemical
25	(	O	O
26	1	O	O
27	mg	O	O
28	/	O	O
29	kg	O	O
30	ip	O	O
31	/	O	O
32	week	O	O
33	)	O	O
34	,	O	O
35	or	O	O
36	the	O	O
37	combination	O	O
38	of	O	O
39	the	O	O
40	two	O	O
41	drugs	O	O
42	.	O	O

0	Heart	O	O
1	mitochondria	O	E-Disease
2	isolated	O	O
3	from	O	O
4	doxorubicin	S-Chemical	S-Chemical
5	-	O	O
6	treated	O	O
7	rats	O	O
8	exhibited	O	O
9	depressed	O	O
10	rates	O	O
11	for	O	O
12	state	O	O
13	3	O	O
14	respiration	O	O
15	(	O	O
16	336	O	O
17	+	O	O
18	/	O	O
19	-	O	O
20	26	O	O
21	versus	O	O
22	425	O	O
23	+	O	O
24	/	O	O
25	-	O	O
26	53	O	O
27	natom	O	O
28	O	O	O
29	/	O	O
30	min	O	O
31	/	O	O
32	mg	O	O
33	protein	O	O
34	)	O	O
35	and	O	O
36	a	O	O
37	lower	O	O
38	respiratory	O	O
39	control	O	O
40	ratio	O	O
41	(	O	O
42	RCR	O	O
43	)	O	O
44	(	O	O
45	4	O	O
46	.	O	O
47	3	O	O
48	+	O	O
49	/	O	O
50	-	O	O
51	0	O	O
52	.	O	O
53	6	O	O
54	versus	O	O
55	5	O	O
56	.	O	O
57	8	O	O
58	+	O	O
59	/	O	O
60	-	O	O
61	0	O	O
62	.	O	O
63	4	O	O
64	)	O	O
65	compared	O	O
66	with	O	O
67	cardiac	O	B-Disease
68	mitochondria	O	E-Disease
69	isolated	O	O
70	from	O	O
71	saline	O	S-Chemical
72	-	O	O
73	treated	O	O
74	rats	O	O
75	.	O	O

0	Mitochondrial	O	O
1	calcium	S-Chemical	O
2	-	O	O
3	loading	O	O
4	capacity	O	O
5	and	O	O
6	the	O	O
7	activity	O	O
8	of	O	O
9	NADH	O	S-Chemical
10	-	O	E-Chemical
11	dehydrogenase	O	E-Chemical
12	were	O	O
13	also	O	O
14	suppressed	O	O
15	in	O	O
16	cardiac	O	B-Disease
17	mitochondria	O	E-Disease
18	from	O	O
19	doxorubicin	S-Chemical	S-Chemical
20	-	O	O
21	treated	O	O
22	rats	O	O
23	.	O	O

0	Doxorubicin	S-Chemical	S-Chemical
1	treatment	O	O
2	also	O	O
3	caused	O	O
4	a	O	O
5	decrease	O	O
6	in	O	O
7	RCR	O	O
8	for	O	O
9	liver	O	O
10	mitochondria	O	E-Disease
11	(	O	O
12	3	O	O
13	.	O	O
14	9	O	O
15	+	O	O
16	/	O	O
17	-	O	O
18	0	O	O
19	.	O	O
20	9	O	O
21	versus	O	O
22	5	O	O
23	.	O	O
24	6	O	O
25	+	O	O
26	/	O	O
27	-	O	O
28	0	O	O
29	.	O	O
30	7	O	O
31	for	O	O
32	control	O	O
33	rats	O	O
34	)	O	O
35	and	O	O
36	inhibition	O	O
37	of	O	O
38	hepatic	O	S-Disease
39	cytochrome	O	S-Chemical
40	oxidase	O	E-Chemical
41	activity	O	O
42	.	O	O

0	Coadministration	O	O
1	of	O	O
2	carvedilol	S-Chemical	S-Chemical
3	decreased	O	O
4	the	O	O
5	extent	O	O
6	of	O	O
7	cellular	O	B-Disease
8	vacuolization	O	E-Disease
9	in	O	O
10	cardiac	O	B-Disease
11	myocytes	O	E-Disease
12	and	O	O
13	prevented	O	O
14	the	O	O
15	inhibitory	O	O
16	effect	O	O
17	of	O	O
18	doxorubicin	S-Chemical	S-Chemical
19	on	O	O
20	mitochondrial	O	B-Disease
21	respiration	O	E-Disease
22	in	O	O
23	both	O	O
24	heart	O	O
25	and	O	O
26	liver	O	O
27	.	O	O

0	Carvedilol	S-Chemical	S-Chemical
1	also	O	O
2	prevented	O	O
3	the	O	O
4	decrease	O	O
5	in	O	O
6	mitochondrial	O	O
7	Ca	S-Chemical	E-Chemical
8	(	O	O
9	2	O	O
10	+	O	O
11	)	O	O
12	loading	O	O
13	capacity	O	O
14	and	O	O
15	the	O	O
16	inhibition	O	O
17	of	O	O
18	the	O	O
19	respiratory	O	B-Disease
20	complexes	O	E-Disease
21	of	O	O
22	heart	O	B-Disease
23	mitochondria	O	E-Disease
24	caused	O	O
25	by	O	O
26	doxorubicin	S-Chemical	S-Chemical
27	.	O	O

0	Carvedilol	S-Chemical	S-Chemical
1	by	O	O
2	itself	O	O
3	did	O	O
4	not	O	O
5	affect	O	O
6	any	O	O
7	of	O	O
8	the	O	O
9	parameters	O	O
10	measured	O	O
11	for	O	O
12	heart	O	S-Disease
13	or	O	O
14	liver	O	B-Disease
15	mitochondria	O	E-Disease
16	.	O	O

0	It	O	O
1	is	O	O
2	concluded	O	O
3	that	O	O
4	this	O	O
5	protection	O	O
6	by	O	O
7	carvedilol	S-Chemical	S-Chemical
8	against	O	O
9	both	O	O
10	the	O	O
11	structural	O	O
12	and	O	O
13	functional	O	O
14	cardiac	O	B-Disease
15	tissue	O	I-Disease
16	damage	O	E-Disease
17	may	O	O
18	afford	O	O
19	significant	O	O
20	clinical	O	O
21	advantage	O	O
22	in	O	O
23	minimizing	O	O
24	the	O	O
25	dose	O	O
26	-	O	O
27	limiting	O	O
28	mitochondrial	B-Disease	B-Disease
29	dysfunction	E-Disease	E-Disease
30	and	O	O
31	cardiomyopathy	S-Disease	S-Disease
32	that	O	O
33	accompanies	O	O
34	long	O	O
35	-	O	O
36	term	O	O
37	doxorubicin	S-Chemical	S-Chemical
38	therapy	O	O
39	in	O	O
40	cancer	S-Disease	S-Disease
41	patients	O	O
42	.	O	O

0	Cocaine	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	hyperactivity	S-Disease	S-Disease
4	is	O	O
5	more	O	O
6	influenced	O	O
7	by	O	O
8	adenosine	S-Chemical	S-Chemical
9	receptor	O	O
10	agonists	O	O
11	than	O	O
12	amphetamine	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	hyperactivity	S-Disease	S-Disease
16	.	O	O

0	The	O	O
1	influence	O	O
2	of	O	O
3	adenosine	S-Chemical	B-Chemical
4	receptor	O	O
5	agonists	O	O
6	and	O	O
7	antagonists	O	O
8	on	O	O
9	cocaine	S-Chemical	S-Chemical
10	-	O	O
11	and	O	O
12	amphetamine	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	hyperactivity	S-Disease	S-Disease
16	was	O	O
17	examined	O	O
18	in	O	O
19	mice	O	O
20	.	O	O

0	All	O	O
1	adenosine	S-Chemical	S-Chemical
2	receptor	O	O
3	agonists	O	O
4	significantly	O	O
5	decreased	B-Disease	O
6	the	I-Disease	O
7	locomotor	I-Disease	I-Disease
8	activity	E-Disease	E-Disease
9	in	O	O
10	mice	O	O
11	,	O	O
12	and	O	O
13	the	O	O
14	effects	O	O
15	were	O	O
16	dose	O	O
17	-	O	O
18	dependent	O	O
19	.	O	O

0	It	O	O
1	seems	O	O
2	that	O	O
3	adenosine	S-Chemical	B-Chemical
4	A1	O	E-Chemical
5	and	O	O
6	A2	O	S-Disease
7	receptors	O	O
8	might	O	O
9	be	O	O
10	involved	O	O
11	in	O	O
12	this	O	O
13	reaction	O	O
14	.	O	O

0	Moreover	O	O
1	,	O	O
2	all	O	O
3	adenosine	S-Chemical	S-Chemical
4	receptor	O	O
5	agonists	O	O
6	:	O	O
7	2	B-Chemical	B-Chemical
8	-	I-Chemical	I-Chemical
9	p	I-Chemical	I-Chemical
10	-	I-Chemical	I-Chemical
11	(	I-Chemical	O
12	2	I-Chemical	I-Chemical
13	-	I-Chemical	O
14	carboxyethyl	I-Chemical	S-Chemical
15	)	I-Chemical	O
16	phenethylamino	I-Chemical	S-Chemical
17	-	I-Chemical	I-Chemical
18	5	I-Chemical	I-Chemical
19	'	I-Chemical	I-Chemical
20	-	I-Chemical	I-Chemical
21	N	I-Chemical	E-Chemical
22	-	I-Chemical	I-Chemical
23	ethylcarboxamidoadenosine	E-Chemical	E-Chemical
24	(	O	O
25	CGS	B-Chemical	B-Chemical
26	21680	E-Chemical	E-Chemical
27	)	O	O
28	,	O	O
29	A2A	O	S-Chemical
30	receptor	O	O
31	agonist	O	O
32	,	O	O
33	N6	B-Chemical	B-Chemical
34	-	I-Chemical	I-Chemical
35	cyclopentyladenosine	E-Chemical	B-Chemical
36	(	O	O
37	CPA	S-Chemical	S-Chemical
38	)	O	O
39	,	O	O
40	A1	O	S-Disease
41	receptor	O	O
42	agonist	O	O
43	,	O	O
44	and	O	O
45	5	B-Chemical	B-Chemical
46	'	I-Chemical	I-Chemical
47	-	I-Chemical	I-Chemical
48	N	I-Chemical	I-Chemical
49	-	I-Chemical	I-Chemical
50	ethylcarboxamidoadenosine	E-Chemical	E-Chemical
51	(	O	O
52	NECA	S-Chemical	S-Chemical
53	)	O	O
54	,	O	O
55	A2	O	S-Disease
56	/	O	O
57	A1	O	E-Chemical
58	receptor	O	O
59	agonist	O	O
60	significantly	O	O
61	and	O	O
62	dose	O	O
63	-	O	O
64	dependently	O	O
65	decreased	O	O
66	cocaine	S-Chemical	S-Chemical
67	-	O	O
68	induced	O	O
69	locomotor	O	B-Disease
70	activity	O	E-Disease
71	.	O	O

0	CPA	S-Chemical	S-Chemical
1	reduced	O	O
2	cocaine	S-Chemical	S-Chemical
3	action	O	O
4	at	O	O
5	the	O	O
6	doses	O	O
7	which	O	O
8	,	O	O
9	given	O	O
10	alone	O	O
11	,	O	O
12	did	O	O
13	not	O	O
14	influence	O	O
15	motility	O	O
16	,	O	O
17	while	O	O
18	CGS	B-Chemical	B-Chemical
19	21680	E-Chemical	E-Chemical
20	and	O	O
21	NECA	S-Chemical	S-Chemical
22	decreased	O	O
23	the	O	O
24	action	O	O
25	of	O	O
26	cocaine	S-Chemical	S-Chemical
27	at	O	O
28	the	O	O
29	doses	O	O
30	which	O	O
31	,	O	O
32	given	O	O
33	alone	O	O
34	,	O	O
35	decreased	O	O
36	locomotor	O	B-Disease
37	activity	O	E-Disease
38	in	O	O
39	animals	O	O
40	.	O	O

0	These	O	O
1	results	O	O
2	suggest	O	O
3	the	O	O
4	involvement	O	O
5	of	O	O
6	both	O	O
7	adenosine	S-Chemical	S-Chemical
8	receptors	O	O
9	in	O	O
10	the	O	O
11	action	O	O
12	of	O	O
13	cocaine	S-Chemical	S-Chemical
14	although	O	O
15	agonists	O	O
16	of	O	O
17	A1	O	S-Disease
18	receptors	O	O
19	seem	O	O
20	to	O	O
21	have	O	O
22	stronger	O	O
23	influence	O	O
24	on	O	O
25	it	O	O
26	.	O	O

0	The	O	O
1	selective	O	O
2	blockade	O	O
3	of	O	O
4	A2	O	B-Chemical
5	adenosine	S-Chemical	E-Chemical
6	receptor	O	O
7	by	O	O
8	DMPX	S-Chemical	S-Chemical
9	(	O	O
10	3	B-Chemical	O
11	,	I-Chemical	O
12	7	I-Chemical	O
13	-	I-Chemical	I-Chemical
14	dimethyl	I-Chemical	I-Chemical
15	-	I-Chemical	I-Chemical
16	1	I-Chemical	I-Chemical
17	-	I-Chemical	I-Chemical
18	propargylxanthine	E-Chemical	E-Chemical
19	)	O	O
20	significantly	O	O
21	enhanced	O	O
22	cocaine	S-Chemical	S-Chemical
23	-	O	O
24	induced	O	O
25	locomotor	O	S-Disease
26	activity	O	O
27	of	O	O
28	animals	O	O
29	.	O	O

0	Caffeine	S-Chemical	S-Chemical
1	had	O	O
2	similar	O	O
3	action	O	O
4	but	O	O
5	the	O	O
6	effect	O	O
7	was	O	O
8	not	O	O
9	significant	O	O
10	.	O	O

0	CPT	S-Chemical	S-Chemical
1	(	O	O
2	8	B-Chemical	O
3	-	I-Chemical	O
4	cyclopentyltheophylline	E-Chemical	S-Chemical
5	)	O	O
6	-	O	O
7	-	O	O
8	A1	O	E-Chemical
9	receptor	O	O
10	antagonist	O	O
11	,	O	O
12	did	O	O
13	not	O	O
14	show	O	O
15	any	O	O
16	influence	O	O
17	in	O	O
18	this	O	O
19	test	O	O
20	.	O	O

0	Similarly	O	O
1	,	O	O
2	all	O	O
3	adenosine	S-Chemical	S-Chemical
4	receptor	O	O
5	agonists	O	O
6	decreased	O	O
7	amphetamine	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	hyperactivity	S-Disease	S-Disease
11	,	O	O
12	but	O	O
13	at	O	O
14	the	O	O
15	higher	O	O
16	doses	O	O
17	than	O	O
18	those	O	O
19	which	O	O
20	were	O	O
21	active	O	O
22	in	O	O
23	cocaine	S-Chemical	S-Chemical
24	-	O	O
25	induced	O	O
26	hyperactivity	S-Disease	S-Disease
27	.	O	O

0	The	O	O
1	selective	O	O
2	blockade	O	O
3	of	O	O
4	A2	O	B-Chemical
5	adenosine	S-Chemical	E-Chemical
6	receptors	O	O
7	(	O	O
8	DMPX	S-Chemical	S-Chemical
9	)	O	O
10	and	O	O
11	non	O	O
12	-	O	O
13	selective	O	O
14	blockade	O	O
15	of	O	O
16	adenosine	S-Chemical	S-Chemical
17	receptors	O	O
18	(	O	O
19	caffeine	S-Chemical	S-Chemical
20	)	O	O
21	significantly	O	O
22	increased	O	O
23	the	O	O
24	action	O	O
25	of	O	O
26	amphetamine	S-Chemical	S-Chemical
27	in	O	O
28	the	O	O
29	locomotor	O	O
30	activity	O	O
31	test	O	O
32	.	O	O

0	Our	O	O
1	results	O	O
2	have	O	O
3	shown	O	O
4	that	O	O
5	all	O	O
6	adenosine	S-Chemical	S-Chemical
7	receptor	O	O
8	agonists	O	O
9	(	O	O
10	A1	O	S-Disease
11	and	O	O
12	A2	O	S-Disease
13	)	O	O
14	reduce	O	O
15	cocaine	S-Chemical	S-Chemical
16	-	O	O
17	and	O	O
18	amphetamine	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	locomotor	O	B-Disease
22	activity	O	E-Disease
23	and	O	O
24	indicate	O	O
25	that	O	O
26	cocaine	S-Chemical	S-Chemical
27	-	O	O
28	induced	O	O
29	hyperactivity	S-Disease	S-Disease
30	is	O	O
31	more	O	O
32	influenced	O	O
33	by	O	O
34	adenosine	S-Chemical	S-Chemical
35	receptor	O	O
36	agonists	O	O
37	(	O	O
38	particularly	O	O
39	A1	O	S-Disease
40	receptors	O	O
41	)	O	O
42	than	O	O
43	amphetamine	S-Chemical	S-Chemical
44	-	O	O
45	induced	O	O
46	hyperactivity	S-Disease	S-Disease
47	.	O	O

0	Amiodarone	S-Chemical	S-Chemical
1	and	O	O
2	the	O	O
3	risk	O	O
4	of	O	O
5	bradyarrhythmia	S-Disease	S-Disease
6	requiring	O	O
7	permanent	O	O
8	pacemaker	O	O
9	in	O	O
10	elderly	O	O
11	patients	O	O
12	with	O	O
13	atrial	B-Disease	B-Disease
14	fibrillation	E-Disease	E-Disease
15	and	O	O
16	prior	O	O
17	myocardial	B-Disease	B-Disease
18	infarction	E-Disease	E-Disease
19	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	The	O	O
3	aim	O	O
4	of	O	O
5	this	O	O
6	study	O	O
7	was	O	O
8	to	O	O
9	determine	O	O
10	whether	O	O
11	the	O	O
12	use	O	O
13	of	O	O
14	amiodarone	S-Chemical	S-Chemical
15	in	O	O
16	patients	O	O
17	with	O	O
18	atrial	B-Disease	B-Disease
19	fibrillation	E-Disease	E-Disease
20	(	O	O
21	AF	S-Disease	S-Chemical
22	)	O	O
23	increases	O	O
24	the	O	O
25	risk	O	O
26	of	O	O
27	bradyarrhythmia	S-Disease	S-Disease
28	requiring	O	O
29	a	O	O
30	permanent	O	O
31	pacemaker	O	O
32	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Reports	O	O
3	of	O	O
4	severe	O	O
5	bradyarrhythmia	S-Disease	S-Disease
6	during	O	O
7	amiodarone	S-Chemical	S-Chemical
8	therapy	O	O
9	are	O	O
10	infrequent	O	O
11	and	O	O
12	limited	O	O
13	to	O	O
14	studies	O	O
15	assessing	O	O
16	the	O	O
17	therapy	O	O
18	'	O	O
19	s	O	O
20	use	O	O
21	in	O	O
22	the	O	O
23	management	O	O
24	of	O	O
25	patients	O	O
26	with	O	O
27	ventricular	B-Disease	B-Disease
28	arrhythmias	E-Disease	E-Disease
29	.	O	O

0	METHODS	O	O
1	:	O	O
2	A	O	O
3	study	O	O
4	cohort	O	O
5	of	O	O
6	8	O	O
7	,	O	O
8	770	O	O
9	patients	O	O
10	age	O	O
11	>	O	O
12	or	O	O
13	=	O	O
14	65	O	O
15	years	O	O
16	with	O	O
17	a	O	O
18	new	O	O
19	diagnosis	O	O
20	of	O	O
21	AF	S-Disease	S-Chemical
22	was	O	O
23	identified	O	O
24	from	O	O
25	a	O	O
26	provincewide	O	O
27	database	O	O
28	of	O	O
29	Quebec	O	S-Chemical
30	residents	O	O
31	with	O	O
32	a	O	O
33	myocardial	B-Disease	B-Disease
34	infarction	E-Disease	E-Disease
35	(	O	O
36	MI	S-Disease	S-Disease
37	)	O	O
38	between	O	O
39	1991	O	O
40	and	O	O
41	1999	O	O
42	.	O	O

0	Using	O	O
1	a	O	O
2	nested	O	O
3	case	O	O
4	-	O	O
5	control	O	O
6	design	O	O
7	,	O	O
8	477	O	O
9	cases	O	O
10	of	O	O
11	bradyarrhythmia	S-Disease	S-Disease
12	requiring	O	O
13	a	O	O
14	permanent	O	O
15	pacemaker	O	O
16	were	O	O
17	matched	O	O
18	(	O	O
19	1	O	O
20	:	O	O
21	4	O	O
22	)	O	O
23	to	O	O
24	1	O	O
25	,	O	O
26	908	O	O
27	controls	O	O
28	.	O	O

0	Multivariable	O	O
1	logistic	O	O
2	regression	O	O
3	was	O	O
4	used	O	O
5	to	O	O
6	estimate	O	O
7	the	O	O
8	odds	O	O
9	ratio	O	O
10	(	O	O
11	OR	O	O
12	)	O	O
13	of	O	O
14	pacemaker	O	O
15	insertion	O	O
16	associated	O	O
17	with	O	O
18	amiodarone	S-Chemical	S-Chemical
19	use	O	O
20	,	O	O
21	controlling	O	O
22	for	O	O
23	baseline	O	O
24	risk	O	O
25	factors	O	O
26	and	O	O
27	exposure	O	O
28	to	O	O
29	sotalol	S-Chemical	S-Chemical
30	,	O	O
31	Class	O	O
32	I	O	O
33	antiarrhythmic	O	O
34	agents	O	O
35	,	O	O
36	beta	O	O
37	-	O	O
38	blockers	O	O
39	,	O	O
40	calcium	S-Chemical	B-Disease
41	channel	O	O
42	blockers	O	O
43	,	O	O
44	and	O	O
45	digoxin	S-Chemical	S-Disease
46	.	O	O

0	RESULTS	O	O
1	:	O	O
2	amiodarone	S-Chemical	S-Chemical
3	use	O	O
4	was	O	O
5	associated	O	O
6	with	O	O
7	an	O	O
8	increased	O	O
9	risk	O	O
10	of	O	O
11	pacemaker	O	O
12	insertion	O	O
13	(	O	O
14	OR	O	O
15	:	O	O
16	2	O	O
17	.	O	O
18	14	O	O
19	,	O	O
20	95	O	O
21	%	O	O
22	confidence	O	O
23	interval	O	O
24	[	O	O
25	CI	O	S-Chemical
26	]	O	O
27	:	O	O
28	1	O	O
29	.	O	O
30	30	O	O
31	to	O	O
32	3	O	O
33	.	O	O
34	54	O	O
35	)	O	O
36	.	O	O

0	Digoxin	S-Chemical	S-Chemical
1	was	O	O
2	the	O	O
3	only	O	O
4	other	O	O
5	medication	O	O
6	associated	O	O
7	with	O	O
8	an	O	O
9	increased	O	O
10	risk	O	O
11	of	O	O
12	pacemaker	O	S-Disease
13	insertion	O	O
14	(	O	O
15	OR	O	S-Disease
16	:	O	O
17	1	O	O
18	.	O	O
19	78	O	O
20	,	O	O
21	95	O	O
22	%	O	O
23	CI	O	S-Chemical
24	:	O	O
25	1	O	O
26	.	O	O
27	37	O	O
28	to	O	O
29	2	O	O
30	.	O	O
31	31	O	O
32	)	O	O
33	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	This	O	O
3	study	O	O
4	suggests	O	O
5	that	O	O
6	the	O	O
7	use	O	O
8	of	O	O
9	amiodarone	S-Chemical	S-Chemical
10	in	O	O
11	elderly	O	O
12	patients	O	O
13	with	O	O
14	AF	S-Disease	S-Chemical
15	and	O	O
16	a	O	O
17	previous	O	O
18	MI	S-Disease	S-Disease
19	increases	O	O
20	the	O	O
21	risk	O	O
22	of	O	O
23	bradyarrhythmia	S-Disease	S-Disease
24	requiring	O	O
25	a	O	O
26	permanent	O	O
27	pacemaker	O	O
28	.	O	O

0	The	O	O
1	finding	O	O
2	of	O	O
3	an	O	O
4	augmented	O	O
5	risk	O	O
6	of	O	O
7	pacemaker	O	S-Disease
8	insertion	O	O
9	in	O	O
10	elderly	O	O
11	women	O	O
12	receiving	O	O
13	amiodarone	S-Chemical	S-Chemical
14	requires	O	O
15	further	O	O
16	investigation	O	O
17	.	O	O

0	Indomethacin	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	morphologic	O	O
4	changes	O	O
5	in	O	O
6	the	O	O
7	rat	O	O
8	urinary	O	O
9	bladder	O	I-Disease
10	epithelium	O	E-Disease
11	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	To	O	O
3	evaluate	O	O
4	the	O	O
5	morphologic	O	O
6	changes	O	O
7	in	O	O
8	rat	O	O
9	urothelium	O	E-Disease
10	induced	O	O
11	by	O	O
12	indomethacin	S-Chemical	S-Chemical
13	.	O	O

0	Nonsteroidal	O	O
1	anti	O	O
2	-	O	O
3	inflammatory	O	S-Disease
4	drug	O	O
5	-	O	O
6	induced	O	O
7	cystitis	S-Disease	S-Disease
8	is	O	O
9	a	O	O
10	poorly	O	O
11	recognized	O	O
12	and	O	O
13	under	O	O
14	-	O	O
15	reported	O	O
16	condition	O	O
17	.	O	O

0	In	O	O
1	addition	O	O
2	to	O	O
3	tiaprofenic	B-Chemical	S-Chemical
4	acid	E-Chemical	O
5	,	O	O
6	indomethacin	S-Chemical	S-Chemical
7	has	O	O
8	been	O	O
9	reported	O	O
10	to	O	O
11	be	O	O
12	associated	O	O
13	with	O	O
14	this	O	O
15	condition	O	O
16	.	O	O

0	METHODS	O	O
1	:	O	O
2	Three	O	O
3	groups	O	O
4	were	O	O
5	established	O	O
6	:	O	O
7	a	O	O
8	control	O	O
9	group	O	O
10	(	O	O
11	n	O	O
12	=	O	O
13	10	O	O
14	)	O	O
15	,	O	O
16	a	O	O
17	high	O	O
18	-	O	O
19	dose	O	O
20	group	O	O
21	(	O	O
22	n	O	O
23	=	O	O
24	10	O	O
25	)	O	O
26	,	O	O
27	treated	O	O
28	with	O	O
29	one	O	O
30	intraperitoneal	O	O
31	injection	O	O
32	of	O	O
33	indomethacin	S-Chemical	S-Chemical
34	20	O	O
35	mg	O	O
36	/	O	O
37	kg	O	O
38	,	O	O
39	and	O	O
40	a	O	O
41	therapeutic	O	O
42	dose	O	O
43	group	O	O
44	(	O	O
45	n	O	O
46	=	O	O
47	10	O	O
48	)	O	O
49	in	O	O
50	which	O	O
51	oral	O	O
52	indomethacin	S-Chemical	S-Disease
53	was	O	O
54	administered	O	O
55	3	O	O
56	.	O	O
57	25	O	O
58	mg	O	O
59	/	O	O
60	kg	O	O
61	body	O	O
62	weight	O	O
63	daily	O	O
64	for	O	O
65	3	O	O
66	weeks	O	O
67	.	O	O

0	When	O	O
1	compared	O	O
2	with	O	O
3	the	O	O
4	control	O	O
5	group	O	O
6	,	O	O
7	both	O	O
8	indomethacin	S-Chemical	O
9	groups	O	O
10	revealed	O	O
11	statistically	O	O
12	increased	O	O
13	numbers	O	O
14	of	O	O
15	mast	O	B-Disease
16	cells	O	O
17	in	O	O
18	the	O	O
19	mucosa	O	O
20	(	O	O
21	P	O	S-Disease
22	<	O	O
23	0	O	O
24	.	O	O
25	0001	O	O
26	)	O	O
27	and	O	O
28	penetration	O	O
29	of	O	O
30	lanthanum	B-Chemical	S-Chemical
31	nitrate	E-Chemical	E-Chemical
32	through	O	O
33	intercellular	O	O
34	areas	O	O
35	of	O	O
36	the	O	O
37	epithelium	O	O
38	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Indomethacin	S-Chemical	S-Chemical
3	resulted	O	O
4	in	O	O
5	histopathologic	O	S-Disease
6	findings	O	O
7	typical	O	O
8	of	O	O
9	interstitial	B-Disease	O
10	cystitis	E-Disease	S-Disease
11	,	O	O
12	such	O	O
13	as	O	O
14	leaky	O	O
15	bladder	O	B-Disease
16	epithelium	O	E-Disease
17	and	O	O
18	mucosal	O	O
19	mastocytosis	S-Disease	S-Disease
20	.	O	O

0	The	O	O
1	true	O	O
2	incidence	O	O
3	of	O	O
4	nonsteroidal	O	O
5	anti	O	O
6	-	O	O
7	inflammatory	O	S-Disease
8	drug	O	O
9	-	O	O
10	induced	O	O
11	cystitis	S-Disease	S-Disease
12	in	O	O
13	humans	O	O
14	must	O	O
15	be	O	O
16	clarified	O	O
17	by	O	O
18	prospective	O	O
19	clinical	O	O
20	trials	O	O
21	.	O	O

0	An	O	O
1	open	O	O
2	-	O	O
3	label	O	O
4	phase	O	O
5	II	O	O
6	study	O	O
7	of	O	O
8	low	O	O
9	-	O	O
10	dose	O	O
11	thalidomide	S-Chemical	S-Chemical
12	in	O	O
13	androgen	S-Chemical	B-Disease
14	-	O	O
15	independent	O	O
16	prostate	B-Disease	B-Disease
17	cancer	E-Disease	E-Disease
18	.	O	O

0	The	O	O
1	antiangiogenic	O	O
2	effects	O	O
3	of	O	O
4	thalidomide	S-Chemical	S-Chemical
5	have	O	O
6	been	O	O
7	assessed	O	O
8	in	O	O
9	clinical	O	O
10	trials	O	O
11	in	O	O
12	patients	O	O
13	with	O	O
14	various	O	O
15	solid	O	O
16	and	O	O
17	haematological	B-Disease	O
18	malignancies	E-Disease	S-Disease
19	.	O	O

0	Thalidomide	S-Chemical	S-Chemical
1	blocks	O	O
2	the	O	O
3	activity	O	O
4	of	O	O
5	angiogenic	O	O
6	agents	O	O
7	including	O	O
8	bFGF	O	S-Chemical
9	,	O	O
10	VEGF	O	S-Chemical
11	and	O	O
12	IL	O	S-Disease
13	-	O	E-Chemical
14	6	O	E-Disease
15	.	O	O

0	We	O	O
1	undertook	O	O
2	an	O	O
3	open	O	O
4	-	O	O
5	label	O	O
6	study	O	O
7	using	O	O
8	thalidomide	S-Chemical	S-Chemical
9	100	O	O
10	mg	O	O
11	once	O	O
12	daily	O	O
13	for	O	O
14	up	O	O
15	to	O	O
16	6	O	O
17	months	O	O
18	in	O	O
19	20	O	O
20	men	O	O
21	with	O	O
22	androgen	S-Chemical	B-Disease
23	-	O	O
24	independent	O	O
25	prostate	B-Disease	B-Disease
26	cancer	E-Disease	E-Disease
27	.	O	O

0	Patients	O	O
1	underwent	O	O
2	regular	O	O
3	measurement	O	O
4	of	O	O
5	prostate	O	S-Disease
6	-	O	O
7	specific	O	O
8	antigen	O	O
9	(	O	O
10	PSA	O	S-Chemical
11	)	O	O
12	,	O	O
13	urea	S-Chemical	S-Disease
14	and	O	O
15	electrolytes	O	O
16	,	O	O
17	serum	O	O
18	bFGF	O	S-Disease
19	and	O	O
20	VEGF	O	S-Disease
21	.	O	O

0	Adverse	O	O
1	effects	O	O
2	included	O	O
3	constipation	S-Disease	O
4	,	O	O
5	morning	O	O
6	drowsiness	S-Disease	S-Disease
7	,	O	O
8	dizziness	S-Disease	O
9	and	O	O
10	rash	S-Disease	O
11	,	O	O
12	and	O	O
13	resulted	O	O
14	in	O	O
15	withdrawal	O	O
16	from	O	O
17	the	O	O
18	study	O	O
19	by	O	O
20	three	O	O
21	men	O	O
22	.	O	O

0	Evidence	O	O
1	of	O	O
2	peripheral	B-Disease	B-Disease
3	sensory	I-Disease	I-Disease
4	neuropathy	E-Disease	I-Disease
5	was	O	O
6	found	O	O
7	in	O	O
8	nine	O	O
9	of	O	O
10	13	O	O
11	men	O	O
12	before	O	O
13	treatment	O	O
14	.	O	O

0	In	O	O
1	the	O	O
2	seven	O	O
3	men	O	O
4	who	O	O
5	completed	O	O
6	six	O	O
7	months	O	O
8	on	O	O
9	thalidomide	S-Chemical	S-Disease
10	,	O	O
11	subclinical	O	O
12	evidence	O	O
13	of	O	O
14	peripheral	B-Disease	B-Disease
15	neuropathy	E-Disease	E-Disease
16	was	O	O
17	found	O	O
18	in	O	O
19	four	O	O
20	before	O	O
21	treatment	O	O
22	,	O	O
23	but	O	O
24	in	O	O
25	all	O	O
26	seven	O	O
27	at	O	O
28	repeat	O	O
29	testing	O	O
30	.	O	O

0	The	O	O
1	findings	O	O
2	indicate	O	O
3	that	O	O
4	thalidomide	S-Chemical	S-Chemical
5	may	O	O
6	be	O	O
7	an	O	O
8	option	O	O
9	for	O	O
10	patients	O	O
11	who	O	O
12	have	O	O
13	failed	O	O
14	other	O	O
15	forms	O	O
16	of	O	O
17	therapy	O	O
18	,	O	O
19	provided	O	O
20	close	O	O
21	follow	O	O
22	-	O	O
23	up	O	O
24	is	O	O
25	maintained	O	O
26	for	O	O
27	development	O	O
28	of	O	O
29	peripheral	B-Disease	B-Disease
30	neuropathy	E-Disease	E-Disease
31	.	O	O

0	Central	B-Disease	O
1	nervous	I-Disease	I-Disease
2	system	I-Disease	I-Disease
3	toxicity	E-Disease	E-Disease
4	following	O	O
5	the	O	O
6	administration	O	O
7	of	O	O
8	levobupivacaine	S-Chemical	S-Chemical
9	for	O	O
10	lumbar	O	B-Disease
11	plexus	O	E-Disease
12	block	O	E-Disease
13	:	O	O
14	A	O	O
15	report	O	O
16	of	O	O
17	two	O	O
18	cases	O	O
19	.	O	O

0	BACKGROUND	O	O
1	AND	O	O
2	OBJECTIVES	O	O
3	:	O	O
4	Central	B-Disease	B-Disease
5	nervous	I-Disease	I-Disease
6	system	I-Disease	E-Disease
7	and	I-Disease	O
8	cardiac	I-Disease	B-Disease
9	toxicity	E-Disease	E-Disease
10	following	O	O
11	the	O	O
12	administration	O	O
13	of	O	O
14	local	O	O
15	anesthetics	O	O
16	is	O	O
17	a	O	O
18	recognized	O	O
19	complication	O	O
20	of	O	O
21	regional	O	O
22	anesthesia	O	O
23	.	O	O

0	Levobupivacaine	S-Chemical	S-Chemical
1	,	O	O
2	the	O	O
3	pure	O	O
4	S	O	S-Chemical
5	(	O	O
6	-	O	O
7	)	O	O
8	enantiomer	O	O
9	of	O	O
10	bupivacaine	S-Chemical	S-Chemical
11	,	O	O
12	was	O	O
13	developed	O	O
14	to	O	O
15	improve	O	O
16	the	O	O
17	cardiac	O	S-Disease
18	safety	O	O
19	profile	O	O
20	of	O	O
21	bupivacaine	S-Chemical	S-Chemical
22	.	O	O

0	We	O	O
1	describe	O	O
2	2	O	O
3	cases	O	O
4	of	O	O
5	grand	B-Disease	O
6	mal	I-Disease	O
7	seizures	E-Disease	S-Disease
8	following	O	O
9	accidental	O	O
10	intravascular	O	O
11	injection	O	O
12	of	O	O
13	levobupivacaine	S-Chemical	S-Chemical
14	.	O	O

0	Immediately	O	O
1	after	O	O
2	the	O	O
3	administration	O	O
4	of	O	O
5	levobupivacaine	S-Chemical	S-Chemical
6	0	O	O
7	.	O	O
8	5	O	O
9	%	O	O
10	with	O	O
11	epinephrine	S-Chemical	S-Chemical
12	2	O	O
13	.	O	O
14	5	O	O
15	microgram	O	O
16	/	O	O
17	mL	O	O
18	,	O	O
19	the	O	O
20	patients	O	O
21	developed	O	O
22	grand	B-Disease	O
23	mal	I-Disease	E-Disease
24	seizures	E-Disease	E-Disease
25	,	O	O
26	despite	O	O
27	negative	O	O
28	aspiration	O	O
29	for	O	O
30	blood	O	O
31	and	O	O
32	no	O	O
33	clinical	O	O
34	signs	O	O
35	of	O	O
36	intravenous	O	O
37	epinephrine	S-Chemical	S-Disease
38	administration	O	O
39	.	O	O

0	The	O	O
1	seizures	S-Disease	S-Disease
2	were	O	O
3	successfully	O	O
4	treated	O	O
5	with	O	O
6	sodium	B-Chemical	B-Chemical
7	thiopental	E-Chemical	E-Chemical
8	in	O	O
9	addition	O	O
10	to	O	O
11	succinylcholine	S-Chemical	S-Chemical
12	in	O	O
13	1	O	O
14	patient	O	O
15	.	O	O

0	Neither	O	O
1	patient	O	O
2	developed	O	O
3	signs	O	O
4	of	O	O
5	cardiovascular	B-Disease	B-Disease
6	toxicity	E-Disease	E-Disease
7	.	O	O

0	Both	O	O
1	patients	O	O
2	were	O	O
3	treated	O	O
4	preoperatively	O	O
5	with	O	O
6	beta	O	O
7	-	O	O
8	adrenergic	O	O
9	antagonist	O	O
10	medications	O	O
11	,	O	O
12	which	O	O
13	may	O	O
14	have	O	O
15	masked	O	O
16	the	O	O
17	cardiovascular	O	O
18	signs	O	O
19	of	O	O
20	the	O	O
21	unintentional	O	O
22	intravascular	O	O
23	administration	O	O
24	of	O	O
25	levobupivacaine	S-Chemical	S-Chemical
26	with	O	O
27	epinephrine	S-Chemical	S-Chemical
28	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Although	O	O
3	levobupivacaine	S-Chemical	S-Chemical
4	may	O	O
5	have	O	O
6	a	O	O
7	safer	O	O
8	cardiac	B-Disease	B-Disease
9	toxicity	E-Disease	E-Disease
10	profile	O	O
11	than	O	O
12	racemic	O	B-Disease
13	bupivacaine	S-Chemical	E-Chemical
14	,	O	O
15	if	O	O
16	adequate	O	O
17	amounts	O	O
18	of	O	O
19	levobupivacaine	S-Chemical	S-Chemical
20	reach	O	O
21	the	O	O
22	circulation	O	O
23	,	O	O
24	it	O	O
25	will	O	O
26	result	O	O
27	in	O	O
28	convulsions	S-Disease	O
29	.	O	O

0	Plasma	O	O
1	concentrations	O	O
2	sufficient	O	O
3	to	O	O
4	result	O	O
5	in	O	O
6	central	B-Disease	B-Disease
7	nervous	I-Disease	I-Disease
8	system	I-Disease	I-Disease
9	toxicity	E-Disease	S-Disease
10	did	O	O
11	not	O	O
12	produce	O	O
13	manifestations	O	O
14	of	O	O
15	cardiac	B-Disease	B-Disease
16	toxicity	E-Disease	E-Disease
17	in	O	O
18	these	O	O
19	2	O	O
20	patients	O	O
21	.	O	O

0	Amiodarone	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	torsade	B-Disease	S-Disease
4	de	I-Disease	O
5	pointes	E-Disease	O
6	during	O	O
7	bladder	O	O
8	irrigation	O	O
9	:	O	O
10	an	O	O
11	unusual	O	O
12	presentation	O	O
13	-	O	O
14	-	O	O
15	a	O	O
16	case	O	O
17	report	O	O
18	.	O	O

0	The	O	O
1	authors	O	O
2	present	O	O
3	a	O	O
4	case	O	O
5	of	O	O
6	early	O	O
7	(	O	O
8	within	O	O
9	4	O	O
10	days	O	O
11	)	O	O
12	development	O	O
13	of	O	O
14	torsade	B-Disease	S-Chemical
15	de	I-Disease	O
16	pointes	E-Disease	O
17	(	O	O
18	TdP	S-Disease	S-Chemical
19	)	O	O
20	associated	O	O
21	with	O	O
22	oral	O	O
23	amiodarone	S-Chemical	S-Chemical
24	therapy	O	O
25	.	O	O

0	Consistent	O	O
1	with	O	O
2	other	O	O
3	reports	O	O
4	this	O	O
5	case	O	O
6	of	O	O
7	TdP	S-Disease	S-Chemical
8	occurred	O	O
9	in	O	O
10	the	O	O
11	context	O	O
12	of	O	O
13	multiple	O	O
14	exacerbating	O	O
15	factors	O	O
16	including	O	O
17	hypokalemia	S-Disease	S-Disease
18	and	O	O
19	digoxin	S-Chemical	S-Chemical
20	excess	O	O
21	.	O	O

0	Transient	O	O
1	prolongation	O	O
2	of	O	O
3	the	O	O
4	QT	O	O
5	during	O	O
6	bladder	O	O
7	irrigation	O	O
8	prompted	O	O
9	the	O	O
10	episode	O	O
11	of	O	O
12	TdP	S-Disease	S-Chemical
13	.	O	O

0	It	O	O
1	is	O	O
2	well	O	O
3	known	O	O
4	that	O	O
5	bradycardia	S-Disease	S-Disease
6	exacerbates	O	O
7	acquired	O	O
8	TdP	S-Disease	S-Chemical
9	.	O	O

0	The	O	O
1	authors	O	O
2	speculate	O	O
3	that	O	O
4	the	O	O
5	increased	O	O
6	vagal	O	O
7	tone	O	O
8	during	O	O
9	bladder	O	O
10	irrigation	O	O
11	,	O	O
12	a	O	O
13	vagal	O	O
14	maneuver	O	O
15	,	O	O
16	in	O	O
17	the	O	O
18	context	O	O
19	of	O	O
20	amiodarone	S-Chemical	S-Chemical
21	therapy	O	O
22	resulted	O	O
23	in	O	O
24	amiodarone	S-Chemical	S-Chemical
25	-	O	O
26	induced	O	O
27	proarrhythmia	S-Disease	S-Disease
28	.	O	O

0	In	O	O
1	the	O	O
2	absence	O	O
3	of	O	O
4	amiodarone	S-Chemical	S-Chemical
5	therapy	O	O
6	,	O	O
7	a	O	O
8	second	O	O
9	bladder	O	O
10	irrigation	O	O
11	did	O	O
12	not	O	O
13	induce	O	O
14	TdP	S-Disease	S-Chemical
15	despite	O	O
16	hypokalemia	S-Disease	S-Disease
17	and	O	O
18	hypomagnesemia	S-Disease	S-Disease
19	.	O	O

0	Anaesthetic	O	O
1	complications	O	O
2	associated	O	O
3	with	O	O
4	myotonia	B-Disease	S-Disease
5	congenita	E-Disease	O
6	:	O	O
7	case	O	O
8	study	O	O
9	and	O	O
10	comparison	O	O
11	with	O	O
12	other	O	O
13	myotonic	B-Disease	B-Disease
14	disorders	E-Disease	E-Disease
15	.	O	O

0	Myotonia	B-Disease	S-Disease
1	congenita	E-Disease	O
2	(	O	O
3	MC	S-Disease	S-Disease
4	)	O	O
5	is	O	O
6	caused	O	O
7	by	O	O
8	a	O	O
9	defect	O	S-Disease
10	in	O	O
11	the	O	O
12	skeletal	O	B-Disease
13	muscle	O	I-Disease
14	chloride	S-Chemical	I-Disease
15	channel	O	E-Disease
16	function	O	E-Disease
17	,	O	O
18	which	O	O
19	may	O	O
20	cause	O	O
21	sustained	B-Disease	O
22	membrane	I-Disease	O
23	depolarisation	E-Disease	E-Disease
24	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	previously	O	O
4	healthy	O	O
5	32	O	O
6	-	O	O
7	year	O	O
8	-	O	O
9	old	O	O
10	woman	O	O
11	who	O	O
12	developed	O	O
13	a	O	O
14	life	O	O
15	-	O	O
16	threatening	O	O
17	muscle	B-Disease	B-Disease
18	spasm	E-Disease	E-Disease
19	and	O	O
20	secondary	O	O
21	ventilation	O	O
22	difficulties	O	O
23	following	O	O
24	a	O	O
25	preoperative	O	O
26	injection	O	O
27	of	O	O
28	suxamethonium	S-Chemical	S-Chemical
29	.	O	O

0	The	O	O
1	muscle	B-Disease	O
2	spasms	E-Disease	S-Disease
3	disappeared	O	O
4	spontaneously	O	O
5	and	O	O
6	the	O	O
7	surgery	O	O
8	proceeded	O	O
9	without	O	O
10	further	O	O
11	problems	O	O
12	.	O	O

0	When	O	O
1	subsequently	O	O
2	questioned	O	O
3	,	O	O
4	she	O	O
5	reported	O	O
6	minor	O	O
7	symptoms	O	O
8	suggesting	O	O
9	a	O	O
10	myotonic	B-Disease	S-Disease
11	condition	E-Disease	O
12	.	O	O

0	Myotonia	S-Disease	S-Disease
1	was	O	O
2	found	O	O
3	on	O	O
4	clinical	O	O
5	examination	O	O
6	and	O	O
7	EMG	O	S-Disease
8	.	O	O

0	The	O	O
1	diagnosis	O	O
2	MC	S-Disease	S-Chemical
3	was	O	O
4	confirmed	O	O
5	genetically	O	O
6	.	O	O

0	We	O	O
1	give	O	O
2	a	O	O
3	brief	O	O
4	overview	O	O
5	of	O	O
6	ion	B-Disease	B-Disease
7	channel	I-Disease	I-Disease
8	disorders	E-Disease	E-Disease
9	including	O	O
10	malignant	B-Disease	B-Disease
11	hyperthermia	E-Disease	E-Disease
12	and	O	O
13	their	O	O
14	anaesthetic	O	O
15	considerations	O	O
16	.	O	O

0	Respiratory	O	O
1	pattern	O	O
2	in	O	O
3	a	O	O
4	rat	O	O
5	model	O	O
6	of	O	O
7	epilepsy	S-Disease	S-Disease
8	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	Apnea	S-Disease	S-Disease
3	is	O	O
4	known	O	O
5	to	O	O
6	occur	O	O
7	during	O	O
8	seizures	S-Disease	S-Disease
9	,	O	O
10	but	O	O
11	systematic	O	O
12	studies	O	O
13	of	O	O
14	ictal	O	B-Disease
15	respiratory	O	I-Disease
16	changes	O	E-Disease
17	in	O	O
18	adults	O	O
19	are	O	O
20	few	O	O
21	.	O	O

0	Here	O	O
1	we	O	O
2	sought	O	O
3	to	O	O
4	generate	O	O
5	information	O	O
6	with	O	O
7	regard	O	O
8	to	O	O
9	the	O	O
10	interictal	O	O
11	period	O	O
12	in	O	O
13	animals	O	O
14	with	O	O
15	pilocarpine	S-Chemical	S-Chemical
16	-	O	O
17	induced	O	O
18	epilepsy	S-Disease	S-Disease
19	.	O	O

0	METHODS	O	O
1	:	O	O
2	Twelve	O	O
3	rats	O	O
4	(	O	O
5	six	O	O
6	chronically	O	O
7	epileptic	S-Disease	O
8	animals	O	O
9	and	O	O
10	six	O	O
11	controls	O	O
12	)	O	O
13	were	O	O
14	anesthetized	O	O
15	,	O	O
16	given	O	O
17	tracheotomies	O	S-Disease
18	,	O	O
19	and	O	O
20	subjected	O	O
21	to	O	O
22	hyperventilation	S-Disease	S-Disease
23	or	O	O
24	hypoventilation	O	S-Disease
25	conditions	O	O
26	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	hyperventilation	S-Disease	O
4	maneuver	O	O
5	caused	O	O
6	a	O	O
7	decrease	O	O
8	in	O	O
9	spontaneous	O	O
10	ventilation	O	S-Disease
11	in	O	O
12	pilocarpine	S-Chemical	S-Chemical
13	-	O	O
14	treated	O	O
15	and	O	O
16	control	O	O
17	rats	O	O
18	.	O	O

0	Although	O	O
1	VE	O	S-Chemical
2	had	O	O
3	a	O	O
4	similar	O	O
5	decrease	O	O
6	in	O	O
7	both	O	O
8	groups	O	O
9	,	O	O
10	in	O	O
11	the	O	O
12	epileptic	S-Disease	O
13	group	O	O
14	,	O	O
15	the	O	O
16	decrease	O	O
17	in	O	O
18	VE	O	S-Disease
19	was	O	O
20	due	O	O
21	to	O	O
22	a	O	O
23	significant	O	O
24	(	O	O
25	p	O	O
26	<	O	O
27	0	O	O
28	.	O	O
29	05	O	O
30	)	O	O
31	increase	O	O
32	in	O	O
33	TE	O	S-Disease
34	peak	O	O
35	in	O	O
36	relation	O	O
37	to	O	O
38	that	O	O
39	of	O	O
40	the	O	O
41	control	O	O
42	animals	O	O
43	.	O	O

0	In	O	O
1	the	O	O
2	epileptic	S-Disease	O
3	group	O	O
4	,	O	O
5	the	O	O
6	increase	O	S-Disease
7	in	O	O
8	VE	O	S-Disease
9	was	O	O
10	mediated	O	O
11	by	O	O
12	a	O	O
13	significant	O	O
14	(	O	O
15	p	O	O
16	<	O	O
17	0	O	O
18	.	O	O
19	05	O	O
20	)	O	O
21	decrease	O	O
22	in	O	O
23	TE	O	S-Disease
24	peak	O	O
25	compared	O	O
26	with	O	O
27	the	O	O
28	control	O	O
29	group	O	O
30	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	data	O	O
4	indicate	O	O
5	that	O	O
6	pilocarpine	S-Chemical	S-Chemical
7	-	O	O
8	treated	O	O
9	animals	O	O
10	have	O	O
11	an	O	O
12	altered	O	O
13	ability	O	O
14	to	O	O
15	react	O	O
16	to	O	O
17	(	O	O
18	or	O	O
19	compensate	O	O
20	for	O	O
21	)	O	O
22	blood	O	B-Disease
23	gas	O	E-Disease
24	changes	O	O
25	with	O	O
26	changes	O	O
27	in	O	O
28	ventilation	O	S-Disease
29	and	O	O
30	suggest	O	O
31	that	O	O
32	it	O	O
33	is	O	O
34	centrally	O	O
35	determined	O	O
36	.	O	O

0	We	O	O
1	speculate	O	O
2	on	O	O
3	the	O	O
4	possible	O	O
5	relation	O	O
6	of	O	O
7	the	O	O
8	current	O	O
9	findings	O	O
10	on	O	O
11	treating	O	O
12	different	O	O
13	epilepsy	S-Disease	S-Disease
14	-	O	O
15	associated	O	O
16	conditions	O	O
17	.	O	O

0	Fatal	O	O
1	myeloencephalopathy	S-Disease	S-Disease
2	due	O	O
3	to	O	O
4	intrathecal	O	O
5	vincristine	S-Chemical	S-Disease
6	administration	O	O
7	.	O	O

0	Vincristine	S-Chemical	S-Chemical
1	was	O	O
2	accidentally	O	O
3	given	O	O
4	intrathecally	O	O
5	to	O	O
6	a	O	O
7	child	O	O
8	with	O	O
9	leukaemia	S-Disease	S-Disease
10	,	O	O
11	producing	O	O
12	sensory	B-Disease	B-Disease
13	and	I-Disease	O
14	motor	I-Disease	B-Disease
15	dysfunction	E-Disease	E-Disease
16	followed	O	O
17	by	O	O
18	encephalopathy	S-Disease	S-Disease
19	and	O	O
20	death	O	O
21	.	O	O

0	Separate	O	O
1	times	O	O
2	for	O	O
3	administering	O	O
4	vincristine	S-Chemical	S-Chemical
5	and	O	O
6	intrathecal	O	O
7	therapy	O	O
8	is	O	O
9	recommended	O	O
10	.	O	O

0	Progesterone	S-Chemical	O
1	potentiation	O	O
2	of	O	O
3	bupivacaine	S-Chemical	S-Chemical
4	arrhythmogenicity	O	O
5	in	O	O
6	pentobarbital	S-Chemical	S-Chemical
7	-	O	O
8	anesthetized	O	O
9	rats	O	O
10	and	O	O
11	beating	O	O
12	rat	O	O
13	heart	O	O
14	cell	O	O
15	cultures	O	O
16	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	progesterone	S-Chemical	S-Chemical
4	treatment	O	O
5	on	O	O
6	bupivacaine	S-Chemical	B-Chemical
7	arrhythmogenicity	O	S-Disease
8	in	O	O
9	beating	O	O
10	rat	O	O
11	heart	O	I-Disease
12	myocyte	O	I-Disease
13	cultures	O	O
14	and	O	O
15	on	O	O
16	anesthetized	O	O
17	rats	O	O
18	were	O	O
19	determined	O	O
20	.	O	O

0	After	O	O
1	determining	O	O
2	the	O	O
3	bupivacaine	S-Chemical	B-Chemical
4	AD50	O	S-Chemical
5	(	O	O
6	the	O	O
7	concentration	O	O
8	of	O	O
9	bupivacaine	S-Chemical	S-Chemical
10	that	O	O
11	caused	O	O
12	50	O	O
13	%	O	O
14	of	O	O
15	all	O	O
16	beating	O	O
17	rat	O	O
18	heart	O	I-Disease
19	myocyte	O	I-Disease
20	cultures	O	O
21	to	O	O
22	become	O	O
23	arrhythmic	S-Disease	O
24	)	O	O
25	,	O	O
26	we	O	O
27	determined	O	O
28	the	O	O
29	effect	O	O
30	of	O	O
31	1	O	O
32	-	O	O
33	hour	O	O
34	progesterone	S-Chemical	O
35	HCl	S-Chemical	S-Disease
36	exposure	O	O
37	on	O	O
38	myocyte	O	S-Disease
39	contractile	O	S-Disease
40	rhythm	O	O
41	.	O	O

0	Each	O	O
1	concentration	O	O
2	of	O	O
3	progesterone	S-Chemical	S-Chemical
4	(	O	O
5	6	O	O
6	.	O	O
7	25	O	O
8	,	O	O
9	12	O	O
10	.	O	O
11	5	O	O
12	,	O	O
13	25	O	O
14	,	O	O
15	and	O	O
16	50	O	O
17	micrograms	O	O
18	/	O	O
19	ml	O	O
20	)	O	O
21	caused	O	O
22	a	O	O
23	significant	O	O
24	and	O	O
25	concentration	O	O
26	-	O	O
27	dependent	O	O
28	reduction	O	O
29	in	O	O
30	the	O	O
31	AD50	O	B-Chemical
32	for	O	O
33	bupivacaine	S-Chemical	S-Chemical
34	.	O	O

0	Estradiol	S-Chemical	O
1	treatment	O	O
2	also	O	O
3	increased	O	O
4	the	O	O
5	arrhythmogenicity	O	O
6	of	O	O
7	bupivacaine	S-Chemical	S-Chemical
8	in	O	O
9	myocyte	O	S-Disease
10	cultures	O	O
11	,	O	O
12	but	O	O
13	was	O	O
14	only	O	O
15	one	O	O
16	fourth	O	O
17	as	O	O
18	potent	O	O
19	as	O	O
20	progesterone	S-Chemical	S-Chemical
21	.	O	O

0	Neither	O	O
1	progesterone	S-Chemical	S-Chemical
2	nor	O	O
3	estradiol	S-Chemical	S-Chemical
4	effects	O	O
5	on	O	O
6	bupivacaine	S-Chemical	S-Chemical
7	arrhythmogenicity	O	S-Disease
8	were	O	O
9	potentiated	O	O
10	by	O	O
11	epinephrine	S-Chemical	S-Chemical
12	.	O	O

0	Chronic	O	O
1	progesterone	S-Chemical	S-Disease
2	pretreatment	O	O
3	(	O	O
4	5	O	O
5	mg	O	O
6	/	O	O
7	kg	O	O
8	/	O	O
9	day	O	O
10	for	O	O
11	21	O	O
12	days	O	O
13	)	O	O
14	caused	O	O
15	a	O	O
16	significant	O	O
17	increase	O	S-Disease
18	in	O	O
19	bupivacaine	S-Chemical	B-Chemical
20	arrhythmogenicity	O	S-Disease
21	in	O	O
22	intact	O	O
23	pentobarbital	S-Chemical	B-Chemical
24	-	O	O
25	anesthetized	O	O
26	rats	O	O
27	.	O	O

0	There	O	O
1	was	O	O
2	a	O	O
3	significant	O	O
4	decrease	O	O
5	in	O	O
6	the	O	O
7	time	O	O
8	to	O	O
9	onset	O	O
10	of	O	O
11	arrhythmia	S-Disease	S-Disease
12	as	O	O
13	compared	O	O
14	with	O	O
15	control	O	O
16	nonprogesterone	O	O
17	-	O	O
18	treated	O	O
19	rats	O	O
20	(	O	O
21	6	O	O
22	.	O	O
23	2	O	O
24	+	O	O
25	/	O	O
26	-	O	O
27	1	O	O
28	.	O	O
29	3	O	O
30	vs	O	O
31	.	O	O
32	30	O	O
33	.	O	O
34	8	O	O
35	+	O	O
36	/	O	O
37	-	O	O
38	2	O	O
39	.	O	O
40	5	O	O
41	min	O	O
42	,	O	O
43	mean	O	O
44	+	O	O
45	/	O	O
46	-	O	O
47	SE	O	O
48	)	O	O
49	.	O	O

0	The	O	O
1	results	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	indicate	O	O
6	that	O	O
7	progesterone	S-Chemical	S-Chemical
8	can	O	O
9	potentiate	O	O
10	bupivacaine	S-Chemical	S-Chemical
11	arrhythmogenicity	O	S-Disease
12	both	O	O
13	in	O	O
14	vivo	O	O
15	and	O	O
16	in	O	O
17	vitro	O	O
18	.	O	O

0	Potentiation	O	O
1	of	O	O
2	bupivacaine	S-Chemical	S-Chemical
3	arrhythmia	S-Disease	S-Disease
4	in	O	O
5	myocyte	O	S-Disease
6	cultures	O	O
7	suggests	O	O
8	that	O	O
9	this	O	O
10	effect	O	O
11	is	O	O
12	at	O	O
13	least	O	O
14	partly	O	O
15	mediated	O	O
16	at	O	O
17	the	O	O
18	myocyte	O	S-Disease
19	level	O	O
20	.	O	O

0	Increased	O	O
1	serum	O	O
2	soluble	O	O
3	Fas	O	S-Chemical
4	in	O	O
5	patients	O	O
6	with	O	O
7	acute	B-Disease	B-Disease
8	liver	I-Disease	I-Disease
9	failure	E-Disease	E-Disease
10	due	O	O
11	to	O	O
12	paracetamol	S-Chemical	S-Chemical
13	overdose	S-Disease	O
14	.	O	O

0	BACKGROUND	O	O
1	/	O	O
2	AIMS	O	O
3	:	O	O
4	Experimental	O	O
5	studies	O	O
6	have	O	O
7	suggested	O	O
8	that	O	O
9	apoptosis	O	O
10	via	O	O
11	the	O	O
12	Fas	O	B-Chemical
13	/	O	O
14	Fas	O	O
15	Ligand	O	O
16	signaling	O	O
17	system	O	O
18	may	O	O
19	play	O	O
20	an	O	O
21	important	O	O
22	role	O	O
23	in	O	O
24	the	O	O
25	development	O	O
26	of	O	O
27	acute	B-Disease	B-Disease
28	liver	I-Disease	I-Disease
29	failure	E-Disease	E-Disease
30	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	the	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	investigate	O	O
8	the	O	O
9	soluble	O	O
10	form	O	O
11	of	O	O
12	Fas	O	S-Chemical
13	in	O	O
14	patients	O	O
15	with	O	O
16	acute	B-Disease	B-Disease
17	liver	I-Disease	I-Disease
18	failure	E-Disease	E-Disease
19	.	O	O

0	METHODOLOGY	O	O
1	:	O	O
2	Serum	O	O
3	levels	O	O
4	of	O	O
5	sFas	O	O
6	(	O	O
7	soluble	O	O
8	Fas	O	S-Chemical
9	)	O	O
10	were	O	O
11	measured	O	O
12	by	O	O
13	ELISA	O	S-Chemical
14	in	O	O
15	24	O	O
16	patients	O	O
17	with	O	O
18	acute	B-Disease	B-Disease
19	liver	I-Disease	I-Disease
20	failure	E-Disease	E-Disease
21	and	O	O
22	10	O	O
23	normal	O	O
24	control	O	O
25	subjects	O	O
26	.	O	O

0	Serum	O	O
1	levels	O	O
2	of	O	O
3	tumor	S-Disease	B-Disease
4	necrosis	S-Disease	I-Disease
5	factor	O	E-Disease
6	-	O	O
7	alpha	O	O
8	and	O	O
9	interferon	O	S-Chemical
10	-	O	O
11	gamma	O	O
12	were	O	O
13	also	O	O
14	determined	O	O
15	by	O	O
16	ELISA	O	S-Chemical
17	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Serum	O	O
3	sFas	O	O
4	was	O	O
5	significantly	O	O
6	increased	O	O
7	in	O	O
8	patients	O	O
9	with	O	O
10	acute	B-Disease	B-Disease
11	liver	I-Disease	I-Disease
12	failure	E-Disease	E-Disease
13	(	O	O
14	median	O	O
15	,	O	O
16	26	O	O
17	.	O	O
18	8	O	O
19	U	O	O
20	/	O	O
21	mL	O	O
22	;	O	O
23	range	O	O
24	,	O	O
25	6	O	O
26	.	O	O
27	9	O	O
28	-	O	O
29	52	O	O
30	.	O	O
31	7	O	O
32	U	O	O
33	/	O	O
34	mL	O	O
35	)	O	O
36	compared	O	O
37	to	O	O
38	the	O	O
39	normal	O	O
40	controls	O	O
41	(	O	O
42	median	O	O
43	,	O	O
44	8	O	O
45	.	O	O
46	6	O	O
47	U	O	O
48	/	O	O
49	mL	O	O
50	;	O	O
51	range	O	O
52	,	O	O
53	6	O	O
54	.	O	O
55	5	O	O
56	-	O	O
57	12	O	O
58	.	O	O
59	0	O	O
60	U	O	O
61	/	O	O
62	mL	O	O
63	,	O	O
64	P	O	S-Disease
65	<	O	O
66	0	O	O
67	.	O	O
68	0001	O	O
69	)	O	O
70	.	O	O

0	Levels	O	O
1	were	O	O
2	significantly	O	O
3	greater	O	O
4	in	O	O
5	patients	O	O
6	with	O	O
7	acute	B-Disease	B-Disease
8	liver	I-Disease	I-Disease
9	failure	E-Disease	E-Disease
10	due	O	O
11	to	O	O
12	paracetamol	S-Chemical	S-Chemical
13	overdose	S-Disease	O
14	(	O	O
15	median	O	O
16	,	O	O
17	28	O	O
18	.	O	O
19	7	O	O
20	U	O	O
21	/	O	O
22	mL	O	O
23	;	O	O
24	range	O	O
25	,	O	O
26	12	O	O
27	.	O	O
28	8	O	O
29	-	O	O
30	52	O	O
31	.	O	O
32	7	O	O
33	U	O	O
34	/	O	O
35	mL	O	O
36	,	O	O
37	n	O	O
38	=	O	O
39	17	O	O
40	)	O	O
41	than	O	O
42	those	O	O
43	due	O	O
44	to	O	O
45	non	O	O
46	-	O	O
47	A	O	O
48	to	O	O
49	E	O	S-Disease
50	hepatitis	S-Disease	S-Disease
51	(	O	O
52	median	O	O
53	,	O	O
54	12	O	O
55	.	O	O
56	5	O	O
57	U	O	O
58	/	O	O
59	mL	O	O
60	;	O	O
61	range	O	O
62	,	O	O
63	6	O	O
64	.	O	O
65	9	O	O
66	-	O	O
67	46	O	O
68	.	O	O
69	0	O	O
70	U	O	O
71	/	O	O
72	mL	O	O
73	,	O	O
74	n	O	O
75	=	O	O
76	7	O	O
77	,	O	O
78	P	O	S-Disease
79	<	O	O
80	0	O	O
81	.	O	O
82	01	O	O
83	)	O	O
84	.	O	O

0	A	O	O
1	significant	O	O
2	correlation	O	O
3	was	O	O
4	observed	O	O
5	between	O	O
6	serum	O	O
7	sFas	O	S-Disease
8	levels	O	O
9	and	O	O
10	aspartate	S-Chemical	S-Chemical
11	aminotransferase	O	S-Disease
12	(	O	O
13	r	O	O
14	=	O	O
15	0	O	O
16	.	O	O
17	613	O	O
18	,	O	O
19	P	O	S-Disease
20	<	O	O
21	0	O	O
22	.	O	O
23	01	O	O
24	)	O	O
25	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	increased	O	O
4	concentration	O	O
5	of	O	O
6	sFas	O	S-Disease
7	in	O	O
8	serum	O	O
9	of	O	O
10	patients	O	O
11	with	O	O
12	acute	B-Disease	B-Disease
13	liver	I-Disease	I-Disease
14	failure	E-Disease	E-Disease
15	may	O	O
16	reflect	O	O
17	activation	O	O
18	of	O	O
19	Fas	O	S-Chemical
20	-	O	O
21	mediated	O	O
22	apoptosis	O	S-Disease
23	in	O	O
24	the	O	O
25	liver	O	O
26	and	O	O
27	this	O	O
28	together	O	O
29	with	O	O
30	increased	O	O
31	tumor	S-Disease	B-Disease
32	necrosis	S-Disease	I-Disease
33	factor	O	E-Disease
34	-	O	O
35	alpha	O	O
36	may	O	O
37	be	O	O
38	an	O	O
39	important	O	O
40	factor	O	O
41	in	O	O
42	liver	O	B-Disease
43	cell	O	I-Disease
44	loss	O	E-Disease
45	.	O	O

0	Bilateral	O	O
1	subthalamic	O	O
2	nucleus	O	O
3	stimulation	O	O
4	for	O	O
5	Parkinson	B-Disease	B-Disease
6	'	I-Disease	I-Disease
7	s	I-Disease	I-Disease
8	disease	E-Disease	E-Disease
9	.	O	O

0	High	O	O
1	frequency	O	O
2	stimulation	O	O
3	of	O	O
4	the	O	O
5	subthalamic	O	O
6	nucleus	O	O
7	(	O	O
8	STN	O	S-Disease
9	)	O	O
10	is	O	O
11	known	O	O
12	to	O	O
13	ameliorate	O	O
14	the	O	O
15	signs	O	O
16	and	O	O
17	symptoms	O	O
18	of	O	O
19	advanced	O	O
20	Parkinson	B-Disease	B-Disease
21	'	I-Disease	I-Disease
22	s	I-Disease	I-Disease
23	disease	E-Disease	E-Disease
24	.	O	O

0	METHOD	O	S-Disease
1	:	O	O
2	Twenty	O	O
3	-	O	O
4	three	O	O
5	patients	O	O
6	suffering	O	O
7	from	O	O
8	severe	O	O
9	Parkinson	B-Disease	B-Disease
10	'	I-Disease	I-Disease
11	s	I-Disease	I-Disease
12	disease	E-Disease	E-Disease
13	(	O	O
14	Stages	O	O
15	III	O	O
16	-	O	O
17	V	O	O
18	on	O	O
19	Hoehn	O	S-Chemical
20	and	O	O
21	Yahr	O	S-Chemical
22	scale	O	O
23	)	O	O
24	and	O	O
25	,	O	O
26	particularly	O	O
27	bradykinesia	S-Disease	S-Disease
28	,	O	O
29	rigidity	S-Disease	O
30	,	O	O
31	and	O	O
32	levodopa	S-Chemical	S-Chemical
33	-	O	O
34	induced	O	O
35	dyskinesias	S-Disease	S-Disease
36	underwent	O	O
37	bilateral	O	O
38	implantation	O	O
39	of	O	O
40	electrodes	O	O
41	in	O	O
42	the	O	O
43	STN	O	S-Disease
44	.	O	O

0	Preoperative	O	O
1	and	O	O
2	postoperative	O	O
3	assessments	O	O
4	of	O	O
5	these	O	O
6	patients	O	O
7	at	O	O
8	1	O	O
9	,	O	O
10	3	O	O
11	,	O	O
12	6	O	O
13	and	O	O
14	12	O	O
15	months	O	O
16	follow	O	O
17	-	O	O
18	up	O	O
19	,	O	O
20	in	O	O
21	"	O	O
22	on	O	O
23	"	O	O
24	and	O	O
25	"	O	O
26	off	O	O
27	"	O	O
28	drug	O	O
29	conditions	O	O
30	,	O	O
31	was	O	O
32	carried	O	O
33	out	O	O
34	using	O	O
35	Unified	O	O
36	Parkinson	B-Disease	B-Disease
37	'	I-Disease	I-Disease
38	s	I-Disease	I-Disease
39	Disease	E-Disease	E-Disease
40	Rating	O	O
41	Scale	O	O
42	,	O	O
43	Hoehn	O	S-Chemical
44	and	O	O
45	Yahr	O	S-Chemical
46	staging	O	O
47	,	O	O
48	England	O	S-Chemical
49	activities	O	O
50	of	O	O
51	daily	O	O
52	living	O	O
53	score	O	O
54	and	O	O
55	video	O	O
56	recordings	O	O
57	.	O	O

0	RESULTS	O	O
1	:	O	O
2	After	O	O
3	one	O	O
4	year	O	O
5	of	O	O
6	electrical	O	O
7	stimulation	O	O
8	of	O	O
9	the	O	O
10	STN	O	S-Disease
11	,	O	O
12	the	O	O
13	patients	O	O
14	'	O	O
15	scores	O	O
16	for	O	O
17	activities	O	O
18	of	O	O
19	daily	O	O
20	living	O	O
21	and	O	O
22	motor	O	O
23	examination	O	O
24	scores	O	O
25	(	O	O
26	Unified	O	O
27	Parkinson	B-Disease	B-Disease
28	'	I-Disease	I-Disease
29	s	I-Disease	I-Disease
30	Disease	E-Disease	E-Disease
31	Rating	O	O
32	Scale	O	O
33	parts	O	O
34	II	O	O
35	and	O	O
36	III	O	O
37	)	O	O
38	off	O	O
39	medication	O	O
40	improved	O	O
41	by	O	O
42	62	O	O
43	%	O	O
44	and	O	O
45	61	O	O
46	%	O	O
47	respectively	O	O
48	(	O	O
49	p	O	O
50	<	O	O
51	0	O	O
52	.	O	O
53	0005	O	O
54	)	O	O
55	.	O	O

0	The	O	O
1	subscores	O	O
2	for	O	O
3	the	O	O
4	akinesia	S-Disease	S-Disease
5	,	O	O
6	rigidity	S-Disease	O
7	,	O	O
8	tremor	S-Disease	S-Disease
9	and	O	O
10	gait	O	O
11	also	O	O
12	improved	O	O
13	.	O	O

0	The	O	O
1	average	O	O
2	levodopa	S-Chemical	S-Chemical
3	dose	O	O
4	decreased	O	O
5	from	O	O
6	813	O	O
7	mg	O	O
8	to	O	O
9	359	O	O
10	mg	O	O
11	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Bilateral	O	O
3	subthalamic	O	O
4	nucleus	O	O
5	stimulation	O	O
6	is	O	O
7	an	O	O
8	effective	O	O
9	treatment	O	O
10	for	O	O
11	advanced	O	O
12	Parkinson	B-Disease	I-Disease
13	'	I-Disease	I-Disease
14	s	I-Disease	I-Disease
15	disease	E-Disease	E-Disease
16	.	O	O

0	It	O	O
1	reduces	O	O
2	the	O	O
3	severity	O	O
4	of	O	O
5	"	O	O
6	off	O	O
7	"	O	O
8	phase	O	O
9	symptoms	O	O
10	,	O	O
11	improves	O	O
12	the	O	O
13	axial	O	O
14	symptoms	O	O
15	and	O	O
16	reduces	O	O
17	levodopa	S-Chemical	S-Chemical
18	requirements	O	O
19	.	O	O

0	The	O	O
1	reduction	O	O
2	in	O	O
3	the	O	O
4	levodopa	S-Chemical	S-Chemical
5	dose	O	O
6	is	O	O
7	useful	O	O
8	in	O	O
9	controlling	O	O
10	drug	B-Disease	O
11	-	I-Disease	O
12	induced	I-Disease	O
13	dyskinesias	E-Disease	S-Disease
14	.	O	O

0	Acute	B-Disease	O
1	renal	I-Disease	B-Disease
2	failure	E-Disease	E-Disease
3	occurring	O	O
4	during	O	O
5	intravenous	O	O
6	desferrioxamine	S-Chemical	S-Chemical
7	therapy	O	O
8	:	O	O
9	recovery	O	O
10	after	O	O
11	haemodialysis	O	S-Disease
12	.	O	O

0	A	O	O
1	patient	O	O
2	with	O	O
3	transfusion	O	O
4	-	O	O
5	dependent	O	O
6	thalassemia	S-Disease	S-Disease
7	was	O	O
8	undergoing	O	O
9	home	O	O
10	intravenous	O	O
11	desferrioxamine	S-Chemical	S-Chemical
12	(	O	O
13	DFX	S-Chemical	S-Chemical
14	)	O	O
15	treatment	O	O
16	by	O	O
17	means	O	O
18	of	O	O
19	a	O	O
20	totally	O	O
21	implanted	O	O
22	system	O	O
23	because	O	O
24	of	O	O
25	his	O	O
26	poor	O	O
27	compliance	O	O
28	with	O	O
29	the	O	O
30	nightly	O	O
31	subcutaneous	O	O
32	therapy	O	O
33	.	O	O

0	Due	O	O
1	to	O	O
2	an	O	O
3	accidental	O	O
4	malfunctioning	O	O
5	of	O	O
6	the	O	O
7	infusion	O	O
8	pump	O	O
9	,	O	O
10	the	O	O
11	patient	O	O
12	was	O	O
13	inadvertently	O	O
14	administered	O	O
15	a	O	O
16	toxic	O	O
17	dosage	O	O
18	of	O	O
19	the	O	O
20	drug	O	O
21	which	O	O
22	caused	O	O
23	renal	B-Disease	B-Disease
24	insufficiency	E-Disease	E-Disease
25	.	O	O

0	Given	O	O
1	the	O	O
2	progressive	O	O
3	deterioration	O	O
4	of	O	O
5	the	O	O
6	symptoms	O	O
7	and	O	O
8	of	O	O
9	the	O	O
10	laboratory	O	O
11	values	O	O
12	,	O	O
13	despite	O	O
14	adequate	O	O
15	medical	O	O
16	treatment	O	O
17	,	O	O
18	a	O	O
19	decision	O	O
20	was	O	O
21	made	O	O
22	to	O	O
23	introduce	O	O
24	haemodialytical	O	S-Disease
25	therapy	O	O
26	in	O	O
27	order	O	O
28	to	O	O
29	remove	O	O
30	the	O	O
31	drug	O	O
32	and	O	O
33	therapy	O	O
34	reduce	O	O
35	the	O	O
36	nephrotoxicity	S-Disease	S-Disease
37	.	O	O

0	From	O	O
1	the	O	O
2	results	O	O
3	obtained	O	O
4	,	O	O
5	haemodialysis	O	S-Disease
6	can	O	O
7	therefore	O	O
8	be	O	O
9	suggested	O	O
10	as	O	O
11	a	O	O
12	useful	O	O
13	therapy	O	O
14	in	O	O
15	rare	O	O
16	cases	O	O
17	of	O	O
18	progressive	O	B-Disease
19	acute	B-Disease	I-Disease
20	renal	I-Disease	I-Disease
21	failure	E-Disease	E-Disease
22	caused	O	O
23	by	O	O
24	desferrioxamine	S-Chemical	S-Chemical
25	.	O	O

0	Ocular	O	B-Disease
1	motility	O	O
2	changes	O	O
3	after	O	O
4	subtenon	O	S-Disease
5	carboplatin	S-Chemical	S-Chemical
6	chemotherapy	O	O
7	for	O	O
8	retinoblastoma	S-Disease	S-Disease
9	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Focal	O	O
3	subtenon	O	O
4	carboplatin	S-Chemical	S-Chemical
5	injections	O	O
6	have	O	O
7	recently	O	O
8	been	O	O
9	used	O	O
10	as	O	O
11	a	O	O
12	presumably	O	O
13	toxicity	S-Disease	S-Disease
14	-	O	O
15	free	O	O
16	adjunct	O	O
17	to	O	O
18	systemic	O	O
19	chemotherapy	O	O
20	for	O	O
21	intraocular	O	O
22	retinoblastoma	S-Disease	E-Disease
23	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	report	O	O
4	our	O	O
5	clinical	O	O
6	experience	O	O
7	with	O	O
8	abnormal	B-Disease	B-Disease
9	ocular	I-Disease	B-Disease
10	motility	E-Disease	E-Disease
11	in	O	O
12	patients	O	O
13	treated	O	O
14	with	O	O
15	subtenon	O	S-Disease
16	carboplatin	S-Chemical	S-Chemical
17	chemotherapy	O	O
18	.	O	O

0	METHODS	O	O
1	:	O	O
2	We	O	O
3	noted	O	O
4	abnormal	B-Disease	O
5	ocular	I-Disease	B-Disease
6	motility	E-Disease	E-Disease
7	in	O	O
8	10	O	O
9	consecutive	O	O
10	patients	O	O
11	with	O	O
12	retinoblastoma	S-Disease	S-Disease
13	who	O	O
14	had	O	O
15	received	O	O
16	subtenon	O	O
17	carboplatin	S-Chemical	S-Chemical
18	.	O	O

0	During	O	O
1	ocular	O	B-Disease
2	manipulation	O	O
3	under	O	O
4	general	O	O
5	anesthesia	O	O
6	,	O	O
7	we	O	O
8	assessed	O	O
9	their	O	O
10	eyes	O	O
11	by	O	O
12	forced	O	O
13	duction	O	I-Disease
14	testing	O	O
15	,	O	O
16	comparing	O	O
17	ocular	O	B-Disease
18	motility	O	E-Disease
19	after	O	O
20	tumor	S-Disease	B-Disease
21	control	O	O
22	with	O	O
23	ocular	O	B-Disease
24	motility	O	E-Disease
25	at	O	O
26	diagnosis	O	O
27	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Limitation	O	O
3	of	O	O
4	ocular	O	B-Disease
5	motility	O	E-Disease
6	was	O	O
7	detected	O	O
8	in	O	O
9	all	O	O
10	12	O	O
11	eyes	O	O
12	of	O	O
13	10	O	O
14	patients	O	O
15	treated	O	O
16	for	O	O
17	intraocular	O	O
18	retinoblastoma	S-Disease	E-Disease
19	with	O	O
20	1	O	O
21	to	O	O
22	6	O	O
23	injections	O	O
24	of	O	O
25	subtenon	O	O
26	carboplatin	S-Chemical	S-Chemical
27	as	O	O
28	part	O	O
29	of	O	O
30	multimodality	O	O
31	therapy	O	O
32	.	O	O

0	Histopathological	O	O
1	examination	O	O
2	revealed	O	O
3	many	O	O
4	lipophages	O	S-Disease
5	in	O	O
6	the	O	O
7	periorbital	O	O
8	fat	O	O
9	surrounding	O	O
10	the	O	O
11	optic	O	B-Disease
12	nerve	O	E-Disease
13	in	O	O
14	1	O	O
15	eye	O	O
16	,	O	O
17	indicative	O	O
18	of	O	O
19	phagocytosis	O	O
20	of	O	O
21	previously	O	O
22	existing	O	O
23	fat	O	O
24	cells	O	O
25	and	O	O
26	suggesting	O	O
27	prior	O	O
28	fat	O	B-Disease
29	necrosis	S-Disease	E-Disease
30	.	O	O

0	The	O	O
1	enucleations	O	S-Disease
2	were	O	O
3	technically	O	O
4	difficult	O	O
5	and	O	O
6	hazardous	O	O
7	for	O	O
8	globe	O	O
9	rupture	S-Disease	O
10	because	O	O
11	of	O	O
12	extensive	O	O
13	orbital	O	B-Disease
14	soft	O	I-Disease
15	tissue	O	O
16	adhesions	O	O
17	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Subtenon	O	S-Chemical
3	carboplatin	S-Chemical	E-Chemical
4	chemotherapy	O	O
5	is	O	O
6	associated	O	O
7	with	O	O
8	significant	O	O
9	fibrosis	S-Disease	S-Disease
10	of	O	O
11	orbital	O	B-Disease
12	soft	O	E-Disease
13	tissues	O	E-Disease
14	,	O	O
15	leading	O	O
16	to	O	O
17	mechanical	O	O
18	restriction	O	O
19	of	O	O
20	eye	O	O
21	movements	O	E-Disease
22	and	O	O
23	making	O	O
24	subsequent	O	O
25	enucleation	O	S-Disease
26	difficult	O	O
27	.	O	O

0	Subtenon	O	S-Chemical
1	carboplatin	S-Chemical	S-Chemical
2	is	O	O
3	not	O	O
4	free	O	O
5	of	O	O
6	toxicity	S-Disease	S-Disease
7	,	O	O
8	and	O	O
9	its	O	O
10	use	O	O
11	is	O	O
12	best	O	O
13	restricted	O	O
14	to	O	O
15	specific	O	O
16	indications	O	O
17	.	O	O

0	Ethambutol	S-Chemical	S-Chemical
1	and	O	O
2	optic	B-Disease	B-Disease
3	neuropathy	E-Disease	E-Disease
4	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	To	O	O
3	demonstrate	O	O
4	the	O	O
5	association	O	O
6	between	O	O
7	ethambutol	S-Chemical	S-Chemical
8	and	O	O
9	optic	B-Disease	B-Disease
10	neuropathy	E-Disease	E-Disease
11	.	O	O

0	METHOD	O	O
1	:	O	O
2	Thirteen	O	O
3	patients	O	O
4	who	O	O
5	developed	O	O
6	optic	B-Disease	B-Disease
7	neuropathy	E-Disease	I-Disease
8	after	O	O
9	being	O	O
10	treated	O	O
11	with	O	O
12	ethambutol	S-Chemical	S-Chemical
13	for	O	O
14	tuberculosis	B-Disease	B-Disease
15	of	I-Disease	I-Disease
16	the	I-Disease	I-Disease
17	lung	I-Disease	E-Disease
18	or	I-Disease	O
19	lymph	I-Disease	I-Disease
20	node	E-Disease	E-Disease
21	at	O	O
22	Siriraj	O	S-Chemical
23	Hospital	O	O
24	between	O	O
25	1997	O	O
26	and	O	O
27	2001	O	O
28	were	O	O
29	retrospectively	O	O
30	reviewed	O	O
31	.	O	O

0	RESULTS	O	O
1	:	O	O
2	All	O	O
3	patients	O	O
4	had	O	O
5	optic	B-Disease	B-Disease
6	neuropathy	E-Disease	I-Disease
7	between	O	O
8	1	O	O
9	to	O	O
10	6	O	O
11	months	O	O
12	(	O	O
13	mean	O	O
14	=	O	O
15	2	O	O
16	.	O	O
17	9	O	O
18	months	O	O
19	)	O	O
20	after	O	O
21	starting	O	O
22	ethambutol	S-Chemical	S-Chemical
23	therapy	O	O
24	at	O	O
25	a	O	O
26	dosage	O	O
27	ranging	O	O
28	from	O	O
29	13	O	O
30	to	O	O
31	20	O	O
32	mg	O	O
33	/	O	O
34	kg	O	O
35	/	O	O
36	day	O	O
37	(	O	O
38	mean	O	O
39	=	O	O
40	17	O	O
41	mg	O	O
42	/	O	O
43	kg	O	O
44	/	O	O
45	day	O	O
46	)	O	O
47	.	O	O

0	Of	O	O
1	6	O	O
2	patients	O	O
3	with	O	O
4	irreversible	O	O
5	visual	B-Disease	O
6	impairment	E-Disease	O
7	,	O	O
8	4	O	O
9	patients	O	O
10	had	O	O
11	diabetes	B-Disease	B-Disease
12	mellitus	E-Disease	E-Disease
13	,	O	O
14	glaucoma	S-Disease	S-Disease
15	and	O	O
16	a	O	O
17	history	O	O
18	of	O	O
19	heavy	O	O
20	smoking	O	S-Disease
21	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Early	O	O
3	recognition	O	O
4	of	O	O
5	optic	B-Disease	B-Disease
6	neuropathy	E-Disease	I-Disease
7	should	O	O
8	be	O	O
9	considered	O	O
10	in	O	O
11	patients	O	O
12	with	O	O
13	ethambutol	S-Chemical	S-Chemical
14	therapy	O	O
15	.	O	O

0	A	O	O
1	low	O	O
2	dose	O	O
3	and	O	O
4	prompt	O	O
5	discontinuation	O	O
6	of	O	O
7	the	O	O
8	drug	O	O
9	is	O	O
10	recommended	O	O
11	particularly	O	O
12	in	O	O
13	individuals	O	O
14	with	O	O
15	diabetes	B-Disease	B-Disease
16	mellitus	E-Disease	E-Disease
17	,	O	O
18	glaucoma	S-Disease	S-Disease
19	or	O	O
20	who	O	O
21	are	O	O
22	heavy	O	O
23	smokers	O	O
24	.	O	O

0	Treatment	O	O
1	of	O	O
2	compensatory	O	O
3	gustatory	B-Disease	O
4	hyperhidrosis	E-Disease	E-Disease
5	with	O	O
6	topical	O	O
7	glycopyrrolate	S-Chemical	S-Chemical
8	.	O	O

0	Gustatory	B-Disease	O
1	hyperhidrosis	E-Disease	S-Disease
2	is	O	O
3	facial	O	O
4	sweating	S-Disease	O
5	usually	O	O
6	associated	O	O
7	with	O	O
8	the	O	O
9	eating	O	O
10	of	O	O
11	hot	O	O
12	spicy	O	O
13	food	O	O
14	or	O	O
15	even	O	O
16	smelling	O	O
17	this	O	O
18	food	O	O
19	.	O	O

0	Current	O	O
1	options	O	O
2	of	O	O
3	treatment	O	O
4	include	O	O
5	oral	O	O
6	anticholinergic	O	O
7	drugs	O	O
8	,	O	O
9	the	O	O
10	topical	O	O
11	application	O	O
12	of	O	O
13	anticholinergics	O	O
14	or	O	O
15	aluminum	B-Chemical	B-Disease
16	chloride	E-Chemical	E-Disease
17	,	O	O
18	and	O	O
19	the	O	O
20	injection	O	O
21	of	O	O
22	botulinum	O	B-Disease
23	toxin	O	E-Disease
24	.	O	O

0	Thirteen	O	O
1	patients	O	O
2	have	O	O
3	been	O	O
4	treated	O	O
5	to	O	O
6	date	O	O
7	with	O	O
8	1	O	O
9	.	O	O
10	5	O	O
11	%	O	O
12	or	O	O
13	2	O	O
14	%	O	O
15	topical	O	O
16	glycopyrrolate	S-Chemical	S-Chemical
17	.	O	O

0	All	O	O
1	patients	O	O
2	had	O	O
3	gustatory	B-Disease	O
4	hyperhidrosis	E-Disease	S-Disease
5	,	O	O
6	which	O	O
7	interfered	O	O
8	with	O	O
9	their	O	O
10	social	O	O
11	activities	O	O
12	,	O	O
13	after	O	O
14	transthroacic	O	O
15	endoscopic	O	O
16	sympathectomy	O	O
17	,	O	O
18	and	O	O
19	which	O	O
20	was	O	O
21	associated	O	O
22	with	O	O
23	compensatory	O	O
24	focal	O	B-Disease
25	hyperhidrosis	S-Disease	E-Disease
26	.	O	O

0	After	O	O
1	applying	O	O
2	topical	O	O
3	glycopyrrolate	S-Chemical	S-Chemical
4	,	O	O
5	the	O	O
6	subjective	O	O
7	effect	O	O
8	was	O	O
9	excellent	O	O
10	(	O	O
11	no	O	O
12	sweating	S-Disease	O
13	after	O	O
14	eating	O	O
15	hot	O	O
16	spicy	O	O
17	food	O	O
18	)	O	O
19	in	O	O
20	10	O	O
21	patients	O	O
22	(	O	O
23	77	O	O
24	%	O	O
25	)	O	O
26	,	O	O
27	and	O	O
28	fair	O	O
29	(	O	O
30	clearly	O	O
31	reduced	O	O
32	sweating	S-Disease	O
33	)	O	O
34	in	O	O
35	3	O	O
36	patients	O	O
37	(	O	O
38	23	O	O
39	%	O	O
40	)	O	O
41	.	O	O

0	Adverse	O	O
1	effects	O	O
2	included	O	O
3	a	O	O
4	mildly	O	O
5	dry	B-Disease	O
6	mouth	E-Disease	O
7	and	O	O
8	a	O	O
9	sore	B-Disease	O
10	throat	E-Disease	O
11	in	O	O
12	2	O	O
13	patients	O	O
14	(	O	O
15	2	O	O
16	%	O	O
17	glycopyrrolate	S-Chemical	S-Disease
18	)	O	O
19	,	O	O
20	a	O	O
21	light	O	O
22	headache	S-Disease	S-Disease
23	in	O	O
24	1	O	O
25	patient	O	O
26	(	O	O
27	1	O	O
28	.	O	O
29	5	O	O
30	%	O	O
31	glycopyrrolate	S-Chemical	S-Disease
32	)	O	O
33	.	O	O

0	The	O	O
1	topical	O	O
2	application	O	O
3	of	O	O
4	a	O	O
5	glycopyrrolate	S-Chemical	S-Chemical
6	pad	O	O
7	appeared	O	O
8	to	O	O
9	be	O	O
10	safe	O	O
11	,	O	O
12	efficacious	O	O
13	,	O	O
14	well	O	O
15	tolerated	O	O
16	,	O	O
17	and	O	O
18	a	O	O
19	convenient	O	O
20	method	O	O
21	of	O	O
22	treatment	O	O
23	for	O	O
24	moderate	O	O
25	to	O	O
26	severe	O	O
27	symptoms	O	O
28	of	O	O
29	gustatory	B-Disease	S-Disease
30	hyperhidrosis	E-Disease	S-Disease
31	in	O	O
32	post	O	O
33	transthoracic	O	O
34	endoscopic	O	O
35	sympathectomy	O	O
36	or	O	O
37	sympathicotomy	O	O
38	patients	O	O
39	,	O	O
40	with	O	O
41	few	O	O
42	side	O	O
43	effects	O	O
44	.	O	O

0	Neuroleptic	S-Chemical	S-Disease
1	-	O	O
2	associated	O	O
3	hyperprolactinemia	S-Disease	S-Disease
4	.	O	O

0	Can	O	O
1	it	O	O
2	be	O	O
3	treated	O	O
4	with	O	O
5	bromocriptine	S-Chemical	S-Chemical
6	?	O	O

0	Six	O	O
1	stable	O	O
2	psychiatric	O	O
3	outpatients	O	O
4	with	O	O
5	hyperprolactinemia	S-Disease	S-Disease
6	and	O	O
7	amenorrhea	S-Disease	S-Chemical
8	/	O	I-Disease
9	oligomenorrhea	S-Disease	E-Chemical
10	associated	O	O
11	with	O	O
12	their	O	O
13	neuroleptic	B-Chemical	S-Disease
14	medications	E-Chemical	O
15	were	O	O
16	treated	O	O
17	with	O	O
18	bromocriptine	S-Chemical	S-Chemical
19	.	O	O

0	Daily	O	O
1	dosages	O	O
2	of	O	O
3	5	O	O
4	-	O	O
5	10	O	O
6	mg	O	O
7	corrected	O	O
8	the	O	O
9	hyperprolactinemia	S-Disease	S-Disease
10	and	O	O
11	restored	O	O
12	menstruation	O	O
13	in	O	O
14	four	O	O
15	of	O	O
16	the	O	O
17	six	O	O
18	patients	O	O
19	.	O	O

0	One	O	O
1	woman	O	O
2	,	O	O
3	however	O	O
4	,	O	O
5	developed	O	O
6	worsened	O	O
7	psychiatric	B-Disease	O
8	symptoms	E-Disease	O
9	while	O	O
10	taking	O	O
11	bromocriptine	S-Chemical	S-Chemical
12	,	O	O
13	and	O	O
14	it	O	O
15	was	O	O
16	discontinued	O	O
17	.	O	O

0	Thus	O	O
1	,	O	O
2	three	O	O
3	of	O	O
4	six	O	O
5	patients	O	O
6	had	O	O
7	their	O	O
8	menstrual	O	O
9	irregularity	O	S-Disease
10	successfully	O	O
11	corrected	O	O
12	with	O	O
13	bromocriptine	S-Chemical	S-Chemical
14	.	O	O

0	This	O	O
1	suggests	O	O
2	that	O	O
3	bromocriptine	S-Chemical	S-Chemical
4	should	O	O
5	be	O	O
6	further	O	O
7	evaluated	O	O
8	as	O	O
9	potential	O	O
10	therapy	O	O
11	for	O	O
12	neuroleptic	S-Chemical	S-Disease
13	-	O	O
14	associated	O	O
15	hyperprolactinemia	S-Disease	S-Disease
16	and	O	O
17	amenorrhea	S-Disease	B-Chemical
18	/	O	I-Disease
19	galactorrhea	S-Disease	E-Chemical
20	.	O	O

0	Ethacrynic	B-Chemical	S-Chemical
1	acid	E-Chemical	E-Chemical
2	-	O	O
3	induced	O	O
4	convulsions	S-Disease	O
5	and	O	O
6	brain	O	O
7	neurotransmitters	O	S-Disease
8	in	O	O
9	mice	O	O
10	.	O	O

0	Intracerebroventricular	O	O
1	injection	O	O
2	of	O	O
3	ethacrynic	B-Chemical	S-Chemical
4	acid	E-Chemical	S-Disease
5	(	O	O
6	50	O	O
7	%	O	O
8	convulsive	S-Disease	O
9	dose	O	O
10	;	O	O
11	50	O	O
12	micrograms	O	O
13	/	O	O
14	mouse	O	O
15	)	O	O
16	accelerated	O	O
17	the	O	O
18	synthesis	O	O
19	/	O	O
20	turnover	O	O
21	of	O	O
22	5	B-Chemical	B-Chemical
23	-	I-Chemical	I-Chemical
24	hydroxytryptamine	E-Chemical	E-Chemical
25	(	O	O
26	5	B-Chemical	O
27	-	I-Chemical	O
28	HT	E-Chemical	O
29	)	O	O
30	but	O	O
31	suppressed	O	O
32	the	O	O
33	synthesis	O	O
34	of	O	O
35	gamma	B-Chemical	S-Chemical
36	-	I-Chemical	I-Chemical
37	aminobutyric	I-Chemical	E-Chemical
38	acid	E-Chemical	E-Chemical
39	and	O	O
40	acetylcholine	S-Chemical	S-Chemical
41	in	O	O
42	mouse	O	O
43	brain	O	O
44	.	O	O

0	These	O	O
1	effects	O	O
2	were	O	O
3	completely	O	O
4	antagonized	O	O
5	by	O	O
6	pretreatment	O	O
7	with	O	O
8	a	O	O
9	glutamate	S-Chemical	S-Chemical
10	/	O	O
11	N	B-Chemical	I-Chemical
12	-	I-Chemical	I-Chemical
13	methyl	I-Chemical	E-Chemical
14	-	I-Chemical	I-Chemical
15	D	I-Chemical	E-Chemical
16	-	I-Chemical	I-Chemical
17	aspartate	E-Chemical	E-Chemical
18	antagonist	O	O
19	,	O	O
20	aminophosphonovaleric	B-Chemical	S-Chemical
21	acid	E-Chemical	E-Disease
22	.	O	O

0	In	O	O
1	ethacrynic	B-Chemical	S-Chemical
2	acid	E-Chemical	E-Chemical
3	-	O	O
4	induced	O	O
5	convulsions	S-Disease	O
6	,	O	O
7	these	O	O
8	neurotransmitter	O	O
9	systems	O	O
10	may	O	O
11	be	O	O
12	differentially	O	O
13	modulated	O	O
14	,	O	O
15	probably	O	O
16	through	O	O
17	activation	O	O
18	of	O	O
19	glutaminergic	O	S-Chemical
20	neurons	O	O
21	in	O	O
22	the	O	O
23	brain	O	O
24	.	O	O

0	Pharmacology	O	O
1	of	O	O
2	gamma	B-Chemical	B-Disease
3	-	I-Chemical	O
4	aminobutyric	I-Chemical	I-Disease
5	acidA	E-Chemical	O
6	receptor	O	O
7	complex	O	O
8	after	O	O
9	the	O	O
10	in	O	O
11	vivo	O	O
12	administration	O	O
13	of	O	O
14	the	O	O
15	anxioselective	O	O
16	and	O	O
17	anticonvulsant	O	O
18	beta	B-Chemical	S-Chemical
19	-	I-Chemical	O
20	carboline	E-Chemical	S-Chemical
21	derivative	O	O
22	abecarnil	S-Chemical	S-Chemical
23	.	O	O

0	In	O	O
1	rodents	O	O
2	,	O	O
3	the	O	O
4	effect	O	O
5	of	O	O
6	the	O	O
7	beta	B-Chemical	S-Chemical
8	-	I-Chemical	O
9	carboline	E-Chemical	S-Chemical
10	derivative	O	O
11	isopropyl	B-Chemical	S-Chemical
12	-	I-Chemical	O
13	6	I-Chemical	I-Chemical
14	-	I-Chemical	I-Chemical
15	benzyloxy	I-Chemical	E-Chemical
16	-	I-Chemical	I-Chemical
17	4	I-Chemical	E-Chemical
18	-	I-Chemical	I-Chemical
19	methoxymethyl	I-Chemical	S-Chemical
20	-	I-Chemical	O
21	beta	I-Chemical	I-Chemical
22	-	I-Chemical	O
23	carboline	I-Chemical	S-Chemical
24	-	I-Chemical	O
25	3	I-Chemical	E-Chemical
26	-	I-Chemical	O
27	carboxylate	E-Chemical	O
28	(	O	O
29	abecarrnil	S-Chemical	O
30	)	O	O
31	,	O	O
32	a	O	O
33	new	O	O
34	ligand	O	O
35	for	O	O
36	benzodiazepine	S-Chemical	S-Disease
37	receptors	O	O
38	possessing	O	O
39	anxiolytic	O	O
40	and	O	O
41	anticonvulsant	O	O
42	properties	O	O
43	,	O	O
44	was	O	O
45	evaluated	O	O
46	on	O	O
47	the	O	O
48	function	O	O
49	of	O	O
50	central	O	O
51	gamma	B-Chemical	I-Disease
52	-	I-Chemical	I-Disease
53	aminobutyric	I-Chemical	E-Chemical
54	acid	E-Chemical	E-Disease
55	(	O	O
56	GABA	S-Chemical	S-Chemical
57	)	O	O
58	A	O	O
59	receptor	O	O
60	complex	O	O
61	,	O	O
62	both	O	O
63	in	O	O
64	vitro	O	O
65	and	O	O
66	in	O	O
67	vivo	O	O
68	.	O	O

0	Added	O	O
1	in	O	O
2	vitro	O	O
3	to	O	O
4	rat	O	O
5	cortical	O	O
6	membrane	O	O
7	preparation	O	O
8	,	O	O
9	abecarnil	S-Chemical	S-Chemical
10	increased	O	O
11	[	O	O
12	3H	O	E-Chemical
13	]	O	O
14	GABA	S-Chemical	S-Chemical
15	binding	O	O
16	,	O	O
17	enhanced	O	O
18	muscimol	S-Chemical	S-Chemical
19	-	O	O
20	stimulated	O	O
21	36Cl	O	O
22	-	O	O
23	uptake	O	O
24	and	O	O
25	reduced	O	O
26	the	O	O
27	binding	O	O
28	of	O	O
29	t	B-Chemical	S-Chemical
30	-	I-Chemical	O
31	[	I-Chemical	O
32	35S	I-Chemical	O
33	]	I-Chemical	O
34	butylbicyclophosphorothionate	E-Chemical	S-Chemical
35	(	O	O
36	[	B-Chemical	O
37	35S	I-Chemical	O
38	]	I-Chemical	O
39	TBPS	E-Chemical	O
40	)	O	O
41	.	O	O

0	These	O	O
1	effects	O	O
2	were	O	O
3	similar	O	O
4	to	O	O
5	those	O	O
6	induced	O	O
7	by	O	O
8	diazepam	S-Chemical	S-Chemical
9	,	O	O
10	whereas	O	O
11	the	O	O
12	partial	O	O
13	agonist	O	O
14	Ro	B-Chemical	B-Chemical
15	16	I-Chemical	E-Chemical
16	-	I-Chemical	I-Chemical
17	6028	E-Chemical	E-Chemical
18	(	O	O
19	tert	B-Chemical	S-Chemical
20	-	I-Chemical	I-Chemical
21	butyl	I-Chemical	E-Chemical
22	-	I-Chemical	I-Chemical
23	(	I-Chemical	O
24	S	I-Chemical	I-Chemical
25	)	I-Chemical	O
26	-	I-Chemical	I-Chemical
27	8	I-Chemical	E-Chemical
28	-	I-Chemical	I-Chemical
29	bromo	I-Chemical	O
30	-	I-Chemical	I-Chemical
31	11	I-Chemical	O
32	,	I-Chemical	O
33	12	I-Chemical	O
34	,	I-Chemical	O
35	13	I-Chemical	O
36	,	I-Chemical	O
37	13a	I-Chemical	O
38	-	I-Chemical	O
39	tetrahydro	I-Chemical	E-Chemical
40	-	I-Chemical	I-Chemical
41	9	I-Chemical	E-Chemical
42	-	I-Chemical	I-Chemical
43	oxo	I-Chemical	O
44	-	I-Chemical	I-Chemical
45	9H	I-Chemical	E-Chemical
46	-	I-Chemical	O
47	imidazo	I-Chemical	E-Chemical
48	[	I-Chemical	O
49	1	I-Chemical	O
50	,	I-Chemical	O
51	5	I-Chemical	O
52	-	I-Chemical	I-Chemical
53	a	I-Chemical	I-Chemical
54	]	I-Chemical	O
55	-	I-Chemical	I-Chemical
56	pyrrolo	I-Chemical	E-Chemical
57	-	I-Chemical	I-Chemical
58	[	I-Chemical	O
59	2	I-Chemical	I-Chemical
60	,	I-Chemical	O
61	1	I-Chemical	I-Chemical
62	-	I-Chemical	I-Chemical
63	c	I-Chemical	I-Chemical
64	]	I-Chemical	O
65	[	I-Chemical	O
66	1	I-Chemical	I-Chemical
67	,	I-Chemical	O
68	4	I-Chemical	O
69	]	I-Chemical	O
70	benzodiazepine	I-Chemical	E-Chemical
71	-	I-Chemical	I-Chemical
72	1	I-Chemical	I-Chemical
73	-	I-Chemical	I-Chemical
74	carboxylate	E-Chemical	E-Chemical
75	)	O	O
76	showed	O	O
77	very	O	O
78	weak	O	O
79	efficacy	O	O
80	in	O	O
81	these	O	O
82	biochemical	O	O
83	tests	O	O
84	.	O	O

0	After	O	O
1	i	O	O
2	.	O	O
3	p	O	O
4	.	O	O
5	injection	O	O
6	to	O	O
7	rats	O	O
8	,	O	O
9	abecarnil	S-Chemical	S-Chemical
10	and	O	O
11	diazepam	S-Chemical	S-Chemical
12	decreased	O	O
13	in	O	O
14	a	O	O
15	time	O	O
16	-	O	O
17	dependent	O	O
18	and	O	O
19	dose	O	O
20	-	O	O
21	related	O	O
22	(	O	O
23	0	O	O
24	.	O	O
25	25	O	O
26	-	O	O
27	20	O	O
28	mg	O	O
29	/	O	O
30	kg	O	O
31	i	O	O
32	.	O	O
33	p	O	O
34	.	O	O
35	)	O	O
36	manner	O	O
37	[	B-Chemical	O
38	35S	I-Chemical	O
39	]	I-Chemical	O
40	TBPS	E-Chemical	O
41	binding	O	O
42	measured	O	O
43	ex	O	O
44	vivo	O	O
45	in	O	O
46	the	O	O
47	cerebral	O	O
48	cortex	O	O
49	.	O	O

0	Moreover	O	O
1	,	O	O
2	both	O	O
3	drugs	O	O
4	at	O	O
5	the	O	O
6	dose	O	O
7	of	O	O
8	0	O	O
9	.	O	O
10	5	O	O
11	mg	O	O
12	/	O	O
13	kg	O	O
14	antagonized	O	O
15	completely	O	O
16	the	O	O
17	convulsant	O	O
18	activity	O	O
19	and	O	O
20	the	O	O
21	increase	O	O
22	of	O	O
23	[	B-Chemical	O
24	35S	I-Chemical	O
25	]	I-Chemical	O
26	TBPS	E-Chemical	O
27	binding	O	O
28	induced	O	O
29	by	O	O
30	isoniazide	S-Chemical	S-Chemical
31	(	O	O
32	350	O	O
33	mg	O	O
34	/	O	O
35	kg	O	O
36	s	O	O
37	.	O	O
38	c	O	O
39	.	O	O
40	)	O	O
41	as	O	O
42	well	O	O
43	as	O	O
44	the	O	O
45	increase	O	O
46	of	O	O
47	[	B-Chemical	O
48	35S	I-Chemical	O
49	]	I-Chemical	O
50	TBPS	E-Chemical	O
51	binding	O	O
52	induced	O	O
53	by	O	O
54	foot	O	O
55	-	O	O
56	shock	O	S-Disease
57	stress	O	O
58	.	O	O

0	To	O	O
1	better	O	O
2	correlate	O	O
3	the	O	O
4	biochemical	O	O
5	and	O	O
6	the	O	O
7	pharmacological	O	O
8	effects	O	O
9	,	O	O
10	we	O	O
11	studied	O	O
12	the	O	O
13	action	O	O
14	of	O	O
15	abecarnil	S-Chemical	S-Chemical
16	on	O	O
17	[	B-Chemical	O
18	35S	I-Chemical	O
19	]	I-Chemical	O
20	TBPS	E-Chemical	O
21	binding	O	O
22	,	O	O
23	exploratory	O	O
24	motility	O	O
25	and	O	O
26	on	O	O
27	isoniazid	S-Chemical	S-Chemical
28	-	O	O
29	induced	O	O
30	biochemical	O	O
31	and	O	O
32	pharmacological	O	O
33	effects	O	O
34	in	O	O
35	mice	O	O
36	.	O	O

0	In	O	O
1	these	O	O
2	animals	O	O
3	,	O	O
4	abecarnil	S-Chemical	S-Chemical
5	produced	O	O
6	a	O	O
7	paralleled	O	O
8	dose	O	O
9	-	O	O
10	dependent	O	O
11	(	O	O
12	0	O	O
13	.	O	O
14	05	O	O
15	-	O	O
16	1	O	O
17	mg	O	O
18	/	O	O
19	kg	O	O
20	i	O	O
21	.	O	O
22	p	O	O
23	.	O	O
24	)	O	O
25	reduction	O	O
26	of	O	O
27	both	O	O
28	motor	O	B-Disease
29	behavior	O	E-Disease
30	and	O	O
31	cortical	O	S-Disease
32	[	O	O
33	35S	O	O
34	]	O	O
35	TBPS	O	O
36	binding	O	O
37	.	O	O

0	Moreover	O	O
1	,	O	O
2	0	O	O
3	.	O	O
4	05	O	O
5	mg	O	O
6	/	O	O
7	kg	O	O
8	of	O	O
9	this	O	O
10	beta	B-Chemical	S-Chemical
11	-	I-Chemical	O
12	carboline	E-Chemical	S-Chemical
13	reduced	O	O
14	markedly	O	O
15	the	O	O
16	increase	O	O
17	of	O	O
18	[	B-Chemical	O
19	35S	I-Chemical	O
20	]	I-Chemical	O
21	TBPS	E-Chemical	O
22	binding	O	O
23	and	O	O
24	the	O	O
25	convulsions	S-Disease	O
26	induced	O	O
27	by	O	O
28	isoniazid	S-Chemical	S-Chemical
29	(	O	O
30	200	O	O
31	mg	O	O
32	/	O	O
33	kg	O	O
34	s	O	O
35	.	O	O
36	c	O	O
37	.	O	O
38	)	O	O
39	.	O	O
40	(	O	O
41	ABSTRACT	O	S-Disease
42	TRUNCATED	O	O
43	AT	O	O
44	250	O	O
45	WORDS	O	S-Disease
46	)	O	O

0	Recurrent	O	O
1	myocardial	B-Disease	B-Disease
2	infarction	E-Disease	E-Disease
3	in	O	O
4	a	O	O
5	postpartum	O	O
6	patient	O	O
7	receiving	O	O
8	bromocriptine	S-Chemical	S-Chemical
9	.	O	O

0	Myocardial	B-Disease	B-Disease
1	infarction	E-Disease	O
2	in	O	O
3	puerperium	O	S-Disease
4	is	O	O
5	infrequently	O	O
6	reported	O	O
7	.	O	O

0	Spasm	S-Disease	O
1	,	O	O
2	coronary	O	B-Disease
3	dissection	O	E-Disease
4	,	O	O
5	or	O	O
6	atheromatous	O	O
7	etiology	O	O
8	has	O	O
9	been	O	O
10	described	O	O
11	.	O	O

0	Bromocriptine	S-Chemical	S-Chemical
1	has	O	O
2	been	O	O
3	implicated	O	O
4	in	O	O
5	several	O	O
6	previous	O	O
7	case	O	O
8	reports	O	O
9	of	O	O
10	myocardial	B-Disease	B-Disease
11	infarction	E-Disease	E-Disease
12	in	O	O
13	the	O	O
14	puerperium	O	S-Disease
15	.	O	O

0	Although	O	O
1	generally	O	O
2	regarded	O	O
3	as	O	O
4	"	O	O
5	safe	O	O
6	,	O	O
7	"	O	O
8	possible	O	O
9	serious	O	O
10	cardiac	O	S-Disease
11	effects	O	O
12	of	O	O
13	bromocriptine	S-Chemical	S-Chemical
14	should	O	O
15	be	O	O
16	acknowledged	O	O
17	.	O	O

0	Asterixis	S-Disease	S-Chemical
1	induced	O	O
2	by	O	O
3	carbamazepine	S-Chemical	S-Chemical
4	therapy	O	O
5	.	O	O

0	There	O	O
1	are	O	O
2	very	O	O
3	few	O	O
4	reports	O	O
5	about	O	O
6	asterixis	S-Disease	S-Chemical
7	as	O	O
8	a	O	O
9	side	O	O
10	effect	O	O
11	of	O	O
12	treatment	O	O
13	with	O	O
14	psychopharmacologic	O	S-Disease
15	agents	O	O
16	.	O	O

0	In	O	O
1	this	O	O
2	report	O	O
3	we	O	O
4	present	O	O
5	four	O	O
6	patients	O	O
7	treated	O	O
8	with	O	O
9	a	O	O
10	combination	O	O
11	of	O	O
12	different	O	O
13	psychotropic	O	S-Disease
14	drugs	O	O
15	,	O	O
16	in	O	O
17	whom	O	O
18	asterixis	S-Disease	S-Disease
19	was	O	O
20	triggered	O	O
21	either	O	O
22	by	O	O
23	adding	O	O
24	carbamazepine	S-Chemical	S-Chemical
25	(	O	O
26	CBZ	S-Chemical	S-Chemical
27	)	O	O
28	to	O	O
29	a	O	O
30	treatment	O	O
31	regimen	O	O
32	,	O	O
33	or	O	O
34	by	O	O
35	increasing	O	O
36	its	O	O
37	dosage	O	O
38	.	O	O

0	Neither	O	O
1	dosage	O	O
2	nor	O	O
3	serum	O	O
4	levels	O	O
5	of	O	O
6	CBZ	S-Chemical	S-Chemical
7	were	O	O
8	in	O	O
9	a	O	O
10	higher	O	O
11	range	O	O
12	.	O	O

0	We	O	O
1	consider	O	O
2	asterixis	S-Disease	S-Chemical
3	to	O	O
4	be	O	O
5	an	O	O
6	easily	O	O
7	overlooked	O	O
8	sign	O	O
9	of	O	O
10	neurotoxicity	S-Disease	S-Disease
11	,	O	O
12	which	O	O
13	may	O	O
14	occur	O	O
15	even	O	O
16	at	O	O
17	low	O	O
18	or	O	O
19	moderate	O	O
20	dosage	O	O
21	levels	O	O
22	,	O	O
23	if	O	O
24	certain	O	O
25	drugs	O	O
26	as	O	O
27	lithium	S-Chemical	S-Chemical
28	or	O	O
29	clozapine	S-Chemical	S-Chemical
30	are	O	O
31	used	O	O
32	in	O	O
33	combination	O	O
34	with	O	O
35	CBZ	S-Chemical	S-Chemical
36	.	O	O

0	Pharmacodynamics	O	O
1	of	O	O
2	the	O	O
3	hypotensive	S-Disease	O
4	effect	O	O
5	of	O	O
6	levodopa	S-Chemical	S-Chemical
7	in	O	O
8	parkinsonian	S-Disease	S-Disease
9	patients	O	O
10	.	O	O

0	Blood	O	O
1	pressure	O	O
2	effects	O	O
3	of	O	O
4	i	O	O
5	.	O	O
6	v	O	O
7	.	O	O
8	levodopa	S-Chemical	S-Chemical
9	were	O	O
10	examined	O	O
11	in	O	O
12	parkinsonian	S-Disease	S-Disease
13	patients	O	O
14	with	O	O
15	stable	O	O
16	and	O	O
17	fluctuating	O	O
18	responses	O	O
19	to	O	O
20	levodopa	S-Chemical	S-Chemical
21	.	O	O

0	The	O	O
1	magnitude	O	O
2	of	O	O
3	the	O	O
4	hypotensive	S-Disease	O
5	effect	O	O
6	of	O	O
7	levodopa	S-Chemical	S-Chemical
8	was	O	O
9	concentration	O	O
10	dependent	O	O
11	and	O	O
12	was	O	O
13	fit	O	O
14	to	O	O
15	an	O	O
16	Emax	O	S-Chemical
17	model	O	O
18	in	O	O
19	fluctuating	O	O
20	responders	O	O
21	.	O	O

0	Stable	O	O
1	responders	O	O
2	demonstrated	O	O
3	a	O	O
4	small	O	O
5	hypotensive	S-Disease	S-Disease
6	response	O	O
7	.	O	O

0	Baseline	O	O
1	blood	O	O
2	pressures	O	O
3	were	O	O
4	higher	O	O
5	in	O	O
6	fluctuating	O	O
7	patients	O	O
8	;	O	O
9	a	O	O
10	higher	O	O
11	baseline	O	O
12	blood	O	O
13	pressure	O	O
14	correlated	O	O
15	with	O	O
16	greater	O	O
17	hypotensive	S-Disease	S-Disease
18	effects	O	O
19	.	O	O

0	Antiparkinsonian	O	O
1	effects	O	O
2	of	O	O
3	levodopa	S-Chemical	S-Chemical
4	temporally	O	O
5	correlated	O	O
6	with	O	O
7	blood	O	O
8	pressure	O	E-Disease
9	changes	O	O
10	.	O	O

0	Phenylalanine	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	large	O	O
4	neutral	O	O
5	amino	B-Chemical	O
6	acid	E-Chemical	O
7	(	O	O
8	LNAA	O	S-Disease
9	)	O	O
10	competing	O	O
11	with	O	O
12	levodopa	S-Chemical	S-Chemical
13	for	O	O
14	transport	O	O
15	across	O	O
16	the	O	O
17	blood	O	O
18	-	O	I-Disease
19	brain	O	I-Disease
20	barrier	O	E-Disease
21	,	O	O
22	reduced	O	O
23	the	O	O
24	hypotensive	S-Disease	S-Disease
25	and	O	O
26	antiparkinsonian	O	O
27	effects	O	O
28	of	O	O
29	levodopa	S-Chemical	S-Chemical
30	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	levodopa	S-Chemical	S-Chemical
4	has	O	O
5	a	O	O
6	central	O	O
7	hypotensive	S-Disease	O
8	action	O	O
9	that	O	O
10	parallels	O	O
11	the	O	O
12	motor	O	O
13	effects	O	O
14	in	O	O
15	fluctuating	O	O
16	patients	O	O
17	.	O	O

0	The	O	O
1	hypotensive	S-Disease	O
2	effect	O	O
3	appears	O	O
4	to	O	O
5	be	O	O
6	related	O	O
7	to	O	O
8	the	O	O
9	higher	O	O
10	baseline	O	O
11	blood	O	O
12	pressure	O	O
13	we	O	O
14	observed	O	O
15	in	O	O
16	fluctuating	O	O
17	patients	O	O
18	relative	O	O
19	to	O	O
20	stable	O	O
21	patients	O	O
22	.	O	O

0	Syndrome	B-Disease	O
1	of	I-Disease	O
2	inappropriate	I-Disease	O
3	secretion	I-Disease	S-Disease
4	of	I-Disease	O
5	antidiuretic	I-Disease	O
6	hormone	E-Disease	S-Disease
7	after	O	O
8	infusional	O	O
9	vincristine	S-Chemical	S-Disease
10	.	O	O

0	A	O	O
1	77	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	woman	O	O
7	with	O	O
8	refractory	O	O
9	multiple	B-Disease	O
10	myeloma	E-Disease	S-Disease
11	was	O	O
12	treated	O	O
13	with	O	O
14	a	O	O
15	4	O	O
16	-	O	O
17	day	O	O
18	continuous	O	O
19	intravenous	O	O
20	infusion	O	O
21	of	O	O
22	vincristine	S-Chemical	S-Chemical
23	and	O	O
24	doxorubicin	S-Chemical	S-Chemical
25	and	O	O
26	4	O	O
27	days	O	O
28	of	O	O
29	oral	O	O
30	dexamethasone	S-Chemical	S-Chemical
31	.	O	O

0	Nine	O	O
1	days	O	O
2	after	O	O
3	her	O	O
4	second	O	O
5	cycle	O	O
6	she	O	O
7	presented	O	O
8	with	O	O
9	lethargy	S-Disease	S-Disease
10	and	O	O
11	weakness	S-Disease	S-Disease
12	associated	O	O
13	with	O	O
14	hyponatremia	S-Disease	S-Disease
15	.	O	O

0	Evaluation	O	O
1	revealed	O	O
2	the	O	O
3	syndrome	B-Disease	O
4	of	I-Disease	O
5	inappropriate	I-Disease	O
6	secretion	I-Disease	S-Disease
7	of	I-Disease	O
8	antidiuretic	I-Disease	O
9	hormone	E-Disease	S-Disease
10	,	O	O
11	which	O	O
12	was	O	O
13	attributed	O	O
14	to	O	O
15	the	O	O
16	vincristine	S-Chemical	S-Disease
17	infusion	O	O
18	.	O	O

0	After	O	O
1	normal	O	O
2	serum	O	O
3	sodium	S-Chemical	S-Disease
4	levels	O	O
5	returned	O	O
6	,	O	O
7	further	O	O
8	doxorubicin	S-Chemical	S-Chemical
9	and	O	O
10	dexamethasone	S-Chemical	S-Chemical
11	chemotherapy	O	O
12	without	O	O
13	vincristine	S-Chemical	S-Chemical
14	did	O	O
15	not	O	O
16	produce	O	O
17	this	O	O
18	complication	O	O
19	.	O	O

0	Heart	B-Disease	B-Disease
1	failure	E-Disease	E-Disease
2	:	O	O
3	to	O	O
4	digitalise	O	O
5	or	O	O
6	not	O	O
7	?	O	O

0	Despite	O	O
1	extensive	O	O
2	clinical	O	O
3	experience	O	O
4	the	O	O
5	role	O	O
6	of	O	O
7	digoxin	S-Chemical	S-Chemical
8	is	O	O
9	still	O	O
10	not	O	O
11	well	O	O
12	defined	O	O
13	.	O	O

0	In	O	O
1	patients	O	O
2	with	O	O
3	atrial	B-Disease	B-Disease
4	fibrillation	E-Disease	I-Disease
5	digoxin	S-Chemical	S-Disease
6	is	O	O
7	beneficial	O	O
8	for	O	O
9	ventricular	O	O
10	rate	O	O
11	control	O	O
12	.	O	O

0	For	O	O
1	patients	O	O
2	in	O	O
3	sinus	O	B-Disease
4	rhythm	O	O
5	and	O	O
6	heart	B-Disease	B-Disease
7	failure	E-Disease	E-Disease
8	the	O	O
9	situation	O	O
10	is	O	O
11	less	O	O
12	clear	O	O
13	.	O	O

0	Digoxin	S-Chemical	S-Chemical
1	has	O	O
2	a	O	O
3	narrow	O	O
4	therapeutic	O	O
5	:	O	O
6	toxic	O	O
7	ratio	O	O
8	and	O	O
9	concentrations	O	O
10	are	O	O
11	affected	O	O
12	by	O	O
13	a	O	O
14	number	O	O
15	of	O	O
16	drugs	O	O
17	.	O	O

0	Also	O	O
1	,	O	O
2	digoxin	S-Chemical	S-Chemical
3	has	O	O
4	undesirable	O	O
5	effects	O	O
6	such	O	O
7	as	O	O
8	increasing	O	O
9	peripheral	O	B-Disease
10	resistance	O	E-Disease
11	and	O	O
12	myocardial	O	B-Disease
13	demands	O	E-Disease
14	,	O	O
15	and	O	O
16	causing	O	O
17	arrhythmias	S-Disease	O
18	.	O	O

0	More	O	O
1	convincing	O	O
2	evidence	O	O
3	is	O	O
4	required	O	O
5	showing	O	O
6	that	O	O
7	digoxin	S-Chemical	S-Chemical
8	improves	O	O
9	symptoms	O	O
10	or	O	O
11	exercise	O	S-Disease
12	capacity	O	O
13	.	O	O

0	Pooled	O	O
1	analysis	O	O
2	of	O	O
3	the	O	O
4	effects	O	O
5	of	O	O
6	other	O	O
7	inotropic	O	O
8	drugs	O	O
9	shows	O	O
10	an	O	O
11	excess	O	O
12	mortality	O	O
13	and	O	O
14	there	O	O
15	is	O	O
16	a	O	O
17	possibility	O	O
18	that	O	O
19	digoxin	S-Chemical	S-Chemical
20	may	O	O
21	increase	O	O
22	mortality	O	O
23	after	O	O
24	myocardial	B-Disease	B-Disease
25	infarction	E-Disease	E-Disease
26	(	O	O
27	MI	S-Disease	S-Disease
28	)	O	O
29	.	O	O

0	Angiotensin	S-Chemical	S-Disease
1	-	O	O
2	converting	O	O
3	enzyme	O	O
4	(	O	O
5	ACE	O	S-Chemical
6	)	O	O
7	inhibitors	O	O
8	should	O	O
9	be	O	O
10	used	O	O
11	first	O	O
12	as	O	O
13	they	O	O
14	are	O	O
15	safer	O	O
16	,	O	O
17	do	O	O
18	not	O	O
19	require	O	O
20	blood	O	O
21	level	O	O
22	monitoring	O	O
23	,	O	O
24	modify	O	O
25	progression	O	O
26	of	O	O
27	disease	O	S-Disease
28	,	O	O
29	relieve	O	O
30	symptoms	O	O
31	,	O	O
32	improve	O	O
33	exercise	O	S-Disease
34	tolerance	O	O
35	and	O	O
36	reduce	O	O
37	mortality	O	O
38	.	O	O

0	Caution	O	O
1	should	O	O
2	be	O	O
3	exercised	O	O
4	in	O	O
5	using	O	O
6	digoxin	S-Chemical	S-Chemical
7	until	O	O
8	large	O	O
9	mortality	O	O
10	trials	O	O
11	are	O	O
12	completed	O	O
13	showing	O	O
14	either	O	O
15	benefit	O	O
16	or	O	O
17	harm	O	O
18	.	O	O

0	Until	O	O
1	then	O	O
2	digoxin	S-Chemical	S-Chemical
3	should	O	O
4	be	O	O
5	considered	O	O
6	a	O	O
7	third	O	O
8	-	O	O
9	line	O	O
10	therapy	O	O
11	.	O	O

0	Isradipine	S-Chemical	S-Chemical
1	treatment	O	O
2	for	O	O
3	hypertension	S-Disease	S-Disease
4	in	O	O
5	general	O	O
6	practice	O	O
7	in	O	O
8	Hong	O	O
9	Kong	O	O
10	.	O	O

0	A	O	O
1	6	O	O
2	-	O	O
3	week	O	O
4	open	O	O
5	study	O	O
6	of	O	O
7	the	O	O
8	introduction	O	O
9	of	O	O
10	isradipine	S-Chemical	S-Chemical
11	treatment	O	O
12	was	O	O
13	conducted	O	O
14	in	O	O
15	general	O	O
16	practice	O	O
17	in	O	O
18	Hong	O	O
19	Kong	O	O
20	.	O	O

0	303	O	O
1	Chinese	O	S-Chemical
2	patients	O	O
3	with	O	O
4	mild	O	O
5	to	O	O
6	moderate	O	O
7	hypertension	S-Disease	S-Disease
8	entered	O	O
9	the	O	O
10	study	O	O
11	.	O	O

0	The	O	O
1	main	O	O
2	side	O	O
3	-	O	O
4	effects	O	O
5	were	O	O
6	headache	S-Disease	S-Disease
7	,	O	O
8	dizziness	S-Disease	S-Disease
9	,	O	O
10	palpitation	S-Disease	O
11	and	O	O
12	flushing	S-Disease	S-Disease
13	and	O	O
14	these	O	O
15	were	O	O
16	not	O	O
17	more	O	O
18	frequent	O	O
19	than	O	O
20	reported	O	O
21	in	O	O
22	other	O	O
23	studies	O	O
24	with	O	O
25	isradipine	S-Chemical	S-Chemical
26	or	O	O
27	with	O	O
28	placebo	O	S-Disease
29	.	O	O

0	Similar	O	O
1	reductions	O	O
2	occurred	O	O
3	in	O	O
4	standing	O	O
5	blood	O	O
6	pressure	O	O
7	and	O	O
8	there	O	O
9	was	O	O
10	no	O	O
11	evidence	O	O
12	of	O	O
13	postural	B-Disease	B-Disease
14	hypotension	E-Disease	E-Disease
15	.	O	O

0	Pharmacological	O	O
1	characteristics	O	O
2	and	O	O
3	side	O	O
4	effects	O	O
5	of	O	O
6	a	O	O
7	new	O	O
8	galenic	O	S-Chemical
9	formulation	O	O
10	of	O	O
11	propofol	S-Chemical	S-Chemical
12	without	O	O
13	soyabean	O	S-Chemical
14	oil	O	O
15	.	O	O

0	We	O	O
1	compared	O	O
2	the	O	O
3	pharmacokinetics	O	O
4	,	O	O
5	pharmacodynamics	O	O
6	and	O	O
7	safety	O	O
8	profile	O	O
9	of	O	O
10	a	O	O
11	new	O	O
12	galenic	O	S-Chemical
13	formulation	O	O
14	of	O	O
15	propofol	S-Chemical	S-Chemical
16	(	O	O
17	AM149	O	S-Chemical
18	1	O	O
19	%	O	O
20	)	O	O
21	,	O	O
22	which	O	O
23	does	O	O
24	not	O	O
25	contain	O	O
26	soyabean	O	S-Chemical
27	oil	O	O
28	,	O	O
29	with	O	O
30	a	O	O
31	standard	O	O
32	formulation	O	O
33	of	O	O
34	propofol	S-Chemical	S-Chemical
35	(	O	O
36	Disoprivan	S-Chemical	S-Chemical
37	1	O	O
38	%	O	O
39	)	O	O
40	.	O	O

0	In	O	O
1	a	O	O
2	randomised	O	O
3	,	O	O
4	double	O	O
5	-	O	O
6	blind	O	O
7	,	O	O
8	cross	O	O
9	-	O	O
10	over	O	O
11	study	O	O
12	,	O	O
13	30	O	O
14	healthy	O	O
15	volunteers	O	O
16	received	O	O
17	a	O	O
18	single	O	O
19	intravenous	O	O
20	bolus	O	S-Disease
21	injection	O	O
22	of	O	O
23	2	O	O
24	.	O	O
25	5	O	O
26	mg	O	O
27	.	O	O
28	kg	O	O
29	-	O	O
30	1	O	O
31	propofol	S-Chemical	S-Chemical
32	.	O	O

0	Plasma	O	O
1	propofol	S-Chemical	E-Chemical
2	levels	O	O
3	were	O	O
4	measured	O	O
5	for	O	O
6	48	O	O
7	h	O	O
8	following	O	O
9	drug	O	O
10	administration	O	O
11	and	O	O
12	evaluated	O	O
13	according	O	O
14	to	O	O
15	a	O	O
16	three	O	O
17	-	O	O
18	compartment	O	O
19	model	O	O
20	.	O	O

0	The	O	O
1	pharmacodynamic	O	O
2	parameters	O	O
3	assessed	O	O
4	included	O	O
5	induction	O	O
6	and	O	O
7	emergence	O	O
8	times	O	O
9	,	O	O
10	respiratory	O	S-Disease
11	and	O	O
12	cardiovascular	O	O
13	effects	O	O
14	,	O	O
15	and	O	O
16	pain	S-Disease	S-Disease
17	on	O	O
18	injection	O	O
19	.	O	O

0	Owing	O	O
1	to	O	O
2	a	O	O
3	high	O	O
4	incidence	O	O
5	of	O	O
6	thrombophlebitis	S-Disease	S-Disease
7	,	O	O
8	the	O	O
9	study	O	O
10	was	O	O
11	terminated	O	O
12	prematurely	O	O
13	and	O	O
14	only	O	O
15	the	O	O
16	data	O	O
17	of	O	O
18	the	O	O
19	two	O	O
20	parallel	O	O
21	treatment	O	O
22	groups	O	O
23	(	O	O
24	15	O	O
25	patients	O	O
26	in	O	O
27	each	O	O
28	group	O	O
29	)	O	O
30	were	O	O
31	analysed	O	O
32	.	O	O

0	Pain	S-Disease	O
1	on	O	O
2	injection	O	O
3	(	O	O
4	80	O	O
5	vs	O	O
6	.	O	O
7	20	O	O
8	%	O	O
9	,	O	O
10	p	O	O
11	<	O	O
12	0	O	O
13	.	O	O
14	01	O	O
15	)	O	O
16	and	O	O
17	thrombophlebitis	S-Disease	S-Disease
18	(	O	O
19	93	O	O
20	.	O	O
21	3	O	O
22	vs	O	O
23	.	O	O
24	6	O	O
25	.	O	O
26	6	O	O
27	%	O	O
28	,	O	O
29	p	O	O
30	<	O	O
31	0	O	O
32	.	O	O
33	001	O	O
34	)	O	O
35	occurred	O	O
36	more	O	O
37	frequently	O	O
38	with	O	O
39	AM149	O	B-Chemical
40	than	O	O
41	with	O	O
42	Disoprivan	S-Chemical	B-Chemical
43	.	O	O

0	Although	O	O
1	both	O	O
2	formulations	O	O
3	had	O	O
4	similar	O	O
5	pharmacokinetic	O	O
6	and	O	O
7	pharmacodynamic	O	O
8	profiles	O	O
9	the	O	O
10	new	O	O
11	formulation	O	O
12	is	O	O
13	not	O	O
14	suitable	O	O
15	for	O	O
16	clinical	O	O
17	use	O	O
18	due	O	O
19	to	O	O
20	the	O	O
21	high	O	O
22	incidence	O	O
23	of	O	O
24	thrombophlebitis	S-Disease	S-Disease
25	produced	O	O
26	.	O	O

0	Pure	B-Disease	O
1	red	I-Disease	O
2	cell	I-Disease	O
3	aplasia	E-Disease	O
4	,	O	O
5	toxic	B-Disease	S-Disease
6	dermatitis	E-Disease	S-Disease
7	and	O	O
8	lymphadenopathy	S-Disease	S-Disease
9	in	O	O
10	a	O	O
11	patient	O	O
12	taking	O	O
13	diphenylhydantoin	S-Chemical	S-Chemical
14	.	O	O

0	A	O	O
1	patient	O	O
2	taking	O	O
3	diphenylhydantoin	S-Chemical	S-Chemical
4	for	O	O
5	3	O	O
6	weeks	O	O
7	developed	O	O
8	a	O	O
9	generalized	O	O
10	skin	B-Disease	B-Disease
11	rash	E-Disease	E-Disease
12	,	O	O
13	lymphadenopathy	S-Disease	S-Disease
14	and	O	O
15	pure	B-Disease	O
16	red	I-Disease	B-Disease
17	cell	I-Disease	I-Disease
18	aplasia	E-Disease	E-Disease
19	.	O	O

0	Skin	B-Disease	O
1	rash	E-Disease	O
2	is	O	O
3	a	O	O
4	well	O	O
5	-	O	O
6	known	O	O
7	complication	O	O
8	of	O	O
9	diphenylhydantoin	S-Chemical	S-Chemical
10	treatment	O	O
11	as	O	O
12	is	O	O
13	benign	O	O
14	and	O	O
15	malignant	O	O
16	lymphadenopathy	S-Disease	S-Disease
17	.	O	O

0	Pure	B-Disease	O
1	red	I-Disease	O
2	cell	I-Disease	O
3	aplasia	E-Disease	E-Disease
4	associated	O	O
5	with	O	O
6	diphenylhydantoin	S-Chemical	S-Chemical
7	medication	O	O
8	has	O	O
9	been	O	O
10	reported	O	O
11	in	O	O
12	3	O	O
13	patients	O	O
14	.	O	O

0	The	O	O
1	exact	O	O
2	mechanism	O	O
3	by	O	O
4	which	O	O
5	diphenylhydantoin	S-Chemical	S-Chemical
6	exerts	O	O
7	its	O	O
8	toxic	O	O
9	effects	O	O
10	is	O	O
11	not	O	O
12	known	O	O
13	.	O	O

0	In	O	O
1	this	O	O
2	patient	O	O
3	the	O	O
4	time	O	O
5	relation	O	O
6	between	O	O
7	the	O	O
8	ingestion	O	O
9	of	O	O
10	diphenylhydantoin	S-Chemical	S-Chemical
11	and	O	O
12	the	O	O
13	occurrence	O	O
14	of	O	O
15	the	O	O
16	skin	B-Disease	O
17	rash	E-Disease	E-Disease
18	,	O	O
19	lymphadenopathy	S-Disease	S-Disease
20	and	O	O
21	pure	B-Disease	O
22	red	I-Disease	B-Disease
23	cell	I-Disease	I-Disease
24	aplasia	E-Disease	E-Disease
25	is	O	O
26	very	O	O
27	suggestive	O	O
28	of	O	O
29	a	O	O
30	direct	O	O
31	connection	O	O
32	.	O	O

0	Vinorelbine	S-Chemical	S-Chemical
1	-	O	O
2	related	O	O
3	cardiac	O	B-Disease
4	events	O	E-Disease
5	:	O	O
6	a	O	O
7	meta	O	O
8	-	O	O
9	analysis	O	O
10	of	O	O
11	randomized	O	O
12	clinical	O	O
13	trials	O	O
14	.	O	O

0	Several	O	O
1	cases	O	O
2	of	O	O
3	cardiac	O	B-Disease
4	adverse	O	I-Disease
5	reactions	O	E-Disease
6	related	O	O
7	to	O	O
8	vinorelbine	S-Chemical	S-Chemical
9	(	O	O
10	VNR	S-Chemical	S-Chemical
11	)	O	O
12	have	O	O
13	been	O	O
14	reported	O	O
15	in	O	O
16	the	O	O
17	literature	O	O
18	.	O	O

0	In	O	O
1	order	O	O
2	to	O	O
3	quantify	O	O
4	the	O	O
5	incidence	O	O
6	of	O	O
7	these	O	O
8	cardiac	O	B-Disease
9	events	O	O
10	,	O	O
11	we	O	O
12	performed	O	O
13	a	O	O
14	meta	O	O
15	-	O	O
16	analysis	O	O
17	of	O	O
18	clinical	O	O
19	trials	O	O
20	comparing	O	O
21	VNR	S-Chemical	S-Chemical
22	with	O	O
23	other	O	O
24	chemotherapeutic	O	O
25	agents	O	O
26	in	O	O
27	the	O	O
28	treatment	O	O
29	of	O	O
30	various	O	O
31	malignancies	S-Disease	S-Disease
32	.	O	O

0	Randomized	O	O
1	clinical	O	O
2	trials	O	O
3	comparing	O	O
4	VNR	S-Chemical	S-Disease
5	with	O	O
6	other	O	O
7	drugs	O	O
8	in	O	O
9	the	O	O
10	treatment	O	O
11	of	O	O
12	cancer	S-Disease	S-Disease
13	were	O	O
14	searched	O	O
15	in	O	O
16	Medline	O	S-Chemical
17	,	O	O
18	Embase	O	S-Chemical
19	,	O	O
20	Evidence	O	B-Disease
21	-	O	O
22	based	O	I-Disease
23	Medicine	O	I-Disease
24	Reviews	O	E-Disease
25	databases	O	O
26	and	O	O
27	the	O	O
28	Cochrane	O	O
29	library	O	O
30	from	O	O
31	1987	O	O
32	to	O	O
33	2002	O	O
34	.	O	O

0	We	O	O
1	found	O	O
2	19	O	O
3	trials	O	O
4	,	O	O
5	involving	O	O
6	2441	O	O
7	patients	O	O
8	treated	O	O
9	by	O	O
10	VNR	S-Chemical	S-Chemical
11	and	O	O
12	2050	O	O
13	control	O	O
14	patients	O	O
15	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	cardiac	O	B-Disease
4	events	O	E-Disease
5	with	O	O
6	VNR	S-Chemical	S-Chemical
7	was	O	O
8	1	O	O
9	.	O	O
10	19	O	O
11	%	O	O
12	[	O	O
13	95	O	O
14	%	O	O
15	confidence	O	O
16	interval	O	O
17	(	O	O
18	CI	O	S-Chemical
19	)	O	O
20	(	O	O
21	0	O	O
22	.	O	O
23	75	O	O
24	;	O	O
25	1	O	O
26	.	O	O
27	67	O	O
28	)	O	O
29	]	O	O
30	.	O	O

0	There	O	O
1	was	O	O
2	no	O	O
3	difference	O	O
4	in	O	O
5	the	O	O
6	risk	O	O
7	of	O	O
8	cardiac	O	B-Disease
9	events	O	E-Disease
10	between	O	O
11	VNR	S-Chemical	S-Disease
12	and	O	O
13	other	O	O
14	drugs	O	O
15	[	O	O
16	odds	O	O
17	ratio	O	O
18	:	O	O
19	0	O	O
20	.	O	O
21	92	O	O
22	,	O	O
23	95	O	O
24	%	O	O
25	CI	O	S-Chemical
26	(	O	O
27	0	O	O
28	.	O	O
29	54	O	O
30	;	O	O
31	1	O	O
32	.	O	O
33	55	O	O
34	)	O	O
35	]	O	O
36	.	O	O

0	The	O	O
1	risk	O	O
2	of	O	O
3	VNR	S-Chemical	S-Disease
4	cardiac	O	S-Disease
5	events	O	O
6	was	O	O
7	similar	O	O
8	to	O	O
9	vindesine	S-Chemical	S-Disease
10	(	O	O
11	VDS	S-Chemical	S-Chemical
12	)	O	O
13	and	O	O
14	other	O	O
15	cardiotoxic	S-Disease	O
16	drugs	O	O
17	[	O	O
18	fluorouracil	S-Chemical	S-Chemical
19	,	O	O
20	anthracyclines	S-Chemical	S-Disease
21	,	O	O
22	gemcitabine	S-Chemical	S-Chemical
23	(	O	O
24	GEM	S-Chemical	S-Chemical
25	)	O	O
26	em	O	O
27	leader	O	O
28	]	O	O
29	.	O	O

0	Even	O	O
1	if	O	O
2	it	O	O
3	did	O	O
4	not	O	O
5	reach	O	O
6	statistical	O	O
7	significance	O	O
8	because	O	O
9	of	O	O
10	a	O	O
11	few	O	O
12	number	O	O
13	of	O	O
14	cases	O	O
15	,	O	O
16	the	O	O
17	risk	O	O
18	was	O	O
19	lower	O	O
20	in	O	O
21	trials	O	O
22	excluding	O	O
23	patients	O	O
24	with	O	O
25	cardiac	O	B-Disease
26	history	O	O
27	,	O	O
28	and	O	O
29	seemed	O	O
30	to	O	O
31	be	O	O
32	higher	O	O
33	in	O	O
34	trials	O	O
35	including	O	O
36	patients	O	O
37	with	O	O
38	pre	O	O
39	-	O	O
40	existing	O	O
41	cardiac	B-Disease	B-Disease
42	diseases	E-Disease	E-Disease
43	.	O	O

0	Vinorelbine	S-Chemical	S-Chemical
1	-	O	O
2	related	O	O
3	cardiac	O	B-Disease
4	events	O	E-Disease
5	concern	O	O
6	about	O	O
7	1	O	O
8	%	O	O
9	of	O	O
10	treated	O	O
11	patients	O	O
12	in	O	O
13	clinical	O	O
14	trials	O	O
15	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	risk	O	O
4	associated	O	O
5	with	O	O
6	VNR	S-Chemical	S-Chemical
7	seems	O	O
8	to	O	O
9	be	O	O
10	similar	O	O
11	to	O	O
12	that	O	O
13	of	O	O
14	other	O	O
15	chemotherapeutic	O	O
16	agents	O	O
17	in	O	O
18	the	O	O
19	same	O	O
20	indications	O	O
21	.	O	O

0	MRI	O	O
1	findings	O	O
2	of	O	O
3	hypoxic	O	B-Disease
4	cortical	O	I-Disease
5	laminar	O	I-Disease
6	necrosis	S-Disease	E-Disease
7	in	O	O
8	a	O	O
9	child	O	O
10	with	O	O
11	hemolytic	B-Disease	O
12	anemia	E-Disease	S-Disease
13	crisis	O	O
14	.	O	O

0	We	O	O
1	present	O	O
2	magnetic	O	O
3	resonance	O	O
4	imaging	O	O
5	findings	O	O
6	of	O	O
7	a	O	O
8	5	O	O
9	-	O	O
10	year	O	O
11	-	O	O
12	old	O	O
13	girl	O	O
14	who	O	O
15	had	O	O
16	a	O	O
17	rapidly	O	O
18	installing	O	O
19	hemolytic	B-Disease	O
20	anemia	E-Disease	O
21	crisis	O	O
22	induced	O	O
23	by	O	O
24	trimethoprim	B-Chemical	S-Chemical
25	-	I-Chemical	O
26	sulfomethoxazole	E-Chemical	S-Chemical
27	,	O	O
28	resulting	O	O
29	in	O	O
30	cerebral	B-Disease	B-Disease
31	anoxia	E-Disease	E-Disease
32	leading	O	O
33	to	O	O
34	permanent	O	O
35	damage	O	O
36	.	O	O

0	Magnetic	O	O
1	Resonance	O	O
2	imaging	O	O
3	revealed	O	O
4	cortical	O	B-Disease
5	laminar	O	I-Disease
6	necrosis	S-Disease	E-Disease
7	in	O	O
8	arterial	O	B-Disease
9	border	O	I-Disease
10	zones	O	O
11	in	O	O
12	both	O	O
13	cerebral	O	B-Disease
14	hemispheres	O	E-Disease
15	,	O	O
16	ischemic	O	O
17	changes	O	O
18	in	O	O
19	subcortical	O	O
20	white	O	O
21	matter	O	O
22	of	O	O
23	left	O	O
24	cerebral	O	O
25	hemisphere	O	O
26	,	O	O
27	and	O	O
28	in	O	O
29	the	O	O
30	left	O	O
31	putamen	O	S-Disease
32	.	O	O

0	Although	O	O
1	cortical	O	B-Disease
2	laminar	O	I-Disease
3	necrosis	S-Disease	E-Disease
4	is	O	O
5	a	O	O
6	classic	O	O
7	entity	O	O
8	in	O	O
9	adulthood	O	O
10	related	O	O
11	to	O	O
12	conditions	O	O
13	of	O	O
14	energy	O	B-Disease
15	depletions	O	E-Disease
16	,	O	O
17	there	O	O
18	are	O	O
19	few	O	O
20	reports	O	O
21	available	O	O
22	in	O	O
23	children	O	O
24	.	O	O

0	The	O	O
1	natural	O	O
2	history	O	O
3	of	O	O
4	Vigabatrin	S-Chemical	S-Chemical
5	associated	O	O
6	visual	B-Disease	B-Disease
7	field	I-Disease	I-Disease
8	defects	E-Disease	E-Disease
9	in	O	O
10	patients	O	O
11	electing	O	O
12	to	O	O
13	continue	O	O
14	their	O	O
15	medication	O	O
16	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	To	O	O
3	determine	O	O
4	the	O	O
5	natural	O	O
6	history	O	O
7	of	O	O
8	visual	B-Disease	B-Disease
9	field	I-Disease	I-Disease
10	defects	E-Disease	E-Disease
11	in	O	O
12	a	O	O
13	group	O	O
14	of	O	O
15	patients	O	O
16	known	O	O
17	to	O	O
18	have	O	O
19	Vigabatrin	S-Chemical	S-Chemical
20	-	O	O
21	associated	O	O
22	changes	O	O
23	who	O	O
24	elected	O	O
25	to	O	O
26	continue	O	O
27	the	O	O
28	medication	O	O
29	because	O	O
30	of	O	O
31	good	O	O
32	seizure	S-Disease	S-Disease
33	control	O	O
34	.	O	O

0	METHODS	O	O
1	:	O	O
2	All	O	O
3	patients	O	O
4	taking	O	O
5	Vigabatrin	S-Chemical	S-Chemical
6	alone	O	O
7	or	O	O
8	in	O	O
9	combination	O	O
10	with	O	O
11	other	O	O
12	antiepileptic	O	O
13	drugs	O	O
14	for	O	O
15	at	O	O
16	least	O	O
17	5	O	O
18	years	O	O
19	(	O	O
20	range	O	O
21	5	O	O
22	-	O	O
23	12	O	O
24	years	O	O
25	)	O	O
26	were	O	O
27	entered	O	O
28	into	O	O
29	a	O	O
30	visual	O	O
31	surveillance	O	O
32	programme	O	O
33	.	O	O

0	Following	O	O
1	already	O	O
2	published	O	O
3	methodology	O	O
4	(	O	O
5	Eye	O	S-Disease
6	2002	O	O
7	;	O	O
8	16	O	O
9	;	O	O
10	567	O	O
11	-	O	O
12	571	O	O
13	)	O	O
14	monocular	O	O
15	mean	O	O
16	radial	O	O
17	degrees	O	O
18	(	O	O
19	MRDs	O	S-Disease
20	)	O	O
21	to	O	O
22	the	O	O
23	I	O	B-Chemical
24	/	O	I-Chemical
25	4e	O	O
26	isopter	O	O
27	on	O	O
28	Goldmann	O	O
29	perimetry	O	O
30	was	O	O
31	calculated	O	O
32	for	O	O
33	the	O	O
34	right	O	O
35	eye	O	O
36	at	O	O
37	the	O	O
38	time	O	O
39	of	O	O
40	discovery	O	O
41	of	O	O
42	a	O	O
43	visual	B-Disease	O
44	field	I-Disease	O
45	defect	E-Disease	S-Disease
46	and	O	O
47	again	O	O
48	after	O	O
49	not	O	O
50	less	O	O
51	than	O	O
52	18	O	O
53	months	O	O
54	follow	O	O
55	-	O	O
56	up	O	O
57	.	O	O

0	Only	O	O
1	one	O	O
2	patient	O	O
3	demonstrated	O	O
4	a	O	O
5	deterioration	B-Disease	O
6	in	I-Disease	O
7	visual	I-Disease	O
8	field	E-Disease	O
9	during	O	O
10	the	O	O
11	study	O	O
12	period	O	O
13	and	O	O
14	discontinued	O	O
15	treatment	O	O
16	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Established	O	O
3	visual	B-Disease	O
4	field	I-Disease	B-Disease
5	defects	E-Disease	E-Disease
6	presumed	O	O
7	to	O	O
8	be	O	O
9	due	O	O
10	to	O	O
11	Vigabatrin	S-Chemical	S-Chemical
12	therapy	O	O
13	did	O	O
14	not	O	O
15	usually	O	O
16	progress	O	O
17	in	O	O
18	spite	O	O
19	of	O	O
20	continuing	O	O
21	use	O	O
22	of	O	O
23	the	O	O
24	medication	O	O
25	.	O	O

0	These	O	O
1	data	O	O
2	give	O	O
3	support	O	O
4	to	O	O
5	the	O	O
6	hypothesis	O	O
7	that	O	O
8	the	O	O
9	pathogenesis	O	O
10	of	O	O
11	Vigabatrin	S-Chemical	S-Chemical
12	-	O	O
13	associated	O	O
14	visual	B-Disease	B-Disease
15	field	I-Disease	I-Disease
16	defects	E-Disease	E-Disease
17	may	O	O
18	be	O	O
19	an	O	O
20	idiosyncratic	O	O
21	adverse	O	O
22	drug	O	O
23	reaction	O	O
24	rather	O	O
25	than	O	O
26	dose	O	O
27	-	O	O
28	dependent	O	O
29	toxicity	S-Disease	S-Disease
30	.	O	O

0	Induction	O	O
1	of	O	O
2	rosaceiform	O	B-Disease
3	dermatitis	S-Disease	E-Disease
4	during	O	O
5	treatment	O	O
6	of	O	O
7	facial	B-Disease	B-Disease
8	inflammatory	I-Disease	I-Disease
9	dermatoses	E-Disease	E-Disease
10	with	O	O
11	tacrolimus	S-Chemical	B-Disease
12	ointment	O	E-Disease
13	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Tacrolimus	S-Chemical	S-Chemical
3	ointment	O	E-Disease
4	is	O	O
5	increasingly	O	O
6	used	O	O
7	for	O	O
8	anti	O	O
9	-	O	O
10	inflammatory	O	S-Disease
11	treatment	O	O
12	of	O	O
13	sensitive	O	O
14	areas	O	O
15	such	O	O
16	as	O	O
17	the	O	O
18	face	O	O
19	,	O	O
20	and	O	O
21	recent	O	O
22	observations	O	O
23	indicate	O	O
24	that	O	O
25	the	O	O
26	treatment	O	O
27	is	O	O
28	effective	O	O
29	in	O	O
30	steroid	S-Chemical	S-Chemical
31	-	O	O
32	aggravated	O	O
33	rosacea	S-Disease	S-Disease
34	and	O	O
35	perioral	B-Disease	B-Disease
36	dermatitis	E-Disease	I-Disease
37	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	rosaceiform	O	B-Disease
4	dermatitis	S-Disease	E-Disease
5	as	O	O
6	a	O	O
7	complication	O	O
8	of	O	O
9	treatment	O	O
10	with	O	O
11	tacrolimus	S-Chemical	B-Disease
12	ointment	O	E-Disease
13	.	O	O

0	OBSERVATIONS	O	O
1	:	O	O
2	Six	O	O
3	adult	O	O
4	patients	O	O
5	with	O	O
6	inflammatory	B-Disease	B-Disease
7	facial	I-Disease	I-Disease
8	dermatoses	E-Disease	E-Disease
9	were	O	O
10	treated	O	O
11	with	O	O
12	tacrolimus	S-Chemical	S-Chemical
13	ointment	O	E-Disease
14	because	O	O
15	of	O	O
16	the	O	O
17	ineffectiveness	O	O
18	of	O	O
19	standard	O	O
20	treatments	O	O
21	.	O	O

0	Within	O	O
1	2	O	O
2	to	O	O
3	3	O	O
4	weeks	O	O
5	of	O	O
6	initially	O	O
7	effective	O	O
8	and	O	O
9	well	O	O
10	-	O	O
11	tolerated	O	O
12	treatment	O	O
13	,	O	O
14	3	O	O
15	patients	O	O
16	with	O	O
17	a	O	O
18	history	O	O
19	of	O	O
20	rosacea	S-Disease	S-Chemical
21	and	O	O
22	1	O	O
23	with	O	O
24	a	O	O
25	history	O	O
26	of	O	O
27	acne	S-Disease	S-Chemical
28	experienced	O	O
29	sudden	O	O
30	worsening	O	O
31	with	O	O
32	pustular	O	B-Disease
33	rosaceiform	O	I-Disease
34	lesions	O	S-Disease
35	.	O	O

0	In	O	O
1	1	O	O
2	patient	O	O
3	with	O	O
4	eyelid	O	O
5	eczema	S-Disease	E-Disease
6	,	O	O
7	rosaceiform	O	B-Disease
8	periocular	B-Disease	I-Disease
9	dermatitis	E-Disease	E-Disease
10	gradually	O	O
11	appeared	O	O
12	after	O	O
13	3	O	O
14	weeks	O	O
15	of	O	O
16	treatment	O	O
17	.	O	O

0	In	O	O
1	1	O	O
2	patient	O	O
3	with	O	O
4	atopic	B-Disease	B-Disease
5	dermatitis	E-Disease	E-Disease
6	,	O	O
7	telangiectatic	O	S-Disease
8	and	O	O
9	papular	B-Disease	B-Disease
10	rosacea	E-Disease	E-Disease
11	insidiously	O	O
12	appeared	O	O
13	after	O	O
14	5	O	O
15	months	O	O
16	of	O	O
17	treatment	O	O
18	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Our	O	O
3	observations	O	O
4	suggest	O	O
5	that	O	O
6	the	O	O
7	spectrum	O	O
8	of	O	O
9	rosaceiform	O	B-Disease
10	dermatitis	S-Disease	E-Disease
11	as	O	O
12	a	O	O
13	complication	O	O
14	of	O	O
15	treatment	O	O
16	with	O	O
17	tacrolimus	S-Chemical	B-Disease
18	ointment	O	E-Disease
19	is	O	O
20	heterogeneous	O	O
21	.	O	O

0	A	O	O
1	variety	O	O
2	of	O	O
3	factors	O	O
4	,	O	O
5	such	O	O
6	as	O	O
7	vasoactive	O	O
8	properties	O	O
9	of	O	O
10	tacrolimus	S-Chemical	S-Chemical
11	,	O	O
12	proliferation	O	S-Disease
13	of	O	O
14	Demodex	O	S-Chemical
15	due	O	O
16	to	O	O
17	local	O	O
18	immunosuppression	O	S-Disease
19	,	O	O
20	and	O	O
21	the	O	O
22	occlusive	O	O
23	properties	O	O
24	of	O	O
25	the	O	O
26	ointment	O	O
27	,	O	O
28	may	O	O
29	be	O	O
30	involved	O	O
31	in	O	O
32	the	O	O
33	observed	O	O
34	phenomena	O	O
35	.	O	O

0	Intravascular	O	O
1	hemolysis	S-Disease	O
2	and	O	O
3	acute	B-Disease	B-Disease
4	renal	I-Disease	I-Disease
5	failure	E-Disease	E-Disease
6	following	O	O
7	intermittent	O	O
8	rifampin	S-Chemical	S-Chemical
9	therapy	O	O
10	.	O	O

0	Renal	B-Disease	B-Disease
1	failure	E-Disease	E-Disease
2	is	O	O
3	a	O	O
4	rare	O	O
5	complication	O	O
6	associated	O	O
7	with	O	O
8	the	O	O
9	use	O	O
10	of	O	O
11	rifampin	S-Chemical	S-Chemical
12	.	O	O

0	Intravascular	O	O
1	hemolysis	S-Disease	O
2	leading	O	O
3	to	O	O
4	acute	B-Disease	B-Disease
5	renal	I-Disease	I-Disease
6	failure	E-Disease	E-Disease
7	following	O	O
8	rifampin	S-Chemical	S-Chemical
9	therapy	O	O
10	is	O	O
11	extremely	O	O
12	rare	O	O
13	.	O	O

0	Two	O	O
1	patients	O	O
2	with	O	O
3	leprosy	S-Disease	S-Disease
4	who	O	O
5	developed	O	O
6	hemolysis	S-Disease	O
7	and	O	O
8	acute	B-Disease	B-Disease
9	renal	I-Disease	I-Disease
10	failure	E-Disease	E-Disease
11	following	O	O
12	rifampin	S-Chemical	S-Chemical
13	are	O	O
14	reported	O	O
15	.	O	O

0	Structural	O	O
1	abnormalities	O	O
2	in	O	O
3	the	O	O
4	brains	O	O
5	of	O	O
6	human	O	O
7	subjects	O	O
8	who	O	O
9	use	O	O
10	methamphetamine	S-Chemical	S-Chemical
11	.	O	O

0	We	O	O
1	visualize	O	O
2	,	O	O
3	for	O	O
4	the	O	O
5	first	O	O
6	time	O	O
7	,	O	O
8	the	O	O
9	profile	O	O
10	of	O	O
11	structural	B-Disease	O
12	deficits	I-Disease	E-Disease
13	in	I-Disease	O
14	the	I-Disease	O
15	human	I-Disease	O
16	brain	E-Disease	O
17	associated	O	O
18	with	O	O
19	chronic	O	B-Disease
20	methamphetamine	S-Chemical	E-Chemical
21	(	O	O
22	MA	S-Chemical	S-Chemical
23	)	O	O
24	abuse	O	E-Disease
25	.	O	O

0	Studies	O	O
1	of	O	O
2	human	O	O
3	subjects	O	O
4	who	O	O
5	have	O	O
6	used	O	O
7	MA	S-Chemical	S-Chemical
8	chronically	O	O
9	have	O	O
10	revealed	O	O
11	deficits	O	O
12	in	O	O
13	dopaminergic	O	O
14	and	O	O
15	serotonergic	O	B-Disease
16	systems	O	E-Disease
17	and	O	O
18	cerebral	O	B-Disease
19	metabolic	B-Disease	I-Disease
20	abnormalities	E-Disease	E-Disease
21	.	O	O

0	Using	O	O
1	magnetic	O	O
2	resonance	O	O
3	imaging	O	O
4	(	O	O
5	MRI	O	O
6	)	O	O
7	and	O	O
8	new	O	O
9	computational	O	O
10	brain	O	O
11	-	O	O
12	mapping	O	O
13	techniques	O	O
14	,	O	O
15	we	O	O
16	determined	O	O
17	the	O	O
18	pattern	O	O
19	of	O	O
20	structural	O	O
21	brain	O	I-Disease
22	alterations	O	E-Disease
23	associated	O	O
24	with	O	O
25	chronic	O	B-Disease
26	MA	S-Chemical	B-Disease
27	abuse	O	E-Disease
28	in	O	O
29	human	O	O
30	subjects	O	O
31	and	O	O
32	related	O	O
33	these	O	O
34	deficits	O	O
35	to	O	O
36	cognitive	B-Disease	B-Disease
37	impairment	E-Disease	E-Disease
38	.	O	O

0	We	O	O
1	used	O	O
2	high	O	O
3	-	O	O
4	resolution	O	O
5	MRI	O	S-Disease
6	and	O	O
7	surface	O	O
8	-	O	O
9	based	O	O
10	computational	O	O
11	image	O	O
12	analyses	O	O
13	to	O	O
14	map	O	O
15	regional	O	O
16	abnormalities	B-Disease	O
17	in	I-Disease	O
18	the	I-Disease	O
19	cortex	I-Disease	O
20	,	I-Disease	O
21	hippocampus	I-Disease	S-Disease
22	,	I-Disease	O
23	white	I-Disease	O
24	matter	I-Disease	O
25	,	I-Disease	O
26	and	I-Disease	O
27	ventricles	E-Disease	S-Disease
28	in	O	O
29	22	O	O
30	human	O	O
31	subjects	O	O
32	who	O	O
33	used	O	O
34	MA	S-Chemical	S-Chemical
35	and	O	O
36	21	O	O
37	age	O	O
38	-	O	O
39	matched	O	O
40	,	O	O
41	healthy	O	O
42	controls	O	O
43	.	O	O

0	Cortical	O	O
1	maps	O	O
2	revealed	O	O
3	severe	O	O
4	gray	O	O
5	-	O	O
6	matter	O	O
7	deficits	O	O
8	in	O	O
9	the	O	O
10	cingulate	O	S-Disease
11	,	O	O
12	limbic	O	S-Disease
13	,	O	O
14	and	O	O
15	paralimbic	O	O
16	cortices	O	O
17	of	O	O
18	MA	S-Chemical	B-Disease
19	abusers	O	E-Disease
20	(	O	O
21	averaging	O	O
22	11	O	O
23	.	O	O
24	3	O	O
25	%	O	O
26	below	O	O
27	control	O	O
28	;	O	O
29	p	O	O
30	<	O	O
31	0	O	O
32	.	O	O
33	05	O	O
34	)	O	O
35	.	O	O

0	On	O	O
1	average	O	O
2	,	O	O
3	MA	S-Chemical	S-Chemical
4	abusers	O	O
5	had	O	O
6	7	O	O
7	.	O	O
8	8	O	O
9	%	O	O
10	smaller	O	O
11	hippocampal	O	S-Disease
12	volumes	O	O
13	than	O	O
14	control	O	O
15	subjects	O	O
16	(	O	O
17	p	O	O
18	<	O	O
19	0	O	O
20	.	O	O
21	01	O	O
22	;	O	O
23	left	O	O
24	,	O	O
25	p	O	O
26	=	O	O
27	0	O	O
28	.	O	O
29	01	O	O
30	;	O	O
31	right	O	O
32	,	O	O
33	p	O	O
34	<	O	O
35	0	O	O
36	.	O	O
37	05	O	O
38	)	O	O
39	and	O	O
40	significant	O	O
41	white	O	O
42	-	O	O
43	matter	O	O
44	hypertrophy	S-Disease	S-Disease
45	(	O	O
46	7	O	O
47	.	O	O
48	0	O	O
49	%	O	O
50	;	O	O
51	p	O	O
52	<	O	O
53	0	O	O
54	.	O	O
55	01	O	O
56	)	O	O
57	.	O	O

0	MRI	O	O
1	-	O	O
2	based	O	O
3	maps	O	O
4	suggest	O	O
5	that	O	O
6	chronic	O	B-Disease
7	methamphetamine	S-Chemical	E-Chemical
8	abuse	O	E-Disease
9	causes	O	O
10	a	O	O
11	selective	O	O
12	pattern	O	O
13	of	O	O
14	cerebral	O	B-Disease
15	deterioration	O	E-Disease
16	that	O	O
17	contributes	O	O
18	to	O	O
19	impaired	B-Disease	O
20	memory	I-Disease	B-Disease
21	performance	E-Disease	O
22	.	O	O

0	MA	S-Chemical	S-Chemical
1	may	O	O
2	selectively	O	O
3	damage	O	O
4	the	O	O
5	medial	O	O
6	temporal	O	O
7	lobe	O	O
8	and	O	O
9	,	O	O
10	consistent	O	O
11	with	O	O
12	metabolic	O	O
13	studies	O	O
14	,	O	O
15	the	O	O
16	cingulate	O	B-Disease
17	-	O	O
18	limbic	O	I-Disease
19	cortex	O	O
20	,	O	O
21	inducing	O	O
22	neuroadaptation	O	O
23	,	O	O
24	neuropil	O	S-Disease
25	reduction	O	O
26	,	O	O
27	or	O	O
28	cell	O	O
29	death	O	E-Disease
30	.	O	O

0	Prominent	O	O
1	white	O	O
2	-	O	O
3	matter	O	O
4	hypertrophy	S-Disease	S-Disease
5	may	O	O
6	result	O	O
7	from	O	O
8	altered	O	O
9	myelination	O	S-Disease
10	and	O	O
11	adaptive	O	O
12	glial	O	O
13	changes	O	O
14	,	O	O
15	including	O	O
16	gliosis	S-Disease	S-Disease
17	secondary	O	O
18	to	O	O
19	neuronal	B-Disease	B-Disease
20	damage	E-Disease	E-Disease
21	.	O	O

0	These	O	O
1	brain	O	O
2	substrates	O	O
3	may	O	O
4	help	O	O
5	account	O	O
6	for	O	O
7	the	O	O
8	symptoms	O	O
9	of	O	O
10	MA	S-Chemical	S-Chemical
11	abuse	O	E-Disease
12	,	O	O
13	providing	O	O
14	therapeutic	O	O
15	targets	O	O
16	for	O	O
17	drug	O	O
18	-	O	O
19	induced	O	O
20	brain	B-Disease	B-Disease
21	injury	E-Disease	E-Disease
22	.	O	O

0	Disruption	O	O
1	of	O	O
2	hepatic	O	B-Disease
3	lipid	O	I-Disease
4	homeostasis	O	E-Disease
5	in	O	O
6	mice	O	O
7	after	O	O
8	amiodarone	S-Chemical	S-Chemical
9	treatment	O	O
10	is	O	O
11	associated	O	O
12	with	O	O
13	peroxisome	O	B-Disease
14	proliferator	O	I-Disease
15	-	O	O
16	activated	O	O
17	receptor	O	O
18	-	O	O
19	alpha	O	O
20	target	O	O
21	gene	O	O
22	activation	O	O
23	.	O	O

0	Amiodarone	S-Chemical	S-Chemical
1	,	O	O
2	an	O	O
3	efficacious	O	O
4	and	O	O
5	widely	O	O
6	used	O	O
7	antiarrhythmic	O	O
8	agent	O	O
9	,	O	O
10	has	O	O
11	been	O	O
12	reported	O	O
13	to	O	O
14	cause	O	O
15	hepatotoxicity	S-Disease	S-Chemical
16	in	O	O
17	some	O	O
18	patients	O	O
19	.	O	O

0	To	O	O
1	gain	O	O
2	insight	O	O
3	into	O	O
4	the	O	O
5	mechanism	O	O
6	of	O	O
7	this	O	O
8	unwanted	O	O
9	effect	O	O
10	,	O	O
11	mice	O	O
12	were	O	O
13	administered	O	O
14	various	O	O
15	doses	O	O
16	of	O	O
17	amiodarone	S-Chemical	S-Chemical
18	and	O	O
19	examined	O	O
20	for	O	O
21	changes	O	O
22	in	O	O
23	hepatic	O	S-Disease
24	histology	O	S-Disease
25	and	O	O
26	gene	O	O
27	regulation	O	O
28	.	O	O

0	Amiodarone	S-Chemical	S-Chemical
1	induced	O	O
2	hepatomegaly	S-Disease	S-Disease
3	,	O	O
4	hepatocyte	O	S-Disease
5	microvesicular	O	O
6	lipid	O	E-Disease
7	accumulation	O	O
8	,	O	O
9	and	O	O
10	a	O	O
11	significant	O	O
12	decrease	O	O
13	in	O	O
14	serum	O	O
15	triglycerides	S-Chemical	S-Disease
16	and	O	O
17	glucose	S-Chemical	S-Disease
18	.	O	O

0	Northern	O	O
1	blot	O	O
2	analysis	O	O
3	of	O	O
4	hepatic	O	S-Chemical
5	RNA	O	O
6	revealed	O	O
7	a	O	O
8	dose	O	O
9	-	O	O
10	dependent	O	O
11	increase	O	O
12	in	O	O
13	the	O	O
14	expression	O	O
15	of	O	O
16	a	O	O
17	number	O	O
18	of	O	O
19	genes	O	O
20	critical	O	O
21	for	O	O
22	fatty	B-Chemical	B-Disease
23	acid	E-Chemical	I-Disease
24	oxidation	O	E-Disease
25	,	O	O
26	lipoprotein	O	S-Chemical
27	assembly	O	O
28	,	O	O
29	and	O	O
30	lipid	O	S-Chemical
31	transport	O	O
32	.	O	O

0	The	O	O
1	absence	O	O
2	of	O	O
3	induction	O	O
4	of	O	O
5	these	O	O
6	genes	O	O
7	as	O	O
8	well	O	O
9	as	O	O
10	hepatomegaly	S-Disease	S-Disease
11	in	O	O
12	PPARalpha	O	S-Disease
13	knockout	O	O
14	[	O	O
15	PPARalpha	O	S-Chemical
16	-	O	O
17	/	O	O
18	-	O	E-Chemical
19	]	O	O
20	mice	O	O
21	indicated	O	O
22	that	O	O
23	the	O	O
24	effects	O	O
25	of	O	O
26	amiodarone	S-Chemical	S-Chemical
27	were	O	O
28	dependent	O	O
29	upon	O	O
30	the	O	O
31	presence	O	O
32	of	O	O
33	a	O	O
34	functional	O	O
35	PPARalpha	O	S-Disease
36	gene	O	O
37	.	O	O

0	Compared	O	O
1	to	O	O
2	wild	O	O
3	-	O	O
4	type	O	O
5	mice	O	O
6	,	O	O
7	treatment	O	O
8	of	O	O
9	PPARalpha	O	S-Chemical
10	-	O	O
11	/	O	O
12	-	O	O
13	mice	O	O
14	with	O	O
15	amiodarone	S-Chemical	S-Chemical
16	resulted	O	O
17	in	O	O
18	an	O	O
19	increased	O	O
20	rate	O	O
21	and	O	O
22	extent	O	O
23	of	O	O
24	total	O	O
25	body	O	O
26	weight	B-Disease	O
27	loss	E-Disease	O
28	.	O	O

0	The	O	O
1	inability	O	O
2	of	O	O
3	amiodarone	S-Chemical	S-Chemical
4	to	O	O
5	directly	O	O
6	activate	O	O
7	either	O	O
8	human	O	O
9	or	O	O
10	mouse	O	O
11	PPARalpha	O	S-Disease
12	transiently	O	O
13	expressed	O	O
14	in	O	O
15	human	O	O
16	HepG2	O	S-Chemical
17	hepatoma	S-Disease	E-Chemical
18	cells	O	O
19	indicates	O	O
20	that	O	O
21	the	O	O
22	effects	O	O
23	of	O	O
24	amiodarone	S-Chemical	S-Chemical
25	on	O	O
26	the	O	O
27	function	O	O
28	of	O	O
29	this	O	O
30	receptor	O	O
31	were	O	O
32	indirect	O	O
33	.	O	O

0	Based	O	O
1	upon	O	O
2	these	O	O
3	results	O	O
4	,	O	O
5	we	O	O
6	conclude	O	O
7	that	O	O
8	amiodarone	S-Chemical	S-Chemical
9	disrupts	O	O
10	hepatic	O	S-Disease
11	lipid	O	B-Disease
12	homeostasis	O	E-Disease
13	and	O	O
14	that	O	O
15	the	O	O
16	increased	O	O
17	expression	O	O
18	of	O	O
19	PPARalpha	O	S-Chemical
20	target	O	O
21	genes	O	O
22	is	O	O
23	secondary	O	O
24	to	O	O
25	this	O	O
26	toxic	O	O
27	effect	O	O
28	.	O	O

0	These	O	O
1	results	O	O
2	provide	O	O
3	important	O	O
4	new	O	O
5	mechanistic	O	O
6	information	O	O
7	regarding	O	O
8	the	O	O
9	hepatotoxic	S-Disease	S-Disease
10	effects	O	O
11	of	O	O
12	amiodarone	S-Chemical	S-Chemical
13	and	O	O
14	indicate	O	O
15	that	O	O
16	PPARalpha	O	S-Chemical
17	protects	O	O
18	against	O	O
19	amiodarone	S-Chemical	S-Chemical
20	-	O	O
21	induced	O	O
22	hepatotoxicity	S-Disease	S-Disease
23	.	O	O

0	Safety	O	O
1	and	O	O
2	compliance	O	O
3	with	O	O
4	once	O	O
5	-	O	O
6	daily	O	O
7	niacin	B-Chemical	S-Chemical
8	extended	I-Chemical	O
9	-	I-Chemical	O
10	release	I-Chemical	O
11	/	I-Chemical	O
12	lovastatin	E-Chemical	S-Chemical
13	as	O	O
14	initial	O	O
15	therapy	O	O
16	in	O	O
17	the	O	O
18	Impact	O	O
19	of	O	O
20	Medical	O	O
21	Subspecialty	O	O
22	on	O	O
23	Patient	O	O
24	Compliance	O	O
25	to	O	O
26	Treatment	O	O
27	(	O	O
28	IMPACT	O	O
29	)	O	O
30	study	O	O
31	.	O	O

0	Niacin	B-Chemical	S-Chemical
1	extended	I-Chemical	O
2	-	I-Chemical	O
3	release	I-Chemical	O
4	/	I-Chemical	O
5	lovastatin	E-Chemical	E-Chemical
6	is	O	O
7	a	O	O
8	new	O	O
9	combination	O	O
10	product	O	O
11	approved	O	O
12	for	O	O
13	treatment	O	O
14	of	O	O
15	primary	O	O
16	hypercholesterolemia	S-Disease	S-Disease
17	and	O	O
18	mixed	O	O
19	dyslipidemia	S-Disease	S-Disease
20	.	O	O

0	This	O	O
1	open	O	O
2	-	O	O
3	labeled	O	O
4	,	O	O
5	multicenter	O	O
6	study	O	O
7	evaluated	O	O
8	the	O	O
9	safety	O	O
10	of	O	O
11	bedtime	O	O
12	niacin	B-Chemical	S-Chemical
13	extended	I-Chemical	O
14	-	I-Chemical	O
15	release	I-Chemical	O
16	/	I-Chemical	O
17	lovastatin	E-Chemical	S-Disease
18	when	O	O
19	dosed	O	O
20	as	O	O
21	initial	O	O
22	therapy	O	O
23	and	O	O
24	patient	O	O
25	compliance	O	O
26	to	O	O
27	treatment	O	O
28	in	O	O
29	various	O	O
30	clinical	O	O
31	practice	O	O
32	settings	O	O
33	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	4	O	O
4	,	O	O
5	499	O	O
6	patients	O	O
7	with	O	O
8	dyslipidemia	S-Disease	S-Disease
9	requiring	O	O
10	drug	O	O
11	intervention	O	O
12	was	O	O
13	enrolled	O	O
14	at	O	O
15	1	O	O
16	,	O	O
17	081	O	O
18	sites	O	O
19	.	O	O

0	Patients	O	O
1	were	O	O
2	treated	O	O
3	with	O	O
4	1	O	O
5	tablet	O	O
6	(	O	O
7	500	O	O
8	mg	O	O
9	of	O	O
10	niacin	S-Chemical	S-Chemical
11	extended	O	O
12	-	O	O
13	release	O	O
14	/	O	O
15	20	O	O
16	mg	O	O
17	of	O	O
18	lovastatin	S-Chemical	S-Chemical
19	)	O	O
20	once	O	O
21	nightly	O	O
22	for	O	O
23	4	O	O
24	weeks	O	O
25	and	O	O
26	then	O	O
27	2	O	O
28	tablets	O	O
29	for	O	O
30	8	O	O
31	weeks	O	O
32	.	O	O

0	Patients	O	O
1	also	O	O
2	received	O	O
3	dietary	O	O
4	counseling	O	O
5	,	O	O
6	educational	O	O
7	materials	O	O
8	,	O	O
9	and	O	O
10	reminders	O	O
11	to	O	O
12	call	O	O
13	a	O	O
14	toll	O	O
15	-	O	O
16	free	O	O
17	number	O	O
18	that	O	O
19	provided	O	O
20	further	O	O
21	education	O	O
22	about	O	O
23	dyslipidemia	S-Disease	S-Disease
24	and	O	O
25	niacin	B-Chemical	S-Chemical
26	extended	I-Chemical	O
27	-	I-Chemical	O
28	release	I-Chemical	O
29	/	I-Chemical	O
30	lovastatin	E-Chemical	S-Disease
31	.	O	O

0	Primary	O	O
1	end	O	O
2	points	O	O
3	were	O	O
4	study	O	O
5	compliance	O	O
6	,	O	O
7	increases	O	O
8	in	O	O
9	liver	O	B-Disease
10	transaminases	O	E-Disease
11	to	O	O
12	>	O	O
13	3	O	O
14	times	O	O
15	the	O	O
16	upper	O	O
17	limit	O	O
18	of	O	O
19	normal	O	O
20	,	O	O
21	and	O	O
22	clinical	O	O
23	myopathy	S-Disease	S-Disease
24	.	O	O

0	Compliance	O	O
1	to	O	O
2	niacin	B-Chemical	B-Chemical
3	extended	I-Chemical	E-Chemical
4	-	I-Chemical	O
5	release	I-Chemical	S-Disease
6	/	I-Chemical	O
7	lovastatin	E-Chemical	E-Chemical
8	was	O	O
9	77	O	O
10	%	O	O
11	,	O	O
12	with	O	O
13	3	O	O
14	,	O	O
15	245	O	O
16	patients	O	O
17	completing	O	O
18	the	O	O
19	study	O	O
20	.	O	O

0	Flushing	S-Disease	S-Chemical
1	was	O	O
2	the	O	O
3	most	O	O
4	common	O	O
5	adverse	O	O
6	event	O	O
7	,	O	O
8	reported	O	O
9	by	O	O
10	18	O	O
11	%	O	O
12	of	O	O
13	patients	O	O
14	and	O	O
15	leading	O	O
16	to	O	O
17	discontinuation	O	O
18	by	O	O
19	6	O	O
20	%	O	O
21	.	O	O

0	Incidence	O	O
1	of	O	O
2	increased	O	O
3	aspartate	S-Chemical	S-Chemical
4	aminotransferase	O	E-Chemical
5	and	O	O
6	/	O	O
7	or	O	O
8	alanine	S-Chemical	S-Chemical
9	aminotransferase	O	E-Chemical
10	>	O	O
11	3	O	O
12	times	O	O
13	the	O	O
14	upper	O	O
15	limit	O	O
16	of	O	O
17	normal	O	O
18	was	O	O
19	<	O	O
20	0	O	O
21	.	O	O
22	3	O	O
23	%	O	O
24	.	O	O

0	An	O	O
1	increase	O	O
2	of	O	O
3	creatine	S-Chemical	B-Chemical
4	phosphokinase	O	E-Chemical
5	to	O	O
6	>	O	O
7	5	O	O
8	times	O	O
9	the	O	O
10	upper	O	O
11	limit	O	O
12	of	O	O
13	normal	O	O
14	occurred	O	O
15	in	O	O
16	0	O	O
17	.	O	O
18	24	O	O
19	%	O	O
20	of	O	O
21	patients	O	O
22	,	O	O
23	and	O	O
24	no	O	O
25	cases	O	O
26	of	O	O
27	drug	O	O
28	-	O	O
29	induced	O	O
30	myopathy	S-Disease	B-Disease
31	were	O	O
32	observed	O	O
33	.	O	O

0	Niacin	B-Chemical	S-Chemical
1	extended	I-Chemical	O
2	-	I-Chemical	O
3	release	I-Chemical	O
4	/	I-Chemical	O
5	lovastatin	E-Chemical	E-Chemical
6	1	O	O
7	,	O	O
8	000	O	O
9	/	O	O
10	40	O	O
11	mg	O	O
12	,	O	O
13	dosed	O	O
14	as	O	O
15	initial	O	O
16	therapy	O	O
17	,	O	O
18	was	O	O
19	associated	O	O
20	with	O	O
21	good	O	O
22	compliance	O	O
23	and	O	O
24	safety	O	O
25	and	O	O
26	had	O	O
27	very	O	O
28	low	O	O
29	incidences	O	O
30	of	O	O
31	increased	O	O
32	liver	O	O
33	and	O	O
34	muscle	O	B-Disease
35	enzymes	O	E-Disease
36	.	O	O

0	Protective	O	O
1	effect	O	O
2	of	O	O
3	Terminalia	B-Chemical	B-Disease
4	chebula	E-Chemical	E-Disease
5	against	O	O
6	experimental	O	O
7	myocardial	B-Disease	B-Disease
8	injury	E-Disease	E-Disease
9	induced	O	O
10	by	O	O
11	isoproterenol	S-Chemical	S-Chemical
12	.	O	O

0	Cardioprotective	O	O
1	effect	O	O
2	of	O	O
3	ethanolic	B-Chemical	S-Disease
4	extract	I-Chemical	O
5	of	I-Chemical	O
6	Terminalia	I-Chemical	B-Disease
7	chebula	I-Chemical	E-Disease
8	fruits	E-Chemical	O
9	(	O	O
10	500	O	O
11	mg	O	O
12	/	O	O
13	kg	O	O
14	body	O	O
15	wt	O	O
16	)	O	O
17	was	O	O
18	examined	O	O
19	in	O	O
20	isoproterenol	S-Chemical	S-Chemical
21	(	O	O
22	200	O	O
23	mg	O	O
24	/	O	O
25	kg	O	O
26	body	O	O
27	wt	O	O
28	)	O	O
29	induced	O	O
30	myocardial	B-Disease	B-Disease
31	damage	E-Disease	E-Disease
32	in	O	O
33	rats	O	O
34	.	O	O

0	In	O	O
1	isoproterenol	S-Chemical	S-Chemical
2	administered	O	O
3	rats	O	O
4	,	O	O
5	the	O	O
6	level	O	O
7	of	O	O
8	lipid	O	B-Chemical
9	peroxides	S-Chemical	E-Chemical
10	increased	O	O
11	significantly	O	O
12	in	O	O
13	the	O	O
14	serum	O	O
15	and	O	O
16	heart	O	O
17	.	O	O

0	Histopathological	O	O
1	examination	O	O
2	was	O	O
3	carried	O	O
4	out	O	O
5	to	O	O
6	confirm	O	O
7	the	O	O
8	myocardial	O	B-Disease
9	necrosis	S-Disease	E-Disease
10	.	O	O

0	T	B-Chemical	S-Chemical
1	.	I-Chemical	O
2	chebula	I-Chemical	E-Chemical
3	extract	E-Chemical	O
4	pretreatment	O	O
5	was	O	O
6	found	O	O
7	to	O	O
8	ameliorate	O	O
9	the	O	O
10	effect	O	O
11	of	O	O
12	isoproterenol	S-Chemical	S-Chemical
13	on	O	O
14	lipid	O	B-Chemical
15	peroxide	S-Chemical	I-Disease
16	formation	O	S-Disease
17	and	O	O
18	retained	O	O
19	the	O	O
20	activities	O	O
21	of	O	O
22	the	O	O
23	diagnostic	O	O
24	marker	O	O
25	enzymes	O	O
26	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	postoperative	O	O
4	anxiety	S-Disease	S-Disease
5	due	O	O
6	to	O	O
7	low	O	O
8	dose	O	O
9	droperidol	S-Chemical	S-Chemical
10	used	O	O
11	with	O	O
12	patient	O	O
13	-	O	O
14	controlled	O	O
15	analgesia	O	O
16	.	O	O

0	Postoperatively	O	O
1	,	O	O
2	she	O	O
3	was	O	O
4	given	O	O
5	a	O	O
6	patient	O	O
7	-	O	O
8	controlled	O	O
9	analgesia	O	O
10	device	O	O
11	delivering	O	O
12	boluses	O	S-Disease
13	of	O	O
14	diamorphine	S-Chemical	S-Chemical
15	0	O	O
16	.	O	O
17	5	O	O
18	mg	O	O
19	and	O	O
20	droperidol	S-Chemical	S-Chemical
21	0	O	O
22	.	O	O
23	025	O	O
24	mg	O	O
25	.	O	O

0	The	O	O
1	diagnosis	O	O
2	of	O	O
3	droperidol	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	psychological	B-Disease	O
7	disturbance	E-Disease	E-Disease
8	was	O	O
9	not	O	O
10	made	O	O
11	straight	O	O
12	away	O	O
13	although	O	O
14	on	O	O
15	subsequent	O	O
16	close	O	O
17	questioning	O	O
18	the	O	O
19	patient	O	O
20	gave	O	O
21	a	O	O
22	very	O	O
23	clear	O	O
24	history	O	O
25	.	O	O

0	After	O	O
1	she	O	O
2	had	O	O
3	received	O	O
4	a	O	O
5	total	O	O
6	of	O	O
7	only	O	O
8	0	O	O
9	.	O	O
10	9	O	O
11	mg	O	O
12	droperidol	S-Chemical	S-Disease
13	,	O	O
14	a	O	O
15	syringe	O	S-Disease
16	containing	O	O
17	diamorphine	S-Chemical	S-Chemical
18	only	O	O
19	was	O	O
20	substituted	O	O
21	and	O	O
22	her	O	O
23	unease	O	O
24	resolved	O	O
25	completely	O	O
26	.	O	O

0	Accurate	O	O
1	patient	O	O
2	history	O	O
3	contributes	O	O
4	to	O	O
5	differentiating	O	O
6	diabetes	B-Disease	B-Disease
7	insipidus	E-Disease	E-Disease
8	:	O	O
9	a	O	O
10	case	O	O
11	study	O	O
12	.	O	O

0	The	O	O
1	case	O	O
2	discussed	O	O
3	herein	O	O
4	initially	O	O
5	appeared	O	O
6	to	O	O
7	be	O	O
8	neurogenic	B-Disease	O
9	diabetes	I-Disease	B-Disease
10	insipidus	E-Disease	E-Disease
11	(	O	O
12	DI	S-Disease	S-Disease
13	)	O	O
14	secondary	O	O
15	to	O	O
16	a	O	O
17	traumatic	B-Disease	B-Disease
18	brain	I-Disease	I-Disease
19	injury	E-Disease	E-Disease
20	.	O	O

0	The	O	O
1	nursing	O	O
2	staff	O	O
3	,	O	O
4	by	O	O
5	reviewing	O	O
6	the	O	O
7	patient	O	O
8	'	O	O
9	s	O	O
10	health	O	O
11	history	O	O
12	with	O	O
13	his	O	O
14	family	O	O
15	,	O	O
16	discovered	O	O
17	a	O	O
18	history	O	O
19	of	O	O
20	polydipsia	S-Disease	S-Disease
21	and	O	O
22	long	O	O
23	-	O	O
24	standing	O	O
25	lithium	S-Chemical	S-Disease
26	use	O	O
27	.	O	O

0	Lithium	S-Chemical	S-Chemical
1	is	O	O
2	implicated	O	O
3	in	O	O
4	drug	O	O
5	-	O	O
6	induced	O	O
7	nephrogenic	B-Disease	B-Disease
8	DI	E-Disease	E-Disease
9	,	O	O
10	and	O	O
11	because	O	O
12	the	O	O
13	patient	O	O
14	had	O	O
15	not	O	O
16	received	O	O
17	lithium	S-Chemical	S-Disease
18	since	O	O
19	being	O	O
20	admitted	O	O
21	to	O	O
22	the	O	O
23	hospital	O	O
24	,	O	O
25	his	O	O
26	treatment	O	O
27	changed	O	O
28	to	O	O
29	focus	O	O
30	on	O	O
31	nephrogenic	B-Disease	S-Disease
32	DI	E-Disease	S-Disease
33	.	O	O

0	By	O	O
1	combining	O	O
2	information	O	O
3	from	O	O
4	the	O	O
5	patient	O	O
6	history	O	O
7	,	O	O
8	the	O	O
9	physical	O	O
10	examination	O	O
11	,	O	O
12	and	O	O
13	radiologic	O	O
14	and	O	O
15	laboratory	O	O
16	studies	O	O
17	,	O	O
18	the	O	O
19	critical	O	O
20	care	O	O
21	team	O	O
22	demonstrated	O	O
23	that	O	O
24	the	O	O
25	patient	O	O
26	had	O	O
27	been	O	O
28	self	O	O
29	-	O	O
30	treating	O	O
31	his	O	O
32	lithium	S-Chemical	S-Disease
33	-	O	O
34	induced	O	O
35	nephrogenic	B-Disease	S-Disease
36	DI	E-Disease	S-Disease
37	and	O	O
38	developed	O	O
39	neurogenic	B-Disease	B-Disease
40	DI	E-Disease	E-Disease
41	secondary	O	O
42	to	O	O
43	brain	B-Disease	B-Disease
44	trauma	E-Disease	E-Disease
45	.	O	O

0	Thus	O	O
1	successful	O	O
2	treatment	O	O
3	required	O	O
4	that	O	O
5	nephrogenic	O	S-Disease
6	and	O	O
7	neurogenic	B-Disease	B-Disease
8	DI	E-Disease	E-Disease
9	be	O	O
10	treated	O	O
11	concomitantly	O	O
12	.	O	O

0	Factors	O	O
1	contributing	O	O
2	to	O	O
3	ribavirin	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	anemia	S-Disease	S-Disease
7	.	O	O

0	BACKGROUND	O	O
1	AND	O	O
2	AIM	O	S-Disease
3	:	O	O
4	Interferon	S-Chemical	O
5	and	O	O
6	ribavirin	S-Chemical	S-Chemical
7	combination	O	O
8	therapy	O	O
9	for	O	O
10	chronic	B-Disease	B-Disease
11	hepatitis	I-Disease	I-Disease
12	C	E-Disease	E-Disease
13	produces	O	O
14	hemolytic	B-Disease	O
15	anemia	E-Disease	S-Disease
16	.	O	O

0	This	O	O
1	study	O	O
2	was	O	O
3	conducted	O	O
4	to	O	O
5	identify	O	O
6	the	O	O
7	factors	O	O
8	contributing	O	O
9	to	O	O
10	ribavirin	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	anemia	S-Disease	S-Disease
14	.	O	O

0	METHODS	O	O
1	:	O	O
2	Eighty	O	O
3	-	O	O
4	eight	O	O
5	patients	O	O
6	with	O	O
7	chronic	B-Disease	B-Disease
8	hepatitis	I-Disease	I-Disease
9	C	E-Disease	E-Disease
10	who	O	O
11	received	O	O
12	interferon	B-Chemical	S-Chemical
13	-	I-Chemical	O
14	alpha	I-Chemical	E-Chemical
15	-	I-Chemical	O
16	2b	E-Chemical	O
17	at	O	O
18	a	O	O
19	dose	O	O
20	of	O	O
21	6	O	O
22	MU	O	O
23	administered	O	O
24	intramuscularly	O	O
25	for	O	O
26	24	O	O
27	weeks	O	O
28	in	O	O
29	combination	O	O
30	with	O	O
31	ribavirin	S-Chemical	S-Chemical
32	administered	O	O
33	orally	O	O
34	at	O	O
35	a	O	O
36	dose	O	O
37	of	O	O
38	600	O	O
39	mg	O	O
40	or	O	O
41	800	O	O
42	mg	O	O
43	participated	O	O
44	in	O	O
45	the	O	O
46	study	O	O
47	.	O	O

0	A	O	O
1	hemoglobin	O	O
2	concentration	O	O
3	of	O	O
4	<	O	O
5	10	O	O
6	g	O	O
7	/	O	O
8	dL	O	O
9	was	O	O
10	defined	O	O
11	as	O	O
12	ribavirin	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	anemia	S-Disease	S-Disease
16	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Ribavirin	S-Chemical	S-Chemical
3	-	O	O
4	induced	O	O
5	anemia	S-Disease	S-Disease
6	occurred	O	O
7	in	O	O
8	18	O	O
9	(	O	O
10	20	O	O
11	.	O	O
12	5	O	O
13	%	O	O
14	)	O	O
15	patients	O	O
16	during	O	O
17	treatment	O	O
18	.	O	O

0	A	O	O
1	2	O	O
2	g	O	O
3	/	O	O
4	dL	O	O
5	decrease	O	O
6	in	O	O
7	hemoglobin	O	O
8	concentrations	O	O
9	in	O	O
10	patients	O	O
11	with	O	O
12	anemia	S-Disease	S-Disease
13	was	O	O
14	observed	O	O
15	at	O	O
16	week	O	O
17	2	O	O
18	after	O	O
19	the	O	O
20	start	O	O
21	of	O	O
22	treatment	O	O
23	.	O	O

0	A	O	O
1	significant	O	O
2	relationship	O	O
3	was	O	O
4	observed	O	O
5	between	O	O
6	the	O	O
7	rate	O	O
8	of	O	O
9	reduction	O	O
10	of	O	O
11	hemoglobin	O	O
12	concentrations	O	O
13	at	O	O
14	week	O	O
15	2	O	O
16	and	O	O
17	the	O	O
18	severity	O	O
19	of	O	O
20	anemia	S-Disease	S-Disease
21	(	O	O
22	P	O	S-Disease
23	<	O	O
24	0	O	O
25	.	O	O
26	01	O	O
27	)	O	O
28	.	O	O

0	Such	O	O
1	factors	O	O
2	as	O	O
3	sex	O	O
4	(	O	O
5	female	O	O
6	)	O	O
7	,	O	O
8	age	O	O
9	(	O	O
10	>	O	O
11	or	O	O
12	=	O	O
13	60	O	O
14	years	O	O
15	old	O	O
16	)	O	O
17	,	O	O
18	and	O	O
19	the	O	O
20	ribavirin	S-Chemical	S-Chemical
21	dose	O	O
22	by	O	O
23	body	O	O
24	weight	O	O
25	(	O	O
26	12	O	O
27	mg	O	O
28	/	O	O
29	kg	O	O
30	or	O	O
31	more	O	O
32	)	O	O
33	were	O	O
34	significant	O	O
35	by	O	O
36	univariate	O	O
37	analysis	O	O
38	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Careful	O	O
3	administration	O	O
4	is	O	O
5	necessary	O	O
6	in	O	O
7	patients	O	O
8	>	O	O
9	or	O	O
10	=	O	O
11	60	O	O
12	years	O	O
13	old	O	O
14	,	O	O
15	in	O	O
16	female	O	O
17	patients	O	O
18	,	O	O
19	and	O	O
20	in	O	O
21	patients	O	O
22	receiving	O	O
23	a	O	O
24	ribavirin	S-Chemical	S-Chemical
25	dose	O	O
26	of	O	O
27	12	O	O
28	mg	O	O
29	/	O	O
30	kg	O	O
31	or	O	O
32	more	O	O
33	.	O	O

0	Zidovudine	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	hepatitis	S-Disease	S-Disease
4	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	acute	O	B-Disease
4	hepatitis	S-Disease	E-Disease
5	induced	O	O
6	by	O	O
7	zidovudine	S-Chemical	S-Chemical
8	in	O	O
9	a	O	O
10	38	O	O
11	-	O	O
12	year	O	O
13	-	O	O
14	old	O	O
15	patient	O	O
16	with	O	O
17	AIDS	S-Disease	S-Chemical
18	is	O	O
19	presented	O	O
20	.	O	O

0	The	O	O
1	mechanism	O	O
2	whereby	O	O
3	the	O	O
4	hepatitis	S-Disease	S-Disease
5	was	O	O
6	induced	O	O
7	is	O	O
8	not	O	O
9	known	O	O
10	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	patient	O	O
4	tolerated	O	O
5	well	O	O
6	an	O	O
7	alternative	O	O
8	reverse	O	O
9	transcriptase	O	O
10	inhibitor	O	O
11	,	O	O
12	2	B-Chemical	B-Chemical
13	'	I-Chemical	I-Chemical
14	3	I-Chemical	I-Chemical
15	'	I-Chemical	I-Chemical
16	dideoxyinosine	E-Chemical	S-Chemical
17	.	O	O

0	Physicians	O	O
1	caring	O	O
2	for	O	O
3	patients	O	O
4	with	O	O
5	AIDS	S-Disease	S-Disease
6	should	O	O
7	be	O	O
8	aware	O	O
9	of	O	O
10	this	O	O
11	hitherto	O	O
12	rarely	O	O
13	reported	O	O
14	complication	O	O
15	.	O	O

0	Oxidative	O	O
1	damage	O	O
2	precedes	O	O
3	nitrative	O	O
4	damage	O	O
5	in	O	O
6	adriamycin	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	cardiac	O	B-Disease
10	mitochondrial	B-Disease	I-Disease
11	injury	E-Disease	E-Disease
12	.	O	O

0	The	O	O
1	purpose	O	O
2	of	O	O
3	the	O	O
4	present	O	O
5	study	O	O
6	was	O	O
7	to	O	O
8	determine	O	O
9	if	O	O
10	elevated	O	O
11	reactive	O	O
12	oxygen	S-Chemical	E-Chemical
13	(	O	O
14	ROS	O	S-Disease
15	)	O	O
16	/	O	O
17	nitrogen	S-Chemical	O
18	species	O	O
19	(	O	O
20	RNS	O	O
21	)	O	O
22	reported	O	O
23	to	O	O
24	be	O	O
25	present	O	O
26	in	O	O
27	adriamycin	S-Chemical	S-Chemical
28	(	O	O
29	ADR	S-Chemical	S-Chemical
30	)	O	O
31	-	O	O
32	induced	O	O
33	cardiotoxicity	S-Disease	S-Disease
34	actually	O	O
35	resulted	O	O
36	in	O	O
37	cardiomyocyte	O	O
38	oxidative	O	O
39	/	O	O
40	nitrative	O	O
41	damage	O	O
42	,	O	O
43	and	O	O
44	to	O	O
45	quantitatively	O	O
46	determine	O	O
47	the	O	O
48	time	O	O
49	course	O	O
50	and	O	O
51	subcellular	O	O
52	localization	O	O
53	of	O	O
54	these	O	O
55	postulated	O	O
56	damage	O	O
57	products	O	O
58	using	O	O
59	an	O	O
60	in	O	O
61	vivo	O	O
62	approach	O	O
63	.	O	O

0	B6C3	O	B-Chemical
1	mice	O	O
2	were	O	O
3	treated	O	O
4	with	O	O
5	a	O	O
6	single	O	O
7	dose	O	O
8	of	O	O
9	20	O	O
10	mg	O	O
11	/	O	O
12	kg	O	O
13	ADR	S-Chemical	S-Chemical
14	.	O	O

0	Ultrastructural	O	O
1	damage	O	O
2	and	O	O
3	levels	O	O
4	of	O	O
5	4	B-Chemical	B-Chemical
6	-	I-Chemical	I-Chemical
7	hydroxy	I-Chemical	I-Chemical
8	-	I-Chemical	I-Chemical
9	2	I-Chemical	I-Chemical
10	-	I-Chemical	I-Chemical
11	nonenal	E-Chemical	E-Chemical
12	(	O	O
13	4HNE	S-Chemical	S-Chemical
14	)	O	O
15	-	O	O
16	protein	O	O
17	adducts	O	O
18	and	O	O
19	3	B-Chemical	S-Chemical
20	-	I-Chemical	I-Chemical
21	nitrotyrosine	E-Chemical	E-Chemical
22	(	O	O
23	3NT	S-Chemical	O
24	)	O	O
25	were	O	O
26	analyzed	O	O
27	.	O	O

0	Analysis	O	O
1	of	O	O
2	4HNE	S-Chemical	S-Chemical
3	protein	O	O
4	adducts	O	O
5	by	O	O
6	immunogold	O	O
7	electron	O	O
8	microscopy	O	O
9	showed	O	O
10	appearance	O	O
11	of	O	O
12	4HNE	S-Chemical	S-Chemical
13	protein	O	O
14	adducts	O	O
15	in	O	O
16	mitochondria	O	S-Disease
17	as	O	O
18	early	O	O
19	as	O	O
20	3	O	O
21	hours	O	O
22	,	O	O
23	with	O	O
24	a	O	O
25	peak	O	O
26	at	O	O
27	6	O	O
28	hours	O	O
29	and	O	O
30	subsequent	O	O
31	decline	O	O
32	at	O	O
33	24	O	O
34	hours	O	O
35	.	O	O

0	3NT	S-Chemical	O
1	levels	O	O
2	were	O	O
3	significantly	O	O
4	increased	O	O
5	in	O	O
6	all	O	O
7	subcellular	O	O
8	compartments	O	O
9	at	O	O
10	6	O	O
11	hours	O	O
12	and	O	O
13	subsequently	O	O
14	declined	O	O
15	at	O	O
16	24	O	O
17	hours	O	O
18	.	O	O

0	Our	O	O
1	data	O	O
2	showed	O	O
3	ADR	S-Chemical	S-Chemical
4	induced	O	O
5	4HNE	S-Chemical	S-Disease
6	-	O	O
7	protein	O	O
8	adducts	O	O
9	in	O	O
10	mitochondria	O	S-Disease
11	at	O	O
12	the	O	O
13	same	O	O
14	time	O	O
15	point	O	O
16	as	O	O
17	when	O	O
18	mitochondrial	B-Disease	B-Disease
19	injury	E-Disease	E-Disease
20	initially	O	O
21	appeared	O	O
22	.	O	O

0	These	O	O
1	results	O	O
2	document	O	O
3	for	O	O
4	the	O	O
5	first	O	O
6	time	O	O
7	in	O	O
8	vivo	O	O
9	that	O	O
10	mitochondrial	B-Disease	B-Disease
11	oxidative	I-Disease	O
12	damage	E-Disease	E-Disease
13	precedes	O	O
14	nitrative	O	O
15	damage	O	O
16	.	O	O

0	The	O	O
1	progressive	O	O
2	nature	O	O
3	of	O	O
4	mitochondrial	B-Disease	B-Disease
5	injury	E-Disease	E-Disease
6	suggests	O	O
7	that	O	O
8	mitochondria	O	S-Disease
9	,	O	O
10	not	O	O
11	other	O	O
12	subcellular	O	O
13	organelles	O	O
14	,	O	O
15	are	O	O
16	the	O	O
17	major	O	O
18	site	O	O
19	of	O	O
20	intracellular	O	O
21	injury	O	O
22	.	O	O

0	Sotalol	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	coronary	B-Disease	B-Disease
4	spasm	E-Disease	E-Disease
5	in	O	O
6	a	O	O
7	patient	O	O
8	with	O	O
9	dilated	B-Disease	O
10	cardiomyopathy	E-Disease	S-Disease
11	associated	O	O
12	with	O	O
13	sustained	O	O
14	ventricular	B-Disease	B-Disease
15	tachycardia	E-Disease	E-Disease
16	.	O	O

0	A	O	O
1	54	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	man	O	O
7	with	O	O
8	severe	O	O
9	left	O	O
10	ventricular	B-Disease	B-Disease
11	dysfunction	E-Disease	E-Disease
12	due	O	O
13	to	O	O
14	dilated	B-Disease	S-Disease
15	cardiomyopathy	E-Disease	B-Disease
16	was	O	O
17	referred	O	O
18	to	O	O
19	our	O	O
20	hospital	O	O
21	for	O	O
22	symptomatic	O	O
23	incessant	O	O
24	sustained	O	O
25	ventricular	B-Disease	O
26	tachycardia	E-Disease	E-Disease
27	(	O	O
28	VT	S-Disease	O
29	)	O	O
30	.	O	O

0	After	O	O
1	the	O	O
2	administration	O	O
3	of	O	O
4	nifekalant	B-Chemical	S-Chemical
5	hydrochloride	E-Chemical	E-Chemical
6	,	O	O
7	sustained	O	O
8	VT	S-Disease	S-Disease
9	was	O	O
10	terminated	O	O
11	.	O	O

0	An	O	O
1	alternate	O	O
2	class	O	O
3	III	O	O
4	agent	O	O
5	,	O	O
6	sotalol	S-Chemical	S-Chemical
7	,	O	O
8	was	O	O
9	also	O	O
10	effective	O	O
11	for	O	O
12	the	O	O
13	prevention	O	O
14	of	O	O
15	VT	S-Disease	S-Disease
16	.	O	O

0	However	O	O
1	,	O	O
2	one	O	O
3	month	O	O
4	after	O	O
5	switching	O	O
6	over	O	O
7	nifekalant	S-Chemical	S-Chemical
8	to	O	O
9	sotalol	S-Chemical	S-Chemical
10	,	O	O
11	a	O	O
12	short	O	O
13	duration	O	O
14	of	O	O
15	ST	O	S-Disease
16	elevation	O	E-Disease
17	was	O	O
18	documented	O	O
19	in	O	O
20	ECG	O	S-Disease
21	monitoring	O	O
22	at	O	O
23	almost	O	O
24	the	O	O
25	same	O	O
26	time	O	O
27	for	O	O
28	three	O	O
29	consecutive	O	O
30	days	O	O
31	.	O	O

0	ST	O	B-Disease
1	elevation	O	E-Disease
2	with	O	O
3	chest	O	O
4	discomfort	O	O
5	disappeared	O	O
6	since	O	O
7	he	O	O
8	began	O	O
9	taking	O	O
10	long	O	O
11	-	O	O
12	acting	O	O
13	diltiazem	S-Chemical	S-Chemical
14	.	O	O

0	Coronary	B-Disease	B-Disease
1	vasospasm	E-Disease	E-Disease
2	may	O	O
3	be	O	O
4	induced	O	O
5	by	O	O
6	the	O	O
7	non	O	O
8	-	O	O
9	selective	O	O
10	beta	O	O
11	-	O	O
12	blocking	O	O
13	properties	O	O
14	of	O	O
15	sotalol	S-Chemical	S-Chemical
16	.	O	O

0	Effects	O	O
1	of	O	O
2	the	O	O
3	antidepressant	O	O
4	trazodone	S-Chemical	S-Chemical
5	,	O	O
6	a	O	O
7	5	B-Chemical	O
8	-	I-Chemical	O
9	HT	E-Chemical	O
10	2A	O	O
11	/	O	O
12	2C	O	O
13	receptor	O	O
14	antagonist	O	O
15	,	O	O
16	on	O	O
17	dopamine	S-Chemical	S-Chemical
18	-	O	O
19	dependent	O	O
20	behaviors	O	O
21	in	O	O
22	rats	O	O
23	.	O	O

0	RATIONALE	O	O
1	:	O	O
2	5	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	Hydroxytryptamine	E-Chemical	S-Chemical
5	,	O	O
6	via	O	O
7	stimulation	O	O
8	of	O	O
9	5	B-Chemical	O
10	-	I-Chemical	O
11	HT	E-Chemical	O
12	2C	O	O
13	receptors	O	O
14	,	O	O
15	exerts	O	O
16	a	O	O
17	tonic	O	S-Disease
18	inhibitory	O	O
19	influence	O	O
20	on	O	O
21	dopaminergic	O	O
22	neurotransmission	O	S-Disease
23	,	O	O
24	whereas	O	O
25	activation	O	O
26	of	O	O
27	5	B-Chemical	O
28	-	I-Chemical	O
29	HT	E-Chemical	O
30	2A	O	O
31	receptors	O	O
32	enhances	O	O
33	stimulated	O	O
34	DAergic	O	B-Disease
35	neurotransmission	O	E-Disease
36	.	O	O

0	The	O	O
1	antidepressant	O	O
2	trazodone	S-Chemical	S-Chemical
3	is	O	O
4	a	O	O
5	5	B-Chemical	O
6	-	I-Chemical	O
7	HT	E-Chemical	O
8	2A	O	O
9	/	O	O
10	2C	O	O
11	receptor	O	O
12	antagonist	O	O
13	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	To	O	O
3	evaluate	O	O
4	the	O	O
5	effect	O	O
6	of	O	O
7	trazodone	S-Chemical	S-Chemical
8	treatment	O	O
9	on	O	O
10	behaviors	O	O
11	dependent	O	O
12	on	O	O
13	the	O	O
14	functional	O	O
15	status	O	O
16	of	O	O
17	the	O	O
18	nigrostriatal	O	O
19	DAergic	O	B-Disease
20	system	O	E-Disease
21	.	O	O

0	METHODS	O	O
1	:	O	O
2	The	O	O
3	effect	O	O
4	of	O	O
5	pretreatment	O	O
6	with	O	O
7	trazodone	S-Chemical	S-Chemical
8	on	O	O
9	dexamphetamine	S-Chemical	S-Chemical
10	-	O	O
11	and	O	O
12	apomorphine	S-Chemical	S-Disease
13	-	O	O
14	induced	O	O
15	oral	B-Disease	O
16	stereotypies	E-Disease	S-Disease
17	,	O	O
18	on	O	O
19	catalepsy	S-Disease	O
20	induced	O	O
21	by	O	O
22	haloperidol	S-Chemical	S-Chemical
23	and	O	O
24	apomorphine	S-Chemical	O
25	(	O	O
26	0	O	O
27	.	O	O
28	05	O	O
29	mg	O	O
30	/	O	O
31	kg	O	O
32	,	O	O
33	i	O	O
34	.	O	O
35	p	O	O
36	.	O	O
37	)	O	O
38	,	O	O
39	on	O	O
40	ergometrine	S-Chemical	S-Disease
41	-	O	O
42	induced	O	O
43	wet	O	O
44	dog	O	O
45	shake	O	O
46	(	O	O
47	WDS	O	S-Disease
48	)	O	O
49	behavior	O	O
50	and	O	O
51	fluoxetine	S-Chemical	S-Chemical
52	-	O	O
53	induced	O	O
54	penile	O	S-Disease
55	erections	O	S-Disease
56	was	O	O
57	studied	O	O
58	in	O	O
59	rats	O	O
60	.	O	O

0	We	O	O
1	also	O	O
2	investigated	O	O
3	whether	O	O
4	trazodone	S-Chemical	S-Chemical
5	induces	O	O
6	catalepsy	S-Disease	S-Disease
7	in	O	O
8	rats	O	O
9	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Trazodone	S-Chemical	S-Chemical
3	at	O	O
4	2	O	O
5	.	O	O
6	5	O	O
7	-	O	O
8	20	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	i	O	O
13	.	O	O
14	p	O	O
15	.	O	O
16	did	O	O
17	not	O	O
18	induce	O	O
19	catalepsy	S-Disease	S-Disease
20	,	O	O
21	and	O	O
22	did	O	O
23	not	O	O
24	antagonize	O	O
25	apomorphine	S-Chemical	S-Chemical
26	(	O	O
27	1	O	O
28	.	O	O
29	5	O	O
30	and	O	O
31	3	O	O
32	mg	O	O
33	/	O	O
34	kg	O	O
35	)	O	O
36	stereotypy	O	O
37	and	O	O
38	apomorphine	S-Chemical	S-Disease
39	(	O	O
40	0	O	O
41	.	O	O
42	05	O	O
43	mg	O	O
44	/	O	O
45	kg	O	O
46	)	O	O
47	-	O	O
48	induced	O	O
49	catalepsy	S-Disease	S-Disease
50	.	O	O

0	However	O	O
1	,	O	O
2	pretreatment	O	O
3	with	O	O
4	5	O	O
5	,	O	O
6	10	O	O
7	and	O	O
8	20	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	i	O	O
13	.	O	O
14	p	O	O
15	.	O	O
16	trazodone	S-Chemical	S-Chemical
17	enhanced	O	O
18	dexamphetamine	S-Chemical	S-Chemical
19	stereotypy	O	S-Disease
20	,	O	O
21	and	O	O
22	antagonized	O	O
23	haloperidol	S-Chemical	S-Chemical
24	catalepsy	S-Disease	S-Disease
25	,	O	O
26	ergometrine	S-Chemical	S-Disease
27	-	O	O
28	induced	O	O
29	WDS	O	S-Disease
30	behavior	O	O
31	and	O	O
32	fluoxetine	S-Chemical	S-Chemical
33	-	O	O
34	induced	O	O
35	penile	O	S-Disease
36	erections	O	S-Disease
37	.	O	O

0	Trazodone	S-Chemical	S-Chemical
1	at	O	O
2	30	O	O
3	,	O	O
4	40	O	O
5	and	O	O
6	50	O	O
7	mg	O	O
8	/	O	O
9	kg	O	O
10	i	O	O
11	.	O	O
12	p	O	O
13	.	O	O
14	induced	O	O
15	catalepsy	S-Disease	S-Disease
16	and	O	O
17	antagonized	O	O
18	apomorphine	S-Chemical	S-Chemical
19	and	O	O
20	dexamphetamine	S-Chemical	S-Chemical
21	stereotypies	O	O
22	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Our	O	O
3	results	O	O
4	indicate	O	O
5	that	O	O
6	trazodone	S-Chemical	S-Chemical
7	at	O	O
8	2	O	O
9	.	O	O
10	5	O	O
11	-	O	O
12	20	O	O
13	mg	O	O
14	/	O	O
15	kg	O	O
16	does	O	O
17	not	O	O
18	block	O	O
19	pre	O	O
20	-	O	O
21	and	O	O
22	postsynaptic	O	O
23	striatal	O	O
24	D2	O	B-Chemical
25	DA	O	E-Chemical
26	receptors	O	O
27	,	O	O
28	while	O	O
29	at	O	O
30	30	O	O
31	,	O	O
32	40	O	O
33	and	O	O
34	50	O	O
35	mg	O	O
36	/	O	O
37	kg	O	O
38	it	O	O
39	blocks	O	O
40	postsynaptic	O	O
41	striatal	O	O
42	D2	O	B-Chemical
43	DA	O	E-Chemical
44	receptors	O	O
45	.	O	O

0	Furthermore	O	O
1	,	O	O
2	at	O	O
3	5	O	O
4	,	O	O
5	10	O	O
6	and	O	O
7	20	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	,	O	O
12	trazodone	S-Chemical	S-Chemical
13	blocks	O	O
14	5	B-Chemical	O
15	-	I-Chemical	O
16	HT	E-Chemical	O
17	2A	O	O
18	and	O	O
19	5	B-Chemical	O
20	-	I-Chemical	O
21	HT	E-Chemical	O
22	2C	O	O
23	receptors	O	O
24	.	O	O

0	We	O	O
1	suggest	O	O
2	that	O	O
3	trazodone	S-Chemical	S-Chemical
4	(	O	O
5	5	O	O
6	,	O	O
7	10	O	O
8	and	O	O
9	20	O	O
10	mg	O	O
11	/	O	O
12	kg	O	O
13	)	O	O
14	,	O	O
15	by	O	O
16	blocking	O	O
17	the	O	O
18	5	B-Chemical	O
19	-	I-Chemical	O
20	HT	E-Chemical	O
21	2C	O	O
22	receptors	O	O
23	,	O	O
24	releases	O	O
25	the	O	O
26	nigrostriatal	O	O
27	DAergic	O	B-Disease
28	neurons	O	O
29	from	O	O
30	tonic	O	S-Disease
31	inhibition	O	O
32	caused	O	O
33	by	O	O
34	5	B-Chemical	O
35	-	I-Chemical	O
36	HT	E-Chemical	O
37	,	O	O
38	and	O	O
39	thereby	O	O
40	potentiates	O	O
41	dexamphetamine	S-Chemical	O
42	stereotypy	O	O
43	and	O	O
44	antagonizes	O	O
45	haloperidol	S-Chemical	S-Chemical
46	catalepsy	S-Disease	S-Disease
47	.	O	O

0	Swallowing	B-Disease	O
1	abnormalities	E-Disease	O
2	and	O	O
3	dyskinesia	S-Disease	S-Disease
4	in	O	O
5	Parkinson	B-Disease	B-Disease
6	'	I-Disease	I-Disease
7	s	I-Disease	I-Disease
8	disease	E-Disease	E-Disease
9	.	O	O

0	Gastrointestinal	B-Disease	B-Disease
1	abnormalities	E-Disease	E-Disease
2	in	O	O
3	Parkinson	B-Disease	B-Disease
4	'	I-Disease	I-Disease
5	s	I-Disease	I-Disease
6	disease	E-Disease	E-Disease
7	(	O	O
8	PD	S-Disease	S-Disease
9	)	O	O
10	have	O	O
11	been	O	O
12	known	O	O
13	for	O	O
14	almost	O	O
15	two	O	O
16	centuries	O	O
17	,	O	O
18	but	O	O
19	many	O	O
20	aspects	O	O
21	concerning	O	O
22	their	O	O
23	pathophysiology	O	O
24	have	O	O
25	not	O	O
26	been	O	O
27	completely	O	O
28	clarified	O	O
29	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	characterize	O	O
8	the	O	O
9	oropharyngeal	O	O
10	dynamics	O	O
11	in	O	O
12	PD	S-Disease	S-Disease
13	patients	O	O
14	with	O	O
15	and	O	O
16	without	O	O
17	levodopa	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	dyskinesia	S-Disease	S-Disease
21	.	O	O

0	Fifteen	O	O
1	dyskinetic	S-Disease	S-Disease
2	,	O	O
3	12	O	O
4	nondyskinetic	O	O
5	patients	O	O
6	,	O	O
7	and	O	O
8	a	O	O
9	control	O	O
10	group	O	O
11	were	O	O
12	included	O	O
13	.	O	O

0	Patients	O	O
1	were	O	O
2	asked	O	O
3	about	O	O
4	dysphagia	S-Disease	S-Disease
5	and	O	O
6	evaluated	O	O
7	with	O	O
8	the	O	O
9	Unified	O	O
10	Parkinson	B-Disease	I-Disease
11	'	I-Disease	I-Disease
12	s	I-Disease	I-Disease
13	Disease	E-Disease	E-Disease
14	Rating	O	O
15	Scale	O	O
16	Parts	O	O
17	II	O	O
18	and	O	O
19	III	O	O
20	and	O	O
21	the	O	O
22	Hoehn	O	S-Chemical
23	and	O	O
24	Yahr	O	S-Chemical
25	scale	O	O
26	.	O	O

0	Deglutition	O	O
1	was	O	O
2	assessed	O	O
3	using	O	O
4	modified	O	O
5	barium	S-Chemical	S-Chemical
6	swallow	O	O
7	with	O	O
8	videofluoroscopy	O	O
9	.	O	O

0	Nondyskinetic	O	O
1	patients	O	O
2	,	O	O
3	but	O	O
4	not	O	O
5	the	O	O
6	dyskinetic	S-Disease	O
7	ones	O	O
8	,	O	O
9	showed	O	O
10	less	O	O
11	oropharyngeal	O	O
12	swallowing	O	S-Disease
13	efficiency	O	O
14	(	O	O
15	OPSE	O	S-Chemical
16	)	O	O
17	for	O	O
18	liquid	O	O
19	food	O	O
20	than	O	O
21	controls	O	O
22	(	O	O
23	Dunnett	O	S-Chemical
24	,	O	O
25	P	O	S-Disease
26	=	O	O
27	0	O	O
28	.	O	O
29	02	O	O
30	)	O	O
31	.	O	O

0	Dyskinetic	S-Disease	O
1	patients	O	O
2	tended	O	O
3	to	O	O
4	have	O	O
5	a	O	O
6	greater	O	O
7	OPSE	O	S-Chemical
8	than	O	O
9	nondyskinetic	O	O
10	(	O	O
11	Dunnett	O	S-Chemical
12	,	O	O
13	P	O	O
14	=	O	O
15	0	O	O
16	.	O	O
17	06	O	O
18	)	O	O
19	.	O	O

0	Patients	O	O
1	who	O	O
2	were	O	O
3	using	O	O
4	a	O	O
5	higher	O	O
6	dose	O	O
7	of	O	O
8	levodopa	S-Chemical	S-Chemical
9	had	O	O
10	a	O	O
11	greater	O	O
12	OPSE	O	S-Chemical
13	and	O	O
14	a	O	O
15	trend	O	O
16	toward	O	O
17	a	O	O
18	smaller	O	O
19	oral	O	O
20	transit	O	O
21	time	O	O
22	(	O	O
23	Pearson	O	O
24	'	O	O
25	s	O	O
26	correlation	O	O
27	,	O	O
28	P	O	S-Disease
29	=	O	O
30	0	O	O
31	.	O	O
32	01	O	O
33	and	O	O
34	0	O	O
35	.	O	O
36	08	O	O
37	,	O	O
38	respectively	O	O
39	)	O	O
40	.	O	O

0	Neither	O	O
1	the	O	O
2	report	O	O
3	of	O	O
4	dysphagia	S-Disease	S-Disease
5	nor	O	O
6	any	O	O
7	of	O	O
8	the	O	O
9	PD	S-Disease	S-Disease
10	severity	O	O
11	parameters	O	O
12	correlated	O	O
13	to	O	O
14	the	O	O
15	videofluoroscopic	O	O
16	variables	O	O
17	.	O	O

0	In	O	O
1	the	O	O
2	current	O	O
3	study	O	O
4	,	O	O
5	dyskinetic	S-Disease	S-Disease
6	patients	O	O
7	performed	O	O
8	better	O	O
9	in	O	O
10	swallowing	O	S-Disease
11	function	O	O
12	,	O	O
13	which	O	O
14	could	O	O
15	be	O	O
16	explained	O	O
17	on	O	O
18	the	O	O
19	basis	O	O
20	of	O	O
21	a	O	O
22	greater	O	O
23	levodopa	S-Chemical	S-Chemical
24	dose	O	O
25	.	O	O

0	Our	O	O
1	results	O	O
2	suggest	O	O
3	a	O	O
4	role	O	O
5	for	O	O
6	levodopa	S-Chemical	S-Chemical
7	in	O	O
8	the	O	O
9	oral	O	O
10	phase	O	O
11	of	O	O
12	deglutition	O	O
13	and	O	O
14	confirm	O	O
15	that	O	O
16	dysphagia	S-Disease	S-Disease
17	is	O	O
18	not	O	O
19	a	O	O
20	good	O	O
21	predictor	O	O
22	of	O	O
23	deglutition	O	O
24	alterations	O	O
25	in	O	O
26	PD	S-Disease	S-Disease
27	.	O	O

0	Inhibition	O	O
1	of	O	O
2	nuclear	O	O
3	factor	O	O
4	-	O	O
5	kappaB	O	O
6	activation	O	O
7	attenuates	O	O
8	tubulointerstitial	B-Disease	S-Disease
9	nephritis	E-Disease	S-Disease
10	induced	O	O
11	by	O	O
12	gentamicin	S-Chemical	S-Chemical
13	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Animals	O	O
3	treated	O	O
4	with	O	O
5	gentamicin	S-Chemical	S-Chemical
6	can	O	O
7	show	O	O
8	residual	O	O
9	areas	O	O
10	of	O	O
11	interstitial	O	O
12	fibrosis	S-Disease	E-Disease
13	in	O	O
14	the	O	O
15	renal	O	B-Disease
16	cortex	O	E-Disease
17	.	O	O

0	This	O	O
1	study	O	O
2	investigated	O	O
3	the	O	O
4	expression	O	O
5	of	O	O
6	nuclear	O	O
7	factor	O	I-Disease
8	-	O	O
9	kappaB	O	O
10	(	O	O
11	NF	O	O
12	-	O	O
13	kappaB	O	O
14	)	O	O
15	,	O	O
16	mitogen	O	O
17	-	O	O
18	activated	O	O
19	protein	O	O
20	(	O	O
21	MAP	O	S-Chemical
22	)	O	O
23	kinases	O	O
24	and	O	O
25	macrophages	O	O
26	in	O	O
27	the	O	O
28	renal	O	B-Disease
29	cortex	O	E-Disease
30	and	O	O
31	structural	O	O
32	and	O	O
33	functional	O	O
34	renal	O	O
35	changes	O	E-Disease
36	of	O	O
37	rats	O	O
38	treated	O	O
39	with	O	O
40	gentamicin	S-Chemical	S-Chemical
41	or	O	O
42	gentamicin	S-Chemical	S-Chemical
43	+	O	O
44	pyrrolidine	B-Chemical	S-Chemical
45	dithiocarbamate	E-Chemical	E-Chemical
46	(	O	O
47	PDTC	S-Chemical	S-Chemical
48	)	O	O
49	,	O	O
50	an	O	O
51	NF	O	O
52	-	O	O
53	kappaB	O	O
54	inhibitor	O	O
55	.	O	O

0	METHODS	O	O
1	:	O	O
2	38	O	O
3	female	O	O
4	Wistar	O	O
5	rats	O	O
6	were	O	O
7	injected	O	O
8	with	O	O
9	gentamicin	S-Chemical	S-Chemical
10	,	O	O
11	40	O	O
12	mg	O	O
13	/	O	O
14	kg	O	O
15	,	O	O
16	twice	O	O
17	a	O	O
18	day	O	O
19	for	O	O
20	9	O	O
21	days	O	O
22	,	O	O
23	38	O	O
24	with	O	O
25	gentamicin	S-Chemical	S-Chemical
26	+	O	O
27	PDTC	S-Chemical	S-Chemical
28	,	O	O
29	and	O	O
30	28	O	O
31	with	O	O
32	0	O	O
33	.	O	O
34	15	O	O
35	M	O	O
36	NaCl	S-Chemical	S-Chemical
37	solution	O	O
38	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Gentamicin	S-Chemical	S-Chemical
3	-	O	O
4	treated	O	O
5	rats	O	O
6	presented	O	O
7	a	O	O
8	transitory	O	O
9	increase	O	O
10	in	O	O
11	plasma	O	O
12	creatinine	S-Chemical	S-Chemical
13	levels	O	O
14	.	O	O

0	Increased	O	O
1	ED	O	S-Disease
2	-	O	E-Chemical
3	1	O	O
4	,	O	O
5	MAP	O	S-Chemical
6	kinases	O	O
7	and	O	O
8	NF	O	O
9	-	O	O
10	kappaB	O	O
11	staining	O	O
12	were	O	O
13	also	O	O
14	observed	O	O
15	in	O	O
16	the	O	O
17	renal	O	O
18	cortex	O	E-Disease
19	from	O	O
20	all	O	O
21	gentamicin	S-Chemical	S-Chemical
22	-	O	O
23	treated	O	O
24	rats	O	O
25	compared	O	O
26	to	O	O
27	control	O	O
28	(	O	O
29	p	O	O
30	<	O	O
31	0	O	O
32	.	O	O
33	05	O	O
34	)	O	O
35	.	O	O

0	The	O	O
1	animals	O	O
2	killed	O	O
3	on	O	O
4	day	O	O
5	30	O	O
6	also	O	O
7	presented	O	O
8	fibrosis	S-Disease	S-Disease
9	in	O	O
10	the	O	O
11	renal	O	B-Disease
12	cortex	O	E-Disease
13	despite	O	O
14	the	O	O
15	recovery	O	O
16	of	O	O
17	renal	O	B-Disease
18	function	O	E-Disease
19	.	O	O

0	Treatment	O	O
1	with	O	O
2	PDTC	S-Chemical	S-Chemical
3	reduced	O	O
4	the	O	O
5	functional	O	O
6	and	O	O
7	structural	O	O
8	changes	O	O
9	induced	O	O
10	by	O	O
11	gentamicin	S-Chemical	S-Chemical
12	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	These	O	O
3	data	O	O
4	show	O	O
5	that	O	O
6	inhibition	O	O
7	of	O	O
8	NF	O	B-Disease
9	-	O	O
10	kappaB	O	O
11	activation	O	O
12	attenuates	O	O
13	tubulointerstitial	B-Disease	S-Disease
14	nephritis	E-Disease	S-Disease
15	induced	O	O
16	by	O	O
17	gentamicin	S-Chemical	S-Chemical
18	.	O	O

0	Glucose	S-Chemical	S-Chemical
1	metabolism	O	E-Chemical
2	in	O	O
3	patients	O	O
4	with	O	O
5	schizophrenia	S-Disease	S-Disease
6	treated	O	O
7	with	O	O
8	atypical	O	O
9	antipsychotic	O	O
10	agents	O	O
11	:	O	O
12	a	O	O
13	frequently	O	O
14	sampled	O	O
15	intravenous	O	O
16	glucose	S-Chemical	B-Disease
17	tolerance	O	E-Disease
18	test	O	O
19	and	O	O
20	minimal	O	O
21	model	O	O
22	analysis	O	O
23	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	While	O	O
3	the	O	O
4	incidence	O	O
5	of	O	O
6	new	O	O
7	-	O	O
8	onset	O	O
9	diabetes	B-Disease	B-Disease
10	mellitus	E-Disease	E-Disease
11	may	O	O
12	be	O	O
13	increasing	O	O
14	in	O	O
15	patients	O	O
16	with	O	O
17	schizophrenia	S-Disease	B-Disease
18	treated	O	O
19	with	O	O
20	certain	O	O
21	atypical	O	O
22	antipsychotic	O	O
23	agents	O	O
24	,	O	O
25	it	O	O
26	remains	O	O
27	unclear	O	O
28	whether	O	O
29	atypical	O	O
30	agents	O	O
31	are	O	O
32	directly	O	O
33	affecting	O	O
34	glucose	S-Chemical	B-Disease
35	metabolism	O	E-Disease
36	or	O	O
37	simply	O	O
38	increasing	O	O
39	known	O	O
40	risk	O	O
41	factors	O	O
42	for	O	O
43	diabetes	S-Disease	S-Disease
44	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	study	O	O
4	the	O	O
5	2	O	O
6	drugs	O	O
7	most	O	O
8	clearly	O	O
9	implicated	O	O
10	(	O	O
11	clozapine	S-Chemical	S-Chemical
12	and	O	O
13	olanzapine	S-Chemical	S-Chemical
14	)	O	O
15	and	O	O
16	risperidone	S-Chemical	S-Chemical
17	using	O	O
18	a	O	O
19	frequently	O	O
20	sampled	O	O
21	intravenous	O	O
22	glucose	S-Chemical	B-Disease
23	tolerance	O	O
24	test	O	O
25	.	O	O

0	DESIGN	O	O
1	:	O	O
2	A	O	O
3	cross	O	O
4	-	O	O
5	sectional	O	O
6	design	O	O
7	in	O	O
8	stable	O	O
9	,	O	O
10	treated	O	O
11	patients	O	O
12	with	O	O
13	schizophrenia	S-Disease	S-Disease
14	evaluated	O	O
15	using	O	O
16	a	O	O
17	frequently	O	O
18	sampled	O	O
19	intravenous	O	O
20	glucose	S-Chemical	B-Disease
21	tolerance	O	E-Disease
22	test	O	O
23	and	O	O
24	the	O	O
25	Bergman	O	O
26	minimal	O	O
27	model	O	O
28	analysis	O	O
29	.	O	O

0	Patients	O	O
1	Fifty	O	O
2	subjects	O	O
3	signed	O	O
4	informed	O	O
5	consent	O	O
6	and	O	O
7	41	O	O
8	underwent	O	O
9	the	O	O
10	frequently	O	O
11	sampled	O	O
12	intravenous	O	O
13	glucose	S-Chemical	B-Disease
14	tolerance	O	E-Disease
15	test	O	O
16	.	O	O

0	Thirty	O	O
1	-	O	O
2	six	O	O
3	nonobese	O	O
4	subjects	O	O
5	with	O	O
6	schizophrenia	S-Disease	B-Disease
7	or	O	O
8	schizoaffective	B-Disease	B-Disease
9	disorder	E-Disease	E-Disease
10	,	O	O
11	matched	O	O
12	by	O	O
13	body	O	O
14	mass	O	O
15	index	O	O
16	and	O	O
17	treated	O	O
18	with	O	O
19	either	O	O
20	clozapine	S-Chemical	S-Chemical
21	,	O	O
22	olanzapine	S-Chemical	S-Chemical
23	,	O	O
24	or	O	O
25	risperidone	S-Chemical	S-Chemical
26	,	O	O
27	were	O	O
28	included	O	O
29	in	O	O
30	the	O	O
31	analysis	O	O
32	.	O	O

0	MAIN	O	O
1	OUTCOME	O	O
2	MEASURES	O	O
3	:	O	O
4	Fasting	O	O
5	plasma	O	O
6	glucose	S-Chemical	S-Disease
7	and	O	O
8	fasting	O	O
9	serum	O	O
10	insulin	O	S-Disease
11	levels	O	O
12	,	O	O
13	insulin	B-Disease	B-Disease
14	sensitivity	E-Disease	E-Disease
15	index	O	O
16	,	O	O
17	homeostasis	O	S-Disease
18	model	O	O
19	assessment	O	O
20	of	O	O
21	insulin	B-Disease	B-Disease
22	resistance	E-Disease	E-Disease
23	,	O	O
24	and	O	O
25	glucose	S-Chemical	S-Disease
26	effectiveness	O	O
27	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	mean	O	O
4	+	O	O
5	/	O	O
6	-	O	O
7	SD	O	O
8	duration	O	O
9	of	O	O
10	treatment	O	O
11	with	O	O
12	the	O	O
13	identified	O	O
14	atypical	O	O
15	antipsychotic	O	O
16	agent	O	O
17	was	O	O
18	68	O	O
19	.	O	O
20	3	O	O
21	+	O	O
22	/	O	O
23	-	O	O
24	28	O	O
25	.	O	O
26	9	O	O
27	months	O	O
28	(	O	O
29	clozapine	S-Chemical	S-Chemical
30	)	O	O
31	,	O	O
32	29	O	O
33	.	O	O
34	5	O	O
35	+	O	O
36	/	O	O
37	-	O	O
38	17	O	O
39	.	O	O
40	5	O	O
41	months	O	O
42	(	O	O
43	olanzapine	S-Chemical	S-Chemical
44	)	O	O
45	,	O	O
46	and	O	O
47	40	O	O
48	.	O	O
49	9	O	O
50	+	O	O
51	/	O	O
52	-	O	O
53	33	O	O
54	.	O	O
55	7	O	O
56	(	O	O
57	risperidone	S-Chemical	S-Chemical
58	)	O	O
59	.	O	O

0	Fasting	O	O
1	serum	O	O
2	insulin	O	S-Disease
3	concentrations	O	O
4	differed	O	O
5	among	O	O
6	groups	O	O
7	(	O	O
8	F	O	O
9	(	O	O
10	33	O	O
11	)	O	O
12	=	O	O
13	3	O	O
14	.	O	O
15	35	O	O
16	;	O	O
17	P	O	O
18	=	O	O
19	.	O	O
20	047	O	O
21	)	O	O
22	(	O	O
23	clozapine	S-Chemical	S-Chemical
24	>	O	O
25	olanzapine	S-Chemical	S-Chemical
26	>	O	O
27	risperidone	S-Chemical	S-Chemical
28	)	O	O
29	with	O	O
30	significant	O	O
31	differences	O	O
32	between	O	O
33	clozapine	S-Chemical	S-Chemical
34	and	O	O
35	risperidone	S-Chemical	S-Chemical
36	(	O	O
37	t	O	O
38	(	O	O
39	33	O	O
40	)	O	O
41	=	O	O
42	2	O	O
43	.	O	O
44	32	O	O
45	;	O	O
46	P	O	O
47	=	O	O
48	.	O	O
49	03	O	O
50	)	O	O
51	and	O	O
52	olanzapine	S-Chemical	S-Chemical
53	and	O	O
54	risperidone	S-Chemical	S-Chemical
55	(	O	O
56	t	O	O
57	(	O	O
58	33	O	O
59	)	O	O
60	=	O	O
61	2	O	O
62	.	O	O
63	15	O	O
64	;	O	O
65	P	O	O
66	=	O	O
67	.	O	O
68	04	O	O
69	)	O	O
70	.	O	O

0	There	O	O
1	was	O	O
2	a	O	O
3	significant	O	O
4	difference	O	O
5	in	O	O
6	insulin	B-Disease	S-Disease
7	sensitivity	E-Disease	O
8	index	O	O
9	among	O	O
10	groups	O	O
11	(	O	O
12	F	O	S-Chemical
13	(	O	O
14	33	O	O
15	)	O	O
16	=	O	O
17	10	O	O
18	.	O	O
19	66	O	O
20	;	O	O
21	P	O	O
22	<	O	O
23	.	O	O
24	001	O	O
25	)	O	O
26	(	O	O
27	clozapine	S-Chemical	S-Chemical
28	<	O	O
29	olanzapine	S-Chemical	S-Chemical
30	<	O	O
31	risperidone	S-Chemical	S-Chemical
32	)	O	O
33	,	O	O
34	with	O	O
35	subjects	O	O
36	who	O	O
37	received	O	O
38	clozapine	S-Chemical	S-Chemical
39	and	O	O
40	olanzapine	S-Chemical	S-Chemical
41	exhibiting	O	O
42	significant	O	O
43	insulin	B-Disease	S-Chemical
44	resistance	E-Disease	O
45	compared	O	O
46	with	O	O
47	subjects	O	O
48	who	O	O
49	were	O	O
50	treated	O	O
51	with	O	O
52	risperidone	S-Chemical	S-Chemical
53	(	O	O
54	clozapine	S-Chemical	S-Chemical
55	vs	O	O
56	risperidone	S-Chemical	S-Chemical
57	,	O	O
58	t	O	O
59	(	O	O
60	33	O	O
61	)	O	O
62	=	O	O
63	-	O	O
64	4	O	O
65	.	O	O
66	29	O	O
67	;	O	O
68	P	O	S-Disease
69	<	O	O
70	.	O	O
71	001	O	O
72	;	O	O
73	olanzapine	S-Chemical	S-Chemical
74	vs	O	O
75	risperidone	S-Chemical	S-Chemical
76	,	O	O
77	t	O	O
78	(	O	O
79	33	O	O
80	)	O	O
81	=	O	O
82	-	O	O
83	3	O	O
84	.	O	O
85	62	O	O
86	;	O	O
87	P	O	S-Disease
88	=	O	O
89	.	O	O
90	001	O	O
91	[	O	O
92	P	O	O
93	<	O	O
94	.	O	O
95	001	O	O
96	]	O	O
97	)	O	O
98	.	O	O

0	The	O	O
1	homeostasis	O	O
2	model	O	O
3	assessment	O	O
4	of	O	O
5	insulin	B-Disease	S-Disease
6	resistance	E-Disease	O
7	also	O	O
8	differed	O	O
9	significantly	O	O
10	among	O	O
11	groups	O	O
12	(	O	O
13	F	O	S-Disease
14	(	O	O
15	33	O	O
16	)	O	O
17	=	O	O
18	4	O	O
19	.	O	O
20	92	O	O
21	;	O	O
22	P	O	O
23	=	O	O
24	.	O	O
25	01	O	O
26	)	O	O
27	(	O	O
28	clozapine	S-Chemical	S-Chemical
29	>	O	O
30	olanzapine	S-Chemical	S-Chemical
31	>	O	O
32	risperidone	S-Chemical	S-Chemical
33	)	O	O
34	(	O	O
35	clozapine	S-Chemical	S-Chemical
36	vs	O	O
37	risperidone	S-Chemical	S-Chemical
38	,	O	O
39	t	O	O
40	(	O	O
41	33	O	O
42	)	O	O
43	=	O	O
44	2	O	O
45	.	O	O
46	94	O	O
47	;	O	O
48	P	O	O
49	=	O	O
50	.	O	O
51	006	O	O
52	;	O	O
53	olanzapine	S-Chemical	S-Chemical
54	vs	O	O
55	risperidone	S-Chemical	S-Chemical
56	,	O	O
57	t	O	O
58	(	O	O
59	33	O	O
60	)	O	O
61	=	O	O
62	2	O	O
63	.	O	O
64	42	O	O
65	;	O	O
66	P	O	S-Disease
67	=	O	O
68	.	O	O
69	02	O	O
70	)	O	O
71	.	O	O

0	There	O	O
1	was	O	O
2	a	O	O
3	significant	O	O
4	difference	O	O
5	among	O	O
6	groups	O	O
7	in	O	O
8	glucose	S-Chemical	S-Disease
9	effectiveness	O	O
10	(	O	O
11	F	O	S-Chemical
12	(	O	O
13	30	O	O
14	)	O	O
15	=	O	O
16	4	O	O
17	.	O	O
18	18	O	O
19	;	O	O
20	P	O	O
21	=	O	O
22	.	O	O
23	02	O	O
24	)	O	O
25	(	O	O
26	clozapine	S-Chemical	S-Chemical
27	<	O	O
28	olanzapine	S-Chemical	S-Chemical
29	<	O	O
30	risperidone	S-Chemical	S-Chemical
31	)	O	O
32	with	O	O
33	significant	O	O
34	differences	O	O
35	between	O	O
36	clozapine	S-Chemical	S-Chemical
37	and	O	O
38	risperidone	S-Chemical	S-Chemical
39	(	O	O
40	t	O	O
41	(	O	O
42	30	O	O
43	)	O	O
44	=	O	O
45	-	O	O
46	2	O	O
47	.	O	O
48	59	O	O
49	;	O	O
50	P	O	O
51	=	O	O
52	.	O	O
53	02	O	O
54	)	O	O
55	and	O	O
56	olanzapine	S-Chemical	S-Chemical
57	and	O	O
58	risperidone	S-Chemical	S-Chemical
59	(	O	O
60	t	O	O
61	(	O	O
62	30	O	O
63	)	O	O
64	=	O	O
65	-	O	O
66	2	O	O
67	.	O	O
68	34	O	O
69	,	O	O
70	P	O	S-Disease
71	=	O	O
72	.	O	O
73	03	O	O
74	)	O	O
75	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Both	O	O
3	nonobese	O	S-Chemical
4	clozapine	S-Chemical	S-Chemical
5	-	O	O
6	and	O	O
7	olanzapine	S-Chemical	S-Chemical
8	-	O	O
9	treated	O	O
10	groups	O	O
11	displayed	O	O
12	significant	O	O
13	insulin	B-Disease	B-Disease
14	resistance	E-Disease	E-Disease
15	and	O	O
16	impairment	O	O
17	of	O	O
18	glucose	S-Chemical	S-Disease
19	effectiveness	O	O
20	compared	O	O
21	with	O	O
22	risperidone	S-Chemical	S-Chemical
23	-	O	O
24	treated	O	O
25	subjects	O	O
26	.	O	O

0	Patients	O	O
1	taking	O	O
2	clozapine	S-Chemical	S-Chemical
3	and	O	O
4	olanzapine	S-Chemical	S-Chemical
5	must	O	O
6	be	O	O
7	examined	O	O
8	for	O	O
9	insulin	B-Disease	B-Disease
10	resistance	E-Disease	E-Disease
11	and	O	O
12	its	O	O
13	consequences	O	O
14	.	O	O

0	Thoracic	B-Disease	O
1	hematomyelia	E-Disease	O
2	secondary	O	O
3	to	O	O
4	coumadin	S-Chemical	S-Chemical
5	anticoagulant	O	O
6	therapy	O	O
7	:	O	O
8	a	O	O
9	case	O	O
10	report	O	O
11	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	thoracic	B-Disease	S-Disease
4	hematomyelia	E-Disease	E-Disease
5	secondary	O	O
6	to	O	O
7	anticoagulant	O	O
8	therapy	O	O
9	is	O	O
10	presented	O	O
11	.	O	O

0	Mania	S-Disease	O
1	associated	O	O
2	with	O	O
3	fluoxetine	S-Chemical	S-Chemical
4	treatment	O	O
5	in	O	O
6	adolescents	O	O
7	.	O	O

0	Fluoxetine	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	selective	O	O
4	serotonin	S-Chemical	S-Chemical
5	reuptake	O	O
6	inhibitor	O	O
7	,	O	O
8	is	O	O
9	gaining	O	O
10	increased	O	O
11	acceptance	O	O
12	in	O	O
13	the	O	O
14	treatment	O	O
15	of	O	O
16	adolescent	O	O
17	depression	S-Disease	S-Disease
18	.	O	O

0	Generally	O	O
1	safe	O	O
2	and	O	O
3	well	O	O
4	tolerated	O	O
5	by	O	O
6	adults	O	O
7	,	O	O
8	fluoxetine	S-Chemical	S-Chemical
9	has	O	O
10	been	O	O
11	reported	O	O
12	to	O	O
13	induce	O	O
14	mania	S-Disease	S-Disease
15	.	O	O

0	The	O	O
1	cases	O	O
2	of	O	O
3	five	O	O
4	depressed	S-Disease	O
5	adolescents	O	O
6	,	O	O
7	14	O	O
8	-	O	O
9	16	O	O
10	years	O	O
11	of	O	O
12	age	O	O
13	,	O	O
14	who	O	O
15	developed	O	O
16	mania	S-Disease	O
17	during	O	O
18	pharmacotherapy	O	S-Disease
19	with	O	O
20	fluoxetine	S-Chemical	S-Chemical
21	,	O	O
22	are	O	O
23	reported	O	O
24	here	O	O
25	.	O	O

0	Apparent	O	O
1	risk	O	O
2	factors	O	O
3	for	O	O
4	the	O	O
5	development	O	O
6	of	O	O
7	mania	S-Disease	S-Disease
8	or	O	O
9	hypomania	S-Disease	S-Disease
10	during	O	O
11	fluoxetine	S-Chemical	B-Disease
12	pharmacotherapy	O	E-Disease
13	in	O	O
14	this	O	O
15	population	O	O
16	were	O	O
17	the	O	O
18	combination	O	O
19	of	O	O
20	attention	B-Disease	B-Disease
21	-	I-Disease	O
22	deficit	I-Disease	I-Disease
23	hyperactivity	I-Disease	I-Disease
24	disorder	E-Disease	E-Disease
25	and	O	O
26	affective	O	B-Disease
27	instability	O	E-Disease
28	;	O	O
29	major	O	O
30	depression	S-Disease	S-Disease
31	with	O	O
32	psychotic	S-Disease	S-Disease
33	features	O	O
34	;	O	O
35	a	O	O
36	family	O	O
37	history	O	O
38	of	O	O
39	affective	B-Disease	B-Disease
40	disorder	E-Disease	E-Disease
41	,	O	O
42	especially	O	O
43	bipolar	B-Disease	B-Disease
44	disorder	E-Disease	E-Disease
45	;	O	O
46	and	O	O
47	a	O	O
48	diagnosis	O	O
49	of	O	O
50	bipolar	B-Disease	B-Disease
51	disorder	E-Disease	E-Disease
52	.	O	O

0	Further	O	O
1	study	O	O
2	is	O	O
3	needed	O	O
4	to	O	O
5	determine	O	O
6	the	O	O
7	optimal	O	O
8	dosage	O	O
9	and	O	O
10	to	O	O
11	identify	O	O
12	risk	O	O
13	factors	O	O
14	that	O	O
15	increase	O	O
16	individual	O	O
17	vulnerability	O	O
18	to	O	O
19	fluoxetine	S-Chemical	S-Chemical
20	induced	O	O
21	mania	S-Disease	S-Disease
22	in	O	O
23	adolescents	O	O
24	.	O	O

0	Acute	B-Disease	O
1	renal	I-Disease	B-Disease
2	insufficiency	E-Disease	E-Disease
3	after	O	O
4	high	O	O
5	-	O	O
6	dose	O	O
7	melphalan	S-Chemical	S-Chemical
8	in	O	O
9	patients	O	O
10	with	O	O
11	primary	B-Disease	O
12	systemic	I-Disease	B-Disease
13	amyloidosis	E-Disease	E-Disease
14	during	O	O
15	stem	O	B-Disease
16	cell	O	I-Disease
17	transplantation	O	E-Disease
18	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Patients	O	O
3	with	O	O
4	primary	B-Disease	O
5	systemic	I-Disease	B-Disease
6	amyloidosis	E-Disease	E-Disease
7	(	O	O
8	AL	S-Disease	S-Disease
9	)	O	O
10	have	O	O
11	a	O	O
12	poor	O	O
13	prognosis	O	O
14	.	O	O

0	High	O	O
1	-	O	O
2	dose	O	O
3	intravenous	O	O
4	melphalan	S-Chemical	S-Chemical
5	followed	O	O
6	by	O	O
7	peripheral	O	B-Disease
8	blood	O	I-Disease
9	stem	O	I-Disease
10	cell	O	I-Disease
11	transplant	O	E-Disease
12	(	O	O
13	PBSCT	O	S-Disease
14	)	O	O
15	appears	O	O
16	to	O	O
17	be	O	O
18	the	O	O
19	most	O	O
20	promising	O	O
21	therapy	O	O
22	,	O	O
23	but	O	O
24	treatment	O	O
25	mortality	O	O
26	can	O	O
27	be	O	O
28	high	O	O
29	.	O	O

0	The	O	O
1	authors	O	O
2	have	O	O
3	noted	O	O
4	the	O	O
5	development	O	O
6	of	O	O
7	acute	B-Disease	B-Disease
8	renal	I-Disease	I-Disease
9	insufficiency	E-Disease	E-Disease
10	immediately	O	O
11	after	O	O
12	melphalan	S-Chemical	S-Chemical
13	conditioning	O	O
14	.	O	O

0	METHODS	O	O
1	:	O	O
2	Consecutive	O	O
3	AL	S-Disease	S-Disease
4	patients	O	O
5	who	O	O
6	underwent	O	O
7	PBSCT	O	S-Disease
8	were	O	O
9	studied	O	O
10	retrospectively	O	O
11	.	O	O

0	Acute	B-Disease	O
1	renal	I-Disease	B-Disease
2	insufficiency	E-Disease	E-Disease
3	(	O	O
4	ARI	S-Disease	O
5	)	O	O
6	after	O	O
7	high	O	O
8	-	O	O
9	dose	O	O
10	melphalan	S-Chemical	S-Chemical
11	was	O	O
12	defined	O	O
13	by	O	O
14	a	O	O
15	minimum	O	O
16	increase	O	O
17	of	O	O
18	0	O	O
19	.	O	O
20	5	O	O
21	mg	O	O
22	/	O	O
23	dL	O	O
24	(	O	O
25	44	O	O
26	micromol	O	O
27	/	O	O
28	L	O	O
29	)	O	O
30	in	O	O
31	the	O	O
32	serum	O	O
33	creatinine	S-Chemical	S-Chemical
34	level	O	O
35	that	O	O
36	is	O	O
37	greater	O	O
38	than	O	O
39	50	O	O
40	%	O	O
41	of	O	O
42	baseline	O	O
43	immediately	O	O
44	after	O	O
45	conditioning	O	O
46	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Of	O	O
3	the	O	O
4	80	O	O
5	patients	O	O
6	studied	O	O
7	,	O	O
8	ARI	S-Disease	O
9	developed	O	O
10	in	O	O
11	18	O	O
12	.	O	O
13	8	O	O
14	%	O	O
15	of	O	O
16	the	O	O
17	patients	O	O
18	after	O	O
19	high	O	O
20	-	O	O
21	dose	O	O
22	melphalan	S-Chemical	S-Chemical
23	.	O	O

0	Univariate	O	O
1	analysis	O	O
2	identified	O	O
3	age	O	O
4	,	O	O
5	hypoalbuminemia	S-Disease	S-Disease
6	,	O	O
7	heavy	O	O
8	proteinuria	S-Disease	S-Disease
9	,	O	O
10	diuretic	O	S-Chemical
11	use	O	O
12	,	O	O
13	and	O	O
14	urine	O	O
15	sediment	O	O
16	score	O	O
17	(	O	O
18	>	O	O
19	3	O	O
20	)	O	O
21	as	O	O
22	risk	O	O
23	factors	O	O
24	.	O	O

0	Patients	O	O
1	who	O	O
2	had	O	O
3	ARI	S-Disease	O
4	after	O	O
5	high	O	O
6	-	O	O
7	dose	O	O
8	melphalan	S-Chemical	S-Chemical
9	underwent	O	O
10	dialysis	O	O
11	more	O	O
12	often	O	O
13	(	O	O
14	P	O	O
15	=	O	O
16	0	O	O
17	.	O	O
18	007	O	O
19	)	O	O
20	,	O	O
21	and	O	O
22	had	O	O
23	a	O	O
24	worse	O	O
25	1	O	O
26	-	O	O
27	year	O	O
28	survival	O	O
29	(	O	O
30	P	O	O
31	=	O	O
32	0	O	O
33	.	O	O
34	03	O	O
35	)	O	O
36	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	The	O	O
3	timing	O	O
4	of	O	O
5	renal	B-Disease	B-Disease
6	injury	E-Disease	E-Disease
7	strongly	O	O
8	suggests	O	O
9	melphalan	S-Chemical	S-Chemical
10	as	O	O
11	the	O	O
12	causative	O	O
13	agent	O	O
14	.	O	O

0	Ongoing	O	O
1	tubular	B-Disease	B-Disease
2	injury	E-Disease	E-Disease
3	may	O	O
4	be	O	O
5	a	O	O
6	prerequisite	O	O
7	for	O	O
8	renal	B-Disease	B-Disease
9	injury	E-Disease	E-Disease
10	by	O	O
11	melphalan	S-Chemical	S-Chemical
12	as	O	O
13	evidenced	O	O
14	by	O	O
15	the	O	O
16	active	O	O
17	urinary	O	O
18	sediment	O	O
19	.	O	O

0	Development	O	O
1	of	O	O
2	ARI	S-Disease	O
3	adversely	O	O
4	affected	O	O
5	the	O	O
6	outcome	O	O
7	after	O	O
8	PBSCT	O	S-Chemical
9	.	O	O

0	Effective	O	O
1	preventive	O	O
2	measures	O	O
3	may	O	O
4	help	O	O
5	decrease	O	O
6	the	O	O
7	treatment	O	O
8	mortality	O	O
9	of	O	O
10	PBSCT	O	S-Disease
11	in	O	O
12	AL	S-Disease	S-Disease
13	patients	O	O
14	.	O	O

0	Focal	O	O
1	cerebral	B-Disease	B-Disease
2	ischemia	E-Disease	E-Disease
3	in	O	O
4	rats	O	O
5	:	O	O
6	effect	O	O
7	of	O	O
8	phenylephrine	S-Chemical	S-Chemical
9	-	O	O
10	induced	O	O
11	hypertension	S-Disease	S-Disease
12	during	O	O
13	reperfusion	O	O
14	.	O	O

0	After	O	O
1	180	O	O
2	min	O	O
3	of	O	O
4	temporary	O	O
5	middle	B-Disease	O
6	cerebral	I-Disease	I-Disease
7	artery	I-Disease	I-Disease
8	occlusion	E-Disease	E-Disease
9	in	O	O
10	spontaneously	O	O
11	hypertensive	S-Disease	O
12	rats	O	O
13	,	O	O
14	the	O	O
15	effect	O	O
16	of	O	O
17	phenylephrine	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	hypertension	S-Disease	S-Disease
21	on	O	O
22	ischemic	B-Disease	B-Disease
23	brain	I-Disease	I-Disease
24	injury	E-Disease	E-Disease
25	and	O	O
26	blood	O	B-Disease
27	-	O	I-Disease
28	brain	O	I-Disease
29	barrier	O	E-Disease
30	permeability	O	S-Disease
31	was	O	O
32	determined	O	O
33	.	O	O

0	Blood	O	O
1	pressure	O	O
2	was	O	O
3	manipulated	O	O
4	by	O	O
5	one	O	O
6	of	O	O
7	the	O	O
8	following	O	O
9	schedules	O	O
10	during	O	O
11	120	O	O
12	min	O	O
13	of	O	O
14	reperfusion	O	O
15	:	O	O
16	Control	O	O
17	,	O	O
18	normotensive	O	O
19	reperfusion	O	O
20	;	O	O
21	90	O	O
22	/	O	O
23	hypertension	S-Disease	S-Disease
24	(	O	O
25	90	O	O
26	/	O	O
27	HTN	S-Disease	O
28	)	O	O
29	,	O	O
30	blood	O	O
31	pressure	O	O
32	was	O	O
33	increased	O	O
34	by	O	O
35	35	O	O
36	mm	O	O
37	Hg	O	O
38	during	O	O
39	the	O	O
40	initial	O	O
41	90	O	O
42	min	O	O
43	of	O	O
44	reperfusion	O	O
45	only	O	O
46	;	O	O
47	15	O	O
48	/	O	O
49	hypertension	S-Disease	O
50	(	O	O
51	15	O	O
52	/	O	O
53	HTN	S-Disease	O
54	)	O	O
55	,	O	O
56	normotensive	O	O
57	reperfusion	O	O
58	for	O	O
59	30	O	O
60	min	O	O
61	followed	O	O
62	by	O	O
63	15	O	O
64	min	O	O
65	of	O	O
66	hypertension	S-Disease	S-Disease
67	and	O	O
68	75	O	O
69	min	O	O
70	of	O	O
71	normotension	O	S-Chemical
72	.	O	O

0	Part	O	O
1	A	O	O
2	,	O	O
3	for	O	O
4	eight	O	O
5	rats	O	O
6	in	O	O
7	each	O	O
8	group	O	O
9	brain	B-Disease	O
10	injury	E-Disease	S-Disease
11	was	O	O
12	evaluated	O	O
13	by	O	O
14	staining	O	O
15	tissue	O	O
16	using	O	O
17	2	B-Chemical	O
18	,	I-Chemical	O
19	3	I-Chemical	O
20	,	I-Chemical	O
21	5	I-Chemical	O
22	-	I-Chemical	O
23	triphenyltetrazolium	I-Chemical	S-Chemical
24	chloride	E-Chemical	E-Chemical
25	and	O	O
26	edema	S-Disease	S-Disease
27	was	O	O
28	evaluated	O	O
29	by	O	O
30	microgravimetry	O	O
31	.	O	O

0	Brain	B-Disease	O
1	injury	E-Disease	O
2	(	O	O
3	percentage	O	O
4	of	O	O
5	the	O	O
6	ischemic	B-Disease	O
7	hemisphere	E-Disease	O
8	)	O	O
9	was	O	O
10	less	O	O
11	in	O	O
12	the	O	O
13	15	O	O
14	/	O	O
15	HTN	S-Disease	O
16	group	O	O
17	(	O	O
18	16	O	O
19	+	O	O
20	/	O	O
21	-	O	O
22	6	O	O
23	,	O	O
24	mean	O	O
25	+	O	O
26	/	O	O
27	-	O	O
28	SD	O	O
29	)	O	O
30	versus	O	O
31	the	O	O
32	90	O	O
33	/	O	O
34	HTN	S-Disease	O
35	group	O	O
36	(	O	O
37	30	O	O
38	+	O	O
39	/	O	O
40	-	O	O
41	6	O	O
42	)	O	O
43	,	O	O
44	which	O	O
45	was	O	O
46	in	O	O
47	turn	O	O
48	less	O	O
49	than	O	O
50	the	O	O
51	control	O	O
52	group	O	O
53	(	O	O
54	42	O	O
55	+	O	O
56	/	O	O
57	-	O	O
58	5	O	O
59	)	O	O
60	.	O	O

0	Specific	O	O
1	gravity	O	O
2	was	O	O
3	greater	O	O
4	in	O	O
5	the	O	O
6	15	O	O
7	/	O	O
8	HTN	S-Disease	O
9	group	O	O
10	(	O	O
11	1	O	O
12	.	O	O
13	043	O	O
14	+	O	O
15	/	O	O
16	-	O	O
17	0	O	O
18	.	O	O
19	002	O	O
20	)	O	O
21	versus	O	O
22	the	O	O
23	90	O	O
24	/	O	O
25	HTN	S-Disease	O
26	(	O	O
27	1	O	O
28	.	O	O
29	036	O	O
30	+	O	O
31	/	O	O
32	-	O	O
33	0	O	O
34	.	O	O
35	003	O	O
36	)	O	O
37	and	O	O
38	control	O	O
39	(	O	O
40	1	O	O
41	.	O	O
42	037	O	O
43	+	O	O
44	/	O	O
45	-	O	O
46	0	O	O
47	.	O	O
48	003	O	O
49	)	O	O
50	groups	O	O
51	.	O	O

0	Evans	B-Chemical	B-Chemical
1	Blue	E-Chemical	O
2	(	O	O
3	mug	O	O
4	g	O	O
5	-	O	O
6	1	O	O
7	of	O	O
8	brain	O	O
9	tissue	O	O
10	)	O	O
11	was	O	O
12	greater	O	O
13	in	O	O
14	the	O	O
15	90	O	O
16	/	O	O
17	HTN	S-Disease	O
18	group	O	O
19	(	O	O
20	24	O	O
21	.	O	O
22	4	O	O
23	+	O	O
24	/	O	O
25	-	O	O
26	6	O	O
27	.	O	O
28	0	O	O
29	)	O	O
30	versus	O	O
31	the	O	O
32	control	O	O
33	group	O	O
34	(	O	O
35	12	O	O
36	.	O	O
37	3	O	O
38	+	O	O
39	/	O	O
40	-	O	O
41	4	O	O
42	.	O	O
43	1	O	O
44	)	O	O
45	,	O	O
46	which	O	O
47	was	O	O
48	in	O	O
49	turn	O	O
50	greater	O	O
51	than	O	O
52	the	O	O
53	15	O	O
54	/	O	O
55	HTN	S-Disease	O
56	group	O	O
57	(	O	O
58	7	O	O
59	.	O	O
60	3	O	O
61	+	O	O
62	/	O	O
63	-	O	O
64	3	O	O
65	.	O	O
66	2	O	O
67	)	O	O
68	.	O	O

0	This	O	O
1	study	O	O
2	supports	O	O
3	a	O	O
4	hypothesis	O	O
5	that	O	O
6	during	O	O
7	reperfusion	O	O
8	,	O	O
9	a	O	O
10	short	O	O
11	interval	O	O
12	of	O	O
13	hypertension	S-Disease	S-Disease
14	decreases	O	O
15	brain	B-Disease	B-Disease
16	injury	E-Disease	E-Disease
17	and	O	O
18	edema	S-Disease	S-Disease
19	;	O	O
20	and	O	O
21	that	O	O
22	sustained	O	O
23	hypertension	S-Disease	S-Disease
24	increases	O	O
25	the	O	O
26	risk	O	O
27	of	O	O
28	vasogenic	B-Disease	S-Disease
29	edema	E-Disease	S-Disease
30	.	O	O

0	People	O	O
1	aged	O	O
2	over	O	O
3	75	O	O
4	in	O	O
5	atrial	B-Disease	B-Disease
6	fibrillation	E-Disease	E-Disease
7	on	O	O
8	warfarin	S-Chemical	S-Chemical
9	:	O	O
10	the	O	O
11	rate	O	O
12	of	O	O
13	major	O	O
14	hemorrhage	S-Disease	S-Disease
15	and	O	O
16	stroke	S-Disease	S-Disease
17	in	O	O
18	more	O	O
19	than	O	O
20	500	O	O
21	patient	O	O
22	-	O	O
23	years	O	O
24	of	O	O
25	follow	O	O
26	-	O	O
27	up	O	O
28	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	To	O	O
3	determine	O	O
4	the	O	O
5	incidence	O	O
6	of	O	O
7	major	O	O
8	hemorrhage	S-Disease	S-Disease
9	and	O	O
10	stroke	S-Disease	S-Disease
11	in	O	O
12	people	O	O
13	aged	O	O
14	76	O	O
15	and	O	O
16	older	O	O
17	with	O	O
18	atrial	B-Disease	B-Disease
19	fibrillation	E-Disease	E-Disease
20	on	O	O
21	adjusted	O	O
22	-	O	O
23	dose	O	O
24	warfarin	S-Chemical	S-Chemical
25	who	O	O
26	had	O	O
27	been	O	O
28	recently	O	O
29	been	O	O
30	admitted	O	O
31	to	O	O
32	hospital	O	O
33	.	O	O

0	PARTICIPANTS	O	O
1	:	O	O
2	Two	O	O
3	hundred	O	O
4	thirty	O	O
5	-	O	O
6	five	O	O
7	patients	O	O
8	aged	O	O
9	76	O	O
10	and	O	O
11	older	O	O
12	admitted	O	O
13	to	O	O
14	a	O	O
15	major	O	O
16	healthcare	O	O
17	network	O	O
18	between	O	O
19	July	O	O
20	1	O	O
21	,	O	O
22	2001	O	O
23	,	O	O
24	and	O	O
25	June	O	O
26	30	O	O
27	,	O	O
28	2002	O	O
29	,	O	O
30	with	O	O
31	atrial	B-Disease	B-Disease
32	fibrillation	E-Disease	E-Disease
33	on	O	O
34	warfarin	S-Chemical	S-Chemical
35	were	O	O
36	enrolled	O	O
37	.	O	O

0	MEASUREMENTS	O	O
1	:	O	O
2	Information	O	O
3	regarding	O	O
4	major	O	O
5	bleeding	S-Disease	S-Disease
6	episodes	O	O
7	,	O	O
8	strokes	S-Disease	S-Disease
9	,	O	O
10	and	O	O
11	warfarin	S-Chemical	S-Chemical
12	use	O	O
13	was	O	O
14	obtained	O	O
15	from	O	O
16	patients	O	O
17	,	O	O
18	relatives	O	O
19	,	O	O
20	primary	O	O
21	physicians	O	O
22	,	O	O
23	and	O	O
24	medical	O	O
25	records	O	O
26	.	O	O

0	Total	O	O
1	follow	O	O
2	-	O	O
3	up	O	O
4	on	O	O
5	warfarin	S-Chemical	S-Chemical
6	was	O	O
7	530	O	O
8	years	O	O
9	(	O	O
10	mean	O	O
11	28	O	O
12	months	O	O
13	)	O	O
14	.	O	O

0	There	O	O
1	were	O	O
2	53	O	O
3	major	O	O
4	hemorrhages	S-Disease	O
5	,	O	O
6	for	O	O
7	an	O	O
8	annual	O	O
9	rate	O	O
10	of	O	O
11	10	O	O
12	.	O	O
13	0	O	O
14	%	O	O
15	,	O	O
16	including	O	O
17	24	O	O
18	(	O	O
19	45	O	O
20	.	O	O
21	3	O	O
22	%	O	O
23	)	O	O
24	life	O	O
25	-	O	O
26	threatening	O	O
27	and	O	O
28	five	O	O
29	(	O	O
30	9	O	O
31	.	O	O
32	4	O	O
33	%	O	O
34	)	O	O
35	fatal	O	O
36	bleeds	O	S-Disease
37	.	O	O

0	The	O	O
1	annual	O	O
2	stroke	S-Disease	S-Disease
3	rate	O	O
4	after	O	O
5	initiation	O	O
6	of	O	O
7	warfarin	S-Chemical	S-Chemical
8	was	O	O
9	2	O	O
10	.	O	O
11	6	O	O
12	%	O	O
13	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	The	O	O
3	rate	O	O
4	of	O	O
5	major	O	O
6	hemorrhage	S-Disease	S-Disease
7	was	O	O
8	high	O	O
9	in	O	O
10	this	O	O
11	old	O	O
12	,	O	O
13	frail	O	O
14	group	O	O
15	,	O	O
16	but	O	O
17	excluding	O	O
18	fatalities	O	O
19	,	O	O
20	resulted	O	O
21	in	O	O
22	no	O	O
23	long	O	O
24	-	O	O
25	term	O	O
26	sequelae	O	O
27	,	O	O
28	and	O	O
29	the	O	O
30	stroke	S-Disease	S-Disease
31	rate	O	O
32	on	O	O
33	warfarin	S-Chemical	S-Chemical
34	was	O	O
35	low	O	O
36	,	O	O
37	demonstrating	O	O
38	how	O	O
39	effective	O	O
40	warfarin	S-Chemical	S-Chemical
41	treatment	O	O
42	is	O	O
43	.	O	O

0	Safety	O	O
1	of	O	O
2	celecoxib	S-Chemical	S-Chemical
3	in	O	O
4	patients	O	O
5	with	O	O
6	adverse	O	O
7	skin	B-Disease	B-Disease
8	reactions	E-Disease	E-Disease
9	to	O	O
10	acetaminophen	S-Chemical	S-Chemical
11	(	O	O
12	paracetamol	S-Chemical	S-Chemical
13	)	O	O
14	and	O	O
15	nimesulide	S-Chemical	S-Chemical
16	associated	O	O
17	or	O	O
18	not	O	O
19	with	O	O
20	common	O	O
21	non	O	O
22	-	O	O
23	steroidal	O	S-Chemical
24	anti	O	O
25	-	O	O
26	inflammatory	O	S-Disease
27	drugs	O	O
28	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Acetaminophen	S-Chemical	S-Chemical
3	(	O	O
4	paracetamol	S-Chemical	S-Chemical
5	-	O	O
6	-	O	O
7	P	S-Chemical	O
8	)	O	O
9	and	O	O
10	Nimesulide	S-Chemical	S-Chemical
11	(	O	O
12	N	S-Chemical	O
13	)	O	O
14	are	O	O
15	widely	O	O
16	used	O	O
17	analgesic	O	O
18	-	O	O
19	antipyretic	O	O
20	/	O	O
21	anti	O	O
22	-	O	O
23	inflammatory	O	S-Disease
24	drugs	O	O
25	.	O	O

0	The	O	O
1	rate	O	O
2	of	O	O
3	adverse	O	O
4	hypersensitivity	S-Disease	S-Disease
5	reactions	O	O
6	to	O	O
7	these	O	O
8	agents	O	O
9	is	O	O
10	generally	O	O
11	low	O	O
12	.	O	O

0	Celecoxib	S-Chemical	S-Chemical
1	(	O	O
2	CE	S-Chemical	O
3	)	O	O
4	is	O	O
5	a	O	O
6	novel	O	O
7	drug	O	O
8	,	O	O
9	with	O	O
10	high	O	O
11	selectivity	O	O
12	and	O	O
13	affinity	O	O
14	for	O	O
15	COX	O	S-Chemical
16	-	O	O
17	2	O	O
18	enzyme	O	O
19	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	We	O	O
3	evaluated	O	O
4	the	O	O
5	tolerability	O	O
6	of	O	O
7	CE	S-Chemical	S-Chemical
8	in	O	O
9	a	O	O
10	group	O	O
11	of	O	O
12	patients	O	O
13	with	O	O
14	documented	O	O
15	history	O	O
16	of	O	O
17	adverse	O	O
18	cutaneous	B-Disease	B-Disease
19	reactions	E-Disease	E-Disease
20	to	O	O
21	P	S-Chemical	S-Chemical
22	and	O	O
23	N	S-Chemical	S-Disease
24	associated	O	O
25	or	O	O
26	not	O	O
27	to	O	O
28	classic	O	O
29	NSAIDs	O	S-Chemical
30	.	O	O

0	METHODS	O	O
1	:	O	O
2	We	O	O
3	studied	O	O
4	9	O	O
5	patients	O	O
6	with	O	O
7	hypersensitivity	S-Disease	S-Disease
8	to	O	O
9	P	S-Chemical	S-Chemical
10	and	O	O
11	N	S-Chemical	S-Disease
12	with	O	O
13	or	O	O
14	without	O	O
15	associated	O	O
16	reactions	O	O
17	to	O	O
18	classic	O	O
19	NSAIDs	O	S-Chemical
20	.	O	O

0	The	O	O
1	diagnosis	O	O
2	of	O	O
3	P	S-Chemical	S-Disease
4	and	O	O
5	N	S-Chemical	O
6	-	O	O
7	induced	O	O
8	skin	B-Disease	O
9	reactions	E-Disease	E-Disease
10	was	O	O
11	based	O	O
12	in	O	O
13	vivo	O	O
14	challenge	O	O
15	.	O	O

0	After	O	O
1	three	O	O
2	days	O	O
3	,	O	O
4	a	O	O
5	cumulative	O	O
6	dosage	O	O
7	of	O	O
8	200	O	O
9	mg	O	O
10	of	O	O
11	CE	S-Chemical	S-Disease
12	in	O	O
13	refracted	O	O
14	doses	O	O
15	were	O	O
16	given	O	O
17	.	O	O

0	The	O	O
1	challenge	O	O
2	was	O	O
3	considered	O	O
4	positive	O	O
5	if	O	O
6	one	O	O
7	or	O	O
8	more	O	O
9	of	O	O
10	the	O	O
11	following	O	O
12	appeared	O	O
13	:	O	O
14	erythema	S-Disease	S-Disease
15	,	O	O
16	rush	O	S-Disease
17	or	O	O
18	urticaria	S-Disease	S-Disease
19	-	O	O
20	angioedema	S-Disease	S-Disease
21	.	O	O

0	RESULTS	O	O
1	:	O	O
2	No	O	O
3	reaction	O	O
4	was	O	O
5	observed	O	O
6	with	O	O
7	placebo	O	S-Disease
8	and	O	O
9	eight	O	O
10	patients	O	O
11	(	O	O
12	88	O	O
13	.	O	O
14	8	O	O
15	%	O	O
16	)	O	O
17	tolerated	O	O
18	CE	S-Chemical	O
19	.	O	O

0	Only	O	O
1	one	O	O
2	patient	O	O
3	developed	O	O
4	a	O	O
5	moderate	O	O
6	angioedema	S-Disease	O
7	of	O	O
8	the	O	O
9	lips	O	O
10	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Only	O	O
3	one	O	O
4	hypersensitivity	S-Disease	O
5	reaction	O	O
6	to	O	O
7	CE	S-Chemical	S-Disease
8	was	O	O
9	documented	O	O
10	among	O	O
11	9	O	O
12	P	S-Chemical	O
13	and	O	O
14	N	S-Chemical	O
15	-	O	O
16	highly	O	O
17	NSAIDs	O	S-Disease
18	intolerant	O	O
19	patients	O	O
20	.	O	O

0	Thus	O	O
1	,	O	O
2	we	O	O
3	conclude	O	O
4	that	O	O
5	CE	S-Chemical	S-Chemical
6	is	O	O
7	a	O	O
8	reasonably	O	O
9	safe	O	O
10	alternative	O	O
11	to	O	O
12	be	O	O
13	used	O	O
14	in	O	O
15	subjects	O	O
16	who	O	O
17	do	O	O
18	not	O	O
19	tolerate	O	O
20	P	S-Chemical	S-Chemical
21	and	O	O
22	N	S-Chemical	S-Disease
23	.	O	O

0	Case	O	O
1	-	O	O
2	control	O	O
3	study	O	O
4	of	O	O
5	regular	O	O
6	analgesic	O	O
7	and	O	O
8	nonsteroidal	O	O
9	anti	O	O
10	-	O	O
11	inflammatory	O	E-Disease
12	use	O	O
13	and	O	O
14	end	B-Disease	O
15	-	I-Disease	O
16	stage	I-Disease	O
17	renal	I-Disease	B-Disease
18	disease	E-Disease	E-Disease
19	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Studies	O	O
3	on	O	O
4	the	O	O
5	association	O	O
6	between	O	O
7	the	O	O
8	long	O	O
9	-	O	O
10	term	O	O
11	use	O	O
12	of	O	O
13	aspirin	S-Chemical	S-Chemical
14	and	O	O
15	other	O	O
16	analgesic	O	O
17	and	O	O
18	nonsteroidal	O	O
19	anti	O	O
20	-	O	O
21	inflammatory	O	S-Disease
22	drugs	O	O
23	(	O	O
24	NSAIDs	O	S-Disease
25	)	O	O
26	and	O	O
27	end	B-Disease	O
28	-	I-Disease	O
29	stage	I-Disease	O
30	renal	I-Disease	B-Disease
31	disease	E-Disease	E-Disease
32	(	O	O
33	ESRD	S-Disease	S-Disease
34	)	O	O
35	have	O	O
36	given	O	O
37	conflicting	O	O
38	results	O	O
39	.	O	O

0	In	O	O
1	order	O	O
2	to	O	O
3	examine	O	O
4	this	O	O
5	association	O	O
6	,	O	O
7	a	O	O
8	case	O	O
9	-	O	O
10	control	O	O
11	study	O	O
12	with	O	O
13	incident	O	O
14	cases	O	O
15	of	O	O
16	ESRD	S-Disease	S-Disease
17	was	O	O
18	carried	O	O
19	out	O	O
20	.	O	O

0	METHODS	O	O
1	:	O	O
2	The	O	O
3	cases	O	O
4	were	O	O
5	all	O	O
6	patients	O	O
7	entering	O	O
8	the	O	O
9	local	O	O
10	dialysis	O	O
11	program	O	O
12	because	O	O
13	of	O	O
14	ESRD	S-Disease	S-Disease
15	in	O	O
16	the	O	O
17	study	O	O
18	area	O	O
19	between	O	O
20	June	O	O
21	1	O	O
22	,	O	O
23	1995	O	O
24	and	O	O
25	November	O	O
26	30	O	O
27	,	O	O
28	1997	O	O
29	.	O	O

0	They	O	O
1	were	O	O
2	classified	O	O
3	according	O	O
4	to	O	O
5	the	O	O
6	underlying	O	O
7	disease	O	S-Disease
8	,	O	O
9	which	O	O
10	had	O	O
11	presumably	O	O
12	led	O	O
13	them	O	O
14	to	O	O
15	ESRD	S-Disease	S-Disease
16	.	O	O

0	For	O	O
1	specific	O	O
2	groups	O	O
3	of	O	O
4	drugs	O	O
5	,	O	O
6	the	O	O
7	risks	O	O
8	were	O	O
9	1	O	O
10	.	O	O
11	56	O	O
12	(	O	O
13	1	O	O
14	.	O	O
15	05	O	O
16	-	O	O
17	2	O	O
18	.	O	O
19	30	O	O
20	)	O	O
21	for	O	O
22	aspirin	S-Chemical	S-Chemical
23	,	O	O
24	1	O	O
25	.	O	O
26	03	O	O
27	(	O	O
28	0	O	O
29	.	O	O
30	60	O	O
31	-	O	O
32	1	O	O
33	.	O	O
34	76	O	O
35	)	O	O
36	for	O	O
37	pyrazolones	S-Chemical	S-Chemical
38	,	O	O
39	0	O	O
40	.	O	O
41	80	O	O
42	(	O	O
43	0	O	O
44	.	O	O
45	39	O	O
46	-	O	O
47	1	O	O
48	.	O	O
49	63	O	O
50	)	O	O
51	for	O	O
52	paracetamol	S-Chemical	S-Disease
53	,	O	O
54	and	O	O
55	0	O	O
56	.	O	O
57	94	O	O
58	(	O	O
59	0	O	O
60	.	O	O
61	57	O	O
62	-	O	O
63	1	O	O
64	.	O	O
65	56	O	O
66	)	O	O
67	for	O	O
68	nonaspirin	O	O
69	NSAIDs	O	S-Disease
70	.	O	O

0	The	O	O
1	risk	O	O
2	of	O	O
3	ESRD	S-Disease	S-Disease
4	associated	O	O
5	with	O	O
6	aspirin	S-Chemical	S-Chemical
7	was	O	O
8	related	O	O
9	to	O	O
10	the	O	O
11	cumulated	O	O
12	dose	O	O
13	and	O	O
14	duration	O	O
15	of	O	O
16	use	O	O
17	,	O	O
18	and	O	O
19	it	O	O
20	was	O	O
21	particularly	O	O
22	high	O	O
23	among	O	O
24	the	O	O
25	subset	O	O
26	of	O	O
27	patients	O	O
28	with	O	O
29	vascular	O	B-Disease
30	nephropathy	S-Disease	E-Disease
31	as	O	O
32	underlying	O	O
33	disease	O	S-Disease
34	[	O	O
35	2	O	O
36	.	O	O
37	35	O	O
38	(	O	O
39	1	O	O
40	.	O	O
41	17	O	O
42	-	O	O
43	4	O	O
44	.	O	O
45	72	O	O
46	)	O	O
47	]	O	O
48	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Our	O	O
3	data	O	O
4	indicate	O	O
5	that	O	O
6	long	O	O
7	-	O	O
8	term	O	O
9	use	O	O
10	of	O	O
11	nonaspirin	O	S-Disease
12	analgesic	O	O
13	drugs	O	O
14	and	O	O
15	NSAIDs	O	S-Chemical
16	is	O	O
17	not	O	O
18	associated	O	O
19	with	O	O
20	an	O	O
21	increased	O	O
22	risk	O	O
23	of	O	O
24	ESRD	S-Disease	S-Disease
25	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	chronic	O	O
4	use	O	O
5	of	O	O
6	aspirin	S-Chemical	S-Chemical
7	may	O	O
8	increase	O	O
9	the	O	O
10	risk	O	O
11	of	O	O
12	ESRD	S-Disease	S-Disease
13	.	O	O

0	Two	O	O
1	cases	O	O
2	of	O	O
3	amisulpride	S-Chemical	S-Chemical
4	overdose	S-Disease	O
5	:	O	O
6	a	O	O
7	cause	O	O
8	for	O	O
9	prolonged	B-Disease	O
10	QT	I-Disease	O
11	syndrome	E-Disease	O
12	.	O	O

0	Two	O	O
1	cases	O	O
2	of	O	O
3	deliberate	O	O
4	self	O	O
5	-	O	O
6	poisoning	S-Disease	S-Disease
7	with	O	O
8	5	O	O
9	g	O	O
10	and	O	O
11	3	O	O
12	.	O	O
13	6	O	O
14	g	O	O
15	of	O	O
16	amisulpride	S-Chemical	S-Chemical
17	,	O	O
18	respectively	O	O
19	,	O	O
20	are	O	O
21	reported	O	O
22	.	O	O

0	In	O	O
1	both	O	O
2	cases	O	O
3	,	O	O
4	QT	B-Disease	O
5	prolongation	E-Disease	O
6	and	O	O
7	hypocalcaemia	S-Disease	S-Disease
8	were	O	O
9	noted	O	O
10	.	O	O

0	The	O	O
1	QT	B-Disease	O
2	prolongation	E-Disease	O
3	appeared	O	O
4	to	O	O
5	respond	O	O
6	to	O	O
7	administration	O	O
8	of	O	O
9	i	O	O
10	.	O	O
11	v	O	O
12	.	O	O
13	calcium	B-Chemical	B-Chemical
14	gluconate	E-Chemical	E-Chemical
15	.	O	O

0	Growth	O	O
1	-	O	O
2	associated	O	O
3	protein	O	O
4	43	O	O
5	expression	O	O
6	in	O	O
7	hippocampal	O	S-Disease
8	molecular	O	O
9	layer	O	O
10	of	O	O
11	chronic	O	B-Disease
12	epileptic	S-Disease	E-Disease
13	rats	O	O
14	treated	O	O
15	with	O	O
16	cycloheximide	S-Chemical	S-Chemical
17	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	GAP43	O	S-Chemical
3	has	O	O
4	been	O	O
5	thought	O	O
6	to	O	O
7	be	O	O
8	linked	O	O
9	with	O	O
10	mossy	O	B-Disease
11	fiber	O	O
12	sprouting	O	O
13	(	O	O
14	MFS	O	S-Chemical
15	)	O	O
16	in	O	O
17	various	O	O
18	experimental	O	O
19	models	O	O
20	of	O	O
21	epilepsy	S-Disease	S-Disease
22	.	O	O

0	To	O	O
1	investigate	O	O
2	how	O	O
3	GAP43	O	S-Chemical
4	expression	O	O
5	(	O	O
6	GAP43	O	S-Chemical
7	-	O	E-Chemical
8	ir	O	O
9	)	O	O
10	correlates	O	O
11	with	O	O
12	MFS	O	S-Disease
13	,	O	O
14	we	O	O
15	assessed	O	O
16	the	O	O
17	intensity	O	O
18	(	O	O
19	densitometry	O	O
20	)	O	O
21	and	O	O
22	extension	O	O
23	(	O	O
24	width	O	O
25	)	O	O
26	of	O	O
27	GAP43	O	S-Chemical
28	-	O	E-Chemical
29	ir	O	E-Chemical
30	in	O	O
31	the	O	O
32	inner	O	O
33	molecular	O	O
34	layer	O	O
35	of	O	O
36	the	O	O
37	dentate	O	O
38	gyrus	O	S-Disease
39	(	O	O
40	IML	O	S-Disease
41	)	O	O
42	of	O	O
43	rats	O	O
44	subject	O	O
45	to	O	O
46	status	B-Disease	O
47	epilepticus	E-Disease	S-Disease
48	induced	O	O
49	by	O	O
50	pilocarpine	S-Chemical	S-Chemical
51	(	O	O
52	Pilo	S-Chemical	S-Chemical
53	)	O	O
54	,	O	O
55	previously	O	O
56	injected	O	O
57	or	O	O
58	not	O	O
59	with	O	O
60	cycloheximide	S-Chemical	S-Chemical
61	(	O	O
62	CHX	S-Chemical	S-Chemical
63	)	O	O
64	,	O	O
65	which	O	O
66	has	O	O
67	been	O	O
68	shown	O	O
69	to	O	O
70	inhibit	O	O
71	MFS	O	S-Disease
72	.	O	O

0	METHODS	O	O
1	:	O	O
2	CHX	S-Chemical	S-Chemical
3	was	O	O
4	injected	O	O
5	before	O	O
6	the	O	O
7	Pilo	S-Chemical	S-Chemical
8	injection	O	O
9	in	O	O
10	adult	O	O
11	Wistar	O	O
12	rats	O	O
13	.	O	O

0	The	O	O
1	Pilo	S-Chemical	S-Chemical
2	group	O	O
3	was	O	O
4	injected	O	O
5	with	O	O
6	the	O	O
7	same	O	O
8	drugs	O	O
9	,	O	O
10	except	O	O
11	for	O	O
12	CHX	S-Chemical	S-Chemical
13	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Densitometry	O	S-Disease
3	showed	O	O
4	no	O	O
5	significant	O	O
6	difference	O	O
7	regarding	O	O
8	GAP43	O	S-Chemical
9	-	O	E-Chemical
10	ir	O	O
11	in	O	O
12	the	O	O
13	IML	O	S-Disease
14	between	O	O
15	Pilo	S-Chemical	S-Chemical
16	,	O	O
17	CHX	S-Chemical	S-Chemical
18	+	O	O
19	Pilo	S-Chemical	S-Chemical
20	,	O	O
21	and	O	O
22	control	O	O
23	groups	O	O
24	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	results	O	O
4	of	O	O
5	the	O	O
6	width	O	O
7	of	O	O
8	the	O	O
9	GAP43	O	S-Chemical
10	-	O	O
11	ir	O	O
12	band	O	O
13	in	O	O
14	the	O	O
15	IML	O	S-Chemical
16	showed	O	O
17	that	O	O
18	CHX	S-Chemical	S-Chemical
19	+	O	O
20	Pilo	S-Chemical	S-Chemical
21	and	O	O
22	control	O	O
23	animals	O	O
24	had	O	O
25	a	O	O
26	significantly	O	O
27	larger	O	O
28	band	O	O
29	(	O	O
30	p	O	O
31	=	O	O
32	0	O	O
33	.	O	O
34	03	O	O
35	)	O	O
36	as	O	O
37	compared	O	O
38	with	O	O
39	that	O	O
40	in	O	O
41	the	O	O
42	Pilo	S-Chemical	S-Chemical
43	group	O	O
44	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Our	O	O
3	current	O	O
4	finding	O	O
5	that	O	O
6	animals	O	O
7	in	O	O
8	the	O	O
9	CHX	S-Chemical	S-Chemical
10	+	O	O
11	Pilo	S-Chemical	S-Chemical
12	group	O	O
13	have	O	O
14	a	O	O
15	GAP43	O	S-Chemical
16	-	O	O
17	ir	O	O
18	band	O	O
19	in	O	O
20	the	O	O
21	IML	O	S-Chemical
22	,	O	O
23	similar	O	O
24	to	O	O
25	that	O	O
26	of	O	O
27	controls	O	O
28	,	O	O
29	reinforces	O	O
30	prior	O	O
31	data	O	O
32	on	O	O
33	the	O	O
34	blockade	O	O
35	of	O	O
36	MFS	O	S-Disease
37	in	O	O
38	these	O	O
39	animals	O	O
40	.	O	O

0	The	O	O
1	change	O	O
2	in	O	O
3	GAP43	O	B-Chemical
4	-	O	E-Chemical
5	ir	O	E-Chemical
6	present	O	O
7	in	O	O
8	Pilo	S-Chemical	S-Chemical
9	-	O	O
10	treated	O	O
11	animals	O	O
12	was	O	O
13	a	O	O
14	thinning	O	O
15	of	O	O
16	the	O	O
17	band	O	O
18	to	O	O
19	a	O	O
20	very	O	O
21	narrow	O	O
22	layer	O	O
23	just	O	O
24	above	O	O
25	the	O	O
26	granule	O	O
27	cell	O	O
28	layer	O	O
29	that	O	O
30	is	O	O
31	likely	O	O
32	to	O	O
33	be	O	O
34	associated	O	O
35	with	O	O
36	the	O	O
37	loss	O	O
38	of	O	O
39	hilar	O	O
40	cell	O	O
41	projections	O	O
42	that	O	O
43	express	O	O
44	GAP	O	B-Chemical
45	-	O	E-Chemical
46	43	O	E-Chemical
47	.	O	O

0	Nicotine	S-Chemical	S-Chemical
1	antagonizes	O	O
2	caffeine	S-Chemical	S-Chemical
3	-	O	O
4	but	O	O
5	not	O	O
6	pentylenetetrazole	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	anxiogenic	O	O
10	effect	O	O
11	in	O	O
12	mice	O	O
13	.	O	O

0	RATIONALE	O	O
1	:	O	O
2	Nicotine	S-Chemical	S-Chemical
3	and	O	O
4	caffeine	S-Chemical	S-Chemical
5	are	O	O
6	widely	O	O
7	consumed	O	O
8	licit	O	O
9	psychoactive	O	S-Disease
10	drugs	O	O
11	worldwide	O	O
12	.	O	O

0	Although	O	O
1	some	O	O
2	studies	O	O
3	in	O	O
4	experimental	O	O
5	animals	O	O
6	indicate	O	O
7	clear	O	O
8	pharmacological	O	O
9	interactions	O	O
10	between	O	O
11	them	O	O
12	,	O	O
13	no	O	O
14	studies	O	O
15	have	O	O
16	shown	O	O
17	a	O	O
18	specific	O	O
19	interaction	O	O
20	on	O	O
21	anxiety	S-Disease	S-Disease
22	responses	O	O
23	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	The	O	O
3	present	O	O
4	study	O	O
5	investigates	O	O
6	the	O	O
7	effects	O	O
8	of	O	O
9	nicotine	S-Chemical	S-Chemical
10	on	O	O
11	anxiety	S-Disease	S-Disease
12	induced	O	O
13	by	O	O
14	caffeine	S-Chemical	S-Chemical
15	and	O	O
16	another	O	O
17	anxiogenic	O	O
18	drug	O	O
19	,	O	O
20	pentylenetetrazole	S-Chemical	S-Chemical
21	,	O	O
22	in	O	O
23	mice	O	O
24	.	O	O

0	The	O	O
1	elevated	O	O
2	plus	O	O
3	-	O	O
4	maze	O	O
5	(	O	O
6	EPM	O	O
7	)	O	O
8	test	O	O
9	was	O	O
10	used	O	O
11	to	O	O
12	evaluate	O	O
13	the	O	O
14	effects	O	O
15	of	O	O
16	drugs	O	O
17	on	O	O
18	anxiety	S-Disease	S-Disease
19	.	O	O

0	METHODS	O	O
1	:	O	O
2	Adult	O	O
3	male	O	O
4	Swiss	O	O
5	Webster	O	S-Disease
6	mice	O	O
7	(	O	O
8	25	O	O
9	-	O	O
10	32	O	O
11	g	O	O
12	)	O	O
13	were	O	O
14	given	O	O
15	nicotine	S-Chemical	S-Chemical
16	(	O	O
17	0	O	O
18	.	O	O
19	05	O	O
20	-	O	O
21	0	O	O
22	.	O	O
23	25	O	O
24	mg	O	O
25	/	O	O
26	kg	O	O
27	s	O	O
28	.	O	O
29	c	O	O
30	.	O	O
31	)	O	O
32	or	O	O
33	saline	O	S-Chemical
34	10	O	O
35	min	O	O
36	before	O	O
37	caffeine	S-Chemical	S-Chemical
38	(	O	O
39	70	O	O
40	mg	O	O
41	/	O	O
42	kg	O	O
43	i	O	O
44	.	O	O
45	p	O	O
46	.	O	O
47	)	O	O
48	or	O	O
49	pentylenetetrazole	S-Chemical	S-Chemical
50	(	O	O
51	15	O	O
52	and	O	O
53	30	O	O
54	mg	O	O
55	/	O	O
56	kg	O	O
57	i	O	O
58	.	O	O
59	p	O	O
60	.	O	O
61	)	O	O
62	injections	O	O
63	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Nicotine	S-Chemical	S-Chemical
3	(	O	O
4	0	O	O
5	.	O	O
6	05	O	O
7	-	O	O
8	0	O	O
9	.	O	O
10	25	O	O
11	mg	O	O
12	/	O	O
13	kg	O	O
14	)	O	O
15	itself	O	O
16	did	O	O
17	not	O	O
18	produce	O	O
19	any	O	O
20	significant	O	O
21	effect	O	O
22	in	O	O
23	the	O	O
24	EPM	O	O
25	test	O	O
26	,	O	O
27	whereas	O	O
28	caffeine	S-Chemical	S-Chemical
29	(	O	O
30	70	O	O
31	mg	O	O
32	/	O	O
33	kg	O	O
34	)	O	O
35	and	O	O
36	pentylenetetrazole	S-Chemical	S-Chemical
37	(	O	O
38	30	O	O
39	mg	O	O
40	/	O	O
41	kg	O	O
42	)	O	O
43	produced	O	O
44	an	O	O
45	anxiogenic	O	O
46	effect	O	O
47	,	O	O
48	apparent	O	O
49	with	O	O
50	decreases	O	O
51	in	O	O
52	open	O	O
53	-	O	O
54	arm	O	O
55	time	O	O
56	and	O	O
57	entry	O	O
58	.	O	O

0	Nicotine	S-Chemical	S-Chemical
1	(	O	O
2	0	O	O
3	.	O	O
4	25	O	O
5	mg	O	O
6	/	O	O
7	kg	O	O
8	)	O	O
9	pretreatment	O	O
10	blocked	O	O
11	the	O	O
12	caffeine	S-Chemical	S-Chemical
13	-	O	O
14	but	O	O
15	not	O	O
16	pentylenetetrazole	S-Chemical	S-Chemical
17	-	O	O
18	induced	O	O
19	anxiety	S-Disease	S-Disease
20	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Our	O	O
3	results	O	O
4	suggest	O	O
5	that	O	O
6	the	O	O
7	antagonistic	O	O
8	effect	O	O
9	of	O	O
10	nicotine	S-Chemical	S-Chemical
11	on	O	O
12	caffeine	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	anxiety	S-Disease	S-Disease
16	is	O	O
17	specific	O	O
18	to	O	O
19	caffeine	S-Chemical	S-Chemical
20	,	O	O
21	instead	O	O
22	of	O	O
23	a	O	O
24	non	O	O
25	-	O	O
26	specific	O	O
27	anxiolytic	O	O
28	effect	O	O
29	.	O	O

0	Thus	O	O
1	,	O	O
2	it	O	O
3	may	O	O
4	extend	O	O
5	the	O	O
6	current	O	O
7	findings	O	O
8	on	O	O
9	the	O	O
10	interaction	O	O
11	between	O	O
12	nicotine	S-Chemical	S-Chemical
13	and	O	O
14	caffeine	S-Chemical	S-Chemical
15	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Hormone	O	O
3	therapy	O	O
4	(	O	O
5	HT	O	O
6	)	O	O
7	is	O	O
8	widely	O	O
9	used	O	O
10	for	O	O
11	controlling	O	O
12	menopausal	B-Disease	S-Disease
13	symptoms	E-Disease	O
14	.	O	O

0	It	O	O
1	has	O	O
2	also	O	O
3	been	O	O
4	used	O	O
5	for	O	O
6	the	O	O
7	management	O	O
8	and	O	O
9	prevention	O	O
10	of	O	O
11	cardiovascular	B-Disease	B-Disease
12	disease	E-Disease	E-Disease
13	,	O	O
14	osteoporosis	S-Disease	S-Disease
15	and	O	O
16	dementia	S-Disease	S-Disease
17	in	O	O
18	older	O	O
19	women	O	O
20	but	O	O
21	the	O	O
22	evidence	O	O
23	supporting	O	O
24	its	O	O
25	use	O	O
26	for	O	O
27	these	O	O
28	indications	O	O
29	is	O	O
30	largely	O	O
31	observational	O	O
32	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	To	O	O
3	assess	O	O
4	the	O	O
5	effect	O	O
6	of	O	O
7	long	O	O
8	-	O	O
9	term	O	O
10	HT	O	O
11	on	O	O
12	mortality	O	O
13	,	O	O
14	heart	B-Disease	B-Disease
15	disease	E-Disease	E-Disease
16	,	O	O
17	venous	B-Disease	B-Disease
18	thromboembolism	E-Disease	E-Disease
19	,	O	O
20	stroke	S-Disease	S-Disease
21	,	O	O
22	transient	B-Disease	O
23	ischaemic	I-Disease	O
24	attacks	E-Disease	S-Disease
25	,	O	O
26	breast	B-Disease	B-Disease
27	cancer	E-Disease	E-Disease
28	,	O	O
29	colorectal	B-Disease	B-Disease
30	cancer	E-Disease	E-Disease
31	,	O	O
32	ovarian	B-Disease	B-Disease
33	cancer	E-Disease	E-Disease
34	,	O	O
35	endometrial	B-Disease	B-Disease
36	cancer	E-Disease	E-Disease
37	,	O	O
38	gallbladder	B-Disease	B-Disease
39	disease	E-Disease	E-Disease
40	,	O	O
41	cognitive	O	B-Disease
42	function	O	E-Disease
43	,	O	O
44	dementia	S-Disease	S-Disease
45	,	O	O
46	fractures	S-Disease	S-Disease
47	and	O	O
48	quality	O	O
49	of	O	I-Disease
50	life	O	O
51	.	O	O

0	SELECTION	O	O
1	CRITERIA	O	O
2	:	O	O
3	Randomised	O	O
4	double	O	O
5	-	O	O
6	blind	O	O
7	trials	O	O
8	of	O	O
9	HT	O	O
10	(	O	O
11	oestrogens	S-Chemical	S-Disease
12	with	O	O
13	or	O	O
14	without	O	O
15	progestogens	S-Chemical	O
16	)	O	O
17	versus	O	O
18	placebo	O	S-Disease
19	,	O	O
20	taken	O	O
21	for	O	O
22	at	O	O
23	least	O	O
24	one	O	O
25	year	O	O
26	by	O	O
27	perimenopausal	O	O
28	or	O	O
29	postmenopausal	O	O
30	women	O	O
31	.	O	O

0	In	O	O
1	relatively	O	O
2	healthy	O	O
3	women	O	O
4	,	O	O
5	combined	O	O
6	continuous	O	O
7	HT	O	O
8	significantly	O	O
9	increased	O	O
10	the	O	O
11	risk	O	O
12	of	O	O
13	venous	B-Disease	B-Disease
14	thromboembolism	E-Disease	E-Disease
15	or	O	O
16	coronary	O	S-Disease
17	event	O	O
18	(	O	O
19	after	O	O
20	one	O	O
21	year	O	O
22	'	O	O
23	s	O	O
24	use	O	O
25	)	O	O
26	,	O	O
27	stroke	S-Disease	S-Disease
28	(	O	O
29	after	O	O
30	3	O	O
31	years	O	O
32	)	O	O
33	,	O	O
34	breast	B-Disease	B-Disease
35	cancer	E-Disease	E-Disease
36	(	O	O
37	after	O	O
38	5	O	O
39	years	O	O
40	)	O	O
41	and	O	O
42	gallbladder	B-Disease	B-Disease
43	disease	E-Disease	E-Disease
44	.	O	O

0	Long	O	O
1	-	O	O
2	term	O	O
3	oestrogen	S-Chemical	S-Disease
4	-	O	O
5	only	O	O
6	HT	O	O
7	also	O	O
8	significantly	O	O
9	increased	O	O
10	the	O	O
11	risk	O	O
12	of	O	O
13	stroke	S-Disease	S-Disease
14	and	O	O
15	gallbladder	B-Disease	B-Disease
16	disease	E-Disease	E-Disease
17	.	O	O

0	Overall	O	O
1	,	O	O
2	the	O	O
3	only	O	O
4	statistically	O	O
5	significant	O	O
6	benefits	O	O
7	of	O	O
8	HT	O	S-Disease
9	were	O	O
10	a	O	O
11	decreased	O	O
12	incidence	O	O
13	of	O	O
14	fractures	S-Disease	S-Disease
15	and	O	O
16	colon	B-Disease	B-Disease
17	cancer	E-Disease	E-Disease
18	with	O	O
19	long	O	O
20	-	O	O
21	term	O	O
22	use	O	O
23	.	O	O

0	Among	O	O
1	relatively	O	O
2	healthy	O	O
3	women	O	O
4	over	O	O
5	65	O	O
6	years	O	O
7	taking	O	O
8	continuous	O	O
9	combined	O	O
10	HT	O	O
11	,	O	O
12	there	O	O
13	was	O	O
14	a	O	O
15	statistically	O	O
16	significant	O	O
17	increase	O	O
18	in	O	O
19	the	O	O
20	incidence	O	O
21	of	O	O
22	dementia	S-Disease	S-Disease
23	.	O	O

0	Among	O	O
1	women	O	O
2	with	O	O
3	cardiovascular	B-Disease	B-Disease
4	disease	E-Disease	E-Disease
5	,	O	O
6	long	O	O
7	-	O	O
8	term	O	O
9	use	O	O
10	of	O	O
11	combined	O	O
12	continuous	O	O
13	HT	O	O
14	significantly	O	O
15	increased	O	O
16	the	O	O
17	risk	O	O
18	of	O	O
19	venous	B-Disease	B-Disease
20	thromboembolism	E-Disease	E-Disease
21	.	O	O

0	However	O	O
1	,	O	O
2	one	O	O
3	trial	O	O
4	analysed	O	O
5	subgroups	O	O
6	of	O	O
7	2839	O	O
8	relatively	O	O
9	healthy	O	O
10	50	O	O
11	to	O	O
12	59	O	O
13	year	O	O
14	-	O	O
15	old	O	O
16	women	O	O
17	taking	O	O
18	combined	O	O
19	continuous	O	O
20	HT	O	O
21	and	O	O
22	1637	O	O
23	taking	O	O
24	oestrogen	S-Chemical	S-Chemical
25	-	O	O
26	only	O	O
27	HT	O	O
28	,	O	O
29	versus	O	O
30	similar	O	O
31	-	O	O
32	sized	O	O
33	placebo	O	O
34	groups	O	O
35	.	O	O

0	The	O	O
1	only	O	O
2	significantly	O	O
3	increased	O	O
4	risk	O	O
5	reported	O	O
6	was	O	O
7	for	O	O
8	venous	B-Disease	B-Disease
9	thromboembolism	E-Disease	E-Disease
10	in	O	O
11	women	O	O
12	taking	O	O
13	combined	O	O
14	continuous	O	O
15	HT	O	O
16	;	O	O
17	their	O	O
18	absolute	O	O
19	risk	O	O
20	remained	O	O
21	very	O	O
22	low	O	O
23	.	O	O

0	AUTHORS	O	O
1	'	O	O
2	CONCLUSIONS	O	O
3	:	O	O
4	HT	O	O
5	is	O	O
6	not	O	O
7	indicated	O	O
8	for	O	O
9	the	O	O
10	routine	O	O
11	management	O	O
12	of	O	O
13	chronic	B-Disease	B-Disease
14	disease	E-Disease	E-Disease
15	.	O	O

0	Drug	B-Disease	O
1	-	I-Disease	O
2	induced	I-Disease	O
3	liver	I-Disease	B-Disease
4	injury	E-Disease	E-Disease
5	:	O	O
6	an	O	O
7	analysis	O	O
8	of	O	O
9	461	O	O
10	incidences	O	O
11	submitted	O	O
12	to	O	O
13	the	O	O
14	Spanish	O	S-Chemical
15	registry	O	O
16	over	O	O
17	a	O	O
18	10	O	O
19	-	O	O
20	year	O	O
21	period	O	O
22	.	O	O

0	BACKGROUND	O	O
1	&	O	O
2	AIMS	O	O
3	:	O	O
4	Progress	O	O
5	in	O	O
6	the	O	O
7	understanding	O	O
8	of	O	O
9	susceptibility	O	O
10	factors	O	O
11	to	O	O
12	drug	B-Disease	O
13	-	I-Disease	O
14	induced	I-Disease	O
15	liver	I-Disease	B-Disease
16	injury	E-Disease	E-Disease
17	(	O	O
18	DILI	S-Disease	S-Disease
19	)	O	O
20	and	O	O
21	outcome	O	O
22	predictability	O	O
23	are	O	O
24	hampered	O	O
25	by	O	O
26	the	O	O
27	lack	O	O
28	of	O	O
29	systematic	O	O
30	programs	O	O
31	to	O	O
32	detect	O	O
33	bona	O	S-Disease
34	fide	O	S-Chemical
35	cases	O	O
36	.	O	O

0	METHODS	O	O
1	:	O	O
2	A	O	O
3	cooperative	O	O
4	network	O	O
5	was	O	O
6	created	O	O
7	in	O	O
8	1994	O	O
9	in	O	O
10	Spain	O	S-Chemical
11	to	O	O
12	identify	O	O
13	all	O	O
14	suspicions	O	O
15	of	O	O
16	DILI	S-Disease	S-Chemical
17	following	O	O
18	a	O	O
19	prospective	O	O
20	structured	O	O
21	report	O	O
22	form	O	O
23	.	O	O

0	The	O	O
1	liver	B-Disease	B-Disease
2	damage	E-Disease	E-Disease
3	was	O	O
4	characterized	O	O
5	according	O	O
6	to	O	O
7	hepatocellular	O	S-Disease
8	,	O	O
9	cholestatic	S-Disease	S-Disease
10	,	O	O
11	and	O	O
12	mixed	O	O
13	laboratory	O	O
14	criteria	O	O
15	and	O	O
16	to	O	O
17	histologic	O	O
18	criteria	O	O
19	when	O	O
20	available	O	O
21	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Since	O	O
3	April	O	O
4	1994	O	O
5	to	O	O
6	August	O	O
7	2004	O	O
8	,	O	O
9	461	O	O
10	out	O	O
11	of	O	O
12	570	O	O
13	submitted	O	O
14	cases	O	O
15	,	O	O
16	involving	O	O
17	505	O	O
18	drugs	O	O
19	,	O	O
20	were	O	O
21	deemed	O	O
22	to	O	O
23	be	O	O
24	related	O	O
25	to	O	O
26	DILI	S-Disease	S-Chemical
27	.	O	O

0	The	O	O
1	antiinfective	O	O
2	group	O	O
3	of	O	O
4	drugs	O	O
5	was	O	O
6	the	O	O
7	more	O	O
8	frequently	O	O
9	incriminated	O	O
10	,	O	O
11	amoxicillin	B-Chemical	S-Chemical
12	-	I-Chemical	O
13	clavulanate	E-Chemical	S-Chemical
14	accounting	O	O
15	for	O	O
16	the	O	O
17	12	O	O
18	.	O	O
19	8	O	O
20	%	O	O
21	of	O	O
22	the	O	O
23	whole	O	O
24	series	O	O
25	.	O	O

0	Indeed	O	O
1	,	O	O
2	the	O	O
3	incidence	O	O
4	of	O	O
5	liver	O	B-Disease
6	transplantation	O	E-Disease
7	and	O	O
8	death	O	O
9	in	O	O
10	this	O	O
11	group	O	O
12	was	O	O
13	11	O	O
14	.	O	O
15	7	O	O
16	%	O	O
17	if	O	O
18	patients	O	O
19	had	O	O
20	jaundice	S-Disease	O
21	at	O	O
22	presentation	O	O
23	,	O	O
24	whereas	O	O
25	the	O	O
26	corresponding	O	O
27	figure	O	O
28	was	O	O
29	3	O	O
30	.	O	O
31	8	O	O
32	%	O	O
33	in	O	O
34	nonjaundiced	O	O
35	patients	O	O
36	(	O	O
37	P	O	O
38	<	O	O
39	.	O	O
40	04	O	O
41	)	O	O
42	.	O	O

0	Factors	O	O
1	associated	O	O
2	with	O	O
3	the	O	O
4	development	O	O
5	of	O	O
6	fulminant	B-Disease	O
7	hepatic	I-Disease	S-Disease
8	failure	E-Disease	E-Disease
9	were	O	O
10	female	O	O
11	sex	O	O
12	(	O	O
13	OR	O	O
14	=	O	O
15	25	O	O
16	;	O	O
17	95	O	O
18	%	O	O
19	CI	O	S-Chemical
20	:	O	O
21	4	O	O
22	.	O	O
23	1	O	O
24	-	O	O
25	151	O	O
26	;	O	O
27	P	O	O
28	<	O	O
29	.	O	O
30	0001	O	O
31	)	O	O
32	,	O	O
33	hepatocellular	O	S-Disease
34	damage	O	E-Disease
35	(	O	O
36	OR	O	S-Disease
37	=	O	O
38	7	O	O
39	.	O	O
40	9	O	O
41	;	O	O
42	95	O	O
43	%	O	O
44	CI	O	S-Disease
45	:	O	O
46	1	O	O
47	.	O	O
48	6	O	O
49	-	O	O
50	37	O	O
51	;	O	O
52	P	O	O
53	<	O	O
54	.	O	O
55	009	O	O
56	)	O	O
57	,	O	O
58	and	O	O
59	higher	O	O
60	baseline	O	O
61	plasma	O	O
62	bilirubin	S-Chemical	S-Chemical
63	value	O	O
64	(	O	O
65	OR	O	S-Disease
66	=	O	O
67	1	O	O
68	.	O	O
69	15	O	O
70	;	O	O
71	95	O	O
72	%	O	O
73	CI	O	S-Chemical
74	:	O	O
75	1	O	O
76	.	O	O
77	09	O	O
78	-	O	O
79	1	O	O
80	.	O	O
81	22	O	O
82	;	O	O
83	P	O	S-Disease
84	<	O	O
85	.	O	O
86	0001	O	O
87	)	O	O
88	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Patients	O	O
3	with	O	O
4	drug	O	O
5	-	O	O
6	induced	O	O
7	hepatocellular	O	B-Disease
8	jaundice	S-Disease	E-Disease
9	have	O	O
10	11	O	O
11	.	O	O
12	7	O	O
13	%	O	O
14	chance	O	O
15	of	O	O
16	progressing	O	O
17	to	O	O
18	death	O	O
19	or	O	O
20	transplantation	O	S-Disease
21	.	O	O

0	Amoxicillin	B-Chemical	S-Chemical
1	-	I-Chemical	O
2	clavulanate	E-Chemical	S-Chemical
3	stands	O	O
4	out	O	O
5	as	O	O
6	the	O	O
7	most	O	O
8	common	O	O
9	drug	O	O
10	related	O	O
11	to	O	O
12	DILI	S-Disease	S-Chemical
13	.	O	O

0	Morphological	O	O
1	evaluation	O	O
2	of	O	O
3	the	O	O
4	effect	O	O
5	of	O	O
6	d	B-Chemical	S-Chemical
7	-	I-Chemical	B-Chemical
8	ribose	E-Chemical	E-Chemical
9	on	O	O
10	adriamycin	S-Chemical	S-Chemical
11	-	O	O
12	evoked	O	O
13	cardiotoxicity	S-Disease	S-Disease
14	in	O	O
15	rats	O	O
16	.	O	O

0	The	O	O
1	influence	O	O
2	of	O	O
3	d	B-Chemical	S-Chemical
4	-	I-Chemical	B-Chemical
5	ribose	E-Chemical	E-Chemical
6	on	O	O
7	adriamycin	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	myocardiopathy	S-Disease	S-Disease
11	in	O	O
12	rats	O	O
13	was	O	O
14	studied	O	O
15	.	O	O

0	Adriamycin	S-Chemical	S-Chemical
1	in	O	O
2	the	O	O
3	cumulative	O	O
4	dose	O	O
5	of	O	O
6	25	O	O
7	mg	O	O
8	/	O	O
9	kg	O	O
10	evoked	O	O
11	fully	O	O
12	developed	O	O
13	cardiac	B-Disease	B-Disease
14	toxicity	E-Disease	E-Disease
15	.	O	O

0	D	B-Chemical	B-Chemical
1	-	I-Chemical	I-Chemical
2	ribose	E-Chemical	E-Chemical
3	in	O	O
4	the	O	O
5	multiple	O	O
6	doses	O	O
7	of	O	O
8	200	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	did	O	O
13	not	O	O
14	influence	O	O
15	ADR	S-Chemical	S-Chemical
16	cardiotoxicity	S-Disease	S-Disease
17	.	O	O

0	In	O	O
1	vivo	O	O
2	evidences	O	O
3	suggesting	O	O
4	the	O	O
5	role	O	O
6	of	O	O
7	oxidative	O	O
8	stress	O	S-Disease
9	in	O	O
10	pathogenesis	O	O
11	of	O	O
12	vancomycin	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	nephrotoxicity	S-Disease	S-Disease
16	:	O	O
17	protection	O	O
18	by	O	O
19	erdosteine	S-Chemical	S-Chemical
20	.	O	O

0	The	O	O
1	aims	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	were	O	O
6	to	O	O
7	examine	O	O
8	vancomycin	S-Chemical	S-Chemical
9	(	O	O
10	VCM	S-Chemical	S-Chemical
11	)	O	O
12	-	O	O
13	induced	O	O
14	oxidative	O	O
15	stress	O	O
16	that	O	O
17	promotes	O	O
18	production	O	O
19	of	O	O
20	reactive	O	B-Disease
21	oxygen	S-Chemical	I-Disease
22	species	O	E-Disease
23	(	O	O
24	ROS	O	S-Disease
25	)	O	O
26	and	O	O
27	to	O	O
28	investigate	O	O
29	the	O	O
30	role	O	O
31	of	O	O
32	erdosteine	S-Chemical	S-Chemical
33	,	O	O
34	an	O	O
35	expectorant	O	O
36	agent	O	O
37	,	O	O
38	which	O	O
39	has	O	O
40	also	O	O
41	antioxidant	O	O
42	properties	O	O
43	,	O	O
44	on	O	O
45	kidney	O	O
46	tissue	O	O
47	against	O	O
48	the	O	O
49	possible	O	O
50	VCM	S-Chemical	S-Chemical
51	-	O	O
52	induced	O	O
53	renal	B-Disease	S-Disease
54	impairment	E-Disease	E-Disease
55	in	O	O
56	rats	O	O
57	.	O	O

0	Rats	O	O
1	were	O	O
2	divided	O	O
3	into	O	O
4	three	O	O
5	groups	O	O
6	:	O	O
7	sham	O	S-Chemical
8	,	O	O
9	VCM	S-Chemical	S-Chemical
10	and	O	O
11	VCM	S-Chemical	S-Disease
12	plus	O	O
13	erdosteine	S-Chemical	S-Chemical
14	.	O	O

0	VCM	S-Chemical	S-Chemical
1	was	O	O
2	administrated	O	O
3	intraperitoneally	O	O
4	(	O	O
5	i	O	O
6	.	O	O
7	p	O	O
8	.	O	O
9	)	O	O
10	with	O	O
11	200mgkg	O	O
12	(	O	O
13	-	O	O
14	1	O	O
15	)	O	O
16	twice	O	O
17	daily	O	O
18	for	O	O
19	7	O	O
20	days	O	O
21	.	O	O

0	Erdosteine	S-Chemical	S-Chemical
1	was	O	O
2	administered	O	O
3	orally	O	O
4	.	O	O

0	VCM	S-Chemical	S-Chemical
1	administration	O	O
2	to	O	O
3	control	O	O
4	rats	O	O
5	significantly	O	O
6	increased	O	O
7	renal	O	I-Disease
8	malondialdehyde	S-Chemical	E-Chemical
9	(	O	O
10	MDA	S-Chemical	S-Disease
11	)	O	O
12	and	O	O
13	urinary	O	O
14	N	O	B-Chemical
15	-	O	I-Chemical
16	acetyl	O	E-Chemical
17	-	O	I-Chemical
18	beta	O	I-Disease
19	-	O	I-Chemical
20	d	O	E-Chemical
21	-	O	I-Chemical
22	glucosaminidase	O	E-Chemical
23	(	O	O
24	NAG	O	S-Chemical
25	,	O	O
26	a	O	O
27	marker	O	O
28	of	O	O
29	renal	B-Disease	B-Disease
30	tubular	I-Disease	I-Disease
31	injury	E-Disease	E-Disease
32	)	O	O
33	excretion	O	O
34	but	O	O
35	decreased	O	O
36	superoxide	S-Chemical	S-Disease
37	dismutase	O	O
38	(	O	O
39	SOD	O	S-Disease
40	)	O	O
41	and	O	O
42	catalase	O	S-Disease
43	(	O	O
44	CAT	O	S-Disease
45	)	O	O
46	activities	O	O
47	.	O	O

0	Erdosteine	S-Chemical	S-Chemical
1	administration	O	O
2	with	O	O
3	VCM	S-Chemical	S-Disease
4	injections	O	O
5	caused	O	O
6	significantly	O	O
7	decreased	O	O
8	renal	O	B-Disease
9	MDA	S-Chemical	E-Disease
10	and	O	O
11	urinary	O	O
12	NAG	O	E-Chemical
13	excretion	O	O
14	,	O	O
15	and	O	O
16	increased	O	O
17	SOD	O	S-Disease
18	activity	O	E-Disease
19	,	O	O
20	but	O	O
21	not	O	O
22	CAT	O	S-Disease
23	activity	O	O
24	in	O	O
25	renal	O	B-Disease
26	tissue	O	E-Disease
27	when	O	O
28	compared	O	O
29	with	O	O
30	VCM	S-Chemical	S-Chemical
31	alone	O	O
32	.	O	O

0	Erdosteine	S-Chemical	S-Chemical
1	showed	O	O
2	histopathological	O	S-Disease
3	protection	O	O
4	against	O	O
5	VCM	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	nephrotoxicity	S-Disease	S-Disease
9	.	O	O

0	There	O	O
1	were	O	O
2	a	O	O
3	significant	O	O
4	dilatation	O	O
5	of	O	O
6	tubular	O	B-Disease
7	lumens	O	E-Disease
8	,	O	O
9	extensive	O	O
10	epithelial	O	O
11	cell	O	I-Disease
12	vacuolization	O	S-Disease
13	,	O	O
14	atrophy	S-Disease	S-Disease
15	,	O	O
16	desquamation	S-Disease	S-Disease
17	,	O	O
18	and	O	O
19	necrosis	S-Disease	S-Disease
20	in	O	O
21	VCM	S-Chemical	S-Chemical
22	-	O	O
23	treated	O	O
24	rats	O	O
25	more	O	O
26	than	O	O
27	those	O	O
28	of	O	O
29	the	O	O
30	control	O	O
31	and	O	O
32	the	O	O
33	erdosteine	S-Chemical	S-Chemical
34	groups	O	O
35	.	O	O

0	Erdosteine	S-Chemical	S-Chemical
1	caused	O	O
2	a	O	O
3	marked	O	O
4	reduction	O	O
5	in	O	O
6	the	O	O
7	extent	O	O
8	of	O	O
9	tubular	O	B-Disease
10	damage	O	E-Disease
11	.	O	O

0	It	O	O
1	is	O	O
2	concluded	O	O
3	that	O	O
4	oxidative	O	O
5	tubular	O	B-Disease
6	damage	O	E-Disease
7	plays	O	O
8	an	O	O
9	important	O	O
10	role	O	O
11	in	O	O
12	the	O	O
13	VCM	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	nephrotoxicity	S-Disease	S-Disease
17	and	O	O
18	the	O	O
19	modulation	O	O
20	of	O	O
21	oxidative	O	O
22	stress	O	S-Disease
23	with	O	O
24	erdosteine	S-Chemical	S-Chemical
25	reduces	O	O
26	the	O	O
27	VCM	S-Chemical	S-Chemical
28	-	O	O
29	induced	O	O
30	kidney	B-Disease	B-Disease
31	damage	E-Disease	E-Disease
32	both	O	O
33	at	O	O
34	the	O	O
35	biochemical	O	O
36	and	O	O
37	histological	O	O
38	levels	O	O
39	.	O	O

0	Gemfibrozil	S-Chemical	S-Chemical
1	-	O	O
2	lovastatin	S-Chemical	S-Chemical
3	therapy	O	O
4	for	O	O
5	primary	O	O
6	hyperlipoproteinemias	S-Disease	S-Disease
7	.	O	O

0	The	O	O
1	specific	O	O
2	aim	O	O
3	of	O	O
4	this	O	O
5	retrospective	O	O
6	,	O	O
7	observational	O	O
8	study	O	O
9	was	O	O
10	to	O	O
11	assess	O	O
12	safety	O	O
13	and	O	O
14	efficacy	O	O
15	of	O	O
16	long	O	O
17	-	O	O
18	term	O	O
19	(	O	O
20	21	O	O
21	months	O	O
22	/	O	O
23	patient	O	O
24	)	O	O
25	,	O	O
26	open	O	O
27	-	O	O
28	label	O	O
29	,	O	O
30	gemfibrozil	S-Chemical	S-Chemical
31	-	O	O
32	lovastatin	S-Chemical	S-Chemical
33	treatment	O	O
34	in	O	O
35	80	O	O
36	patients	O	O
37	with	O	O
38	primary	O	O
39	mixed	O	O
40	hyperlipidemia	S-Disease	S-Disease
41	(	O	O
42	68	O	O
43	%	O	O
44	of	O	O
45	whom	O	O
46	had	O	O
47	atherosclerotic	B-Disease	B-Disease
48	vascular	I-Disease	I-Disease
49	disease	E-Disease	E-Disease
50	)	O	O
51	.	O	O

0	Because	O	O
1	ideal	O	O
2	lipid	O	S-Disease
3	targets	O	O
4	were	O	O
5	not	O	O
6	reached	O	O
7	(	O	O
8	low	O	O
9	-	O	O
10	density	O	O
11	lipoprotein	O	S-Disease
12	(	O	O
13	LDL	O	S-Disease
14	)	O	O
15	cholesterol	S-Chemical	S-Chemical
16	less	O	O
17	than	O	O
18	130	O	O
19	mg	O	O
20	/	O	O
21	dl	O	O
22	,	O	O
23	high	O	O
24	-	O	O
25	density	O	O
26	lipoprotein	O	S-Chemical
27	(	O	O
28	HDL	O	S-Disease
29	)	O	O
30	cholesterol	S-Chemical	S-Chemical
31	greater	O	O
32	than	O	O
33	35	O	O
34	mg	O	O
35	/	O	O
36	dl	O	O
37	,	O	O
38	or	O	O
39	total	O	O
40	cholesterol	S-Chemical	S-Chemical
41	/	O	O
42	HDL	O	S-Disease
43	cholesterol	S-Chemical	S-Disease
44	less	O	O
45	than	O	O
46	4	O	O
47	.	O	O
48	5	O	O
49	mg	O	O
50	/	O	O
51	dl	O	O
52	)	O	O
53	with	O	O
54	diet	O	O
55	plus	O	O
56	a	O	O
57	single	O	O
58	drug	O	O
59	,	O	O
60	gemfibrozil	S-Chemical	S-Chemical
61	(	O	O
62	1	O	O
63	.	O	O
64	2	O	O
65	g	O	O
66	/	O	O
67	day	O	O
68	)	O	O
69	-	O	O
70	lovastatin	S-Chemical	S-Chemical
71	(	O	O
72	primarily	O	O
73	20	O	O
74	or	O	O
75	40	O	O
76	mg	O	O
77	)	O	O
78	treatment	O	O
79	was	O	O
80	given	O	O
81	.	O	O

0	Follow	O	O
1	-	O	O
2	up	O	O
3	visits	O	O
4	were	O	O
5	scheduled	O	O
6	with	O	O
7	2	O	O
8	-	O	O
9	drug	O	O
10	therapy	O	O
11	every	O	O
12	6	O	O
13	to	O	O
14	8	O	O
15	weeks	O	O
16	,	O	O
17	an	O	O
18	average	O	O
19	of	O	O
20	10	O	O
21	.	O	O
22	3	O	O
23	visits	O	O
24	per	O	O
25	patient	O	O
26	,	O	O
27	with	O	O
28	741	O	O
29	batteries	O	O
30	of	O	O
31	6	O	O
32	liver	O	O
33	function	O	E-Disease
34	tests	O	O
35	and	O	O
36	714	O	O
37	creatine	S-Chemical	S-Chemical
38	phosphokinase	O	O
39	levels	O	O
40	measured	O	O
41	.	O	O

0	Of	O	O
1	the	O	O
2	714	O	O
3	creatine	S-Chemical	S-Chemical
4	phosphokinase	O	O
5	levels	O	O
6	,	O	O
7	9	O	O
8	%	O	O
9	were	O	O
10	high	O	O
11	;	O	O
12	only	O	O
13	1	O	O
14	(	O	O
15	0	O	O
16	.	O	O
17	1	O	O
18	%	O	O
19	)	O	O
20	was	O	O
21	greater	O	O
22	than	O	O
23	or	O	O
24	equal	O	O
25	to	O	O
26	3	O	O
27	times	O	O
28	the	O	O
29	upper	O	O
30	normal	O	O
31	limit	O	O
32	.	O	O

0	With	O	O
1	2	O	O
2	-	O	O
3	drug	O	O
4	therapy	O	O
5	,	O	O
6	mean	O	O
7	total	O	O
8	cholesterol	S-Chemical	S-Chemical
9	decreased	O	O
10	22	O	O
11	%	O	O
12	from	O	O
13	255	O	O
14	to	O	O
15	200	O	O
16	mg	O	O
17	/	O	O
18	dl	O	O
19	,	O	O
20	triglyceride	S-Chemical	S-Chemical
21	levels	O	O
22	decreased	O	O
23	35	O	O
24	%	O	O
25	from	O	O
26	236	O	O
27	to	O	O
28	154	O	O
29	mg	O	O
30	/	O	O
31	dl	O	O
32	,	O	O
33	LDL	O	S-Disease
34	cholesterol	S-Chemical	S-Chemical
35	decreased	O	O
36	26	O	O
37	%	O	O
38	from	O	O
39	176	O	O
40	to	O	O
41	131	O	O
42	mg	O	O
43	/	O	O
44	dl	O	O
45	,	O	O
46	and	O	O
47	the	O	O
48	total	O	O
49	cholesterol	S-Chemical	S-Chemical
50	/	O	O
51	HDL	O	S-Disease
52	cholesterol	S-Chemical	E-Chemical
53	ratio	O	O
54	decreased	O	O
55	24	O	O
56	%	O	O
57	from	O	O
58	7	O	O
59	.	O	O
60	1	O	O
61	to	O	O
62	5	O	O
63	.	O	O
64	4	O	O
65	,	O	O
66	all	O	O
67	p	O	O
68	less	O	O
69	than	O	O
70	or	O	O
71	equal	O	O
72	to	O	O
73	0	O	O
74	.	O	O
75	0001	O	O
76	.	O	O

0	Myositis	S-Disease	S-Chemical
1	,	O	O
2	attributable	O	O
3	to	O	O
4	the	O	O
5	drug	O	O
6	combination	O	O
7	and	O	O
8	symptomatic	O	O
9	enough	O	O
10	to	O	O
11	discontinue	O	O
12	it	O	O
13	,	O	O
14	occurred	O	O
15	in	O	O
16	3	O	O
17	%	O	O
18	of	O	O
19	patients	O	O
20	,	O	O
21	and	O	O
22	in	O	O
23	1	O	O
24	%	O	O
25	with	O	O
26	concurrent	O	O
27	high	O	O
28	creatine	S-Chemical	S-Chemical
29	phosphokinase	O	O
30	(	O	O
31	769	O	O
32	U	O	O
33	/	O	O
34	liter	O	O
35	)	O	O
36	;	O	O
37	no	O	O
38	patients	O	O
39	had	O	O
40	rhabdomyolysis	S-Disease	O
41	or	O	O
42	myoglobinuria	S-Disease	S-Disease
43	.	O	O
44	(	O	O
45	ABSTRACT	O	S-Disease
46	TRUNCATED	O	O
47	AT	O	O
48	250	O	O
49	WORDS	O	S-Disease
50	)	O	O

0	Does	O	O
1	domperidone	S-Chemical	S-Chemical
2	potentiate	O	O
3	mirtazapine	S-Chemical	S-Chemical
4	-	O	O
5	associated	O	O
6	restless	B-Disease	B-Disease
7	legs	I-Disease	I-Disease
8	syndrome	E-Disease	E-Disease
9	?	O	O

0	There	O	O
1	is	O	O
2	now	O	O
3	evidence	O	O
4	to	O	O
5	suggest	O	O
6	a	O	O
7	central	O	O
8	role	O	O
9	for	O	O
10	the	O	O
11	dopaminergic	O	O
12	system	O	O
13	in	O	O
14	restless	B-Disease	B-Disease
15	legs	I-Disease	I-Disease
16	syndrome	E-Disease	E-Disease
17	(	O	O
18	RLS	S-Disease	S-Disease
19	)	O	O
20	.	O	O

0	For	O	O
1	example	O	O
2	,	O	O
3	the	O	O
4	symptoms	O	O
5	of	O	O
6	RLS	S-Disease	S-Disease
7	can	O	O
8	be	O	O
9	dramatically	O	O
10	improved	O	O
11	by	O	O
12	levodopa	S-Chemical	S-Chemical
13	and	O	O
14	dopamine	S-Chemical	O
15	agonists	O	O
16	,	O	O
17	whereas	O	O
18	central	O	O
19	dopamine	S-Chemical	I-Disease
20	D2	O	I-Disease
21	receptor	O	O
22	antagonists	O	O
23	can	O	O
24	induce	O	O
25	or	O	O
26	aggravate	O	O
27	RLS	S-Disease	S-Disease
28	symptoms	O	O
29	.	O	O

0	To	O	O
1	our	O	O
2	knowledge	O	O
3	,	O	O
4	there	O	O
5	is	O	O
6	no	O	O
7	previous	O	O
8	report	O	O
9	regarding	O	O
10	whether	O	O
11	domperidone	S-Chemical	S-Chemical
12	,	O	O
13	a	O	O
14	peripheral	O	O
15	dopamine	S-Chemical	I-Disease
16	D2	O	I-Disease
17	receptor	O	O
18	antagonist	O	O
19	,	O	O
20	can	O	O
21	also	O	O
22	induce	O	O
23	or	O	O
24	aggravate	O	O
25	symptoms	O	O
26	of	O	O
27	RLS	S-Disease	S-Disease
28	.	O	O

0	Mirtazapine	S-Chemical	B-Chemical
1	,	O	O
2	the	O	O
3	first	O	O
4	noradrenergic	O	S-Disease
5	and	O	O
6	specific	O	O
7	serotonergic	O	S-Disease
8	antidepressant	O	O
9	(	O	O
10	NaSSA	O	S-Chemical
11	)	O	O
12	,	O	O
13	has	O	O
14	been	O	O
15	associated	O	O
16	with	O	O
17	RLS	S-Disease	S-Disease
18	in	O	O
19	several	O	O
20	recent	O	O
21	publications	O	O
22	.	O	O

0	The	O	O
1	authors	O	O
2	report	O	O
3	here	O	O
4	a	O	O
5	depressed	O	O
6	patient	O	O
7	comorbid	O	O
8	with	O	O
9	postprandial	B-Disease	O
10	dyspepsia	E-Disease	S-Disease
11	who	O	O
12	developed	O	O
13	RLS	S-Disease	S-Disease
14	after	O	O
15	mirtazapine	S-Chemical	S-Chemical
16	had	O	O
17	been	O	O
18	added	O	O
19	to	O	O
20	his	O	O
21	domperidone	S-Chemical	S-Chemical
22	therapy	O	O
23	.	O	O

0	Our	O	O
1	patient	O	O
2	started	O	O
3	to	O	O
4	have	O	O
5	symptoms	O	O
6	of	O	O
7	RLS	S-Disease	S-Disease
8	only	O	O
9	after	O	O
10	he	O	O
11	had	O	O
12	been	O	O
13	treated	O	O
14	with	O	O
15	mirtazapine	S-Chemical	S-Chemical
16	,	O	O
17	and	O	O
18	his	O	O
19	RLS	S-Disease	S-Disease
20	symptoms	O	O
21	resolved	O	O
22	completely	O	O
23	upon	O	O
24	discontinuation	O	O
25	of	O	O
26	his	O	O
27	mirtazapine	S-Chemical	S-Chemical
28	.	O	O

0	Such	O	O
1	a	O	O
2	temporal	O	O
3	relationship	O	O
4	between	O	O
5	the	O	O
6	use	O	O
7	of	O	O
8	mirtazapine	S-Chemical	S-Chemical
9	and	O	O
10	the	O	O
11	symptoms	O	O
12	of	O	O
13	RLS	S-Disease	S-Disease
14	in	O	O
15	our	O	O
16	patient	O	O
17	did	O	O
18	not	O	O
19	support	O	O
20	a	O	O
21	potentiating	O	O
22	effect	O	O
23	of	O	O
24	domperione	S-Chemical	S-Chemical
25	on	O	O
26	mirtazapine	S-Chemical	S-Chemical
27	-	O	O
28	associated	O	O
29	RLS	S-Disease	S-Disease
30	.	O	O

0	However	O	O
1	,	O	O
2	physicians	O	O
3	should	O	O
4	be	O	O
5	aware	O	O
6	of	O	O
7	the	O	O
8	possibility	O	O
9	that	O	O
10	mirtazapine	S-Chemical	S-Chemical
11	can	O	O
12	be	O	O
13	associated	O	O
14	with	O	O
15	RLS	S-Disease	S-Disease
16	in	O	O
17	some	O	O
18	individuals	O	O
19	,	O	O
20	especially	O	O
21	those	O	O
22	receiving	O	O
23	concomitant	O	O
24	dopamine	S-Chemical	B-Disease
25	D2	O	E-Chemical
26	receptor	O	O
27	antagonists	O	O
28	.	O	O

0	Antiandrogenic	O	O
1	therapy	O	O
2	can	O	O
3	cause	O	O
4	coronary	B-Disease	B-Disease
5	arterial	I-Disease	I-Disease
6	disease	E-Disease	E-Disease
7	.	O	O

0	AIM	O	O
1	:	O	O
2	To	O	O
3	study	O	O
4	the	O	O
5	change	O	O
6	of	O	O
7	lipid	O	S-Chemical
8	metabolism	O	E-Disease
9	by	O	O
10	antiandrogen	O	O
11	therapy	O	O
12	in	O	O
13	patients	O	O
14	with	O	O
15	prostate	B-Disease	B-Disease
16	cancer	E-Disease	E-Disease
17	.	O	O

0	MATERIALS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	We	O	O
5	studied	O	O
6	with	O	O
7	a	O	O
8	2	O	O
9	.	O	O
10	5	O	O
11	years	O	O
12	follow	O	O
13	-	O	O
14	up	O	O
15	the	O	O
16	changes	O	O
17	in	O	O
18	plasma	O	O
19	cholesterols	S-Chemical	S-Chemical
20	(	O	O
21	C	S-Chemical	O
22	)	O	O
23	,	O	O
24	triglycerides	S-Chemical	S-Disease
25	(	O	O
26	TG	S-Chemical	O
27	)	O	O
28	,	O	O
29	lipoproteins	O	S-Chemical
30	(	O	O
31	LP	O	O
32	)	O	O
33	,	O	O
34	and	O	O
35	apolipoproteins	O	O
36	(	O	O
37	Apo	O	S-Chemical
38	)	O	O
39	B	O	O
40	-	O	O
41	100	O	O
42	,	O	O
43	A	O	O
44	-	O	O
45	I	O	O
46	,	O	O
47	and	O	O
48	A	O	S-Disease
49	-	O	O
50	II	O	O
51	pro	O	O
52	fi	O	S-Disease
53	les	O	O
54	in	O	O
55	24	O	O
56	patients	O	O
57	of	O	O
58	mean	O	O
59	age	O	O
60	60	O	O
61	years	O	O
62	with	O	O
63	low	O	O
64	risk	O	O
65	prostate	B-Disease	B-Disease
66	cancer	E-Disease	E-Disease
67	(	O	O
68	stage	O	O
69	:	O	O
70	T1cN0M0	O	S-Disease
71	,	O	O
72	Gleason	O	S-Chemical
73	score	O	O
74	:	O	O
75	2	O	O
76	-	O	O
77	5	O	O
78	)	O	O
79	during	O	O
80	treatment	O	O
81	with	O	O
82	cyproterone	B-Chemical	B-Chemical
83	acetate	E-Chemical	E-Chemical
84	(	O	O
85	CPA	S-Chemical	S-Disease
86	)	O	O
87	without	O	O
88	surgical	O	O
89	management	O	O
90	or	O	O
91	radiation	O	S-Disease
92	therapy	O	O
93	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Significant	O	O
3	decreases	O	O
4	of	O	O
5	HDL	O	S-Chemical
6	-	O	E-Chemical
7	C	O	E-Chemical
8	,	O	O
9	Apo	O	B-Chemical
10	A	O	E-Chemical
11	-	O	I-Chemical
12	I	O	O
13	and	O	O
14	Apo	O	B-Chemical
15	A	O	E-Chemical
16	-	O	I-Chemical
17	II	O	O
18	and	O	O
19	an	O	O
20	increase	O	O
21	of	O	O
22	triglyceride	S-Chemical	S-Chemical
23	levels	O	O
24	in	O	O
25	VLDL	O	S-Chemical
26	were	O	O
27	induced	O	O
28	by	O	O
29	CPA	S-Chemical	S-Chemical
30	.	O	O

0	After	O	O
1	a	O	O
2	period	O	O
3	of	O	O
4	2	O	O
5	.	O	O
6	5	O	O
7	years	O	O
8	on	O	O
9	CPA	S-Chemical	S-Chemical
10	treatment	O	O
11	,	O	O
12	four	O	O
13	patients	O	O
14	out	O	O
15	of	O	O
16	twenty	O	O
17	-	O	O
18	four	O	O
19	were	O	O
20	found	O	O
21	to	O	O
22	be	O	O
23	affected	O	O
24	by	O	O
25	coronary	B-Disease	B-Disease
26	heart	I-Disease	I-Disease
27	disease	E-Disease	E-Disease
28	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Ischaemic	O	O
3	coronary	B-Disease	B-Disease
4	arteriosclerosis	E-Disease	E-Disease
5	with	O	O
6	an	O	O
7	incidence	O	O
8	rate	O	O
9	of	O	O
10	16	O	O
11	.	O	O
12	6	O	O
13	%	O	O
14	as	O	O
15	caused	O	O
16	by	O	O
17	prolonged	O	O
18	CPA	S-Chemical	S-Chemical
19	therapy	O	O
20	is	O	O
21	mediated	O	O
22	through	O	O
23	changes	O	O
24	in	O	O
25	HDL	O	B-Chemical
26	cholesterol	S-Chemical	E-Chemical
27	,	O	O
28	Apo	O	B-Chemical
29	A	O	E-Chemical
30	-	O	O
31	I	O	O
32	and	O	O
33	Apo	O	B-Chemical
34	A	O	E-Chemical
35	-	O	O
36	II	O	O
37	pro	O	O
38	fi	O	S-Disease
39	les	O	O
40	,	O	O
41	other	O	O
42	than	O	O
43	the	O	O
44	well	O	O
45	-	O	O
46	known	O	O
47	hyperglyceridemic	B-Disease	S-Disease
48	effect	E-Disease	O
49	caused	O	O
50	by	O	O
51	estrogen	S-Chemical	S-Chemical
52	.	O	O

0	5	B-Chemical	O
1	-	I-Chemical	O
2	Fluorouracil	E-Chemical	S-Chemical
3	cardiotoxicity	S-Disease	S-Disease
4	induced	O	O
5	by	O	O
6	alpha	B-Chemical	B-Chemical
7	-	I-Chemical	I-Chemical
8	fluoro	I-Chemical	E-Chemical
9	-	I-Chemical	I-Chemical
10	beta	I-Chemical	I-Disease
11	-	I-Chemical	I-Chemical
12	alanine	E-Chemical	E-Chemical
13	.	O	O

0	Cardiotoxicity	S-Disease	S-Disease
1	is	O	O
2	a	O	O
3	rare	O	O
4	complication	O	O
5	occurring	O	O
6	during	O	O
7	5	B-Chemical	B-Chemical
8	-	I-Chemical	I-Chemical
9	fluorouracil	E-Chemical	S-Chemical
10	(	O	O
11	5	B-Chemical	O
12	-	I-Chemical	O
13	FU	E-Chemical	O
14	)	O	O
15	treatment	O	O
16	for	O	O
17	malignancies	S-Disease	S-Disease
18	.	O	O

0	We	O	O
1	herein	O	O
2	report	O	O
3	the	O	O
4	case	O	O
5	of	O	O
6	a	O	O
7	70	O	O
8	-	O	O
9	year	O	O
10	-	O	O
11	old	O	O
12	man	O	O
13	with	O	O
14	5	B-Chemical	O
15	-	I-Chemical	O
16	FU	E-Chemical	O
17	-	O	O
18	induced	O	O
19	cardiotoxicity	S-Disease	S-Disease
20	,	O	O
21	in	O	O
22	whom	O	O
23	a	O	O
24	high	O	O
25	serum	O	O
26	level	O	O
27	of	O	O
28	alpha	B-Chemical	B-Chemical
29	-	I-Chemical	I-Chemical
30	fluoro	I-Chemical	B-Chemical
31	-	I-Chemical	I-Chemical
32	beta	I-Chemical	I-Disease
33	-	I-Chemical	I-Chemical
34	alanine	E-Chemical	E-Chemical
35	(	O	O
36	FBAL	S-Chemical	S-Chemical
37	)	O	O
38	was	O	O
39	observed	O	O
40	.	O	O

0	The	O	O
1	patient	O	O
2	,	O	O
3	who	O	O
4	had	O	O
5	unresectable	O	O
6	colon	B-Disease	B-Disease
7	cancer	E-Disease	E-Disease
8	metastases	O	O
9	to	O	O
10	the	O	O
11	liver	O	O
12	and	O	O
13	lung	O	O
14	,	O	O
15	was	O	O
16	referred	O	O
17	to	O	O
18	us	O	O
19	for	O	O
20	chemotherapy	O	O
21	from	O	O
22	an	O	O
23	affiliated	O	O
24	hospital	O	O
25	;	O	O
26	he	O	O
27	had	O	O
28	no	O	O
29	cardiac	O	B-Disease
30	history	O	O
31	.	O	O

0	After	O	O
1	admission	O	O
2	,	O	O
3	the	O	O
4	patient	O	O
5	received	O	O
6	a	O	O
7	continuous	O	O
8	intravenous	O	O
9	infusion	O	O
10	of	O	O
11	5	B-Chemical	O
12	-	I-Chemical	O
13	FU	E-Chemical	O
14	(	O	O
15	1000	O	O
16	mg	O	O
17	/	O	O
18	day	O	O
19	)	O	O
20	,	O	O
21	during	O	O
22	which	O	O
23	precordial	B-Disease	O
24	pain	E-Disease	S-Disease
25	with	O	O
26	right	B-Disease	O
27	bundle	I-Disease	O
28	branch	I-Disease	O
29	block	E-Disease	O
30	occurred	O	O
31	concomitantly	O	O
32	with	O	O
33	a	O	O
34	high	O	O
35	serum	O	O
36	FBAL	S-Chemical	S-Chemical
37	concentration	O	O
38	of	O	O
39	1955	O	O
40	ng	O	O
41	/	O	O
42	ml	O	O
43	.	O	O

0	Both	O	O
1	the	O	O
2	precordial	B-Disease	O
3	pain	E-Disease	S-Disease
4	and	O	O
5	the	O	O
6	electrocardiographic	O	O
7	changes	O	O
8	disappeared	O	O
9	spontaneously	O	O
10	after	O	O
11	the	O	O
12	discontinuation	O	O
13	of	O	O
14	5	B-Chemical	S-Disease
15	-	I-Chemical	O
16	FU	E-Chemical	S-Disease
17	.	O	O

0	As	O	O
1	the	O	O
2	precordial	B-Disease	O
3	pain	E-Disease	S-Disease
4	in	O	O
5	this	O	O
6	patient	O	O
7	was	O	O
8	considered	O	O
9	to	O	O
10	have	O	O
11	been	O	O
12	due	O	O
13	to	O	O
14	5	B-Chemical	O
15	-	I-Chemical	O
16	FU	E-Chemical	O
17	-	O	O
18	induced	O	O
19	cardiotoxicity	S-Disease	S-Disease
20	,	O	O
21	the	O	O
22	administration	O	O
23	of	O	O
24	5	B-Chemical	O
25	-	I-Chemical	O
26	FU	E-Chemical	S-Disease
27	was	O	O
28	abandoned	O	O
29	.	O	O

0	Instead	O	O
1	,	O	O
2	oral	O	O
3	administration	O	O
4	of	O	O
5	S	O	B-Chemical
6	-	O	E-Chemical
7	1	O	E-Chemical
8	(	O	O
9	a	O	O
10	derivative	O	O
11	of	O	O
12	5	B-Chemical	O
13	-	I-Chemical	O
14	FU	E-Chemical	O
15	)	O	O
16	,	O	O
17	at	O	O
18	200	O	O
19	mg	O	O
20	/	O	O
21	day	O	O
22	twice	O	O
23	a	O	O
24	week	O	O
25	,	O	O
26	was	O	O
27	instituted	O	O
28	,	O	O
29	because	O	O
30	S	O	B-Chemical
31	-	O	E-Chemical
32	1	O	O
33	has	O	O
34	a	O	O
35	strong	O	O
36	inhibitory	O	O
37	effect	O	O
38	on	O	O
39	dihydropyrimidine	S-Chemical	S-Chemical
40	dehydrogenase	O	O
41	,	O	O
42	which	O	O
43	catalyzes	O	O
44	the	O	O
45	degradative	O	O
46	of	O	O
47	5	B-Chemical	B-Chemical
48	-	I-Chemical	O
49	FU	E-Chemical	E-Chemical
50	into	O	O
51	FBAL	S-Chemical	S-Chemical
52	.	O	O

0	The	O	O
1	serum	O	O
2	FBAL	S-Chemical	S-Chemical
3	concentration	O	O
4	subsequently	O	O
5	decreased	O	O
6	to	O	O
7	352	O	O
8	ng	O	O
9	/	O	O
10	ml	O	O
11	,	O	O
12	the	O	O
13	same	O	O
14	as	O	O
15	the	O	O
16	value	O	O
17	measured	O	O
18	on	O	O
19	the	O	O
20	first	O	O
21	day	O	O
22	of	O	O
23	S	O	B-Chemical
24	-	O	O
25	1	O	O
26	administration	O	O
27	.	O	O

0	Thereafter	O	O
1	,	O	O
2	no	O	O
3	cardiac	B-Disease	S-Disease
4	symptoms	E-Disease	O
5	were	O	O
6	observed	O	O
7	.	O	O

0	The	O	O
1	experience	O	O
2	of	O	O
3	this	O	O
4	case	O	O
5	,	O	O
6	together	O	O
7	with	O	O
8	a	O	O
9	review	O	O
10	of	O	O
11	the	O	O
12	literature	O	O
13	,	O	O
14	suggests	O	O
15	that	O	O
16	FBAL	S-Chemical	S-Chemical
17	is	O	O
18	related	O	O
19	to	O	O
20	5	B-Chemical	O
21	-	I-Chemical	O
22	FU	E-Chemical	S-Disease
23	-	O	O
24	induced	O	O
25	cardiotoxicity	S-Disease	S-Disease
26	.	O	O

0	S	O	B-Chemical
1	-	O	I-Chemical
2	1	O	E-Chemical
3	may	O	O
4	be	O	O
5	administered	O	O
6	safely	O	O
7	to	O	O
8	patients	O	O
9	with	O	O
10	5	B-Chemical	O
11	-	I-Chemical	O
12	FU	E-Chemical	S-Disease
13	-	O	O
14	induced	O	O
15	cardiotoxicity	S-Disease	S-Disease
16	.	O	O

0	Hepatocellular	B-Disease	O
1	carcinoma	E-Disease	E-Chemical
2	in	O	O
3	Fanconi	B-Disease	B-Chemical
4	'	I-Disease	E-Chemical
5	s	I-Disease	O
6	anemia	E-Disease	O
7	treated	O	O
8	with	O	O
9	androgen	S-Chemical	S-Chemical
10	and	O	O
11	corticosteroid	S-Chemical	S-Chemical
12	.	O	O

0	The	O	O
1	case	O	O
2	of	O	O
3	an	O	O
4	11	O	O
5	-	O	O
6	year	O	O
7	-	O	O
8	old	O	O
9	boy	O	O
10	is	O	O
11	reported	O	O
12	who	O	O
13	was	O	O
14	known	O	O
15	to	O	O
16	have	O	O
17	Fanconi	B-Disease	B-Chemical
18	'	I-Disease	I-Disease
19	s	I-Disease	O
20	anemia	E-Disease	E-Disease
21	for	O	O
22	3	O	O
23	years	O	O
24	and	O	O
25	was	O	O
26	treated	O	O
27	with	O	O
28	androgens	S-Chemical	S-Disease
29	,	O	O
30	corticosteroids	S-Chemical	S-Chemical
31	and	O	O
32	transfusions	O	O
33	.	O	O

0	Two	O	O
1	weeks	O	O
2	before	O	O
3	his	O	O
4	death	O	O
5	he	O	O
6	was	O	O
7	readmitted	O	O
8	because	O	O
9	of	O	O
10	aplastic	O	O
11	crisis	O	E-Disease
12	with	O	O
13	septicemia	S-Disease	S-Disease
14	and	O	O
15	marked	O	O
16	abnormalities	O	O
17	in	O	O
18	liver	O	B-Disease
19	function	O	E-Disease
20	and	O	O
21	died	O	O
22	of	O	O
23	hemorrhagic	B-Disease	O
24	bronchopneumonia	E-Disease	S-Disease
25	.	O	O

0	At	O	O
1	autopsy	O	O
2	peliosis	S-Disease	O
3	and	O	O
4	multiple	O	O
5	hepatic	B-Disease	S-Disease
6	tumors	E-Disease	S-Disease
7	were	O	O
8	found	O	O
9	which	O	O
10	histologically	O	O
11	proved	O	O
12	to	O	O
13	be	O	O
14	well	O	O
15	-	O	O
16	differentiated	O	O
17	hepatocellular	B-Disease	B-Disease
18	carcinoma	E-Disease	E-Disease
19	.	O	O

0	This	O	O
1	case	O	O
2	contributes	O	O
3	to	O	O
4	the	O	O
5	previous	O	O
6	observations	O	O
7	that	O	O
8	non	O	O
9	-	O	O
10	metastasizing	O	O
11	hepatic	B-Disease	S-Disease
12	neoplasms	E-Disease	S-Disease
13	and	O	O
14	peliosis	S-Disease	S-Disease
15	can	O	O
16	develop	O	O
17	in	O	O
18	patients	O	O
19	with	O	O
20	androgen	S-Chemical	S-Chemical
21	-	O	O
22	and	O	O
23	corticosteroid	S-Chemical	S-Chemical
24	-	O	O
25	treated	O	O
26	Fanconi	B-Disease	B-Chemical
27	'	I-Disease	I-Disease
28	s	I-Disease	I-Disease
29	anemia	E-Disease	S-Disease
30	.	O	O

0	The	O	O
1	influence	O	O
2	of	O	O
3	the	O	O
4	time	O	O
5	interval	O	O
6	between	O	O
7	monoHER	S-Chemical	S-Chemical
8	and	O	O
9	doxorubicin	S-Chemical	S-Chemical
10	administration	O	O
11	on	O	O
12	the	O	O
13	protection	O	O
14	against	O	O
15	doxorubicin	S-Chemical	S-Chemical
16	-	O	O
17	induced	O	O
18	cardiotoxicity	S-Disease	S-Disease
19	in	O	O
20	mice	O	O
21	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	Despite	O	O
3	its	O	O
4	well	O	O
5	-	O	O
6	known	O	O
7	cardiotoxicity	S-Disease	S-Disease
8	,	O	O
9	the	O	O
10	anthracyclin	O	S-Chemical
11	doxorubicin	S-Chemical	E-Chemical
12	(	O	O
13	DOX	S-Chemical	S-Chemical
14	)	O	O
15	continues	O	O
16	to	O	O
17	be	O	O
18	an	O	O
19	effective	O	O
20	and	O	O
21	widely	O	O
22	used	O	O
23	chemotherapeutic	O	O
24	agent	O	O
25	.	O	O

0	DOX	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	cardiac	B-Disease	B-Disease
4	damage	E-Disease	E-Disease
5	presumably	O	O
6	results	O	O
7	from	O	O
8	the	O	O
9	formation	O	O
10	of	O	O
11	free	O	O
12	radicals	O	O
13	by	O	O
14	DOX	S-Chemical	S-Chemical
15	.	O	O

0	Reactive	O	O
1	oxygen	S-Chemical	O
2	species	O	O
3	particularly	O	O
4	affect	O	O
5	the	O	O
6	cardiac	O	B-Disease
7	myocytes	O	E-Disease
8	because	O	O
9	these	O	O
10	cells	O	O
11	seem	O	O
12	to	O	O
13	have	O	O
14	a	O	O
15	relatively	O	O
16	poor	O	O
17	antioxidant	O	O
18	defense	O	O
19	system	O	O
20	.	O	O

0	The	O	O
1	semisynthetic	O	O
2	flavonoid	S-Chemical	O
3	monohydroxyethylrutoside	S-Chemical	S-Disease
4	(	O	O
5	monoHER	S-Chemical	S-Chemical
6	)	O	O
7	showed	O	O
8	cardioprotection	O	O
9	against	O	O
10	DOX	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	cardiotoxicity	S-Disease	S-Disease
14	through	O	O
15	its	O	O
16	radical	O	O
17	scavenging	O	O
18	and	O	O
19	iron	S-Chemical	O
20	chelating	O	O
21	properties	O	O
22	.	O	O

0	Because	O	O
1	of	O	O
2	the	O	O
3	relatively	O	O
4	short	O	O
5	final	O	O
6	half	O	O
7	-	O	O
8	life	O	O
9	of	O	O
10	monoHER	S-Chemical	S-Disease
11	(	O	O
12	about	O	O
13	30	O	O
14	min	O	O
15	)	O	O
16	,	O	O
17	it	O	O
18	is	O	O
19	expected	O	O
20	that	O	O
21	the	O	O
22	time	O	O
23	interval	O	O
24	between	O	O
25	monoHER	S-Chemical	S-Disease
26	and	O	O
27	DOX	S-Chemical	S-Chemical
28	might	O	O
29	be	O	O
30	of	O	O
31	influence	O	O
32	on	O	O
33	the	O	O
34	cardioprotective	O	O
35	effect	O	O
36	of	O	O
37	monoHER	S-Chemical	S-Disease
38	.	O	O

0	METHODS	O	O
1	:	O	O
2	Six	O	O
3	groups	O	O
4	of	O	O
5	6	O	O
6	BALB	O	O
7	/	O	O
8	c	O	O
9	mice	O	O
10	were	O	O
11	treated	O	O
12	with	O	O
13	saline	O	S-Chemical
14	,	O	O
15	DOX	S-Chemical	S-Chemical
16	alone	O	O
17	or	O	O
18	DOX	S-Chemical	S-Chemical
19	(	O	O
20	4	O	O
21	mg	O	O
22	/	O	O
23	kg	O	O
24	i	O	O
25	.	O	O
26	v	O	O
27	.	O	O
28	)	O	O
29	preceded	O	O
30	by	O	O
31	monoHER	S-Chemical	O
32	(	O	O
33	500	O	O
34	mg	O	O
35	/	O	O
36	kg	O	O
37	i	O	O
38	.	O	O
39	p	O	O
40	.	O	O
41	)	O	O
42	with	O	O
43	an	O	O
44	interval	O	O
45	of	O	O
46	10	O	O
47	,	O	O
48	30	O	O
49	,	O	O
50	60	O	O
51	or	O	O
52	120	O	O
53	min	O	O
54	.	O	O

0	Their	O	O
1	cardiac	O	O
2	tissues	O	O
3	were	O	O
4	processed	O	O
5	for	O	O
6	light	O	O
7	microscopy	O	O
8	,	O	O
9	after	O	O
10	which	O	O
11	cardiomyocyte	B-Disease	B-Disease
12	damage	E-Disease	E-Disease
13	was	O	O
14	evaluated	O	O
15	according	O	O
16	to	O	O
17	Billingham	O	S-Chemical
18	(	O	O
19	in	O	O
20	Cancer	S-Disease	B-Disease
21	Treat	O	I-Disease
22	Rep	O	E-Disease
23	62	O	O
24	(	O	O
25	6	O	O
26	)	O	O
27	:	O	O
28	865	O	O
29	-	O	O
30	872	O	O
31	,	O	O
32	1978	O	O
33	)	O	O
34	.	O	O

0	Microscopic	O	O
1	evaluation	O	O
2	revealed	O	O
3	that	O	O
4	treatment	O	O
5	with	O	O
6	DOX	S-Chemical	S-Chemical
7	alone	O	O
8	induced	O	O
9	significant	O	O
10	cardiac	B-Disease	B-Disease
11	damage	E-Disease	E-Disease
12	in	O	O
13	comparison	O	O
14	to	O	O
15	the	O	O
16	saline	O	S-Chemical
17	control	O	O
18	group	O	O
19	(	O	O
20	P	O	S-Chemical
21	<	O	O
22	0	O	O
23	.	O	O
24	001	O	O
25	)	O	O
26	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	number	O	O
4	of	O	O
5	damaged	O	O
6	cardiomyocytes	O	S-Disease
7	was	O	O
8	9	O	O
9	.	O	O
10	6	O	O
11	-	O	O
12	fold	O	O
13	(	O	O
14	95	O	O
15	%	O	O
16	CI	O	S-Chemical
17	4	O	O
18	.	O	O
19	4	O	O
20	-	O	O
21	21	O	O
22	.	O	O
23	0	O	O
24	)	O	O
25	higher	O	O
26	in	O	O
27	mice	O	O
28	treated	O	O
29	with	O	O
30	DOX	S-Chemical	S-Chemical
31	alone	O	O
32	than	O	O
33	that	O	O
34	in	O	O
35	animals	O	O
36	of	O	O
37	the	O	O
38	control	O	O
39	group	O	O
40	.	O	O

0	The	O	O
1	ratio	O	O
2	of	O	O
3	aberrant	O	O
4	cardiomyocytes	O	O
5	in	O	O
6	mice	O	O
7	treated	O	O
8	with	O	O
9	DOX	S-Chemical	S-Chemical
10	preceded	O	O
11	by	O	O
12	monoHER	S-Chemical	S-Disease
13	and	O	O
14	those	O	O
15	in	O	O
16	mice	O	O
17	treated	O	O
18	with	O	O
19	saline	O	S-Chemical
20	ranged	O	O
21	from	O	O
22	1	O	O
23	.	O	O
24	6	O	O
25	to	O	O
26	2	O	O
27	.	O	O
28	8	O	O
29	(	O	O
30	mean	O	O
31	2	O	O
32	.	O	O
33	2	O	O
34	,	O	O
35	95	O	O
36	%	O	O
37	CI	O	S-Chemical
38	1	O	O
39	.	O	O
40	2	O	O
41	-	O	O
42	4	O	O
43	.	O	O
44	1	O	O
45	,	O	O
46	P	O	O
47	=	O	O
48	0	O	O
49	.	O	O
50	019	O	O
51	)	O	O
52	.	O	O

0	The	O	O
1	mean	O	O
2	protective	O	O
3	effect	O	O
4	by	O	O
5	adding	O	O
6	monoHER	S-Chemical	S-Chemical
7	before	O	O
8	DOX	S-Chemical	S-Chemical
9	led	O	O
10	to	O	O
11	a	O	O
12	significant	O	O
13	4	O	O
14	.	O	O
15	4	O	O
16	-	O	O
17	fold	O	O
18	reduction	O	O
19	(	O	O
20	P	O	S-Disease
21	<	O	O
22	0	O	O
23	.	O	O
24	001	O	O
25	,	O	O
26	95	O	O
27	%	O	O
28	CI	O	S-Chemical
29	2	O	O
30	.	O	O
31	3	O	O
32	-	O	O
33	8	O	O
34	.	O	O
35	2	O	O
36	)	O	O
37	of	O	O
38	abnormal	O	O
39	cardiomyocytes	O	S-Disease
40	.	O	O

0	This	O	O
1	protective	O	O
2	effect	O	O
3	did	O	O
4	not	O	O
5	depend	O	O
6	on	O	O
7	the	O	O
8	time	O	O
9	interval	O	O
10	between	O	O
11	monoHER	S-Chemical	S-Disease
12	and	O	O
13	DOX	S-Chemical	S-Chemical
14	administration	O	O
15	(	O	O
16	P	O	O
17	=	O	O
18	0	O	O
19	.	O	O
20	345	O	O
21	)	O	O
22	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	The	O	O
3	results	O	O
4	indicate	O	O
5	that	O	O
6	in	O	O
7	an	O	O
8	outpatient	O	O
9	clinical	O	O
10	setting	O	O
11	monoHER	S-Chemical	S-Disease
12	may	O	O
13	be	O	O
14	administered	O	O
15	shortly	O	O
16	before	O	O
17	DOX	S-Chemical	S-Chemical
18	.	O	O

0	Clinical	O	O
1	evaluation	O	O
2	of	O	O
3	adverse	O	O
4	effects	O	O
5	during	O	O
6	bepridil	S-Chemical	S-Chemical
7	administration	O	O
8	for	O	O
9	atrial	B-Disease	B-Disease
10	fibrillation	I-Disease	E-Disease
11	and	I-Disease	O
12	flutter	E-Disease	S-Disease
13	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Bepridil	B-Chemical	S-Chemical
3	hydrochloride	E-Chemical	E-Chemical
4	(	O	O
5	Bpd	S-Chemical	S-Chemical
6	)	O	O
7	has	O	O
8	attracted	O	O
9	attention	O	O
10	as	O	O
11	an	O	O
12	effective	O	O
13	drug	O	O
14	for	O	O
15	atrial	B-Disease	B-Disease
16	fibrillation	E-Disease	E-Disease
17	(	O	O
18	AF	S-Disease	S-Chemical
19	)	O	O
20	and	O	O
21	atrial	B-Disease	B-Disease
22	flutter	E-Disease	E-Disease
23	(	O	O
24	AFL	S-Disease	S-Chemical
25	)	O	O
26	.	O	O

0	However	O	O
1	,	O	O
2	serious	O	O
3	adverse	O	O
4	effects	O	O
5	,	O	O
6	including	O	O
7	torsade	B-Disease	B-Disease
8	de	I-Disease	I-Disease
9	pointes	E-Disease	E-Chemical
10	(	O	O
11	Tdp	S-Disease	S-Chemical
12	)	O	O
13	,	O	O
14	have	O	O
15	been	O	O
16	reported	O	O
17	.	O	O

0	METHODS	O	O
1	AND	O	O
2	RESULTS	O	O
3	:	O	O
4	Adverse	O	O
5	effects	O	O
6	of	O	O
7	Bpd	S-Chemical	S-Chemical
8	requiring	O	O
9	discontinuation	O	O
10	of	O	O
11	treatment	O	O
12	were	O	O
13	evaluated	O	O
14	.	O	O

0	Bpd	S-Chemical	O
1	was	O	O
2	administered	O	O
3	to	O	O
4	459	O	O
5	patients	O	O
6	(	O	O
7	361	O	O
8	males	O	O
9	,	O	O
10	63	O	O
11	+	O	O
12	/	O	O
13	-	O	O
14	12	O	O
15	years	O	O
16	old	O	O
17	)	O	O
18	comprising	O	O
19	378	O	O
20	AF	S-Disease	S-Chemical
21	and	O	O
22	81	O	O
23	AFL	S-Disease	S-Chemical
24	cases	O	O
25	.	O	O

0	There	O	O
1	was	O	O
2	marked	O	O
3	QT	B-Disease	O
4	prolongation	E-Disease	O
5	greater	O	O
6	than	O	O
7	0	O	O
8	.	O	O
9	55	O	O
10	s	O	O
11	in	O	O
12	13	O	O
13	patients	O	O
14	,	O	O
15	bradycardia	S-Disease	O
16	less	O	O
17	than	O	O
18	40	O	O
19	beats	O	O
20	/	O	O
21	min	O	O
22	in	O	O
23	6	O	O
24	patients	O	O
25	,	O	O
26	dizziness	S-Disease	O
27	and	O	O
28	general	O	O
29	fatigue	S-Disease	S-Disease
30	in	O	O
31	1	O	O
32	patient	O	O
33	each	O	O
34	.	O	O

0	In	O	O
1	4	O	O
2	of	O	O
3	13	O	O
4	patients	O	O
5	with	O	O
6	QT	B-Disease	O
7	prolongation	E-Disease	O
8	,	O	O
9	Tdp	S-Disease	S-Chemical
10	occurred	O	O
11	.	O	O

0	The	O	O
1	major	O	O
2	triggering	O	O
3	factors	O	O
4	of	O	O
5	Tdp	S-Disease	S-Chemical
6	were	O	O
7	hypokalemia	S-Disease	S-Disease
8	and	O	O
9	sudden	O	O
10	decrease	O	O
11	in	O	O
12	heart	O	B-Disease
13	rate	O	E-Disease
14	.	O	O

0	There	O	O
1	were	O	O
2	no	O	O
3	differences	O	O
4	in	O	O
5	the	O	O
6	clinical	O	O
7	backgrounds	O	O
8	of	O	O
9	the	O	O
10	patients	O	O
11	with	O	O
12	and	O	O
13	without	O	O
14	Tdp	S-Disease	S-Chemical
15	other	O	O
16	than	O	O
17	LAD	O	S-Disease
18	and	O	O
19	age	O	O
20	,	O	O
21	which	O	O
22	were	O	O
23	larger	O	O
24	and	O	O
25	older	O	O
26	in	O	O
27	the	O	O
28	patients	O	O
29	with	O	O
30	Tdp	S-Disease	S-Chemical
31	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Careful	O	O
3	observation	O	O
4	of	O	O
5	serum	O	O
6	potassium	S-Chemical	S-Disease
7	concentration	O	O
8	and	O	O
9	the	O	O
10	ECG	O	S-Disease
11	should	O	O
12	always	O	O
13	be	O	O
14	done	O	O
15	during	O	O
16	Bpd	S-Chemical	S-Chemical
17	administration	O	O
18	,	O	O
19	particularly	O	O
20	in	O	O
21	elderly	O	O
22	patients	O	O
23	.	O	O

0	Enhanced	O	O
1	isoproterenol	S-Chemical	S-Chemical
2	-	O	O
3	induced	O	O
4	cardiac	B-Disease	B-Disease
5	hypertrophy	E-Disease	E-Disease
6	in	O	O
7	transgenic	O	O
8	rats	O	O
9	with	O	O
10	low	O	O
11	brain	O	O
12	angiotensinogen	O	E-Disease
13	.	O	O

0	We	O	O
1	have	O	O
2	previously	O	O
3	shown	O	O
4	that	O	O
5	a	O	O
6	permanent	O	O
7	deficiency	O	S-Disease
8	in	O	O
9	the	O	O
10	brain	O	O
11	renin	O	E-Chemical
12	-	O	O
13	angiotensin	S-Chemical	O
14	system	O	O
15	(	O	O
16	RAS	O	S-Disease
17	)	O	O
18	may	O	O
19	increase	O	O
20	the	O	O
21	sensitivity	O	O
22	of	O	O
23	the	O	O
24	baroreflex	O	S-Disease
25	control	O	O
26	of	O	O
27	heart	O	B-Disease
28	rate	O	E-Disease
29	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	we	O	O
4	aimed	O	O
5	at	O	O
6	studying	O	O
7	the	O	O
8	involvement	O	O
9	of	O	O
10	the	O	O
11	brain	O	O
12	RAS	O	S-Disease
13	in	O	O
14	the	O	O
15	cardiac	O	B-Disease
16	reactivity	O	E-Disease
17	to	O	O
18	the	O	O
19	beta	O	O
20	-	O	O
21	adrenoceptor	O	E-Chemical
22	(	O	O
23	beta	O	O
24	-	O	O
25	AR	O	O
26	)	O	O
27	agonist	O	O
28	isoproterenol	S-Chemical	S-Disease
29	(	O	O
30	Iso	S-Chemical	S-Chemical
31	)	O	O
32	.	O	O

0	In	O	O
1	isolated	O	O
2	hearts	O	O
3	,	O	O
4	Iso	S-Chemical	S-Chemical
5	induced	O	O
6	a	O	O
7	significantly	O	O
8	greater	O	O
9	increase	O	O
10	in	O	O
11	left	O	O
12	ventricular	O	B-Disease
13	(	O	O
14	LV	O	O
15	)	O	O
16	pressure	O	O
17	and	O	O
18	maximal	O	O
19	contraction	O	O
20	(	O	O
21	+	O	O
22	dP	O	O
23	/	O	O
24	dt	O	O
25	(	O	O
26	max	O	O
27	)	O	O
28	)	O	O
29	in	O	O
30	the	O	O
31	TGR	O	S-Disease
32	than	O	O
33	in	O	O
34	the	O	O
35	Sprague	O	O
36	-	O	O
37	Dawley	O	O
38	(	O	O
39	SD	O	O
40	)	O	O
41	rats	O	O
42	.	O	O

0	LV	B-Disease	O
1	hypertrophy	E-Disease	S-Disease
2	induced	O	O
3	by	O	O
4	Iso	S-Chemical	S-Chemical
5	treatment	O	O
6	was	O	O
7	significantly	O	O
8	higher	O	O
9	in	O	O
10	TGR	O	S-Disease
11	than	O	O
12	in	O	O
13	SD	O	O
14	rats	O	O
15	(	O	O
16	in	O	O
17	g	O	O
18	LV	O	O
19	wt	O	O
20	/	O	O
21	100	O	O
22	g	O	O
23	body	O	O
24	wt	O	O
25	,	O	O
26	0	O	O
27	.	O	O
28	28	O	O
29	+	O	O
30	/	O	O
31	-	O	O
32	0	O	O
33	.	O	O
34	004	O	O
35	vs	O	O
36	.	O	O
37	0	O	O
38	.	O	O
39	24	O	O
40	+	O	O
41	/	O	O
42	-	O	O
43	0	O	O
44	.	O	O
45	004	O	O
46	,	O	O
47	respectively	O	O
48	)	O	O
49	.	O	O

0	The	O	O
1	greater	O	O
2	LV	B-Disease	O
3	hypertrophy	E-Disease	S-Disease
4	in	O	O
5	TGR	O	S-Disease
6	rats	O	O
7	was	O	O
8	associated	O	O
9	with	O	O
10	more	O	O
11	pronounced	O	O
12	downregulation	O	O
13	of	O	O
14	beta	O	S-Chemical
15	-	O	O
16	AR	O	S-Disease
17	and	O	O
18	upregulation	O	O
19	of	O	O
20	LV	O	B-Disease
21	beta	O	I-Disease
22	-	O	I-Disease
23	AR	O	I-Disease
24	kinase	O	E-Disease
25	-	O	O
26	1	O	O
27	mRNA	O	O
28	levels	O	O
29	compared	O	O
30	with	O	O
31	those	O	O
32	in	O	O
33	SD	O	O
34	rats	O	O
35	.	O	O

0	The	O	O
1	decrease	O	O
2	in	O	O
3	the	O	O
4	heart	O	O
5	rate	O	O
6	(	O	O
7	HR	O	O
8	)	O	O
9	induced	O	O
10	by	O	O
11	the	O	O
12	beta	O	O
13	-	O	O
14	AR	O	O
15	antagonist	O	O
16	metoprolol	S-Chemical	S-Chemical
17	in	O	O
18	conscious	O	O
19	rats	O	O
20	was	O	O
21	significantly	O	O
22	attenuated	O	O
23	in	O	O
24	TGR	O	S-Disease
25	compared	O	O
26	with	O	O
27	SD	O	O
28	rats	O	O
29	(	O	O
30	-	O	O
31	9	O	O
32	.	O	O
33	9	O	O
34	+	O	O
35	/	O	O
36	-	O	O
37	1	O	O
38	.	O	O
39	7	O	O
40	%	O	O
41	vs	O	O
42	.	O	O
43	-	O	O
44	18	O	O
45	.	O	O
46	1	O	O
47	+	O	O
48	/	O	O
49	-	O	O
50	1	O	O
51	.	O	O
52	5	O	O
53	%	O	O
54	)	O	O
55	,	O	O
56	whereas	O	O
57	the	O	O
58	effect	O	O
59	of	O	O
60	parasympathetic	O	O
61	blockade	O	O
62	by	O	O
63	atropine	S-Chemical	S-Chemical
64	on	O	O
65	HR	O	O
66	was	O	O
67	similar	O	O
68	in	O	O
69	both	O	O
70	strains	O	O
71	.	O	O

0	These	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	TGR	O	S-Chemical
5	are	O	O
6	more	O	O
7	sensitive	O	O
8	to	O	O
9	beta	O	O
10	-	O	O
11	AR	O	O
12	agonist	O	O
13	-	O	O
14	induced	O	O
15	cardiac	B-Disease	B-Disease
16	inotropic	E-Disease	E-Disease
17	response	O	O
18	and	O	O
19	hypertrophy	S-Disease	S-Disease
20	,	O	O
21	possibly	O	O
22	due	O	O
23	to	O	O
24	chronically	O	O
25	low	O	O
26	sympathetic	O	B-Disease
27	outflow	O	E-Disease
28	directed	O	O
29	to	O	O
30	the	O	O
31	heart	O	O
32	.	O	O

0	Drug	O	O
1	-	O	O
2	induced	O	O
3	long	B-Disease	O
4	QT	I-Disease	O
5	syndrome	E-Disease	O
6	in	O	O
7	injection	O	O
8	drug	O	O
9	users	O	O
10	receiving	O	O
11	methadone	S-Chemical	S-Chemical
12	:	O	O
13	high	O	O
14	frequency	O	O
15	in	O	O
16	hospitalized	O	O
17	patients	O	O
18	and	O	O
19	risk	O	O
20	factors	O	O
21	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Drug	O	O
3	-	O	O
4	induced	O	O
5	long	B-Disease	O
6	QT	I-Disease	I-Disease
7	syndrome	E-Disease	S-Disease
8	is	O	O
9	a	O	O
10	serious	O	O
11	adverse	O	O
12	drug	O	O
13	reaction	O	O
14	.	O	O

0	Methadone	S-Chemical	S-Chemical
1	prolongs	O	O
2	the	O	O
3	QT	O	O
4	interval	O	O
5	in	O	O
6	vitro	O	O
7	in	O	O
8	a	O	O
9	dose	O	O
10	-	O	O
11	dependent	O	O
12	manner	O	O
13	.	O	O

0	In	O	O
1	the	O	O
2	inpatient	O	O
3	setting	O	O
4	,	O	O
5	the	O	O
6	frequency	O	O
7	of	O	O
8	QT	B-Disease	O
9	interval	I-Disease	O
10	prolongation	E-Disease	O
11	with	O	O
12	methadone	S-Chemical	S-Chemical
13	treatment	O	O
14	,	O	O
15	its	O	O
16	dose	O	O
17	dependence	O	O
18	,	O	O
19	and	O	O
20	the	O	O
21	importance	O	O
22	of	O	O
23	cofactors	O	O
24	such	O	O
25	as	O	O
26	drug	O	O
27	-	O	O
28	drug	O	O
29	interactions	O	O
30	remain	O	O
31	unknown	O	O
32	.	O	O

0	METHODS	O	O
1	:	O	O
2	We	O	O
3	performed	O	O
4	a	O	O
5	systematic	O	O
6	,	O	O
7	retrospective	O	O
8	study	O	O
9	comparing	O	O
10	active	O	O
11	or	O	O
12	former	O	O
13	intravenous	O	O
14	drug	O	O
15	users	O	O
16	receiving	O	O
17	methadone	S-Chemical	S-Chemical
18	and	O	O
19	those	O	O
20	not	O	O
21	receiving	O	O
22	methadone	S-Chemical	S-Chemical
23	among	O	O
24	all	O	O
25	patients	O	O
26	hospitalized	O	O
27	over	O	O
28	a	O	O
29	5	O	O
30	-	O	O
31	year	O	O
32	period	O	O
33	in	O	O
34	a	O	O
35	tertiary	O	O
36	care	O	O
37	hospital	O	O
38	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	167	O	O
4	patients	O	O
5	receiving	O	O
6	methadone	S-Chemical	S-Chemical
7	fulfilled	O	O
8	the	O	O
9	inclusion	O	O
10	criteria	O	O
11	and	O	O
12	were	O	O
13	compared	O	O
14	with	O	O
15	a	O	O
16	control	O	O
17	group	O	O
18	of	O	O
19	80	O	O
20	injection	O	O
21	drug	O	O
22	users	O	O
23	not	O	O
24	receiving	O	O
25	methadone	S-Chemical	S-Chemical
26	.	O	O

0	In	O	O
1	addition	O	O
2	to	O	O
3	methadone	S-Chemical	S-Chemical
4	dose	O	O
5	,	O	O
6	15	O	O
7	demographic	O	O
8	,	O	O
9	biological	O	O
10	,	O	O
11	and	O	O
12	pharmacological	O	O
13	variables	O	O
14	were	O	O
15	considered	O	O
16	as	O	O
17	potential	O	O
18	risk	O	O
19	factors	O	O
20	for	O	O
21	QT	B-Disease	S-Disease
22	prolongation	E-Disease	O
23	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Among	O	O
3	167	O	O
4	methadone	S-Chemical	S-Chemical
5	maintenance	O	O
6	patients	O	O
7	,	O	O
8	the	O	O
9	prevalence	O	O
10	of	O	O
11	QTc	O	O
12	prolongation	O	O
13	to	O	O
14	0	O	O
15	.	O	O
16	50	O	O
17	second	O	O
18	(	O	O
19	(	O	O
20	1	O	O
21	/	O	O
22	2	O	O
23	)	O	O
24	)	O	O
25	or	O	O
26	longer	O	O
27	was	O	O
28	16	O	O
29	.	O	O
30	2	O	O
31	%	O	O
32	compared	O	O
33	with	O	O
34	0	O	O
35	%	O	O
36	in	O	O
37	80	O	O
38	control	O	O
39	subjects	O	O
40	.	O	O

0	Six	O	O
1	patients	O	O
2	(	O	O
3	3	O	O
4	.	O	O
5	6	O	O
6	%	O	O
7	)	O	O
8	in	O	O
9	the	O	O
10	methadone	S-Chemical	S-Chemical
11	group	O	O
12	presented	O	O
13	torsades	B-Disease	O
14	de	I-Disease	O
15	pointes	E-Disease	O
16	.	O	O

0	QTc	O	O
1	length	O	O
2	was	O	O
3	weakly	O	O
4	but	O	O
5	significantly	O	O
6	associated	O	O
7	with	O	O
8	methadone	S-Chemical	S-Chemical
9	daily	O	O
10	dose	O	O
11	(	O	O
12	Spearman	O	O
13	rank	O	O
14	correlation	O	O
15	coefficient	O	O
16	,	O	O
17	0	O	O
18	.	O	O
19	20	O	O
20	;	O	O
21	P	O	O
22	<	O	O
23	.	O	O
24	01	O	O
25	)	O	O
26	.	O	O

0	Multivariate	O	O
1	regression	O	O
2	analysis	O	O
3	allowed	O	O
4	attribution	O	O
5	of	O	O
6	31	O	O
7	.	O	O
8	8	O	O
9	%	O	O
10	of	O	O
11	QTc	O	O
12	variability	O	O
13	to	O	O
14	methadone	S-Chemical	S-Chemical
15	dose	O	O
16	,	O	O
17	cytochrome	O	B-Chemical
18	P	O	E-Chemical
19	-	O	O
20	450	O	O
21	3A4	O	O
22	drug	O	O
23	-	O	O
24	drug	O	O
25	interactions	O	O
26	,	O	O
27	hypokalemia	S-Disease	S-Disease
28	,	O	O
29	and	O	O
30	altered	O	O
31	liver	O	B-Disease
32	function	O	E-Disease
33	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	QT	B-Disease	O
3	interval	I-Disease	O
4	prolongation	E-Disease	O
5	in	O	O
6	methadone	S-Chemical	S-Chemical
7	maintenance	O	O
8	patients	O	O
9	hospitalized	O	O
10	in	O	O
11	a	O	O
12	tertiary	O	O
13	care	O	O
14	center	O	O
15	is	O	O
16	a	O	O
17	frequent	O	O
18	finding	O	O
19	.	O	O

0	Methadone	S-Chemical	S-Disease
1	dose	O	O
2	,	O	O
3	presence	O	O
4	of	O	O
5	cytochrome	O	B-Chemical
6	P	O	E-Chemical
7	-	O	O
8	450	O	O
9	3A4	O	S-Disease
10	inhibitors	O	O
11	,	O	O
12	potassium	S-Chemical	S-Disease
13	level	O	O
14	,	O	O
15	and	O	O
16	liver	O	O
17	function	O	E-Disease
18	contribute	O	O
19	to	O	O
20	QT	B-Disease	O
21	prolongation	E-Disease	O
22	.	O	O

0	Long	B-Disease	O
1	QT	I-Disease	O
2	syndrome	E-Disease	O
3	can	O	O
4	occur	O	O
5	with	O	O
6	low	O	O
7	doses	O	O
8	of	O	O
9	methadone	S-Chemical	S-Chemical
10	.	O	O

0	Mechanisms	O	O
1	of	O	O
2	hypertension	S-Disease	S-Disease
3	induced	O	O
4	by	O	O
5	nitric	B-Chemical	B-Disease
6	oxide	E-Chemical	E-Disease
7	(	O	O
8	NO	S-Chemical	S-Chemical
9	)	O	O
10	deficiency	O	S-Disease
11	:	O	O
12	focus	O	O
13	on	O	O
14	venous	O	B-Disease
15	function	O	E-Disease
16	.	O	O

0	Loss	O	O
1	of	O	O
2	endothelial	O	O
3	cell	O	O
4	-	O	O
5	derived	O	O
6	nitric	B-Chemical	B-Disease
7	oxide	E-Chemical	E-Disease
8	(	O	O
9	NO	S-Chemical	S-Chemical
10	)	O	O
11	in	O	O
12	hypertension	S-Disease	S-Disease
13	is	O	O
14	a	O	O
15	hallmark	O	O
16	of	O	O
17	arterial	B-Disease	B-Disease
18	dysfunction	E-Disease	E-Disease
19	.	O	O

0	Experimental	O	O
1	hypertension	S-Disease	S-Disease
2	created	O	O
3	by	O	O
4	the	O	O
5	removal	O	O
6	of	O	O
7	NO	S-Chemical	S-Chemical
8	,	O	O
9	however	O	O
10	,	O	O
11	involves	O	O
12	mechanisms	O	O
13	in	O	O
14	addition	O	O
15	to	O	O
16	decreased	O	O
17	arterial	O	B-Disease
18	vasodilator	O	E-Disease
19	activity	O	E-Disease
20	.	O	O

0	We	O	O
1	hypothesized	O	O
2	that	O	O
3	increased	O	O
4	venous	O	B-Disease
5	smooth	O	I-Disease
6	muscle	O	E-Disease
7	(	O	O
8	venomotor	O	S-Disease
9	)	O	O
10	tone	O	O
11	plays	O	O
12	a	O	O
13	role	O	O
14	in	O	O
15	Nomega	B-Chemical	S-Chemical
16	-	I-Chemical	I-Chemical
17	nitro	I-Chemical	E-Chemical
18	-	I-Chemical	I-Chemical
19	L	I-Chemical	E-Chemical
20	-	I-Chemical	I-Chemical
21	arginine	E-Chemical	E-Chemical
22	(	O	O
23	LNNA	S-Chemical	S-Disease
24	)	O	O
25	hypertension	S-Disease	S-Disease
26	through	O	O
27	these	O	O
28	mechanisms	O	O
29	.	O	O

0	Rats	O	O
1	were	O	O
2	treated	O	O
3	with	O	O
4	the	O	O
5	NO	S-Chemical	S-Chemical
6	synthase	O	O
7	inhibitor	O	O
8	LNNA	S-Chemical	S-Chemical
9	(	O	O
10	0	O	O
11	.	O	O
12	5	O	O
13	g	O	O
14	/	O	O
15	L	O	O
16	in	O	O
17	drinking	O	O
18	water	O	O
19	)	O	O
20	for	O	O
21	2	O	O
22	weeks	O	O
23	.	O	O

0	Mean	O	O
1	arterial	O	O
2	pressure	O	O
3	of	O	O
4	conscious	O	O
5	rats	O	O
6	was	O	O
7	119	O	O
8	+	O	O
9	/	O	O
10	-	O	O
11	2	O	O
12	mm	O	O
13	Hg	O	O
14	in	O	O
15	control	O	O
16	and	O	O
17	194	O	O
18	+	O	O
19	/	O	O
20	-	O	O
21	5	O	O
22	mm	O	O
23	Hg	O	O
24	in	O	O
25	LNNA	S-Chemical	O
26	rats	O	O
27	(	O	O
28	P	O	O
29	<	O	O
30	0	O	O
31	.	O	O
32	05	O	O
33	)	O	O
34	.	O	O

0	Maximal	O	O
1	contraction	O	O
2	to	O	O
3	norepinephrine	S-Chemical	S-Chemical
4	was	O	O
5	modestly	O	O
6	reduced	O	O
7	in	O	O
8	arteries	O	O
9	from	O	O
10	LNNA	S-Chemical	S-Disease
11	compared	O	O
12	with	O	O
13	control	O	O
14	rats	O	O
15	whereas	O	O
16	the	O	O
17	maximum	O	O
18	contraction	O	O
19	to	O	O
20	ET	O	S-Chemical
21	-	O	E-Chemical
22	1	O	E-Disease
23	was	O	O
24	significantly	O	O
25	reduced	O	O
26	(	O	O
27	54	O	O
28	%	O	O
29	control	O	O
30	)	O	O
31	.	O	O

0	Maximum	O	O
1	contraction	O	O
2	of	O	O
3	vena	O	B-Disease
4	cava	O	E-Disease
5	to	O	O
6	norepinephrine	S-Chemical	S-Chemical
7	(	O	O
8	37	O	O
9	%	O	O
10	control	O	O
11	)	O	O
12	also	O	O
13	was	O	O
14	reduced	O	O
15	but	O	O
16	no	O	O
17	change	O	O
18	in	O	O
19	response	O	O
20	to	O	O
21	ET	O	S-Chemical
22	-	O	E-Chemical
23	1	O	E-Disease
24	was	O	O
25	observed	O	O
26	.	O	O

0	Mean	O	O
1	circulatory	O	O
2	filling	O	O
3	pressure	O	O
4	,	O	O
5	an	O	O
6	in	O	O
7	vivo	O	O
8	measure	O	O
9	of	O	O
10	venomotor	O	S-Disease
11	tone	O	E-Disease
12	,	O	O
13	was	O	O
14	not	O	O
15	elevated	O	O
16	in	O	O
17	LNNA	S-Chemical	S-Disease
18	hypertension	S-Disease	S-Disease
19	at	O	O
20	1	O	O
21	or	O	O
22	2	O	O
23	weeks	O	O
24	after	O	O
25	LNNA	S-Chemical	S-Disease
26	.	O	O

0	The	O	O
1	superoxide	S-Chemical	S-Disease
2	scavenger	O	O
3	tempol	S-Chemical	O
4	(	O	O
5	30	O	O
6	,	O	O
7	100	O	O
8	,	O	O
9	and	O	O
10	300	O	O
11	micromol	O	O
12	kg	O	O
13	(	O	O
14	-	O	O
15	1	O	O
16	)	O	O
17	,	O	O
18	IV	O	O
19	)	O	O
20	did	O	O
21	not	O	O
22	change	O	O
23	arterial	O	O
24	pressure	O	O
25	in	O	O
26	control	O	O
27	rats	O	O
28	but	O	O
29	caused	O	O
30	a	O	O
31	dose	O	O
32	-	O	O
33	dependent	O	O
34	decrease	O	O
35	in	O	O
36	LNNA	S-Chemical	S-Disease
37	rats	O	O
38	(	O	O
39	-	O	O
40	18	O	O
41	+	O	O
42	/	O	O
43	-	O	O
44	8	O	O
45	,	O	O
46	-	O	O
47	26	O	O
48	+	O	O
49	/	O	O
50	-	O	O
51	15	O	O
52	,	O	O
53	and	O	O
54	-	O	O
55	54	O	O
56	+	O	O
57	/	O	O
58	-	O	O
59	11	O	O
60	mm	O	O
61	Hg	O	O
62	)	O	O
63	.	O	O

0	Similarly	O	O
1	,	O	O
2	ganglionic	O	S-Chemical
3	blockade	O	O
4	with	O	O
5	hexamethonium	S-Chemical	S-Chemical
6	caused	O	O
7	a	O	O
8	significantly	O	O
9	greater	O	O
10	fall	O	O
11	in	O	O
12	LNNA	S-Chemical	S-Disease
13	hypertensive	S-Disease	S-Disease
14	rats	O	O
15	(	O	O
16	76	O	O
17	+	O	O
18	/	O	O
19	-	O	O
20	9	O	O
21	mm	O	O
22	Hg	O	O
23	)	O	O
24	compared	O	O
25	with	O	O
26	control	O	O
27	rats	O	O
28	(	O	O
29	35	O	O
30	+	O	O
31	/	O	O
32	-	O	O
33	10	O	O
34	mm	O	O
35	Hg	O	O
36	)	O	O
37	.	O	O

0	Carotid	O	S-Chemical
1	arteries	O	O
2	,	O	O
3	vena	O	B-Disease
4	cava	O	E-Disease
5	,	O	O
6	and	O	O
7	sympathetic	O	B-Disease
8	ganglia	O	E-Disease
9	from	O	O
10	LNNA	S-Chemical	S-Disease
11	rats	O	O
12	had	O	O
13	higher	O	O
14	basal	O	O
15	levels	O	O
16	of	O	O
17	superoxide	S-Chemical	S-Chemical
18	compared	O	O
19	with	O	O
20	those	O	O
21	from	O	O
22	control	O	O
23	rats	O	O
24	.	O	O

0	These	O	O
1	data	O	O
2	suggest	O	O
3	that	O	O
4	while	O	O
5	NO	S-Chemical	S-Chemical
6	deficiency	O	E-Disease
7	increases	O	O
8	oxidative	O	O
9	stress	O	O
10	and	O	O
11	sympathetic	O	B-Disease
12	activity	O	E-Disease
13	in	O	O
14	both	O	O
15	arterial	O	B-Disease
16	and	O	O
17	venous	O	B-Disease
18	vessels	O	O
19	,	O	O
20	the	O	O
21	impact	O	O
22	on	O	O
23	veins	O	S-Disease
24	does	O	O
25	not	O	O
26	make	O	O
27	a	O	O
28	major	O	O
29	contribution	O	O
30	to	O	O
31	this	O	O
32	form	O	O
33	of	O	O
34	hypertension	S-Disease	S-Disease
35	.	O	O

0	Association	O	O
1	of	O	O
2	DRD2	O	S-Chemical
3	polymorphisms	O	O
4	and	O	O
5	chlorpromazine	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	extrapyramidal	B-Disease	B-Disease
9	syndrome	E-Disease	E-Disease
10	in	O	O
11	Chinese	O	B-Disease
12	schizophrenic	S-Disease	E-Disease
13	patients	O	O
14	.	O	O

0	AIM	O	O
1	:	O	O
2	Extrapyramidal	B-Disease	O
3	syndrome	E-Disease	O
4	(	O	O
5	EPS	S-Disease	O
6	)	O	O
7	is	O	O
8	most	O	O
9	commonly	O	O
10	affected	O	O
11	by	O	O
12	typical	O	O
13	antipsychotic	O	O
14	drugs	O	O
15	that	O	O
16	have	O	O
17	a	O	O
18	high	O	O
19	affinity	O	O
20	with	O	O
21	the	O	O
22	D2	O	B-Chemical
23	receptor	O	O
24	.	O	O

0	Recently	O	O
1	,	O	O
2	many	O	O
3	research	O	O
4	groups	O	O
5	have	O	O
6	reported	O	O
7	on	O	O
8	the	O	O
9	positive	O	O
10	relationship	O	O
11	between	O	O
12	the	O	O
13	genetic	O	O
14	variations	O	O
15	in	O	O
16	the	O	O
17	DRD2	O	S-Chemical
18	gene	O	O
19	and	O	O
20	the	O	O
21	therapeutic	O	O
22	response	O	O
23	in	O	O
24	schizophrenia	S-Disease	B-Disease
25	patients	O	O
26	as	O	O
27	a	O	O
28	result	O	O
29	of	O	O
30	the	O	O
31	role	O	O
32	of	O	O
33	variations	O	O
34	in	O	O
35	the	O	O
36	receptor	O	O
37	in	O	O
38	modulating	O	O
39	receptor	O	O
40	expression	O	O
41	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	,	O	O
4	we	O	O
5	evaluate	O	O
6	the	O	O
7	role	O	O
8	DRD2	O	S-Chemical
9	plays	O	O
10	in	O	O
11	chlorpromazine	S-Chemical	S-Chemical
12	-	O	O
13	induced	O	O
14	EPS	S-Disease	O
15	in	O	O
16	schizophrenic	S-Disease	S-Disease
17	patients	O	O
18	.	O	O

0	METHODS	O	O
1	:	O	O
2	We	O	O
3	identified	O	O
4	seven	O	O
5	SNP	O	O
6	(	O	O
7	single	O	O
8	nucleotide	O	O
9	polymorphism	O	O
10	)	O	O
11	(	O	O
12	-	O	O
13	141Cins	O	O
14	>	O	O
15	del	O	O
16	,	O	O
17	TaqIB	O	S-Chemical
18	,	O	O
19	TaqID	O	S-Chemical
20	,	O	O
21	Ser311Cys	O	B-Chemical
22	,	O	O
23	rs6275	O	S-Disease
24	,	O	O
25	rs6277	O	S-Disease
26	and	O	O
27	TaqIA	O	S-Chemical
28	)	O	O
29	in	O	O
30	the	O	O
31	DRD2	O	S-Disease
32	gene	O	O
33	in	O	O
34	146	O	O
35	schizophrenic	S-Disease	O
36	inpatients	O	O
37	(	O	O
38	59	O	O
39	with	O	O
40	EPS	S-Disease	O
41	and	O	O
42	87	O	O
43	without	O	O
44	EPS	S-Disease	O
45	according	O	O
46	to	O	O
47	the	O	O
48	Simpson	O	S-Disease
49	-	O	I-Disease
50	Angus	O	S-Disease
51	Scale	O	O
52	)	O	O
53	treated	O	O
54	with	O	O
55	chlorpromazine	S-Chemical	S-Chemical
56	after	O	O
57	8	O	O
58	weeks	O	O
59	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Our	O	O
3	results	O	O
4	did	O	O
5	not	O	O
6	lend	O	O
7	strong	O	O
8	support	O	O
9	to	O	O
10	the	O	O
11	view	O	O
12	that	O	O
13	the	O	O
14	genetic	O	O
15	variation	O	O
16	of	O	O
17	the	O	O
18	DRD2	O	S-Disease
19	gene	O	O
20	plays	O	O
21	a	O	O
22	major	O	O
23	role	O	O
24	in	O	O
25	the	O	O
26	individually	O	O
27	variable	O	O
28	adverse	O	O
29	effect	O	O
30	induced	O	O
31	by	O	O
32	chlorpromazine	S-Chemical	S-Chemical
33	,	O	O
34	at	O	O
35	least	O	O
36	in	O	O
37	Chinese	O	S-Chemical
38	patients	O	O
39	with	O	O
40	schizophrenia	S-Disease	S-Disease
41	.	O	O

0	Our	O	O
1	results	O	O
2	confirmed	O	O
3	a	O	O
4	previous	O	O
5	study	O	O
6	on	O	O
7	the	O	O
8	relationship	O	O
9	between	O	O
10	DRD2	O	S-Chemical
11	and	O	O
12	EPS	S-Disease	O
13	in	O	O
14	Caucasians	O	O
15	.	O	O

0	Physical	O	O
1	training	O	O
2	decreases	O	O
3	susceptibility	O	O
4	to	O	O
5	subsequent	O	O
6	pilocarpine	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	seizures	S-Disease	S-Disease
10	in	O	O
11	the	O	O
12	rat	O	O
13	.	O	O

0	Regular	O	O
1	motor	O	B-Disease
2	activity	O	E-Disease
3	has	O	O
4	many	O	O
5	benefits	O	O
6	for	O	O
7	mental	O	O
8	and	O	O
9	physical	O	O
10	condition	O	O
11	but	O	O
12	its	O	O
13	implications	O	O
14	for	O	O
15	epilepsy	S-Disease	S-Disease
16	are	O	O
17	still	O	O
18	controversial	O	O
19	.	O	O

0	In	O	O
1	order	O	O
2	to	O	O
3	elucidate	O	O
4	this	O	O
5	problem	O	O
6	,	O	O
7	we	O	O
8	have	O	O
9	studied	O	O
10	the	O	O
11	effect	O	O
12	of	O	O
13	long	O	O
14	-	O	O
15	term	O	O
16	physical	O	O
17	activity	O	O
18	on	O	O
19	susceptibility	O	O
20	to	O	O
21	subsequent	O	O
22	seizures	S-Disease	S-Disease
23	.	O	O

0	Thereafter	O	O
1	,	O	O
2	seizures	S-Disease	S-Disease
3	were	O	O
4	induced	O	O
5	by	O	O
6	pilocarpine	S-Chemical	S-Chemical
7	injections	O	O
8	in	O	O
9	trained	O	O
10	and	O	O
11	non	O	O
12	-	O	O
13	trained	O	O
14	control	O	O
15	groups	O	O
16	.	O	O

0	During	O	O
1	the	O	O
2	acute	O	O
3	period	O	O
4	of	O	O
5	status	B-Disease	O
6	epilepticus	E-Disease	E-Disease
7	,	O	O
8	we	O	O
9	measured	O	O
10	:	O	O
11	(	O	O
12	1	O	O
13	)	O	O
14	the	O	O
15	latency	O	O
16	of	O	O
17	the	O	O
18	first	O	O
19	motor	O	O
20	sign	O	O
21	,	O	O
22	(	O	O
23	2	O	O
24	)	O	O
25	the	O	O
26	intensity	O	O
27	of	O	O
28	seizures	S-Disease	S-Disease
29	,	O	O
30	(	O	O
31	3	O	O
32	)	O	O
33	the	O	O
34	time	O	O
35	when	O	O
36	it	O	O
37	occurred	O	O
38	within	O	O
39	the	O	O
40	6	O	O
41	-	O	O
42	h	O	O
43	observation	O	O
44	period	O	O
45	,	O	O
46	and	O	O
47	(	O	O
48	4	O	O
49	)	O	O
50	the	O	O
51	time	O	O
52	when	O	O
53	the	O	O
54	acute	O	O
55	period	O	O
56	ended	O	O
57	.	O	O

0	All	O	O
1	these	O	O
2	behavioral	O	O
3	parameters	O	O
4	showed	O	O
5	statistically	O	O
6	significant	O	O
7	changes	O	O
8	suggesting	O	O
9	that	O	O
10	regular	O	O
11	physical	O	O
12	exercises	O	O
13	decrease	O	O
14	susceptibility	O	O
15	to	O	O
16	subsequently	O	O
17	induced	O	O
18	seizures	S-Disease	S-Disease
19	and	O	O
20	ameliorate	O	O
21	the	O	O
22	course	O	O
23	of	O	O
24	experimentally	O	O
25	induced	O	O
26	status	B-Disease	O
27	epilepticus	E-Disease	E-Disease
28	.	O	O

0	Tonic	O	S-Chemical
1	dopaminergic	O	O
2	stimulation	O	O
3	impairs	B-Disease	O
4	associative	I-Disease	O
5	learning	E-Disease	O
6	in	O	O
7	healthy	O	O
8	subjects	O	O
9	.	O	O

0	Endogenous	O	O
1	dopamine	S-Chemical	S-Chemical
2	plays	O	O
3	a	O	O
4	central	O	O
5	role	O	O
6	in	O	O
7	salience	O	O
8	coding	O	O
9	during	O	O
10	associative	O	O
11	learning	O	O
12	.	O	O

0	Administration	O	O
1	of	O	O
2	the	O	O
3	dopamine	S-Chemical	S-Chemical
4	precursor	O	O
5	levodopa	S-Chemical	S-Chemical
6	enhances	O	O
7	learning	O	O
8	in	O	O
9	healthy	O	O
10	subjects	O	O
11	and	O	O
12	stroke	S-Disease	S-Disease
13	patients	O	O
14	.	O	O

0	Because	O	O
1	levodopa	S-Chemical	S-Chemical
2	increases	O	O
3	both	O	O
4	phasic	O	S-Disease
5	and	O	O
6	tonic	O	S-Disease
7	dopaminergic	O	O
8	neurotransmission	O	S-Disease
9	,	O	O
10	the	O	O
11	critical	O	O
12	mechanism	O	O
13	mediating	O	O
14	the	O	O
15	enhancement	O	O
16	of	O	O
17	learning	O	O
18	is	O	O
19	unresolved	O	O
20	.	O	O

0	Subjects	O	O
1	received	O	O
2	the	O	O
3	tonically	O	O
4	stimulating	O	O
5	dopamine	S-Chemical	O
6	-	O	O
7	receptor	O	O
8	agonist	O	O
9	pergolide	S-Chemical	S-Chemical
10	(	O	O
11	0	O	O
12	.	O	O
13	1	O	O
14	mg	O	O
15	)	O	O
16	vs	O	O
17	placebo	O	O
18	120	O	O
19	min	O	O
20	before	O	O
21	training	O	O
22	on	O	O
23	each	O	O
24	training	O	O
25	day	O	O
26	.	O	O

0	The	O	O
1	dopamine	S-Chemical	S-Chemical
2	agonist	O	O
3	significantly	O	O
4	impaired	B-Disease	O
5	novel	I-Disease	O
6	word	I-Disease	O
7	learning	E-Disease	O
8	compared	O	O
9	to	O	O
10	placebo	O	S-Disease
11	.	O	O

0	Subjects	O	O
1	treated	O	O
2	with	O	O
3	pergolide	S-Chemical	S-Chemical
4	also	O	O
5	showed	O	O
6	restricted	O	O
7	emotional	O	O
8	responses	O	O
9	compared	O	O
10	to	O	O
11	the	O	O
12	PLACEBO	O	S-Chemical
13	group	O	O
14	.	O	O

0	The	O	O
1	extent	O	O
2	of	O	O
3	'	O	O
4	flattened	O	S-Disease
5	'	O	O
6	affect	O	O
7	with	O	O
8	pergolide	S-Chemical	S-Chemical
9	was	O	O
10	related	O	O
11	to	O	O
12	the	O	O
13	degree	O	O
14	of	O	O
15	learning	O	O
16	inhibition	O	O
17	.	O	O

0	These	O	O
1	findings	O	O
2	suggest	O	O
3	that	O	O
4	tonic	O	B-Disease
5	occupation	O	E-Disease
6	of	O	O
7	dopamine	S-Chemical	S-Disease
8	receptors	O	O
9	impairs	O	O
10	learning	O	O
11	by	O	O
12	competition	O	O
13	with	O	O
14	phasic	O	S-Disease
15	dopamine	S-Chemical	S-Disease
16	signals	O	O
17	.	O	O

0	Thus	O	O
1	,	O	O
2	phasic	O	S-Disease
3	signaling	O	O
4	seems	O	O
5	to	O	O
6	be	O	O
7	the	O	O
8	critical	O	O
9	mechanism	O	O
10	by	O	O
11	which	O	O
12	dopamine	S-Chemical	S-Chemical
13	enhances	O	O
14	associative	O	O
15	learning	O	O
16	in	O	O
17	healthy	O	O
18	subjects	O	O
19	and	O	O
20	stroke	S-Disease	S-Disease
21	patients	O	O
22	.	O	O

0	Minocycline	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	vasculitis	S-Disease	S-Disease
4	fulfilling	O	O
5	the	O	O
6	criteria	O	O
7	of	O	O
8	polyarteritis	B-Disease	B-Disease
9	nodosa	E-Disease	E-Disease
10	.	O	O

0	A	O	O
1	47	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	man	O	O
7	who	O	O
8	had	O	O
9	been	O	O
10	taking	O	O
11	minocycline	S-Chemical	S-Chemical
12	for	O	O
13	palmoplantar	B-Disease	B-Disease
14	pustulosis	E-Disease	E-Disease
15	developed	O	O
16	fever	S-Disease	S-Disease
17	,	O	O
18	myalgias	S-Disease	S-Disease
19	,	O	O
20	polyneuropathy	S-Disease	S-Disease
21	,	O	O
22	and	O	O
23	testicular	B-Disease	B-Disease
24	pain	E-Disease	E-Disease
25	,	O	O
26	with	O	O
27	elevated	O	O
28	C	O	B-Chemical
29	-	O	I-Disease
30	reactive	O	I-Disease
31	protein	O	E-Disease
32	(	O	O
33	CRP	O	O
34	)	O	O
35	.	O	O

0	These	O	O
1	manifestations	O	O
2	met	O	O
3	the	O	O
4	American	O	I-Chemical
5	College	O	I-Disease
6	of	O	I-Disease
7	Rheumatology	O	I-Disease
8	1990	O	O
9	criteria	O	O
10	for	O	O
11	the	O	O
12	classification	O	O
13	of	O	O
14	polyarteritis	B-Disease	B-Disease
15	nodosa	E-Disease	E-Disease
16	.	O	O

0	Stopping	O	O
1	minocycline	S-Chemical	S-Chemical
2	led	O	O
3	to	O	O
4	amelioration	O	O
5	of	O	O
6	symptoms	O	O
7	and	O	O
8	normalization	O	O
9	of	O	O
10	CRP	O	S-Disease
11	level	O	O
12	.	O	O

0	To	O	O
1	our	O	O
2	knowledge	O	O
3	,	O	O
4	this	O	O
5	is	O	O
6	the	O	O
7	second	O	O
8	case	O	O
9	of	O	O
10	minocycline	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	vasculitis	S-Disease	S-Disease
14	satisfying	O	O
15	the	O	O
16	criteria	O	O
17	.	O	O

0	Differential	O	O
1	diagnosis	O	O
2	for	O	O
3	drug	O	O
4	-	O	O
5	induced	O	O
6	disease	O	E-Disease
7	is	O	O
8	invaluable	O	O
9	even	O	O
10	for	O	O
11	patients	O	O
12	with	O	O
13	classical	O	O
14	polyarteritis	B-Disease	B-Disease
15	nodosa	E-Disease	E-Disease
16	.	O	O

0	Intramuscular	O	O
1	hepatitis	B-Disease	B-Disease
2	B	E-Disease	I-Disease
3	immune	O	B-Disease
4	globulin	O	E-Disease
5	combined	O	O
6	with	O	O
7	lamivudine	S-Chemical	S-Chemical
8	in	O	O
9	prevention	O	O
10	of	O	O
11	hepatitis	B-Disease	B-Disease
12	B	E-Disease	E-Disease
13	recurrence	O	O
14	after	O	O
15	liver	O	B-Disease
16	transplantation	O	E-Disease
17	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Combined	O	O
3	hepatitis	B-Disease	B-Disease
4	B	E-Disease	I-Disease
5	immune	O	B-Disease
6	globulin	O	E-Disease
7	(	O	O
8	HBIg	O	S-Disease
9	)	O	O
10	and	O	O
11	lamivudine	S-Chemical	S-Chemical
12	in	O	O
13	prophylaxis	O	O
14	of	O	O
15	the	O	O
16	recurrence	O	O
17	of	O	O
18	hepatitis	B-Disease	S-Disease
19	B	E-Disease	E-Disease
20	after	O	O
21	liver	O	B-Disease
22	transplantation	O	E-Disease
23	has	O	O
24	significantly	O	O
25	improved	O	O
26	the	O	O
27	survival	O	O
28	of	O	O
29	HBsAg	S-Chemical	O
30	positive	O	O
31	patients	O	O
32	.	O	O

0	This	O	O
1	study	O	O
2	was	O	O
3	undertaken	O	O
4	to	O	O
5	evaluate	O	O
6	the	O	O
7	outcomes	O	O
8	of	O	O
9	liver	O	B-Disease
10	transplantation	O	E-Disease
11	for	O	O
12	patients	O	O
13	with	O	O
14	hepatitis	B-Disease	B-Disease
15	B	E-Disease	I-Disease
16	virus	O	E-Disease
17	(	O	O
18	HBV	O	O
19	)	O	O
20	.	O	O

0	METHODS	O	O
1	:	O	O
2	A	O	O
3	retrospective	O	O
4	chart	O	O
5	analysis	O	O
6	and	O	O
7	a	O	O
8	review	O	O
9	of	O	O
10	the	O	O
11	organ	O	B-Disease
12	transplant	O	E-Disease
13	database	O	O
14	identified	O	O
15	51	O	O
16	patients	O	O
17	(	O	O
18	43	O	O
19	men	O	O
20	and	O	O
21	8	O	O
22	women	O	O
23	)	O	O
24	transplanted	O	O
25	for	O	O
26	benign	O	O
27	HBV	O	O
28	-	O	O
29	related	O	O
30	cirrhotic	B-Disease	B-Disease
31	diseases	E-Disease	E-Disease
32	between	O	O
33	June	O	O
34	2002	O	O
35	and	O	O
36	December	O	O
37	2004	O	O
38	who	O	O
39	had	O	O
40	survived	O	O
41	more	O	O
42	than	O	O
43	3	O	O
44	months	O	O
45	.	O	O

0	A	O	O
1	daily	O	O
2	oral	O	O
3	dose	O	O
4	of	O	O
5	100	O	O
6	mg	O	O
7	lamivudine	S-Chemical	S-Chemical
8	for	O	O
9	2	O	O
10	weeks	O	O
11	before	O	O
12	transplantation	O	O
13	for	O	O
14	10	O	O
15	patients	O	O
16	enabled	O	O
17	57	O	O
18	.	O	O
19	1	O	O
20	%	O	O
21	(	O	O
22	4	O	O
23	/	O	O
24	7	O	O
25	)	O	O
26	and	O	O
27	62	O	O
28	.	O	O
29	5	O	O
30	%	O	O
31	(	O	O
32	5	O	O
33	/	O	O
34	8	O	O
35	)	O	O
36	of	O	O
37	HBV	O	O
38	-	O	I-Disease
39	DNA	O	O
40	and	O	O
41	HBeAg	S-Chemical	O
42	positive	O	O
43	patients	O	O
44	respectively	O	O
45	to	O	O
46	convert	O	O
47	to	O	O
48	be	O	O
49	negative	O	O
50	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Lamivudine	S-Chemical	S-Chemical
3	combined	O	O
4	with	O	O
5	intramuscular	O	O
6	HBIg	O	S-Disease
7	can	O	O
8	effectively	O	O
9	prevent	O	O
10	allograft	O	S-Disease
11	from	O	O
12	the	O	O
13	recurrence	O	O
14	of	O	O
15	HBV	O	O
16	after	O	O
17	liver	O	B-Disease
18	transplantation	O	E-Disease
19	.	O	O

0	Anticonvulsant	O	O
1	effect	O	O
2	of	O	O
3	eslicarbazepine	B-Chemical	S-Chemical
4	acetate	E-Chemical	E-Chemical
5	(	O	O
6	BIA	B-Chemical	B-Chemical
7	2	I-Chemical	E-Chemical
8	-	I-Chemical	I-Chemical
9	093	E-Chemical	E-Chemical
10	)	O	O
11	on	O	O
12	seizures	S-Disease	S-Disease
13	induced	O	O
14	by	O	O
15	microperfusion	O	O
16	of	O	O
17	picrotoxin	S-Chemical	S-Chemical
18	in	O	O
19	the	O	O
20	hippocampus	O	S-Disease
21	of	O	O
22	freely	O	O
23	moving	O	O
24	rats	O	O
25	.	O	O

0	Eslicarbazepine	B-Chemical	S-Chemical
1	acetate	E-Chemical	E-Chemical
2	(	O	O
3	BIA	B-Chemical	B-Chemical
4	2	I-Chemical	E-Chemical
5	-	I-Chemical	O
6	093	E-Chemical	E-Chemical
7	,	O	O
8	S	B-Chemical	B-Chemical
9	-	I-Chemical	I-Chemical
10	(	I-Chemical	O
11	-	I-Chemical	I-Chemical
12	)	I-Chemical	O
13	-	I-Chemical	I-Chemical
14	10	I-Chemical	O
15	-	I-Chemical	I-Chemical
16	acetoxy	I-Chemical	E-Chemical
17	-	I-Chemical	O
18	10	I-Chemical	O
19	,	I-Chemical	O
20	11	I-Chemical	O
21	-	I-Chemical	O
22	dihydro	I-Chemical	S-Chemical
23	-	I-Chemical	O
24	5H	I-Chemical	E-Chemical
25	-	I-Chemical	O
26	dibenzo	I-Chemical	S-Disease
27	/	I-Chemical	O
28	b	I-Chemical	O
29	,	I-Chemical	O
30	f	I-Chemical	O
31	/	I-Chemical	O
32	azepine	I-Chemical	O
33	-	I-Chemical	O
34	5	I-Chemical	O
35	-	I-Chemical	O
36	carboxamide	E-Chemical	E-Chemical
37	)	O	O
38	is	O	O
39	a	O	O
40	novel	O	O
41	antiepileptic	O	O
42	drug	O	O
43	,	O	O
44	now	O	O
45	in	O	O
46	Phase	O	O
47	III	O	O
48	clinical	O	O
49	trials	O	O
50	,	O	O
51	designed	O	O
52	with	O	O
53	the	O	O
54	aim	O	O
55	of	O	O
56	improving	O	O
57	efficacy	O	O
58	and	O	O
59	safety	O	O
60	in	O	O
61	comparison	O	O
62	with	O	O
63	the	O	O
64	structurally	O	O
65	related	O	O
66	drugs	O	O
67	carbamazepine	S-Chemical	S-Chemical
68	(	O	O
69	CBZ	S-Chemical	S-Chemical
70	)	O	O
71	and	O	O
72	oxcarbazepine	S-Chemical	S-Chemical
73	(	O	O
74	OXC	S-Chemical	S-Chemical
75	)	O	O
76	.	O	O

0	We	O	O
1	have	O	O
2	studied	O	O
3	the	O	O
4	effects	O	O
5	of	O	O
6	oral	O	O
7	treatment	O	O
8	with	O	O
9	eslicarbazepine	B-Chemical	S-Chemical
10	acetate	E-Chemical	E-Chemical
11	on	O	O
12	a	O	O
13	whole	O	O
14	-	O	O
15	animal	O	O
16	model	O	O
17	in	O	O
18	which	O	O
19	partial	O	O
20	seizures	S-Disease	S-Disease
21	can	O	O
22	be	O	O
23	elicited	O	O
24	repeatedly	O	O
25	on	O	O
26	different	O	O
27	days	O	O
28	without	O	O
29	changes	O	O
30	in	O	O
31	threshold	O	O
32	or	O	O
33	seizure	S-Disease	S-Disease
34	patterns	O	O
35	.	O	O

0	In	O	O
1	the	O	O
2	animals	O	O
3	treated	O	O
4	with	O	O
5	threshold	O	O
6	doses	O	O
7	of	O	O
8	picrotoxin	S-Chemical	S-Chemical
9	,	O	O
10	the	O	O
11	average	O	O
12	number	O	O
13	of	O	O
14	seizures	S-Disease	S-Disease
15	was	O	O
16	2	O	O
17	.	O	O
18	3	O	O
19	+	O	O
20	/	O	O
21	-	O	O
22	1	O	O
23	.	O	O
24	2	O	O
25	,	O	O
26	and	O	O
27	average	O	O
28	seizure	S-Disease	S-Disease
29	duration	O	O
30	was	O	O
31	39	O	O
32	.	O	O
33	5	O	O
34	+	O	O
35	/	O	O
36	-	O	O
37	8	O	O
38	.	O	O
39	4s	O	O
40	.	O	O

0	Pre	O	O
1	-	O	O
2	treatment	O	O
3	with	O	O
4	a	O	O
5	dose	O	O
6	of	O	O
7	30	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	2h	O	O
12	before	O	O
13	picrotoxin	S-Chemical	S-Chemical
14	microperfusion	O	O
15	prevented	O	O
16	seizures	S-Disease	S-Disease
17	in	O	O
18	the	O	O
19	75	O	O
20	%	O	O
21	of	O	O
22	the	O	O
23	rats	O	O
24	.	O	O

0	Lower	O	O
1	doses	O	O
2	(	O	O
3	3	O	O
4	and	O	O
5	10mg	O	O
6	/	O	O
7	kg	O	O
8	)	O	O
9	did	O	O
10	not	O	O
11	suppress	O	O
12	seizures	S-Disease	S-Disease
13	,	O	O
14	however	O	O
15	,	O	O
16	after	O	O
17	administration	O	O
18	of	O	O
19	10mg	O	O
20	/	O	O
21	kg	O	O
22	,	O	O
23	significant	O	O
24	reductions	O	O
25	in	O	O
26	seizures	S-Disease	S-Disease
27	duration	O	O
28	(	O	O
29	24	O	O
30	.	O	O
31	3	O	O
32	+	O	O
33	/	O	O
34	-	O	O
35	6	O	O
36	.	O	O
37	8s	O	O
38	)	O	O
39	and	O	O
40	seizure	S-Disease	O
41	number	O	O
42	(	O	O
43	1	O	O
44	.	O	O
45	6	O	O
46	+	O	O
47	/	O	O
48	-	O	O
49	0	O	O
50	.	O	O
51	34	O	O
52	)	O	O
53	were	O	O
54	found	O	O
55	.	O	O

0	No	O	O
1	adverse	O	O
2	effects	O	O
3	of	O	O
4	eslicarbazepine	B-Chemical	S-Chemical
5	acetate	E-Chemical	E-Chemical
6	were	O	O
7	observed	O	O
8	in	O	O
9	the	O	O
10	behavioral	O	O
11	/	O	O
12	EEG	O	O
13	patterns	O	O
14	studied	O	O
15	,	O	O
16	including	O	O
17	sleep	O	O
18	/	O	I-Disease
19	wakefulness	O	O
20	cycle	O	O
21	,	O	O
22	at	O	O
23	the	O	O
24	doses	O	O
25	studied	O	O
26	.	O	O

0	Acute	B-Disease	O
1	renal	I-Disease	B-Disease
2	failure	E-Disease	E-Disease
3	associated	O	O
4	with	O	O
5	prolonged	O	O
6	intake	O	O
7	of	O	O
8	slimming	O	O
9	pills	O	O
10	containing	O	O
11	anthraquinones	S-Chemical	S-Disease
12	.	O	O

0	Chinese	B-Chemical	S-Chemical
1	herbal	E-Chemical	O
2	medicine	O	O
3	preparations	O	O
4	are	O	O
5	widely	O	O
6	available	O	O
7	and	O	O
8	often	O	O
9	regarded	O	O
10	by	O	O
11	the	O	O
12	public	O	O
13	as	O	O
14	natural	O	O
15	and	O	O
16	safe	O	O
17	remedies	O	O
18	for	O	O
19	a	O	O
20	variety	O	O
21	of	O	O
22	medical	O	O
23	conditions	O	O
24	.	O	O

0	Nephropathy	S-Disease	S-Disease
1	caused	O	O
2	by	O	O
3	Chinese	B-Chemical	S-Chemical
4	herbs	E-Chemical	O
5	has	O	O
6	previously	O	O
7	been	O	O
8	reported	O	O
9	,	O	O
10	usually	O	O
11	involving	O	O
12	the	O	O
13	use	O	O
14	of	O	O
15	aristolochic	B-Chemical	S-Chemical
16	acids	E-Chemical	E-Disease
17	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	23	O	O
4	-	O	O
5	year	O	O
6	-	O	O
7	old	O	O
8	woman	O	O
9	who	O	O
10	developed	O	O
11	acute	B-Disease	B-Disease
12	renal	I-Disease	I-Disease
13	failure	E-Disease	E-Disease
14	following	O	O
15	prolonged	O	O
16	use	O	O
17	of	O	O
18	a	O	O
19	proprietary	O	O
20	Chinese	B-Chemical	S-Chemical
21	herbal	E-Chemical	O
22	slimming	O	O
23	pill	O	O
24	that	O	O
25	contained	O	O
26	anthraquinone	S-Chemical	S-Chemical
27	derivatives	O	O
28	,	O	O
29	extracted	O	O
30	from	O	O
31	Rhizoma	O	B-Chemical
32	Rhei	O	E-Chemical
33	(	O	O
34	rhubarb	O	S-Chemical
35	)	O	O
36	.	O	O

0	The	O	O
1	renal	B-Disease	B-Disease
2	injury	E-Disease	E-Disease
3	was	O	O
4	probably	O	O
5	aggravated	O	O
6	by	O	O
7	the	O	O
8	concomitant	O	O
9	intake	O	O
10	of	O	O
11	a	O	O
12	non	O	O
13	-	O	O
14	steroidal	O	S-Chemical
15	anti	O	O
16	-	O	O
17	inflammatory	O	S-Disease
18	drug	O	O
19	,	O	O
20	diclofenac	S-Chemical	B-Chemical
21	.	O	O

0	Renal	O	O
1	pathology	O	O
2	was	O	O
3	that	O	O
4	of	O	O
5	hypocellular	O	B-Disease
6	interstitial	O	O
7	fibrosis	S-Disease	E-Disease
8	.	O	O

0	Spontaneous	O	O
1	renal	O	O
2	recovery	O	O
3	occurred	O	O
4	upon	O	O
5	cessation	O	O
6	of	O	O
7	the	O	O
8	slimming	O	O
9	pills	O	O
10	,	O	O
11	but	O	O
12	mild	O	O
13	interstitial	O	O
14	fibrosis	S-Disease	E-Disease
15	and	O	O
16	tubular	O	B-Disease
17	atrophy	S-Disease	E-Disease
18	was	O	O
19	still	O	O
20	evident	O	O
21	histologically	O	O
22	4	O	O
23	months	O	O
24	later	O	O
25	.	O	O

0	Although	O	O
1	a	O	O
2	causal	O	O
3	relationship	O	O
4	between	O	O
5	the	O	O
6	use	O	O
7	of	O	O
8	an	O	O
9	anthraquinone	S-Chemical	S-Chemical
10	-	O	O
11	containing	O	O
12	herbal	O	O
13	agent	O	O
14	and	O	O
15	renal	B-Disease	B-Disease
16	injury	E-Disease	E-Disease
17	remains	O	O
18	to	O	O
19	be	O	O
20	proven	O	O
21	,	O	O
22	phytotherapy	O	O
23	-	O	O
24	associated	O	O
25	interstitial	O	O
26	nephropathy	S-Disease	E-Disease
27	should	O	O
28	be	O	O
29	considered	O	O
30	in	O	O
31	patients	O	O
32	who	O	O
33	present	O	O
34	with	O	O
35	unexplained	O	O
36	renal	B-Disease	B-Disease
37	failure	E-Disease	E-Disease
38	.	O	O

0	Chloroacetaldehyde	S-Chemical	S-Chemical
1	as	O	O
2	a	O	O
3	sulfhydryl	S-Chemical	S-Chemical
4	reagent	O	O
5	:	O	O
6	the	O	O
7	role	O	O
8	of	O	O
9	critical	O	O
10	thiol	S-Chemical	S-Disease
11	groups	O	O
12	in	O	O
13	ifosfamide	S-Chemical	S-Chemical
14	nephropathy	S-Disease	S-Disease
15	.	O	O

0	Chloroacetaldehyde	S-Chemical	S-Chemical
1	(	O	O
2	CAA	S-Chemical	S-Chemical
3	)	O	O
4	is	O	O
5	a	O	O
6	metabolite	O	O
7	of	O	O
8	the	O	O
9	alkylating	O	O
10	agent	O	O
11	ifosfamide	S-Chemical	S-Chemical
12	(	O	O
13	IFO	S-Chemical	S-Chemical
14	)	O	O
15	and	O	O
16	putatively	O	O
17	responsible	O	O
18	for	O	O
19	renal	B-Disease	B-Disease
20	damage	E-Disease	E-Disease
21	following	O	O
22	anti	O	O
23	-	O	O
24	tumor	S-Disease	S-Disease
25	therapy	O	O
26	with	O	O
27	IFO	S-Chemical	S-Chemical
28	.	O	O

0	Depletion	O	O
1	of	O	O
2	sulfhydryl	S-Chemical	S-Chemical
3	(	O	O
4	SH	S-Chemical	S-Disease
5	)	O	O
6	groups	O	O
7	has	O	O
8	been	O	O
9	reported	O	O
10	from	O	O
11	cell	O	O
12	culture	O	O
13	,	O	O
14	animal	O	O
15	and	O	O
16	clinical	O	O
17	studies	O	O
18	.	O	O

0	In	O	O
1	this	O	O
2	work	O	O
3	the	O	O
4	effect	O	O
5	of	O	O
6	CAA	S-Chemical	S-Chemical
7	on	O	O
8	human	O	O
9	proximal	O	O
10	tubule	O	S-Disease
11	cells	O	O
12	in	O	O
13	primary	O	O
14	culture	O	O
15	(	O	O
16	hRPTEC	O	S-Disease
17	)	O	O
18	was	O	O
19	investigated	O	O
20	.	O	O

0	Toxicity	S-Disease	O
1	of	O	O
2	CAA	S-Chemical	S-Chemical
3	was	O	O
4	determined	O	O
5	by	O	O
6	protein	O	O
7	content	O	O
8	,	O	O
9	cell	O	O
10	number	O	O
11	,	O	O
12	LDH	O	S-Disease
13	release	O	O
14	,	O	O
15	trypan	B-Chemical	S-Chemical
16	blue	E-Chemical	O
17	exclusion	O	O
18	assay	O	O
19	and	O	O
20	caspase	O	S-Disease
21	-	O	O
22	3	O	O
23	activity	O	O
24	.	O	O

0	Free	O	O
1	thiols	S-Chemical	S-Disease
2	were	O	O
3	measured	O	O
4	by	O	O
5	the	O	O
6	method	O	O
7	of	O	O
8	Ellman	O	S-Chemical
9	.	O	O

0	CAA	S-Chemical	S-Chemical
1	reduced	O	O
2	hRPTEC	O	O
3	cell	O	O
4	number	O	O
5	and	O	O
6	protein	O	O
7	,	O	O
8	induced	O	O
9	a	O	O
10	loss	O	O
11	in	O	O
12	free	O	O
13	intracellular	O	O
14	thiols	S-Chemical	S-Disease
15	and	O	O
16	an	O	O
17	increase	O	O
18	in	O	O
19	necrosis	S-Disease	B-Disease
20	markers	O	O
21	.	O	O

0	CAA	S-Chemical	S-Chemical
1	but	O	O
2	not	O	O
3	acrolein	S-Chemical	S-Chemical
4	inhibited	O	O
5	the	O	O
6	cysteine	S-Chemical	S-Chemical
7	proteases	O	O
8	caspase	O	S-Disease
9	-	O	O
10	3	O	O
11	,	O	O
12	caspase	O	S-Chemical
13	-	O	O
14	8	O	E-Chemical
15	and	O	O
16	cathepsin	O	S-Disease
17	B	O	O
18	.	O	O

0	Caspase	O	O
1	activation	O	O
2	by	O	O
3	cisplatin	S-Chemical	S-Chemical
4	was	O	O
5	inhibited	O	O
6	by	O	O
7	CAA	S-Chemical	S-Chemical
8	.	O	O

0	In	O	O
1	cells	O	O
2	stained	O	O
3	with	O	O
4	fluorescent	O	O
5	dyes	O	O
6	targeting	O	O
7	lysosomes	O	S-Disease
8	,	O	O
9	CAA	S-Chemical	S-Chemical
10	induced	O	O
11	an	O	O
12	increase	O	O
13	in	O	O
14	lysosomal	O	S-Disease
15	size	O	O
16	and	O	O
17	lysosomal	O	S-Disease
18	leakage	O	S-Disease
19	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	CAA	S-Chemical	S-Chemical
4	on	O	O
5	cysteine	S-Chemical	S-Chemical
6	protease	O	O
7	activities	O	O
8	and	O	O
9	thiols	S-Chemical	S-Disease
10	could	O	O
11	be	O	O
12	reproduced	O	O
13	in	O	O
14	cell	O	B-Disease
15	lysate	O	E-Disease
16	.	O	O

0	Acidification	O	O
1	,	O	O
2	which	O	O
3	slowed	O	O
4	the	O	O
5	reaction	O	O
6	of	O	O
7	CAA	S-Chemical	S-Chemical
8	with	O	O
9	thiol	S-Chemical	S-Disease
10	donors	O	O
11	,	O	O
12	could	O	O
13	also	O	O
14	attenuate	O	O
15	effects	O	O
16	of	O	O
17	CAA	S-Chemical	S-Chemical
18	on	O	O
19	necrosis	S-Disease	S-Disease
20	markers	O	O
21	,	O	O
22	thiol	S-Chemical	S-Chemical
23	depletion	O	O
24	and	O	O
25	cysteine	S-Chemical	S-Chemical
26	protease	O	O
27	inhibition	O	O
28	in	O	O
29	living	O	O
30	cells	O	O
31	.	O	O

0	Thus	O	O
1	,	O	O
2	CAA	S-Chemical	S-Chemical
3	directly	O	O
4	reacts	O	O
5	with	O	O
6	cellular	O	O
7	protein	O	O
8	and	O	O
9	non	O	O
10	-	O	O
11	protein	O	O
12	thiols	S-Chemical	O
13	,	O	O
14	mediating	O	O
15	its	O	O
16	toxicity	S-Disease	S-Disease
17	on	O	O
18	hRPTEC	O	S-Chemical
19	.	O	O

0	Therefore	O	O
1	,	O	O
2	urinary	O	S-Disease
3	acidification	O	E-Disease
4	could	O	O
5	be	O	O
6	an	O	O
7	option	O	O
8	to	O	O
9	prevent	O	O
10	IFO	S-Chemical	B-Disease
11	nephropathy	S-Disease	E-Disease
12	in	O	O
13	patients	O	O
14	.	O	O

0	Stereological	O	O
1	methods	O	O
2	reveal	O	O
3	the	O	O
4	robust	O	O
5	size	O	O
6	and	O	O
7	stability	O	O
8	of	O	O
9	ectopic	O	O
10	hilar	O	O
11	granule	O	S-Disease
12	cells	O	O
13	after	O	O
14	pilocarpine	S-Chemical	S-Chemical
15	-	O	O
16	induced	O	O
17	status	B-Disease	B-Disease
18	epilepticus	E-Disease	E-Disease
19	in	O	O
20	the	O	O
21	adult	O	O
22	rat	O	O
23	.	O	O

0	Following	O	O
1	status	B-Disease	O
2	epilepticus	E-Disease	O
3	in	O	O
4	the	O	O
5	rat	O	O
6	,	O	O
7	dentate	O	O
8	granule	O	I-Disease
9	cell	O	I-Disease
10	neurogenesis	O	E-Disease
11	increases	O	O
12	greatly	O	O
13	,	O	O
14	and	O	O
15	many	O	O
16	of	O	O
17	the	O	O
18	new	O	O
19	neurons	O	O
20	appear	O	O
21	to	O	O
22	develop	O	O
23	ectopically	O	O
24	,	O	O
25	in	O	O
26	the	O	O
27	hilar	O	O
28	region	O	O
29	of	O	O
30	the	O	O
31	hippocampal	O	S-Disease
32	formation	O	O
33	.	O	O

0	It	O	O
1	has	O	O
2	been	O	O
3	suggested	O	O
4	that	O	O
5	the	O	O
6	ectopic	O	O
7	hilar	O	O
8	granule	O	S-Disease
9	cells	O	O
10	could	O	O
11	contribute	O	O
12	to	O	O
13	the	O	O
14	spontaneous	O	O
15	seizures	S-Disease	S-Disease
16	that	O	O
17	ultimately	O	O
18	develop	O	O
19	after	O	O
20	status	B-Disease	O
21	epilepticus	E-Disease	E-Disease
22	.	O	O

0	To	O	O
1	quantify	O	O
2	this	O	O
3	population	O	O
4	,	O	O
5	the	O	O
6	total	O	O
7	number	O	O
8	of	O	O
9	ectopic	O	O
10	hilar	O	O
11	granule	O	S-Disease
12	cells	O	O
13	was	O	O
14	estimated	O	O
15	using	O	O
16	unbiased	O	O
17	stereology	O	O
18	at	O	O
19	different	O	O
20	times	O	O
21	after	O	O
22	pilocarpine	S-Chemical	S-Chemical
23	-	O	O
24	induced	O	O
25	status	B-Disease	O
26	epilepticus	E-Disease	S-Disease
27	.	O	O

0	The	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	the	O	O
5	size	O	O
6	of	O	O
7	the	O	O
8	hilar	O	O
9	ectopic	O	O
10	granule	O	O
11	cell	O	O
12	population	O	O
13	after	O	O
14	status	B-Disease	O
15	epilepticus	E-Disease	E-Disease
16	is	O	O
17	substantial	O	O
18	,	O	O
19	and	O	O
20	stable	O	O
21	over	O	O
22	time	O	O
23	.	O	O

0	Interestingly	O	O
1	,	O	O
2	the	O	O
3	size	O	O
4	of	O	O
5	the	O	O
6	population	O	O
7	appears	O	O
8	to	O	O
9	be	O	O
10	correlated	O	O
11	with	O	O
12	the	O	O
13	frequency	O	O
14	of	O	O
15	behavioral	O	B-Disease
16	seizures	S-Disease	E-Disease
17	,	O	O
18	because	O	O
19	animals	O	O
20	with	O	O
21	more	O	O
22	ectopic	O	O
23	granule	O	S-Disease
24	cells	O	O
25	in	O	O
26	the	O	O
27	hilus	O	O
28	have	O	O
29	more	O	O
30	frequent	O	O
31	behavioral	O	O
32	seizures	S-Disease	S-Disease
33	.	O	O

0	The	O	O
1	results	O	O
2	provide	O	O
3	new	O	O
4	insight	O	O
5	into	O	O
6	the	O	O
7	potential	O	O
8	role	O	O
9	of	O	O
10	ectopic	O	S-Disease
11	hilar	O	O
12	granule	O	S-Disease
13	cells	O	O
14	in	O	O
15	the	O	O
16	pilocarpine	S-Chemical	S-Chemical
17	model	O	O
18	of	O	O
19	temporal	B-Disease	B-Disease
20	lobe	I-Disease	I-Disease
21	epilepsy	E-Disease	E-Disease
22	.	O	O

0	A	O	O
1	prospective	O	O
2	,	O	O
3	open	O	O
4	-	O	O
5	label	O	O
6	trial	O	O
7	of	O	O
8	galantamine	S-Chemical	S-Chemical
9	in	O	O
10	autistic	B-Disease	B-Disease
11	disorder	E-Disease	E-Disease
12	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	Post	O	O
3	-	O	O
4	mortem	O	O
5	studies	O	O
6	have	O	O
7	reported	O	O
8	abnormalities	O	O
9	of	O	O
10	the	O	O
11	cholinergic	O	B-Disease
12	system	O	E-Disease
13	in	O	O
14	autism	S-Disease	S-Disease
15	.	O	O

0	The	O	O
1	purpose	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	assess	O	O
8	the	O	O
9	use	O	O
10	of	O	O
11	galantamine	S-Chemical	S-Chemical
12	,	O	O
13	an	O	O
14	acetylcholinesterase	O	S-Chemical
15	inhibitor	O	O
16	and	O	O
17	nicotinic	O	S-Disease
18	receptor	O	O
19	modulator	O	O
20	,	O	O
21	in	O	O
22	the	O	O
23	treatment	O	O
24	of	O	O
25	interfering	O	O
26	behaviors	O	O
27	in	O	O
28	children	O	O
29	with	O	O
30	autism	S-Disease	S-Disease
31	.	O	O

0	METHODS	O	O
1	:	O	O
2	Thirteen	O	O
3	medication	O	O
4	-	O	O
5	free	O	O
6	children	O	O
7	with	O	O
8	autism	S-Disease	S-Disease
9	(	O	O
10	mean	O	O
11	age	O	O
12	,	O	O
13	8	O	O
14	.	O	O
15	8	O	O
16	+	O	O
17	/	O	O
18	-	O	O
19	3	O	O
20	.	O	O
21	5	O	O
22	years	O	O
23	)	O	O
24	participated	O	O
25	in	O	O
26	a	O	O
27	12	O	O
28	-	O	O
29	week	O	O
30	,	O	O
31	open	O	O
32	-	O	O
33	label	O	O
34	trial	O	O
35	of	O	O
36	galantamine	S-Chemical	S-Chemical
37	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Patients	O	O
3	showed	O	O
4	a	O	O
5	significant	O	O
6	reduction	O	O
7	in	O	O
8	parent	O	O
9	-	O	O
10	rated	O	O
11	irritability	S-Disease	O
12	and	O	O
13	social	O	O
14	withdrawal	O	O
15	on	O	O
16	the	O	O
17	ABC	O	S-Disease
18	as	O	O
19	well	O	O
20	as	O	O
21	significant	O	O
22	improvements	O	O
23	in	O	O
24	emotional	O	O
25	lability	O	E-Disease
26	and	O	O
27	inattention	O	O
28	on	O	O
29	the	O	O
30	Conners	O	O
31	'	O	O
32	Parent	O	O
33	Rating	O	O
34	Scale	O	O
35	-	O	O
36	-	O	O
37	Revised	O	O
38	.	O	O

0	Overall	O	O
1	,	O	O
2	galantamine	S-Chemical	S-Chemical
3	was	O	O
4	well	O	O
5	-	O	O
6	tolerated	O	O
7	,	O	O
8	with	O	O
9	no	O	O
10	significant	O	O
11	adverse	O	O
12	effects	O	O
13	apart	O	O
14	from	O	O
15	headaches	S-Disease	S-Disease
16	in	O	O
17	one	O	O
18	patient	O	O
19	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	In	O	O
3	this	O	O
4	open	O	O
5	trial	O	O
6	,	O	O
7	galantamine	S-Chemical	S-Chemical
8	was	O	O
9	well	O	O
10	-	O	O
11	tolerated	O	O
12	and	O	O
13	appeared	O	O
14	to	O	O
15	be	O	O
16	beneficial	O	O
17	for	O	O
18	the	O	O
19	treatment	O	O
20	of	O	O
21	interfering	O	B-Disease
22	behaviors	O	E-Disease
23	in	O	O
24	children	O	O
25	with	O	O
26	autism	S-Disease	S-Disease
27	,	O	O
28	particularly	O	O
29	aggression	S-Disease	S-Disease
30	,	O	O
31	behavioral	B-Disease	B-Disease
32	dyscontrol	E-Disease	E-Disease
33	,	O	O
34	and	O	O
35	inattention	S-Disease	O
36	.	O	O

0	Randomized	O	O
1	comparison	O	O
2	of	O	O
3	olanzapine	S-Chemical	S-Chemical
4	versus	O	O
5	risperidone	S-Chemical	S-Chemical
6	for	O	O
7	the	O	O
8	treatment	O	O
9	of	O	O
10	first	O	O
11	-	O	O
12	episode	O	O
13	schizophrenia	S-Disease	S-Disease
14	:	O	O
15	4	O	O
16	-	O	O
17	month	O	O
18	outcomes	O	O
19	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	The	O	O
3	authors	O	O
4	compared	O	O
5	4	O	O
6	-	O	O
7	month	O	O
8	treatment	O	O
9	outcomes	O	O
10	for	O	O
11	olanzapine	S-Chemical	S-Chemical
12	versus	O	O
13	risperidone	S-Chemical	S-Chemical
14	in	O	O
15	patients	O	O
16	with	O	O
17	first	O	O
18	-	O	O
19	episode	O	O
20	schizophrenia	S-Disease	B-Disease
21	spectrum	O	I-Disease
22	disorders	O	E-Disease
23	.	O	O

0	METHOD	O	O
1	:	O	O
2	One	O	O
3	hundred	O	O
4	twelve	O	O
5	subjects	O	O
6	(	O	O
7	70	O	O
8	%	O	O
9	male	O	O
10	;	O	O
11	mean	O	O
12	age	O	O
13	=	O	O
14	23	O	O
15	.	O	O
16	3	O	O
17	years	O	O
18	[	O	O
19	SD	O	O
20	=	O	O
21	5	O	O
22	.	O	O
23	1	O	O
24	]	O	O
25	)	O	O
26	with	O	O
27	first	O	O
28	-	O	O
29	episode	O	O
30	schizophrenia	S-Disease	S-Disease
31	(	O	O
32	75	O	O
33	%	O	O
34	)	O	O
35	,	O	O
36	schizophreniform	B-Disease	B-Disease
37	disorder	E-Disease	E-Disease
38	(	O	O
39	17	O	O
40	%	O	O
41	)	O	O
42	,	O	O
43	or	O	O
44	schizoaffective	B-Disease	S-Disease
45	disorder	E-Disease	S-Disease
46	(	O	O
47	8	O	O
48	%	O	O
49	)	O	O
50	were	O	O
51	randomly	O	O
52	assigned	O	O
53	to	O	O
54	treatment	O	O
55	with	O	O
56	olanzapine	S-Chemical	S-Chemical
57	(	O	O
58	2	O	O
59	.	O	O
60	5	O	O
61	-	O	O
62	20	O	O
63	mg	O	O
64	/	O	O
65	day	O	O
66	)	O	O
67	or	O	O
68	risperidone	S-Chemical	S-Chemical
69	(	O	O
70	1	O	O
71	-	O	O
72	6	O	O
73	mg	O	O
74	/	O	O
75	day	O	O
76	)	O	O
77	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Response	O	O
3	rates	O	O
4	did	O	O
5	not	O	O
6	significantly	O	O
7	differ	O	O
8	between	O	O
9	olanzapine	S-Chemical	S-Chemical
10	(	O	O
11	43	O	O
12	.	O	O
13	7	O	O
14	%	O	O
15	,	O	O
16	95	O	O
17	%	O	O
18	CI	O	S-Chemical
19	=	O	O
20	28	O	O
21	.	O	O
22	8	O	O
23	%	O	O
24	-	O	O
25	58	O	O
26	.	O	O
27	6	O	O
28	%	O	O
29	)	O	O
30	and	O	O
31	risperidone	S-Chemical	S-Chemical
32	(	O	O
33	54	O	O
34	.	O	O
35	3	O	O
36	%	O	O
37	,	O	O
38	95	O	O
39	%	O	O
40	CI	O	S-Chemical
41	=	O	O
42	39	O	O
43	.	O	O
44	9	O	O
45	%	O	O
46	-	O	O
47	68	O	O
48	.	O	O
49	7	O	O
50	%	O	O
51	)	O	O
52	.	O	O

0	Among	O	O
1	those	O	O
2	responding	O	O
3	to	O	O
4	treatment	O	O
5	,	O	O
6	more	O	O
7	subjects	O	O
8	in	O	O
9	the	O	O
10	olanzapine	S-Chemical	S-Chemical
11	group	O	O
12	(	O	O
13	40	O	O
14	.	O	O
15	9	O	O
16	%	O	O
17	,	O	O
18	95	O	O
19	%	O	O
20	CI	O	S-Chemical
21	=	O	O
22	16	O	O
23	.	O	O
24	8	O	O
25	%	O	O
26	-	O	O
27	65	O	O
28	.	O	O
29	0	O	O
30	%	O	O
31	)	O	O
32	than	O	O
33	in	O	O
34	the	O	O
35	risperidone	S-Chemical	S-Chemical
36	group	O	O
37	(	O	O
38	18	O	O
39	.	O	O
40	9	O	O
41	%	O	O
42	,	O	O
43	95	O	O
44	%	O	O
45	CI	O	S-Chemical
46	=	O	O
47	0	O	O
48	%	O	O
49	-	O	O
50	39	O	O
51	.	O	O
52	2	O	O
53	%	O	O
54	)	O	O
55	had	O	O
56	subsequent	O	O
57	ratings	O	O
58	not	O	O
59	meeting	O	O
60	response	O	O
61	criteria	O	O
62	.	O	O

0	Negative	O	O
1	symptom	O	O
2	outcomes	O	O
3	and	O	O
4	measures	O	O
5	of	O	O
6	parkinsonism	S-Disease	S-Disease
7	and	O	O
8	akathisia	S-Disease	S-Disease
9	did	O	O
10	not	O	O
11	differ	O	O
12	between	O	O
13	medications	O	O
14	.	O	O

0	Extrapyramidal	B-Disease	O
1	symptom	E-Disease	O
2	severity	O	O
3	scores	O	O
4	were	O	O
5	1	O	O
6	.	O	O
7	4	O	O
8	(	O	O
9	95	O	O
10	%	O	O
11	CI	O	S-Chemical
12	=	O	O
13	1	O	O
14	.	O	O
15	2	O	O
16	-	O	O
17	1	O	O
18	.	O	O
19	6	O	O
20	)	O	O
21	with	O	O
22	risperidone	S-Chemical	S-Chemical
23	and	O	O
24	1	O	O
25	.	O	O
26	2	O	O
27	(	O	O
28	95	O	O
29	%	O	O
30	CI	O	S-Chemical
31	=	O	O
32	1	O	O
33	.	O	O
34	0	O	O
35	-	O	O
36	1	O	O
37	.	O	O
38	4	O	O
39	)	O	O
40	with	O	O
41	olanzapine	S-Chemical	S-Chemical
42	.	O	O

0	Significantly	O	O
1	more	O	O
2	weight	B-Disease	O
3	gain	E-Disease	O
4	occurred	O	O
5	with	O	O
6	olanzapine	S-Chemical	S-Chemical
7	than	O	O
8	with	O	O
9	risperidone	S-Chemical	S-Chemical
10	:	O	O
11	the	O	O
12	increase	O	O
13	in	O	O
14	weight	O	O
15	at	O	O
16	4	O	O
17	months	O	O
18	relative	O	O
19	to	O	O
20	baseline	O	O
21	weight	O	O
22	was	O	O
23	17	O	O
24	.	O	O
25	3	O	O
26	%	O	O
27	(	O	O
28	95	O	O
29	%	O	O
30	CI	O	S-Chemical
31	=	O	O
32	14	O	O
33	.	O	O
34	2	O	O
35	%	O	O
36	-	O	O
37	20	O	O
38	.	O	O
39	5	O	O
40	%	O	O
41	)	O	O
42	with	O	O
43	olanzapine	S-Chemical	S-Chemical
44	and	O	O
45	11	O	O
46	.	O	O
47	3	O	O
48	%	O	O
49	(	O	O
50	95	O	O
51	%	O	O
52	CI	O	S-Chemical
53	=	O	O
54	8	O	O
55	.	O	O
56	4	O	O
57	%	O	O
58	-	O	O
59	14	O	O
60	.	O	O
61	3	O	O
62	%	O	O
63	)	O	O
64	with	O	O
65	risperidone	S-Chemical	S-Chemical
66	.	O	O

0	Body	O	O
1	mass	O	O
2	index	O	O
3	at	O	O
4	baseline	O	O
5	and	O	O
6	at	O	O
7	4	O	O
8	months	O	O
9	was	O	O
10	24	O	O
11	.	O	O
12	3	O	O
13	(	O	O
14	95	O	O
15	%	O	O
16	CI	O	S-Chemical
17	=	O	O
18	22	O	O
19	.	O	O
20	8	O	O
21	-	O	O
22	25	O	O
23	.	O	O
24	7	O	O
25	)	O	O
26	versus	O	O
27	28	O	O
28	.	O	O
29	2	O	O
30	(	O	O
31	95	O	O
32	%	O	O
33	CI	O	S-Chemical
34	=	O	O
35	26	O	O
36	.	O	O
37	7	O	O
38	-	O	O
39	29	O	O
40	.	O	O
41	7	O	O
42	)	O	O
43	with	O	O
44	olanzapine	S-Chemical	S-Chemical
45	and	O	O
46	23	O	O
47	.	O	O
48	9	O	O
49	(	O	O
50	95	O	O
51	%	O	O
52	CI	O	O
53	=	O	O
54	22	O	O
55	.	O	O
56	5	O	O
57	-	O	O
58	25	O	O
59	.	O	O
60	3	O	O
61	)	O	O
62	versus	O	O
63	26	O	O
64	.	O	O
65	7	O	O
66	(	O	O
67	95	O	O
68	%	O	O
69	CI	O	S-Chemical
70	=	O	O
71	25	O	O
72	.	O	O
73	2	O	O
74	-	O	O
75	28	O	O
76	.	O	O
77	2	O	O
78	)	O	O
79	with	O	O
80	risperidone	S-Chemical	S-Chemical
81	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Clinical	O	O
3	outcomes	O	O
4	with	O	O
5	risperidone	S-Chemical	S-Chemical
6	were	O	O
7	equal	O	O
8	to	O	O
9	those	O	O
10	with	O	O
11	olanzapine	S-Chemical	S-Chemical
12	,	O	O
13	and	O	O
14	response	O	O
15	may	O	O
16	be	O	O
17	more	O	O
18	stable	O	O
19	.	O	O

0	Olanzapine	S-Chemical	S-Chemical
1	may	O	O
2	have	O	O
3	an	O	O
4	advantage	O	O
5	for	O	O
6	motor	O	O
7	side	O	O
8	effects	O	O
9	.	O	O

0	Both	O	O
1	medications	O	O
2	caused	O	O
3	substantial	O	O
4	rapid	O	O
5	weight	B-Disease	O
6	gain	E-Disease	O
7	,	O	O
8	but	O	O
9	weight	B-Disease	O
10	gain	E-Disease	O
11	was	O	O
12	greater	O	O
13	with	O	O
14	olanzapine	S-Chemical	S-Chemical
15	.	O	O

0	Early	O	O
1	paracentral	O	O
2	visual	B-Disease	O
3	field	I-Disease	I-Disease
4	loss	E-Disease	E-Disease
5	in	O	O
6	patients	O	O
7	taking	O	O
8	hydroxychloroquine	S-Chemical	S-Chemical
9	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	review	O	O
4	the	O	O
5	natural	O	O
6	history	O	O
7	and	O	O
8	ocular	O	B-Disease
9	and	O	O
10	systemic	O	O
11	adverse	O	O
12	effects	O	O
13	of	O	O
14	patients	O	O
15	taking	O	O
16	hydroxychloroquine	B-Chemical	S-Chemical
17	sulfate	E-Chemical	E-Chemical
18	who	O	O
19	attended	O	O
20	an	O	O
21	ophthalmic	O	S-Disease
22	screening	O	O
23	program	O	O
24	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Records	O	O
3	of	O	O
4	262	O	O
5	patients	O	O
6	who	O	O
7	were	O	O
8	taking	O	O
9	hydroxychloroquine	S-Chemical	S-Chemical
10	and	O	O
11	screened	O	O
12	in	O	O
13	the	O	O
14	Department	O	B-Disease
15	of	O	I-Disease
16	Ophthalmology	O	E-Chemical
17	were	O	O
18	reviewed	O	O
19	.	O	O

0	Thirty	O	O
1	-	O	O
2	five	O	O
3	patients	O	O
4	(	O	O
5	13	O	O
6	.	O	O
7	4	O	O
8	%	O	O
9	)	O	O
10	had	O	O
11	visual	B-Disease	O
12	field	I-Disease	I-Disease
13	abnormalities	E-Disease	E-Disease
14	,	O	O
15	which	O	O
16	were	O	O
17	attributed	O	O
18	to	O	O
19	hydroxychloroquine	S-Chemical	S-Chemical
20	treatment	O	O
21	in	O	O
22	4	O	O
23	patients	O	O
24	(	O	O
25	1	O	O
26	.	O	O
27	5	O	O
28	%	O	O
29	)	O	O
30	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	current	O	O
4	study	O	O
5	used	O	O
6	a	O	O
7	protocol	O	O
8	of	O	O
9	visual	O	O
10	acuity	O	O
11	and	O	O
12	color	O	O
13	vision	O	O
14	assessment	O	O
15	,	O	O
16	funduscopy	O	S-Disease
17	,	O	O
18	and	O	O
19	Humphrey	O	B-Chemical
20	10	O	E-Chemical
21	-	O	O
22	2	O	O
23	visual	O	O
24	field	O	O
25	testing	O	O
26	and	O	O
27	shows	O	O
28	that	O	O
29	visual	B-Disease	O
30	field	I-Disease	I-Disease
31	defects	E-Disease	E-Disease
32	appeared	O	O
33	before	O	O
34	any	O	O
35	corresponding	O	O
36	changes	O	O
37	in	O	O
38	any	O	O
39	other	O	O
40	tested	O	O
41	clinical	O	O
42	parameters	O	O
43	;	O	O
44	the	O	O
45	defects	O	S-Disease
46	were	O	O
47	reproducible	O	O
48	and	O	O
49	the	O	O
50	test	O	O
51	parameters	O	O
52	were	O	O
53	reliable	O	O
54	.	O	O

0	Patients	O	O
1	taking	O	O
2	hydroxychloroquine	S-Chemical	S-Chemical
3	can	O	O
4	demonstrate	O	O
5	a	O	O
6	toxic	O	O
7	reaction	O	O
8	in	O	O
9	the	O	O
10	retina	O	O
11	despite	O	O
12	the	O	O
13	absence	O	O
14	of	O	O
15	known	O	O
16	risk	O	O
17	factors	O	O
18	.	O	O

0	Peri	O	O
1	-	O	O
2	operative	O	O
3	atrioventricular	B-Disease	S-Disease
4	block	E-Disease	O
5	as	O	O
6	a	O	O
7	result	O	O
8	of	O	O
9	chemotherapy	O	O
10	with	O	O
11	epirubicin	S-Chemical	S-Chemical
12	and	O	O
13	paclitaxel	S-Chemical	S-Disease
14	.	O	O

0	A	O	O
1	47	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	woman	O	O
7	presented	O	O
8	for	O	O
9	mastectomy	O	S-Disease
10	and	O	O
11	immediate	O	O
12	latissimus	O	B-Disease
13	dorsi	O	I-Disease
14	flap	O	O
15	reconstruction	O	O
16	having	O	O
17	been	O	O
18	diagnosed	O	O
19	with	O	O
20	carcinoma	B-Disease	S-Disease
21	of	I-Disease	O
22	the	I-Disease	O
23	breast	E-Disease	O
24	6	O	O
25	months	O	O
26	previously	O	O
27	.	O	O

0	In	O	O
1	the	O	O
2	preceding	O	O
3	months	O	O
4	she	O	O
5	had	O	O
6	received	O	O
7	neo	O	O
8	-	O	O
9	adjuvant	O	O
10	chemotherapy	O	O
11	with	O	O
12	epirubicin	S-Chemical	S-Chemical
13	,	O	O
14	paclitaxel	S-Chemical	S-Chemical
15	(	O	O
16	Taxol	S-Chemical	S-Chemical
17	)	O	O
18	and	O	O
19	cyclophosphamide	S-Chemical	S-Chemical
20	.	O	O

0	She	O	O
1	was	O	O
2	found	O	O
3	to	O	O
4	be	O	O
5	bradycardic	S-Disease	O
6	at	O	O
7	pre	O	O
8	-	O	O
9	operative	O	O
10	assessment	O	O
11	but	O	O
12	had	O	O
13	no	O	O
14	cardiac	O	B-Disease
15	symptoms	O	O
16	.	O	O

0	Second	O	O
1	degree	O	O
2	Mobitz	O	S-Chemical
3	type	O	O
4	II	O	O
5	atrioventricular	B-Disease	B-Disease
6	block	E-Disease	E-Disease
7	was	O	O
8	diagnosed	O	O
9	on	O	O
10	electrocardiogram	O	O
11	,	O	O
12	and	O	O
13	temporary	O	O
14	transvenous	O	O
15	ventricular	O	S-Disease
16	pacing	O	O
17	instituted	O	O
18	in	O	O
19	the	O	O
20	peri	O	O
21	-	O	O
22	operative	O	O
23	period	O	O
24	.	O	O

0	We	O	O
1	discuss	O	O
2	how	O	O
3	evidence	O	O
4	-	O	O
5	based	O	O
6	guidelines	O	O
7	would	O	O
8	not	O	O
9	have	O	O
10	been	O	O
11	helpful	O	O
12	in	O	O
13	this	O	O
14	case	O	O
15	,	O	O
16	and	O	O
17	how	O	O
18	chemotherapy	O	O
19	can	O	O
20	exhibit	O	O
21	substantial	O	O
22	cardiotoxicity	S-Disease	S-Disease
23	that	O	O
24	may	O	O
25	develop	O	O
26	over	O	O
27	many	O	O
28	years	O	O
29	.	O	O

0	Risks	O	O
1	and	O	O
2	benefits	O	O
3	of	O	O
4	COX	B-Chemical	S-Chemical
5	-	I-Chemical	O
6	2	I-Chemical	O
7	inhibitors	E-Chemical	O
8	vs	O	O
9	non	O	O
10	-	O	O
11	selective	O	O
12	NSAIDs	O	S-Disease
13	:	O	O
14	does	O	O
15	their	O	O
16	cardiovascular	O	O
17	risk	O	O
18	exceed	O	O
19	their	O	O
20	gastrointestinal	O	B-Disease
21	benefit	O	O
22	?	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	The	O	O
3	risk	O	O
4	of	O	O
5	acute	B-Disease	B-Disease
6	myocardial	I-Disease	I-Disease
7	infarction	E-Disease	E-Disease
8	(	O	O
9	AMI	S-Disease	S-Chemical
10	)	O	O
11	with	O	O
12	COX	B-Chemical	S-Chemical
13	-	I-Chemical	E-Chemical
14	2	I-Chemical	O
15	inhibitors	E-Chemical	O
16	may	O	O
17	offset	O	O
18	their	O	O
19	gastrointestinal	O	S-Disease
20	(	O	O
21	GI	O	S-Disease
22	)	O	O
23	benefit	O	O
24	compared	O	O
25	with	O	O
26	non	O	O
27	-	O	O
28	selective	O	O
29	(	O	O
30	NS	O	O
31	)	O	O
32	non	B-Chemical	O
33	-	I-Chemical	O
34	steroidal	I-Chemical	S-Disease
35	anti	I-Chemical	O
36	-	I-Chemical	O
37	inflammatory	I-Chemical	S-Disease
38	drugs	E-Chemical	O
39	(	O	O
40	NSAIDs	O	O
41	)	O	O
42	.	O	O

0	We	O	O
1	aimed	O	O
2	to	O	O
3	compare	O	O
4	the	O	O
5	risks	O	O
6	of	O	O
7	hospitalization	O	O
8	for	O	O
9	AMI	S-Disease	S-Disease
10	and	O	O
11	GI	B-Disease	B-Disease
12	bleeding	E-Disease	E-Disease
13	among	O	O
14	elderly	O	O
15	patients	O	O
16	using	O	O
17	COX	B-Chemical	S-Chemical
18	-	I-Chemical	O
19	2	I-Chemical	O
20	inhibitors	E-Chemical	O
21	,	O	O
22	NS	O	S-Chemical
23	-	O	E-Chemical
24	NSAIDs	O	E-Chemical
25	and	O	O
26	acetaminophen	S-Chemical	S-Chemical
27	.	O	O

0	METHODS	O	O
1	:	O	O
2	We	O	O
3	conducted	O	O
4	a	O	O
5	retrospective	O	O
6	cohort	O	O
7	study	O	O
8	using	O	O
9	administrative	O	O
10	data	O	O
11	of	O	O
12	patients	O	O
13	>	O	O
14	or	O	O
15	=	O	O
16	65	O	O
17	years	O	O
18	of	O	O
19	age	O	O
20	who	O	O
21	filled	O	O
22	a	O	O
23	prescription	O	O
24	for	O	O
25	NSAID	O	S-Chemical
26	or	O	O
27	acetaminophen	S-Chemical	S-Chemical
28	during	O	O
29	1999	O	O
30	-	O	O
31	2002	O	O
32	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Person	O	O
3	-	O	O
4	years	O	O
5	of	O	O
6	exposure	O	O
7	among	O	O
8	non	O	O
9	-	O	O
10	users	O	O
11	of	O	O
12	aspirin	S-Chemical	S-Chemical
13	were	O	O
14	:	O	O
15	75	O	O
16	,	O	O
17	761	O	O
18	to	O	O
19	acetaminophen	S-Chemical	S-Chemical
20	,	O	O
21	42	O	O
22	,	O	O
23	671	O	O
24	to	O	O
25	rofecoxib	S-Chemical	S-Chemical
26	65	O	O
27	,	O	O
28	860	O	O
29	to	O	O
30	celecoxib	S-Chemical	S-Chemical
31	,	O	O
32	and	O	O
33	37	O	O
34	,	O	O
35	495	O	O
36	to	O	O
37	NS	O	O
38	-	O	O
39	NSAIDs	O	S-Disease
40	.	O	O

0	Among	O	O
1	users	O	O
2	of	O	O
3	aspirin	S-Chemical	S-Chemical
4	,	O	O
5	they	O	O
6	were	O	O
7	:	O	O
8	14	O	O
9	,	O	O
10	671	O	O
11	to	O	O
12	rofecoxib	S-Chemical	S-Chemical
13	,	O	O
14	22	O	O
15	,	O	O
16	875	O	O
17	to	O	O
18	celecoxib	S-Chemical	S-Chemical
19	,	O	O
20	9	O	O
21	,	O	O
22	832	O	O
23	to	O	O
24	NS	O	S-Disease
25	-	O	O
26	NSAIDs	O	S-Disease
27	and	O	O
28	38	O	O
29	,	O	O
30	048	O	O
31	to	O	O
32	acetaminophen	S-Chemical	S-Chemical
33	.	O	O

0	Among	O	O
1	non	O	O
2	-	O	O
3	users	O	O
4	of	O	O
5	aspirin	S-Chemical	S-Chemical
6	,	O	O
7	the	O	O
8	adjusted	O	O
9	hazard	O	O
10	ratios	O	O
11	(	O	O
12	95	O	O
13	%	O	O
14	confidence	O	O
15	interval	O	O
16	)	O	O
17	of	O	O
18	hospitalization	O	O
19	for	O	O
20	AMI	S-Disease	S-Chemical
21	/	O	I-Disease
22	GI	O	E-Chemical
23	vs	O	O
24	the	O	O
25	acetaminophen	S-Chemical	S-Chemical
26	(	O	O
27	with	O	O
28	no	O	O
29	aspirin	S-Chemical	S-Chemical
30	)	O	O
31	group	O	O
32	were	O	O
33	:	O	O
34	rofecoxib	S-Chemical	S-Chemical
35	1	O	O
36	.	O	O
37	27	O	O
38	(	O	O
39	1	O	O
40	.	O	O
41	13	O	O
42	,	O	O
43	1	O	O
44	.	O	O
45	42	O	O
46	)	O	O
47	,	O	O
48	celecoxib	S-Chemical	S-Chemical
49	0	O	O
50	.	O	O
51	93	O	O
52	(	O	O
53	0	O	O
54	.	O	O
55	83	O	O
56	,	O	O
57	1	O	O
58	.	O	O
59	03	O	O
60	)	O	O
61	,	O	O
62	naproxen	S-Chemical	S-Chemical
63	1	O	O
64	.	O	O
65	59	O	O
66	(	O	O
67	1	O	O
68	.	O	O
69	31	O	O
70	,	O	O
71	1	O	O
72	.	O	O
73	93	O	O
74	)	O	O
75	,	O	O
76	diclofenac	S-Chemical	S-Chemical
77	1	O	E-Chemical
78	.	O	O
79	17	O	O
80	(	O	O
81	0	O	O
82	.	O	O
83	99	O	O
84	,	O	O
85	1	O	O
86	.	O	O
87	38	O	O
88	)	O	O
89	and	O	O
90	ibuprofen	S-Chemical	S-Chemical
91	1	O	O
92	.	O	O
93	05	O	O
94	(	O	O
95	0	O	O
96	.	O	O
97	74	O	O
98	,	O	O
99	1	O	O
100	.	O	O
101	51	O	O
102	)	O	O
103	.	O	O

0	Among	O	O
1	users	O	O
2	of	O	O
3	aspirin	S-Chemical	S-Chemical
4	,	O	O
5	they	O	O
6	were	O	O
7	:	O	O
8	rofecoxib	S-Chemical	S-Chemical
9	1	O	O
10	.	O	O
11	73	O	O
12	(	O	O
13	1	O	O
14	.	O	O
15	52	O	O
16	,	O	O
17	1	O	O
18	.	O	O
19	98	O	O
20	)	O	O
21	,	O	O
22	celecoxib	S-Chemical	S-Chemical
23	1	O	O
24	.	O	O
25	34	O	O
26	(	O	O
27	1	O	O
28	.	O	O
29	19	O	O
30	,	O	O
31	1	O	O
32	.	O	O
33	52	O	O
34	)	O	O
35	,	O	O
36	ibuprofen	S-Chemical	S-Chemical
37	1	O	O
38	.	O	O
39	51	O	O
40	(	O	O
41	0	O	O
42	.	O	O
43	95	O	O
44	,	O	O
45	2	O	O
46	.	O	O
47	41	O	O
48	)	O	O
49	,	O	O
50	diclofenac	S-Chemical	S-Chemical
51	1	O	O
52	.	O	O
53	69	O	O
54	(	O	O
55	1	O	O
56	.	O	O
57	35	O	O
58	,	O	O
59	2	O	O
60	.	O	O
61	10	O	O
62	)	O	O
63	,	O	O
64	naproxen	S-Chemical	S-Chemical
65	1	O	O
66	.	O	O
67	35	O	O
68	(	O	O
69	0	O	O
70	.	O	O
71	97	O	O
72	,	O	O
73	1	O	O
74	.	O	O
75	88	O	O
76	)	O	O
77	and	O	O
78	acetaminophen	S-Chemical	S-Chemical
79	1	O	O
80	.	O	O
81	29	O	O
82	(	O	O
83	1	O	O
84	.	O	O
85	17	O	O
86	,	O	O
87	1	O	O
88	.	O	O
89	42	O	O
90	)	O	O
91	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Among	O	O
3	non	O	O
4	-	O	O
5	users	O	O
6	of	O	O
7	aspirin	S-Chemical	S-Chemical
8	,	O	O
9	naproxen	S-Chemical	S-Chemical
10	seemed	O	O
11	to	O	O
12	carry	O	O
13	the	O	O
14	highest	O	O
15	risk	O	O
16	for	O	O
17	AMI	S-Disease	B-Disease
18	/	O	I-Disease
19	GI	B-Disease	I-Disease
20	bleeding	E-Disease	E-Disease
21	.	O	O

0	The	O	O
1	AMI	S-Disease	B-Chemical
2	/	O	I-Disease
3	GI	O	I-Disease
4	toxicity	S-Disease	S-Disease
5	of	O	O
6	celecoxib	S-Chemical	S-Chemical
7	was	O	O
8	similar	O	O
9	to	O	O
10	that	O	O
11	of	O	O
12	acetaminophen	S-Chemical	S-Chemical
13	and	O	O
14	seemed	O	O
15	to	O	O
16	be	O	O
17	better	O	O
18	than	O	O
19	those	O	O
20	of	O	O
21	rofecoxib	S-Chemical	S-Chemical
22	and	O	O
23	NS	O	S-Chemical
24	-	O	E-Chemical
25	NSAIDs	O	E-Chemical
26	.	O	O

0	Among	O	O
1	users	O	O
2	of	O	O
3	aspirin	S-Chemical	S-Chemical
4	,	O	O
5	both	O	O
6	celecoxib	S-Chemical	S-Chemical
7	and	O	O
8	naproxen	S-Chemical	S-Chemical
9	seemed	O	O
10	to	O	O
11	be	O	O
12	the	O	O
13	least	O	O
14	toxic	O	O
15	.	O	O

0	Quinine	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	arrhythmia	S-Disease	S-Disease
4	in	O	O
5	a	O	O
6	patient	O	O
7	with	O	O
8	severe	B-Disease	O
9	malaria	E-Disease	S-Disease
10	.	O	O

0	It	O	O
1	was	O	O
2	reported	O	O
3	that	O	O
4	there	O	O
5	was	O	O
6	a	O	O
7	case	O	O
8	of	O	O
9	severe	B-Disease	O
10	malaria	E-Disease	S-Disease
11	patient	O	O
12	with	O	O
13	jaundice	S-Disease	S-Disease
14	who	O	O
15	presented	O	O
16	with	O	O
17	arrhythmia	S-Disease	O
18	(	O	O
19	premature	B-Disease	O
20	ventricular	I-Disease	B-Disease
21	contraction	E-Disease	E-Disease
22	)	O	O
23	while	O	O
24	getting	O	O
25	quinine	S-Chemical	S-Chemical
26	infusion	O	O
27	was	O	O
28	reported	O	O
29	.	O	O

0	A	O	O
1	man	O	O
2	,	O	O
3	25	O	O
4	years	O	O
5	old	O	O
6	,	O	O
7	was	O	O
8	admitted	O	O
9	to	O	O
10	hospital	O	O
11	with	O	O
12	high	O	O
13	fever	S-Disease	S-Disease
14	,	O	O
15	chill	S-Disease	O
16	,	O	O
17	vomiting	S-Disease	S-Disease
18	,	O	O
19	jaundice	S-Disease	O
20	.	O	O

0	On	O	O
1	admission	O	O
2	,	O	O
3	laboratory	O	O
4	examination	O	O
5	showed	O	O
6	Plasmodium	O	S-Chemical
7	falciparum	O	E-Chemical
8	(	O	O
9	+	O	O
10	+	O	O
11	+	O	O
12	+	O	O
13	)	O	O
14	,	O	O
15	total	O	O
16	bilirubin	S-Chemical	S-Chemical
17	8	O	O
18	.	O	O
19	25	O	O
20	mg	O	O
21	/	O	O
22	dL	O	O
23	,	O	O
24	conjugated	O	O
25	bilirubin	S-Chemical	S-Chemical
26	4	O	O
27	.	O	O
28	36	O	O
29	mg	O	O
30	/	O	O
31	dL	O	O
32	,	O	O
33	unconjugated	O	O
34	bilirubin	S-Chemical	S-Chemical
35	3	O	O
36	.	O	O
37	89	O	O
38	mg	O	O
39	/	O	O
40	dL	O	O
41	,	O	O
42	potassium	S-Chemical	O
43	3	O	O
44	.	O	O
45	52	O	O
46	meq	O	O
47	/	O	O
48	L	O	O
49	Patient	O	O
50	was	O	O
51	diagnosed	O	O
52	as	O	O
53	severe	B-Disease	O
54	malaria	E-Disease	S-Disease
55	with	O	O
56	jaundice	S-Disease	S-Disease
57	and	O	O
58	got	O	O
59	quinine	S-Chemical	S-Chemical
60	infusion	O	O
61	in	O	O
62	dextrose	S-Chemical	S-Chemical
63	5	O	O
64	%	O	O
65	500	O	O
66	mg	O	O
67	/	O	O
68	8	O	O
69	hour	O	O
70	.	O	O

0	On	O	O
1	the	O	O
2	second	O	O
3	day	O	O
4	the	O	O
5	patient	O	O
6	had	O	O
7	vomitus	S-Disease	S-Disease
8	,	O	O
9	diarrhea	S-Disease	S-Disease
10	,	O	O
11	tinnitus	S-Disease	S-Disease
12	,	O	O
13	loss	B-Disease	B-Disease
14	of	I-Disease	I-Disease
15	hearing	E-Disease	S-Disease
16	.	O	O

0	After	O	O
1	30	O	O
2	hours	O	O
3	of	O	O
4	quinine	S-Chemical	S-Chemical
5	infusion	O	O
6	the	O	O
7	patient	O	O
8	felt	O	O
9	palpitation	S-Disease	O
10	and	O	O
11	electrocardiography	O	O
12	(	O	O
13	ECG	O	S-Disease
14	)	O	O
15	recording	O	O
16	showed	O	O
17	premature	B-Disease	O
18	ventricular	I-Disease	B-Disease
19	contraction	E-Disease	E-Disease
20	(	O	O
21	PVC	S-Disease	S-Chemical
22	)	O	O
23	>	O	O
24	5	O	O
25	x	O	O
26	/	O	O
27	minute	O	O
28	,	O	O
29	trigemini	O	S-Disease
30	,	O	O
31	constant	O	O
32	type	O	O
33	-	O	O
34	-	O	O
35	sinoatrial	B-Disease	S-Disease
36	block	E-Disease	O
37	,	O	O
38	positive	O	O
39	U	O	S-Disease
40	wave	O	O
41	.	O	O

0	He	O	O
1	was	O	O
2	treated	O	O
3	with	O	O
4	lidocaine	S-Chemical	S-Chemical
5	50	O	O
6	mg	O	O
7	intravenously	O	O
8	followed	O	O
9	by	O	O
10	infusion	O	O
11	1500	O	O
12	mg	O	O
13	in	O	O
14	dextrose	S-Chemical	O
15	5	O	O
16	%	O	O
17	/	O	O
18	24	O	O
19	hour	O	O
20	and	O	O
21	potassium	B-Chemical	B-Chemical
22	aspartate	E-Chemical	E-Chemical
23	tablet	O	O
24	.	O	O

0	Quinine	S-Chemical	S-Chemical
1	infusion	O	O
2	was	O	O
3	discontinued	O	O
4	and	O	O
5	changed	O	O
6	with	O	O
7	sulfate	O	S-Chemical
8	quinine	S-Chemical	S-Chemical
9	tablets	O	O
10	.	O	O

0	Three	O	O
1	hours	O	O
2	later	O	O
3	the	O	O
4	patient	O	O
5	felt	O	O
6	better	O	O
7	,	O	O
8	the	O	O
9	frequency	O	O
10	of	O	O
11	PVC	S-Disease	S-Chemical
12	reduced	O	O
13	to	O	O
14	4	O	O
15	-	O	O
16	5	O	O
17	x	O	O
18	/	O	O
19	minute	O	O
20	and	O	O
21	on	O	O
22	the	O	O
23	third	O	O
24	day	O	O
25	ECG	O	S-Chemical
26	was	O	O
27	normal	O	O
28	,	O	O
29	potassium	S-Chemical	S-Chemical
30	level	O	O
31	was	O	O
32	3	O	O
33	.	O	O
34	34	O	O
35	meq	O	O
36	/	O	O
37	L	O	O
38	.	O	O

0	Quinine	S-Chemical	S-Chemical
1	,	O	O
2	like	O	O
3	quinidine	S-Chemical	S-Chemical
4	,	O	O
5	is	O	O
6	a	O	O
7	chincona	O	S-Chemical
8	alkaloid	O	E-Disease
9	that	O	O
10	has	O	O
11	anti	O	O
12	-	O	O
13	arrhythmic	S-Disease	O
14	property	O	O
15	,	O	O
16	although	O	O
17	it	O	O
18	also	O	O
19	pro	O	O
20	-	O	O
21	arrhythmic	S-Disease	O
22	that	O	O
23	can	O	O
24	cause	O	O
25	various	O	O
26	arrhythmias	S-Disease	O
27	,	O	O
28	including	O	O
29	severe	O	O
30	arrhythmia	S-Disease	S-Disease
31	such	O	O
32	as	O	O
33	multiple	O	O
34	PVC	S-Disease	S-Chemical
35	.	O	O

0	Administration	O	O
1	of	O	O
2	parenteral	O	O
3	quinine	S-Chemical	S-Chemical
4	must	O	O
5	be	O	O
6	done	O	O
7	carefully	O	O
8	and	O	O
9	with	O	O
10	good	O	O
11	observation	O	O
12	because	O	O
13	of	O	O
14	its	O	O
15	pro	O	O
16	-	O	O
17	arrhythmic	S-Disease	O
18	effect	O	O
19	,	O	O
20	especially	O	O
21	in	O	O
22	older	O	O
23	patients	O	O
24	who	O	O
25	have	O	O
26	heart	B-Disease	B-Disease
27	diseases	E-Disease	E-Disease
28	or	O	O
29	patients	O	O
30	with	O	O
31	electrolyte	B-Disease	O
32	disorder	E-Disease	S-Disease
33	(	O	O
34	hypokalemia	S-Disease	S-Disease
35	)	O	O
36	which	O	O
37	frequently	O	O
38	occurs	O	O
39	due	O	O
40	to	O	O
41	vomiting	S-Disease	S-Disease
42	and	O	O
43	or	O	O
44	diarrhea	S-Disease	S-Disease
45	in	O	O
46	malaria	S-Disease	S-Disease
47	cases	O	O
48	.	O	O

0	Penicillamine	S-Chemical	S-Chemical
1	-	O	O
2	related	O	O
3	lichenoid	B-Disease	B-Disease
4	dermatitis	E-Disease	E-Disease
5	and	O	O
6	utility	O	O
7	of	O	O
8	zinc	B-Chemical	B-Chemical
9	acetate	E-Chemical	E-Chemical
10	in	O	O
11	a	O	O
12	Wilson	B-Disease	B-Disease
13	disease	E-Disease	E-Disease
14	patient	O	O
15	with	O	O
16	hepatic	O	S-Disease
17	presentation	O	O
18	,	O	O
19	anxiety	S-Disease	S-Disease
20	and	O	O
21	SPECT	O	S-Disease
22	abnormalities	O	S-Disease
23	.	O	O

0	Wilson	B-Disease	I-Disease
1	'	I-Disease	I-Disease
2	s	I-Disease	I-Disease
3	disease	E-Disease	E-Disease
4	is	O	O
5	an	O	O
6	autosomal	O	O
7	recessive	O	O
8	disorder	O	S-Disease
9	of	O	O
10	hepatic	O	S-Disease
11	copper	S-Chemical	B-Disease
12	metabolism	O	E-Disease
13	with	O	O
14	consequent	O	O
15	copper	S-Chemical	B-Disease
16	accumulation	O	E-Disease
17	and	O	O
18	toxicity	S-Disease	S-Disease
19	in	O	O
20	many	O	O
21	tissues	O	O
22	and	O	O
23	consequent	O	O
24	hepatic	B-Disease	O
25	,	I-Disease	O
26	neurologic	I-Disease	O
27	and	I-Disease	O
28	psychiatric	I-Disease	B-Disease
29	disorders	E-Disease	E-Disease
30	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	Wilson	B-Disease	B-Disease
6	'	I-Disease	I-Disease
7	s	I-Disease	I-Disease
8	disease	E-Disease	E-Disease
9	with	O	O
10	chronic	B-Disease	B-Disease
11	liver	I-Disease	I-Disease
12	disease	E-Disease	E-Disease
13	;	O	O
14	moreover	O	O
15	,	O	O
16	in	O	O
17	our	O	O
18	patient	O	O
19	,	O	O
20	presenting	O	O
21	also	O	O
22	with	O	O
23	high	O	O
24	levels	O	O
25	of	O	O
26	state	O	B-Disease
27	anxiety	S-Disease	E-Disease
28	without	O	O
29	depression	S-Disease	S-Disease
30	,	O	O
31	99mTc	O	O
32	-	O	O
33	ECD	O	O
34	-	O	O
35	SPECT	O	O
36	showed	O	O
37	cortical	O	O
38	hypoperfusion	O	S-Disease
39	in	O	O
40	frontal	O	O
41	lobes	O	O
42	,	O	O
43	more	O	O
44	marked	O	O
45	on	O	O
46	the	O	O
47	left	O	O
48	frontal	O	O
49	lobe	O	O
50	.	O	O

0	During	O	O
1	the	O	O
2	follow	O	O
3	-	O	O
4	up	O	O
5	of	O	O
6	our	O	O
7	patient	O	O
8	,	O	O
9	penicillamine	S-Chemical	S-Chemical
10	was	O	O
11	interrupted	O	O
12	after	O	O
13	the	O	O
14	appearance	O	O
15	of	O	O
16	a	O	O
17	lichenoid	B-Disease	B-Disease
18	dermatitis	E-Disease	E-Disease
19	,	O	O
20	and	O	O
21	zinc	B-Chemical	B-Chemical
22	acetate	E-Chemical	E-Chemical
23	permitted	O	O
24	to	O	O
25	continue	O	O
26	the	O	O
27	successful	O	O
28	treatment	O	O
29	of	O	O
30	the	O	O
31	patient	O	O
32	without	O	O
33	side	O	O
34	-	O	O
35	effects	O	O
36	.	O	O

0	In	O	O
1	our	O	O
2	case	O	O
3	the	O	O
4	therapy	O	O
5	with	O	O
6	zinc	B-Chemical	S-Chemical
7	acetate	E-Chemical	E-Chemical
8	represented	O	O
9	an	O	O
10	effective	O	O
11	treatment	O	O
12	for	O	O
13	a	O	O
14	Wilson	B-Disease	B-Disease
15	'	I-Disease	I-Disease
16	s	I-Disease	I-Disease
17	disease	E-Disease	E-Disease
18	patient	O	O
19	in	O	O
20	which	O	O
21	penicillamine	S-Chemical	S-Chemical
22	-	O	O
23	related	O	O
24	side	O	O
25	effects	O	O
26	appeared	O	O
27	.	O	O

0	The	O	O
1	safety	O	O
2	of	O	O
3	the	O	O
4	zinc	B-Chemical	O
5	acetate	E-Chemical	E-Chemical
6	allowed	O	O
7	us	O	O
8	to	O	O
9	avoid	O	O
10	other	O	O
11	potentially	O	O
12	toxic	O	O
13	chelating	O	O
14	drugs	O	O
15	;	O	O
16	this	O	O
17	observation	O	O
18	is	O	O
19	in	O	O
20	line	O	O
21	with	O	O
22	the	O	O
23	growing	O	O
24	evidence	O	O
25	on	O	O
26	the	O	O
27	efficacy	O	O
28	of	O	O
29	the	O	O
30	drug	O	O
31	in	O	O
32	the	O	O
33	treatment	O	O
34	of	O	O
35	Wilson	B-Disease	B-Disease
36	'	I-Disease	I-Disease
37	s	I-Disease	I-Disease
38	disease	E-Disease	E-Disease
39	.	O	O

0	Since	O	O
1	most	O	O
2	of	O	O
3	Wilson	B-Disease	B-Disease
4	'	I-Disease	I-Disease
5	s	I-Disease	I-Disease
6	disease	E-Disease	S-Disease
7	penicillamine	S-Chemical	S-Disease
8	-	O	O
9	treated	O	O
10	patients	O	O
11	do	O	O
12	not	O	O
13	seem	O	O
14	to	O	O
15	develop	O	O
16	this	O	O
17	skin	B-Disease	B-Disease
18	lesion	E-Disease	E-Disease
19	,	O	O
20	it	O	O
21	could	O	O
22	be	O	O
23	conceivable	O	O
24	that	O	O
25	a	O	O
26	specific	O	O
27	genetic	O	O
28	factor	O	O
29	is	O	O
30	involved	O	O
31	in	O	O
32	drug	O	O
33	response	O	O
34	.	O	O

0	Further	O	O
1	studies	O	O
2	are	O	O
3	needed	O	O
4	for	O	O
5	a	O	O
6	better	O	O
7	clarification	O	O
8	of	O	O
9	Wilson	B-Disease	B-Disease
10	'	I-Disease	I-Disease
11	s	I-Disease	I-Disease
12	disease	E-Disease	E-Disease
13	therapy	O	O
14	,	O	O
15	and	O	O
16	in	O	O
17	particular	O	O
18	to	O	O
19	differentiate	O	O
20	specific	O	O
21	therapies	O	O
22	for	O	O
23	different	O	O
24	Wilson	B-Disease	B-Disease
25	'	I-Disease	I-Disease
26	s	I-Disease	I-Disease
27	disease	E-Disease	E-Disease
28	phenotypes	O	O
29	.	O	O

0	A	O	O
1	dramatic	O	O
2	drop	B-Disease	O
3	in	I-Disease	O
4	blood	I-Disease	O
5	pressure	E-Disease	O
6	following	O	O
7	prehospital	O	O
8	GTN	S-Chemical	S-Chemical
9	administration	O	O
10	.	O	O

0	A	O	O
1	male	O	O
2	in	O	O
3	his	O	O
4	sixties	O	O
5	with	O	O
6	no	O	O
7	history	O	O
8	of	O	O
9	cardiac	O	B-Disease
10	chest	B-Disease	I-Disease
11	pain	E-Disease	E-Disease
12	awoke	O	O
13	with	O	O
14	chest	B-Disease	O
15	pain	E-Disease	E-Disease
16	following	O	O
17	an	O	O
18	afternoon	O	O
19	sleep	O	O
20	.	O	O

0	The	O	O
1	patient	O	O
2	'	O	O
3	s	O	O
4	observations	O	O
5	were	O	O
6	within	O	O
7	normal	O	O
8	limits	O	O
9	,	O	O
10	he	O	O
11	was	O	O
12	administered	O	O
13	oxygen	S-Chemical	O
14	via	O	O
15	a	O	O
16	face	O	O
17	mask	O	O
18	and	O	O
19	glyceryl	B-Chemical	B-Chemical
20	trinitrate	E-Chemical	E-Chemical
21	(	O	O
22	GTN	S-Chemical	S-Chemical
23	)	O	O
24	.	O	O

0	Several	O	O
1	minutes	O	O
2	after	O	O
3	the	O	O
4	GTN	S-Chemical	S-Chemical
5	the	O	O
6	patient	O	O
7	experienced	O	O
8	a	O	O
9	sudden	O	O
10	drop	B-Disease	O
11	in	I-Disease	O
12	blood	I-Disease	O
13	pressure	E-Disease	O
14	and	O	O
15	heart	O	S-Disease
16	rate	O	O
17	,	O	O
18	this	O	O
19	was	O	O
20	rectified	O	O
21	by	O	O
22	atropine	B-Chemical	B-Chemical
23	sulphate	E-Chemical	E-Chemical
24	and	O	O
25	a	O	O
26	fluid	O	O
27	challenge	O	O
28	.	O	O

0	Prehospital	O	O
1	care	O	O
2	providers	O	O
3	who	O	O
4	are	O	O
5	managing	O	O
6	any	O	O
7	patient	O	O
8	with	O	O
9	a	O	O
10	syncopal	B-Disease	O
11	episode	E-Disease	O
12	that	O	O
13	fails	O	O
14	to	O	O
15	recover	O	O
16	within	O	O
17	a	O	O
18	reasonable	O	O
19	time	O	O
20	frame	O	O
21	should	O	O
22	consider	O	O
23	the	O	O
24	Bezold	O	S-Chemical
25	-	O	I-Disease
26	Jarisch	O	S-Disease
27	reflex	O	S-Disease
28	as	O	O
29	the	O	O
30	cause	O	O
31	and	O	O
32	manage	O	O
33	the	O	O
34	patient	O	O
35	accordingly	O	O
36	.	O	O

0	Chronic	O	O
1	lesion	O	O
2	of	O	O
3	rostral	O	B-Disease
4	ventrolateral	O	E-Disease
5	medulla	O	E-Disease
6	in	O	O
7	spontaneously	O	O
8	hypertensive	S-Disease	O
9	rats	O	O
10	.	O	O

0	We	O	O
1	studied	O	O
2	the	O	O
3	effects	O	O
4	of	O	O
5	chronic	O	S-Disease
6	selective	O	O
7	neuronal	O	B-Disease
8	lesion	O	E-Disease
9	of	O	O
10	rostral	O	B-Disease
11	ventrolateral	O	E-Disease
12	medulla	O	E-Disease
13	on	O	O
14	mean	O	O
15	arterial	O	B-Disease
16	pressure	O	E-Disease
17	,	O	O
18	heart	O	B-Disease
19	rate	O	E-Disease
20	,	O	O
21	and	O	O
22	neurogenic	O	O
23	tone	O	O
24	in	O	O
25	conscious	O	O
26	,	O	O
27	unrestrained	O	O
28	spontaneously	O	O
29	hypertensive	S-Disease	O
30	rats	O	O
31	.	O	O

0	The	O	O
1	lesions	O	O
2	were	O	O
3	placed	O	O
4	via	O	O
5	bilateral	O	O
6	microinjections	O	O
7	of	O	O
8	30	O	O
9	nmol	O	O
10	/	O	O
11	200	O	O
12	nl	O	O
13	N	B-Chemical	B-Chemical
14	-	I-Chemical	I-Chemical
15	methyl	I-Chemical	I-Chemical
16	-	I-Chemical	I-Chemical
17	D	I-Chemical	I-Chemical
18	-	I-Chemical	I-Chemical
19	aspartic	I-Chemical	E-Chemical
20	acid	E-Chemical	E-Disease
21	.	O	O

0	The	O	O
1	restimulation	O	O
2	of	O	O
3	this	O	O
4	area	O	O
5	with	O	O
6	N	B-Chemical	B-Chemical
7	-	I-Chemical	I-Chemical
8	methyl	I-Chemical	E-Chemical
9	-	I-Chemical	I-Chemical
10	D	I-Chemical	I-Chemical
11	-	I-Chemical	I-Chemical
12	aspartic	I-Chemical	E-Chemical
13	acid	E-Chemical	E-Disease
14	15	O	O
15	days	O	O
16	postlesion	O	O
17	failed	O	O
18	to	O	O
19	produce	O	O
20	a	O	O
21	pressor	O	S-Disease
22	response	O	O
23	.	O	O

0	The	O	O
1	ganglionic	O	S-Disease
2	blocker	O	O
3	trimethaphan	S-Chemical	S-Chemical
4	(	O	O
5	5	O	O
6	mg	O	O
7	/	O	O
8	kg	O	O
9	i	O	O
10	.	O	O
11	v	O	O
12	.	O	O
13	)	O	O
14	caused	O	O
15	similar	O	O
16	reductions	O	O
17	in	O	O
18	mean	O	O
19	arterial	O	B-Disease
20	pressure	O	E-Disease
21	in	O	O
22	both	O	O
23	lesioned	O	O
24	and	O	O
25	sham	O	S-Disease
26	groups	O	O
27	.	O	O

0	The	O	O
1	trimethaphan	S-Chemical	S-Chemical
2	-	O	O
3	induced	O	O
4	hypotension	S-Disease	S-Disease
5	was	O	O
6	accompanied	O	O
7	by	O	O
8	a	O	O
9	significant	O	O
10	bradycardia	S-Disease	O
11	in	O	O
12	lesioned	O	O
13	rats	O	O
14	(	O	O
15	-	O	O
16	32	O	O
17	+	O	O
18	/	O	O
19	-	O	O
20	13	O	O
21	beats	O	O
22	per	O	O
23	minute	O	O
24	)	O	O
25	but	O	O
26	a	O	O
27	tachycardia	S-Disease	O
28	in	O	O
29	sham	O	O
30	rats	O	O
31	(	O	O
32	+	O	O
33	33	O	O
34	+	O	O
35	/	O	O
36	-	O	O
37	12	O	O
38	beats	O	O
39	per	O	O
40	minute	O	O
41	)	O	O
42	1	O	O
43	day	O	O
44	postlesion	O	O
45	.	O	O

0	Therefore	O	O
1	,	O	O
2	rostral	O	B-Disease
3	ventrolateral	O	E-Disease
4	medulla	O	E-Disease
5	neurons	O	O
6	appear	O	O
7	to	O	O
8	play	O	O
9	a	O	O
10	significant	O	O
11	role	O	O
12	in	O	O
13	maintaining	O	O
14	hypertension	S-Disease	S-Disease
15	in	O	O
16	conscious	O	O
17	spontaneously	O	O
18	hypertensive	S-Disease	S-Disease
19	rats	O	O
20	.	O	O

0	Spinal	O	O
1	or	O	O
2	suprabulbar	O	S-Disease
3	structures	O	O
4	could	O	O
5	be	O	O
6	responsible	O	O
7	for	O	O
8	the	O	O
9	gradual	O	O
10	recovery	O	O
11	of	O	O
12	the	O	O
13	hypertension	S-Disease	S-Disease
14	in	O	O
15	the	O	O
16	lesioned	O	O
17	rats	O	O
18	.	O	O

0	Acute	B-Disease	O
1	encephalopathy	E-Disease	S-Disease
2	and	O	O
3	cerebral	B-Disease	B-Disease
4	vasospasm	E-Disease	E-Disease
5	after	O	O
6	multiagent	O	O
7	chemotherapy	O	O
8	including	O	O
9	PEG	B-Chemical	S-Chemical
10	-	I-Chemical	I-Disease
11	asparaginase	E-Chemical	E-Chemical
12	and	O	O
13	intrathecal	O	O
14	cytarabine	S-Chemical	S-Chemical
15	for	O	O
16	the	O	O
17	treatment	O	O
18	of	O	O
19	acute	B-Disease	B-Disease
20	lymphoblastic	I-Disease	I-Disease
21	leukemia	E-Disease	E-Disease
22	.	O	O

0	A	O	O
1	7	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	girl	O	O
7	with	O	O
8	an	O	O
9	unusual	O	O
10	reaction	O	O
11	to	O	O
12	induction	O	O
13	chemotherapy	O	O
14	for	O	O
15	precursor	O	O
16	B	O	O
17	-	O	O
18	cell	O	O
19	acute	B-Disease	I-Disease
20	lymphoblastic	I-Disease	I-Disease
21	leukemia	E-Disease	E-Disease
22	(	O	O
23	ALL	S-Disease	S-Disease
24	)	O	O
25	is	O	O
26	described	O	O
27	.	O	O

0	The	O	O
1	patient	O	O
2	developed	O	O
3	acute	B-Disease	S-Disease
4	encephalopathy	E-Disease	S-Disease
5	evidenced	O	O
6	by	O	O
7	behavioral	O	O
8	changes	O	O
9	,	O	O
10	aphasia	S-Disease	O
11	,	O	O
12	incontinence	S-Disease	O
13	,	O	O
14	visual	B-Disease	O
15	hallucinations	E-Disease	S-Disease
16	,	O	O
17	and	O	O
18	right	O	O
19	-	O	O
20	sided	O	O
21	weakness	S-Disease	S-Disease
22	with	O	O
23	diffuse	O	O
24	cerebral	B-Disease	B-Disease
25	vasospasm	E-Disease	E-Disease
26	on	O	O
27	magnetic	O	O
28	resonance	O	O
29	angiography	O	O
30	after	O	O
31	the	O	O
32	administration	O	O
33	of	O	O
34	intrathecal	O	O
35	cytarabine	S-Chemical	S-Chemical
36	.	O	O

0	Vincristine	S-Chemical	S-Chemical
1	,	O	O
2	dexamethasone	S-Chemical	S-Chemical
3	,	O	O
4	and	O	O
5	polyethylene	B-Chemical	S-Chemical
6	glycol	I-Chemical	E-Chemical
7	-	I-Chemical	O
8	asparaginase	E-Chemical	S-Chemical
9	were	O	O
10	also	O	O
11	administered	O	O
12	before	O	O
13	the	O	O
14	episode	O	O
15	as	O	O
16	part	O	O
17	of	O	O
18	induction	O	O
19	therapy	O	O
20	.	O	O

0	Comparison	O	O
1	of	O	O
2	valsartan	S-Chemical	S-Chemical
3	/	O	O
4	hydrochlorothiazide	S-Chemical	E-Chemical
5	combination	O	O
6	therapy	O	O
7	at	O	O
8	doses	O	O
9	up	O	O
10	to	O	O
11	320	O	O
12	/	O	O
13	25	O	O
14	mg	O	O
15	versus	O	O
16	monotherapy	O	O
17	:	O	O
18	a	O	O
19	double	O	O
20	-	O	O
21	blind	O	O
22	,	O	O
23	placebo	O	O
24	-	O	O
25	controlled	O	O
26	study	O	O
27	followed	O	O
28	by	O	O
29	long	O	O
30	-	O	O
31	term	O	O
32	combination	O	O
33	therapy	O	O
34	in	O	O
35	hypertensive	S-Disease	O
36	adults	O	O
37	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	One	O	O
3	third	O	O
4	of	O	O
5	patients	O	O
6	treated	O	O
7	for	O	O
8	hypertension	S-Disease	S-Disease
9	attain	O	O
10	adequate	O	O
11	blood	O	O
12	pressure	O	O
13	(	O	O
14	BP	O	O
15	)	O	O
16	control	O	O
17	,	O	O
18	and	O	O
19	multidrug	O	O
20	regimens	O	O
21	are	O	O
22	often	O	O
23	required	O	O
24	.	O	O

0	Given	O	O
1	the	O	O
2	lifelong	O	O
3	nature	O	O
4	of	O	O
5	hypertension	S-Disease	S-Disease
6	,	O	O
7	there	O	O
8	is	O	O
9	a	O	O
10	need	O	O
11	to	O	O
12	evaluate	O	O
13	the	O	O
14	long	O	O
15	-	O	O
16	term	O	O
17	efficacy	O	O
18	and	O	O
19	tolerability	O	O
20	of	O	O
21	higher	O	O
22	doses	O	O
23	of	O	O
24	combination	O	O
25	anti	O	O
26	-	O	O
27	hypertensive	S-Disease	S-Disease
28	therapies	O	O
29	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	This	O	O
3	study	O	O
4	investigated	O	O
5	the	O	O
6	efficacy	O	O
7	and	O	O
8	tolerability	O	O
9	of	O	O
10	valsartan	S-Chemical	S-Chemical
11	(	O	O
12	VAL	S-Chemical	S-Disease
13	)	O	O
14	or	O	O
15	hydrochlorothiazide	S-Chemical	S-Chemical
16	(	O	O
17	HCTZ	S-Chemical	S-Chemical
18	)	O	O
19	-	O	O
20	monotherapy	O	O
21	and	O	O
22	higher	O	O
23	-	O	O
24	dose	O	O
25	combinations	O	O
26	in	O	O
27	patients	O	O
28	with	O	O
29	essential	B-Disease	O
30	hypertension	E-Disease	S-Disease
31	.	O	O

0	Patients	O	O
1	with	O	O
2	essential	B-Disease	O
3	hypertension	E-Disease	S-Disease
4	(	O	O
5	mean	O	O
6	sitting	O	O
7	diastolic	O	S-Disease
8	BP	O	S-Disease
9	[	O	O
10	MSDBP	O	S-Disease
11	]	O	O
12	,	O	O
13	>	O	O
14	or	O	O
15	=	O	O
16	95	O	O
17	mm	O	O
18	Hg	O	O
19	and	O	O
20	<	O	O
21	110	O	O
22	mm	O	O
23	Hg	O	O
24	)	O	O
25	were	O	O
26	randomized	O	O
27	to	O	O
28	1	O	O
29	of	O	O
30	8	O	O
31	treatment	O	O
32	groups	O	O
33	:	O	O
34	VAL	S-Chemical	O
35	160	O	O
36	or	O	O
37	320	O	O
38	mg	O	O
39	;	O	O
40	HCTZ	S-Chemical	O
41	12	O	O
42	.	O	O
43	5	O	O
44	or	O	O
45	25	O	O
46	mg	O	O
47	;	O	O
48	VAL	S-Chemical	O
49	/	O	O
50	HCTZ	S-Chemical	O
51	160	O	O
52	/	O	O
53	12	O	O
54	.	O	O
55	5	O	O
56	,	O	O
57	320	O	O
58	/	O	O
59	12	O	O
60	.	O	O
61	5	O	O
62	,	O	O
63	or	O	O
64	320	O	O
65	/	O	O
66	25	O	O
67	mg	O	O
68	;	O	O
69	or	O	O
70	placebo	O	S-Disease
71	.	O	O

0	VAL	S-Chemical	O
1	/	O	O
2	HCTZ	S-Chemical	O
3	320	O	O
4	/	O	O
5	12	O	O
6	.	O	O
7	5	O	O
8	and	O	O
9	320	O	O
10	/	O	O
11	25	O	O
12	mg	O	O
13	were	O	O
14	further	O	O
15	investigated	O	O
16	in	O	O
17	a	O	O
18	54	O	O
19	-	O	O
20	week	O	O
21	,	O	O
22	open	O	O
23	-	O	O
24	label	O	O
25	extension	O	O
26	.	O	O

0	All	O	O
1	active	O	O
2	treatments	O	O
3	were	O	O
4	associated	O	O
5	with	O	O
6	significantly	O	O
7	reduced	O	O
8	MSSBP	O	S-Disease
9	and	O	O
10	MSDBP	O	S-Disease
11	during	O	O
12	the	O	O
13	core	O	O
14	8	O	O
15	-	O	O
16	week	O	O
17	study	O	O
18	,	O	O
19	with	O	O
20	each	O	O
21	monotherapy	O	O
22	significantly	O	O
23	contributing	O	O
24	to	O	O
25	the	O	O
26	overall	O	O
27	effect	O	O
28	of	O	O
29	combination	O	O
30	therapy	O	O
31	(	O	O
32	VAL	S-Chemical	S-Disease
33	and	O	O
34	HCTZ	S-Chemical	S-Disease
35	,	O	O
36	P	O	S-Disease
37	<	O	O
38	0	O	O
39	.	O	O
40	001	O	O
41	)	O	O
42	.	O	O

0	The	O	O
1	mean	O	O
2	reduction	O	O
3	in	O	O
4	MSSBP	O	S-Disease
5	/	O	O
6	MSDBP	O	S-Disease
7	with	O	O
8	VAL	S-Chemical	O
9	/	O	O
10	HCTZ	S-Chemical	O
11	320	O	O
12	/	O	O
13	25	O	O
14	mg	O	O
15	was	O	O
16	24	O	O
17	.	O	O
18	7	O	O
19	/	O	O
20	16	O	O
21	.	O	O
22	6	O	O
23	mm	O	O
24	Hg	O	O
25	,	O	O
26	compared	O	O
27	with	O	O
28	5	O	O
29	.	O	O
30	9	O	O
31	/	O	O
32	7	O	O
33	.	O	O
34	0	O	O
35	mm	O	O
36	Hg	O	O
37	with	O	O
38	placebo	O	O
39	.	O	O

0	The	O	O
1	reduction	O	O
2	in	O	O
3	MSSBP	O	S-Disease
4	was	O	O
5	significantly	O	O
6	greater	O	O
7	with	O	O
8	VAL	S-Chemical	O
9	/	O	O
10	HCTZ	S-Chemical	O
11	320	O	O
12	/	O	O
13	25	O	O
14	mg	O	O
15	compared	O	O
16	with	O	O
17	VAL	S-Chemical	O
18	/	O	O
19	HCTZ	S-Chemical	O
20	160	O	O
21	/	O	O
22	12	O	O
23	.	O	O
24	5	O	O
25	mg	O	O
26	(	O	O
27	P	O	O
28	<	O	O
29	0	O	O
30	.	O	O
31	002	O	O
32	)	O	O
33	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	hypokalemia	S-Disease	S-Disease
4	was	O	O
5	lower	O	O
6	with	O	O
7	VAL	S-Chemical	S-Disease
8	/	O	O
9	HCTZ	S-Chemical	E-Chemical
10	combinations	O	O
11	(	O	O
12	1	O	O
13	.	O	O
14	8	O	O
15	%	O	O
16	-	O	O
17	6	O	O
18	.	O	O
19	1	O	O
20	%	O	O
21	)	O	O
22	than	O	O
23	with	O	O
24	HCTZ	S-Chemical	S-Disease
25	monotherapies	O	S-Disease
26	(	O	O
27	7	O	O
28	.	O	O
29	1	O	O
30	%	O	O
31	-	O	O
32	13	O	O
33	.	O	O
34	3	O	O
35	%	O	O
36	)	O	O
37	.	O	O

0	The	O	O
1	efficacy	O	O
2	and	O	O
3	tolerability	O	O
4	of	O	O
5	VAL	S-Chemical	S-Disease
6	/	O	O
7	HCTZ	S-Chemical	S-Disease
8	combinations	O	O
9	were	O	O
10	maintained	O	O
11	during	O	O
12	the	O	O
13	extension	O	O
14	(	O	O
15	797	O	O
16	patients	O	O
17	)	O	O
18	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	In	O	O
3	this	O	O
4	study	O	O
5	population	O	O
6	,	O	O
7	combination	O	O
8	therapies	O	O
9	with	O	O
10	VAL	S-Chemical	S-Disease
11	/	O	I-Disease
12	HCTZ	S-Chemical	E-Chemical
13	were	O	O
14	associated	O	O
15	with	O	O
16	significantly	O	O
17	greater	O	O
18	BP	O	S-Chemical
19	reductions	O	O
20	compared	O	O
21	with	O	O
22	either	O	O
23	monotherapy	O	O
24	,	O	O
25	were	O	O
26	well	O	O
27	tolerated	O	O
28	,	O	O
29	and	O	O
30	were	O	O
31	associated	O	O
32	with	O	O
33	less	O	O
34	hypokalemia	S-Disease	S-Disease
35	than	O	O
36	HCTZ	S-Chemical	S-Disease
37	alone	O	O
38	.	O	O

0	Succimer	S-Chemical	O
1	chelation	O	O
2	improves	O	O
3	learning	O	O
4	,	O	O
5	attention	O	O
6	,	O	O
7	and	O	O
8	arousal	O	O
9	regulation	O	O
10	in	O	O
11	lead	S-Chemical	O
12	-	O	O
13	exposed	O	O
14	rats	O	O
15	but	O	O
16	produces	O	O
17	lasting	O	O
18	cognitive	B-Disease	B-Disease
19	impairment	E-Disease	E-Disease
20	in	O	O
21	the	O	O
22	absence	O	O
23	of	O	O
24	lead	S-Chemical	O
25	exposure	O	O
26	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	There	O	O
3	is	O	O
4	growing	O	O
5	pressure	O	O
6	for	O	O
7	clinicians	O	O
8	to	O	O
9	prescribe	O	O
10	chelation	O	S-Disease
11	therapy	O	O
12	at	O	O
13	only	O	O
14	slightly	O	O
15	elevated	O	O
16	blood	O	B-Disease
17	lead	S-Chemical	E-Disease
18	levels	O	O
19	.	O	O

0	However	O	O
1	,	O	O
2	very	O	O
3	few	O	O
4	studies	O	O
5	have	O	O
6	evaluated	O	O
7	whether	O	O
8	chelation	O	S-Disease
9	improves	O	O
10	cognitive	O	O
11	outcomes	O	O
12	in	O	O
13	Pb	S-Chemical	S-Disease
14	-	O	O
15	exposed	O	O
16	children	O	O
17	,	O	O
18	or	O	O
19	whether	O	O
20	these	O	O
21	agents	O	O
22	have	O	O
23	adverse	O	O
24	effects	O	O
25	that	O	O
26	may	O	O
27	affect	O	O
28	brain	O	O
29	development	O	E-Disease
30	in	O	O
31	the	O	O
32	absence	O	O
33	of	O	O
34	Pb	S-Chemical	S-Chemical
35	exposure	O	O
36	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	The	O	O
3	present	O	O
4	study	O	O
5	was	O	O
6	designed	O	O
7	to	O	O
8	answer	O	O
9	these	O	O
10	questions	O	O
11	,	O	O
12	using	O	O
13	a	O	O
14	rodent	O	O
15	model	O	O
16	of	O	O
17	early	O	O
18	childhood	O	O
19	Pb	S-Chemical	S-Chemical
20	exposure	O	O
21	and	O	O
22	treatment	O	O
23	with	O	O
24	succimer	S-Chemical	S-Disease
25	,	O	O
26	a	O	O
27	widely	O	O
28	used	O	O
29	chelating	O	O
30	agent	O	O
31	for	O	O
32	the	O	O
33	treatment	O	O
34	of	O	O
35	Pb	B-Disease	S-Chemical
36	poisoning	E-Disease	S-Disease
37	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Pb	S-Chemical	O
3	exposure	O	O
4	produced	O	O
5	lasting	O	O
6	impairments	B-Disease	O
7	in	I-Disease	O
8	learning	I-Disease	O
9	,	I-Disease	O
10	attention	I-Disease	O
11	,	I-Disease	O
12	inhibitory	I-Disease	O
13	control	I-Disease	O
14	,	I-Disease	O
15	and	I-Disease	O
16	arousal	I-Disease	O
17	regulation	E-Disease	O
18	,	O	O
19	paralleling	O	O
20	the	O	O
21	areas	O	O
22	of	O	O
23	dysfunction	O	S-Disease
24	seen	O	O
25	in	O	O
26	Pb	S-Chemical	S-Chemical
27	-	O	O
28	exposed	O	O
29	children	O	O
30	.	O	O

0	Succimer	S-Chemical	O
1	treatment	O	O
2	of	O	O
3	the	O	O
4	Pb	S-Chemical	S-Chemical
5	-	O	O
6	exposed	O	O
7	rats	O	O
8	significantly	O	O
9	improved	O	O
10	learning	O	O
11	,	O	O
12	attention	O	O
13	,	O	O
14	and	O	O
15	arousal	O	O
16	regulation	O	O
17	,	O	O
18	although	O	O
19	the	O	O
20	efficacy	O	O
21	of	O	O
22	the	O	O
23	treatment	O	O
24	varied	O	O
25	as	O	O
26	a	O	O
27	function	O	O
28	of	O	O
29	the	O	O
30	Pb	S-Chemical	S-Disease
31	exposure	O	O
32	level	O	O
33	and	O	O
34	the	O	O
35	specific	O	O
36	functional	O	O
37	deficit	O	O
38	.	O	O

0	In	O	O
1	contrast	O	O
2	,	O	O
3	succimer	S-Chemical	O
4	treatment	O	O
5	of	O	O
6	rats	O	O
7	not	O	O
8	previously	O	O
9	exposed	O	O
10	to	O	O
11	Pb	S-Chemical	S-Chemical
12	produced	O	O
13	lasting	O	O
14	and	O	O
15	pervasive	O	O
16	cognitive	B-Disease	B-Disease
17	and	I-Disease	O
18	affective	I-Disease	B-Disease
19	dysfunction	E-Disease	E-Disease
20	comparable	O	O
21	in	O	O
22	magnitude	O	O
23	to	O	O
24	that	O	O
25	produced	O	O
26	by	O	O
27	the	O	O
28	higher	O	O
29	Pb	S-Chemical	O
30	exposure	O	O
31	regimen	O	O
32	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	These	O	O
3	are	O	O
4	the	O	O
5	first	O	O
6	data	O	O
7	,	O	O
8	to	O	O
9	our	O	O
10	knowledge	O	O
11	,	O	O
12	to	O	O
13	show	O	O
14	that	O	O
15	treatment	O	O
16	with	O	O
17	any	O	O
18	chelating	O	O
19	agent	O	O
20	can	O	O
21	alleviate	O	O
22	cognitive	B-Disease	B-Disease
23	deficits	E-Disease	E-Disease
24	due	O	O
25	to	O	O
26	Pb	S-Chemical	S-Chemical
27	exposure	O	O
28	.	O	O

0	These	O	O
1	findings	O	O
2	suggest	O	O
3	that	O	O
4	it	O	O
5	may	O	O
6	be	O	O
7	possible	O	O
8	to	O	O
9	identify	O	O
10	a	O	O
11	succimer	S-Chemical	O
12	treatment	O	O
13	protocol	O	O
14	that	O	O
15	improves	O	O
16	cognitive	O	O
17	outcomes	O	O
18	in	O	O
19	Pb	S-Chemical	S-Disease
20	-	O	O
21	exposed	O	O
22	children	O	O
23	.	O	O

0	However	O	O
1	,	O	O
2	they	O	O
3	also	O	O
4	suggest	O	O
5	that	O	O
6	succimer	S-Chemical	S-Chemical
7	treatment	O	O
8	should	O	O
9	be	O	O
10	strongly	O	O
11	discouraged	O	O
12	for	O	O
13	children	O	O
14	who	O	O
15	do	O	O
16	not	O	O
17	have	O	O
18	elevated	O	O
19	tissue	O	O
20	levels	O	O
21	of	O	O
22	Pb	S-Chemical	S-Chemical
23	or	O	O
24	other	O	O
25	heavy	O	O
26	metals	O	O
27	.	O	O

0	Caffeine	S-Chemical	S-Chemical
1	challenge	O	O
2	test	O	O
3	in	O	O
4	panic	B-Disease	B-Disease
5	disorder	E-Disease	E-Disease
6	and	O	O
7	depression	S-Disease	S-Disease
8	with	O	O
9	panic	B-Disease	B-Disease
10	attacks	E-Disease	E-Disease
11	.	O	O

0	Our	O	O
1	aim	O	O
2	was	O	O
3	to	O	O
4	observe	O	O
5	if	O	O
6	patients	O	O
7	with	O	O
8	panic	B-Disease	B-Disease
9	disorder	E-Disease	E-Disease
10	(	O	O
11	PD	S-Disease	S-Disease
12	)	O	O
13	and	O	O
14	patients	O	O
15	with	O	O
16	major	B-Disease	O
17	depression	E-Disease	B-Disease
18	with	O	O
19	panic	B-Disease	B-Disease
20	attacks	E-Disease	E-Disease
21	(	O	O
22	MDP	S-Disease	S-Chemical
23	)	O	O
24	(	O	O
25	Diagnostic	O	O
26	and	O	O
27	Statistical	O	B-Disease
28	Manual	O	I-Disease
29	of	O	I-Disease
30	Mental	B-Disease	I-Disease
31	Disorders	E-Disease	E-Disease
32	,	O	O
33	Fourth	O	O
34	Edition	O	O
35	criteria	O	O
36	)	O	O
37	respond	O	O
38	in	O	O
39	a	O	O
40	similar	O	O
41	way	O	O
42	to	O	O
43	the	O	O
44	induction	O	O
45	of	O	O
46	panic	B-Disease	B-Disease
47	attacks	E-Disease	E-Disease
48	by	O	O
49	an	O	O
50	oral	O	O
51	caffeine	S-Chemical	S-Chemical
52	challenge	O	O
53	test	O	O
54	.	O	O

0	We	O	O
1	randomly	O	O
2	selected	O	O
3	29	O	O
4	patients	O	O
5	with	O	O
6	PD	S-Disease	S-Disease
7	,	O	O
8	27	O	O
9	with	O	O
10	MDP	S-Disease	S-Chemical
11	,	O	O
12	25	O	O
13	with	O	O
14	major	B-Disease	O
15	depression	E-Disease	S-Disease
16	without	O	O
17	panic	B-Disease	B-Disease
18	attacks	E-Disease	E-Disease
19	(	O	O
20	MD	S-Disease	S-Disease
21	)	O	O
22	,	O	O
23	and	O	O
24	28	O	O
25	healthy	O	O
26	volunteers	O	O
27	.	O	O

0	In	O	O
1	a	O	O
2	randomized	O	O
3	double	O	O
4	-	O	O
5	blind	O	O
6	experiment	O	O
7	performed	O	O
8	in	O	O
9	2	O	O
10	occasions	O	O
11	7	O	O
12	days	O	O
13	apart	O	O
14	,	O	O
15	480	O	O
16	mg	O	O
17	caffeine	S-Chemical	S-Chemical
18	and	O	O
19	a	O	O
20	caffeine	S-Chemical	S-Chemical
21	-	O	O
22	free	O	O
23	(	O	O
24	placebo	O	O
25	)	O	O
26	solution	O	O
27	were	O	O
28	administered	O	O
29	in	O	O
30	a	O	O
31	coffee	O	O
32	form	O	O
33	and	O	O
34	anxiety	S-Disease	S-Disease
35	scales	O	O
36	were	O	O
37	applied	O	O
38	before	O	O
39	and	O	O
40	after	O	O
41	each	O	O
42	test	O	O
43	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	58	O	O
4	.	O	O
5	6	O	O
6	%	O	O
7	(	O	O
8	n	O	O
9	=	O	O
10	17	O	O
11	)	O	O
12	of	O	O
13	patients	O	O
14	with	O	O
15	PD	S-Disease	S-Disease
16	,	O	O
17	44	O	O
18	.	O	O
19	4	O	O
20	%	O	O
21	(	O	O
22	n	O	O
23	=	O	O
24	12	O	O
25	)	O	O
26	of	O	O
27	patients	O	O
28	with	O	O
29	MDP	S-Disease	S-Chemical
30	,	O	O
31	12	O	O
32	.	O	O
33	0	O	O
34	%	O	O
35	(	O	O
36	n	O	O
37	=	O	O
38	3	O	O
39	)	O	O
40	of	O	O
41	patients	O	O
42	with	O	O
43	MD	S-Disease	S-Disease
44	,	O	O
45	and	O	O
46	7	O	O
47	.	O	O
48	1	O	O
49	%	O	O
50	(	O	O
51	n	O	O
52	=	O	O
53	2	O	O
54	)	O	O
55	of	O	O
56	control	O	O
57	subjects	O	O
58	had	O	O
59	a	O	O
60	panic	B-Disease	S-Disease
61	attack	E-Disease	O
62	after	O	O
63	the	O	O
64	480	O	O
65	-	O	O
66	mg	O	O
67	caffeine	S-Chemical	S-Chemical
68	challenge	O	O
69	test	O	O
70	(	O	O
71	chi	O	S-Disease
72	(	O	O
73	2	O	O
74	)	O	O
75	(	O	O
76	3	O	O
77	)	O	O
78	=	O	O
79	16	O	O
80	.	O	O
81	22	O	O
82	,	O	O
83	P	O	S-Disease
84	=	O	O
85	.	O	O
86	001	O	O
87	)	O	O
88	.	O	O

0	The	O	O
1	patients	O	O
2	with	O	O
3	PD	S-Disease	S-Disease
4	and	O	O
5	MDP	S-Disease	S-Chemical
6	were	O	O
7	more	O	O
8	sensitive	O	O
9	to	O	O
10	caffeine	S-Chemical	S-Chemical
11	than	O	O
12	were	O	O
13	patients	O	O
14	with	O	O
15	MD	S-Disease	S-Disease
16	and	O	O
17	healthy	O	O
18	volunteers	O	O
19	.	O	O

0	No	O	O
1	panic	B-Disease	O
2	attack	E-Disease	O
3	was	O	O
4	observed	O	O
5	after	O	O
6	the	O	O
7	caffeine	S-Chemical	S-Chemical
8	-	O	O
9	free	O	O
10	solution	O	O
11	intake	O	O
12	.	O	O

0	The	O	O
1	patients	O	O
2	with	O	O
3	MD	S-Disease	S-Disease
4	had	O	O
5	a	O	O
6	lower	O	O
7	heart	O	O
8	rate	O	O
9	response	O	O
10	to	O	O
11	the	O	O
12	test	O	O
13	than	O	O
14	all	O	O
15	the	O	O
16	other	O	O
17	groups	O	O
18	(	O	O
19	2	O	O
20	-	O	O
21	way	O	O
22	analysis	O	O
23	of	O	O
24	variance	O	O
25	,	O	O
26	group	O	O
27	by	O	O
28	time	O	O
29	interaction	O	O
30	with	O	O
31	Greenhouse	O	S-Chemical
32	-	O	O
33	Geisser	O	S-Chemical
34	correction	O	O
35	:	O	O
36	F	O	S-Disease
37	(	O	O
38	3	O	O
39	,	O	O
40	762	O	O
41	)	O	O
42	=	O	O
43	2	O	O
44	.	O	O
45	85	O	O
46	,	O	O
47	P	O	O
48	=	O	O
49	.	O	O
50	026	O	O
51	)	O	O
52	.	O	O

0	Our	O	O
1	data	O	O
2	suggest	O	O
3	that	O	O
4	there	O	O
5	is	O	O
6	an	O	O
7	association	O	O
8	between	O	O
9	panic	B-Disease	B-Disease
10	attacks	E-Disease	E-Disease
11	,	O	O
12	no	O	O
13	matter	O	O
14	if	O	O
15	associated	O	O
16	with	O	O
17	PD	S-Disease	S-Disease
18	or	O	O
19	MDP	S-Disease	S-Chemical
20	,	O	O
21	and	O	O
22	hyperreactivity	O	S-Disease
23	to	O	O
24	an	O	O
25	oral	O	O
26	caffeine	S-Chemical	S-Chemical
27	challenge	O	O
28	test	O	O
29	.	O	O

0	Mitral	O	B-Disease
1	annuloplasty	O	E-Disease
2	as	O	O
3	a	O	O
4	ventricular	O	S-Disease
5	restoration	O	O
6	method	O	O
7	for	O	O
8	the	O	O
9	failing	B-Disease	O
10	left	I-Disease	B-Disease
11	ventricle	E-Disease	E-Disease
12	:	O	O
13	a	O	O
14	pilot	O	O
15	study	O	O
16	.	O	O

0	BACKGROUND	O	O
1	AND	O	O
2	AIM	O	O
3	OF	O	O
4	THE	O	O
5	STUDY	O	O
6	:	O	O
7	Undersized	O	O
8	mitral	O	B-Disease
9	annuloplasty	O	E-Disease
10	(	O	O
11	MAP	O	S-Chemical
12	)	O	O
13	is	O	O
14	effective	O	O
15	in	O	O
16	patients	O	O
17	with	O	O
18	dilated	B-Disease	O
19	cardiomyopathy	E-Disease	S-Disease
20	and	O	O
21	functional	O	O
22	mitral	B-Disease	B-Disease
23	regurgitation	E-Disease	O
24	(	O	O
25	MR	S-Disease	S-Disease
26	)	O	O
27	since	O	O
28	,	O	O
29	as	O	O
30	well	O	O
31	as	O	O
32	addressing	O	O
33	the	O	O
34	MR	S-Disease	S-Disease
35	,	O	O
36	the	O	O
37	MAP	O	S-Disease
38	may	O	O
39	also	O	O
40	reshape	O	O
41	the	O	O
42	dilated	O	S-Disease
43	left	O	O
44	ventricular	O	S-Disease
45	(	O	O
46	LV	O	S-Disease
47	)	O	O
48	base	O	O
49	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	direct	O	O
4	benefits	O	O
5	of	O	O
6	this	O	O
7	possible	O	O
8	reshaping	O	O
9	on	O	O
10	LV	O	S-Disease
11	function	O	S-Disease
12	in	O	O
13	the	O	O
14	absence	O	O
15	of	O	O
16	underlying	O	O
17	MR	S-Disease	S-Disease
18	remain	O	O
19	incompletely	O	O
20	understood	O	O
21	.	O	O

0	The	O	O
1	study	O	O
2	aim	O	O
3	was	O	O
4	to	O	O
5	identify	O	O
6	these	O	O
7	benefits	O	O
8	in	O	O
9	a	O	O
10	canine	O	S-Disease
11	model	O	O
12	of	O	O
13	acute	O	B-Disease
14	heart	B-Disease	I-Disease
15	failure	E-Disease	E-Disease
16	.	O	O

0	Acute	O	O
1	heart	B-Disease	B-Disease
2	failure	E-Disease	E-Disease
3	was	O	O
4	induced	O	O
5	by	O	O
6	propranolol	S-Chemical	S-Chemical
7	and	O	O
8	volume	O	O
9	loading	O	O
10	after	O	O
11	weaning	O	O
12	from	O	O
13	cardiopulmonary	O	B-Disease
14	bypass	O	E-Disease
15	;	O	O
16	an	O	O
17	absence	O	O
18	of	O	O
19	MR	S-Disease	S-Disease
20	was	O	O
21	confirmed	O	O
22	by	O	O
23	echocardiography	O	O
24	.	O	O

0	Data	O	O
1	were	O	O
2	acquired	O	O
3	at	O	O
4	baseline	O	O
5	,	O	O
6	after	O	O
7	induction	O	O
8	of	O	O
9	acute	O	B-Disease
10	heart	B-Disease	I-Disease
11	failure	E-Disease	E-Disease
12	,	O	O
13	and	O	O
14	after	O	O
15	MAP	O	S-Chemical
16	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	The	O	O
3	data	O	O
4	acquired	O	O
5	suggest	O	O
6	that	O	O
7	isolated	O	O
8	MAP	O	S-Chemical
9	may	O	O
10	have	O	O
11	certain	O	O
12	benefits	O	O
13	on	O	O
14	LV	O	S-Disease
15	dimension	O	O
16	/	O	O
17	function	O	O
18	in	O	O
19	acute	O	B-Disease
20	heart	B-Disease	I-Disease
21	failure	E-Disease	E-Disease
22	,	O	O
23	even	O	O
24	in	O	O
25	the	O	O
26	absence	O	O
27	of	O	O
28	MR	S-Disease	S-Disease
29	.	O	O

0	However	O	O
1	,	O	O
2	further	O	O
3	investigations	O	O
4	are	O	O
5	warranted	O	O
6	in	O	O
7	a	O	O
8	model	O	O
9	of	O	O
10	chronic	O	B-Disease
11	heart	B-Disease	I-Disease
12	failure	E-Disease	E-Disease
13	.	O	O

0	Piperacillin	B-Chemical	S-Chemical
1	/	I-Chemical	O
2	tazobactam	E-Chemical	E-Chemical
3	-	O	O
4	induced	O	O
5	seizure	S-Disease	S-Disease
6	rapidly	O	O
7	reversed	O	O
8	by	O	O
9	high	O	O
10	flux	O	O
11	hemodialysis	O	O
12	in	O	O
13	a	O	O
14	patient	O	O
15	on	O	O
16	peritoneal	O	O
17	dialysis	O	S-Disease
18	.	O	O

0	Despite	O	O
1	popular	O	O
2	use	O	O
3	of	O	O
4	piperacillin	S-Chemical	S-Chemical
5	,	O	O
6	the	O	O
7	dire	O	O
8	neurotoxicity	S-Disease	O
9	associated	O	O
10	with	O	O
11	piperacillin	S-Chemical	S-Chemical
12	still	O	O
13	goes	O	O
14	unrecognized	O	O
15	,	O	O
16	leading	O	O
17	to	O	O
18	a	O	O
19	delay	O	O
20	in	O	O
21	appropriate	O	O
22	management	O	O
23	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	57	O	O
4	-	O	O
5	year	O	O
6	-	O	O
7	old	O	O
8	woman	O	O
9	with	O	O
10	end	B-Disease	O
11	-	I-Disease	O
12	stage	I-Disease	O
13	renal	I-Disease	B-Disease
14	disease	E-Disease	E-Disease
15	receiving	O	O
16	continuous	O	O
17	ambulatory	O	O
18	peritoneal	O	O
19	dialysis	O	O
20	(	O	O
21	CAPD	O	S-Disease
22	)	O	O
23	,	O	O
24	who	O	O
25	developed	O	O
26	slurred	O	O
27	speech	O	O
28	,	O	O
29	tremor	S-Disease	S-Disease
30	,	O	O
31	bizarre	O	O
32	behavior	O	O
33	,	O	O
34	progressive	O	O
35	mental	O	O
36	confusion	S-Disease	E-Disease
37	,	O	O
38	and	O	O
39	2	O	O
40	episodes	O	O
41	of	O	O
42	generalized	O	O
43	tonic	B-Disease	B-Disease
44	-	I-Disease	I-Disease
45	clonic	I-Disease	I-Disease
46	seizure	E-Disease	S-Disease
47	(	O	O
48	GTCS	S-Disease	S-Chemical
49	)	O	O
50	after	O	O
51	5	O	O
52	doses	O	O
53	of	O	O
54	piperacillin	B-Chemical	B-Chemical
55	/	I-Chemical	I-Chemical
56	tazobactam	E-Chemical	E-Chemical
57	(	O	O
58	2	O	O
59	g	O	O
60	/	O	O
61	250	O	O
62	mg	O	O
63	)	O	O
64	were	O	O
65	given	O	O
66	for	O	O
67	bronchiectasis	S-Disease	S-Disease
68	with	O	O
69	secondary	B-Disease	O
70	infection	E-Disease	S-Disease
71	.	O	O

0	The	O	O
1	laboratory	O	O
2	data	O	O
3	revealed	O	O
4	normal	O	O
5	plasma	O	O
6	electrolyte	O	O
7	and	O	O
8	ammonia	S-Chemical	S-Chemical
9	levels	O	O
10	but	O	O
11	leukocytosis	S-Disease	S-Disease
12	.	O	O

0	Neurologic	O	O
1	examinations	O	O
2	showed	O	O
3	dysarthria	S-Disease	S-Disease
4	and	O	O
5	bilateral	O	O
6	Babinski	O	S-Chemical
7	sign	O	O
8	.	O	O

0	Despite	O	O
1	the	O	O
2	use	O	O
3	of	O	O
4	antiepileptic	O	O
5	agents	O	O
6	,	O	O
7	another	O	O
8	GTCS	S-Disease	S-Chemical
9	episode	O	O
10	recurred	O	O
11	after	O	O
12	the	O	O
13	sixth	O	O
14	dose	O	O
15	of	O	O
16	piperacillin	B-Chemical	S-Chemical
17	/	I-Chemical	I-Disease
18	tazobactam	E-Chemical	E-Chemical
19	.	O	O

0	Brain	O	O
1	magnetic	O	I-Disease
2	resonance	O	O
3	imaging	O	O
4	did	O	O
5	not	O	O
6	demonstrate	O	O
7	acute	O	O
8	infarction	S-Disease	O
9	and	O	O
10	organic	B-Disease	B-Disease
11	brain	I-Disease	I-Disease
12	lesions	E-Disease	E-Disease
13	.	O	O

0	Piperacillin	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	encephalopathy	S-Disease	S-Disease
4	should	O	O
5	be	O	O
6	considered	O	O
7	in	O	O
8	any	O	O
9	uremic	S-Disease	S-Disease
10	patients	O	O
11	with	O	O
12	unexplained	O	O
13	neurological	O	O
14	manifestations	O	O
15	.	O	O

0	CAPD	O	S-Chemical
1	is	O	O
2	inefficient	O	O
3	in	O	O
4	removing	O	O
5	piperacillin	S-Chemical	S-Chemical
6	,	O	O
7	whereas	O	O
8	hemodialysis	O	O
9	can	O	O
10	rapidly	O	O
11	terminate	O	O
12	the	O	O
13	piperacillin	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	encephalopathy	S-Disease	S-Disease
17	.	O	O

0	Frequency	O	O
1	of	O	O
2	transient	O	O
3	ipsilateral	O	O
4	vocal	B-Disease	B-Disease
5	cord	I-Disease	I-Disease
6	paralysis	E-Disease	E-Disease
7	in	O	O
8	patients	O	O
9	undergoing	O	O
10	carotid	O	B-Disease
11	endarterectomy	O	E-Disease
12	under	O	O
13	local	O	O
14	anesthesia	O	O
15	.	O	O

0	Temporary	O	O
1	ipsilateral	O	O
2	vocal	B-Disease	B-Disease
3	nerve	I-Disease	E-Disease
4	palsies	E-Disease	E-Disease
5	due	O	O
6	to	O	O
7	local	O	O
8	anesthetics	O	O
9	have	O	O
10	been	O	O
11	described	O	O
12	,	O	O
13	however	O	O
14	.	O	O

0	Such	O	O
1	complications	O	O
2	are	O	O
3	most	O	O
4	important	O	O
5	in	O	O
6	situations	O	O
7	where	O	O
8	there	O	O
9	is	O	O
10	a	O	O
11	pre	O	O
12	-	O	O
13	existing	O	O
14	contralateral	O	O
15	paralysis	S-Disease	O
16	.	O	O

0	Anesthesia	O	O
1	was	O	O
2	performed	O	O
3	by	O	O
4	injecting	O	O
5	20	O	O
6	to	O	O
7	40	O	O
8	mL	O	O
9	of	O	O
10	a	O	O
11	mixture	O	O
12	of	O	O
13	long	O	O
14	-	O	O
15	acting	O	O
16	(	O	O
17	ropivacaine	S-Chemical	S-Chemical
18	)	O	O
19	and	O	O
20	short	O	O
21	-	O	O
22	acting	O	O
23	(	O	O
24	prilocaine	S-Chemical	S-Chemical
25	)	O	O
26	anesthetic	O	O
27	.	O	O

0	Twelve	O	O
1	patients	O	O
2	(	O	O
3	43	O	O
4	%	O	O
5	)	O	O
6	were	O	O
7	found	O	O
8	to	O	O
9	have	O	O
10	intraoperative	O	O
11	ipsilateral	O	O
12	vocal	B-Disease	B-Disease
13	cord	I-Disease	I-Disease
14	paralysis	E-Disease	E-Disease
15	.	O	O

0	There	O	O
1	were	O	O
2	no	O	O
3	significant	O	O
4	differences	O	O
5	in	O	O
6	operating	O	O
7	time	O	O
8	or	O	O
9	volume	O	O
10	or	O	O
11	frequency	O	O
12	of	O	O
13	anesthetic	O	O
14	administration	O	O
15	in	O	O
16	patients	O	O
17	with	O	O
18	temporary	O	O
19	vocal	B-Disease	B-Disease
20	cord	I-Disease	I-Disease
21	paralysis	E-Disease	E-Disease
22	compared	O	O
23	with	O	O
24	those	O	O
25	without	O	O
26	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Local	O	O
3	anesthesia	O	O
4	led	O	O
5	to	O	O
6	temporary	O	O
7	ipsilateral	O	O
8	vocal	B-Disease	B-Disease
9	cord	I-Disease	E-Disease
10	paralysis	E-Disease	E-Disease
11	in	O	O
12	almost	O	O
13	half	O	O
14	of	O	O
15	these	O	O
16	patients	O	O
17	.	O	O

0	Because	O	O
1	pre	O	O
2	-	O	O
3	existing	O	O
4	paralysis	S-Disease	O
5	is	O	O
6	of	O	O
7	a	O	O
8	relevant	O	O
9	frequency	O	O
10	(	O	O
11	up	O	O
12	to	O	O
13	3	O	O
14	%	O	O
15	)	O	O
16	,	O	O
17	a	O	O
18	preoperative	O	O
19	evaluation	O	O
20	of	O	O
21	vocal	O	B-Disease
22	cord	O	I-Disease
23	function	O	E-Disease
24	before	O	O
25	carotid	O	B-Disease
26	endarterectomy	O	E-Disease
27	under	O	O
28	local	O	O
29	anesthesia	O	O
30	is	O	O
31	recommended	O	O
32	to	O	O
33	avoid	O	O
34	intraoperative	O	O
35	bilateral	O	O
36	paralysis	S-Disease	S-Disease
37	.	O	O

0	In	O	O
1	patients	O	O
2	with	O	O
3	preoperative	O	O
4	contralateral	O	O
5	vocal	B-Disease	B-Disease
6	cord	I-Disease	I-Disease
7	paralysis	E-Disease	E-Disease
8	,	O	O
9	surgery	O	O
10	under	O	O
11	general	O	O
12	anesthesia	O	O
13	should	O	O
14	be	O	O
15	considered	O	O
16	.	O	O

0	Impaired	B-Disease	O
1	fear	I-Disease	O
2	recognition	E-Disease	O
3	in	O	O
4	regular	O	O
5	recreational	O	O
6	cocaine	S-Chemical	S-Disease
7	users	O	O
8	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	the	O	O
4	present	O	O
5	study	O	O
6	was	O	O
7	to	O	O
8	conduct	O	O
9	the	O	O
10	first	O	O
11	investigation	O	O
12	of	O	O
13	facial	O	O
14	expression	O	E-Disease
15	recognition	O	E-Disease
16	performance	O	O
17	in	O	O
18	recreational	O	O
19	cocaine	S-Chemical	E-Disease
20	users	O	O
21	.	O	O

0	MATERIALS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	Three	O	O
5	groups	O	O
6	,	O	O
7	comprised	O	O
8	of	O	O
9	21	O	O
10	cocaine	S-Chemical	S-Chemical
11	naive	O	O
12	participants	O	O
13	(	O	O
14	CN	O	S-Chemical
15	)	O	O
16	,	O	O
17	30	O	O
18	occasional	O	O
19	cocaine	S-Chemical	S-Chemical
20	(	O	O
21	OC	O	S-Chemical
22	)	O	O
23	,	O	O
24	and	O	O
25	48	O	O
26	regular	O	O
27	recreational	O	O
28	cocaine	S-Chemical	S-Disease
29	(	O	O
30	RC	O	O
31	)	O	O
32	users	O	O
33	,	O	O
34	were	O	O
35	compared	O	O
36	.	O	O

0	RESULTS	O	O
1	:	O	O
2	There	O	O
3	were	O	O
4	no	O	O
5	group	O	O
6	differences	O	O
7	in	O	O
8	psychopathology	O	O
9	or	O	O
10	"	O	O
11	eyes	O	O
12	task	O	O
13	"	O	O
14	performance	O	O
15	,	O	O
16	but	O	O
17	the	O	O
18	RC	O	O
19	group	O	O
20	,	O	O
21	who	O	O
22	otherwise	O	O
23	had	O	O
24	similar	O	O
25	illicit	O	O
26	substance	O	O
27	use	O	O
28	histories	O	O
29	to	O	O
30	the	O	O
31	OC	O	S-Chemical
32	group	O	O
33	,	O	O
34	exhibited	O	O
35	impaired	B-Disease	O
36	fear	I-Disease	O
37	recognition	E-Disease	O
38	accuracy	O	O
39	compared	O	O
40	to	O	O
41	the	O	O
42	OC	O	S-Chemical
43	and	O	O
44	CN	O	B-Chemical
45	groups	O	O
46	.	O	O

0	The	O	O
1	selective	O	O
2	deficit	B-Disease	O
3	in	I-Disease	O
4	fear	I-Disease	O
5	recognition	E-Disease	O
6	accuracy	O	O
7	manifested	O	O
8	by	O	O
9	the	O	O
10	RC	O	O
11	group	O	O
12	cannot	O	O
13	be	O	O
14	explained	O	O
15	by	O	O
16	the	O	O
17	subacute	O	O
18	effects	O	O
19	of	O	O
20	cocaine	S-Chemical	S-Chemical
21	,	O	O
22	or	O	O
23	ecstasy	S-Chemical	S-Disease
24	,	O	O
25	because	O	O
26	recent	O	O
27	and	O	O
28	less	O	O
29	recent	O	O
30	users	O	O
31	of	O	O
32	these	O	O
33	drugs	O	O
34	within	O	O
35	this	O	O
36	group	O	O
37	were	O	O
38	similarly	O	O
39	impaired	O	O
40	.	O	O

0	Possible	O	O
1	parallels	O	O
2	between	O	O
3	RC	O	O
4	users	O	O
5	and	O	O
6	psychopaths	S-Disease	S-Disease
7	with	O	O
8	respect	O	O
9	to	O	O
10	impaired	B-Disease	O
11	fear	I-Disease	B-Disease
12	recognition	E-Disease	E-Disease
13	,	O	O
14	amygdala	B-Disease	B-Disease
15	dysfunction	E-Disease	E-Disease
16	,	O	O
17	and	O	O
18	etiology	O	O
19	are	O	O
20	discussed	O	O
21	.	O	O

0	Damage	B-Disease	O
1	of	I-Disease	O
2	substantia	I-Disease	O
3	nigra	I-Disease	O
4	pars	I-Disease	S-Disease
5	reticulata	E-Disease	E-Disease
6	during	O	O
7	pilocarpine	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	status	B-Disease	B-Disease
11	epilepticus	E-Disease	E-Disease
12	in	O	O
13	the	O	O
14	rat	O	O
15	:	O	O
16	immunohistochemical	O	O
17	study	O	O
18	of	O	O
19	neurons	O	O
20	,	O	O
21	astrocytes	O	S-Disease
22	and	O	O
23	serum	O	O
24	-	O	O
25	protein	O	O
26	extravasation	O	O
27	.	O	O

0	The	O	O
1	substantia	O	O
2	nigra	O	S-Disease
3	has	O	O
4	a	O	O
5	gating	O	O
6	function	O	O
7	controlling	O	O
8	the	O	O
9	spread	O	O
10	of	O	O
11	epileptic	B-Disease	B-Disease
12	seizure	E-Disease	I-Disease
13	activity	O	E-Disease
14	.	O	O

0	Additionally	O	O
1	,	O	O
2	in	O	O
3	models	O	O
4	of	O	O
5	prolonged	B-Disease	O
6	status	I-Disease	O
7	epilepticus	E-Disease	S-Disease
8	the	O	O
9	pars	O	S-Disease
10	reticulata	O	O
11	of	O	O
12	substantia	O	O
13	nigra	O	S-Disease
14	(	O	O
15	SNR	O	S-Chemical
16	)	O	O
17	suffers	O	O
18	from	O	O
19	a	O	O
20	massive	O	O
21	lesion	O	S-Disease
22	which	O	O
23	may	O	O
24	arise	O	O
25	from	O	O
26	a	O	O
27	massive	O	O
28	metabolic	B-Disease	S-Disease
29	derangement	E-Disease	O
30	and	O	O
31	hyperexcitation	O	O
32	developing	O	O
33	in	O	O
34	the	O	O
35	activated	O	O
36	SNR	O	S-Disease
37	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	,	O	O
4	status	B-Disease	O
5	epilepticus	E-Disease	S-Disease
6	was	O	O
7	induced	O	O
8	by	O	O
9	systemic	O	O
10	injection	O	O
11	of	O	O
12	pilocarpine	S-Chemical	S-Chemical
13	in	O	O
14	rats	O	O
15	.	O	O

0	Animals	O	O
1	surviving	O	O
2	20	O	O
3	,	O	O
4	30	O	O
5	,	O	O
6	40	O	O
7	,	O	O
8	60	O	O
9	min	O	O
10	,	O	O
11	2	O	O
12	,	O	O
13	3	O	O
14	,	O	O
15	6	O	O
16	hours	O	O
17	,	O	O
18	1	O	O
19	,	O	O
20	2	O	O
21	,	O	O
22	and	O	O
23	3	O	O
24	days	O	O
25	after	O	O
26	induction	O	O
27	of	O	O
28	status	B-Disease	O
29	epilepticus	E-Disease	E-Disease
30	were	O	O
31	perfusion	O	O
32	-	O	O
33	fixed	O	O
34	,	O	O
35	and	O	O
36	brains	O	O
37	processed	O	O
38	for	O	O
39	immunohistochemical	O	O
40	staining	O	O
41	of	O	O
42	SNR	O	S-Chemical
43	.	O	O

0	Nissl	O	S-Chemical
1	-	O	O
2	staining	O	O
3	and	O	O
4	antibodies	O	O
5	against	O	O
6	the	O	O
7	neuron	O	B-Disease
8	-	O	O
9	specific	O	O
10	calcium	S-Chemical	S-Chemical
11	-	O	O
12	binding	O	O
13	protein	O	O
14	,	O	O
15	parvalbumin	O	S-Chemical
16	,	O	O
17	served	O	O
18	to	O	O
19	detect	O	O
20	neuronal	B-Disease	B-Disease
21	damage	E-Disease	E-Disease
22	in	O	O
23	SNR	O	S-Chemical
24	.	O	O

0	Antibodies	O	O
1	against	O	O
2	the	O	O
3	astroglia	O	O
4	-	O	O
5	specific	O	O
6	cytoskeletal	O	S-Disease
7	protein	O	O
8	,	O	O
9	glial	O	O
10	fibrillary	O	O
11	acidic	O	O
12	protein	O	O
13	(	O	O
14	GFAP	O	S-Chemical
15	)	O	O
16	,	O	O
17	and	O	O
18	against	O	O
19	the	O	O
20	glial	O	O
21	calcium	S-Chemical	O
22	-	O	O
23	binding	O	O
24	protein	O	O
25	,	O	O
26	S	O	O
27	-	O	O
28	100	O	O
29	protein	O	O
30	,	O	O
31	were	O	O
32	used	O	O
33	to	O	O
34	assess	O	O
35	the	O	O
36	status	O	O
37	of	O	O
38	astrocytes	O	S-Chemical
39	.	O	O

0	Immunohistochemical	O	O
1	staining	O	O
2	for	O	O
3	serum	O	S-Disease
4	-	O	O
5	albumin	O	S-Chemical
6	and	O	O
7	immunoglobulins	O	S-Disease
8	in	O	O
9	brain	O	O
10	tissue	O	O
11	was	O	O
12	taken	O	O
13	as	O	O
14	indicator	O	O
15	of	O	O
16	blood	O	B-Disease
17	-	O	I-Disease
18	brain	O	I-Disease
19	barrier	O	E-Disease
20	disturbances	O	E-Disease
21	and	O	O
22	vasogenic	B-Disease	O
23	edema	E-Disease	S-Disease
24	formation	O	O
25	.	O	O

0	Immunohistochemical	O	O
1	staining	O	O
2	indicated	O	O
3	loss	O	O
4	of	O	O
5	GFAP	O	S-Chemical
6	-	O	O
7	staining	O	O
8	already	O	O
9	at	O	O
10	30	O	O
11	min	O	O
12	after	O	O
13	induction	O	O
14	of	O	O
15	seizures	S-Disease	S-Disease
16	in	O	O
17	an	O	O
18	oval	O	O
19	focus	O	O
20	situated	O	O
21	in	O	O
22	the	O	O
23	center	O	O
24	of	O	O
25	SNR	O	S-Chemical
26	while	O	O
27	sparing	O	O
28	medial	O	O
29	and	O	O
30	lateral	O	O
31	aspects	O	O
32	.	O	O

0	By	O	O
1	2	O	O
2	hours	O	O
3	,	O	O
4	parvalbumin	O	S-Chemical
5	-	O	O
6	staining	O	O
7	changed	O	O
8	in	O	O
9	the	O	O
10	central	O	O
11	SNR	O	S-Disease
12	indicating	O	O
13	neuronal	B-Disease	B-Disease
14	damage	E-Disease	E-Disease
15	,	O	O
16	and	O	O
17	Nissl	O	S-Chemical
18	-	O	O
19	staining	O	O
20	visualized	O	O
21	some	O	O
22	neuronal	O	B-Disease
23	distortion	O	E-Disease
24	.	O	O

0	By	O	O
1	6	O	O
2	h	O	O
3	,	O	O
4	vasogenic	B-Disease	O
5	edema	E-Disease	O
6	covered	O	O
7	the	O	O
8	lesioned	B-Disease	O
9	SNR	E-Disease	S-Chemical
10	.	O	O

0	In	O	O
1	a	O	O
2	further	O	O
3	group	O	O
4	of	O	O
5	animals	O	O
6	surviving	O	O
7	1	O	O
8	to	O	O
9	5	O	O
10	days	O	O
11	,	O	O
12	conventional	O	O
13	paraffin	O	S-Disease
14	-	O	O
15	sections	O	O
16	confirmed	O	O
17	the	O	O
18	neuronal	O	B-Disease
19	and	O	O
20	glial	O	O
21	damage	B-Disease	E-Disease
22	of	I-Disease	O
23	SNR	E-Disease	S-Chemical
24	.	O	O

0	Both	O	O
1	cell	O	O
2	elements	O	O
3	may	O	O
4	suffer	O	O
5	in	O	O
6	common	O	O
7	from	O	O
8	metabolic	O	B-Disease
9	disturbance	O	E-Disease
10	and	O	O
11	neurotransmitter	B-Disease	S-Disease
12	dysfunction	E-Disease	S-Disease
13	as	O	O
14	occur	O	O
15	during	O	O
16	massive	O	O
17	status	B-Disease	O
18	epilepticus	E-Disease	E-Disease
19	.	O	O

0	Neuroprotective	O	O
1	effects	O	O
2	of	O	O
3	melatonin	S-Chemical	S-Chemical
4	upon	O	O
5	the	O	O
6	offspring	O	O
7	cerebellar	O	B-Disease
8	cortex	O	E-Disease
9	in	O	O
10	the	O	O
11	rat	O	O
12	model	O	O
13	of	O	O
14	BCNU	S-Chemical	S-Chemical
15	-	O	O
16	induced	O	O
17	cortical	B-Disease	B-Disease
18	dysplasia	E-Disease	E-Disease
19	.	O	O

0	Cortical	B-Disease	O
1	dysplasia	E-Disease	E-Disease
2	is	O	O
3	a	O	O
4	malformation	O	O
5	characterized	O	O
6	by	O	O
7	defects	O	S-Disease
8	in	O	O
9	proliferation	O	E-Disease
10	,	O	O
11	migration	O	O
12	and	O	O
13	maturation	O	O
14	.	O	O

0	This	O	O
1	study	O	O
2	was	O	O
3	designed	O	O
4	to	O	O
5	evaluate	O	O
6	the	O	O
7	alterations	O	O
8	in	O	O
9	offspring	O	O
10	rat	O	O
11	cerebellum	O	S-Disease
12	induced	O	O
13	by	O	O
14	maternal	O	O
15	exposure	O	O
16	to	O	O
17	carmustine	S-Chemical	S-Chemical
18	-	O	O
19	[	O	O
20	1	B-Chemical	O
21	,	I-Chemical	O
22	3	I-Chemical	O
23	-	I-Chemical	O
24	bis	I-Chemical	O
25	(	I-Chemical	O
26	2	I-Chemical	O
27	-	I-Chemical	I-Chemical
28	chloroethyl	I-Chemical	S-Chemical
29	)	I-Chemical	O
30	-	I-Chemical	O
31	1	I-Chemical	I-Chemical
32	-	I-Chemical	I-Chemical
33	nitrosoure	E-Chemical	E-Chemical
34	]	O	O
35	(	O	O
36	BCNU	S-Chemical	S-Chemical
37	)	O	O
38	and	O	O
39	to	O	O
40	investigate	O	O
41	the	O	O
42	effects	O	O
43	of	O	O
44	exogenous	O	O
45	melatonin	S-Chemical	S-Chemical
46	upon	O	O
47	cerebellar	O	S-Disease
48	BCNU	S-Chemical	S-Disease
49	-	O	O
50	induced	O	O
51	cortical	B-Disease	S-Disease
52	dysplasia	E-Disease	E-Disease
53	,	O	O
54	using	O	O
55	histological	O	O
56	and	O	O
57	biochemical	O	O
58	analyses	O	O
59	.	O	O

0	Pregnant	O	O
1	Wistar	O	O
2	rats	O	O
3	were	O	O
4	assigned	O	O
5	to	O	O
6	five	O	O
7	groups	O	O
8	:	O	O
9	intact	O	O
10	-	O	O
11	control	O	O
12	,	O	O
13	saline	O	S-Chemical
14	-	O	O
15	control	O	O
16	,	O	O
17	melatonin	S-Chemical	S-Chemical
18	-	O	O
19	treated	O	O
20	,	O	O
21	BCNU	S-Chemical	S-Chemical
22	-	O	O
23	exposed	O	O
24	and	O	O
25	BCNU	S-Chemical	S-Chemical
26	-	O	O
27	exposed	O	O
28	plus	O	O
29	melatonin	S-Chemical	S-Chemical
30	.	O	O

0	Rats	O	O
1	were	O	O
2	exposed	O	O
3	to	O	O
4	BCNU	S-Chemical	S-Chemical
5	on	O	O
6	embryonic	O	O
7	day	O	O
8	15	O	O
9	and	O	O
10	melatonin	S-Chemical	S-Chemical
11	was	O	O
12	given	O	O
13	until	O	O
14	delivery	O	O
15	.	O	O

0	Immuno	O	O
1	/	O	O
2	histochemistry	O	E-Chemical
3	and	O	O
4	electron	O	O
5	microscopy	O	O
6	were	O	O
7	carried	O	O
8	out	O	O
9	on	O	O
10	the	O	O
11	offspring	O	O
12	cerebellum	O	S-Disease
13	,	O	O
14	and	O	O
15	levels	O	O
16	of	O	O
17	malondialdehyde	S-Chemical	S-Chemical
18	and	O	O
19	superoxide	S-Chemical	S-Chemical
20	dismutase	O	O
21	were	O	O
22	determined	O	O
23	.	O	O

0	Histopathologically	O	O
1	,	O	O
2	typical	O	O
3	findings	O	O
4	were	O	O
5	observed	O	O
6	in	O	O
7	the	O	O
8	cerebella	O	S-Disease
9	from	O	O
10	the	O	O
11	control	O	O
12	groups	O	O
13	,	O	O
14	but	O	O
15	the	O	O
16	findings	O	O
17	consistent	O	O
18	with	O	O
19	early	O	O
20	embryonic	O	O
21	development	O	O
22	were	O	O
23	noted	O	O
24	in	O	O
25	BCNU	S-Chemical	S-Chemical
26	-	O	O
27	exposed	O	O
28	cortical	B-Disease	B-Disease
29	dysplasia	E-Disease	E-Disease
30	group	O	O
31	.	O	O

0	There	O	O
1	was	O	O
2	a	O	O
3	marked	O	O
4	increase	O	O
5	in	O	O
6	the	O	O
7	number	O	O
8	of	O	O
9	TUNEL	O	S-Disease
10	positive	O	O
11	cells	O	O
12	and	O	O
13	nestin	O	S-Disease
14	positive	O	O
15	cells	O	O
16	in	O	O
17	BCNU	S-Chemical	S-Chemical
18	-	O	O
19	exposed	O	O
20	group	O	O
21	,	O	O
22	but	O	O
23	a	O	O
24	decreased	O	O
25	immunoreactivity	O	O
26	to	O	O
27	glial	O	O
28	fibrillary	O	O
29	acidic	O	O
30	protein	O	O
31	,	O	O
32	synaptophysin	O	O
33	and	O	O
34	transforming	O	O
35	growth	O	B-Disease
36	factor	O	E-Disease
37	beta1	O	E-Chemical
38	was	O	O
39	observed	O	O
40	,	O	O
41	indicating	O	O
42	a	O	O
43	delayed	O	O
44	maturation	O	O
45	,	O	O
46	and	O	O
47	melatonin	S-Chemical	S-Chemical
48	significantly	O	O
49	reversed	O	O
50	these	O	O
51	changes	O	O
52	.	O	O

0	Malondialdehyde	S-Chemical	S-Chemical
1	level	O	O
2	in	O	O
3	BCNU	S-Chemical	S-Chemical
4	-	O	O
5	exposed	O	O
6	group	O	O
7	was	O	O
8	higher	O	O
9	than	O	O
10	those	O	O
11	in	O	O
12	control	O	O
13	groups	O	O
14	and	O	O
15	melatonin	S-Chemical	S-Chemical
16	decreased	O	O
17	malondialdehyde	S-Chemical	S-Chemical
18	levels	O	O
19	in	O	O
20	BCNU	S-Chemical	S-Chemical
21	group	O	O
22	(	O	O
23	P	O	S-Disease
24	<	O	O
25	0	O	O
26	.	O	O
27	01	O	O
28	)	O	O
29	,	O	O
30	while	O	O
31	there	O	O
32	were	O	O
33	no	O	O
34	significant	O	O
35	differences	O	O
36	in	O	O
37	the	O	O
38	superoxide	S-Chemical	S-Chemical
39	dismutase	O	O
40	levels	O	O
41	between	O	O
42	these	O	O
43	groups	O	O
44	.	O	O

0	These	O	O
1	data	O	O
2	suggest	O	O
3	that	O	O
4	exposure	O	O
5	of	O	O
6	animals	O	O
7	to	O	O
8	BCNU	S-Chemical	S-Chemical
9	during	O	O
10	pregnancy	O	O
11	leads	O	O
12	to	O	O
13	delayed	O	O
14	maturation	O	O
15	of	O	O
16	offspring	O	O
17	cerebellum	O	S-Disease
18	and	O	O
19	melatonin	S-Chemical	S-Chemical
20	protects	O	O
21	the	O	O
22	cerebellum	O	S-Chemical
23	against	O	O
24	the	O	O
25	effects	O	O
26	of	O	O
27	BCNU	S-Chemical	S-Chemical
28	.	O	O

0	Reduced	O	O
1	cardiotoxicity	S-Disease	O
2	of	O	O
3	doxorubicin	S-Chemical	S-Chemical
4	given	O	O
5	in	O	O
6	the	O	O
7	form	O	O
8	of	O	O
9	N	B-Chemical	S-Chemical
10	-	I-Chemical	I-Chemical
11	(	I-Chemical	O
12	2	I-Chemical	O
13	-	I-Chemical	I-Chemical
14	hydroxypropyl	I-Chemical	I-Chemical
15	)	I-Chemical	O
16	methacrylamide	E-Chemical	S-Chemical
17	conjugates	O	O
18	:	O	O
19	and	O	O
20	experimental	O	O
21	study	O	O
22	in	O	O
23	the	O	O
24	rat	O	O
25	.	O	O

0	A	O	O
1	rat	O	O
2	model	O	O
3	was	O	O
4	used	O	O
5	to	O	O
6	evaluate	O	O
7	the	O	O
8	general	O	O
9	acute	O	S-Disease
10	toxicity	S-Disease	S-Disease
11	and	O	O
12	the	O	O
13	late	O	O
14	cardiotoxicity	S-Disease	S-Disease
15	of	O	O
16	4	O	O
17	mg	O	O
18	/	O	O
19	kg	O	O
20	doxorubicin	S-Chemical	S-Chemical
21	(	O	O
22	DOX	S-Chemical	S-Chemical
23	)	O	O
24	given	O	O
25	either	O	O
26	as	O	O
27	free	O	O
28	drug	O	O
29	or	O	O
30	in	O	O
31	the	O	O
32	form	O	O
33	of	O	O
34	three	O	O
35	N	B-Chemical	B-Chemical
36	-	I-Chemical	I-Chemical
37	(	I-Chemical	O
38	2	I-Chemical	O
39	-	I-Chemical	I-Chemical
40	hydroxypropyl	I-Chemical	O
41	)	I-Chemical	O
42	methacrylamide	E-Chemical	S-Chemical
43	(	O	O
44	HPMA	S-Chemical	S-Chemical
45	)	O	O
46	copolymer	O	O
47	conjugates	O	O
48	.	O	O

0	In	O	O
1	these	O	O
2	HPMA	S-Chemical	S-Chemical
3	copolymers	O	O
4	,	O	O
5	DOX	S-Chemical	S-Chemical
6	was	O	O
7	covalently	O	O
8	bound	O	O
9	via	O	O
10	peptide	O	O
11	linkages	O	O
12	that	O	O
13	were	O	O
14	either	O	O
15	non	O	O
16	-	O	O
17	biodegradable	O	O
18	(	O	O
19	Gly	O	S-Chemical
20	-	O	O
21	Gly	O	E-Chemical
22	)	O	O
23	or	O	O
24	degradable	O	O
25	by	O	O
26	lysosomal	O	O
27	proteinases	O	O
28	(	O	O
29	Gly	B-Chemical	S-Chemical
30	-	I-Chemical	O
31	Phe	I-Chemical	S-Chemical
32	-	I-Chemical	O
33	Leu	I-Chemical	S-Disease
34	-	I-Chemical	O
35	Gly	E-Chemical	E-Chemical
36	)	O	O
37	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	one	O	O
4	biodegradable	O	O
5	conjugate	O	O
6	containing	O	O
7	galactosamine	S-Chemical	S-Chemical
8	was	O	O
9	used	O	O
10	;	O	O
11	this	O	O
12	residue	O	O
13	was	O	O
14	targeted	O	O
15	to	O	O
16	the	O	O
17	liver	O	O
18	.	O	O

0	Over	O	O
1	the	O	O
2	first	O	O
3	3	O	O
4	weeks	O	O
5	after	O	O
6	the	O	O
7	i	O	O
8	.	O	O
9	v	O	O
10	.	O	O
11	administration	O	O
12	of	O	O
13	free	O	O
14	and	O	O
15	polymer	O	O
16	-	O	O
17	bound	O	O
18	DOX	S-Chemical	S-Chemical
19	,	O	O
20	all	O	O
21	animals	O	O
22	showed	O	O
23	a	O	O
24	transient	O	O
25	reduction	O	O
26	in	O	O
27	body	O	O
28	weight	O	O
29	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	maximal	O	O
4	reduction	O	O
5	in	O	O
6	body	O	O
7	weight	O	O
8	seen	O	O
9	in	O	O
10	animals	O	O
11	that	O	O
12	received	O	O
13	polymer	O	O
14	-	O	O
15	bound	O	O
16	DOX	S-Chemical	S-Chemical
17	(	O	O
18	4	O	O
19	mg	O	O
20	/	O	O
21	kg	O	O
22	)	O	O
23	was	O	O
24	significantly	O	O
25	lower	O	O
26	than	O	O
27	that	O	O
28	observed	O	O
29	in	O	O
30	those	O	O
31	that	O	O
32	received	O	O
33	free	O	O
34	DOX	S-Chemical	S-Chemical
35	(	O	O
36	4	O	O
37	mg	O	O
38	/	O	O
39	kg	O	O
40	)	O	O
41	or	O	O
42	a	O	O
43	mixture	O	O
44	of	O	O
45	the	O	O
46	unmodified	O	O
47	parent	O	O
48	HPMA	S-Chemical	S-Chemical
49	copolymer	O	O
50	and	O	O
51	free	O	O
52	DOX	S-Chemical	S-Chemical
53	(	O	O
54	4	O	O
55	mg	O	O
56	/	O	O
57	kg	O	O
58	;	O	O
59	P	O	O
60	less	O	O
61	than	O	O
62	0	O	O
63	.	O	O
64	01	O	O
65	)	O	O
66	.	O	O

0	Throughout	O	O
1	the	O	O
2	study	O	O
3	(	O	O
4	20	O	O
5	weeks	O	O
6	)	O	O
7	,	O	O
8	deaths	O	O
9	related	O	O
10	to	O	O
11	cardiotoxicity	S-Disease	S-Disease
12	were	O	O
13	observed	O	O
14	only	O	O
15	in	O	O
16	animals	O	O
17	that	O	O
18	received	O	O
19	either	O	O
20	free	O	O
21	DOX	S-Chemical	S-Chemical
22	or	O	O
23	the	O	O
24	mixture	O	O
25	of	O	O
26	HPMA	S-Chemical	S-Chemical
27	copolymer	O	O
28	and	O	O
29	free	O	O
30	DOX	S-Chemical	S-Chemical
31	;	O	O
32	in	O	O
33	these	O	O
34	cases	O	O
35	,	O	O
36	histological	O	O
37	investigations	O	O
38	revealed	O	O
39	marked	O	O
40	changes	O	O
41	in	O	O
42	the	O	O
43	heart	O	O
44	that	O	O
45	were	O	O
46	consistent	O	O
47	with	O	O
48	DOX	S-Chemical	S-Chemical
49	-	O	O
50	induced	O	O
51	cardiotoxicity	S-Disease	S-Disease
52	.	O	O

0	Sequential	O	O
1	measurements	O	O
2	of	O	O
3	cardiac	O	S-Disease
4	output	O	O
5	in	O	O
6	surviving	O	O
7	animals	O	O
8	that	O	O
9	received	O	O
10	either	O	O
11	free	O	O
12	DOX	S-Chemical	S-Chemical
13	or	O	O
14	the	O	O
15	mixture	O	O
16	of	O	O
17	HPMA	S-Chemical	S-Chemical
18	copolymer	O	O
19	and	O	O
20	free	O	O
21	DOX	S-Chemical	S-Chemical
22	showed	O	O
23	a	O	O
24	reduction	O	O
25	of	O	O
26	approximately	O	O
27	30	O	O
28	%	O	O
29	in	O	O
30	function	O	O
31	beginning	O	O
32	at	O	O
33	the	O	O
34	4th	O	O
35	week	O	O
36	after	O	O
37	drug	O	O
38	administration	O	O
39	.	O	O

0	Animals	O	O
1	that	O	O
2	were	O	O
3	given	O	O
4	the	O	O
5	HPMA	S-Chemical	S-Chemical
6	copolymer	O	O
7	conjugates	O	O
8	containing	O	O
9	DOX	S-Chemical	S-Chemical
10	exhibited	O	O
11	no	O	O
12	significant	O	O
13	change	O	O
14	in	O	O
15	cardiac	O	B-Disease
16	output	O	E-Disease
17	throughout	O	O
18	the	O	O
19	study	O	O
20	(	O	O
21	P	O	S-Disease
22	less	O	O
23	than	O	O
24	0	O	O
25	.	O	O
26	05	O	O
27	)	O	O
28	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	no	O	O
4	significant	O	O
5	histological	O	O
6	change	O	O
7	was	O	O
8	observed	O	O
9	in	O	O
10	the	O	O
11	heart	O	O
12	of	O	O
13	animals	O	O
14	that	O	O
15	received	O	O
16	DOX	S-Chemical	S-Chemical
17	in	O	O
18	the	O	O
19	form	O	O
20	of	O	O
21	HPMA	S-Chemical	S-Chemical
22	copolymer	O	O
23	conjugates	O	O
24	and	O	O
25	were	O	O
26	killed	O	O
27	at	O	O
28	the	O	O
29	end	O	O
30	of	O	O
31	the	O	O
32	study	O	O
33	.	O	O

0	Corneal	B-Disease	O
1	ulcers	E-Disease	O
2	associated	O	O
3	with	O	O
4	aerosolized	O	O
5	crack	B-Chemical	B-Disease
6	cocaine	E-Chemical	E-Disease
7	use	O	O
8	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	We	O	O
3	report	O	O
4	4	O	O
5	cases	O	O
6	of	O	O
7	corneal	B-Disease	B-Disease
8	ulcers	E-Disease	E-Disease
9	associated	O	O
10	with	O	O
11	drug	B-Disease	O
12	abuse	E-Disease	O
13	.	O	O

0	The	O	O
1	pathogenesis	O	O
2	of	O	O
3	these	O	O
4	ulcers	S-Disease	O
5	and	O	O
6	management	O	O
7	of	O	O
8	these	O	O
9	patients	O	O
10	are	O	O
11	also	O	O
12	reviewed	O	O
13	.	O	O

0	METHODS	O	O
1	:	O	O
2	Review	O	O
3	of	O	O
4	all	O	O
5	cases	O	O
6	of	O	O
7	corneal	B-Disease	B-Disease
8	ulcers	E-Disease	E-Disease
9	associated	O	O
10	with	O	O
11	drug	B-Disease	O
12	abuse	E-Disease	O
13	seen	O	O
14	at	O	O
15	our	O	O
16	institution	O	O
17	from	O	O
18	July	O	O
19	2006	O	O
20	to	O	O
21	December	O	O
22	2006	O	O
23	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Four	O	O
3	patients	O	O
4	with	O	O
5	corneal	B-Disease	O
6	ulcers	E-Disease	E-Disease
7	associated	O	O
8	with	O	O
9	crack	B-Chemical	B-Disease
10	cocaine	E-Chemical	E-Disease
11	use	O	O
12	were	O	O
13	reviewed	O	O
14	.	O	O

0	All	O	O
1	corneal	B-Disease	B-Disease
2	ulcers	E-Disease	E-Disease
3	were	O	O
4	cultured	O	O
5	,	O	O
6	and	O	O
7	the	O	O
8	patients	O	O
9	were	O	O
10	admitted	O	O
11	to	O	O
12	the	O	O
13	hospital	O	O
14	for	O	O
15	intensive	O	O
16	topical	O	O
17	antibiotic	O	O
18	treatment	O	O
19	.	O	O

0	Each	O	O
1	patient	O	O
2	received	O	O
3	comprehensive	O	O
4	health	O	O
5	care	O	O
6	,	O	O
7	including	O	O
8	medical	O	O
9	and	O	O
10	substance	B-Disease	O
11	abuse	E-Disease	O
12	consultations	O	O
13	.	O	O

0	The	O	O
1	infections	S-Disease	S-Disease
2	responded	O	O
3	to	O	O
4	antibiotic	O	O
5	treatment	O	O
6	.	O	O

0	Two	O	O
1	patients	O	O
2	needed	O	O
3	a	O	O
4	lateral	O	O
5	tarsorrhaphy	O	S-Disease
6	for	O	O
7	persistent	O	O
8	epithelial	B-Disease	B-Disease
9	defects	E-Disease	E-Disease
10	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Aerosolized	O	O
3	crack	B-Chemical	B-Disease
4	cocaine	E-Chemical	E-Disease
5	use	O	O
6	can	O	O
7	be	O	O
8	associated	O	O
9	with	O	O
10	the	O	O
11	development	O	O
12	of	O	O
13	corneal	B-Disease	B-Disease
14	ulcers	E-Disease	E-Disease
15	.	O	O

0	Drug	B-Disease	O
1	abuse	E-Disease	O
2	provides	O	O
3	additional	O	O
4	challenges	O	O
5	for	O	O
6	management	O	O
7	.	O	O

0	Not	O	O
1	only	O	O
2	treatment	O	O
3	of	O	O
4	their	O	O
5	infections	S-Disease	S-Disease
6	but	O	O
7	also	O	O
8	the	O	O
9	overall	O	O
10	poor	O	O
11	health	O	O
12	of	O	O
13	the	O	O
14	patients	O	O
15	and	O	O
16	increased	O	O
17	risk	O	O
18	of	O	O
19	noncompliance	O	O
20	need	O	O
21	to	O	O
22	be	O	O
23	addressed	O	O
24	.	O	O

0	Comprehensive	O	O
1	care	O	O
2	may	O	O
3	provide	O	O
4	the	O	O
5	patient	O	O
6	the	O	O
7	opportunity	O	O
8	to	O	O
9	discontinue	O	O
10	their	O	O
11	substance	B-Disease	B-Disease
12	abuse	E-Disease	E-Disease
13	,	O	O
14	improve	O	O
15	their	O	O
16	overall	O	O
17	health	O	O
18	,	O	O
19	and	O	O
20	prevent	O	O
21	future	O	O
22	corneal	O	B-Disease
23	complications	O	E-Disease
24	.	O	O

0	Topical	O	O
1	0	O	O
2	.	O	O
3	025	O	O
4	%	O	O
5	capsaicin	S-Chemical	S-Chemical
6	in	O	O
7	chronic	O	B-Disease
8	post	B-Disease	I-Disease
9	-	I-Disease	O
10	herpetic	I-Disease	B-Disease
11	neuralgia	E-Disease	E-Disease
12	:	O	O
13	efficacy	O	O
14	,	O	O
15	predictors	O	O
16	of	O	O
17	response	O	O
18	and	O	O
19	long	O	O
20	-	O	O
21	term	O	O
22	course	O	O
23	.	O	O

0	In	O	O
1	order	O	O
2	to	O	O
3	evaluate	O	O
4	the	O	O
5	efficacy	O	O
6	,	O	O
7	time	O	O
8	-	O	O
9	course	O	O
10	of	O	O
11	action	O	O
12	and	O	O
13	predictors	O	O
14	of	O	O
15	response	O	O
16	to	O	O
17	topical	O	S-Disease
18	capsaicin	S-Chemical	S-Chemical
19	,	O	O
20	39	O	O
21	patients	O	O
22	with	O	O
23	chronic	O	B-Disease
24	post	B-Disease	I-Disease
25	-	I-Disease	O
26	herpetic	I-Disease	B-Disease
27	neuralgia	E-Disease	E-Disease
28	(	O	O
29	PHN	S-Disease	S-Chemical
30	)	O	O
31	,	O	O
32	median	O	O
33	duration	O	O
34	24	O	O
35	months	O	O
36	,	O	O
37	were	O	O
38	treated	O	O
39	with	O	O
40	0	O	O
41	.	O	O
42	025	O	O
43	%	O	O
44	capsaicin	S-Chemical	S-Chemical
45	cream	O	O
46	for	O	O
47	8	O	O
48	weeks	O	O
49	.	O	O

0	During	O	O
1	therapy	O	O
2	the	O	O
3	patients	O	O
4	rated	O	O
5	their	O	O
6	pain	S-Disease	O
7	on	O	O
8	a	O	O
9	visual	O	O
10	analogue	O	O
11	scale	O	O
12	(	O	O
13	VAS	O	O
14	)	O	O
15	and	O	O
16	a	O	O
17	verbal	O	O
18	outcome	O	O
19	scale	O	O
20	.	O	O

0	Nineteen	O	O
1	patients	O	O
2	(	O	O
3	48	O	O
4	.	O	O
5	7	O	O
6	%	O	O
7	)	O	O
8	substantially	O	O
9	improved	O	O
10	after	O	O
11	the	O	O
12	8	O	O
13	-	O	O
14	week	O	O
15	trial	O	O
16	;	O	O
17	5	O	O
18	(	O	O
19	12	O	O
20	.	O	O
21	8	O	O
22	%	O	O
23	)	O	O
24	discontinued	O	O
25	therapy	O	O
26	due	O	O
27	to	O	O
28	side	O	O
29	-	O	O
30	effects	O	O
31	such	O	O
32	as	O	O
33	intolerable	O	O
34	capsaicin	S-Chemical	S-Chemical
35	-	O	O
36	induced	O	O
37	burning	O	S-Disease
38	sensations	O	O
39	(	O	O
40	4	O	O
41	)	O	O
42	or	O	O
43	mastitis	S-Disease	S-Disease
44	(	O	O
45	1	O	O
46	)	O	O
47	;	O	O
48	15	O	O
49	(	O	O
50	38	O	O
51	.	O	O
52	5	O	O
53	%	O	O
54	)	O	O
55	reported	O	O
56	no	O	O
57	benefit	O	O
58	.	O	O

0	Treatment	O	O
1	effect	O	O
2	was	O	O
3	not	O	O
4	dependent	O	O
5	on	O	O
6	patient	O	O
7	'	O	O
8	s	O	O
9	age	O	O
10	,	O	O
11	duration	O	O
12	or	O	O
13	localization	O	O
14	of	O	O
15	PHN	S-Disease	S-Chemical
16	(	O	O
17	trigeminal	O	B-Disease
18	involvement	O	E-Disease
19	was	O	O
20	excluded	O	O
21	)	O	O
22	,	O	O
23	sensory	B-Disease	B-Disease
24	disturbance	E-Disease	E-Disease
25	or	O	O
26	pain	S-Disease	S-Disease
27	character	O	O
28	.	O	O

0	Treatment	O	O
1	response	O	O
2	was	O	O
3	not	O	O
4	correlated	O	O
5	with	O	O
6	the	O	O
7	incidence	O	O
8	,	O	O
9	time	O	O
10	-	O	O
11	course	O	O
12	or	O	O
13	severity	O	O
14	of	O	O
15	capsaicin	S-Chemical	S-Chemical
16	-	O	O
17	induced	O	O
18	burning	O	S-Disease
19	.	O	O

0	If	O	O
1	confirmed	O	O
2	in	O	O
3	controlled	O	O
4	trials	O	O
5	,	O	O
6	the	O	O
7	long	O	O
8	-	O	O
9	term	O	O
10	results	O	O
11	of	O	O
12	this	O	O
13	open	O	O
14	,	O	O
15	non	O	O
16	-	O	O
17	randomized	O	O
18	study	O	O
19	might	O	O
20	indicate	O	O
21	that	O	O
22	the	O	O
23	analgesic	O	O
24	effect	O	O
25	of	O	O
26	capsaicin	S-Chemical	S-Chemical
27	in	O	O
28	PHN	S-Disease	S-Chemical
29	is	O	O
30	mediated	O	O
31	by	O	O
32	both	O	O
33	interference	O	O
34	with	O	O
35	neuropeptide	O	O
36	metabolism	O	S-Disease
37	and	O	O
38	morphological	O	O
39	changes	O	O
40	(	O	O
41	perhaps	O	O
42	degeneration	O	O
43	)	O	O
44	of	O	O
45	nociceptive	O	O
46	afferents	O	O
47	.	O	O

0	Myo	B-Chemical	B-Chemical
1	-	I-Chemical	I-Chemical
2	inositol	I-Chemical	E-Chemical
3	-	I-Chemical	I-Chemical
4	1	I-Chemical	E-Chemical
5	-	I-Chemical	I-Chemical
6	phosphate	E-Chemical	O
7	(	O	O
8	MIP	S-Chemical	S-Chemical
9	)	O	O
10	synthase	O	O
11	inhibition	O	O
12	:	O	O
13	in	O	O
14	-	O	O
15	vivo	O	O
16	study	O	O
17	in	O	O
18	rats	O	O
19	.	O	O

0	Lithium	S-Chemical	S-Chemical
1	and	O	O
2	valproate	S-Chemical	S-Disease
3	are	O	O
4	the	O	O
5	prototypic	O	O
6	mood	O	O
7	stabilizers	O	O
8	and	O	O
9	have	O	O
10	diverse	O	O
11	structures	O	O
12	and	O	O
13	targets	O	O
14	.	O	O

0	Both	O	O
1	drugs	O	O
2	influence	O	O
3	inositol	S-Chemical	S-Chemical
4	metabolism	O	O
5	.	O	O

0	Lithium	S-Chemical	S-Chemical
1	inhibits	O	O
2	IMPase	O	S-Chemical
3	and	O	O
4	valproate	S-Chemical	O
5	inhibits	O	O
6	MIP	S-Chemical	S-Chemical
7	synthase	O	O
8	.	O	O

0	This	O	O
1	study	O	O
2	shows	O	O
3	that	O	O
4	MIP	S-Chemical	S-Chemical
5	synthase	O	O
6	inhibition	O	O
7	does	O	O
8	not	O	O
9	replicate	O	O
10	or	O	O
11	augment	O	O
12	the	O	O
13	effects	O	O
14	of	O	O
15	lithium	S-Chemical	S-Chemical
16	in	O	O
17	the	O	O
18	inositol	S-Chemical	S-Chemical
19	sensitive	O	O
20	pilocarpine	S-Chemical	S-Chemical
21	-	O	O
22	induced	O	O
23	seizures	S-Disease	S-Disease
24	model	O	O
25	.	O	O

0	This	O	O
1	lack	O	O
2	of	O	O
3	effects	O	O
4	may	O	O
5	stem	O	O
6	from	O	O
7	the	O	O
8	low	O	O
9	contribution	O	O
10	of	O	O
11	de	O	O
12	-	O	O
13	novo	O	O
14	synthesis	O	O
15	to	O	O
16	cellular	O	O
17	inositol	S-Chemical	O
18	supply	O	O
19	or	O	O
20	to	O	O
21	the	O	O
22	inhibition	O	O
23	of	O	O
24	the	O	O
25	de	O	O
26	-	O	O
27	novo	O	O
28	synthesis	O	O
29	by	O	O
30	lithium	S-Chemical	S-Chemical
31	itself	O	O
32	.	O	O

0	Non	O	O
1	-	O	O
2	steroidal	O	S-Chemical
3	anti	O	O
4	-	O	O
5	inflammatory	O	S-Disease
6	drugs	O	O
7	-	O	O
8	associated	O	O
9	acute	O	B-Disease
10	interstitial	B-Disease	I-Disease
11	nephritis	E-Disease	E-Disease
12	with	O	O
13	granular	O	O
14	tubular	O	I-Disease
15	basement	O	I-Disease
16	membrane	O	E-Disease
17	deposits	O	O
18	.	O	O

0	Acute	B-Disease	O
1	tubulo	I-Disease	B-Disease
2	-	I-Disease	O
3	interstitial	I-Disease	O
4	nephritis	E-Disease	E-Disease
5	(	O	O
6	ATIN	S-Disease	S-Chemical
7	)	O	O
8	is	O	O
9	an	O	O
10	important	O	O
11	cause	O	O
12	of	O	O
13	acute	B-Disease	B-Disease
14	renal	I-Disease	I-Disease
15	failure	E-Disease	E-Disease
16	resulting	O	O
17	from	O	O
18	a	O	O
19	variety	O	O
20	of	O	O
21	insults	O	O
22	,	O	O
23	including	O	O
24	immune	O	B-Disease
25	complex	O	E-Disease
26	-	O	O
27	mediated	O	O
28	tubulo	B-Disease	S-Disease
29	-	I-Disease	O
30	interstitial	I-Disease	O
31	injury	E-Disease	S-Disease
32	,	O	O
33	but	O	O
34	drugs	O	O
35	such	O	O
36	as	O	O
37	non	O	O
38	-	O	O
39	steroidal	O	S-Disease
40	anti	O	O
41	-	O	O
42	inflammatory	O	S-Disease
43	drugs	O	O
44	(	O	O
45	NSAIDs	O	S-Disease
46	)	O	O
47	are	O	O
48	a	O	O
49	far	O	O
50	more	O	O
51	frequent	O	O
52	cause	O	O
53	.	O	O

0	Overall	O	O
1	,	O	O
2	as	O	O
3	an	O	O
4	entity	O	O
5	,	O	O
6	ATIN	S-Disease	S-Chemical
7	remains	O	O
8	under	O	O
9	-	O	O
10	diagnosed	O	O
11	,	O	O
12	as	O	O
13	symptoms	O	O
14	resolve	O	O
15	spontaneously	O	O
16	if	O	O
17	the	O	O
18	medication	O	O
19	is	O	O
20	stopped	O	O
21	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	a	O	O
4	14	O	O
5	-	O	O
6	year	O	O
7	-	O	O
8	old	O	O
9	boy	O	O
10	who	O	O
11	developed	O	O
12	acute	B-Disease	B-Disease
13	renal	I-Disease	I-Disease
14	failure	E-Disease	E-Disease
15	2	O	O
16	weeks	O	O
17	after	O	O
18	aortic	O	B-Disease
19	valve	O	E-Disease
20	surgery	O	E-Disease
21	.	O	O

0	He	O	O
1	was	O	O
2	put	O	O
3	on	O	O
4	aspirin	S-Chemical	S-Chemical
5	following	O	O
6	surgery	O	O
7	and	O	O
8	took	O	O
9	ibuprofen	S-Chemical	S-Chemical
10	for	O	O
11	fever	S-Disease	S-Disease
12	for	O	O
13	nearly	O	O
14	a	O	O
15	week	O	O
16	prior	O	O
17	to	O	O
18	presentation	O	O
19	.	O	O

0	He	O	O
1	then	O	O
2	presented	O	O
3	to	O	O
4	the	O	O
5	emergency	O	O
6	department	O	O
7	feeling	O	O
8	quite	O	O
9	ill	O	O
10	and	O	O
11	was	O	O
12	found	O	O
13	to	O	O
14	have	O	O
15	a	O	O
16	blood	B-Chemical	O
17	urea	I-Chemical	I-Disease
18	nitrogen	E-Chemical	O
19	(	O	O
20	BUN	S-Chemical	O
21	)	O	O
22	concentration	O	O
23	of	O	O
24	of	O	O
25	147	O	O
26	mg	O	O
27	/	O	O
28	dl	O	O
29	,	O	O
30	creatinine	S-Chemical	S-Chemical
31	of	O	O
32	15	O	O
33	.	O	O
34	3	O	O
35	mg	O	O
36	/	O	O
37	dl	O	O
38	and	O	O
39	serum	O	O
40	potassium	S-Chemical	O
41	of	O	O
42	8	O	O
43	.	O	O
44	7	O	O
45	mEq	O	O
46	/	O	O
47	l	O	O
48	.	O	O

0	A	O	O
1	kidney	O	O
2	biopsy	O	O
3	showed	O	O
4	inflammatory	O	S-Disease
5	infiltrate	O	O
6	consistent	O	O
7	with	O	O
8	ATIN	S-Disease	S-Chemical
9	.	O	O

0	He	O	O
1	needed	O	O
2	dialysis	O	O
3	for	O	O
4	2	O	O
5	weeks	O	O
6	and	O	O
7	was	O	O
8	treated	O	O
9	successfully	O	O
10	with	O	O
11	steroids	S-Chemical	S-Chemical
12	for	O	O
13	6	O	O
14	months	O	O
15	.	O	O

0	His	O	O
1	renal	O	B-Disease
2	recovery	O	E-Disease
3	and	O	O
4	disappearance	O	O
5	of	O	O
6	proteinuria	S-Disease	S-Disease
7	took	O	O
8	a	O	O
9	year	O	O
10	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	this	O	O
4	is	O	O
5	a	O	O
6	first	O	O
7	report	O	O
8	of	O	O
9	NSAIDs	O	S-Chemical
10	-	O	O
11	associated	O	O
12	ATIN	S-Disease	S-Disease
13	,	O	O
14	showing	O	O
15	deposits	O	O
16	of	O	O
17	granular	O	O
18	immune	O	I-Disease
19	complex	O	E-Disease
20	present	O	O
21	only	O	O
22	in	O	O
23	the	O	O
24	TBM	O	S-Chemical
25	and	O	O
26	not	O	O
27	in	O	O
28	the	O	O
29	glomeruli	O	S-Disease
30	.	O	O

0	Rifampicin	S-Chemical	S-Chemical
1	-	O	O
2	associated	O	O
3	segmental	O	O
4	necrotizing	O	O
5	glomerulonephritis	S-Disease	S-Disease
6	in	O	O
7	staphylococcal	B-Disease	O
8	endocarditis	E-Disease	S-Disease
9	.	O	O

0	Segmental	O	O
1	necrotising	O	O
2	glomerulonephritis	S-Disease	S-Disease
3	has	O	O
4	been	O	O
5	reported	O	O
6	as	O	O
7	complication	O	O
8	of	O	O
9	rifampicin	S-Chemical	S-Chemical
10	therapy	O	O
11	in	O	O
12	patients	O	O
13	receiving	O	O
14	treatment	O	O
15	for	O	O
16	tuberculosis	S-Disease	S-Disease
17	.	O	O

0	Changing	O	O
1	epidemiology	O	O
2	of	O	O
3	infections	S-Disease	S-Disease
4	such	O	O
5	as	O	O
6	infective	B-Disease	O
7	endocarditis	E-Disease	E-Disease
8	(	O	O
9	IE	S-Disease	S-Chemical
10	)	O	O
11	has	O	O
12	led	O	O
13	to	O	O
14	an	O	O
15	increase	O	O
16	in	O	O
17	the	O	O
18	use	O	O
19	of	O	O
20	rifampicin	S-Chemical	S-Chemical
21	for	O	O
22	Staphylococcal	B-Disease	B-Disease
23	infections	E-Disease	E-Disease
24	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	patient	O	O
7	with	O	O
8	Staphylococcal	B-Disease	B-Chemical
9	IE	E-Disease	E-Chemical
10	who	O	O
11	developed	O	O
12	acute	B-Disease	B-Disease
13	renal	I-Disease	I-Disease
14	failure	E-Disease	E-Disease
15	secondary	O	O
16	to	O	O
17	a	O	O
18	segmental	O	O
19	necrotising	O	O
20	glomerulonephritis	S-Disease	S-Disease
21	while	O	O
22	being	O	O
23	treated	O	O
24	with	O	O
25	rifampicin	S-Chemical	S-Chemical
26	,	O	O
27	and	O	O
28	review	O	O
29	the	O	O
30	literature	O	O
31	regarding	O	O
32	this	O	O
33	complication	O	O
34	of	O	O
35	rifampicin	S-Chemical	S-Chemical
36	therapy	O	O
37	.	O	O

0	Rate	O	O
1	of	O	O
2	YMDD	O	O
3	motif	O	O
4	mutants	O	O
5	in	O	O
6	lamivudine	S-Chemical	S-Chemical
7	-	O	O
8	untreated	O	O
9	Iranian	O	S-Chemical
10	patients	O	O
11	with	O	O
12	chronic	B-Disease	B-Disease
13	hepatitis	I-Disease	I-Disease
14	B	I-Disease	I-Disease
15	virus	I-Disease	E-Disease
16	infection	E-Disease	E-Disease
17	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Lamivudine	S-Chemical	S-Chemical
3	is	O	O
4	used	O	O
5	for	O	O
6	the	O	O
7	treatment	O	O
8	of	O	O
9	chronic	B-Disease	B-Disease
10	hepatitis	I-Disease	I-Disease
11	B	E-Disease	E-Disease
12	patients	O	O
13	.	O	O

0	Recent	O	O
1	studies	O	O
2	show	O	O
3	that	O	O
4	the	O	O
5	YMDD	O	O
6	motif	O	O
7	mutants	O	O
8	(	O	O
9	resistant	O	O
10	hepatitis	B-Disease	B-Disease
11	B	E-Disease	I-Disease
12	virus	O	E-Disease
13	)	O	O
14	occur	O	O
15	as	O	O
16	natural	O	O
17	genome	O	O
18	variability	O	O
19	in	O	O
20	lamivudine	S-Chemical	S-Chemical
21	-	O	O
22	untreated	O	O
23	chronic	B-Disease	B-Disease
24	hepatitis	I-Disease	I-Disease
25	B	E-Disease	E-Disease
26	patients	O	O
27	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	we	O	O
4	aimed	O	O
5	to	O	O
6	determine	O	O
7	the	O	O
8	rate	O	O
9	of	O	O
10	YMDD	O	O
11	motif	O	O
12	mutants	O	O
13	in	O	O
14	lamivudine	S-Chemical	S-Chemical
15	-	O	O
16	untreated	O	O
17	chronic	B-Disease	B-Disease
18	hepatitis	I-Disease	I-Disease
19	B	E-Disease	E-Disease
20	patients	O	O
21	in	O	O
22	Iran	O	S-Chemical
23	.	O	O

0	PATIENTS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	A	O	O
5	total	O	O
6	of	O	O
7	77	O	O
8	chronic	B-Disease	B-Disease
9	hepatitis	I-Disease	I-Disease
10	B	E-Disease	E-Disease
11	patients	O	O
12	who	O	O
13	had	O	O
14	not	O	O
15	been	O	O
16	treated	O	O
17	with	O	O
18	lamivudine	S-Chemical	S-Chemical
19	were	O	O
20	included	O	O
21	in	O	O
22	the	O	O
23	study	O	O
24	.	O	O

0	All	O	O
1	patients	O	O
2	were	O	O
3	also	O	O
4	tested	O	O
5	for	O	O
6	liver	O	O
7	enzymes	O	E-Disease
8	,	O	O
9	anti	O	O
10	-	O	O
11	HCV	O	S-Disease
12	,	O	O
13	HBeAg	S-Chemical	O
14	,	O	O
15	and	O	O
16	anti	O	O
17	-	O	O
18	HBe	O	O
19	.	O	O

0	HBeAg	S-Chemical	S-Chemical
1	was	O	O
2	positive	O	O
3	in	O	O
4	40	O	O
5	%	O	O
6	and	O	O
7	anti	O	O
8	-	O	O
9	HBe	O	E-Chemical
10	in	O	O
11	60	O	O
12	%	O	O
13	of	O	O
14	the	O	O
15	patients	O	O
16	.	O	O

0	YMDD	O	O
1	motif	O	O
2	mutants	O	O
3	were	O	O
4	not	O	O
5	detected	O	O
6	in	O	O
7	any	O	O
8	of	O	O
9	the	O	O
10	patients	O	O
11	despite	O	O
12	the	O	O
13	liver	O	B-Disease
14	enzyme	O	E-Disease
15	levels	O	O
16	and	O	O
17	the	O	O
18	presence	O	O
19	of	O	O
20	HBeAg	S-Chemical	O
21	or	O	O
22	anti	O	O
23	-	O	O
24	HBe	O	O
25	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Although	O	O
3	the	O	O
4	natural	O	O
5	occurrence	O	O
6	of	O	O
7	YMDD	O	O
8	motif	O	O
9	mutants	O	O
10	in	O	O
11	lamivudine	S-Chemical	S-Chemical
12	-	O	O
13	untreated	O	O
14	patients	O	O
15	with	O	O
16	chronic	B-Disease	B-Disease
17	hepatitis	I-Disease	I-Disease
18	B	E-Disease	E-Disease
19	has	O	O
20	been	O	O
21	reported	O	O
22	,	O	O
23	these	O	O
24	mutants	O	O
25	were	O	O
26	not	O	O
27	detected	O	O
28	in	O	O
29	Iranian	O	O
30	lamivudine	S-Chemical	S-Chemical
31	-	O	O
32	untreated	O	O
33	chronic	B-Disease	B-Disease
34	hepatitis	I-Disease	I-Disease
35	B	E-Disease	E-Disease
36	patients	O	O
37	.	O	O

0	Branch	O	O
1	retinal	B-Disease	O
2	vein	I-Disease	I-Disease
3	occlusion	E-Disease	E-Disease
4	and	O	O
5	fluoxetine	S-Chemical	S-Chemical
6	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	branch	O	O
4	retinal	B-Disease	O
5	vein	I-Disease	I-Disease
6	occlusion	E-Disease	E-Disease
7	associated	O	O
8	with	O	O
9	fluoxetine	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	secondary	O	O
13	hypertension	S-Disease	S-Disease
14	is	O	O
15	described	O	O
16	.	O	O

0	Although	O	O
1	an	O	O
2	infrequent	O	O
3	complication	O	O
4	of	O	O
5	selective	O	O
6	serotonin	S-Chemical	S-Chemical
7	reuptake	O	O
8	inhibitor	O	O
9	therapy	O	O
10	,	O	O
11	it	O	O
12	is	O	O
13	important	O	O
14	that	O	O
15	ophthalmologists	O	S-Disease
16	are	O	O
17	aware	O	O
18	that	O	O
19	these	O	O
20	agents	O	O
21	can	O	O
22	cause	O	O
23	hypertension	S-Disease	S-Disease
24	because	O	O
25	this	O	O
26	class	O	O
27	of	O	O
28	drugs	O	O
29	is	O	O
30	widely	O	O
31	prescribed	O	O
32	.	O	O

0	The	O	O
1	differential	O	O
2	effects	O	O
3	of	O	O
4	bupivacaine	S-Chemical	S-Chemical
5	and	O	O
6	lidocaine	S-Chemical	S-Chemical
7	on	O	O
8	prostaglandin	B-Chemical	S-Disease
9	E2	E-Chemical	I-Disease
10	release	O	O
11	,	O	O
12	cyclooxygenase	O	S-Chemical
13	gene	O	O
14	expression	O	O
15	and	O	O
16	pain	S-Disease	S-Disease
17	in	O	O
18	a	O	O
19	clinical	O	O
20	pain	S-Disease	O
21	model	O	O
22	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	In	O	O
3	addition	O	O
4	to	O	O
5	blocking	O	O
6	nociceptive	O	O
7	input	O	O
8	from	O	O
9	surgical	O	O
10	sites	O	O
11	,	O	O
12	long	O	O
13	-	O	O
14	acting	O	O
15	local	O	O
16	anesthetics	O	O
17	might	O	O
18	directly	O	O
19	modulate	O	O
20	inflammation	S-Disease	S-Disease
21	.	O	O

0	In	O	O
1	the	O	O
2	present	O	O
3	study	O	O
4	,	O	O
5	we	O	O
6	describe	O	O
7	the	O	O
8	proinflammatory	O	O
9	effects	O	O
10	of	O	O
11	bupivacaine	S-Chemical	S-Chemical
12	on	O	O
13	local	O	O
14	prostaglandin	B-Chemical	B-Disease
15	E2	E-Chemical	E-Chemical
16	(	O	O
17	PGE2	S-Chemical	S-Chemical
18	)	O	O
19	production	O	O
20	and	O	O
21	cyclooxygenase	O	S-Chemical
22	(	O	O
23	COX	O	S-Chemical
24	)	O	O
25	gene	O	O
26	expression	O	O
27	that	O	O
28	increases	O	O
29	postoperative	B-Disease	O
30	pain	E-Disease	S-Disease
31	in	O	O
32	human	O	O
33	subjects	O	O
34	.	O	O

0	METHODS	O	O
1	:	O	O
2	Subjects	O	O
3	(	O	O
4	n	O	O
5	=	O	O
6	114	O	O
7	)	O	O
8	undergoing	O	O
9	extraction	O	O
10	of	O	O
11	impacted	O	O
12	third	O	O
13	molars	O	O
14	received	O	O
15	either	O	O
16	2	O	O
17	%	O	O
18	lidocaine	S-Chemical	S-Disease
19	or	O	O
20	0	O	O
21	.	O	O
22	5	O	O
23	%	O	O
24	bupivacaine	S-Chemical	S-Chemical
25	before	O	O
26	surgery	O	O
27	and	O	O
28	either	O	O
29	rofecoxib	S-Chemical	S-Chemical
30	50	O	O
31	mg	O	O
32	or	O	O
33	placebo	O	O
34	orally	O	O
35	90	O	O
36	min	O	O
37	before	O	O
38	surgery	O	O
39	and	O	O
40	for	O	O
41	the	O	O
42	following	O	O
43	48	O	O
44	h	O	O
45	.	O	O

0	After	O	O
1	extraction	O	O
2	,	O	O
3	a	O	O
4	microdialysis	O	O
5	probe	O	O
6	was	O	O
7	placed	O	O
8	at	O	O
9	the	O	O
10	surgical	O	O
11	site	O	O
12	for	O	O
13	PGE2	S-Chemical	S-Chemical
14	and	O	O
15	thromboxane	B-Chemical	B-Chemical
16	B2	E-Chemical	E-Chemical
17	(	O	O
18	TXB2	S-Chemical	S-Chemical
19	)	O	O
20	measurements	O	O
21	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	bupivacaine	S-Chemical	S-Chemical
4	/	O	O
5	rofecoxib	S-Chemical	E-Chemical
6	group	O	O
7	reported	O	O
8	significantly	O	O
9	less	O	O
10	pain	S-Disease	S-Disease
11	,	O	O
12	as	O	O
13	assessed	O	O
14	by	O	O
15	a	O	O
16	visual	O	O
17	analog	O	O
18	scale	O	O
19	,	O	O
20	compared	O	O
21	with	O	O
22	the	O	O
23	other	O	O
24	three	O	O
25	treatment	O	O
26	groups	O	O
27	over	O	O
28	the	O	O
29	first	O	O
30	4	O	O
31	h	O	O
32	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	bupivacaine	S-Chemical	S-Chemical
4	/	O	O
5	placebo	O	E-Chemical
6	group	O	O
7	reported	O	O
8	significantly	O	O
9	more	O	O
10	pain	S-Disease	S-Disease
11	at	O	O
12	24	O	O
13	h	O	O
14	and	O	O
15	PGE2	S-Chemical	S-Chemical
16	levels	O	O
17	during	O	O
18	the	O	O
19	first	O	O
20	4	O	O
21	h	O	O
22	were	O	O
23	significantly	O	O
24	higher	O	O
25	than	O	O
26	the	O	O
27	other	O	O
28	three	O	O
29	treatment	O	O
30	groups	O	O
31	.	O	O

0	Moreover	O	O
1	,	O	O
2	bupivacaine	S-Chemical	S-Chemical
3	significantly	O	O
4	increased	O	O
5	COX	O	S-Chemical
6	-	O	E-Chemical
7	2	O	E-Disease
8	gene	O	O
9	expression	O	O
10	at	O	O
11	48	O	O
12	h	O	O
13	as	O	O
14	compared	O	O
15	with	O	O
16	the	O	O
17	lidocaine	S-Chemical	S-Chemical
18	/	O	O
19	placebo	O	S-Disease
20	group	O	O
21	.	O	O

0	Thromboxane	S-Chemical	S-Chemical
1	levels	O	O
2	were	O	O
3	not	O	O
4	significantly	O	O
5	affected	O	O
6	by	O	O
7	any	O	O
8	of	O	O
9	the	O	O
10	treatments	O	O
11	,	O	O
12	indicating	O	O
13	that	O	O
14	the	O	O
15	effects	O	O
16	seen	O	O
17	were	O	O
18	attributable	O	O
19	to	O	O
20	inhibition	O	O
21	of	O	O
22	COX	O	S-Chemical
23	-	O	E-Chemical
24	2	O	E-Disease
25	,	O	O
26	but	O	O
27	not	O	O
28	COX	O	S-Chemical
29	-	O	E-Chemical
30	1	O	E-Disease
31	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	These	O	O
3	results	O	O
4	suggest	O	O
5	that	O	O
6	bupivacaine	S-Chemical	S-Chemical
7	stimulates	O	O
8	COX	O	S-Disease
9	-	O	E-Chemical
10	2	O	E-Disease
11	gene	O	O
12	expression	O	O
13	after	O	O
14	tissue	B-Disease	O
15	injury	E-Disease	O
16	,	O	O
17	which	O	O
18	is	O	O
19	associated	O	O
20	with	O	O
21	higher	O	O
22	PGE2	S-Chemical	S-Chemical
23	production	O	O
24	and	O	O
25	pain	S-Disease	S-Disease
26	after	O	O
27	the	O	O
28	local	O	O
29	anesthetic	O	O
30	effect	O	O
31	dissipates	O	O
32	.	O	O

0	p75NTR	O	S-Chemical
1	expression	O	O
2	in	O	O
3	rat	O	O
4	urinary	O	O
5	bladder	O	I-Disease
6	sensory	O	O
7	neurons	O	O
8	and	O	O
9	spinal	O	B-Disease
10	cord	O	E-Disease
11	with	O	O
12	cyclophosphamide	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	cystitis	S-Disease	S-Disease
16	.	O	O

0	Previous	O	O
1	studies	O	O
2	have	O	O
3	examined	O	O
4	the	O	O
5	expression	O	O
6	and	O	O
7	regulation	O	O
8	of	O	O
9	tyrosine	S-Chemical	S-Chemical
10	kinase	O	I-Disease
11	receptors	O	O
12	(	O	O
13	Trks	O	S-Chemical
14	)	O	O
15	in	O	O
16	micturition	O	O
17	reflexes	O	O
18	with	O	O
19	urinary	B-Disease	B-Disease
20	bladder	I-Disease	I-Disease
21	inflammation	E-Disease	E-Disease
22	.	O	O

0	The	O	O
1	present	O	O
2	studies	O	O
3	examine	O	O
4	the	O	O
5	expression	O	O
6	and	O	O
7	regulation	O	O
8	of	O	O
9	another	O	O
10	receptor	O	O
11	known	O	O
12	to	O	O
13	bind	O	O
14	NGF	O	S-Disease
15	,	O	O
16	p75	O	S-Disease
17	(	O	O
18	NTR	O	O
19	)	O	O
20	,	O	O
21	after	O	O
22	various	O	O
23	durations	O	O
24	of	O	O
25	bladder	B-Disease	B-Disease
26	inflammation	E-Disease	E-Disease
27	induced	O	O
28	by	O	O
29	cyclophosphamide	S-Chemical	S-Chemical
30	(	O	O
31	CYP	S-Chemical	S-Chemical
32	)	O	O
33	.	O	O

0	CYP	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	cystitis	S-Disease	S-Disease
4	increased	O	O
5	(	O	O
6	P	O	O
7	<	O	O
8	or	O	O
9	=	O	O
10	0	O	O
11	.	O	O
12	001	O	O
13	)	O	O
14	p75	O	O
15	(	O	O
16	NTR	O	O
17	)	O	O
18	expression	O	O
19	in	O	O
20	the	O	O
21	superficial	O	O
22	lateral	O	O
23	and	O	O
24	medial	O	O
25	dorsal	O	O
26	horn	O	O
27	in	O	O
28	L1	O	S-Disease
29	-	O	O
30	L2	O	O
31	and	O	O
32	L6	O	O
33	-	O	O
34	S1	O	O
35	spinal	O	O
36	segments	O	O
37	.	O	O

0	The	O	O
1	number	O	O
2	of	O	O
3	p75	O	O
4	(	O	O
5	NTR	O	O
6	)	O	O
7	-	O	O
8	immunoreactive	O	O
9	(	O	O
10	-	O	O
11	IR	O	S-Disease
12	)	O	O
13	cells	O	O
14	in	O	O
15	the	O	O
16	lumbosacral	O	O
17	dorsal	O	I-Disease
18	root	O	I-Disease
19	ganglia	O	E-Disease
20	(	O	O
21	DRG	O	S-Chemical
22	)	O	O
23	also	O	O
24	increased	O	O
25	(	O	O
26	P	O	O
27	<	O	O
28	or	O	O
29	=	O	O
30	0	O	O
31	.	O	O
32	05	O	O
33	)	O	O
34	with	O	O
35	CYP	S-Chemical	S-Chemical
36	-	O	O
37	induced	O	O
38	cystitis	S-Disease	S-Disease
39	(	O	O
40	acute	O	O
41	,	O	O
42	intermediate	O	O
43	,	O	O
44	and	O	O
45	chronic	O	O
46	)	O	O
47	.	O	O

0	Quantitative	O	O
1	,	O	O
2	real	O	O
3	-	O	O
4	time	O	O
5	polymerase	O	O
6	chain	O	O
7	reaction	O	O
8	also	O	O
9	demonstrated	O	O
10	significant	O	O
11	increases	O	O
12	(	O	O
13	P	O	S-Disease
14	<	O	O
15	or	O	O
16	=	O	O
17	0	O	O
18	.	O	O
19	01	O	O
20	)	O	O
21	in	O	O
22	p75	O	S-Disease
23	(	O	O
24	NTR	O	O
25	)	O	O
26	mRNA	O	O
27	in	O	O
28	DRG	O	S-Disease
29	with	O	O
30	intermediate	O	O
31	and	O	O
32	chronic	O	O
33	CYP	S-Chemical	S-Chemical
34	-	O	O
35	induced	O	O
36	cystitis	S-Disease	S-Disease
37	.	O	O

0	In	O	O
1	bladder	O	O
2	afferent	O	O
3	cells	O	O
4	in	O	O
5	DRG	O	S-Disease
6	,	O	O
7	p75	O	S-Disease
8	(	O	O
9	NTR	O	O
10	)	O	O
11	-	O	O
12	IR	O	S-Disease
13	was	O	O
14	also	O	O
15	increased	O	O
16	(	O	O
17	P	O	O
18	<	O	O
19	or	O	O
20	=	O	O
21	0	O	O
22	.	O	O
23	01	O	O
24	)	O	O
25	with	O	O
26	cystitis	S-Disease	S-Disease
27	.	O	O

0	These	O	O
1	studies	O	O
2	demonstrate	O	O
3	that	O	O
4	p75	O	S-Chemical
5	(	O	O
6	NTR	O	O
7	)	O	O
8	expression	O	O
9	in	O	O
10	micturition	O	S-Disease
11	reflexes	O	O
12	is	O	O
13	present	O	O
14	constitutively	O	O
15	and	O	O
16	modified	O	O
17	by	O	O
18	bladder	B-Disease	B-Disease
19	inflammation	E-Disease	E-Disease
20	.	O	O

0	Azathioprine	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	suicidal	O	B-Disease
4	erythrocyte	O	I-Disease
5	death	O	E-Disease
6	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Azathioprine	S-Chemical	S-Chemical
3	is	O	O
4	widely	O	O
5	used	O	O
6	as	O	O
7	an	O	O
8	immunosuppressive	O	O
9	drug	O	O
10	.	O	O

0	The	O	O
1	side	O	O
2	effects	O	O
3	of	O	O
4	azathioprine	S-Chemical	S-Chemical
5	include	O	O
6	anemia	S-Disease	S-Disease
7	,	O	O
8	which	O	O
9	has	O	O
10	been	O	O
11	attributed	O	O
12	to	O	O
13	bone	O	B-Disease
14	marrow	O	I-Disease
15	suppression	O	O
16	.	O	O

0	Alternatively	O	O
1	,	O	O
2	anemia	S-Disease	O
3	could	O	O
4	result	O	O
5	from	O	O
6	accelerated	O	O
7	suicidal	O	B-Disease
8	erythrocyte	O	I-Disease
9	death	O	E-Disease
10	or	O	O
11	eryptosis	O	S-Disease
12	,	O	O
13	which	O	O
14	is	O	O
15	characterized	O	O
16	by	O	O
17	exposure	O	O
18	of	O	O
19	phosphatidylserine	S-Chemical	S-Chemical
20	(	O	O
21	PS	S-Chemical	O
22	)	O	O
23	at	O	O
24	the	O	O
25	erythrocyte	O	S-Disease
26	surface	O	O
27	and	O	O
28	by	O	O
29	cell	O	O
30	shrinkage	O	O
31	.	O	O

0	METHODS	O	O
1	:	O	O
2	The	O	O
3	present	O	O
4	experiments	O	O
5	explored	O	O
6	whether	O	O
7	azathioprine	S-Chemical	S-Chemical
8	influences	O	O
9	eryptosis	O	S-Disease
10	.	O	O

0	According	O	O
1	to	O	O
2	annexin	O	O
3	V	O	O
4	binding	O	O
5	,	O	O
6	erythrocytes	O	S-Disease
7	from	O	O
8	patients	O	O
9	indeed	O	O
10	showed	O	O
11	a	O	O
12	significant	O	O
13	increase	O	O
14	of	O	O
15	PS	S-Chemical	S-Disease
16	exposure	O	E-Disease
17	within	O	O
18	1	O	O
19	week	O	O
20	of	O	O
21	treatment	O	O
22	with	O	O
23	azathioprine	S-Chemical	S-Chemical
24	.	O	O

0	In	O	O
1	a	O	O
2	second	O	O
3	series	O	O
4	,	O	O
5	cytosolic	O	S-Chemical
6	Ca2	S-Chemical	B-Chemical
7	+	O	O
8	activity	O	O
9	(	O	O
10	Fluo3	S-Chemical	B-Chemical
11	fluorescence	O	O
12	)	O	O
13	,	O	O
14	cell	O	O
15	volume	O	O
16	(	O	O
17	forward	O	O
18	scatter	O	O
19	)	O	O
20	,	O	O
21	and	O	O
22	PS	S-Chemical	S-Disease
23	-	O	E-Chemical
24	exposure	O	O
25	(	O	O
26	annexin	O	B-Disease
27	V	O	E-Disease
28	binding	O	O
29	)	O	O
30	were	O	O
31	determined	O	O
32	by	O	O
33	FACS	O	O
34	analysis	O	O
35	in	O	O
36	erythrocytes	O	S-Disease
37	from	O	O
38	healthy	O	O
39	volunteers	O	O
40	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Exposure	O	O
3	to	O	O
4	azathioprine	S-Chemical	S-Chemical
5	(	O	O
6	>	O	O
7	or	O	O
8	=	O	O
9	2	O	O
10	microg	O	O
11	/	O	O
12	mL	O	O
13	)	O	O
14	for	O	O
15	48	O	O
16	hours	O	O
17	increased	O	O
18	cytosolic	O	S-Chemical
19	Ca2	S-Chemical	B-Chemical
20	+	O	E-Chemical
21	activity	O	O
22	and	O	O
23	annexin	O	O
24	V	O	E-Chemical
25	binding	O	O
26	and	O	O
27	decreased	O	O
28	forward	O	O
29	scatter	O	O
30	.	O	O

0	The	O	O
1	effect	O	O
2	of	O	O
3	azathioprine	S-Chemical	S-Chemical
4	on	O	O
5	both	O	O
6	annexin	O	B-Chemical
7	V	O	E-Chemical
8	binding	O	O
9	and	O	O
10	forward	O	O
11	scatter	O	O
12	was	O	O
13	significantly	O	O
14	blunted	O	O
15	in	O	O
16	the	O	O
17	nominal	O	O
18	absence	O	O
19	of	O	O
20	extracellular	O	O
21	Ca2	S-Chemical	B-Chemical
22	+	O	E-Chemical
23	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Azathioprine	S-Chemical	S-Chemical
3	triggers	O	O
4	suicidal	O	B-Disease
5	erythrocyte	O	I-Disease
6	death	O	E-Disease
7	,	O	O
8	an	O	O
9	effect	O	O
10	presumably	O	O
11	contributing	O	O
12	to	O	O
13	azathioprine	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	anemia	S-Disease	S-Disease
17	.	O	O

0	Levetiracetam	S-Chemical	S-Chemical
1	as	O	O
2	an	O	O
3	adjunct	O	O
4	to	O	O
5	phenobarbital	S-Chemical	S-Disease
6	treatment	O	O
7	in	O	O
8	cats	O	O
9	with	O	O
10	suspected	O	O
11	idiopathic	B-Disease	B-Disease
12	epilepsy	E-Disease	E-Disease
13	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	assess	O	O
4	pharmacokinetics	O	O
5	,	O	O
6	efficacy	O	O
7	,	O	O
8	and	O	O
9	tolerability	O	O
10	of	O	O
11	oral	O	O
12	levetiracetam	S-Chemical	S-Chemical
13	administered	O	O
14	as	O	O
15	an	O	O
16	adjunct	O	O
17	to	O	O
18	phenobarbital	S-Chemical	O
19	treatment	O	O
20	in	O	O
21	cats	O	O
22	with	O	O
23	poorly	O	O
24	controlled	O	O
25	suspected	O	O
26	idiopathic	B-Disease	S-Disease
27	epilepsy	E-Disease	S-Disease
28	.	O	O

0	ANIMALS	O	O
1	:	O	O
2	12	O	O
3	cats	O	O
4	suspected	O	O
5	to	O	O
6	have	O	O
7	idiopathic	B-Disease	B-Disease
8	epilepsy	E-Disease	E-Disease
9	that	O	O
10	was	O	O
11	poorly	O	O
12	controlled	O	O
13	with	O	O
14	phenobarbital	S-Chemical	S-Disease
15	or	O	O
16	that	O	O
17	had	O	O
18	unacceptable	O	O
19	adverse	O	O
20	effects	O	O
21	when	O	O
22	treated	O	O
23	with	O	O
24	phenobarbital	S-Chemical	S-Chemical
25	.	O	O

0	PROCEDURES	O	O
1	:	O	O
2	Cats	O	O
3	were	O	O
4	treated	O	O
5	with	O	O
6	levetiracetam	S-Chemical	S-Chemical
7	(	O	O
8	20	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	[	O	O
13	9	O	O
14	.	O	O
15	1	O	O
16	mg	O	O
17	/	O	O
18	lb	O	O
19	]	O	O
20	,	O	O
21	PO	O	S-Chemical
22	,	O	O
23	q	O	O
24	8	O	O
25	h	O	O
26	)	O	O
27	.	O	O

0	After	O	O
1	a	O	O
2	minimum	O	O
3	of	O	O
4	1	O	O
5	week	O	O
6	of	O	O
7	treatment	O	O
8	,	O	O
9	serum	O	O
10	levetiracetam	S-Chemical	S-Chemical
11	concentrations	O	O
12	were	O	O
13	measured	O	O
14	before	O	O
15	and	O	O
16	2	O	O
17	,	O	O
18	4	O	O
19	,	O	O
20	and	O	O
21	6	O	O
22	hours	O	O
23	after	O	O
24	drug	O	O
25	administration	O	O
26	,	O	O
27	and	O	O
28	maximum	O	O
29	and	O	O
30	minimum	O	O
31	serum	O	O
32	concentrations	O	O
33	and	O	O
34	elimination	O	O
35	half	O	O
36	-	O	O
37	life	O	O
38	were	O	O
39	calculated	O	O
40	.	O	O

0	Seizure	S-Disease	O
1	frequencies	O	O
2	before	O	O
3	and	O	O
4	after	O	O
5	initiation	O	O
6	of	O	O
7	levetiracetam	S-Chemical	S-Chemical
8	treatment	O	O
9	were	O	O
10	compared	O	O
11	,	O	O
12	and	O	O
13	adverse	O	O
14	effects	O	O
15	were	O	O
16	recorded	O	O
17	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Median	O	O
3	maximum	O	O
4	serum	O	O
5	levetiracetam	S-Chemical	S-Chemical
6	concentration	O	O
7	was	O	O
8	25	O	O
9	.	O	O
10	5	O	O
11	microg	O	O
12	/	O	O
13	mL	O	O
14	,	O	O
15	median	O	O
16	minimum	O	O
17	serum	O	O
18	levetiracetam	S-Chemical	S-Chemical
19	concentration	O	O
20	was	O	O
21	8	O	O
22	.	O	O
23	3	O	O
24	microg	O	O
25	/	O	O
26	mL	O	O
27	,	O	O
28	and	O	O
29	median	O	O
30	elimination	O	O
31	half	O	O
32	-	O	O
33	life	O	O
34	was	O	O
35	2	O	O
36	.	O	O
37	9	O	O
38	hours	O	O
39	.	O	O

0	Median	O	O
1	seizure	S-Disease	O
2	frequency	O	O
3	prior	O	O
4	to	O	O
5	treatment	O	O
6	with	O	O
7	levetiracetam	S-Chemical	S-Chemical
8	(	O	O
9	2	O	O
10	.	O	O
11	1	O	O
12	seizures	S-Disease	O
13	/	O	O
14	mo	O	O
15	)	O	O
16	was	O	O
17	significantly	O	O
18	higher	O	O
19	than	O	O
20	median	O	O
21	seizure	S-Disease	S-Disease
22	frequency	O	O
23	after	O	O
24	initiation	O	O
25	of	O	O
26	levetiracetam	S-Chemical	S-Chemical
27	treatment	O	O
28	(	O	O
29	0	O	O
30	.	O	O
31	42	O	O
32	seizures	S-Disease	O
33	/	O	O
34	mo	O	O
35	)	O	O
36	,	O	O
37	and	O	O
38	7	O	O
39	of	O	O
40	10	O	O
41	cats	O	O
42	were	O	O
43	classified	O	O
44	as	O	O
45	having	O	O
46	responded	O	O
47	to	O	O
48	levetiracetam	S-Chemical	S-Chemical
49	treatment	O	O
50	(	O	O
51	ie	O	O
52	,	O	O
53	reduction	O	O
54	in	O	O
55	seizure	S-Disease	S-Disease
56	frequency	O	O
57	of	O	O
58	>	O	O
59	or	O	O
60	=	O	O
61	50	O	O
62	%	O	O
63	)	O	O
64	.	O	O

0	Two	O	O
1	cats	O	O
2	had	O	O
3	transient	O	O
4	lethargy	S-Disease	S-Disease
5	and	O	O
6	inappetence	S-Disease	O
7	.	O	O

0	CONCLUSIONS	O	O
1	AND	O	O
2	CLINICAL	O	O
3	RELEVANCE	O	O
4	:	O	O
5	Results	O	O
6	suggested	O	O
7	that	O	O
8	levetiracetam	S-Chemical	S-Chemical
9	is	O	O
10	well	O	O
11	tolerated	O	O
12	in	O	O
13	cats	O	O
14	and	O	O
15	may	O	O
16	be	O	O
17	useful	O	O
18	as	O	O
19	an	O	O
20	adjunct	O	O
21	to	O	O
22	phenobarbital	S-Chemical	O
23	treatment	O	O
24	in	O	O
25	cats	O	O
26	with	O	O
27	idiopathic	B-Disease	O
28	epilepsy	E-Disease	O
29	.	O	O

0	Serotonin	S-Chemical	S-Chemical
1	reuptake	O	O
2	inhibitors	O	O
3	,	O	O
4	paranoia	S-Disease	O
5	,	O	O
6	and	O	O
7	the	O	O
8	ventral	O	O
9	basal	O	I-Disease
10	ganglia	O	E-Disease
11	.	O	O

0	Antidepressants	O	O
1	have	O	O
2	previously	O	O
3	been	O	O
4	associated	O	O
5	with	O	O
6	paranoid	S-Disease	B-Disease
7	reactions	O	E-Disease
8	in	O	O
9	psychiatric	O	O
10	patients	O	O
11	.	O	O

0	Five	O	O
1	cases	O	O
2	of	O	O
3	paranoid	S-Disease	S-Disease
4	exacerbation	O	O
5	with	O	O
6	the	O	O
7	serotonin	S-Chemical	S-Chemical
8	reuptake	O	O
9	inhibitors	O	O
10	fluoxetine	S-Chemical	S-Chemical
11	and	O	O
12	amitriptyline	S-Chemical	S-Chemical
13	are	O	O
14	reported	O	O
15	here	O	O
16	.	O	O

0	Elements	O	O
1	common	O	O
2	to	O	O
3	these	O	O
4	cases	O	O
5	included	O	O
6	a	O	O
7	history	O	O
8	of	O	O
9	paranoid	S-Disease	S-Disease
10	symptomatology	O	O
11	and	O	O
12	the	O	O
13	concomitant	O	O
14	occurrence	O	O
15	of	O	O
16	depressive	B-Disease	B-Disease
17	and	I-Disease	O
18	psychotic	I-Disease	S-Disease
19	symptoms	E-Disease	O
20	.	O	O

0	Complicated	O	O
1	depressive	B-Disease	B-Disease
2	disorders	E-Disease	E-Disease
3	(	O	O
4	including	O	O
5	atypicality	O	O
6	of	O	O
7	course	O	O
8	and	O	O
9	symptomatology	O	O
10	,	O	O
11	chronicity	O	S-Disease
12	,	O	O
13	psychosis	S-Disease	S-Disease
14	,	O	O
15	bipolarity	O	O
16	,	O	O
17	and	O	O
18	secondary	O	O
19	onset	O	O
20	in	O	O
21	the	O	O
22	course	O	O
23	of	O	O
24	a	O	O
25	primary	O	O
26	psychosis	S-Disease	S-Disease
27	)	O	O
28	may	O	O
29	present	O	O
30	particular	O	O
31	vulnerability	O	O
32	to	O	O
33	paranoid	S-Disease	S-Disease
34	exacerbations	O	O
35	associated	O	O
36	with	O	O
37	serotonin	S-Chemical	S-Chemical
38	reuptake	O	O
39	inhibitors	O	O
40	.	O	O

0	Although	O	O
1	the	O	O
2	pharmacology	O	O
3	and	O	O
4	neurobiology	O	O
5	of	O	O
6	paranoia	S-Disease	O
7	remain	O	O
8	cryptic	O	O
9	,	O	O
10	several	O	O
11	mechanisms	O	O
12	,	O	O
13	including	O	O
14	5HT3	O	S-Disease
15	receptor	O	O
16	-	O	O
17	mediated	O	O
18	dopamine	S-Chemical	S-Disease
19	release	O	O
20	,	O	O
21	beta	O	B-Disease
22	-	O	O
23	noradrenergic	O	S-Disease
24	receptor	O	O
25	downregulation	O	O
26	,	O	O
27	or	O	O
28	GABAB	O	S-Chemical
29	receptor	O	O
30	upregulation	O	O
31	acting	O	O
32	in	O	O
33	the	O	O
34	vicinity	O	O
35	of	O	O
36	the	O	O
37	ventral	O	O
38	basal	O	B-Disease
39	ganglia	O	E-Disease
40	(	O	O
41	possibly	O	O
42	in	O	O
43	lateral	O	O
44	orbitofrontal	O	S-Disease
45	or	O	O
46	anterior	O	O
47	cingulate	O	S-Disease
48	circuits	O	O
49	)	O	O
50	,	O	O
51	might	O	O
52	apply	O	O
53	to	O	O
54	this	O	O
55	phenomenon	O	O
56	.	O	O

0	These	O	O
1	cases	O	O
2	call	O	O
3	attention	O	O
4	to	O	O
5	possible	O	O
6	paranoid	S-Disease	O
7	exacerbations	O	O
8	with	O	O
9	serotonin	S-Chemical	S-Chemical
10	reuptake	O	O
11	blockers	O	S-Disease
12	in	O	O
13	select	O	O
14	patients	O	O
15	and	O	O
16	raise	O	O
17	neurobiological	O	O
18	considerations	O	O
19	regarding	O	O
20	paranoia	S-Disease	O
21	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Spinal	O	B-Disease
3	anaesthesia	O	E-Disease
4	is	O	O
5	widely	O	O
6	employed	O	O
7	in	O	O
8	clinical	O	O
9	practice	O	O
10	but	O	O
11	has	O	O
12	the	O	O
13	main	O	O
14	drawback	O	O
15	of	O	O
16	post	O	O
17	-	O	O
18	spinal	O	B-Disease
19	block	O	E-Disease
20	hypotension	S-Disease	E-Disease
21	.	O	O

0	In	O	O
1	the	O	O
2	lateral	O	O
3	position	O	O
4	with	O	O
5	operative	O	O
6	side	O	O
7	down	O	O
8	,	O	O
9	patients	O	O
10	recived	O	O
11	10	O	O
12	mg	O	O
13	(	O	O
14	2mls	O	O
15	)	O	O
16	of	O	O
17	0	O	O
18	.	O	O
19	5	O	O
20	%	O	O
21	hyperbaric	O	O
22	bupivacaine	S-Chemical	S-Chemical
23	through	O	O
24	a	O	O
25	25	O	O
26	-	O	O
27	gauge	O	O
28	spinal	O	O
29	needle	O	O
30	.	O	O

0	Blood	O	O
1	pressure	O	O
2	,	O	O
3	heart	O	O
4	rate	O	O
5	,	O	O
6	respiratory	O	B-Disease
7	rate	O	E-Disease
8	and	O	O
9	oxygen	S-Chemical	B-Disease
10	saturation	O	E-Disease
11	were	O	O
12	monitored	O	O
13	over	O	O
14	1	O	O
15	hour	O	O
16	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Three	O	O
3	patients	O	O
4	(	O	O
5	8	O	O
6	.	O	O
7	1	O	O
8	%	O	O
9	)	O	O
10	in	O	O
11	the	O	O
12	unilateral	O	O
13	group	O	O
14	and	O	O
15	5	O	O
16	(	O	O
17	13	O	O
18	.	O	O
19	5	O	O
20	%	O	O
21	)	O	O
22	in	O	O
23	the	O	O
24	conventional	O	O
25	group	O	O
26	developed	O	O
27	hypotension	S-Disease	S-Disease
28	,	O	O
29	P	O	S-Disease
30	=	O	O
31	0	O	O
32	.	O	O
33	71	O	O
34	.	O	O

0	Four	O	O
1	(	O	O
2	10	O	O
3	.	O	O
4	8	O	O
5	%	O	O
6	)	O	O
7	patients	O	O
8	in	O	O
9	the	O	O
10	conventional	O	O
11	group	O	O
12	and	O	O
13	1	O	O
14	(	O	O
15	2	O	O
16	.	O	O
17	7	O	O
18	%	O	O
19	)	O	O
20	in	O	O
21	the	O	O
22	unilateral	O	O
23	group	O	O
24	,	O	O
25	P	O	S-Disease
26	=	O	O
27	0	O	O
28	.	O	O
29	17	O	O
30	required	O	O
31	epinephrine	S-Chemical	S-Disease
32	infusion	O	O
33	to	O	O
34	treat	O	O
35	hypotension	S-Disease	S-Disease
36	.	O	O

0	The	O	O
1	mean	O	O
2	respiratory	O	S-Disease
3	rate	O	O
4	and	O	O
5	oxygen	S-Chemical	S-Disease
6	saturations	O	S-Disease
7	in	O	O
8	the	O	O
9	two	O	O
10	groups	O	O
11	were	O	O
12	similar	O	O
13	.	O	O

0	Also	O	O
1	,	O	O
2	the	O	O
3	type	O	O
4	of	O	O
5	spinal	O	B-Disease
6	block	O	E-Disease
7	instituted	O	O
8	affected	O	O
9	neither	O	O
10	the	O	O
11	respiratory	O	S-Disease
12	rate	O	O
13	nor	O	O
14	the	O	O
15	arterial	O	B-Disease
16	oxygen	S-Chemical	I-Disease
17	saturation	O	E-Disease
18	.	O	O

0	Spectrum	O	O
1	of	O	O
2	adverse	O	O
3	events	O	O
4	after	O	O
5	generic	O	O
6	HAART	O	O
7	in	O	O
8	southern	O	O
9	Indian	O	B-Disease
10	HIV	B-Disease	I-Disease
11	-	I-Disease	I-Disease
12	infected	E-Disease	E-Disease
13	patients	O	O
14	.	O	O

0	To	O	O
1	determine	O	O
2	the	O	O
3	incidence	O	O
4	of	O	O
5	clinically	O	O
6	significant	O	O
7	adverse	O	O
8	events	O	O
9	after	O	O
10	long	O	O
11	-	O	O
12	term	O	O
13	,	O	O
14	fixed	O	O
15	-	O	O
16	dose	O	O
17	,	O	O
18	generic	O	O
19	highly	O	O
20	active	O	O
21	antiretroviral	O	O
22	therapy	O	O
23	(	O	O
24	HAART	O	O
25	)	O	O
26	use	O	O
27	among	O	O
28	HIV	B-Disease	S-Chemical
29	-	I-Disease	I-Disease
30	infected	E-Disease	E-Disease
31	individuals	O	O
32	in	O	O
33	South	O	O
34	India	O	O
35	,	O	O
36	we	O	O
37	examined	O	O
38	the	O	O
39	experiences	O	O
40	of	O	O
41	3154	O	O
42	HIV	B-Disease	S-Chemical
43	-	I-Disease	I-Disease
44	infected	E-Disease	O
45	individuals	O	O
46	who	O	O
47	received	O	O
48	a	O	O
49	minimum	O	O
50	of	O	O
51	3	O	O
52	months	O	O
53	of	O	O
54	generic	O	O
55	HAART	O	O
56	between	O	O
57	February	O	O
58	1996	O	O
59	and	O	O
60	December	O	O
61	2006	O	O
62	at	O	O
63	a	O	O
64	tertiary	O	O
65	HIV	O	S-Chemical
66	care	O	O
67	referral	O	O
68	center	O	O
69	in	O	O
70	South	O	O
71	India	O	O
72	.	O	O

0	The	O	O
1	most	O	O
2	common	O	O
3	regimens	O	O
4	were	O	O
5	3TC	S-Chemical	O
6	+	O	O
7	d4T	S-Chemical	O
8	+	O	O
9	nevirapine	S-Chemical	S-Chemical
10	(	O	O
11	NVP	S-Chemical	S-Disease
12	)	O	O
13	(	O	O
14	54	O	O
15	.	O	O
16	8	O	O
17	%	O	O
18	)	O	O
19	,	O	O
20	zidovudine	S-Chemical	S-Chemical
21	(	O	O
22	AZT	S-Chemical	S-Chemical
23	)	O	O
24	+	O	O
25	3TC	S-Chemical	O
26	+	O	O
27	NVP	S-Chemical	S-Disease
28	(	O	O
29	14	O	O
30	.	O	O
31	5	O	O
32	%	O	O
33	)	O	O
34	,	O	O
35	3TC	S-Chemical	O
36	+	O	O
37	d4T	S-Chemical	O
38	+	O	O
39	efavirenz	S-Chemical	O
40	(	O	O
41	EFV	S-Chemical	S-Disease
42	)	O	O
43	(	O	O
44	20	O	O
45	.	O	O
46	1	O	O
47	%	O	O
48	)	O	O
49	,	O	O
50	and	O	O
51	AZT	S-Chemical	S-Chemical
52	+	O	O
53	3TC	S-Chemical	O
54	+	O	O
55	EFV	S-Chemical	S-Disease
56	(	O	O
57	5	O	O
58	.	O	O
59	4	O	O
60	%	O	O
61	)	O	O
62	.	O	O

0	The	O	O
1	most	O	O
2	common	O	O
3	adverse	O	O
4	events	O	O
5	and	O	O
6	median	O	O
7	CD4	O	O
8	at	O	O
9	time	O	O
10	of	O	O
11	event	O	O
12	were	O	O
13	rash	S-Disease	O
14	(	O	O
15	15	O	O
16	.	O	O
17	2	O	O
18	%	O	O
19	;	O	O
20	CD4	O	O
21	,	O	O
22	285	O	O
23	cells	O	O
24	/	O	O
25	microL	O	O
26	)	O	O
27	and	O	O
28	peripheral	B-Disease	O
29	neuropathy	E-Disease	E-Disease
30	(	O	O
31	9	O	O
32	.	O	O
33	0	O	O
34	%	O	O
35	and	O	O
36	348	O	O
37	cells	O	O
38	/	O	O
39	microL	O	O
40	)	O	O
41	.	O	O

0	Clinically	O	O
1	significant	O	O
2	anemia	S-Disease	O
3	(	O	O
4	hemoglobin	O	O
5	<	O	O
6	7	O	O
7	g	O	O
8	/	O	O
9	dL	O	O
10	)	O	O
11	was	O	O
12	observed	O	O
13	in	O	O
14	5	O	O
15	.	O	O
16	4	O	O
17	%	O	O
18	of	O	O
19	patients	O	O
20	(	O	O
21	CD4	O	O
22	,	O	O
23	165	O	O
24	cells	O	O
25	/	O	O
26	microL	O	O
27	)	O	O
28	and	O	O
29	hepatitis	S-Disease	S-Disease
30	(	O	O
31	clinical	O	O
32	jaundice	S-Disease	O
33	with	O	O
34	alanine	S-Chemical	B-Chemical
35	aminotransferase	O	E-Chemical
36	>	O	O
37	5	O	O
38	times	O	O
39	upper	O	O
40	limits	O	O
41	of	O	O
42	normal	O	O
43	)	O	O
44	in	O	O
45	3	O	O
46	.	O	O
47	5	O	O
48	%	O	O
49	of	O	O
50	patients	O	O
51	(	O	O
52	CD4	O	O
53	,	O	O
54	260	O	O
55	cells	O	O
56	/	O	O
57	microL	O	O
58	)	O	O
59	.	O	O

0	Women	O	O
1	were	O	O
2	significantly	O	O
3	more	O	O
4	likely	O	O
5	to	O	O
6	experience	O	O
7	lactic	B-Disease	B-Disease
8	acidosis	E-Disease	I-Disease
9	,	O	O
10	while	O	O
11	men	O	O
12	were	O	O
13	significantly	O	O
14	more	O	O
15	likely	O	O
16	to	O	O
17	experience	O	O
18	immune	B-Disease	B-Disease
19	reconstitution	I-Disease	I-Disease
20	syndrome	E-Disease	E-Disease
21	(	O	O
22	p	O	O
23	<	O	O
24	0	O	O
25	.	O	O
26	05	O	O
27	)	O	O
28	.	O	O

0	Among	O	O
1	the	O	O
2	patients	O	O
3	with	O	O
4	1	O	O
5	year	O	O
6	of	O	O
7	follow	O	O
8	-	O	O
9	up	O	O
10	,	O	O
11	NVP	S-Chemical	S-Chemical
12	therapy	O	O
13	was	O	O
14	significantly	O	O
15	associated	O	O
16	with	O	O
17	developing	O	O
18	rash	S-Disease	S-Disease
19	and	O	O
20	d4T	S-Chemical	S-Disease
21	therapy	O	O
22	with	O	O
23	developing	O	O
24	peripheral	B-Disease	B-Disease
25	neuropathy	E-Disease	E-Disease
26	(	O	O
27	p	O	O
28	<	O	O
29	0	O	O
30	.	O	O
31	05	O	O
32	)	O	O
33	.	O	O

0	Anemia	S-Disease	O
1	and	O	O
2	hepatitis	S-Disease	S-Disease
3	often	O	O
4	occur	O	O
5	within	O	O
6	12	O	O
7	weeks	O	O
8	of	O	O
9	initiating	O	O
10	generic	O	O
11	HAART	O	O
12	.	O	O

0	Frequent	O	O
1	and	O	O
2	early	O	O
3	monitoring	O	O
4	for	O	O
5	these	O	O
6	toxicities	S-Disease	O
7	is	O	O
8	warranted	O	O
9	in	O	O
10	developing	O	O
11	countries	O	O
12	where	O	O
13	generic	O	O
14	HAART	O	O
15	is	O	O
16	increasingly	O	O
17	available	O	O
18	.	O	O

0	Thalidomide	S-Chemical	S-Disease
1	and	O	O
2	sensory	B-Disease	O
3	neurotoxicity	E-Disease	E-Disease
4	:	O	O
5	a	O	O
6	neurophysiological	O	O
7	study	O	O
8	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Recent	O	O
3	studies	O	O
4	confirmed	O	O
5	a	O	O
6	high	O	O
7	incidence	O	O
8	of	O	O
9	sensory	B-Disease	B-Disease
10	axonal	I-Disease	I-Disease
11	neuropathy	E-Disease	I-Disease
12	in	O	O
13	patients	O	O
14	treated	O	O
15	with	O	O
16	different	O	O
17	doses	O	O
18	of	O	O
19	thalidomide	S-Chemical	S-Chemical
20	.	O	O

0	The	O	O
1	study	O	O
2	'	O	O
3	s	O	O
4	aims	O	O
5	were	O	O
6	to	O	O
7	measure	O	O
8	variations	O	O
9	in	O	O
10	sural	O	B-Disease
11	nerve	O	I-Disease
12	sensory	O	I-Disease
13	action	O	I-Disease
14	potential	O	E-Disease
15	(	O	O
16	SAP	O	S-Disease
17	)	O	O
18	amplitude	O	O
19	in	O	O
20	patients	O	O
21	with	O	O
22	refractory	O	O
23	cutaneous	B-Disease	B-Disease
24	lupus	I-Disease	I-Disease
25	erythematosus	E-Disease	E-Disease
26	(	O	O
27	CLE	S-Disease	S-Chemical
28	)	O	O
29	treated	O	O
30	with	O	O
31	thalidomide	S-Chemical	S-Chemical
32	and	O	O
33	use	O	O
34	these	O	O
35	findings	O	O
36	to	O	O
37	identify	O	O
38	the	O	O
39	neurotoxic	S-Disease	O
40	potential	O	O
41	of	O	O
42	thalidomide	S-Chemical	S-Chemical
43	and	O	O
44	the	O	O
45	recovery	O	O
46	capacity	O	O
47	of	O	O
48	sensory	O	O
49	fibres	O	O
50	after	O	O
51	discontinuation	O	O
52	of	O	O
53	treatment	O	O
54	.	O	O

0	PATIENTS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	Clinical	O	O
5	and	O	O
6	electrophysiological	O	O
7	data	O	O
8	in	O	O
9	12	O	O
10	female	O	O
11	patients	O	O
12	with	O	O
13	CLE	S-Disease	S-Chemical
14	during	O	O
15	treatment	O	O
16	with	O	O
17	thalidomide	S-Chemical	S-Chemical
18	and	O	O
19	up	O	O
20	to	O	O
21	47	O	O
22	months	O	O
23	after	O	O
24	discontinuation	O	O
25	of	O	O
26	treatment	O	O
27	were	O	O
28	analysed	O	O
29	.	O	O

0	Five	O	O
1	patients	O	O
2	complained	O	O
3	of	O	O
4	paresthesias	S-Disease	O
5	and	O	O
6	leg	O	O
7	cramps	S-Disease	E-Disease
8	.	O	O

0	After	O	O
1	thalidomide	S-Chemical	S-Chemical
2	treatment	O	O
3	,	O	O
4	sural	O	S-Disease
5	SAP	O	I-Disease
6	amplitude	O	O
7	recovered	O	O
8	in	O	O
9	3	O	O
10	patients	O	O
11	.	O	O

0	At	O	O
1	detection	O	O
2	of	O	O
3	reduction	O	O
4	in	O	O
5	sural	O	B-Disease
6	nerve	O	I-Disease
7	SAP	O	I-Disease
8	amplitude	O	O
9	,	O	O
10	the	O	O
11	median	O	O
12	thalidomide	S-Chemical	S-Disease
13	cumulative	O	O
14	dose	O	O
15	was	O	O
16	21	O	O
17	.	O	O
18	4	O	O
19	g	O	O
20	.	O	O

0	The	O	O
1	threshold	O	O
2	neurotoxic	S-Disease	O
3	dosage	O	O
4	is	O	O
5	lower	O	O
6	than	O	O
7	previously	O	O
8	reported	O	O
9	.	O	O

0	This	O	O
1	electrophysiological	O	O
2	parameter	O	O
3	provides	O	O
4	information	O	O
5	about	O	O
6	subclinical	O	O
7	neurotoxic	S-Disease	O
8	potential	O	O
9	of	O	O
10	thalidomide	S-Chemical	S-Chemical
11	but	O	O
12	is	O	O
13	not	O	O
14	helpful	O	O
15	in	O	O
16	predicting	O	O
17	the	O	O
18	appearance	O	O
19	of	O	O
20	sensory	O	O
21	symptoms	O	O
22	.	O	O

0	Five	O	O
1	cases	O	O
2	of	O	O
3	encephalitis	S-Disease	S-Disease
4	during	O	O
5	treatment	O	O
6	of	O	O
7	loiasis	S-Disease	S-Disease
8	with	O	O
9	diethylcarbamazine	S-Chemical	S-Chemical
10	.	O	O

0	Five	O	O
1	cases	O	O
2	of	O	O
3	encephalitis	S-Disease	S-Disease
4	following	O	O
5	treatment	O	O
6	with	O	O
7	diethylcarbamazine	S-Chemical	S-Chemical
8	(	O	O
9	DEC	S-Chemical	S-Chemical
10	)	O	O
11	were	O	O
12	observed	O	O
13	in	O	O
14	Congolese	O	S-Chemical
15	patients	O	O
16	with	O	O
17	Loa	O	B-Chemical
18	loa	O	I-Disease
19	filariasis	S-Disease	E-Disease
20	.	O	O

0	The	O	O
1	notable	O	O
2	fact	O	O
3	was	O	O
4	that	O	O
5	this	O	O
6	complication	O	O
7	occurred	O	O
8	in	O	O
9	three	O	O
10	patients	O	O
11	hospitalized	O	O
12	before	O	O
13	treatment	O	O
14	began	O	O
15	,	O	O
16	with	O	O
17	whom	O	O
18	particularly	O	O
19	strict	O	O
20	therapeutic	O	O
21	precautions	O	O
22	were	O	O
23	taken	O	O
24	,	O	O
25	i	O	O
26	.	O	O
27	e	O	O
28	.	O	O
29	,	O	O
30	initial	O	O
31	dose	O	O
32	less	O	O
33	than	O	O
34	10	O	O
35	mg	O	O
36	of	O	O
37	DEC	S-Chemical	S-Chemical
38	,	O	O
39	very	O	O
40	gradual	O	O
41	dose	O	O
42	increases	O	O
43	,	O	O
44	and	O	O
45	associated	O	O
46	anti	O	O
47	-	O	O
48	allergic	O	B-Disease
49	treatment	O	O
50	.	O	O

0	The	O	O
1	relationship	O	O
2	between	O	O
3	the	O	O
4	occurrence	O	O
5	of	O	O
6	encephalitis	S-Disease	S-Disease
7	and	O	O
8	the	O	O
9	decrease	O	O
10	in	O	O
11	microfilaremia	S-Disease	S-Disease
12	is	O	O
13	evident	O	O
14	.	O	O

0	Amiodarone	S-Chemical	S-Chemical
1	-	O	O
2	related	O	O
3	pulmonary	B-Disease	B-Disease
4	mass	E-Disease	E-Disease
5	and	O	O
6	unique	O	O
7	membranous	B-Disease	S-Disease
8	glomerulonephritis	E-Disease	S-Disease
9	in	O	O
10	a	O	O
11	patient	O	O
12	with	O	O
13	valvular	B-Disease	O
14	heart	I-Disease	I-Disease
15	disease	E-Disease	E-Disease
16	:	O	O
17	Diagnostic	O	O
18	pitfall	O	O
19	and	O	O
20	new	O	O
21	findings	O	O
22	.	O	O

0	Amiodarone	S-Chemical	S-Chemical
1	is	O	O
2	an	O	O
3	anti	O	O
4	-	O	O
5	arrhythmic	S-Disease	O
6	drug	O	O
7	for	O	O
8	life	O	O
9	-	O	O
10	threatening	O	O
11	tachycardia	S-Disease	S-Disease
12	,	O	O
13	but	O	O
14	various	O	O
15	adverse	O	O
16	effects	O	O
17	have	O	O
18	been	O	O
19	reported	O	O
20	.	O	O

0	Reported	O	O
1	herein	O	O
2	is	O	O
3	an	O	O
4	autopsy	O	O
5	case	O	O
6	of	O	O
7	valvular	B-Disease	O
8	heart	I-Disease	I-Disease
9	disease	E-Disease	E-Disease
10	,	O	O
11	in	O	O
12	a	O	O
13	patient	O	O
14	who	O	O
15	developed	O	O
16	a	O	O
17	lung	B-Disease	O
18	mass	E-Disease	O
19	(	O	O
20	1	O	O
21	.	O	O
22	5	O	O
23	cm	O	O
24	in	O	O
25	diameter	O	O
26	)	O	O
27	and	O	O
28	proteinuria	S-Disease	S-Disease
29	(	O	O
30	2	O	O
31	.	O	O
32	76	O	O
33	g	O	O
34	/	O	O
35	day	O	O
36	)	O	O
37	after	O	O
38	treatment	O	O
39	with	O	O
40	amiodarone	S-Chemical	S-Chemical
41	for	O	O
42	a	O	O
43	long	O	O
44	time	O	O
45	.	O	O

0	The	O	O
1	lung	B-Disease	O
2	mass	E-Disease	O
3	was	O	O
4	highly	O	O
5	suspected	O	O
6	to	O	O
7	be	O	O
8	lung	B-Disease	B-Disease
9	cancer	E-Disease	E-Disease
10	on	O	O
11	CT	O	O
12	and	O	O
13	positron	O	O
14	emission	O	O
15	tomography	O	O
16	,	O	O
17	but	O	O
18	histologically	O	O
19	the	O	O
20	lesion	O	O
21	was	O	O
22	composed	O	O
23	of	O	O
24	lymphoplasmacytic	O	O
25	infiltrates	O	O
26	in	O	O
27	alveolar	O	O
28	walls	O	O
29	and	O	O
30	intra	O	O
31	-	O	O
32	alveolar	O	S-Disease
33	accumulation	O	O
34	of	O	O
35	foamy	O	S-Disease
36	macrophages	O	O
37	containing	O	O
38	characteristic	O	O
39	myelinoid	O	S-Disease
40	bodies	O	O
41	,	O	O
42	indicating	O	O
43	that	O	O
44	it	O	O
45	was	O	O
46	an	O	O
47	amiodarone	S-Chemical	S-Chemical
48	-	O	O
49	related	O	O
50	lesion	O	S-Disease
51	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	the	O	O
4	lung	O	O
5	tissue	O	O
6	had	O	O
7	unevenly	O	O
8	distributed	O	O
9	hemosiderin	S-Disease	S-Disease
10	deposition	O	O
11	,	O	O
12	and	O	O
13	abnormally	O	O
14	tortuous	O	O
15	capillaries	O	O
16	were	O	O
17	seen	O	O
18	in	O	O
19	the	O	O
20	mass	O	O
21	and	O	O
22	in	O	O
23	heavily	O	O
24	hemosiderotic	S-Disease	O
25	lung	O	O
26	portions	O	O
27	outside	O	O
28	the	O	O
29	mass	O	O
30	.	O	O

0	Autoimmune	B-Disease	O
1	diseases	E-Disease	S-Disease
2	,	O	O
3	viral	B-Disease	B-Disease
4	hepatitis	E-Disease	E-Disease
5	,	O	O
6	malignant	O	O
7	neoplasms	S-Disease	S-Disease
8	or	O	O
9	other	O	O
10	diseases	O	S-Disease
11	with	O	O
12	a	O	O
13	known	O	O
14	relationship	O	O
15	to	O	O
16	membranous	B-Disease	S-Disease
17	glomerulonephritis	E-Disease	S-Disease
18	were	O	O
19	not	O	O
20	found	O	O
21	.	O	O

0	The	O	O
1	present	O	O
2	case	O	O
3	highlights	O	O
4	the	O	O
5	possibility	O	O
6	that	O	O
7	differential	O	O
8	diagnosis	O	O
9	between	O	O
10	an	O	O
11	amiodarone	S-Chemical	S-Chemical
12	-	O	O
13	related	O	O
14	pulmonary	B-Disease	B-Disease
15	lesion	E-Disease	E-Disease
16	and	O	O
17	a	O	O
18	neoplasm	S-Disease	S-Disease
19	can	O	O
20	be	O	O
21	very	O	O
22	difficult	O	O
23	radiologically	O	O
24	,	O	O
25	and	O	O
26	suggests	O	O
27	that	O	O
28	membranous	B-Disease	S-Chemical
29	glomerulonephritis	E-Disease	E-Chemical
30	might	O	O
31	be	O	O
32	another	O	O
33	possible	O	O
34	complication	O	O
35	of	O	O
36	amiodarone	S-Chemical	S-Chemical
37	treatment	O	O
38	.	O	O

0	Risk	O	O
1	of	O	O
2	coronary	B-Disease	B-Disease
3	artery	I-Disease	I-Disease
4	disease	E-Disease	E-Disease
5	associated	O	O
6	with	O	O
7	initial	O	O
8	sulphonylurea	S-Chemical	S-Chemical
9	treatment	O	O
10	of	O	O
11	patients	O	O
12	with	O	O
13	type	B-Disease	B-Disease
14	2	I-Disease	O
15	diabetes	E-Disease	S-Disease
16	:	O	O
17	a	O	O
18	matched	O	O
19	case	O	O
20	-	O	O
21	control	O	O
22	study	O	O
23	.	O	O

0	AIMS	O	O
1	:	O	O
2	This	O	O
3	study	O	O
4	sought	O	O
5	to	O	O
6	assess	O	O
7	the	O	O
8	risk	O	O
9	of	O	O
10	developing	O	O
11	coronary	B-Disease	B-Disease
12	artery	I-Disease	I-Disease
13	disease	E-Disease	E-Disease
14	(	O	O
15	CAD	S-Disease	S-Disease
16	)	O	O
17	associated	O	O
18	with	O	O
19	initial	O	O
20	treatment	O	O
21	of	O	O
22	type	B-Disease	B-Disease
23	2	I-Disease	I-Disease
24	diabetes	E-Disease	S-Disease
25	with	O	O
26	different	O	O
27	sulphonylureas	S-Chemical	S-Chemical
28	.	O	O

0	METHODS	O	O
1	:	O	O
2	In	O	O
3	type	B-Disease	O
4	2	I-Disease	O
5	diabetic	E-Disease	S-Disease
6	patients	O	O
7	,	O	O
8	cases	O	O
9	who	O	O
10	developed	O	O
11	CAD	S-Disease	S-Disease
12	were	O	O
13	compared	O	O
14	retrospectively	O	O
15	with	O	O
16	controls	O	O
17	that	O	O
18	did	O	O
19	not	O	O
20	.	O	O

0	The	O	O
1	20	O	O
2	-	O	O
3	year	O	O
4	risk	O	O
5	of	O	O
6	CAD	S-Disease	S-Disease
7	at	O	O
8	diagnosis	O	O
9	of	O	O
10	diabetes	S-Disease	S-Disease
11	,	O	O
12	using	O	O
13	the	O	O
14	UKPDS	O	S-Chemical
15	risk	O	O
16	engine	O	O
17	,	O	O
18	was	O	O
19	used	O	O
20	to	O	O
21	match	O	O
22	cases	O	O
23	with	O	O
24	controls	O	O
25	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	76	O	O
4	cases	O	O
5	of	O	O
6	CAD	S-Disease	S-Disease
7	were	O	O
8	compared	O	O
9	with	O	O
10	152	O	O
11	controls	O	O
12	.	O	O

0	The	O	O
1	hazard	O	O
2	of	O	O
3	developing	O	O
4	CAD	S-Disease	S-Disease
5	(	O	O
6	95	O	O
7	%	O	O
8	CI	O	S-Disease
9	)	O	O
10	associated	O	O
11	with	O	O
12	initial	O	O
13	treatment	O	O
14	increased	O	O
15	by	O	O
16	2	O	O
17	.	O	O
18	4	O	O
19	-	O	O
20	fold	O	O
21	(	O	O
22	1	O	O
23	.	O	O
24	3	O	O
25	-	O	O
26	4	O	O
27	.	O	O
28	3	O	O
29	,	O	O
30	P	O	O
31	=	O	O
32	0	O	O
33	.	O	O
34	004	O	O
35	)	O	O
36	with	O	O
37	glibenclamide	S-Chemical	S-Chemical
38	;	O	O
39	2	O	O
40	-	O	O
41	fold	O	O
42	(	O	O
43	0	O	O
44	.	O	O
45	9	O	O
46	-	O	O
47	4	O	O
48	.	O	O
49	6	O	O
50	,	O	O
51	P	O	O
52	=	O	O
53	0	O	O
54	.	O	O
55	099	O	O
56	)	O	O
57	with	O	O
58	glipizide	S-Chemical	S-Chemical
59	;	O	O
60	2	O	O
61	.	O	O
62	9	O	O
63	-	O	O
64	fold	O	O
65	(	O	O
66	1	O	O
67	.	O	O
68	6	O	O
69	-	O	O
70	5	O	O
71	.	O	O
72	1	O	O
73	,	O	O
74	P	O	S-Disease
75	=	O	O
76	0	O	O
77	.	O	O
78	000	O	O
79	)	O	O
80	with	O	O
81	either	O	O
82	,	O	O
83	and	O	O
84	was	O	O
85	unchanged	O	O
86	with	O	O
87	metformin	S-Chemical	S-Chemical
88	.	O	O

0	The	O	O
1	hazard	O	O
2	decreased	O	O
3	0	O	O
4	.	O	O
5	3	O	O
6	-	O	O
7	fold	O	O
8	(	O	O
9	0	O	O
10	.	O	O
11	7	O	O
12	-	O	O
13	1	O	O
14	.	O	O
15	7	O	O
16	,	O	O
17	P	O	S-Disease
18	=	O	O
19	0	O	O
20	.	O	O
21	385	O	O
22	)	O	O
23	with	O	O
24	glimepiride	S-Chemical	S-Chemical
25	,	O	O
26	0	O	O
27	.	O	O
28	4	O	O
29	-	O	O
30	fold	O	O
31	(	O	O
32	0	O	O
33	.	O	O
34	7	O	O
35	-	O	O
36	1	O	O
37	.	O	O
38	3	O	O
39	,	O	O
40	P	O	O
41	=	O	O
42	0	O	O
43	.	O	O
44	192	O	O
45	)	O	O
46	with	O	O
47	gliclazide	S-Chemical	S-Chemical
48	,	O	O
49	and	O	O
50	0	O	O
51	.	O	O
52	4	O	O
53	-	O	O
54	fold	O	O
55	(	O	O
56	0	O	O
57	.	O	O
58	7	O	O
59	-	O	O
60	1	O	O
61	.	O	O
62	1	O	O
63	,	O	O
64	P	O	S-Disease
65	=	O	O
66	0	O	O
67	.	O	O
68	09	O	O
69	)	O	O
70	with	O	O
71	either	O	O
72	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Initiating	O	O
3	treatment	O	O
4	of	O	O
5	type	B-Disease	B-Disease
6	2	I-Disease	I-Disease
7	diabetes	E-Disease	S-Disease
8	with	O	O
9	glibenclamide	S-Chemical	S-Chemical
10	or	O	O
11	glipizide	S-Chemical	S-Chemical
12	is	O	O
13	associated	O	O
14	with	O	O
15	increased	O	O
16	risk	O	O
17	of	O	O
18	CAD	S-Disease	S-Disease
19	in	O	O
20	comparison	O	O
21	to	O	O
22	gliclazide	S-Chemical	S-Chemical
23	or	O	O
24	glimepiride	S-Chemical	S-Chemical
25	.	O	O

0	If	O	O
1	confirmed	O	O
2	,	O	O
3	this	O	O
4	may	O	O
5	be	O	O
6	important	O	O
7	because	O	O
8	most	O	O
9	Indian	O	S-Chemical
10	patients	O	O
11	receive	O	O
12	the	O	O
13	cheaper	O	O
14	older	O	O
15	sulphonylureas	S-Chemical	S-Chemical
16	,	O	O
17	and	O	O
18	present	O	O
19	guidelines	O	O
20	do	O	O
21	not	O	O
22	distinguish	O	O
23	between	O	O
24	individual	O	O
25	agents	O	O
26	.	O	O

0	Reduced	O	O
1	progression	O	O
2	of	O	O
3	adriamycin	S-Chemical	S-Chemical
4	nephropathy	S-Disease	S-Disease
5	in	O	O
6	spontaneously	O	O
7	hypertensive	S-Disease	O
8	rats	O	O
9	treated	O	O
10	by	O	O
11	losartan	S-Chemical	S-Chemical
12	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	The	O	O
3	aim	O	O
4	of	O	O
5	the	O	O
6	study	O	O
7	was	O	O
8	to	O	O
9	investigate	O	O
10	the	O	O
11	antihypertensive	O	O
12	effects	O	O
13	of	O	O
14	angiotensin	B-Chemical	B-Disease
15	II	E-Chemical	I-Disease
16	type	O	I-Disease
17	-	O	O
18	1	O	O
19	receptor	O	O
20	blocker	O	O
21	,	O	O
22	losartan	S-Chemical	S-Chemical
23	,	O	O
24	and	O	O
25	its	O	O
26	potential	O	O
27	in	O	O
28	slowing	O	O
29	down	O	O
30	renal	B-Disease	I-Disease
31	disease	E-Disease	E-Disease
32	progression	O	O
33	in	O	O
34	spontaneously	O	O
35	hypertensive	S-Disease	O
36	rats	O	O
37	(	O	O
38	SHR	O	O
39	)	O	O
40	with	O	O
41	adriamycin	S-Chemical	S-Chemical
42	(	O	O
43	ADR	S-Chemical	S-Chemical
44	)	O	O
45	nephropathy	S-Disease	S-Disease
46	.	O	O

0	Groups	O	O
1	ADR	S-Chemical	S-Chemical
2	(	O	O
3	6	O	O
4	)	O	O
5	,	O	O
6	ADR	S-Chemical	S-Chemical
7	+	O	O
8	LOS	S-Chemical	S-Disease
9	(	O	O
10	6	O	O
11	)	O	O
12	and	O	O
13	ADR	S-Chemical	S-Chemical
14	(	O	O
15	12	O	O
16	)	O	O
17	,	O	O
18	and	O	O
19	ADR	S-Chemical	S-Chemical
20	+	O	O
21	LOS	S-Chemical	S-Disease
22	(	O	O
23	12	O	O
24	)	O	O
25	received	O	O
26	ADR	S-Chemical	S-Chemical
27	(	O	O
28	2	O	O
29	mg	O	O
30	/	O	O
31	kg	O	O
32	/	O	O
33	b	O	O
34	.	O	O
35	w	O	O
36	.	O	O
37	i	O	O
38	.	O	O
39	v	O	O
40	.	O	O
41	)	O	O
42	twice	O	O
43	in	O	O
44	a	O	O
45	3	O	O
46	-	O	O
47	week	O	O
48	interval	O	O
49	.	O	O

0	Group	O	O
1	ADR	S-Chemical	S-Chemical
2	+	O	O
3	LOS	S-Chemical	S-Disease
4	(	O	O
5	6	O	O
6	)	O	O
7	received	O	O
8	losartan	S-Chemical	S-Disease
9	(	O	O
10	10	O	O
11	mg	O	O
12	/	O	O
13	kg	O	O
14	/	O	O
15	b	O	O
16	.	O	O
17	w	O	O
18	.	O	O
19	/	O	O
20	day	O	O
21	by	O	O
22	gavages	O	O
23	)	O	O
24	for	O	O
25	6	O	O
26	weeks	O	O
27	and	O	O
28	group	O	O
29	ADR	S-Chemical	S-Chemical
30	+	O	O
31	LOS	S-Chemical	S-Disease
32	(	O	O
33	12	O	O
34	)	O	O
35	for	O	O
36	12	O	O
37	weeks	O	O
38	after	O	O
39	second	O	O
40	injection	O	O
41	of	O	O
42	ADR	S-Chemical	S-Chemical
43	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Short	O	O
3	-	O	O
4	term	O	O
5	losartan	S-Chemical	S-Disease
6	treatment	O	O
7	,	O	O
8	besides	O	O
9	antihypertensive	O	O
10	effect	O	O
11	,	O	O
12	improved	O	O
13	glomerular	O	B-Disease
14	filtration	O	E-Disease
15	rate	O	O
16	and	O	O
17	ameliorated	O	O
18	glomerulosclerosis	S-Disease	S-Disease
19	resulting	O	O
20	in	O	O
21	decreased	O	O
22	proteinuria	S-Disease	S-Disease
23	.	O	O

0	Prolonged	O	O
1	treatment	O	O
2	with	O	O
3	losartan	S-Chemical	S-Chemical
4	showed	O	O
5	further	O	O
6	reduction	O	O
7	of	O	O
8	glomerulosclerosis	S-Disease	S-Chemical
9	associated	O	O
10	with	O	O
11	reduced	O	O
12	progression	O	O
13	of	O	O
14	tubular	O	B-Disease
15	atrophy	S-Disease	E-Disease
16	and	O	O
17	interstitial	B-Disease	O
18	fibrosis	E-Disease	E-Disease
19	,	O	O
20	thus	O	O
21	preventing	O	O
22	heavy	O	B-Disease
23	proteinuria	S-Disease	I-Disease
24	and	O	O
25	chronic	B-Disease	B-Disease
26	renal	I-Disease	I-Disease
27	failure	E-Disease	E-Disease
28	.	O	O

0	Losartan	S-Chemical	S-Chemical
1	reduced	O	O
2	uraemia	S-Disease	S-Disease
3	and	O	O
4	increased	O	O
5	urea	S-Chemical	B-Disease
6	clearance	O	S-Disease
7	in	O	O
8	advanced	O	O
9	ADR	S-Chemical	B-Disease
10	nephropathy	S-Disease	E-Disease
11	in	O	O
12	SHR	O	S-Disease
13	.	O	O

0	Histological	O	O
1	examination	O	O
2	showed	O	O
3	that	O	O
4	losartan	S-Chemical	S-Chemical
5	could	O	O
6	prevent	O	O
7	tubular	O	B-Disease
8	atrophy	S-Disease	E-Disease
9	,	O	O
10	interstitial	O	O
11	infiltration	O	O
12	and	O	O
13	fibrosis	S-Disease	S-Disease
14	in	O	O
15	ADR	S-Chemical	B-Disease
16	nephropathy	S-Disease	E-Disease
17	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Losartan	S-Chemical	S-Chemical
3	reduces	O	O
4	the	O	O
5	rate	O	O
6	of	O	O
7	progression	O	O
8	of	O	O
9	ADR	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	focal	B-Disease	B-Disease
13	segmental	I-Disease	I-Disease
14	glomerulosclerosis	E-Disease	I-Disease
15	to	O	O
16	end	B-Disease	O
17	-	I-Disease	O
18	stage	I-Disease	O
19	renal	I-Disease	B-Disease
20	disease	E-Disease	E-Disease
21	in	O	O
22	SHR	O	S-Disease
23	.	O	O

0	The	O	O
1	risks	O	O
2	of	O	O
3	aprotinin	O	S-Chemical
4	and	O	O
5	tranexamic	B-Chemical	S-Chemical
6	acid	E-Chemical	E-Disease
7	in	O	O
8	cardiac	O	B-Disease
9	surgery	O	E-Disease
10	:	O	O
11	a	O	O
12	one	O	O
13	-	O	O
14	year	O	O
15	follow	O	O
16	-	O	O
17	up	O	O
18	of	O	O
19	1188	O	O
20	consecutive	O	O
21	patients	O	O
22	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Our	O	O
3	aim	O	O
4	was	O	O
5	to	O	O
6	investigate	O	O
7	postoperative	O	O
8	complications	O	O
9	and	O	O
10	mortality	O	O
11	after	O	O
12	administration	O	O
13	of	O	O
14	aprotinin	O	S-Chemical
15	compared	O	O
16	to	O	O
17	tranexamic	B-Chemical	S-Chemical
18	acid	E-Chemical	E-Disease
19	in	O	O
20	an	O	O
21	unselected	O	O
22	,	O	O
23	consecutive	O	O
24	cohort	O	O
25	.	O	O

0	During	O	O
1	the	O	O
2	first	O	O
3	5	O	O
4	mo	O	O
5	,	O	O
6	596	O	O
7	patients	O	O
8	received	O	O
9	aprotinin	O	S-Chemical
10	(	O	O
11	Group	O	O
12	A	O	O
13	)	O	O
14	;	O	O
15	in	O	O
16	the	O	O
17	next	O	O
18	5	O	O
19	mo	O	O
20	,	O	O
21	592	O	O
22	patients	O	O
23	were	O	O
24	treated	O	O
25	with	O	O
26	tranexamic	B-Chemical	S-Chemical
27	acid	E-Chemical	E-Disease
28	(	O	O
29	Group	O	O
30	T	O	O
31	)	O	O
32	.	O	O

0	Postoperatively	O	O
1	,	O	O
2	a	O	O
3	significantly	O	O
4	higher	O	O
5	incidence	O	O
6	of	O	O
7	seizures	S-Disease	S-Disease
8	was	O	O
9	found	O	O
10	in	O	O
11	Group	O	O
12	T	O	O
13	(	O	O
14	4	O	O
15	.	O	O
16	6	O	O
17	%	O	O
18	vs	O	O
19	1	O	O
20	.	O	O
21	2	O	O
22	%	O	O
23	,	O	O
24	P	O	S-Chemical
25	<	O	O
26	0	O	O
27	.	O	O
28	001	O	O
29	)	O	O
30	.	O	O

0	Persistent	O	O
1	atrial	O	B-Disease
2	fibrillation	O	E-Disease
3	(	O	O
4	7	O	O
5	.	O	O
6	9	O	O
7	%	O	O
8	vs	O	O
9	2	O	O
10	.	O	O
11	3	O	O
12	%	O	O
13	,	O	O
14	P	O	S-Chemical
15	=	O	O
16	0	O	O
17	.	O	O
18	020	O	O
19	)	O	O
20	and	O	O
21	renal	B-Disease	B-Disease
22	failure	E-Disease	E-Disease
23	(	O	O
24	9	O	O
25	.	O	O
26	7	O	O
27	%	O	O
28	vs	O	O
29	1	O	O
30	.	O	O
31	7	O	O
32	%	O	O
33	,	O	O
34	P	O	O
35	=	O	O
36	0	O	O
37	.	O	O
38	002	O	O
39	)	O	O
40	were	O	O
41	also	O	O
42	more	O	O
43	common	O	O
44	in	O	O
45	Group	O	O
46	T	O	O
47	,	O	O
48	in	O	O
49	the	O	O
50	primary	O	O
51	valve	O	O
52	surgery	O	O
53	subgroup	O	O
54	.	O	O

0	On	O	O
1	the	O	O
2	contrary	O	O
3	,	O	O
4	among	O	O
5	primary	O	O
6	coronary	O	B-Disease
7	artery	O	I-Disease
8	bypass	O	I-Disease
9	surgery	O	E-Disease
10	patients	O	O
11	,	O	O
12	there	O	O
13	were	O	O
14	more	O	O
15	acute	O	O
16	myocardial	B-Disease	B-Disease
17	infarctions	E-Disease	E-Disease
18	and	O	O
19	renal	B-Disease	I-Disease
20	dysfunction	E-Disease	E-Disease
21	in	O	O
22	Group	O	O
23	A	O	O
24	(	O	O
25	5	O	O
26	.	O	O
27	8	O	O
28	%	O	O
29	vs	O	O
30	2	O	O
31	.	O	O
32	0	O	O
33	%	O	O
34	,	O	O
35	P	O	S-Disease
36	=	O	O
37	0	O	O
38	.	O	O
39	027	O	O
40	;	O	O
41	22	O	O
42	.	O	O
43	5	O	O
44	%	O	O
45	vs	O	O
46	15	O	O
47	.	O	O
48	2	O	O
49	%	O	O
50	,	O	O
51	P	O	S-Chemical
52	=	O	O
53	0	O	O
54	.	O	O
55	036	O	O
56	,	O	O
57	respectively	O	O
58	)	O	O
59	.	O	O

0	Administration	O	O
1	of	O	O
2	aprotinin	O	S-Chemical
3	should	O	O
4	be	O	O
5	avoided	O	O
6	in	O	O
7	coronary	O	B-Disease
8	artery	O	I-Disease
9	bypass	O	I-Disease
10	graft	O	E-Disease
11	and	O	O
12	high	O	O
13	risk	O	O
14	patients	O	O
15	,	O	O
16	whereas	O	O
17	administration	O	O
18	of	O	O
19	tranexamic	B-Chemical	S-Chemical
20	acid	E-Chemical	E-Disease
21	is	O	O
22	not	O	O
23	recommended	O	O
24	in	O	O
25	valve	O	B-Disease
26	surgery	O	O
27	.	O	O

0	Delirium	S-Disease	O
1	in	O	O
2	an	O	O
3	elderly	O	O
4	woman	O	O
5	possibly	O	O
6	associated	O	O
7	with	O	O
8	administration	O	O
9	of	O	O
10	misoprostol	S-Chemical	S-Chemical
11	.	O	O

0	Misoprostol	S-Chemical	S-Chemical
1	has	O	O
2	been	O	O
3	associated	O	O
4	with	O	O
5	adverse	O	O
6	reactions	O	S-Disease
7	,	O	O
8	including	O	O
9	gastrointestinal	O	B-Disease
10	symptoms	O	E-Disease
11	,	O	O
12	gynecologic	O	O
13	problems	O	E-Disease
14	,	O	O
15	and	O	O
16	headache	S-Disease	S-Disease
17	.	O	O

0	We	O	O
1	present	O	O
2	a	O	O
3	case	O	O
4	in	O	O
5	which	O	O
6	an	O	O
7	89	O	O
8	-	O	O
9	year	O	O
10	-	O	O
11	old	O	O
12	woman	O	O
13	in	O	O
14	a	O	O
15	long	O	O
16	-	O	O
17	term	O	O
18	care	O	O
19	facility	O	O
20	became	O	O
21	confused	O	O
22	after	O	O
23	the	O	O
24	initiation	O	O
25	of	O	O
26	misoprostol	S-Chemical	S-Chemical
27	therapy	O	O
28	.	O	O

0	Her	O	O
1	delirium	S-Disease	S-Disease
2	significantly	O	O
3	improved	O	O
4	after	O	O
5	misoprostol	S-Chemical	S-Chemical
6	was	O	O
7	discontinued	O	O
8	and	O	O
9	her	O	O
10	mental	O	O
11	status	O	O
12	returned	O	O
13	to	O	O
14	normal	O	O
15	within	O	O
16	a	O	O
17	week	O	O
18	.	O	O

0	Because	O	O
1	no	O	O
2	other	O	O
3	factors	O	O
4	related	O	O
5	to	O	O
6	this	O	O
7	patient	O	O
8	changed	O	O
9	significantly	O	O
10	,	O	O
11	the	O	O
12	delirium	S-Disease	O
13	experienced	O	O
14	by	O	O
15	this	O	O
16	patient	O	O
17	possibly	O	O
18	resulted	O	O
19	from	O	O
20	misoprostol	S-Chemical	S-Chemical
21	therapy	O	O
22	.	O	O

0	The	O	O
1	biological	O	O
2	properties	O	O
3	of	O	O
4	the	O	O
5	optical	O	O
6	isomers	O	O
7	of	O	O
8	propranolol	S-Chemical	S-Chemical
9	and	O	O
10	their	O	O
11	effects	O	O
12	on	O	O
13	cardiac	B-Disease	B-Disease
14	arrhythmias	E-Disease	E-Disease
15	.	O	O

0	The	O	O
1	optical	O	O
2	isomers	O	O
3	of	O	O
4	propranolol	S-Chemical	S-Chemical
5	have	O	O
6	been	O	O
7	compared	O	O
8	for	O	O
9	their	O	O
10	beta	O	O
11	-	O	O
12	blocking	O	O
13	and	O	O
14	antiarrhythmic	O	O
15	activities	O	O
16	.	O	O
17	2	O	O
18	.	O	O

0	In	O	O
1	blocking	O	O
2	the	O	O
3	positive	O	O
4	inotropic	O	O
5	and	O	O
6	chronotropic	O	S-Disease
7	responses	O	O
8	to	O	O
9	isoprenaline	S-Chemical	S-Chemical
10	,	O	O
11	(	O	O
12	+	O	O
13	)	O	O
14	-	O	O
15	propranolol	S-Chemical	S-Chemical
16	had	O	O
17	less	O	O
18	than	O	O
19	one	O	O
20	hundredth	O	O
21	the	O	O
22	potency	O	O
23	of	O	O
24	(	O	O
25	-	O	S-Chemical
26	)	O	O
27	-	O	O
28	propranolol	S-Chemical	S-Chemical
29	.	O	O

0	At	O	O
1	dose	O	O
2	levels	O	O
3	of	O	O
4	(	O	O
5	+	O	O
6	)	O	O
7	-	O	O
8	propranolol	S-Chemical	S-Chemical
9	which	O	O
10	attenuated	O	O
11	the	O	O
12	responses	O	O
13	to	O	O
14	isoprenaline	S-Chemical	S-Chemical
15	,	O	O
16	there	O	O
17	was	O	O
18	a	O	O
19	significant	O	O
20	prolongation	O	O
21	of	O	O
22	the	O	O
23	PR	O	O
24	interval	O	O
25	of	O	O
26	the	O	O
27	electrocardiogram	O	O
28	.	O	O
29	3	O	O
30	.	O	O

0	The	O	O
1	metabolic	O	O
2	responses	O	O
3	to	O	O
4	isoprenaline	S-Chemical	S-Disease
5	in	O	O
6	dogs	O	O
7	(	O	O
8	an	O	O
9	increase	O	O
10	in	O	O
11	circulating	O	O
12	glucose	S-Chemical	S-Disease
13	,	O	O
14	lactate	S-Chemical	S-Disease
15	and	O	O
16	free	O	B-Disease
17	fatty	B-Chemical	I-Disease
18	acids	E-Chemical	E-Disease
19	)	O	O
20	were	O	O
21	all	O	O
22	blocked	O	O
23	by	O	O
24	(	O	O
25	-	O	S-Chemical
26	)	O	S-Chemical
27	-	O	O
28	propranolol	S-Chemical	S-Chemical
29	.	O	O

0	(	O	O
1	+	O	O
2	)	O	O
3	-	O	O
4	Propranolol	S-Chemical	S-Chemical
5	had	O	O
6	no	O	O
7	effect	O	O
8	on	O	O
9	fatty	B-Chemical	B-Disease
10	acid	E-Chemical	I-Disease
11	mobilization	O	E-Disease
12	but	O	O
13	significantly	O	O
14	reduced	O	O
15	the	O	O
16	increments	O	O
17	in	O	O
18	both	O	O
19	lactate	S-Chemical	S-Disease
20	and	O	O
21	glucose	S-Chemical	S-Disease
22	.	O	O
23	4	O	O
24	.	O	O

0	Both	O	O
1	isomers	O	O
2	of	O	O
3	propranolol	S-Chemical	S-Chemical
4	possessed	O	O
5	similar	O	O
6	depressant	O	O
7	potency	O	O
8	on	O	O
9	isolated	O	O
10	atrial	O	B-Disease
11	muscle	O	E-Disease
12	taken	O	O
13	from	O	O
14	guinea	O	O
15	-	O	O
16	pigs	O	O
17	.	O	O
18	5	O	O
19	.	O	O

0	The	O	O
1	isomers	O	O
2	of	O	O
3	propranolol	S-Chemical	S-Chemical
4	exhibited	O	O
5	similar	O	O
6	local	O	O
7	anaesthetic	O	O
8	potencies	O	O
9	on	O	O
10	an	O	O
11	isolated	O	O
12	frog	O	O
13	nerve	O	O
14	preparation	O	O
15	at	O	O
16	a	O	O
17	level	O	O
18	approximately	O	O
19	three	O	O
20	times	O	O
21	that	O	O
22	of	O	O
23	procaine	S-Chemical	S-Chemical
24	.	O	O

0	Both	O	O
1	isomers	O	O
2	of	O	O
3	propranolol	S-Chemical	S-Chemical
4	were	O	O
5	capable	O	O
6	of	O	O
7	preventing	O	O
8	adrenaline	S-Chemical	S-Disease
9	-	O	O
10	induced	O	O
11	cardiac	B-Disease	B-Disease
12	arrhythmias	E-Disease	E-Disease
13	in	O	O
14	cats	O	O
15	anaesthetized	O	O
16	with	O	O
17	halothane	S-Chemical	S-Chemical
18	,	O	O
19	but	O	O
20	the	O	O
21	mean	O	O
22	dose	O	O
23	of	O	O
24	(	O	O
25	-	O	S-Chemical
26	)	O	O
27	-	O	S-Chemical
28	propranolol	S-Chemical	S-Chemical
29	was	O	O
30	0	O	O
31	.	O	O
32	09	O	O
33	+	O	O
34	/	O	O
35	-	O	O
36	0	O	O
37	.	O	O
38	02	O	O
39	mg	O	O
40	/	O	O
41	kg	O	O
42	whereas	O	O
43	that	O	O
44	of	O	O
45	(	O	O
46	+	O	O
47	)	O	O
48	-	O	O
49	propranolol	S-Chemical	S-Chemical
50	was	O	O
51	4	O	O
52	.	O	O
53	2	O	O
54	+	O	O
55	/	O	O
56	-	O	O
57	1	O	O
58	.	O	O
59	2	O	O
60	mg	O	O
61	/	O	O
62	kg	O	O
63	.	O	O

0	At	O	O
1	the	O	O
2	effective	O	O
3	dose	O	O
4	level	O	O
5	of	O	O
6	(	O	O
7	+	O	O
8	)	O	O
9	-	O	O
10	propranolol	S-Chemical	S-Chemical
11	there	O	O
12	was	O	O
13	a	O	O
14	significant	O	O
15	prolongation	O	O
16	of	O	O
17	the	O	O
18	PR	O	O
19	interval	O	O
20	of	O	O
21	the	O	O
22	electrocardiogram	O	O
23	.	O	O

0	Blockade	O	O
1	of	O	O
2	arrhythmias	S-Disease	S-Disease
3	with	O	O
4	both	O	O
5	isomers	O	O
6	was	O	O
7	surmountable	O	O
8	by	O	O
9	increasing	O	O
10	the	O	O
11	dose	O	O
12	of	O	O
13	adrenaline	S-Chemical	S-Disease
14	.	O	O
15	7	O	O
16	.	O	O

0	Both	O	O
1	isomers	O	O
2	of	O	O
3	propranolol	S-Chemical	S-Chemical
4	were	O	O
5	also	O	O
6	capable	O	O
7	of	O	O
8	reversing	O	O
9	ventricular	B-Disease	O
10	tachycardia	E-Disease	S-Disease
11	caused	O	O
12	by	O	O
13	ouabain	S-Chemical	S-Chemical
14	in	O	O
15	anaesthetized	O	O
16	cats	O	O
17	and	O	O
18	dogs	O	O
19	.	O	O

0	The	O	O
1	dose	O	O
2	of	O	O
3	(	O	S-Chemical
4	-	O	B-Chemical
5	)	O	I-Chemical
6	-	O	I-Chemical
7	propranolol	S-Chemical	S-Chemical
8	was	O	O
9	significantly	O	O
10	smaller	O	O
11	than	O	O
12	that	O	O
13	of	O	O
14	(	O	O
15	+	O	O
16	)	O	O
17	-	O	O
18	propranolol	S-Chemical	S-Chemical
19	in	O	O
20	both	O	O
21	species	O	O
22	but	O	O
23	much	O	O
24	higher	O	O
25	than	O	O
26	that	O	O
27	required	O	O
28	to	O	O
29	produce	O	O
30	evidence	O	O
31	of	O	O
32	beta	O	S-Disease
33	-	O	O
34	blockade	O	O
35	.	O	O
36	8	O	O
37	.	O	O

0	Topotecan	S-Chemical	S-Chemical
1	in	O	O
2	combination	O	O
3	with	O	O
4	radiotherapy	O	S-Disease
5	in	O	O
6	unresectable	O	O
7	glioblastoma	S-Disease	S-Disease
8	:	O	O
9	a	O	O
10	phase	O	O
11	2	O	O
12	study	O	O
13	.	O	O

0	Improving	O	O
1	glioblastoma	B-Disease	B-Disease
2	multiforme	E-Disease	O
3	(	O	O
4	GBM	S-Disease	S-Disease
5	)	O	O
6	treatment	O	O
7	with	O	O
8	radio	O	O
9	-	O	O
10	chemotherapy	O	O
11	remains	O	O
12	a	O	O
13	challenge	O	O
14	.	O	O

0	Topotecan	S-Chemical	S-Chemical
1	is	O	O
2	an	O	O
3	attractive	O	O
4	option	O	O
5	as	O	O
6	it	O	O
7	exhibits	O	O
8	growth	O	O
9	inhibition	O	O
10	of	O	O
11	human	O	O
12	glioma	S-Disease	S-Disease
13	as	O	O
14	well	O	O
15	as	O	O
16	brain	O	O
17	penetration	O	E-Disease
18	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	assessed	O	O
4	the	O	O
5	combination	O	O
6	of	O	O
7	radiotherapy	O	S-Disease
8	(	O	O
9	60	O	O
10	Gy	O	O
11	/	O	O
12	30	O	O
13	fractions	O	O
14	/	O	O
15	40	O	O
16	days	O	O
17	)	O	O
18	and	O	O
19	topotecan	S-Chemical	S-Chemical
20	(	O	O
21	0	O	O
22	.	O	O
23	9	O	O
24	mg	O	O
25	/	O	O
26	m	O	O
27	(	O	O
28	2	O	O
29	)	O	O
30	/	O	O
31	day	O	O
32	on	O	O
33	days	O	O
34	1	O	O
35	-	O	O
36	5	O	O
37	on	O	O
38	weeks	O	O
39	1	O	O
40	,	O	O
41	3	O	O
42	and	O	O
43	5	O	O
44	)	O	O
45	in	O	O
46	50	O	O
47	adults	O	O
48	with	O	O
49	histologically	O	O
50	proven	O	O
51	and	O	O
52	untreated	O	O
53	GBM	S-Disease	S-Chemical
54	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	non	O	O
4	-	O	O
5	hematological	O	O
6	toxicities	S-Disease	O
7	was	O	O
8	low	O	O
9	and	O	O
10	grade	O	O
11	3	O	O
12	-	O	O
13	4	O	O
14	hematological	O	O
15	toxicities	S-Disease	S-Disease
16	were	O	O
17	reported	O	O
18	in	O	O
19	20	O	O
20	patients	O	O
21	(	O	O
22	mainly	O	O
23	lymphopenia	S-Disease	S-Disease
24	and	O	O
25	neutropenia	S-Disease	S-Disease
26	)	O	O
27	.	O	O

0	Topotecan	S-Chemical	S-Chemical
1	in	O	O
2	combination	O	O
3	with	O	O
4	radiotherapy	O	S-Disease
5	was	O	O
6	well	O	O
7	tolerated	O	O
8	.	O	O

0	However	O	O
1	,	O	O
2	while	O	O
3	response	O	O
4	and	O	O
5	stabilization	O	O
6	concerned	O	O
7	one	O	O
8	-	O	O
9	third	O	O
10	of	O	O
11	the	O	O
12	patients	O	O
13	,	O	O
14	the	O	O
15	study	O	O
16	did	O	O
17	not	O	O
18	show	O	O
19	increased	O	O
20	benefits	O	O
21	in	O	O
22	terms	O	O
23	of	O	O
24	survival	O	O
25	in	O	O
26	patients	O	O
27	with	O	O
28	unresectable	O	O
29	GBM	S-Disease	S-Chemical
30	.	O	O

0	Long	O	O
1	-	O	O
2	term	O	O
3	lithium	S-Chemical	S-Chemical
4	therapy	O	O
5	leading	O	O
6	to	O	O
7	hyperparathyroidism	S-Disease	S-Disease
8	:	O	O
9	a	O	O
10	case	O	O
11	report	O	O
12	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	This	O	O
3	paper	O	O
4	reviews	O	O
5	the	O	O
6	effect	O	O
7	of	O	O
8	chronic	O	B-Disease
9	lithium	S-Chemical	I-Disease
10	therapy	O	O
11	on	O	O
12	serum	O	O
13	calcium	S-Chemical	S-Disease
14	level	O	O
15	and	O	O
16	parathyroid	O	B-Disease
17	glands	O	E-Disease
18	,	O	O
19	its	O	O
20	pathogenesis	O	O
21	,	O	O
22	and	O	O
23	treatment	O	O
24	options	O	O
25	.	O	O

0	We	O	O
1	examined	O	O
2	the	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	lithium	S-Chemical	S-Chemical
7	-	O	O
8	treated	O	O
9	patient	O	O
10	who	O	O
11	had	O	O
12	recurrent	O	O
13	hypercalcemia	S-Disease	S-Disease
14	to	O	O
15	better	O	O
16	understand	O	O
17	the	O	O
18	disease	O	S-Disease
19	process	O	O
20	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Primary	B-Disease	O
3	hyperparathyroidism	E-Disease	S-Disease
4	is	O	O
5	a	O	O
6	rare	O	O
7	but	O	O
8	potentially	O	O
9	life	O	O
10	-	O	O
11	threatening	O	O
12	side	O	O
13	effect	O	O
14	of	O	O
15	long	O	O
16	-	O	O
17	term	O	O
18	lithium	S-Chemical	S-Chemical
19	therapy	O	O
20	.	O	O

0	PRACTICAL	O	O
1	IMPLICATIONS	O	O
2	:	O	O
3	As	O	O
4	much	O	O
5	as	O	O
6	15	O	O
7	%	O	O
8	of	O	O
9	lithium	S-Chemical	S-Chemical
10	-	O	O
11	treated	O	O
12	patients	O	O
13	become	O	O
14	hypercalcemic	S-Disease	S-Disease
15	.	O	O

0	By	O	O
1	routinely	O	O
2	monitoring	O	O
3	serum	O	O
4	calcium	S-Chemical	S-Disease
5	levels	O	O
6	,	O	O
7	healthcare	O	O
8	providers	O	O
9	can	O	O
10	improve	O	O
11	the	O	O
12	quality	O	O
13	of	O	O
14	life	O	O
15	of	O	O
16	this	O	O
17	patient	O	O
18	group	O	O
19	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	The	O	O
3	purpose	O	O
4	of	O	O
5	this	O	O
6	study	O	O
7	was	O	O
8	to	O	O
9	compare	O	O
10	surgical	O	O
11	conditions	O	O
12	,	O	O
13	including	O	O
14	the	O	O
15	amount	O	O
16	of	O	O
17	intraoperative	O	O
18	bleeding	S-Disease	S-Disease
19	as	O	O
20	well	O	O
21	as	O	O
22	intraoperative	O	O
23	blood	O	O
24	pressure	O	O
25	,	O	O
26	during	O	O
27	functional	O	O
28	endoscopic	O	O
29	sinus	O	B-Disease
30	surgery	O	E-Disease
31	(	O	O
32	FESS	O	O
33	)	O	O
34	using	O	O
35	flexible	O	O
36	reinforced	O	O
37	laryngeal	O	O
38	mask	O	O
39	airway	O	O
40	(	O	O
41	FRLMA	O	S-Disease
42	)	O	O
43	versus	O	O
44	endotracheal	O	O
45	tube	O	O
46	(	O	O
47	ETT	O	S-Disease
48	)	O	O
49	in	O	O
50	maintaining	O	O
51	controlled	O	O
52	hypotension	S-Disease	S-Disease
53	anesthesia	O	S-Disease
54	induced	O	O
55	by	O	O
56	propofol	S-Chemical	S-Chemical
57	-	O	I-Disease
58	remifentanil	S-Chemical	E-Chemical
59	total	O	O
60	i	O	O
61	.	O	O
62	v	O	O
63	.	O	O
64	anesthesia	O	O
65	(	O	O
66	TIVA	O	S-Disease
67	)	O	O
68	.	O	O

0	METHODS	O	O
1	:	O	O
2	Sixty	O	O
3	normotensive	O	O
4	American	O	I-Chemical
5	Society	O	I-Disease
6	of	O	I-Disease
7	Anesthesiologists	O	S-Chemical
8	I	O	O
9	-	O	O
10	II	O	O
11	adult	O	O
12	patients	O	O
13	undergoing	O	O
14	FESS	O	S-Disease
15	under	O	O
16	controlled	O	O
17	hypotension	S-Disease	S-Disease
18	anesthesia	O	O
19	caused	O	O
20	by	O	O
21	propofol	S-Chemical	S-Chemical
22	-	O	I-Disease
23	remifentanil	S-Chemical	S-Chemical
24	-	O	O
25	TIVA	O	S-Disease
26	were	O	O
27	randomly	O	O
28	assigned	O	O
29	into	O	O
30	two	O	O
31	groups	O	O
32	:	O	O
33	group	O	O
34	I	O	O
35	,	O	O
36	FRLMA	O	S-Disease
37	;	O	O
38	group	O	O
39	II	O	O
40	,	O	O
41	ETT	O	S-Disease
42	.	O	O

0	Hemorrhage	S-Disease	O
1	was	O	O
2	measured	O	O
3	and	O	O
4	the	O	O
5	visibility	O	O
6	of	O	O
7	the	O	O
8	operative	O	O
9	field	O	O
10	was	O	O
11	evaluated	O	O
12	according	O	O
13	to	O	O
14	a	O	O
15	six	O	O
16	-	O	O
17	point	O	O
18	scale	O	O
19	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Controlled	O	O
3	hypotension	S-Disease	S-Disease
4	was	O	O
5	achieved	O	O
6	within	O	O
7	a	O	O
8	shorter	O	O
9	period	O	O
10	using	O	O
11	laryngeal	O	O
12	mask	O	O
13	using	O	O
14	lower	O	O
15	rates	O	O
16	of	O	O
17	remifentanil	S-Chemical	S-Chemical
18	infusion	O	O
19	and	O	O
20	lower	O	O
21	total	O	O
22	dose	O	O
23	of	O	O
24	remifentanil	S-Chemical	S-Chemical
25	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	In	O	O
3	summary	O	O
4	,	O	O
5	our	O	O
6	results	O	O
7	indicate	O	O
8	that	O	O
9	airway	O	O
10	management	O	O
11	using	O	O
12	FRLMA	O	S-Chemical
13	during	O	O
14	controlled	O	O
15	hypotension	S-Disease	S-Disease
16	anesthesia	O	O
17	provided	O	O
18	better	O	O
19	surgical	O	O
20	conditions	O	O
21	in	O	O
22	terms	O	O
23	of	O	O
24	quality	O	O
25	of	O	O
26	operative	O	O
27	field	O	O
28	and	O	O
29	blood	O	B-Disease
30	loss	O	E-Disease
31	and	O	O
32	allowed	O	O
33	for	O	O
34	convenient	O	O
35	induced	O	O
36	hypotension	S-Disease	S-Disease
37	with	O	O
38	low	O	O
39	doses	O	O
40	of	O	O
41	remifentanil	S-Chemical	S-Chemical
42	during	O	O
43	TIVA	O	S-Disease
44	in	O	O
45	patients	O	O
46	undergoing	O	O
47	FESS	O	S-Disease
48	.	O	O

0	Nonalcoholic	B-Disease	O
1	fatty	I-Disease	B-Disease
2	liver	I-Disease	I-Disease
3	disease	E-Disease	E-Disease
4	during	O	O
5	valproate	S-Chemical	O
6	therapy	O	O
7	.	O	O

0	Valproic	B-Chemical	S-Chemical
1	acid	E-Chemical	O
2	(	O	O
3	VPA	S-Chemical	S-Chemical
4	)	O	O
5	is	O	O
6	effective	O	O
7	for	O	O
8	the	O	O
9	treatment	O	O
10	of	O	O
11	many	O	O
12	types	O	O
13	of	O	O
14	epilepsy	S-Disease	S-Disease
15	,	O	O
16	but	O	O
17	its	O	O
18	use	O	O
19	can	O	O
20	be	O	O
21	associated	O	O
22	with	O	O
23	an	O	O
24	increase	O	O
25	in	O	O
26	body	O	O
27	weight	O	E-Disease
28	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	nonalcoholic	B-Disease	O
6	fatty	I-Disease	B-Disease
7	liver	I-Disease	I-Disease
8	disease	E-Disease	E-Disease
9	(	O	O
10	NAFLD	S-Disease	S-Disease
11	)	O	O
12	arising	O	O
13	in	O	O
14	a	O	O
15	child	O	O
16	who	O	O
17	developed	O	O
18	obesity	S-Disease	B-Disease
19	during	O	O
20	VPA	S-Chemical	S-Chemical
21	treatment	O	O
22	.	O	O

0	Laboratory	O	O
1	data	O	O
2	revealed	O	O
3	hyperinsulinemia	S-Disease	S-Disease
4	with	O	O
5	insulin	B-Disease	B-Disease
6	resistance	E-Disease	E-Disease
7	.	O	O

0	After	O	O
1	the	O	O
2	withdrawal	O	O
3	of	O	O
4	VPA	S-Chemical	S-Chemical
5	therapy	O	O
6	,	O	O
7	our	O	O
8	patient	O	O
9	showed	O	O
10	a	O	O
11	significant	O	O
12	weight	B-Disease	B-Disease
13	loss	E-Disease	E-Disease
14	,	O	O
15	a	O	O
16	decrease	O	O
17	of	O	O
18	body	O	B-Disease
19	mass	O	I-Disease
20	index	O	O
21	,	O	O
22	and	O	O
23	normalization	O	O
24	of	O	O
25	metabolic	O	S-Disease
26	and	O	O
27	endocrine	O	O
28	parameters	O	O
29	;	O	O
30	moreover	O	O
31	,	O	O
32	ultrasound	O	O
33	measurements	O	O
34	showed	O	O
35	a	O	O
36	complete	O	O
37	normalization	O	O
38	.	O	O

0	The	O	O
1	present	O	O
2	case	O	O
3	suggests	O	O
4	that	O	O
5	obesity	S-Disease	S-Disease
6	,	O	O
7	hyperinsulinemia	S-Disease	S-Disease
8	,	O	O
9	insulin	B-Disease	B-Disease
10	resistance	E-Disease	E-Disease
11	,	O	O
12	and	O	O
13	long	O	O
14	-	O	O
15	term	O	O
16	treatment	O	O
17	with	O	O
18	VPA	S-Chemical	S-Chemical
19	may	O	O
20	be	O	O
21	all	O	O
22	associated	O	O
23	with	O	O
24	the	O	O
25	development	O	O
26	of	O	O
27	NAFLD	S-Disease	S-Chemical
28	;	O	O
29	this	O	O
30	side	O	O
31	effect	O	O
32	is	O	O
33	reversible	O	O
34	after	O	O
35	VPA	S-Chemical	S-Chemical
36	withdrawal	O	O
37	.	O	O

0	Carbimazole	S-Chemical	S-Chemical
1	induced	O	O
2	ANCA	B-Disease	B-Disease
3	positive	I-Disease	I-Disease
4	vasculitis	E-Disease	S-Disease
5	.	O	O

0	Anti	B-Chemical	O
1	-	I-Chemical	O
2	thyroid	I-Chemical	S-Disease
3	drugs	E-Chemical	O
4	,	O	O
5	like	O	O
6	carbimazole	S-Chemical	S-Chemical
7	and	O	O
8	propylthiouracil	S-Chemical	S-Chemical
9	(	O	O
10	PTU	S-Chemical	S-Disease
11	)	O	O
12	are	O	O
13	commonly	O	O
14	prescribed	O	O
15	for	O	O
16	the	O	O
17	treatment	O	O
18	of	O	O
19	hyperthyroidism	S-Disease	S-Disease
20	.	O	O

0	One	O	O
1	should	O	O
2	be	O	O
3	aware	O	O
4	of	O	O
5	the	O	O
6	side	O	O
7	effects	O	O
8	of	O	O
9	antithyroid	B-Chemical	O
10	medications	E-Chemical	O
11	.	O	O

0	Antineutrophil	B-Disease	B-Disease
1	cytoplasmic	I-Disease	E-Disease
2	antibody	I-Disease	E-Disease
3	(	I-Disease	O
4	ANCA	I-Disease	S-Chemical
5	)	I-Disease	O
6	-	I-Disease	O
7	-	I-Disease	O
8	associated	I-Disease	O
9	vasculitis	E-Disease	S-Disease
10	is	O	O
11	a	O	O
12	potentially	O	O
13	life	O	O
14	-	O	O
15	threatening	O	O
16	adverse	O	O
17	effect	O	O
18	of	O	O
19	antithyroidmedications	S-Chemical	S-Disease
20	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	patient	O	O
4	with	O	O
5	Graves	B-Disease	B-Disease
6	'	I-Disease	I-Disease
7	disease	E-Disease	E-Disease
8	who	O	O
9	developed	O	O
10	ANCA	O	B-Disease
11	positive	O	I-Disease
12	carbimazole	S-Chemical	E-Chemical
13	induced	O	O
14	vasculitis	S-Disease	S-Disease
15	.	O	O

0	The	O	O
1	episode	O	O
2	was	O	O
3	characterized	O	O
4	by	O	O
5	a	O	O
6	vasculitic	S-Disease	O
7	skin	B-Disease	O
8	rash	E-Disease	E-Disease
9	associated	O	O
10	with	O	O
11	large	O	O
12	joint	O	B-Disease
13	arthritis	S-Disease	E-Disease
14	,	O	O
15	pyrexia	S-Disease	S-Disease
16	and	O	O
17	parotiditis	S-Disease	S-Disease
18	but	O	O
19	no	O	O
20	renal	O	B-Disease
21	or	O	O
22	pulmonary	O	B-Disease
23	involvement	O	E-Disease
24	.	O	O

0	He	O	O
1	was	O	O
2	referred	O	O
3	to	O	O
4	us	O	O
5	for	O	O
6	neurological	O	O
7	evaluation	O	O
8	because	O	O
9	he	O	O
10	had	O	O
11	difficulty	O	O
12	in	O	O
13	getting	O	O
14	up	O	O
15	from	O	O
16	squatting	O	O
17	position	O	O
18	and	O	O
19	was	O	O
20	suspected	O	O
21	to	O	O
22	have	O	O
23	myositis	S-Disease	S-Disease
24	.	O	O

0	Carbimazole	S-Chemical	S-Chemical
1	and	O	O
2	methimazole	S-Chemical	S-Chemical
3	have	O	O
4	a	O	O
5	lower	O	O
6	incidence	O	O
7	of	O	O
8	reported	O	O
9	ANCA	O	S-Chemical
10	positive	O	O
11	side	O	O
12	effects	O	O
13	than	O	O
14	PUT	O	S-Chemical
15	.	O	O

0	To	O	O
1	the	O	O
2	best	O	O
3	of	O	O
4	our	O	O
5	knowledge	O	O
6	this	O	O
7	is	O	O
8	the	O	O
9	first	O	O
10	ANCA	O	B-Disease
11	positive	O	I-Disease
12	carbimazole	S-Chemical	E-Chemical
13	induced	O	O
14	vasculitis	S-Disease	S-Disease
15	case	O	O
16	reported	O	O
17	from	O	O
18	India	O	S-Chemical
19	.	O	O

0	Aspirin	S-Chemical	O
1	for	O	O
2	the	O	O
3	primary	O	O
4	prevention	O	O
5	of	O	O
6	cardiovascular	O	O
7	events	O	O
8	:	O	O
9	an	O	O
10	update	O	O
11	of	O	O
12	the	O	O
13	evidence	O	O
14	for	O	O
15	the	O	O
16	U	O	O
17	.	O	O
18	S	O	O
19	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Coronary	B-Disease	B-Disease
3	heart	I-Disease	I-Disease
4	disease	E-Disease	E-Disease
5	and	O	O
6	cerebrovascular	B-Disease	B-Disease
7	disease	E-Disease	E-Disease
8	are	O	O
9	leading	O	O
10	causes	O	O
11	of	O	O
12	death	O	S-Disease
13	in	O	O
14	the	O	O
15	United	O	O
16	States	O	O
17	.	O	O

0	Preventive	O	O
1	Services	O	I-Disease
2	Task	O	I-Disease
3	Force	O	S-Disease
4	(	O	O
5	USPSTF	O	S-Chemical
6	)	O	O
7	strongly	O	O
8	recommended	O	O
9	that	O	O
10	clinicians	O	O
11	discuss	O	O
12	aspirin	S-Chemical	S-Disease
13	with	O	O
14	adults	O	O
15	who	O	O
16	are	O	O
17	at	O	O
18	increased	O	O
19	risk	O	O
20	for	O	O
21	coronary	B-Disease	B-Disease
22	heart	I-Disease	I-Disease
23	disease	E-Disease	E-Disease
24	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	To	O	O
3	determine	O	O
4	the	O	O
5	benefits	O	O
6	and	O	O
7	harms	O	O
8	of	O	O
9	taking	O	O
10	aspirin	S-Chemical	S-Chemical
11	for	O	O
12	the	O	O
13	primary	O	O
14	prevention	O	O
15	of	O	O
16	myocardial	B-Disease	B-Disease
17	infarctions	E-Disease	E-Disease
18	,	O	O
19	strokes	S-Disease	S-Disease
20	,	O	O
21	and	O	O
22	death	O	O
23	.	O	O

0	STUDY	O	O
1	SELECTION	O	O
2	:	O	O
3	English	O	O
4	-	O	O
5	language	O	O
6	randomized	O	O
7	,	O	O
8	controlled	O	O
9	trials	O	O
10	(	O	O
11	RCTs	O	O
12	)	O	O
13	;	O	O
14	case	O	O
15	-	O	O
16	control	O	O
17	studies	O	O
18	;	O	O
19	meta	O	O
20	-	O	O
21	analyses	O	O
22	;	O	O
23	and	O	O
24	systematic	O	O
25	reviews	O	O
26	of	O	O
27	aspirin	S-Chemical	S-Chemical
28	versus	O	O
29	control	O	O
30	for	O	O
31	the	O	O
32	primary	O	O
33	prevention	O	O
34	of	O	O
35	cardiovascular	B-Disease	B-Disease
36	disease	E-Disease	E-Disease
37	(	O	O
38	CVD	S-Disease	S-Chemical
39	)	O	O
40	were	O	O
41	selected	O	O
42	to	O	O
43	answer	O	O
44	the	O	O
45	following	O	O
46	questions	O	O
47	:	O	O
48	Does	O	O
49	aspirin	S-Chemical	S-Chemical
50	decrease	O	O
51	coronary	O	B-Disease
52	heart	O	I-Disease
53	events	O	E-Disease
54	,	O	O
55	strokes	S-Disease	S-Disease
56	,	O	O
57	death	O	O
58	from	O	O
59	coronary	O	B-Disease
60	heart	O	I-Disease
61	events	O	E-Disease
62	or	O	O
63	stroke	S-Disease	S-Disease
64	,	O	O
65	or	O	O
66	all	O	O
67	-	O	O
68	cause	O	O
69	mortality	O	S-Disease
70	in	O	O
71	adults	O	O
72	without	O	O
73	known	O	O
74	CVD	S-Disease	S-Chemical
75	?	O	O

0	Does	O	O
1	aspirin	S-Chemical	S-Chemical
2	increase	O	O
3	gastrointestinal	B-Disease	B-Disease
4	bleeding	E-Disease	E-Disease
5	or	O	O
6	hemorrhagic	B-Disease	O
7	strokes	E-Disease	S-Disease
8	?	O	O

0	DATA	O	O
1	SYNTHESIS	O	O
2	:	O	O
3	New	O	O
4	evidence	O	O
5	from	O	O
6	1	O	O
7	good	O	O
8	-	O	O
9	quality	O	O
10	RCT	O	O
11	,	O	O
12	1	O	O
13	good	O	O
14	-	O	O
15	quality	O	O
16	meta	O	O
17	-	O	O
18	analysis	O	O
19	,	O	O
20	and	O	O
21	2	O	O
22	fair	O	O
23	-	O	O
24	quality	O	O
25	subanalyses	O	O
26	of	O	O
27	RCTs	O	O
28	demonstrates	O	O
29	that	O	O
30	aspirin	S-Chemical	S-Chemical
31	use	O	O
32	reduces	O	O
33	the	O	O
34	number	O	O
35	of	O	O
36	CVD	S-Disease	B-Chemical
37	events	O	O
38	in	O	O
39	patients	O	O
40	without	O	O
41	known	O	O
42	CVD	S-Disease	B-Chemical
43	.	O	O

0	Men	O	O
1	in	O	O
2	these	O	O
3	studies	O	O
4	experienced	O	O
5	fewer	O	O
6	myocardial	B-Disease	B-Disease
7	infarctions	E-Disease	E-Disease
8	and	O	O
9	women	O	O
10	experienced	O	O
11	fewer	O	O
12	ischemic	O	B-Disease
13	strokes	S-Disease	E-Disease
14	.	O	O

0	Aspirin	S-Chemical	S-Chemical
1	does	O	O
2	not	O	O
3	seem	O	O
4	to	O	O
5	affect	O	O
6	CVD	S-Disease	B-Disease
7	mortality	O	E-Disease
8	or	O	O
9	all	O	O
10	-	O	O
11	cause	O	O
12	mortality	O	O
13	in	O	O
14	either	O	O
15	men	O	O
16	or	O	O
17	women	O	O
18	.	O	O

0	The	O	O
1	use	O	O
2	of	O	O
3	aspirin	S-Chemical	S-Chemical
4	for	O	O
5	primary	O	O
6	prevention	O	O
7	increases	O	O
8	the	O	O
9	risk	O	O
10	for	O	O
11	major	O	O
12	bleeding	S-Disease	B-Disease
13	events	O	O
14	,	O	O
15	primarily	O	O
16	gastrointestinal	B-Disease	B-Disease
17	bleeding	E-Disease	E-Disease
18	events	O	O
19	,	O	O
20	in	O	O
21	both	O	O
22	men	O	O
23	and	O	O
24	women	O	O
25	.	O	O

0	Men	O	O
1	have	O	O
2	an	O	O
3	increased	O	O
4	risk	O	O
5	for	O	O
6	hemorrhagic	B-Disease	S-Disease
7	strokes	E-Disease	S-Disease
8	with	O	O
9	aspirin	S-Chemical	S-Chemical
10	use	O	O
11	.	O	O

0	A	O	O
1	new	O	O
2	RCT	O	O
3	and	O	O
4	meta	O	O
5	-	O	O
6	analysis	O	O
7	suggest	O	O
8	that	O	O
9	the	O	O
10	risk	O	O
11	for	O	O
12	hemorrhagic	B-Disease	S-Disease
13	strokes	E-Disease	E-Disease
14	in	O	O
15	women	O	O
16	is	O	O
17	not	O	O
18	statistically	O	O
19	significantly	O	O
20	increased	O	O
21	.	O	O

0	LIMITATIONS	O	O
1	:	O	O
2	New	O	O
3	evidence	O	O
4	on	O	O
5	aspirin	S-Chemical	S-Chemical
6	for	O	O
7	the	O	O
8	primary	O	O
9	prevention	O	O
10	of	O	O
11	CVD	S-Disease	S-Chemical
12	is	O	O
13	limited	O	O
14	.	O	O

0	The	O	O
1	dose	O	O
2	of	O	O
3	aspirin	S-Chemical	S-Chemical
4	used	O	O
5	in	O	O
6	the	O	O
7	RCTs	O	O
8	varied	O	O
9	,	O	O
10	which	O	O
11	prevented	O	O
12	the	O	O
13	estimation	O	O
14	of	O	O
15	the	O	O
16	most	O	O
17	appropriate	O	O
18	dose	O	O
19	for	O	O
20	primary	O	O
21	prevention	O	O
22	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Aspirin	S-Chemical	S-Chemical
3	reduces	O	O
4	the	O	O
5	risk	O	O
6	for	O	O
7	myocardial	B-Disease	B-Disease
8	infarction	E-Disease	E-Disease
9	in	O	O
10	men	O	O
11	and	O	O
12	strokes	S-Disease	S-Disease
13	in	O	O
14	women	O	O
15	.	O	O

0	Aspirin	S-Chemical	S-Chemical
1	use	O	O
2	increases	O	O
3	the	O	O
4	risk	O	O
5	for	O	O
6	serious	O	O
7	bleeding	S-Disease	B-Disease
8	events	O	O
9	.	O	O

0	Reducing	O	O
1	harm	O	O
2	associated	O	O
3	with	O	O
4	anticoagulation	O	O
5	:	O	O
6	practical	O	O
7	considerations	O	O
8	of	O	O
9	argatroban	S-Chemical	S-Chemical
10	therapy	O	O
11	in	O	O
12	heparin	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	thrombocytopenia	S-Disease	S-Disease
16	.	O	O

0	Argatroban	S-Chemical	S-Chemical
1	is	O	O
2	a	O	O
3	hepatically	O	O
4	metabolized	O	O
5	,	O	O
6	direct	O	O
7	thrombin	O	O
8	inhibitor	O	O
9	used	O	O
10	for	O	O
11	prophylaxis	O	O
12	or	O	O
13	treatment	O	O
14	of	O	O
15	thrombosis	S-Disease	S-Disease
16	in	O	O
17	heparin	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	thrombocytopenia	S-Disease	S-Disease
21	(	O	O
22	HIT	S-Disease	S-Disease
23	)	O	O
24	and	O	O
25	for	O	O
26	patients	O	O
27	with	O	O
28	or	O	O
29	at	O	O
30	risk	O	O
31	of	O	O
32	HIT	S-Disease	S-Disease
33	undergoing	O	O
34	percutaneous	O	O
35	coronary	O	E-Disease
36	intervention	O	O
37	(	O	O
38	PCI	O	O
39	)	O	O
40	.	O	O

0	The	O	O
1	objective	O	O
2	of	O	O
3	this	O	O
4	review	O	O
5	is	O	O
6	to	O	O
7	summarize	O	O
8	practical	O	O
9	considerations	O	O
10	of	O	O
11	argatroban	S-Chemical	S-Chemical
12	therapy	O	O
13	in	O	O
14	HIT	S-Disease	S-Disease
15	.	O	O

0	The	O	O
1	US	O	O
2	FDA	O	O
3	-	O	O
4	recommended	O	O
5	argatroban	S-Chemical	O
6	dose	O	O
7	in	O	O
8	HIT	S-Disease	O
9	is	O	O
10	2	O	O
11	microg	O	O
12	/	O	O
13	kg	O	O
14	/	O	O
15	min	O	O
16	(	O	O
17	reduced	O	O
18	in	O	O
19	patients	O	O
20	with	O	O
21	hepatic	B-Disease	S-Disease
22	impairment	E-Disease	O
23	and	O	O
24	in	O	O
25	paediatric	O	O
26	patients	O	O
27	)	O	O
28	,	O	O
29	adjusted	O	O
30	to	O	O
31	achieve	O	O
32	activated	O	O
33	partial	O	O
34	thromboplastin	O	S-Disease
35	times	O	O
36	(	O	O
37	aPTTs	O	O
38	)	O	O
39	1	O	O
40	.	O	O
41	5	O	O
42	-	O	O
43	3	O	O
44	times	O	O
45	baseline	O	O
46	(	O	O
47	not	O	O
48	>	O	O
49	100	O	O
50	seconds	O	O
51	)	O	O
52	.	O	O

0	Contemporary	O	O
1	experiences	O	O
2	indicate	O	O
3	that	O	O
4	reduced	O	O
5	doses	O	O
6	are	O	O
7	also	O	O
8	needed	O	O
9	in	O	O
10	patients	O	O
11	with	O	O
12	conditions	O	O
13	associated	O	O
14	with	O	O
15	hepatic	O	S-Disease
16	hypoperfusion	O	S-Disease
17	,	O	O
18	e	O	O
19	.	O	O
20	g	O	O
21	.	O	O
22	heart	B-Disease	B-Disease
23	failure	E-Disease	E-Disease
24	,	O	O
25	yet	O	O
26	are	O	O
27	unnecessary	O	O
28	for	O	O
29	renal	B-Disease	B-Disease
30	dysfunction	E-Disease	E-Disease
31	,	O	O
32	adult	O	O
33	age	O	O
34	,	O	O
35	sex	O	O
36	,	O	O
37	race	O	O
38	/	O	I-Disease
39	ethnicity	O	O
40	or	O	O
41	obesity	S-Disease	S-Disease
42	.	O	O

0	Argatroban	S-Chemical	S-Chemical
1	0	O	O
2	.	O	O
3	5	O	O
4	-	O	O
5	1	O	O
6	.	O	O
7	2	O	O
8	microg	O	O
9	/	O	O
10	kg	O	O
11	/	O	O
12	min	O	O
13	typically	O	O
14	supports	O	O
15	therapeutic	O	O
16	aPTTs	O	O
17	.	O	O

0	For	O	O
1	PCI	O	O
2	,	O	O
3	argatroban	S-Chemical	S-Chemical
4	has	O	O
5	not	O	O
6	been	O	O
7	investigated	O	O
8	in	O	O
9	hepatically	O	S-Disease
10	impaired	O	O
11	patients	O	O
12	;	O	O
13	dose	O	O
14	adjustment	O	O
15	is	O	O
16	unnecessary	O	O
17	for	O	O
18	adult	O	O
19	age	O	O
20	,	O	O
21	sex	O	O
22	,	O	O
23	race	O	O
24	/	O	I-Disease
25	ethnicity	O	O
26	or	O	O
27	obesity	S-Disease	S-Disease
28	,	O	O
29	and	O	O
30	lesser	O	O
31	doses	O	O
32	may	O	O
33	be	O	O
34	adequate	O	O
35	with	O	O
36	concurrent	O	O
37	glycoprotein	O	B-Chemical
38	IIb	O	E-Chemical
39	/	O	O
40	IIIa	O	O
41	inhibition	O	O
42	.	O	O

0	Argatroban	S-Chemical	S-Chemical
1	prolongs	O	O
2	the	O	O
3	International	O	B-Disease
4	Normalized	O	I-Disease
5	Ratio	O	E-Disease
6	,	O	O
7	and	O	O
8	published	O	O
9	approaches	O	O
10	for	O	O
11	monitoring	O	O
12	the	O	O
13	argatroban	S-Chemical	S-Chemical
14	-	O	O
15	to	O	I-Disease
16	-	O	O
17	warfarin	S-Chemical	S-Chemical
18	transition	O	O
19	should	O	O
20	be	O	O
21	followed	O	O
22	.	O	O

0	Major	O	O
1	bleeding	S-Disease	O
2	with	O	O
3	argatroban	S-Chemical	S-Chemical
4	is	O	O
5	0	O	O
6	-	O	O
7	10	O	O
8	%	O	O
9	in	O	O
10	the	O	O
11	non	O	O
12	-	O	O
13	interventional	O	O
14	setting	O	O
15	and	O	O
16	0	O	O
17	-	O	O
18	5	O	O
19	.	O	O
20	8	O	O
21	%	O	O
22	periprocedurally	O	O
23	.	O	O

0	Argatroban	S-Chemical	S-Chemical
1	has	O	O
2	no	O	O
3	specific	O	O
4	antidote	O	O
5	,	O	O
6	and	O	O
7	if	O	O
8	excessive	O	O
9	anticoagulation	O	O
10	occurs	O	O
11	,	O	O
12	argatroban	S-Chemical	S-Chemical
13	infusion	O	O
14	should	O	O
15	be	O	O
16	stopped	O	O
17	or	O	O
18	reduced	O	O
19	.	O	O

0	Improved	O	O
1	familiarity	O	O
2	of	O	O
3	healthcare	O	O
4	professionals	O	O
5	with	O	O
6	argatroban	S-Chemical	S-Chemical
7	therapy	O	O
8	in	O	O
9	HIT	S-Disease	S-Disease
10	,	O	O
11	including	O	O
12	in	O	O
13	special	O	O
14	populations	O	O
15	and	O	O
16	during	O	O
17	PCI	O	O
18	,	O	O
19	may	O	O
20	facilitate	O	O
21	reduction	O	O
22	of	O	O
23	harm	O	O
24	associated	O	O
25	with	O	O
26	HIT	S-Disease	S-Disease
27	(	O	O
28	e	O	O
29	.	O	O
30	g	O	O
31	.	O	O
32	fewer	O	O
33	thromboses	O	O
34	)	O	O
35	or	O	O
36	its	O	O
37	treatment	O	O
38	(	O	O
39	e	O	O
40	.	O	O
41	g	O	O
42	.	O	O
43	fewer	O	O
44	argatroban	S-Chemical	O
45	medication	O	O
46	errors	O	O
47	)	O	O
48	.	O	O

0	Rhabdomyolysis	S-Disease	S-Disease
1	and	O	O
2	brain	O	B-Disease
3	ischemic	B-Disease	E-Disease
4	stroke	E-Disease	E-Disease
5	in	O	O
6	a	O	O
7	heroin	S-Chemical	S-Chemical
8	-	O	O
9	dependent	O	O
10	male	O	O
11	under	O	O
12	methadone	S-Chemical	S-Chemical
13	maintenance	O	O
14	therapy	O	O
15	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	There	O	O
3	are	O	O
4	several	O	O
5	complications	O	O
6	associated	O	O
7	with	O	O
8	heroin	B-Disease	S-Disease
9	abuse	E-Disease	E-Disease
10	,	O	O
11	some	O	O
12	of	O	O
13	which	O	O
14	are	O	O
15	life	O	O
16	-	O	O
17	threatening	O	O
18	.	O	O

0	Methadone	S-Chemical	S-Chemical
1	may	O	O
2	aggravate	O	O
3	this	O	O
4	problem	O	O
5	.	O	O

0	RESULTS	O	O
1	:	O	O
2	A	O	O
3	33	O	O
4	-	O	O
5	year	O	O
6	-	O	O
7	old	O	O
8	man	O	O
9	presented	O	O
10	with	O	O
11	rhabdomyolysis	S-Disease	S-Disease
12	and	O	O
13	cerebral	O	B-Disease
14	ischemic	B-Disease	I-Disease
15	stroke	E-Disease	E-Disease
16	after	O	O
17	intravenous	O	O
18	heroin	S-Chemical	S-Disease
19	.	O	O

0	He	O	O
1	had	O	O
2	used	O	O
3	heroin	S-Chemical	O
4	since	O	O
5	age	O	O
6	20	O	O
7	,	O	O
8	and	O	O
9	had	O	O
10	used	O	O
11	150	O	O
12	mg	O	O
13	methadone	S-Chemical	S-Chemical
14	daily	O	O
15	for	O	O
16	6	O	O
17	months	O	O
18	.	O	O

0	He	O	O
1	was	O	O
2	found	O	O
3	unconsciousness	S-Disease	O
4	at	O	O
5	home	O	O
6	and	O	O
7	was	O	O
8	sent	O	O
9	to	O	O
10	our	O	O
11	hospital	O	O
12	.	O	O

0	In	O	O
1	the	O	O
2	ICU	O	O
3	,	O	O
4	we	O	O
5	found	O	O
6	rhabdomyolysis	S-Disease	S-Disease
7	,	O	O
8	acute	B-Disease	B-Disease
9	renal	I-Disease	I-Disease
10	failure	E-Disease	E-Disease
11	and	O	O
12	acute	O	B-Disease
13	respiratory	B-Disease	I-Disease
14	failure	E-Disease	E-Disease
15	.	O	O

0	After	O	O
1	transfer	O	O
2	to	O	O
3	an	O	O
4	internal	O	O
5	ward	O	O
6	,	O	O
7	we	O	O
8	noted	O	O
9	aphasia	S-Disease	O
10	and	O	O
11	weakness	S-Disease	S-Disease
12	of	O	O
13	his	O	O
14	left	O	O
15	limbs	O	O
16	.	O	O

0	After	O	O
1	MRI	O	S-Disease
2	,	O	O
3	we	O	O
4	found	O	O
5	cerebral	B-Disease	B-Disease
6	ischemic	I-Disease	E-Disease
7	infarction	E-Disease	E-Disease
8	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Those	O	O
3	using	O	O
4	methadone	S-Chemical	S-Chemical
5	and	O	O
6	heroin	S-Chemical	S-Chemical
7	simultaneously	O	O
8	may	O	O
9	increase	O	O
10	risk	O	O
11	of	O	O
12	rhabdomyolysis	S-Disease	B-Disease
13	and	O	O
14	ischemic	B-Disease	B-Disease
15	stroke	E-Disease	E-Disease
16	.	O	O

0	Patients	O	O
1	under	O	O
2	methadone	S-Chemical	S-Chemical
3	maintenance	O	O
4	therapy	O	O
5	should	O	O
6	be	O	O
7	warned	O	O
8	regarding	O	O
9	these	O	O
10	serious	O	O
11	adverse	O	O
12	events	O	O
13	.	O	O

0	Hypotheses	O	O
1	of	O	O
2	heroin	S-Chemical	S-Chemical
3	-	O	O
4	related	O	O
5	rhabdomyolysis	S-Disease	S-Disease
6	and	O	O
7	stroke	S-Disease	S-Disease
8	in	O	O
9	heroin	S-Chemical	S-Disease
10	abusers	O	O
11	are	O	O
12	discussed	O	O
13	.	O	O

0	Increased	O	O
1	vulnerability	O	O
2	to	O	O
3	6	B-Chemical	B-Chemical
4	-	I-Chemical	I-Chemical
5	hydroxydopamine	E-Chemical	E-Chemical
6	lesion	O	E-Disease
7	and	O	O
8	reduced	O	O
9	development	O	O
10	of	O	O
11	dyskinesias	S-Disease	S-Disease
12	in	O	O
13	mice	O	O
14	lacking	O	O
15	CB1	O	B-Disease
16	cannabinoid	O	E-Disease
17	receptors	O	O
18	.	O	O

0	Motor	O	O
1	impairment	O	O
2	,	O	O
3	dopamine	S-Chemical	S-Chemical
4	(	O	O
5	DA	S-Chemical	S-Disease
6	)	O	O
7	neuronal	O	O
8	activity	O	O
9	and	O	O
10	proenkephalin	S-Chemical	S-Disease
11	(	O	O
12	PENK	S-Chemical	S-Chemical
13	)	O	O
14	gene	O	O
15	expression	O	O
16	in	O	O
17	the	O	O
18	caudate	O	S-Chemical
19	-	O	O
20	putamen	O	S-Chemical
21	(	O	O
22	CPu	O	S-Chemical
23	)	O	O
24	were	O	O
25	measured	O	O
26	in	O	O
27	6	B-Chemical	O
28	-	I-Chemical	O
29	OHDA	E-Chemical	O
30	-	O	O
31	lesioned	O	O
32	and	O	O
33	treated	O	O
34	(	O	O
35	L	B-Chemical	B-Chemical
36	-	I-Chemical	I-Chemical
37	DOPA	I-Chemical	E-Chemical
38	+	I-Chemical	O
39	benserazide	E-Chemical	S-Chemical
40	)	O	O
41	CB1	O	B-Chemical
42	KO	O	E-Chemical
43	and	O	O
44	WT	O	O
45	mice	O	O
46	.	O	O

0	A	O	O
1	lesion	O	O
2	induced	O	O
3	by	O	O
4	6	B-Chemical	S-Chemical
5	-	I-Chemical	I-Chemical
6	OHDA	E-Chemical	E-Chemical
7	produced	O	O
8	more	O	O
9	severe	O	O
10	motor	O	B-Disease
11	deterioration	O	E-Disease
12	in	O	O
13	CB1	O	B-Chemical
14	KO	O	E-Chemical
15	mice	O	O
16	accompanied	O	O
17	by	O	O
18	more	O	O
19	loss	O	O
20	of	O	O
21	DA	S-Chemical	S-Disease
22	neurons	O	O
23	and	O	O
24	increased	O	O
25	PENK	S-Chemical	S-Chemical
26	gene	O	O
27	expression	O	O
28	in	O	O
29	the	O	O
30	CPu	O	S-Chemical
31	.	O	O

0	CB1	O	B-Chemical
1	KO	O	E-Chemical
2	mice	O	O
3	exhibited	O	O
4	higher	O	O
5	MDA	S-Chemical	S-Disease
6	levels	O	O
7	and	O	O
8	iNOS	O	O
9	protein	O	O
10	expression	O	O
11	in	O	O
12	the	O	O
13	CPu	O	S-Chemical
14	and	O	O
15	Cg	O	S-Chemical
16	compared	O	O
17	to	O	O
18	WT	O	O
19	mice	O	O
20	.	O	O

0	Treatment	O	O
1	with	O	O
2	L	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	DOPA	I-Chemical	E-Chemical
5	+	I-Chemical	E-Disease
6	benserazide	E-Chemical	S-Chemical
7	(	O	O
8	12	O	O
9	weeks	O	O
10	)	O	O
11	resulted	O	O
12	in	O	O
13	less	O	O
14	severe	O	O
15	dyskinesias	S-Disease	S-Disease
16	in	O	O
17	CB1	O	B-Disease
18	KO	O	E-Disease
19	than	O	O
20	in	O	O
21	WT	O	O
22	mice	O	O
23	.	O	O

0	The	O	O
1	results	O	O
2	revealed	O	O
3	that	O	O
4	the	O	O
5	lack	O	O
6	of	O	O
7	cannabinoid	O	S-Disease
8	CB1	O	S-Chemical
9	receptors	O	O
10	increased	O	O
11	the	O	O
12	severity	O	O
13	of	O	O
14	motor	O	B-Disease
15	impairment	O	E-Disease
16	and	O	O
17	DA	S-Chemical	B-Disease
18	lesion	O	E-Disease
19	,	O	O
20	and	O	O
21	reduced	O	O
22	L	B-Chemical	B-Chemical
23	-	I-Chemical	I-Chemical
24	DOPA	E-Chemical	E-Chemical
25	-	O	O
26	induced	O	O
27	dyskinesias	S-Disease	S-Disease
28	.	O	O

0	These	O	O
1	results	O	O
2	suggest	O	O
3	that	O	O
4	activation	O	O
5	of	O	O
6	CB1	O	S-Chemical
7	receptors	O	O
8	offers	O	O
9	neuroprotection	O	O
10	against	O	O
11	dopaminergic	O	O
12	lesion	O	S-Disease
13	and	O	O
14	the	O	O
15	development	O	O
16	of	O	O
17	L	B-Chemical	B-Chemical
18	-	I-Chemical	I-Chemical
19	DOPA	E-Chemical	E-Chemical
20	-	O	O
21	induced	O	O
22	dyskinesias	S-Disease	S-Disease
23	.	O	O

0	Hepatocellular	O	S-Chemical
1	oxidant	O	O
2	stress	O	O
3	following	O	O
4	intestinal	O	O
5	ischemia	S-Disease	E-Disease
6	-	O	O
7	reperfusion	B-Disease	O
8	injury	E-Disease	E-Disease
9	.	O	O

0	Reperfusion	O	O
1	of	O	O
2	ischemic	S-Disease	S-Disease
3	intestine	O	E-Disease
4	results	O	O
5	in	O	O
6	acute	O	B-Disease
7	liver	B-Disease	I-Disease
8	dysfunction	E-Disease	E-Disease
9	characterized	O	O
10	by	O	O
11	hepatocellular	O	S-Disease
12	enzyme	O	O
13	release	O	O
14	into	O	O
15	plasma	O	O
16	,	O	O
17	reduction	O	O
18	in	O	O
19	bile	O	B-Disease
20	flow	O	E-Disease
21	rate	O	O
22	,	O	O
23	and	O	O
24	neutrophil	O	S-Disease
25	sequestration	O	O
26	within	O	O
27	the	O	O
28	liver	O	O
29	.	O	O

0	The	O	O
1	pathophysiology	O	O
2	underlying	O	O
3	this	O	O
4	acute	O	S-Disease
5	hepatic	B-Disease	I-Disease
6	injury	E-Disease	S-Disease
7	is	O	O
8	unknown	O	O
9	.	O	O

0	This	O	O
1	study	O	O
2	was	O	O
3	undertaken	O	O
4	to	O	O
5	determine	O	O
6	whether	O	O
7	oxidants	O	O
8	are	O	O
9	associated	O	O
10	with	O	O
11	the	O	O
12	hepatic	B-Disease	S-Disease
13	injury	E-Disease	S-Disease
14	and	O	O
15	to	O	O
16	determine	O	O
17	the	O	O
18	relative	O	O
19	value	O	O
20	of	O	O
21	several	O	O
22	indirect	O	O
23	methods	O	O
24	of	O	O
25	assessing	O	O
26	oxidant	O	O
27	exposure	O	O
28	in	O	O
29	vivo	O	O
30	.	O	O

0	Rats	O	O
1	were	O	O
2	subjected	O	O
3	to	O	O
4	a	O	O
5	standardized	O	O
6	intestinal	O	O
7	ischemia	S-Disease	E-Disease
8	-	O	O
9	reperfusion	B-Disease	O
10	injury	E-Disease	S-Disease
11	.	O	O

0	Hepatic	O	S-Disease
1	tissue	O	O
2	was	O	O
3	assayed	O	O
4	for	O	O
5	lipid	O	B-Chemical
6	peroxidation	O	O
7	products	O	O
8	and	O	O
9	oxidized	B-Chemical	O
10	and	I-Chemical	O
11	reduced	I-Chemical	O
12	glutathione	E-Chemical	S-Chemical
13	.	O	O

0	There	O	O
1	was	O	O
2	no	O	O
3	change	O	O
4	in	O	O
5	hepatic	O	S-Disease
6	tissue	O	O
7	total	O	O
8	glutathione	S-Chemical	S-Disease
9	following	O	O
10	intestinal	O	O
11	ischemia	S-Disease	E-Disease
12	-	O	O
13	reperfusion	B-Disease	O
14	injury	E-Disease	E-Disease
15	.	O	O

0	Oxidized	B-Chemical	O
1	glutathione	E-Chemical	S-Chemical
2	(	O	O
3	GSSG	S-Chemical	S-Chemical
4	)	O	O
5	increased	O	O
6	significantly	O	O
7	following	O	O
8	30	O	O
9	and	O	O
10	60	O	O
11	min	O	O
12	of	O	O
13	reperfusion	O	O
14	.	O	O

0	An	O	O
1	increase	O	O
2	in	O	O
3	GSSG	S-Chemical	S-Disease
4	within	O	O
5	hepatic	O	O
6	tissue	O	O
7	during	O	O
8	intestinal	O	O
9	reperfusion	O	O
10	suggests	O	O
11	exposure	O	O
12	of	O	O
13	hepatocytes	O	S-Chemical
14	to	O	O
15	an	O	O
16	oxidant	O	O
17	stress	O	O
18	.	O	O

0	These	O	O
1	data	O	O
2	also	O	O
3	suggest	O	O
4	that	O	O
5	the	O	O
6	measurement	O	O
7	of	O	O
8	tissue	O	O
9	GSSG	S-Chemical	S-Disease
10	may	O	O
11	be	O	O
12	a	O	O
13	more	O	O
14	sensitive	O	O
15	indicator	O	O
16	of	O	O
17	oxidant	O	O
18	stress	O	S-Disease
19	than	O	O
20	measurement	O	O
21	of	O	O
22	products	O	O
23	of	O	O
24	lipid	O	S-Chemical
25	peroxidation	O	E-Disease
26	.	O	O

0	Animal	O	O
1	model	O	O
2	of	O	O
3	mania	S-Disease	O
4	induced	O	O
5	by	O	O
6	ouabain	S-Chemical	S-Chemical
7	:	O	O
8	Evidence	O	O
9	of	O	O
10	oxidative	O	O
11	stress	O	O
12	in	O	O
13	submitochondrial	O	O
14	particles	O	O
15	of	O	O
16	the	O	O
17	rat	O	O
18	brain	O	O
19	.	O	O

0	The	O	O
1	intracerebroventricular	O	O
2	(	O	O
3	ICV	O	S-Disease
4	)	O	O
5	administration	O	O
6	of	O	O
7	ouabain	S-Chemical	S-Chemical
8	(	O	O
9	a	O	O
10	Na	S-Chemical	S-Chemical
11	(	O	O
12	+	O	O
13	)	O	O
14	/	O	O
15	K	S-Chemical	O
16	(	O	O
17	+	O	O
18	)	O	O
19	-	O	O
20	ATPase	O	O
21	inhibitor	O	O
22	)	O	O
23	in	O	O
24	rats	O	O
25	has	O	O
26	been	O	O
27	suggested	O	O
28	to	O	O
29	mimic	O	O
30	some	O	O
31	symptoms	O	O
32	of	O	O
33	human	O	O
34	bipolar	B-Disease	B-Disease
35	mania	E-Disease	E-Disease
36	.	O	O

0	Clinical	O	O
1	studies	O	O
2	have	O	O
3	shown	O	O
4	that	O	O
5	bipolar	B-Disease	B-Disease
6	disorder	E-Disease	E-Disease
7	may	O	O
8	be	O	O
9	related	O	O
10	to	O	O
11	mitochondrial	B-Disease	B-Disease
12	dysfunction	E-Disease	E-Disease
13	.	O	O

0	Herein	O	O
1	,	O	O
2	we	O	O
3	investigated	O	O
4	the	O	O
5	behavioral	O	O
6	and	O	O
7	biochemical	O	O
8	effects	O	O
9	induced	O	O
10	by	O	O
11	the	O	O
12	ICV	O	S-Disease
13	administration	O	O
14	of	O	O
15	ouabain	S-Chemical	S-Chemical
16	in	O	O
17	rats	O	O
18	.	O	O

0	To	O	O
1	achieve	O	O
2	this	O	O
3	aim	O	O
4	,	O	O
5	the	O	O
6	effects	O	O
7	of	O	O
8	ouabain	S-Chemical	S-Chemical
9	injection	O	O
10	immediately	O	O
11	after	O	O
12	and	O	O
13	7	O	O
14	days	O	O
15	following	O	O
16	a	O	O
17	single	O	O
18	ICV	O	S-Disease
19	administration	O	O
20	(	O	O
21	at	O	O
22	concentrations	O	O
23	of	O	O
24	10	O	O
25	(	O	O
26	-	O	O
27	2	O	O
28	)	O	O
29	and	O	O
30	10	O	O
31	(	O	O
32	-	O	O
33	3	O	O
34	)	O	O
35	M	O	O
36	)	O	O
37	on	O	O
38	locomotion	O	O
39	was	O	O
40	measured	O	O
41	using	O	O
42	the	O	O
43	open	O	O
44	-	O	O
45	field	O	O
46	test	O	O
47	.	O	O

0	Additionally	O	O
1	,	O	O
2	thiobarbituric	B-Chemical	S-Chemical
3	acid	E-Chemical	O
4	reactive	O	O
5	substances	O	O
6	(	O	O
7	TBARSs	O	S-Chemical
8	)	O	O
9	and	O	O
10	superoxide	S-Chemical	S-Chemical
11	production	O	O
12	were	O	O
13	measured	O	O
14	in	O	O
15	submitochondrial	O	O
16	particles	O	O
17	of	O	O
18	the	O	O
19	prefrontal	O	O
20	cortex	O	O
21	,	O	O
22	hippocampus	O	S-Disease
23	,	O	O
24	striatum	O	O
25	and	O	O
26	amygdala	O	S-Chemical
27	.	O	O

0	Our	O	O
1	findings	O	O
2	demonstrated	O	O
3	that	O	O
4	ouabain	S-Chemical	S-Chemical
5	at	O	O
6	10	O	O
7	(	O	O
8	-	O	O
9	2	O	O
10	)	O	O
11	and	O	O
12	10	O	O
13	(	O	O
14	-	O	O
15	3	O	O
16	)	O	O
17	M	O	O
18	induced	O	O
19	hyperlocomotion	S-Disease	S-Disease
20	in	O	O
21	rats	O	O
22	,	O	O
23	and	O	O
24	this	O	O
25	response	O	O
26	remained	O	O
27	up	O	O
28	to	O	O
29	7	O	O
30	days	O	O
31	following	O	O
32	a	O	O
33	single	O	O
34	ICV	O	S-Disease
35	injection	O	O
36	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	we	O	O
4	observed	O	O
5	that	O	O
6	the	O	O
7	persistent	O	O
8	increase	O	O
9	in	O	O
10	the	O	O
11	rat	O	O
12	spontaneous	O	O
13	locomotion	O	O
14	is	O	O
15	associated	O	O
16	with	O	O
17	increased	O	O
18	TBARS	O	S-Disease
19	levels	O	O
20	and	O	O
21	superoxide	S-Chemical	S-Chemical
22	generation	O	O
23	in	O	O
24	submitochondrial	O	O
25	particles	O	O
26	in	O	O
27	the	O	O
28	prefrontal	O	O
29	cortex	O	O
30	,	O	O
31	striatum	O	O
32	and	O	O
33	amygdala	O	S-Disease
34	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	ouabain	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	mania	S-Disease	S-Disease
7	-	O	O
8	like	O	O
9	behavior	O	O
10	may	O	O
11	provide	O	O
12	a	O	O
13	useful	O	O
14	animal	O	O
15	model	O	O
16	to	O	O
17	test	O	O
18	the	O	O
19	hypothesis	O	O
20	of	O	O
21	the	O	O
22	involvement	O	O
23	of	O	O
24	oxidative	O	O
25	stress	O	S-Disease
26	in	O	O
27	bipolar	B-Disease	B-Disease
28	disorder	E-Disease	E-Disease
29	.	O	O

0	Intraoperative	O	O
1	dialysis	O	O
2	during	O	O
3	liver	O	B-Disease
4	transplantation	O	E-Disease
5	with	O	O
6	citrate	S-Chemical	S-Chemical
7	dialysate	O	S-Disease
8	.	O	O

0	Liver	O	O
1	transplantation	O	O
2	for	O	O
3	acutely	O	O
4	ill	O	O
5	patients	O	O
6	with	O	O
7	fulminant	B-Disease	O
8	liver	I-Disease	B-Disease
9	failure	E-Disease	E-Disease
10	carries	O	O
11	high	O	O
12	intraoperative	O	O
13	and	O	O
14	immediate	O	O
15	postoperative	O	O
16	risks	O	O
17	.	O	O

0	These	O	O
1	are	O	O
2	increased	O	O
3	with	O	O
4	the	O	O
5	presence	O	O
6	of	O	O
7	concomitant	O	O
8	acute	B-Disease	B-Disease
9	kidney	I-Disease	I-Disease
10	injury	E-Disease	E-Disease
11	(	O	O
12	AKI	S-Disease	S-Disease
13	)	O	O
14	and	O	O
15	intraoperative	O	O
16	dialysis	O	S-Disease
17	is	O	O
18	sometimes	O	O
19	required	O	O
20	to	O	O
21	allow	O	O
22	the	O	O
23	transplant	O	O
24	to	O	O
25	proceed	O	O
26	.	O	O

0	The	O	O
1	derangements	O	O
2	in	O	O
3	the	O	O
4	procoagulant	O	O
5	and	O	O
6	anticoagulant	O	O
7	pathways	O	O
8	during	O	O
9	fulminant	B-Disease	O
10	liver	I-Disease	B-Disease
11	failure	E-Disease	E-Disease
12	can	O	O
13	lead	O	O
14	to	O	O
15	difficulties	O	O
16	with	O	O
17	anticoagulation	O	O
18	during	O	O
19	dialysis	O	S-Disease
20	,	O	O
21	especially	O	O
22	when	O	O
23	continued	O	O
24	in	O	O
25	the	O	O
26	operating	O	O
27	room	O	O
28	.	O	O

0	Systemic	O	O
1	anticoagulation	O	O
2	is	O	O
3	unsafe	O	O
4	and	O	O
5	regional	O	O
6	citrate	S-Chemical	S-Chemical
7	anticoagulation	O	O
8	in	O	O
9	the	O	O
10	absence	O	O
11	of	O	O
12	a	O	O
13	functional	O	O
14	liver	O	O
15	carries	O	O
16	the	O	O
17	risk	O	O
18	of	O	O
19	citrate	S-Chemical	S-Chemical
20	toxicity	S-Disease	S-Disease
21	.	O	O

0	Citrate	S-Chemical	O
1	dialysate	O	O
2	,	O	O
3	a	O	O
4	new	O	O
5	dialysate	O	O
6	with	O	O
7	citric	B-Chemical	S-Chemical
8	acid	E-Chemical	E-Disease
9	can	O	O
10	be	O	O
11	used	O	O
12	for	O	O
13	anticoagulation	O	O
14	in	O	O
15	patients	O	O
16	who	O	O
17	cannot	O	O
18	tolerate	O	O
19	heparin	S-Chemical	S-Chemical
20	or	O	O
21	regional	O	O
22	citrate	S-Chemical	S-Chemical
23	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	40	O	O
7	-	O	O
8	year	O	O
9	-	O	O
10	old	O	O
11	female	O	O
12	with	O	O
13	acetaminophen	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	fulminant	B-Disease	S-Disease
17	liver	I-Disease	B-Disease
18	failure	E-Disease	E-Disease
19	with	O	O
20	associated	O	O
21	AKI	S-Disease	S-Chemical
22	who	O	O
23	underwent	O	O
24	intraoperative	O	O
25	dialytic	O	O
26	support	O	O
27	during	O	O
28	liver	O	B-Disease
29	transplantation	O	E-Disease
30	anticoagulated	O	O
31	with	O	O
32	citrate	S-Chemical	S-Chemical
33	dialysate	O	O
34	during	O	O
35	the	O	O
36	entire	O	O
37	procedure	O	O
38	.	O	O

0	The	O	O
1	patient	O	O
2	tolerated	O	O
3	the	O	O
4	procedure	O	O
5	well	O	O
6	without	O	O
7	any	O	O
8	signs	O	O
9	of	O	O
10	citrate	S-Chemical	S-Chemical
11	toxicity	S-Disease	S-Disease
12	and	O	O
13	maintained	O	O
14	adequate	O	O
15	anticoagulation	O	O
16	for	O	O
17	patency	O	O
18	of	O	O
19	the	O	O
20	dialysis	O	O
21	circuit	O	O
22	.	O	O

0	Citrate	S-Chemical	O
1	dialysate	O	O
2	is	O	O
3	a	O	O
4	safe	O	O
5	alternative	O	O
6	for	O	O
7	intradialytic	O	O
8	support	O	O
9	of	O	O
10	liver	O	B-Disease
11	transplantation	O	E-Disease
12	in	O	O
13	fulminant	B-Disease	O
14	liver	I-Disease	B-Disease
15	failure	E-Disease	E-Disease
16	.	O	O

0	Delirium	S-Disease	O
1	in	O	O
2	a	O	O
3	patient	O	O
4	with	O	O
5	toxic	O	O
6	flecainide	S-Chemical	S-Disease
7	plasma	O	O
8	concentrations	O	O
9	:	O	O
10	the	O	O
11	role	O	O
12	of	O	O
13	a	O	O
14	pharmacokinetic	O	O
15	drug	O	O
16	interaction	O	O
17	with	O	O
18	paroxetine	S-Chemical	S-Chemical
19	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	describe	O	O
4	a	O	O
5	case	O	O
6	of	O	O
7	flecainide	S-Chemical	S-Disease
8	-	O	O
9	induced	O	O
10	delirium	S-Disease	S-Disease
11	associated	O	O
12	with	O	O
13	a	O	O
14	pharmacokinetic	O	O
15	drug	O	O
16	interaction	O	O
17	with	O	O
18	paroxetine	S-Chemical	S-Chemical
19	.	O	O

0	CASE	O	O
1	SUMMARY	O	O
2	:	O	O
3	A	O	O
4	69	O	O
5	-	O	O
6	year	O	O
7	-	O	O
8	old	O	O
9	white	O	O
10	female	O	O
11	presented	O	O
12	to	O	O
13	the	O	O
14	emergency	O	O
15	department	O	O
16	with	O	O
17	a	O	O
18	history	O	O
19	of	O	O
20	confusion	S-Disease	O
21	and	O	O
22	paranoia	S-Disease	O
23	over	O	O
24	the	O	O
25	past	O	O
26	several	O	O
27	days	O	O
28	.	O	O

0	On	O	O
1	admission	O	O
2	the	O	O
3	patient	O	O
4	was	O	O
5	taking	O	O
6	carvedilol	S-Chemical	S-Chemical
7	12	O	O
8	mg	O	O
9	twice	O	O
10	daily	O	O
11	,	O	O
12	warfarin	S-Chemical	S-Chemical
13	2	O	O
14	mg	O	O
15	/	O	O
16	day	O	O
17	,	O	O
18	folic	B-Chemical	S-Chemical
19	acid	E-Chemical	E-Disease
20	1	O	O
21	mg	O	O
22	/	O	O
23	day	O	O
24	,	O	O
25	levothyroxine	S-Chemical	S-Chemical
26	100	O	O
27	microg	O	O
28	/	O	O
29	day	O	O
30	,	O	O
31	pantoprazole	S-Chemical	S-Chemical
32	40	O	O
33	mg	O	O
34	/	O	O
35	day	O	O
36	,	O	O
37	paroxetine	S-Chemical	S-Chemical
38	40	O	O
39	mg	O	O
40	/	O	O
41	day	O	O
42	,	O	O
43	and	O	O
44	flecainide	S-Chemical	S-Chemical
45	100	O	O
46	mg	O	O
47	twice	O	O
48	daily	O	O
49	.	O	O

0	Flecainide	S-Chemical	S-Chemical
1	had	O	O
2	been	O	O
3	started	O	O
4	2	O	O
5	weeks	O	O
6	prior	O	O
7	for	O	O
8	atrial	B-Disease	B-Disease
9	fibrillation	E-Disease	E-Disease
10	.	O	O

0	Laboratory	O	O
1	test	O	O
2	findings	O	O
3	on	O	O
4	admission	O	O
5	were	O	O
6	notable	O	O
7	only	O	O
8	for	O	O
9	a	O	O
10	flecainide	S-Chemical	S-Disease
11	plasma	O	O
12	concentration	O	O
13	of	O	O
14	1360	O	O
15	microg	O	O
16	/	O	O
17	L	O	O
18	(	O	O
19	reference	O	O
20	range	O	O
21	200	O	O
22	-	O	O
23	1000	O	O
24	)	O	O
25	.	O	O

0	A	O	O
1	metabolic	O	O
2	drug	O	O
3	interaction	O	O
4	between	O	O
5	flecainide	S-Chemical	S-Chemical
6	and	O	O
7	paroxetine	S-Chemical	S-Chemical
8	,	O	O
9	which	O	O
10	the	O	O
11	patient	O	O
12	had	O	O
13	been	O	O
14	taking	O	O
15	for	O	O
16	more	O	O
17	than	O	O
18	5	O	O
19	years	O	O
20	,	O	O
21	was	O	O
22	considered	O	O
23	.	O	O

0	Paroxetine	S-Chemical	S-Chemical
1	was	O	O
2	discontinued	O	O
3	and	O	O
4	the	O	O
5	dose	O	O
6	of	O	O
7	flecainide	S-Chemical	S-Chemical
8	was	O	O
9	reduced	O	O
10	to	O	O
11	50	O	O
12	mg	O	O
13	twice	O	O
14	daily	O	O
15	.	O	O

0	Her	O	O
1	delirium	S-Disease	S-Disease
2	resolved	O	O
3	3	O	O
4	days	O	O
5	later	O	O
6	.	O	O

0	DISCUSSION	O	O
1	:	O	O
2	Flecainide	S-Chemical	S-Chemical
3	and	O	O
4	pharmacologically	O	O
5	similar	O	O
6	agents	O	O
7	that	O	O
8	interact	O	O
9	with	O	O
10	sodium	S-Chemical	O
11	channels	O	O
12	may	O	O
13	cause	O	O
14	delirium	S-Disease	S-Disease
15	in	O	O
16	susceptible	O	O
17	patients	O	O
18	.	O	O

0	A	O	O
1	MEDLINE	O	O
2	search	O	O
3	(	O	O
4	1966	O	O
5	-	O	O
6	January	O	O
7	2009	O	O
8	)	O	O
9	revealed	O	O
10	one	O	O
11	in	O	O
12	vivo	O	O
13	pharmacokinetic	O	O
14	study	O	O
15	on	O	O
16	the	O	O
17	interaction	O	O
18	between	O	O
19	flecainide	S-Chemical	S-Chemical
20	,	O	O
21	a	O	O
22	CYP2D6	O	S-Chemical
23	substrate	O	O
24	,	O	O
25	and	O	O
26	paroxetine	S-Chemical	S-Chemical
27	,	O	O
28	a	O	O
29	CYP2D6	O	S-Chemical
30	inhibitor	O	O
31	,	O	O
32	as	O	O
33	well	O	O
34	as	O	O
35	3	O	O
36	case	O	O
37	reports	O	O
38	of	O	O
39	flecainide	S-Chemical	S-Chemical
40	-	O	O
41	induced	O	O
42	delirium	S-Disease	S-Disease
43	.	O	O

0	According	O	O
1	to	O	O
2	the	O	O
3	Naranjo	O	S-Chemical
4	probability	O	O
5	scale	O	O
6	,	O	O
7	flecainide	S-Chemical	S-Chemical
8	was	O	O
9	the	O	O
10	probable	O	O
11	cause	O	O
12	of	O	O
13	the	O	O
14	patient	O	O
15	'	O	O
16	s	O	O
17	delirium	S-Disease	O
18	;	O	O
19	the	O	O
20	Horn	O	B-Disease
21	Drug	O	I-Disease
22	Interaction	O	O
23	Probability	O	O
24	Scale	O	O
25	indicates	O	O
26	a	O	O
27	possible	O	O
28	pharmacokinetic	O	O
29	drug	O	O
30	interaction	O	O
31	between	O	O
32	flecainide	S-Chemical	S-Chemical
33	and	O	O
34	paroxetine	S-Chemical	S-Chemical
35	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Supratherapeutic	O	O
3	flecainide	S-Chemical	S-Chemical
4	plasma	O	O
5	concentrations	O	O
6	may	O	O
7	cause	O	O
8	delirium	S-Disease	S-Disease
9	.	O	O

0	Because	O	O
1	toxicity	S-Disease	S-Disease
2	may	O	O
3	occur	O	O
4	when	O	O
5	flecainide	S-Chemical	S-Chemical
6	is	O	O
7	prescribed	O	O
8	with	O	O
9	paroxetine	S-Chemical	S-Chemical
10	and	O	O
11	other	O	O
12	potent	O	O
13	CYP2D6	O	S-Chemical
14	inhibitors	O	O
15	,	O	O
16	flecainide	S-Chemical	S-Chemical
17	plasma	O	O
18	concentrations	O	O
19	should	O	O
20	be	O	O
21	monitored	O	O
22	closely	O	O
23	with	O	O
24	commencement	O	O
25	of	O	O
26	CYP2D6	O	B-Chemical
27	inhibitors	O	O
28	.	O	O

0	Efficacy	O	O
1	of	O	O
2	everolimus	S-Chemical	S-Chemical
3	(	O	O
4	RAD001	S-Chemical	S-Disease
5	)	O	O
6	in	O	O
7	patients	O	O
8	with	O	O
9	advanced	O	O
10	NSCLC	S-Disease	S-Disease
11	previously	O	O
12	treated	O	O
13	with	O	O
14	chemotherapy	O	O
15	alone	O	O
16	or	O	O
17	with	O	O
18	chemotherapy	O	O
19	and	O	O
20	EGFR	O	S-Chemical
21	inhibitors	O	O
22	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Treatment	O	O
3	options	O	O
4	are	O	O
5	scarce	O	O
6	in	O	O
7	pretreated	O	O
8	advanced	O	O
9	non	B-Disease	O
10	-	I-Disease	O
11	small	I-Disease	I-Disease
12	-	I-Disease	O
13	cell	I-Disease	I-Disease
14	lung	I-Disease	I-Disease
15	cancer	E-Disease	E-Disease
16	(	O	O
17	NSCLC	S-Disease	S-Disease
18	)	O	O
19	patients	O	O
20	.	O	O

0	RAD001	S-Chemical	S-Chemical
1	,	O	O
2	an	O	O
3	oral	O	O
4	inhibitor	O	O
5	of	O	O
6	the	O	O
7	mammalian	O	O
8	target	O	O
9	of	O	O
10	rapamycin	S-Chemical	S-Chemical
11	(	O	O
12	mTOR	O	S-Disease
13	)	O	O
14	,	O	O
15	has	O	O
16	shown	O	O
17	phase	O	O
18	I	O	O
19	efficacy	O	O
20	in	O	O
21	NSCLC	S-Disease	S-Disease
22	.	O	O

0	METHODS	O	O
1	:	O	O
2	Stage	O	O
3	IIIb	O	O
4	or	O	O
5	IV	O	O
6	NSCLC	S-Disease	O
7	patients	O	O
8	,	O	O
9	with	O	O
10	two	O	O
11	or	O	O
12	fewer	O	O
13	prior	O	O
14	chemotherapy	O	O
15	regimens	O	O
16	,	O	O
17	one	O	O
18	platinum	S-Chemical	O
19	based	O	O
20	(	O	O
21	stratum	O	O
22	1	O	O
23	)	O	O
24	or	O	O
25	both	O	O
26	chemotherapy	O	O
27	and	O	O
28	epidermal	O	O
29	growth	O	B-Disease
30	factor	O	O
31	receptor	O	O
32	tyrosine	S-Chemical	S-Disease
33	kinase	O	O
34	inhibitors	O	O
35	(	O	O
36	stratum	O	O
37	2	O	O
38	)	O	O
39	,	O	O
40	received	O	O
41	RAD001	S-Chemical	S-Disease
42	10	O	O
43	mg	O	O
44	/	O	O
45	day	O	O
46	until	O	O
47	progression	O	O
48	or	O	O
49	unacceptable	O	O
50	toxicity	S-Disease	S-Disease
51	.	O	O

0	Analyses	O	O
1	of	O	O
2	markers	O	O
3	associated	O	O
4	with	O	O
5	the	O	O
6	mTOR	O	O
7	pathway	O	O
8	were	O	O
9	carried	O	O
10	out	O	O
11	on	O	O
12	archival	O	O
13	tumor	S-Disease	E-Disease
14	from	O	O
15	a	O	O
16	subgroup	O	O
17	using	O	O
18	immunohistochemistry	O	O
19	(	O	O
20	IHC	O	S-Chemical
21	)	O	O
22	and	O	O
23	direct	O	O
24	mutation	O	O
25	sequencing	O	O
26	.	O	O

0	Common	O	O
1	>	O	O
2	or	O	O
3	=	O	O
4	grade	O	O
5	3	O	O
6	events	O	O
7	were	O	O
8	fatigue	S-Disease	S-Disease
9	,	O	O
10	dyspnea	S-Disease	S-Disease
11	,	O	O
12	stomatitis	S-Disease	S-Disease
13	,	O	O
14	anemia	S-Disease	S-Disease
15	,	O	O
16	and	O	O
17	thrombocytopenia	S-Disease	S-Disease
18	.	O	O

0	Pneumonitis	S-Disease	S-Chemical
1	,	O	O
2	probably	O	O
3	or	O	O
4	possibly	O	O
5	related	O	O
6	,	O	O
7	mainly	O	O
8	grade	O	O
9	1	O	O
10	/	O	O
11	2	O	O
12	,	O	O
13	occurred	O	O
14	in	O	O
15	25	O	O
16	%	O	O
17	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	RAD001	S-Chemical	S-Disease
3	10	O	O
4	mg	O	O
5	/	O	O
6	day	O	O
7	was	O	O
8	well	O	O
9	tolerated	O	O
10	,	O	O
11	showing	O	O
12	modest	O	O
13	clinical	O	O
14	activity	O	O
15	in	O	O
16	pretreated	O	O
17	NSCLC	S-Disease	S-Chemical
18	.	O	O

0	Evaluation	O	O
1	of	O	O
2	RAD001	S-Chemical	S-Chemical
3	plus	O	O
4	standard	O	O
5	therapy	O	O
6	for	O	O
7	metastatic	O	O
8	NSCLC	S-Disease	S-Disease
9	continues	O	O
10	.	O	O

0	Posttransplant	O	O
1	anemia	S-Disease	O
2	:	O	O
3	the	O	O
4	role	O	O
5	of	O	O
6	sirolimus	S-Chemical	S-Disease
7	.	O	O

0	Posttransplant	O	O
1	anemia	S-Disease	O
2	is	O	O
3	a	O	O
4	common	O	O
5	problem	O	O
6	that	O	O
7	may	O	O
8	hinder	O	O
9	patients	O	O
10	'	O	O
11	quality	O	O
12	of	O	O
13	life	O	O
14	.	O	O

0	A	O	O
1	variety	O	O
2	of	O	O
3	factors	O	O
4	have	O	O
5	been	O	O
6	identified	O	O
7	that	O	O
8	increase	O	O
9	the	O	O
10	risk	O	O
11	of	O	O
12	posttransplant	O	O
13	anemia	S-Disease	S-Disease
14	,	O	O
15	of	O	O
16	which	O	O
17	the	O	O
18	level	O	O
19	of	O	O
20	renal	O	B-Disease
21	function	O	E-Disease
22	is	O	O
23	most	O	O
24	important	O	O
25	.	O	O

0	Sirolimus	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	mammalian	O	O
4	target	O	O
5	of	O	O
6	rapamycin	S-Chemical	S-Chemical
7	inhibitor	O	O
8	,	O	O
9	has	O	O
10	been	O	O
11	implicated	O	O
12	as	O	O
13	playing	O	O
14	a	O	O
15	special	O	O
16	role	O	O
17	in	O	O
18	posttransplant	O	O
19	anemia	S-Disease	S-Disease
20	.	O	O

0	This	O	O
1	review	O	O
2	considers	O	O
3	anemia	S-Disease	O
4	associated	O	O
5	with	O	O
6	sirolimus	S-Chemical	S-Disease
7	,	O	O
8	including	O	O
9	its	O	O
10	presentation	O	O
11	,	O	O
12	mechanisms	O	O
13	,	O	O
14	and	O	O
15	management	O	O
16	.	O	O

0	Coronary	O	O
1	computerized	O	O
2	tomography	O	O
3	angiography	O	O
4	for	O	O
5	rapid	O	O
6	discharge	O	O
7	of	O	O
8	low	O	O
9	-	O	O
10	risk	O	O
11	patients	O	O
12	with	O	O
13	cocaine	S-Chemical	S-Chemical
14	-	O	O
15	associated	O	O
16	chest	B-Disease	B-Disease
17	pain	E-Disease	E-Disease
18	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Most	O	O
3	patients	O	O
4	presenting	O	O
5	to	O	O
6	emergency	O	O
7	departments	O	O
8	(	O	O
9	EDs	O	S-Disease
10	)	O	O
11	with	O	O
12	cocaine	S-Chemical	S-Chemical
13	-	O	O
14	associated	O	O
15	chest	B-Disease	B-Disease
16	pain	E-Disease	E-Disease
17	are	O	O
18	admitted	O	O
19	for	O	O
20	at	O	O
21	least	O	O
22	12	O	O
23	hours	O	O
24	and	O	O
25	receive	O	O
26	a	O	O
27	"	O	O
28	rule	O	O
29	out	O	O
30	acute	B-Disease	B-Disease
31	coronary	I-Disease	I-Disease
32	syndrome	E-Disease	E-Disease
33	"	O	O
34	protocol	O	O
35	,	O	O
36	often	O	O
37	with	O	O
38	noninvasive	O	O
39	testing	O	O
40	prior	O	O
41	to	O	O
42	discharge	O	O
43	.	O	O

0	In	O	O
1	patients	O	O
2	without	O	O
3	cocaine	S-Chemical	S-Chemical
4	use	O	O
5	,	O	O
6	coronary	O	S-Disease
7	computerized	O	O
8	tomography	O	O
9	angiography	O	O
10	(	O	O
11	CTA	O	S-Disease
12	)	O	O
13	has	O	O
14	been	O	O
15	shown	O	O
16	to	O	O
17	be	O	O
18	useful	O	O
19	for	O	O
20	identifying	O	O
21	a	O	O
22	group	O	O
23	of	O	O
24	patients	O	O
25	at	O	O
26	low	O	O
27	risk	O	O
28	for	O	O
29	cardiac	O	B-Disease
30	events	O	E-Disease
31	who	O	O
32	can	O	O
33	be	O	O
34	safely	O	O
35	discharged	O	O
36	.	O	O

0	It	O	O
1	is	O	O
2	unclear	O	O
3	whether	O	O
4	a	O	O
5	coronary	O	B-Disease
6	CTA	O	E-Disease
7	strategy	O	O
8	would	O	O
9	be	O	O
10	efficacious	O	O
11	in	O	O
12	cocaine	S-Chemical	S-Chemical
13	-	O	O
14	associated	O	O
15	chest	B-Disease	B-Disease
16	pain	E-Disease	E-Disease
17	,	O	O
18	as	O	O
19	coronary	B-Disease	B-Disease
20	vasospasm	E-Disease	E-Disease
21	may	O	O
22	account	O	O
23	for	O	O
24	some	O	O
25	of	O	O
26	the	O	O
27	ischemia	S-Disease	S-Disease
28	.	O	O

0	We	O	O
1	studied	O	O
2	whether	O	O
3	a	O	O
4	negative	O	O
5	coronary	O	B-Disease
6	CTA	O	E-Disease
7	in	O	O
8	patients	O	O
9	with	O	O
10	cocaine	S-Chemical	S-Chemical
11	-	O	O
12	associated	O	O
13	chest	B-Disease	B-Disease
14	pain	E-Disease	E-Disease
15	could	O	O
16	identify	O	O
17	a	O	O
18	subset	O	O
19	safe	O	O
20	for	O	O
21	discharge	O	O
22	.	O	O

0	METHODS	O	O
1	:	O	O
2	We	O	O
3	prospectively	O	O
4	evaluated	O	O
5	the	O	O
6	safety	O	O
7	of	O	O
8	coronary	O	B-Disease
9	CTA	O	E-Disease
10	for	O	O
11	low	O	O
12	-	O	O
13	risk	O	O
14	patients	O	O
15	who	O	O
16	presented	O	O
17	to	O	O
18	the	O	O
19	ED	O	S-Disease
20	with	O	O
21	cocaineassociated	O	S-Chemical
22	chest	B-Disease	B-Disease
23	pain	E-Disease	E-Disease
24	(	O	O
25	self	O	O
26	-	O	O
27	reported	O	O
28	or	O	O
29	positive	O	O
30	urine	O	O
31	test	O	O
32	)	O	O
33	.	O	O

0	Patients	O	O
1	with	O	O
2	negative	O	O
3	coronary	O	B-Disease
4	CTA	O	E-Disease
5	(	O	O
6	maximal	O	O
7	stenosis	S-Disease	S-Disease
8	less	O	O
9	than	O	O
10	50	O	O
11	%	O	O
12	)	O	O
13	were	O	O
14	discharged	O	O
15	.	O	O

0	The	O	O
1	main	O	O
2	outcome	O	O
3	was	O	O
4	30	O	O
5	-	O	O
6	day	O	O
7	cardiovascular	O	B-Disease
8	death	O	E-Disease
9	or	O	O
10	myocardial	B-Disease	B-Disease
11	infarction	E-Disease	E-Disease
12	.	O	O

0	RESULTS	O	O
1	:	O	O
2	A	O	O
3	total	O	O
4	of	O	O
5	59	O	O
6	patients	O	O
7	with	O	O
8	cocaine	S-Chemical	S-Chemical
9	-	O	O
10	associated	O	O
11	chest	B-Disease	B-Disease
12	pain	E-Disease	E-Disease
13	were	O	O
14	evaluated	O	O
15	.	O	O

0	Six	O	O
1	patients	O	O
2	had	O	O
3	coronary	B-Disease	B-Disease
4	stenosis	E-Disease	E-Disease
5	>	O	O
6	or	O	O
7	=	O	O
8	50	O	O
9	%	O	O
10	.	O	O

0	During	O	O
1	the	O	O
2	30	O	O
3	-	O	O
4	day	O	O
5	follow	O	O
6	-	O	O
7	up	O	O
8	period	O	O
9	,	O	O
10	no	O	O
11	patients	O	O
12	died	O	O
13	of	O	O
14	a	O	O
15	cardiovascular	O	O
16	event	O	O
17	(	O	O
18	0	O	O
19	%	O	O
20	;	O	O
21	95	O	O
22	%	O	O
23	CI	O	S-Chemical
24	,	O	O
25	0	O	O
26	-	O	O
27	6	O	O
28	.	O	O
29	1	O	O
30	%	O	O
31	)	O	O
32	and	O	O
33	no	O	O
34	patient	O	O
35	sustained	O	O
36	a	O	O
37	nonfatal	O	O
38	myocardial	B-Disease	S-Disease
39	infarction	E-Disease	E-Disease
40	(	O	O
41	0	O	O
42	%	O	O
43	;	O	O
44	95	O	O
45	%	O	O
46	CI	O	S-Chemical
47	,	O	O
48	0	O	O
49	-	O	O
50	6	O	O
51	.	O	O
52	1	O	O
53	%	O	O
54	)	O	O
55	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Although	O	O
3	cocaine	S-Chemical	S-Chemical
4	-	O	O
5	associated	O	O
6	myocardial	B-Disease	B-Disease
7	ischemia	E-Disease	E-Disease
8	can	O	O
9	result	O	O
10	from	O	O
11	coronary	O	B-Disease
12	vasoconstriction	O	E-Disease
13	,	O	O
14	patients	O	O
15	with	O	O
16	cocaine	S-Chemical	S-Chemical
17	associated	O	O
18	chest	B-Disease	B-Disease
19	pain	E-Disease	E-Disease
20	,	O	O
21	a	O	O
22	non	O	O
23	-	O	O
24	ischemic	S-Disease	S-Disease
25	ECG	O	S-Disease
26	,	O	O
27	and	O	O
28	a	O	O
29	TIMI	O	S-Disease
30	risk	O	O
31	score	O	O
32	<	O	O
33	2	O	O
34	may	O	O
35	be	O	O
36	safely	O	O
37	discharged	O	O
38	from	O	O
39	the	O	O
40	ED	O	S-Disease
41	after	O	O
42	a	O	O
43	negative	O	O
44	coronary	O	B-Disease
45	CTA	O	E-Disease
46	with	O	O
47	a	O	O
48	low	O	O
49	risk	O	O
50	of	O	O
51	30	O	O
52	-	O	O
53	day	O	O
54	adverse	O	S-Disease
55	events	O	O
56	.	O	O

0	Bilateral	O	O
1	haemorrhagic	B-Disease	O
2	infarction	I-Disease	O
3	of	I-Disease	O
4	the	I-Disease	O
5	globus	I-Disease	O
6	pallidus	E-Disease	S-Disease
7	after	O	O
8	cocaine	S-Chemical	S-Chemical
9	and	O	O
10	alcohol	S-Chemical	B-Disease
11	intoxication	O	E-Disease
12	.	O	O

0	Cocaine	S-Chemical	S-Chemical
1	is	O	O
2	a	O	O
3	risk	O	O
4	factor	O	O
5	for	O	O
6	both	O	O
7	ischemic	B-Disease	S-Disease
8	and	I-Disease	O
9	haemorrhagic	I-Disease	S-Disease
10	stroke	E-Disease	S-Disease
11	.	O	O

0	We	O	O
1	present	O	O
2	the	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	31	O	O
7	-	O	O
8	year	O	O
9	-	O	O
10	old	O	O
11	man	O	O
12	with	O	O
13	bilateral	O	O
14	ischemia	B-Disease	S-Disease
15	of	I-Disease	O
16	the	I-Disease	O
17	globus	I-Disease	B-Disease
18	pallidus	E-Disease	E-Disease
19	after	O	O
20	excessive	O	O
21	alcohol	S-Chemical	S-Disease
22	and	O	O
23	intranasal	O	O
24	cocaine	S-Chemical	S-Chemical
25	use	O	O
26	.	O	O

0	Drug	O	O
1	-	O	O
2	related	O	O
3	globus	B-Disease	B-Disease
4	pallidus	I-Disease	E-Disease
5	infarctions	E-Disease	E-Disease
6	are	O	O
7	most	O	O
8	often	O	O
9	associated	O	O
10	with	O	O
11	heroin	S-Chemical	S-Chemical
12	.	O	O

0	Bilateral	O	O
1	basal	B-Disease	O
2	ganglia	I-Disease	I-Disease
3	infarcts	E-Disease	O
4	after	O	O
5	the	O	O
6	use	O	O
7	of	O	O
8	cocaine	S-Chemical	S-Chemical
9	,	O	O
10	without	O	O
11	concurrent	O	O
12	heroin	S-Chemical	S-Disease
13	use	O	O
14	,	O	O
15	have	O	O
16	never	O	O
17	been	O	O
18	reported	O	O
19	.	O	O

0	In	O	O
1	our	O	O
2	patient	O	O
3	,	O	O
4	transient	O	O
5	cardiac	B-Disease	B-Disease
6	arrhythmia	E-Disease	E-Disease
7	or	O	O
8	respiratory	B-Disease	B-Disease
9	dysfunction	E-Disease	E-Disease
10	related	O	O
11	to	O	O
12	cocaine	S-Chemical	S-Chemical
13	and	O	O
14	/	O	O
15	or	O	O
16	ethanol	S-Chemical	S-Disease
17	use	O	O
18	were	O	O
19	the	O	O
20	most	O	O
21	likely	O	O
22	causes	O	O
23	of	O	O
24	cerebral	B-Disease	B-Disease
25	hypoperfusion	E-Disease	E-Disease
26	.	O	O

0	Late	O	O
1	fulminant	O	O
2	posterior	B-Disease	O
3	reversible	I-Disease	O
4	encephalopathy	I-Disease	B-Disease
5	syndrome	E-Disease	E-Disease
6	after	O	O
7	liver	O	B-Disease
8	transplant	O	E-Disease
9	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	Posterior	B-Disease	O
3	leukoencephalopathy	E-Disease	S-Disease
4	due	O	O
5	to	O	O
6	calcineurin	O	S-Chemical
7	-	O	O
8	inhibitor	O	O
9	-	O	O
10	related	O	O
11	neurotoxicity	S-Disease	S-Disease
12	is	O	O
13	a	O	O
14	rare	O	O
15	but	O	O
16	severe	O	O
17	complication	O	O
18	that	O	O
19	results	O	O
20	from	O	O
21	treatment	O	O
22	with	O	O
23	immunosuppressive	O	O
24	agents	O	O
25	(	O	O
26	primarily	O	O
27	those	O	O
28	administered	O	O
29	after	O	O
30	a	O	O
31	liver	O	O
32	or	O	O
33	kidney	O	B-Disease
34	transplant	O	E-Disease
35	)	O	O
36	.	O	O

0	CASE	O	O
1	:	O	O
2	We	O	O
3	report	O	O
4	the	O	O
5	case	O	O
6	of	O	O
7	a	O	O
8	46	O	O
9	-	O	O
10	year	O	O
11	-	O	O
12	old	O	O
13	woman	O	O
14	who	O	O
15	received	O	O
16	a	O	O
17	liver	O	B-Disease
18	transplant	O	E-Disease
19	in	O	O
20	our	O	O
21	center	O	O
22	as	O	O
23	treatment	O	O
24	for	O	O
25	alcoholic	B-Disease	B-Disease
26	cirrhosis	E-Disease	E-Disease
27	and	O	O
28	in	O	O
29	whom	O	O
30	either	O	O
31	a	O	O
32	fulminant	O	O
33	course	O	O
34	of	O	O
35	posterior	B-Disease	O
36	leukoencephalopathy	E-Disease	S-Disease
37	or	O	O
38	posterior	B-Disease	O
39	reversible	I-Disease	O
40	encephalopathy	I-Disease	S-Disease
41	syndrome	E-Disease	S-Disease
42	developed	O	O
43	110	O	O
44	days	O	O
45	after	O	O
46	transplant	O	O
47	.	O	O

0	Switching	O	O
1	the	O	O
2	immunosuppressive	O	S-Disease
3	regimen	O	O
4	from	O	O
5	tacrolimus	S-Chemical	S-Chemical
6	to	O	O
7	cyclosporine	S-Chemical	S-Chemical
8	did	O	O
9	not	O	O
10	improve	O	O
11	the	O	O
12	clinical	O	O
13	situation	O	O
14	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Posterior	B-Disease	O
3	reversible	I-Disease	O
4	encephalopathy	I-Disease	B-Disease
5	syndrome	E-Disease	E-Disease
6	after	O	O
7	liver	O	B-Disease
8	transplant	O	E-Disease
9	is	O	O
10	rare	O	O
11	.	O	O

0	Prolonged	O	O
1	hypothermia	S-Disease	S-Disease
2	as	O	O
3	a	O	O
4	bridge	O	O
5	to	O	O
6	recovery	O	O
7	for	O	O
8	cerebral	B-Disease	B-Disease
9	edema	E-Disease	E-Disease
10	and	O	O
11	intracranial	B-Disease	O
12	hypertension	E-Disease	S-Disease
13	associated	O	O
14	with	O	O
15	fulminant	B-Disease	S-Disease
16	hepatic	I-Disease	S-Disease
17	failure	E-Disease	E-Disease
18	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	To	O	O
3	review	O	O
4	evidence	O	O
5	-	O	O
6	based	O	O
7	treatment	O	O
8	options	O	O
9	in	O	O
10	patients	O	O
11	with	O	O
12	cerebral	B-Disease	B-Disease
13	edema	E-Disease	E-Disease
14	complicating	O	O
15	fulminant	B-Disease	O
16	hepatic	I-Disease	B-Disease
17	failure	E-Disease	E-Disease
18	(	O	O
19	FHF	S-Disease	S-Chemical
20	)	O	O
21	and	O	O
22	discuss	O	O
23	the	O	O
24	potential	O	O
25	applications	O	O
26	of	O	O
27	hypothermia	S-Disease	S-Disease
28	.	O	O

0	METHOD	O	O
1	:	O	O
2	Case	O	O
3	-	O	O
4	based	O	O
5	observations	O	O
6	from	O	O
7	a	O	O
8	medical	O	O
9	intensive	O	O
10	care	O	O
11	unit	O	O
12	(	O	O
13	MICU	O	S-Disease
14	)	O	O
15	in	O	O
16	a	O	O
17	tertiary	O	O
18	care	O	O
19	facility	O	O
20	in	O	O
21	a	O	O
22	27	O	O
23	-	O	O
24	year	O	O
25	-	O	O
26	old	O	O
27	female	O	O
28	with	O	O
29	FHF	S-Disease	S-Chemical
30	from	O	O
31	acetaminophen	S-Chemical	S-Chemical
32	and	O	O
33	resultant	O	O
34	cerebral	B-Disease	B-Disease
35	edema	E-Disease	E-Disease
36	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Our	O	O
3	patient	O	O
4	was	O	O
5	admitted	O	O
6	to	O	O
7	the	O	O
8	MICU	O	S-Chemical
9	after	O	O
10	being	O	O
11	found	O	O
12	unresponsive	O	O
13	with	O	O
14	presumed	O	O
15	toxicity	S-Disease	S-Disease
16	from	O	O
17	acetaminophen	S-Chemical	S-Chemical
18	which	O	O
19	was	O	O
20	ingested	O	O
21	over	O	O
22	a	O	O
23	2	O	O
24	-	O	O
25	day	O	O
26	period	O	O
27	.	O	O

0	Initial	O	O
1	evaluation	O	O
2	confirmed	O	O
3	FHF	S-Disease	S-Chemical
4	from	O	O
5	acetaminophen	S-Chemical	S-Chemical
6	and	O	O
7	cerebral	B-Disease	B-Disease
8	edema	E-Disease	E-Disease
9	.	O	O

0	The	O	O
1	patient	O	O
2	was	O	O
3	treated	O	O
4	with	O	O
5	hyperosmolar	O	S-Disease
6	therapy	O	O
7	,	O	O
8	hyperventilation	S-Disease	S-Disease
9	,	O	O
10	sedation	O	O
11	,	O	O
12	and	O	O
13	chemical	O	O
14	paralysis	S-Disease	S-Disease
15	.	O	O

0	We	O	O
1	then	O	O
2	initiated	O	O
3	therapeutic	O	O
4	hypothermia	S-Disease	S-Disease
5	which	O	O
6	was	O	O
7	continued	O	O
8	for	O	O
9	5	O	O
10	days	O	O
11	.	O	O

0	At	O	O
1	re	O	O
2	-	O	O
3	warming	O	O
4	,	O	O
5	patient	O	O
6	had	O	O
7	resolution	O	O
8	of	O	O
9	her	O	O
10	cerebral	B-Disease	B-Disease
11	edema	E-Disease	E-Disease
12	and	O	O
13	intracranial	B-Disease	O
14	hypertension	E-Disease	S-Disease
15	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	In	O	O
3	patients	O	O
4	with	O	O
5	FHF	S-Disease	S-Chemical
6	and	O	O
7	cerebral	B-Disease	B-Disease
8	edema	E-Disease	E-Disease
9	from	O	O
10	acetaminophen	S-Chemical	S-Chemical
11	overdose	S-Disease	O
12	,	O	O
13	prolonged	O	O
14	therapeutic	O	O
15	hypothermia	S-Disease	S-Disease
16	could	O	O
17	potentially	O	O
18	be	O	O
19	used	O	O
20	as	O	O
21	a	O	O
22	life	O	O
23	saving	O	O
24	therapy	O	O
25	and	O	O
26	a	O	O
27	bridge	O	O
28	to	O	O
29	hepatic	O	S-Disease
30	and	O	O
31	neurological	O	O
32	recovery	O	O
33	.	O	O

0	A	O	O
1	clinical	O	O
2	trial	O	O
3	of	O	O
4	hypothermia	S-Disease	S-Disease
5	in	O	O
6	patients	O	O
7	with	O	O
8	this	O	O
9	condition	O	O
10	is	O	O
11	warranted	O	O
12	.	O	O

0	Binasal	B-Disease	O
1	visual	I-Disease	O
2	field	I-Disease	I-Disease
3	defects	E-Disease	E-Disease
4	are	O	O
5	not	O	O
6	specific	O	O
7	to	O	O
8	vigabatrin	S-Chemical	S-Chemical
9	.	O	O

0	This	O	O
1	study	O	O
2	investigated	O	O
3	the	O	O
4	visual	B-Disease	O
5	defects	E-Disease	O
6	associated	O	O
7	with	O	O
8	the	O	O
9	antiepileptic	O	O
10	drug	O	O
11	vigabatrin	S-Chemical	S-Disease
12	(	O	O
13	VGB	S-Chemical	S-Chemical
14	)	O	O
15	.	O	O

0	Two	O	O
1	hundred	O	O
2	four	O	O
3	people	O	O
4	with	O	O
5	epilepsy	S-Disease	S-Disease
6	were	O	O
7	grouped	O	O
8	on	O	O
9	the	O	O
10	basis	O	O
11	of	O	O
12	antiepileptic	O	O
13	drug	O	O
14	therapy	O	O
15	(	O	O
16	current	O	O
17	,	O	O
18	previous	O	O
19	,	O	O
20	or	O	O
21	no	O	O
22	exposure	O	O
23	to	O	O
24	VGB	S-Chemical	S-Chemical
25	)	O	O
26	.	O	O

0	Groups	O	O
1	were	O	O
2	matched	O	O
3	with	O	O
4	respect	O	O
5	to	O	O
6	age	O	O
7	,	O	O
8	gender	O	O
9	,	O	O
10	and	O	O
11	seizure	S-Disease	S-Disease
12	frequency	O	O
13	.	O	O

0	Bilateral	O	O
1	visual	O	O
2	field	O	O
3	constriction	O	O
4	was	O	O
5	observed	O	O
6	in	O	O
7	59	O	O
8	%	O	O
9	of	O	O
10	patients	O	O
11	currently	O	O
12	taking	O	O
13	VGB	S-Chemical	S-Chemical
14	,	O	O
15	43	O	O
16	%	O	O
17	of	O	O
18	patients	O	O
19	who	O	O
20	previously	O	O
21	took	O	O
22	VGB	S-Chemical	S-Chemical
23	,	O	O
24	and	O	O
25	24	O	O
26	%	O	O
27	of	O	O
28	patients	O	O
29	with	O	O
30	no	O	O
31	exposure	O	O
32	to	O	O
33	VGB	S-Chemical	S-Chemical
34	.	O	O

0	Assessment	O	O
1	of	O	O
2	retinal	O	S-Disease
3	function	O	O
4	revealed	O	O
5	abnormal	O	O
6	responses	O	O
7	in	O	O
8	48	O	O
9	%	O	O
10	of	O	O
11	current	O	O
12	VGB	S-Chemical	S-Chemical
13	users	O	O
14	and	O	O
15	22	O	O
16	%	O	O
17	of	O	O
18	prior	O	O
19	VGB	S-Chemical	S-Chemical
20	users	O	O
21	,	O	O
22	but	O	O
23	in	O	O
24	none	O	O
25	of	O	O
26	the	O	O
27	patients	O	O
28	without	O	O
29	previous	O	O
30	exposure	O	O
31	to	O	O
32	VGB	S-Chemical	S-Chemical
33	.	O	O

0	Bilateral	B-Disease	O
1	visual	I-Disease	O
2	field	I-Disease	O
3	abnormalities	E-Disease	O
4	are	O	O
5	common	O	O
6	in	O	O
7	the	O	O
8	treated	O	O
9	epilepsy	S-Disease	S-Disease
10	population	O	O
11	,	O	O
12	irrespective	O	O
13	of	O	O
14	drug	O	O
15	history	O	O
16	.	O	O

0	Assessment	O	O
1	by	O	O
2	conventional	O	O
3	static	O	O
4	perimetry	O	O
5	may	O	O
6	neither	O	O
7	be	O	O
8	sufficiently	O	O
9	sensitive	O	O
10	nor	O	O
11	specific	O	O
12	to	O	O
13	reliably	O	O
14	identify	O	O
15	retinal	B-Disease	B-Disease
16	toxicity	E-Disease	E-Disease
17	associated	O	O
18	with	O	O
19	VGB	S-Chemical	S-Chemical
20	.	O	O

0	Smoking	O	O
1	of	O	O
2	crack	B-Chemical	B-Disease
3	cocaine	E-Chemical	E-Disease
4	as	O	O
5	a	O	O
6	risk	O	O
7	factor	O	O
8	for	O	O
9	HIV	B-Disease	B-Disease
10	infection	E-Disease	E-Disease
11	among	O	O
12	people	O	O
13	who	O	O
14	use	O	O
15	injection	O	O
16	drugs	O	O
17	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Little	O	O
3	is	O	O
4	known	O	O
5	about	O	O
6	the	O	O
7	possible	O	O
8	role	O	O
9	that	O	O
10	smoking	O	O
11	crack	B-Chemical	B-Disease
12	cocaine	E-Chemical	E-Disease
13	has	O	O
14	on	O	O
15	the	O	O
16	incidence	O	O
17	of	O	O
18	HIV	B-Disease	B-Disease
19	infection	E-Disease	E-Disease
20	.	O	O

0	Given	O	O
1	the	O	O
2	increasing	O	O
3	use	O	O
4	of	O	O
5	crack	B-Chemical	B-Disease
6	cocaine	E-Chemical	E-Disease
7	,	O	O
8	we	O	O
9	sought	O	O
10	to	O	O
11	examine	O	O
12	whether	O	O
13	use	O	O
14	of	O	O
15	this	O	O
16	illicit	O	O
17	drug	O	O
18	has	O	O
19	become	O	O
20	a	O	O
21	risk	O	O
22	factor	O	O
23	for	O	O
24	HIV	B-Disease	B-Disease
25	infection	E-Disease	E-Disease
26	.	O	O

0	To	O	O
1	determine	O	O
2	whether	O	O
3	the	O	O
4	risk	O	O
5	of	O	O
6	HIV	B-Disease	B-Disease
7	seroconversion	E-Disease	E-Disease
8	among	O	O
9	daily	O	O
10	smokers	O	O
11	of	O	O
12	crack	B-Chemical	B-Disease
13	cocaine	E-Chemical	E-Disease
14	changed	O	O
15	over	O	O
16	time	O	O
17	,	O	O
18	we	O	O
19	used	O	O
20	Cox	O	O
21	proportional	O	O
22	hazards	O	O
23	regression	O	O
24	and	O	O
25	divided	O	O
26	the	O	O
27	study	O	O
28	into	O	O
29	3	O	O
30	periods	O	O
31	:	O	O
32	May	O	O
33	1	O	O
34	,	O	O
35	1996	O	O
36	-	O	O
37	Nov	O	O
38	.	O	O

0	Of	O	O
1	these	O	O
2	,	O	O
3	137	O	O
4	acquired	O	O
5	HIV	B-Disease	B-Disease
6	infection	E-Disease	E-Disease
7	during	O	O
8	follow	O	O
9	-	O	O
10	up	O	O
11	.	O	O

0	The	O	O
1	mean	O	O
2	proportion	O	O
3	of	O	O
4	participants	O	O
5	who	O	O
6	reported	O	O
7	daily	O	O
8	smoking	O	O
9	of	O	O
10	crack	B-Chemical	B-Disease
11	cocaine	E-Chemical	E-Disease
12	increased	O	O
13	from	O	O
14	11	O	O
15	.	O	O
16	6	O	O
17	%	O	O
18	in	O	O
19	period	O	O
20	1	O	O
21	to	O	O
22	39	O	O
23	.	O	O
24	7	O	O
25	%	O	O
26	in	O	O
27	period	O	O
28	3	O	O
29	.	O	O

0	After	O	O
1	adjusting	O	O
2	for	O	O
3	potential	O	O
4	confounders	O	O
5	,	O	O
6	we	O	O
7	found	O	O
8	that	O	O
9	the	O	O
10	risk	O	O
11	of	O	O
12	HIV	B-Disease	B-Disease
13	seroconversion	E-Disease	E-Disease
14	among	O	O
15	participants	O	O
16	who	O	O
17	were	O	O
18	daily	O	O
19	smokers	O	O
20	of	O	O
21	crack	B-Chemical	B-Disease
22	cocaine	E-Chemical	E-Disease
23	increased	O	O
24	over	O	O
25	time	O	O
26	(	O	O
27	period	O	O
28	1	O	O
29	:	O	O
30	hazard	O	O
31	ratio	O	O
32	[	O	O
33	HR	O	O
34	]	O	O
35	1	O	O
36	.	O	O
37	03	O	O
38	,	O	O
39	95	O	O
40	%	O	O
41	confidence	O	O
42	interval	O	O
43	[	O	O
44	CI	O	S-Disease
45	]	O	O
46	0	O	O
47	.	O	O
48	57	O	O
49	-	O	O
50	1	O	O
51	.	O	O
52	85	O	O
53	;	O	O
54	period	O	O
55	2	O	O
56	:	O	O
57	HR	O	O
58	1	O	O
59	.	O	O
60	68	O	O
61	,	O	O
62	95	O	O
63	%	O	O
64	CI	O	S-Disease
65	1	O	O
66	.	O	O
67	01	O	O
68	-	O	O
69	2	O	O
70	.	O	O
71	80	O	O
72	;	O	O
73	and	O	O
74	period	O	O
75	3	O	O
76	:	O	O
77	HR	O	O
78	2	O	O
79	.	O	O
80	74	O	O
81	,	O	O
82	95	O	O
83	%	O	O
84	CI	O	S-Chemical
85	1	O	O
86	.	O	O
87	06	O	O
88	-	O	O
89	7	O	O
90	.	O	O
91	11	O	O
92	)	O	O
93	.	O	O

0	INTERPRETATION	O	O
1	:	O	O
2	Smoking	O	O
3	of	O	O
4	crack	B-Chemical	B-Disease
5	cocaine	E-Chemical	E-Disease
6	was	O	O
7	found	O	O
8	to	O	O
9	be	O	O
10	an	O	O
11	independent	O	O
12	risk	O	O
13	factor	O	O
14	for	O	O
15	HIV	B-Disease	B-Disease
16	seroconversion	E-Disease	E-Disease
17	among	O	O
18	people	O	O
19	who	O	O
20	were	O	O
21	injection	O	O
22	drug	O	O
23	users	O	O
24	.	O	O

0	This	O	O
1	finding	O	O
2	points	O	O
3	to	O	O
4	the	O	O
5	urgent	O	O
6	need	O	O
7	for	O	O
8	evidence	O	O
9	-	O	O
10	based	O	O
11	public	O	O
12	health	O	O
13	initiatives	O	O
14	targeted	O	O
15	at	O	O
16	people	O	O
17	who	O	O
18	smoke	O	O
19	crack	B-Chemical	O
20	cocaine	E-Chemical	E-Disease
21	.	O	O

0	Fluoxetine	S-Chemical	S-Chemical
1	improves	O	O
2	the	O	O
3	memory	B-Disease	O
4	deficits	E-Disease	O
5	caused	O	O
6	by	O	O
7	the	O	O
8	chemotherapy	O	O
9	agent	O	O
10	5	B-Chemical	S-Chemical
11	-	I-Chemical	I-Chemical
12	fluorouracil	E-Chemical	S-Chemical
13	.	O	O

0	Cancer	S-Disease	O
1	patients	O	O
2	who	O	O
3	have	O	O
4	been	O	O
5	treated	O	O
6	with	O	O
7	systemic	O	O
8	adjuvant	O	O
9	chemotherapy	O	O
10	have	O	O
11	described	O	O
12	experiencing	O	O
13	deteriorations	O	O
14	in	O	O
15	cognition	O	O
16	.	O	O

0	A	O	O
1	widely	O	O
2	used	O	O
3	chemotherapeutic	O	O
4	agent	O	O
5	,	O	O
6	5	B-Chemical	B-Chemical
7	-	I-Chemical	I-Chemical
8	fluorouracil	E-Chemical	S-Chemical
9	(	O	O
10	5	B-Chemical	O
11	-	I-Chemical	O
12	FU	E-Chemical	S-Disease
13	)	O	O
14	,	O	O
15	readily	O	O
16	crosses	O	O
17	the	O	O
18	blood	O	B-Disease
19	-	O	I-Disease
20	brain	O	I-Disease
21	barrier	O	E-Disease
22	and	O	O
23	so	O	O
24	could	O	O
25	have	O	O
26	a	O	O
27	direct	O	O
28	effect	O	O
29	on	O	O
30	brain	O	O
31	function	O	O
32	.	O	O

0	In	O	O
1	contrast	O	O
2	reports	O	O
3	indicate	O	O
4	that	O	O
5	hippocampal	O	S-Disease
6	dependent	O	O
7	neurogenesis	O	S-Disease
8	and	O	O
9	cognition	O	S-Disease
10	are	O	O
11	enhanced	O	O
12	by	O	O
13	the	O	O
14	SSRI	S-Chemical	S-Chemical
15	antidepressant	O	O
16	Fluoxetine	S-Chemical	S-Chemical
17	.	O	O

0	In	O	O
1	this	O	O
2	investigation	O	O
3	the	O	O
4	behavioural	O	O
5	effects	O	O
6	of	O	O
7	chronic	O	S-Disease
8	(	O	O
9	two	O	O
10	week	O	O
11	)	O	O
12	treatment	O	O
13	with	O	O
14	5	B-Chemical	O
15	-	I-Chemical	O
16	FU	E-Chemical	O
17	and	O	O
18	(	O	O
19	three	O	O
20	weeks	O	O
21	)	O	O
22	with	O	O
23	Fluoxetine	S-Chemical	S-Chemical
24	either	O	O
25	separately	O	O
26	or	O	O
27	in	O	O
28	combination	O	O
29	with	O	O
30	5	B-Chemical	O
31	-	I-Chemical	O
32	FU	E-Chemical	O
33	were	O	O
34	tested	O	O
35	on	O	O
36	adult	O	O
37	Lister	O	B-Disease
38	hooded	O	O
39	rats	O	O
40	.	O	O

0	Behavioural	O	O
1	effects	O	O
2	were	O	O
3	tested	O	O
4	using	O	O
5	a	O	O
6	context	O	O
7	dependent	O	O
8	conditioned	O	O
9	emotional	O	O
10	response	O	O
11	test	O	O
12	(	O	O
13	CER	O	S-Disease
14	)	O	O
15	which	O	O
16	showed	O	O
17	that	O	O
18	animals	O	O
19	treated	O	O
20	with	O	O
21	5	B-Chemical	O
22	-	I-Chemical	O
23	FU	E-Chemical	S-Disease
24	had	O	O
25	a	O	O
26	significant	O	O
27	reduction	O	O
28	in	O	O
29	freezing	O	O
30	time	O	O
31	compared	O	O
32	to	O	O
33	controls	O	O
34	.	O	O

0	Animals	O	O
1	treated	O	O
2	only	O	O
3	with	O	O
4	5	B-Chemical	O
5	-	I-Chemical	O
6	FU	E-Chemical	O
7	showed	O	O
8	significant	O	O
9	deficits	O	O
10	in	O	O
11	their	O	O
12	ability	O	O
13	to	O	O
14	carry	O	O
15	out	O	O
16	the	O	O
17	OLR	O	S-Chemical
18	task	O	O
19	but	O	O
20	co	O	O
21	administration	O	O
22	of	O	O
23	Fluoxetine	S-Chemical	S-Chemical
24	improved	O	O
25	their	O	O
26	performance	O	O
27	.	O	O

0	5	B-Chemical	O
1	-	I-Chemical	O
2	FU	E-Chemical	O
3	chemotherapy	O	O
4	caused	O	O
5	a	O	O
6	significant	O	O
7	reduction	O	O
8	in	O	O
9	the	O	O
10	number	O	O
11	of	O	O
12	proliferating	O	O
13	cells	O	O
14	in	O	O
15	the	O	O
16	sub	O	O
17	granular	O	O
18	zone	O	O
19	of	O	O
20	the	O	O
21	dentate	O	B-Disease
22	gyrus	O	S-Disease
23	compared	O	O
24	to	O	O
25	controls	O	O
26	.	O	O

0	This	O	O
1	reduction	O	O
2	was	O	O
3	eliminated	O	O
4	when	O	O
5	Fluoxetine	S-Chemical	S-Chemical
6	was	O	O
7	co	O	O
8	administered	O	O
9	with	O	O
10	5	B-Chemical	O
11	-	I-Chemical	O
12	FU	E-Chemical	O
13	.	O	O

0	Fluoxetine	S-Chemical	S-Chemical
1	on	O	O
2	its	O	O
3	own	O	O
4	had	O	O
5	no	O	O
6	effect	O	O
7	on	O	O
8	proliferating	O	O
9	cell	O	O
10	number	O	O
11	or	O	O
12	behaviour	O	O
13	.	O	O

0	These	O	O
1	findings	O	O
2	suggest	O	O
3	that	O	O
4	5	B-Chemical	S-Chemical
5	-	I-Chemical	O
6	FU	E-Chemical	E-Chemical
7	can	O	O
8	negatively	O	O
9	affect	O	O
10	both	O	O
11	cell	O	B-Disease
12	proliferation	O	E-Disease
13	and	O	O
14	hippocampal	O	B-Disease
15	dependent	O	O
16	working	O	O
17	memory	O	O
18	and	O	O
19	that	O	O
20	these	O	O
21	deficits	O	O
22	can	O	O
23	be	O	O
24	reversed	O	O
25	by	O	O
26	the	O	O
27	simultaneous	O	O
28	administration	O	O
29	of	O	O
30	the	O	O
31	antidepressant	O	O
32	Fluoxetine	S-Chemical	S-Chemical
33	.	O	O

0	Liver	O	O
1	-	O	O
2	specific	O	O
3	ablation	O	O
4	of	O	O
5	integrin	O	S-Disease
6	-	O	O
7	linked	O	O
8	kinase	O	S-Disease
9	in	O	O
10	mice	O	O
11	results	O	O
12	in	O	O
13	enhanced	O	O
14	and	O	O
15	prolonged	O	O
16	cell	O	O
17	proliferation	O	E-Disease
18	and	O	O
19	hepatomegaly	S-Disease	S-Disease
20	after	O	O
21	phenobarbital	S-Chemical	S-Disease
22	administration	O	O
23	.	O	O

0	This	O	O
1	study	O	O
2	investigates	O	O
3	the	O	O
4	role	O	O
5	of	O	O
6	ILK	O	S-Chemical
7	in	O	O
8	liver	O	O
9	enlargement	O	E-Disease
10	induced	O	O
11	by	O	O
12	phenobarbital	S-Chemical	S-Disease
13	(	O	O
14	PB	S-Chemical	S-Disease
15	)	O	O
16	.	O	O

0	Wild	O	O
1	-	O	O
2	type	O	O
3	(	O	O
4	WT	O	O
5	)	O	O
6	and	O	O
7	ILK	O	S-Chemical
8	:	O	O
9	liver	O	O
10	-	O	O
11	/	O	O
12	-	O	O
13	mice	O	O
14	were	O	O
15	given	O	O
16	PB	S-Chemical	O
17	(	O	O
18	0	O	O
19	.	O	O
20	1	O	O
21	%	O	O
22	in	O	O
23	drinking	O	O
24	water	O	O
25	)	O	O
26	for	O	O
27	10	O	O
28	days	O	O
29	.	O	O

0	Livers	O	O
1	were	O	O
2	harvested	O	O
3	on	O	O
4	2	O	O
5	,	O	O
6	5	O	O
7	,	O	O
8	and	O	O
9	10	O	O
10	days	O	O
11	during	O	O
12	PB	S-Chemical	S-Disease
13	administration	O	O
14	.	O	O

0	There	O	O
1	were	O	O
2	slightly	O	O
3	increased	O	O
4	proliferating	O	O
5	cell	O	O
6	nuclear	O	I-Disease
7	antigen	O	O
8	-	O	I-Disease
9	positive	O	O
10	cells	O	O
11	in	O	O
12	the	O	O
13	ILK	O	S-Chemical
14	/	O	O
15	liver	O	O
16	-	O	O
17	/	O	O
18	-	O	O
19	animals	O	O
20	at	O	O
21	day	O	O
22	2	O	O
23	as	O	O
24	compared	O	O
25	to	O	O
26	WT	O	B-Chemical
27	after	O	O
28	PB	S-Chemical	O
29	administration	O	O
30	.	O	O

0	ILK	O	S-Chemical
1	/	O	O
2	liver	O	O
3	-	O	O
4	/	O	E-Chemical
5	-	O	O
6	mice	O	O
7	also	O	O
8	showed	O	O
9	increased	O	O
10	expression	O	O
11	of	O	O
12	key	O	O
13	genes	O	O
14	involved	O	O
15	in	O	O
16	hepatocyte	O	S-Chemical
17	proliferation	O	S-Disease
18	at	O	O
19	different	O	O
20	time	O	O
21	points	O	O
22	during	O	O
23	PB	S-Chemical	O
24	administration	O	O
25	.	O	O

0	Lack	O	O
1	of	O	O
2	ILK	O	S-Chemical
3	in	O	O
4	the	O	O
5	hepatocytes	O	O
6	imparts	O	O
7	prolonged	O	O
8	proliferative	O	O
9	response	O	O
10	not	O	O
11	only	O	O
12	to	O	O
13	stimuli	O	O
14	related	O	O
15	to	O	O
16	liver	O	B-Disease
17	regeneration	O	E-Disease
18	but	O	O
19	also	O	O
20	to	O	O
21	xenobiotic	O	S-Chemical
22	chemical	O	O
23	mitogens	O	O
24	,	O	O
25	such	O	O
26	as	O	O
27	PB	S-Chemical	S-Chemical
28	.	O	O

0	Decreased	O	O
1	Expression	O	O
2	of	O	O
3	Na	S-Chemical	S-Chemical
4	/	O	O
5	K	S-Chemical	O
6	-	O	O
7	ATPase	O	O
8	,	O	O
9	NHE3	O	S-Chemical
10	,	O	O
11	NBC1	O	S-Chemical
12	,	O	O
13	AQP1	O	S-Chemical
14	and	O	O
15	OAT	O	S-Chemical
16	in	O	O
17	Gentamicin	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	Nephropathy	S-Disease	S-Disease
21	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	was	O	O
4	aimed	O	O
5	to	O	O
6	determine	O	O
7	whether	O	O
8	there	O	O
9	is	O	O
10	an	O	O
11	altered	O	O
12	regulation	O	O
13	of	O	O
14	tubular	O	B-Disease
15	transporters	O	E-Disease
16	in	O	O
17	gentamicin	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	nephropathy	S-Disease	S-Disease
21	.	O	O

0	Sprague	O	O
1	-	O	O
2	Dawley	O	O
3	male	O	O
4	rats	O	O
5	(	O	O
6	200	O	O
7	~	O	O
8	250	O	O
9	g	O	O
10	)	O	O
11	were	O	O
12	subcutaneously	O	O
13	injected	O	O
14	with	O	O
15	gentamicin	S-Chemical	S-Chemical
16	(	O	O
17	100	O	O
18	mg	O	O
19	/	O	O
20	kg	O	O
21	per	O	O
22	day	O	O
23	)	O	O
24	for	O	O
25	7	O	O
26	days	O	O
27	,	O	O
28	and	O	O
29	the	O	O
30	expression	O	O
31	of	O	O
32	tubular	O	S-Disease
33	transporters	O	O
34	was	O	O
35	determined	O	O
36	by	O	O
37	immunoblotting	O	O
38	and	O	O
39	immunohistochemistry	O	O
40	.	O	O

0	Gentamicin	S-Chemical	S-Chemical
1	-	O	O
2	treated	O	O
3	rats	O	O
4	exhibited	O	O
5	significantly	O	O
6	decreased	O	O
7	creatinine	S-Chemical	S-Chemical
8	clearance	O	S-Disease
9	along	O	O
10	with	O	O
11	increased	O	O
12	plasma	O	O
13	creatinine	S-Chemical	S-Chemical
14	levels	O	O
15	.	O	O

0	Accordingly	O	O
1	,	O	O
2	the	O	O
3	fractional	O	O
4	excretion	O	O
5	of	O	O
6	sodium	S-Chemical	S-Disease
7	increased	O	O
8	.	O	O

0	Immunoblotting	O	O
1	and	O	O
2	immunohistochemistry	O	S-Disease
3	revealed	O	O
4	decreased	O	O
5	expression	O	O
6	of	O	O
7	Na	S-Chemical	S-Chemical
8	(	O	O
9	+	O	O
10	)	O	O
11	/	O	O
12	K	S-Chemical	O
13	(	O	O
14	+	O	O
15	)	O	O
16	-	O	O
17	ATPase	O	O
18	,	O	O
19	NHE3	O	S-Chemical
20	,	O	O
21	NBC1	O	S-Chemical
22	,	O	O
23	and	O	O
24	AQP1	O	S-Chemical
25	in	O	O
26	the	O	O
27	kidney	O	O
28	of	O	O
29	gentamicin	S-Chemical	S-Chemical
30	-	O	O
31	treated	O	O
32	rats	O	O
33	.	O	O

0	Gentamicin	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	nephropathy	S-Disease	S-Disease
4	may	O	O
5	at	O	O
6	least	O	O
7	in	O	O
8	part	O	O
9	be	O	O
10	causally	O	O
11	related	O	O
12	with	O	O
13	a	O	O
14	decreased	O	O
15	expression	O	O
16	of	O	O
17	Na	S-Chemical	S-Chemical
18	(	O	O
19	+	O	O
20	)	O	O
21	/	O	O
22	K	S-Chemical	O
23	(	O	O
24	+	O	O
25	)	O	O
26	-	O	O
27	ATPase	O	O
28	,	O	O
29	NHE3	O	B-Chemical
30	,	O	O
31	NBC1	O	B-Chemical
32	,	O	O
33	AQP1	O	S-Chemical
34	and	O	O
35	OAT	O	S-Chemical
36	.	O	O

0	Acute	B-Disease	O
1	renal	I-Disease	B-Disease
2	failure	E-Disease	E-Disease
3	after	O	O
4	high	O	O
5	-	O	O
6	dose	O	O
7	methotrexate	S-Chemical	S-Chemical
8	therapy	O	O
9	in	O	O
10	a	O	O
11	patient	O	O
12	with	O	O
13	ileostomy	O	S-Disease
14	.	O	O

0	High	O	O
1	-	O	O
2	dose	O	O
3	methotrexate	S-Chemical	S-Chemical
4	(	O	O
5	HD	O	B-Disease
6	-	O	I-Disease
7	MTX	S-Chemical	E-Chemical
8	)	O	O
9	is	O	O
10	an	O	O
11	important	O	O
12	treatment	O	O
13	for	O	O
14	Burkitt	B-Disease	B-Disease
15	lymphoma	E-Disease	E-Disease
16	,	O	O
17	but	O	O
18	can	O	O
19	cause	O	O
20	hepatic	B-Disease	S-Disease
21	and	I-Disease	O
22	renal	I-Disease	B-Disease
23	toxicity	E-Disease	E-Disease
24	when	O	O
25	its	O	O
26	clearance	O	O
27	is	O	O
28	delayed	O	O
29	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	acute	B-Disease	B-Disease
6	renal	I-Disease	I-Disease
7	failure	E-Disease	E-Disease
8	after	O	O
9	HD	O	B-Chemical
10	-	O	I-Disease
11	MTX	S-Chemical	E-Chemical
12	therapy	O	O
13	in	O	O
14	a	O	O
15	patient	O	O
16	with	O	O
17	ileostomy	O	S-Disease
18	,	O	O
19	The	O	O
20	patient	O	O
21	was	O	O
22	a	O	O
23	3	O	O
24	-	O	O
25	year	O	O
26	-	O	O
27	old	O	O
28	boy	O	O
29	who	O	O
30	had	O	O
31	received	O	O
32	a	O	O
33	living	O	O
34	-	O	O
35	related	O	O
36	liver	O	O
37	transplantation	O	O
38	for	O	O
39	congenital	O	O
40	biliary	B-Disease	B-Disease
41	atresia	E-Disease	E-Disease
42	.	O	O

0	At	O	O
1	day	O	O
2	833	O	O
3	after	O	O
4	the	O	O
5	transplantation	O	O
6	,	O	O
7	he	O	O
8	was	O	O
9	diagnosed	O	O
10	with	O	O
11	PTLD	S-Disease	S-Disease
12	(	O	O
13	post	B-Disease	O
14	-	I-Disease	O
15	transplantation	I-Disease	O
16	lymphoproliferative	I-Disease	B-Disease
17	disorder	E-Disease	E-Disease
18	,	O	O
19	Burkitt	B-Disease	S-Chemical
20	-	I-Disease	O
21	type	I-Disease	O
22	malignant	I-Disease	B-Disease
23	lymphoma	E-Disease	E-Disease
24	)	O	O
25	.	O	O

0	Subsequent	O	O
1	HD	O	B-Chemical
2	-	O	I-Disease
3	MTX	S-Chemical	E-Chemical
4	therapy	O	O
5	caused	O	O
6	acute	B-Disease	B-Disease
7	renal	I-Disease	I-Disease
8	failure	E-Disease	E-Disease
9	that	O	O
10	required	O	O
11	continuous	O	O
12	hemodialysis	O	O
13	.	O	O

0	We	O	O
1	supposed	O	O
2	that	O	O
3	intravascular	O	O
4	hypovolemia	S-Disease	S-Disease
5	due	O	O
6	to	O	O
7	substantial	O	O
8	drainage	O	O
9	from	O	O
10	the	O	O
11	ileostoma	O	S-Disease
12	caused	O	O
13	acute	B-Disease	B-Disease
14	prerenal	I-Disease	I-Disease
15	failure	E-Disease	E-Disease
16	.	O	O

0	After	O	O
1	recovery	O	O
2	of	O	O
3	his	O	O
4	renal	O	B-Disease
5	function	O	E-Disease
6	,	O	O
7	we	O	O
8	could	O	O
9	safely	O	O
10	treat	O	O
11	the	O	O
12	patient	O	O
13	with	O	O
14	HD	O	B-Disease
15	-	O	I-Disease
16	MTX	S-Chemical	E-Disease
17	therapy	O	O
18	by	O	O
19	controlling	O	O
20	drainage	O	O
21	from	O	O
22	ileostoma	O	S-Disease
23	with	O	O
24	total	O	O
25	parenteral	O	O
26	nutrition	O	O
27	.	O	O

0	Longitudinal	O	O
1	association	O	O
2	of	O	O
3	alcohol	S-Chemical	S-Disease
4	use	O	O
5	with	O	O
6	HIV	B-Disease	B-Disease
7	disease	E-Disease	E-Disease
8	progression	O	O
9	and	O	O
10	psychological	O	O
11	health	O	O
12	of	O	O
13	women	O	O
14	with	O	O
15	HIV	O	S-Disease
16	.	O	O

0	We	O	O
1	evaluated	O	O
2	the	O	O
3	association	O	O
4	of	O	O
5	alcohol	S-Chemical	S-Disease
6	consumption	O	O
7	and	O	O
8	depression	S-Disease	S-Disease
9	,	O	O
10	and	O	O
11	their	O	O
12	effects	O	O
13	on	O	O
14	HIV	B-Disease	B-Disease
15	disease	E-Disease	E-Disease
16	progression	O	E-Disease
17	among	O	O
18	women	O	O
19	with	O	O
20	HIV	O	S-Disease
21	.	O	O

0	The	O	O
1	participants	O	O
2	had	O	O
3	physical	O	O
4	examination	O	O
5	,	O	O
6	medical	O	O
7	record	O	O
8	extraction	O	O
9	,	O	O
10	and	O	O
11	venipuncture	O	O
12	,	O	O
13	CD4	O	B-Disease
14	+	O	O
15	T	O	O
16	-	O	O
17	cell	O	O
18	counts	O	O
19	determination	O	O
20	,	O	O
21	measurement	O	O
22	of	O	O
23	depression	S-Disease	S-Disease
24	symptoms	O	O
25	(	O	O
26	using	O	O
27	the	O	O
28	self	O	O
29	-	O	O
30	report	O	O
31	Center	O	O
32	for	O	O
33	Epidemiological	O	O
34	Studies	O	O
35	-	O	O
36	Depression	S-Disease	S-Disease
37	Scale	O	O
38	)	O	O
39	,	O	O
40	and	O	O
41	alcohol	S-Chemical	O
42	use	O	O
43	assessment	O	O
44	at	O	O
45	enrollment	O	O
46	,	O	O
47	and	O	O
48	semiannually	O	O
49	until	O	O
50	March	O	O
51	2000	O	O
52	.	O	O

0	There	O	O
1	was	O	O
2	no	O	O
3	significant	O	O
4	association	O	O
5	between	O	O
6	level	O	O
7	of	O	O
8	alcohol	S-Chemical	S-Disease
9	use	O	O
10	and	O	O
11	CD4	O	B-Disease
12	+	O	O
13	T	O	O
14	-	O	O
15	cell	O	O
16	counts	O	O
17	.	O	O

0	When	O	O
1	participants	O	O
2	were	O	O
3	stratified	O	O
4	by	O	O
5	antiretroviral	O	O
6	therapy	O	O
7	(	O	O
8	ART	O	O
9	)	O	O
10	use	O	O
11	,	O	O
12	the	O	O
13	association	O	O
14	between	O	O
15	alcohol	S-Chemical	S-Disease
16	and	O	O
17	CD4	O	B-Disease
18	+	O	I-Disease
19	T	O	I-Disease
20	-	O	I-Disease
21	cell	O	E-Disease
22	did	O	O
23	not	O	O
24	reach	O	O
25	statistical	O	O
26	significance	O	O
27	.	O	O

0	The	O	O
1	association	O	O
2	between	O	O
3	alcohol	S-Chemical	S-Disease
4	consumption	O	O
5	and	O	O
6	depression	S-Disease	S-Disease
7	was	O	O
8	significant	O	O
9	(	O	O
10	p	O	O
11	<	O	O
12	0	O	O
13	.	O	O
14	001	O	O
15	)	O	O
16	.	O	O

0	Depression	S-Disease	S-Disease
1	had	O	O
2	a	O	O
3	significant	O	O
4	negative	O	O
5	effect	O	O
6	on	O	O
7	CD4	O	B-Disease
8	+	O	I-Disease
9	T	O	I-Disease
10	-	O	I-Disease
11	cell	O	O
12	counts	O	O
13	over	O	O
14	time	O	O
15	regardless	O	O
16	of	O	O
17	ART	O	O
18	use	O	O
19	.	O	O

0	Our	O	O
1	findings	O	O
2	suggest	O	O
3	that	O	O
4	alcohol	S-Chemical	S-Chemical
5	consumption	O	O
6	has	O	O
7	a	O	O
8	direct	O	O
9	association	O	O
10	with	O	O
11	depression	S-Disease	S-Disease
12	.	O	O

0	Moreover	O	O
1	,	O	O
2	depression	S-Disease	S-Disease
3	is	O	O
4	associated	O	O
5	with	O	O
6	HIV	B-Disease	B-Disease
7	disease	E-Disease	E-Disease
8	progression	O	O
9	.	O	O

0	Our	O	O
1	findings	O	O
2	have	O	O
3	implications	O	O
4	for	O	O
5	the	O	O
6	provision	O	O
7	of	O	O
8	alcohol	S-Chemical	O
9	use	O	O
10	interventions	O	O
11	and	O	O
12	psychological	O	O
13	resources	O	O
14	to	O	O
15	improve	O	O
16	the	O	O
17	health	O	O
18	of	O	O
19	women	O	O
20	with	O	O
21	HIV	O	S-Chemical
22	.	O	O

0	Chemokine	O	O
1	CCL2	O	S-Disease
2	and	O	O
3	its	O	O
4	receptor	O	O
5	CCR2	O	S-Disease
6	are	O	O
7	increased	O	O
8	in	O	O
9	the	O	O
10	hippocampus	O	S-Disease
11	following	O	O
12	pilocarpine	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	status	B-Disease	B-Disease
16	epilepticus	E-Disease	E-Disease
17	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Neuroinflammation	S-Disease	S-Disease
3	occurs	O	O
4	after	O	O
5	seizures	S-Disease	S-Disease
6	and	O	O
7	is	O	O
8	implicated	O	O
9	in	O	O
10	epileptogenesis	O	O
11	.	O	O

0	CCR2	O	S-Chemical
1	is	O	O
2	a	O	O
3	chemokine	O	O
4	receptor	O	O
5	for	O	O
6	CCL2	O	S-Chemical
7	and	O	O
8	their	O	O
9	interaction	O	O
10	mediates	O	O
11	monocyte	O	B-Disease
12	infiltration	O	O
13	in	O	O
14	the	O	O
15	neuroinflammatory	S-Disease	O
16	cascade	O	O
17	triggered	O	O
18	in	O	O
19	different	O	O
20	brain	O	O
21	pathologies	O	O
22	.	O	O

0	In	O	O
1	this	O	O
2	work	O	O
3	CCR2	O	S-Disease
4	and	O	O
5	CCL2	O	S-Disease
6	expression	O	O
7	were	O	O
8	examined	O	O
9	following	O	O
10	status	B-Disease	O
11	epilepticus	E-Disease	S-Disease
12	(	O	O
13	SE	S-Disease	O
14	)	O	O
15	induced	O	O
16	by	O	O
17	pilocarpine	S-Chemical	S-Chemical
18	injection	O	O
19	.	O	O

0	METHODS	O	O
1	:	O	O
2	SE	S-Disease	O
3	was	O	O
4	induced	O	O
5	by	O	O
6	pilocarpine	S-Chemical	S-Chemical
7	injection	O	O
8	.	O	O

0	Control	O	O
1	rats	O	O
2	were	O	O
3	injected	O	O
4	with	O	O
5	saline	O	S-Chemical
6	instead	O	O
7	of	O	O
8	pilocarpine	S-Chemical	S-Chemical
9	.	O	O

0	Five	O	O
1	days	O	O
2	after	O	O
3	SE	S-Disease	O
4	,	O	O
5	CCR2	O	O
6	staining	O	O
7	in	O	O
8	neurons	O	O
9	and	O	O
10	glial	O	O
11	cells	O	O
12	was	O	O
13	examined	O	O
14	using	O	O
15	imunohistochemical	O	S-Disease
16	analyses	O	O
17	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Increased	O	O
3	CCR2	O	S-Disease
4	was	O	O
5	observed	O	O
6	in	O	O
7	the	O	O
8	hippocampus	O	S-Disease
9	after	O	O
10	SE	S-Disease	S-Disease
11	.	O	O

0	Seizures	S-Disease	O
1	also	O	O
2	resulted	O	O
3	in	O	O
4	alterations	O	O
5	to	O	O
6	the	O	O
7	cell	O	O
8	types	O	O
9	expressing	O	O
10	CCR2	O	S-Disease
11	.	O	O

0	Increased	O	O
1	numbers	O	O
2	of	O	O
3	neurons	O	O
4	that	O	O
5	expressed	O	O
6	CCR2	O	S-Disease
7	was	O	O
8	observed	O	O
9	following	O	O
10	SE	S-Disease	S-Disease
11	.	O	O

0	Microglial	O	O
1	cells	O	O
2	were	O	O
3	more	O	O
4	closely	O	O
5	apposed	O	O
6	to	O	O
7	the	O	O
8	CCR2	O	O
9	-	O	O
10	labeled	O	O
11	cells	O	O
12	in	O	O
13	SE	S-Disease	O
14	rats	O	O
15	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	rats	O	O
4	that	O	O
5	experienced	O	O
6	SE	S-Disease	O
7	exhibited	O	O
8	CCR2	O	O
9	-	O	O
10	labeling	O	O
11	in	O	O
12	populations	O	O
13	of	O	O
14	hypertrophied	S-Disease	S-Disease
15	astrocytes	O	S-Disease
16	,	O	O
17	especially	O	O
18	in	O	O
19	CA1	O	S-Chemical
20	and	O	O
21	dentate	O	S-Disease
22	gyrus	O	S-Disease
23	.	O	O

0	Examination	O	O
1	of	O	O
2	CCL2	O	O
3	expression	O	O
4	showed	O	O
5	that	O	O
6	it	O	O
7	was	O	O
8	elevated	O	O
9	in	O	O
10	the	O	O
11	hippocampus	O	S-Disease
12	following	O	O
13	SE	S-Disease	S-Disease
14	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	The	O	O
3	data	O	O
4	show	O	O
5	that	O	O
6	CCR2	O	S-Disease
7	and	O	O
8	CCL2	O	S-Chemical
9	are	O	O
10	up	O	O
11	-	O	O
12	regulated	O	O
13	in	O	O
14	the	O	O
15	hippocampus	O	S-Disease
16	after	O	O
17	pilocarpine	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	SE	S-Disease	S-Disease
21	.	O	O

0	Seizures	S-Disease	O
1	also	O	O
2	result	O	O
3	in	O	O
4	changes	O	O
5	to	O	O
6	CCR2	O	B-Disease
7	receptor	O	O
8	expression	O	O
9	in	O	O
10	neurons	O	O
11	and	O	O
12	astrocytes	O	S-Disease
13	.	O	O

0	These	O	O
1	changes	O	O
2	might	O	O
3	be	O	O
4	involved	O	O
5	in	O	O
6	detrimental	O	O
7	neuroplasticity	O	O
8	and	O	O
9	neuroinflammatory	S-Disease	O
10	changes	O	O
11	that	O	O
12	occur	O	O
13	following	O	O
14	seizures	S-Disease	S-Disease
15	.	O	O

0	Metallothionein	S-Chemical	S-Chemical
1	induction	O	O
2	reduces	O	O
3	caspase	O	S-Disease
4	-	O	O
5	3	O	O
6	activity	O	O
7	and	O	O
8	TNFalpha	O	S-Disease
9	levels	O	O
10	with	O	O
11	preservation	O	O
12	of	O	O
13	cognitive	O	B-Disease
14	function	O	E-Disease
15	and	O	O
16	intact	O	O
17	hippocampal	O	B-Disease
18	neurons	O	E-Disease
19	in	O	O
20	carmustine	S-Chemical	S-Chemical
21	-	O	O
22	treated	O	O
23	rats	O	O
24	.	O	O

0	On	O	O
1	the	O	O
2	other	O	O
3	hand	O	O
4	,	O	O
5	induction	O	O
6	of	O	O
7	metallothionein	S-Chemical	S-Chemical
8	(	O	O
9	MT	S-Chemical	S-Disease
10	)	O	O
11	by	O	O
12	ZnSO	B-Chemical	S-Chemical
13	(	I-Chemical	O
14	4	I-Chemical	O
15	)	E-Chemical	O
16	and	O	O
17	its	O	O
18	role	O	O
19	in	O	O
20	neuroprotection	O	S-Disease
21	has	O	O
22	been	O	O
23	documented	O	O
24	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	aimed	O	O
4	to	O	O
5	explore	O	O
6	the	O	O
7	effect	O	O
8	of	O	O
9	MT	S-Chemical	B-Disease
10	induction	O	O
11	on	O	O
12	carmustine	S-Chemical	S-Chemical
13	(	O	O
14	BCNU	S-Chemical	S-Chemical
15	)	O	O
16	-	O	O
17	induced	O	O
18	hippocampal	O	B-Disease
19	cognitive	B-Disease	I-Disease
20	dysfunction	E-Disease	E-Disease
21	in	O	O
22	rats	O	O
23	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	60	O	O
4	male	O	O
5	Wistar	O	O
6	albino	O	O
7	rats	O	O
8	were	O	O
9	randomly	O	O
10	divided	O	O
11	into	O	O
12	four	O	O
13	groups	O	O
14	(	O	O
15	15	O	O
16	/	O	O
17	group	O	O
18	)	O	O
19	:	O	O
20	The	O	O
21	control	O	O
22	group	O	O
23	injected	O	O
24	with	O	O
25	single	O	O
26	doses	O	O
27	of	O	O
28	normal	O	O
29	saline	O	S-Chemical
30	(	O	O
31	i	O	O
32	.	O	O
33	c	O	O
34	.	O	O
35	v	O	O
36	)	O	O
37	followed	O	O
38	24	O	O
39	h	O	O
40	later	O	O
41	by	O	O
42	BCNU	S-Chemical	S-Chemical
43	solvent	O	O
44	(	O	O
45	i	O	O
46	.	O	O
47	v	O	O
48	)	O	O
49	.	O	O

0	The	O	O
1	second	O	O
2	group	O	O
3	administered	O	O
4	ZnSO	B-Chemical	S-Chemical
5	(	I-Chemical	O
6	4	I-Chemical	O
7	)	E-Chemical	O
8	(	O	O
9	0	O	O
10	.	O	O
11	1	O	O
12	micromol	O	O
13	/	O	O
14	10	O	O
15	microl	O	O
16	normal	O	O
17	saline	O	O
18	,	O	O
19	i	O	O
20	.	O	O
21	c	O	O
22	.	O	O
23	v	O	O
24	,	O	O
25	once	O	O
26	)	O	O
27	then	O	O
28	BCNU	S-Chemical	S-Chemical
29	solvent	O	O
30	(	O	O
31	i	O	O
32	.	O	O
33	v	O	O
34	)	O	O
35	after	O	O
36	24	O	O
37	h	O	O
38	.	O	O

0	Third	O	O
1	group	O	O
2	received	O	O
3	BCNU	S-Chemical	S-Chemical
4	(	O	O
5	20	O	O
6	mg	O	O
7	/	O	O
8	kg	O	O
9	,	O	O
10	i	O	O
11	.	O	O
12	v	O	O
13	,	O	O
14	once	O	O
15	)	O	O
16	24	O	O
17	h	O	O
18	after	O	O
19	injection	O	O
20	with	O	O
21	normal	O	O
22	saline	O	S-Disease
23	(	O	O
24	i	O	O
25	.	O	O
26	c	O	O
27	.	O	O
28	v	O	O
29	)	O	O
30	.	O	O

0	Fourth	O	O
1	group	O	O
2	received	O	O
3	a	O	O
4	single	O	O
5	dose	O	O
6	of	O	O
7	ZnSO	B-Chemical	S-Chemical
8	(	I-Chemical	O
9	4	I-Chemical	O
10	)	E-Chemical	O
11	(	O	O
12	0	O	O
13	.	O	O
14	1	O	O
15	micromol	O	O
16	/	O	O
17	10	O	O
18	microl	O	O
19	normal	O	O
20	saline	O	O
21	,	O	O
22	i	O	O
23	.	O	O
24	c	O	O
25	.	O	O
26	v	O	O
27	)	O	O
28	then	O	O
29	BCNU	S-Chemical	S-Chemical
30	(	O	O
31	20	O	O
32	mg	O	O
33	/	O	O
34	kg	O	O
35	,	O	O
36	i	O	O
37	.	O	O
38	v	O	O
39	,	O	O
40	once	O	O
41	)	O	O
42	after	O	O
43	24	O	O
44	h	O	O
45	.	O	O

0	The	O	O
1	obtained	O	O
2	data	O	O
3	revealed	O	O
4	that	O	O
5	BCNU	S-Chemical	S-Chemical
6	administration	O	O
7	resulted	O	O
8	in	O	O
9	deterioration	B-Disease	O
10	of	I-Disease	O
11	learning	I-Disease	O
12	and	I-Disease	O
13	short	I-Disease	O
14	-	I-Disease	O
15	term	I-Disease	O
16	memory	E-Disease	O
17	(	O	O
18	STM	O	S-Disease
19	)	O	O
20	,	O	O
21	as	O	O
22	measured	O	O
23	by	O	O
24	using	O	O
25	radial	O	O
26	arm	O	O
27	water	O	O
28	maze	O	O
29	,	O	O
30	accompanied	O	O
31	with	O	O
32	decreased	O	O
33	hippocampal	O	B-Disease
34	glutathione	S-Chemical	E-Chemical
35	reductase	O	O
36	(	O	O
37	GR	O	S-Chemical
38	)	O	O
39	activity	O	O
40	and	O	O
41	reduced	O	O
42	glutathione	S-Chemical	S-Chemical
43	(	O	O
44	GSH	S-Chemical	S-Chemical
45	)	O	O
46	content	O	O
47	.	O	O

0	Also	O	O
1	,	O	O
2	BCNU	S-Chemical	S-Chemical
3	administration	O	O
4	increased	O	O
5	serum	O	O
6	tumor	S-Disease	B-Disease
7	necrosis	S-Disease	I-Disease
8	factor	O	E-Disease
9	-	O	O
10	alpha	O	O
11	(	O	O
12	TNFalpha	O	S-Disease
13	)	O	O
14	,	O	O
15	hippocampal	O	S-Disease
16	MT	S-Chemical	S-Disease
17	and	O	O
18	malondialdehyde	S-Chemical	S-Disease
19	(	O	O
20	MDA	S-Chemical	S-Chemical
21	)	O	O
22	contents	O	O
23	as	O	O
24	well	O	O
25	as	O	O
26	caspase	O	S-Disease
27	-	O	O
28	3	O	O
29	activity	O	O
30	in	O	O
31	addition	O	O
32	to	O	O
33	histological	O	O
34	alterations	O	O
35	.	O	O

0	ZnSO	B-Chemical	S-Chemical
1	(	I-Chemical	O
2	4	I-Chemical	O
3	)	E-Chemical	O
4	pretreatment	O	O
5	counteracted	O	O
6	BCNU	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	inhibition	O	O
10	of	O	O
11	GR	O	S-Chemical
12	and	O	O
13	depletion	O	O
14	of	O	O
15	GSH	S-Chemical	S-Chemical
16	and	O	O
17	resulted	O	O
18	in	O	O
19	significant	O	O
20	reduction	O	O
21	in	O	O
22	the	O	O
23	levels	O	O
24	of	O	O
25	MDA	S-Chemical	S-Chemical
26	and	O	O
27	TNFalpha	O	S-Disease
28	as	O	O
29	well	O	O
30	as	O	O
31	the	O	O
32	activity	O	O
33	of	O	O
34	caspase	O	S-Chemical
35	-	O	O
36	3	O	O
37	.	O	O

0	The	O	O
1	histological	O	O
2	features	O	O
3	were	O	O
4	improved	O	O
5	in	O	O
6	hippocampus	O	S-Disease
7	of	O	O
8	rats	O	O
9	treated	O	O
10	with	O	O
11	ZnSO	B-Chemical	S-Chemical
12	(	I-Chemical	O
13	4	I-Chemical	O
14	)	E-Chemical	O
15	+	O	O
16	BCNU	S-Chemical	S-Disease
17	compared	O	O
18	to	O	O
19	only	O	O
20	BCNU	S-Chemical	S-Chemical
21	-	O	O
22	treated	O	O
23	animals	O	O
24	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	MT	S-Chemical	O
4	induction	O	O
5	halts	O	O
6	BCNU	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	hippocampal	O	B-Disease
10	toxicity	S-Disease	E-Disease
11	as	O	O
12	it	O	O
13	prevented	O	O
14	GR	O	S-Chemical
15	inhibition	O	O
16	and	O	O
17	GSH	S-Chemical	S-Chemical
18	depletion	O	O
19	and	O	O
20	counteracted	O	O
21	the	O	O
22	increased	O	O
23	levels	O	O
24	of	O	O
25	TNFalpha	O	S-Disease
26	,	O	O
27	MDA	S-Chemical	S-Chemical
28	and	O	O
29	caspase	O	S-Disease
30	-	O	O
31	3	O	O
32	activity	O	O
33	with	O	O
34	subsequent	O	O
35	preservation	O	O
36	of	O	O
37	cognition	O	O
38	.	O	O

0	Fatal	O	O
1	carbamazepine	S-Chemical	S-Chemical
2	induced	O	O
3	fulminant	B-Disease	O
4	eosinophilic	E-Disease	S-Disease
5	(	O	O
6	hypersensitivity	S-Disease	S-Disease
7	)	O	O
8	myocarditis	S-Disease	B-Disease
9	:	O	O
10	emphasis	O	O
11	on	O	O
12	anatomical	O	O
13	and	O	O
14	histological	O	O
15	characteristics	O	O
16	,	O	O
17	mechanisms	O	O
18	and	O	O
19	genetics	O	O
20	of	O	O
21	drug	B-Disease	O
22	hypersensitivity	E-Disease	S-Disease
23	and	O	O
24	differential	O	O
25	diagnosis	O	O
26	.	O	O

0	The	O	O
1	most	O	O
2	severe	O	O
3	adverse	O	O
4	reactions	O	O
5	to	O	O
6	carbamazepine	S-Chemical	S-Chemical
7	have	O	O
8	been	O	O
9	observed	O	O
10	in	O	O
11	the	O	O
12	haemopoietic	O	O
13	system	O	O
14	,	O	O
15	the	O	O
16	liver	O	O
17	and	O	O
18	the	O	O
19	cardiovascular	O	O
20	system	O	O
21	.	O	O

0	A	O	O
1	frequently	O	O
2	fatal	O	O
3	,	O	O
4	although	O	O
5	exceptionally	O	O
6	rare	O	O
7	side	O	O
8	effect	O	O
9	of	O	O
10	carbamazepine	S-Chemical	S-Chemical
11	is	O	O
12	necrotizing	O	O
13	eosinophilic	O	S-Disease
14	(	O	O
15	hypersensitivity	S-Disease	S-Disease
16	)	O	O
17	myocarditis	S-Disease	S-Disease
18	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	hypersensitivity	S-Disease	S-Disease
6	myocarditis	S-Disease	S-Disease
7	secondary	O	O
8	to	O	O
9	administration	O	O
10	of	O	O
11	carbamazepine	S-Chemical	S-Chemical
12	.	O	O

0	Acute	O	O
1	hypersensitivity	S-Disease	S-Disease
2	myocarditis	S-Disease	S-Disease
3	was	O	O
4	not	O	O
5	suspected	O	O
6	clinically	O	O
7	,	O	O
8	and	O	O
9	the	O	O
10	diagnosis	O	O
11	was	O	O
12	made	O	O
13	post	O	O
14	-	O	O
15	mortem	O	O
16	.	O	O

0	Clinically	O	O
1	,	O	O
2	death	O	O
3	was	O	O
4	due	O	O
5	to	O	O
6	cardiogenic	B-Disease	B-Disease
7	shock	E-Disease	E-Disease
8	.	O	O

0	To	O	O
1	best	O	O
2	of	O	O
3	our	O	O
4	knowledge	O	O
5	this	O	O
6	is	O	O
7	the	O	O
8	second	O	O
9	case	O	O
10	of	O	O
11	fatal	O	O
12	carbamazepine	S-Chemical	S-Chemical
13	induced	O	O
14	myocarditis	S-Disease	S-Disease
15	reported	O	O
16	in	O	O
17	English	O	O
18	literature	O	O
19	.	O	O

0	Neuropsychiatric	O	O
1	behaviors	O	O
2	in	O	O
3	the	O	O
4	MPTP	S-Chemical	S-Chemical
5	marmoset	O	O
6	model	O	O
7	of	O	O
8	Parkinson	B-Disease	B-Disease
9	'	I-Disease	I-Disease
10	s	I-Disease	I-Disease
11	disease	E-Disease	E-Disease
12	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	Neuropsychiatric	O	S-Disease
3	symptoms	O	O
4	are	O	O
5	increasingly	O	O
6	recognised	O	O
7	as	O	O
8	a	O	O
9	significant	O	O
10	problem	O	O
11	in	O	O
12	patients	O	O
13	with	O	O
14	Parkinson	B-Disease	B-Disease
15	'	I-Disease	I-Disease
16	s	I-Disease	I-Disease
17	disease	E-Disease	E-Disease
18	(	O	O
19	PD	S-Disease	S-Disease
20	)	O	O
21	.	O	O

0	These	O	O
1	symptoms	O	O
2	may	O	O
3	be	O	O
4	due	O	O
5	to	O	O
6	'	O	O
7	sensitisation	O	O
8	'	O	O
9	following	O	O
10	repeated	O	O
11	levodopa	S-Chemical	S-Chemical
12	treatment	O	O
13	or	O	O
14	a	O	O
15	direct	O	O
16	effect	O	O
17	of	O	O
18	dopamine	S-Chemical	S-Chemical
19	on	O	O
20	the	O	O
21	disease	O	S-Disease
22	state	O	O
23	.	O	O

0	The	O	O
1	levodopa	S-Chemical	S-Chemical
2	-	O	O
3	treated	O	O
4	MPTP	S-Chemical	S-Chemical
5	-	O	O
6	lesioned	O	O
7	marmoset	O	S-Disease
8	was	O	O
9	used	O	O
10	as	O	O
11	a	O	O
12	model	O	O
13	of	O	O
14	neuropsychiatric	B-Disease	O
15	symptoms	E-Disease	O
16	in	O	O
17	PD	S-Disease	S-Disease
18	patients	O	O
19	.	O	O

0	Here	O	O
1	we	O	O
2	compare	O	O
3	the	O	O
4	time	O	O
5	course	O	O
6	of	O	O
7	levodopa	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	motor	O	O
11	fluctuations	O	O
12	and	O	O
13	neuropsychiatric	B-Disease	O
14	-	I-Disease	O
15	like	I-Disease	O
16	behaviors	E-Disease	O
17	to	O	O
18	determine	O	O
19	the	O	O
20	relationship	O	O
21	between	O	O
22	duration	O	O
23	of	O	O
24	treatment	O	O
25	and	O	O
26	onset	O	O
27	of	O	O
28	symptoms	O	O
29	.	O	O

0	METHODS	O	O
1	:	O	O
2	Marmosets	O	S-Chemical
3	were	O	O
4	administered	O	O
5	1	B-Chemical	B-Chemical
6	-	I-Chemical	I-Chemical
7	methyl	I-Chemical	B-Chemical
8	-	I-Chemical	I-Chemical
9	4	I-Chemical	I-Chemical
10	-	I-Chemical	I-Chemical
11	phenyl	I-Chemical	E-Chemical
12	-	I-Chemical	E-Chemical
13	1	I-Chemical	O
14	,	I-Chemical	O
15	2	I-Chemical	O
16	,	I-Chemical	O
17	3	I-Chemical	O
18	,	I-Chemical	O
19	6	I-Chemical	O
20	-	I-Chemical	I-Chemical
21	tetrahydropyridine	E-Chemical	E-Chemical
22	(	O	O
23	2	O	O
24	.	O	O
25	0	O	O
26	mg	O	O
27	/	O	O
28	kg	O	O
29	s	O	O
30	.	O	O
31	c	O	O
32	.	O	O
33	)	O	O
34	for	O	O
35	five	O	O
36	days	O	O
37	,	O	O
38	resulting	O	O
39	in	O	O
40	stable	O	O
41	parkinsonism	S-Disease	S-Disease
42	.	O	O

0	Levodopa	S-Chemical	S-Chemical
1	(	O	O
2	15	O	O
3	mg	O	O
4	/	O	O
5	kg	O	O
6	and	O	O
7	benserazide	S-Chemical	S-Chemical
8	,	O	O
9	3	O	O
10	.	O	O
11	75	O	O
12	mg	O	O
13	/	O	O
14	kg	O	O
15	)	O	O
16	p	O	O
17	.	O	O
18	o	O	O
19	.	O	O

0	Animals	O	O
1	were	O	O
2	evaluated	O	O
3	for	O	O
4	parkinsonian	B-Disease	S-Disease
5	disability	E-Disease	E-Disease
6	,	O	O
7	dyskinesia	S-Disease	S-Disease
8	and	O	O
9	on	O	O
10	-	O	O
11	time	O	O
12	(	O	O
13	motor	O	B-Disease
14	fluctuations	O	E-Disease
15	)	O	O
16	and	O	O
17	neuropsychiatric	B-Disease	O
18	-	I-Disease	O
19	like	I-Disease	O
20	behaviors	E-Disease	O
21	on	O	O
22	Day	O	B-Disease
23	0	O	E-Disease
24	(	O	O
25	prior	O	O
26	to	O	O
27	levodopa	S-Chemical	S-Chemical
28	)	O	O
29	and	O	O
30	on	O	O
31	Days	O	O
32	1	O	O
33	,	O	O
34	7	O	O
35	,	O	O
36	13	O	O
37	,	O	O
38	27	O	O
39	and	O	O
40	30	O	O
41	of	O	O
42	treatment	O	O
43	using	O	O
44	post	O	O
45	hoc	O	O
46	DVD	O	O
47	analysis	O	O
48	by	O	O
49	a	O	O
50	trained	O	O
51	rater	O	O
52	,	O	O
53	blind	O	O
54	to	O	O
55	the	O	O
56	treatment	O	O
57	day	O	O
58	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	neuropsychiatric	B-Disease	O
4	-	I-Disease	O
5	like	I-Disease	O
6	behavior	E-Disease	O
7	rating	O	O
8	scale	O	O
9	demonstrated	O	O
10	high	O	O
11	interrater	O	O
12	reliability	O	O
13	between	O	O
14	three	O	O
15	trained	O	O
16	raters	O	O
17	of	O	O
18	differing	O	O
19	professional	O	O
20	backgrounds	O	O
21	.	O	O

0	As	O	O
1	anticipated	O	O
2	,	O	O
3	animals	O	O
4	exhibited	O	O
5	a	O	O
6	progressive	O	O
7	increase	O	S-Disease
8	in	O	O
9	levodopa	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	motor	O	B-Disease
13	fluctuations	O	E-Disease
14	,	O	O
15	dyskinesia	S-Disease	S-Disease
16	and	O	O
17	wearing	O	O
18	-	O	O
19	off	O	O
20	,	O	O
21	that	O	O
22	correlated	O	O
23	with	O	O
24	the	O	O
25	duration	O	O
26	of	O	O
27	levodopa	S-Chemical	S-Chemical
28	therapy	O	O
29	.	O	O

0	In	O	O
1	contrast	O	O
2	,	O	O
3	levodopa	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	neuropsychiatric	B-Disease	O
7	-	I-Disease	O
8	like	I-Disease	O
9	behaviors	E-Disease	O
10	were	O	O
11	present	O	O
12	on	O	O
13	Day	O	O
14	1	O	O
15	of	O	O
16	levodopa	S-Chemical	S-Chemical
17	treatment	O	O
18	and	O	O
19	their	O	O
20	severity	O	O
21	did	O	O
22	not	O	O
23	correlate	O	O
24	with	O	O
25	duration	O	O
26	of	O	O
27	treatment	O	O
28	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	data	O	O
4	suggest	O	O
5	that	O	O
6	neuropsychiatric	B-Disease	B-Disease
7	disorders	E-Disease	E-Disease
8	in	O	O
9	PD	S-Disease	S-Disease
10	are	O	O
11	more	O	O
12	likely	O	O
13	an	O	O
14	interaction	O	O
15	between	O	O
16	levodopa	S-Chemical	S-Chemical
17	and	O	O
18	the	O	O
19	disease	O	S-Disease
20	state	O	O
21	than	O	O
22	a	O	O
23	consequence	O	O
24	of	O	O
25	sensitisation	O	O
26	to	O	O
27	repeated	O	O
28	dopaminergic	O	O
29	therapy	O	O
30	.	O	O

0	Contrast	B-Chemical	O
1	medium	E-Chemical	O
2	nephrotoxicity	S-Disease	S-Disease
3	after	O	O
4	renal	O	B-Disease
5	artery	O	E-Disease
6	and	O	O
7	coronary	O	B-Disease
8	angioplasty	O	E-Disease
9	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Renal	B-Disease	B-Disease
3	dysfunction	E-Disease	E-Disease
4	induced	O	O
5	by	O	O
6	iodinated	O	S-Chemical
7	contrast	B-Chemical	O
8	medium	E-Chemical	O
9	(	O	O
10	CM	S-Chemical	S-Chemical
11	)	O	O
12	administration	O	O
13	can	O	O
14	minimize	O	O
15	the	O	O
16	benefit	O	O
17	of	O	O
18	the	O	O
19	interventional	O	O
20	procedure	O	O
21	in	O	O
22	patients	O	O
23	undergoing	O	O
24	renal	O	B-Disease
25	angioplasty	O	E-Disease
26	(	O	O
27	PTRA	O	S-Disease
28	)	O	O
29	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	To	O	O
3	compare	O	O
4	the	O	O
5	susceptibility	O	O
6	to	O	O
7	nephrotoxic	S-Disease	O
8	effect	O	O
9	of	O	O
10	CM	S-Chemical	S-Chemical
11	in	O	O
12	patients	O	O
13	undergoing	O	O
14	PTRA	O	S-Disease
15	with	O	O
16	that	O	O
17	of	O	O
18	patients	O	O
19	submitted	O	O
20	to	O	O
21	percutaneous	O	O
22	coronary	O	S-Disease
23	intervention	O	O
24	(	O	O
25	PCI	O	O
26	)	O	O
27	.	O	O

0	MATERIAL	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	A	O	O
5	total	O	O
6	of	O	O
7	33	O	O
8	patients	O	O
9	successfully	O	O
10	treated	O	O
11	with	O	O
12	PTRA	O	S-Disease
13	(	O	O
14	PTRA	O	S-Disease
15	group	O	O
16	,	O	O
17	mean	O	O
18	age	O	O
19	70	O	O
20	+	O	O
21	/	O	O
22	-	O	O
23	12	O	O
24	years	O	O
25	,	O	O
26	23	O	O
27	female	O	O
28	,	O	O
29	basal	O	O
30	creatinine	S-Chemical	S-Chemical
31	1	O	O
32	.	O	O
33	46	O	O
34	+	O	O
35	/	O	O
36	-	O	O
37	0	O	O
38	.	O	O
39	79	O	O
40	,	O	O
41	range	O	O
42	0	O	O
43	.	O	O
44	7	O	O
45	-	O	O
46	4	O	O
47	.	O	O
48	9	O	O
49	mg	O	O
50	/	O	O
51	dl	O	O
52	)	O	O
53	were	O	O
54	compared	O	O
55	with	O	O
56	33	O	O
57	patients	O	O
58	undergoing	O	O
59	successful	O	O
60	PCI	O	O
61	(	O	O
62	PCI	O	O
63	group	O	O
64	)	O	O
65	,	O	O
66	matched	O	O
67	for	O	O
68	basal	O	O
69	creatinine	S-Chemical	E-Chemical
70	(	O	O
71	1	O	O
72	.	O	O
73	44	O	O
74	+	O	O
75	/	O	O
76	-	O	O
77	0	O	O
78	.	O	O
79	6	O	O
80	,	O	O
81	range	O	O
82	0	O	O
83	.	O	O
84	7	O	O
85	-	O	O
86	3	O	O
87	.	O	O
88	4	O	O
89	mg	O	O
90	/	O	O
91	dl	O	O
92	)	O	O
93	,	O	O
94	gender	O	O
95	,	O	O
96	and	O	O
97	age	O	O
98	.	O	O

0	In	O	O
1	both	O	O
2	groups	O	O
3	postprocedural	O	O
4	(	O	O
5	48	O	O
6	h	O	O
7	)	O	O
8	serum	O	O
9	creatinine	S-Chemical	S-Chemical
10	was	O	O
11	measured	O	O
12	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Postprocedural	O	O
3	creatinine	S-Chemical	S-Chemical
4	level	O	O
5	decreased	O	O
6	nonsignificantly	O	O
7	in	O	O
8	the	O	O
9	PTRA	O	S-Chemical
10	group	O	O
11	(	O	O
12	1	O	O
13	.	O	O
14	46	O	O
15	+	O	O
16	/	O	O
17	-	O	O
18	0	O	O
19	.	O	O
20	8	O	O
21	vs	O	O
22	.	O	O
23	1	O	O
24	.	O	O
25	34	O	O
26	+	O	O
27	/	O	O
28	-	O	O
29	0	O	O
30	.	O	O
31	5	O	O
32	mg	O	O
33	/	O	O
34	dl	O	O
35	,	O	O
36	P	O	O
37	=	O	O
38	NS	O	O
39	)	O	O
40	and	O	O
41	increased	O	O
42	significantly	O	O
43	in	O	O
44	the	O	O
45	PCI	O	O
46	group	O	O
47	(	O	O
48	1	O	O
49	.	O	O
50	44	O	O
51	+	O	O
52	/	O	O
53	-	O	O
54	0	O	O
55	.	O	O
56	6	O	O
57	vs	O	O
58	.	O	O
59	1	O	O
60	.	O	O
61	57	O	O
62	+	O	O
63	/	O	O
64	-	O	O
65	0	O	O
66	.	O	O
67	7	O	O
68	mg	O	O
69	/	O	O
70	dl	O	O
71	,	O	O
72	P	O	S-Chemical
73	<	O	O
74	0	O	O
75	.	O	O
76	02	O	O
77	)	O	O
78	.	O	O

0	Changes	O	O
1	in	O	O
2	serum	O	O
3	creatinine	S-Chemical	S-Chemical
4	after	O	O
5	intervention	O	O
6	(	O	O
7	after	O	O
8	-	O	O
9	before	O	O
10	)	O	O
11	were	O	O
12	significantly	O	O
13	different	O	O
14	between	O	O
15	the	O	O
16	PTRA	O	S-Disease
17	and	O	O
18	PCI	O	O
19	groups	O	O
20	(	O	O
21	-	O	O
22	0	O	O
23	.	O	O
24	12	O	O
25	+	O	O
26	/	O	O
27	-	O	O
28	0	O	O
29	.	O	O
30	5	O	O
31	vs	O	O
32	.	O	O
33	0	O	O
34	.	O	O
35	13	O	O
36	+	O	O
37	/	O	O
38	-	O	O
39	0	O	O
40	.	O	O
41	3	O	O
42	,	O	O
43	P	O	S-Disease
44	=	O	O
45	0	O	O
46	.	O	O
47	014	O	O
48	)	O	O
49	.	O	O

0	This	O	O
1	difference	O	O
2	was	O	O
3	not	O	O
4	related	O	O
5	to	O	O
6	either	O	O
7	a	O	O
8	different	O	O
9	clinical	O	O
10	risk	O	O
11	profile	O	O
12	or	O	O
13	to	O	O
14	the	O	O
15	volume	O	O
16	of	O	O
17	CM	S-Chemical	S-Chemical
18	administered	O	O
19	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	In	O	O
3	this	O	O
4	preliminary	O	O
5	study	O	O
6	patients	O	O
7	submitted	O	O
8	to	O	O
9	PTRA	O	S-Chemical
10	showed	O	O
11	a	O	O
12	lower	O	O
13	susceptibility	O	O
14	to	O	O
15	renal	B-Disease	B-Disease
16	damage	E-Disease	E-Disease
17	induced	O	O
18	by	O	O
19	CM	S-Chemical	S-Chemical
20	administration	O	O
21	than	O	O
22	PCI	O	S-Disease
23	patients	O	O
24	.	O	O

0	The	O	O
1	effectiveness	O	O
2	of	O	O
3	PTRA	O	S-Chemical
4	on	O	O
5	renal	O	B-Disease
6	function	O	E-Disease
7	seems	O	O
8	to	O	O
9	be	O	O
10	barely	O	O
11	influenced	O	O
12	by	O	O
13	CM	S-Chemical	S-Chemical
14	toxicity	S-Disease	S-Disease
15	.	O	O

0	Diphenhydramine	S-Chemical	S-Chemical
1	prevents	O	O
2	the	O	O
3	haemodynamic	O	O
4	changes	O	O
5	of	O	O
6	cimetidine	S-Chemical	S-Chemical
7	in	O	O
8	ICU	O	O
9	patients	O	O
10	.	O	O

0	Cimetidine	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	histamine	S-Chemical	S-Chemical
4	2	O	O
5	(	O	O
6	H2	O	O
7	)	O	O
8	antagonist	O	O
9	,	O	O
10	produces	O	O
11	a	O	O
12	decrease	O	O
13	in	O	O
14	arterial	O	B-Disease
15	pressure	O	E-Disease
16	due	O	O
17	to	O	O
18	vasodilatation	O	O
19	,	O	O
20	especially	O	O
21	in	O	O
22	critically	O	O
23	ill	O	O
24	patients	O	O
25	.	O	O

0	This	O	O
1	may	O	O
2	be	O	O
3	because	O	O
4	cimetidine	S-Chemical	S-Chemical
5	acts	O	O
6	as	O	O
7	a	O	O
8	histamine	S-Chemical	S-Chemical
9	agonist	O	O
10	.	O	O

0	We	O	O
1	,	O	O
2	therefore	O	O
3	,	O	O
4	investigated	O	O
5	the	O	O
6	effects	O	O
7	of	O	O
8	the	O	O
9	histamine	S-Chemical	S-Chemical
10	1	O	O
11	(	O	O
12	H1	O	O
13	)	O	O
14	receptor	O	O
15	antagonist	O	O
16	,	O	O
17	diphenhydramine	S-Chemical	S-Chemical
18	,	O	O
19	on	O	O
20	the	O	O
21	haemodynamic	O	O
22	changes	O	O
23	observed	O	O
24	after	O	O
25	cimetidine	S-Chemical	S-Chemical
26	in	O	O
27	ICU	O	O
28	patients	O	O
29	.	O	O

0	In	O	O
1	a	O	O
2	random	O	O
3	fashion	O	O
4	,	O	O
5	they	O	O
6	received	O	O
7	cimetidine	S-Chemical	S-Chemical
8	200	O	O
9	mg	O	O
10	iv	O	O
11	on	O	O
12	one	O	O
13	day	O	O
14	,	O	O
15	and	O	O
16	on	O	O
17	the	O	O
18	other	O	O
19	,	O	O
20	a	O	O
21	pretreatment	O	O
22	of	O	O
23	diphenhydramine	S-Chemical	S-Chemical
24	40	O	O
25	mg	O	O
26	iv	O	O
27	with	O	O
28	cimetidine	S-Chemical	S-Chemical
29	200	O	O
30	mg	O	O
31	iv	O	O
32	.	O	O

0	In	O	O
1	the	O	O
2	non	O	O
3	-	O	O
4	pretreatment	O	O
5	group	O	O
6	,	O	O
7	mean	O	O
8	arterial	O	O
9	pressure	O	O
10	(	O	O
11	MAP	O	S-Disease
12	)	O	O
13	decreased	O	O
14	from	O	O
15	107	O	O
16	.	O	O
17	4	O	O
18	+	O	O
19	/	O	O
20	-	O	O
21	8	O	O
22	.	O	O
23	4	O	O
24	mmHg	O	O
25	to	O	O
26	86	O	O
27	.	O	O
28	7	O	O
29	+	O	O
30	/	O	O
31	-	O	O
32	11	O	O
33	.	O	O
34	4	O	O
35	mmHg	O	O
36	(	O	O
37	P	O	O
38	less	O	O
39	than	O	O
40	0	O	O
41	.	O	O
42	01	O	O
43	)	O	O
44	two	O	O
45	minutes	O	O
46	after	O	O
47	cimetidine	S-Chemical	S-Chemical
48	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	an	O	O
4	H1	O	O
5	antagonist	O	O
6	may	O	O
7	be	O	O
8	useful	O	O
9	in	O	O
10	preventing	O	O
11	hypotension	S-Disease	S-Disease
12	caused	O	O
13	by	O	O
14	iv	O	S-Chemical
15	cimetidine	S-Chemical	S-Chemical
16	,	O	O
17	since	O	O
18	the	O	O
19	vasodilating	O	O
20	activity	O	O
21	of	O	O
22	cimetidine	S-Chemical	S-Chemical
23	is	O	O
24	mediated	O	O
25	,	O	O
26	in	O	O
27	part	O	O
28	,	O	O
29	through	O	O
30	the	O	O
31	H1	O	O
32	receptor	O	O
33	.	O	O

0	Medical	O	O
1	and	O	O
2	psychiatric	O	O
3	outcomes	O	O
4	for	O	O
5	patients	O	O
6	transplanted	O	O
7	for	O	O
8	acetaminophen	S-Chemical	S-Chemical
9	-	O	O
10	induced	O	O
11	acute	B-Disease	B-Disease
12	liver	I-Disease	I-Disease
13	failure	E-Disease	E-Disease
14	:	O	O
15	a	O	O
16	case	O	O
17	-	O	O
18	control	O	O
19	study	O	O
20	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Acetaminophen	S-Chemical	S-Chemical
3	-	O	O
4	induced	O	O
5	hepatotoxicity	S-Disease	S-Disease
6	is	O	O
7	the	O	O
8	most	O	O
9	common	O	O
10	cause	O	O
11	of	O	O
12	acute	B-Disease	B-Disease
13	liver	I-Disease	I-Disease
14	failure	E-Disease	E-Disease
15	(	O	O
16	ALF	S-Disease	S-Disease
17	)	O	O
18	in	O	O
19	the	O	O
20	UK	O	O
21	.	O	O

0	AIMS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	We	O	O
5	compared	O	O
6	the	O	O
7	severity	O	O
8	of	O	O
9	pretransplant	O	O
10	illness	O	S-Disease
11	,	O	O
12	psychiatric	O	B-Disease
13	co	O	O
14	-	O	O
15	morbidity	O	O
16	,	O	O
17	medical	O	O
18	and	O	O
19	psychosocial	O	O
20	outcomes	O	O
21	of	O	O
22	all	O	O
23	patients	O	O
24	who	O	O
25	had	O	O
26	undergone	O	O
27	liver	O	B-Disease
28	transplantation	O	E-Disease
29	(	O	O
30	LT	O	O
31	)	O	O
32	emergently	O	O
33	between	O	O
34	1999	O	O
35	-	O	O
36	2004	O	O
37	for	O	O
38	acetaminophen	S-Chemical	S-Chemical
39	-	O	O
40	induced	O	O
41	ALF	S-Disease	S-Disease
42	(	O	O
43	n	O	O
44	=	O	O
45	36	O	O
46	)	O	O
47	with	O	O
48	age	O	O
49	-	O	O
50	and	O	O
51	sex	O	O
52	-	O	O
53	matched	O	O
54	patients	O	O
55	undergoing	O	O
56	emergent	O	O
57	LT	O	S-Disease
58	for	O	O
59	non	O	O
60	-	O	O
61	acetaminophen	S-Chemical	S-Chemical
62	-	O	O
63	induced	O	O
64	ALF	S-Disease	S-Disease
65	(	O	O
66	n	O	O
67	=	O	O
68	35	O	O
69	)	O	O
70	and	O	O
71	elective	O	S-Disease
72	LT	O	S-Disease
73	for	O	O
74	chronic	B-Disease	B-Disease
75	liver	I-Disease	I-Disease
76	disease	E-Disease	E-Disease
77	(	O	O
78	CLD	S-Disease	S-Chemical
79	,	O	O
80	n	O	O
81	=	O	O
82	34	O	O
83	)	O	O
84	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Acetaminophen	S-Chemical	S-Chemical
3	-	O	O
4	induced	O	O
5	ALF	S-Disease	S-Disease
6	patients	O	O
7	undergoing	O	O
8	LT	O	S-Disease
9	had	O	O
10	a	O	O
11	greater	O	O
12	severity	O	O
13	of	O	O
14	pre	O	O
15	-	O	O
16	LT	O	O
17	illness	O	S-Disease
18	reflected	O	O
19	by	O	O
20	higher	O	O
21	Acute	O	B-Disease
22	Physiology	O	E-Disease
23	and	O	O
24	Chronic	O	O
25	Health	O	I-Disease
26	Evaluation	O	O
27	II	O	O
28	scores	O	O
29	and	O	O
30	requirement	O	O
31	for	O	O
32	organ	O	O
33	support	O	O
34	compared	O	O
35	with	O	O
36	the	O	O
37	other	O	O
38	two	O	O
39	groups	O	O
40	.	O	O

0	Twenty	O	O
1	(	O	O
2	56	O	O
3	%	O	O
4	)	O	O
5	acetaminophen	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	ALF	S-Disease	S-Disease
9	patients	O	O
10	had	O	O
11	a	O	O
12	formal	O	O
13	psychiatric	O	O
14	diagnosis	O	O
15	before	O	O
16	LT	O	O
17	(	O	O
18	non	O	O
19	-	O	O
20	acetaminophen	S-Chemical	S-Chemical
21	-	O	O
22	induced	O	O
23	ALF	S-Disease	S-Disease
24	=	O	O
25	0	O	O
26	/	O	O
27	35	O	O
28	,	O	O
29	CLD	S-Disease	S-Chemical
30	=	O	O
31	2	O	O
32	/	O	O
33	34	O	O
34	;	O	O
35	P	O	O
36	<	O	O
37	0	O	O
38	.	O	O
39	01	O	O
40	for	O	O
41	all	O	O
42	)	O	O
43	and	O	O
44	nine	O	O
45	(	O	O
46	25	O	O
47	%	O	O
48	)	O	O
49	had	O	O
50	a	O	O
51	previous	O	O
52	suicide	O	O
53	attempt	O	O
54	.	O	O

0	During	O	O
1	follow	O	O
2	-	O	O
3	up	O	O
4	(	O	O
5	median	O	O
6	5	O	O
7	years	O	O
8	)	O	O
9	,	O	O
10	there	O	O
11	were	O	O
12	no	O	O
13	significant	O	O
14	differences	O	O
15	in	O	O
16	rejection	O	O
17	(	O	O
18	acute	O	S-Disease
19	and	O	I-Disease
20	chronic	O	S-Disease
21	)	O	O
22	,	O	O
23	graft	O	O
24	failure	O	E-Disease
25	or	O	O
26	survival	O	O
27	between	O	O
28	the	O	O
29	groups	O	O
30	(	O	O
31	acetaminophen	S-Chemical	S-Chemical
32	-	O	O
33	induced	O	O
34	ALF	S-Disease	S-Disease
35	1	O	O
36	year	O	O
37	87	O	O
38	%	O	O
39	,	O	O
40	5	O	O
41	years	O	O
42	75	O	O
43	%	O	O
44	;	O	O
45	non	O	O
46	-	O	O
47	acetaminophen	S-Chemical	S-Chemical
48	-	O	O
49	induced	O	O
50	ALF	S-Disease	S-Disease
51	88	O	O
52	%	O	O
53	,	O	O
54	78	O	O
55	%	O	O
56	;	O	O
57	CLD	S-Disease	S-Chemical
58	93	O	O
59	%	O	O
60	,	O	O
61	82	O	O
62	%	O	O
63	:	O	O
64	P	O	O
65	>	O	O
66	0	O	O
67	.	O	O
68	6	O	O
69	log	O	O
70	rank	O	O
71	)	O	O
72	.	O	O

0	Two	O	O
1	acetaminophen	S-Chemical	S-Chemical
2	-	O	O
3	induced	O	O
4	ALF	S-Disease	S-Disease
5	patients	O	O
6	reattempted	O	O
7	suicide	O	S-Disease
8	post	O	O
9	-	O	O
10	LT	O	O
11	(	O	O
12	one	O	O
13	died	O	O
14	8	O	O
15	years	O	O
16	post	O	O
17	-	O	O
18	LT	O	O
19	)	O	O
20	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Despite	O	O
3	a	O	O
4	high	O	O
5	prevalence	O	O
6	of	O	O
7	psychiatric	O	B-Disease
8	disturbance	O	E-Disease
9	,	O	O
10	outcomes	O	O
11	for	O	O
12	patients	O	O
13	transplanted	O	O
14	emergently	O	O
15	for	O	O
16	acetaminophen	S-Chemical	S-Chemical
17	-	O	O
18	induced	O	O
19	ALF	S-Disease	S-Disease
20	were	O	O
21	comparable	O	O
22	to	O	O
23	those	O	O
24	transplanted	O	O
25	for	O	O
26	non	O	O
27	-	O	O
28	acetaminophen	S-Chemical	S-Chemical
29	-	O	O
30	induced	O	O
31	ALF	S-Disease	S-Disease
32	and	O	O
33	electively	O	O
34	for	O	O
35	CLD	S-Disease	S-Chemical
36	.	O	O

0	Antithrombotic	O	O
1	drug	O	O
2	use	O	O
3	,	O	O
4	cerebral	B-Disease	B-Disease
5	microbleeds	E-Disease	E-Disease
6	,	O	O
7	and	O	O
8	intracerebral	B-Disease	O
9	hemorrhage	E-Disease	S-Disease
10	:	O	O
11	a	O	O
12	systematic	O	O
13	review	O	O
14	of	O	O
15	published	O	O
16	and	O	O
17	unpublished	O	O
18	studies	O	O
19	.	O	O

0	BACKGROUND	O	O
1	AND	O	O
2	PURPOSE	O	O
3	:	O	O
4	Cerebral	B-Disease	S-Chemical
5	microbleeds	E-Disease	O
6	(	O	O
7	MB	S-Disease	O
8	)	O	O
9	are	O	O
10	potential	O	O
11	risk	O	O
12	factors	O	O
13	for	O	O
14	intracerebral	B-Disease	O
15	hemorrhage	E-Disease	O
16	(	O	O
17	ICH	S-Disease	S-Chemical
18	)	O	O
19	,	O	O
20	but	O	O
21	it	O	O
22	is	O	O
23	unclear	O	O
24	if	O	O
25	they	O	O
26	are	O	O
27	a	O	O
28	contraindication	O	O
29	to	O	O
30	using	O	O
31	antithrombotic	O	O
32	drugs	O	O
33	.	O	O

0	Insights	O	O
1	could	O	O
2	be	O	O
3	gained	O	O
4	by	O	O
5	pooling	O	O
6	data	O	O
7	on	O	O
8	MB	S-Disease	S-Disease
9	frequency	O	O
10	stratified	O	O
11	by	O	O
12	antithrombotic	O	O
13	use	O	O
14	in	O	O
15	cohorts	O	O
16	with	O	O
17	ICH	S-Disease	S-Chemical
18	and	O	O
19	ischemic	B-Disease	B-Disease
20	stroke	E-Disease	E-Disease
21	(	O	O
22	IS	S-Disease	S-Disease
23	)	O	O
24	/	O	O
25	transient	B-Disease	O
26	ischemic	I-Disease	S-Disease
27	attack	E-Disease	S-Disease
28	(	O	O
29	TIA	S-Disease	S-Disease
30	)	O	O
31	.	O	O

0	METHODS	O	O
1	:	O	O
2	We	O	O
3	performed	O	O
4	a	O	O
5	systematic	O	O
6	review	O	O
7	of	O	O
8	published	O	O
9	and	O	O
10	unpublished	O	O
11	data	O	O
12	from	O	O
13	cohorts	O	O
14	with	O	O
15	stroke	S-Disease	S-Disease
16	or	O	O
17	TIA	S-Disease	S-Disease
18	to	O	O
19	compare	O	O
20	the	O	O
21	presence	O	O
22	of	O	O
23	MB	S-Disease	S-Disease
24	in	O	O
25	:	O	O
26	(	O	O
27	1	O	O
28	)	O	O
29	antithrombotic	O	O
30	users	O	O
31	vs	O	O
32	nonantithrombotic	O	O
33	users	O	O
34	with	O	O
35	ICH	S-Disease	S-Chemical
36	;	O	O
37	(	O	O
38	2	O	O
39	)	O	O
40	antithrombotic	O	O
41	users	O	O
42	vs	O	O
43	nonusers	O	O
44	with	O	O
45	IS	S-Disease	S-Disease
46	/	O	I-Disease
47	TIA	S-Disease	E-Chemical
48	;	O	O
49	and	O	O
50	(	O	O
51	3	O	O
52	)	O	O
53	ICH	S-Disease	S-Chemical
54	vs	O	O
55	ischemic	S-Disease	S-Disease
56	events	O	O
57	stratified	O	O
58	by	O	O
59	antithrombotic	O	O
60	use	O	O
61	.	O	O

0	We	O	O
1	also	O	O
2	analyzed	O	O
3	published	O	O
4	and	O	O
5	unpublished	O	O
6	follow	O	O
7	-	O	O
8	up	O	O
9	data	O	O
10	to	O	O
11	determine	O	O
12	the	O	O
13	risk	O	O
14	of	O	O
15	ICH	S-Disease	S-Chemical
16	in	O	O
17	antithrombotic	O	O
18	users	O	O
19	with	O	O
20	MB	S-Disease	S-Disease
21	.	O	O

0	RESULTS	O	O
1	:	O	O
2	In	O	O
3	a	O	O
4	pooled	O	O
5	analysis	O	O
6	of	O	O
7	1460	O	O
8	ICH	S-Disease	S-Disease
9	and	O	O
10	3817	O	O
11	IS	S-Disease	O
12	/	O	O
13	TIA	S-Disease	O
14	,	O	O
15	MB	S-Disease	O
16	were	O	O
17	more	O	O
18	frequent	O	O
19	in	O	O
20	ICH	S-Disease	S-Disease
21	vs	O	O
22	IS	S-Disease	S-Disease
23	/	O	O
24	TIA	S-Disease	S-Disease
25	in	O	O
26	all	O	O
27	treatment	O	O
28	groups	O	O
29	,	O	O
30	but	O	O
31	the	O	O
32	excess	O	O
33	increased	O	O
34	from	O	O
35	2	O	O
36	.	O	O
37	8	O	O
38	(	O	O
39	odds	O	O
40	ratio	O	O
41	;	O	O
42	range	O	O
43	,	O	O
44	2	O	O
45	.	O	O
46	3	O	O
47	-	O	O
48	3	O	O
49	.	O	O
50	5	O	O
51	)	O	O
52	in	O	O
53	nonantithrombotic	O	O
54	users	O	O
55	to	O	O
56	5	O	O
57	.	O	O
58	7	O	O
59	(	O	O
60	range	O	O
61	,	O	O
62	3	O	O
63	.	O	O
64	4	O	O
65	-	O	O
66	9	O	O
67	.	O	O
68	7	O	O
69	)	O	O
70	in	O	O
71	antiplatelet	O	O
72	users	O	O
73	and	O	O
74	8	O	O
75	.	O	O
76	0	O	O
77	(	O	O
78	range	O	O
79	,	O	O
80	3	O	O
81	.	O	O
82	5	O	O
83	-	O	O
84	17	O	O
85	.	O	O
86	8	O	O
87	)	O	O
88	in	O	O
89	warfarin	S-Chemical	S-Chemical
90	users	O	O
91	(	O	O
92	P	O	S-Disease
93	difference	O	O
94	=	O	O
95	0	O	O
96	.	O	O
97	01	O	O
98	)	O	O
99	.	O	O

0	There	O	O
1	was	O	O
2	also	O	O
3	an	O	O
4	excess	O	O
5	of	O	O
6	MB	S-Disease	O
7	in	O	O
8	warfarin	S-Chemical	S-Chemical
9	users	O	O
10	vs	O	O
11	nonusers	O	O
12	with	O	O
13	ICH	S-Disease	S-Chemical
14	(	O	O
15	OR	O	O
16	,	O	O
17	2	O	O
18	.	O	O
19	7	O	O
20	;	O	O
21	95	O	O
22	%	O	O
23	CI	O	S-Chemical
24	,	O	O
25	1	O	O
26	.	O	O
27	6	O	O
28	-	O	O
29	4	O	O
30	.	O	O
31	4	O	O
32	;	O	O
33	P	O	O
34	<	O	O
35	0	O	O
36	.	O	O
37	001	O	O
38	)	O	O
39	but	O	O
40	none	O	O
41	in	O	O
42	warfarin	S-Chemical	S-Chemical
43	users	O	O
44	with	O	O
45	IS	S-Disease	O
46	/	O	O
47	TIA	S-Disease	O
48	(	O	O
49	OR	O	O
50	,	O	O
51	1	O	O
52	.	O	O
53	3	O	O
54	;	O	O
55	95	O	O
56	%	O	O
57	CI	O	S-Chemical
58	,	O	O
59	0	O	O
60	.	O	O
61	9	O	O
62	-	O	O
63	1	O	O
64	.	O	O
65	7	O	O
66	;	O	O
67	P	O	S-Disease
68	=	O	O
69	0	O	O
70	.	O	O
71	33	O	O
72	;	O	O
73	P	O	O
74	difference	O	O
75	=	O	O
76	0	O	O
77	.	O	O
78	01	O	O
79	)	O	O
80	.	O	O

0	There	O	O
1	was	O	O
2	a	O	O
3	smaller	O	O
4	excess	O	O
5	of	O	O
6	MB	S-Disease	O
7	in	O	O
8	antiplatelet	O	O
9	users	O	O
10	vs	O	O
11	nonusers	O	O
12	with	O	O
13	ICH	S-Disease	S-Chemical
14	(	O	O
15	OR	O	O
16	,	O	O
17	1	O	O
18	.	O	O
19	7	O	O
20	;	O	O
21	95	O	O
22	%	O	O
23	CI	O	S-Chemical
24	,	O	O
25	1	O	O
26	.	O	O
27	3	O	O
28	-	O	O
29	2	O	O
30	.	O	O
31	3	O	O
32	;	O	O
33	P	O	O
34	<	O	O
35	0	O	O
36	.	O	O
37	001	O	O
38	)	O	O
39	,	O	O
40	but	O	O
41	findings	O	O
42	were	O	O
43	similar	O	O
44	for	O	O
45	antiplatelet	O	O
46	users	O	O
47	with	O	O
48	IS	S-Disease	S-Disease
49	/	O	O
50	TIA	S-Disease	O
51	(	O	O
52	OR	O	O
53	,	O	O
54	1	O	O
55	.	O	O
56	4	O	O
57	;	O	O
58	95	O	O
59	%	O	O
60	CI	O	S-Chemical
61	,	O	O
62	1	O	O
63	.	O	O
64	2	O	O
65	-	O	O
66	1	O	O
67	.	O	O
68	7	O	O
69	;	O	O
70	P	O	S-Disease
71	<	O	O
72	0	O	O
73	.	O	O
74	001	O	O
75	;	O	O
76	P	O	S-Disease
77	difference	O	O
78	=	O	O
79	0	O	O
80	.	O	O
81	25	O	O
82	)	O	O
83	.	O	O

0	In	O	O
1	pooled	O	O
2	follow	O	O
3	-	O	O
4	up	O	O
5	data	O	O
6	for	O	O
7	768	O	O
8	antithrombotic	O	O
9	users	O	O
10	,	O	O
11	presence	O	O
12	of	O	O
13	MB	S-Disease	S-Disease
14	at	O	O
15	baseline	O	O
16	was	O	O
17	associated	O	O
18	with	O	O
19	a	O	O
20	substantially	O	O
21	increased	O	O
22	risk	O	O
23	of	O	O
24	subsequent	O	O
25	ICH	S-Disease	S-Chemical
26	(	O	O
27	OR	O	O
28	,	O	O
29	12	O	O
30	.	O	O
31	1	O	O
32	;	O	O
33	95	O	O
34	%	O	O
35	CI	O	S-Chemical
36	,	O	O
37	3	O	O
38	.	O	O
39	4	O	O
40	-	O	O
41	42	O	O
42	.	O	O
43	5	O	O
44	;	O	O
45	P	O	O
46	<	O	O
47	0	O	O
48	.	O	O
49	001	O	O
50	)	O	O
51	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	excess	O	O
4	of	O	O
5	MB	S-Disease	S-Disease
6	in	O	O
7	warfarin	S-Chemical	S-Chemical
8	users	O	O
9	with	O	O
10	ICH	S-Disease	S-Chemical
11	compared	O	O
12	to	O	O
13	other	O	O
14	groups	O	O
15	suggests	O	O
16	that	O	O
17	MB	S-Disease	S-Chemical
18	increase	O	O
19	the	O	O
20	risk	O	O
21	of	O	O
22	warfarin	S-Chemical	S-Chemical
23	-	O	O
24	associated	O	O
25	ICH	S-Disease	S-Chemical
26	.	O	O

0	Studies	O	O
1	of	O	O
2	synergy	O	O
3	between	O	O
4	morphine	S-Chemical	S-Chemical
5	and	O	O
6	a	O	O
7	novel	O	O
8	sodium	S-Chemical	B-Disease
9	channel	O	E-Disease
10	blocker	O	E-Disease
11	,	O	O
12	CNSB002	S-Chemical	B-Chemical
13	,	O	O
14	in	O	O
15	rat	O	O
16	models	O	O
17	of	O	O
18	inflammatory	O	B-Disease
19	and	O	I-Disease
20	neuropathic	B-Disease	B-Disease
21	pain	E-Disease	E-Disease
22	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	This	O	O
3	study	O	O
4	determined	O	O
5	the	O	O
6	antihyperalgesic	O	O
7	effect	O	O
8	of	O	O
9	CNSB002	S-Chemical	S-Chemical
10	,	O	O
11	a	O	O
12	sodium	S-Chemical	B-Disease
13	channel	O	E-Disease
14	blocker	O	E-Disease
15	with	O	O
16	antioxidant	O	O
17	properties	O	O
18	given	O	O
19	alone	O	O
20	and	O	O
21	in	O	O
22	combinations	O	O
23	with	O	O
24	morphine	S-Chemical	S-Chemical
25	in	O	O
26	rat	O	O
27	models	O	O
28	of	O	O
29	inflammatory	O	S-Disease
30	and	O	O
31	neuropathic	B-Disease	O
32	pain	E-Disease	E-Disease
33	.	O	O

0	DESIGN	O	O
1	:	O	O
2	Dose	O	O
3	response	O	O
4	curves	O	O
5	for	O	O
6	nonsedating	O	O
7	doses	O	O
8	of	O	O
9	morphine	S-Chemical	S-Chemical
10	and	O	O
11	CNSB002	S-Chemical	S-Chemical
12	given	O	O
13	intraperitoneally	O	O
14	alone	O	O
15	and	O	O
16	together	O	O
17	in	O	O
18	combinations	O	O
19	were	O	O
20	constructed	O	O
21	for	O	O
22	antihyperalgesic	O	O
23	effect	O	O
24	using	O	O
25	paw	O	O
26	withdrawal	O	O
27	from	O	O
28	noxious	O	O
29	heat	O	O
30	in	O	O
31	two	O	O
32	rat	O	O
33	pain	S-Disease	O
34	models	O	O
35	:	O	O
36	carrageenan	S-Chemical	S-Chemical
37	-	O	O
38	induced	O	O
39	paw	O	S-Disease
40	inflammation	S-Disease	S-Disease
41	and	O	O
42	streptozotocin	S-Chemical	S-Disease
43	(	O	O
44	STZ	S-Chemical	S-Chemical
45	)	O	E-Chemical
46	-	O	O
47	induced	O	O
48	diabetic	B-Disease	S-Disease
49	neuropathy	E-Disease	S-Disease
50	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	maximum	O	O
4	nonsedating	O	O
5	doses	O	O
6	were	O	O
7	:	O	O
8	morphine	S-Chemical	S-Chemical
9	,	O	O
10	3	O	O
11	.	O	O
12	2	O	O
13	mg	O	O
14	/	O	O
15	kg	O	O
16	;	O	O
17	CNSB002	S-Chemical	S-Chemical
18	10	O	O
19	.	O	O
20	0	O	O
21	mg	O	O
22	/	O	O
23	kg	O	O
24	;	O	O
25	5	O	O
26	.	O	O
27	0	O	O
28	mg	O	O
29	/	O	O
30	kg	O	O
31	CNSB002	S-Chemical	S-Disease
32	with	O	O
33	morphine	S-Chemical	S-Disease
34	3	O	O
35	.	O	O
36	2	O	O
37	mg	O	O
38	/	O	O
39	kg	O	O
40	in	O	O
41	combination	O	O
42	.	O	O

0	The	O	O
1	doses	O	O
2	calculated	O	O
3	to	O	O
4	cause	O	O
5	50	O	O
6	%	O	O
7	reversal	O	O
8	of	O	O
9	hyperalgesia	S-Disease	S-Disease
10	(	O	O
11	ED50	O	S-Disease
12	)	O	O
13	were	O	O
14	7	O	O
15	.	O	O
16	54	O	O
17	(	O	O
18	1	O	O
19	.	O	O
20	81	O	O
21	)	O	O
22	and	O	O
23	4	O	O
24	.	O	O
25	83	O	O
26	(	O	O
27	1	O	O
28	.	O	O
29	54	O	O
30	)	O	O
31	in	O	O
32	the	O	O
33	carrageenan	S-Chemical	S-Chemical
34	model	O	O
35	and	O	O
36	44	O	O
37	.	O	O
38	18	O	O
39	(	O	O
40	1	O	O
41	.	O	O
42	37	O	O
43	)	O	O
44	and	O	O
45	9	O	O
46	.	O	O
47	14	O	O
48	(	O	O
49	1	O	O
50	.	O	O
51	24	O	O
52	)	O	O
53	in	O	O
54	the	O	O
55	STZ	S-Chemical	S-Disease
56	-	O	O
57	induced	O	O
58	neuropathy	S-Disease	O
59	model	O	O
60	for	O	O
61	CNSB002	S-Chemical	B-Chemical
62	and	O	O
63	morphine	S-Chemical	S-Disease
64	,	O	O
65	respectively	O	O
66	(	O	O
67	mg	O	O
68	/	O	O
69	kg	O	O
70	;	O	O
71	mean	O	O
72	,	O	O
73	SEM	O	S-Disease
74	)	O	O
75	.	O	O

0	The	O	O
1	ED50	O	S-Disease
2	values	O	O
3	for	O	O
4	morphine	S-Chemical	S-Chemical
5	when	O	O
6	given	O	O
7	in	O	O
8	combination	O	O
9	with	O	O
10	CNSB002	S-Chemical	S-Chemical
11	(	O	O
12	5	O	O
13	mg	O	O
14	/	O	O
15	kg	O	O
16	)	O	O
17	were	O	O
18	less	O	O
19	than	O	O
20	the	O	O
21	maximum	O	O
22	nonsedating	O	O
23	dose	O	O
24	:	O	O
25	0	O	O
26	.	O	O
27	56	O	O
28	(	O	O
29	1	O	O
30	.	O	O
31	55	O	O
32	)	O	O
33	in	O	O
34	the	O	O
35	carrageenan	S-Chemical	S-Chemical
36	model	O	O
37	and	O	O
38	1	O	O
39	.	O	O
40	37	O	O
41	(	O	O
42	1	O	O
43	.	O	O
44	23	O	O
45	)	O	O
46	in	O	O
47	the	O	O
48	neuropathy	S-Disease	O
49	model	O	O
50	(	O	O
51	mg	O	O
52	/	O	O
53	kg	O	O
54	;	O	O
55	mean	O	O
56	,	O	O
57	SEM	O	S-Disease
58	)	O	O
59	.	O	O

0	The	O	O
1	antinociception	O	O
2	after	O	O
3	morphine	S-Chemical	S-Chemical
4	(	O	O
5	3	O	O
6	.	O	O
7	2	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	)	O	O
12	was	O	O
13	increased	O	O
14	by	O	O
15	co	O	O
16	-	O	O
17	administration	O	O
18	with	O	O
19	CNSB002	S-Chemical	S-Chemical
20	from	O	O
21	28	O	O
22	.	O	O
23	0	O	O
24	and	O	O
25	31	O	O
26	.	O	O
27	7	O	O
28	%	O	O
29	to	O	O
30	114	O	O
31	.	O	O
32	6	O	O
33	and	O	O
34	56	O	O
35	.	O	O
36	9	O	O
37	%	O	O
38	reversal	O	O
39	of	O	O
40	hyperalgesia	S-Disease	S-Disease
41	in	O	O
42	the	O	O
43	inflammatory	O	S-Disease
44	and	O	O
45	neuropathic	S-Disease	O
46	models	O	O
47	,	O	O
48	respectively	O	O
49	(	O	O
50	P	O	O
51	<	O	O
52	0	O	O
53	.	O	O
54	01	O	O
55	;	O	O
56	one	O	O
57	-	O	O
58	way	O	O
59	analysis	O	O
60	of	O	O
61	variance	O	O
62	-	O	O
63	significantly	O	O
64	greater	O	O
65	than	O	O
66	either	O	O
67	drug	O	O
68	given	O	O
69	alone	O	O
70	)	O	O
71	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	maximum	O	O
4	antihyperalgesic	O	O
5	effect	O	O
6	achievable	O	O
7	with	O	O
8	nonsedating	O	O
9	doses	O	O
10	of	O	O
11	morphine	S-Chemical	S-Chemical
12	may	O	O
13	be	O	O
14	increased	O	O
15	significantly	O	O
16	when	O	O
17	the	O	O
18	drug	O	O
19	is	O	O
20	used	O	O
21	in	O	O
22	combination	O	O
23	with	O	O
24	CNSB002	S-Chemical	S-Chemical
25	.	O	O

0	Heparin	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	thrombocytopenia	S-Disease	S-Disease
4	:	O	O
5	a	O	O
6	practical	O	O
7	review	O	O
8	.	O	O

0	Heparin	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	thrombocytopenia	S-Disease	S-Disease
4	(	O	O
5	HIT	S-Disease	S-Disease
6	)	O	O
7	remains	O	O
8	under	O	O
9	-	O	O
10	recognized	O	O
11	despite	O	O
12	its	O	O
13	potentially	O	O
14	devastating	O	O
15	outcomes	O	O
16	.	O	O

0	It	O	O
1	begins	O	O
2	when	O	O
3	heparin	S-Chemical	S-Chemical
4	exposure	O	O
5	stimulates	O	O
6	the	O	O
7	formation	O	O
8	of	O	O
9	heparin	S-Chemical	S-Chemical
10	-	O	O
11	platelet	O	I-Disease
12	factor	O	O
13	4	O	O
14	antibodies	O	O
15	,	O	O
16	which	O	O
17	in	O	O
18	turn	O	O
19	triggers	O	O
20	the	O	O
21	release	O	O
22	of	O	O
23	procoagulant	O	O
24	platelet	O	O
25	particles	O	O
26	.	O	O

0	Thrombosis	S-Disease	S-Disease
1	and	O	O
2	thrombocytopenia	S-Disease	S-Disease
3	that	O	O
4	follow	O	O
5	comprise	O	O
6	the	O	O
7	2	O	O
8	hallmark	O	O
9	traits	O	O
10	of	O	O
11	HIT	S-Disease	S-Disease
12	,	O	O
13	with	O	O
14	the	O	O
15	former	O	O
16	largely	O	O
17	responsible	O	O
18	for	O	O
19	significant	O	O
20	vascular	O	B-Disease
21	complications	O	E-Disease
22	.	O	O

0	The	O	O
1	prevalence	O	O
2	of	O	O
3	HIT	S-Disease	S-Disease
4	varies	O	O
5	among	O	O
6	several	O	O
7	subgroups	O	O
8	,	O	O
9	with	O	O
10	greater	O	O
11	incidence	O	O
12	in	O	O
13	surgical	O	O
14	as	O	O
15	compared	O	O
16	with	O	O
17	medical	O	O
18	populations	O	O
19	.	O	O

0	HIT	S-Disease	S-Disease
1	must	O	O
2	be	O	O
3	acknowledged	O	O
4	for	O	O
5	its	O	O
6	intense	O	O
7	predilection	O	O
8	for	O	O
9	thrombosis	S-Disease	S-Disease
10	and	O	O
11	suspected	O	O
12	whenever	O	O
13	thrombosis	S-Disease	S-Disease
14	occurs	O	O
15	after	O	O
16	heparin	S-Chemical	S-Chemical
17	exposure	O	O
18	.	O	O

0	The	O	O
1	treatment	O	O
2	of	O	O
3	HIT	S-Disease	S-Disease
4	mandates	O	O
5	an	O	O
6	immediate	O	O
7	cessation	O	O
8	of	O	O
9	all	O	O
10	heparin	S-Chemical	S-Chemical
11	exposure	O	O
12	and	O	O
13	the	O	O
14	institution	O	O
15	of	O	O
16	an	O	O
17	antithrombotic	O	O
18	therapy	O	O
19	,	O	O
20	most	O	O
21	commonly	O	O
22	using	O	O
23	a	O	O
24	direct	B-Chemical	O
25	thrombin	I-Chemical	O
26	inhibitor	E-Chemical	O
27	.	O	O

0	Current	O	O
1	"	O	O
2	diagnostic	O	O
3	"	O	O
4	tests	O	O
5	,	O	O
6	which	O	O
7	primarily	O	O
8	include	O	O
9	functional	O	O
10	and	O	O
11	antigenic	O	O
12	assays	O	O
13	,	O	O
14	have	O	O
15	more	O	O
16	of	O	O
17	a	O	O
18	confirmatory	O	O
19	than	O	O
20	diagnostic	O	O
21	role	O	O
22	in	O	O
23	the	O	O
24	management	O	O
25	of	O	O
26	HIT	S-Disease	S-Disease
27	.	O	O

0	Special	O	O
1	attention	O	O
2	must	O	O
3	be	O	O
4	paid	O	O
5	to	O	O
6	cardiac	O	S-Disease
7	patients	O	O
8	who	O	O
9	are	O	O
10	often	O	O
11	exposed	O	O
12	to	O	O
13	heparin	S-Chemical	S-Chemical
14	multiple	O	O
15	times	O	O
16	during	O	O
17	their	O	O
18	course	O	O
19	of	O	O
20	treatment	O	O
21	.	O	O

0	Direct	B-Chemical	O
1	thrombin	I-Chemical	S-Disease
2	inhibitors	E-Chemical	O
3	are	O	O
4	appropriate	O	O
5	,	O	O
6	evidence	O	O
7	-	O	O
8	based	O	O
9	alternatives	O	O
10	to	O	O
11	heparin	S-Chemical	S-Chemical
12	in	O	O
13	patients	O	O
14	with	O	O
15	a	O	O
16	history	O	O
17	of	O	O
18	HIT	S-Disease	S-Disease
19	,	O	O
20	who	O	O
21	need	O	O
22	to	O	O
23	undergo	O	O
24	percutaneous	O	O
25	coronary	O	S-Disease
26	intervention	O	O
27	.	O	O

0	As	O	O
1	heparin	S-Chemical	S-Chemical
2	remains	O	O
3	one	O	O
4	of	O	O
5	the	O	O
6	most	O	O
7	frequently	O	O
8	used	O	O
9	medications	O	O
10	today	O	O
11	with	O	O
12	potential	O	O
13	for	O	O
14	HIT	S-Disease	S-Disease
15	with	O	O
16	every	O	O
17	heparin	S-Chemical	S-Chemical
18	exposure	O	O
19	,	O	O
20	a	O	O
21	close	O	O
22	vigilance	O	O
23	of	O	O
24	platelet	O	S-Disease
25	counts	O	O
26	must	O	O
27	be	O	O
28	practiced	O	O
29	whenever	O	O
30	heparin	S-Chemical	S-Chemical
31	is	O	O
32	initiated	O	O
33	.	O	O

0	Abductor	O	O
1	paralysis	S-Disease	O
2	after	O	O
3	botox	S-Chemical	O
4	injection	O	O
5	for	O	O
6	adductor	B-Disease	O
7	spasmodic	I-Disease	O
8	dysphonia	E-Disease	S-Disease
9	.	O	O

0	OBJECTIVES	O	O
1	/	O	O
2	HYPOTHESIS	O	O
3	:	O	O
4	Botulinum	O	S-Chemical
5	toxin	O	E-Disease
6	(	O	O
7	Botox	S-Chemical	S-Chemical
8	)	O	O
9	injections	O	O
10	into	O	O
11	the	O	O
12	thyroarytenoid	O	B-Disease
13	muscles	O	O
14	are	O	O
15	the	O	O
16	current	O	O
17	standard	O	O
18	of	O	O
19	care	O	O
20	for	O	O
21	adductor	B-Disease	O
22	spasmodic	I-Disease	O
23	dysphonia	E-Disease	S-Disease
24	(	O	O
25	ADSD	S-Disease	S-Disease
26	)	O	O
27	.	O	O

0	Reported	O	O
1	adverse	O	O
2	effects	O	O
3	include	O	O
4	a	O	O
5	period	O	O
6	of	O	O
7	breathiness	O	S-Disease
8	,	O	O
9	throat	B-Disease	B-Disease
10	pain	E-Disease	E-Disease
11	,	O	O
12	and	O	O
13	difficulty	O	O
14	with	O	O
15	swallowing	O	O
16	liquids	O	O
17	.	O	O

0	Here	O	O
1	we	O	O
2	report	O	O
3	multiple	O	O
4	cases	O	O
5	of	O	O
6	bilateral	O	O
7	abductor	O	O
8	paralysis	S-Disease	O
9	following	O	O
10	Botox	S-Chemical	S-Chemical
11	injections	O	O
12	for	O	O
13	ADSD	S-Disease	S-Chemical
14	,	O	O
15	a	O	O
16	complication	O	O
17	previously	O	O
18	unreported	O	O
19	.	O	O

0	METHODS	O	O
1	:	O	O
2	Patients	O	O
3	that	O	O
4	received	O	O
5	Botox	S-Chemical	S-Chemical
6	injections	O	O
7	for	O	O
8	spasmodic	B-Disease	O
9	dysphonia	E-Disease	S-Disease
10	between	O	O
11	January	O	O
12	2000	O	O
13	and	O	O
14	October	O	O
15	2009	O	O
16	were	O	O
17	evaluated	O	O
18	.	O	O

0	Patients	O	O
1	with	O	O
2	ADSD	S-Disease	S-Chemical
3	were	O	O
4	identified	O	O
5	.	O	O

0	For	O	O
1	patients	O	O
2	with	O	O
3	bilateral	O	O
4	abductor	O	O
5	paralysis	S-Disease	O
6	,	O	O
7	age	O	O
8	,	O	O
9	sex	O	O
10	,	O	O
11	paralytic	O	O
12	Botox	S-Chemical	S-Chemical
13	dose	O	O
14	,	O	O
15	prior	O	O
16	Botox	S-Chemical	S-Chemical
17	dose	O	O
18	,	O	O
19	and	O	O
20	course	O	O
21	following	O	O
22	paralysis	S-Disease	O
23	were	O	O
24	noted	O	O
25	.	O	O

0	RESULTS	O	O
1	:	O	O
2	From	O	O
3	a	O	O
4	database	O	O
5	of	O	O
6	452	O	O
7	patients	O	O
8	receiving	O	O
9	Botox	S-Chemical	S-Chemical
10	,	O	O
11	352	O	O
12	patients	O	O
13	had	O	O
14	been	O	O
15	diagnosed	O	O
16	with	O	O
17	ADSD	S-Disease	S-Chemical
18	.	O	O

0	Of	O	O
1	these	O	O
2	352	O	O
3	patients	O	O
4	,	O	O
5	eight	O	O
6	patients	O	O
7	suffered	O	O
8	bilateral	O	O
9	abductor	O	O
10	paralysis	S-Disease	S-Disease
11	,	O	O
12	and	O	O
13	two	O	O
14	suffered	O	O
15	this	O	O
16	complication	O	O
17	twice	O	O
18	.	O	O

0	Most	O	O
1	patients	O	O
2	had	O	O
3	received	O	O
4	treatments	O	O
5	prior	O	O
6	to	O	O
7	abductor	O	O
8	paralysis	S-Disease	O
9	and	O	O
10	continued	O	O
11	receiving	O	O
12	after	O	O
13	paralysis	S-Disease	S-Disease
14	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	abductor	O	O
4	paralysis	S-Disease	O
5	after	O	O
6	Botox	S-Chemical	S-Chemical
7	injection	O	O
8	for	O	O
9	ADSD	S-Disease	S-Chemical
10	was	O	O
11	0	O	O
12	.	O	O
13	34	O	O
14	%	O	O
15	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Bilateral	O	O
3	abductor	O	O
4	paralysis	S-Disease	O
5	is	O	O
6	a	O	O
7	rare	O	O
8	complication	O	O
9	of	O	O
10	Botox	S-Chemical	S-Chemical
11	injections	O	O
12	for	O	O
13	ADSD	S-Disease	S-Chemical
14	,	O	O
15	causing	O	O
16	difficulty	O	O
17	with	O	O
18	breathing	O	O
19	upon	O	O
20	exertion	O	O
21	.	O	O

0	The	O	O
1	likely	O	O
2	mechanism	O	O
3	of	O	O
4	paralysis	S-Disease	O
5	is	O	O
6	diffusion	O	O
7	of	O	O
8	Botox	S-Chemical	S-Chemical
9	around	O	O
10	the	O	O
11	muscular	O	O
12	process	O	O
13	of	O	O
14	the	O	O
15	arytenoid	O	S-Disease
16	to	O	O
17	the	O	O
18	posterior	O	O
19	cricoarytenoid	O	I-Disease
20	muscles	O	O
21	.	O	O

0	The	O	O
1	paralysis	S-Disease	O
2	is	O	O
3	temporary	O	O
4	,	O	O
5	and	O	O
6	watchful	O	O
7	waiting	O	O
8	with	O	O
9	restriction	O	O
10	of	O	O
11	activity	O	S-Disease
12	is	O	O
13	the	O	O
14	recommended	O	O
15	management	O	O
16	.	O	O

0	Mitochondrial	B-Disease	O
1	impairment	E-Disease	O
2	contributes	O	O
3	to	O	O
4	cocaine	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	cardiac	B-Disease	B-Disease
8	dysfunction	E-Disease	E-Disease
9	:	O	O
10	Prevention	O	O
11	by	O	O
12	the	O	O
13	targeted	O	O
14	antioxidant	O	O
15	MitoQ	S-Chemical	S-Chemical
16	.	O	O

0	The	O	O
1	goal	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	assess	O	O
8	mitochondrial	O	B-Disease
9	function	O	E-Disease
10	and	O	O
11	ROS	O	S-Disease
12	production	O	S-Disease
13	in	O	O
14	an	O	O
15	experimental	O	O
16	model	O	O
17	of	O	O
18	cocaine	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	cardiac	B-Disease	B-Disease
22	dysfunction	E-Disease	E-Disease
23	.	O	O

0	We	O	O
1	hypothesized	O	O
2	that	O	O
3	cocaine	B-Disease	S-Chemical
4	abuse	E-Disease	O
5	may	O	O
6	lead	O	O
7	to	O	O
8	altered	O	O
9	mitochondrial	O	B-Disease
10	function	O	E-Disease
11	that	O	O
12	in	O	O
13	turn	O	O
14	may	O	O
15	cause	O	O
16	left	B-Disease	B-Disease
17	ventricular	I-Disease	B-Disease
18	dysfunction	E-Disease	E-Disease
19	.	O	O

0	Seven	O	O
1	days	O	O
2	of	O	O
3	cocaine	S-Chemical	S-Chemical
4	administration	O	O
5	to	O	O
6	rats	O	O
7	led	O	O
8	to	O	O
9	an	O	O
10	increased	O	O
11	oxygen	S-Chemical	S-Disease
12	consumption	O	O
13	detected	O	O
14	in	O	O
15	cardiac	O	B-Disease
16	fibers	O	O
17	,	O	O
18	specifically	O	O
19	through	O	O
20	complex	O	O
21	I	O	O
22	and	O	O
23	complex	O	O
24	III	O	O
25	.	O	O

0	In	O	O
1	parallel	O	O
2	there	O	O
3	was	O	O
4	a	O	O
5	decrease	O	O
6	in	O	O
7	ATP	S-Chemical	S-Disease
8	synthesis	O	O
9	,	O	O
10	whereas	O	O
11	no	O	O
12	difference	O	O
13	was	O	O
14	observed	O	O
15	in	O	O
16	subsarcolemmal	O	O
17	mitochondria	O	S-Disease
18	.	O	O

0	This	O	O
1	uncoupling	O	O
2	effect	O	O
3	on	O	O
4	oxidative	O	O
5	phosphorylation	O	S-Disease
6	was	O	O
7	not	O	O
8	detectable	O	O
9	after	O	O
10	short	O	O
11	-	O	O
12	term	O	O
13	exposure	O	O
14	to	O	O
15	cocaine	S-Chemical	S-Chemical
16	,	O	O
17	suggesting	O	O
18	that	O	O
19	these	O	O
20	mitochondrial	B-Disease	B-Disease
21	abnormalities	E-Disease	E-Disease
22	were	O	O
23	a	O	O
24	late	O	O
25	rather	O	O
26	than	O	O
27	a	O	O
28	primary	O	O
29	event	O	O
30	in	O	O
31	the	O	O
32	pathological	O	O
33	response	O	O
34	to	O	O
35	cocaine	S-Chemical	S-Chemical
36	.	O	O

0	MitoQ	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	mitochondrial	O	O
4	-	O	O
5	targeted	O	O
6	antioxidant	O	O
7	,	O	O
8	was	O	O
9	shown	O	O
10	to	O	O
11	completely	O	O
12	prevent	O	O
13	these	O	O
14	mitochondrial	B-Disease	B-Disease
15	abnormalities	E-Disease	E-Disease
16	as	O	O
17	well	O	O
18	as	O	O
19	cardiac	B-Disease	B-Disease
20	dysfunction	E-Disease	E-Disease
21	characterized	O	O
22	here	O	O
23	by	O	O
24	a	O	O
25	diastolic	B-Disease	B-Disease
26	dysfunction	E-Disease	E-Disease
27	studied	O	O
28	with	O	O
29	a	O	O
30	conductance	O	O
31	catheter	O	O
32	to	O	O
33	obtain	O	O
34	pressure	O	O
35	-	O	O
36	volume	O	O
37	data	O	O
38	.	O	O

0	Taken	O	O
1	together	O	O
2	,	O	O
3	these	O	O
4	results	O	O
5	extend	O	O
6	previous	O	O
7	studies	O	O
8	and	O	O
9	demonstrate	O	O
10	that	O	O
11	cocaine	S-Chemical	S-Chemical
12	-	O	O
13	induced	O	O
14	cardiac	B-Disease	B-Disease
15	dysfunction	E-Disease	E-Disease
16	may	O	O
17	be	O	O
18	due	O	O
19	to	O	O
20	a	O	O
21	mitochondrial	B-Disease	B-Disease
22	defect	E-Disease	E-Disease
23	.	O	O

0	Trimethoprim	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	immune	O	B-Disease
4	hemolytic	B-Disease	E-Disease
5	anemia	E-Disease	E-Disease
6	in	O	O
7	a	O	O
8	pediatric	O	O
9	oncology	O	O
10	patient	O	O
11	presenting	O	O
12	as	O	O
13	an	O	O
14	acute	O	B-Disease
15	hemolytic	O	O
16	transfusion	O	I-Disease
17	reaction	O	E-Disease
18	.	O	O

0	A	O	O
1	10	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	male	O	O
7	with	O	O
8	acute	B-Disease	B-Disease
9	leukemia	E-Disease	E-Disease
10	presented	O	O
11	with	O	O
12	post	O	O
13	-	O	O
14	chemotherapy	O	O
15	anemia	S-Disease	S-Disease
16	.	O	O

0	During	O	O
1	red	O	O
2	cell	O	O
3	transfusion	O	O
4	,	O	O
5	he	O	O
6	developed	O	O
7	hemoglobinuria	S-Disease	O
8	.	O	O

0	Drug	O	O
1	-	O	O
2	induced	O	O
3	immune	O	O
4	hemolytic	B-Disease	E-Disease
5	anemia	E-Disease	E-Disease
6	was	O	O
7	suspected	O	O
8	because	O	O
9	of	O	O
10	positive	O	O
11	direct	O	O
12	antiglobulin	O	O
13	test	O	O
14	,	O	O
15	negative	O	O
16	eluate	O	O
17	,	O	O
18	and	O	O
19	microspherocytes	O	O
20	on	O	O
21	smear	O	O
22	pre	O	O
23	-	O	O
24	and	O	O
25	post	O	O
26	-	O	O
27	transfusion	O	O
28	.	O	O

0	Drug	O	O
1	studies	O	O
2	using	O	O
3	the	O	O
4	indirect	O	O
5	antiglobulin	O	O
6	test	O	O
7	were	O	O
8	strongly	O	O
9	positive	O	O
10	with	O	O
11	trimethoprim	S-Chemical	S-Chemical
12	and	O	O
13	trimethoprim	B-Chemical	S-Chemical
14	-	I-Chemical	I-Disease
15	sulfamethoxazole	E-Chemical	S-Chemical
16	but	O	O
17	negative	O	O
18	with	O	O
19	sulfamethoxazole	S-Chemical	S-Chemical
20	.	O	O

0	Other	O	O
1	causes	O	O
2	of	O	O
3	anemia	S-Disease	S-Disease
4	should	O	O
5	be	O	O
6	considered	O	O
7	in	O	O
8	patients	O	O
9	with	O	O
10	worse	O	O
11	-	O	O
12	than	O	O
13	-	O	O
14	expected	O	O
15	anemia	S-Disease	S-Disease
16	after	O	O
17	chemotherapy	O	O
18	.	O	O

0	Furthermore	O	O
1	,	O	O
2	hemolysis	S-Disease	O
3	during	O	O
4	transfusion	O	O
5	is	O	O
6	not	O	O
7	always	O	O
8	a	O	O
9	transfusion	O	O
10	reaction	O	O
11	.	O	O

0	Verapamil	S-Chemical	S-Chemical
1	stimulation	O	O
2	test	O	O
3	in	O	O
4	hyperprolactinemia	S-Disease	S-Disease
5	:	O	O
6	loss	O	O
7	of	O	O
8	prolactin	O	S-Chemical
9	response	O	O
10	in	O	O
11	anatomic	O	O
12	or	O	O
13	functional	O	O
14	stalk	O	O
15	effect	O	O
16	.	O	O

0	AIM	O	O
1	:	O	O
2	Verapamil	S-Chemical	S-Chemical
3	stimulation	O	O
4	test	O	O
5	was	O	O
6	previously	O	O
7	investigated	O	O
8	as	O	O
9	a	O	O
10	tool	O	O
11	for	O	O
12	differential	O	O
13	diagnosis	O	O
14	of	O	O
15	hyperprolactinemia	S-Disease	S-Disease
16	,	O	O
17	but	O	O
18	with	O	O
19	conflicting	O	O
20	results	O	O
21	.	O	O

0	Macroprolactinemia	S-Disease	S-Chemical
1	was	O	O
2	never	O	O
3	considered	O	O
4	in	O	O
5	those	O	O
6	previous	O	O
7	studies	O	O
8	.	O	O

0	Here	O	O
1	,	O	O
2	we	O	O
3	aimed	O	O
4	to	O	O
5	re	O	O
6	-	O	O
7	investigate	O	O
8	the	O	O
9	diagnostic	O	O
10	value	O	O
11	of	O	O
12	verapamil	S-Chemical	S-Chemical
13	in	O	O
14	a	O	O
15	population	O	O
16	who	O	O
17	were	O	O
18	all	O	O
19	screened	O	O
20	for	O	O
21	macroprolactinemia	S-Disease	S-Disease
22	.	O	O

0	Prolactin	O	S-Chemical
1	responses	O	O
2	to	O	O
3	verapamil	S-Chemical	S-Chemical
4	in	O	O
5	65	O	O
6	female	O	O
7	patients	O	O
8	(	O	O
9	age	O	O
10	:	O	O
11	29	O	O
12	.	O	O
13	9	O	O
14	+	O	O
15	/	O	O
16	-	O	O
17	8	O	O
18	.	O	O
19	1	O	O
20	years	O	O
21	)	O	O
22	with	O	O
23	hyperprolactinemia	S-Disease	S-Disease
24	were	O	O
25	tested	O	O
26	in	O	O
27	a	O	O
28	descriptive	O	O
29	,	O	O
30	matched	O	O
31	case	O	O
32	-	O	O
33	control	O	O
34	study	O	O
35	.	O	O

0	METHODS	O	O
1	:	O	O
2	Verapamil	S-Chemical	S-Chemical
3	80	O	O
4	mg	O	O
5	,	O	O
6	p	O	O
7	.	O	O
8	o	O	O
9	.	O	O
10	was	O	O
11	administered	O	O
12	,	O	O
13	and	O	O
14	then	O	O
15	PRL	O	O
16	levels	O	O
17	were	O	O
18	measured	O	O
19	at	O	O
20	8th	O	O
21	and	O	O
22	16th	O	O
23	hours	O	O
24	,	O	O
25	by	O	O
26	immunometric	O	O
27	chemiluminescence	O	O
28	.	O	O

0	Verapamil	S-Chemical	S-Chemical
1	responsiveness	O	O
2	was	O	O
3	determined	O	O
4	by	O	O
5	peak	O	O
6	percent	O	O
7	change	O	O
8	in	O	O
9	basal	O	O
10	prolactin	O	S-Disease
11	levels	O	O
12	(	O	O
13	PRL	O	S-Disease
14	)	O	O
15	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Verapamil	S-Chemical	S-Chemical
3	significantly	O	O
4	increased	O	O
5	PRL	O	S-Disease
6	levels	O	O
7	in	O	O
8	healthy	O	O
9	controls	O	O
10	(	O	O
11	N	O	S-Disease
12	.	O	O
13	8	O	O
14	,	O	O
15	PRL	O	O
16	:	O	O
17	183	O	O
18	%	O	O
19	)	O	O
20	,	O	O
21	macroprolactinoma	S-Disease	S-Chemical
22	(	O	O
23	N	O	O
24	.	O	O
25	8	O	O
26	,	O	O
27	PRL	O	O
28	:	O	O
29	7	O	O
30	%	O	O
31	)	O	O
32	,	O	O
33	microprolactinoma	S-Disease	O
34	(	O	O
35	N	O	O
36	.	O	O
37	19	O	O
38	,	O	O
39	PRL	O	O
40	:	O	O
41	21	O	O
42	%	O	O
43	)	O	O
44	,	O	O
45	macroprolactinemia	S-Disease	S-Disease
46	(	O	O
47	N	O	S-Disease
48	.	O	O
49	23	O	O
50	,	O	O
51	PRL	O	S-Disease
52	:	O	O
53	126	O	O
54	%	O	O
55	)	O	O
56	,	O	O
57	but	O	O
58	not	O	O
59	in	O	O
60	pseudoprolactinoma	S-Disease	S-Disease
61	(	O	O
62	N	O	S-Disease
63	.	O	O
64	8	O	O
65	,	O	O
66	PRL	O	S-Disease
67	:	O	O
68	0	O	O
69	.	O	O
70	8	O	O
71	%	O	O
72	)	O	O
73	,	O	O
74	and	O	O
75	risperidone	S-Chemical	S-Chemical
76	-	O	O
77	induced	O	O
78	hyperprolactinemia	S-Disease	S-Disease
79	(	O	O
80	N	O	S-Disease
81	.	O	O
82	7	O	O
83	,	O	O
84	PRL	O	S-Disease
85	:	O	O
86	3	O	O
87	%	O	O
88	)	O	O
89	.	O	O

0	ROC	O	O
1	curve	O	O
2	analysis	O	O
3	revealed	O	O
4	that	O	O
5	unresponsiveness	O	O
6	to	O	O
7	verapamil	S-Chemical	S-Disease
8	defined	O	O
9	as	O	O
10	PRL	O	S-Disease
11	<	O	O
12	7	O	O
13	%	O	O
14	,	O	O
15	discriminated	O	O
16	anatomical	O	O
17	or	O	O
18	functional	O	O
19	stalk	O	O
20	effect	O	O
21	(	O	O
22	sensitivity	O	O
23	:	O	O
24	74	O	O
25	%	O	O
26	,	O	O
27	specificity	O	O
28	:	O	O
29	73	O	O
30	%	O	O
31	,	O	O
32	AUC	O	O
33	:	O	O
34	0	O	O
35	.	O	O
36	855	O	O
37	+	O	O
38	/	O	O
39	-	O	O
40	0	O	O
41	.	O	O
42	04	O	O
43	,	O	O
44	P	O	O
45	<	O	O
46	0	O	O
47	.	O	O
48	001	O	O
49	,	O	O
50	CI	O	S-Disease
51	:	O	O
52	0	O	O
53	.	O	O
54	768	O	O
55	-	O	O
56	0	O	O
57	.	O	O
58	942	O	O
59	)	O	O
60	associated	O	O
61	with	O	O
62	pseudoprolactinoma	S-Disease	S-Disease
63	or	O	O
64	risperidone	S-Chemical	S-Chemical
65	-	O	O
66	induced	O	O
67	hyperprolactinemia	S-Disease	S-Disease
68	,	O	O
69	respectively	O	O
70	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Verapamil	S-Chemical	S-Chemical
3	responsiveness	O	O
4	is	O	O
5	not	O	O
6	a	O	O
7	reliable	O	O
8	finding	O	O
9	for	O	O
10	the	O	O
11	differential	O	O
12	diagnosis	O	O
13	of	O	O
14	hyperprolactinemia	S-Disease	S-Disease
15	.	O	O

0	However	O	O
1	,	O	O
2	verapamil	S-Chemical	S-Chemical
3	unresponsiveness	O	O
4	discriminates	O	O
5	stalk	O	O
6	effect	O	O
7	(	O	O
8	i	O	O
9	.	O	O
10	e	O	O
11	.	O	O
12	,	O	O
13	anatomically	O	O
14	or	O	O
15	functionally	O	O
16	inhibited	O	O
17	dopaminergic	O	O
18	tonus	O	S-Disease
19	)	O	O
20	from	O	O
21	other	O	O
22	causes	O	O
23	of	O	O
24	hyperprolactinemia	S-Disease	S-Disease
25	with	O	O
26	varying	O	O
27	degrees	O	O
28	of	O	O
29	responsiveness	O	O
30	.	O	O

0	Blockade	O	O
1	of	O	O
2	endothelial	O	O
3	-	O	O
4	mesenchymal	O	S-Disease
5	transition	O	O
6	by	O	O
7	a	O	O
8	Smad3	O	S-Chemical
9	inhibitor	O	O
10	delays	O	O
11	the	O	O
12	early	O	O
13	development	O	O
14	of	O	O
15	streptozotocin	S-Chemical	S-Chemical
16	-	O	O
17	induced	O	O
18	diabetic	B-Disease	S-Disease
19	nephropathy	E-Disease	S-Disease
20	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	A	O	O
3	multicenter	O	O
4	,	O	O
5	controlled	O	O
6	trial	O	O
7	showed	O	O
8	that	O	O
9	early	O	O
10	blockade	O	O
11	of	O	O
12	the	O	O
13	renin	O	B-Disease
14	-	O	I-Disease
15	angiotensin	S-Chemical	O
16	system	O	O
17	in	O	O
18	patients	O	O
19	with	O	O
20	type	B-Disease	B-Disease
21	1	I-Disease	I-Disease
22	diabetes	E-Disease	S-Disease
23	and	O	O
24	normoalbuminuria	O	S-Disease
25	did	O	O
26	not	O	O
27	retard	O	O
28	the	O	O
29	progression	O	O
30	of	O	O
31	nephropathy	S-Disease	S-Disease
32	,	O	O
33	suggesting	O	O
34	that	O	O
35	other	O	O
36	mechanism	O	O
37	(	O	O
38	s	O	O
39	)	O	O
40	are	O	O
41	involved	O	O
42	in	O	O
43	the	O	O
44	pathogenesis	O	O
45	of	O	O
46	early	O	O
47	diabetic	B-Disease	B-Disease
48	nephropathy	E-Disease	E-Disease
49	(	O	O
50	diabetic	B-Disease	B-Chemical
51	nephropathy	E-Disease	I-Disease
52	)	O	O
53	.	O	O

0	We	O	O
1	have	O	O
2	previously	O	O
3	demonstrated	O	O
4	that	O	O
5	endothelial	O	S-Disease
6	-	O	I-Disease
7	mesenchymal	O	E-Chemical
8	-	O	O
9	transition	O	S-Disease
10	(	O	O
11	EndoMT	O	S-Chemical
12	)	O	O
13	contributes	O	O
14	to	O	O
15	the	O	O
16	early	O	O
17	development	O	O
18	of	O	O
19	renal	O	B-Disease
20	interstitial	O	I-Disease
21	fibrosis	S-Disease	S-Disease
22	independently	O	O
23	of	O	O
24	microalbuminuria	O	S-Disease
25	in	O	O
26	mice	O	O
27	with	O	O
28	streptozotocin	S-Chemical	S-Disease
29	(	O	O
30	STZ	S-Chemical	S-Disease
31	)	O	O
32	-	O	O
33	induced	O	O
34	diabetes	S-Disease	S-Disease
35	.	O	O

0	In	O	O
1	the	O	O
2	present	O	O
3	study	O	O
4	,	O	O
5	we	O	O
6	hypothesized	O	O
7	that	O	O
8	blocking	O	O
9	EndoMT	O	S-Chemical
10	reduces	O	O
11	the	O	O
12	early	O	O
13	development	O	O
14	of	O	O
15	diabetic	B-Disease	B-Disease
16	nephropathy	E-Disease	E-Disease
17	.	O	O

0	Blocking	O	O
1	studies	O	O
2	using	O	O
3	receptor	O	O
4	for	O	O
5	AGE	O	B-Chemical
6	siRNA	O	E-Chemical
7	and	O	O
8	a	O	O
9	specific	O	O
10	inhibitor	O	O
11	of	O	O
12	Smad3	O	S-Chemical
13	(	O	O
14	SIS3	O	S-Chemical
15	)	O	O
16	were	O	O
17	performed	O	O
18	in	O	O
19	MMECs	O	S-Disease
20	and	O	O
21	in	O	O
22	STZ	S-Chemical	S-Chemical
23	-	O	O
24	induced	O	O
25	diabetic	B-Disease	S-Disease
26	nephropathy	E-Disease	S-Disease
27	in	O	O
28	Tie2	O	B-Chemical
29	-	O	I-Chemical
30	Cre	O	E-Chemical
31	;	O	O
32	Loxp	O	S-Chemical
33	-	O	O
34	EGFP	O	S-Disease
35	mice	O	O
36	.	O	O

0	Immunoprecipitation	O	O
1	/	O	O
2	Western	O	O
3	blotting	O	O
4	showed	O	O
5	that	O	O
6	Smad3	O	S-Chemical
7	was	O	O
8	activated	O	O
9	by	O	O
10	AGEs	O	S-Chemical
11	but	O	O
12	was	O	O
13	inhibited	O	O
14	by	O	O
15	SIS3	O	S-Chemical
16	in	O	O
17	MMECs	O	S-Disease
18	and	O	O
19	in	O	O
20	STZ	S-Chemical	S-Disease
21	-	O	O
22	induced	O	O
23	diabetic	B-Disease	S-Disease
24	nephropathy	E-Disease	S-Disease
25	.	O	O

0	Confocal	O	O
1	microscopy	O	O
2	and	O	O
3	real	O	O
4	-	O	O
5	time	O	O
6	PCR	O	O
7	further	O	O
8	demonstrated	O	O
9	that	O	O
10	SIS3	O	S-Chemical
11	abrogated	O	O
12	EndoMT	O	S-Chemical
13	,	O	O
14	reduced	O	O
15	renal	O	I-Disease
16	fibrosis	S-Disease	E-Disease
17	,	O	O
18	and	O	O
19	retarded	O	O
20	progression	O	O
21	of	O	O
22	nephropathy	S-Disease	S-Disease
23	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	EndoMT	O	S-Chemical
3	is	O	O
4	a	O	O
5	novel	O	O
6	pathway	O	O
7	leading	O	O
8	to	O	O
9	early	O	O
10	development	O	O
11	of	O	O
12	diabetic	B-Disease	B-Disease
13	nephropathy	E-Disease	E-Disease
14	.	O	O

0	Blockade	O	O
1	of	O	O
2	EndoMT	O	S-Chemical
3	by	O	O
4	SIS3	O	S-Chemical
5	may	O	O
6	provide	O	O
7	a	O	O
8	new	O	O
9	strategy	O	O
10	to	O	O
11	retard	O	O
12	the	O	O
13	progression	O	O
14	of	O	O
15	diabetic	B-Disease	B-Disease
16	nephropathy	E-Disease	I-Disease
17	and	O	O
18	other	O	O
19	diabetes	B-Disease	S-Disease
20	complications	E-Disease	O
21	.	O	O

0	Cytostatic	O	O
1	and	O	O
2	anti	O	O
3	-	O	O
4	angiogenic	O	O
5	effects	O	O
6	of	O	O
7	temsirolimus	S-Chemical	S-Chemical
8	in	O	O
9	refractory	O	O
10	mantle	B-Disease	B-Disease
11	cell	I-Disease	I-Disease
12	lymphoma	E-Disease	E-Disease
13	.	O	O

0	Mantle	B-Disease	O
1	cell	I-Disease	O
2	lymphoma	E-Disease	E-Disease
3	(	O	O
4	MCL	S-Disease	S-Chemical
5	)	O	O
6	is	O	O
7	a	O	O
8	rare	O	O
9	and	O	O
10	aggressive	O	O
11	type	O	O
12	of	O	O
13	B	B-Disease	O
14	-	I-Disease	O
15	cell	I-Disease	O
16	non	I-Disease	I-Disease
17	-	I-Disease	O
18	Hodgkin	I-Disease	O
19	'	I-Disease	I-Disease
20	s	I-Disease	I-Disease
21	lymphoma	E-Disease	E-Disease
22	.	O	O

0	However	O	O
1	,	O	O
2	a	O	O
3	38	O	O
4	%	O	O
5	remission	O	O
6	rate	O	O
7	has	O	O
8	been	O	O
9	recently	O	O
10	reported	O	O
11	in	O	O
12	refractory	O	O
13	MCL	S-Disease	S-Chemical
14	treated	O	O
15	with	O	O
16	temsirolimus	S-Chemical	S-Chemical
17	,	O	O
18	a	O	O
19	mTOR	O	O
20	inhibitor	O	O
21	.	O	O
22	Here	O	O
23	we	O	O
24	had	O	O
25	the	O	O
26	opportunity	O	O
27	to	O	O
28	study	O	O
29	a	O	O
30	case	O	O
31	of	O	O
32	refractory	O	O
33	MCL	S-Disease	S-Disease
34	who	O	O
35	had	O	O
36	tumor	S-Disease	S-Disease
37	regression	O	O
38	two	O	O
39	months	O	O
40	after	O	O
41	temsirolimus	S-Chemical	S-Disease
42	treatment	O	O
43	,	O	O
44	and	O	O
45	a	O	O
46	progression	O	O
47	-	O	O
48	free	O	O
49	survival	O	O
50	of	O	O
51	10	O	O
52	months	O	O
53	.	O	O

0	In	O	O
1	this	O	O
2	case	O	O
3	,	O	O
4	lymph	O	B-Disease
5	node	O	E-Disease
6	biopsies	O	O
7	were	O	O
8	performed	O	O
9	before	O	O
10	and	O	O
11	six	O	O
12	months	O	O
13	after	O	O
14	temsirolimus	S-Chemical	S-Chemical
15	therapy	O	O
16	.	O	O

0	Comparison	O	O
1	of	O	O
2	the	O	O
3	two	O	O
4	biopsies	O	O
5	showed	O	O
6	that	O	O
7	temsirolimus	S-Chemical	S-Chemical
8	inhibited	O	O
9	tumor	S-Disease	B-Disease
10	cell	O	I-Disease
11	proliferation	O	E-Disease
12	through	O	O
13	cell	O	O
14	cycle	O	I-Disease
15	arrest	O	E-Disease
16	,	O	O
17	but	O	O
18	did	O	O
19	not	O	O
20	induce	O	O
21	any	O	O
22	change	O	O
23	in	O	O
24	the	O	O
25	number	O	O
26	of	O	O
27	apoptotic	O	O
28	tumor	S-Disease	S-Disease
29	cells	O	O
30	.	O	O

0	Apart	O	O
1	from	O	O
2	this	O	O
3	cytostatic	O	S-Disease
4	effect	O	O
5	,	O	O
6	temsirolimus	S-Chemical	S-Chemical
7	had	O	O
8	an	O	O
9	antiangiogenic	O	O
10	effect	O	O
11	with	O	O
12	decrease	O	O
13	of	O	O
14	tumor	S-Disease	S-Disease
15	microvessel	O	I-Disease
16	density	O	S-Disease
17	and	O	O
18	of	O	O
19	VEGF	O	S-Chemical
20	expression	O	O
21	.	O	O

0	Moreover	O	O
1	,	O	O
2	numerous	O	O
3	patchy	O	O
4	,	O	O
5	well	O	O
6	-	O	O
7	limited	O	O
8	fibrotic	O	S-Disease
9	areas	O	O
10	,	O	O
11	compatible	O	O
12	with	O	O
13	post	O	O
14	-	O	O
15	necrotic	S-Disease	B-Disease
16	tissue	O	O
17	repair	O	O
18	,	O	O
19	were	O	O
20	found	O	O
21	after	O	O
22	6	O	O
23	-	O	O
24	month	O	O
25	temsirolimus	S-Chemical	S-Disease
26	therapy	O	O
27	.	O	O

0	Thus	O	O
1	,	O	O
2	temsirolimus	S-Chemical	S-Chemical
3	reduced	O	O
4	tumor	S-Disease	S-Disease
5	burden	O	E-Disease
6	through	O	O
7	associated	O	O
8	cytostatic	O	S-Disease
9	and	O	O
10	anti	O	O
11	-	O	O
12	angiogenic	O	O
13	effects	O	O
14	.	O	O
15	This	O	O
16	dual	O	O
17	effect	O	O
18	of	O	O
19	temsirolimus	S-Chemical	S-Chemical
20	on	O	O
21	tumor	S-Disease	S-Disease
22	tissue	O	O
23	could	O	O
24	contribute	O	O
25	to	O	O
26	its	O	O
27	recently	O	O
28	reported	O	O
29	efficiency	O	O
30	in	O	O
31	refractory	O	O
32	MCL	S-Disease	S-Chemical
33	resistant	O	O
34	to	O	O
35	conventional	O	O
36	chemotherapy	O	O
37	.	O	O

0	Acute	B-Disease	O
1	renal	I-Disease	B-Disease
2	failure	E-Disease	E-Disease
3	due	O	O
4	to	O	O
5	rifampicin	S-Chemical	S-Chemical
6	.	O	O

0	A	O	O
1	23	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	male	O	O
7	patient	O	O
8	with	O	O
9	bacteriologically	O	O
10	proven	O	O
11	pulmonary	B-Disease	B-Disease
12	tuberculosis	E-Disease	E-Disease
13	was	O	O
14	treated	O	O
15	with	O	O
16	the	O	O
17	various	O	O
18	regimens	O	O
19	of	O	O
20	antituberculosis	O	O
21	drugs	O	O
22	for	O	O
23	nearly	O	O
24	15	O	O
25	months	O	O
26	.	O	O

0	Rifampicin	S-Chemical	S-Chemical
1	was	O	O
2	administered	O	O
3	thrice	O	O
4	as	O	O
5	one	O	O
6	of	O	O
7	the	O	O
8	3	O	O
9	-	O	O
10	4	O	O
11	drug	O	O
12	regimen	O	O
13	and	O	O
14	each	O	O
15	time	O	O
16	he	O	O
17	developed	O	O
18	untoward	O	O
19	side	O	O
20	effects	O	O
21	like	O	O
22	nausea	S-Disease	S-Disease
23	,	O	O
24	vomiting	S-Disease	S-Disease
25	and	O	O
26	fever	S-Disease	S-Disease
27	with	O	O
28	chills	O	S-Disease
29	and	O	O
30	rigors	O	O
31	.	O	O

0	Syncope	S-Disease	O
1	caused	O	O
2	by	O	O
3	hyperkalemia	S-Disease	S-Disease
4	during	O	O
5	use	O	O
6	of	O	O
7	a	O	O
8	combined	O	O
9	therapy	O	O
10	with	O	O
11	the	O	O
12	angiotensin	S-Chemical	O
13	-	O	O
14	converting	O	O
15	enzyme	O	O
16	inhibitor	O	O
17	and	O	O
18	spironolactone	S-Chemical	S-Disease
19	.	O	O

0	A	O	O
1	76	O	O
2	year	O	O
3	-	O	O
4	old	O	O
5	woman	O	O
6	with	O	O
7	a	O	O
8	history	O	O
9	of	O	O
10	coronary	O	B-Disease
11	artery	O	I-Disease
12	bypass	O	E-Disease
13	grafting	O	E-Disease
14	and	O	O
15	prior	O	O
16	myocardial	B-Disease	B-Disease
17	infarction	E-Disease	E-Disease
18	was	O	O
19	transferred	O	O
20	to	O	O
21	the	O	O
22	emergency	O	O
23	room	O	O
24	with	O	O
25	loss	B-Disease	O
26	of	I-Disease	O
27	consciousness	E-Disease	O
28	due	O	O
29	to	O	O
30	marked	O	O
31	bradycardia	S-Disease	O
32	caused	O	O
33	by	O	O
34	hyperkalemia	S-Disease	S-Disease
35	.	O	O

0	The	O	O
1	concentration	O	O
2	of	O	O
3	serum	O	O
4	potassium	S-Chemical	O
5	was	O	O
6	high	O	O
7	,	O	O
8	and	O	O
9	normal	O	O
10	sinus	O	B-Disease
11	rhythm	O	E-Disease
12	was	O	O
13	restored	O	O
14	after	O	O
15	correction	O	O
16	of	O	O
17	the	O	O
18	serum	O	O
19	potassium	S-Chemical	S-Disease
20	level	O	O
21	.	O	O

0	The	O	O
1	cause	O	O
2	of	O	O
3	hyperkalemia	S-Disease	S-Disease
4	was	O	O
5	considered	O	O
6	to	O	O
7	be	O	O
8	several	O	O
9	doses	O	O
10	of	O	O
11	spiranolactone	S-Chemical	S-Chemical
12	,	O	O
13	an	O	O
14	aldosterone	S-Chemical	S-Chemical
15	antagonist	O	O
16	,	O	O
17	in	O	O
18	addition	O	O
19	to	O	O
20	the	O	O
21	long	O	O
22	-	O	O
23	term	O	O
24	intake	O	O
25	of	O	O
26	ramipril	S-Chemical	S-Chemical
27	,	O	O
28	an	O	O
29	ACE	O	S-Disease
30	inhibitor	O	O
31	.	O	O

0	Clinicians	O	O
1	should	O	O
2	be	O	O
3	alert	O	O
4	to	O	O
5	the	O	O
6	possibility	O	O
7	of	O	O
8	hyperkalemia	S-Disease	S-Disease
9	,	O	O
10	especially	O	O
11	in	O	O
12	elderly	O	O
13	patients	O	O
14	using	O	O
15	ACE	O	B-Chemical
16	/	O	I-Disease
17	ARB	O	E-Chemical
18	in	O	O
19	combination	O	O
20	with	O	O
21	potassium	S-Chemical	B-Disease
22	sparing	O	O
23	agents	O	O
24	and	O	O
25	who	O	O
26	have	O	O
27	mild	O	O
28	renal	B-Disease	B-Disease
29	disturbance	E-Disease	E-Disease
30	.	O	O

0	Diffuse	O	O
1	skeletal	O	B-Disease
2	pain	S-Disease	E-Disease
3	after	O	O
4	administration	O	O
5	of	O	O
6	alendronate	S-Chemical	S-Chemical
7	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Osteoporosis	S-Disease	S-Disease
3	is	O	O
4	caused	O	O
5	by	O	O
6	bone	O	B-Disease
7	resorption	O	E-Disease
8	in	O	O
9	excess	O	O
10	of	O	O
11	bone	O	B-Disease
12	formation	O	E-Disease
13	,	O	O
14	and	O	O
15	bisphosphonates	S-Chemical	S-Disease
16	,	O	O
17	are	O	O
18	used	O	O
19	to	O	O
20	inhibit	O	O
21	bone	O	B-Disease
22	resorption	O	E-Disease
23	.	O	O

0	Alendronate	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	biphosphonate	S-Chemical	S-Chemical
4	,	O	O
5	is	O	O
6	effective	O	O
7	for	O	O
8	both	O	O
9	the	O	O
10	treatment	O	O
11	and	O	O
12	prevention	O	O
13	of	O	O
14	osteoporosis	S-Disease	S-Disease
15	in	O	O
16	postmenopausal	O	O
17	women	O	O
18	.	O	O

0	Musculoskeletal	B-Disease	O
1	pain	E-Disease	S-Disease
2	may	O	O
3	be	O	O
4	an	O	O
5	important	O	O
6	side	O	O
7	effect	O	O
8	in	O	O
9	these	O	O
10	patients	O	O
11	.	O	O

0	We	O	O
1	presented	O	O
2	a	O	O
3	patient	O	O
4	admitted	O	O
5	to	O	O
6	our	O	O
7	out	O	O
8	-	O	O
9	patient	O	O
10	clinic	O	O
11	with	O	O
12	diffuse	O	O
13	skeletal	O	B-Disease
14	pain	S-Disease	E-Disease
15	after	O	O
16	three	O	O
17	consecutive	O	O
18	administration	O	O
19	of	O	O
20	alendronate	S-Chemical	S-Chemical
21	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	We	O	O
3	conclude	O	O
4	that	O	O
5	patients	O	O
6	with	O	O
7	osteoporosis	S-Disease	S-Disease
8	can	O	O
9	report	O	O
10	pain	S-Disease	S-Disease
11	,	O	O
12	and	O	O
13	bisphosphonate	S-Chemical	S-Disease
14	-	O	O
15	related	O	O
16	pain	S-Disease	S-Disease
17	should	O	O
18	also	O	O
19	be	O	O
20	considered	O	O
21	before	O	O
22	ascribing	O	O
23	this	O	O
24	complaint	O	O
25	to	O	O
26	osteoporosis	S-Disease	S-Disease
27	.	O	O

0	Cerebrospinal	O	B-Disease
1	fluid	O	E-Disease
2	penetration	O	O
3	of	O	O
4	high	O	O
5	-	O	O
6	dose	O	O
7	daptomycin	S-Chemical	S-Chemical
8	in	O	O
9	suspected	O	O
10	Staphylococcus	O	B-Disease
11	aureus	O	I-Disease
12	meningitis	S-Disease	E-Disease
13	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	report	O	O
4	a	O	O
5	case	O	O
6	of	O	O
7	methicillin	S-Chemical	S-Chemical
8	-	O	O
9	sensitive	O	O
10	Staphylococcus	O	B-Disease
11	aureus	O	E-Disease
12	(	O	O
13	MSSA	O	S-Chemical
14	)	O	O
15	bacteremia	S-Disease	S-Disease
16	with	O	O
17	suspected	O	O
18	MSSA	O	B-Disease
19	meningitis	S-Disease	E-Disease
20	treated	O	O
21	with	O	O
22	high	O	O
23	-	O	O
24	dose	O	O
25	daptomycin	S-Chemical	S-Chemical
26	assessed	O	O
27	with	O	O
28	concurrent	O	O
29	serum	O	O
30	and	O	O
31	cerebrospinal	O	B-Disease
32	fluid	O	E-Disease
33	(	O	O
34	CSF	O	S-Chemical
35	)	O	O
36	concentrations	O	O
37	.	O	O

0	CASE	O	O
1	SUMMARY	O	O
2	:	O	O
3	A	O	O
4	54	O	O
5	-	O	O
6	year	O	O
7	-	O	O
8	old	O	O
9	male	O	O
10	presented	O	O
11	to	O	O
12	the	O	O
13	emergency	O	O
14	department	O	O
15	with	O	O
16	generalized	O	O
17	weakness	S-Disease	S-Disease
18	and	O	O
19	presumed	O	O
20	health	O	O
21	-	O	O
22	care	O	O
23	-	O	O
24	associated	O	O
25	pneumonia	S-Disease	S-Disease
26	shown	O	O
27	on	O	O
28	chest	O	O
29	radiograph	O	O
30	.	O	O

0	Treatment	O	O
1	was	O	O
2	empirically	O	O
3	initiated	O	O
4	with	O	O
5	vancomycin	S-Chemical	S-Chemical
6	,	O	O
7	levofloxacin	S-Chemical	S-Chemical
8	,	O	O
9	and	O	O
10	piperacillin	S-Chemical	S-Chemical
11	/	O	I-Disease
12	tazobactam	S-Chemical	E-Chemical
13	.	O	O

0	Blood	O	O
1	cultures	O	O
2	revealed	O	O
3	S	O	B-Chemical
4	.	O	B-Disease
5	aureus	O	E-Chemical
6	susceptible	O	O
7	to	O	O
8	oxacillin	S-Chemical	S-Chemical
9	.	O	O

0	Empiric	O	O
1	antibiotic	O	O
2	treatment	O	O
3	was	O	O
4	narrowed	O	O
5	to	O	O
6	nafcillin	S-Chemical	S-Chemical
7	on	O	O
8	day	O	O
9	4	O	O
10	.	O	O

0	On	O	O
1	day	O	O
2	8	O	O
3	,	O	O
4	the	O	O
5	patient	O	O
6	developed	O	O
7	acute	B-Disease	B-Disease
8	renal	I-Disease	I-Disease
9	failure	E-Disease	E-Disease
10	(	O	O
11	serum	O	O
12	creatinine	S-Chemical	S-Chemical
13	1	O	O
14	.	O	O
15	9	O	O
16	mg	O	O
17	/	O	O
18	dL	O	O
19	,	O	O
20	increased	O	O
21	from	O	O
22	1	O	O
23	.	O	O
24	2	O	O
25	mg	O	O
26	/	O	O
27	dL	O	O
28	the	O	O
29	previous	O	O
30	day	O	O
31	and	O	O
32	0	O	O
33	.	O	O
34	8	O	O
35	mg	O	O
36	/	O	O
37	dL	O	O
38	on	O	O
39	admission	O	O
40	)	O	O
41	.	O	O

0	The	O	O
1	patient	O	O
2	'	O	O
3	s	O	O
4	Glasgow	O	B-Chemical
5	Coma	O	E-Chemical
6	Score	O	O
7	was	O	O
8	3	O	O
9	,	O	O
10	with	O	O
11	normal	O	O
12	findings	O	O
13	shown	O	O
14	on	O	O
15	computed	O	O
16	tomography	O	O
17	scan	O	O
18	of	O	O
19	the	O	O
20	head	O	O
21	72	O	O
22	hours	O	O
23	following	O	O
24	an	O	O
25	episode	O	O
26	of	O	O
27	cardiac	B-Disease	B-Disease
28	arrest	E-Disease	E-Disease
29	on	O	O
30	day	O	O
31	10	O	O
32	.	O	O

0	The	O	O
1	patient	O	O
2	experienced	O	O
3	relapsing	O	O
4	MSSA	O	B-Disease
5	bacteremia	S-Disease	E-Disease
6	on	O	O
7	day	O	O
8	9	O	O
9	,	O	O
10	increasing	O	O
11	the	O	O
12	suspicion	O	O
13	for	O	O
14	a	O	O
15	central	O	B-Disease
16	nervous	O	I-Disease
17	system	O	E-Disease
18	(	O	O
19	CNS	O	S-Disease
20	)	O	O
21	infection	S-Disease	E-Disease
22	.	O	O

0	Nafcillin	S-Chemical	S-Chemical
1	was	O	O
2	discontinued	O	O
3	and	O	O
4	daptomycin	S-Chemical	S-Chemical
5	9	O	O
6	mg	O	O
7	/	O	O
8	kg	O	O
9	daily	O	O
10	was	O	O
11	initiated	O	O
12	for	O	O
13	suspected	O	O
14	meningitis	S-Disease	S-Disease
15	and	O	O
16	was	O	O
17	continued	O	O
18	until	O	O
19	the	O	O
20	patient	O	O
21	'	O	O
22	s	O	O
23	death	O	O
24	on	O	O
25	day	O	O
26	16	O	O
27	.	O	O

0	Daptomycin	S-Chemical	S-Chemical
1	serum	O	O
2	and	O	O
3	CSF	O	S-Disease
4	trough	O	O
5	concentrations	O	O
6	were	O	O
7	11	O	O
8	.	O	O
9	21	O	O
10	ug	O	O
11	/	O	O
12	mL	O	O
13	and	O	O
14	0	O	O
15	.	O	O
16	52	O	O
17	ug	O	O
18	/	O	O
19	mL	O	O
20	,	O	O
21	respectively	O	O
22	,	O	O
23	prior	O	O
24	to	O	O
25	the	O	O
26	third	O	O
27	dose	O	O
28	.	O	O

0	Creatine	S-Chemical	S-Chemical
1	kinase	O	O
2	levels	O	O
3	were	O	O
4	normal	O	O
5	prior	O	O
6	to	O	O
7	daptomycin	S-Chemical	S-Chemical
8	therapy	O	O
9	and	O	O
10	were	O	O
11	not	O	O
12	reassessed	O	O
13	.	O	O

0	DISCUSSION	O	O
1	:	O	O
2	Daptomycin	S-Chemical	S-Chemical
3	was	O	O
4	initiated	O	O
5	in	O	O
6	our	O	O
7	patient	O	O
8	secondary	O	O
9	to	O	O
10	possible	O	O
11	nafcillin	S-Chemical	S-Chemical
12	-	O	O
13	induced	O	O
14	acute	O	B-Disease
15	interstitial	B-Disease	I-Disease
16	nephritis	E-Disease	E-Disease
17	and	O	O
18	relapsing	O	O
19	bacteremia	S-Disease	S-Disease
20	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	High	O	O
3	-	O	O
4	dose	O	O
5	daptomycin	S-Chemical	S-Chemical
6	may	O	O
7	be	O	O
8	an	O	O
9	alternative	O	O
10	option	O	O
11	for	O	O
12	MSSA	O	B-Disease
13	bacteremia	S-Disease	E-Disease
14	with	O	O
15	or	O	O
16	without	O	O
17	a	O	O
18	CNS	O	S-Disease
19	source	O	O
20	in	O	O
21	patients	O	O
22	who	O	O
23	have	O	O
24	failed	O	O
25	or	O	O
26	cannot	O	O
27	tolerate	O	O
28	standard	O	O
29	therapy	O	O
30	.	O	O

0	Further	O	O
1	clinical	O	O
2	evaluation	O	O
3	in	O	O
4	patients	O	O
5	with	O	O
6	confirmed	O	O
7	meningitis	S-Disease	S-Disease
8	is	O	O
9	warranted	O	O
10	.	O	O

0	The	O	O
1	role	O	O
2	of	O	O
3	nitric	B-Chemical	S-Chemical
4	oxide	E-Chemical	E-Chemical
5	in	O	O
6	convulsions	S-Disease	O
7	induced	O	O
8	by	O	O
9	lindane	S-Chemical	S-Chemical
10	in	O	O
11	rats	O	O
12	.	O	O

0	Lindane	S-Chemical	S-Chemical
1	is	O	O
2	an	O	O
3	organochloride	O	S-Chemical
4	pesticide	O	O
5	and	O	O
6	scabicide	O	S-Disease
7	.	O	O

0	It	O	O
1	evokes	O	O
2	convulsions	S-Disease	O
3	mainly	O	O
4	trough	O	O
5	the	O	O
6	blockage	O	O
7	of	O	O
8	GABA	S-Chemical	S-Chemical
9	(	O	O
10	A	O	O
11	)	O	O
12	receptors	O	O
13	.	O	O

0	Nitric	B-Chemical	S-Chemical
1	oxide	E-Chemical	E-Chemical
2	(	O	O
3	NO	S-Chemical	S-Chemical
4	)	O	O
5	,	O	O
6	gaseous	O	O
7	neurotransmitter	O	S-Disease
8	,	O	O
9	has	O	O
10	contradictor	O	O
11	role	O	O
12	in	O	O
13	epileptogenesis	O	O
14	due	O	O
15	to	O	O
16	opposite	O	O
17	effects	O	O
18	of	O	O
19	L	B-Chemical	B-Chemical
20	-	I-Chemical	I-Chemical
21	arginine	E-Chemical	E-Chemical
22	,	O	O
23	precursor	O	O
24	of	O	O
25	NO	S-Chemical	S-Chemical
26	syntheses	O	O
27	(	O	O
28	NOS	O	S-Disease
29	)	O	O
30	,	O	O
31	and	O	O
32	L	B-Chemical	B-Chemical
33	-	I-Chemical	I-Chemical
34	NAME	E-Chemical	E-Chemical
35	(	O	O
36	NOS	O	O
37	inhibitor	O	O
38	)	O	O
39	observed	O	O
40	in	O	O
41	different	O	O
42	epilepsy	S-Disease	S-Disease
43	models	O	O
44	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	the	O	O
4	current	O	O
5	study	O	O
6	was	O	O
7	to	O	O
8	determine	O	O
9	the	O	O
10	effects	O	O
11	of	O	O
12	NO	S-Chemical	S-Chemical
13	on	O	O
14	the	O	O
15	behavioral	O	O
16	and	O	O
17	EEG	O	S-Disease
18	characteristics	O	O
19	of	O	O
20	lindane	S-Chemical	S-Chemical
21	-	O	O
22	induced	O	O
23	epilepsy	S-Disease	S-Disease
24	in	O	O
25	male	O	O
26	Wistar	O	O
27	albino	O	O
28	rats	O	O
29	.	O	O

0	The	O	O
1	administration	O	O
2	of	O	O
3	L	B-Chemical	B-Chemical
4	-	I-Chemical	I-Chemical
5	arginine	E-Chemical	E-Chemical
6	(	O	O
7	600	O	O
8	,	O	O
9	800	O	O
10	and	O	O
11	1000	O	O
12	mg	O	O
13	/	O	O
14	kg	O	O
15	,	O	O
16	i	O	O
17	.	O	O
18	p	O	O
19	.	O	O
20	)	O	O
21	in	O	O
22	dose	O	O
23	-	O	O
24	dependent	O	O
25	manner	O	O
26	significantly	O	O
27	increased	O	O
28	convulsion	S-Disease	O
29	incidence	O	O
30	and	O	O
31	severity	O	O
32	and	O	O
33	shortened	O	O
34	latency	O	O
35	time	O	O
36	to	O	O
37	first	O	O
38	convulsion	S-Disease	O
39	elicited	O	O
40	by	O	O
41	lower	O	O
42	lindane	S-Chemical	S-Chemical
43	dose	O	O
44	(	O	O
45	4	O	O
46	mg	O	O
47	/	O	O
48	kg	O	O
49	,	O	O
50	i	O	O
51	.	O	O
52	p	O	O
53	.	O	O
54	)	O	O
55	.	O	O

0	On	O	O
1	the	O	O
2	contrary	O	O
3	,	O	O
4	pretreatment	O	O
5	with	O	O
6	L	B-Chemical	B-Chemical
7	-	I-Chemical	I-Chemical
8	NAME	E-Chemical	E-Chemical
9	(	O	O
10	500	O	O
11	,	O	O
12	700	O	O
13	and	O	O
14	900	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	,	O	O
19	i	O	O
20	.	O	O
21	p	O	O
22	.	O	O
23	)	O	O
24	decreased	O	O
25	convulsion	S-Disease	O
26	incidence	O	O
27	and	O	O
28	severity	O	O
29	and	O	O
30	prolonged	O	O
31	latency	O	O
32	time	O	O
33	to	O	O
34	convulsion	S-Disease	O
35	following	O	O
36	injection	O	O
37	with	O	O
38	a	O	O
39	convulsive	S-Disease	O
40	dose	O	O
41	of	O	O
42	lindane	S-Chemical	S-Chemical
43	(	O	O
44	8	O	O
45	mg	O	O
46	/	O	O
47	kg	O	O
48	,	O	O
49	i	O	O
50	.	O	O
51	p	O	O
52	.	O	O
53	)	O	O
54	.	O	O

0	EEG	O	O
1	analyses	O	O
2	showed	O	O
3	increase	O	O
4	of	O	O
5	number	O	O
6	and	O	O
7	duration	O	O
8	of	O	O
9	ictal	O	O
10	periods	O	O
11	in	O	O
12	EEG	O	S-Disease
13	of	O	O
14	rats	O	O
15	receiving	O	O
16	l	B-Chemical	S-Chemical
17	-	I-Chemical	I-Chemical
18	arginine	E-Chemical	E-Chemical
19	prior	O	O
20	to	O	O
21	lindane	S-Chemical	S-Chemical
22	and	O	O
23	decrease	O	O
24	of	O	O
25	this	O	O
26	number	O	O
27	in	O	O
28	rats	O	O
29	pretreated	O	O
30	with	O	O
31	L	B-Chemical	B-Chemical
32	-	I-Chemical	I-Chemical
33	NAME	E-Chemical	E-Chemical
34	.	O	O

0	These	O	O
1	results	O	O
2	support	O	O
3	the	O	O
4	conclusion	O	O
5	that	O	O
6	NO	S-Chemical	S-Chemical
7	plays	O	O
8	a	O	O
9	role	O	O
10	of	O	O
11	endogenous	O	O
12	convulsant	O	O
13	in	O	O
14	rat	O	O
15	model	O	O
16	of	O	O
17	lindane	S-Chemical	S-Chemical
18	seizures	S-Disease	E-Disease
19	.	O	O

0	Severe	O	O
1	polyneuropathy	S-Disease	S-Disease
2	and	O	O
3	motor	O	B-Disease
4	loss	O	E-Disease
5	after	O	O
6	intrathecal	O	O
7	thiotepa	S-Chemical	S-Disease
8	combination	O	O
9	chemotherapy	O	O
10	:	O	O
11	description	O	O
12	of	O	O
13	two	O	O
14	cases	O	O
15	.	O	O

0	Two	O	O
1	cases	O	O
2	of	O	O
3	severe	O	O
4	delayed	O	O
5	neurologic	B-Disease	O
6	toxicity	E-Disease	S-Disease
7	related	O	O
8	to	O	O
9	the	O	O
10	administration	O	O
11	of	O	O
12	intrathecal	O	O
13	(	O	O
14	IT	O	S-Disease
15	)	O	O
16	combination	O	O
17	chemotherapy	O	O
18	including	O	O
19	thiotepa	S-Chemical	S-Chemical
20	(	O	O
21	TSPA	S-Chemical	S-Disease
22	)	O	O
23	are	O	O
24	presented	O	O
25	.	O	O

0	Both	O	O
1	cases	O	O
2	developed	O	O
3	axonal	B-Disease	O
4	neuropathy	E-Disease	I-Disease
5	with	O	O
6	motor	O	O
7	predominance	O	O
8	in	O	O
9	the	O	O
10	lower	O	O
11	extremities	O	O
12	1	O	O
13	and	O	O
14	6	O	O
15	months	O	O
16	after	O	O
17	IT	O	S-Chemical
18	chemotherapy	O	O
19	was	O	O
20	administered	O	O
21	.	O	O

0	Neurologic	B-Disease	O
1	toxicities	E-Disease	O
2	have	O	O
3	been	O	O
4	described	O	O
5	with	O	O
6	IT	O	B-Chemical
7	-	O	I-Chemical
8	methotrexate	S-Chemical	S-Chemical
9	,	O	O
10	IT	O	B-Chemical
11	-	O	I-Chemical
12	cytosine	B-Chemical	I-Chemical
13	arabinoside	E-Chemical	E-Chemical
14	and	O	O
15	IT	O	B-Chemical
16	-	O	I-Chemical
17	TSPA	S-Chemical	E-Chemical
18	.	O	O

0	To	O	O
1	our	O	O
2	knowledge	O	O
3	,	O	O
4	however	O	O
5	,	O	O
6	axonal	B-Disease	O
7	neuropathy	E-Disease	I-Disease
8	following	O	O
9	administration	O	O
10	of	O	O
11	these	O	O
12	three	O	O
13	agents	O	O
14	has	O	O
15	not	O	O
16	been	O	O
17	previously	O	O
18	described	O	O
19	.	O	O

0	In	O	O
1	spite	O	O
2	of	O	O
3	the	O	O
4	fact	O	O
5	that	O	O
6	TSPA	S-Chemical	S-Chemical
7	is	O	O
8	a	O	O
9	useful	O	O
10	IT	O	O
11	agent	O	O
12	,	O	O
13	its	O	O
14	combination	O	O
15	with	O	O
16	MTX	S-Chemical	S-Chemical
17	,	O	O
18	ara	B-Chemical	S-Disease
19	-	I-Chemical	O
20	C	E-Chemical	O
21	and	O	O
22	radiotherapy	O	S-Disease
23	could	O	O
24	cause	O	O
25	severe	O	O
26	neurotoxicity	S-Disease	S-Disease
27	.	O	O

0	This	O	O
1	unexpected	O	O
2	complication	O	O
3	indicates	O	O
4	the	O	O
5	need	O	O
6	for	O	O
7	further	O	O
8	toxicology	O	O
9	research	O	O
10	on	O	O
11	IT	O	S-Chemical
12	-	O	O
13	TSPA	S-Chemical	E-Chemical
14	.	O	O

0	Effects	O	O
1	of	O	O
2	cromakalim	S-Chemical	S-Chemical
3	and	O	O
4	pinacidil	S-Chemical	S-Chemical
5	on	O	O
6	large	O	O
7	epicardial	O	S-Disease
8	and	O	O
9	small	O	O
10	coronary	O	B-Disease
11	arteries	O	E-Disease
12	in	O	O
13	conscious	O	O
14	dogs	O	O
15	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	i	O	O
4	.	O	O
5	v	O	O
6	.	O	O
7	bolus	O	O
8	administration	O	O
9	of	O	O
10	cromakalim	S-Chemical	S-Chemical
11	(	O	O
12	1	O	O
13	-	O	O
14	10	O	O
15	micrograms	O	O
16	/	O	O
17	kg	O	O
18	)	O	O
19	and	O	O
20	pinacidil	S-Chemical	S-Chemical
21	(	O	O
22	3	O	O
23	-	O	O
24	100	O	O
25	micrograms	O	O
26	/	O	O
27	kg	O	O
28	)	O	O
29	on	O	O
30	large	O	O
31	(	O	O
32	circumflex	O	O
33	artery	O	O
34	)	O	O
35	and	O	O
36	small	O	O
37	coronary	O	O
38	arteries	O	O
39	and	O	O
40	on	O	O
41	systemic	O	O
42	hemodynamics	O	O
43	were	O	O
44	investigated	O	O
45	in	O	O
46	chronically	O	O
47	instrumented	O	O
48	conscious	O	O
49	dogs	O	O
50	and	O	O
51	compared	O	O
52	to	O	O
53	those	O	O
54	of	O	O
55	nitroglycerin	S-Chemical	S-Chemical
56	(	O	O
57	0	O	O
58	.	O	O
59	03	O	O
60	-	O	O
61	10	O	O
62	micrograms	O	O
63	/	O	O
64	kg	O	O
65	)	O	O
66	.	O	O

0	Nitroglycerin	S-Chemical	S-Chemical
1	,	O	O
2	up	O	O
3	to	O	O
4	0	O	O
5	.	O	O
6	3	O	O
7	micrograms	O	O
8	/	O	O
9	kg	O	O
10	,	O	O
11	selectively	O	O
12	increased	O	O
13	circumflex	O	B-Disease
14	artery	O	I-Disease
15	diameter	O	O
16	(	O	O
17	CxAD	O	S-Chemical
18	)	O	O
19	without	O	O
20	simultaneously	O	O
21	affecting	O	O
22	any	O	O
23	other	O	O
24	cardiac	O	S-Disease
25	or	O	O
26	systemic	O	O
27	hemodynamic	O	O
28	parameter	O	O
29	.	O	O

0	In	O	O
1	contrast	O	O
2	,	O	O
3	cromakalim	S-Chemical	S-Chemical
4	and	O	O
5	pinacidil	S-Chemical	S-Chemical
6	at	O	O
7	all	O	O
8	doses	O	O
9	and	O	O
10	nitroglycerin	S-Chemical	S-Chemical
11	at	O	O
12	doses	O	O
13	higher	O	O
14	than	O	O
15	0	O	O
16	.	O	O
17	3	O	O
18	micrograms	O	O
19	/	O	O
20	kg	O	O
21	simultaneously	O	O
22	and	O	O
23	dose	O	O
24	-	O	O
25	dependently	O	O
26	increased	O	O
27	CxAD	O	S-Chemical
28	,	O	O
29	coronary	O	B-Disease
30	blood	O	I-Disease
31	flow	O	E-Disease
32	and	O	O
33	heart	O	O
34	rate	O	O
35	and	O	O
36	decreased	O	O
37	coronary	O	B-Disease
38	vascular	O	I-Disease
39	resistance	O	E-Disease
40	and	O	O
41	aortic	O	S-Disease
42	pressure	O	O
43	.	O	O

0	Cromakalim	S-Chemical	S-Chemical
1	was	O	O
2	approximately	O	O
3	8	O	O
4	-	O	O
5	to	O	O
6	9	O	O
7	.	O	O
8	5	O	O
9	-	O	O
10	fold	O	O
11	more	O	O
12	potent	O	O
13	than	O	O
14	pinacidil	S-Chemical	S-Chemical
15	in	O	O
16	increasing	O	O
17	CxAD	O	S-Chemical
18	.	O	O

0	Vasodilation	O	O
1	of	O	O
2	large	O	O
3	and	O	O
4	small	O	O
5	coronary	O	S-Disease
6	vessels	O	E-Disease
7	and	O	O
8	hypotension	S-Disease	S-Disease
9	induced	O	O
10	by	O	O
11	cromakalim	S-Chemical	S-Chemical
12	and	O	O
13	pinacidil	S-Chemical	S-Chemical
14	were	O	O
15	not	O	O
16	affected	O	O
17	by	O	O
18	prior	O	O
19	combined	O	O
20	beta	B-Chemical	O
21	adrenergic	I-Chemical	O
22	and	I-Chemical	O
23	muscarinic	I-Chemical	S-Disease
24	receptors	I-Chemical	O
25	blockade	E-Chemical	O
26	but	O	O
27	drug	O	O
28	-	O	O
29	induced	O	O
30	tachycardia	S-Disease	S-Disease
31	was	O	O
32	abolished	O	O
33	.	O	O

0	When	O	O
1	circumflex	O	O
2	artery	O	O
3	blood	O	O
4	flow	O	O
5	was	O	O
6	maintained	O	O
7	constant	O	O
8	,	O	O
9	the	O	O
10	increases	O	O
11	in	O	O
12	CxAD	O	S-Chemical
13	induced	O	O
14	by	O	O
15	cromakalim	S-Chemical	S-Chemical
16	(	O	O
17	10	O	O
18	micrograms	O	O
19	/	O	O
20	kg	O	O
21	)	O	O
22	,	O	O
23	pinacidil	S-Chemical	S-Disease
24	(	O	O
25	30	O	O
26	micrograms	O	O
27	/	O	O
28	kg	O	O
29	)	O	O
30	and	O	O
31	nitroglycerin	S-Chemical	S-Chemical
32	(	O	O
33	10	O	O
34	micrograms	O	O
35	/	O	O
36	kg	O	O
37	)	O	O
38	were	O	O
39	reduced	O	O
40	by	O	O
41	68	O	O
42	+	O	O
43	/	O	O
44	-	O	O
45	7	O	O
46	,	O	O
47	54	O	O
48	+	O	O
49	/	O	O
50	-	O	O
51	9	O	O
52	and	O	O
53	1	O	O
54	+	O	O
55	/	O	O
56	-	O	O
57	1	O	O
58	%	O	O
59	,	O	O
60	respectively	O	O
61	.	O	O

0	Thus	O	O
1	,	O	O
2	whereas	O	O
3	nitroglycerin	S-Chemical	S-Chemical
4	preferentially	O	O
5	and	O	O
6	flow	O	O
7	-	O	O
8	independently	O	O
9	dilates	O	O
10	large	O	O
11	coronary	O	B-Disease
12	arteries	O	I-Disease
13	,	O	O
14	cromakalim	S-Chemical	S-Chemical
15	and	O	O
16	pinacidil	S-Chemical	S-Chemical
17	dilate	O	O
18	both	O	O
19	large	O	O
20	and	O	O
21	small	O	O
22	coronary	O	B-Disease
23	arteries	O	E-Disease
24	and	O	O
25	this	O	O
26	effect	O	O
27	is	O	O
28	not	O	O
29	dependent	O	O
30	upon	O	O
31	the	O	O
32	simultaneous	O	O
33	beta	O	O
34	adrenoceptors	O	E-Chemical
35	-	O	O
36	mediated	O	O
37	rise	O	O
38	in	O	O
39	myocardial	O	B-Disease
40	metabolic	O	E-Disease
41	demand	O	E-Disease
42	.	O	O

0	Finally	O	O
1	,	O	O
2	two	O	O
3	mechanisms	O	O
4	at	O	O
5	least	O	O
6	,	O	O
7	direct	O	O
8	vasodilation	O	S-Disease
9	and	O	O
10	flow	O	S-Disease
11	dependency	O	O
12	,	O	O
13	are	O	O
14	involved	O	O
15	in	O	O
16	the	O	O
17	cromakalim	S-Chemical	S-Chemical
18	-	O	O
19	and	O	O
20	pinacidil	S-Chemical	S-Chemical
21	-	O	O
22	induced	O	O
23	increase	O	S-Disease
24	in	O	O
25	CxAD	O	S-Chemical
26	.	O	O

0	Mefenamic	B-Chemical	S-Chemical
1	acid	E-Chemical	O
2	-	O	O
3	induced	O	O
4	neutropenia	S-Disease	S-Disease
5	and	O	O
6	renal	B-Disease	B-Disease
7	failure	E-Disease	E-Disease
8	in	O	O
9	elderly	O	O
10	females	O	O
11	with	O	O
12	hypothyroidism	S-Disease	S-Disease
13	.	O	O

0	We	O	O
1	report	O	O
2	mefenamic	B-Chemical	S-Chemical
3	acid	E-Chemical	O
4	-	O	O
5	induced	O	O
6	non	O	O
7	-	O	O
8	oliguric	O	B-Disease
9	renal	B-Disease	I-Disease
10	failure	E-Disease	E-Disease
11	and	O	O
12	severe	O	O
13	neutropenia	S-Disease	S-Disease
14	occurring	O	O
15	simultaneously	O	O
16	in	O	O
17	two	O	O
18	elderly	O	O
19	females	O	O
20	.	O	O

0	The	O	O
1	neutropenia	S-Disease	S-Disease
2	was	O	O
3	due	O	O
4	to	O	O
5	maturation	O	O
6	arrest	O	S-Disease
7	of	O	O
8	the	O	O
9	myeloid	O	B-Disease
10	series	O	O
11	in	O	O
12	one	O	O
13	patient	O	O
14	.	O	O

0	Both	O	O
1	patients	O	O
2	were	O	O
3	also	O	O
4	hypothyroid	S-Disease	S-Disease
5	,	O	O
6	but	O	O
7	it	O	O
8	is	O	O
9	not	O	O
10	clear	O	O
11	whether	O	O
12	this	O	O
13	was	O	O
14	a	O	O
15	predisposing	O	O
16	factor	O	O
17	to	O	O
18	the	O	O
19	development	O	O
20	of	O	O
21	these	O	O
22	adverse	O	O
23	reactions	O	O
24	.	O	O

0	However	O	O
1	,	O	O
2	it	O	O
3	would	O	O
4	seem	O	O
5	prudent	O	O
6	not	O	O
7	to	O	O
8	use	O	O
9	mefenamic	B-Chemical	S-Chemical
10	acid	E-Chemical	E-Disease
11	in	O	O
12	hypothyroid	S-Disease	S-Disease
13	patients	O	O
14	until	O	O
15	the	O	O
16	hypothyroidism	S-Disease	S-Disease
17	has	O	O
18	been	O	O
19	corrected	O	O
20	.	O	O

0	Etiology	O	O
1	of	O	O
2	hypercalcemia	S-Disease	S-Disease
3	in	O	O
4	hemodialysis	O	O
5	patients	O	O
6	on	O	O
7	calcium	B-Chemical	B-Chemical
8	carbonate	E-Chemical	E-Chemical
9	therapy	O	O
10	.	O	O

0	Fourteen	O	O
1	of	O	O
2	39	O	O
3	dialysis	O	O
4	patients	O	O
5	(	O	O
6	36	O	O
7	%	O	O
8	)	O	O
9	became	O	O
10	hypercalcemic	S-Disease	S-Disease
11	after	O	O
12	switching	O	O
13	to	O	O
14	calcium	B-Chemical	B-Chemical
15	carbonate	E-Chemical	E-Chemical
16	as	O	O
17	their	O	O
18	principal	O	O
19	phosphate	S-Chemical	S-Disease
20	binder	O	O
21	.	O	O

0	In	O	O
1	order	O	O
2	to	O	O
3	identify	O	O
4	risk	O	O
5	factors	O	O
6	associated	O	O
7	with	O	O
8	the	O	O
9	development	O	O
10	of	O	O
11	hypercalcemia	S-Disease	S-Disease
12	,	O	O
13	indirect	O	O
14	parameters	O	O
15	of	O	O
16	intestinal	O	O
17	calcium	S-Chemical	B-Disease
18	reabsorption	O	E-Disease
19	and	O	O
20	bone	O	B-Disease
21	turnover	O	E-Disease
22	rate	O	O
23	in	O	O
24	these	O	O
25	14	O	O
26	patients	O	O
27	were	O	O
28	compared	O	O
29	with	O	O
30	results	O	O
31	in	O	O
32	14	O	O
33	eucalcemic	O	O
34	patients	O	O
35	matched	O	O
36	for	O	O
37	age	O	O
38	,	O	O
39	sex	O	O
40	,	O	O
41	length	O	O
42	of	O	O
43	time	O	O
44	on	O	O
45	dialysis	O	O
46	,	O	O
47	and	O	O
48	etiology	O	O
49	of	O	O
50	renal	B-Disease	B-Disease
51	disease	E-Disease	E-Disease
52	.	O	O

0	In	O	O
1	addition	O	O
2	to	O	O
3	experiencing	O	O
4	hypercalcemic	S-Disease	O
5	episodes	O	O
6	with	O	O
7	peak	O	O
8	calcium	S-Chemical	S-Disease
9	values	O	O
10	of	O	O
11	2	O	O
12	.	O	O
13	7	O	O
14	to	O	O
15	3	O	O
16	.	O	O
17	8	O	O
18	mmol	O	O
19	/	O	O
20	L	O	O
21	(	O	O
22	10	O	O
23	.	O	O
24	7	O	O
25	to	O	O
26	15	O	O
27	.	O	O
28	0	O	O
29	mg	O	O
30	/	O	O
31	dL	O	O
32	)	O	O
33	,	O	O
34	patients	O	O
35	in	O	O
36	the	O	O
37	hypercalcemic	S-Disease	O
38	group	O	O
39	exhibited	O	O
40	a	O	O
41	significant	O	O
42	increase	O	O
43	in	O	O
44	the	O	O
45	mean	O	O
46	calcium	S-Chemical	S-Disease
47	concentration	O	O
48	obtained	O	O
49	during	O	O
50	6	O	O
51	months	O	O
52	before	O	O
53	the	O	O
54	switch	O	O
55	,	O	O
56	compared	O	O
57	with	O	O
58	the	O	O
59	mean	O	O
60	value	O	O
61	obtained	O	O
62	during	O	O
63	the	O	O
64	7	O	O
65	months	O	O
66	of	O	O
67	observation	O	O
68	after	O	O
69	the	O	O
70	switch	O	O
71	(	O	O
72	2	O	O
73	.	O	O
74	4	O	O
75	+	O	O
76	/	O	O
77	-	O	O
78	0	O	O
79	.	O	O
80	03	O	O
81	to	O	O
82	2	O	O
83	.	O	O
84	5	O	O
85	+	O	O
86	/	O	O
87	-	O	O
88	0	O	O
89	.	O	O
90	03	O	O
91	mmol	O	O
92	/	O	O
93	L	O	O
94	[	O	O
95	9	O	O
96	.	O	O
97	7	O	O
98	+	O	O
99	/	O	O
100	-	O	O
101	0	O	O
102	.	O	O
103	2	O	O
104	to	O	O
105	10	O	O
106	.	O	O
107	2	O	O
108	+	O	O
109	/	O	O
110	-	O	O
111	0	O	O
112	.	O	O
113	1	O	O
114	mg	O	O
115	/	O	O
116	dL	O	O
117	]	O	O
118	,	O	O
119	P	O	S-Chemical
120	=	O	O
121	0	O	O
122	.	O	O
123	006	O	O
124	)	O	O
125	.	O	O

0	In	O	O
1	contrast	O	O
2	,	O	O
3	eucalcemic	O	S-Disease
4	patients	O	O
5	exhibited	O	O
6	no	O	O
7	change	O	O
8	in	O	O
9	mean	O	O
10	calcium	S-Chemical	S-Disease
11	values	O	O
12	over	O	O
13	the	O	O
14	same	O	O
15	time	O	O
16	period	O	O
17	(	O	O
18	2	O	O
19	.	O	O
20	3	O	O
21	+	O	O
22	/	O	O
23	-	O	O
24	0	O	O
25	.	O	O
26	05	O	O
27	to	O	O
28	2	O	O
29	.	O	O
30	3	O	O
31	+	O	O
32	/	O	O
33	-	O	O
34	0	O	O
35	.	O	O
36	05	O	O
37	mmol	O	O
38	/	O	O
39	L	O	O
40	[	O	O
41	9	O	O
42	.	O	O
43	2	O	O
44	+	O	O
45	/	O	O
46	-	O	O
47	0	O	O
48	.	O	O
49	2	O	O
50	to	O	O
51	9	O	O
52	.	O	O
53	2	O	O
54	+	O	O
55	/	O	O
56	-	O	O
57	0	O	O
58	.	O	O
59	2	O	O
60	mg	O	O
61	/	O	O
62	dL	O	O
63	]	O	O
64	)	O	O
65	.	O	O

0	CaCO3	S-Chemical	S-Chemical
1	dosage	O	O
2	,	O	O
3	calculated	O	O
4	dietary	O	O
5	calcium	S-Chemical	S-Disease
6	intake	O	O
7	,	O	O
8	and	O	O
9	circulating	O	O
10	levels	O	O
11	of	O	O
12	vitamin	B-Chemical	B-Disease
13	D	E-Chemical	E-Disease
14	metabolites	O	O
15	were	O	O
16	similar	O	O
17	in	O	O
18	both	O	O
19	groups	O	O
20	.	O	O

0	Physical	O	O
1	activity	O	O
2	index	O	O
3	and	O	O
4	predialysis	O	O
5	serum	O	O
6	bicarbonate	S-Chemical	S-Disease
7	levels	O	O
8	also	O	O
9	were	O	O
10	similar	O	O
11	in	O	O
12	both	O	O
13	groups	O	O
14	.	O	O

0	Late	O	O
1	-	O	O
2	onset	O	O
3	scleroderma	B-Disease	B-Disease
4	renal	I-Disease	I-Disease
5	crisis	E-Disease	E-Disease
6	induced	O	O
7	by	O	O
8	tacrolimus	S-Chemical	S-Chemical
9	and	O	O
10	prednisolone	S-Chemical	S-Chemical
11	:	O	O
12	a	O	O
13	case	O	O
14	report	O	O
15	.	O	O

0	Scleroderma	B-Disease	B-Disease
1	renal	I-Disease	I-Disease
2	crisis	E-Disease	E-Disease
3	(	O	O
4	SRC	S-Disease	S-Disease
5	)	O	O
6	is	O	O
7	a	O	O
8	rare	O	O
9	complication	O	O
10	of	O	O
11	systemic	B-Disease	B-Disease
12	sclerosis	E-Disease	E-Disease
13	(	O	O
14	SSc	S-Disease	S-Chemical
15	)	O	O
16	but	O	O
17	can	O	O
18	be	O	O
19	severe	O	O
20	enough	O	O
21	to	O	O
22	require	O	O
23	temporary	O	O
24	or	O	O
25	permanent	O	O
26	renal	O	B-Disease
27	replacement	O	E-Disease
28	therapy	O	O
29	.	O	O

0	Moderate	O	O
1	to	O	O
2	high	O	O
3	dose	O	O
4	corticosteroid	S-Chemical	S-Chemical
5	use	O	O
6	is	O	O
7	recognized	O	O
8	as	O	O
9	a	O	O
10	major	O	O
11	risk	O	O
12	factor	O	O
13	for	O	O
14	SRC	S-Disease	S-Disease
15	.	O	O

0	Furthermore	O	O
1	,	O	O
2	there	O	O
3	have	O	O
4	been	O	O
5	reports	O	O
6	of	O	O
7	thrombotic	B-Disease	S-Disease
8	microangiopathy	E-Disease	O
9	precipitated	O	O
10	by	O	O
11	cyclosporine	S-Chemical	S-Chemical
12	in	O	O
13	patients	O	O
14	with	O	O
15	SSc	S-Disease	S-Chemical
16	.	O	O

0	In	O	O
1	this	O	O
2	article	O	O
3	,	O	O
4	we	O	O
5	report	O	O
6	a	O	O
7	patient	O	O
8	with	O	O
9	SRC	S-Disease	S-Disease
10	induced	O	O
11	by	O	O
12	tacrolimus	S-Chemical	S-Chemical
13	and	O	O
14	corticosteroids	S-Chemical	S-Chemical
15	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	work	O	O
5	is	O	O
6	to	O	O
7	call	O	O
8	attention	O	O
9	to	O	O
10	the	O	O
11	risk	O	O
12	of	O	O
13	tacrolimus	S-Chemical	S-Chemical
14	use	O	S-Disease
15	in	O	O
16	patients	O	O
17	with	O	O
18	SSc	S-Disease	S-Disease
19	.	O	O

0	Methyldopa	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	hemolytic	B-Disease	O
4	anemia	E-Disease	S-Disease
5	in	O	O
6	a	O	O
7	15	O	O
8	year	O	O
9	old	O	O
10	presenting	O	O
11	as	O	O
12	near	O	O
13	-	O	O
14	syncope	S-Disease	O
15	.	O	O

0	Methyldopa	S-Chemical	S-Chemical
1	is	O	O
2	an	O	O
3	antihypertensive	O	O
4	medication	O	O
5	which	O	O
6	is	O	O
7	available	O	O
8	generically	O	O
9	and	O	O
10	under	O	O
11	the	O	O
12	trade	O	O
13	name	O	O
14	Aldomet	S-Chemical	S-Chemical
15	that	O	O
16	is	O	O
17	widely	O	O
18	prescribed	O	O
19	in	O	O
20	the	O	O
21	adult	O	O
22	population	O	O
23	and	O	O
24	infrequently	O	O
25	used	O	O
26	in	O	O
27	children	O	O
28	.	O	O

0	Methyldopa	S-Chemical	S-Chemical
1	causes	O	O
2	an	O	O
3	autoimmune	B-Disease	O
4	hemolytic	I-Disease	O
5	anemia	E-Disease	S-Disease
6	in	O	O
7	a	O	O
8	small	O	O
9	percentage	O	O
10	of	O	O
11	patients	O	O
12	who	O	O
13	take	O	O
14	the	O	O
15	drug	O	O
16	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	methyldopa	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	hemolytic	B-Disease	O
9	anemia	E-Disease	E-Disease
10	in	O	O
11	a	O	O
12	15	O	O
13	-	O	O
14	year	O	O
15	-	O	O
16	old	O	O
17	boy	O	O
18	who	O	O
19	presented	O	O
20	to	O	O
21	the	O	O
22	emergency	B-Disease	O
23	department	E-Disease	O
24	with	O	O
25	near	O	O
26	-	O	O
27	syncope	S-Disease	O
28	.	O	O

0	The	O	O
1	boy	O	O
2	had	O	O
3	been	O	O
4	treated	O	O
5	with	O	O
6	intravenous	O	O
7	methyldopa	S-Chemical	S-Chemical
8	during	O	O
9	a	O	O
10	trauma	S-Disease	O
11	admission	O	O
12	seven	O	O
13	weeks	O	O
14	prior	O	O
15	to	O	O
16	presentation	O	O
17	.	O	O

0	Transfusion	O	O
1	and	O	O
2	corticosteroid	S-Chemical	S-Chemical
3	therapy	O	O
4	resulted	O	O
5	in	O	O
6	a	O	O
7	complete	O	O
8	recovery	O	O
9	of	O	O
10	the	O	O
11	patient	O	O
12	.	O	O

0	A	O	O
1	brief	O	O
2	review	O	O
3	of	O	O
4	autoimmune	O	O
5	and	O	O
6	drug	O	O
7	-	O	O
8	induced	O	O
9	hemolytic	B-Disease	O
10	anemias	E-Disease	S-Disease
11	is	O	O
12	provided	O	O
13	.	O	O

0	The	O	O
1	risk	O	O
2	and	O	O
3	associated	O	O
4	factors	O	O
5	of	O	O
6	methamphetamine	S-Chemical	S-Chemical
7	psychosis	S-Disease	S-Disease
8	in	O	O
9	methamphetamine	S-Chemical	S-Chemical
10	-	O	O
11	dependent	O	O
12	patients	O	O
13	in	O	O
14	Malaysia	O	O
15	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	The	O	O
3	objective	O	O
4	of	O	O
5	this	O	O
6	study	O	O
7	was	O	O
8	to	O	O
9	determine	O	O
10	the	O	O
11	risk	O	O
12	of	O	O
13	lifetime	O	O
14	and	O	O
15	current	O	O
16	methamphetamine	S-Chemical	S-Chemical
17	-	O	O
18	induced	O	O
19	psychosis	S-Disease	S-Disease
20	in	O	O
21	patients	O	O
22	with	O	O
23	methamphetamine	S-Chemical	S-Chemical
24	dependence	O	S-Disease
25	.	O	O

0	The	O	O
1	association	O	O
2	between	O	O
3	psychiatric	O	B-Disease
4	co	O	E-Disease
5	-	O	O
6	morbidity	O	S-Disease
7	and	O	O
8	methamphetamine	S-Chemical	S-Chemical
9	-	O	O
10	induced	O	O
11	psychosis	S-Disease	S-Disease
12	was	O	O
13	also	O	O
14	studied	O	O
15	.	O	O

0	Patients	O	O
1	with	O	O
2	the	O	O
3	diagnosis	O	O
4	of	O	O
5	methamphetamine	S-Chemical	S-Chemical
6	based	O	O
7	on	O	O
8	DSM	O	S-Chemical
9	-	O	E-Chemical
10	IV	O	E-Disease
11	were	O	O
12	interviewed	O	O
13	using	O	O
14	the	O	O
15	Mini	O	O
16	International	O	I-Disease
17	Neuropsychiatric	O	E-Disease
18	Interview	O	O
19	(	O	O
20	M	O	S-Disease
21	.	O	I-Disease
22	I	O	I-Disease
23	.	O	I-Disease
24	N	O	E-Chemical
25	.	O	O
26	I	O	E-Disease
27	.	O	O
28	)	O	O
29	for	O	O
30	methamphetamine	S-Chemical	S-Chemical
31	-	O	O
32	induced	O	O
33	psychosis	S-Disease	S-Disease
34	and	O	O
35	other	O	O
36	Axis	O	B-Disease
37	I	O	I-Disease
38	psychiatric	B-Disease	B-Disease
39	disorders	E-Disease	E-Disease
40	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Of	O	O
3	292	O	O
4	subjects	O	O
5	,	O	O
6	47	O	O
7	.	O	O
8	9	O	O
9	%	O	O
10	of	O	O
11	the	O	O
12	subjects	O	O
13	had	O	O
14	a	O	O
15	past	O	O
16	history	O	O
17	of	O	O
18	psychotic	B-Disease	S-Disease
19	symptoms	E-Disease	O
20	and	O	O
21	13	O	O
22	.	O	O
23	0	O	O
24	%	O	O
25	of	O	O
26	the	O	O
27	patients	O	O
28	were	O	O
29	having	O	O
30	current	O	O
31	psychotic	B-Disease	S-Disease
32	symptoms	E-Disease	O
33	.	O	O

0	Co	O	O
1	-	O	O
2	morbid	O	O
3	major	O	O
4	depressive	B-Disease	I-Disease
5	disorder	E-Disease	E-Disease
6	(	O	O
7	OR	O	O
8	=	O	O
9	7	O	O
10	.	O	O
11	18	O	O
12	,	O	O
13	95	O	O
14	CI	O	O
15	=	O	O
16	2	O	O
17	.	O	O
18	612	O	O
19	-	O	O
20	19	O	O
21	.	O	O
22	708	O	O
23	)	O	O
24	,	O	O
25	bipolar	B-Disease	B-Disease
26	disorder	E-Disease	E-Disease
27	(	O	O
28	OR	O	O
29	=	O	O
30	13	O	O
31	.	O	O
32	807	O	O
33	,	O	O
34	95	O	O
35	CI	O	O
36	=	O	O
37	5	O	O
38	.	O	O
39	194	O	O
40	-	O	O
41	36	O	O
42	.	O	O
43	706	O	O
44	)	O	O
45	,	O	O
46	antisocial	B-Disease	O
47	personality	I-Disease	I-Disease
48	disorder	E-Disease	E-Disease
49	(	O	O
50	OR	O	O
51	=	O	O
52	12	O	O
53	.	O	O
54	619	O	O
55	,	O	O
56	95	O	O
57	CI	O	S-Disease
58	=	O	O
59	6	O	O
60	.	O	O
61	702	O	O
62	-	O	O
63	23	O	O
64	.	O	O
65	759	O	O
66	)	O	O
67	and	O	O
68	heavy	O	O
69	methamphetamine	S-Chemical	S-Chemical
70	uses	O	O
71	were	O	O
72	significantly	O	O
73	associated	O	O
74	with	O	O
75	lifetime	O	O
76	methamphetamine	S-Chemical	S-Chemical
77	-	O	O
78	induced	O	O
79	psychosis	S-Disease	S-Disease
80	after	O	O
81	adjusted	O	O
82	for	O	O
83	other	O	O
84	factors	O	O
85	.	O	O

0	Major	B-Disease	O
1	depressive	I-Disease	I-Disease
2	disorder	E-Disease	E-Disease
3	(	O	O
4	OR	O	S-Disease
5	=	O	O
6	2	O	O
7	.	O	O
8	870	O	O
9	,	O	O
10	CI	O	S-Disease
11	=	O	O
12	1	O	O
13	.	O	O
14	154	O	O
15	-	O	O
16	7	O	O
17	.	O	O
18	142	O	O
19	)	O	O
20	and	O	O
21	antisocial	B-Disease	O
22	personality	I-Disease	I-Disease
23	disorder	E-Disease	E-Disease
24	(	O	O
25	OR	O	S-Disease
26	=	O	O
27	3	O	O
28	.	O	O
29	299	O	O
30	,	O	O
31	95	O	O
32	CI	O	S-Disease
33	=	O	O
34	1	O	O
35	.	O	O
36	375	O	O
37	-	O	O
38	7	O	O
39	.	O	O
40	914	O	O
41	)	O	O
42	were	O	O
43	the	O	O
44	only	O	O
45	factors	O	O
46	associated	O	O
47	with	O	O
48	current	O	O
49	psychosis	S-Disease	S-Disease
50	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	There	O	O
3	was	O	O
4	a	O	O
5	high	O	O
6	risk	O	O
7	of	O	O
8	psychosis	S-Disease	S-Disease
9	in	O	O
10	patients	O	O
11	with	O	O
12	methamphetamine	S-Chemical	S-Chemical
13	dependence	O	E-Disease
14	.	O	O

0	It	O	O
1	was	O	O
2	associated	O	O
3	with	O	O
4	co	O	O
5	-	O	O
6	morbid	O	O
7	affective	B-Disease	B-Disease
8	disorder	E-Disease	E-Disease
9	,	O	O
10	antisocial	B-Disease	O
11	personality	E-Disease	E-Disease
12	,	O	O
13	and	O	O
14	heavy	O	O
15	methamphetamine	S-Chemical	S-Chemical
16	use	O	O
17	.	O	O

0	It	O	O
1	is	O	O
2	recommended	O	O
3	that	O	O
4	all	O	O
5	cases	O	O
6	of	O	O
7	methamphetamine	S-Chemical	S-Chemical
8	dependence	O	E-Disease
9	should	O	O
10	be	O	O
11	screened	O	O
12	for	O	O
13	psychotic	B-Disease	S-Disease
14	symptoms	E-Disease	O
15	.	O	O

0	Cerebellar	O	B-Disease
1	sensory	O	I-Disease
2	processing	O	I-Disease
3	alterations	O	O
4	impact	O	O
5	motor	O	B-Disease
6	cortical	O	I-Disease
7	plasticity	O	E-Disease
8	in	O	O
9	Parkinson	B-Disease	B-Disease
10	'	I-Disease	I-Disease
11	s	I-Disease	I-Disease
12	disease	E-Disease	E-Disease
13	:	O	O
14	clues	O	O
15	from	O	O
16	dyskinetic	S-Disease	S-Disease
17	patients	O	O
18	.	O	O

0	The	O	O
1	plasticity	O	O
2	of	O	O
3	primary	O	O
4	motor	O	O
5	cortex	O	E-Disease
6	(	O	O
7	M1	O	S-Disease
8	)	O	O
9	in	O	O
10	patients	O	O
11	with	O	O
12	Parkinson	B-Disease	B-Disease
13	'	I-Disease	I-Disease
14	s	I-Disease	I-Disease
15	disease	E-Disease	E-Disease
16	(	O	O
17	PD	S-Disease	S-Disease
18	)	O	O
19	and	O	O
20	levodopa	S-Chemical	S-Chemical
21	-	O	O
22	induced	O	O
23	dyskinesias	S-Disease	S-Disease
24	(	O	O
25	LIDs	S-Disease	S-Disease
26	)	O	O
27	is	O	O
28	severely	O	O
29	impaired	O	O
30	.	O	O

0	This	O	O
1	study	O	O
2	demonstrates	O	O
3	that	O	O
4	the	O	O
5	deficient	O	O
6	sensorimotor	O	O
7	M1	O	S-Disease
8	plasticity	O	O
9	in	O	O
10	16	O	O
11	patients	O	O
12	with	O	O
13	LIDs	S-Disease	S-Disease
14	could	O	O
15	be	O	O
16	reinstated	O	O
17	by	O	O
18	a	O	O
19	single	O	O
20	session	O	O
21	of	O	O
22	real	O	O
23	inhibitory	O	O
24	cerebellar	O	S-Disease
25	stimulation	O	O
26	but	O	O
27	not	O	O
28	sham	O	O
29	stimulation	O	O
30	.	O	O

0	The	O	O
1	benefit	O	O
2	of	O	O
3	inhibitory	O	O
4	cerebellar	O	S-Disease
5	stimulation	O	O
6	on	O	O
7	LIDs	S-Disease	S-Disease
8	is	O	O
9	known	O	O
10	.	O	O

0	To	O	O
1	explore	O	O
2	whether	O	O
3	this	O	O
4	benefit	O	O
5	is	O	O
6	linked	O	O
7	to	O	O
8	the	O	O
9	restoration	O	O
10	of	O	O
11	sensorimotor	O	O
12	plasticity	O	O
13	of	O	O
14	M1	O	S-Disease
15	,	O	O
16	we	O	O
17	conducted	O	O
18	an	O	O
19	additional	O	O
20	study	O	O
21	looking	O	O
22	at	O	O
23	changes	O	O
24	in	O	O
25	LIDs	S-Disease	S-Disease
26	and	O	O
27	PAS	O	S-Disease
28	-	O	O
29	induced	O	O
30	plasticity	O	O
31	after	O	O
32	10	O	O
33	sessions	O	O
34	of	O	O
35	either	O	O
36	bilateral	O	O
37	,	O	O
38	real	O	O
39	inhibitory	O	O
40	cerebellar	O	S-Disease
41	stimulation	O	O
42	or	O	O
43	sham	O	O
44	stimulation	O	O
45	.	O	O

0	These	O	O
1	results	O	O
2	suggest	O	O
3	that	O	O
4	alterations	O	O
5	in	O	O
6	cerebellar	O	B-Disease
7	sensory	O	O
8	processing	O	O
9	function	O	O
10	,	O	O
11	occurring	O	O
12	secondary	O	O
13	to	O	O
14	abnormal	O	O
15	basal	O	B-Disease
16	ganglia	O	E-Disease
17	signals	O	O
18	reaching	O	O
19	it	O	O
20	,	O	O
21	may	O	O
22	be	O	O
23	an	O	O
24	important	O	O
25	element	O	O
26	contributing	O	O
27	to	O	O
28	the	O	O
29	maladaptive	O	O
30	sensorimotor	O	O
31	plasticity	O	O
32	of	O	O
33	M1	O	S-Disease
34	and	O	O
35	the	O	O
36	emergence	O	O
37	of	O	O
38	abnormal	B-Disease	O
39	involuntary	I-Disease	O
40	movements	E-Disease	O
41	.	O	O

0	The	O	O
1	long	O	O
2	-	O	O
3	term	O	O
4	safety	O	O
5	of	O	O
6	danazol	S-Chemical	S-Chemical
7	in	O	O
8	women	O	O
9	with	O	O
10	hereditary	B-Disease	O
11	angioedema	E-Disease	S-Disease
12	.	O	O

0	Although	O	O
1	the	O	O
2	short	O	O
3	-	O	O
4	term	O	O
5	safety	O	O
6	(	O	O
7	less	O	O
8	than	O	O
9	or	O	O
10	equal	O	O
11	to	O	O
12	6	O	O
13	months	O	O
14	)	O	O
15	of	O	O
16	danazol	S-Chemical	S-Chemical
17	has	O	O
18	been	O	O
19	established	O	O
20	in	O	O
21	a	O	O
22	variety	O	O
23	of	O	O
24	settings	O	O
25	,	O	O
26	no	O	O
27	information	O	O
28	exists	O	O
29	as	O	O
30	to	O	O
31	its	O	O
32	long	O	O
33	-	O	O
34	term	O	O
35	safety	O	O
36	.	O	O

0	We	O	O
1	therefore	O	O
2	investigated	O	O
3	the	O	O
4	long	O	O
5	-	O	O
6	term	O	O
7	safety	O	O
8	of	O	O
9	danazol	S-Chemical	S-Chemical
10	by	O	O
11	performing	O	O
12	a	O	O
13	retrospective	O	O
14	chart	O	O
15	review	O	O
16	of	O	O
17	60	O	O
18	female	O	O
19	patients	O	O
20	with	O	O
21	hereditary	B-Disease	O
22	angioedema	E-Disease	S-Disease
23	treated	O	O
24	with	O	O
25	danazol	S-Chemical	S-Chemical
26	for	O	O
27	a	O	O
28	continuous	O	O
29	period	O	O
30	of	O	O
31	6	O	O
32	months	O	O
33	or	O	O
34	longer	O	O
35	.	O	O

0	Menstrual	B-Disease	O
1	abnormalities	E-Disease	O
2	(	O	O
3	79	O	O
4	%	O	O
5	)	O	O
6	,	O	O
7	weight	B-Disease	S-Disease
8	gain	E-Disease	O
9	(	O	O
10	60	O	O
11	%	O	O
12	)	O	O
13	,	O	O
14	muscle	B-Disease	B-Disease
15	cramps	E-Disease	E-Disease
16	/	O	O
17	myalgias	S-Disease	S-Disease
18	(	O	O
19	40	O	O
20	%	O	O
21	)	O	O
22	,	O	O
23	and	O	O
24	transaminase	O	O
25	elevations	O	O
26	(	O	O
27	40	O	O
28	%	O	O
29	)	O	O
30	were	O	O
31	the	O	O
32	most	O	O
33	common	O	O
34	adverse	O	O
35	reactions	O	O
36	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	,	O	O
4	despite	O	O
5	a	O	O
6	relatively	O	O
7	high	O	O
8	incidence	O	O
9	of	O	O
10	adverse	O	O
11	reactions	O	O
12	,	O	O
13	danazol	S-Chemical	S-Chemical
14	has	O	O
15	proven	O	O
16	to	O	O
17	be	O	O
18	remarkably	O	O
19	safe	O	O
20	over	O	O
21	the	O	O
22	long	O	O
23	-	O	O
24	term	O	O
25	in	O	O
26	this	O	O
27	group	O	O
28	of	O	O
29	patients	O	O
30	.	O	O

0	The	O	O
1	function	O	O
2	of	O	O
3	P2X3	O	S-Disease
4	receptor	O	O
5	and	O	O
6	NK1	O	O
7	receptor	O	O
8	antagonists	O	O
9	on	O	O
10	cyclophosphamide	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	cystitis	S-Disease	S-Disease
14	in	O	O
15	rats	O	O
16	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	The	O	O
3	purpose	O	O
4	of	O	O
5	the	O	O
6	study	O	O
7	is	O	O
8	to	O	O
9	explore	O	O
10	the	O	O
11	function	O	O
12	of	O	O
13	P2X3	O	S-Chemical
14	and	O	O
15	NK1	O	O
16	receptors	O	O
17	antagonists	O	O
18	on	O	O
19	cyclophosphamide	S-Chemical	S-Chemical
20	(	O	O
21	CYP	S-Chemical	S-Chemical
22	)	O	O
23	-	O	O
24	induced	O	O
25	cystitis	S-Disease	S-Disease
26	in	O	O
27	rats	O	O
28	.	O	O

0	The	O	O
1	rats	O	O
2	in	O	O
3	the	O	O
4	control	O	O
5	group	O	O
6	were	O	O
7	intraperitoneally	O	O
8	(	O	O
9	i	O	O
10	.	O	O
11	p	O	O
12	.	O	O
13	)	O	O
14	injected	O	O
15	with	O	O
16	0	O	O
17	.	O	O
18	9	O	O
19	%	O	O
20	saline	O	S-Chemical
21	(	O	O
22	4	O	O
23	ml	O	O
24	/	O	O
25	kg	O	O
26	)	O	O
27	;	O	O
28	the	O	O
29	rats	O	O
30	in	O	O
31	the	O	O
32	model	O	O
33	group	O	O
34	were	O	O
35	i	O	O
36	.	O	O
37	p	O	O
38	.	O	O
39	injected	O	O
40	with	O	O
41	CYP	S-Chemical	S-Chemical
42	(	O	O
43	150	O	O
44	mg	O	O
45	/	O	O
46	kg	O	O
47	)	O	O
48	;	O	O
49	and	O	O
50	the	O	O
51	rats	O	O
52	in	O	O
53	the	O	O
54	intervention	O	O
55	group	O	O
56	were	O	O
57	i	O	O
58	.	O	O
59	p	O	O
60	.	O	O
61	injected	O	O
62	with	O	O
63	CYP	S-Chemical	S-Chemical
64	with	O	O
65	subsequently	O	O
66	perfusion	O	O
67	of	O	O
68	bladder	O	O
69	with	O	O
70	P2X3	O	B-Chemical
71	and	O	O
72	NK1	O	O
73	receptors	O	O
74	'	O	O
75	antagonists	O	O
76	,	O	O
77	Suramin	S-Chemical	S-Chemical
78	and	O	O
79	GR	B-Chemical	B-Chemical
80	82334	E-Chemical	E-Chemical
81	.	O	O

0	Spontaneous	O	O
1	pain	S-Disease	S-Disease
2	behaviors	O	O
3	following	O	O
4	the	O	O
5	administration	O	O
6	of	O	O
7	CYP	S-Chemical	S-Chemical
8	were	O	O
9	observed	O	O
10	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Cyclophosphamide	S-Chemical	S-Chemical
3	treatment	O	O
4	increased	O	O
5	the	O	O
6	spontaneous	O	O
7	pain	S-Disease	B-Disease
8	behaviors	O	E-Disease
9	scores	O	O
10	.	O	O

0	Histological	O	O
1	changes	O	O
2	evident	O	O
3	in	O	O
4	model	O	O
5	and	O	O
6	intervention	O	O
7	groups	O	O
8	rats	O	O
9	'	O	O
10	bladder	O	O
11	included	O	O
12	edema	S-Disease	S-Disease
13	,	O	O
14	vasodilation	O	O
15	,	O	O
16	and	O	O
17	infiltration	O	O
18	of	O	O
19	inflammatory	O	B-Disease
20	cells	O	E-Disease
21	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	In	O	O
3	CYP	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	cystitis	S-Disease	S-Disease
7	,	O	O
8	the	O	O
9	expression	O	O
10	of	O	O
11	P2X3	O	S-Chemical
12	and	O	O
13	NK1	O	S-Disease
14	receptors	O	O
15	increased	O	O
16	in	O	O
17	urothelium	O	S-Disease
18	and	O	O
19	/	O	O
20	or	O	O
21	suburothelium	O	O
22	.	O	O

0	Patient	O	O
1	tolerance	O	O
2	study	O	O
3	of	O	O
4	topical	O	O
5	chlorhexidine	B-Chemical	S-Chemical
6	diphosphanilate	E-Chemical	E-Chemical
7	:	O	O
8	a	O	O
9	new	O	O
10	topical	O	O
11	agent	O	O
12	for	O	O
13	burns	S-Disease	S-Disease
14	.	O	O

0	Effective	O	O
1	topical	O	O
2	antimicrobial	O	O
3	agents	O	O
4	decrease	O	O
5	infection	S-Disease	S-Disease
6	and	O	O
7	mortality	O	O
8	in	O	O
9	burn	S-Disease	S-Disease
10	patients	O	O
11	.	O	O

0	Chlorhexidine	B-Chemical	S-Chemical
1	phosphanilate	E-Chemical	E-Chemical
2	(	O	O
3	CHP	S-Chemical	S-Chemical
4	)	O	O
5	,	O	O
6	a	O	O
7	new	O	O
8	broad	O	O
9	-	O	O
10	spectrum	O	O
11	antimicrobial	O	O
12	agent	O	O
13	,	O	O
14	has	O	O
15	been	O	O
16	evaluated	O	O
17	as	O	O
18	a	O	O
19	topical	O	O
20	burn	S-Disease	O
21	wound	O	O
22	dressing	O	O
23	in	O	O
24	cream	O	O
25	form	O	O
26	,	O	O
27	but	O	O
28	preliminary	O	O
29	clinical	O	O
30	trials	O	O
31	reported	O	O
32	that	O	O
33	it	O	O
34	was	O	O
35	painful	O	O
36	upon	O	O
37	application	O	O
38	.	O	O

0	This	O	O
1	study	O	O
2	compared	O	O
3	various	O	O
4	concentrations	O	O
5	of	O	O
6	CHP	S-Chemical	S-Chemical
7	to	O	O
8	determine	O	O
9	if	O	O
10	a	O	O
11	tolerable	O	O
12	concentration	O	O
13	could	O	O
14	be	O	O
15	identified	O	O
16	with	O	O
17	retention	O	O
18	of	O	O
19	antimicrobial	O	O
20	efficacy	O	O
21	.	O	O

0	Twenty	O	O
1	-	O	O
2	nine	O	O
3	burn	S-Disease	O
4	patients	O	O
5	,	O	O
6	each	O	O
7	with	O	O
8	two	O	O
9	similar	O	O
10	burns	S-Disease	S-Disease
11	which	O	O
12	could	O	O
13	be	O	O
14	separately	O	O
15	treated	O	O
16	,	O	O
17	were	O	O
18	given	O	O
19	pairs	O	O
20	of	O	O
21	treatments	O	O
22	at	O	O
23	successive	O	O
24	12	O	O
25	-	O	O
26	h	O	O
27	intervals	O	O
28	over	O	O
29	a	O	O
30	3	O	O
31	-	O	O
32	day	O	O
33	period	O	O
34	.	O	O

0	One	O	O
1	burn	S-Disease	O
2	site	O	O
3	was	O	O
4	treated	O	O
5	with	O	O
6	each	O	O
7	of	O	O
8	four	O	O
9	different	O	O
10	CHP	S-Chemical	S-Chemical
11	concentrations	O	O
12	,	O	O
13	from	O	O
14	0	O	O
15	.	O	O
16	25	O	O
17	per	O	O
18	cent	O	O
19	to	O	O
20	2	O	O
21	per	O	O
22	cent	O	O
23	,	O	O
24	their	O	O
25	vehicle	O	O
26	,	O	O
27	and	O	O
28	1	O	O
29	per	O	O
30	cent	O	O
31	silver	B-Chemical	O
32	sulphadiazine	E-Chemical	S-Chemical
33	(	O	O
34	AgSD	S-Chemical	S-Chemical
35	)	O	O
36	cream	O	O
37	,	O	O
38	an	O	O
39	antimicrobial	O	O
40	agent	O	O
41	frequently	O	O
42	used	O	O
43	for	O	O
44	topical	O	O
45	treatment	O	O
46	of	O	O
47	burn	S-Disease	S-Disease
48	wounds	O	S-Disease
49	.	O	O

0	The	O	O
1	other	O	O
2	site	O	O
3	was	O	O
4	always	O	O
5	treated	O	O
6	with	O	O
7	AgSD	S-Chemical	S-Chemical
8	cream	O	O
9	.	O	O

0	There	O	O
1	was	O	O
2	a	O	O
3	direct	O	O
4	relationship	O	O
5	between	O	O
6	CHP	S-Chemical	S-Chemical
7	concentration	O	O
8	and	O	O
9	patients	O	O
10	'	O	O
11	ratings	O	O
12	of	O	O
13	pain	S-Disease	S-Disease
14	on	O	O
15	an	O	O
16	analogue	O	O
17	scale	O	O
18	.	O	O

0	The	O	O
1	0	O	O
2	.	O	O
3	25	O	O
4	per	O	O
5	cent	O	O
6	CHP	S-Chemical	S-Disease
7	cream	O	O
8	was	O	O
9	closest	O	O
10	to	O	O
11	AgSD	S-Chemical	S-Chemical
12	in	O	O
13	pain	S-Disease	B-Disease
14	tolerance	O	E-Disease
15	;	O	O
16	however	O	O
17	,	O	O
18	none	O	O
19	of	O	O
20	the	O	O
21	treatments	O	O
22	differed	O	O
23	statistically	O	O
24	from	O	O
25	AgSD	S-Chemical	S-Chemical
26	or	O	O
27	from	O	O
28	each	O	O
29	other	O	O
30	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	ease	O	O
4	of	O	O
5	application	O	O
6	of	O	O
7	CHP	S-Chemical	S-Chemical
8	creams	O	O
9	was	O	O
10	less	O	O
11	satisfactory	O	O
12	than	O	O
13	that	O	O
14	of	O	O
15	AgSD	S-Chemical	S-Chemical
16	.	O	O

0	It	O	O
1	was	O	O
2	concluded	O	O
3	that	O	O
4	formulations	O	O
5	at	O	O
6	or	O	O
7	below	O	O
8	0	O	O
9	.	O	O
10	5	O	O
11	per	O	O
12	cent	O	O
13	CHP	S-Chemical	S-Chemical
14	may	O	O
15	prove	O	O
16	acceptable	O	O
17	for	O	O
18	wound	O	O
19	care	O	O
20	,	O	O
21	but	O	O
22	the	O	O
23	vehicle	O	O
24	system	O	O
25	needs	O	O
26	pharmaceutical	O	O
27	improvement	O	O
28	to	O	O
29	render	O	O
30	it	O	O
31	more	O	O
32	tolerable	O	O
33	and	O	O
34	easier	O	O
35	to	O	O
36	use	O	O
37	.	O	O

0	Acute	O	O
1	hepatitis	S-Disease	S-Disease
2	associated	O	O
3	with	O	O
4	clopidogrel	S-Chemical	S-Chemical
5	:	O	O
6	a	O	O
7	case	O	O
8	report	O	O
9	and	O	O
10	review	O	O
11	of	O	O
12	the	O	O
13	literature	O	O
14	.	O	O

0	Drug	O	O
1	-	O	O
2	induced	O	O
3	hepatotoxicity	S-Disease	S-Chemical
4	is	O	O
5	a	O	O
6	common	O	O
7	cause	O	O
8	of	O	O
9	acute	O	B-Disease
10	hepatitis	S-Disease	E-Disease
11	,	O	O
12	and	O	O
13	the	O	O
14	recognition	O	O
15	of	O	O
16	the	O	O
17	responsible	O	O
18	drug	O	O
19	may	O	O
20	be	O	O
21	difficult	O	O
22	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	clopidogrel	S-Chemical	S-Chemical
6	-	O	O
7	related	O	O
8	acute	O	B-Disease
9	hepatitis	S-Disease	E-Disease
10	.	O	O

0	Reports	O	O
1	about	O	O
2	cases	O	O
3	of	O	O
4	hepatotoxicity	S-Disease	S-Chemical
5	due	O	O
6	to	O	O
7	clopidogrel	S-Chemical	S-Chemical
8	are	O	O
9	increasing	O	O
10	in	O	O
11	the	O	O
12	last	O	O
13	few	O	O
14	years	O	O
15	,	O	O
16	after	O	O
17	the	O	O
18	increased	O	O
19	use	O	O
20	of	O	O
21	this	O	O
22	drug	O	O
23	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	we	O	O
4	believe	O	O
5	that	O	O
6	physicians	O	O
7	should	O	O
8	carefully	O	O
9	consider	O	O
10	the	O	O
11	risk	O	O
12	of	O	O
13	drug	O	O
14	-	O	O
15	induced	O	O
16	hepatic	B-Disease	S-Disease
17	injury	E-Disease	E-Disease
18	when	O	O
19	clopidogrel	S-Chemical	S-Chemical
20	is	O	O
21	prescribed	O	O
22	.	O	O

0	Bortezomib	S-Chemical	S-Chemical
1	and	O	O
2	dexamethasone	S-Chemical	S-Chemical
3	as	O	O
4	salvage	O	O
5	therapy	O	O
6	in	O	O
7	patients	O	O
8	with	O	O
9	relapsed	O	O
10	/	O	O
11	refractory	O	O
12	multiple	B-Disease	O
13	myeloma	E-Disease	S-Disease
14	:	O	O
15	analysis	O	O
16	of	O	O
17	long	O	O
18	-	O	O
19	term	O	O
20	clinical	O	O
21	outcomes	O	O
22	.	O	O

0	Bortezomib	S-Chemical	S-Chemical
1	(	O	O
2	bort	S-Chemical	O
3	)	O	O
4	-	O	O
5	dexamethasone	S-Chemical	S-Chemical
6	(	O	O
7	dex	S-Chemical	O
8	)	O	O
9	is	O	O
10	an	O	O
11	effective	O	O
12	therapy	O	O
13	for	O	O
14	relapsed	O	O
15	/	O	O
16	refractory	O	O
17	(	O	O
18	R	O	O
19	/	O	O
20	R	O	O
21	)	O	O
22	multiple	B-Disease	O
23	myeloma	E-Disease	S-Disease
24	(	O	O
25	MM	S-Disease	S-Disease
26	)	O	O
27	.	O	O

0	This	O	O
1	retrospective	O	O
2	study	O	O
3	investigated	O	O
4	the	O	O
5	combination	O	O
6	of	O	O
7	bort	S-Chemical	O
8	(	O	O
9	1	O	O
10	.	O	O
11	3	O	O
12	mg	O	O
13	/	O	O
14	m	O	O
15	(	O	O
16	2	O	O
17	)	O	O
18	on	O	O
19	days	O	O
20	1	O	O
21	,	O	O
22	4	O	O
23	,	O	O
24	8	O	O
25	,	O	O
26	and	O	O
27	11	O	O
28	every	O	O
29	3	O	O
30	weeks	O	O
31	)	O	O
32	and	O	O
33	dex	S-Chemical	O
34	(	O	O
35	20	O	O
36	mg	O	O
37	on	O	O
38	the	O	O
39	day	O	O
40	of	O	O
41	and	O	O
42	the	O	O
43	day	O	O
44	after	O	O
45	bort	S-Chemical	O
46	)	O	O
47	as	O	O
48	salvage	O	O
49	treatment	O	O
50	in	O	O
51	85	O	O
52	patients	O	O
53	with	O	O
54	R	O	O
55	/	O	O
56	R	O	O
57	MM	S-Disease	O
58	after	O	O
59	prior	O	O
60	autologous	O	O
61	stem	O	O
62	cell	O	I-Disease
63	transplantation	O	S-Disease
64	or	O	O
65	conventional	O	O
66	chemotherapy	O	O
67	.	O	O

0	Eighty	O	O
1	-	O	O
2	seven	O	O
3	percent	O	O
4	of	O	O
5	the	O	O
6	patients	O	O
7	had	O	O
8	received	O	O
9	immunomodulatory	O	O
10	drugs	O	O
11	included	O	O
12	in	O	O
13	some	O	O
14	line	O	O
15	of	O	O
16	therapy	O	O
17	before	O	O
18	bort	S-Chemical	S-Disease
19	-	O	O
20	dex	S-Chemical	O
21	.	O	O

0	The	O	O
1	median	O	O
2	number	O	O
3	of	O	O
4	bort	S-Chemical	O
5	-	O	O
6	dex	S-Chemical	O
7	cycles	O	O
8	was	O	O
9	6	O	O
10	,	O	O
11	up	O	O
12	to	O	O
13	a	O	O
14	maximum	O	O
15	of	O	O
16	12	O	O
17	cycles	O	O
18	.	O	O

0	The	O	O
1	most	O	O
2	relevant	O	O
3	adverse	O	O
4	event	O	O
5	was	O	O
6	peripheral	B-Disease	B-Disease
7	neuropathy	E-Disease	E-Disease
8	,	O	O
9	which	O	O
10	occurred	O	O
11	in	O	O
12	78	O	O
13	%	O	O
14	of	O	O
15	the	O	O
16	patients	O	O
17	(	O	O
18	grade	O	O
19	II	O	O
20	,	O	O
21	38	O	O
22	%	O	O
23	;	O	O
24	grade	O	O
25	III	O	O
26	,	O	O
27	21	O	O
28	%	O	O
29	)	O	O
30	and	O	O
31	led	O	O
32	to	O	O
33	treatment	O	O
34	discontinuation	O	O
35	in	O	O
36	6	O	O
37	%	O	O
38	.	O	O

0	Prolonged	O	O
1	PFS	O	S-Disease
2	and	O	O
3	OS	O	S-Disease
4	were	O	O
5	observed	O	O
6	in	O	O
7	patients	O	O
8	achieving	O	O
9	CR	O	S-Disease
10	and	O	O
11	receiving	O	O
12	bort	S-Chemical	S-Disease
13	-	O	O
14	dex	S-Chemical	O
15	a	O	O
16	single	O	O
17	line	O	O
18	of	O	O
19	prior	O	O
20	therapy	O	O
21	.	O	O

0	Bort	S-Chemical	S-Chemical
1	-	O	O
2	dex	S-Chemical	E-Chemical
3	was	O	O
4	an	O	O
5	effective	O	O
6	salvage	O	O
7	treatment	O	O
8	for	O	O
9	MM	S-Disease	S-Disease
10	patients	O	O
11	,	O	O
12	particularly	O	O
13	for	O	O
14	those	O	O
15	in	O	O
16	first	O	O
17	relapse	O	O
18	.	O	O

0	Pubertal	O	O
1	exposure	O	O
2	to	O	O
3	Bisphenol	B-Chemical	B-Chemical
4	A	E-Chemical	E-Chemical
5	increases	O	O
6	anxiety	S-Disease	S-Disease
7	-	O	O
8	like	O	O
9	behavior	O	O
10	and	O	O
11	decreases	O	O
12	acetylcholinesterase	O	S-Chemical
13	activity	O	O
14	of	O	O
15	hippocampus	O	S-Disease
16	in	O	O
17	adult	O	O
18	male	O	O
19	mice	O	O
20	.	O	O

0	The	O	O
1	negative	O	O
2	effects	O	O
3	of	O	O
4	Bisphenol	B-Chemical	B-Chemical
5	A	E-Chemical	E-Chemical
6	(	O	O
7	BPA	S-Chemical	S-Chemical
8	)	O	O
9	on	O	O
10	neurodevelopment	O	S-Disease
11	and	O	O
12	behaviors	O	O
13	have	O	O
14	been	O	O
15	well	O	O
16	established	O	O
17	.	O	O

0	Acetylcholinesterase	O	S-Chemical
1	(	O	O
2	AChE	O	S-Chemical
3	)	O	O
4	is	O	O
5	a	O	O
6	regulatory	O	O
7	enzyme	O	O
8	which	O	O
9	is	O	O
10	involved	O	O
11	in	O	O
12	anxiety	S-Disease	S-Disease
13	-	O	O
14	like	O	O
15	behavior	O	O
16	.	O	O

0	This	O	O
1	study	O	O
2	investigated	O	O
3	behavioral	O	O
4	phenotypes	O	O
5	and	O	O
6	AChE	O	B-Disease
7	activity	O	E-Disease
8	in	O	O
9	male	O	O
10	mice	O	O
11	following	O	O
12	BPA	S-Chemical	S-Chemical
13	exposure	O	E-Disease
14	during	O	O
15	puberty	O	S-Disease
16	.	O	O

0	On	O	O
1	postnatal	O	O
2	day	O	O
3	(	O	O
4	PND	O	O
5	)	O	O
6	35	O	O
7	,	O	O
8	male	O	O
9	mice	O	O
10	were	O	O
11	exposed	O	O
12	to	O	O
13	50mg	O	O
14	BPA	S-Chemical	S-Chemical
15	/	O	O
16	kg	O	O
17	diet	O	O
18	per	O	O
19	day	O	O
20	for	O	O
21	a	O	O
22	period	O	O
23	of	O	O
24	35	O	O
25	days	O	O
26	.	O	O

0	Results	O	O
1	from	O	O
2	our	O	O
3	behavioral	O	O
4	phenotyping	O	O
5	indicated	O	O
6	that	O	O
7	anxiety	S-Disease	S-Disease
8	-	O	O
9	like	O	O
10	behavior	O	O
11	was	O	O
12	increased	O	O
13	in	O	O
14	mice	O	O
15	exposed	O	O
16	to	O	O
17	BPA	S-Chemical	S-Chemical
18	.	O	O

0	AChE	O	S-Chemical
1	activity	O	O
2	was	O	O
3	significantly	O	O
4	decreased	O	O
5	in	O	O
6	the	O	O
7	hippocampus	O	S-Disease
8	of	O	O
9	mice	O	O
10	with	O	O
11	BPA	S-Chemical	S-Chemical
12	compared	O	O
13	to	O	O
14	control	O	O
15	mice	O	O
16	,	O	O
17	whereas	O	O
18	no	O	O
19	difference	O	O
20	was	O	O
21	found	O	O
22	in	O	O
23	the	O	O
24	prefrontal	O	O
25	cortex	O	O
26	,	O	O
27	hypothalamus	O	S-Disease
28	and	O	O
29	cerebellum	O	S-Disease
30	.	O	O

0	Our	O	O
1	findings	O	O
2	showed	O	O
3	that	O	O
4	pubertal	O	O
5	BPA	S-Chemical	S-Chemical
6	exposure	O	E-Disease
7	increased	O	O
8	anxiety	S-Disease	B-Disease
9	-	O	O
10	like	O	O
11	behavior	O	E-Disease
12	,	O	O
13	which	O	O
14	may	O	O
15	be	O	O
16	associated	O	O
17	with	O	O
18	decreased	O	O
19	AChE	O	B-Disease
20	activity	O	E-Disease
21	of	O	I-Disease
22	the	O	O
23	hippocampus	O	S-Disease
24	in	O	O
25	adult	O	O
26	male	O	O
27	mice	O	O
28	.	O	O

0	Further	O	O
1	studies	O	O
2	are	O	O
3	necessary	O	O
4	to	O	O
5	investigate	O	O
6	the	O	O
7	cholinergic	O	S-Chemical
8	signaling	O	O
9	of	O	O
10	the	O	O
11	hippocampus	O	S-Disease
12	in	O	O
13	PBE	O	S-Chemical
14	induced	O	O
15	anxiety	S-Disease	B-Disease
16	-	O	O
17	like	O	O
18	behaviors	O	O
19	.	O	O

0	Biochemical	O	O
1	effects	O	O
2	of	O	O
3	Solidago	O	B-Chemical
4	virgaurea	O	E-Chemical
5	extract	O	O
6	on	O	O
7	experimental	O	O
8	cardiotoxicity	S-Disease	S-Disease
9	.	O	O

0	Cardiovascular	B-Disease	B-Disease
1	diseases	E-Disease	E-Disease
2	(	O	O
3	CVDs	S-Disease	S-Chemical
4	)	O	O
5	are	O	O
6	the	O	O
7	major	O	O
8	health	O	O
9	problem	O	O
10	of	O	O
11	advanced	O	O
12	as	O	O
13	well	O	O
14	as	O	O
15	developing	O	O
16	countries	O	O
17	of	O	O
18	the	O	O
19	world	O	O
20	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	the	O	O
4	present	O	O
5	study	O	O
6	was	O	O
7	to	O	O
8	investigate	O	O
9	the	O	O
10	protective	O	O
11	effect	O	O
12	of	O	O
13	the	O	O
14	Solidago	O	B-Chemical
15	virgaurea	O	E-Chemical
16	extract	O	O
17	on	O	O
18	isoproterenol	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	cardiotoxicity	S-Disease	S-Disease
22	in	O	O
23	rats	O	O
24	.	O	O

0	The	O	O
1	subcutaneous	O	O
2	injection	O	O
3	of	O	O
4	isoproterenol	S-Chemical	S-Chemical
5	(	O	O
6	30	O	O
7	mg	O	O
8	/	O	O
9	kg	O	O
10	)	O	O
11	into	O	O
12	rats	O	O
13	twice	O	O
14	at	O	O
15	an	O	O
16	interval	O	O
17	of	O	O
18	24	O	O
19	h	O	O
20	,	O	O
21	for	O	O
22	two	O	O
23	consecutive	O	O
24	days	O	O
25	,	O	O
26	led	O	O
27	to	O	O
28	a	O	O
29	significant	O	O
30	increase	O	O
31	in	O	O
32	serum	O	O
33	lactate	S-Chemical	O
34	dehydrogenase	O	O
35	,	O	O
36	creatine	S-Chemical	S-Chemical
37	phosphokinase	O	O
38	,	O	O
39	alanine	S-Chemical	S-Chemical
40	transaminase	O	O
41	,	O	O
42	aspartate	S-Chemical	S-Chemical
43	transaminase	O	O
44	,	O	O
45	and	O	O
46	angiotensin	S-Chemical	O
47	-	O	O
48	converting	O	O
49	enzyme	O	O
50	activities	O	O
51	,	O	O
52	total	O	O
53	cholesterol	S-Chemical	S-Chemical
54	,	O	O
55	triglycerides	S-Chemical	S-Chemical
56	,	O	O
57	free	O	O
58	serum	O	O
59	fatty	B-Chemical	B-Disease
60	acid	E-Chemical	E-Disease
61	,	O	O
62	cardiac	O	B-Disease
63	tissue	O	I-Disease
64	malondialdehyde	S-Chemical	E-Disease
65	(	O	O
66	MDA	S-Chemical	S-Disease
67	)	O	O
68	,	O	O
69	and	O	O
70	nitric	B-Chemical	B-Disease
71	oxide	E-Chemical	E-Disease
72	levels	O	O
73	and	O	O
74	a	O	O
75	significant	O	O
76	decrease	O	O
77	in	O	O
78	levels	O	O
79	of	O	O
80	glutathione	S-Chemical	S-Chemical
81	and	O	O
82	superoxide	S-Chemical	B-Disease
83	dismutase	O	E-Disease
84	in	O	O
85	cardiac	O	B-Disease
86	tissue	O	E-Disease
87	as	O	O
88	compared	O	O
89	to	O	O
90	the	O	O
91	normal	O	O
92	control	O	O
93	group	O	O
94	(	O	O
95	P	O	S-Disease
96	<	O	O
97	0	O	O
98	.	O	O
99	05	O	O
100	)	O	O
101	.	O	O

0	Pretreatment	O	O
1	with	O	O
2	S	O	B-Chemical
3	.	O	O
4	virgaurea	O	E-Chemical
5	extract	O	O
6	for	O	O
7	5	O	O
8	weeks	O	O
9	at	O	O
10	a	O	O
11	dose	O	O
12	of	O	O
13	250	O	O
14	mg	O	O
15	/	O	O
16	kg	O	O
17	followed	O	O
18	by	O	O
19	isoproterenol	S-Chemical	S-Chemical
20	injection	O	O
21	significantly	O	O
22	prevented	O	O
23	the	O	O
24	observed	O	O
25	alterations	O	O
26	.	O	O

0	Captopril	S-Chemical	S-Chemical
1	(	O	O
2	50	O	O
3	mg	O	O
4	/	O	O
5	kg	O	O
6	/	O	O
7	day	O	O
8	,	O	O
9	given	O	O
10	orally	O	O
11	)	O	O
12	,	O	O
13	an	O	O
14	inhibitor	O	O
15	of	O	O
16	angiotensin	S-Chemical	O
17	-	O	O
18	converting	O	O
19	enzyme	O	O
20	used	O	O
21	as	O	O
22	a	O	O
23	standard	O	O
24	cardioprotective	O	O
25	drug	O	O
26	,	O	O
27	was	O	O
28	used	O	O
29	as	O	O
30	a	O	O
31	positive	O	O
32	control	O	O
33	in	O	O
34	this	O	O
35	study	O	O
36	.	O	O

0	The	O	O
1	data	O	O
2	of	O	O
3	the	O	O
4	present	O	O
5	study	O	O
6	suggest	O	O
7	that	O	O
8	S	O	B-Chemical
9	.	O	O
10	virgaurea	O	E-Chemical
11	extract	O	O
12	exerts	O	O
13	its	O	O
14	protective	O	O
15	effect	O	O
16	by	O	O
17	decreasing	O	O
18	MDA	S-Chemical	S-Chemical
19	level	O	O
20	and	O	O
21	increasing	O	O
22	the	O	O
23	antioxidant	O	O
24	status	O	O
25	in	O	O
26	isoproterenol	S-Chemical	S-Chemical
27	-	O	O
28	treated	O	O
29	rats	O	O
30	.	O	O

0	"	O	O
1	Real	O	O
2	-	O	O
3	world	O	O
4	"	O	O
5	data	O	O
6	on	O	O
7	the	O	O
8	efficacy	O	O
9	and	O	O
10	safety	O	O
11	of	O	O
12	lenalidomide	S-Chemical	S-Chemical
13	and	O	O
14	dexamethasone	S-Chemical	S-Chemical
15	in	O	O
16	patients	O	O
17	with	O	O
18	relapsed	O	O
19	/	O	O
20	refractory	O	O
21	multiple	B-Disease	O
22	myeloma	E-Disease	S-Disease
23	who	O	O
24	were	O	O
25	treated	O	O
26	according	O	O
27	to	O	O
28	the	O	O
29	standard	O	O
30	clinical	O	O
31	practice	O	O
32	:	O	O
33	a	O	O
34	study	O	O
35	of	O	O
36	the	O	O
37	Greek	O	B-Disease
38	Myeloma	S-Disease	E-Disease
39	Study	O	O
40	Group	O	O
41	.	O	O

0	Lenalidomide	S-Chemical	S-Chemical
1	and	O	O
2	dexamethasone	S-Chemical	S-Chemical
3	(	O	O
4	RD	S-Chemical	S-Disease
5	)	O	O
6	is	O	O
7	a	O	O
8	standard	O	O
9	of	O	O
10	care	O	O
11	for	O	O
12	relapsed	O	O
13	/	O	O
14	refractory	O	O
15	multiple	B-Disease	O
16	myeloma	E-Disease	S-Disease
17	(	O	O
18	RRMM	S-Disease	O
19	)	O	O
20	,	O	O
21	but	O	O
22	there	O	O
23	is	O	O
24	limited	O	O
25	published	O	O
26	data	O	O
27	on	O	O
28	its	O	O
29	efficacy	O	O
30	and	O	O
31	safety	O	O
32	in	O	O
33	the	O	O
34	"	O	O
35	real	O	O
36	world	O	O
37	"	O	O
38	(	O	O
39	RW	O	O
40	)	O	O
41	,	O	O
42	according	O	O
43	to	O	O
44	the	O	O
45	International	O	B-Disease
46	Society	O	I-Disease
47	of	O	I-Disease
48	Pharmacoeconomics	O	I-Disease
49	and	O	I-Disease
50	Outcomes	O	I-Disease
51	Research	O	E-Disease
52	definition	O	O
53	.	O	O

0	We	O	O
1	studied	O	O
2	212	O	O
3	RRMM	S-Disease	O
4	patients	O	O
5	who	O	O
6	received	O	O
7	RD	S-Chemical	O
8	in	O	O
9	RW	O	O
10	.	O	O

0	Median	O	O
1	time	O	O
2	to	O	O
3	CR	O	O
4	when	O	O
5	RD	S-Chemical	O
6	was	O	O
7	given	O	O
8	as	O	O
9	2nd	O	O
10	or	O	O
11	>	O	O
12	2	O	O
13	(	O	O
14	nd	O	O
15	)	O	O
16	-	O	O
17	line	O	O
18	treatment	O	O
19	at	O	O
20	4	O	O
21	and	O	O
22	11	O	O
23	months	O	O
24	,	O	O
25	respectively	O	O
26	.	O	O

0	Quality	O	O
1	of	O	O
2	response	O	O
3	was	O	O
4	independent	O	O
5	of	O	O
6	previous	O	O
7	lines	O	O
8	of	O	O
9	therapies	O	O
10	or	O	O
11	previous	O	O
12	exposure	O	O
13	to	O	O
14	thalidomide	S-Chemical	S-Chemical
15	or	O	O
16	bortezomib	S-Chemical	S-Chemical
17	.	O	O

0	Median	O	O
1	duration	O	O
2	of	O	O
3	response	O	O
4	was	O	O
5	34	O	O
6	.	O	O
7	4	O	O
8	months	O	O
9	,	O	O
10	and	O	O
11	it	O	O
12	was	O	O
13	higher	O	O
14	in	O	O
15	patients	O	O
16	who	O	O
17	received	O	O
18	RD	S-Chemical	S-Disease
19	until	O	O
20	progression	O	O
21	(	O	O
22	not	O	O
23	reached	O	O
24	versus	O	O
25	19	O	O
26	months	O	O
27	,	O	O
28	p	O	O
29	<	O	O
30	0	O	O
31	.	O	O
32	001	O	O
33	)	O	O
34	.	O	O

0	Adverse	O	O
1	events	O	O
2	were	O	O
3	reported	O	O
4	in	O	O
5	68	O	O
6	.	O	O
7	9	O	O
8	%	O	O
9	of	O	O
10	patients	O	O
11	(	O	O
12	myelosuppression	S-Disease	S-Disease
13	in	O	O
14	49	O	O
15	.	O	O
16	4	O	O
17	%	O	O
18	)	O	O
19	and	O	O
20	12	O	O
21	.	O	O
22	7	O	O
23	%	O	O
24	of	O	O
25	patients	O	O
26	needed	O	O
27	hospitalization	O	O
28	.	O	O

0	Peripheral	B-Disease	O
1	neuropathy	E-Disease	S-Disease
2	was	O	O
3	observed	O	O
4	only	O	O
5	in	O	O
6	2	O	O
7	.	O	O
8	5	O	O
9	%	O	O
10	of	O	O
11	patients	O	O
12	and	O	O
13	deep	B-Disease	O
14	vein	I-Disease	I-Disease
15	thrombosis	E-Disease	S-Disease
16	in	O	O
17	5	O	O
18	.	O	O
19	7	O	O
20	%	O	O
21	.	O	O

0	Performance	O	O
1	status	O	O
2	(	O	O
3	PS	O	O
4	)	O	O
5	and	O	O
6	initial	O	O
7	lenalidomide	S-Chemical	S-Chemical
8	dose	O	O
9	predicted	O	O
10	for	O	O
11	treatment	O	O
12	discontinuation	O	O
13	.	O	O

0	Our	O	O
1	study	O	O
2	confirms	O	O
3	that	O	O
4	RD	S-Chemical	S-Disease
5	is	O	O
6	effective	O	O
7	and	O	O
8	safe	O	O
9	in	O	O
10	RRMM	S-Disease	S-Disease
11	in	O	O
12	the	O	O
13	RW	O	O
14	;	O	O
15	it	O	O
16	produces	O	O
17	durable	O	O
18	responses	O	O
19	especially	O	O
20	in	O	O
21	patients	O	O
22	who	O	O
23	continue	O	O
24	on	O	O
25	treatment	O	O
26	till	O	O
27	progression	O	O
28	and	O	O
29	improves	O	O
30	humoral	O	B-Disease
31	immunity	O	E-Disease
32	even	O	O
33	in	O	O
34	patients	O	O
35	with	O	O
36	stable	O	O
37	disease	O	S-Disease
38	.	O	O

0	The	O	O
1	cytogenetic	O	O
2	action	O	O
3	of	O	O
4	ifosfamide	S-Chemical	S-Chemical
5	,	O	O
6	mesna	S-Chemical	S-Chemical
7	,	O	O
8	and	O	O
9	their	O	O
10	combination	O	O
11	on	O	O
12	peripheral	O	O
13	rabbit	O	O
14	lymphocytes	O	I-Disease
15	:	O	O
16	an	O	O
17	in	O	O
18	vivo	O	O
19	/	O	O
20	in	O	O
21	vitro	O	O
22	cytogenetic	O	S-Disease
23	study	O	O
24	.	O	O

0	Ifosfamide	S-Chemical	S-Chemical
1	(	O	O
2	IFO	S-Chemical	S-Chemical
3	)	O	O
4	is	O	O
5	an	O	O
6	alkylating	O	O
7	nitrogen	S-Chemical	O
8	mustard	O	E-Disease
9	,	O	O
10	administrated	O	O
11	as	O	O
12	an	O	O
13	antineoplasmic	O	O
14	agent	O	O
15	.	O	O

0	It	O	O
1	is	O	O
2	characterized	O	O
3	by	O	O
4	its	O	O
5	intense	O	O
6	urotoxic	O	S-Disease
7	action	O	O
8	,	O	O
9	leading	O	O
10	to	O	O
11	hemorrhagic	B-Disease	O
12	cystitis	E-Disease	S-Disease
13	.	O	O

0	This	O	O
1	side	O	O
2	effect	O	O
3	of	O	O
4	IFO	S-Chemical	S-Chemical
5	raises	O	O
6	the	O	O
7	requirement	O	O
8	for	O	O
9	the	O	O
10	co	O	O
11	-	O	O
12	administration	O	O
13	with	O	O
14	sodium	B-Chemical	B-Chemical
15	2	I-Chemical	I-Chemical
16	-	I-Chemical	I-Chemical
17	sulfanylethanesulfonate	E-Chemical	S-Chemical
18	(	O	O
19	Mesna	S-Chemical	S-Chemical
20	)	O	O
21	aiming	O	O
22	to	O	O
23	avoid	O	O
24	or	O	O
25	minimize	O	O
26	this	O	O
27	effect	O	O
28	.	O	O

0	IFO	S-Chemical	S-Chemical
1	and	O	O
2	Mesna	S-Chemical	S-Chemical
3	were	O	O
4	administrated	O	O
5	separately	O	O
6	on	O	O
7	rabbit	O	O
8	'	O	O
9	s	O	O
10	lymphocytes	O	O
11	in	O	O
12	vivo	O	O
13	,	O	O
14	which	O	O
15	were	O	O
16	later	O	O
17	developed	O	O
18	in	O	O
19	vitro	O	O
20	.	O	O

0	Mesna	S-Chemical	S-Chemical
1	'	O	O
2	s	O	O
3	action	O	O
4	,	O	O
5	in	O	O
6	conjunction	O	O
7	with	O	O
8	IFO	S-Chemical	S-Chemical
9	reduces	O	O
10	the	O	O
11	frequency	O	O
12	of	O	O
13	SCEs	O	S-Disease
14	,	O	O
15	in	O	O
16	comparison	O	O
17	with	O	O
18	the	O	O
19	SCEs	O	S-Disease
20	recordings	O	O
21	obtained	O	O
22	when	O	O
23	IFO	S-Chemical	S-Chemical
24	is	O	O
25	administered	O	O
26	alone	O	O
27	.	O	O

0	In	O	O
1	addition	O	O
2	to	O	O
3	this	O	O
4	,	O	O
5	when	O	O
6	high	O	O
7	concentrations	O	O
8	of	O	O
9	Mesna	S-Chemical	S-Chemical
10	were	O	O
11	administered	O	O
12	alone	O	O
13	significant	O	O
14	reductions	O	O
15	of	O	O
16	the	O	O
17	PRI	O	S-Disease
18	were	O	O
19	noted	O	O
20	,	O	O
21	than	O	O
22	with	O	O
23	IFO	S-Chemical	S-Chemical
24	acting	O	O
25	at	O	O
26	the	O	O
27	same	O	O
28	concentration	O	O
29	on	O	O
30	the	O	O
31	lymphocytes	O	S-Disease
32	.	O	O

0	Mesna	S-Chemical	S-Chemical
1	significantly	O	O
2	reduces	O	O
3	IFO	S-Chemical	S-Chemical
4	'	O	O
5	s	O	O
6	genotoxicity	S-Disease	O
7	,	O	O
8	while	O	O
9	when	O	O
10	administered	O	O
11	in	O	O
12	high	O	O
13	concentrations	O	O
14	it	O	O
15	acts	O	O
16	in	O	O
17	an	O	O
18	inhibitory	O	O
19	fashion	O	O
20	on	O	O
21	the	O	O
22	cytostatic	O	O
23	action	O	O
24	of	O	O
25	the	O	O
26	drug	O	O
27	.	O	O

0	Risk	O	O
1	factors	O	O
2	and	O	O
3	predictors	O	O
4	of	O	O
5	levodopa	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	dyskinesia	S-Disease	S-Disease
9	among	O	O
10	multiethnic	O	O
11	Malaysians	O	O
12	with	O	O
13	Parkinson	B-Disease	B-Disease
14	'	I-Disease	I-Disease
15	s	I-Disease	I-Disease
16	disease	E-Disease	E-Disease
17	.	O	O

0	Chronic	O	O
1	pulsatile	O	O
2	levodopa	S-Chemical	S-Chemical
3	therapy	O	O
4	for	O	O
5	Parkinson	B-Disease	B-Disease
6	'	I-Disease	I-Disease
7	s	I-Disease	I-Disease
8	disease	E-Disease	E-Disease
9	(	O	O
10	PD	S-Disease	S-Disease
11	)	O	O
12	leads	O	O
13	to	O	O
14	the	O	O
15	development	O	O
16	of	O	O
17	motor	O	B-Disease
18	fluctuations	O	E-Disease
19	and	O	O
20	dyskinesia	S-Disease	S-Disease
21	.	O	O

0	We	O	O
1	studied	O	O
2	the	O	O
3	prevalence	O	O
4	and	O	O
5	predictors	O	O
6	of	O	O
7	levodopa	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	dyskinesia	S-Disease	S-Disease
11	among	O	O
12	multiethnic	O	O
13	Malaysian	O	O
14	patients	O	O
15	with	O	O
16	PD	S-Disease	S-Disease
17	.	O	O

0	METHODS	O	O
1	:	O	O
2	This	O	O
3	is	O	O
4	a	O	O
5	cross	O	O
6	-	O	O
7	sectional	O	O
8	study	O	O
9	involving	O	O
10	95	O	O
11	patients	O	O
12	with	O	O
13	PD	S-Disease	S-Disease
14	on	O	O
15	uninterrupted	O	O
16	levodopa	S-Chemical	S-Chemical
17	therapy	O	O
18	for	O	O
19	at	O	O
20	least	O	O
21	6	O	O
22	months	O	O
23	.	O	O

0	The	O	O
1	predictors	O	O
2	of	O	O
3	dyskinesia	S-Disease	S-Disease
4	were	O	O
5	determined	O	O
6	using	O	O
7	multivariate	O	O
8	logistic	O	O
9	regression	O	O
10	analysis	O	O
11	.	O	O

0	Dyskinesia	S-Disease	S-Disease
1	was	O	O
2	present	O	O
3	in	O	O
4	44	O	O
5	%	O	O
6	(	O	O
7	n	O	O
8	=	O	O
9	42	O	O
10	)	O	O
11	with	O	O
12	median	O	O
13	levodopa	S-Chemical	S-Chemical
14	therapy	O	O
15	of	O	O
16	3	O	O
17	years	O	O
18	.	O	O

0	Eighty	O	O
1	-	O	O
2	one	O	O
3	percent	O	O
4	of	O	O
5	patients	O	O
6	with	O	O
7	dyskinesia	S-Disease	S-Disease
8	had	O	O
9	clinical	O	O
10	fluctuations	O	O
11	.	O	O

0	Patients	O	O
1	with	O	O
2	dyskinesia	S-Disease	S-Disease
3	had	O	O
4	lower	O	O
5	onset	O	O
6	age	O	O
7	(	O	O
8	p	O	O
9	<	O	O
10	0	O	O
11	.	O	O
12	001	O	O
13	)	O	O
14	,	O	O
15	longer	O	O
16	duration	O	O
17	of	O	O
18	levodopa	S-Chemical	S-Chemical
19	therapy	O	O
20	(	O	O
21	p	O	O
22	<	O	O
23	0	O	O
24	.	O	O
25	001	O	O
26	)	O	O
27	,	O	O
28	longer	O	O
29	disease	O	S-Disease
30	duration	O	O
31	(	O	O
32	p	O	O
33	<	O	O
34	0	O	O
35	.	O	O
36	001	O	O
37	)	O	O
38	,	O	O
39	higher	O	O
40	total	O	O
41	daily	O	O
42	levodopa	S-Chemical	S-Chemical
43	dose	O	O
44	(	O	O
45	p	O	O
46	<	O	O
47	0	O	O
48	.	O	O
49	001	O	O
50	)	O	O
51	,	O	O
52	and	O	O
53	higher	O	O
54	total	O	O
55	UPDRS	O	O
56	scores	O	O
57	(	O	O
58	p	O	O
59	=	O	O
60	0	O	O
61	.	O	O
62	005	O	O
63	)	O	O
64	than	O	O
65	patients	O	O
66	without	O	O
67	dyskinesia	S-Disease	S-Disease
68	.	O	O

0	The	O	O
1	three	O	O
2	significant	O	O
3	predictors	O	O
4	of	O	O
5	dyskinesia	S-Disease	S-Disease
6	were	O	O
7	duration	O	O
8	of	O	O
9	levodopa	S-Chemical	S-Chemical
10	therapy	O	O
11	,	O	O
12	onset	O	O
13	age	O	O
14	,	O	O
15	and	O	O
16	total	O	O
17	daily	O	O
18	levodopa	S-Chemical	S-Chemical
19	dose	O	O
20	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	prevalence	O	O
4	of	O	O
5	levodopa	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	dyskinesia	S-Disease	S-Disease
9	in	O	O
10	our	O	O
11	patients	O	O
12	was	O	O
13	44	O	O
14	%	O	O
15	.	O	O

0	The	O	O
1	most	O	O
2	significant	O	O
3	predictors	O	O
4	were	O	O
5	duration	O	O
6	of	O	O
7	levodopa	S-Chemical	S-Chemical
8	therapy	O	O
9	,	O	O
10	total	O	O
11	daily	O	O
12	levodopa	S-Chemical	S-Chemical
13	dose	O	O
14	,	O	O
15	and	O	O
16	onset	O	O
17	age	O	O
18	.	O	O

0	Dose	O	O
1	-	O	O
2	dependent	O	O
3	neurotoxicity	S-Disease	S-Disease
4	of	O	O
5	high	O	O
6	-	O	O
7	dose	O	O
8	busulfan	S-Chemical	S-Chemical
9	in	O	O
10	children	O	O
11	:	O	O
12	a	O	O
13	clinical	O	O
14	and	O	O
15	pharmacological	O	O
16	study	O	O
17	.	O	O

0	Busulfan	S-Chemical	S-Chemical
1	is	O	O
2	known	O	O
3	to	O	O
4	be	O	O
5	neurotoxic	S-Disease	O
6	in	O	O
7	animals	O	O
8	and	O	O
9	humans	O	O
10	,	O	O
11	but	O	O
12	its	O	O
13	acute	O	B-Disease
14	neurotoxicity	S-Disease	E-Disease
15	remains	O	O
16	poorly	O	O
17	characterized	O	O
18	in	O	O
19	children	O	O
20	.	O	O

0	We	O	O
1	report	O	O
2	here	O	O
3	a	O	O
4	retrospective	O	O
5	study	O	O
6	of	O	O
7	123	O	O
8	children	O	O
9	(	O	O
10	median	O	O
11	age	O	O
12	,	O	O
13	6	O	O
14	.	O	O
15	5	O	O
16	years	O	O
17	)	O	O
18	receiving	O	O
19	high	O	O
20	-	O	O
21	dose	O	O
22	busulfan	S-Chemical	S-Chemical
23	in	O	O
24	combined	O	O
25	chemotherapy	O	O
26	before	O	O
27	bone	O	B-Disease
28	marrow	O	I-Disease
29	transplantation	O	E-Disease
30	for	O	O
31	malignant	O	O
32	solid	O	B-Disease
33	tumors	S-Disease	E-Disease
34	,	O	O
35	brain	B-Disease	B-Disease
36	tumors	E-Disease	E-Disease
37	excluded	O	O
38	.	O	O

0	Busulfan	S-Chemical	S-Chemical
1	was	O	O
2	given	O	O
3	p	O	O
4	.	O	O
5	o	O	O
6	.	O	O
7	,	O	O
8	every	O	O
9	6	O	O
10	hours	O	O
11	for	O	O
12	16	O	O
13	doses	O	O
14	over	O	O
15	4	O	O
16	days	O	O
17	.	O	O

0	Ninety	O	O
1	-	O	O
2	six	O	O
3	patients	O	O
4	were	O	O
5	not	O	O
6	given	O	O
7	anticonvulsive	O	O
8	prophylaxis	O	O
9	;	O	O
10	7	O	O
11	(	O	O
12	7	O	O
13	.	O	O
14	5	O	O
15	%	O	O
16	)	O	O
17	developed	O	O
18	seizures	S-Disease	S-Disease
19	during	O	O
20	the	O	O
21	4	O	O
22	days	O	O
23	of	O	O
24	the	O	O
25	busulfan	S-Chemical	S-Disease
26	course	O	O
27	or	O	O
28	within	O	O
29	24	O	O
30	h	O	O
31	after	O	O
32	the	O	O
33	last	O	O
34	dosing	O	O
35	.	O	O

0	When	O	O
1	the	O	O
2	total	O	O
3	busulfan	S-Chemical	S-Chemical
4	dose	O	O
5	was	O	O
6	taken	O	O
7	into	O	O
8	account	O	O
9	,	O	O
10	there	O	O
11	was	O	O
12	a	O	O
13	significant	O	O
14	difference	O	O
15	in	O	O
16	terms	O	O
17	of	O	O
18	neurotoxicity	S-Disease	S-Disease
19	incidence	O	O
20	among	O	O
21	patients	O	O
22	under	O	O
23	16	O	O
24	mg	O	O
25	/	O	O
26	kg	O	O
27	(	O	O
28	1	O	O
29	of	O	O
30	57	O	O
31	,	O	O
32	1	O	O
33	.	O	O
34	7	O	O
35	%	O	O
36	)	O	O
37	and	O	O
38	patients	O	O
39	under	O	O
40	600	O	O
41	mg	O	O
42	/	O	O
43	m2	O	O
44	(	O	O
45	6	O	O
46	of	O	O
47	39	O	O
48	,	O	O
49	15	O	O
50	.	O	O
51	4	O	O
52	%	O	O
53	)	O	O
54	(	O	O
55	P	O	O
56	less	O	O
57	than	O	O
58	0	O	O
59	.	O	O
60	02	O	O
61	)	O	O
62	.	O	O

0	Twenty	O	O
1	-	O	O
2	seven	O	O
3	patients	O	O
4	were	O	O
5	given	O	O
6	a	O	O
7	600	O	O
8	-	O	O
9	mg	O	O
10	/	O	O
11	m2	O	O
12	busulfan	S-Chemical	S-Chemical
13	total	O	O
14	dose	O	O
15	with	O	O
16	continuous	O	O
17	i	O	O
18	.	O	O
19	v	O	O
20	.	O	O
21	infusion	O	O
22	of	O	O
23	clonazepam	S-Chemical	S-Chemical
24	;	O	O
25	none	O	O
26	had	O	O
27	any	O	O
28	neurological	B-Disease	O
29	symptoms	E-Disease	O
30	.	O	O

0	Busulfan	S-Chemical	S-Chemical
1	levels	O	O
2	were	O	O
3	measured	O	O
4	by	O	O
5	a	O	O
6	gas	O	O
7	chromatographic	O	O
8	-	O	O
9	mass	O	O
10	spectrometry	O	O
11	assay	O	O
12	in	O	O
13	the	O	O
14	plasma	O	O
15	and	O	O
16	cerebrospinal	O	B-Disease
17	fluid	O	O
18	of	O	O
19	9	O	O
20	children	O	O
21	without	O	O
22	central	B-Disease	B-Disease
23	nervous	I-Disease	I-Disease
24	system	I-Disease	I-Disease
25	disease	E-Disease	E-Disease
26	under	O	O
27	600	O	O
28	mg	O	O
29	/	O	O
30	m2	O	O
31	busulfan	S-Chemical	S-Chemical
32	with	O	O
33	clonazepam	S-Chemical	S-Chemical
34	:	O	O
35	busulfan	S-Chemical	S-Disease
36	cerebrospinal	O	S-Disease
37	fluid	O	O
38	:	O	O
39	plasma	O	O
40	ratio	O	O
41	was	O	O
42	1	O	O
43	.	O	O
44	39	O	O
45	.	O	O

0	This	O	O
1	was	O	O
2	significantly	O	O
3	different	O	O
4	(	O	O
5	P	O	O
6	less	O	O
7	than	O	O
8	0	O	O
9	.	O	O
10	02	O	O
11	)	O	O
12	from	O	O
13	the	O	O
14	cerebrospinal	O	O
15	fluid	O	O
16	:	O	O
17	plasma	O	O
18	ratio	O	O
19	previously	O	O
20	defined	O	O
21	in	O	O
22	children	O	O
23	receiving	O	O
24	a	O	O
25	16	O	O
26	-	O	O
27	mg	O	O
28	/	O	O
29	kg	O	O
30	total	O	O
31	dose	O	O
32	of	O	O
33	busulfan	S-Chemical	S-Chemical
34	.	O	O

0	This	O	O
1	study	O	O
2	shows	O	O
3	that	O	O
4	busulfan	S-Chemical	B-Chemical
5	neurotoxicity	S-Disease	S-Disease
6	is	O	O
7	dose	O	O
8	-	O	O
9	dependent	O	O
10	in	O	O
11	children	O	O
12	and	O	O
13	efficiently	O	O
14	prevented	O	O
15	by	O	O
16	clonazepam	S-Chemical	S-Chemical
17	.	O	O

0	A	O	O
1	busulfan	S-Chemical	S-Chemical
2	dose	O	O
3	calculated	O	O
4	on	O	O
5	the	O	O
6	basis	O	O
7	of	O	O
8	body	O	O
9	surface	O	O
10	area	O	O
11	,	O	O
12	resulting	O	O
13	in	O	O
14	higher	O	O
15	doses	O	O
16	in	O	O
17	young	O	O
18	children	O	O
19	,	O	O
20	was	O	O
21	followed	O	O
22	by	O	O
23	increased	O	O
24	neurotoxicity	S-Disease	S-Disease
25	,	O	O
26	close	O	O
27	to	O	O
28	neurotoxicity	S-Disease	S-Disease
29	incidence	O	O
30	observed	O	O
31	in	O	O
32	adults	O	O
33	.	O	O

0	Since	O	O
1	plasma	O	O
2	pharmacokinetic	O	O
3	studies	O	O
4	showed	O	O
5	a	O	O
6	faster	O	O
7	busulfan	S-Chemical	S-Disease
8	clearance	O	S-Disease
9	in	O	O
10	children	O	O
11	than	O	O
12	in	O	O
13	adults	O	O
14	,	O	O
15	this	O	O
16	new	O	O
17	dose	O	O
18	may	O	O
19	approximate	O	O
20	more	O	O
21	closely	O	O
22	the	O	O
23	adult	O	O
24	systemic	O	O
25	exposure	O	O
26	obtained	O	O
27	after	O	O
28	the	O	O
29	usual	O	O
30	16	O	O
31	-	O	O
32	mg	O	O
33	/	O	O
34	kg	O	O
35	total	O	O
36	dose	O	O
37	,	O	O
38	with	O	O
39	potential	O	O
40	inferences	O	O
41	in	O	O
42	terms	O	O
43	of	O	O
44	anticancer	O	O
45	or	O	O
46	myeloablative	O	O
47	effects	O	O
48	.	O	O

0	The	O	O
1	busulfan	S-Chemical	S-Chemical
2	dose	O	O
3	in	O	O
4	children	O	O
5	and	O	O
6	infants	O	O
7	undergoing	O	O
8	bone	O	B-Disease
9	marrow	O	I-Disease
10	transplantation	O	E-Disease
11	should	O	O
12	be	O	O
13	reconsidered	O	O
14	on	O	O
15	the	O	O
16	basis	O	O
17	of	O	O
18	pharmacokinetic	O	O
19	studies	O	O
20	.	O	O

0	An	O	O
1	unexpected	O	O
2	diagnosis	O	O
3	in	O	O
4	a	O	O
5	renal	O	S-Disease
6	-	O	O
7	transplant	O	E-Disease
8	patient	O	O
9	with	O	O
10	proteinuria	S-Disease	S-Disease
11	treated	O	O
12	with	O	O
13	everolimus	S-Chemical	S-Disease
14	:	O	O
15	AL	S-Disease	B-Disease
16	amyloidosis	S-Disease	I-Disease
17	.	O	O

0	Proteinuria	S-Disease	S-Chemical
1	is	O	O
2	an	O	O
3	expected	O	O
4	complication	O	O
5	in	O	O
6	transplant	O	O
7	patients	O	O
8	treated	O	O
9	with	O	O
10	mammalian	O	O
11	target	O	O
12	of	O	O
13	rapamycin	S-Chemical	S-Chemical
14	inhibitors	O	O
15	(	O	O
16	mTOR	O	S-Chemical
17	-	O	E-Chemical
18	i	O	E-Disease
19	)	O	O
20	.	O	O

0	However	O	O
1	,	O	O
2	clinical	O	O
3	suspicion	O	O
4	should	O	O
5	always	O	O
6	be	O	O
7	supported	O	O
8	by	O	O
9	histological	O	O
10	evidence	O	O
11	in	O	O
12	order	O	O
13	to	O	O
14	investigate	O	O
15	potential	O	O
16	alternate	O	O
17	diagnoses	O	O
18	such	O	O
19	as	O	O
20	acute	O	B-Disease
21	or	O	O
22	chronic	O	B-Disease
23	rejection	O	E-Disease
24	,	O	O
25	interstitial	O	O
26	fibrosis	S-Disease	E-Disease
27	and	O	O
28	tubular	O	B-Disease
29	atrophy	S-Disease	E-Disease
30	,	O	O
31	or	O	O
32	recurrent	O	O
33	or	O	O
34	de	O	O
35	novo	O	O
36	glomerulopathy	S-Disease	S-Disease
37	.	O	O

0	In	O	O
1	this	O	O
2	case	O	O
3	we	O	O
4	report	O	O
5	the	O	O
6	unexpected	O	O
7	diagnosis	O	O
8	of	O	O
9	amyloidosis	S-Disease	S-Chemical
10	in	O	O
11	a	O	O
12	renal	O	B-Disease
13	-	O	O
14	transplant	O	E-Disease
15	patient	O	O
16	with	O	O
17	pre	O	O
18	-	O	O
19	transplant	O	O
20	monoclonal	O	B-Disease
21	gammapathy	O	E-Disease
22	of	O	O
23	undetermined	O	O
24	significance	O	O
25	who	O	O
26	developed	O	O
27	proteinuria	S-Disease	S-Disease
28	after	O	O
29	conversion	O	O
30	from	O	O
31	tacrolimus	S-Chemical	S-Chemical
32	to	O	O
33	everolimus	S-Chemical	S-Disease
34	.	O	O

0	Long	O	O
1	-	O	O
2	term	O	O
3	oral	O	O
4	galactose	S-Chemical	S-Chemical
5	treatment	O	O
6	prevents	O	O
7	cognitive	B-Disease	B-Disease
8	deficits	E-Disease	E-Disease
9	in	O	O
10	male	O	O
11	Wistar	O	O
12	rats	O	O
13	treated	O	O
14	intracerebroventricularly	O	O
15	with	O	O
16	streptozotocin	S-Chemical	S-Chemical
17	.	O	O

0	Basic	O	O
1	and	O	O
2	clinical	O	O
3	research	O	O
4	has	O	O
5	demonstrated	O	O
6	that	O	O
7	dementia	S-Disease	S-Disease
8	of	O	O
9	sporadic	O	O
10	Alzheimer	B-Disease	B-Disease
11	'	I-Disease	I-Disease
12	s	I-Disease	I-Disease
13	disease	E-Disease	E-Disease
14	(	O	O
15	sAD	O	S-Chemical
16	)	O	O
17	type	O	O
18	is	O	O
19	associated	O	O
20	with	O	O
21	dysfunction	O	O
22	of	O	O
23	the	O	O
24	insulin	O	S-Chemical
25	-	O	O
26	receptor	O	O
27	(	O	O
28	IR	O	S-Chemical
29	)	O	O
30	system	O	O
31	followed	O	O
32	by	O	O
33	decreased	O	O
34	glucose	S-Chemical	S-Disease
35	transport	O	O
36	via	O	O
37	glucose	S-Chemical	B-Disease
38	transporter	O	O
39	GLUT4	O	S-Chemical
40	and	O	O
41	decreased	O	O
42	glucose	S-Chemical	S-Disease
43	metabolism	O	S-Disease
44	in	O	O
45	brain	O	O
46	cells	O	O
47	.	O	O

0	An	O	O
1	alternative	O	O
2	source	O	O
3	of	O	O
4	energy	O	O
5	is	O	O
6	d	B-Chemical	S-Chemical
7	-	I-Chemical	I-Chemical
8	galactose	E-Chemical	E-Chemical
9	(	O	O
10	the	O	O
11	C	O	B-Chemical
12	-	O	I-Chemical
13	4	O	E-Chemical
14	-	O	O
15	epimer	O	O
16	of	O	O
17	d	B-Chemical	S-Chemical
18	-	I-Chemical	I-Chemical
19	glucose	E-Chemical	E-Chemical
20	)	O	O
21	which	O	O
22	is	O	O
23	transported	O	O
24	into	O	O
25	the	O	O
26	brain	O	O
27	by	O	O
28	insulin	O	S-Chemical
29	-	O	O
30	independent	O	O
31	GLUT3	O	S-Chemical
32	transporter	O	O
33	where	O	O
34	it	O	O
35	might	O	O
36	be	O	O
37	metabolized	O	O
38	to	O	O
39	glucose	S-Chemical	S-Disease
40	via	O	O
41	the	O	O
42	Leloir	O	S-Chemical
43	pathway	O	O
44	.	O	O

0	Exclusively	O	O
1	parenteral	O	O
2	daily	O	O
3	injections	O	O
4	of	O	O
5	galactose	S-Chemical	S-Chemical
6	induce	O	O
7	memory	B-Disease	O
8	deterioration	E-Disease	O
9	in	O	O
10	rodents	O	O
11	and	O	O
12	are	O	O
13	used	O	O
14	to	O	O
15	generate	O	O
16	animal	O	O
17	aging	O	E-Disease
18	model	O	O
19	,	O	O
20	but	O	O
21	the	O	O
22	effects	O	O
23	of	O	O
24	oral	O	O
25	galactose	S-Chemical	S-Chemical
26	treatment	O	O
27	on	O	O
28	cognitive	O	B-Disease
29	functions	O	E-Disease
30	have	O	O
31	never	O	O
32	been	O	O
33	tested	O	O
34	.	O	O

0	We	O	O
1	have	O	O
2	investigated	O	O
3	the	O	O
4	effects	O	O
5	of	O	O
6	continuous	O	O
7	daily	O	O
8	oral	O	O
9	galactose	S-Chemical	S-Disease
10	(	O	O
11	200	O	O
12	mg	O	O
13	/	O	O
14	kg	O	O
15	/	O	O
16	day	O	O
17	)	O	O
18	treatment	O	O
19	on	O	O
20	cognitive	B-Disease	B-Disease
21	deficits	E-Disease	E-Disease
22	in	O	O
23	streptozotocin	S-Chemical	S-Chemical
24	-	O	O
25	induced	O	O
26	(	O	O
27	STZ	S-Chemical	S-Chemical
28	-	O	I-Disease
29	icv	O	E-Chemical
30	)	O	O
31	rat	O	O
32	model	O	O
33	of	O	O
34	sAD	O	S-Chemical
35	,	O	O
36	tested	O	O
37	by	O	O
38	Morris	O	B-Disease
39	Water	O	I-Disease
40	Maze	O	E-Disease
41	and	O	O
42	Passive	O	O
43	Avoidance	O	O
44	test	O	O
45	,	O	O
46	respectively	O	O
47	.	O	O

0	One	O	O
1	month	O	O
2	of	O	O
3	oral	O	O
4	galactose	S-Chemical	S-Chemical
5	treatment	O	O
6	initiated	O	O
7	immediately	O	O
8	after	O	O
9	the	O	O
10	STZ	S-Chemical	S-Chemical
11	-	O	I-Chemical
12	icv	O	E-Chemical
13	administration	O	O
14	,	O	O
15	successfully	O	O
16	prevented	O	O
17	development	O	O
18	of	O	O
19	the	O	O
20	STZ	S-Chemical	S-Chemical
21	-	O	I-Disease
22	icv	O	E-Chemical
23	-	O	O
24	induced	O	O
25	cognitive	B-Disease	B-Disease
26	deficits	E-Disease	E-Disease
27	.	O	O

0	Beneficial	O	O
1	effect	O	O
2	of	O	O
3	oral	O	O
4	galactose	S-Chemical	S-Chemical
5	was	O	O
6	independent	O	O
7	of	O	O
8	the	O	O
9	rat	O	O
10	age	O	O
11	and	O	O
12	of	O	O
13	the	O	O
14	galactose	S-Chemical	S-Disease
15	dose	O	O
16	ranging	O	O
17	from	O	O
18	100	O	O
19	to	O	O
20	300	O	O
21	mg	O	O
22	/	O	O
23	kg	O	O
24	/	O	O
25	day	O	O
26	.	O	O

0	Additionally	O	O
1	,	O	O
2	oral	O	O
3	galactose	S-Chemical	S-Chemical
4	administration	O	O
5	led	O	O
6	to	O	O
7	the	O	O
8	appearance	O	O
9	of	O	O
10	galactose	S-Chemical	S-Chemical
11	in	O	O
12	the	O	O
13	blood	O	O
14	.	O	O

0	The	O	O
1	increase	O	O
2	of	O	O
3	galactose	S-Chemical	S-Chemical
4	concentration	O	O
5	in	O	O
6	the	O	O
7	cerebrospinal	O	B-Disease
8	fluid	O	E-Disease
9	was	O	O
10	several	O	O
11	times	O	O
12	lower	O	O
13	after	O	O
14	oral	O	O
15	than	O	O
16	after	O	O
17	parenteral	O	O
18	administration	O	O
19	of	O	O
20	the	O	O
21	same	O	O
22	galactose	S-Chemical	S-Chemical
23	dose	O	O
24	.	O	O

0	Oral	O	O
1	galactose	S-Chemical	E-Chemical
2	exposure	O	O
3	might	O	O
4	have	O	O
5	beneficial	O	O
6	effects	O	O
7	on	O	O
8	learning	O	O
9	and	O	O
10	memory	O	B-Disease
11	ability	O	E-Disease
12	and	O	O
13	could	O	O
14	be	O	O
15	worth	O	O
16	investigating	O	O
17	for	O	O
18	improvement	O	O
19	of	O	O
20	cognitive	B-Disease	B-Disease
21	deficits	E-Disease	E-Disease
22	associated	O	O
23	with	O	O
24	glucose	B-Disease	B-Disease
25	hypometabolism	E-Disease	E-Disease
26	in	O	O
27	AD	S-Disease	S-Disease
28	.	O	O

0	An	O	O
1	investigation	O	O
2	of	O	O
3	the	O	O
4	pattern	O	O
5	of	O	O
6	kidney	B-Disease	B-Disease
7	injury	E-Disease	E-Disease
8	in	O	O
9	HIV	O	B-Disease
10	-	O	I-Disease
11	positive	O	E-Disease
12	persons	O	O
13	exposed	O	O
14	to	O	O
15	tenofovir	B-Chemical	S-Chemical
16	disoproxil	I-Chemical	I-Disease
17	fumarate	E-Chemical	S-Disease
18	:	O	O
19	an	O	O
20	examination	O	O
21	of	O	O
22	a	O	O
23	large	O	O
24	population	O	O
25	database	O	O
26	(	O	O
27	MHRA	O	S-Chemical
28	database	O	O
29	)	O	O
30	.	O	O

0	The	O	O
1	potential	O	O
2	for	O	O
3	tenofovir	S-Chemical	S-Chemical
4	to	O	O
5	cause	O	O
6	a	O	O
7	range	O	O
8	of	O	O
9	kidney	O	B-Disease
10	syndromes	O	E-Disease
11	has	O	O
12	been	O	O
13	established	O	O
14	from	O	O
15	mechanistic	O	O
16	and	O	O
17	randomised	O	O
18	clinical	O	O
19	trials	O	O
20	.	O	O

0	We	O	O
1	undertook	O	O
2	a	O	O
3	descriptive	O	O
4	analysis	O	O
5	of	O	O
6	Yellow	O	O
7	Card	O	O
8	records	O	O
9	of	O	O
10	407	O	O
11	HIV	O	B-Disease
12	-	O	I-Disease
13	positive	O	E-Disease
14	persons	O	O
15	taking	O	O
16	tenofovir	B-Chemical	S-Chemical
17	disoproxil	I-Chemical	O
18	fumarate	E-Chemical	S-Disease
19	(	O	O
20	TDF	S-Chemical	S-Chemical
21	)	O	O
22	as	O	O
23	part	O	O
24	of	O	O
25	their	O	O
26	antiretroviral	O	O
27	therapy	O	O
28	regimen	O	O
29	and	O	O
30	submitted	O	O
31	to	O	O
32	the	O	O
33	Medicines	O	B-Disease
34	and	O	I-Disease
35	Healthcare	O	I-Disease
36	Products	O	I-Disease
37	Regulatory	O	I-Disease
38	Agency	O	S-Chemical
39	(	O	O
40	MHRA	O	S-Disease
41	)	O	O
42	with	O	O
43	suspected	O	O
44	kidney	O	O
45	adverse	O	O
46	effects	O	O
47	.	O	O

0	Reports	O	O
1	that	O	O
2	satisfy	O	O
3	defined	O	O
4	criteria	O	O
5	were	O	O
6	classified	O	O
7	as	O	O
8	acute	B-Disease	B-Disease
9	kidney	I-Disease	I-Disease
10	injury	E-Disease	E-Disease
11	,	O	O
12	kidney	B-Disease	B-Disease
13	tubular	I-Disease	I-Disease
14	dysfunction	E-Disease	E-Disease
15	and	O	O
16	Fanconi	B-Disease	B-Disease
17	syndrome	E-Disease	E-Disease
18	.	O	O

0	Of	O	O
1	the	O	O
2	407	O	O
3	Yellow	O	B-Disease
4	Card	O	E-Disease
5	records	O	O
6	analysed	O	O
7	,	O	O
8	106	O	O
9	satisfied	O	O
10	criteria	O	O
11	for	O	O
12	TDF	S-Chemical	S-Chemical
13	-	O	O
14	related	O	O
15	kidney	B-Disease	B-Disease
16	disease	E-Disease	E-Disease
17	,	O	O
18	of	O	O
19	which	O	O
20	53	O	O
21	(	O	O
22	50	O	O
23	%	O	O
24	)	O	O
25	had	O	O
26	features	O	O
27	of	O	O
28	kidney	B-Disease	B-Disease
29	tubular	I-Disease	E-Disease
30	dysfunction	E-Disease	E-Disease
31	,	O	O
32	35	O	O
33	(	O	O
34	33	O	O
35	%	O	O
36	)	O	O
37	were	O	O
38	found	O	O
39	to	O	O
40	have	O	O
41	features	O	O
42	of	O	O
43	glomerular	B-Disease	B-Disease
44	dysfunction	E-Disease	E-Disease
45	and	O	O
46	18	O	O
47	(	O	O
48	17	O	O
49	%	O	O
50	)	O	O
51	had	O	O
52	Fanconi	B-Disease	B-Disease
53	syndrome	E-Disease	E-Disease
54	.	O	O

0	The	O	O
1	median	O	O
2	TDF	S-Chemical	S-Chemical
3	exposure	O	O
4	was	O	O
5	316	O	O
6	days	O	O
7	(	O	O
8	interquartile	O	O
9	range	O	O
10	120	O	O
11	-	O	O
12	740	O	O
13	)	O	O
14	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	hospitalisation	O	O
4	for	O	O
5	TDF	S-Chemical	B-Disease
6	kidney	O	E-Disease
7	adverse	O	E-Disease
8	effects	O	O
9	was	O	O
10	high	O	O
11	,	O	O
12	particularly	O	O
13	amongst	O	O
14	patients	O	O
15	with	O	O
16	features	O	O
17	of	O	O
18	Fanconi	B-Disease	B-Disease
19	syndrome	E-Disease	E-Disease
20	.	O	O

0	Cessation	O	O
1	of	O	O
2	TDF	S-Chemical	S-Chemical
3	was	O	O
4	associated	O	O
5	with	O	O
6	complete	O	O
7	restoration	O	O
8	of	O	O
9	kidney	O	B-Disease
10	function	O	E-Disease
11	in	O	O
12	up	O	O
13	half	O	O
14	of	O	O
15	the	O	O
16	patients	O	O
17	in	O	O
18	this	O	O
19	report	O	O
20	.	O	O

0	Incidence	O	O
1	of	O	O
2	postoperative	B-Disease	O
3	delirium	E-Disease	S-Disease
4	is	O	O
5	high	O	O
6	even	O	O
7	in	O	O
8	a	O	O
9	population	O	O
10	without	O	O
11	known	O	O
12	risk	O	O
13	factors	O	O
14	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	Postoperative	B-Disease	O
3	delirium	E-Disease	S-Disease
4	is	O	O
5	a	O	O
6	recognized	O	O
7	complication	O	O
8	in	O	O
9	populations	O	O
10	at	O	O
11	risk	O	O
12	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	is	O	O
6	to	O	O
7	assess	O	O
8	the	O	O
9	prevalence	O	O
10	of	O	O
11	early	O	O
12	postoperative	B-Disease	O
13	delirium	E-Disease	S-Disease
14	in	O	O
15	a	O	O
16	population	O	O
17	without	O	O
18	known	O	O
19	risk	O	O
20	factors	O	O
21	admitted	O	O
22	to	O	O
23	the	O	O
24	ICU	O	O
25	for	O	O
26	postoperative	O	O
27	monitoring	O	O
28	after	O	O
29	elective	O	O
30	major	O	O
31	surgery	O	O
32	.	O	O

0	Exclusion	O	O
1	criteria	O	O
2	were	O	O
3	any	O	O
4	preexisting	O	O
5	predisposing	O	O
6	factor	O	O
7	for	O	O
8	delirium	S-Disease	S-Disease
9	or	O	O
10	other	O	O
11	potentially	O	O
12	confounding	O	O
13	neurological	B-Disease	O
14	dysfunctions	E-Disease	S-Disease
15	.	O	O

0	Patients	O	O
1	were	O	O
2	assessed	O	O
3	daily	O	O
4	using	O	O
5	the	O	O
6	confusion	S-Disease	O
7	assessment	O	O
8	method	O	O
9	for	O	O
10	the	O	O
11	ICU	O	S-Disease
12	scale	O	O
13	for	O	O
14	3	O	O
15	days	O	O
16	after	O	O
17	the	O	O
18	surgical	O	O
19	procedure	O	O
20	.	O	O

0	Early	O	O
1	postoperative	B-Disease	O
2	delirium	E-Disease	S-Disease
3	incidence	O	O
4	risk	O	O
5	factors	O	O
6	were	O	O
7	then	O	O
8	assessed	O	O
9	through	O	O
10	three	O	O
11	different	O	O
12	multiple	O	O
13	regression	O	O
14	models	O	O
15	.	O	O

0	RESULTS	O	O
1	:	O	O
2	According	O	O
3	to	O	O
4	the	O	O
5	confusion	O	O
6	assessment	O	O
7	method	O	O
8	for	O	O
9	the	O	O
10	ICU	O	S-Disease
11	scale	O	O
12	,	O	O
13	28	O	O
14	%	O	O
15	of	O	O
16	patients	O	O
17	were	O	O
18	diagnosed	O	O
19	with	O	O
20	early	O	O
21	postoperative	B-Disease	O
22	delirium	E-Disease	S-Disease
23	.	O	O

0	The	O	O
1	use	O	O
2	of	O	O
3	thiopentone	S-Chemical	S-Chemical
4	was	O	O
5	significantly	O	O
6	associated	O	O
7	with	O	O
8	an	O	O
9	eight	O	O
10	-	O	O
11	fold	O	O
12	-	O	O
13	higher	O	O
14	risk	O	O
15	for	O	O
16	delirium	S-Disease	S-Disease
17	compared	O	O
18	to	O	O
19	propofol	S-Chemical	S-Chemical
20	(	O	O
21	57	O	O
22	.	O	O
23	1	O	O
24	%	O	O
25	vs	O	O
26	.	O	O
27	7	O	O
28	.	O	O
29	1	O	O
30	%	O	O
31	,	O	O
32	RR	O	O
33	=	O	O
34	8	O	O
35	.	O	O
36	0	O	O
37	,	O	O
38	X2	O	O
39	=	O	O
40	4	O	O
41	.	O	O
42	256	O	O
43	;	O	O
44	df	O	O
45	=	O	O
46	1	O	O
47	;	O	O
48	0	O	O
49	.	O	O
50	05	O	O
51	<	O	O
52	p	O	O
53	<	O	O
54	0	O	O
55	.	O	O
56	02	O	O
57	)	O	O
58	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	In	O	O
3	this	O	O
4	study	O	O
5	early	O	O
6	postoperative	B-Disease	O
7	delirium	E-Disease	S-Disease
8	was	O	O
9	found	O	O
10	to	O	O
11	be	O	O
12	a	O	O
13	very	O	O
14	common	O	O
15	complication	O	O
16	after	O	O
17	major	O	O
18	surgery	O	O
19	,	O	O
20	even	O	O
21	in	O	O
22	a	O	O
23	population	O	O
24	without	O	O
25	known	O	O
26	risk	O	O
27	factors	O	O
28	.	O	O

0	Thiopentone	S-Chemical	S-Chemical
1	was	O	O
2	independently	O	O
3	associated	O	O
4	with	O	O
5	an	O	O
6	increase	O	O
7	in	O	O
8	its	O	O
9	relative	O	O
10	risk	O	O
11	.	O	O

0	A	O	O
1	single	O	O
2	neurotoxic	S-Disease	O
3	dose	O	O
4	of	O	O
5	methamphetamine	S-Chemical	S-Chemical
6	induces	O	O
7	a	O	O
8	long	O	O
9	-	O	O
10	lasting	O	O
11	depressive	S-Disease	B-Disease
12	-	O	I-Disease
13	like	O	O
14	behaviour	O	O
15	in	O	O
16	mice	O	O
17	.	O	O

0	Methamphetamine	S-Chemical	S-Chemical
1	(	O	O
2	METH	S-Chemical	S-Chemical
3	)	O	O
4	triggers	O	O
5	a	O	O
6	disruption	O	O
7	of	O	O
8	the	O	O
9	monoaminergic	O	S-Disease
10	system	O	O
11	and	O	O
12	METH	S-Chemical	S-Chemical
13	abuse	O	O
14	leads	O	O
15	to	O	O
16	negative	O	O
17	emotional	O	O
18	states	O	O
19	including	O	O
20	depressive	B-Disease	O
21	symptoms	E-Disease	O
22	during	O	O
23	drug	O	O
24	withdrawal	O	O
25	.	O	O

0	However	O	O
1	,	O	O
2	it	O	O
3	is	O	O
4	currently	O	O
5	unknown	O	O
6	if	O	O
7	the	O	O
8	acute	O	S-Disease
9	toxic	O	O
10	dosage	O	O
11	of	O	O
12	METH	S-Chemical	S-Chemical
13	also	O	O
14	causes	O	O
15	a	O	O
16	long	O	O
17	-	O	O
18	lasting	O	O
19	depressive	S-Disease	B-Disease
20	phenotype	O	E-Disease
21	and	O	O
22	persistent	O	O
23	monoaminergic	O	B-Disease
24	deficits	O	E-Disease
25	.	O	O

0	Thus	O	O
1	,	O	O
2	we	O	O
3	now	O	O
4	assessed	O	O
5	the	O	O
6	depressive	S-Disease	O
7	-	O	O
8	like	O	O
9	behaviour	O	O
10	in	O	O
11	mice	O	O
12	at	O	O
13	early	O	O
14	and	O	O
15	long	O	O
16	-	O	O
17	term	O	O
18	periods	O	O
19	following	O	O
20	a	O	O
21	single	O	O
22	high	O	O
23	METH	S-Chemical	S-Disease
24	dose	O	O
25	(	O	O
26	30	O	O
27	mg	O	O
28	/	O	O
29	kg	O	O
30	,	O	O
31	i	O	O
32	.	O	O
33	p	O	O
34	.	O	O
35	)	O	O
36	.	O	O

0	METH	S-Chemical	S-Disease
1	did	O	O
2	not	O	O
3	alter	O	O
4	the	O	O
5	motor	O	O
6	function	O	O
7	and	O	O
8	procedural	O	O
9	memory	O	O
10	of	O	O
11	mice	O	O
12	as	O	O
13	assessed	O	O
14	by	O	O
15	swimming	O	O
16	speed	O	O
17	and	O	O
18	escape	O	O
19	latency	O	O
20	to	O	O
21	find	O	O
22	the	O	O
23	platform	O	O
24	in	O	O
25	a	O	O
26	cued	O	O
27	version	O	O
28	of	O	O
29	the	O	O
30	water	O	O
31	maze	O	O
32	task	O	O
33	.	O	O

0	However	O	O
1	,	O	O
2	METH	S-Chemical	S-Chemical
3	significantly	O	O
4	increased	O	O
5	the	O	O
6	immobility	O	O
7	time	O	O
8	in	O	O
9	the	O	O
10	tail	O	O
11	suspension	O	O
12	test	O	O
13	at	O	O
14	3	O	O
15	and	O	O
16	49	O	O
17	days	O	O
18	post	O	O
19	-	O	O
20	administration	O	O
21	.	O	O

0	This	O	O
1	depressive	S-Disease	O
2	-	O	O
3	like	O	O
4	profile	O	O
5	induced	O	O
6	by	O	O
7	METH	S-Chemical	S-Chemical
8	was	O	O
9	accompanied	O	O
10	by	O	O
11	a	O	O
12	marked	O	O
13	depletion	O	O
14	of	O	O
15	frontostriatal	O	S-Disease
16	dopaminergic	O	S-Disease
17	and	O	O
18	serotonergic	O	S-Disease
19	neurotransmission	O	S-Disease
20	,	O	O
21	indicated	O	O
22	by	O	O
23	a	O	O
24	reduction	O	O
25	in	O	O
26	the	O	O
27	levels	O	O
28	of	O	O
29	dopamine	S-Chemical	S-Chemical
30	,	O	O
31	DOPAC	S-Chemical	S-Chemical
32	and	O	O
33	HVA	S-Chemical	S-Disease
34	,	O	O
35	tyrosine	S-Chemical	S-Chemical
36	hydroxylase	O	E-Chemical
37	and	O	O
38	serotonin	S-Chemical	S-Chemical
39	,	O	O
40	observed	O	O
41	at	O	O
42	both	O	O
43	3	O	O
44	and	O	O
45	49	O	O
46	days	O	O
47	post	O	O
48	-	O	O
49	administration	O	O
50	.	O	O

0	In	O	O
1	parallel	O	O
2	,	O	O
3	another	O	O
4	neurochemical	O	O
5	feature	O	O
6	of	O	O
7	depression	S-Disease	S-Disease
8	-	O	O
9	-	O	O
10	astroglial	O	B-Disease
11	dysfunction	O	E-Disease
12	-	O	O
13	-	O	O
14	was	O	O
15	unaffected	O	O
16	in	O	O
17	the	O	O
18	cortex	O	O
19	and	O	O
20	the	O	O
21	striatal	O	O
22	levels	O	O
23	of	O	O
24	the	O	O
25	astrocytic	O	O
26	protein	O	O
27	marker	O	O
28	,	O	O
29	glial	O	O
30	fibrillary	O	O
31	acidic	O	O
32	protein	O	O
33	,	O	O
34	were	O	O
35	only	O	O
36	transiently	O	O
37	increased	O	O
38	at	O	O
39	3	O	O
40	days	O	O
41	.	O	O

0	These	O	O
1	findings	O	O
2	demonstrate	O	O
3	for	O	O
4	the	O	O
5	first	O	O
6	time	O	O
7	that	O	O
8	a	O	O
9	single	O	O
10	high	O	O
11	dose	O	O
12	of	O	O
13	METH	S-Chemical	S-Chemical
14	induces	O	O
15	long	O	O
16	-	O	O
17	lasting	O	O
18	depressive	S-Disease	B-Disease
19	-	O	O
20	like	O	O
21	behaviour	O	O
22	in	O	O
23	mice	O	O
24	associated	O	O
25	with	O	O
26	a	O	O
27	persistent	O	O
28	disruption	O	O
29	of	O	O
30	frontostriatal	O	S-Disease
31	dopaminergic	O	S-Disease
32	and	O	O
33	serotonergic	O	S-Disease
34	homoeostasis	O	O
35	.	O	O

0	Linezolid	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	optic	B-Disease	B-Disease
4	neuropathy	E-Disease	E-Disease
5	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	progressive	O	O
6	loss	B-Disease	O
7	of	I-Disease	O
8	vision	E-Disease	S-Disease
9	associated	O	O
10	with	O	O
11	linezolid	S-Chemical	S-Disease
12	therapy	O	O
13	.	O	O

0	A	O	O
1	45	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	male	O	O
7	patient	O	O
8	who	O	O
9	was	O	O
10	on	O	O
11	treatment	O	O
12	with	O	O
13	multiple	O	O
14	second	O	O
15	-	O	O
16	line	O	O
17	anti	O	O
18	-	O	O
19	tuberculous	O	S-Disease
20	drugs	O	O
21	including	O	O
22	linezolid	S-Chemical	S-Chemical
23	and	O	O
24	ethambutol	S-Chemical	S-Chemical
25	for	O	O
26	extensively	B-Disease	O
27	drug	I-Disease	O
28	-	I-Disease	O
29	resistant	I-Disease	O
30	tuberculosis	E-Disease	S-Disease
31	(	O	O
32	XDR	B-Disease	S-Chemical
33	-	I-Disease	O
34	TB	E-Disease	E-Disease
35	)	O	O
36	presented	O	O
37	to	O	O
38	us	O	O
39	with	O	O
40	painless	O	O
41	progressive	O	O
42	loss	B-Disease	O
43	of	I-Disease	O
44	vision	E-Disease	O
45	in	O	O
46	both	O	O
47	eyes	O	O
48	.	O	O

0	Color	O	O
1	vision	O	O
2	was	O	O
3	defective	O	O
4	and	O	O
5	fundus	O	O
6	examination	O	O
7	revealed	O	O
8	optic	B-Disease	B-Disease
9	disc	I-Disease	I-Disease
10	edema	E-Disease	E-Disease
11	in	O	O
12	both	O	O
13	eyes	O	O
14	.	O	O

0	Ethambutol	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	toxic	B-Disease	B-Disease
4	optic	I-Disease	I-Disease
5	neuropathy	E-Disease	S-Disease
6	was	O	O
7	suspected	O	O
8	and	O	O
9	tablet	O	O
10	ethambutol	S-Chemical	S-Chemical
11	was	O	O
12	withdrawn	O	O
13	.	O	O

0	Deterioration	B-Disease	O
1	of	I-Disease	O
2	vision	E-Disease	S-Disease
3	occurred	O	O
4	despite	O	O
5	withdrawal	O	O
6	of	O	O
7	ethambutol	S-Chemical	S-Chemical
8	.	O	O

0	Discontinuation	O	O
1	of	O	O
2	linezolid	S-Chemical	S-Chemical
3	resulted	O	O
4	in	O	O
5	marked	O	O
6	improvement	O	O
7	of	O	O
8	vision	O	S-Disease
9	.	O	O

0	Our	O	O
1	report	O	O
2	emphasizes	O	O
3	the	O	O
4	need	O	O
5	for	O	O
6	monitoring	O	O
7	of	O	O
8	visual	O	O
9	function	O	E-Disease
10	in	O	O
11	patients	O	O
12	on	O	O
13	long	O	O
14	-	O	O
15	term	O	O
16	linezolid	S-Chemical	S-Disease
17	treatment	O	O
18	.	O	O

0	Resuscitation	O	O
1	with	O	O
2	lipid	O	S-Chemical
3	,	O	O
4	epinephrine	S-Chemical	S-Chemical
5	,	O	O
6	or	O	O
7	both	O	O
8	in	O	O
9	levobupivacaine	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	cardiac	B-Disease	B-Disease
13	toxicity	E-Disease	E-Disease
14	in	O	O
15	newborn	O	O
16	piglets	O	S-Disease
17	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	The	O	O
3	optimal	O	O
4	dosing	O	O
5	regimens	O	O
6	of	O	O
7	lipid	O	B-Disease
8	emulsion	O	E-Disease
9	,	O	O
10	epinephrine	S-Chemical	S-Chemical
11	,	O	O
12	or	O	O
13	both	O	O
14	are	O	O
15	not	O	O
16	yet	O	O
17	determined	O	O
18	in	O	O
19	neonates	O	O
20	in	O	O
21	cases	O	O
22	of	O	O
23	local	O	O
24	anaesthetic	O	O
25	systemic	O	O
26	toxicity	S-Disease	S-Disease
27	(	O	O
28	LAST	O	O
29	)	O	O
30	.	O	O

0	METHODS	O	O
1	:	O	O
2	Newborn	O	O
3	piglets	O	O
4	received	O	O
5	levobupivacaine	S-Chemical	S-Chemical
6	until	O	O
7	cardiovascular	B-Disease	B-Disease
8	collapse	E-Disease	E-Disease
9	occurred	O	O
10	.	O	O

0	Standard	O	O
1	cardiopulmonary	O	O
2	resuscitation	O	O
3	was	O	O
4	started	O	O
5	and	O	O
6	electrocardiogram	O	O
7	(	O	O
8	ECG	O	S-Disease
9	)	O	O
10	was	O	O
11	monitored	O	O
12	for	O	O
13	ventricular	B-Disease	B-Disease
14	tachycardia	E-Disease	E-Disease
15	,	O	O
16	fibrillation	S-Disease	S-Disease
17	,	O	O
18	or	O	O
19	QRS	O	O
20	prolongation	O	O
21	.	O	O

0	Piglets	O	O
1	were	O	O
2	then	O	O
3	randomly	O	O
4	allocated	O	O
5	to	O	O
6	four	O	O
7	groups	O	O
8	:	O	O
9	control	O	O
10	(	O	O
11	saline	O	S-Chemical
12	)	O	O
13	,	O	O
14	Intralipid	O	S-Chemical
15	(	O	O
16	)	O	O
17	alone	O	O
18	,	O	O
19	epinephrine	S-Chemical	S-Chemical
20	alone	O	O
21	,	O	O
22	or	O	O
23	a	O	O
24	combination	O	O
25	of	O	O
26	Intralipd	O	S-Chemical
27	plus	O	O
28	epinephrine	S-Chemical	S-Chemical
29	.	O	O

0	The	O	O
1	number	O	O
2	of	O	O
3	ECG	O	S-Disease
4	abnormalities	O	O
5	was	O	O
6	zero	O	O
7	in	O	O
8	the	O	O
9	Intralipid	O	S-Chemical
10	only	O	O
11	group	O	O
12	,	O	O
13	but	O	O
14	14	O	O
15	and	O	O
16	17	O	O
17	,	O	O
18	respectively	O	O
19	,	O	O
20	in	O	O
21	the	O	O
22	epinephrine	S-Chemical	S-Disease
23	and	O	O
24	epinephrine	S-Chemical	S-Chemical
25	plus	O	O
26	lipid	O	S-Disease
27	groups	O	O
28	(	O	O
29	P	O	S-Disease
30	<	O	O
31	0	O	O
32	.	O	O
33	05	O	O
34	)	O	O
35	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Lipid	O	S-Chemical
3	emulsion	O	O
4	with	O	O
5	or	O	O
6	without	O	O
7	epinephrine	S-Chemical	S-Chemical
8	,	O	O
9	or	O	O
10	epinephrine	S-Chemical	S-Chemical
11	alone	O	O
12	were	O	O
13	equally	O	O
14	effective	O	O
15	in	O	O
16	achieving	O	O
17	a	O	O
18	return	O	O
19	to	O	O
20	spontaneous	O	O
21	circulation	O	O
22	in	O	O
23	this	O	O
24	model	O	O
25	of	O	O
26	LAST	O	O
27	.	O	O

0	Epinephrine	S-Chemical	S-Chemical
1	alone	O	O
2	or	O	O
3	in	O	O
4	combination	O	O
5	with	O	O
6	lipid	O	S-Chemical
7	was	O	O
8	associated	O	O
9	with	O	O
10	an	O	O
11	increased	O	O
12	number	O	O
13	of	O	O
14	ECG	O	B-Disease
15	abnormalities	O	E-Disease
16	compared	O	O
17	with	O	O
18	lipid	O	B-Disease
19	emulsion	O	E-Disease
20	alone	O	O
21	.	O	O

0	Incidence	O	O
1	of	O	O
2	heparin	S-Chemical	S-Chemical
3	-	O	O
4	induced	O	O
5	thrombocytopenia	B-Disease	S-Disease
6	type	I-Disease	O
7	II	E-Disease	O
8	and	O	O
9	postoperative	O	O
10	recovery	O	O
11	of	O	O
12	platelet	O	S-Disease
13	count	O	O
14	in	O	O
15	liver	O	B-Disease
16	graft	O	E-Disease
17	recipients	O	O
18	:	O	O
19	a	O	O
20	retrospective	O	O
21	cohort	O	O
22	analysis	O	O
23	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Thrombocytopenia	S-Disease	S-Disease
3	in	O	O
4	patients	O	O
5	with	O	O
6	end	B-Disease	O
7	-	I-Disease	O
8	stage	I-Disease	O
9	liver	I-Disease	B-Disease
10	disease	E-Disease	E-Disease
11	is	O	O
12	a	O	O
13	common	O	O
14	disorder	O	S-Disease
15	caused	O	O
16	mainly	O	O
17	by	O	O
18	portal	B-Disease	B-Disease
19	hypertension	E-Disease	E-Disease
20	,	O	O
21	low	O	O
22	levels	O	O
23	of	O	O
24	thrombopoetin	O	S-Chemical
25	,	O	O
26	and	O	O
27	endotoxemia	S-Disease	S-Disease
28	.	O	O

0	The	O	O
1	impact	O	O
2	of	O	O
3	immune	O	O
4	-	O	O
5	mediated	O	O
6	heparin	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	thrombocytopenia	B-Disease	S-Disease
10	type	I-Disease	O
11	II	E-Disease	O
12	(	O	O
13	HIT	B-Disease	S-Disease
14	type	I-Disease	O
15	II	E-Disease	O
16	)	O	O
17	as	O	O
18	a	O	O
19	cause	O	O
20	of	O	O
21	thrombocytopenia	S-Disease	S-Disease
22	after	O	O
23	liver	O	B-Disease
24	transplantation	O	E-Disease
25	is	O	O
26	not	O	O
27	yet	O	O
28	understood	O	O
29	,	O	O
30	with	O	O
31	few	O	O
32	literature	O	O
33	citations	O	O
34	reporting	O	O
35	contradictory	O	O
36	results	O	O
37	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	our	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	demonstrate	O	O
8	the	O	O
9	perioperative	O	O
10	course	O	O
11	of	O	O
12	thrombocytopenia	S-Disease	S-Disease
13	after	O	O
14	liver	O	B-Disease
15	transplantation	O	E-Disease
16	and	O	O
17	determine	O	O
18	the	O	O
19	occurrence	O	O
20	of	O	O
21	clinical	O	O
22	HIT	B-Disease	S-Disease
23	type	I-Disease	O
24	II	E-Disease	O
25	.	O	O

0	METHOD	O	O
1	:	O	O
2	We	O	O
3	retrospectively	O	O
4	evaluated	O	O
5	the	O	O
6	medical	O	O
7	records	O	O
8	of	O	O
9	205	O	O
10	consecutive	O	O
11	adult	O	O
12	patients	O	O
13	who	O	O
14	underwent	O	O
15	full	O	O
16	-	O	O
17	size	O	O
18	liver	O	B-Disease
19	transplantation	O	E-Disease
20	between	O	O
21	January	O	O
22	2006	O	O
23	and	O	O
24	December	O	O
25	2010	O	O
26	due	O	O
27	to	O	O
28	end	B-Disease	O
29	-	I-Disease	O
30	stage	I-Disease	O
31	or	I-Disease	O
32	malignant	I-Disease	O
33	liver	I-Disease	B-Disease
34	disease	E-Disease	E-Disease
35	.	O	O

0	Preoperative	O	O
1	platelet	O	S-Disease
2	count	O	O
3	,	O	O
4	postoperative	O	O
5	course	O	O
6	of	O	O
7	platelets	O	S-Disease
8	,	O	O
9	and	O	O
10	clinical	O	O
11	signs	O	O
12	of	O	O
13	HIT	B-Disease	S-Disease
14	type	I-Disease	O
15	II	E-Disease	O
16	were	O	O
17	analyzed	O	O
18	.	O	O

0	RESULTS	O	O
1	:	O	O
2	A	O	O
3	total	O	O
4	of	O	O
5	155	O	O
6	(	O	O
7	75	O	O
8	.	O	O
9	6	O	O
10	%	O	O
11	)	O	O
12	of	O	O
13	205	O	O
14	patients	O	O
15	had	O	O
16	thrombocytopenia	S-Disease	S-Disease
17	before	O	O
18	transplantation	O	S-Disease
19	,	O	O
20	significantly	O	O
21	influenced	O	O
22	by	O	O
23	Model	O	O
24	of	O	O
25	End	B-Disease	O
26	-	I-Disease	O
27	Stage	I-Disease	O
28	Liver	I-Disease	B-Disease
29	Disease	E-Disease	E-Disease
30	score	O	O
31	and	O	O
32	liver	B-Disease	B-Disease
33	cirrhosis	E-Disease	E-Disease
34	.	O	O

0	Regarding	O	O
1	HIT	B-Disease	B-Disease
2	II	E-Disease	E-Disease
3	,	O	O
4	there	O	O
5	were	O	O
6	four	O	O
7	(	O	O
8	1	O	O
9	.	O	O
10	95	O	O
11	%	O	O
12	)	O	O
13	patients	O	O
14	with	O	O
15	a	O	O
16	background	O	O
17	of	O	O
18	HIT	B-Disease	B-Disease
19	type	I-Disease	I-Disease
20	II	E-Disease	O
21	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	incidence	O	O
4	of	O	O
5	HIT	S-Disease	S-Disease
6	in	O	O
7	patients	O	O
8	with	O	O
9	end	B-Disease	O
10	-	I-Disease	O
11	stage	I-Disease	O
12	hepatic	I-Disease	B-Disease
13	failure	E-Disease	E-Disease
14	is	O	O
15	,	O	O
16	with	O	O
17	about	O	O
18	1	O	O
19	.	O	O
20	95	O	O
21	%	O	O
22	,	O	O
23	rare	O	O
24	.	O	O

0	For	O	O
1	further	O	O
2	reduction	O	O
3	of	O	O
4	HIT	B-Disease	S-Disease
5	type	I-Disease	O
6	II	E-Disease	O
7	,	O	O
8	the	O	O
9	use	O	O
10	of	O	O
11	intravenous	O	O
12	heparin	S-Chemical	S-Chemical
13	should	O	O
14	be	O	O
15	avoided	O	O
16	and	O	O
17	the	O	O
18	prophylactic	O	O
19	anticoagulation	O	O
20	should	O	O
21	be	O	O
22	performed	O	O
23	with	O	O
24	low	O	O
25	-	O	O
26	molecular	O	O
27	-	O	O
28	weight	O	O
29	heparin	S-Chemical	S-Chemical
30	after	O	O
31	normalization	O	O
32	of	O	O
33	platelet	O	S-Disease
34	count	O	O
35	.	O	O

0	Takotsubo	B-Disease	S-Chemical
1	syndrome	E-Disease	E-Disease
2	(	O	O
3	or	O	O
4	apical	B-Disease	O
5	ballooning	I-Disease	B-Disease
6	syndrome	E-Disease	E-Disease
7	)	O	O
8	secondary	O	O
9	to	O	O
10	Zolmitriptan	S-Chemical	S-Chemical
11	.	O	O

0	Takotsubo	B-Disease	B-Disease
1	syndrome	E-Disease	E-Disease
2	(	O	O
3	TS	S-Disease	S-Disease
4	)	O	O
5	,	O	O
6	also	O	O
7	known	O	O
8	as	O	O
9	broken	B-Disease	B-Disease
10	heart	I-Disease	I-Disease
11	syndrome	E-Disease	E-Disease
12	,	O	O
13	is	O	O
14	characterized	O	O
15	by	O	O
16	left	O	O
17	ventricle	O	I-Disease
18	apical	O	O
19	ballooning	O	E-Disease
20	with	O	O
21	elevated	O	O
22	cardiac	O	B-Disease
23	biomarkers	O	E-Disease
24	and	O	O
25	electrocardiographic	O	O
26	changes	O	O
27	suggestive	O	O
28	of	O	O
29	an	O	O
30	acute	B-Disease	B-Disease
31	coronary	I-Disease	I-Disease
32	syndrome	E-Disease	E-Disease
33	(	O	O
34	ie	O	O
35	,	O	O
36	ST	O	S-Disease
37	-	O	O
38	segment	O	O
39	elevation	O	O
40	,	O	O
41	T	O	O
42	wave	O	O
43	inversions	O	O
44	,	O	O
45	and	O	O
46	pathologic	O	O
47	Q	O	O
48	waves	O	O
49	)	O	O
50	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	54	O	O
6	-	O	O
7	year	O	O
8	-	O	O
9	old	O	O
10	woman	O	O
11	with	O	O
12	medical	O	O
13	history	O	O
14	of	O	O
15	mitral	B-Disease	B-Disease
16	valve	I-Disease	E-Disease
17	prolapse	E-Disease	O
18	and	O	O
19	migraines	S-Disease	S-Disease
20	,	O	O
21	who	O	O
22	was	O	O
23	admitted	O	O
24	to	O	O
25	the	O	O
26	hospital	O	O
27	for	O	O
28	substernal	O	O
29	chest	B-Disease	I-Disease
30	pain	E-Disease	E-Disease
31	and	O	O
32	electrocardiogram	O	O
33	demonstrated	O	O
34	1	O	O
35	/	O	O
36	2	O	O
37	mm	O	O
38	ST	O	S-Disease
39	-	O	O
40	segment	O	O
41	elevation	O	O
42	in	O	O
43	leads	O	O
44	II	O	O
45	,	O	O
46	III	O	O
47	,	O	O
48	aVF	O	O
49	,	O	O
50	V5	O	O
51	,	O	O
52	and	O	O
53	V6	O	S-Disease
54	and	O	O
55	positive	O	O
56	troponin	O	B-Chemical
57	I	O	E-Chemical
58	.	O	O

0	Emergent	O	O
1	coronary	O	S-Disease
2	angiogram	O	E-Disease
3	revealed	O	O
4	normal	O	O
5	coronary	O	B-Disease
6	arteries	O	I-Disease
7	with	O	O
8	moderately	O	O
9	reduced	O	O
10	left	O	O
11	ventricular	O	B-Disease
12	ejection	O	E-Disease
13	fraction	O	O
14	with	O	O
15	wall	O	B-Disease
16	motion	O	E-Disease
17	abnormalities	O	O
18	consistent	O	O
19	with	O	O
20	TS	S-Disease	S-Disease
21	.	O	O

0	Detailed	O	O
1	history	O	O
2	obtained	O	O
3	retrospectively	O	O
4	revealed	O	O
5	that	O	O
6	the	O	O
7	patient	O	O
8	took	O	O
9	zolmitriptan	S-Chemical	S-Chemical
10	sparingly	O	O
11	only	O	O
12	when	O	O
13	she	O	O
14	had	O	O
15	migraines	S-Disease	S-Disease
16	.	O	O

0	But	O	O
1	before	O	O
2	this	O	O
3	event	O	O
4	,	O	O
5	she	O	O
6	was	O	O
7	taking	O	O
8	zolmitriptan	S-Chemical	S-Chemical
9	2	O	O
10	-	O	O
11	3	O	O
12	times	O	O
13	daily	O	O
14	for	O	O
15	several	O	O
16	days	O	O
17	because	O	O
18	of	O	O
19	a	O	O
20	persistent	O	O
21	migraine	B-Disease	B-Disease
22	headache	E-Disease	E-Disease
23	.	O	O

0	There	O	O
1	was	O	O
2	no	O	O
3	evidence	O	O
4	of	O	O
5	any	O	O
6	recent	O	O
7	stress	O	O
8	or	O	O
9	status	B-Disease	O
10	migrainosus	E-Disease	S-Disease
11	.	O	O

0	Extensive	O	O
1	literature	O	O
2	search	O	O
3	revealed	O	O
4	multiple	O	O
5	cases	O	O
6	of	O	O
7	coronary	B-Disease	B-Disease
8	artery	I-Disease	I-Disease
9	vasospasm	E-Disease	E-Disease
10	secondary	O	O
11	to	O	O
12	zolmitriptan	S-Chemical	S-Chemical
13	,	O	O
14	but	O	O
15	none	O	O
16	of	O	O
17	the	O	O
18	cases	O	O
19	were	O	O
20	associated	O	O
21	with	O	O
22	TS	S-Disease	S-Disease
23	.	O	O

0	Depression	S-Disease	O
1	,	O	O
2	impulsiveness	S-Disease	O
3	,	O	O
4	sleep	O	O
5	,	O	O
6	and	O	O
7	memory	O	O
8	in	O	O
9	past	O	O
10	and	O	O
11	present	O	O
12	polydrug	O	O
13	users	O	O
14	of	O	O
15	3	B-Chemical	B-Chemical
16	,	I-Chemical	O
17	4	I-Chemical	I-Chemical
18	-	I-Chemical	I-Chemical
19	methylenedioxymethamphetamine	E-Chemical	S-Chemical
20	(	O	O
21	MDMA	S-Chemical	S-Chemical
22	,	O	O
23	ecstasy	S-Chemical	S-Disease
24	)	O	O
25	.	O	O

0	RATIONALE	O	O
1	:	O	O
2	Ecstasy	S-Chemical	S-Chemical
3	(	O	O
4	3	B-Chemical	S-Chemical
5	,	I-Chemical	O
6	4	I-Chemical	I-Chemical
7	-	I-Chemical	O
8	methylenedioxymethamphetamine	E-Chemical	S-Chemical
9	,	O	O
10	MDMA	S-Chemical	S-Chemical
11	)	O	O
12	is	O	O
13	a	O	O
14	worldwide	O	O
15	recreational	O	O
16	drug	O	O
17	of	O	O
18	abuse	O	O
19	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	The	O	O
3	present	O	O
4	study	O	O
5	aimed	O	O
6	to	O	O
7	be	O	O
8	the	O	O
9	largest	O	O
10	to	O	O
11	date	O	O
12	in	O	O
13	sample	O	O
14	size	O	O
15	and	O	O
16	5HT	O	O
17	-	O	O
18	related	O	O
19	behaviors	O	O
20	;	O	O
21	the	O	O
22	first	O	O
23	to	O	O
24	compare	O	O
25	present	O	O
26	ecstasy	S-Chemical	S-Disease
27	users	O	O
28	with	O	O
29	past	O	O
30	users	O	O
31	after	O	O
32	an	O	O
33	abstinence	O	O
34	of	O	O
35	4	O	O
36	or	O	O
37	more	O	O
38	years	O	O
39	,	O	O
40	and	O	O
41	the	O	O
42	first	O	O
43	to	O	O
44	include	O	O
45	robust	O	O
46	controls	O	O
47	for	O	O
48	other	O	O
49	recreational	O	O
50	substances	O	O
51	.	O	O

0	METHODS	O	O
1	:	O	O
2	A	O	O
3	sample	O	O
4	of	O	O
5	997	O	O
6	participants	O	O
7	(	O	O
8	52	O	O
9	%	O	O
10	male	O	O
11	)	O	O
12	was	O	O
13	recruited	O	O
14	to	O	O
15	four	O	O
16	control	O	O
17	groups	O	O
18	(	O	O
19	non	O	O
20	-	O	O
21	drug	O	O
22	(	O	O
23	ND	O	S-Disease
24	)	O	O
25	,	O	O
26	alcohol	S-Chemical	B-Chemical
27	/	O	I-Chemical
28	nicotine	S-Chemical	E-Chemical
29	(	O	O
30	AN	S-Chemical	S-Disease
31	)	O	O
32	,	O	O
33	cannabis	S-Chemical	B-Chemical
34	/	O	O
35	alcohol	S-Chemical	I-Chemical
36	/	O	I-Chemical
37	nicotine	S-Chemical	E-Chemical
38	(	O	O
39	CAN	S-Chemical	S-Chemical
40	)	O	O
41	,	O	O
42	non	O	O
43	-	O	O
44	ecstasy	S-Chemical	O
45	polydrug	O	O
46	(	O	O
47	PD	O	O
48	)	O	O
49	)	O	O
50	,	O	O
51	and	O	O
52	two	O	O
53	ecstasy	S-Chemical	S-Disease
54	polydrug	O	O
55	groups	O	O
56	(	O	O
57	present	O	O
58	(	O	O
59	MDMA	S-Chemical	S-Chemical
60	)	O	O
61	and	O	O
62	past	O	O
63	users	O	O
64	(	O	O
65	EX	O	S-Chemical
66	-	O	I-Disease
67	MDMA	S-Chemical	E-Chemical
68	)	O	O
69	.	O	O

0	Participants	O	O
1	completed	O	O
2	a	O	O
3	drug	O	O
4	history	O	O
5	questionnaire	O	O
6	,	O	O
7	Beck	O	B-Disease
8	Depression	S-Disease	I-Disease
9	Inventory	O	E-Disease
10	,	O	O
11	Barratt	O	B-Disease
12	Impulsiveness	S-Disease	I-Disease
13	Scale	O	O
14	,	O	O
15	Pittsburgh	O	B-Disease
16	Sleep	O	I-Disease
17	Quality	O	I-Disease
18	Index	O	E-Disease
19	,	O	O
20	and	O	O
21	Wechsler	O	B-Chemical
22	Memory	O	I-Disease
23	Scale	O	E-Disease
24	-	O	O
25	Revised	O	O
26	which	O	O
27	,	O	O
28	in	O	O
29	total	O	O
30	,	O	O
31	provided	O	O
32	13	O	O
33	psychometric	O	O
34	measures	O	O
35	.	O	O

0	RESULTS	O	O
1	:	O	O
2	While	O	O
3	the	O	O
4	CAN	S-Chemical	S-Disease
5	and	O	O
6	PD	O	S-Disease
7	groups	O	O
8	tended	O	O
9	to	O	O
10	record	O	O
11	greater	O	O
12	deficits	O	O
13	than	O	O
14	the	O	O
15	non	O	O
16	-	O	O
17	drug	O	O
18	controls	O	O
19	,	O	O
20	the	O	O
21	MDMA	S-Chemical	S-Chemical
22	and	O	O
23	EX	O	S-Chemical
24	-	O	O
25	MDMA	S-Chemical	E-Chemical
26	groups	O	O
27	recorded	O	O
28	greater	O	O
29	deficits	O	O
30	than	O	O
31	all	O	O
32	the	O	O
33	control	O	O
34	groups	O	O
35	on	O	O
36	ten	O	O
37	of	O	O
38	the	O	O
39	13	O	O
40	psychometric	O	O
41	measures	O	O
42	.	O	O

0	Strikingly	O	O
1	,	O	O
2	despite	O	O
3	prolonged	O	O
4	abstinence	O	O
5	(	O	O
6	mean	O	O
7	,	O	O
8	4	O	O
9	.	O	O
10	98	O	O
11	;	O	O
12	range	O	O
13	,	O	O
14	4	O	O
15	-	O	O
16	9	O	O
17	years	O	O
18	)	O	O
19	,	O	O
20	past	O	O
21	ecstasy	S-Chemical	S-Disease
22	users	O	O
23	showed	O	O
24	few	O	O
25	signs	O	O
26	of	O	O
27	recovery	O	O
28	.	O	O

0	Compared	O	O
1	with	O	O
2	present	O	O
3	ecstasy	S-Chemical	S-Disease
4	users	O	O
5	,	O	O
6	the	O	O
7	past	O	O
8	users	O	O
9	showed	O	O
10	no	O	O
11	change	O	O
12	for	O	O
13	ten	O	O
14	measures	O	O
15	,	O	O
16	increased	O	O
17	impairment	O	O
18	for	O	O
19	two	O	O
20	measures	O	O
21	,	O	O
22	and	O	O
23	improvement	O	O
24	on	O	O
25	just	O	O
26	one	O	O
27	measure	O	O
28	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Given	O	O
3	this	O	O
4	record	O	O
5	of	O	O
6	impaired	B-Disease	O
7	memory	E-Disease	O
8	and	O	O
9	clinically	O	O
10	significant	O	O
11	levels	O	O
12	of	O	O
13	depression	S-Disease	S-Disease
14	,	O	O
15	impulsiveness	S-Disease	O
16	,	O	O
17	and	O	O
18	sleep	B-Disease	B-Disease
19	disturbance	E-Disease	E-Disease
20	,	O	O
21	the	O	O
22	prognosis	O	O
23	for	O	O
24	the	O	O
25	current	O	O
26	generation	O	O
27	of	O	O
28	ecstasy	S-Chemical	S-Disease
29	users	O	O
30	is	O	O
31	a	O	O
32	major	O	O
33	cause	O	O
34	for	O	O
35	concern	O	O
36	.	O	O

0	Association	O	O
1	of	O	O
2	common	O	O
3	genetic	O	O
4	variants	O	O
5	of	O	O
6	HOMER1	O	S-Disease
7	gene	O	O
8	with	O	O
9	levodopa	S-Chemical	S-Chemical
10	adverse	O	O
11	effects	O	O
12	in	O	O
13	Parkinson	B-Disease	B-Disease
14	'	I-Disease	I-Disease
15	s	I-Disease	I-Disease
16	disease	E-Disease	E-Disease
17	patients	O	O
18	.	O	O

0	Levodopa	S-Chemical	S-Chemical
1	is	O	O
2	the	O	O
3	most	O	O
4	effective	O	O
5	symptomatic	O	O
6	therapy	O	O
7	for	O	O
8	Parkinson	B-Disease	B-Disease
9	'	I-Disease	I-Disease
10	s	I-Disease	I-Disease
11	disease	E-Disease	E-Disease
12	,	O	O
13	but	O	O
14	its	O	O
15	chronic	O	O
16	use	O	O
17	could	O	O
18	lead	O	O
19	to	O	O
20	chronic	O	B-Disease
21	adverse	O	E-Disease
22	outcomes	O	O
23	,	O	O
24	such	O	O
25	as	O	O
26	motor	O	B-Disease
27	fluctuations	O	E-Disease
28	,	O	O
29	dyskinesia	S-Disease	S-Disease
30	and	O	O
31	visual	B-Disease	O
32	hallucinations	E-Disease	O
33	.	O	O

0	HOMER1	O	S-Chemical
1	is	O	O
2	a	O	O
3	protein	O	O
4	with	O	O
5	pivotal	O	O
6	function	O	O
7	in	O	O
8	glutamate	S-Chemical	S-Chemical
9	transmission	O	O
10	,	O	O
11	which	O	O
12	has	O	O
13	been	O	O
14	related	O	O
15	to	O	O
16	the	O	O
17	pathogenesis	O	O
18	of	O	O
19	these	O	O
20	complications	O	O
21	.	O	O

0	This	O	O
1	study	O	O
2	investigates	O	O
3	whether	O	O
4	polymorphisms	O	O
5	in	O	O
6	the	O	O
7	HOMER1	O	S-Disease
8	gene	O	O
9	promoter	O	O
10	region	O	O
11	are	O	O
12	associated	O	O
13	with	O	O
14	the	O	O
15	occurrence	O	O
16	of	O	O
17	the	O	O
18	chronic	O	S-Disease
19	complications	O	O
20	of	O	O
21	levodopa	S-Chemical	S-Chemical
22	therapy	O	O
23	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	205	O	O
4	patients	O	O
5	with	O	O
6	idiopathic	B-Disease	B-Disease
7	Parkinson	I-Disease	B-Disease
8	'	I-Disease	I-Disease
9	s	I-Disease	I-Disease
10	disease	E-Disease	E-Disease
11	were	O	O
12	investigated	O	O
13	.	O	O

0	The	O	O
1	rs4704559	O	O
2	G	O	O
3	allele	O	O
4	was	O	O
5	associated	O	O
6	with	O	O
7	a	O	O
8	lower	O	O
9	prevalence	O	O
10	of	O	O
11	dyskinesia	S-Disease	S-Disease
12	(	O	O
13	prevalence	O	O
14	ratio	O	O
15	(	O	O
16	PR	O	O
17	)	O	O
18	=	O	O
19	0	O	O
20	.	O	O
21	615	O	O
22	,	O	O
23	95	O	O
24	%	O	O
25	confidence	O	O
26	interval	O	O
27	(	O	O
28	CI	O	S-Chemical
29	)	O	O
30	0	O	O
31	.	O	O
32	426	O	O
33	-	O	O
34	0	O	O
35	.	O	O
36	887	O	O
37	,	O	O
38	P	O	O
39	=	O	O
40	0	O	O
41	.	O	O
42	009	O	O
43	)	O	O
44	and	O	O
45	visual	B-Disease	O
46	hallucinations	E-Disease	O
47	(	O	O
48	PR	O	O
49	=	O	O
50	0	O	O
51	.	O	O
52	515	O	O
53	,	O	O
54	95	O	O
55	%	O	O
56	CI	O	S-Disease
57	0	O	O
58	.	O	O
59	295	O	O
60	-	O	O
61	0	O	O
62	.	O	O
63	899	O	O
64	,	O	O
65	P	O	S-Disease
66	=	O	O
67	0	O	O
68	.	O	O
69	020	O	O
70	)	O	O
71	.	O	O

0	Our	O	O
1	data	O	O
2	suggest	O	O
3	that	O	O
4	HOMER1	O	S-Disease
5	rs4704559	O	O
6	G	O	O
7	allele	O	O
8	has	O	O
9	a	O	O
10	protective	O	O
11	role	O	O
12	for	O	O
13	the	O	O
14	development	O	O
15	of	O	O
16	levodopa	S-Chemical	S-Chemical
17	adverse	O	O
18	effects	O	O
19	.	O	O

0	Crocin	S-Chemical	S-Chemical
1	improves	O	O
2	lipid	O	S-Chemical
3	dysregulation	O	E-Disease
4	in	O	O
5	subacute	O	O
6	diazinon	S-Chemical	S-Chemical
7	exposure	O	O
8	through	O	O
9	ERK1	O	B-Chemical
10	/	O	O
11	2	O	O
12	pathway	O	O
13	in	O	O
14	rat	O	O
15	liver	O	O
16	.	O	O

0	INTRODUCTION	O	O
1	:	O	O
2	Diazinon	S-Chemical	S-Chemical
3	Yis	O	E-Chemical
4	one	O	O
5	of	O	O
6	the	O	O
7	most	O	O
8	broadly	O	O
9	used	O	O
10	organophosphorus	S-Chemical	S-Chemical
11	insecticides	O	O
12	in	O	O
13	agriculture	O	O
14	.	O	O

0	It	O	O
1	has	O	O
2	been	O	O
3	shown	O	O
4	that	O	O
5	exposure	O	O
6	to	O	O
7	diazinon	S-Chemical	S-Chemical
8	may	O	O
9	interfere	O	O
10	with	O	O
11	lipid	O	B-Disease
12	metabolism	O	E-Disease
13	.	O	O

0	Moreover	O	O
1	,	O	O
2	the	O	O
3	hypolipidemic	O	O
4	effect	O	O
5	of	O	O
6	crocin	S-Chemical	S-Chemical
7	has	O	O
8	been	O	O
9	established	O	O
10	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	evaluate	O	O
8	changes	O	O
9	in	O	O
10	the	O	O
11	regulation	O	O
12	of	O	O
13	lipid	O	B-Disease
14	metabolism	O	E-Disease
15	,	O	O
16	ERK	O	S-Disease
17	and	O	O
18	LDLr	O	S-Disease
19	expression	O	O
20	in	O	O
21	the	O	O
22	liver	O	O
23	of	O	O
24	rats	O	O
25	exposed	O	O
26	to	O	O
27	subacute	O	O
28	diazinon	S-Chemical	S-Chemical
29	.	O	O

0	Furthermore	O	O
1	ameliorating	O	O
2	effect	O	O
3	of	O	O
4	crocin	S-Chemical	S-Chemical
5	on	O	O
6	diazinon	S-Chemical	S-Chemical
7	induced	O	O
8	disturbed	O	B-Disease
9	cholesterol	S-Chemical	B-Chemical
10	homeostasis	O	E-Disease
11	was	O	O
12	studied	O	O
13	.	O	O

0	METHODS	O	O
1	:	O	O
2	24	O	O
3	Rats	O	O
4	were	O	O
5	divided	O	O
6	into	O	O
7	4	O	O
8	groups	O	O
9	and	O	O
10	received	O	O
11	following	O	O
12	treatments	O	O
13	for	O	O
14	4	O	O
15	weeks	O	O
16	;	O	O
17	Corn	O	S-Chemical
18	oil	O	O
19	(	O	O
20	control	O	O
21	)	O	O
22	,	O	O
23	diazinon	S-Chemical	S-Chemical
24	(	O	O
25	15mg	O	O
26	/	O	O
27	kg	O	O
28	per	O	O
29	day	O	O
30	,	O	O
31	orally	O	O
32	)	O	O
33	and	O	O
34	crocin	S-Chemical	S-Chemical
35	(	O	O
36	12	O	O
37	.	O	O
38	5	O	O
39	and	O	O
40	25mg	O	O
41	/	O	O
42	kg	O	O
43	per	O	O
44	day	O	O
45	,	O	O
46	intraperitoneally	O	O
47	)	O	O
48	in	O	O
49	combination	O	O
50	with	O	O
51	diazinon	S-Chemical	S-Chemical
52	(	O	O
53	15	O	O
54	mg	O	O
55	/	O	O
56	kg	O	O
57	)	O	O
58	.	O	O

0	The	O	O
1	levels	O	O
2	of	O	O
3	cholesterol	S-Chemical	S-Chemical
4	,	O	O
5	triglyceride	S-Chemical	S-Chemical
6	and	O	O
7	LDL	O	S-Disease
8	in	O	O
9	blood	O	O
10	of	O	O
11	rats	O	O
12	were	O	O
13	analyzed	O	O
14	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Our	O	O
3	data	O	O
4	showed	O	O
5	that	O	O
6	subacute	O	O
7	exposure	O	O
8	to	O	O
9	diazinon	S-Chemical	S-Chemical
10	significantly	O	O
11	increased	O	O
12	concentrations	O	O
13	of	O	O
14	cholesterol	S-Chemical	S-Chemical
15	,	O	O
16	triglyceride	S-Chemical	S-Chemical
17	and	O	O
18	LDL	O	S-Disease
19	.	O	O

0	Moreover	O	O
1	diazinon	S-Chemical	S-Chemical
2	decreased	O	O
3	ERK1	O	S-Disease
4	/	O	O
5	2	O	O
6	protein	O	O
7	phosphorylation	O	O
8	and	O	O
9	LDLr	O	S-Disease
10	transcript	O	O
11	.	O	O

0	Crocin	S-Chemical	S-Chemical
1	reduced	O	O
2	inhibition	O	O
3	of	O	O
4	ERK	O	S-Disease
5	activation	O	O
6	and	O	O
7	diazinon	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	hyperlipemia	S-Disease	S-Disease
11	and	O	O
12	increased	O	O
13	levels	O	O
14	of	O	O
15	LDLr	O	O
16	transcript	O	O
17	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Crocin	S-Chemical	S-Chemical
3	may	O	O
4	be	O	O
5	considered	O	O
6	as	O	O
7	a	O	O
8	novel	O	O
9	protective	O	O
10	agent	O	O
11	in	O	O
12	diazinon	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	hyperlipemia	S-Disease	S-Disease
16	through	O	O
17	modulating	O	O
18	of	O	O
19	ERK	O	S-Disease
20	pathway	O	O
21	and	O	O
22	increase	O	O
23	of	O	O
24	LDLr	O	S-Disease
25	expression	O	O
26	.	O	O

0	GEM	S-Chemical	S-Chemical
1	-	O	O
2	P	O	O
3	chemotherapy	O	O
4	is	O	O
5	active	O	O
6	in	O	O
7	the	O	O
8	treatment	O	O
9	of	O	O
10	relapsed	O	O
11	Hodgkin	B-Disease	B-Disease
12	lymphoma	E-Disease	E-Disease
13	.	O	O

0	Hodgkin	B-Disease	B-Disease
1	lymphoma	E-Disease	E-Disease
2	(	O	O
3	HL	S-Disease	S-Disease
4	)	O	O
5	is	O	O
6	a	O	O
7	relatively	O	O
8	chemosensitive	O	O
9	malignancy	S-Disease	S-Disease
10	.	O	O

0	Regimens	O	O
1	commonly	O	O
2	used	O	O
3	often	O	O
4	require	O	O
5	inpatient	O	O
6	administration	O	O
7	and	O	O
8	can	O	O
9	be	O	O
10	difficult	O	O
11	to	O	O
12	deliver	O	O
13	due	O	O
14	to	O	O
15	toxicity	S-Disease	S-Disease
16	.	O	O

0	Gemcitabine	S-Chemical	S-Chemical
1	and	O	O
2	cisplatin	S-Chemical	S-Chemical
3	have	O	O
4	activity	O	O
5	in	O	O
6	HL	S-Disease	S-Disease
7	,	O	O
8	non	O	O
9	-	O	O
10	overlapping	O	O
11	toxicity	S-Disease	S-Disease
12	with	O	O
13	first	O	O
14	-	O	O
15	line	O	O
16	chemotherapeutics	O	O
17	,	O	O
18	and	O	O
19	may	O	O
20	be	O	O
21	delivered	O	O
22	in	O	O
23	an	O	O
24	outpatient	O	O
25	setting	O	O
26	.	O	O

0	In	O	O
1	this	O	O
2	retrospective	O	O
3	single	O	O
4	-	O	O
5	centre	O	O
6	analysis	O	O
7	,	O	O
8	patients	O	O
9	with	O	O
10	relapsed	O	O
11	or	O	O
12	refractory	O	O
13	HL	S-Disease	O
14	treated	O	O
15	with	O	O
16	gemcitabine	S-Chemical	S-Chemical
17	1	O	O
18	,	O	O
19	000	O	O
20	mg	O	O
21	/	O	O
22	m	O	O
23	(	O	O
24	2	O	O
25	)	O	O
26	day	O	O
27	(	O	O
28	D	O	O
29	)	O	O
30	1	O	O
31	,	O	O
32	D8	O	B-Chemical
33	and	O	O
34	D15	O	S-Chemical
35	;	O	O
36	methylprednisolone	S-Chemical	S-Chemical
37	1	O	O
38	,	O	O
39	000	O	O
40	mg	O	O
41	D1	O	S-Chemical
42	-	O	O
43	5	O	O
44	;	O	O
45	and	O	O
46	cisplatin	S-Chemical	S-Chemical
47	100	O	O
48	mg	O	O
49	/	O	O
50	m	O	O
51	(	O	O
52	2	O	O
53	)	O	O
54	D15	O	S-Chemical
55	,	O	O
56	every	O	O
57	28	O	O
58	days	O	O
59	(	O	O
60	GEM	S-Chemical	S-Chemical
61	-	O	I-Disease
62	P	O	E-Chemical
63	)	O	O
64	were	O	O
65	included	O	O
66	.	O	O

0	Demographic	O	O
1	,	O	O
2	survival	O	O
3	,	O	O
4	response	O	O
5	and	O	O
6	toxicity	S-Disease	S-Disease
7	data	O	O
8	were	O	O
9	recorded	O	O
10	.	O	O

0	One	O	O
1	hundred	O	O
2	and	O	O
3	twenty	O	O
4	-	O	O
5	two	O	O
6	cycles	O	O
7	of	O	O
8	GEM	S-Chemical	S-Chemical
9	-	O	E-Chemical
10	P	O	O
11	were	O	O
12	administered	O	O
13	in	O	O
14	total	O	O
15	(	O	O
16	median	O	O
17	3	O	O
18	cycles	O	O
19	;	O	O
20	range	O	O
21	1	O	O
22	-	O	O
23	6	O	O
24	)	O	O
25	.	O	O

0	Twenty	O	O
1	of	O	O
2	41	O	O
3	(	O	O
4	48	O	O
5	%	O	O
6	)	O	O
7	patients	O	O
8	received	O	O
9	GEM	S-Chemical	S-Chemical
10	-	O	I-Disease
11	P	O	E-Disease
12	as	O	O
13	second	O	O
14	-	O	O
15	line	O	O
16	treatment	O	O
17	and	O	O
18	11	O	O
19	/	O	O
20	41	O	O
21	(	O	O
22	27	O	O
23	%	O	O
24	)	O	O
25	as	O	O
26	third	O	O
27	-	O	O
28	line	O	O
29	therapy	O	O
30	.	O	O

0	Overall	O	O
1	response	O	O
2	rate	O	O
3	(	O	O
4	ORR	O	O
5	)	O	O
6	to	O	O
7	GEM	S-Chemical	S-Chemical
8	-	O	E-Chemical
9	P	O	E-Disease
10	in	O	O
11	the	O	O
12	entire	O	O
13	cohort	O	O
14	was	O	O
15	80	O	O
16	%	O	O
17	(	O	O
18	complete	O	O
19	response	O	O
20	(	O	O
21	CR	O	O
22	)	O	O
23	37	O	O
24	%	O	O
25	,	O	O
26	partial	O	O
27	response	O	O
28	44	O	O
29	%	O	O
30	)	O	O
31	with	O	O
32	14	O	O
33	/	O	O
34	15	O	O
35	CR	O	O
36	confirmed	O	O
37	as	O	O
38	a	O	O
39	metabolic	O	O
40	CR	O	O
41	on	O	O
42	PET	O	S-Disease
43	and	O	O
44	ORR	O	S-Disease
45	of	O	O
46	85	O	O
47	%	O	O
48	in	O	O
49	the	O	O
50	20	O	O
51	second	O	O
52	-	O	O
53	line	O	O
54	patients	O	O
55	.	O	O

0	The	O	O
1	most	O	O
2	common	O	O
3	grade	O	O
4	3	O	O
5	/	O	O
6	4	O	O
7	toxicities	S-Disease	O
8	were	O	O
9	haematological	O	O
10	:	O	O
11	neutropenia	S-Disease	S-Disease
12	54	O	O
13	%	O	O
14	and	O	O
15	thrombocytopenia	S-Disease	S-Disease
16	51	O	O
17	%	O	O
18	.	O	O

0	Median	O	O
1	follow	O	O
2	-	O	O
3	up	O	O
4	from	O	O
5	the	O	O
6	start	O	O
7	of	O	O
8	GEM	S-Chemical	S-Chemical
9	-	O	E-Chemical
10	P	O	E-Disease
11	was	O	O
12	4	O	O
13	.	O	O
14	5	O	O
15	years	O	O
16	.	O	O

0	Following	O	O
1	GEM	S-Chemical	S-Chemical
2	-	O	I-Disease
3	P	O	O
4	,	O	O
5	5	O	O
6	-	O	O
7	year	O	O
8	progression	O	O
9	-	O	O
10	free	O	O
11	survival	O	O
12	was	O	O
13	46	O	O
14	%	O	O
15	(	O	O
16	95	O	O
17	%	O	O
18	confidence	O	O
19	interval	O	O
20	(	O	O
21	CI	O	S-Chemical
22	)	O	O
23	,	O	O
24	30	O	O
25	-	O	O
26	62	O	O
27	%	O	O
28	)	O	O
29	and	O	O
30	5	O	O
31	-	O	O
32	year	O	O
33	overall	O	O
34	survival	O	O
35	was	O	O
36	59	O	O
37	%	O	O
38	(	O	O
39	95	O	O
40	%	O	O
41	CI	O	S-Chemical
42	,	O	O
43	43	O	O
44	-	O	O
45	74	O	O
46	%	O	O
47	)	O	O
48	.	O	O

0	GEM	S-Chemical	S-Chemical
1	-	O	E-Chemical
2	P	O	O
3	is	O	O
4	a	O	O
5	salvage	O	O
6	chemotherapy	O	O
7	with	O	O
8	relatively	O	O
9	high	O	O
10	response	O	O
11	rates	O	O
12	,	O	O
13	leading	O	O
14	to	O	O
15	successful	O	O
16	transplantation	O	O
17	in	O	O
18	appropriate	O	O
19	patients	O	O
20	,	O	O
21	in	O	O
22	the	O	O
23	treatment	O	O
24	of	O	O
25	relapsed	O	O
26	or	O	O
27	refractory	O	O
28	HL	S-Disease	S-Disease
29	.	O	O

0	Basal	O	O
1	functioning	O	O
2	of	O	O
3	the	O	O
4	hypothalamic	O	S-Disease
5	-	O	O
6	pituitary	O	B-Disease
7	-	O	O
8	adrenal	O	O
9	(	O	O
10	HPA	O	S-Disease
11	)	O	O
12	axis	O	O
13	and	O	O
14	psychological	O	O
15	distress	O	O
16	in	O	O
17	recreational	O	B-Disease
18	ecstasy	S-Chemical	S-Disease
19	polydrug	O	O
20	users	O	O
21	.	O	O

0	RATIONALE	O	O
1	:	O	O
2	Ecstasy	S-Chemical	S-Chemical
3	(	O	O
4	MDMA	S-Chemical	S-Chemical
5	)	O	O
6	is	O	O
7	a	O	O
8	psychostimulant	O	O
9	drug	O	O
10	which	O	O
11	is	O	O
12	increasingly	O	O
13	associated	O	O
14	with	O	O
15	psychobiological	B-Disease	O
16	dysfunction	E-Disease	S-Disease
17	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	The	O	O
3	current	O	O
4	study	O	O
5	is	O	O
6	the	O	O
7	first	O	O
8	to	O	O
9	explore	O	O
10	the	O	O
11	effects	O	O
12	of	O	O
13	ecstasy	S-Chemical	S-Chemical
14	-	O	O
15	polydrug	O	S-Disease
16	use	O	O
17	on	O	O
18	psychological	O	O
19	distress	O	E-Disease
20	and	O	O
21	basal	O	O
22	functioning	O	O
23	of	O	O
24	the	O	O
25	HPA	O	B-Disease
26	axis	O	O
27	through	O	O
28	assessing	O	O
29	the	O	O
30	secretion	O	O
31	of	O	O
32	cortisol	S-Chemical	S-Chemical
33	across	O	O
34	the	O	O
35	diurnal	O	O
36	period	O	O
37	.	O	O

0	METHOD	O	O
1	:	O	O
2	Seventy	O	O
3	-	O	O
4	six	O	O
5	participants	O	O
6	(	O	O
7	21	O	O
8	nonusers	O	O
9	,	O	O
10	29	O	O
11	light	O	O
12	ecstasy	S-Chemical	S-Chemical
13	-	O	O
14	polydrug	O	O
15	users	O	O
16	,	O	O
17	26	O	O
18	heavy	O	O
19	ecstasy	S-Chemical	S-Disease
20	-	O	O
21	polydrug	O	O
22	users	O	O
23	)	O	O
24	completed	O	O
25	a	O	O
26	substance	O	O
27	use	O	O
28	inventory	O	O
29	and	O	O
30	measures	O	O
31	of	O	O
32	psychological	O	O
33	distress	O	O
34	at	O	O
35	baseline	O	O
36	,	O	O
37	then	O	O
38	two	O	O
39	consecutive	O	O
40	days	O	O
41	of	O	O
42	cortisol	S-Chemical	S-Chemical
43	sampling	O	O
44	(	O	O
45	on	O	O
46	awakening	O	O
47	,	O	O
48	30	O	O
49	min	O	O
50	post	O	O
51	awakening	O	O
52	,	O	O
53	between	O	O
54	1400	O	O
55	and	O	O
56	1600	O	O
57	hours	O	O
58	and	O	O
59	pre	O	O
60	bedtime	O	O
61	)	O	O
62	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Both	O	O
3	user	O	O
4	groups	O	O
5	exhibited	O	O
6	significantly	O	O
7	greater	O	O
8	levels	O	O
9	of	O	O
10	anxiety	S-Disease	S-Disease
11	and	O	O
12	depression	S-Disease	S-Disease
13	than	O	O
14	nonusers	O	O
15	.	O	O

0	On	O	O
1	day	O	O
2	1	O	O
3	,	O	O
4	all	O	O
5	participants	O	O
6	exhibited	O	O
7	a	O	O
8	typical	O	O
9	cortisol	S-Chemical	S-Chemical
10	profile	O	O
11	,	O	O
12	though	O	O
13	light	O	O
14	users	O	O
15	had	O	O
16	significantly	O	O
17	elevated	O	O
18	levels	O	O
19	pre	O	O
20	-	O	O
21	bed	O	O
22	.	O	O

0	On	O	O
1	day	O	O
2	2	O	O
3	,	O	O
4	heavy	O	O
5	users	O	O
6	demonstrated	O	O
7	elevated	O	O
8	levels	O	O
9	upon	O	O
10	awakening	O	O
11	and	O	O
12	all	O	O
13	ecstasy	S-Chemical	S-Chemical
14	-	O	O
15	polydrug	O	E-Chemical
16	users	O	O
17	demonstrated	O	O
18	elevated	O	O
19	pre	O	O
20	-	O	O
21	bed	O	O
22	levels	O	O
23	compared	O	O
24	to	O	O
25	non	O	O
26	-	O	O
27	users	O	O
28	.	O	O

0	Significant	O	O
1	between	O	O
2	group	O	O
3	differences	O	O
4	were	O	O
5	also	O	O
6	observed	O	O
7	in	O	O
8	afternoon	O	O
9	cortisol	S-Chemical	S-Chemical
10	levels	O	O
11	and	O	O
12	in	O	O
13	overall	O	O
14	cortisol	S-Chemical	S-Chemical
15	secretion	O	O
16	across	O	O
17	the	O	O
18	day	O	O
19	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	increases	O	O
4	in	O	O
5	anxiety	S-Disease	S-Disease
6	and	O	O
7	depression	S-Disease	S-Disease
8	are	O	O
9	in	O	O
10	line	O	O
11	with	O	O
12	previous	O	O
13	observations	O	O
14	in	O	O
15	recreational	O	O
16	ecstasy	S-Chemical	S-Disease
17	-	O	O
18	polydrug	O	S-Disease
19	users	O	O
20	.	O	O

0	Dysregulated	O	O
1	diurnal	O	S-Disease
2	cortisol	S-Chemical	S-Chemical
3	may	O	O
4	be	O	O
5	indicative	O	O
6	of	O	O
7	inappropriate	O	O
8	anticipation	O	O
9	of	O	O
10	forthcoming	O	O
11	demands	O	O
12	and	O	O
13	hypersecretion	O	S-Disease
14	may	O	O
15	lead	O	O
16	to	O	O
17	the	O	O
18	increased	O	O
19	psychological	O	O
20	and	O	O
21	physical	O	O
22	morbidity	O	O
23	associated	O	O
24	with	O	O
25	heavy	O	O
26	recreational	O	O
27	use	O	O
28	of	O	O
29	ecstasy	S-Chemical	S-Disease
30	.	O	O

0	Ifosfamide	S-Chemical	S-Chemical
1	related	O	O
2	encephalopathy	S-Disease	S-Disease
3	:	O	O
4	the	O	O
5	need	O	O
6	for	O	O
7	a	O	O
8	timely	O	O
9	EEG	O	S-Disease
10	evaluation	O	O
11	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Ifosfamide	S-Chemical	S-Chemical
3	is	O	O
4	an	O	O
5	alkylating	O	O
6	agent	O	O
7	useful	O	O
8	in	O	O
9	the	O	O
10	treatment	O	O
11	of	O	O
12	a	O	O
13	wide	O	O
14	range	O	O
15	of	O	O
16	cancers	S-Disease	S-Disease
17	including	O	O
18	sarcomas	S-Disease	S-Disease
19	,	O	O
20	lymphoma	S-Disease	S-Disease
21	,	O	O
22	gynecologic	B-Disease	S-Disease
23	and	I-Disease	O
24	testicular	I-Disease	B-Disease
25	cancers	E-Disease	E-Disease
26	.	O	O

0	Encephalopathy	S-Disease	S-Chemical
1	has	O	O
2	been	O	O
3	reported	O	O
4	in	O	O
5	10	O	O
6	-	O	O
7	40	O	O
8	%	O	O
9	of	O	O
10	patients	O	O
11	receiving	O	O
12	high	O	O
13	-	O	O
14	dose	O	O
15	IV	O	O
16	ifosfamide	S-Chemical	S-Chemical
17	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	highlight	O	O
4	the	O	O
5	role	O	O
6	of	O	O
7	electroencephalogram	O	S-Disease
8	(	O	O
9	EEG	O	S-Disease
10	)	O	O
11	in	O	O
12	the	O	O
13	early	O	O
14	detection	O	O
15	and	O	O
16	management	O	O
17	of	O	O
18	ifosfamide	S-Chemical	S-Chemical
19	related	O	O
20	encephalopathy	S-Disease	S-Disease
21	.	O	O

0	METHODS	O	O
1	:	O	O
2	Retrospective	O	O
3	chart	O	O
4	review	O	O
5	including	O	O
6	clinical	O	O
7	data	O	O
8	and	O	O
9	EEG	O	S-Disease
10	recordings	O	O
11	was	O	O
12	done	O	O
13	on	O	O
14	five	O	O
15	patients	O	O
16	,	O	O
17	admitted	O	O
18	to	O	O
19	MD	O	B-Disease
20	Anderson	O	I-Disease
21	Cancer	S-Disease	I-Disease
22	Center	O	E-Disease
23	between	O	O
24	years	O	O
25	2009	O	O
26	and	O	O
27	2012	O	O
28	,	O	O
29	who	O	O
30	developed	O	O
31	ifosfamide	S-Chemical	S-Chemical
32	related	O	O
33	acute	O	S-Disease
34	encephalopathy	S-Disease	S-Disease
35	.	O	O

0	RESULTS	O	O
1	:	O	O
2	All	O	O
3	five	O	O
4	patients	O	O
5	experienced	O	O
6	symptoms	O	O
7	of	O	O
8	encephalopathy	S-Disease	S-Disease
9	soon	O	O
10	after	O	O
11	(	O	O
12	within	O	O
13	12	O	O
14	h	O	O
15	-	O	O
16	2	O	O
17	days	O	O
18	)	O	O
19	receiving	O	O
20	ifosfamide	S-Chemical	S-Chemical
21	.	O	O

0	Two	O	O
1	patients	O	O
2	developed	O	O
3	generalized	O	O
4	convulsions	S-Disease	S-Disease
5	while	O	O
6	one	O	O
7	patient	O	O
8	developed	O	O
9	continuous	O	O
10	non	B-Disease	O
11	-	I-Disease	O
12	convulsive	I-Disease	O
13	status	I-Disease	B-Disease
14	epilepticus	E-Disease	E-Disease
15	(	O	O
16	NCSE	S-Disease	S-Disease
17	)	O	O
18	that	O	O
19	required	O	O
20	ICU	O	S-Disease
21	admission	O	O
22	and	O	O
23	intubation	O	O
24	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Severity	O	O
3	of	O	O
4	ifosfamide	S-Chemical	S-Chemical
5	related	O	O
6	encephalopathy	S-Disease	S-Disease
7	correlates	O	O
8	with	O	O
9	EEG	O	B-Disease
10	changes	O	E-Disease
11	.	O	O

0	We	O	O
1	suggest	O	O
2	a	O	O
3	timely	O	O
4	EEG	O	S-Disease
5	evaluation	O	O
6	for	O	O
7	patients	O	O
8	receiving	O	O
9	ifosfamide	S-Chemical	S-Chemical
10	who	O	O
11	develop	O	O
12	features	O	O
13	of	O	O
14	encephalopathy	S-Disease	S-Disease
15	.	O	O

0	Incidence	O	O
1	of	O	O
2	contrast	S-Chemical	O
3	-	O	O
4	induced	O	O
5	nephropathy	S-Disease	S-Disease
6	in	O	O
7	hospitalised	O	O
8	patients	O	O
9	with	O	O
10	cancer	S-Disease	S-Disease
11	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	To	O	O
3	determine	O	O
4	the	O	O
5	frequency	O	O
6	of	O	O
7	and	O	O
8	possible	O	O
9	factors	O	O
10	related	O	O
11	to	O	O
12	contrast	S-Chemical	O
13	-	O	O
14	induced	O	O
15	nephropathy	S-Disease	S-Disease
16	(	O	O
17	CIN	O	S-Chemical
18	)	O	O
19	in	O	O
20	hospitalised	O	O
21	patients	O	O
22	with	O	O
23	cancer	S-Disease	S-Disease
24	.	O	O

0	Patients	O	O
1	with	O	O
2	risk	O	O
3	factors	O	O
4	for	O	O
5	acute	B-Disease	B-Disease
6	renal	I-Disease	I-Disease
7	failure	E-Disease	E-Disease
8	were	O	O
9	excluded	O	O
10	.	O	O

0	Blood	O	O
1	samples	O	O
2	were	O	O
3	examined	O	O
4	the	O	O
5	day	O	O
6	before	O	O
7	contrast	S-Chemical	O
8	-	O	O
9	enhanced	O	O
10	computed	O	O
11	tomography	O	O
12	(	O	O
13	CT	O	O
14	)	O	O
15	and	O	O
16	serially	O	O
17	for	O	O
18	3	O	O
19	days	O	O
20	thereafter	O	O
21	.	O	O

0	CIN	O	S-Chemical
1	was	O	O
2	defined	O	O
3	as	O	O
4	an	O	O
5	increase	O	O
6	in	O	O
7	serum	O	O
8	creatinine	S-Chemical	S-Chemical
9	(	O	O
10	Cr	S-Chemical	S-Chemical
11	)	O	O
12	of	O	O
13	0	O	O
14	.	O	O
15	5	O	O
16	mg	O	O
17	/	O	O
18	dl	O	O
19	or	O	O
20	more	O	O
21	,	O	O
22	or	O	O
23	elevation	O	O
24	of	O	O
25	Cr	S-Chemical	S-Chemical
26	to	O	O
27	25	O	O
28	%	O	O
29	over	O	O
30	baseline	O	O
31	.	O	O

0	CIN	O	S-Chemical
1	was	O	O
2	significantly	O	O
3	more	O	O
4	after	O	O
5	treatment	O	O
6	with	O	O
7	bevacizumab	S-Chemical	S-Chemical
8	/	O	O
9	irinotecan	S-Chemical	S-Disease
10	(	O	O
11	P	O	S-Disease
12	=	O	O
13	0	O	O
14	.	O	O
15	021	O	O
16	)	O	O
17	and	O	O
18	in	O	O
19	patients	O	O
20	with	O	O
21	hypertension	S-Disease	S-Disease
22	(	O	O
23	P	O	S-Chemical
24	=	O	O
25	0	O	O
26	.	O	O
27	044	O	O
28	)	O	O
29	.	O	O

0	CIN	O	S-Chemical
1	developed	O	O
2	4	O	O
3	.	O	O
4	5	O	O
5	-	O	O
6	times	O	O
7	more	O	O
8	frequently	O	O
9	in	O	O
10	patients	O	O
11	with	O	O
12	cancer	S-Disease	S-Disease
13	who	O	O
14	had	O	O
15	undergone	O	O
16	recent	O	O
17	chemotherapy	O	O
18	.	O	O

0	Hypertension	S-Disease	S-Disease
1	and	O	O
2	the	O	O
3	combination	O	O
4	of	O	O
5	bevacizumab	S-Chemical	S-Chemical
6	/	O	O
7	irinotecan	S-Chemical	E-Chemical
8	may	O	O
9	be	O	O
10	additional	O	O
11	risk	O	O
12	factors	O	O
13	for	O	O
14	CIN	O	S-Chemical
15	development	O	O
16	.	O	O

0	Contrast	S-Chemical	O
1	-	O	O
2	induced	O	O
3	nephropathy	S-Disease	S-Disease
4	(	O	O
5	CIN	O	S-Chemical
6	)	O	O
7	is	O	O
8	a	O	O
9	concern	O	O
10	for	O	O
11	oncological	O	O
12	patients	O	O
13	undergoing	O	O
14	CT	O	S-Disease
15	.	O	O

0	.	O	O
1	Hypertension	S-Disease	S-Disease
2	and	O	O
3	treatment	O	O
4	with	O	O
5	bevacizumab	S-Chemical	S-Chemical
6	appear	O	O
7	to	O	O
8	be	O	O
9	additional	O	O
10	risk	O	O
11	factors	O	O
12	.	O	O

0	Syndrome	B-Disease	O
1	of	I-Disease	O
2	inappropriate	I-Disease	O
3	antidiuretic	I-Disease	O
4	hormone	E-Disease	S-Disease
5	secretion	O	S-Disease
6	associated	O	O
7	with	O	O
8	desvenlafaxine	S-Chemical	S-Chemical
9	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	report	O	O
4	a	O	O
5	case	O	O
6	of	O	O
7	syndrome	B-Disease	O
8	of	I-Disease	O
9	inappropriate	I-Disease	O
10	anti	I-Disease	O
11	-	I-Disease	O
12	diuretic	I-Disease	B-Disease
13	hormone	E-Disease	E-Disease
14	(	O	O
15	SIADH	S-Disease	S-Chemical
16	)	O	O
17	secretion	O	S-Disease
18	associated	O	O
19	with	O	O
20	desvenlafaxine	S-Chemical	S-Chemical
21	.	O	O

0	CASE	O	O
1	SUMMARY	O	O
2	:	O	O
3	A	O	O
4	57	O	O
5	-	O	O
6	year	O	O
7	old	O	O
8	female	O	O
9	with	O	O
10	hyponatraemia	S-Disease	S-Disease
11	.	O	O

0	Her	O	O
1	medications	O	O
2	included	O	O
3	desvenlafaxine	S-Chemical	S-Chemical
4	,	O	O
5	and	O	O
6	symptoms	O	O
7	included	O	O
8	nausea	S-Disease	S-Disease
9	,	O	O
10	anxiety	S-Disease	S-Disease
11	and	O	O
12	confusion	S-Disease	S-Disease
13	.	O	O

0	The	O	O
1	serum	O	O
2	sodium	S-Chemical	O
3	at	O	O
4	this	O	O
5	time	O	O
6	was	O	O
7	120	O	O
8	mmol	O	O
9	/	O	O
10	L	O	O
11	,	O	O
12	serum	O	O
13	osmolality	O	O
14	was	O	O
15	263	O	O
16	mosmol	O	O
17	/	O	O
18	kg	O	O
19	,	O	O
20	urine	O	O
21	osmolality	O	O
22	410	O	O
23	mosmol	O	O
24	/	O	O
25	kg	O	O
26	and	O	O
27	urine	O	O
28	sodium	S-Chemical	O
29	63	O	O
30	mmol	O	O
31	/	O	O
32	L	O	O
33	,	O	O
34	consistent	O	O
35	with	O	O
36	a	O	O
37	diagnosis	O	O
38	of	O	O
39	SIADH	S-Disease	S-Chemical
40	.	O	O

0	Desvenlafaxine	S-Chemical	S-Chemical
1	was	O	O
2	ceased	O	O
3	and	O	O
4	fluid	O	O
5	restriction	O	O
6	implemented	O	O
7	.	O	O

0	After	O	O
1	4	O	O
2	days	O	O
3	the	O	O
4	sodium	S-Chemical	O
5	increased	O	O
6	to	O	O
7	128	O	O
8	mmol	O	O
9	/	O	O
10	L	O	O
11	and	O	O
12	fluid	O	B-Disease
13	restriction	O	E-Disease
14	was	O	O
15	relaxed	O	O
16	.	O	O

0	During	O	O
1	her	O	O
2	further	O	O
3	3	O	O
4	weeks	O	O
5	inpatient	O	O
6	admission	O	O
7	the	O	O
8	serum	O	O
9	sodium	S-Chemical	O
10	ranged	O	O
11	from	O	O
12	134	O	O
13	to	O	O
14	137	O	O
15	mmol	O	O
16	/	O	O
17	L	O	O
18	during	O	O
19	treatment	O	O
20	with	O	O
21	mirtazapine	S-Chemical	S-Chemical
22	.	O	O

0	DISCUSSION	O	O
1	:	O	O
2	SIADH	S-Disease	S-Chemical
3	has	O	O
4	been	O	O
5	widely	O	O
6	reported	O	O
7	with	O	O
8	a	O	O
9	range	O	O
10	of	O	O
11	antidepressants	O	O
12	.	O	O

0	This	O	O
1	case	O	O
2	report	O	O
3	suggests	O	O
4	that	O	O
5	desvenlafaxine	S-Chemical	S-Chemical
6	might	O	O
7	cause	O	O
8	clinically	O	O
9	significant	O	O
10	hyponatremia	S-Disease	S-Disease
11	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Clinicians	O	O
3	should	O	O
4	be	O	O
5	aware	O	O
6	of	O	O
7	the	O	O
8	potential	O	O
9	for	O	O
10	antidepressants	O	O
11	to	O	O
12	cause	O	O
13	hyponatremia	S-Disease	S-Disease
14	,	O	O
15	and	O	O
16	take	O	O
17	appropriate	O	O
18	corrective	O	O
19	action	O	O
20	where	O	O
21	necessary	O	O
22	.	O	O

0	Oxidative	O	O
1	stress	O	O
2	on	O	O
3	cardiotoxicity	S-Disease	S-Disease
4	after	O	O
5	treatment	O	O
6	with	O	O
7	single	O	O
8	and	O	O
9	multiple	O	O
10	doses	O	O
11	of	O	O
12	doxorubicin	S-Chemical	S-Chemical
13	.	O	O

0	The	O	O
1	mechanism	O	O
2	of	O	O
3	doxorubicin	S-Chemical	S-Chemical
4	(	O	O
5	DOX	S-Chemical	S-Chemical
6	)	O	O
7	-	O	O
8	induced	O	O
9	cardiotoxicity	S-Disease	S-Disease
10	remains	O	O
11	controversial	O	O
12	.	O	O

0	Wistar	O	O
1	rats	O	O
2	(	O	O
3	n	O	O
4	=	O	O
5	66	O	O
6	)	O	O
7	received	O	O
8	DOX	S-Chemical	S-Chemical
9	injections	O	O
10	intraperitoneally	O	O
11	and	O	O
12	were	O	O
13	randomly	O	O
14	assigned	O	O
15	to	O	O
16	2	O	O
17	experimental	O	O
18	protocols	O	O
19	:	O	O
20	(	O	O
21	1	O	O
22	)	O	O
23	rats	O	O
24	were	O	O
25	killed	O	O
26	before	O	O
27	(	O	O
28	-	O	O
29	24	O	O
30	h	O	O
31	,	O	O
32	n	O	O
33	=	O	O
34	8	O	O
35	)	O	O
36	and	O	O
37	24	O	O
38	h	O	O
39	after	O	O
40	(	O	O
41	+	O	O
42	24	O	O
43	h	O	O
44	,	O	O
45	n	O	O
46	=	O	O
47	8	O	O
48	)	O	O
49	a	O	O
50	single	O	O
51	dose	O	O
52	of	O	O
53	DOX	S-Chemical	S-Chemical
54	(	O	O
55	4	O	O
56	mg	O	O
57	/	O	O
58	kg	O	O
59	body	O	O
60	weight	O	O
61	)	O	O
62	to	O	O
63	determine	O	O
64	the	O	O
65	DOX	S-Chemical	S-Chemical
66	acute	O	S-Disease
67	effect	O	O
68	and	O	O
69	(	O	O
70	2	O	O
71	)	O	O
72	rats	O	O
73	(	O	O
74	n	O	O
75	=	O	O
76	58	O	O
77	)	O	O
78	received	O	O
79	4	O	O
80	injections	O	O
81	of	O	O
82	DOX	S-Chemical	S-Chemical
83	(	O	O
84	4	O	O
85	mg	O	O
86	/	O	O
87	kg	O	O
88	body	O	O
89	weight	O	O
90	/	O	O
91	week	O	O
92	)	O	O
93	and	O	O
94	were	O	O
95	killed	O	O
96	before	O	O
97	the	O	O
98	first	O	O
99	injection	O	O
100	(	O	O
101	M0	O	S-Disease
102	)	O	O
103	and	O	O
104	1	O	O
105	week	O	O
106	after	O	O
107	each	O	O
108	injection	O	O
109	(	O	O
110	M1	O	S-Disease
111	,	O	O
112	M2	O	S-Disease
113	,	O	O
114	M3	O	S-Disease
115	,	O	O
116	and	O	O
117	M4	O	S-Disease
118	)	O	O
119	to	O	O
120	determine	O	O
121	the	O	O
122	chronological	O	O
123	effects	O	O
124	.	O	O

0	Single	O	O
1	dose	O	O
2	of	O	O
3	DOX	S-Chemical	S-Chemical
4	was	O	O
5	associated	O	O
6	with	O	O
7	increased	O	O
8	cardiac	B-Disease	B-Disease
9	disarrangement	E-Disease	E-Disease
10	,	O	O
11	necrosis	S-Disease	S-Disease
12	,	O	O
13	and	O	O
14	DNA	O	O
15	damage	O	E-Disease
16	(	O	O
17	strand	O	O
18	breaks	O	O
19	(	O	O
20	SBs	O	S-Disease
21	)	O	O
22	and	O	O
23	oxidized	O	O
24	pyrimidines	O	S-Chemical
25	)	O	O
26	and	O	O
27	decreased	O	O
28	TAP	O	S-Disease
29	.	O	O

0	The	O	O
1	chronological	O	O
2	study	O	O
3	showed	O	O
4	an	O	O
5	effect	O	O
6	of	O	O
7	a	O	O
8	cumulative	O	O
9	dose	O	O
10	on	O	O
11	body	O	O
12	weight	O	O
13	(	O	O
14	R	O	O
15	=	O	O
16	-	O	O
17	0	O	O
18	.	O	O
19	99	O	O
20	,	O	O
21	p	O	O
22	=	O	O
23	0	O	O
24	.	O	O
25	011	O	O
26	)	O	O
27	,	O	O
28	necrosis	S-Disease	S-Disease
29	(	O	O
30	R	O	O
31	=	O	O
32	1	O	O
33	.	O	O
34	00	O	O
35	,	O	O
36	p	O	O
37	=	O	O
38	0	O	O
39	.	O	O
40	004	O	O
41	)	O	O
42	,	O	O
43	TAP	O	S-Disease
44	(	O	O
45	R	O	O
46	=	O	O
47	0	O	O
48	.	O	O
49	95	O	O
50	,	O	O
51	p	O	O
52	=	O	O
53	0	O	O
54	.	O	O
55	049	O	O
56	)	O	O
57	,	O	O
58	and	O	O
59	DNA	O	O
60	SBs	O	O
61	(	O	O
62	R	O	O
63	=	O	O
64	-	O	O
65	0	O	O
66	.	O	O
67	95	O	O
68	,	O	O
69	p	O	O
70	=	O	O
71	0	O	O
72	.	O	O
73	049	O	O
74	)	O	O
75	.	O	O

0	DNA	O	O
1	SBs	O	O
2	damage	O	O
3	was	O	O
4	negatively	O	O
5	associated	O	O
6	with	O	O
7	TAP	O	S-Disease
8	(	O	O
9	R	O	O
10	=	O	O
11	-	O	O
12	0	O	O
13	.	O	O
14	98	O	O
15	,	O	O
16	p	O	O
17	=	O	O
18	0	O	O
19	.	O	O
20	018	O	O
21	)	O	O
22	,	O	O
23	and	O	O
24	necrosis	S-Disease	S-Disease
25	(	O	O
26	R	O	O
27	=	O	O
28	-	O	O
29	0	O	O
30	.	O	O
31	97	O	O
32	,	O	O
33	p	O	O
34	=	O	O
35	0	O	O
36	.	O	O
37	027	O	O
38	)	O	O
39	.	O	O

0	Our	O	O
1	results	O	O
2	suggest	O	O
3	that	O	O
4	oxidative	O	O
5	damage	O	S-Disease
6	is	O	O
7	associated	O	O
8	with	O	O
9	acute	O	B-Disease
10	cardiotoxicity	S-Disease	E-Disease
11	induced	O	O
12	by	O	O
13	a	O	O
14	single	O	O
15	dose	O	O
16	of	O	O
17	DOX	S-Chemical	S-Chemical
18	only	O	O
19	.	O	O

0	Increased	O	O
1	resistance	O	O
2	to	O	O
3	the	O	O
4	oxidative	O	O
5	stress	O	O
6	is	O	O
7	plausible	O	O
8	for	O	O
9	the	O	O
10	multiple	O	O
11	dose	O	O
12	of	O	O
13	DOX	S-Chemical	S-Chemical
14	.	O	O

0	Thus	O	O
1	,	O	O
2	different	O	O
3	mechanisms	O	O
4	may	O	O
5	be	O	O
6	involved	O	O
7	in	O	O
8	acute	O	B-Disease
9	toxicity	S-Disease	E-Disease
10	versus	O	O
11	chronic	O	B-Disease
12	toxicity	S-Disease	E-Disease
13	.	O	O

0	Tacrolimus	S-Chemical	S-Chemical
1	-	O	O
2	related	O	O
3	seizure	S-Disease	S-Disease
4	after	O	O
5	pediatric	O	O
6	liver	O	B-Disease
7	transplantation	O	E-Disease
8	-	O	O
9	-	O	O
10	a	O	O
11	single	O	O
12	-	O	O
13	center	O	O
14	experience	O	O
15	.	O	O

0	To	O	O
1	identify	O	O
2	the	O	O
3	risk	O	O
4	factors	O	O
5	for	O	O
6	new	O	O
7	-	O	O
8	onset	O	O
9	seizures	S-Disease	S-Disease
10	after	O	O
11	pediatric	O	O
12	LT	O	S-Disease
13	and	O	O
14	to	O	O
15	assess	O	O
16	their	O	O
17	clinical	O	O
18	implications	O	O
19	and	O	O
20	long	O	O
21	-	O	O
22	term	O	O
23	prognosis	O	O
24	.	O	O

0	Patients	O	O
1	were	O	O
2	divided	O	O
3	into	O	O
4	seizures	S-Disease	S-Disease
5	group	O	O
6	and	O	O
7	a	O	O
8	non	O	O
9	-	O	O
10	seizures	S-Disease	S-Disease
11	group	O	O
12	.	O	O

0	Seizures	S-Disease	O
1	occurred	O	O
2	in	O	O
3	four	O	O
4	children	O	O
5	,	O	O
6	an	O	O
7	incidence	O	O
8	of	O	O
9	14	O	O
10	.	O	O
11	8	O	O
12	%	O	O
13	.	O	O

0	All	O	O
1	exhibited	O	O
2	generalized	O	O
3	tonic	B-Disease	B-Disease
4	-	I-Disease	I-Disease
5	clonic	I-Disease	I-Disease
6	seizures	E-Disease	S-Disease
7	within	O	O
8	the	O	O
9	first	O	O
10	two	O	O
11	wk	O	O
12	after	O	O
13	LT	O	S-Disease
14	.	O	O

0	Univariate	O	O
1	analysis	O	O
2	showed	O	O
3	that	O	O
4	the	O	O
5	risk	O	O
6	factors	O	O
7	associated	O	O
8	with	O	O
9	seizures	S-Disease	S-Disease
10	after	O	O
11	pediatric	O	O
12	LT	O	S-Disease
13	included	O	O
14	gender	O	O
15	,	O	O
16	pediatric	O	O
17	end	B-Disease	O
18	-	I-Disease	O
19	stage	I-Disease	O
20	liver	I-Disease	B-Disease
21	disease	E-Disease	E-Disease
22	score	O	O
23	before	O	O
24	surgery	O	O
25	,	O	O
26	Child	O	O
27	-	O	O
28	Pugh	O	O
29	score	O	O
30	before	O	O
31	surgery	O	O
32	,	O	O
33	serum	O	O
34	total	O	O
35	bilirubin	S-Chemical	S-Chemical
36	after	O	O
37	surgery	O	O
38	,	O	O
39	and	O	O
40	trough	O	O
41	TAC	S-Chemical	S-Disease
42	level	O	O
43	.	O	O

0	Multivariate	O	O
1	analysis	O	O
2	showed	O	O
3	that	O	O
4	trough	O	O
5	TAC	S-Chemical	S-Disease
6	level	O	O
7	was	O	O
8	the	O	O
9	only	O	O
10	independent	O	O
11	risk	O	O
12	factor	O	O
13	associated	O	O
14	with	O	O
15	the	O	O
16	seizures	S-Disease	S-Disease
17	.	O	O

0	All	O	O
1	children	O	O
2	who	O	O
3	experienced	O	O
4	seizures	S-Disease	S-Disease
5	survived	O	O
6	with	O	O
7	good	O	O
8	graft	O	S-Disease
9	function	O	O
10	and	O	O
11	remained	O	O
12	seizure	S-Disease	S-Disease
13	-	O	O
14	free	O	O
15	without	O	O
16	anti	O	O
17	-	O	O
18	epileptic	S-Disease	S-Disease
19	drugs	O	O
20	over	O	O
21	a	O	O
22	mean	O	O
23	follow	O	O
24	-	O	O
25	up	O	O
26	period	O	O
27	of	O	O
28	33	O	O
29	.	O	O
30	7	O	O
31	+	O	O
32	14	O	O
33	.	O	O
34	6	O	O
35	months	O	O
36	.	O	O

0	High	O	O
1	trough	O	O
2	TAC	S-Chemical	S-Disease
3	level	O	O
4	was	O	O
5	the	O	O
6	predominant	O	O
7	factor	O	O
8	that	O	O
9	contributed	O	O
10	to	O	O
11	seizures	S-Disease	S-Disease
12	in	O	O
13	the	O	O
14	early	O	O
15	post	O	O
16	-	O	O
17	operative	O	O
18	period	O	O
19	after	O	O
20	pediatric	O	O
21	LT	O	S-Disease
22	.	O	O

0	High	O	O
1	PELD	O	O
2	and	O	O
3	Child	O	O
4	-	O	O
5	Pugh	O	O
6	scores	O	O
7	before	O	O
8	LT	O	S-Disease
9	and	O	O
10	high	O	O
11	post	O	O
12	-	O	O
13	operative	O	O
14	serum	O	O
15	Tbil	O	S-Chemical
16	may	O	O
17	be	O	O
18	contributory	O	O
19	risk	O	O
20	factors	O	O
21	for	O	O
22	TAC	S-Chemical	S-Disease
23	-	O	O
24	related	O	O
25	seizures	S-Disease	S-Disease
26	.	O	O

0	The	O	O
1	flavonoid	S-Chemical	S-Disease
2	apigenin	S-Chemical	S-Chemical
3	delays	O	O
4	forgetting	O	O
5	of	O	O
6	passive	O	O
7	avoidance	O	O
8	conditioning	O	O
9	in	O	O
10	rats	O	O
11	.	O	O

0	The	O	O
1	present	O	O
2	experiments	O	O
3	were	O	O
4	performed	O	O
5	to	O	O
6	study	O	O
7	the	O	O
8	effect	O	O
9	of	O	O
10	the	O	O
11	flavonoid	S-Chemical	S-Disease
12	apigenin	S-Chemical	S-Chemical
13	(	O	O
14	20	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	intraperitoneally	O	O
19	(	O	O
20	i	O	O
21	.	O	O
22	p	O	O
23	.	O	O
24	)	O	O
25	,	O	O
26	1	O	O
27	h	O	O
28	before	O	O
29	acquisition	O	O
30	)	O	O
31	,	O	O
32	on	O	O
33	24	O	O
34	h	O	O
35	retention	O	O
36	performance	O	O
37	and	O	O
38	forgetting	O	O
39	of	O	O
40	a	O	O
41	step	O	O
42	-	O	O
43	through	O	O
44	passive	O	O
45	avoidance	O	O
46	task	O	O
47	,	O	O
48	in	O	O
49	young	O	O
50	male	O	O
51	Wistar	O	O
52	rats	O	O
53	.	O	O

0	There	O	O
1	were	O	O
2	no	O	O
3	differences	O	O
4	between	O	O
5	saline	O	S-Chemical
6	-	O	O
7	and	O	O
8	apigenin	S-Chemical	S-Chemical
9	-	O	O
10	treated	O	O
11	groups	O	O
12	in	O	O
13	the	O	O
14	24	O	O
15	h	O	O
16	retention	O	O
17	trial	O	O
18	.	O	O

0	Furthermore	O	O
1	,	O	O
2	apigenin	S-Chemical	S-Chemical
3	did	O	O
4	not	O	O
5	prevent	O	O
6	the	O	O
7	amnesia	S-Disease	S-Disease
8	induced	O	O
9	by	O	O
10	scopolamine	S-Chemical	S-Chemical
11	(	O	O
12	1mg	O	O
13	/	O	O
14	kg	O	O
15	,	O	O
16	i	O	O
17	.	O	O
18	p	O	O
19	.	O	O
20	,	O	O
21	30	O	O
22	min	O	O
23	before	O	O
24	the	O	O
25	acquisition	O	O
26	)	O	O
27	.	O	O

0	The	O	O
1	saline	O	O
2	-	O	O
3	and	O	O
4	apigenin	S-Chemical	S-Chemical
5	-	O	O
6	treated	O	O
7	rats	O	O
8	that	O	O
9	did	O	O
10	not	O	O
11	step	O	O
12	through	O	O
13	into	O	O
14	the	O	O
15	dark	O	O
16	compartment	O	O
17	during	O	O
18	the	O	O
19	cut	O	O
20	-	O	O
21	off	O	O
22	time	O	O
23	(	O	O
24	540	O	O
25	s	O	O
26	)	O	O
27	were	O	O
28	retested	O	O
29	weekly	O	O
30	for	O	O
31	up	O	O
32	to	O	O
33	eight	O	O
34	weeks	O	O
35	.	O	O

0	In	O	O
1	the	O	O
2	saline	O	O
3	treated	O	O
4	group	O	O
5	,	O	O
6	the	O	O
7	first	O	O
8	significant	O	O
9	decline	O	O
10	in	O	O
11	passive	O	O
12	avoidance	O	O
13	response	O	O
14	was	O	O
15	observed	O	O
16	at	O	O
17	four	O	O
18	weeks	O	O
19	,	O	O
20	and	O	O
21	complete	O	O
22	memory	B-Disease	O
23	loss	E-Disease	E-Disease
24	was	O	O
25	found	O	O
26	five	O	O
27	weeks	O	O
28	after	O	O
29	the	O	O
30	acquisition	O	O
31	of	O	O
32	the	O	O
33	passive	O	O
34	avoidance	O	O
35	task	O	O
36	.	O	O

0	At	O	O
1	the	O	O
2	end	O	O
3	of	O	O
4	the	O	O
5	experimental	O	O
6	period	O	O
7	,	O	O
8	60	O	O
9	%	O	O
10	of	O	O
11	the	O	O
12	animals	O	O
13	treated	O	O
14	with	O	O
15	apigenin	S-Chemical	S-Chemical
16	still	O	O
17	did	O	O
18	not	O	O
19	step	O	O
20	through	O	O
21	.	O	O

0	These	O	O
1	data	O	O
2	suggest	O	O
3	that	O	O
4	1	O	O
5	)	O	O
6	apigenin	S-Chemical	S-Chemical
7	delays	O	O
8	the	O	O
9	long	O	O
10	-	O	O
11	term	O	O
12	forgetting	O	O
13	but	O	O
14	did	O	O
15	not	O	O
16	modulate	O	O
17	the	O	O
18	24	O	O
19	h	O	O
20	retention	O	O
21	of	O	O
22	fear	O	O
23	memory	O	O
24	and	O	O
25	2	O	O
26	)	O	O
27	the	O	O
28	obtained	O	O
29	beneficial	O	O
30	effect	O	O
31	of	O	O
32	apigenin	S-Chemical	S-Chemical
33	on	O	O
34	the	O	O
35	passive	O	O
36	avoidance	O	O
37	conditioning	O	O
38	is	O	O
39	mediated	O	O
40	by	O	O
41	mechanisms	O	O
42	that	O	O
43	do	O	O
44	not	O	O
45	implicate	O	O
46	its	O	O
47	action	O	O
48	on	O	O
49	the	O	O
50	muscarinic	O	S-Disease
51	cholinergic	O	S-Disease
52	system	O	O
53	.	O	O

0	Histamine	S-Chemical	S-Chemical
1	antagonists	O	O
2	and	O	O
3	d	B-Chemical	B-Chemical
4	-	I-Chemical	I-Chemical
5	tubocurarine	E-Chemical	E-Chemical
6	-	O	O
7	induced	O	O
8	hypotension	S-Disease	S-Disease
9	in	O	O
10	cardiac	O	S-Disease
11	surgical	O	O
12	patients	O	O
13	.	O	O

0	Hemodynamic	O	O
1	effects	O	O
2	and	O	O
3	histamine	S-Chemical	S-Chemical
4	release	O	O
5	by	O	O
6	bolus	O	S-Chemical
7	injection	O	O
8	of	O	O
9	0	O	O
10	.	O	O
11	35	O	O
12	mg	O	O
13	/	O	O
14	kg	O	O
15	of	O	O
16	d	B-Chemical	S-Chemical
17	-	I-Chemical	I-Chemical
18	tubocurarine	E-Chemical	E-Chemical
19	were	O	O
20	studied	O	O
21	in	O	O
22	24	O	O
23	patients	O	O
24	.	O	O

0	H1	O	O
1	-	O	O
2	and	O	O
3	H2	O	O
4	-	O	O
5	histamine	S-Chemical	E-Chemical
6	antagonists	O	O
7	or	O	O
8	placebo	O	S-Disease
9	were	O	O
10	given	O	O
11	before	O	O
12	dosing	O	O
13	with	O	O
14	d	B-Chemical	S-Chemical
15	-	I-Chemical	O
16	tubocurarine	E-Chemical	E-Chemical
17	in	O	O
18	a	O	O
19	randomized	O	O
20	double	O	O
21	-	O	O
22	blind	O	O
23	fashion	O	O
24	to	O	O
25	four	O	O
26	groups	O	O
27	:	O	O
28	group	O	O
29	1	O	O
30	-	O	O
31	-	O	O
32	placebo	O	O
33	;	O	O
34	group	O	O
35	2	O	O
36	-	O	I-Chemical
37	-	O	O
38	cimetidine	S-Chemical	S-Chemical
39	,	O	O
40	4	O	O
41	mg	O	O
42	/	O	O
43	kg	O	O
44	,	O	O
45	plus	O	O
46	placebo	O	O
47	;	O	O
48	group	O	O
49	3	O	O
50	-	O	I-Chemical
51	-	O	I-Chemical
52	chlorpheniramine	S-Chemical	S-Chemical
53	,	O	O
54	0	O	O
55	.	O	O
56	1	O	O
57	mg	O	O
58	/	O	O
59	kg	O	O
60	,	O	O
61	plus	O	O
62	placebo	O	S-Disease
63	;	O	O
64	and	O	O
65	group	O	O
66	4	O	E-Chemical
67	-	O	I-Chemical
68	-	O	I-Chemical
69	cimetidine	S-Chemical	E-Chemical
70	plus	O	O
71	chlorpheniramine	S-Chemical	S-Chemical
72	.	O	O

0	Histamine	S-Chemical	S-Chemical
1	release	O	O
2	occurred	O	O
3	in	O	O
4	most	O	O
5	patients	O	O
6	,	O	O
7	the	O	O
8	highest	O	O
9	level	O	O
10	2	O	O
11	minutes	O	O
12	after	O	O
13	d	B-Chemical	S-Chemical
14	-	I-Chemical	O
15	tubocurarine	E-Chemical	E-Chemical
16	dosing	O	O
17	.	O	O

0	Group	O	O
1	1	O	O
2	had	O	O
3	a	O	O
4	moderate	O	O
5	negative	O	O
6	correlation	O	O
7	between	O	O
8	plasma	O	O
9	histamine	S-Chemical	I-Disease
10	change	O	E-Disease
11	and	O	O
12	systemic	O	B-Disease
13	vascular	O	I-Disease
14	resistance	O	E-Disease
15	(	O	O
16	r	O	O
17	=	O	O
18	0	O	O
19	.	O	O
20	58	O	O
21	;	O	O
22	P	O	O
23	less	O	O
24	than	O	O
25	0	O	O
26	.	O	O
27	05	O	O
28	)	O	O
29	not	O	O
30	present	O	O
31	in	O	O
32	group	O	O
33	4	O	O
34	.	O	O

0	These	O	O
1	data	O	O
2	demonstrate	O	O
3	that	O	O
4	the	O	O
5	hemodynamic	O	O
6	changes	O	O
7	associated	O	O
8	with	O	O
9	d	B-Chemical	S-Chemical
10	-	I-Chemical	O
11	tubocurarine	E-Chemical	E-Chemical
12	dosing	O	O
13	are	O	O
14	only	O	O
15	partially	O	O
16	explained	O	O
17	by	O	O
18	histamine	S-Chemical	S-Chemical
19	release	O	O
20	.	O	O

0	Cholecystokinin	B-Chemical	S-Chemical
1	-	I-Chemical	O
2	octapeptide	E-Chemical	S-Chemical
3	restored	O	O
4	morphine	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	hippocampal	O	S-Disease
8	long	O	O
9	-	O	O
10	term	O	O
11	potentiation	O	O
12	impairment	O	O
13	in	O	O
14	rats	O	O
15	.	O	O

0	Cholecystokinin	B-Chemical	S-Chemical
1	-	I-Chemical	O
2	octapeptide	E-Chemical	E-Chemical
3	(	O	O
4	CCK	B-Chemical	B-Chemical
5	-	I-Chemical	E-Chemical
6	8	E-Chemical	E-Chemical
7	)	O	O
8	,	O	O
9	which	O	O
10	is	O	O
11	a	O	O
12	typical	O	O
13	brain	O	O
14	-	O	O
15	gut	O	O
16	peptide	O	O
17	,	O	O
18	exerts	O	O
19	a	O	O
20	wide	O	O
21	range	O	O
22	of	O	O
23	biological	O	O
24	activities	O	O
25	on	O	O
26	the	O	O
27	central	O	O
28	nervous	O	I-Disease
29	system	O	E-Disease
30	.	O	O

0	We	O	O
1	have	O	O
2	previously	O	O
3	reported	O	O
4	that	O	O
5	CCK	B-Chemical	B-Chemical
6	-	I-Chemical	E-Chemical
7	8	E-Chemical	E-Chemical
8	significantly	O	O
9	alleviated	O	O
10	morphine	S-Chemical	S-Disease
11	-	O	O
12	induced	O	O
13	amnesia	S-Disease	S-Disease
14	and	O	O
15	reversed	O	O
16	spine	O	B-Disease
17	density	O	O
18	decreases	O	O
19	in	O	O
20	the	O	O
21	CA1	O	S-Disease
22	region	O	O
23	of	O	O
24	the	O	O
25	hippocampus	O	S-Disease
26	in	O	O
27	morphine	S-Chemical	S-Disease
28	-	O	O
29	treated	O	O
30	animals	O	O
31	.	O	O

0	Here	O	O
1	,	O	O
2	we	O	O
3	investigated	O	O
4	the	O	O
5	effects	O	O
6	of	O	O
7	CCK	B-Chemical	S-Chemical
8	-	I-Chemical	E-Chemical
9	8	E-Chemical	E-Chemical
10	on	O	O
11	long	O	O
12	-	O	O
13	term	O	O
14	potentiation	O	O
15	(	O	O
16	LTP	O	S-Chemical
17	)	O	O
18	in	O	O
19	the	O	O
20	lateral	O	O
21	perforant	O	O
22	path	O	O
23	(	O	O
24	LPP	O	S-Chemical
25	)	O	O
26	-	O	O
27	granule	O	O
28	cell	O	O
29	synapse	O	O
30	of	O	O
31	rat	O	O
32	dentate	O	O
33	gyrus	O	S-Disease
34	(	O	O
35	DG	O	S-Chemical
36	)	O	O
37	in	O	O
38	acute	O	O
39	saline	O	S-Disease
40	or	O	O
41	morphine	S-Chemical	S-Disease
42	-	O	O
43	treated	O	O
44	rats	O	O
45	.	O	O

0	Acute	O	O
1	morphine	S-Chemical	O
2	(	O	O
3	30mg	O	O
4	/	O	O
5	kg	O	O
6	,	O	O
7	s	O	O
8	.	O	O
9	c	O	O
10	.	O	O
11	)	O	O
12	treatment	O	O
13	significantly	O	O
14	attenuated	O	O
15	hippocampal	O	B-Disease
16	LTP	O	E-Disease
17	and	O	O
18	CCK	B-Chemical	S-Disease
19	-	I-Chemical	E-Chemical
20	8	E-Chemical	O
21	(	O	O
22	1ug	O	O
23	,	O	O
24	i	O	O
25	.	O	O
26	c	O	O
27	.	O	O
28	v	O	O
29	.	O	O
30	)	O	O
31	restored	O	O
32	the	O	O
33	amplitude	O	O
34	of	O	O
35	PS	O	O
36	that	O	O
37	was	O	O
38	attenuated	O	O
39	by	O	O
40	morphine	S-Chemical	S-Disease
41	injection	O	O
42	.	O	O

0	Furthermore	O	O
1	,	O	O
2	microinjection	O	O
3	of	O	O
4	CCK	B-Chemical	B-Chemical
5	-	I-Chemical	E-Chemical
6	8	E-Chemical	E-Chemical
7	(	O	O
8	0	O	O
9	.	O	O
10	1	O	O
11	and	O	O
12	1ug	O	O
13	,	O	O
14	i	O	O
15	.	O	O
16	c	O	O
17	.	O	O
18	v	O	O
19	.	O	O
20	)	O	O
21	also	O	O
22	significantly	O	O
23	augmented	O	O
24	hippocampal	O	B-Disease
25	LTP	O	E-Disease
26	in	O	O
27	saline	O	S-Chemical
28	-	O	O
29	treated	O	O
30	(	O	O
31	1ml	O	O
32	/	O	O
33	kg	O	O
34	,	O	O
35	s	O	O
36	.	O	O
37	c	O	O
38	.	O	O
39	)	O	O
40	rats	O	O
41	.	O	O

0	Pre	O	O
1	-	O	O
2	treatment	O	O
3	of	O	O
4	the	O	O
5	CCK2	O	S-Disease
6	receptor	O	O
7	antagonist	O	O
8	L	O	S-Disease
9	-	O	E-Chemical
10	365	O	O
11	,	O	O
12	260	O	O
13	(	O	O
14	10ug	O	O
15	,	O	O
16	i	O	O
17	.	O	O
18	c	O	O
19	.	O	O
20	v	O	O
21	)	O	O
22	reversed	O	O
23	the	O	O
24	effects	O	O
25	of	O	O
26	CCK	B-Chemical	B-Chemical
27	-	I-Chemical	E-Chemical
28	8	E-Chemical	E-Disease
29	,	O	O
30	but	O	O
31	the	O	O
32	CCK1	O	S-Disease
33	receptor	O	O
34	antagonist	O	O
35	L	O	S-Disease
36	-	O	S-Disease
37	364	O	O
38	,	O	O
39	718	O	O
40	(	O	O
41	10ug	O	O
42	,	O	O
43	i	O	O
44	.	O	O
45	c	O	O
46	.	O	O
47	v	O	O
48	)	O	O
49	did	O	O
50	not	O	O
51	.	O	O

0	The	O	O
1	present	O	O
2	results	O	O
3	demonstrate	O	O
4	that	O	O
5	CCK	B-Chemical	B-Chemical
6	-	I-Chemical	E-Chemical
7	8	E-Chemical	E-Chemical
8	attenuates	O	O
9	the	O	O
10	effect	O	O
11	of	O	O
12	morphine	S-Chemical	S-Chemical
13	on	O	O
14	hippocampal	O	S-Disease
15	LTP	O	S-Disease
16	through	O	O
17	CCK2	O	B-Chemical
18	receptors	O	O
19	and	O	O
20	suggest	O	O
21	an	O	O
22	ameliorative	O	O
23	function	O	O
24	of	O	O
25	CCK	B-Chemical	B-Chemical
26	-	I-Chemical	E-Chemical
27	8	E-Chemical	E-Chemical
28	on	O	O
29	morphine	S-Chemical	S-Disease
30	-	O	O
31	induced	O	O
32	memory	B-Disease	O
33	impairment	E-Disease	O
34	.	O	O

0	Glial	O	O
1	activation	O	O
2	and	O	O
3	post	O	O
4	-	O	O
5	synaptic	O	O
6	neurotoxicity	S-Disease	S-Disease
7	:	O	O
8	the	O	O
9	key	O	O
10	events	O	O
11	in	O	O
12	Streptozotocin	S-Chemical	S-Chemical
13	(	O	O
14	ICV	O	S-Chemical
15	)	O	O
16	induced	O	O
17	memory	B-Disease	O
18	impairment	E-Disease	O
19	in	O	O
20	rats	O	O
21	.	O	O

0	In	O	O
1	the	O	O
2	present	O	O
3	study	O	O
4	the	O	O
5	role	O	O
6	of	O	O
7	glial	O	O
8	activation	O	O
9	and	O	O
10	post	O	O
11	synaptic	O	O
12	toxicity	S-Disease	E-Disease
13	in	O	O
14	ICV	O	S-Disease
15	Streptozotocin	S-Chemical	S-Chemical
16	(	O	O
17	STZ	S-Chemical	S-Disease
18	)	O	O
19	induced	O	O
20	memory	B-Disease	B-Disease
21	impaired	E-Disease	O
22	rats	O	O
23	was	O	O
24	explored	O	O
25	.	O	O

0	In	O	O
1	experiment	O	O
2	set	O	O
3	up	O	O
4	1	O	O
5	:	O	O
6	Memory	B-Disease	O
7	deficit	E-Disease	O
8	was	O	O
9	found	O	O
10	in	O	O
11	Morris	O	O
12	water	O	O
13	maze	O	O
14	test	O	O
15	on	O	O
16	14	O	O
17	-	O	O
18	16	O	O
19	days	O	O
20	after	O	O
21	STZ	S-Chemical	S-Disease
22	(	O	O
23	ICV	O	S-Disease
24	;	O	O
25	3mg	O	O
26	/	O	O
27	Kg	O	O
28	)	O	O
29	administration	O	O
30	.	O	O

0	STZ	S-Chemical	S-Chemical
1	causes	O	O
2	increased	O	O
3	expression	O	O
4	of	O	O
5	GFAP	O	S-Chemical
6	,	O	O
7	CD11b	O	S-Chemical
8	and	O	O
9	TNF	O	S-Disease
10	-	O	O
11	a	O	O
12	indicating	O	O
13	glial	O	O
14	activation	O	O
15	and	O	O
16	neuroinflammation	S-Disease	S-Disease
17	.	O	O

0	STZ	S-Chemical	S-Chemical
1	also	O	O
2	significantly	O	O
3	increased	O	O
4	the	O	O
5	level	O	O
6	of	O	O
7	ROS	O	S-Disease
8	,	O	O
9	nitrite	S-Chemical	S-Chemical
10	,	O	O
11	Ca	S-Chemical	S-Chemical
12	(	O	O
13	2	O	O
14	+	O	O
15	)	O	O
16	and	O	O
17	reduced	O	O
18	the	O	O
19	mitochondrial	O	S-Disease
20	activity	O	O
21	in	O	O
22	synaptosomal	O	O
23	preparation	O	O
24	illustrating	O	O
25	free	O	O
26	radical	O	O
27	generation	O	O
28	and	O	O
29	excitotoxicity	S-Disease	O
30	.	O	O

0	Increased	O	O
1	expression	O	O
2	and	O	O
3	activity	O	O
4	of	O	O
5	Caspase	O	S-Chemical
6	-	O	E-Chemical
7	3	O	E-Chemical
8	was	O	O
9	also	O	O
10	observed	O	O
11	in	O	O
12	STZ	S-Chemical	S-Chemical
13	treated	O	O
14	rat	O	O
15	which	O	O
16	specify	O	O
17	apoptotic	O	B-Disease
18	cell	O	I-Disease
19	death	O	E-Disease
20	in	O	O
21	hippocampus	O	S-Disease
22	and	O	O
23	cortex	O	O
24	.	O	O

0	STZ	S-Chemical	S-Chemical
1	treatment	O	O
2	showed	O	O
3	decrease	O	O
4	expression	O	O
5	of	O	O
6	post	O	O
7	synaptic	O	O
8	markers	O	O
9	CaMKIIa	O	S-Chemical
10	and	O	O
11	PSD	O	B-Chemical
12	-	O	E-Chemical
13	95	O	O
14	,	O	O
15	while	O	O
16	,	O	O
17	expression	O	O
18	of	O	O
19	pre	O	O
20	synaptic	O	O
21	markers	O	O
22	(	O	O
23	synaptophysin	O	S-Disease
24	and	O	O
25	SNAP	O	S-Chemical
26	-	O	O
27	25	O	O
28	)	O	O
29	remains	O	O
30	unaltered	O	O
31	indicating	O	O
32	selective	O	O
33	post	O	O
34	synaptic	O	O
35	neurotoxicity	S-Disease	S-Disease
36	.	O	O

0	Oral	O	O
1	treatment	O	O
2	with	O	O
3	Memantine	S-Chemical	S-Chemical
4	(	O	O
5	10mg	O	O
6	/	O	O
7	kg	O	O
8	)	O	O
9	and	O	O
10	Ibuprofen	S-Chemical	S-Chemical
11	(	O	O
12	50	O	O
13	mg	O	O
14	/	O	O
15	kg	O	O
16	)	O	O
17	daily	O	O
18	for	O	O
19	13	O	O
20	days	O	O
21	attenuated	O	O
22	STZ	S-Chemical	S-Chemical
23	induced	O	O
24	glial	O	S-Disease
25	activation	O	O
26	,	O	O
27	apoptotic	O	O
28	cell	O	O
29	death	O	E-Disease
30	and	O	O
31	post	O	O
32	synaptic	O	O
33	neurotoxicity	S-Disease	S-Disease
34	in	O	O
35	rat	O	O
36	brain	O	O
37	.	O	O

0	Further	O	O
1	,	O	O
2	in	O	O
3	experiment	O	O
4	set	O	O
5	up	O	O
6	2	O	O
7	:	O	O
8	where	O	O
9	memory	O	O
10	function	O	O
11	was	O	O
12	not	O	O
13	affected	O	O
14	i	O	O
15	.	O	O
16	e	O	O
17	.	O	O
18	7	O	O
19	-	O	O
20	9	O	O
21	days	O	O
22	after	O	O
23	STZ	S-Chemical	S-Chemical
24	treatment	O	O
25	.	O	O

0	The	O	O
1	level	O	O
2	of	O	O
3	GFAP	O	S-Chemical
4	,	O	O
5	CD11b	O	S-Chemical
6	,	O	O
7	TNF	O	S-Disease
8	-	O	O
9	a	O	O
10	,	O	O
11	ROS	O	S-Disease
12	and	O	O
13	nitrite	S-Chemical	S-Disease
14	levels	O	O
15	were	O	O
16	increased	O	O
17	.	O	O

0	On	O	O
1	the	O	O
2	other	O	O
3	hand	O	O
4	,	O	O
5	apoptotic	O	O
6	marker	O	O
7	,	O	O
8	synaptic	O	O
9	markers	O	O
10	,	O	O
11	mitochondrial	O	B-Disease
12	activity	O	E-Disease
13	and	O	O
14	Ca	S-Chemical	S-Chemical
15	(	O	O
16	2	O	O
17	+	O	O
18	)	O	O
19	levels	O	O
20	remained	O	O
21	unaffected	O	O
22	.	O	O

0	Collective	O	O
1	data	O	O
2	indicates	O	O
3	that	O	O
4	neuroinflammatory	S-Disease	O
5	process	O	O
6	and	O	O
7	oxidative	O	O
8	stress	O	O
9	occurs	O	O
10	earlier	O	O
11	to	O	O
12	apoptosis	O	O
13	and	O	O
14	does	O	O
15	not	O	O
16	affect	O	O
17	memory	O	O
18	function	O	O
19	.	O	O

0	Present	O	O
1	study	O	O
2	clearly	O	O
3	suggests	O	O
4	that	O	O
5	glial	O	O
6	activation	O	O
7	and	O	O
8	post	O	O
9	synaptic	O	O
10	neurotoxicity	S-Disease	S-Disease
11	are	O	O
12	the	O	O
13	key	O	O
14	factors	O	O
15	in	O	O
16	STZ	S-Chemical	B-Disease
17	induced	O	O
18	memory	B-Disease	B-Disease
19	impairment	E-Disease	E-Disease
20	and	O	O
21	neuronal	O	B-Disease
22	cell	O	I-Disease
23	death	O	E-Disease
24	.	O	O

0	Comparison	O	O
1	of	O	O
2	effects	O	O
3	of	O	O
4	isotonic	O	S-Disease
5	sodium	B-Chemical	B-Disease
6	chloride	E-Chemical	E-Disease
7	with	O	O
8	diltiazem	S-Chemical	S-Chemical
9	in	O	O
10	prevention	O	O
11	of	O	O
12	contrast	S-Chemical	O
13	-	O	O
14	induced	O	O
15	nephropathy	S-Disease	S-Disease
16	.	O	O

0	INTRODUCTION	O	O
1	AND	O	O
2	OBJECTIVE	O	O
3	:	O	O
4	Contrast	S-Chemical	O
5	-	O	O
6	induced	O	O
7	nephropathy	S-Disease	S-Disease
8	(	O	O
9	CIN	O	S-Chemical
10	)	O	O
11	significantly	O	O
12	increases	O	O
13	the	O	O
14	morbidity	O	O
15	and	O	O
16	mortality	O	O
17	of	O	O
18	patients	O	O
19	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	is	O	O
6	to	O	O
7	investigate	O	O
8	and	O	O
9	compare	O	O
10	the	O	O
11	protective	O	O
12	effects	O	O
13	of	O	O
14	isotonic	O	S-Disease
15	sodium	B-Chemical	B-Disease
16	chloride	E-Chemical	E-Disease
17	with	O	O
18	sodium	B-Chemical	B-Chemical
19	bicarbonate	E-Chemical	E-Chemical
20	infusion	O	O
21	and	O	O
22	isotonic	O	O
23	sodium	B-Chemical	B-Chemical
24	chloride	E-Chemical	E-Chemical
25	infusion	O	O
26	with	O	O
27	diltiazem	S-Chemical	S-Chemical
28	,	O	O
29	a	O	O
30	calcium	S-Chemical	B-Disease
31	channel	O	O
32	blocker	O	O
33	,	O	O
34	in	O	O
35	preventing	O	O
36	CIN	O	S-Chemical
37	.	O	O

0	MATERIALS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	Our	O	O
5	study	O	O
6	included	O	O
7	patients	O	O
8	who	O	O
9	were	O	O
10	administered	O	O
11	30	O	O
12	-	O	O
13	60	O	O
14	mL	O	O
15	of	O	O
16	iodinated	O	S-Chemical
17	contrast	S-Chemical	O
18	agent	O	O
19	for	O	O
20	percutaneous	O	O
21	coronary	O	E-Disease
22	angiography	O	E-Disease
23	(	O	O
24	PCAG	O	S-Chemical
25	)	O	O
26	,	O	O
27	all	O	O
28	with	O	O
29	creatinine	S-Chemical	S-Chemical
30	values	O	O
31	between	O	O
32	1	O	O
33	.	O	O
34	1	O	O
35	and	O	O
36	3	O	O
37	.	O	O
38	1	O	O
39	mg	O	O
40	/	O	O
41	dL	O	O
42	.	O	O

0	The	O	O
1	first	O	O
2	group	O	O
3	of	O	O
4	patients	O	O
5	was	O	O
6	administered	O	O
7	isotonic	O	O
8	sodium	B-Chemical	B-Chemical
9	chloride	E-Chemical	E-Chemical
10	;	O	O
11	the	O	O
12	second	O	O
13	group	O	O
14	was	O	O
15	administered	O	O
16	a	O	O
17	solution	O	O
18	that	O	O
19	of	O	O
20	5	O	O
21	%	O	O
22	dextrose	S-Chemical	O
23	and	O	O
24	sodium	B-Chemical	B-Chemical
25	bicarbonate	E-Chemical	E-Chemical
26	,	O	O
27	while	O	O
28	the	O	O
29	third	O	O
30	group	O	O
31	was	O	O
32	administered	O	O
33	isotonic	O	O
34	sodium	B-Chemical	B-Chemical
35	chloride	E-Chemical	E-Chemical
36	before	O	O
37	and	O	O
38	after	O	O
39	the	O	O
40	contrast	S-Chemical	O
41	injection	O	O
42	.	O	O

0	The	O	O
1	third	O	O
2	group	O	O
3	received	O	O
4	an	O	O
5	additional	O	O
6	injection	O	O
7	of	O	O
8	diltiazem	S-Chemical	S-Chemical
9	the	O	O
10	day	O	O
11	before	O	O
12	and	O	O
13	first	O	O
14	2	O	O
15	days	O	O
16	after	O	O
17	the	O	O
18	contrast	S-Chemical	O
19	injection	O	O
20	.	O	O

0	All	O	O
1	of	O	O
2	the	O	O
3	patients	O	O
4	'	O	O
5	plasma	O	O
6	blood	B-Chemical	O
7	urea	I-Chemical	I-Disease
8	nitrogen	E-Chemical	S-Disease
9	(	O	O
10	BUN	S-Chemical	S-Disease
11	)	O	O
12	and	O	O
13	creatinine	S-Chemical	S-Chemical
14	levels	O	O
15	were	O	O
16	measured	O	O
17	on	O	O
18	the	O	O
19	second	O	O
20	and	O	O
21	seventh	O	O
22	day	O	O
23	after	O	O
24	the	O	O
25	administration	O	O
26	of	O	O
27	intravenous	O	O
28	contrast	S-Chemical	O
29	material	O	O
30	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	basal	O	O
4	creatinine	S-Chemical	S-Chemical
5	levels	O	O
6	were	O	O
7	similar	O	O
8	for	O	O
9	all	O	O
10	three	O	O
11	groups	O	O
12	(	O	O
13	p	O	O
14	>	O	O
15	0	O	O
16	.	O	O
17	05	O	O
18	)	O	O
19	.	O	O

0	Among	O	O
1	a	O	O
2	total	O	O
3	of	O	O
4	60	O	O
5	patients	O	O
6	included	O	O
7	in	O	O
8	the	O	O
9	study	O	O
10	,	O	O
11	16	O	O
12	patients	O	O
13	developed	O	O
14	acute	B-Disease	B-Disease
15	renal	I-Disease	I-Disease
16	failure	E-Disease	E-Disease
17	(	O	O
18	ARF	S-Disease	O
19	)	O	O
20	on	O	O
21	the	O	O
22	second	O	O
23	day	O	O
24	after	O	O
25	contrast	S-Chemical	O
26	material	O	O
27	was	O	O
28	injected	O	O
29	(	O	O
30	26	O	O
31	.	O	O
32	6	O	O
33	%	O	O
34	)	O	O
35	.	O	O

0	The	O	O
1	number	O	O
2	of	O	O
3	patients	O	O
4	who	O	O
5	developed	O	O
6	ARF	S-Disease	O
7	on	O	O
8	the	O	O
9	second	O	O
10	day	O	O
11	after	O	O
12	the	O	O
13	injection	O	O
14	in	O	O
15	the	O	O
16	first	O	O
17	group	O	O
18	was	O	O
19	five	O	O
20	(	O	O
21	25	O	O
22	%	O	O
23	)	O	O
24	,	O	O
25	in	O	O
26	the	O	O
27	second	O	O
28	group	O	O
29	was	O	O
30	six	O	O
31	(	O	O
32	30	O	O
33	%	O	O
34	)	O	O
35	and	O	O
36	the	O	O
37	third	O	O
38	group	O	O
39	was	O	O
40	five	O	O
41	(	O	O
42	25	O	O
43	%	O	O
44	)	O	O
45	(	O	O
46	p	O	O
47	>	O	O
48	0	O	O
49	.	O	O
50	05	O	O
51	)	O	O
52	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	There	O	O
3	was	O	O
4	no	O	O
5	significant	O	O
6	difference	O	O
7	between	O	O
8	isotonic	O	O
9	sodium	B-Chemical	B-Chemical
10	chloride	E-Chemical	E-Chemical
11	,	O	O
12	sodium	B-Chemical	S-Chemical
13	bicarbonate	E-Chemical	E-Chemical
14	and	O	O
15	isotonic	O	O
16	sodium	B-Chemical	B-Chemical
17	chloride	E-Chemical	E-Chemical
18	with	O	O
19	diltiazem	S-Chemical	S-Chemical
20	application	O	O
21	in	O	O
22	prevention	O	O
23	of	O	O
24	CIN	O	S-Chemical
25	.	O	O

0	Neurocognitive	O	O
1	and	O	O
2	neuroradiologic	O	O
3	central	O	I-Disease
4	nervous	O	I-Disease
5	system	O	E-Disease
6	late	O	O
7	effects	O	O
8	in	O	O
9	children	O	O
10	treated	O	O
11	on	O	O
12	Pediatric	O	B-Disease
13	Oncology	O	I-Disease
14	Group	O	E-Disease
15	(	O	O
16	POG	O	S-Chemical
17	)	O	O
18	P9605	O	B-Chemical
19	(	O	O
20	standard	O	O
21	risk	O	O
22	)	O	O
23	and	O	O
24	P9201	O	B-Chemical
25	(	O	O
26	lesser	O	O
27	risk	O	O
28	)	O	O
29	acute	B-Disease	O
30	lymphoblastic	I-Disease	B-Disease
31	leukemia	E-Disease	E-Disease
32	protocols	O	O
33	(	O	O
34	ACCL0131	O	B-Chemical
35	)	O	O
36	:	O	O
37	a	O	O
38	methotrexate	S-Chemical	S-Chemical
39	consequence	O	O
40	?	O	O

0	Concerns	O	O
1	about	O	O
2	long	O	O
3	-	O	O
4	term	O	O
5	methotrexate	S-Chemical	S-Chemical
6	(	O	O
7	MTX	S-Chemical	S-Disease
8	)	O	O
9	neurotoxicity	S-Disease	S-Disease
10	in	O	O
11	the	O	O
12	1990s	O	O
13	led	O	O
14	to	O	O
15	modifications	O	O
16	in	O	O
17	intrathecal	O	O
18	(	O	O
19	IT	O	S-Disease
20	)	O	O
21	therapy	O	O
22	,	O	O
23	leucovorin	O	S-Chemical
24	rescue	O	O
25	,	O	O
26	and	O	O
27	frequency	O	O
28	of	O	O
29	systemic	O	O
30	MTX	S-Chemical	S-Disease
31	administration	O	O
32	in	O	O
33	children	O	O
34	with	O	O
35	acute	B-Disease	O
36	lymphoblastic	I-Disease	I-Disease
37	leukemia	E-Disease	E-Disease
38	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	,	O	O
4	neurocognitive	O	O
5	outcomes	O	O
6	and	O	O
7	neuroradiologic	O	O
8	evidence	O	O
9	of	O	O
10	leukoencephalopathy	S-Disease	S-Disease
11	were	O	O
12	compared	O	O
13	in	O	O
14	children	O	O
15	treated	O	O
16	with	O	O
17	intense	O	O
18	central	O	B-Disease
19	nervous	O	I-Disease
20	system	O	E-Disease
21	(	O	O
22	CNS	O	S-Chemical
23	)	O	O
24	-	O	O
25	directed	O	O
26	therapy	O	O
27	(	O	O
28	P9605	O	B-Chemical
29	)	O	O
30	versus	O	O
31	those	O	O
32	receiving	O	O
33	fewer	O	O
34	CNS	O	S-Chemical
35	-	O	O
36	directed	O	O
37	treatment	O	O
38	days	O	O
39	during	O	O
40	intensive	O	O
41	consolidation	O	O
42	(	O	O
43	P9201	O	B-Chemical
44	)	O	O
45	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	66	O	O
4	children	O	O
5	from	O	O
6	16	O	O
7	Pediatric	O	I-Chemical
8	Oncology	O	I-Disease
9	Group	O	S-Chemical
10	institutions	O	O
11	with	O	O
12	"	O	O
13	standard	O	O
14	-	O	O
15	risk	O	O
16	"	O	O
17	acute	B-Disease	B-Disease
18	lymphoblastic	I-Disease	I-Disease
19	leukemia	E-Disease	E-Disease
20	,	O	O
21	1	O	O
22	.	O	O
23	00	O	O
24	to	O	O
25	9	O	O
26	.	O	O
27	99	O	O
28	years	O	O
29	at	O	O
30	diagnosis	O	O
31	,	O	O
32	without	O	O
33	evidence	O	O
34	of	O	O
35	CNS	O	B-Disease
36	leukemia	S-Disease	E-Disease
37	at	O	O
38	diagnosis	O	O
39	were	O	O
40	enrolled	O	O
41	on	O	O
42	ACCL0131	O	B-Chemical
43	:	O	O
44	28	O	O
45	from	O	O
46	P9201	O	B-Chemical
47	and	O	O
48	38	O	O
49	from	O	O
50	P9605	O	B-Chemical
51	.	O	O

0	Significantly	O	O
1	more	O	O
2	P9605	O	S-Chemical
3	patients	O	O
4	developed	O	O
5	leukoencephalopathy	S-Disease	S-Disease
6	compared	O	O
7	with	O	O
8	P9201	O	S-Chemical
9	patients	O	O
10	(	O	O
11	68	O	O
12	%	O	O
13	,	O	O
14	95	O	O
15	%	O	O
16	confidence	O	O
17	interval	O	O
18	49	O	O
19	%	O	O
20	-	O	O
21	83	O	O
22	%	O	O
23	vs	O	O
24	.	O	O
25	22	O	O
26	%	O	O
27	,	O	O
28	95	O	O
29	%	O	O
30	confidence	O	O
31	interval	O	O
32	5	O	O
33	%	O	O
34	-	O	O
35	44	O	O
36	%	O	O
37	;	O	O
38	P	O	O
39	=	O	O
40	0	O	O
41	.	O	O
42	001	O	O
43	)	O	O
44	identified	O	O
45	as	O	O
46	late	O	O
47	as	O	O
48	7	O	O
49	.	O	O
50	7	O	O
51	years	O	O
52	after	O	O
53	the	O	O
54	end	O	O
55	of	O	O
56	treatment	O	O
57	.	O	O

0	Children	O	O
1	on	O	O
2	both	O	O
3	studies	O	O
4	had	O	O
5	significant	O	O
6	attention	B-Disease	O
7	problems	E-Disease	O
8	,	O	O
9	but	O	O
10	P9605	O	S-Chemical
11	children	O	O
12	scored	O	O
13	below	O	O
14	average	O	O
15	on	O	O
16	more	O	O
17	neurocognitive	O	O
18	measures	O	O
19	than	O	O
20	those	O	O
21	treated	O	O
22	on	O	O
23	P9201	O	B-Chemical
24	(	O	O
25	82	O	O
26	%	O	O
27	,	O	O
28	14	O	O
29	/	O	O
30	17	O	O
31	measures	O	O
32	vs	O	O
33	.	O	O
34	24	O	O
35	%	O	O
36	,	O	O
37	4	O	O
38	/	O	O
39	17	O	O
40	measures	O	O
41	)	O	O
42	.	O	O

0	This	O	O
1	supports	O	O
2	ongoing	O	O
3	concerns	O	O
4	about	O	O
5	intensive	O	O
6	MTX	S-Chemical	S-Disease
7	exposure	O	O
8	as	O	O
9	a	O	O
10	major	O	O
11	contributor	O	O
12	to	O	O
13	CNS	O	S-Chemical
14	late	O	O
15	effects	O	O
16	.	O	O

0	Tranexamic	B-Chemical	S-Chemical
1	acid	E-Chemical	E-Chemical
2	overdosage	O	O
3	-	O	O
4	induced	O	O
5	generalized	O	O
6	seizure	S-Disease	B-Disease
7	in	O	I-Disease
8	renal	B-Disease	I-Disease
9	failure	E-Disease	E-Disease
10	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	45	O	O
4	-	O	O
5	year	O	O
6	-	O	O
7	old	O	O
8	lady	O	O
9	with	O	O
10	chronic	B-Disease	B-Disease
11	kidney	I-Disease	I-Disease
12	disease	E-Disease	E-Disease
13	stage	O	O
14	4	O	O
15	due	O	O
16	to	O	O
17	chronic	O	B-Disease
18	tubulointerstial	B-Disease	B-Disease
19	disease	E-Disease	E-Disease
20	.	O	O

0	She	O	O
1	was	O	O
2	admitted	O	O
3	to	O	O
4	our	O	O
5	center	O	O
6	for	O	O
7	severe	O	O
8	anemia	S-Disease	S-Disease
9	due	O	O
10	to	O	O
11	menorrhagia	S-Disease	S-Disease
12	and	O	O
13	deterioration	B-Disease	O
14	of	I-Disease	O
15	renal	I-Disease	B-Disease
16	function	E-Disease	E-Disease
17	.	O	O

0	Tranexamic	B-Chemical	S-Chemical
1	acid	E-Chemical	E-Chemical
2	(	O	O
3	TNA	S-Chemical	S-Disease
4	)	O	O
5	1	O	O
6	g	O	O
7	8	O	O
8	-	O	O
9	hourly	O	O
10	was	O	O
11	administered	O	O
12	to	O	O
13	her	O	O
14	to	O	O
15	control	O	O
16	bleeding	S-Disease	S-Disease
17	per	O	O
18	vaginum	O	O
19	.	O	O

0	Two	O	O
1	hours	O	O
2	after	O	O
3	the	O	O
4	sixth	O	O
5	dose	O	O
6	of	O	O
7	TNA	S-Chemical	S-Chemical
8	,	O	O
9	she	O	O
10	had	O	O
11	an	O	O
12	episode	O	O
13	of	O	O
14	generalized	O	O
15	tonic	B-Disease	B-Disease
16	clonic	I-Disease	E-Disease
17	convulsions	E-Disease	E-Disease
18	.	O	O

0	TNA	S-Chemical	S-Chemical
1	was	O	O
2	discontinued	O	O
3	.	O	O

0	Investigations	O	O
1	of	O	O
2	the	O	O
3	patient	O	O
4	revealed	O	O
5	no	O	O
6	biochemical	O	O
7	or	O	O
8	structural	O	B-Disease
9	central	O	I-Disease
10	nervous	B-Disease	I-Disease
11	system	I-Disease	E-Disease
12	abnormalities	E-Disease	E-Disease
13	that	O	O
14	could	O	O
15	have	O	O
16	provoked	O	O
17	the	O	O
18	convulsions	S-Disease	O
19	.	O	O

0	She	O	O
1	had	O	O
2	no	O	O
3	further	O	O
4	episodes	O	O
5	of	O	O
6	convulsion	S-Disease	O
7	till	O	O
8	dis	O	O
9	-	O	O
10	charge	O	O
11	and	O	O
12	during	O	O
13	the	O	O
14	two	O	O
15	months	O	O
16	of	O	O
17	follow	O	O
18	-	O	O
19	up	O	O
20	.	O	O

0	Thus	O	O
1	,	O	O
2	the	O	O
3	precipitating	O	O
4	cause	O	O
5	of	O	O
6	convulsions	S-Disease	O
7	was	O	O
8	believed	O	O
9	to	O	O
10	be	O	O
11	an	O	O
12	overdose	S-Disease	O
13	of	O	O
14	TNA	S-Chemical	S-Chemical
15	.	O	O

0	Pre	O	O
1	-	O	O
2	treatment	O	O
3	of	O	O
4	bupivacaine	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	cardiovascular	B-Disease	B-Disease
8	depression	E-Disease	E-Disease
9	using	O	O
10	different	O	O
11	lipid	O	S-Chemical
12	formulations	O	O
13	of	O	O
14	propofol	S-Chemical	S-Chemical
15	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Pre	O	O
3	-	O	O
4	treatment	O	O
5	with	O	O
6	lipid	O	S-Chemical
7	emulsions	O	O
8	has	O	O
9	been	O	O
10	shown	O	O
11	to	O	O
12	increase	O	O
13	lethal	O	O
14	doses	O	O
15	of	O	O
16	bupivacaine	S-Chemical	S-Chemical
17	,	O	O
18	and	O	O
19	the	O	O
20	lipid	O	S-Chemical
21	content	O	O
22	of	O	O
23	propofol	S-Chemical	S-Chemical
24	may	O	O
25	alleviate	O	O
26	bupivacaine	S-Chemical	S-Chemical
27	-	O	O
28	induced	O	O
29	cardiotoxicity	S-Disease	S-Disease
30	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	is	O	O
6	to	O	O
7	investigate	O	O
8	the	O	O
9	effects	O	O
10	of	O	O
11	propofol	S-Chemical	S-Chemical
12	in	O	O
13	intralipid	O	O
14	or	O	O
15	medialipid	O	S-Disease
16	emulsions	O	O
17	on	O	O
18	bupivacaine	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	cardiotoxicity	S-Disease	S-Disease
22	.	O	O

0	METHODS	O	O
1	:	O	O
2	Rats	O	O
3	were	O	O
4	anaesthetised	O	O
5	with	O	O
6	ketamine	S-Chemical	S-Chemical
7	and	O	O
8	were	O	O
9	given	O	O
10	0	O	O
11	.	O	O
12	5	O	O
13	mg	O	O
14	/	O	O
15	kg	O	O
16	/	O	O
17	min	O	O
18	propofol	S-Chemical	S-Chemical
19	in	O	O
20	intralipid	O	O
21	(	O	O
22	Group	O	O
23	P	O	O
24	)	O	O
25	,	O	O
26	propofol	S-Chemical	S-Chemical
27	in	O	O
28	medialipid	O	O
29	(	O	O
30	Group	O	O
31	L	O	O
32	)	O	O
33	,	O	O
34	or	O	O
35	saline	O	O
36	(	O	O
37	Group	O	O
38	C	O	O
39	)	O	O
40	over	O	O
41	20	O	O
42	min	O	O
43	.	O	O

0	Thereafter	O	O
1	,	O	O
2	2	O	O
3	mg	O	O
4	/	O	O
5	kg	O	O
6	/	O	O
7	min	O	O
8	bupivacaine	S-Chemical	S-Chemical
9	0	O	O
10	.	O	O
11	5	O	O
12	%	O	O
13	was	O	O
14	infused	O	O
15	.	O	O

0	We	O	O
1	recorded	O	O
2	time	O	O
3	to	O	O
4	first	O	O
5	dysrhythmia	S-Disease	S-Disease
6	occurrence	O	O
7	,	O	O
8	respective	O	O
9	times	O	O
10	to	O	O
11	25	O	O
12	%	O	O
13	and	O	O
14	50	O	O
15	%	O	O
16	reduction	O	O
17	of	O	O
18	the	O	O
19	heart	O	S-Disease
20	rate	O	O
21	(	O	O
22	HR	O	O
23	)	O	O
24	and	O	O
25	mean	O	O
26	arterial	O	S-Disease
27	pressure	O	O
28	,	O	O
29	and	O	O
30	time	O	O
31	to	O	O
32	asystole	S-Disease	S-Chemical
33	and	O	O
34	total	O	O
35	amount	O	O
36	of	O	O
37	bupivacaine	S-Chemical	S-Chemical
38	consumption	O	O
39	.	O	O

0	Blood	O	O
1	and	O	O
2	tissue	O	O
3	samples	O	O
4	were	O	O
5	collected	O	O
6	following	O	O
7	asystole	S-Disease	S-Chemical
8	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	time	O	O
4	to	O	O
5	first	O	O
6	dysrhythmia	S-Disease	S-Disease
7	occurrence	O	O
8	,	O	O
9	time	O	O
10	to	O	O
11	25	O	O
12	%	O	O
13	and	O	O
14	50	O	O
15	%	O	O
16	reductions	O	O
17	in	O	O
18	HR	O	O
19	,	O	O
20	and	O	O
21	time	O	O
22	to	O	O
23	asystole	S-Disease	S-Chemical
24	were	O	O
25	longer	O	O
26	in	O	O
27	Group	O	O
28	P	O	O
29	than	O	O
30	the	O	O
31	other	O	O
32	groups	O	O
33	.	O	O

0	The	O	O
1	cumulative	O	O
2	bupivacaine	S-Chemical	S-Chemical
3	dose	O	O
4	given	O	O
5	at	O	O
6	those	O	O
7	time	O	O
8	points	O	O
9	was	O	O
10	higher	O	O
11	in	O	O
12	Group	O	O
13	P	O	O
14	.	O	O
15	Plasma	O	O
16	bupivacaine	S-Chemical	S-Disease
17	levels	O	O
18	were	O	O
19	significantly	O	O
20	lower	O	O
21	in	O	O
22	Group	O	O
23	P	O	O
24	than	O	O
25	in	O	O
26	Group	O	O
27	C	O	O
28	.	O	O
29	Bupivacaine	S-Chemical	S-Chemical
30	levels	O	O
31	in	O	O
32	the	O	O
33	brain	O	O
34	and	O	O
35	heart	O	O
36	were	O	O
37	significantly	O	O
38	lower	O	O
39	in	O	O
40	Group	O	O
41	P	O	O
42	and	O	O
43	Group	O	O
44	L	O	O
45	than	O	O
46	in	O	O
47	Group	O	O
48	C	O	O
49	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	We	O	O
3	conclude	O	O
4	that	O	O
5	pre	O	O
6	-	O	O
7	treatment	O	O
8	with	O	O
9	propofol	S-Chemical	S-Chemical
10	in	O	O
11	intralipid	O	S-Disease
12	,	O	O
13	compared	O	O
14	with	O	O
15	propofol	S-Chemical	S-Chemical
16	in	O	O
17	medialipid	O	S-Disease
18	or	O	O
19	saline	O	S-Chemical
20	,	O	O
21	delayed	O	O
22	the	O	O
23	onset	O	O
24	of	O	O
25	bupivacaine	S-Chemical	S-Chemical
26	-	O	O
27	induced	O	O
28	cardiotoxic	S-Disease	O
29	effects	O	O
30	as	O	O
31	well	O	O
32	as	O	O
33	reduced	O	O
34	plasma	O	O
35	bupivacaine	S-Chemical	S-Disease
36	levels	O	O
37	.	O	O

0	Further	O	O
1	studies	O	O
2	are	O	O
3	needed	O	O
4	to	O	O
5	explore	O	O
6	tissue	O	O
7	bupivacaine	S-Chemical	S-Disease
8	levels	O	O
9	of	O	O
10	propofol	S-Chemical	S-Chemical
11	in	O	O
12	medialipid	O	S-Disease
13	and	O	O
14	adapt	O	O
15	these	O	O
16	results	O	O
17	to	O	O
18	clinical	O	O
19	practice	O	O
20	.	O	O

0	Drug	B-Disease	O
1	-	I-Disease	O
2	Induced	I-Disease	O
3	Acute	I-Disease	O
4	Liver	I-Disease	B-Disease
5	Injury	E-Disease	E-Disease
6	Within	O	O
7	12	O	O
8	Hours	O	O
9	After	O	O
10	Fluvastatin	S-Chemical	S-Chemical
11	Therapy	O	O
12	.	O	O

0	Although	O	O
1	statins	S-Chemical	S-Chemical
2	are	O	O
3	generally	O	O
4	well	O	O
5	-	O	O
6	tolerated	O	O
7	drugs	O	O
8	,	O	O
9	recent	O	O
10	cases	O	O
11	of	O	O
12	drug	B-Disease	O
13	-	I-Disease	O
14	induced	I-Disease	O
15	liver	I-Disease	B-Disease
16	injury	E-Disease	E-Disease
17	associated	O	O
18	with	O	O
19	their	O	O
20	use	O	O
21	have	O	O
22	been	O	O
23	reported	O	O
24	.	O	O

0	A	O	O
1	52	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	Chinese	O	S-Chemical
7	man	O	O
8	reported	O	O
9	with	O	O
10	liver	B-Disease	B-Disease
11	damage	E-Disease	E-Disease
12	,	O	O
13	which	O	O
14	appeared	O	O
15	12	O	O
16	hours	O	O
17	after	O	O
18	beginning	O	O
19	treatment	O	O
20	with	O	O
21	fluvastatin	S-Chemical	S-Chemical
22	.	O	O

0	Patient	O	O
1	presented	O	O
2	with	O	O
3	complaints	O	O
4	of	O	O
5	increasing	O	O
6	nausea	S-Disease	S-Disease
7	,	O	O
8	anorexia	S-Disease	S-Disease
9	,	O	O
10	and	O	O
11	upper	O	O
12	abdominal	B-Disease	O
13	pain	E-Disease	S-Disease
14	.	O	O

0	His	O	O
1	laboratory	O	O
2	values	O	O
3	showed	O	O
4	elevated	O	O
5	creatine	S-Chemical	S-Chemical
6	kinase	O	E-Disease
7	and	O	O
8	transaminases	O	S-Disease
9	.	O	O

0	The	O	O
1	liver	O	O
2	biochemistries	O	O
3	eventually	O	O
4	normalized	O	O
5	within	O	O
6	3	O	O
7	weeks	O	O
8	of	O	O
9	stopping	O	O
10	the	O	O
11	fluvastatin	S-Chemical	S-Chemical
12	.	O	O

0	Therefore	O	O
1	,	O	O
2	when	O	O
3	prescribing	O	O
4	statins	O	S-Chemical
5	,	O	O
6	the	O	O
7	possibility	O	O
8	of	O	O
9	hepatic	B-Disease	S-Disease
10	damage	E-Disease	E-Disease
11	should	O	O
12	be	O	O
13	taken	O	O
14	into	O	O
15	account	O	O
16	.	O	O

0	Fluconazole	S-Chemical	S-Chemical
1	associated	O	O
2	agranulocytosis	S-Disease	S-Disease
3	and	O	O
4	thrombocytopenia	S-Disease	S-Disease
5	.	O	O

0	CASE	O	O
1	:	O	O
2	We	O	O
3	describe	O	O
4	a	O	O
5	second	O	O
6	case	O	O
7	of	O	O
8	fluconazole	S-Chemical	S-Chemical
9	associated	O	O
10	agranulocytosis	S-Disease	S-Disease
11	with	O	O
12	thrombocytopenia	S-Disease	S-Disease
13	and	O	O
14	recovery	O	O
15	upon	O	O
16	discontinuation	O	O
17	of	O	O
18	therapy	O	O
19	.	O	O

0	The	O	O
1	patient	O	O
2	began	O	O
3	to	O	O
4	have	O	O
5	changes	O	O
6	in	O	O
7	white	O	O
8	blood	O	I-Disease
9	cells	O	O
10	and	O	O
11	platelets	O	S-Disease
12	within	O	O
13	48	O	O
14	h	O	O
15	of	O	O
16	administration	O	O
17	of	O	O
18	fluconazole	S-Chemical	S-Chemical
19	and	O	O
20	began	O	O
21	to	O	O
22	recover	O	O
23	with	O	O
24	48	O	O
25	h	O	O
26	of	O	O
27	discontinuation	O	O
28	.	O	O

0	This	O	O
1	case	O	O
2	highlights	O	O
3	that	O	O
4	drug	O	O
5	-	O	O
6	induced	O	O
7	blood	B-Disease	B-Disease
8	dyscrasias	E-Disease	E-Disease
9	can	O	O
10	occur	O	O
11	unexpectedly	O	O
12	as	O	O
13	a	O	O
14	result	O	O
15	of	O	O
16	treatment	O	O
17	with	O	O
18	a	O	O
19	commonly	O	O
20	used	O	O
21	drug	O	O
22	thought	O	O
23	to	O	O
24	be	O	O
25	"	O	O
26	safe	O	O
27	"	O	O
28	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	According	O	O
3	to	O	O
4	Naranjo	O	S-Chemical
5	'	O	O
6	s	O	O
7	algorithm	O	O
8	the	O	O
9	likelihood	O	O
10	that	O	O
11	our	O	O
12	patient	O	O
13	'	O	O
14	s	O	O
15	agranulocytosis	S-Disease	O
16	and	O	O
17	thrombocytopenia	S-Disease	S-Disease
18	occurred	O	O
19	as	O	O
20	a	O	O
21	result	O	O
22	of	O	O
23	therapy	O	O
24	with	O	O
25	fluconazole	S-Chemical	S-Chemical
26	is	O	O
27	probable	O	O
28	,	O	O
29	with	O	O
30	a	O	O
31	total	O	O
32	of	O	O
33	six	O	O
34	points	O	O
35	.	O	O

0	In	O	O
1	particular	O	O
2	the	O	O
3	temporal	O	O
4	relationship	O	O
5	of	O	O
6	bone	B-Disease	B-Disease
7	marrow	I-Disease	I-Disease
8	suppression	E-Disease	O
9	to	O	O
10	the	O	O
11	initiation	O	O
12	of	O	O
13	fluconazole	S-Chemical	S-Chemical
14	and	O	O
15	the	O	O
16	abatement	O	O
17	of	O	O
18	symptoms	O	O
19	that	O	O
20	rapidly	O	O
21	reversed	O	O
22	immediately	O	O
23	following	O	O
24	discontinuation	O	O
25	.	O	O

0	Two	O	O
1	-	O	O
2	dimensional	O	O
3	speckle	O	O
4	tracking	O	O
5	echocardiography	O	O
6	combined	O	O
7	with	O	O
8	high	O	O
9	-	O	O
10	sensitive	O	O
11	cardiac	O	B-Disease
12	troponin	O	I-Disease
13	T	O	E-Disease
14	in	O	O
15	early	O	O
16	detection	O	O
17	and	O	O
18	prediction	O	O
19	of	O	O
20	cardiotoxicity	S-Disease	S-Disease
21	during	O	O
22	epirubicine	S-Chemical	S-Disease
23	-	O	O
24	based	O	O
25	chemotherapy	O	O
26	.	O	O

0	AIMS	O	O
1	:	O	O
2	To	O	O
3	investigate	O	O
4	whether	O	O
5	alterations	O	O
6	of	O	O
7	myocardial	B-Disease	B-Disease
8	strain	E-Disease	E-Disease
9	and	O	O
10	high	O	O
11	-	O	O
12	sensitive	O	O
13	cardiac	O	B-Disease
14	troponin	O	I-Disease
15	T	O	E-Disease
16	(	O	O
17	cTnT	O	S-Chemical
18	)	O	O
19	could	O	O
20	predict	O	O
21	future	O	O
22	cardiac	B-Disease	B-Disease
23	dysfunction	E-Disease	E-Disease
24	in	O	O
25	patients	O	O
26	after	O	O
27	epirubicin	S-Chemical	S-Chemical
28	exposure	O	O
29	.	O	O

0	METHODS	O	O
1	:	O	O
2	Seventy	O	O
3	-	O	O
4	five	O	O
5	patients	O	O
6	with	O	O
7	non	B-Disease	B-Disease
8	-	I-Disease	O
9	Hodgkin	I-Disease	B-Disease
10	lymphoma	E-Disease	E-Disease
11	treated	O	O
12	with	O	O
13	epirubicin	S-Chemical	S-Chemical
14	were	O	O
15	studied	O	O
16	.	O	O

0	Cardiotoxicity	S-Disease	O
1	was	O	O
2	defined	O	O
3	as	O	O
4	a	O	O
5	reduction	O	O
6	of	O	O
7	the	O	O
8	LVEF	O	S-Disease
9	of	O	O
10	>	O	O
11	5	O	O
12	%	O	O
13	to	O	O
14	<	O	O
15	55	O	O
16	%	O	O
17	with	O	O
18	symptoms	O	O
19	of	O	O
20	heart	B-Disease	B-Disease
21	failure	E-Disease	E-Disease
22	or	O	O
23	an	O	O
24	asymptomatic	O	O
25	reduction	O	O
26	of	O	O
27	the	O	O
28	LVEF	O	S-Disease
29	of	O	O
30	>	O	O
31	10	O	O
32	%	O	O
33	to	O	O
34	<	O	O
35	55	O	O
36	%	O	O
37	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Fourteen	O	O
3	patients	O	O
4	(	O	O
5	18	O	O
6	.	O	O
7	67	O	O
8	%	O	O
9	)	O	O
10	developed	O	O
11	cardiotoxicity	S-Disease	S-Disease
12	after	O	O
13	treatment	O	O
14	.	O	O

0	A	O	O
1	>	O	O
2	15	O	O
3	.	O	O
4	9	O	O
5	%	O	O
6	decrease	O	O
7	in	O	O
8	GLS	O	S-Disease
9	[	O	O
10	sensitivity	O	O
11	,	O	O
12	86	O	O
13	%	O	O
14	;	O	O
15	specificity	O	O
16	,	O	O
17	75	O	O
18	%	O	O
19	;	O	O
20	area	O	O
21	under	O	O
22	the	O	O
23	curve	O	O
24	(	O	O
25	AUC	O	S-Disease
26	)	O	O
27	=	O	O
28	0	O	O
29	.	O	O
30	815	O	O
31	;	O	O
32	P	O	O
33	=	O	O
34	0	O	O
35	.	O	O
36	001	O	O
37	]	O	O
38	and	O	O
39	a	O	O
40	>	O	O
41	0	O	O
42	.	O	O
43	004	O	O
44	ng	O	O
45	/	O	O
46	mL	O	O
47	elevation	O	O
48	in	O	O
49	cTnT	O	O
50	(	O	O
51	sensitivity	O	O
52	,	O	O
53	79	O	O
54	%	O	O
55	;	O	O
56	specificity	O	O
57	,	O	O
58	64	O	O
59	%	O	O
60	;	O	O
61	AUC	O	O
62	=	O	O
63	0	O	O
64	.	O	O
65	757	O	O
66	;	O	O
67	P	O	S-Disease
68	=	O	O
69	0	O	O
70	.	O	O
71	005	O	O
72	)	O	O
73	from	O	O
74	baseline	O	O
75	to	O	O
76	the	O	O
77	third	O	O
78	cycle	O	O
79	of	O	O
80	chemotherapy	O	O
81	predicted	O	O
82	later	O	O
83	cardiotoxicity	S-Disease	S-Disease
84	.	O	O

0	The	O	O
1	decrease	O	O
2	in	O	O
3	GLS	O	S-Disease
4	remained	O	O
5	the	O	O
6	only	O	O
7	independent	O	O
8	predictor	O	O
9	of	O	O
10	cardiotoxicity	S-Disease	S-Disease
11	(	O	O
12	P	O	S-Chemical
13	=	O	O
14	0	O	O
15	.	O	O
16	000	O	O
17	)	O	O
18	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	GLS	O	S-Chemical
3	combined	O	O
4	with	O	O
5	cTnT	O	S-Chemical
6	may	O	O
7	provide	O	O
8	a	O	O
9	reliable	O	O
10	and	O	O
11	non	O	O
12	-	O	O
13	invasive	O	O
14	method	O	O
15	to	O	O
16	predict	O	O
17	cardiac	B-Disease	B-Disease
18	dysfunction	E-Disease	E-Disease
19	in	O	O
20	patients	O	O
21	receiving	O	O
22	anthracycline	S-Chemical	S-Chemical
23	-	O	O
24	based	O	O
25	chemotherapy	O	O
26	.	O	O

0	Prevention	O	O
1	of	O	O
2	etomidate	S-Chemical	S-Chemical
3	-	O	O
4	induced	O	O
5	myoclonus	S-Disease	S-Disease
6	:	O	O
7	which	O	O
8	is	O	O
9	superior	O	O
10	:	O	O
11	Fentanyl	S-Chemical	S-Chemical
12	,	O	O
13	midazolam	S-Chemical	S-Chemical
14	,	O	O
15	or	O	O
16	a	O	O
17	combination	O	O
18	?	O	O

0	BACKGROUND	O	O
1	:	O	O
2	In	O	O
3	this	O	O
4	retrospective	O	O
5	comparative	O	O
6	study	O	O
7	,	O	O
8	we	O	O
9	aimed	O	O
10	to	O	O
11	compare	O	O
12	the	O	O
13	effectiveness	O	O
14	of	O	O
15	fentanyl	S-Chemical	S-Chemical
16	,	O	O
17	midazolam	S-Chemical	S-Chemical
18	,	O	O
19	and	O	O
20	a	O	O
21	combination	O	O
22	of	O	O
23	fentanyl	S-Chemical	S-Chemical
24	and	O	O
25	midazolam	S-Chemical	S-Chemical
26	to	O	O
27	prevent	O	O
28	etomidate	S-Chemical	S-Chemical
29	-	O	O
30	induced	O	O
31	myoclonus	S-Disease	S-Chemical
32	.	O	O

0	Depending	O	O
1	on	O	O
2	the	O	O
3	drugs	O	O
4	that	O	O
5	would	O	O
6	be	O	O
7	given	O	O
8	before	O	O
9	the	O	O
10	induction	O	O
11	of	O	O
12	anesthesia	O	O
13	with	O	O
14	etomidate	S-Chemical	S-Chemical
15	,	O	O
16	the	O	O
17	patients	O	O
18	were	O	O
19	separated	O	O
20	into	O	O
21	4	O	O
22	groups	O	O
23	:	O	O
24	no	O	O
25	pretreatment	O	O
26	(	O	O
27	Group	O	O
28	NP	O	O
29	)	O	O
30	,	O	O
31	fentanyl	S-Chemical	S-Chemical
32	1	O	O
33	ug	O	O
34	.	O	O
35	kg	O	O
36	-	O	O
37	1	O	O
38	(	O	O
39	Group	O	O
40	F	O	O
41	)	O	O
42	,	O	O
43	midazolam	S-Chemical	S-Chemical
44	0	O	O
45	.	O	O
46	03	O	O
47	mg	O	O
48	.	O	O
49	kg	O	O
50	-	O	O
51	1	O	O
52	(	O	O
53	Group	O	O
54	M	O	O
55	)	O	O
56	,	O	O
57	and	O	O
58	midazolam	S-Chemical	S-Chemical
59	0	O	O
60	.	O	O
61	015	O	O
62	mg	O	O
63	.	O	O
64	kg	O	O
65	-	O	O
66	1	O	O
67	+	O	O
68	fentanyl	S-Chemical	S-Chemical
69	0	O	O
70	.	O	O
71	5	O	O
72	ug	O	O
73	.	O	O
74	kg	O	O
75	-	O	O
76	1	O	O
77	(	O	O
78	Group	O	O
79	FM	O	O
80	)	O	O
81	.	O	O

0	Patients	O	O
1	who	O	O
2	received	O	O
3	the	O	O
4	same	O	O
5	anesthetic	O	O
6	procedure	O	O
7	were	O	O
8	selected	O	O
9	:	O	O
10	2	O	O
11	minutes	O	O
12	after	O	O
13	intravenous	O	O
14	injections	O	O
15	of	O	O
16	the	O	O
17	pretreatment	O	O
18	drugs	O	O
19	,	O	O
20	anesthesia	O	O
21	is	O	O
22	induced	O	O
23	with	O	O
24	0	O	O
25	.	O	O
26	3	O	O
27	mg	O	O
28	.	O	O
29	kg	O	O
30	-	O	O
31	1	O	O
32	etomidate	S-Chemical	O
33	injected	O	O
34	intravenously	O	O
35	over	O	O
36	a	O	O
37	period	O	O
38	of	O	O
39	20	O	O
40	-	O	O
41	30	O	O
42	seconds	O	O
43	.	O	O

0	Myoclonic	B-Disease	S-Chemical
1	movements	E-Disease	O
2	are	O	O
3	evaluated	O	O
4	,	O	O
5	which	O	O
6	were	O	O
7	observed	O	O
8	and	O	O
9	graded	O	O
10	according	O	O
11	to	O	O
12	clinical	O	O
13	severity	O	O
14	during	O	O
15	the	O	O
16	2	O	O
17	minutes	O	O
18	after	O	O
19	etomidate	S-Chemical	S-Chemical
20	injection	O	O
21	.	O	O

0	The	O	O
1	severity	O	O
2	of	O	O
3	pain	S-Disease	S-Disease
4	due	O	O
5	to	O	O
6	etomidate	S-Chemical	S-Chemical
7	injection	O	O
8	,	O	O
9	mean	O	O
10	arterial	O	B-Disease
11	pressure	O	E-Disease
12	,	O	O
13	heart	O	B-Disease
14	rate	O	E-Disease
15	,	O	O
16	and	O	O
17	adverse	O	O
18	effects	O	O
19	were	O	O
20	also	O	O
21	evaluated	O	O
22	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Study	O	O
3	results	O	O
4	showed	O	O
5	that	O	O
6	myoclonus	S-Disease	S-Disease
7	incidence	O	O
8	was	O	O
9	85	O	O
10	%	O	O
11	,	O	O
12	40	O	O
13	%	O	O
14	,	O	O
15	70	O	O
16	%	O	O
17	,	O	O
18	and	O	O
19	25	O	O
20	%	O	O
21	in	O	O
22	Group	O	O
23	NP	O	E-Chemical
24	,	O	O
25	Group	O	O
26	F	O	E-Chemical
27	,	O	O
28	Group	O	O
29	M	O	E-Chemical
30	,	O	O
31	and	O	O
32	Group	O	O
33	FM	O	S-Disease
34	,	O	O
35	respectively	O	O
36	,	O	O
37	and	O	O
38	were	O	O
39	significantly	O	O
40	lower	O	O
41	in	O	O
42	Group	O	O
43	F	O	E-Chemical
44	and	O	O
45	Group	O	O
46	FM	O	S-Disease
47	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	We	O	O
3	conclude	O	O
4	that	O	O
5	pretreatment	O	O
6	with	O	O
7	fentanyl	S-Chemical	S-Chemical
8	or	O	O
9	combination	O	O
10	of	O	O
11	fentanyl	S-Chemical	S-Chemical
12	and	O	O
13	midazolam	S-Chemical	S-Chemical
14	was	O	O
15	effective	O	O
16	in	O	O
17	preventing	O	O
18	etomidate	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	myoclonus	S-Disease	S-Chemical
22	.	O	O

0	Convulsant	O	O
1	effect	O	O
2	of	O	O
3	lindane	S-Chemical	S-Chemical
4	and	O	O
5	regional	O	O
6	brain	O	O
7	concentration	O	O
8	of	O	O
9	GABA	S-Chemical	S-Chemical
10	and	O	O
11	dopamine	S-Chemical	S-Chemical
12	.	O	O

0	Lindane	S-Chemical	S-Chemical
1	(	O	O
2	gamma	B-Chemical	B-Chemical
3	-	I-Chemical	O
4	hexachlorocyclohexane	E-Chemical	S-Chemical
5	)	O	O
6	is	O	O
7	an	O	O
8	organochlorine	O	S-Chemical
9	insecticide	O	O
10	with	O	O
11	known	O	O
12	neurotoxic	S-Disease	O
13	effects	O	O
14	.	O	O

0	Its	O	O
1	mechanism	O	O
2	of	O	O
3	action	O	O
4	is	O	O
5	not	O	O
6	well	O	O
7	understood	O	O
8	although	O	O
9	it	O	O
10	has	O	O
11	been	O	O
12	proposed	O	O
13	that	O	O
14	lindane	S-Chemical	S-Chemical
15	acts	O	O
16	as	O	O
17	a	O	O
18	non	O	O
19	-	O	O
20	competitive	O	O
21	antagonist	O	O
22	at	O	O
23	the	O	O
24	gamma	B-Chemical	S-Chemical
25	-	I-Chemical	O
26	aminobutyric	I-Chemical	E-Chemical
27	acid	E-Chemical	E-Disease
28	(	O	O
29	GABA	S-Chemical	S-Chemical
30	)	O	O
31	-	O	O
32	A	O	O
33	receptor	O	O
34	.	O	O

0	We	O	O
1	studied	O	O
2	the	O	O
3	effect	O	O
4	of	O	O
5	lindane	S-Chemical	S-Chemical
6	(	O	O
7	150	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	)	O	O
12	on	O	O
13	the	O	O
14	GABAergic	O	S-Chemical
15	and	O	O
16	dopaminergic	O	O
17	systems	O	O
18	by	O	O
19	measuring	O	O
20	the	O	O
21	concentration	O	O
22	of	O	O
23	GABA	S-Chemical	S-Chemical
24	,	O	O
25	dopamine	S-Chemical	S-Chemical
26	and	O	O
27	its	O	O
28	metabolites	O	O
29	in	O	O
30	7	O	O
31	brain	O	O
32	areas	O	O
33	at	O	O
34	the	O	O
35	onset	O	O
36	of	O	O
37	seizures	S-Disease	S-Disease
38	.	O	O

0	All	O	O
1	animals	O	O
2	suffered	O	O
3	tonic	O	B-Disease
4	convulsions	S-Disease	E-Disease
5	at	O	O
6	18	O	O
7	.	O	O
8	3	O	O
9	+	O	O
10	/	O	O
11	-	O	O
12	1	O	O
13	.	O	O
14	4	O	O
15	min	O	O
16	after	O	O
17	lindane	S-Chemical	S-Chemical
18	administration	O	O
19	.	O	O

0	The	O	O
1	concentration	O	O
2	of	O	O
3	GABA	S-Chemical	S-Chemical
4	was	O	O
5	only	O	O
6	slightly	O	O
7	but	O	O
8	significantly	O	O
9	decreased	O	O
10	in	O	O
11	the	O	O
12	colliculi	O	S-Chemical
13	without	O	O
14	modifications	O	O
15	in	O	O
16	the	O	O
17	other	O	O
18	areas	O	O
19	.	O	O

0	The	O	O
1	concentration	O	O
2	of	O	O
3	dopamine	S-Chemical	S-Chemical
4	was	O	O
5	increased	O	O
6	in	O	O
7	the	O	O
8	mesencephalon	O	S-Disease
9	and	O	O
10	that	O	O
11	of	O	O
12	its	O	O
13	metabolite	O	O
14	DOPAC	S-Chemical	S-Chemical
15	was	O	O
16	also	O	O
17	increased	O	O
18	in	O	O
19	the	O	O
20	mesencephalon	O	S-Disease
21	and	O	O
22	the	O	O
23	striatum	O	S-Disease
24	.	O	O

0	Cholestatic	S-Disease	O
1	presentation	O	O
2	of	O	O
3	yellow	O	B-Disease
4	phosphorus	S-Chemical	I-Disease
5	poisoning	S-Disease	E-Disease
6	.	O	O

0	Yellow	O	O
1	phosphorus	S-Chemical	O
2	,	O	O
3	a	O	O
4	component	O	O
5	of	O	O
6	certain	O	O
7	pesticide	O	O
8	pastes	O	O
9	and	O	O
10	fireworks	O	O
11	,	O	O
12	is	O	O
13	well	O	O
14	known	O	O
15	to	O	O
16	cause	O	O
17	hepatotoxicity	S-Disease	S-Chemical
18	.	O	O

0	Poisoning	S-Disease	O
1	with	O	O
2	yellow	O	O
3	phosphorus	S-Chemical	S-Disease
4	classically	O	O
5	manifests	O	O
6	with	O	O
7	acute	B-Disease	B-Disease
8	hepatitis	E-Disease	E-Disease
9	leading	O	O
10	to	O	O
11	acute	B-Disease	B-Disease
12	liver	I-Disease	I-Disease
13	failure	E-Disease	E-Disease
14	which	O	O
15	may	O	O
16	need	O	O
17	liver	O	B-Disease
18	transplantation	O	E-Disease
19	.	O	O

0	We	O	O
1	present	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	yellow	O	O
6	phosphorus	S-Chemical	B-Disease
7	poisoning	S-Disease	E-Disease
8	in	O	O
9	which	O	O
10	a	O	O
11	patient	O	O
12	presented	O	O
13	with	O	O
14	florid	O	O
15	clinical	O	O
16	features	O	O
17	of	O	O
18	cholestasis	S-Disease	S-Disease
19	highlighting	O	O
20	the	O	O
21	fact	O	O
22	that	O	O
23	cholestasis	S-Disease	S-Chemical
24	can	O	O
25	rarely	O	O
26	be	O	O
27	a	O	O
28	presenting	O	O
29	feature	O	O
30	of	O	O
31	yellow	O	O
32	phosphorus	S-Chemical	S-Disease
33	hepatotoxicity	S-Disease	S-Disease
34	.	O	O

0	Vasovagal	B-Disease	O
1	syncope	E-Disease	O
2	and	O	O
3	severe	O	O
4	bradycardia	S-Disease	O
5	following	O	O
6	intranasal	O	O
7	dexmedetomidine	S-Chemical	S-Chemical
8	for	O	O
9	pediatric	O	O
10	procedural	O	O
11	sedation	O	O
12	.	O	O

0	We	O	O
1	report	O	O
2	syncope	S-Disease	O
3	and	O	O
4	bradycardia	S-Disease	O
5	in	O	O
6	an	O	O
7	11	O	O
8	-	O	O
9	year	O	O
10	-	O	O
11	old	O	O
12	girl	O	O
13	following	O	O
14	administration	O	O
15	of	O	O
16	intranasal	O	O
17	dexmedetomidine	S-Chemical	S-Chemical
18	for	O	O
19	sedation	O	O
20	for	O	O
21	a	O	O
22	voiding	O	S-Disease
23	cystourethrogram	O	S-Disease
24	.	O	O

0	The	O	O
1	primary	O	O
2	abnormality	O	O
3	found	O	O
4	was	O	O
5	persistent	O	O
6	bradycardia	S-Disease	O
7	,	O	O
8	and	O	O
9	she	O	O
10	was	O	O
11	admitted	O	O
12	to	O	O
13	the	O	O
14	hospital	O	O
15	for	O	O
16	telemetric	O	O
17	observation	O	O
18	.	O	O

0	The	O	O
1	bradycardia	S-Disease	O
2	lasted	O	O
3	~	O	O
4	2	O	O
5	h	O	O
6	,	O	O
7	and	O	O
8	further	O	O
9	cardiac	O	S-Disease
10	workup	O	O
11	revealed	O	O
12	no	O	O
13	underlying	O	O
14	abnormality	O	O
15	.	O	O

0	Paradoxical	O	O
1	severe	O	O
2	agitation	S-Disease	S-Disease
3	induced	O	O
4	by	O	O
5	add	O	O
6	-	O	O
7	on	O	O
8	high	O	O
9	-	O	O
10	doses	O	O
11	quetiapine	S-Chemical	S-Chemical
12	in	O	O
13	schizo	B-Disease	B-Disease
14	-	I-Disease	I-Disease
15	affective	I-Disease	I-Disease
16	disorder	E-Disease	E-Disease
17	.	O	O

0	We	O	O
1	report	O	O
2	the	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	35	O	O
7	-	O	O
8	year	O	O
9	-	O	O
10	old	O	O
11	patient	O	O
12	suffering	O	O
13	from	O	O
14	schizo	B-Disease	B-Disease
15	-	I-Disease	I-Disease
16	affective	I-Disease	I-Disease
17	disorder	E-Disease	E-Disease
18	since	O	O
19	the	O	O
20	age	O	O
21	of	O	O
22	19	O	O
23	years	O	O
24	,	O	O
25	treated	O	O
26	by	O	O
27	a	O	O
28	combination	O	O
29	of	O	O
30	first	O	O
31	-	O	O
32	generation	O	O
33	antipsychotics	O	O
34	,	O	O
35	zuclopenthixol	S-Chemical	S-Chemical
36	(	O	O
37	100	O	O
38	mg	O	O
39	/	O	O
40	day	O	O
41	)	O	O
42	and	O	O
43	lithium	S-Chemical	S-Chemical
44	(	O	O
45	1200	O	O
46	mg	O	O
47	/	O	O
48	day	O	O
49	)	O	O
50	(	O	O
51	serum	O	O
52	lithium	S-Chemical	S-Disease
53	=	O	O
54	0	O	O
55	.	O	O
56	85	O	O
57	mEq	O	O
58	/	O	O
59	l	O	O
60	)	O	O
61	.	O	O

0	This	O	O
1	patient	O	O
2	had	O	O
3	no	O	O
4	associated	O	O
5	personality	B-Disease	B-Disease
6	disorder	E-Disease	E-Disease
7	(	O	O
8	particularly	O	O
9	no	O	O
10	antisocial	B-Disease	O
11	disorder	E-Disease	E-Disease
12	)	O	O
13	and	O	O
14	no	O	O
15	substance	B-Disease	B-Disease
16	abuse	I-Disease	I-Disease
17	disorder	E-Disease	E-Disease
18	.	O	O

0	Within	O	O
1	the	O	O
2	48	O	O
3	h	O	O
4	following	O	O
5	the	O	O
6	gradual	O	O
7	introduction	O	O
8	of	O	O
9	quetiapine	S-Chemical	S-Chemical
10	(	O	O
11	up	O	O
12	to	O	O
13	600	O	O
14	mg	O	O
15	/	O	O
16	day	O	O
17	)	O	O
18	,	O	O
19	the	O	O
20	patient	O	O
21	presented	O	O
22	severe	O	O
23	agitation	S-Disease	O
24	without	O	O
25	an	O	O
26	environmental	O	O
27	explanation	O	O
28	,	O	O
29	contrasting	O	O
30	with	O	O
31	the	O	O
32	absence	O	O
33	of	O	O
34	a	O	O
35	history	O	O
36	of	O	O
37	aggressiveness	S-Disease	O
38	or	O	O
39	personality	B-Disease	B-Disease
40	disorder	E-Disease	E-Disease
41	.	O	O

0	The	O	O
1	diagnoses	O	O
2	of	O	O
3	manic	S-Disease	B-Disease
4	shift	O	E-Disease
5	and	O	O
6	akathisia	S-Disease	S-Disease
7	were	O	O
8	dismissed	O	O
9	.	O	O

0	The	O	O
1	withdrawal	O	O
2	and	O	O
3	the	O	O
4	gradual	O	O
5	reintroduction	O	O
6	of	O	O
7	quetiapine	S-Chemical	S-Chemical
8	2	O	O
9	weeks	O	O
10	later	O	O
11	,	O	O
12	which	O	O
13	led	O	O
14	to	O	O
15	another	O	O
16	severe	O	O
17	agitation	S-Disease	O
18	,	O	O
19	enabled	O	O
20	us	O	O
21	to	O	O
22	attribute	O	O
23	the	O	O
24	agitation	S-Disease	O
25	specifically	O	O
26	to	O	O
27	quetiapine	S-Chemical	S-Chemical
28	.	O	O

0	Antioxidant	O	O
1	effects	O	O
2	of	O	O
3	bovine	O	B-Chemical
4	lactoferrin	O	E-Chemical
5	on	O	O
6	dexamethasone	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	hypertension	S-Disease	S-Disease
10	in	O	O
11	rat	O	O
12	.	O	O

0	Dexamethasone	S-Chemical	S-Chemical
1	-	O	O
2	(	O	O
3	Dex	S-Chemical	S-Chemical
4	-	O	O
5	)	O	O
6	induced	O	O
7	hypertension	S-Disease	S-Disease
8	is	O	O
9	associated	O	O
10	with	O	O
11	enhanced	O	O
12	oxidative	O	O
13	stress	O	S-Disease
14	.	O	O

0	Lactoferrin	O	S-Chemical
1	(	O	O
2	LF	O	S-Disease
3	)	O	O
4	is	O	O
5	an	O	O
6	iron	S-Chemical	O
7	-	O	O
8	binding	O	O
9	glycoprotein	O	S-Disease
10	with	O	O
11	antihypertensive	O	O
12	properties	O	O
13	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	,	O	O
4	we	O	O
5	investigated	O	O
6	the	O	O
7	effect	O	O
8	of	O	O
9	chronic	O	O
10	administration	O	O
11	of	O	O
12	LF	O	S-Disease
13	on	O	O
14	oxidative	O	O
15	stress	O	S-Disease
16	and	O	O
17	hypertension	S-Disease	S-Disease
18	upon	O	O
19	Dex	S-Chemical	S-Chemical
20	administration	O	O
21	.	O	O

0	Male	O	O
1	Wistar	O	O
2	rats	O	O
3	were	O	O
4	treated	O	O
5	by	O	O
6	Dex	S-Chemical	S-Chemical
7	(	O	O
8	30	O	O
9	u	O	O
10	g	O	O
11	/	O	O
12	kg	O	O
13	/	O	O
14	day	O	O
15	subcutaneously	O	O
16	)	O	O
17	or	O	O
18	saline	O	O
19	for	O	O
20	14	O	O
21	days	O	O
22	.	O	O

0	In	O	O
1	a	O	O
2	prevention	O	O
3	study	O	O
4	,	O	O
5	rats	O	O
6	received	O	O
7	4	O	O
8	days	O	O
9	of	O	O
10	LF	O	O
11	treatment	O	O
12	followed	O	O
13	by	O	O
14	Dex	S-Chemical	S-Chemical
15	and	O	O
16	continued	O	O
17	during	O	O
18	the	O	O
19	test	O	O
20	period	O	O
21	.	O	O

0	Plasma	O	O
1	hydrogen	B-Chemical	O
2	peroxide	E-Chemical	E-Chemical
3	(	O	O
4	H2O2	S-Chemical	O
5	)	O	O
6	concentration	O	O
7	and	O	O
8	ferric	O	S-Chemical
9	reducing	O	O
10	antioxidant	O	O
11	power	O	O
12	(	O	O
13	FRAP	O	S-Chemical
14	)	O	O
15	value	O	O
16	were	O	O
17	determined	O	O
18	.	O	O

0	Dexamethasone	S-Chemical	S-Chemical
1	significantly	O	O
2	increased	O	O
3	SBP	O	S-Disease
4	and	O	O
5	plasma	O	O
6	H2O2	S-Chemical	O
7	level	O	O
8	and	O	O
9	decreased	O	O
10	thymus	O	S-Disease
11	and	O	O
12	body	O	O
13	weights	O	O
14	.	O	O

0	LF	O	S-Disease
1	lowered	O	O
2	(	O	O
3	P	O	O
4	<	O	O
5	0	O	O
6	.	O	O
7	01	O	O
8	)	O	O
9	and	O	O
10	dose	O	O
11	dependently	O	O
12	prevented	O	O
13	(	O	O
14	P	O	O
15	<	O	O
16	0	O	O
17	.	O	O
18	001	O	O
19	)	O	O
20	Dex	S-Chemical	S-Chemical
21	-	O	O
22	induced	O	O
23	hypertension	S-Disease	S-Disease
24	.	O	O

0	LF	O	S-Chemical
1	prevented	O	O
2	body	O	O
3	weight	B-Disease	O
4	loss	E-Disease	O
5	and	O	O
6	significantly	O	O
7	reduced	O	O
8	the	O	O
9	elevated	O	O
10	plasma	O	O
11	H2O2	S-Chemical	S-Disease
12	and	O	O
13	increased	O	O
14	FRAP	O	S-Disease
15	values	O	O
16	.	O	O

0	Chronic	O	O
1	administration	O	O
2	of	O	O
3	LF	O	S-Chemical
4	strongly	O	O
5	reduced	O	O
6	the	O	O
7	blood	O	O
8	pressure	O	O
9	and	O	O
10	production	O	O
11	of	O	O
12	ROS	O	S-Disease
13	and	O	O
14	improved	O	O
15	antioxidant	O	O
16	capacity	O	O
17	in	O	O
18	Dex	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	hypertension	S-Disease	S-Disease
22	,	O	O
23	suggesting	O	O
24	the	O	O
25	role	O	O
26	of	O	O
27	inhibition	O	O
28	of	O	O
29	oxidative	O	O
30	stress	O	S-Disease
31	as	O	O
32	another	O	O
33	mechanism	O	O
34	of	O	O
35	antihypertensive	O	O
36	action	O	O
37	of	O	O
38	LF	O	S-Disease
39	.	O	O

0	The	O	O
1	association	O	O
2	between	O	O
3	tranexamic	B-Chemical	S-Chemical
4	acid	E-Chemical	E-Disease
5	and	O	O
6	convulsive	S-Disease	O
7	seizures	S-Disease	S-Disease
8	after	O	O
9	cardiac	O	B-Disease
10	surgery	O	E-Disease
11	:	O	O
12	a	O	O
13	multivariate	O	O
14	analysis	O	O
15	in	O	O
16	11	O	O
17	529	O	O
18	patients	O	O
19	.	O	O

0	Because	O	O
1	of	O	O
2	a	O	O
3	lack	O	O
4	of	O	O
5	contemporary	O	O
6	data	O	O
7	regarding	O	O
8	seizures	S-Disease	S-Disease
9	after	O	O
10	cardiac	O	B-Disease
11	surgery	O	E-Disease
12	,	O	O
13	we	O	O
14	undertook	O	O
15	a	O	O
16	retrospective	O	O
17	analysis	O	O
18	of	O	O
19	prospectively	O	O
20	collected	O	O
21	data	O	O
22	from	O	O
23	11	O	O
24	529	O	O
25	patients	O	O
26	in	O	O
27	whom	O	O
28	cardiopulmonary	O	O
29	bypass	O	S-Disease
30	was	O	O
31	used	O	O
32	from	O	O
33	January	O	O
34	2004	O	O
35	to	O	O
36	December	O	O
37	2010	O	O
38	.	O	O

0	A	O	O
1	convulsive	S-Disease	O
2	seizure	S-Disease	S-Disease
3	was	O	O
4	defined	O	O
5	as	O	O
6	a	O	O
7	transient	O	O
8	episode	O	O
9	of	O	O
10	disturbed	O	B-Disease
11	brain	O	I-Disease
12	function	O	E-Disease
13	characterised	O	O
14	by	O	O
15	abnormal	B-Disease	O
16	involuntary	I-Disease	O
17	motor	I-Disease	O
18	movements	E-Disease	E-Disease
19	.	O	O

0	Multivariate	O	O
1	regression	O	O
2	analysis	O	O
3	was	O	O
4	performed	O	O
5	to	O	O
6	identify	O	O
7	independent	O	O
8	predictors	O	O
9	of	O	O
10	postoperative	O	O
11	seizures	S-Disease	S-Disease
12	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	100	O	O
4	(	O	O
5	0	O	O
6	.	O	O
7	9	O	O
8	%	O	O
9	)	O	O
10	patients	O	O
11	developed	O	O
12	postoperative	O	O
13	convulsive	S-Disease	B-Disease
14	seizures	S-Disease	E-Disease
15	.	O	O

0	Generalised	B-Disease	O
1	and	I-Disease	O
2	focal	I-Disease	O
3	seizures	E-Disease	S-Disease
4	were	O	O
5	identified	O	O
6	in	O	O
7	68	O	O
8	and	O	O
9	32	O	O
10	patients	O	O
11	,	O	O
12	respectively	O	O
13	.	O	O

0	The	O	O
1	median	O	O
2	(	O	O
3	IQR	O	O
4	[	O	O
5	range	O	O
6	]	O	O
7	)	O	O
8	time	O	O
9	after	O	O
10	surgery	O	O
11	when	O	O
12	the	O	O
13	seizure	S-Disease	S-Disease
14	occurred	O	O
15	was	O	O
16	7	O	O
17	(	O	O
18	6	O	O
19	-	O	O
20	12	O	O
21	[	O	O
22	1	O	O
23	-	O	O
24	216	O	O
25	]	O	O
26	)	O	O
27	h	O	O
28	and	O	O
29	8	O	O
30	(	O	O
31	6	O	O
32	-	O	O
33	11	O	O
34	[	O	O
35	4	O	O
36	-	O	O
37	18	O	O
38	]	O	O
39	)	O	O
40	h	O	O
41	,	O	O
42	respectively	O	O
43	.	O	O

0	Independent	O	O
1	predictors	O	O
2	of	O	O
3	postoperative	O	O
4	seizures	S-Disease	S-Disease
5	included	O	O
6	age	O	O
7	,	O	O
8	female	O	O
9	sex	O	O
10	,	O	O
11	redo	O	O
12	cardiac	O	B-Disease
13	surgery	O	E-Disease
14	,	O	O
15	calcification	O	S-Disease
16	of	O	O
17	ascending	O	B-Disease
18	aorta	O	E-Disease
19	,	O	O
20	congestive	B-Disease	O
21	heart	I-Disease	B-Disease
22	failure	E-Disease	E-Disease
23	,	O	O
24	deep	O	O
25	hypothermic	S-Disease	B-Disease
26	circulatory	O	O
27	arrest	O	E-Disease
28	,	O	O
29	duration	O	O
30	of	O	O
31	aortic	O	S-Disease
32	cross	O	O
33	-	O	O
34	clamp	O	O
35	and	O	O
36	tranexamic	B-Chemical	S-Disease
37	acid	E-Chemical	E-Disease
38	.	O	O

0	When	O	O
1	tested	O	O
2	in	O	O
3	a	O	O
4	multivariate	O	O
5	regression	O	O
6	analysis	O	O
7	,	O	O
8	tranexamic	B-Chemical	S-Chemical
9	acid	E-Chemical	E-Disease
10	was	O	O
11	a	O	O
12	strong	O	O
13	independent	O	O
14	predictor	O	O
15	of	O	O
16	seizures	S-Disease	S-Disease
17	(	O	O
18	OR	O	S-Disease
19	14	O	O
20	.	O	O
21	3	O	O
22	,	O	O
23	95	O	O
24	%	O	O
25	CI	O	S-Chemical
26	5	O	O
27	.	O	O
28	5	O	O
29	-	O	O
30	36	O	O
31	.	O	O
32	7	O	O
33	;	O	O
34	p	O	O
35	<	O	O
36	0	O	O
37	.	O	O
38	001	O	O
39	)	O	O
40	.	O	O

0	Patients	O	O
1	with	O	O
2	convulsive	S-Disease	O
3	seizures	S-Disease	E-Disease
4	had	O	O
5	2	O	O
6	.	O	O
7	5	O	O
8	times	O	O
9	higher	O	O
10	in	O	O
11	-	O	O
12	hospital	O	O
13	mortality	O	O
14	rates	O	O
15	and	O	O
16	twice	O	O
17	the	O	O
18	length	O	O
19	of	O	O
20	hospital	O	O
21	stay	O	O
22	compared	O	O
23	with	O	O
24	patients	O	O
25	without	O	O
26	convulsive	S-Disease	O
27	seizures	S-Disease	E-Disease
28	.	O	O

0	Mean	O	O
1	(	O	O
2	IQR	O	O
3	[	O	O
4	range	O	O
5	]	O	O
6	)	O	O
7	length	O	O
8	of	O	O
9	stay	O	O
10	in	O	O
11	the	O	O
12	intensive	O	O
13	care	O	O
14	unit	O	O
15	was	O	O
16	115	O	O
17	(	O	O
18	49	O	O
19	-	O	O
20	228	O	O
21	[	O	O
22	32	O	O
23	-	O	O
24	481	O	O
25	]	O	O
26	)	O	O
27	h	O	O
28	in	O	O
29	patients	O	O
30	with	O	O
31	convulsive	S-Disease	O
32	seizures	S-Disease	S-Disease
33	compared	O	O
34	with	O	O
35	26	O	O
36	(	O	O
37	22	O	O
38	-	O	O
39	69	O	O
40	[	O	O
41	14	O	O
42	-	O	O
43	1080	O	O
44	]	O	O
45	)	O	O
46	h	O	O
47	in	O	O
48	patients	O	O
49	without	O	O
50	seizures	S-Disease	S-Disease
51	(	O	O
52	p	O	O
53	<	O	O
54	0	O	O
55	.	O	O
56	001	O	O
57	)	O	O
58	.	O	O

0	Convulsive	S-Disease	O
1	seizures	S-Disease	E-Disease
2	are	O	O
3	a	O	O
4	serious	O	O
5	postoperative	B-Disease	O
6	complication	E-Disease	O
7	after	O	O
8	cardiac	O	B-Disease
9	surgery	O	E-Disease
10	.	O	O

0	As	O	O
1	tranexamic	B-Chemical	S-Chemical
2	acid	E-Chemical	E-Chemical
3	is	O	O
4	the	O	O
5	only	O	O
6	modifiable	O	O
7	factor	O	O
8	,	O	O
9	its	O	O
10	administration	O	O
11	,	O	O
12	particularly	O	O
13	in	O	O
14	doses	O	O
15	exceeding	O	O
16	80	O	O
17	mg	O	O
18	.	O	O
19	kg	O	O
20	(	O	O
21	-	O	O
22	1	O	O
23	)	O	O
24	,	O	O
25	should	O	O
26	be	O	O
27	weighed	O	O
28	against	O	O
29	the	O	O
30	risk	O	O
31	of	O	O
32	postoperative	O	O
33	seizures	S-Disease	S-Disease
34	.	O	O

0	Dysfunctional	B-Disease	O
1	overnight	I-Disease	O
2	memory	E-Disease	O
3	consolidation	O	O
4	in	O	O
5	ecstasy	S-Chemical	O
6	users	O	O
7	.	O	O

0	Previous	O	O
1	studies	O	O
2	indicate	O	O
3	that	O	O
4	ecstasy	S-Chemical	S-Disease
5	users	O	O
6	have	O	O
7	marked	O	O
8	and	O	O
9	persistent	O	O
10	neurocognitive	O	O
11	and	O	O
12	sleep	B-Disease	S-Disease
13	-	I-Disease	O
14	related	I-Disease	O
15	impairments	E-Disease	O
16	.	O	O

0	We	O	O
1	extend	O	O
2	past	O	O
3	research	O	O
4	by	O	O
5	examining	O	O
6	overnight	O	O
7	memory	O	O
8	consolidation	O	O
9	among	O	O
10	regular	O	O
11	ecstasy	S-Chemical	S-Disease
12	users	O	O
13	(	O	O
14	n	O	O
15	=	O	O
16	12	O	O
17	)	O	O
18	and	O	O
19	drug	O	O
20	naive	O	O
21	healthy	O	O
22	controls	O	O
23	(	O	O
24	n	O	O
25	=	O	O
26	26	O	O
27	)	O	O
28	.	O	O

0	Ecstasy	S-Chemical	O
1	users	O	O
2	demonstrated	O	O
3	impaired	B-Disease	O
4	overnight	I-Disease	O
5	memory	E-Disease	O
6	consolidation	O	O
7	,	O	O
8	a	O	O
9	finding	O	O
10	that	O	O
11	was	O	O
12	more	O	O
13	pronounced	O	O
14	following	O	O
15	associative	O	O
16	interference	O	O
17	.	O	O

0	Additionally	O	O
1	,	O	O
2	ecstasy	S-Chemical	S-Disease
3	users	O	O
4	demonstrated	O	O
5	impairments	O	O
6	on	O	O
7	tasks	O	O
8	recruiting	O	O
9	frontostriatal	O	O
10	and	O	O
11	hippocampal	O	S-Disease
12	neural	O	O
13	circuitry	O	O
14	,	O	O
15	in	O	O
16	the	O	O
17	domains	O	O
18	of	O	O
19	proactive	O	O
20	interference	O	O
21	memory	O	O
22	,	O	O
23	long	O	O
24	-	O	O
25	term	O	O
26	memory	O	O
27	,	O	O
28	encoding	O	O
29	,	O	O
30	working	O	O
31	memory	O	O
32	and	O	O
33	complex	O	O
34	planning	O	O
35	.	O	O

0	We	O	O
1	suggest	O	O
2	that	O	O
3	ecstasy	S-Chemical	S-Chemical
4	-	O	O
5	associated	O	O
6	dysfunction	O	S-Disease
7	in	O	O
8	fronto	O	O
9	-	O	O
10	temporal	O	O
11	circuitry	O	O
12	may	O	O
13	underlie	O	O
14	overnight	O	O
15	consolidation	O	O
16	memory	B-Disease	O
17	impairments	E-Disease	O
18	in	O	O
19	regular	O	O
20	ecstasy	S-Chemical	S-Disease
21	users	O	O
22	.	O	O

0	Normoammonemic	O	S-Disease
1	encephalopathy	S-Disease	S-Disease
2	:	O	O
3	solely	O	O
4	valproate	S-Chemical	S-Disease
5	induced	O	O
6	or	O	O
7	multiple	O	O
8	mechanisms	O	O
9	?	O	O

0	A	O	O
1	77	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	woman	O	O
7	presented	O	O
8	with	O	O
9	subacute	O	O
10	onset	O	O
11	progressive	O	O
12	confusion	S-Disease	S-Disease
13	,	O	O
14	aggression	S-Disease	S-Disease
15	,	O	O
16	auditory	B-Disease	O
17	hallucinations	E-Disease	O
18	and	O	O
19	delusions	S-Disease	S-Disease
20	.	O	O

0	In	O	O
1	the	O	O
2	preceding	O	O
3	months	O	O
4	,	O	O
5	the	O	O
6	patient	O	O
7	had	O	O
8	a	O	O
9	number	O	O
10	of	O	O
11	admissions	O	O
12	with	O	O
13	transient	O	O
14	unilateral	O	O
15	hemiparesis	S-Disease	O
16	with	O	O
17	facial	O	B-Disease
18	droop	O	E-Disease
19	,	O	O
20	and	O	O
21	had	O	O
22	been	O	O
23	started	O	O
24	on	O	O
25	valproate	S-Chemical	O
26	for	O	O
27	presumed	O	O
28	hemiplegic	B-Disease	O
29	migraine	E-Disease	S-Disease
30	.	O	O

0	Valproate	S-Chemical	S-Chemical
1	was	O	O
2	withdrawn	O	O
3	soon	O	O
4	after	O	O
5	admission	O	O
6	and	O	O
7	her	O	O
8	cognitive	O	O
9	abilities	O	O
10	have	O	O
11	gradually	O	O
12	improved	O	O
13	over	O	O
14	3	O	O
15	months	O	O
16	of	O	O
17	follow	O	O
18	-	O	O
19	up	O	O
20	.	O	O

0	Valproate	S-Chemical	S-Chemical
1	levels	O	O
2	taken	O	O
3	prior	O	O
4	to	O	O
5	withdrawal	O	O
6	were	O	O
7	subtherapeutic	O	O
8	and	O	O
9	the	O	O
10	patient	O	O
11	was	O	O
12	normoammonaemic	O	S-Disease
13	.	O	O

0	EEG	O	O
1	undertaken	O	O
2	during	O	O
3	inpatient	O	O
4	stay	O	O
5	showed	O	O
6	changes	O	O
7	consistent	O	O
8	with	O	O
9	encephalopathy	S-Disease	S-Disease
10	,	O	O
11	and	O	O
12	low	O	O
13	titre	O	B-Disease
14	N	B-Chemical	B-Chemical
15	-	I-Chemical	I-Chemical
16	methyl	I-Chemical	E-Chemical
17	-	I-Chemical	I-Chemical
18	D	I-Chemical	I-Chemical
19	-	I-Chemical	I-Chemical
20	aspartate	E-Chemical	S-Chemical
21	(	O	O
22	NMDA	S-Chemical	S-Disease
23	)	O	O
24	receptor	O	O
25	antibodies	O	O
26	were	O	O
27	present	O	O
28	in	O	O
29	this	O	O
30	patient	O	O
31	.	O	O

0	The	O	O
1	possible	O	O
2	aetiologies	O	O
3	of	O	O
4	valproate	S-Chemical	S-Disease
5	-	O	O
6	induced	O	O
7	encephalopathy	S-Disease	S-Disease
8	and	O	O
9	NMDA	S-Chemical	B-Disease
10	receptor	O	E-Disease
11	-	O	O
12	associated	O	O
13	encephalitis	S-Disease	S-Disease
14	present	O	O
15	a	O	O
16	diagnostic	O	O
17	dilemma	O	O
18	.	O	O

0	Cerebellar	B-Disease	O
1	and	I-Disease	O
2	oculomotor	I-Disease	S-Disease
3	dysfunction	E-Disease	E-Disease
4	induced	O	O
5	by	O	O
6	rapid	O	O
7	infusion	O	O
8	of	O	O
9	pethidine	S-Chemical	S-Chemical
10	.	O	O

0	Pethidine	S-Chemical	S-Chemical
1	is	O	O
2	an	O	O
3	opioid	O	S-Chemical
4	that	O	O
5	gains	O	O
6	its	O	O
7	popularity	O	O
8	for	O	O
9	the	O	O
10	effective	O	O
11	pain	S-Disease	S-Disease
12	control	O	O
13	through	O	O
14	acting	O	O
15	on	O	O
16	the	O	O
17	opioid	O	S-Disease
18	-	O	O
19	receptors	O	O
20	.	O	O

0	However	O	O
1	,	O	O
2	rapid	O	O
3	pain	S-Disease	S-Disease
4	relief	O	O
5	sometimes	O	O
6	brings	O	O
7	about	O	O
8	unfavourable	O	O
9	side	O	O
10	effects	O	O
11	that	O	O
12	largely	O	O
13	limit	O	O
14	its	O	O
15	clinical	O	O
16	utility	O	O
17	.	O	O

0	Common	O	O
1	side	O	O
2	effects	O	O
3	include	O	O
4	nausea	S-Disease	S-Disease
5	,	O	O
6	vomiting	S-Disease	S-Disease
7	and	O	O
8	hypotension	S-Disease	S-Disease
9	.	O	O

0	In	O	O
1	patients	O	O
2	with	O	O
3	impaired	B-Disease	O
4	renal	I-Disease	I-Disease
5	and	I-Disease	I-Disease
6	liver	I-Disease	I-Disease
7	function	E-Disease	E-Disease
8	,	O	O
9	and	O	O
10	those	O	O
11	who	O	O
12	need	O	O
13	long	O	O
14	-	O	O
15	term	O	O
16	pain	S-Disease	S-Disease
17	control	O	O
18	,	O	O
19	pethidine	S-Chemical	S-Chemical
20	may	O	O
21	cause	O	O
22	excitatory	O	O
23	central	O	I-Disease
24	nervous	O	I-Disease
25	system	O	E-Disease
26	(	O	O
27	CNS	O	S-Chemical
28	)	O	O
29	effects	O	O
30	through	O	O
31	its	O	O
32	neurotoxic	S-Disease	O
33	metabolite	O	O
34	,	O	O
35	norpethidine	S-Chemical	S-Chemical
36	,	O	O
37	resulting	O	O
38	in	O	O
39	irritability	S-Disease	O
40	and	O	O
41	seizure	S-Disease	S-Disease
42	attack	O	O
43	.	O	O

0	On	O	O
1	the	O	O
2	contrary	O	O
3	,	O	O
4	though	O	O
5	not	O	O
6	clinically	O	O
7	apparent	O	O
8	,	O	O
9	pethidine	S-Chemical	S-Chemical
10	potentially	O	O
11	causes	O	O
12	inhibitory	O	O
13	impacts	O	O
14	on	O	O
15	the	O	O
16	CNS	O	S-Disease
17	and	O	O
18	impairs	O	O
19	normal	O	O
20	cerebellar	O	S-Disease
21	and	O	O
22	oculomotor	O	S-Disease
23	function	O	O
24	in	O	O
25	the	O	O
26	short	O	O
27	term	O	O
28	.	O	O

0	In	O	O
1	this	O	O
2	case	O	O
3	report	O	O
4	,	O	O
5	we	O	O
6	highlight	O	O
7	opioid	O	S-Chemical
8	'	O	O
9	s	O	O
10	inhibitory	O	O
11	side	O	O
12	effects	O	O
13	on	O	O
14	the	O	O
15	cerebellar	O	S-Disease
16	structure	O	O
17	that	O	O
18	causes	O	O
19	dysmetria	S-Disease	S-Disease
20	,	O	O
21	dysarthria	S-Disease	S-Disease
22	,	O	O
23	reduced	O	O
24	smooth	O	O
25	pursuit	O	O
26	gain	O	O
27	and	O	O
28	decreased	O	O
29	saccadic	O	O
30	velocity	O	O
31	.	O	O

0	Baboon	B-Disease	B-Disease
1	syndrome	E-Disease	E-Disease
2	induced	O	O
3	by	O	O
4	ketoconazole	S-Chemical	S-Chemical
5	.	O	O

0	A	O	O
1	27	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	male	O	O
7	patient	O	O
8	presented	O	O
9	with	O	O
10	a	O	O
11	maculopapular	B-Disease	S-Disease
12	eruption	E-Disease	O
13	on	O	O
14	the	O	O
15	flexural	O	O
16	areas	O	O
17	and	O	O
18	buttocks	O	O
19	after	O	O
20	using	O	O
21	oral	O	O
22	ketoconazole	S-Chemical	S-Chemical
23	.	O	O

0	The	O	O
1	patient	O	O
2	was	O	O
3	diagnosed	O	O
4	with	O	O
5	drug	O	O
6	-	O	O
7	induced	O	O
8	baboon	B-Disease	B-Disease
9	syndrome	E-Disease	E-Disease
10	based	O	O
11	on	O	O
12	his	O	O
13	history	O	O
14	,	O	O
15	which	O	O
16	included	O	O
17	prior	O	O
18	sensitivity	O	O
19	to	O	O
20	topical	O	O
21	ketoconazole	S-Chemical	S-Chemical
22	,	O	O
23	a	O	O
24	physical	O	O
25	examination	O	O
26	,	O	O
27	and	O	O
28	histopathological	O	O
29	findings	O	O
30	.	O	O

0	Baboon	B-Disease	B-Disease
1	syndrome	E-Disease	E-Disease
2	is	O	O
3	a	O	O
4	drug	O	O
5	-	O	O
6	or	O	O
7	contact	O	O
8	allergen	O	O
9	-	O	O
10	related	O	O
11	maculopapular	B-Disease	B-Disease
12	eruption	E-Disease	E-Disease
13	that	O	O
14	typically	O	O
15	involves	O	O
16	the	O	O
17	flexural	O	O
18	and	O	O
19	gluteal	O	B-Disease
20	areas	O	O
21	.	O	O

0	To	O	O
1	the	O	O
2	best	O	O
3	of	O	O
4	our	O	O
5	knowledge	O	O
6	,	O	O
7	this	O	O
8	is	O	O
9	the	O	O
10	first	O	O
11	reported	O	O
12	case	O	O
13	of	O	O
14	ketoconazole	S-Chemical	S-Chemical
15	-	O	O
16	induced	O	O
17	baboon	B-Disease	B-Disease
18	syndrome	E-Disease	E-Disease
19	in	O	O
20	the	O	O
21	English	O	S-Chemical
22	literature	O	O
23	.	O	O

0	A	O	O
1	Case	O	O
2	of	O	O
3	Sudden	B-Disease	O
4	Cardiac	I-Disease	B-Disease
5	Death	E-Disease	E-Disease
6	due	O	O
7	to	O	O
8	Pilsicainide	S-Chemical	S-Chemical
9	-	O	O
10	Induced	O	O
11	Torsades	B-Disease	B-Disease
12	de	I-Disease	I-Disease
13	Pointes	E-Disease	E-Chemical
14	.	O	O

0	An	O	O
1	84	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	male	O	O
7	received	O	O
8	oral	O	O
9	pilsicainide	S-Chemical	S-Chemical
10	,	O	O
11	a	O	O
12	pure	O	O
13	sodium	S-Chemical	O
14	channel	O	O
15	blocker	O	O
16	with	O	O
17	slow	O	O
18	recovery	O	O
19	kinetics	O	O
20	,	O	O
21	to	O	O
22	convert	O	O
23	his	O	O
24	paroxysmal	O	O
25	atrial	B-Disease	B-Disease
26	fibrillation	E-Disease	E-Disease
27	to	O	O
28	a	O	O
29	sinus	O	S-Disease
30	rhythm	O	O
31	;	O	O
32	the	O	O
33	patient	O	O
34	developed	O	O
35	sudden	B-Disease	O
36	cardiac	I-Disease	B-Disease
37	death	E-Disease	E-Disease
38	two	O	O
39	days	O	O
40	later	O	O
41	.	O	O

0	The	O	O
1	Holter	O	S-Chemical
2	electrocardiogram	O	O
3	,	O	O
4	which	O	O
5	was	O	O
6	worn	O	O
7	by	O	O
8	chance	O	O
9	,	O	O
10	revealed	O	O
11	torsade	B-Disease	O
12	de	I-Disease	O
13	pointes	E-Disease	O
14	with	O	O
15	gradually	O	O
16	prolonged	O	O
17	QT	O	O
18	intervals	O	O
19	.	O	O

0	Although	O	O
1	the	O	O
2	patient	O	O
3	'	O	O
4	s	O	O
5	renal	O	B-Disease
6	function	O	E-Disease
7	was	O	O
8	not	O	O
9	highly	O	O
10	impaired	O	O
11	and	O	O
12	the	O	O
13	dose	O	O
14	of	O	O
15	pilsicainide	S-Chemical	S-Chemical
16	was	O	O
17	low	O	O
18	,	O	O
19	the	O	O
20	plasma	O	O
21	concentration	O	O
22	of	O	O
23	pilsicainide	S-Chemical	S-Chemical
24	may	O	O
25	have	O	O
26	been	O	O
27	high	O	O
28	,	O	O
29	which	O	O
30	can	O	O
31	produce	O	O
32	torsades	B-Disease	O
33	de	I-Disease	O
34	pointes	E-Disease	O
35	in	O	O
36	the	O	O
37	octogenarian	O	S-Disease
38	.	O	O

0	Although	O	O
1	the	O	O
2	oral	O	O
3	administration	O	O
4	of	O	O
5	class	O	O
6	IC	O	O
7	drugs	O	O
8	,	O	O
9	including	O	O
10	pilsicainide	S-Chemical	S-Chemical
11	,	O	O
12	is	O	O
13	effective	O	O
14	to	O	O
15	terminate	O	O
16	atrial	B-Disease	B-Disease
17	fibrillation	E-Disease	E-Disease
18	,	O	O
19	careful	O	O
20	consideration	O	O
21	must	O	O
22	be	O	O
23	taken	O	O
24	before	O	O
25	giving	O	O
26	these	O	O
27	drugs	O	O
28	to	O	O
29	octogenarians	O	S-Disease
30	.	O	O

0	All	B-Chemical	O
1	-	I-Chemical	O
2	trans	I-Chemical	O
3	retinoic	I-Chemical	B-Disease
4	acid	E-Chemical	E-Disease
5	-	O	O
6	induced	O	O
7	inflammatory	O	B-Disease
8	myositis	S-Disease	E-Disease
9	in	O	O
10	a	O	O
11	patient	O	O
12	with	O	O
13	acute	B-Disease	B-Disease
14	promyelocytic	I-Disease	I-Disease
15	leukemia	E-Disease	E-Disease
16	.	O	O

0	All	B-Chemical	O
1	-	I-Chemical	O
2	trans	I-Chemical	O
3	retinoic	I-Chemical	E-Chemical
4	acid	E-Chemical	E-Disease
5	(	O	O
6	ATRA	S-Chemical	S-Chemical
7	)	O	O
8	,	O	O
9	a	O	O
10	component	O	O
11	of	O	O
12	standard	O	O
13	therapy	O	O
14	for	O	O
15	acute	B-Disease	B-Disease
16	promyelocytic	I-Disease	I-Disease
17	leukemia	E-Disease	E-Disease
18	(	O	O
19	APL	S-Disease	S-Disease
20	)	O	O
21	,	O	O
22	is	O	O
23	associated	O	O
24	with	O	O
25	potentially	O	O
26	serious	O	O
27	but	O	O
28	treatable	O	O
29	adverse	O	O
30	effects	O	O
31	involving	O	O
32	numerous	O	O
33	organ	O	O
34	systems	O	O
35	,	O	O
36	including	O	O
37	rare	O	O
38	skeletal	O	B-Disease
39	muscle	O	I-Disease
40	involvement	O	E-Disease
41	.	O	O

0	Only	O	O
1	a	O	O
2	handful	O	O
3	of	O	O
4	cases	O	O
5	of	O	O
6	ATRA	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	myositis	S-Disease	S-Disease
10	in	O	O
11	children	O	O
12	have	O	O
13	been	O	O
14	reported	O	O
15	,	O	O
16	and	O	O
17	none	O	O
18	in	O	O
19	the	O	O
20	radiology	O	O
21	literature	O	O
22	.	O	O

0	We	O	O
1	present	O	O
2	such	O	O
3	a	O	O
4	case	O	O
5	in	O	O
6	a	O	O
7	15	O	O
8	-	O	O
9	year	O	O
10	-	O	O
11	old	O	O
12	boy	O	O
13	with	O	O
14	APL	S-Disease	S-Disease
15	,	O	O
16	where	O	O
17	recognition	O	O
18	of	O	O
19	imaging	O	O
20	findings	O	O
21	played	O	O
22	a	O	O
23	crucial	O	O
24	role	O	O
25	in	O	O
26	making	O	O
27	the	O	O
28	diagnosis	O	O
29	and	O	O
30	facilitated	O	O
31	prompt	O	O
32	,	O	O
33	effective	O	O
34	treatment	O	O
35	.	O	O

0	Tolerability	O	O
1	of	O	O
2	lomustine	S-Chemical	S-Chemical
3	in	O	O
4	combination	O	O
5	with	O	O
6	cyclophosphamide	S-Chemical	S-Chemical
7	in	O	O
8	dogs	O	O
9	with	O	O
10	lymphoma	S-Disease	S-Disease
11	.	O	O

0	This	O	O
1	retrospective	O	O
2	study	O	O
3	describes	O	O
4	toxicity	S-Disease	S-Disease
5	associated	O	O
6	with	O	O
7	a	O	O
8	protocol	O	O
9	of	O	O
10	lomustine	S-Chemical	S-Chemical
11	(	O	O
12	CCNU	S-Chemical	S-Chemical
13	)	O	O
14	and	O	O
15	cyclophosphamide	S-Chemical	S-Chemical
16	(	O	O
17	CTX	S-Chemical	S-Chemical
18	)	O	O
19	in	O	O
20	dogs	O	O
21	with	O	O
22	lymphoma	S-Disease	S-Disease
23	.	O	O

0	CCNU	S-Chemical	S-Chemical
1	was	O	O
2	administered	O	O
3	per	O	O
4	os	O	S-Disease
5	(	O	O
6	PO	O	S-Disease
7	)	O	O
8	at	O	O
9	a	O	O
10	targeted	O	O
11	dosage	O	O
12	of	O	O
13	60	O	O
14	mg	O	O
15	/	O	O
16	m	O	O
17	(	O	O
18	2	O	O
19	)	O	O
20	body	O	O
21	surface	O	O
22	area	O	O
23	on	O	O
24	day	O	O
25	0	O	O
26	,	O	O
27	CTX	S-Chemical	S-Chemical
28	was	O	O
29	administered	O	O
30	PO	O	S-Chemical
31	at	O	O
32	a	O	O
33	targeted	O	O
34	dosage	O	O
35	of	O	O
36	250	O	O
37	mg	O	O
38	/	O	O
39	m	O	O
40	(	O	O
41	2	O	O
42	)	O	O
43	divided	O	O
44	over	O	O
45	days	O	O
46	0	O	O
47	through	O	O
48	4	O	O
49	,	O	O
50	and	O	O
51	all	O	O
52	dogs	O	O
53	received	O	O
54	prophylactic	O	O
55	antibiotics	O	O
56	.	O	O

0	Neutropenia	S-Disease	S-Chemical
1	was	O	O
2	the	O	O
3	principal	O	O
4	toxic	O	O
5	effect	O	O
6	,	O	O
7	and	O	O
8	the	O	O
9	overall	O	O
10	frequency	O	O
11	of	O	O
12	grade	O	O
13	4	O	O
14	neutropenia	S-Disease	S-Disease
15	after	O	O
16	the	O	O
17	first	O	O
18	treatment	O	O
19	of	O	O
20	CCNU	S-Chemical	S-Disease
21	/	O	I-Disease
22	CTX	S-Chemical	E-Disease
23	was	O	O
24	30	O	O
25	%	O	O
26	(	O	O
27	95	O	O
28	%	O	O
29	confidence	O	O
30	interval	O	O
31	,	O	O
32	19	O	O
33	-	O	O
34	43	O	O
35	%	O	O
36	)	O	O
37	.	O	O

0	The	O	O
1	mean	O	O
2	body	O	O
3	weight	O	O
4	of	O	O
5	dogs	O	O
6	with	O	O
7	grade	O	O
8	4	O	O
9	neutropenia	S-Disease	S-Disease
10	(	O	O
11	19	O	O
12	.	O	O
13	7	O	O
14	kg	O	O
15	+	O	O
16	13	O	O
17	.	O	O
18	4	O	O
19	kg	O	O
20	)	O	O
21	was	O	O
22	significantly	O	O
23	less	O	O
24	than	O	O
25	the	O	O
26	mean	O	O
27	body	O	O
28	weight	O	O
29	of	O	O
30	dogs	O	O
31	that	O	O
32	did	O	O
33	not	O	O
34	develop	O	O
35	grade	O	O
36	4	O	O
37	neutropenia	S-Disease	S-Disease
38	(	O	O
39	31	O	O
40	.	O	O
41	7	O	O
42	kg	O	O
43	+	O	O
44	12	O	O
45	.	O	O
46	4	O	O
47	kg	O	O
48	;	O	O
49	P	O	O
50	=	O	O
51	.	O	O
52	005	O	O
53	)	O	O
54	.	O	O

0	One	O	O
1	dog	O	O
2	(	O	O
3	3	O	O
4	%	O	O
5	)	O	O
6	developed	O	O
7	hematologic	O	O
8	changes	O	O
9	suggestive	O	O
10	of	O	O
11	hepatotoxicity	S-Disease	S-Chemical
12	.	O	O

0	No	O	O
1	dogs	O	O
2	had	O	O
3	evidence	O	O
4	of	O	O
5	either	O	O
6	renal	B-Disease	B-Disease
7	toxicity	E-Disease	E-Disease
8	or	O	O
9	hemorrhagic	B-Disease	S-Disease
10	cystitis	E-Disease	S-Disease
11	.	O	O

0	On	O	O
1	the	O	O
2	basis	O	O
3	of	O	O
4	the	O	O
5	findings	O	O
6	reported	O	O
7	herein	O	O
8	,	O	O
9	a	O	O
10	dose	O	O
11	of	O	O
12	60	O	O
13	mg	O	O
14	/	O	O
15	m	O	O
16	(	O	O
17	2	O	O
18	)	O	O
19	of	O	O
20	CCNU	S-Chemical	S-Disease
21	combined	O	O
22	with	O	O
23	250	O	O
24	mg	O	O
25	/	O	O
26	m	O	O
27	(	O	O
28	2	O	O
29	)	O	O
30	of	O	O
31	CTX	S-Chemical	S-Disease
32	(	O	O
33	divided	O	O
34	over	O	O
35	5	O	O
36	days	O	O
37	)	O	O
38	q	O	O
39	4	O	O
40	wk	O	O
41	is	O	O
42	tolerable	O	O
43	in	O	O
44	tumor	S-Disease	S-Disease
45	-	O	O
46	bearing	O	O
47	dogs	O	O
48	.	O	O

0	Nelarabine	S-Chemical	S-Chemical
1	neurotoxicity	S-Disease	E-Chemical
2	with	O	O
3	concurrent	O	O
4	intrathecal	O	O
5	chemotherapy	O	O
6	:	O	O
7	Case	O	O
8	report	O	O
9	and	O	O
10	review	O	O
11	of	O	O
12	literature	O	O
13	.	O	O

0	Severe	O	O
1	nelarabine	S-Chemical	S-Chemical
2	neurotoxicity	S-Disease	S-Disease
3	in	O	O
4	a	O	O
5	patient	O	O
6	who	O	O
7	received	O	O
8	concurrent	O	O
9	intrathecal	O	O
10	(	O	O
11	IT	O	S-Disease
12	)	O	O
13	chemotherapy	O	O
14	is	O	O
15	reported	O	O
16	.	O	O

0	A	O	O
1	37	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	Caucasian	O	O
7	woman	O	O
8	with	O	O
9	a	O	O
10	history	O	O
11	of	O	O
12	T	B-Disease	B-Disease
13	-	I-Disease	O
14	cell	I-Disease	I-Disease
15	lymphoblastic	I-Disease	I-Disease
16	lymphoma	E-Disease	E-Disease
17	was	O	O
18	admitted	O	O
19	for	O	O
20	relapsed	O	O
21	disease	O	S-Disease
22	.	O	O

0	She	O	O
1	developed	O	O
2	relapsed	O	O
3	disease	O	S-Disease
4	10	O	O
5	months	O	O
6	later	O	O
7	with	O	O
8	leukemic	S-Disease	S-Disease
9	involvement	O	O
10	.	O	O

0	She	O	O
1	was	O	O
2	re	O	O
3	-	O	O
4	induced	O	O
5	with	O	O
6	nelarabine	S-Chemical	S-Chemical
7	1500	O	O
8	mg	O	O
9	/	O	O
10	m	O	O
11	(	O	O
12	2	O	O
13	)	O	O
14	on	O	O
15	days	O	O
16	1	O	O
17	,	O	O
18	3	O	O
19	,	O	O
20	and	O	O
21	5	O	O
22	with	O	O
23	1	O	O
24	dose	O	O
25	of	O	O
26	IT	O	B-Chemical
27	cytarabine	S-Chemical	E-Chemical
28	100	O	O
29	mg	O	O
30	on	O	O
31	day	O	O
32	2	O	O
33	as	O	O
34	central	O	O
35	nervous	O	I-Disease
36	system	O	E-Disease
37	(	O	O
38	CNS	O	S-Disease
39	)	O	O
40	prophylaxis	O	O
41	.	O	O

0	At	O	O
1	the	O	O
2	time	O	O
3	of	O	O
4	treatment	O	O
5	,	O	O
6	she	O	O
7	was	O	O
8	on	O	O
9	continuous	O	O
10	renal	O	O
11	replacement	O	O
12	therapy	O	O
13	due	O	O
14	to	O	O
15	sequelae	O	O
16	of	O	O
17	tumor	B-Disease	B-Disease
18	lysis	I-Disease	I-Disease
19	syndrome	E-Disease	E-Disease
20	(	O	O
21	TLS	S-Disease	S-Disease
22	)	O	O
23	.	O	O

0	She	O	O
1	received	O	O
2	a	O	O
3	second	O	O
4	cycle	O	O
5	of	O	O
6	nelarabine	S-Chemical	S-Chemical
7	without	O	O
8	additional	O	O
9	IT	O	S-Chemical
10	prophylaxis	O	O
11	one	O	O
12	month	O	O
13	later	O	O
14	.	O	O

0	Predominantly	O	O
1	sensory	O	O
2	,	O	O
3	though	O	O
4	also	O	O
5	motor	O	O
6	and	O	O
7	autonomic	O	O
8	,	O	O
9	peripheral	B-Disease	O
10	neuropathy	E-Disease	O
11	started	O	O
12	in	O	O
13	her	O	O
14	feet	O	O
15	,	O	O
16	ascended	O	O
17	proximally	O	O
18	to	O	O
19	the	O	O
20	mid	O	O
21	-	O	O
22	thoracic	O	O
23	region	O	O
24	,	O	O
25	and	O	O
26	eventually	O	O
27	included	O	O
28	her	O	O
29	distal	O	O
30	upper	O	O
31	extremities	O	O
32	.	O	O

0	Nelarabine	S-Chemical	S-Chemical
1	was	O	O
2	felt	O	O
3	to	O	O
4	be	O	O
5	the	O	O
6	cause	O	O
7	of	O	O
8	her	O	O
9	symptoms	O	O
10	.	O	O

0	Her	O	O
1	neuropathy	S-Disease	O
2	stabilized	O	O
3	and	O	O
4	showed	O	O
5	slight	O	O
6	improvement	O	O
7	and	O	O
8	ultimately	O	O
9	received	O	O
10	an	O	O
11	unrelated	O	O
12	,	O	O
13	reduced	O	O
14	-	O	O
15	intensity	O	O
16	allogeneic	O	O
17	transplant	O	O
18	while	O	O
19	in	O	O
20	complete	O	O
21	remission	O	O
22	,	O	O
23	but	O	O
24	relapsed	O	O
25	disease	O	S-Disease
26	10	O	O
27	weeks	O	O
28	later	O	O
29	.	O	O

0	To	O	O
1	our	O	O
2	knowledge	O	O
3	,	O	O
4	this	O	O
5	is	O	O
6	the	O	O
7	first	O	O
8	published	O	O
9	case	O	O
10	report	O	O
11	of	O	O
12	severe	O	O
13	neurotoxicity	S-Disease	S-Disease
14	caused	O	O
15	by	O	O
16	nelarabine	S-Chemical	S-Chemical
17	in	O	O
18	a	O	O
19	patient	O	O
20	who	O	O
21	received	O	O
22	concurrent	O	O
23	IT	O	S-Disease
24	chemotherapy	O	O
25	.	O	O

0	Valproate	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	hyperammonemic	S-Disease	S-Disease
4	encephalopathy	S-Disease	S-Disease
5	in	O	O
6	a	O	O
7	renal	O	B-Disease
8	transplanted	O	E-Disease
9	patient	O	O
10	.	O	O

0	Neurological	B-Disease	O
1	complications	E-Disease	O
2	after	O	O
3	renal	O	B-Disease
4	transplantation	O	E-Disease
5	constitute	O	O
6	an	O	O
7	important	O	O
8	cause	O	O
9	of	O	O
10	morbidity	O	O
11	and	O	O
12	mortality	O	O
13	.	O	O

0	Valproate	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	hyperammonemic	S-Disease	S-Disease
4	encephalopathy	S-Disease	S-Disease
5	is	O	O
6	an	O	O
7	uncommon	O	O
8	but	O	O
9	serious	O	O
10	effect	O	O
11	of	O	O
12	valproate	S-Chemical	S-Disease
13	treatment	O	O
14	.	O	O

0	Here	O	O
1	,	O	O
2	we	O	O
3	describe	O	O
4	the	O	O
5	case	O	O
6	of	O	O
7	a	O	O
8	15	O	O
9	-	O	O
10	year	O	O
11	-	O	O
12	old	O	O
13	girl	O	O
14	who	O	O
15	was	O	O
16	on	O	O
17	a	O	O
18	long	O	O
19	-	O	O
20	term	O	O
21	therapy	O	O
22	with	O	O
23	valproate	S-Chemical	S-Disease
24	due	O	O
25	to	O	O
26	epilepsy	S-Disease	S-Disease
27	and	O	O
28	revealed	O	O
29	impaired	B-Disease	O
30	consciousness	E-Disease	S-Disease
31	with	O	O
32	hyperammonemia	S-Disease	S-Disease
33	12	O	O
34	days	O	O
35	after	O	O
36	renal	O	B-Disease
37	transplantation	O	E-Disease
38	.	O	O

0	After	O	O
1	withdraw	O	O
2	of	O	O
3	valproate	S-Chemical	O
4	,	O	O
5	patients	O	O
6	'	O	O
7	symptoms	O	O
8	resolved	O	O
9	within	O	O
10	24	O	O
11	h	O	O
12	.	O	O

0	Clinicians	O	O
1	should	O	O
2	increase	O	O
3	their	O	O
4	awareness	O	O
5	for	O	O
6	potential	O	O
7	complication	O	O
8	of	O	O
9	valproate	S-Chemical	S-Disease
10	,	O	O
11	especially	O	O
12	in	O	O
13	transplanted	O	O
14	patients	O	O
15	.	O	O

0	Necrotising	B-Disease	O
1	fasciitis	E-Disease	S-Disease
2	after	O	O
3	bortezomib	S-Chemical	S-Disease
4	and	O	O
5	dexamethasone	S-Chemical	S-Disease
6	-	O	O
7	containing	O	O
8	regimen	O	O
9	in	O	O
10	an	O	O
11	elderly	O	O
12	patient	O	O
13	of	O	O
14	Waldenstrom	B-Disease	B-Disease
15	macroglobulinaemia	E-Disease	E-Disease
16	.	O	O

0	Bortezomib	S-Chemical	S-Chemical
1	and	O	O
2	high	O	O
3	-	O	O
4	dose	O	O
5	dexamethasone	S-Chemical	S-Disease
6	-	O	O
7	containing	O	O
8	regimens	O	O
9	are	O	O
10	considered	O	O
11	to	O	O
12	be	O	O
13	generally	O	O
14	tolerable	O	O
15	with	O	O
16	few	O	O
17	severe	O	O
18	bacterial	B-Disease	B-Disease
19	infections	E-Disease	E-Disease
20	in	O	O
21	patients	O	O
22	with	O	O
23	B	O	O
24	-	O	O
25	cell	O	B-Disease
26	malignancies	S-Disease	E-Disease
27	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	76	O	O
7	-	O	O
8	year	O	O
9	-	O	O
10	old	O	O
11	man	O	O
12	with	O	O
13	Waldenstrom	B-Disease	B-Disease
14	macroglobulinaemia	E-Disease	E-Disease
15	who	O	O
16	suffered	O	O
17	necrotising	B-Disease	O
18	fasciitis	E-Disease	S-Disease
19	without	O	O
20	neutropenia	S-Disease	S-Disease
21	after	O	O
22	the	O	O
23	combination	O	O
24	treatment	O	O
25	with	O	O
26	bortezomib	S-Chemical	S-Chemical
27	,	O	O
28	high	O	O
29	-	O	O
30	dose	O	O
31	dexamethasone	S-Chemical	S-Chemical
32	and	O	O
33	rituximab	O	S-Disease
34	.	O	O

0	Physicians	O	O
1	should	O	O
2	recognise	O	O
3	the	O	O
4	possibility	O	O
5	of	O	O
6	fatal	O	O
7	bacterial	B-Disease	B-Disease
8	infections	E-Disease	E-Disease
9	related	O	O
10	to	O	O
11	bortezomib	S-Chemical	S-Chemical
12	plus	O	O
13	high	O	O
14	-	O	O
15	dose	O	O
16	dexamethasone	S-Chemical	S-Chemical
17	in	O	O
18	elderly	O	O
19	patients	O	O
20	,	O	O
21	and	O	O
22	we	O	O
23	believe	O	O
24	this	O	O
25	case	O	O
26	warrants	O	O
27	further	O	O
28	investigation	O	O
29	.	O	O

0	An	O	O
1	integrated	O	O
2	characterization	O	O
3	of	O	O
4	serological	O	O
5	,	O	O
6	pathological	O	O
7	,	O	O
8	and	O	O
9	functional	O	O
10	events	O	O
11	in	O	O
12	doxorubicin	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	cardiotoxicity	S-Disease	S-Disease
16	.	O	O

0	Many	O	O
1	efficacious	O	O
2	cancer	S-Disease	S-Disease
3	treatments	O	O
4	cause	O	O
5	significant	O	O
6	cardiac	O	B-Disease
7	morbidity	O	E-Disease
8	,	O	O
9	yet	O	O
10	biomarkers	O	O
11	or	O	O
12	functional	O	O
13	indices	O	O
14	of	O	O
15	early	O	O
16	damage	O	S-Disease
17	,	O	O
18	which	O	O
19	would	O	O
20	allow	O	O
21	monitoring	O	O
22	and	O	O
23	intervention	O	O
24	,	O	O
25	are	O	O
26	lacking	O	O
27	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	,	O	O
4	we	O	O
5	have	O	O
6	utilized	O	O
7	a	O	O
8	rat	O	O
9	model	O	O
10	of	O	O
11	progressive	O	O
12	doxorubicin	S-Chemical	S-Chemical
13	(	O	O
14	DOX	S-Chemical	S-Chemical
15	)	O	O
16	-	O	O
17	induced	O	O
18	cardiomyopathy	S-Disease	S-Disease
19	,	O	O
20	applying	O	O
21	multiple	O	O
22	approaches	O	O
23	,	O	O
24	including	O	O
25	cardiac	O	B-Disease
26	magnetic	O	I-Disease
27	resonance	O	I-Disease
28	imaging	O	O
29	(	O	O
30	MRI	O	S-Disease
31	)	O	O
32	,	O	O
33	to	O	O
34	provide	O	O
35	the	O	O
36	most	O	O
37	comprehensive	O	O
38	characterization	O	O
39	to	O	O
40	date	O	O
41	of	O	O
42	the	O	O
43	timecourse	O	O
44	of	O	O
45	serological	O	O
46	,	O	O
47	pathological	O	O
48	,	O	O
49	and	O	O
50	functional	O	O
51	events	O	O
52	underlying	O	O
53	this	O	O
54	toxicity	S-Disease	S-Disease
55	.	O	O

0	Hannover	O	O
1	Wistar	O	O
2	rats	O	O
3	were	O	O
4	dosed	O	O
5	with	O	O
6	1	O	O
7	.	O	O
8	25	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	DOX	S-Chemical	S-Chemical
13	weekly	O	O
14	for	O	O
15	8	O	O
16	weeks	O	O
17	followed	O	O
18	by	O	O
19	a	O	O
20	4	O	O
21	week	O	O
22	off	O	O
23	-	O	O
24	dosing	O	O
25	"	O	O
26	recovery	O	O
27	"	O	O
28	period	O	O
29	.	O	O

0	Electron	O	O
1	microscopy	O	O
2	of	O	O
3	the	O	O
4	myocardium	O	S-Disease
5	revealed	O	O
6	subcellular	B-Disease	O
7	degeneration	E-Disease	O
8	and	O	O
9	marked	O	O
10	mitochondrial	O	B-Disease
11	changes	O	E-Disease
12	after	O	O
13	a	O	O
14	single	O	O
15	dose	O	O
16	.	O	O

0	Histopathological	O	O
1	analysis	O	O
2	revealed	O	O
3	progressive	O	O
4	cardiomyocyte	B-Disease	B-Disease
5	degeneration	E-Disease	E-Disease
6	,	O	O
7	hypertrophy	S-Disease	S-Disease
8	/	O	I-Disease
9	cytomegaly	O	S-Disease
10	,	O	O
11	and	O	O
12	extensive	O	O
13	vacuolation	O	O
14	after	O	O
15	two	O	O
16	doses	O	O
17	.	O	O

0	Extensive	O	O
1	replacement	O	O
2	fibrosis	S-Disease	S-Disease
3	(	O	O
4	quantified	O	O
5	by	O	O
6	Sirius	O	S-Chemical
7	red	O	O
8	staining	O	O
9	)	O	O
10	developed	O	O
11	during	O	O
12	the	O	O
13	off	O	O
14	-	O	O
15	dosing	O	O
16	period	O	O
17	.	O	O

0	Functional	O	O
1	indices	O	O
2	assessed	O	O
3	by	O	O
4	cardiac	O	B-Disease
5	MRI	O	E-Disease
6	(	O	O
7	including	O	O
8	left	O	O
9	ventricular	O	B-Disease
10	ejection	O	E-Disease
11	fraction	O	O
12	(	O	O
13	LVEF	O	S-Disease
14	)	O	O
15	,	O	O
16	cardiac	O	S-Disease
17	output	O	E-Disease
18	,	O	O
19	and	O	O
20	E	O	O
21	/	O	O
22	A	O	O
23	ratio	O	O
24	)	O	O
25	declined	O	O
26	progressively	O	O
27	,	O	O
28	reaching	O	O
29	statistical	O	O
30	significance	O	O
31	after	O	O
32	two	O	O
33	doses	O	O
34	and	O	O
35	culminating	O	O
36	in	O	O
37	"	O	O
38	clinical	O	O
39	"	O	O
40	LV	B-Disease	S-Disease
41	dysfunction	E-Disease	S-Disease
42	by	O	O
43	12	O	O
44	weeks	O	O
45	.	O	O

0	Troponin	O	B-Chemical
1	I	O	E-Chemical
2	levels	O	O
3	positively	O	O
4	correlated	O	O
5	with	O	O
6	delayed	O	O
7	and	O	O
8	peak	O	O
9	gadolinium	S-Chemical	S-Chemical
10	contrast	O	O
11	enhancement	O	O
12	,	O	O
13	histopathological	O	O
14	grading	O	O
15	,	O	O
16	and	O	O
17	diastolic	B-Disease	B-Disease
18	dysfunction	E-Disease	E-Disease
19	.	O	O

0	In	O	O
1	summary	O	O
2	,	O	O
3	subcellular	O	O
4	cardiomyocyte	B-Disease	O
5	degeneration	E-Disease	O
6	was	O	O
7	the	O	O
8	earliest	O	O
9	marker	O	O
10	,	O	O
11	followed	O	O
12	by	O	O
13	progressive	O	O
14	functional	O	O
15	decline	O	O
16	and	O	O
17	histopathological	O	O
18	manifestations	O	O
19	.	O	O

0	However	O	O
1	,	O	O
2	all	O	O
3	indices	O	O
4	predated	O	O
5	"	O	O
6	clinical	O	O
7	"	O	O
8	LV	B-Disease	S-Disease
9	dysfunction	E-Disease	S-Disease
10	and	O	O
11	thus	O	O
12	warrant	O	O
13	further	O	O
14	evaluation	O	O
15	as	O	O
16	predictive	O	O
17	biomarkers	O	O
18	.	O	O

0	Intradermal	O	O
1	glutamate	S-Chemical	S-Chemical
2	and	O	O
3	capsaicin	S-Chemical	S-Chemical
4	injections	O	O
5	:	O	O
6	intra	O	O
7	-	O	O
8	and	O	O
9	interindividual	O	O
10	variability	O	O
11	of	O	O
12	provoked	O	O
13	hyperalgesia	S-Disease	S-Disease
14	and	O	O
15	allodynia	S-Disease	S-Disease
16	.	O	O

0	Intradermal	O	O
1	injections	O	O
2	of	O	O
3	glutamate	S-Chemical	S-Chemical
4	and	O	O
5	capsaicin	S-Chemical	S-Chemical
6	are	O	O
7	attractive	O	O
8	to	O	O
9	use	O	O
10	in	O	O
11	human	O	O
12	experimental	O	O
13	pain	S-Disease	O
14	models	O	O
15	because	O	O
16	hyperalgesia	S-Disease	S-Disease
17	and	O	O
18	allodynia	S-Disease	S-Disease
19	mimic	O	O
20	isolated	O	O
21	aspects	O	O
22	of	O	O
23	clinical	O	O
24	pain	B-Disease	B-Disease
25	disorders	E-Disease	E-Disease
26	.	O	O

0	Twenty	O	O
1	healthy	O	O
2	male	O	O
3	volunteers	O	O
4	(	O	O
5	mean	O	O
6	age	O	O
7	24	O	O
8	years	O	O
9	;	O	O
10	range	O	O
11	18	O	O
12	-	O	O
13	38	O	O
14	years	O	O
15	)	O	O
16	received	O	O
17	intradermal	O	O
18	injections	O	O
19	of	O	O
20	glutamate	S-Chemical	S-Chemical
21	and	O	O
22	capsaicin	S-Chemical	S-Chemical
23	in	O	O
24	the	O	O
25	volar	O	O
26	forearm	O	O
27	.	O	O

0	Magnitudes	O	O
1	of	O	O
2	secondary	O	O
3	pinprick	O	O
4	hyperalgesia	S-Disease	S-Disease
5	and	O	O
6	brush	O	O
7	-	O	O
8	evoked	O	O
9	allodynia	S-Disease	S-Disease
10	were	O	O
11	investigated	O	O
12	using	O	O
13	von	O	O
14	Frey	O	S-Chemical
15	filaments	O	O
16	(	O	O
17	gauges	O	O
18	10	O	O
19	,	O	O
20	15	O	O
21	,	O	O
22	60	O	O
23	and	O	O
24	100	O	O
25	g	O	O
26	)	O	O
27	and	O	O
28	brush	O	O
29	strokes	O	O
30	.	O	O

0	Areas	O	O
1	of	O	O
2	secondary	B-Disease	O
3	hyperalgesia	E-Disease	S-Disease
4	and	O	O
5	allodynia	S-Disease	S-Disease
6	were	O	O
7	quantified	O	O
8	immediately	O	O
9	after	O	O
10	injection	O	O
11	and	O	O
12	after	O	O
13	15	O	O
14	,	O	O
15	30	O	O
16	and	O	O
17	60	O	O
18	min	O	O
19	.	O	O

0	Secondary	O	O
1	pinprick	O	O
2	hyperalgesia	S-Disease	S-Disease
3	was	O	O
4	observed	O	O
5	as	O	O
6	a	O	O
7	marked	O	O
8	increase	O	O
9	in	O	O
10	the	O	O
11	visual	O	O
12	analogue	O	O
13	scale	O	O
14	(	O	O
15	VAS	O	O
16	)	O	O
17	response	O	O
18	to	O	O
19	von	O	O
20	Frey	O	S-Disease
21	gauges	O	O
22	60	O	O
23	and	O	O
24	100	O	O
25	g	O	O
26	(	O	O
27	P	O	O
28	<	O	O
29	0	O	O
30	.	O	O
31	001	O	O
32	)	O	O
33	after	O	O
34	glutamate	S-Chemical	S-Chemical
35	injection	O	O
36	.	O	O

0	For	O	O
1	capsaicin	S-Chemical	S-Chemical
2	,	O	O
3	secondary	O	O
4	pinprick	O	O
5	hyperalgesia	S-Disease	S-Disease
6	was	O	O
7	detected	O	O
8	with	O	O
9	all	O	O
10	von	O	O
11	Frey	O	S-Disease
12	gauges	O	O
13	(	O	O
14	P	O	S-Disease
15	<	O	O
16	0	O	O
17	.	O	O
18	001	O	O
19	)	O	O
20	.	O	O

0	Glutamate	S-Chemical	S-Chemical
1	evoked	O	O
2	reproducible	O	O
3	VAS	O	O
4	response	O	O
5	to	O	O
6	all	O	O
7	von	O	O
8	Frey	O	S-Chemical
9	gauges	O	O
10	(	O	O
11	ICC	O	S-Chemical
12	>	O	O
13	0	O	O
14	.	O	O
15	60	O	O
16	)	O	O
17	and	O	O
18	brush	O	O
19	strokes	O	O
20	(	O	O
21	ICC	O	S-Chemical
22	>	O	O
23	0	O	O
24	.	O	O
25	83	O	O
26	)	O	O
27	.	O	O

0	Capsaicin	S-Chemical	S-Chemical
1	injection	O	O
2	was	O	O
3	reproducible	O	O
4	for	O	O
5	secondary	B-Disease	O
6	hyperalgesia	E-Disease	S-Disease
7	(	O	O
8	ICC	O	S-Chemical
9	>	O	O
10	0	O	O
11	.	O	O
12	70	O	O
13	)	O	O
14	and	O	O
15	allodynia	S-Disease	S-Disease
16	(	O	O
17	ICC	O	S-Chemical
18	>	O	O
19	0	O	O
20	.	O	O
21	71	O	O
22	)	O	O
23	.	O	O

0	Intra	O	O
1	-	O	O
2	individual	O	O
3	variability	O	O
4	was	O	O
5	generally	O	O
6	lower	O	O
7	for	O	O
8	the	O	O
9	VAS	O	O
10	response	O	O
11	to	O	O
12	von	O	B-Disease
13	Frey	O	E-Disease
14	and	O	O
15	brush	O	O
16	compared	O	O
17	with	O	O
18	areas	O	O
19	of	O	O
20	secondary	B-Disease	O
21	hyperalgesia	E-Disease	S-Disease
22	and	O	O
23	allodynia	S-Disease	S-Disease
24	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	glutamate	S-Chemical	S-Chemical
4	and	O	O
5	capsaicin	S-Chemical	S-Chemical
6	yield	O	O
7	reproducible	O	O
8	hyperalgesic	S-Disease	S-Disease
9	and	O	O
10	allodynic	S-Disease	S-Disease
11	responses	O	O
12	,	O	O
13	and	O	O
14	the	O	O
15	present	O	O
16	model	O	O
17	is	O	O
18	well	O	O
19	suited	O	O
20	for	O	O
21	basic	O	O
22	research	O	O
23	,	O	O
24	as	O	O
25	well	O	O
26	as	O	O
27	for	O	O
28	assessing	O	O
29	the	O	O
30	modulation	O	O
31	of	O	O
32	central	O	O
33	phenomena	O	O
34	.	O	O

0	Ocular	O	O
1	-	O	O
2	specific	O	O
3	ER	O	O
4	stress	O	I-Disease
5	reduction	O	O
6	rescues	O	O
7	glaucoma	S-Disease	S-Disease
8	in	O	O
9	murine	O	S-Chemical
10	glucocorticoid	O	S-Disease
11	-	O	O
12	induced	O	O
13	glaucoma	S-Disease	S-Disease
14	.	O	O

0	Administration	O	O
1	of	O	O
2	glucocorticoids	O	S-Chemical
3	induces	O	O
4	ocular	B-Disease	B-Disease
5	hypertension	E-Disease	E-Disease
6	in	O	O
7	some	O	O
8	patients	O	O
9	.	O	O

0	If	O	O
1	untreated	O	O
2	,	O	O
3	these	O	O
4	patients	O	O
5	can	O	O
6	develop	O	O
7	a	O	O
8	secondary	O	O
9	glaucoma	S-Disease	S-Disease
10	that	O	O
11	resembles	O	O
12	primary	B-Disease	O
13	open	I-Disease	O
14	-	I-Disease	O
15	angle	I-Disease	O
16	glaucoma	E-Disease	S-Disease
17	(	O	O
18	POAG	S-Disease	S-Chemical
19	)	O	O
20	.	O	O

0	The	O	O
1	underlying	O	O
2	pathology	O	O
3	of	O	O
4	glucocorticoid	O	S-Chemical
5	-	O	O
6	induced	O	O
7	glaucoma	S-Disease	S-Disease
8	is	O	O
9	not	O	O
10	fully	O	O
11	understood	O	O
12	,	O	O
13	due	O	O
14	in	O	O
15	part	O	O
16	to	O	O
17	lack	O	O
18	of	O	O
19	an	O	O
20	appropriate	O	O
21	animal	O	O
22	model	O	O
23	.	O	O

0	Here	O	O
1	,	O	O
2	we	O	O
3	developed	O	O
4	a	O	O
5	murine	O	S-Chemical
6	model	O	O
7	of	O	O
8	glucocorticoid	O	S-Chemical
9	-	O	O
10	induced	O	O
11	glaucoma	S-Disease	S-Disease
12	that	O	O
13	exhibits	O	O
14	glaucoma	S-Disease	S-Disease
15	features	O	O
16	that	O	O
17	are	O	O
18	observed	O	O
19	in	O	O
20	patients	O	O
21	.	O	O

0	Treatment	O	O
1	of	O	O
2	WT	O	O
3	mice	O	O
4	with	O	O
5	topical	O	O
6	ocular	O	B-Disease
7	0	O	O
8	.	O	O
9	1	O	O
10	%	O	O
11	dexamethasone	S-Chemical	S-Chemical
12	led	O	O
13	to	O	O
14	elevation	O	O
15	of	O	O
16	intraocular	O	O
17	pressure	O	O
18	(	O	O
19	IOP	O	S-Chemical
20	)	O	O
21	,	O	O
22	functional	O	O
23	and	O	O
24	structural	O	O
25	loss	O	O
26	of	O	O
27	retinal	B-Disease	O
28	ganglion	E-Disease	I-Disease
29	cells	O	O
30	,	O	O
31	and	O	O
32	axonal	B-Disease	O
33	degeneration	E-Disease	O
34	,	O	O
35	resembling	O	O
36	glucocorticoid	O	S-Chemical
37	-	O	O
38	induced	O	O
39	glaucoma	S-Disease	S-Disease
40	in	O	O
41	human	O	O
42	patients	O	O
43	.	O	O

0	Furthermore	O	O
1	,	O	O
2	dexamethasone	S-Chemical	S-Chemical
3	-	O	O
4	induced	O	O
5	ocular	B-Disease	B-Disease
6	hypertension	E-Disease	E-Disease
7	was	O	O
8	associated	O	O
9	with	O	O
10	chronic	O	B-Disease
11	ER	O	B-Disease
12	stress	O	E-Disease
13	of	O	O
14	the	O	O
15	trabecular	O	O
16	meshwork	O	E-Disease
17	(	O	O
18	TM	O	S-Disease
19	)	O	O
20	.	O	O

0	Similar	O	O
1	to	O	O
2	patients	O	O
3	,	O	O
4	withdrawal	O	O
5	of	O	O
6	dexamethasone	S-Chemical	S-Chemical
7	treatment	O	O
8	reduced	O	O
9	elevated	O	O
10	IOP	O	S-Disease
11	and	O	O
12	ER	O	B-Disease
13	stress	O	E-Disease
14	in	O	O
15	this	O	O
16	animal	O	O
17	model	O	O
18	.	O	O

0	Dexamethasone	S-Chemical	S-Chemical
1	induced	O	O
2	the	O	O
3	transcriptional	O	O
4	factor	O	O
5	CHOP	O	S-Chemical
6	,	O	O
7	a	O	O
8	marker	O	O
9	for	O	O
10	chronic	O	B-Disease
11	ER	O	I-Disease
12	stress	O	E-Disease
13	,	O	O
14	in	O	O
15	the	O	O
16	anterior	O	O
17	segment	O	O
18	tissues	O	O
19	,	O	O
20	and	O	O
21	Chop	O	S-Chemical
22	deletion	O	O
23	reduced	O	O
24	ER	O	B-Disease
25	stress	O	E-Disease
26	in	O	O
27	these	O	O
28	tissues	O	O
29	and	O	O
30	prevented	O	O
31	dexamethasone	S-Chemical	S-Chemical
32	-	O	O
33	induced	O	O
34	ocular	B-Disease	B-Disease
35	hypertension	E-Disease	E-Disease
36	.	O	O

0	Furthermore	O	O
1	,	O	O
2	reduction	O	O
3	of	O	O
4	ER	O	S-Disease
5	stress	O	O
6	in	O	O
7	the	O	O
8	TM	O	O
9	with	O	O
10	sodium	B-Chemical	B-Chemical
11	4	I-Chemical	E-Chemical
12	-	I-Chemical	I-Chemical
13	phenylbutyrate	E-Chemical	E-Chemical
14	prevented	O	O
15	dexamethasone	S-Chemical	S-Chemical
16	-	O	O
17	induced	O	O
18	ocular	B-Disease	B-Disease
19	hypertension	E-Disease	E-Disease
20	in	O	O
21	WT	O	O
22	mice	O	O
23	.	O	O

0	Our	O	O
1	data	O	O
2	indicate	O	O
3	that	O	O
4	ER	O	S-Disease
5	stress	O	E-Disease
6	contributes	O	O
7	to	O	O
8	glucocorticoid	O	S-Chemical
9	-	O	O
10	induced	O	O
11	ocular	B-Disease	B-Disease
12	hypertension	E-Disease	E-Disease
13	and	O	O
14	suggest	O	O
15	that	O	O
16	reducing	O	O
17	ER	O	B-Disease
18	stress	O	E-Disease
19	has	O	O
20	potential	O	O
21	as	O	O
22	a	O	O
23	therapeutic	O	O
24	strategy	O	O
25	for	O	O
26	treating	O	O
27	glucocorticoid	O	S-Chemical
28	-	O	O
29	induced	O	O
30	glaucoma	S-Disease	S-Disease
31	.	O	O

0	Effects	O	O
1	of	O	O
2	ginsenosides	S-Chemical	S-Chemical
3	on	O	O
4	opioid	O	S-Chemical
5	-	O	O
6	induced	O	O
7	hyperalgesia	S-Disease	S-Disease
8	in	O	O
9	mice	O	O
10	.	O	O

0	Opioid	O	S-Chemical
1	-	O	O
2	induced	O	O
3	hyperalgesia	S-Disease	S-Disease
4	(	O	O
5	OIH	S-Disease	S-Chemical
6	)	O	O
7	is	O	O
8	characterized	O	O
9	by	O	O
10	nociceptive	O	O
11	sensitization	O	O
12	caused	O	O
13	by	O	O
14	the	O	O
15	cessation	O	O
16	of	O	O
17	chronic	O	B-Disease
18	opioid	O	E-Disease
19	use	O	O
20	.	O	O

0	OIH	S-Disease	S-Chemical
1	can	O	O
2	limit	O	O
3	the	O	O
4	clinical	O	O
5	use	O	O
6	of	O	O
7	opioid	O	S-Chemical
8	analgesics	O	O
9	and	O	O
10	complicate	O	O
11	withdrawal	O	O
12	from	O	O
13	opioid	B-Disease	B-Disease
14	addiction	E-Disease	E-Disease
15	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	,	O	O
4	we	O	O
5	investigated	O	O
6	the	O	O
7	effects	O	O
8	of	O	O
9	Re	B-Chemical	S-Chemical
10	,	I-Chemical	O
11	Rg1	I-Chemical	S-Disease
12	,	I-Chemical	O
13	and	I-Chemical	O
14	Rb1	I-Chemical	O
15	ginsenosides	E-Chemical	S-Chemical
16	,	O	O
17	the	O	O
18	bioactive	O	O
19	components	O	O
20	of	O	O
21	ginseng	O	S-Chemical
22	,	O	O
23	on	O	O
24	OIH	S-Disease	S-Chemical
25	.	O	O

0	OIH	S-Disease	S-Chemical
1	was	O	O
2	achieved	O	O
3	in	O	O
4	mice	O	O
5	after	O	O
6	subcutaneous	O	O
7	administration	O	O
8	of	O	O
9	morphine	S-Chemical	S-Chemical
10	for	O	O
11	7	O	O
12	consecutive	O	O
13	days	O	O
14	three	O	O
15	times	O	O
16	per	O	O
17	day	O	O
18	.	O	O

0	During	O	O
1	withdrawal	O	O
2	(	O	O
3	days	O	O
4	8	O	O
5	and	O	O
6	9	O	O
7	)	O	O
8	,	O	O
9	these	O	O
10	mice	O	O
11	were	O	O
12	administered	O	O
13	Re	S-Chemical	S-Chemical
14	,	O	O
15	Rg1	S-Chemical	O
16	,	O	O
17	or	O	O
18	Rb1	S-Chemical	O
19	intragastrically	O	O
20	two	O	O
21	times	O	O
22	per	O	O
23	day	O	O
24	.	O	O

0	On	O	O
1	the	O	O
2	test	O	O
3	day	O	O
4	(	O	O
5	day	O	O
6	10	O	O
7	)	O	O
8	,	O	O
9	mice	O	O
10	were	O	O
11	subjected	O	O
12	to	O	O
13	the	O	O
14	thermal	O	O
15	sensitivity	O	O
16	test	O	O
17	and	O	O
18	the	O	O
19	acetic	B-Chemical	S-Chemical
20	acid	E-Chemical	E-Chemical
21	-	O	O
22	induced	O	O
23	writhing	O	O
24	test	O	O
25	.	O	O

0	Re	S-Chemical	O
1	(	O	O
2	300	O	O
3	mg	O	O
4	/	O	O
5	kg	O	O
6	)	O	O
7	inhibited	O	O
8	OIH	S-Disease	S-Chemical
9	in	O	O
10	both	O	O
11	the	O	O
12	thermal	O	O
13	sensitivity	O	O
14	test	O	O
15	and	O	O
16	the	O	O
17	acetic	B-Chemical	S-Chemical
18	acid	E-Chemical	E-Chemical
19	-	O	O
20	induced	O	O
21	writhing	O	O
22	test	O	O
23	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	Rg1	B-Chemical	O
4	and	I-Chemical	O
5	Rb1	I-Chemical	O
6	ginsenosides	E-Chemical	S-Chemical
7	failed	O	O
8	to	O	O
9	prevent	O	O
10	OIH	S-Disease	S-Chemical
11	in	O	O
12	either	O	O
13	test	O	O
14	.	O	O

0	Furthermore	O	O
1	,	O	O
2	Rg1	S-Chemical	S-Chemical
3	showed	O	O
4	a	O	O
5	tendency	O	O
6	to	O	O
7	aggravate	O	O
8	OIH	S-Disease	S-Chemical
9	in	O	O
10	the	O	O
11	acetic	B-Chemical	S-Chemical
12	acid	E-Chemical	O
13	-	O	O
14	induced	O	O
15	writhing	O	O
16	test	O	O
17	.	O	O

0	Our	O	O
1	data	O	O
2	suggested	O	O
3	that	O	O
4	the	O	O
5	ginsenoside	B-Chemical	S-Chemical
6	Re	E-Chemical	S-Chemical
7	,	O	O
8	but	O	O
9	not	O	O
10	Rg1	S-Chemical	S-Disease
11	or	O	O
12	Rb1	S-Chemical	O
13	,	O	O
14	may	O	O
15	contribute	O	O
16	toward	O	O
17	reversal	O	O
18	of	O	O
19	OIH	S-Disease	S-Chemical
20	.	O	O

0	A	O	O
1	comparison	O	O
2	of	O	O
3	severe	O	O
4	hemodynamic	O	O
5	disturbances	O	O
6	between	O	O
7	dexmedetomidine	S-Chemical	S-Chemical
8	and	O	O
9	propofol	S-Chemical	S-Chemical
10	for	O	O
11	sedation	O	O
12	in	O	O
13	neurocritical	O	O
14	care	O	O
15	patients	O	O
16	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	Dexmedetomidine	S-Chemical	S-Chemical
3	and	O	O
4	propofol	S-Chemical	S-Chemical
5	are	O	O
6	commonly	O	O
7	used	O	O
8	sedatives	O	O
9	in	O	O
10	neurocritical	O	O
11	care	O	O
12	as	O	O
13	they	O	O
14	allow	O	O
15	for	O	O
16	frequent	O	O
17	neurologic	O	O
18	examinations	O	O
19	.	O	O

0	The	O	O
1	primary	O	O
2	objective	O	O
3	of	O	O
4	this	O	O
5	study	O	O
6	is	O	O
7	to	O	O
8	compare	O	O
9	the	O	O
10	prevalence	O	O
11	of	O	O
12	severe	O	O
13	hemodynamic	O	O
14	effects	O	O
15	in	O	O
16	neurocritical	O	O
17	care	O	O
18	patients	O	O
19	receiving	O	O
20	dexmedetomidine	S-Chemical	S-Chemical
21	and	O	O
22	propofol	S-Chemical	S-Chemical
23	.	O	O

0	INTERVENTIONS	O	O
1	:	O	O
2	Continuous	O	O
3	sedation	O	O
4	with	O	O
5	dexmedetomidine	S-Chemical	S-Chemical
6	or	O	O
7	propofol	S-Chemical	S-Chemical
8	.	O	O

0	MEASUREMENTS	O	O
1	AND	O	O
2	MAIN	O	O
3	RESULTS	O	O
4	:	O	O
5	A	O	O
6	total	O	O
7	of	O	O
8	342	O	O
9	patients	O	O
10	(	O	O
11	105	O	O
12	dexmedetomidine	S-Chemical	S-Chemical
13	and	O	O
14	237	O	O
15	propofol	S-Chemical	S-Chemical
16	)	O	O
17	were	O	O
18	included	O	O
19	in	O	O
20	the	O	O
21	analysis	O	O
22	,	O	O
23	with	O	O
24	190	O	O
25	matched	O	O
26	(	O	O
27	95	O	O
28	in	O	O
29	each	O	O
30	group	O	O
31	)	O	O
32	by	O	O
33	propensity	O	O
34	score	O	O
35	.	O	O

0	The	O	O
1	primary	O	O
2	outcome	O	O
3	of	O	O
4	this	O	O
5	study	O	O
6	was	O	O
7	a	O	O
8	composite	O	O
9	of	O	O
10	severe	O	O
11	hypotension	S-Disease	S-Disease
12	(	O	O
13	mean	O	O
14	arterial	O	S-Disease
15	pressure	O	O
16	<	O	O
17	60	O	O
18	mm	O	O
19	Hg	O	O
20	)	O	O
21	and	O	O
22	bradycardia	S-Disease	O
23	(	O	O
24	heart	O	S-Disease
25	rate	O	O
26	<	O	O
27	50	O	O
28	beats	O	O
29	/	O	O
30	min	O	O
31	)	O	O
32	during	O	O
33	sedative	O	O
34	infusion	O	O
35	.	O	O

0	When	O	O
1	analyzed	O	O
2	separately	O	O
3	,	O	O
4	no	O	O
5	differences	O	O
6	could	O	O
7	be	O	O
8	found	O	O
9	in	O	O
10	the	O	O
11	prevalence	O	O
12	of	O	O
13	severe	O	O
14	hypotension	S-Disease	S-Disease
15	or	O	O
16	bradycardia	S-Disease	O
17	in	O	O
18	either	O	O
19	the	O	O
20	unmatched	O	O
21	or	O	O
22	matched	O	O
23	cohorts	O	O
24	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Severe	O	O
3	hypotension	S-Disease	S-Disease
4	and	O	O
5	bradycardia	S-Disease	S-Disease
6	occur	O	O
7	at	O	O
8	similar	O	O
9	prevalence	O	O
10	in	O	O
11	neurocritical	O	O
12	care	O	O
13	patients	O	O
14	who	O	O
15	receive	O	O
16	dexmedetomidine	S-Chemical	S-Chemical
17	or	O	O
18	propofol	S-Chemical	S-Chemical
19	.	O	O

0	Providers	O	O
1	should	O	O
2	similarly	O	O
3	consider	O	O
4	the	O	O
5	likelihood	O	O
6	of	O	O
7	hypotension	S-Disease	S-Disease
8	or	O	O
9	bradycardia	S-Disease	S-Disease
10	before	O	O
11	starting	O	O
12	either	O	O
13	sedative	O	O
14	.	O	O

0	Hydroxytyrosol	S-Chemical	S-Chemical
1	ameliorates	O	O
2	oxidative	O	O
3	stress	O	O
4	and	O	O
5	mitochondrial	B-Disease	B-Disease
6	dysfunction	E-Disease	E-Disease
7	in	O	O
8	doxorubicin	S-Chemical	S-Chemical
9	-	O	O
10	induced	O	O
11	cardiotoxicity	S-Disease	S-Disease
12	in	O	O
13	rats	O	O
14	with	O	O
15	breast	B-Disease	B-Disease
16	cancer	E-Disease	E-Disease
17	.	O	O

0	Oxidative	O	O
1	stress	O	O
2	is	O	O
3	involved	O	O
4	in	O	O
5	several	O	O
6	processes	O	O
7	including	O	O
8	cancer	S-Disease	S-Disease
9	,	O	O
10	aging	O	S-Disease
11	and	O	O
12	cardiovascular	B-Disease	B-Disease
13	disease	E-Disease	E-Disease
14	,	O	O
15	and	O	O
16	has	O	O
17	been	O	O
18	shown	O	O
19	to	O	O
20	potentiate	O	O
21	the	O	O
22	therapeutic	O	O
23	effect	O	O
24	of	O	O
25	drugs	O	O
26	such	O	O
27	as	O	O
28	doxorubicin	S-Chemical	S-Chemical
29	.	O	O

0	Doxorubicin	S-Chemical	S-Chemical
1	causes	O	O
2	significant	O	O
3	cardiotoxicity	S-Disease	S-Disease
4	characterized	O	O
5	by	O	O
6	marked	O	O
7	increases	O	O
8	in	O	O
9	oxidative	O	O
10	stress	O	E-Disease
11	and	O	O
12	mitochondrial	B-Disease	B-Disease
13	dysfunction	E-Disease	E-Disease
14	.	O	O

0	Herein	O	O
1	,	O	O
2	we	O	O
3	investigate	O	O
4	whether	O	O
5	doxorubicin	S-Chemical	S-Chemical
6	-	O	O
7	associated	O	O
8	chronic	O	B-Disease
9	cardiac	B-Disease	I-Disease
10	toxicity	E-Disease	E-Disease
11	can	O	O
12	be	O	O
13	ameliorated	O	O
14	with	O	O
15	the	O	O
16	antioxidant	O	O
17	hydroxytyrosol	S-Chemical	S-Chemical
18	in	O	O
19	rats	O	O
20	with	O	O
21	breast	B-Disease	B-Disease
22	cancer	E-Disease	E-Disease
23	.	O	O

0	Thirty	O	O
1	-	O	O
2	six	O	O
3	rats	O	O
4	bearing	O	O
5	breast	B-Disease	O
6	tumors	E-Disease	E-Disease
7	induced	O	O
8	chemically	O	O
9	were	O	O
10	divided	O	O
11	into	O	O
12	4	O	O
13	groups	O	O
14	:	O	O
15	control	O	O
16	,	O	O
17	hydroxytyrosol	S-Chemical	S-Chemical
18	(	O	O
19	0	O	O
20	.	O	O
21	5mg	O	O
22	/	O	O
23	kg	O	O
24	,	O	O
25	5days	O	O
26	/	O	O
27	week	O	O
28	)	O	O
29	,	O	O
30	doxorubicin	S-Chemical	S-Chemical
31	(	O	O
32	1mg	O	O
33	/	O	O
34	kg	O	O
35	/	O	O
36	week	O	O
37	)	O	O
38	,	O	O
39	and	O	O
40	doxorubicin	S-Chemical	S-Chemical
41	plus	O	O
42	hydroxytyrosol	S-Chemical	S-Chemical
43	.	O	O

0	Cardiac	B-Disease	O
1	disturbances	E-Disease	O
2	at	O	O
3	the	O	O
4	cellular	O	O
5	and	O	O
6	mitochondrial	O	O
7	level	O	O
8	,	O	O
9	mitochondrial	O	O
10	electron	O	I-Disease
11	transport	O	O
12	chain	O	O
13	complexes	O	O
14	I	O	O
15	-	O	O
16	IV	O	O
17	and	O	O
18	apoptosis	O	O
19	-	O	O
20	inducing	O	O
21	factor	O	O
22	,	O	O
23	and	O	O
24	oxidative	O	O
25	stress	O	O
26	markers	O	O
27	have	O	O
28	been	O	O
29	analyzed	O	O
30	.	O	O

0	Hydroxytyrosol	S-Chemical	S-Chemical
1	improved	O	O
2	the	O	O
3	cardiac	B-Disease	B-Disease
4	disturbances	E-Disease	E-Disease
5	enhanced	O	O
6	by	O	O
7	doxorubicin	S-Chemical	S-Chemical
8	by	O	O
9	significantly	O	O
10	reducing	O	O
11	the	O	O
12	percentage	O	O
13	of	O	O
14	altered	O	O
15	mitochondria	O	S-Disease
16	and	O	O
17	oxidative	O	O
18	damage	O	O
19	.	O	O

0	These	O	O
1	results	O	O
2	suggest	O	O
3	that	O	O
4	hydroxytyrosol	S-Chemical	S-Chemical
5	improve	O	O
6	the	O	O
7	mitochondrial	O	O
8	electron	O	I-Disease
9	transport	O	O
10	chain	O	O
11	.	O	O

0	This	O	O
1	study	O	O
2	demonstrates	O	O
3	that	O	O
4	hydroxytyrosol	S-Chemical	S-Chemical
5	protect	O	O
6	rat	O	O
7	heart	B-Disease	B-Disease
8	damage	E-Disease	E-Disease
9	provoked	O	O
10	by	O	O
11	doxorubicin	S-Chemical	S-Chemical
12	decreasing	O	O
13	oxidative	O	O
14	damage	O	O
15	and	O	O
16	mitochondrial	O	S-Disease
17	alterations	O	O
18	.	O	O

0	Amiodarone	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	myxoedema	B-Disease	B-Disease
4	coma	E-Disease	S-Disease
5	.	O	O

0	A	O	O
1	62	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	man	O	O
7	was	O	O
8	found	O	O
9	to	O	O
10	have	O	O
11	bradycardia	S-Disease	O
12	,	O	O
13	hypothermia	S-Disease	S-Disease
14	and	O	O
15	respiratory	B-Disease	B-Disease
16	failure	E-Disease	E-Disease
17	3	O	O
18	weeks	O	O
19	after	O	O
20	initiation	O	O
21	of	O	O
22	amiodarone	S-Chemical	S-Chemical
23	therapy	O	O
24	for	O	O
25	atrial	B-Disease	B-Disease
26	fibrillation	E-Disease	E-Disease
27	.	O	O

0	Thyroid	O	S-Chemical
1	-	O	O
2	stimulating	O	O
3	hormone	O	O
4	was	O	O
5	found	O	O
6	to	O	O
7	be	O	O
8	168	O	O
9	uIU	O	O
10	/	O	O
11	mL	O	O
12	(	O	O
13	nl	O	O
14	.	O	O
15	0	O	O
16	.	O	O
17	3	O	O
18	-	O	O
19	5	O	O
20	uIU	O	O
21	/	O	O
22	mL	O	O
23	)	O	O
24	and	O	O
25	free	O	O
26	thyroxine	S-Chemical	S-Chemical
27	(	O	O
28	FT4	O	S-Chemical
29	)	O	O
30	was	O	O
31	<	O	O
32	0	O	O
33	.	O	O
34	2	O	O
35	ng	O	O
36	/	O	O
37	dL	O	O
38	(	O	O
39	nl	O	O
40	.	O	O
41	0	O	O
42	.	O	O
43	8	O	O
44	-	O	O
45	1	O	O
46	.	O	O
47	8	O	O
48	ng	O	O
49	/	O	O
50	dL	O	O
51	)	O	O
52	.	O	O

0	He	O	O
1	received	O	O
2	intravenous	O	O
3	fluids	O	O
4	,	O	O
5	vasopressor	O	O
6	therapy	O	O
7	and	O	O
8	stress	O	O
9	dose	O	O
10	steroids	S-Chemical	S-Chemical
11	;	O	O
12	he	O	O
13	was	O	O
14	intubated	O	O
15	and	O	O
16	admitted	O	O
17	to	O	O
18	the	O	O
19	intensive	O	O
20	care	O	O
21	unit	O	O
22	.	O	O

0	He	O	O
1	received	O	O
2	500	O	O
3	ug	O	O
4	of	O	O
5	intravenous	O	O
6	levothyroxine	S-Chemical	S-Chemical
7	in	O	O
8	the	O	O
9	first	O	O
10	18	O	O
11	h	O	O
12	of	O	O
13	therapy	O	O
14	,	O	O
15	and	O	O
16	150	O	O
17	ug	O	O
18	intravenous	O	O
19	daily	O	O
20	thereafter	O	O
21	.	O	O

0	The	O	O
1	patient	O	O
2	was	O	O
3	maintained	O	O
4	on	O	O
5	levothyroxine	S-Chemical	B-Chemical
6	175	O	E-Chemical
7	(	O	O
8	g	O	O
9	POorally	O	S-Chemical
10	daily	O	O
11	.	O	O

0	The	O	O
1	24	O	O
2	hour	O	O
3	excretion	O	O
4	of	O	O
5	iodine	S-Chemical	S-Chemical
6	was	O	O
7	3657	O	O
8	(	O	O
9	mcg	O	O
10	(	O	O
11	25	O	O
12	-	O	O
13	756	O	O
14	(	O	O
15	mcg	O	O
16	)	O	O
17	.	O	O

0	The	O	O
1	only	O	O
2	two	O	O
3	cases	O	O
4	of	O	O
5	amiodarone	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	myxoedema	B-Disease	B-Disease
9	coma	E-Disease	E-Disease
10	in	O	O
11	the	O	O
12	literature	O	O
13	report	O	O
14	patient	O	O
15	death	O	O
16	despite	O	O
17	supportive	O	O
18	therapy	O	O
19	and	O	O
20	thyroid	O	B-Disease
21	hormone	O	E-Disease
22	replacement	O	E-Disease
23	.	O	O

0	This	O	O
1	case	O	O
2	represents	O	O
3	the	O	O
4	most	O	O
5	thoroughly	O	O
6	investigated	O	O
7	case	O	O
8	of	O	O
9	amiodarone	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	myxoedema	B-Disease	B-Disease
13	coma	E-Disease	E-Disease
14	with	O	O
15	a	O	O
16	history	O	O
17	significant	O	O
18	for	O	O
19	subclinical	O	O
20	thyroid	B-Disease	B-Disease
21	disease	E-Disease	E-Disease
22	.	O	O

0	Use	O	O
1	of	O	O
2	argatroban	S-Chemical	S-Chemical
3	and	O	O
4	catheter	O	S-Disease
5	-	O	O
6	directed	O	O
7	thrombolysis	S-Disease	S-Disease
8	with	O	O
9	alteplase	O	S-Chemical
10	in	O	O
11	an	O	O
12	oncology	O	O
13	patient	O	O
14	with	O	O
15	heparin	S-Chemical	S-Chemical
16	-	O	O
17	induced	O	O
18	thrombocytopenia	S-Disease	S-Disease
19	with	O	O
20	thrombosis	S-Disease	S-Disease
21	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	The	O	O
3	case	O	O
4	of	O	O
5	an	O	O
6	oncology	O	O
7	patient	O	O
8	who	O	O
9	developed	O	O
10	heparin	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	thrombocytopenia	S-Disease	S-Disease
14	with	O	O
15	thrombosis	S-Disease	S-Disease
16	(	O	O
17	HITT	S-Disease	O
18	)	O	O
19	and	O	O
20	was	O	O
21	treated	O	O
22	with	O	O
23	argatroban	S-Chemical	S-Chemical
24	plus	O	O
25	catheter	O	O
26	-	O	O
27	directed	O	O
28	thrombolysis	S-Disease	O
29	(	O	O
30	CDT	O	S-Disease
31	)	O	O
32	with	O	O
33	alteplase	O	S-Disease
34	is	O	O
35	presented	O	O
36	.	O	O

0	SUMMARY	O	O
1	:	O	O
2	A	O	O
3	63	O	O
4	-	O	O
5	year	O	O
6	-	O	O
7	old	O	O
8	Caucasian	O	S-Disease
9	man	O	O
10	with	O	O
11	renal	O	B-Disease
12	amyloidosis	S-Disease	E-Disease
13	undergoing	O	O
14	peripheral	O	O
15	blood	O	I-Disease
16	stem	O	I-Disease
17	cell	O	O
18	collection	O	O
19	for	O	O
20	an	O	O
21	autologous	O	O
22	stem	O	O
23	cell	O	I-Disease
24	transplant	O	O
25	developed	O	O
26	extensive	O	O
27	bilateral	O	O
28	upper	B-Disease	O
29	-	I-Disease	O
30	extremity	I-Disease	O
31	deep	I-Disease	O
32	venous	I-Disease	I-Disease
33	thrombosis	E-Disease	S-Disease
34	(	O	O
35	DVT	S-Disease	S-Disease
36	)	O	O
37	and	O	O
38	pulmonary	B-Disease	S-Disease
39	embolism	E-Disease	O
40	secondary	O	O
41	to	O	O
42	heparin	S-Chemical	S-Chemical
43	-	O	O
44	induced	O	O
45	thrombocytopenia	S-Disease	S-Disease
46	.	O	O

0	A	O	O
1	continuous	O	O
2	i	O	O
3	.	O	O
4	v	O	O
5	.	O	O
6	infusion	O	O
7	of	O	O
8	argatroban	S-Chemical	S-Chemical
9	was	O	O
10	initiated	O	O
11	,	O	O
12	and	O	O
13	the	O	O
14	patient	O	O
15	was	O	O
16	managed	O	O
17	on	O	O
18	the	O	O
19	general	O	O
20	medical	O	O
21	floor	O	O
22	.	O	O

0	After	O	O
1	one	O	O
2	week	O	O
3	of	O	O
4	therapy	O	O
5	,	O	O
6	he	O	O
7	was	O	O
8	transferred	O	O
9	to	O	O
10	the	O	O
11	intensive	O	O
12	care	O	O
13	unit	O	O
14	with	O	O
15	cardiopulmonary	O	O
16	compromise	O	O
17	related	O	O
18	to	O	O
19	superior	B-Disease	B-Disease
20	vena	I-Disease	I-Disease
21	cava	I-Disease	I-Disease
22	(	I-Disease	O
23	SVC	I-Disease	S-Disease
24	)	I-Disease	O
25	syndrome	E-Disease	S-Disease
26	.	O	O

0	A	O	O
1	percutaneous	O	O
2	mechanical	O	O
3	thrombectomy	O	S-Disease
4	and	O	O
5	CDT	O	S-Disease
6	with	O	O
7	alteplase	O	S-Chemical
8	were	O	O
9	attempted	O	O
10	,	O	O
11	but	O	O
12	the	O	O
13	procedure	O	O
14	was	O	O
15	aborted	O	O
16	due	O	O
17	to	O	O
18	epistaxis	S-Disease	O
19	.	O	O

0	The	O	O
1	epistaxis	S-Disease	S-Disease
2	resolved	O	O
3	the	O	O
4	next	O	O
5	day	O	O
6	,	O	O
7	and	O	O
8	the	O	O
9	patient	O	O
10	was	O	O
11	restarted	O	O
12	on	O	O
13	argatroban	S-Chemical	S-Chemical
14	.	O	O

0	Postthrombectomy	O	O
1	continuous	O	O
2	CDT	O	O
3	with	O	O
4	alteplase	O	S-Chemical
5	was	O	O
6	commenced	O	O
7	while	O	O
8	argatroban	S-Chemical	S-Chemical
9	was	O	O
10	withheld	O	O
11	,	O	O
12	and	O	O
13	complete	O	O
14	patency	O	O
15	of	O	O
16	the	O	O
17	SVC	O	S-Disease
18	and	O	O
19	central	O	O
20	veins	O	E-Disease
21	was	O	O
22	achieved	O	O
23	after	O	O
24	three	O	O
25	days	O	O
26	of	O	O
27	therapy	O	O
28	.	O	O

0	Alteplase	O	S-Chemical
1	was	O	O
2	discontinued	O	O
3	,	O	O
4	and	O	O
5	the	O	O
6	patient	O	O
7	was	O	O
8	reinitiated	O	O
9	on	O	O
10	argatroban	S-Chemical	S-Chemical
11	;	O	O
12	ultimately	O	O
13	,	O	O
14	he	O	O
15	was	O	O
16	transitioned	O	O
17	to	O	O
18	warfarin	S-Chemical	S-Chemical
19	for	O	O
20	long	O	O
21	-	O	O
22	term	O	O
23	anticoagulation	O	O
24	.	O	O

0	Although	O	O
1	the	O	O
2	patient	O	O
3	recovered	O	O
4	,	O	O
5	he	O	O
6	experienced	O	O
7	permanent	O	O
8	vision	B-Disease	B-Disease
9	and	I-Disease	O
10	hearing	I-Disease	B-Disease
11	loss	E-Disease	E-Disease
12	,	O	O
13	as	O	O
14	well	O	O
15	as	O	O
16	end	B-Disease	O
17	-	I-Disease	O
18	stage	I-Disease	O
19	renal	I-Disease	B-Disease
20	disease	E-Disease	E-Disease
21	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	A	O	O
3	63	O	O
4	-	O	O
5	year	O	O
6	-	O	O
7	old	O	O
8	man	O	O
9	with	O	O
10	renal	O	B-Disease
11	amyloidosis	S-Disease	E-Disease
12	and	O	O
13	SVC	B-Disease	B-Disease
14	syndrome	E-Disease	E-Disease
15	secondary	O	O
16	to	O	O
17	HITT	S-Disease	S-Disease
18	was	O	O
19	successfully	O	O
20	treated	O	O
21	with	O	O
22	argatroban	S-Chemical	S-Chemical
23	and	O	O
24	CDT	O	O
25	with	O	O
26	alteplase	O	S-Chemical
27	.	O	O

0	Effects	O	O
1	of	O	O
2	dehydroepiandrosterone	S-Chemical	S-Chemical
3	in	O	O
4	amphetamine	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	schizophrenia	S-Disease	S-Disease
8	models	O	O
9	in	O	O
10	mice	O	O
11	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	examine	O	O
4	the	O	O
5	effects	O	O
6	of	O	O
7	dehydroepiandrosterone	S-Chemical	S-Chemical
8	(	O	O
9	DHEA	S-Chemical	S-Chemical
10	)	O	O
11	on	O	O
12	animal	O	O
13	models	O	O
14	of	O	O
15	schizophrenia	S-Disease	S-Disease
16	.	O	O

0	METHODS	O	O
1	:	O	O
2	Seventy	O	O
3	Swiss	O	S-Chemical
4	albino	O	O
5	female	O	O
6	mice	O	O
7	(	O	O
8	25	O	O
9	-	O	O
10	35	O	O
11	g	O	O
12	)	O	O
13	were	O	O
14	divided	O	O
15	into	O	O
16	4	O	O
17	groups	O	O
18	:	O	O
19	amphetamine	S-Chemical	S-Chemical
20	-	O	O
21	free	O	O
22	(	O	O
23	control	O	O
24	)	O	O
25	,	O	O
26	amphetamine	S-Chemical	S-Chemical
27	,	O	O
28	50	O	O
29	,	O	O
30	and	O	O
31	100	O	O
32	mg	O	O
33	/	O	O
34	kg	O	O
35	DHEA	S-Chemical	S-Disease
36	.	O	O

0	The	O	O
1	DHEA	S-Chemical	S-Chemical
2	was	O	O
3	administered	O	O
4	intraperitoneally	O	O
5	(	O	O
6	ip	O	S-Chemical
7	)	O	O
8	for	O	O
9	5	O	O
10	days	O	O
11	.	O	O

0	Amphetamine	S-Chemical	S-Chemical
1	(	O	O
2	3	O	O
3	mg	O	O
4	/	O	O
5	kg	O	O
6	ip	O	O
7	)	O	O
8	induced	O	O
9	hyper	S-Disease	S-Disease
10	locomotion	O	E-Disease
11	,	O	O
12	apomorphine	S-Chemical	S-Chemical
13	(	O	O
14	1	O	O
15	.	O	O
16	5	O	O
17	mg	O	O
18	/	O	O
19	kg	O	O
20	subcutaneously	O	O
21	[	O	O
22	sc	O	O
23	]	O	O
24	)	O	O
25	induced	O	O
26	climbing	O	O
27	,	O	O
28	and	O	O
29	haloperidol	S-Chemical	S-Chemical
30	(	O	O
31	1	O	O
32	.	O	O
33	5	O	O
34	mg	O	O
35	/	O	O
36	kg	O	O
37	sc	O	O
38	)	O	O
39	induced	O	O
40	catalepsy	S-Disease	O
41	tests	O	O
42	were	O	O
43	used	O	O
44	as	O	O
45	animal	O	O
46	models	O	O
47	of	O	O
48	schizophrenia	S-Disease	S-Disease
49	.	O	O

0	Statistical	O	O
1	analysis	O	O
2	was	O	O
3	carried	O	O
4	out	O	O
5	using	O	O
6	Kruskal	O	S-Chemical
7	-	O	O
8	Wallis	O	O
9	test	O	O
10	for	O	O
11	hyper	S-Disease	S-Disease
12	locomotion	O	E-Disease
13	,	O	O
14	and	O	O
15	one	O	O
16	-	O	O
17	way	O	O
18	ANOVA	O	S-Disease
19	for	O	O
20	climbing	O	S-Disease
21	and	O	O
22	catalepsy	S-Disease	S-Disease
23	tests	O	O
24	.	O	O

0	RESULTS	O	O
1	:	O	O
2	In	O	O
3	the	O	O
4	amphetamine	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	locomotion	O	O
8	test	O	O
9	,	O	O
10	there	O	O
11	were	O	O
12	significant	O	O
13	increases	O	O
14	in	O	O
15	all	O	O
16	movements	O	O
17	compared	O	O
18	with	O	O
19	the	O	O
20	amphetamine	S-Chemical	S-Chemical
21	-	O	O
22	free	O	O
23	group	O	O
24	.	O	O

0	Both	O	O
1	DHEA	S-Chemical	S-Chemical
2	50	O	O
3	mg	O	O
4	/	O	O
5	kg	O	O
6	(	O	O
7	p	O	O
8	<	O	O
9	0	O	O
10	.	O	O
11	05	O	O
12	)	O	O
13	,	O	O
14	and	O	O
15	100	O	O
16	mg	O	O
17	/	O	O
18	kg	O	O
19	(	O	O
20	p	O	O
21	<	O	O
22	0	O	O
23	.	O	O
24	01	O	O
25	)	O	O
26	significantly	O	O
27	decreased	O	O
28	all	O	O
29	movements	O	O
30	compared	O	O
31	with	O	O
32	the	O	O
33	amphetamine	S-Chemical	S-Chemical
34	-	O	O
35	induced	O	O
36	locomotion	O	O
37	group	O	O
38	.	O	O

0	There	O	O
1	was	O	O
2	a	O	O
3	significant	O	O
4	difference	O	O
5	between	O	O
6	groups	O	O
7	in	O	O
8	the	O	O
9	haloperidol	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	catalepsy	S-Disease	S-Disease
13	test	O	O
14	(	O	O
15	p	O	O
16	<	O	O
17	0	O	O
18	.	O	O
19	05	O	O
20	)	O	O
21	.	O	O

0	There	O	O
1	was	O	O
2	no	O	O
3	significant	O	O
4	difference	O	O
5	between	O	O
6	groups	O	O
7	in	O	O
8	terms	O	O
9	of	O	O
10	total	O	O
11	climbing	O	O
12	time	O	O
13	in	O	O
14	the	O	O
15	apomorphine	S-Chemical	O
16	-	O	O
17	induced	O	O
18	climbing	O	O
19	test	O	O
20	(	O	O
21	p	O	O
22	>	O	O
23	0	O	O
24	.	O	O
25	05	O	O
26	)	O	O
27	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	We	O	O
3	observed	O	O
4	that	O	O
5	DHEA	S-Chemical	S-Chemical
6	reduced	O	O
7	locomotor	O	B-Disease
8	activity	O	E-Disease
9	and	O	O
10	increased	O	O
11	catalepsy	S-Disease	S-Disease
12	at	O	O
13	both	O	O
14	doses	O	O
15	,	O	O
16	while	O	O
17	it	O	O
18	had	O	O
19	no	O	O
20	effect	O	O
21	on	O	O
22	climbing	O	O
23	behavior	O	O
24	.	O	O

0	We	O	O
1	suggest	O	O
2	that	O	O
3	DHEA	S-Chemical	S-Chemical
4	displays	O	O
5	typical	O	O
6	neuroleptic	O	S-Disease
7	-	O	O
8	like	O	O
9	effects	O	O
10	,	O	O
11	and	O	O
12	may	O	O
13	be	O	O
14	used	O	O
15	in	O	O
16	the	O	O
17	treatment	O	O
18	of	O	O
19	schizophrenia	S-Disease	B-Disease
20	.	O	O

0	Availability	O	O
1	of	O	O
2	human	O	O
3	induced	O	O
4	pluripotent	O	O
5	stem	O	O
6	cell	O	O
7	-	O	O
8	derived	O	O
9	cardiomyocytes	O	S-Disease
10	in	O	O
11	assessment	O	O
12	of	O	O
13	drug	O	O
14	potential	O	O
15	for	O	O
16	QT	B-Disease	O
17	prolongation	E-Disease	O
18	.	O	O

0	Field	O	O
1	potential	O	O
2	duration	O	O
3	(	O	O
4	FPD	O	S-Disease
5	)	O	O
6	in	O	O
7	human	O	O
8	-	O	O
9	induced	O	O
10	pluripotent	O	O
11	stem	O	O
12	cell	O	O
13	-	O	O
14	derived	O	O
15	cardiomyocytes	O	S-Disease
16	(	O	O
17	hiPS	O	O
18	-	O	O
19	CMs	O	S-Disease
20	)	O	O
21	,	O	O
22	which	O	O
23	can	O	O
24	express	O	O
25	QT	O	O
26	interval	O	O
27	in	O	O
28	an	O	O
29	electrocardiogram	O	O
30	,	O	O
31	is	O	O
32	reported	O	O
33	to	O	O
34	be	O	O
35	a	O	O
36	useful	O	O
37	tool	O	O
38	to	O	O
39	predict	O	O
40	K	S-Chemical	O
41	(	O	O
42	+	O	O
43	)	O	O
44	channel	O	O
45	and	O	O
46	Ca	S-Chemical	S-Chemical
47	(	O	O
48	2	O	O
49	+	O	O
50	)	O	O
51	channel	O	O
52	blocker	O	O
53	effects	O	O
54	on	O	O
55	QT	O	O
56	interval	O	O
57	.	O	O

0	However	O	O
1	,	O	O
2	there	O	O
3	is	O	O
4	no	O	O
5	report	O	O
6	showing	O	O
7	that	O	O
8	this	O	O
9	technique	O	O
10	can	O	O
11	be	O	O
12	used	O	O
13	to	O	O
14	predict	O	O
15	multichannel	O	O
16	blocker	O	O
17	potential	O	O
18	for	O	O
19	QT	B-Disease	O
20	prolongation	E-Disease	O
21	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	is	O	O
6	to	O	O
7	show	O	O
8	that	O	O
9	FPD	O	S-Disease
10	from	O	O
11	MEA	O	S-Chemical
12	(	O	O
13	Multielectrode	O	O
14	array	O	O
15	)	O	O
16	of	O	O
17	hiPS	O	S-Disease
18	-	O	O
19	CMs	O	S-Disease
20	can	O	O
21	detect	O	O
22	QT	B-Disease	O
23	prolongation	E-Disease	O
24	induced	O	O
25	by	O	O
26	multichannel	O	O
27	blockers	O	O
28	.	O	O

0	IKr	O	S-Chemical
1	and	O	O
2	IKs	O	S-Chemical
3	blockers	O	O
4	concentration	O	O
5	-	O	O
6	dependently	O	O
7	prolonged	O	O
8	corrected	O	O
9	FPD	O	S-Disease
10	(	O	O
11	FPDc	O	S-Disease
12	)	O	O
13	,	O	O
14	whereas	O	O
15	Ca	S-Chemical	S-Chemical
16	(	O	O
17	2	O	O
18	+	O	O
19	)	O	O
20	channel	O	O
21	blockers	O	O
22	concentration	O	O
23	-	O	O
24	dependently	O	O
25	shortened	O	O
26	FPDc	O	S-Chemical
27	.	O	O

0	Also	O	O
1	,	O	O
2	the	O	O
3	multichannel	O	O
4	blockers	O	O
5	Amiodarone	S-Chemical	S-Chemical
6	,	O	O
7	Paroxetine	S-Chemical	S-Chemical
8	,	O	O
9	Terfenadine	S-Chemical	S-Chemical
10	and	O	O
11	Citalopram	S-Chemical	S-Chemical
12	prolonged	O	O
13	FPDc	O	S-Chemical
14	in	O	O
15	a	O	O
16	concentration	O	O
17	dependent	O	O
18	manner	O	O
19	.	O	O

0	Finally	O	O
1	,	O	O
2	the	O	O
3	IKr	O	S-Chemical
4	blockers	O	O
5	,	O	O
6	Terfenadine	S-Chemical	S-Chemical
7	and	O	O
8	Citalopram	S-Chemical	S-Chemical
9	,	O	O
10	which	O	O
11	are	O	O
12	reported	O	O
13	to	O	O
14	cause	O	O
15	Torsade	B-Disease	B-Chemical
16	de	I-Disease	I-Disease
17	Pointes	E-Disease	E-Disease
18	(	O	O
19	TdP	S-Disease	S-Chemical
20	)	O	O
21	in	O	O
22	clinical	O	O
23	practice	O	O
24	,	O	O
25	produced	O	O
26	early	O	O
27	afterdepolarization	O	O
28	(	O	O
29	EAD	O	S-Disease
30	)	O	O
31	.	O	O

0	This	O	O
1	study	O	O
2	also	O	O
3	shows	O	O
4	that	O	O
5	this	O	O
6	assay	O	O
7	can	O	O
8	help	O	O
9	detect	O	O
10	EAD	O	S-Disease
11	for	O	O
12	drugs	O	O
13	with	O	O
14	TdP	S-Disease	S-Chemical
15	potential	O	O
16	.	O	O

0	Dermal	O	S-Disease
1	developmental	O	O
2	toxicity	S-Disease	E-Disease
3	of	O	O
4	N	O	S-Chemical
5	-	O	I-Chemical
6	phenylimide	O	E-Chemical
7	herbicides	O	O
8	in	O	O
9	rats	O	O
10	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	S	B-Chemical	B-Chemical
3	-	I-Chemical	B-Chemical
4	53482	E-Chemical	E-Chemical
5	and	O	O
6	S	B-Chemical	B-Chemical
7	-	I-Chemical	E-Chemical
8	23121	E-Chemical	E-Chemical
9	are	O	O
10	N	O	S-Chemical
11	-	O	O
12	phenylimide	O	E-Chemical
13	herbicides	O	O
14	and	O	O
15	produced	O	O
16	embryolethality	S-Disease	O
17	,	O	O
18	teratogenicity	S-Disease	S-Disease
19	(	O	O
20	mainly	O	O
21	ventricular	B-Disease	S-Disease
22	septal	I-Disease	I-Disease
23	defects	E-Disease	S-Disease
24	and	O	O
25	wavy	O	O
26	ribs	O	O
27	)	O	O
28	,	O	O
29	and	O	O
30	growth	B-Disease	O
31	retardation	E-Disease	O
32	in	O	O
33	rats	O	O
34	in	O	O
35	conventional	O	O
36	oral	O	O
37	developmental	O	O
38	toxicity	S-Disease	S-Disease
39	studies	O	O
40	.	O	O

0	Our	O	O
1	objective	O	O
2	in	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	investigate	O	O
8	whether	O	O
9	the	O	O
10	compounds	O	O
11	induce	O	O
12	developmental	O	B-Disease
13	toxicity	S-Disease	E-Disease
14	via	O	O
15	the	O	O
16	dermal	O	S-Disease
17	route	O	O
18	,	O	O
19	which	O	O
20	is	O	O
21	more	O	O
22	relevant	O	O
23	to	O	O
24	occupational	O	O
25	exposure	O	O
26	,	O	O
27	hence	O	O
28	better	O	O
29	addressing	O	O
30	human	O	O
31	health	O	O
32	risks	O	O
33	.	O	O

0	METHODS	O	O
1	:	O	O
2	S	B-Chemical	B-Chemical
3	-	I-Chemical	B-Chemical
4	53482	E-Chemical	E-Chemical
5	was	O	O
6	administered	O	O
7	dermally	O	O
8	to	O	O
9	rats	O	O
10	at	O	O
11	30	O	O
12	,	O	O
13	100	O	O
14	,	O	O
15	and	O	O
16	300	O	O
17	mg	O	O
18	/	O	O
19	kg	O	O
20	during	O	O
21	organogenesis	O	S-Disease
22	,	O	O
23	and	O	O
24	S	B-Chemical	B-Chemical
25	-	I-Chemical	B-Chemical
26	23121	E-Chemical	E-Chemical
27	was	O	O
28	administered	O	O
29	at	O	O
30	200	O	O
31	,	O	O
32	400	O	O
33	,	O	O
34	and	O	O
35	800	O	O
36	mg	O	O
37	/	O	O
38	kg	O	O
39	(	O	O
40	the	O	O
41	maximum	O	O
42	applicable	O	O
43	dose	O	O
44	level	O	O
45	)	O	O
46	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Dermal	O	S-Disease
3	exposure	O	O
4	of	O	O
5	rats	O	O
6	to	O	O
7	S	B-Chemical	B-Chemical
8	-	I-Chemical	I-Chemical
9	53482	E-Chemical	E-Chemical
10	at	O	O
11	300	O	O
12	mg	O	O
13	/	O	O
14	kg	O	O
15	produced	O	O
16	patterns	O	O
17	of	O	O
18	developmental	O	B-Disease
19	toxicity	S-Disease	E-Disease
20	similar	O	O
21	to	O	O
22	those	O	O
23	resulting	O	O
24	from	O	O
25	oral	O	O
26	exposure	O	O
27	.	O	O

0	Toxicity	S-Disease	O
1	included	O	O
2	embryolethality	S-Disease	O
3	,	O	O
4	teratogenicity	S-Disease	S-Disease
5	,	O	O
6	and	O	O
7	growth	B-Disease	B-Disease
8	retardation	E-Disease	E-Disease
9	.	O	O

0	Dermal	O	O
1	administration	O	O
2	of	O	O
3	S	B-Chemical	B-Chemical
4	-	I-Chemical	I-Chemical
5	23121	E-Chemical	E-Chemical
6	at	O	O
7	800	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	resulted	O	O
12	in	O	O
13	an	O	O
14	increased	O	O
15	incidence	O	O
16	of	O	O
17	embryonic	B-Disease	B-Disease
18	death	E-Disease	E-Disease
19	and	O	O
20	ventricular	B-Disease	B-Disease
21	septal	I-Disease	I-Disease
22	defect	E-Disease	E-Disease
23	,	O	O
24	but	O	O
25	retarded	O	O
26	fetal	O	S-Disease
27	growth	O	S-Disease
28	was	O	O
29	not	O	O
30	observed	O	O
31	as	O	O
32	it	O	O
33	was	O	O
34	following	O	O
35	oral	O	O
36	exposure	O	O
37	to	O	O
38	S	B-Chemical	B-Chemical
39	-	I-Chemical	I-Chemical
40	23121	E-Chemical	E-Chemical
41	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Based	O	O
3	on	O	O
4	the	O	O
5	results	O	O
6	,	O	O
7	S	B-Chemical	B-Chemical
8	-	I-Chemical	I-Chemical
9	53482	E-Chemical	E-Chemical
10	and	O	O
11	S	B-Chemical	S-Chemical
12	-	I-Chemical	B-Chemical
13	23121	E-Chemical	E-Chemical
14	were	O	O
15	teratogenic	S-Disease	O
16	when	O	O
17	administered	O	O
18	dermally	O	S-Disease
19	to	O	O
20	pregnant	O	O
21	rats	O	O
22	as	O	O
23	were	O	O
24	the	O	O
25	compounds	O	O
26	administered	O	O
27	orally	O	O
28	.	O	O

0	Rates	O	O
1	of	O	O
2	Renal	B-Disease	B-Disease
3	Toxicity	E-Disease	E-Disease
4	in	O	O
5	Cancer	S-Disease	S-Disease
6	Patients	O	O
7	Receiving	O	O
8	Cisplatin	S-Chemical	S-Chemical
9	With	O	O
10	and	O	O
11	Without	O	O
12	Mannitol	S-Chemical	S-Chemical
13	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Cisplatin	S-Chemical	S-Chemical
3	is	O	O
4	a	O	O
5	widely	O	O
6	used	O	O
7	antineoplastic	O	O
8	.	O	O

0	One	O	O
1	of	O	O
2	the	O	O
3	major	O	O
4	complications	O	O
5	of	O	O
6	cisplatin	S-Chemical	S-Chemical
7	use	O	O
8	is	O	O
9	dose	O	O
10	-	O	O
11	limiting	O	O
12	nephrotoxicity	S-Disease	S-Disease
13	.	O	O

0	There	O	O
1	are	O	O
2	many	O	O
3	strategies	O	O
4	to	O	O
5	prevent	O	O
6	this	O	O
7	toxicity	S-Disease	S-Disease
8	,	O	O
9	including	O	O
10	the	O	O
11	use	O	O
12	of	O	O
13	mannitol	S-Chemical	S-Chemical
14	as	O	O
15	a	O	O
16	nephroprotectant	O	S-Disease
17	in	O	O
18	combination	O	O
19	with	O	O
20	hydration	O	S-Disease
21	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	We	O	O
3	aimed	O	O
4	to	O	O
5	evaluate	O	O
6	the	O	O
7	rates	O	O
8	of	O	O
9	cisplatin	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	nephrotoxicity	S-Disease	S-Disease
13	in	O	O
14	cancer	S-Disease	S-Disease
15	patients	O	O
16	receiving	O	O
17	single	O	O
18	-	O	O
19	agent	O	O
20	cisplatin	S-Chemical	S-Chemical
21	with	O	O
22	and	O	O
23	without	O	O
24	mannitol	S-Chemical	S-Chemical
25	.	O	O

0	METHODS	O	O
1	:	O	O
2	This	O	O
3	single	O	O
4	-	O	O
5	center	O	O
6	retrospective	O	O
7	analysis	O	O
8	was	O	O
9	a	O	O
10	quasi	O	O
11	experiment	O	O
12	created	O	O
13	by	O	O
14	the	O	O
15	national	O	O
16	mannitol	S-Chemical	S-Chemical
17	shortage	O	O
18	.	O	O

0	Data	O	O
1	were	O	O
2	collected	O	O
3	on	O	O
4	adult	O	O
5	cancer	S-Disease	S-Disease
6	patients	O	O
7	receiving	O	O
8	single	O	O
9	-	O	O
10	agent	O	O
11	cisplatin	S-Chemical	S-Chemical
12	as	O	O
13	an	O	O
14	outpatient	O	O
15	from	O	O
16	January	O	O
17	2011	O	O
18	to	O	O
19	September	O	O
20	2012	O	O
21	.	O	O

0	The	O	O
1	primary	O	O
2	outcome	O	O
3	was	O	O
4	acute	B-Disease	B-Disease
5	kidney	I-Disease	I-Disease
6	injury	E-Disease	E-Disease
7	(	O	O
8	AKI	S-Disease	S-Disease
9	)	O	O
10	.	O	O

0	RESULTS	O	O
1	:	O	O
2	We	O	O
3	evaluated	O	O
4	143	O	O
5	patients	O	O
6	who	O	O
7	received	O	O
8	single	O	O
9	-	O	O
10	agent	O	O
11	cisplatin	S-Chemical	S-Chemical
12	;	O	O
13	97	O	O
14	.	O	O
15	2	O	O
16	%	O	O
17	of	O	O
18	patients	O	O
19	had	O	O
20	head	B-Disease	B-Disease
21	and	I-Disease	O
22	neck	I-Disease	B-Disease
23	cancer	E-Disease	E-Disease
24	as	O	O
25	their	O	O
26	primary	O	O
27	malignancy	S-Disease	O
28	.	O	O

0	Patients	O	O
1	who	O	O
2	did	O	O
3	not	O	O
4	receive	O	O
5	mannitol	S-Chemical	S-Chemical
6	were	O	O
7	more	O	O
8	likely	O	O
9	to	O	O
10	develop	O	O
11	nephrotoxicity	S-Disease	S-Disease
12	:	O	O
13	odds	O	O
14	ratio	O	O
15	[	O	O
16	OR	O	O
17	]	O	O
18	=	O	O
19	2	O	O
20	.	O	O
21	646	O	O
22	(	O	O
23	95	O	O
24	%	O	O
25	CI	O	S-Chemical
26	=	O	O
27	1	O	O
28	.	O	O
29	008	O	O
30	,	O	O
31	6	O	O
32	.	O	O
33	944	O	O
34	;	O	O
35	P	O	S-Disease
36	=	O	O
37	0	O	O
38	.	O	O
39	048	O	O
40	)	O	O
41	.	O	O

0	Patients	O	O
1	who	O	O
2	received	O	O
3	the	O	O
4	100	O	O
5	mg	O	O
6	/	O	O
7	m	O	O
8	(	O	O
9	2	O	O
10	)	O	O
11	dosing	O	O
12	and	O	O
13	patients	O	O
14	who	O	O
15	had	O	O
16	a	O	O
17	history	O	O
18	of	O	O
19	hypertension	S-Disease	S-Disease
20	also	O	O
21	had	O	O
22	a	O	O
23	higher	O	O
24	likelihood	O	O
25	of	O	O
26	developing	O	O
27	nephrotoxicity	S-Disease	S-Disease
28	:	O	O
29	OR	O	S-Disease
30	=	O	O
31	11	O	O
32	.	O	O
33	494	O	O
34	(	O	O
35	95	O	O
36	%	O	O
37	CI	O	O
38	=	O	O
39	4	O	O
40	.	O	O
41	149	O	O
42	,	O	O
43	32	O	O
44	.	O	O
45	258	O	O
46	;	O	O
47	P	O	O
48	<	O	O
49	0	O	O
50	.	O	O
51	0001	O	O
52	)	O	O
53	and	O	O
54	OR	O	S-Disease
55	=	O	O
56	3	O	O
57	.	O	O
58	219	O	O
59	(	O	O
60	95	O	O
61	%	O	O
62	CI	O	S-Disease
63	=	O	O
64	1	O	O
65	.	O	O
66	228	O	O
67	,	O	O
68	8	O	O
69	.	O	O
70	439	O	O
71	;	O	O
72	P	O	S-Chemical
73	=	O	O
74	0	O	O
75	.	O	O
76	017	O	O
77	)	O	O
78	,	O	O
79	respectively	O	O
80	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	When	O	O
3	limited	O	O
4	quantities	O	O
5	of	O	O
6	mannitol	S-Chemical	S-Chemical
7	are	O	O
8	available	O	O
9	,	O	O
10	it	O	O
11	should	O	O
12	preferentially	O	O
13	be	O	O
14	given	O	O
15	to	O	O
16	patients	O	O
17	at	O	O
18	particularly	O	O
19	high	O	O
20	risk	O	O
21	of	O	O
22	nephrotoxicity	S-Disease	S-Disease
23	.	O	O

0	Our	O	O
1	analysis	O	O
2	suggests	O	O
3	that	O	O
4	those	O	O
5	patients	O	O
6	receiving	O	O
7	the	O	O
8	dosing	O	O
9	schedule	O	O
10	of	O	O
11	100	O	O
12	mg	O	O
13	/	O	O
14	m	O	O
15	(	O	O
16	2	O	O
17	)	O	O
18	cisplatin	S-Chemical	S-Chemical
19	every	O	O
20	3	O	O
21	weeks	O	O
22	and	O	O
23	those	O	O
24	with	O	O
25	hypertension	S-Disease	S-Disease
26	are	O	O
27	at	O	O
28	the	O	O
29	greatest	O	O
30	risk	O	O
31	of	O	O
32	nephrotoxicity	S-Disease	S-Disease
33	and	O	O
34	would	O	O
35	benefit	O	O
36	from	O	O
37	the	O	O
38	addition	O	O
39	of	O	O
40	mannitol	S-Chemical	S-Chemical
41	.	O	O

0	Metformin	S-Chemical	S-Chemical
1	protects	O	O
2	against	O	O
3	seizures	S-Disease	S-Disease
4	,	O	O
5	learning	B-Disease	O
6	and	I-Disease	O
7	memory	I-Disease	O
8	impairments	E-Disease	O
9	and	O	O
10	oxidative	O	O
11	damage	O	O
12	induced	O	O
13	by	O	O
14	pentylenetetrazole	S-Chemical	S-Chemical
15	-	O	O
16	induced	O	O
17	kindling	O	O
18	in	O	O
19	mice	O	O
20	.	O	O

0	Cognitive	B-Disease	O
1	impairment	E-Disease	O
2	,	O	O
3	the	O	O
4	most	O	O
5	common	O	O
6	and	O	O
7	severe	O	O
8	comorbidity	O	O
9	of	O	O
10	epilepsy	S-Disease	S-Disease
11	,	O	O
12	greatly	O	O
13	diminishes	O	O
14	the	O	O
15	quality	O	O
16	of	O	O
17	life	O	O
18	.	O	O

0	However	O	O
1	,	O	O
2	current	O	O
3	therapeutic	O	O
4	interventions	O	O
5	for	O	O
6	epilepsy	S-Disease	S-Disease
7	can	O	O
8	also	O	O
9	cause	O	O
10	untoward	O	O
11	cognitive	O	S-Disease
12	effects	O	O
13	.	O	O

0	Thus	O	O
1	,	O	O
2	there	O	O
3	is	O	O
4	an	O	O
5	urgent	O	O
6	need	O	O
7	for	O	O
8	new	O	O
9	kinds	O	O
10	of	O	O
11	agents	O	O
12	targeting	O	O
13	both	O	O
14	seizures	S-Disease	S-Disease
15	and	O	O
16	cognition	B-Disease	B-Disease
17	deficits	E-Disease	E-Disease
18	.	O	O

0	Oxidative	O	O
1	stress	O	O
2	is	O	O
3	considered	O	O
4	to	O	O
5	play	O	O
6	an	O	O
7	important	O	O
8	role	O	O
9	in	O	O
10	epileptogenesis	O	O
11	and	O	O
12	cognitive	B-Disease	B-Disease
13	deficits	E-Disease	E-Disease
14	,	O	O
15	and	O	O
16	antioxidants	O	O
17	have	O	O
18	a	O	O
19	putative	O	O
20	antiepileptic	O	O
21	potential	O	O
22	.	O	O

0	Metformin	S-Chemical	S-Chemical
1	,	O	O
2	the	O	O
3	most	O	O
4	commonly	O	O
5	prescribed	O	O
6	antidiabetic	O	O
7	oral	O	O
8	drug	O	O
9	,	O	O
10	has	O	O
11	antioxidant	O	O
12	properties	O	O
13	.	O	O

0	This	O	O
1	study	O	O
2	was	O	O
3	designed	O	O
4	to	O	O
5	evaluate	O	O
6	the	O	O
7	ameliorative	O	O
8	effects	O	O
9	of	O	O
10	metformin	S-Chemical	S-Chemical
11	on	O	O
12	seizures	S-Disease	S-Disease
13	,	O	O
14	cognitive	B-Disease	B-Disease
15	impairment	E-Disease	E-Disease
16	and	O	O
17	brain	O	O
18	oxidative	O	O
19	stress	O	O
20	markers	O	O
21	observed	O	O
22	in	O	O
23	pentylenetetrazole	S-Chemical	S-Chemical
24	-	O	O
25	induced	O	O
26	kindling	O	O
27	animals	O	O
28	.	O	O

0	Male	O	O
1	C57BL	O	B-Chemical
2	/	O	O
3	6	O	O
4	mice	O	O
5	were	O	O
6	administered	O	O
7	with	O	O
8	subconvulsive	O	O
9	dose	O	O
10	of	O	O
11	pentylenetetrazole	S-Chemical	S-Chemical
12	(	O	O
13	37	O	O
14	mg	O	O
15	/	O	O
16	kg	O	O
17	,	O	O
18	i	O	O
19	.	O	O
20	p	O	O
21	.	O	O
22	)	O	O
23	every	O	O
24	other	O	O
25	day	O	O
26	for	O	O
27	14	O	O
28	injections	O	O
29	.	O	O

0	Metformin	S-Chemical	S-Chemical
1	was	O	O
2	injected	O	O
3	intraperitoneally	O	O
4	in	O	O
5	dose	O	O
6	of	O	O
7	200mg	O	O
8	/	O	O
9	kg	O	O
10	along	O	O
11	with	O	O
12	alternate	O	O
13	-	O	O
14	day	O	O
15	PTZ	S-Chemical	S-Chemical
16	.	O	O

0	We	O	O
1	found	O	O
2	that	O	O
3	metformin	S-Chemical	S-Chemical
4	suppressed	O	O
5	the	O	O
6	progression	O	O
7	of	O	O
8	kindling	O	O
9	,	O	O
10	ameliorated	O	O
11	the	O	O
12	cognitive	B-Disease	B-Disease
13	impairment	E-Disease	E-Disease
14	and	O	O
15	decreased	O	O
16	brain	O	B-Disease
17	oxidative	O	O
18	stress	O	E-Disease
19	.	O	O

0	Thus	O	O
1	the	O	O
2	present	O	O
3	study	O	O
4	concluded	O	O
5	that	O	O
6	metformin	S-Chemical	S-Chemical
7	may	O	O
8	be	O	O
9	a	O	O
10	potential	O	O
11	agent	O	O
12	for	O	O
13	the	O	O
14	treatment	O	O
15	of	O	O
16	epilepsy	S-Disease	S-Disease
17	as	O	O
18	well	O	O
19	as	O	O
20	a	O	O
21	protective	O	O
22	medicine	O	O
23	against	O	O
24	cognitive	B-Disease	B-Disease
25	impairment	E-Disease	E-Disease
26	induced	O	O
27	by	O	O
28	seizures	S-Disease	S-Disease
29	.	O	O

0	P53	O	S-Chemical
1	inhibition	O	O
2	exacerbates	O	O
3	late	O	O
4	-	O	O
5	stage	O	O
6	anthracycline	S-Chemical	S-Chemical
7	cardiotoxicity	S-Disease	S-Disease
8	.	O	O

0	AIMS	O	O
1	:	O	O
2	Doxorubicin	S-Chemical	S-Chemical
3	(	O	O
4	DOX	S-Chemical	S-Chemical
5	)	O	O
6	is	O	O
7	an	O	O
8	effective	O	O
9	anti	O	O
10	-	O	O
11	cancer	S-Disease	S-Disease
12	therapeutic	O	O
13	,	O	O
14	but	O	O
15	is	O	O
16	associated	O	O
17	with	O	O
18	both	O	O
19	acute	O	O
20	and	O	O
21	late	O	O
22	-	O	O
23	stage	O	O
24	cardiotoxicity	S-Disease	S-Disease
25	.	O	O

0	Children	O	O
1	are	O	O
2	particularly	O	O
3	sensitive	O	O
4	to	O	O
5	DOX	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	heart	B-Disease	B-Disease
9	failure	E-Disease	E-Disease
10	.	O	O

0	Here	O	O
1	,	O	O
2	the	O	O
3	impact	O	O
4	of	O	O
5	p53	O	S-Chemical
6	inhibition	O	O
7	on	O	O
8	acute	O	O
9	vs	O	O
10	.	O	O
11	late	O	O
12	-	O	O
13	stage	O	O
14	DOX	S-Chemical	S-Chemical
15	cardiotoxicity	S-Disease	E-Disease
16	was	O	O
17	examined	O	O
18	in	O	O
19	a	O	O
20	juvenile	O	O
21	model	O	O
22	.	O	O

0	METHODS	O	O
1	AND	O	O
2	RESULTS	O	O
3	:	O	O
4	Two	O	O
5	-	O	O
6	week	O	O
7	-	O	O
8	old	O	O
9	MHC	O	B-Chemical
10	-	O	I-Disease
11	CB7	O	E-Chemical
12	mice	O	O
13	(	O	O
14	which	O	O
15	express	O	O
16	dominant	O	O
17	-	O	O
18	interfering	O	O
19	p53	O	S-Disease
20	in	O	O
21	cardiomyocytes	O	S-Disease
22	)	O	O
23	and	O	O
24	their	O	O
25	non	O	O
26	-	O	O
27	transgenic	O	O
28	(	O	O
29	NON	O	S-Chemical
30	-	O	O
31	TXG	O	O
32	)	O	O
33	littermates	O	O
34	received	O	O
35	weekly	O	O
36	DOX	S-Chemical	S-Disease
37	injections	O	O
38	for	O	O
39	5	O	O
40	weeks	O	O
41	(	O	O
42	25	O	O
43	mg	O	O
44	/	O	O
45	kg	O	O
46	cumulative	O	O
47	dose	O	O
48	)	O	O
49	.	O	O

0	One	O	O
1	week	O	O
2	after	O	O
3	the	O	O
4	last	O	O
5	DOX	S-Chemical	S-Chemical
6	treatment	O	O
7	(	O	O
8	acute	O	O
9	stage	O	O
10	)	O	O
11	,	O	O
12	MHC	O	B-Chemical
13	-	O	I-Disease
14	CB7	O	E-Chemical
15	mice	O	O
16	exhibited	O	O
17	improved	O	O
18	cardiac	O	B-Disease
19	function	O	E-Disease
20	and	O	O
21	lower	O	O
22	levels	O	O
23	of	O	O
24	cardiomyocyte	O	B-Disease
25	apoptosis	O	E-Disease
26	when	O	O
27	compared	O	O
28	with	O	O
29	the	O	O
30	NON	O	S-Chemical
31	-	O	O
32	TXG	O	E-Chemical
33	mice	O	O
34	.	O	O

0	Surprisingly	O	O
1	,	O	O
2	by	O	O
3	13	O	O
4	weeks	O	O
5	following	O	O
6	the	O	O
7	last	O	O
8	DOX	S-Chemical	S-Chemical
9	treatment	O	O
10	(	O	O
11	late	O	O
12	stage	O	O
13	)	O	O
14	,	O	O
15	MHC	O	B-Chemical
16	-	O	I-Disease
17	CB7	O	E-Chemical
18	exhibited	O	O
19	a	O	O
20	progressive	O	O
21	decrease	O	B-Disease
22	in	O	I-Disease
23	cardiac	O	B-Disease
24	function	O	E-Disease
25	and	O	O
26	higher	O	O
27	rates	O	O
28	of	O	O
29	cardiomyocyte	O	B-Disease
30	apoptosis	O	E-Disease
31	when	O	O
32	compared	O	O
33	with	O	O
34	NON	O	S-Chemical
35	-	O	E-Chemical
36	TXG	O	E-Chemical
37	mice	O	O
38	.	O	O

0	p53	O	O
1	inhibition	O	O
2	blocked	O	O
3	transient	O	O
4	DOX	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	STAT3	O	S-Disease
8	activation	O	O
9	in	O	O
10	MHC	O	B-Disease
11	-	O	I-Disease
12	CB7	O	E-Chemical
13	mice	O	O
14	,	O	O
15	which	O	O
16	was	O	O
17	associated	O	O
18	with	O	O
19	enhanced	O	O
20	induction	O	O
21	of	O	O
22	the	O	O
23	DNA	O	O
24	repair	O	O
25	proteins	O	O
26	Ku70	O	B-Chemical
27	and	O	O
28	Ku80	O	B-Chemical
29	.	O	O

0	Mice	O	O
1	with	O	O
2	cardiomyocyte	O	S-Disease
3	-	O	O
4	restricted	O	O
5	deletion	O	O
6	of	O	O
7	STAT3	O	S-Chemical
8	exhibited	O	O
9	worse	O	O
10	cardiac	O	B-Disease
11	function	O	E-Disease
12	,	O	O
13	higher	O	O
14	levels	O	O
15	of	O	O
16	cardiomyocyte	O	B-Disease
17	apoptosis	O	E-Disease
18	,	O	O
19	and	O	O
20	a	O	O
21	greater	O	O
22	induction	O	O
23	of	O	O
24	Ku70	O	B-Chemical
25	and	O	O
26	Ku80	O	B-Chemical
27	in	O	O
28	response	O	O
29	to	O	O
30	DOX	S-Chemical	S-Chemical
31	treatment	O	O
32	during	O	O
33	the	O	O
34	acute	O	O
35	stage	O	O
36	when	O	O
37	compared	O	O
38	with	O	O
39	control	O	O
40	animals	O	O
41	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	These	O	O
3	data	O	O
4	support	O	O
5	a	O	O
6	model	O	O
7	wherein	O	O
8	a	O	O
9	p53	O	O
10	-	O	O
11	dependent	O	O
12	cardioprotective	O	O
13	pathway	O	O
14	,	O	O
15	mediated	O	O
16	via	O	O
17	STAT3	O	S-Disease
18	activation	O	O
19	,	O	O
20	mitigates	O	O
21	DOX	S-Chemical	S-Chemical
22	-	O	O
23	induced	O	O
24	myocardial	O	B-Disease
25	stress	O	E-Disease
26	during	O	O
27	drug	O	O
28	delivery	O	O
29	.	O	O

0	Furthermore	O	O
1	,	O	O
2	these	O	O
3	data	O	O
4	suggest	O	O
5	an	O	O
6	explanation	O	O
7	as	O	O
8	to	O	O
9	how	O	O
10	p53	O	B-Chemical
11	inhibition	O	O
12	can	O	O
13	result	O	O
14	in	O	O
15	cardioprotection	O	S-Disease
16	during	O	O
17	drug	O	O
18	treatment	O	O
19	and	O	O
20	,	O	O
21	paradoxically	O	O
22	,	O	O
23	enhanced	O	O
24	cardiotoxicity	S-Disease	S-Disease
25	long	O	O
26	after	O	O
27	the	O	O
28	cessation	O	O
29	of	O	O
30	drug	O	O
31	treatment	O	O
32	.	O	O

0	Metronidazole	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	encephalopathy	S-Disease	S-Disease
4	:	O	O
5	an	O	O
6	uncommon	O	O
7	scenario	O	O
8	.	O	O

0	Metronidazole	S-Chemical	S-Chemical
1	can	O	O
2	produce	O	O
3	neurological	O	O
4	complications	O	O
5	although	O	O
6	it	O	O
7	is	O	O
8	not	O	O
9	a	O	O
10	common	O	O
11	scenario	O	O
12	.	O	O

0	We	O	O
1	present	O	O
2	a	O	O
3	case	O	O
4	where	O	O
5	a	O	O
6	patient	O	O
7	developed	O	O
8	features	O	O
9	of	O	O
10	encephalopathy	S-Disease	S-Disease
11	following	O	O
12	prolonged	O	O
13	metronidazole	S-Chemical	S-Disease
14	intake	O	S-Disease
15	.	O	O

0	The	O	O
1	diagnosis	O	O
2	of	O	O
3	metronidazole	S-Chemical	S-Chemical
4	toxicity	S-Disease	S-Disease
5	was	O	O
6	made	O	O
7	by	O	O
8	the	O	O
9	MRI	O	S-Disease
10	findings	O	O
11	and	O	O
12	supported	O	O
13	clinically	O	O
14	.	O	O

0	Aconitine	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	Ca2	S-Chemical	B-Chemical
4	+	O	E-Chemical
5	overload	O	O
6	causes	O	O
7	arrhythmia	S-Disease	S-Disease
8	and	O	O
9	triggers	O	O
10	apoptosis	O	S-Disease
11	through	O	O
12	p38	O	B-Disease
13	MAPK	O	E-Chemical
14	signaling	O	O
15	pathway	O	O
16	in	O	O
17	rats	O	O
18	.	O	O

0	Aconitine	S-Chemical	S-Chemical
1	is	O	O
2	a	O	O
3	major	O	O
4	bioactive	O	O
5	diterpenoid	O	S-Chemical
6	alkaloid	O	O
7	with	O	O
8	high	O	O
9	content	O	O
10	derived	O	O
11	from	O	O
12	herbal	O	O
13	aconitum	O	S-Disease
14	plants	O	O
15	.	O	O

0	Emerging	O	O
1	evidence	O	O
2	indicates	O	O
3	that	O	O
4	voltage	O	O
5	-	O	O
6	dependent	O	O
7	Na	S-Chemical	S-Chemical
8	(	O	O
9	+	O	O
10	)	O	O
11	channels	O	O
12	have	O	O
13	pivotal	O	O
14	roles	O	O
15	in	O	O
16	the	O	O
17	cardiotoxicity	S-Disease	S-Disease
18	of	O	O
19	aconitine	S-Chemical	S-Chemical
20	.	O	O

0	However	O	O
1	,	O	O
2	no	O	O
3	reports	O	O
4	are	O	O
5	available	O	O
6	on	O	O
7	the	O	O
8	role	O	O
9	of	O	O
10	Ca	S-Chemical	S-Chemical
11	(	O	O
12	2	O	O
13	+	O	O
14	)	O	O
15	in	O	O
16	aconitine	S-Chemical	B-Disease
17	poisoning	S-Disease	E-Disease
18	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	,	O	O
4	we	O	O
5	explored	O	O
6	the	O	O
7	importance	O	O
8	of	O	O
9	pathological	O	O
10	Ca	S-Chemical	S-Chemical
11	(	O	O
12	2	O	O
13	+	O	O
14	)	O	O
15	signaling	O	O
16	in	O	O
17	aconitine	S-Chemical	B-Disease
18	poisoning	S-Disease	E-Disease
19	in	O	O
20	vitro	O	O
21	and	O	O
22	in	O	O
23	vivo	O	O
24	.	O	O

0	We	O	O
1	found	O	O
2	that	O	O
3	Ca	S-Chemical	S-Chemical
4	(	O	O
5	2	O	O
6	+	O	O
7	)	O	O
8	overload	O	O
9	lead	O	O
10	to	O	O
11	accelerated	O	O
12	beating	O	O
13	rhythm	O	O
14	in	O	O
15	adult	O	O
16	rat	O	O
17	ventricular	O	O
18	myocytes	O	E-Disease
19	and	O	O
20	caused	O	O
21	arrhythmia	S-Disease	O
22	in	O	O
23	conscious	O	O
24	freely	O	O
25	moving	O	O
26	rats	O	O
27	.	O	O

0	To	O	O
1	investigate	O	O
2	effects	O	O
3	of	O	O
4	aconitine	S-Chemical	S-Chemical
5	on	O	O
6	myocardial	B-Disease	B-Disease
7	injury	E-Disease	E-Disease
8	,	O	O
9	we	O	O
10	performed	O	O
11	cytotoxicity	S-Disease	S-Disease
12	assay	O	O
13	in	O	O
14	neonatal	O	O
15	rat	O	O
16	ventricular	O	B-Disease
17	myocytes	O	E-Disease
18	(	O	O
19	NRVMs	O	O
20	)	O	O
21	,	O	O
22	as	O	O
23	well	O	O
24	as	O	O
25	measured	O	O
26	lactate	S-Chemical	O
27	dehydrogenase	O	O
28	level	O	O
29	in	O	O
30	the	O	O
31	culture	O	O
32	medium	O	O
33	of	O	O
34	NRVMs	O	O
35	and	O	O
36	activities	O	O
37	of	O	O
38	serum	O	O
39	cardiac	O	B-Disease
40	enzymes	O	E-Disease
41	in	O	O
42	rats	O	O
43	.	O	O

0	The	O	O
1	results	O	O
2	showed	O	O
3	that	O	O
4	aconitine	S-Chemical	S-Chemical
5	resulted	O	O
6	in	O	O
7	myocardial	B-Disease	B-Disease
8	injury	E-Disease	E-Disease
9	and	O	O
10	reduced	O	O
11	NRVMs	O	S-Disease
12	viability	O	O
13	dose	O	O
14	-	O	O
15	dependently	O	O
16	.	O	O

0	To	O	O
1	confirm	O	O
2	the	O	O
3	pro	O	O
4	-	O	O
5	apoptotic	O	O
6	effects	O	O
7	,	O	O
8	we	O	O
9	performed	O	O
10	flow	O	O
11	cytometric	O	O
12	detection	O	O
13	,	O	O
14	cardiac	O	B-Disease
15	histology	O	E-Disease
16	,	O	O
17	transmission	O	O
18	electron	O	O
19	microscopy	O	O
20	and	O	O
21	terminal	O	O
22	deoxynucleotidyl	O	O
23	transferase	O	O
24	-	O	O
25	mediated	O	O
26	dUTP	S-Chemical	O
27	-	O	O
28	biotin	S-Chemical	O
29	nick	O	O
30	end	O	O
31	labeling	O	O
32	assay	O	O
33	.	O	O

0	The	O	O
1	results	O	O
2	showed	O	O
3	that	O	O
4	aconitine	S-Chemical	S-Chemical
5	stimulated	O	O
6	apoptosis	O	S-Disease
7	time	O	O
8	-	O	O
9	dependently	O	O
10	.	O	O

0	The	O	O
1	expression	O	O
2	analysis	O	O
3	of	O	O
4	Ca	S-Chemical	S-Chemical
5	(	O	O
6	2	O	O
7	+	O	O
8	)	O	O
9	handling	O	O
10	proteins	O	O
11	demonstrated	O	O
12	that	O	O
13	aconitine	S-Chemical	S-Chemical
14	promoted	O	O
15	Ca	S-Chemical	S-Chemical
16	(	O	O
17	2	O	O
18	+	O	O
19	)	O	O
20	overload	O	O
21	through	O	O
22	the	O	O
23	expression	O	O
24	regulation	O	O
25	of	O	O
26	Ca	S-Chemical	S-Chemical
27	(	O	O
28	2	O	O
29	+	O	O
30	)	O	O
31	handling	O	O
32	proteins	O	O
33	.	O	O

0	Hence	O	O
1	,	O	O
2	our	O	O
3	results	O	O
4	suggest	O	O
5	that	O	O
6	aconitine	S-Chemical	S-Chemical
7	significantly	O	O
8	aggravates	O	O
9	Ca	S-Chemical	S-Chemical
10	(	O	O
11	2	O	O
12	+	O	O
13	)	O	O
14	overload	O	O
15	and	O	O
16	causes	O	O
17	arrhythmia	S-Disease	O
18	and	O	O
19	finally	O	O
20	promotes	O	O
21	apoptotic	O	O
22	development	O	O
23	via	O	O
24	phosphorylation	O	O
25	of	O	O
26	P38	O	B-Chemical
27	mitogen	O	O
28	-	O	O
29	activated	O	O
30	protein	O	O
31	kinase	O	O
32	.	O	O

0	Chronic	O	O
1	treatment	O	O
2	with	O	O
3	metformin	S-Chemical	S-Chemical
4	suppresses	O	O
5	toll	O	B-Disease
6	-	O	O
7	like	O	O
8	receptor	O	B-Disease
9	4	O	E-Disease
10	signaling	O	O
11	and	O	O
12	attenuates	O	O
13	left	B-Disease	O
14	ventricular	I-Disease	B-Disease
15	dysfunction	E-Disease	E-Disease
16	following	O	O
17	myocardial	B-Disease	B-Disease
18	infarction	E-Disease	E-Disease
19	.	O	O

0	Acute	O	O
1	treatment	O	O
2	with	O	O
3	metformin	S-Chemical	S-Chemical
4	has	O	O
5	a	O	O
6	protective	O	O
7	effect	O	O
8	in	O	O
9	myocardial	B-Disease	B-Disease
10	infarction	E-Disease	E-Disease
11	by	O	O
12	suppression	O	O
13	of	O	O
14	inflammatory	O	B-Disease
15	responses	O	E-Disease
16	due	O	O
17	to	O	O
18	activation	O	O
19	of	O	O
20	AMP	S-Chemical	B-Disease
21	-	O	O
22	activated	O	I-Disease
23	protein	O	I-Disease
24	kinase	O	E-Disease
25	(	O	O
26	AMPK	O	S-Chemical
27	)	O	O
28	.	O	O

0	In	O	O
1	the	O	O
2	present	O	O
3	study	O	O
4	,	O	O
5	the	O	O
6	effect	O	O
7	of	O	O
8	chronic	O	S-Disease
9	pre	O	O
10	-	O	O
11	treatment	O	O
12	with	O	O
13	metformin	S-Chemical	S-Chemical
14	on	O	O
15	cardiac	B-Disease	B-Disease
16	dysfunction	E-Disease	E-Disease
17	and	O	O
18	toll	O	B-Disease
19	-	O	I-Disease
20	like	O	I-Disease
21	receptor	O	O
22	4	O	E-Disease
23	(	O	O
24	TLR4	O	S-Chemical
25	)	O	O
26	activities	O	O
27	following	O	O
28	myocardial	B-Disease	B-Disease
29	infarction	E-Disease	E-Disease
30	and	O	O
31	their	O	O
32	relation	O	O
33	with	O	O
34	AMPK	O	S-Chemical
35	were	O	O
36	assessed	O	O
37	.	O	O

0	Male	O	O
1	Wistar	O	O
2	rats	O	O
3	were	O	O
4	randomly	O	O
5	assigned	O	O
6	to	O	O
7	one	O	O
8	of	O	O
9	5	O	O
10	groups	O	O
11	(	O	O
12	n	O	O
13	=	O	O
14	6	O	O
15	)	O	O
16	:	O	O
17	normal	O	O
18	control	O	O
19	and	O	O
20	groups	O	O
21	were	O	O
22	injected	O	O
23	isoproterenol	S-Chemical	S-Chemical
24	after	O	O
25	chronic	O	S-Disease
26	pre	O	O
27	-	O	O
28	treatment	O	O
29	with	O	O
30	0	O	O
31	,	O	O
32	25	O	O
33	,	O	O
34	50	O	O
35	,	O	O
36	or	O	O
37	100mg	O	O
38	/	O	O
39	kg	O	O
40	of	O	O
41	metformin	S-Chemical	S-Chemical
42	twice	O	O
43	daily	O	O
44	for	O	O
45	14	O	O
46	days	O	O
47	.	O	O

0	Isoproterenol	S-Chemical	S-Chemical
1	(	O	O
2	100mg	O	O
3	/	O	O
4	kg	O	O
5	)	O	O
6	was	O	O
7	injected	O	O
8	subcutaneously	O	O
9	on	O	O
10	the	O	O
11	13th	O	O
12	and	O	O
13	14th	O	O
14	days	O	O
15	to	O	O
16	induce	O	O
17	acute	B-Disease	B-Disease
18	myocardial	I-Disease	B-Disease
19	infarction	E-Disease	E-Disease
20	.	O	O

0	Isoproterenol	S-Chemical	S-Chemical
1	alone	O	O
2	decreased	O	O
3	left	O	O
4	ventricular	O	B-Disease
5	systolic	O	E-Disease
6	pressure	O	O
7	and	O	O
8	myocardial	O	B-Disease
9	contractility	O	E-Disease
10	indexed	O	O
11	as	O	O
12	LVdp	O	S-Disease
13	/	O	O
14	dtmax	O	O
15	and	O	O
16	LVdp	O	S-Disease
17	/	O	O
18	dtmin	O	O
19	.	O	O

0	The	O	O
1	left	B-Disease	O
2	ventricular	I-Disease	O
3	dysfunction	E-Disease	E-Disease
4	was	O	O
5	significantly	O	O
6	lower	O	O
7	in	O	O
8	the	O	O
9	groups	O	O
10	treated	O	O
11	with	O	O
12	25	O	O
13	and	O	O
14	50mg	O	O
15	/	O	O
16	kg	O	O
17	of	O	O
18	metformin	S-Chemical	S-Chemical
19	.	O	O

0	Metfromin	O	S-Chemical
1	markedly	O	O
2	lowered	O	O
3	isoproterenol	S-Chemical	B-Chemical
4	-	O	O
5	induced	O	O
6	elevation	O	O
7	in	O	O
8	the	O	O
9	levels	O	O
10	of	O	O
11	TLR4	O	S-Disease
12	mRNA	O	O
13	,	O	O
14	myeloid	O	B-Disease
15	differentiation	O	I-Disease
16	protein	O	E-Disease
17	88	O	E-Disease
18	(	O	O
19	MyD88	O	B-Chemical
20	)	O	O
21	,	O	O
22	tumor	S-Disease	B-Disease
23	necrosis	S-Disease	I-Disease
24	factor	O	E-Disease
25	-	O	O
26	alpha	O	O
27	(	O	O
28	TNF	O	S-Disease
29	-	O	I-Disease
30	a	O	O
31	)	O	O
32	,	O	O
33	and	O	O
34	interleukin	O	B-Chemical
35	6	O	E-Chemical
36	(	O	O
37	IL	O	B-Chemical
38	-	O	E-Chemical
39	6	O	E-Chemical
40	)	O	O
41	in	O	O
42	the	O	O
43	heart	O	O
44	tissues	O	O
45	.	O	O

0	Phosphorylated	O	O
1	AMPKa	O	S-Chemical
2	(	O	O
3	p	O	S-Chemical
4	-	O	O
5	AMPK	O	E-Chemical
6	)	O	O
7	in	O	O
8	the	O	O
9	myocardium	O	S-Disease
10	was	O	O
11	significantly	O	O
12	elevated	O	O
13	by	O	O
14	25mg	O	O
15	/	O	O
16	kg	O	O
17	of	O	O
18	metformin	S-Chemical	S-Chemical
19	,	O	O
20	slightly	O	O
21	by	O	O
22	50mg	O	O
23	/	O	O
24	kg	O	O
25	,	O	O
26	but	O	O
27	not	O	O
28	by	O	O
29	100mg	O	O
30	/	O	O
31	kg	O	O
32	.	O	O

0	Chronic	O	O
1	pre	O	O
2	-	O	O
3	treatment	O	O
4	with	O	O
5	metformin	S-Chemical	S-Chemical
6	reduces	O	O
7	post	O	O
8	-	O	O
9	myocardial	B-Disease	B-Disease
10	infarction	E-Disease	E-Disease
11	cardiac	O	B-Disease
12	dysfunction	O	E-Disease
13	and	O	O
14	suppresses	O	O
15	inflammatory	O	B-Disease
16	responses	O	O
17	,	O	O
18	possibly	O	O
19	through	O	O
20	inhibition	O	O
21	of	O	O
22	TLR4	O	B-Chemical
23	activities	O	O
24	.	O	O

0	Two	O	O
1	cases	O	O
2	of	O	O
3	propylthiouracil	S-Chemical	S-Chemical
4	-	O	O
5	associated	O	O
6	acute	O	B-Disease
7	hepatitis	S-Disease	E-Disease
8	,	O	O
9	one	O	O
10	case	O	O
11	of	O	O
12	fatal	O	O
13	methimazole	S-Chemical	S-Chemical
14	-	O	O
15	associated	O	O
16	hepatocellular	B-Disease	B-Disease
17	necrosis	E-Disease	I-Disease
18	and	O	O
19	one	O	O
20	case	O	O
21	of	O	O
22	propylthiouracil	S-Chemical	S-Chemical
23	-	O	O
24	associated	O	O
25	lupus	B-Disease	S-Disease
26	-	I-Disease	I-Disease
27	like	I-Disease	O
28	syndrome	E-Disease	E-Disease
29	are	O	O
30	described	O	O
31	.	O	O

0	It	O	O
1	is	O	O
2	concluded	O	O
3	that	O	O
4	in	O	O
5	most	O	O
6	circumstances	O	O
7	131I	O	S-Chemical
8	is	O	O
9	the	O	O
10	therapy	O	O
11	of	O	O
12	choice	O	O
13	for	O	O
14	hyperthyroidism	S-Disease	S-Disease
15	.	O	O

0	Neuroleptic	B-Disease	O
1	malignant	I-Disease	I-Disease
2	syndrome	E-Disease	E-Disease
3	induced	O	O
4	by	O	O
5	combination	O	O
6	therapy	O	O
7	with	O	O
8	tetrabenazine	S-Chemical	S-Chemical
9	and	O	O
10	tiapride	S-Chemical	S-Chemical
11	in	O	O
12	a	O	O
13	Japanese	O	S-Chemical
14	patient	O	O
15	with	O	O
16	Huntington	B-Disease	B-Disease
17	'	I-Disease	I-Disease
18	s	I-Disease	I-Disease
19	disease	E-Disease	E-Disease
20	at	O	O
21	the	O	O
22	terminal	O	O
23	stage	O	O
24	of	O	O
25	recurrent	O	O
26	breast	B-Disease	B-Disease
27	cancer	E-Disease	E-Disease
28	.	O	O

0	We	O	O
1	herein	O	O
2	describe	O	O
3	the	O	O
4	case	O	O
5	of	O	O
6	an	O	O
7	81	O	O
8	-	O	O
9	year	O	O
10	-	O	O
11	old	O	O
12	Japanese	O	S-Chemical
13	woman	O	O
14	with	O	O
15	neuroleptic	B-Disease	B-Disease
16	malignant	I-Disease	I-Disease
17	syndrome	E-Disease	E-Disease
18	that	O	O
19	occurred	O	O
20	36	O	O
21	days	O	O
22	after	O	O
23	the	O	O
24	initiation	O	O
25	of	O	O
26	combination	O	O
27	therapy	O	O
28	with	O	O
29	tiapride	S-Chemical	S-Chemical
30	(	O	O
31	75	O	O
32	mg	O	O
33	/	O	O
34	day	O	O
35	)	O	O
36	and	O	O
37	tetrabenazine	S-Chemical	S-Chemical
38	(	O	O
39	12	O	O
40	.	O	O
41	5	O	O
42	mg	O	O
43	/	O	O
44	day	O	O
45	)	O	O
46	for	O	O
47	Huntington	B-Disease	B-Disease
48	'	I-Disease	I-Disease
49	s	I-Disease	I-Disease
50	disease	E-Disease	E-Disease
51	.	O	O

0	The	O	O
1	patient	O	O
2	had	O	O
3	been	O	O
4	treated	O	O
5	with	O	O
6	tiapride	S-Chemical	S-Chemical
7	or	O	O
8	tetrabenazine	S-Chemical	S-Chemical
9	alone	O	O
10	without	O	O
11	any	O	O
12	adverse	O	O
13	effects	O	O
14	before	O	O
15	the	O	O
16	administration	O	O
17	of	O	O
18	the	O	O
19	combination	O	O
20	therapy	O	O
21	.	O	O

0	She	O	O
1	also	O	O
2	had	O	O
3	advanced	O	O
4	breast	B-Disease	B-Disease
5	cancer	E-Disease	E-Disease
6	when	O	O
7	the	O	O
8	combination	O	O
9	therapy	O	O
10	was	O	O
11	initiated	O	O
12	.	O	O

0	To	O	O
1	the	O	O
2	best	O	O
3	of	O	O
4	our	O	O
5	knowledge	O	O
6	,	O	O
7	the	O	O
8	occurrence	O	O
9	of	O	O
10	neuroleptic	B-Disease	B-Disease
11	malignant	I-Disease	I-Disease
12	syndrome	E-Disease	E-Disease
13	due	O	O
14	to	O	O
15	combination	O	O
16	therapy	O	O
17	with	O	O
18	tetrabenazine	S-Chemical	S-Chemical
19	and	O	O
20	tiapride	S-Chemical	S-Chemical
21	has	O	O
22	not	O	O
23	been	O	O
24	previously	O	O
25	reported	O	O
26	.	O	O

0	Tetrabenazine	S-Chemical	S-Chemical
1	should	O	O
2	be	O	O
3	administered	O	O
4	very	O	O
5	carefully	O	O
6	in	O	O
7	combination	O	O
8	with	O	O
9	other	O	O
10	neuroleptic	B-Chemical	S-Disease
11	drugs	E-Chemical	O
12	,	O	O
13	particularly	O	O
14	in	O	O
15	patients	O	O
16	with	O	O
17	a	O	O
18	worsening	O	O
19	general	O	O
20	condition	O	O
21	.	O	O

0	A	O	O
1	metoprolol	S-Chemical	S-Chemical
2	-	O	O
3	terbinafine	S-Chemical	S-Chemical
4	combination	O	O
5	induced	O	O
6	bradycardia	S-Disease	S-Disease
7	.	O	O

0	To	O	O
1	report	O	O
2	a	O	O
3	sinus	B-Disease	B-Disease
4	bradycardia	E-Disease	E-Disease
5	induced	O	O
6	by	O	O
7	metoprolol	S-Chemical	S-Chemical
8	and	O	O
9	terbinafine	S-Chemical	S-Chemical
10	drug	O	O
11	-	O	O
12	drug	O	O
13	interaction	O	O
14	and	O	O
15	its	O	O
16	management	O	O
17	.	O	O

0	A	O	O
1	63	O	O
2	year	O	O
3	-	O	O
4	old	O	O
5	Caucasian	O	O
6	man	O	O
7	on	O	O
8	metoprolol	S-Chemical	S-Chemical
9	200	O	O
10	mg	O	O
11	/	O	O
12	day	O	O
13	for	O	O
14	stable	O	O
15	coronary	B-Disease	B-Disease
16	artery	I-Disease	I-Disease
17	disease	E-Disease	E-Disease
18	was	O	O
19	prescribed	O	O
20	a	O	O
21	90	O	O
22	-	O	O
23	day	O	O
24	course	O	O
25	of	O	O
26	oral	O	O
27	terbinafine	S-Chemical	S-Chemical
28	250	O	O
29	mg	O	O
30	/	O	O
31	day	O	O
32	for	O	O
33	onychomycosis	S-Disease	S-Disease
34	.	O	O

0	On	O	O
1	the	O	O
2	49th	O	O
3	day	O	O
4	of	O	O
5	terbinafine	S-Chemical	S-Chemical
6	therapy	O	O
7	,	O	O
8	he	O	O
9	was	O	O
10	brought	O	O
11	to	O	O
12	the	O	O
13	emergency	O	O
14	room	O	O
15	for	O	O
16	a	O	O
17	decrease	O	O
18	of	O	O
19	his	O	O
20	global	O	O
21	health	O	O
22	status	O	O
23	,	O	O
24	confusion	S-Disease	O
25	and	O	O
26	falls	O	O
27	.	O	O

0	The	O	O
1	electrocardiogram	O	O
2	revealed	O	O
3	a	O	O
4	37	O	O
5	beats	O	O
6	/	O	O
7	min	O	O
8	sinus	B-Disease	B-Disease
9	bradycardia	E-Disease	E-Disease
10	.	O	O

0	A	O	O
1	score	O	O
2	of	O	O
3	7	O	O
4	on	O	O
5	the	O	O
6	Naranjo	O	S-Chemical
7	adverse	B-Disease	O
8	drug	I-Disease	O
9	reaction	E-Disease	O
10	probability	O	O
11	scale	O	O
12	indicates	O	O
13	a	O	O
14	probable	O	O
15	relationship	O	O
16	between	O	O
17	the	O	O
18	patient	O	O
19	'	O	O
20	s	O	O
21	sinus	B-Disease	B-Disease
22	bradycardia	E-Disease	E-Disease
23	and	O	O
24	the	O	O
25	drug	O	O
26	interaction	O	O
27	between	O	O
28	metoprolol	S-Chemical	S-Chemical
29	and	O	O
30	terbinafine	S-Chemical	S-Chemical
31	.	O	O

0	The	O	O
1	heart	O	O
2	rate	O	O
3	ameliorated	O	O
4	first	O	O
5	with	O	O
6	a	O	O
7	decrease	O	O
8	in	O	O
9	the	O	O
10	dose	O	O
11	of	O	O
12	metoprolol	S-Chemical	S-Chemical
13	.	O	O

0	It	O	O
1	was	O	O
2	subsequently	O	O
3	changed	O	O
4	to	O	O
5	bisoprolol	S-Chemical	S-Chemical
6	and	O	O
7	the	O	O
8	heart	O	S-Disease
9	rate	O	O
10	remained	O	O
11	normal	O	O
12	.	O	O

0	By	O	O
1	inhibiting	O	O
2	the	O	O
3	cytochrome	O	B-Chemical
4	P450	O	I-Disease
5	2D6	O	E-Chemical
6	,	O	O
7	terbinafine	S-Chemical	S-Chemical
8	had	O	O
9	decreased	O	O
10	metoprolol	S-Chemical	S-Chemical
11	'	O	O
12	s	O	O
13	clearance	O	S-Disease
14	,	O	O
15	leading	O	O
16	in	O	O
17	metoprolol	S-Chemical	S-Chemical
18	accumulation	O	O
19	which	O	O
20	has	O	O
21	resulted	O	O
22	in	O	O
23	clinically	O	O
24	significant	O	O
25	sinus	B-Disease	B-Disease
26	bradycardia	E-Disease	E-Disease
27	.	O	O

0	Optochiasmatic	O	S-Disease
1	and	O	O
2	peripheral	B-Disease	O
3	neuropathy	E-Disease	S-Disease
4	due	O	O
5	to	O	O
6	ethambutol	S-Chemical	S-Chemical
7	overtreatment	O	O
8	.	O	O

0	Ethambutol	S-Chemical	S-Chemical
1	is	O	O
2	known	O	O
3	to	O	O
4	cause	O	O
5	optic	B-Disease	B-Disease
6	neuropathy	E-Disease	E-Disease
7	and	O	O
8	,	O	O
9	more	O	O
10	rarely	O	O
11	,	O	O
12	axonal	O	O
13	polyneuropathy	S-Disease	S-Disease
14	.	O	O

0	We	O	O
1	characterize	O	O
2	the	O	O
3	clinical	O	O
4	,	O	O
5	neurophysiological	O	O
6	,	O	O
7	and	O	O
8	neuroimaging	O	O
9	findings	O	O
10	in	O	O
11	a	O	O
12	72	O	O
13	-	O	O
14	year	O	O
15	-	O	O
16	old	O	O
17	man	O	O
18	who	O	O
19	developed	O	O
20	visual	B-Disease	B-Disease
21	loss	E-Disease	E-Disease
22	and	O	O
23	paresthesias	S-Disease	O
24	after	O	O
25	11	O	O
26	weeks	O	O
27	of	O	O
28	exposure	O	O
29	to	O	O
30	a	O	O
31	supratherapeutic	O	O
32	dose	O	O
33	of	O	O
34	ethambutol	S-Chemical	S-Chemical
35	.	O	O

0	This	O	O
1	case	O	O
2	demonstrates	O	O
3	the	O	O
4	selective	O	O
5	vulnerability	O	O
6	of	O	O
7	the	O	O
8	anterior	O	O
9	visual	O	O
10	pathways	O	O
11	and	O	O
12	peripheral	O	O
13	nerves	O	O
14	to	O	O
15	ethambutol	S-Chemical	S-Chemical
16	toxicity	S-Disease	E-Disease
17	.	O	O

0	Testosterone	S-Chemical	S-Chemical
1	ameliorates	O	O
2	streptozotocin	S-Chemical	O
3	-	O	O
4	induced	O	O
5	memory	B-Disease	B-Disease
6	impairment	E-Disease	E-Disease
7	in	O	O
8	male	O	O
9	rats	O	O
10	.	O	O

0	AIM	O	O
1	:	O	O
2	To	O	O
3	study	O	O
4	the	O	O
5	effects	O	O
6	of	O	O
7	testosterone	S-Chemical	S-Chemical
8	on	O	O
9	streptozotocin	S-Chemical	S-Chemical
10	(	O	O
11	STZ	S-Chemical	S-Chemical
12	)	O	O
13	-	O	O
14	induced	O	O
15	memory	B-Disease	O
16	impairment	E-Disease	O
17	in	O	O
18	male	O	O
19	rats	O	O
20	.	O	O

0	METHODS	O	O
1	:	O	O
2	Adult	O	O
3	male	O	O
4	Wistar	O	O
5	rats	O	O
6	were	O	O
7	intracerebroventricularly	O	O
8	(	O	O
9	icv	O	O
10	)	O	O
11	infused	O	O
12	with	O	O
13	STZ	S-Chemical	S-Chemical
14	(	O	O
15	750	O	O
16	ug	O	O
17	)	O	O
18	on	O	O
19	d	O	O
20	1	O	O
21	and	O	O
22	d	O	O
23	3	O	O
24	,	O	O
25	and	O	O
26	a	O	O
27	passive	O	O
28	avoidance	O	O
29	task	O	O
30	was	O	O
31	assessed	O	O
32	2	O	O
33	weeks	O	O
34	after	O	O
35	the	O	O
36	first	O	O
37	injection	O	O
38	of	O	O
39	STZ	S-Chemical	S-Chemical
40	.	O	O

0	Testosterone	S-Chemical	S-Chemical
1	(	O	O
2	1	O	O
3	mg	O	O
4	.	O	O
5	kg	O	O
6	(	O	O
7	-	O	O
8	1	O	O
9	)	O	O
10	.	O	O
11	d	O	O
12	(	O	O
13	-	O	O
14	1	O	O
15	)	O	O
16	,	O	O
17	sc	O	O
18	)	O	O
19	,	O	O
20	the	O	O
21	androgen	S-Chemical	S-Chemical
22	receptor	O	O
23	antagonist	O	O
24	flutamide	S-Chemical	S-Chemical
25	(	O	O
26	10	O	O
27	mg	O	O
28	.	O	O
29	kg	O	O
30	(	O	O
31	-	O	O
32	1	O	O
33	)	O	O
34	.	O	O
35	d	O	O
36	(	O	O
37	-	O	O
38	1	O	O
39	)	O	O
40	,	O	O
41	ip	O	O
42	)	O	O
43	,	O	O
44	the	O	O
45	estrogen	S-Chemical	O
46	receptor	O	O
47	antagonist	O	O
48	tamoxifen	S-Chemical	S-Chemical
49	(	O	O
50	1	O	O
51	mg	O	O
52	.	O	O
53	kg	O	O
54	(	O	O
55	-	O	O
56	1	O	O
57	)	O	O
58	.	O	O
59	d	O	O
60	(	O	O
61	-	O	O
62	1	O	O
63	)	O	O
64	,	O	O
65	ip	O	O
66	)	O	O
67	or	O	O
68	the	O	O
69	aromatase	O	O
70	inhibitor	O	O
71	letrozole	S-Chemical	S-Chemical
72	(	O	O
73	4	O	O
74	mg	O	O
75	.	O	O
76	kg	O	O
77	(	O	O
78	-	O	O
79	1	O	O
80	)	O	O
81	.	O	O
82	d	O	O
83	(	O	O
84	-	O	O
85	1	O	O
86	)	O	O
87	,	O	O
88	ip	O	O
89	)	O	O
90	were	O	O
91	administered	O	O
92	for	O	O
93	6	O	O
94	d	O	O
95	after	O	O
96	the	O	O
97	first	O	O
98	injection	O	O
99	of	O	O
100	STZ	S-Chemical	S-Chemical
101	.	O	O

0	RESULTS	O	O
1	:	O	O
2	STZ	S-Chemical	S-Chemical
3	administration	O	O
4	and	O	O
5	castration	O	S-Disease
6	markedly	O	O
7	decreased	O	O
8	both	O	O
9	STL1	O	S-Chemical
10	(	O	O
11	the	O	O
12	short	O	O
13	memory	O	O
14	)	O	O
15	and	O	O
16	STL2	O	S-Chemical
17	(	O	O
18	the	O	O
19	long	O	O
20	memory	O	O
21	)	O	O
22	in	O	O
23	passive	O	O
24	avoidance	O	O
25	tests	O	O
26	.	O	O

0	Testosterone	S-Chemical	S-Chemical
1	replacement	O	O
2	almost	O	O
3	restored	O	O
4	the	O	O
5	STL1	O	S-Disease
6	and	O	O
7	STL2	O	S-Disease
8	in	O	O
9	castrated	O	O
10	rats	O	O
11	,	O	O
12	and	O	O
13	significantly	O	O
14	prolonged	O	O
15	the	O	O
16	STL1	O	S-Chemical
17	and	O	O
18	STL2	O	S-Chemical
19	in	O	O
20	STZ	S-Chemical	S-Disease
21	-	O	O
22	treated	O	O
23	rats	O	O
24	.	O	O

0	Administration	O	O
1	of	O	O
2	flutamide	S-Chemical	S-Chemical
3	,	O	O
4	letrozole	S-Chemical	S-Chemical
5	or	O	O
6	tamoxifen	S-Chemical	S-Chemical
7	significantly	O	O
8	impaired	B-Disease	O
9	the	I-Disease	O
10	memory	E-Disease	O
11	in	O	O
12	intact	O	O
13	rats	O	O
14	,	O	O
15	and	O	O
16	significantly	O	O
17	attenuated	O	O
18	the	O	O
19	testosterone	S-Chemical	S-Chemical
20	replacement	O	O
21	in	O	O
22	improving	O	O
23	STZ	S-Chemical	S-Disease
24	-	O	E-Disease
25	and	O	O
26	castration	O	S-Disease
27	-	O	O
28	induced	O	O
29	memory	B-Disease	O
30	impairment	E-Disease	O
31	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Testosterone	S-Chemical	S-Chemical
3	administration	O	O
4	ameliorates	O	O
5	STZ	S-Chemical	S-Disease
6	-	O	O
7	and	O	O
8	castration	O	S-Disease
9	-	O	O
10	induced	O	O
11	memory	B-Disease	O
12	impairment	E-Disease	O
13	in	O	O
14	male	O	O
15	Wistar	O	O
16	rats	O	O
17	.	O	O

0	Behavioral	O	O
1	and	O	O
2	neurochemical	O	O
3	studies	O	O
4	in	O	O
5	mice	O	O
6	pretreated	O	O
7	with	O	O
8	garcinielliptone	B-Chemical	S-Chemical
9	FC	E-Chemical	S-Disease
10	in	O	O
11	pilocarpine	S-Chemical	S-Chemical
12	-	O	O
13	induced	O	O
14	seizures	S-Disease	S-Disease
15	.	O	O

0	Garcinielliptone	B-Chemical	B-Chemical
1	FC	E-Chemical	S-Disease
2	(	O	O
3	GFC	S-Chemical	S-Disease
4	)	O	O
5	isolated	O	O
6	from	O	O
7	hexanic	O	S-Chemical
8	fraction	O	O
9	seed	O	O
10	extract	O	O
11	of	O	O
12	species	O	O
13	Platonia	O	B-Disease
14	insignis	O	E-Disease
15	Mart	O	S-Disease
16	.	O	O

0	It	O	O
1	is	O	O
2	widely	O	O
3	used	O	O
4	in	O	O
5	folk	O	O
6	medicine	O	O
7	to	O	O
8	treat	O	O
9	skin	B-Disease	B-Disease
10	diseases	E-Disease	E-Disease
11	in	O	O
12	both	O	O
13	humans	O	O
14	and	O	O
15	animals	O	O
16	as	O	O
17	well	O	O
18	as	O	O
19	the	O	O
20	seed	O	O
21	decoction	O	O
22	has	O	O
23	been	O	O
24	used	O	O
25	to	O	O
26	treat	O	O
27	diarrheas	S-Disease	B-Disease
28	and	O	O
29	inflammatory	B-Disease	B-Disease
30	diseases	E-Disease	E-Disease
31	.	O	O

0	However	O	O
1	,	O	O
2	there	O	O
3	is	O	O
4	no	O	O
5	research	O	O
6	on	O	O
7	GFC	S-Chemical	S-Chemical
8	effects	O	O
9	in	O	O
10	the	O	O
11	central	O	I-Disease
12	nervous	O	I-Disease
13	system	O	E-Disease
14	of	O	O
15	rodents	O	O
16	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	aimed	O	O
4	to	O	O
5	evaluate	O	O
6	the	O	O
7	GFC	S-Chemical	S-Disease
8	effects	O	O
9	at	O	O
10	doses	O	O
11	of	O	O
12	25	O	O
13	,	O	O
14	50	O	O
15	or	O	O
16	75	O	O
17	mg	O	O
18	/	O	O
19	kg	O	O
20	on	O	O
21	seizure	S-Disease	O
22	parameters	O	O
23	to	O	O
24	determine	O	O
25	their	O	O
26	anticonvulsant	O	O
27	activity	O	O
28	and	O	O
29	its	O	O
30	effects	O	O
31	on	O	O
32	amino	B-Chemical	O
33	acid	E-Chemical	O
34	(	O	O
35	r	B-Chemical	B-Chemical
36	-	I-Chemical	I-Chemical
37	aminobutyric	I-Chemical	E-Chemical
38	acid	E-Chemical	E-Chemical
39	(	O	O
40	GABA	S-Chemical	S-Chemical
41	)	O	O
42	,	O	O
43	glutamine	S-Chemical	S-Chemical
44	,	O	O
45	aspartate	S-Chemical	S-Chemical
46	and	O	O
47	glutathione	S-Chemical	S-Chemical
48	)	O	O
49	levels	O	O
50	as	O	O
51	well	O	O
52	as	O	O
53	on	O	O
54	acetylcholinesterase	O	S-Chemical
55	(	O	O
56	AChE	O	S-Chemical
57	)	O	O
58	activity	O	S-Disease
59	in	O	O
60	mice	O	O
61	hippocampus	O	S-Disease
62	after	O	O
63	seizures	S-Disease	S-Disease
64	.	O	O

0	GFC	S-Chemical	S-Chemical
1	produced	O	O
2	an	O	O
3	increased	O	O
4	latency	O	O
5	to	O	O
6	first	O	O
7	seizure	S-Disease	O
8	,	O	O
9	at	O	O
10	doses	O	O
11	25mg	O	O
12	/	O	O
13	kg	O	O
14	(	O	O
15	20	O	O
16	.	O	O
17	12	O	O
18	+	O	O
19	2	O	O
20	.	O	O
21	20	O	O
22	min	O	O
23	)	O	O
24	,	O	O
25	50mg	O	O
26	/	O	O
27	kg	O	O
28	(	O	O
29	20	O	O
30	.	O	O
31	95	O	O
32	+	O	O
33	2	O	O
34	.	O	O
35	21	O	O
36	min	O	O
37	)	O	O
38	or	O	O
39	75	O	O
40	mg	O	O
41	/	O	O
42	kg	O	O
43	(	O	O
44	23	O	O
45	.	O	O
46	43	O	O
47	+	O	O
48	1	O	O
49	.	O	O
50	99	O	O
51	min	O	O
52	)	O	O
53	when	O	O
54	compared	O	O
55	with	O	O
56	seized	O	O
57	mice	O	O
58	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	GABA	S-Chemical	S-Chemical
4	content	O	O
5	of	O	O
6	mice	O	O
7	hippocampus	O	S-Disease
8	treated	O	O
9	with	O	O
10	GFC75	O	B-Chemical
11	plus	O	O
12	P400	O	S-Chemical
13	showed	O	O
14	an	O	O
15	increase	O	O
16	of	O	O
17	46	O	O
18	.	O	O
19	90	O	O
20	%	O	O
21	when	O	O
22	compared	O	O
23	with	O	O
24	seized	O	O
25	mice	O	O
26	.	O	O

0	In	O	O
1	aspartate	S-Chemical	S-Chemical
2	,	O	O
3	glutamine	S-Chemical	S-Chemical
4	and	O	O
5	glutamate	S-Chemical	S-Chemical
6	levels	O	O
7	detected	O	O
8	a	O	O
9	decrease	O	O
10	of	O	O
11	5	O	O
12	.	O	O
13	21	O	O
14	%	O	O
15	,	O	O
16	13	O	O
17	.	O	O
18	55	O	O
19	%	O	O
20	and	O	O
21	21	O	O
22	.	O	O
23	80	O	O
24	%	O	O
25	,	O	O
26	respectively	O	O
27	in	O	O
28	mice	O	O
29	hippocampus	O	S-Disease
30	treated	O	O
31	with	O	O
32	GFC75	O	B-Chemical
33	plus	O	O
34	P400	O	S-Chemical
35	when	O	O
36	compared	O	O
37	with	O	O
38	seized	O	O
39	mice	O	O
40	.	O	O

0	The	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	GFC	S-Chemical	S-Chemical
5	can	O	O
6	exert	O	O
7	anticonvulsant	O	O
8	activity	O	O
9	and	O	O
10	reduce	O	O
11	the	O	O
12	frequency	O	O
13	of	O	O
14	installation	O	O
15	of	O	O
16	pilocarpine	S-Chemical	S-Chemical
17	-	O	O
18	induced	O	O
19	status	B-Disease	B-Disease
20	epilepticus	E-Disease	E-Disease
21	,	O	O
22	as	O	O
23	demonstrated	O	O
24	by	O	O
25	increase	O	O
26	in	O	O
27	latency	O	O
28	to	O	O
29	first	O	O
30	seizure	S-Disease	S-Disease
31	and	O	O
32	decrease	O	O
33	in	O	O
34	mortality	O	O
35	rate	O	O
36	of	O	O
37	animals	O	O
38	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	our	O	O
4	data	O	O
5	suggest	O	O
6	that	O	O
7	GFC	S-Chemical	S-Chemical
8	may	O	O
9	influence	O	O
10	in	O	O
11	epileptogenesis	O	O
12	and	O	O
13	promote	O	O
14	anticonvulsant	O	O
15	actions	O	O
16	in	O	O
17	pilocarpine	S-Chemical	S-Chemical
18	model	O	O
19	by	O	O
20	modulating	O	O
21	the	O	O
22	GABA	S-Chemical	S-Chemical
23	and	O	O
24	glutamate	S-Chemical	S-Chemical
25	contents	O	O
26	and	O	O
27	of	O	O
28	AChE	O	S-Chemical
29	activity	O	O
30	in	O	O
31	seized	O	O
32	mice	O	O
33	hippocampus	O	S-Disease
34	.	O	O

0	Standard	O	O
1	operating	O	O
2	procedures	O	O
3	for	O	O
4	antibiotic	O	O
5	therapy	O	O
6	and	O	O
7	the	O	O
8	occurrence	O	O
9	of	O	O
10	acute	B-Disease	B-Disease
11	kidney	I-Disease	I-Disease
12	injury	E-Disease	E-Disease
13	:	O	O
14	a	O	O
15	prospective	O	O
16	,	O	O
17	clinical	O	O
18	,	O	O
19	non	O	O
20	-	O	O
21	interventional	O	O
22	,	O	O
23	observational	O	O
24	study	O	O
25	.	O	O

0	INTRODUCTION	O	O
1	:	O	O
2	Acute	B-Disease	O
3	kidney	I-Disease	B-Disease
4	injury	E-Disease	E-Disease
5	(	O	O
6	AKI	S-Disease	S-Disease
7	)	O	O
8	occurs	O	O
9	in	O	O
10	7	O	O
11	%	O	O
12	of	O	O
13	hospitalized	O	O
14	and	O	O
15	66	O	O
16	%	O	O
17	of	O	O
18	Intensive	O	O
19	Care	O	I-Disease
20	Unit	O	E-Disease
21	(	O	O
22	ICU	O	O
23	)	O	O
24	patients	O	O
25	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	investigate	O	O
8	,	O	O
9	whether	O	O
10	there	O	O
11	is	O	O
12	an	O	O
13	association	O	O
14	between	O	O
15	adherence	O	O
16	to	O	O
17	guidelines	O	O
18	(	O	O
19	standard	O	O
20	operating	O	O
21	procedures	O	O
22	(	O	O
23	SOP	O	S-Chemical
24	)	O	O
25	)	O	O
26	for	O	O
27	potentially	O	O
28	nephrotoxic	S-Disease	O
29	antibiotics	O	O
30	and	O	O
31	the	O	O
32	occurrence	O	O
33	of	O	O
34	AKI	S-Disease	S-Chemical
35	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	675	O	O
4	patients	O	O
5	were	O	O
6	included	O	O
7	;	O	O
8	163	O	O
9	of	O	O
10	these	O	O
11	had	O	O
12	therapy	O	O
13	with	O	O
14	vancomycin	S-Chemical	S-Chemical
15	,	O	O
16	gentamicin	S-Chemical	S-Chemical
17	,	O	O
18	or	O	O
19	tobramycin	S-Chemical	S-Chemical
20	;	O	O
21	were	O	O
22	>	O	O
23	18	O	O
24	years	O	O
25	;	O	O
26	and	O	O
27	treated	O	O
28	in	O	O
29	the	O	O
30	ICU	O	O
31	for	O	O
32	>	O	O
33	24	O	O
34	hours	O	O
35	.	O	O

0	AKI	S-Disease	S-Chemical
1	was	O	O
2	defined	O	O
3	according	O	O
4	to	O	O
5	RIFLE	O	S-Disease
6	criteria	O	O
7	.	O	O

0	Development	O	O
1	of	O	O
2	AKI	S-Disease	S-Chemical
3	was	O	O
4	compared	O	O
5	between	O	O
6	groups	O	O
7	with	O	O
8	exact	O	O
9	Chi2	O	S-Chemical
10	-	O	O
11	test	O	O
12	and	O	O
13	multivariate	O	O
14	logistic	O	O
15	regression	O	O
16	analysis	O	O
17	(	O	O
18	two	O	O
19	-	O	O
20	sided	O	O
21	P	O	O
22	<	O	O
23	0	O	O
24	.	O	O
25	05	O	O
26	)	O	O
27	.	O	O

0	AKI	S-Disease	S-Chemical
1	occurred	O	O
2	significantly	O	O
3	more	O	O
4	often	O	O
5	in	O	O
6	LAG	O	S-Disease
7	with	O	O
8	36	O	O
9	%	O	O
10	versus	O	O
11	21	O	O
12	%	O	O
13	in	O	O
14	HAG	O	S-Disease
15	(	O	O
16	P	O	S-Chemical
17	=	O	O
18	0	O	O
19	.	O	O
20	035	O	O
21	)	O	O
22	.	O	O

0	Basic	O	O
1	characteristics	O	O
2	were	O	O
3	comparable	O	O
4	,	O	O
5	except	O	O
6	an	O	O
7	increased	O	O
8	rate	O	O
9	of	O	O
10	soft	O	O
11	tissue	O	O
12	infections	S-Disease	S-Disease
13	in	O	O
14	LAG	O	S-Disease
15	.	O	O

0	Multivariate	O	O
1	analysis	O	O
2	revealed	O	O
3	an	O	O
4	odds	O	O
5	ratio	O	O
6	of	O	O
7	2	O	O
8	.	O	O
9	5	O	O
10	-	O	O
11	fold	O	O
12	for	O	O
13	LAG	O	O
14	to	O	O
15	develop	O	O
16	AKI	S-Disease	S-Disease
17	compared	O	O
18	with	O	O
19	HAG	O	S-Chemical
20	(	O	O
21	95	O	O
22	%	O	O
23	confidence	O	O
24	interval	O	O
25	1	O	O
26	.	O	O
27	195	O	O
28	to	O	O
29	5	O	O
30	.	O	O
31	124	O	O
32	,	O	O
33	P	O	O
34	=	O	O
35	0	O	O
36	.	O	O
37	039	O	O
38	)	O	O
39	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Low	O	O
3	adherence	O	O
4	to	O	O
5	SOPs	O	S-Chemical
6	for	O	O
7	potentially	O	O
8	nephrotoxic	S-Disease	S-Disease
9	antibiotics	O	O
10	was	O	O
11	associated	O	O
12	with	O	O
13	a	O	O
14	higher	O	O
15	occurrence	O	O
16	of	O	O
17	AKI	S-Disease	S-Chemical
18	.	O	O

0	Rhabdomyolysis	S-Disease	S-Disease
1	in	O	O
2	a	O	O
3	hepatitis	B-Disease	B-Disease
4	C	I-Disease	I-Disease
5	virus	I-Disease	E-Disease
6	infected	E-Disease	O
7	patient	O	O
8	treated	O	O
9	with	O	O
10	telaprevir	S-Chemical	S-Disease
11	and	O	O
12	simvastatin	S-Chemical	S-Chemical
13	.	O	O

0	A	O	O
1	46	O	O
2	-	O	O
3	year	O	O
4	old	O	O
5	man	O	O
6	with	O	O
7	a	O	O
8	chronic	O	B-Disease
9	hepatitis	B-Disease	I-Disease
10	C	I-Disease	I-Disease
11	virus	I-Disease	E-Disease
12	infection	E-Disease	E-Disease
13	received	O	O
14	triple	O	O
15	therapy	O	O
16	with	O	O
17	ribavirin	S-Chemical	S-Chemical
18	,	O	O
19	pegylated	B-Chemical	O
20	interferon	E-Chemical	S-Disease
21	and	O	O
22	telaprevir	S-Chemical	S-Chemical
23	.	O	O

0	The	O	O
1	patient	O	O
2	also	O	O
3	received	O	O
4	simvastatin	S-Chemical	S-Chemical
5	.	O	O

0	One	O	O
1	month	O	O
2	after	O	O
3	starting	O	O
4	the	O	O
5	antiviral	O	O
6	therapy	O	O
7	,	O	O
8	the	O	O
9	patient	O	O
10	was	O	O
11	admitted	O	O
12	to	O	O
13	the	O	O
14	hospital	O	O
15	because	O	O
16	he	O	O
17	developed	O	O
18	rhabdomyolysis	S-Disease	S-Disease
19	.	O	O

0	At	O	O
1	admission	O	O
2	simvastatin	S-Chemical	S-Chemical
3	and	O	O
4	all	O	O
5	antiviral	O	O
6	drugs	O	O
7	were	O	O
8	discontinued	O	O
9	because	O	O
10	toxicity	S-Disease	S-Disease
11	due	O	O
12	to	O	O
13	a	O	O
14	drug	O	O
15	-	O	O
16	drug	O	O
17	interaction	O	O
18	was	O	O
19	suspected	O	O
20	.	O	O

0	The	O	O
1	creatine	S-Chemical	S-Chemical
2	kinase	O	E-Disease
3	peaked	O	O
4	at	O	O
5	62	O	O
6	,	O	O
7	246	O	O
8	IU	O	S-Disease
9	/	O	O
10	L	O	O
11	and	O	O
12	the	O	O
13	patient	O	O
14	was	O	O
15	treated	O	O
16	with	O	O
17	intravenous	O	O
18	normal	O	O
19	saline	O	S-Disease
20	.	O	O

0	Fourteen	O	O
1	days	O	O
2	after	O	O
3	hospitalization	O	O
4	,	O	O
5	creatine	S-Chemical	B-Chemical
6	kinase	O	E-Chemical
7	level	O	O
8	had	O	O
9	returned	O	O
10	to	O	O
11	230	O	O
12	IU	O	O
13	/	O	O
14	L	O	O
15	and	O	O
16	the	O	O
17	patient	O	O
18	was	O	O
19	discharged	O	O
20	.	O	O

0	Telaprevir	S-Chemical	S-Chemical
1	was	O	O
2	considered	O	O
3	the	O	O
4	probable	O	O
5	causative	O	O
6	agent	O	O
7	of	O	O
8	an	O	O
9	interaction	O	O
10	with	O	O
11	simvastatin	S-Chemical	S-Chemical
12	according	O	O
13	to	O	O
14	the	O	O
15	Drug	O	O
16	Interaction	O	O
17	Probability	O	O
18	Scale	O	O
19	.	O	O

0	The	O	O
1	interaction	O	O
2	is	O	O
3	due	O	O
4	to	O	O
5	inhibition	O	O
6	of	O	O
7	CYP3A4	O	B-Chemical
8	-	O	E-Chemical
9	mediated	O	O
10	simvastatin	S-Chemical	S-Chemical
11	clearance	O	S-Disease
12	.	O	O

0	Simvastatin	S-Chemical	S-Chemical
1	plasma	O	O
2	concentration	O	O
3	increased	O	O
4	30	O	O
5	times	O	O
6	in	O	O
7	this	O	O
8	patient	O	O
9	and	O	O
10	statin	S-Chemical	S-Chemical
11	induced	O	O
12	muscle	B-Disease	B-Disease
13	toxicity	E-Disease	E-Disease
14	is	O	O
15	related	O	O
16	to	O	O
17	the	O	O
18	concentration	O	O
19	of	O	O
20	the	O	O
21	statin	S-Chemical	S-Chemical
22	in	O	O
23	blood	O	O
24	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	with	O	O
4	this	O	O
5	case	O	O
6	we	O	O
7	illustrate	O	O
8	that	O	O
9	telaprevir	S-Chemical	S-Chemical
10	as	O	O
11	well	O	O
12	as	O	O
13	statins	S-Chemical	S-Chemical
14	are	O	O
15	susceptible	O	O
16	to	O	O
17	clinical	O	O
18	relevant	O	O
19	drug	O	O
20	-	O	O
21	drug	O	O
22	interactions	O	O
23	.	O	O

0	Combination	O	O
1	of	O	O
2	bortezomib	S-Chemical	S-Chemical
3	,	O	O
4	thalidomide	S-Chemical	S-Chemical
5	,	O	O
6	and	O	O
7	dexamethasone	S-Chemical	S-Chemical
8	(	O	O
9	VTD	O	S-Disease
10	)	O	O
11	as	O	O
12	a	O	O
13	consolidation	O	O
14	therapy	O	O
15	after	O	O
16	autologous	O	O
17	stem	O	O
18	cell	O	O
19	transplantation	O	O
20	for	O	O
21	symptomatic	O	O
22	multiple	B-Disease	O
23	myeloma	E-Disease	S-Disease
24	in	O	O
25	Japanese	O	S-Chemical
26	patients	O	O
27	.	O	O

0	Consolidation	O	O
1	therapy	O	O
2	for	O	O
3	patients	O	O
4	with	O	O
5	multiple	B-Disease	O
6	myeloma	E-Disease	S-Disease
7	(	O	O
8	MM	S-Disease	S-Disease
9	)	O	O
10	has	O	O
11	been	O	O
12	widely	O	O
13	adopted	O	O
14	to	O	O
15	improve	O	O
16	treatment	O	O
17	response	O	O
18	following	O	O
19	autologous	O	O
20	stem	O	B-Disease
21	cell	O	I-Disease
22	transplantation	O	S-Disease
23	.	O	O

0	In	O	O
1	this	O	O
2	study	O	O
3	,	O	O
4	we	O	O
5	retrospectively	O	O
6	analyzed	O	O
7	the	O	O
8	safety	O	O
9	and	O	O
10	efficacy	O	O
11	of	O	O
12	combination	O	O
13	regimen	O	O
14	of	O	O
15	bortezomib	S-Chemical	S-Chemical
16	,	O	O
17	thalidomide	S-Chemical	S-Chemical
18	,	O	O
19	and	O	O
20	dexamethasone	S-Chemical	S-Chemical
21	(	O	O
22	VTD	O	O
23	)	O	O
24	as	O	O
25	consolidation	O	O
26	therapy	O	O
27	in	O	O
28	24	O	O
29	Japanese	O	S-Chemical
30	patients	O	O
31	with	O	O
32	newly	O	O
33	diagnosed	O	O
34	MM	S-Disease	O
35	.	O	O

0	VTD	O	O
1	consisted	O	O
2	of	O	O
3	bortezomib	S-Chemical	S-Chemical
4	at	O	O
5	a	O	O
6	dose	O	O
7	of	O	O
8	1	O	O
9	.	O	O
10	3	O	O
11	mg	O	O
12	/	O	O
13	m	O	O
14	(	O	O
15	2	O	O
16	)	O	O
17	and	O	O
18	dexamethasone	S-Chemical	S-Chemical
19	at	O	O
20	a	O	O
21	dose	O	O
22	of	O	O
23	40	O	O
24	mg	O	O
25	/	O	O
26	day	O	O
27	on	O	O
28	days	O	O
29	1	O	O
30	,	O	O
31	8	O	O
32	,	O	O
33	15	O	O
34	,	O	O
35	and	O	O
36	22	O	O
37	of	O	O
38	a	O	O
39	35	O	O
40	-	O	O
41	day	O	O
42	cycle	O	O
43	,	O	O
44	with	O	O
45	daily	O	O
46	oral	O	O
47	thalidomide	S-Chemical	S-Disease
48	at	O	O
49	a	O	O
50	dose	O	O
51	of	O	O
52	100	O	O
53	mg	O	O
54	/	O	O
55	day	O	O
56	.	O	O

0	Grade	O	O
1	3	O	O
2	-	O	O
3	4	O	O
4	neutropenia	S-Disease	S-Disease
5	and	O	O
6	thrombocytopenia	S-Disease	S-Disease
7	were	O	O
8	documented	O	O
9	in	O	O
10	four	O	O
11	and	O	O
12	three	O	O
13	patients	O	O
14	(	O	O
15	17	O	O
16	and	O	O
17	13	O	O
18	%	O	O
19	)	O	O
20	,	O	O
21	respectively	O	O
22	,	O	O
23	but	O	O
24	drug	O	O
25	dose	O	O
26	reduction	O	O
27	due	O	O
28	to	O	O
29	cytopenia	S-Disease	S-Chemical
30	was	O	O
31	not	O	O
32	required	O	O
33	in	O	O
34	any	O	O
35	case	O	O
36	.	O	O

0	Peripheral	B-Disease	O
1	neuropathy	E-Disease	S-Disease
2	was	O	O
3	common	O	O
4	(	O	O
5	63	O	O
6	%	O	O
7	)	O	O
8	,	O	O
9	but	O	O
10	severe	O	O
11	grade	O	O
12	3	O	O
13	-	O	O
14	4	O	O
15	peripheral	B-Disease	O
16	neuropathy	E-Disease	E-Disease
17	was	O	O
18	not	O	O
19	observed	O	O
20	.	O	O

0	Conversion	O	O
1	to	O	O
2	sirolimus	S-Chemical	S-Chemical
3	ameliorates	O	O
4	cyclosporine	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	nephropathy	S-Disease	S-Disease
8	in	O	O
9	the	O	O
10	rat	O	O
11	:	O	O
12	focus	O	O
13	on	O	O
14	serum	O	O
15	,	O	O
16	urine	O	O
17	,	O	O
18	gene	O	O
19	,	O	O
20	and	O	O
21	protein	O	O
22	renal	O	I-Disease
23	expression	O	O
24	biomarkers	O	O
25	.	O	O

0	Protocols	O	O
1	of	O	O
2	conversion	O	O
3	from	O	O
4	cyclosporin	B-Chemical	B-Chemical
5	A	E-Chemical	E-Chemical
6	(	O	O
7	CsA	S-Chemical	S-Chemical
8	)	O	O
9	to	O	O
10	sirolimus	S-Chemical	S-Disease
11	(	O	O
12	SRL	S-Chemical	S-Disease
13	)	O	O
14	have	O	O
15	been	O	O
16	widely	O	O
17	used	O	O
18	in	O	O
19	immunotherapy	O	S-Disease
20	after	O	O
21	transplantation	O	O
22	to	O	O
23	prevent	O	O
24	CsA	S-Chemical	S-Chemical
25	-	O	O
26	induced	O	O
27	nephropathy	S-Disease	S-Disease
28	,	O	O
29	but	O	O
30	the	O	O
31	molecular	O	O
32	mechanisms	O	O
33	underlying	O	O
34	these	O	O
35	protocols	O	O
36	remain	O	O
37	nuclear	O	O
38	.	O	O

0	This	O	O
1	study	O	O
2	aimed	O	O
3	to	O	O
4	identify	O	O
5	the	O	O
6	molecular	O	O
7	pathways	O	O
8	and	O	O
9	putative	O	O
10	biomarkers	O	O
11	of	O	O
12	CsA	S-Chemical	S-Chemical
13	-	O	O
14	to	O	I-Disease
15	-	O	O
16	SRL	S-Chemical	S-Disease
17	conversion	O	O
18	in	O	O
19	a	O	O
20	rat	O	O
21	model	O	O
22	.	O	O

0	Four	O	O
1	animal	O	O
2	groups	O	O
3	(	O	O
4	n	O	O
5	=	O	O
6	6	O	O
7	)	O	O
8	were	O	O
9	tested	O	O
10	during	O	O
11	9	O	O
12	weeks	O	O
13	:	O	O
14	control	O	O
15	,	O	O
16	CsA	S-Chemical	S-Chemical
17	,	O	O
18	SRL	S-Chemical	S-Disease
19	,	O	O
20	and	O	O
21	conversion	O	O
22	(	O	O
23	CsA	S-Chemical	S-Chemical
24	for	O	O
25	3	O	O
26	weeks	O	O
27	followed	O	O
28	by	O	O
29	SRL	S-Chemical	S-Disease
30	for	O	O
31	6	O	O
32	weeks	O	O
33	)	O	O
34	.	O	O

0	Renal	B-Disease	O
1	lesions	E-Disease	O
2	were	O	O
3	analyzed	O	O
4	in	O	O
5	hematoxylin	S-Chemical	O
6	and	O	O
7	eosin	S-Chemical	S-Chemical
8	,	O	O
9	periodic	O	O
10	acid	O	B-Chemical
11	-	O	O
12	Schiff	O	S-Chemical
13	,	O	O
14	and	O	O
15	Masson	O	S-Chemical
16	'	O	O
17	s	O	O
18	trichrome	O	S-Disease
19	stains	O	O
20	.	O	O

0	SRL	S-Chemical	O
1	-	O	O
2	treated	O	O
3	rats	O	O
4	presented	O	O
5	proteinuria	S-Disease	S-Disease
6	and	O	O
7	NGAL	O	S-Chemical
8	(	O	O
9	serum	O	O
10	and	O	O
11	urinary	O	O
12	)	O	O
13	as	O	O
14	the	O	O
15	best	O	O
16	markers	O	O
17	of	O	O
18	renal	B-Disease	B-Disease
19	impairment	E-Disease	E-Disease
20	.	O	O

0	Short	O	O
1	CsA	S-Chemical	S-Chemical
2	treatment	O	O
3	presented	O	O
4	slight	O	O
5	or	O	O
6	even	O	O
7	absent	O	O
8	kidney	B-Disease	B-Disease
9	lesions	E-Disease	E-Disease
10	and	O	O
11	TGF	O	S-Disease
12	-	O	O
13	b	O	O
14	,	O	O
15	NF	O	O
16	-	O	O
17	kb	O	O
18	,	O	O
19	mTOR	O	O
20	,	O	O
21	PCNA	O	S-Disease
22	,	O	O
23	TP53	O	B-Chemical
24	,	O	O
25	KIM	O	B-Chemical
26	-	O	E-Chemical
27	1	O	E-Chemical
28	,	O	O
29	and	O	O
30	CTGF	O	S-Disease
31	as	O	O
32	relevant	O	O
33	gene	O	O
34	and	O	O
35	protein	O	O
36	changes	O	O
37	.	O	O

0	Prolonged	O	O
1	CsA	S-Chemical	S-Chemical
2	exposure	O	O
3	aggravated	O	O
4	renal	B-Disease	B-Disease
5	damage	E-Disease	E-Disease
6	,	O	O
7	without	O	O
8	clear	O	O
9	changes	O	O
10	on	O	O
11	the	O	O
12	traditional	O	O
13	markers	O	O
14	,	O	O
15	but	O	O
16	with	O	O
17	changes	O	O
18	in	O	O
19	serums	O	O
20	TGF	O	S-Disease
21	-	O	O
22	b	O	O
23	and	O	O
24	IL	O	S-Disease
25	-	O	E-Chemical
26	7	O	O
27	,	O	O
28	TBARs	O	S-Disease
29	clearance	O	O
30	,	O	O
31	and	O	O
32	kidney	O	O
33	TGF	O	S-Disease
34	-	O	O
35	b	O	O
36	and	O	O
37	mTOR	O	O
38	.	O	O

0	Conversion	O	O
1	to	O	O
2	SRL	S-Chemical	S-Disease
3	prevented	O	O
4	CsA	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	renal	B-Disease	B-Disease
8	damage	E-Disease	E-Disease
9	evolution	O	O
10	(	O	O
11	absent	O	O
12	/	O	O
13	mild	O	O
14	grade	O	O
15	lesions	O	O
16	)	O	O
17	,	O	O
18	while	O	O
19	NGAL	O	S-Chemical
20	(	O	O
21	serum	O	O
22	versus	O	O
23	urine	O	O
24	)	O	O
25	seems	O	O
26	to	O	O
27	be	O	O
28	a	O	O
29	feasible	O	O
30	biomarker	O	O
31	of	O	O
32	CsA	S-Chemical	S-Chemical
33	replacement	O	O
34	to	O	O
35	SRL	S-Chemical	S-Disease
36	.	O	O

0	Kinin	O	B-Chemical
1	B2	O	O
2	receptor	O	O
3	deletion	O	O
4	and	O	O
5	blockage	O	O
6	ameliorates	O	O
7	cisplatin	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	acute	B-Disease	B-Disease
11	renal	I-Disease	I-Disease
12	injury	E-Disease	E-Disease
13	.	O	O

0	Cisplatin	S-Chemical	S-Chemical
1	treatment	O	O
2	has	O	O
3	been	O	O
4	adopted	O	O
5	in	O	O
6	some	O	O
7	chemotherapies	O	O
8	;	O	O
9	however	O	O
10	,	O	O
11	this	O	O
12	drug	O	O
13	can	O	O
14	induce	O	O
15	acute	B-Disease	B-Disease
16	kidney	I-Disease	I-Disease
17	injury	E-Disease	E-Disease
18	due	O	O
19	its	O	O
20	ability	O	O
21	to	O	O
22	negatively	O	O
23	affect	O	O
24	renal	O	B-Disease
25	function	O	E-Disease
26	,	O	O
27	augment	O	O
28	serum	O	O
29	levels	O	O
30	of	O	O
31	creatinine	S-Chemical	S-Chemical
32	and	O	O
33	urea	S-Chemical	S-Chemical
34	,	O	O
35	increase	O	O
36	the	O	O
37	acute	B-Disease	O
38	tubular	I-Disease	B-Disease
39	necrosis	E-Disease	E-Disease
40	score	O	O
41	and	O	O
42	up	O	O
43	-	O	O
44	regulate	O	O
45	cytokines	O	S-Disease
46	(	O	O
47	e	O	O
48	.	O	O
49	g	O	O
50	.	O	O
51	,	O	O
52	IL	O	B-Chemical
53	-	O	I-Chemical
54	1b	O	E-Chemical
55	and	O	O
56	TNF	O	S-Disease
57	-	O	I-Disease
58	a	O	E-Chemical
59	)	O	O
60	.	O	O

0	The	O	O
1	kinin	O	B-Chemical
2	B2	O	I-Disease
3	receptor	O	O
4	has	O	O
5	been	O	O
6	associated	O	O
7	with	O	O
8	the	O	O
9	inflammation	S-Disease	S-Disease
10	process	O	O
11	,	O	O
12	as	O	O
13	well	O	O
14	as	O	O
15	the	O	O
16	regulation	O	O
17	of	O	O
18	cytokine	O	S-Chemical
19	expression	O	O
20	,	O	O
21	and	O	O
22	its	O	O
23	deletion	O	O
24	resulted	O	O
25	in	O	O
26	an	O	O
27	improvement	O	O
28	in	O	O
29	the	O	O
30	diabetic	B-Disease	B-Disease
31	nephropathy	E-Disease	S-Disease
32	status	O	O
33	.	O	O

0	To	O	O
1	examine	O	O
2	the	O	O
3	role	O	O
4	of	O	O
5	the	O	O
6	kinin	O	B-Chemical
7	B2	O	I-Disease
8	receptor	O	O
9	in	O	O
10	cisplatin	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	acute	B-Disease	B-Disease
14	kidney	I-Disease	I-Disease
15	injury	E-Disease	E-Disease
16	,	O	O
17	kinin	O	B-Disease
18	B2	O	I-Disease
19	receptor	O	O
20	knockout	O	O
21	mice	O	O
22	were	O	O
23	challenged	O	O
24	with	O	O
25	cisplatin	S-Chemical	S-Chemical
26	.	O	O

0	Additionally	O	O
1	,	O	O
2	WT	O	O
3	mice	O	O
4	were	O	O
5	treated	O	O
6	with	O	O
7	a	O	O
8	B2	O	O
9	receptor	O	O
10	antagonist	O	O
11	after	O	O
12	cisplatin	S-Chemical	S-Chemical
13	administration	O	O
14	.	O	O

0	B2	O	O
1	receptor	O	O
2	-	O	O
3	deficient	O	O
4	mice	O	O
5	were	O	O
6	less	O	O
7	sensitive	O	O
8	to	O	O
9	this	O	O
10	drug	O	O
11	than	O	O
12	the	O	O
13	WT	O	O
14	mice	O	O
15	,	O	O
16	as	O	O
17	shown	O	O
18	by	O	O
19	reduced	O	O
20	weight	B-Disease	B-Disease
21	loss	E-Disease	E-Disease
22	,	O	O
23	better	O	O
24	preservation	O	O
25	of	O	O
26	kidney	O	B-Disease
27	function	O	E-Disease
28	,	O	O
29	down	O	O
30	regulation	O	O
31	of	O	O
32	inflammatory	O	B-Disease
33	cytokines	O	E-Disease
34	and	O	O
35	less	O	O
36	acute	B-Disease	O
37	tubular	I-Disease	B-Disease
38	necrosis	E-Disease	E-Disease
39	.	O	O

0	Moreover	O	O
1	,	O	O
2	treatment	O	O
3	with	O	O
4	the	O	O
5	kinin	O	B-Disease
6	B2	O	I-Disease
7	receptor	O	O
8	antagonist	O	O
9	effectively	O	O
10	reduced	O	O
11	the	O	O
12	levels	O	O
13	of	O	O
14	serum	O	O
15	creatinine	S-Chemical	S-Chemical
16	and	O	O
17	blood	O	B-Disease
18	urea	S-Chemical	E-Disease
19	after	O	O
20	cisplatin	S-Chemical	S-Chemical
21	administration	O	O
22	.	O	O

0	Thus	O	O
1	,	O	O
2	our	O	O
3	data	O	O
4	suggest	O	O
5	that	O	O
6	the	O	O
7	kinin	O	B-Chemical
8	B2	O	I-Disease
9	receptor	O	O
10	is	O	O
11	involved	O	O
12	in	O	O
13	cisplatin	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	acute	B-Disease	B-Disease
17	kidney	I-Disease	I-Disease
18	injury	E-Disease	E-Disease
19	by	O	O
20	mediating	O	O
21	the	O	O
22	necrotic	S-Disease	O
23	process	O	O
24	and	O	O
25	the	O	O
26	expression	O	O
27	of	O	O
28	inflammatory	O	B-Disease
29	cytokines	O	E-Disease
30	,	O	O
31	thus	O	O
32	resulting	O	O
33	in	O	O
34	declined	O	O
35	renal	O	B-Disease
36	function	O	E-Disease
37	.	O	O

0	These	O	O
1	results	O	O
2	highlight	O	O
3	the	O	O
4	kinin	O	B-Chemical
5	B2	O	E-Chemical
6	receptor	O	O
7	antagonist	O	O
8	treatment	O	O
9	in	O	O
10	amelioration	O	O
11	of	O	O
12	nephrotoxicity	S-Disease	S-Disease
13	induced	O	O
14	by	O	O
15	cisplatin	S-Chemical	S-Chemical
16	therapy	O	O
17	.	O	O

0	Safety	O	O
1	and	O	O
2	efficacy	O	O
3	of	O	O
4	fluocinolone	B-Chemical	S-Chemical
5	acetonide	E-Chemical	E-Chemical
6	intravitreal	O	O
7	implant	O	O
8	(	O	O
9	0	O	O
10	.	O	O
11	59	O	O
12	mg	O	O
13	)	O	O
14	in	O	O
15	birdshot	B-Disease	O
16	retinochoroidopathy	E-Disease	S-Disease
17	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	To	O	O
3	report	O	O
4	the	O	O
5	treatment	O	O
6	outcomes	O	O
7	of	O	O
8	the	O	O
9	fluocinolone	B-Chemical	B-Chemical
10	acetonide	E-Chemical	E-Chemical
11	intravitreal	O	O
12	implant	O	O
13	(	O	O
14	0	O	O
15	.	O	O
16	59	O	O
17	mg	O	O
18	)	O	O
19	in	O	O
20	patients	O	O
21	with	O	O
22	birdshot	B-Disease	O
23	retinochoroidopathy	E-Disease	S-Disease
24	whose	O	O
25	disease	O	S-Disease
26	is	O	O
27	refractory	O	O
28	or	O	O
29	intolerant	O	O
30	to	O	O
31	conventional	O	O
32	immunomodulatory	O	O
33	therapy	O	O
34	.	O	O

0	METHODS	O	O
1	:	O	O
2	A	O	O
3	retrospective	O	O
4	case	O	O
5	series	O	O
6	involving	O	O
7	11	O	O
8	birdshot	B-Disease	O
9	retinochoroidopathy	E-Disease	S-Disease
10	patients	O	O
11	(	O	O
12	11	O	O
13	eyes	O	O
14	)	O	O
15	.	O	O

0	Eleven	O	O
1	patients	O	O
2	(	O	O
3	11	O	O
4	eyes	O	O
5	)	O	O
6	underwent	O	O
7	surgery	O	O
8	for	O	O
9	fluocinolone	B-Chemical	S-Chemical
10	acetonide	E-Chemical	E-Chemical
11	implant	O	O
12	(	O	O
13	0	O	O
14	.	O	O
15	59	O	O
16	mg	O	O
17	)	O	O
18	.	O	O

0	Treatment	O	O
1	outcomes	O	O
2	of	O	O
3	interest	O	O
4	were	O	O
5	noted	O	O
6	at	O	O
7	baseline	O	O
8	,	O	O
9	before	O	O
10	fluocinolone	B-Chemical	B-Chemical
11	acetonide	E-Chemical	E-Chemical
12	implant	O	O
13	,	O	O
14	and	O	O
15	then	O	O
16	at	O	O
17	6	O	O
18	months	O	O
19	,	O	O
20	1	O	O
21	year	O	O
22	,	O	O
23	2	O	O
24	years	O	O
25	,	O	O
26	3	O	O
27	years	O	O
28	,	O	O
29	and	O	O
30	beyond	O	O
31	3	O	O
32	years	O	O
33	.	O	O

0	Disease	O	S-Disease
1	activity	O	O
2	markers	O	O
3	,	O	O
4	including	O	O
5	signs	O	O
6	of	O	O
7	ocular	O	B-Disease
8	inflammation	S-Disease	E-Disease
9	,	O	O
10	evidence	O	O
11	of	O	O
12	retinal	B-Disease	O
13	vasculitis	E-Disease	S-Disease
14	,	O	O
15	Swedish	O	S-Chemical
16	interactive	O	O
17	threshold	O	O
18	algorithm	O	O
19	-	O	O
20	short	O	O
21	wavelength	O	O
22	automated	O	O
23	perimetry	O	O
24	Humphrey	O	O
25	visual	O	O
26	field	O	O
27	analysis	O	O
28	,	O	O
29	electroretinographic	O	O
30	parameters	O	O
31	,	O	O
32	and	O	O
33	optical	O	O
34	coherence	O	O
35	tomography	O	O
36	were	O	O
37	recorded	O	O
38	.	O	O

0	Data	O	O
1	on	O	O
2	occurrence	O	O
3	of	O	O
4	cataract	S-Disease	S-Disease
5	and	O	O
6	raised	B-Disease	O
7	intraocular	I-Disease	O
8	pressure	E-Disease	O
9	were	O	O
10	collected	O	O
11	in	O	O
12	all	O	O
13	eyes	O	O
14	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Intraocular	O	O
3	inflammation	S-Disease	E-Disease
4	was	O	O
5	present	O	O
6	in	O	O
7	54	O	O
8	.	O	O
9	5	O	O
10	,	O	O
11	9	O	O
12	.	O	O
13	9	O	O
14	,	O	O
15	11	O	O
16	.	O	O
17	1	O	O
18	,	O	O
19	and	O	O
20	0	O	O
21	%	O	O
22	of	O	O
23	patients	O	O
24	at	O	O
25	baseline	O	O
26	,	O	O
27	6	O	O
28	months	O	O
29	,	O	O
30	1	O	O
31	year	O	O
32	,	O	O
33	2	O	O
34	years	O	O
35	,	O	O
36	3	O	O
37	years	O	O
38	,	O	O
39	and	O	O
40	beyond	O	O
41	3	O	O
42	years	O	O
43	after	O	O
44	receiving	O	O
45	the	O	O
46	implant	O	O
47	,	O	O
48	respectively	O	O
49	.	O	O

0	Active	O	O
1	vasculitis	S-Disease	S-Disease
2	was	O	O
3	noted	O	O
4	in	O	O
5	36	O	O
6	.	O	O
7	3	O	O
8	%	O	O
9	patients	O	O
10	at	O	O
11	baseline	O	O
12	and	O	O
13	0	O	O
14	%	O	O
15	at	O	O
16	3	O	O
17	years	O	O
18	of	O	O
19	follow	O	O
20	-	O	O
21	up	O	O
22	.	O	O

0	More	O	O
1	than	O	O
2	20	O	O
3	%	O	O
4	(	O	O
5	47	O	O
6	.	O	O
7	61	O	O
8	-	O	O
9	67	O	O
10	.	O	O
11	2	O	O
12	%	O	O
13	)	O	O
14	reduction	O	O
15	in	O	O
16	central	O	O
17	retinal	O	I-Disease
18	thickness	O	E-Disease
19	was	O	O
20	noted	O	O
21	in	O	O
22	all	O	O
23	patients	O	O
24	with	O	O
25	cystoid	B-Disease	B-Disease
26	macular	I-Disease	B-Disease
27	edema	E-Disease	E-Disease
28	at	O	O
29	6	O	O
30	months	O	O
31	,	O	O
32	1	O	O
33	year	O	O
34	,	O	O
35	2	O	O
36	years	O	O
37	,	O	O
38	and	O	O
39	3	O	O
40	years	O	O
41	postimplant	O	O
42	.	O	O

0	Adverse	O	O
1	events	O	O
2	included	O	O
3	increased	B-Disease	O
4	intraocular	I-Disease	O
5	pressure	E-Disease	O
6	(	O	O
7	54	O	O
8	.	O	O
9	5	O	O
10	%	O	O
11	)	O	O
12	and	O	O
13	cataract	S-Disease	S-Disease
14	formation	O	O
15	(	O	O
16	100	O	O
17	%	O	O
18	)	O	O
19	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	The	O	O
3	data	O	O
4	suggest	O	O
5	that	O	O
6	fluocinolone	B-Chemical	B-Chemical
7	acetonide	E-Chemical	E-Chemical
8	implant	O	O
9	(	O	O
10	0	O	O
11	.	O	O
12	59	O	O
13	mg	O	O
14	)	O	O
15	helps	O	O
16	to	O	O
17	control	O	O
18	inflammation	S-Disease	S-Disease
19	in	O	O
20	otherwise	O	O
21	treatment	O	O
22	-	O	O
23	refractory	O	O
24	cases	O	O
25	of	O	O
26	birdshot	B-Disease	O
27	retinochoroidopathy	E-Disease	S-Disease
28	.	O	O

0	It	O	O
1	is	O	O
2	associated	O	O
3	with	O	O
4	significant	O	O
5	side	O	O
6	effects	O	O
7	of	O	O
8	cataract	S-Disease	S-Disease
9	and	O	O
10	ocular	B-Disease	B-Disease
11	hypertension	E-Disease	E-Disease
12	requiring	O	O
13	treatment	O	O
14	.	O	O

0	Optimal	O	O
1	precurarizing	O	O
2	dose	O	O
3	of	O	O
4	rocuronium	S-Chemical	S-Chemical
5	to	O	O
6	decrease	O	O
7	fasciculation	S-Disease	O
8	and	O	O
9	myalgia	S-Disease	S-Disease
10	following	O	O
11	succinylcholine	S-Chemical	S-Chemical
12	administration	O	O
13	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Succinylcholine	S-Chemical	S-Chemical
3	commonly	O	O
4	produces	O	O
5	frequent	O	O
6	adverse	O	O
7	effects	O	O
8	,	O	O
9	including	O	O
10	muscle	B-Disease	B-Disease
11	fasciculation	E-Disease	E-Disease
12	and	O	O
13	myalgia	S-Disease	S-Disease
14	.	O	O

0	The	O	O
1	current	O	O
2	study	O	O
3	identified	O	O
4	the	O	O
5	optimal	O	O
6	dose	O	O
7	of	O	O
8	rocuronium	S-Chemical	S-Chemical
9	to	O	O
10	prevent	O	O
11	succinylcholine	S-Chemical	S-Chemical
12	-	O	O
13	induced	O	O
14	fasciculation	S-Disease	S-Disease
15	and	O	O
16	myalgia	S-Disease	S-Disease
17	and	O	O
18	evaluated	O	O
19	the	O	O
20	influence	O	O
21	of	O	O
22	rocuronium	S-Chemical	S-Chemical
23	on	O	O
24	the	O	O
25	speed	O	O
26	of	O	O
27	onset	O	O
28	produced	O	O
29	by	O	O
30	succinylcholine	S-Chemical	S-Chemical
31	.	O	O

0	Patients	O	O
1	were	O	O
2	randomized	O	O
3	to	O	O
4	receive	O	O
5	0	O	O
6	.	O	O
7	02	O	O
8	,	O	O
9	0	O	O
10	.	O	O
11	03	O	O
12	,	O	O
13	0	O	O
14	.	O	O
15	04	O	O
16	,	O	O
17	0	O	O
18	.	O	O
19	05	O	O
20	and	O	O
21	0	O	O
22	.	O	O
23	06	O	O
24	mg	O	O
25	/	O	O
26	kg	O	O
27	rocuronium	S-Chemical	O
28	as	O	O
29	a	O	O
30	precurarizing	O	O
31	dose	O	O
32	.	O	O

0	All	O	O
1	patients	O	O
2	received	O	O
3	succinylcholine	S-Chemical	S-Chemical
4	1	O	O
5	.	O	O
6	5	O	O
7	mg	O	O
8	/	O	O
9	kg	O	O
10	at	O	O
11	2	O	O
12	minutes	O	O
13	after	O	O
14	the	O	O
15	precurarization	O	O
16	,	O	O
17	and	O	O
18	were	O	O
19	assessed	O	O
20	the	O	O
21	incidence	O	O
22	and	O	O
23	severity	O	O
24	of	O	O
25	fasciculations	S-Disease	S-Disease
26	,	O	O
27	while	O	O
28	myalgia	S-Disease	S-Chemical
29	was	O	O
30	assessed	O	O
31	at	O	O
32	24	O	O
33	hours	O	O
34	after	O	O
35	surgery	O	O
36	.	O	O

0	RESULTS	O	O
1	:	O	O
2	The	O	O
3	incidence	O	O
4	and	O	O
5	severity	O	O
6	of	O	O
7	visible	O	O
8	muscle	B-Disease	B-Disease
9	fasciculation	E-Disease	E-Disease
10	was	O	O
11	significantly	O	O
12	less	O	O
13	with	O	O
14	increasing	O	O
15	the	O	O
16	amount	O	O
17	of	O	O
18	precurarizing	O	O
19	dose	O	O
20	of	O	O
21	rocuronium	S-Chemical	S-Chemical
22	(	O	O
23	P	O	O
24	<	O	O
25	0	O	O
26	.	O	O
27	001	O	O
28	)	O	O
29	.	O	O

0	Those	O	O
1	of	O	O
2	myalgia	S-Disease	S-Disease
3	tend	O	O
4	to	O	O
5	decrease	O	O
6	according	O	O
7	to	O	O
8	increasing	O	O
9	the	O	O
10	amount	O	O
11	of	O	O
12	precurarizing	O	O
13	dose	O	O
14	of	O	O
15	rocuronium	S-Chemical	S-Chemical
16	,	O	O
17	but	O	O
18	there	O	O
19	was	O	O
20	no	O	O
21	significance	O	O
22	(	O	O
23	P	O	S-Disease
24	=	O	O
25	0	O	O
26	.	O	O
27	072	O	O
28	)	O	O
29	.	O	O

0	The	O	O
1	onset	O	O
2	time	O	O
3	of	O	O
4	succinylcholine	S-Chemical	S-Chemical
5	was	O	O
6	significantly	O	O
7	longer	O	O
8	with	O	O
9	increasing	O	O
10	the	O	O
11	amount	O	O
12	of	O	O
13	precurarizing	O	O
14	dose	O	O
15	of	O	O
16	rocuronium	S-Chemical	S-Chemical
17	(	O	O
18	P	O	S-Disease
19	<	O	O
20	0	O	O
21	.	O	O
22	001	O	O
23	)	O	O
24	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Precurarization	O	O
3	with	O	O
4	0	O	O
5	.	O	O
6	04	O	O
7	mg	O	O
8	/	O	O
9	kg	O	O
10	rocuronium	S-Chemical	S-Disease
11	was	O	O
12	the	O	O
13	optimal	O	O
14	dose	O	O
15	considering	O	O
16	the	O	O
17	reduction	O	O
18	in	O	O
19	the	O	O
20	incidence	O	O
21	and	O	O
22	severity	O	O
23	of	O	O
24	fasciculation	S-Disease	S-Disease
25	and	O	O
26	myalgia	S-Disease	S-Disease
27	with	O	O
28	acceptable	O	O
29	onset	O	O
30	time	O	O
31	,	O	O
32	and	O	O
33	the	O	O
34	safe	O	O
35	and	O	O
36	effective	O	O
37	precurarization	O	O
38	.	O	O

0	Absence	O	O
1	of	O	O
2	PKC	O	S-Chemical
3	-	O	E-Chemical
4	alpha	O	O
5	attenuates	O	O
6	lithium	S-Chemical	B-Disease
7	-	O	O
8	induced	O	O
9	nephrogenic	B-Disease	B-Disease
10	diabetes	I-Disease	B-Disease
11	insipidus	E-Disease	E-Disease
12	.	O	O

0	Lithium	S-Chemical	S-Chemical
1	,	O	O
2	an	O	O
3	effective	O	O
4	antipsychotic	O	O
5	,	O	O
6	induces	O	O
7	nephrogenic	B-Disease	B-Disease
8	diabetes	I-Disease	B-Disease
9	insipidus	E-Disease	E-Disease
10	(	O	O
11	NDI	S-Disease	S-Chemical
12	)	O	O
13	in	O	O
14	40	O	O
15	%	O	O
16	of	O	O
17	patients	O	O
18	.	O	O

0	The	O	O
1	decreased	O	O
2	capacity	O	O
3	to	O	O
4	concentrate	O	O
5	urine	O	O
6	is	O	O
7	likely	O	O
8	due	O	O
9	to	O	O
10	lithium	S-Chemical	S-Chemical
11	acutely	O	O
12	disrupting	O	O
13	the	O	O
14	cAMP	S-Chemical	S-Chemical
15	pathway	O	O
16	and	O	O
17	chronically	O	O
18	reducing	O	O
19	urea	S-Chemical	S-Chemical
20	transporter	O	O
21	(	O	O
22	UT	O	B-Chemical
23	-	O	E-Chemical
24	A1	O	E-Chemical
25	)	O	O
26	and	O	O
27	water	O	O
28	channel	O	O
29	(	O	O
30	AQP2	O	S-Chemical
31	)	O	O
32	expression	O	O
33	in	O	O
34	the	O	O
35	inner	O	O
36	medulla	O	O
37	.	O	O

0	Targeting	O	O
1	an	O	O
2	alternative	O	O
3	signaling	O	O
4	pathway	O	O
5	,	O	O
6	such	O	O
7	as	O	O
8	PKC	O	S-Disease
9	-	O	O
10	mediated	O	O
11	signaling	O	O
12	,	O	O
13	may	O	O
14	be	O	O
15	an	O	O
16	effective	O	O
17	method	O	O
18	of	O	O
19	treating	O	O
20	lithium	S-Chemical	S-Chemical
21	-	O	O
22	induced	O	O
23	polyuria	S-Disease	S-Disease
24	.	O	O

0	PKC	O	O
1	-	O	O
2	alpha	O	O
3	null	O	O
4	mice	O	O
5	(	O	O
6	PKCa	O	O
7	KO	O	E-Chemical
8	)	O	O
9	and	O	O
10	strain	O	O
11	-	O	O
12	matched	O	O
13	wild	O	O
14	type	O	O
15	(	O	O
16	WT	O	O
17	)	O	O
18	controls	O	O
19	were	O	O
20	treated	O	O
21	with	O	O
22	lithium	S-Chemical	S-Chemical
23	for	O	O
24	0	O	O
25	,	O	O
26	3	O	O
27	or	O	O
28	5	O	O
29	days	O	O
30	.	O	O

0	Animals	O	O
1	were	O	O
2	also	O	O
3	treated	O	O
4	with	O	O
5	lithium	S-Chemical	S-Chemical
6	for	O	O
7	6	O	O
8	weeks	O	O
9	.	O	O

0	Lithium	S-Chemical	S-Chemical
1	-	O	O
2	treated	O	O
3	WT	O	O
4	mice	O	O
5	had	O	O
6	19	O	O
7	-	O	O
8	fold	O	O
9	increased	O	O
10	urine	O	O
11	output	O	O
12	whereas	O	O
13	treated	O	O
14	PKCa	O	O
15	KO	O	E-Chemical
16	animals	O	O
17	had	O	O
18	a	O	O
19	4	O	O
20	-	O	O
21	fold	O	O
22	increase	O	O
23	in	O	O
24	output	O	O
25	.	O	O

0	AQP2	O	S-Chemical
1	and	O	O
2	UT	O	B-Chemical
3	-	O	E-Chemical
4	A1	O	E-Chemical
5	expression	O	O
6	was	O	O
7	lowered	O	O
8	in	O	O
9	6	O	O
10	week	O	O
11	lithium	S-Chemical	S-Disease
12	-	O	O
13	treated	O	O
14	WT	O	O
15	animals	O	O
16	whereas	O	O
17	in	O	O
18	treated	O	O
19	PKCa	O	O
20	KO	O	E-Chemical
21	mice	O	O
22	,	O	O
23	AQP2	O	S-Chemical
24	was	O	O
25	only	O	O
26	reduced	O	O
27	by	O	O
28	2	O	O
29	-	O	O
30	fold	O	O
31	and	O	O
32	UT	O	B-Chemical
33	-	O	I-Chemical
34	A1	O	E-Chemical
35	expression	O	O
36	was	O	O
37	unaffected	O	O
38	.	O	O

0	Urinary	O	O
1	sodium	S-Chemical	O
2	,	O	O
3	potassium	S-Chemical	S-Disease
4	and	O	O
5	calcium	S-Chemical	S-Disease
6	were	O	O
7	elevated	O	O
8	in	O	O
9	lithium	S-Chemical	S-Chemical
10	-	O	O
11	fed	O	O
12	WT	O	S-Disease
13	but	O	O
14	not	O	O
15	in	O	O
16	lithium	S-Chemical	O
17	-	O	O
18	fed	O	O
19	PKCa	O	O
20	KO	O	S-Chemical
21	mice	O	O
22	.	O	O

0	Our	O	O
1	data	O	O
2	show	O	O
3	that	O	O
4	ablation	O	O
5	of	O	O
6	PKCa	O	S-Disease
7	preserves	O	O
8	AQP2	O	S-Chemical
9	and	O	O
10	UT	O	S-Chemical
11	-	O	O
12	A1	O	E-Chemical
13	protein	O	O
14	expression	O	O
15	and	O	O
16	localization	O	O
17	in	O	O
18	lithium	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	NDI	S-Disease	S-Chemical
22	,	O	O
23	and	O	O
24	prevents	O	O
25	the	O	O
26	development	O	O
27	of	O	O
28	the	O	O
29	severe	O	O
30	polyuria	S-Disease	S-Disease
31	associated	O	O
32	with	O	O
33	lithium	S-Chemical	S-Chemical
34	therapy	O	O
35	.	O	O

0	Is	O	O
1	Dysguesia	S-Disease	S-Disease
2	Going	O	O
3	to	O	O
4	be	O	O
5	a	O	O
6	Rare	O	O
7	or	O	O
8	a	O	O
9	Common	O	O
10	Side	O	O
11	-	O	O
12	effect	O	O
13	of	O	O
14	Amlodipine	S-Chemical	S-Chemical
15	?	O	O

0	A	O	O
1	very	O	O
2	rare	O	O
3	side	O	O
4	-	O	O
5	effect	O	O
6	of	O	O
7	amlodipine	S-Chemical	S-Chemical
8	is	O	O
9	dysguesia	S-Disease	S-Disease
10	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	about	O	O
5	a	O	O
6	female	O	O
7	with	O	O
8	essential	O	O
9	hypertension	S-Disease	S-Disease
10	on	O	O
11	drug	O	O
12	treatment	O	O
13	with	O	O
14	amlodipine	S-Chemical	S-Chemical
15	developed	O	O
16	loss	B-Disease	B-Disease
17	of	I-Disease	O
18	taste	I-Disease	B-Disease
19	sensation	E-Disease	E-Disease
20	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	amlodipine	S-Chemical	S-Chemical
4	can	O	O
5	cause	O	O
6	dysguesia	S-Disease	S-Disease
7	.	O	O

0	Here	O	O
1	,	O	O
2	we	O	O
3	describe	O	O
4	the	O	O
5	clinical	O	O
6	presentation	O	O
7	and	O	O
8	review	O	O
9	the	O	O
10	relevant	O	O
11	literature	O	O
12	on	O	O
13	amlodipine	S-Chemical	S-Chemical
14	and	O	O
15	dysguesia	S-Disease	S-Disease
16	.	O	O

0	Rhabdomyolysis	S-Disease	S-Disease
1	in	O	O
2	association	O	O
3	with	O	O
4	simvastatin	S-Chemical	S-Chemical
5	and	O	O
6	dosage	O	O
7	increment	O	O
8	in	O	O
9	clarithromycin	S-Chemical	S-Chemical
10	.	O	O

0	Clarithromycin	S-Chemical	S-Chemical
1	is	O	O
2	the	O	O
3	most	O	O
4	documented	O	O
5	cytochrome	O	O
6	P450	O	I-Disease
7	3A4	O	E-Chemical
8	(	O	O
9	CYP3A4	O	S-Chemical
10	)	O	O
11	inhibitor	O	O
12	to	O	O
13	cause	O	O
14	an	O	O
15	adverse	O	O
16	interaction	O	O
17	with	O	O
18	simvastatin	S-Chemical	S-Chemical
19	.	O	O

0	This	O	O
1	particular	O	O
2	case	O	O
3	is	O	O
4	of	O	O
5	interest	O	O
6	as	O	O
7	rhabdomyolysis	S-Disease	S-Chemical
8	only	O	O
9	occurred	O	O
10	after	O	O
11	an	O	O
12	increase	O	O
13	in	O	O
14	the	O	O
15	dose	O	O
16	of	O	O
17	clarithromycin	S-Chemical	S-Chemical
18	.	O	O

0	The	O	O
1	patient	O	O
2	developed	O	O
3	raised	O	O
4	cardiac	O	S-Disease
5	biomarkers	O	O
6	without	O	O
7	any	O	O
8	obvious	O	O
9	cardiac	O	B-Disease
10	issues	O	E-Disease
11	,	O	O
12	a	O	O
13	phenomenon	O	O
14	that	O	O
15	has	O	O
16	been	O	O
17	linked	O	O
18	to	O	O
19	rhabdomyolysis	S-Disease	S-Disease
20	previously	O	O
21	.	O	O

0	To	O	O
1	date	O	O
2	,	O	O
3	there	O	O
4	has	O	O
5	been	O	O
6	no	O	O
7	reported	O	O
8	effect	O	O
9	of	O	O
10	rhabdomyolysis	S-Disease	S-Disease
11	on	O	O
12	the	O	O
13	structure	O	O
14	and	O	O
15	function	O	O
16	of	O	O
17	cardiac	O	B-Disease
18	muscle	O	E-Disease
19	.	O	O

0	Clinicians	O	O
1	need	O	O
2	to	O	O
3	be	O	O
4	aware	O	O
5	of	O	O
6	prescribing	O	O
7	concomitant	O	O
8	medications	O	O
9	that	O	O
10	increase	O	O
11	the	O	O
12	risk	O	O
13	of	O	O
14	myopathy	S-Disease	S-Disease
15	or	O	O
16	inhibit	O	O
17	the	O	O
18	CYP3A4	O	B-Chemical
19	enzyme	O	O
20	.	O	O

0	Our	O	O
1	case	O	O
2	suggests	O	O
3	that	O	O
4	troponin	O	S-Chemical
5	elevation	O	S-Disease
6	could	O	O
7	be	O	O
8	associated	O	O
9	with	O	O
10	statin	S-Chemical	S-Chemical
11	induced	O	O
12	rhabdomyolysis	S-Disease	S-Disease
13	,	O	O
14	which	O	O
15	may	O	O
16	warrant	O	O
17	further	O	O
18	studies	O	O
19	.	O	O

0	Characterization	O	O
1	of	O	O
2	a	O	O
3	novel	O	O
4	BCHE	O	S-Chemical
5	"	O	O
6	silent	O	O
7	"	O	O
8	allele	O	O
9	:	O	O
10	point	O	O
11	mutation	O	O
12	(	O	O
13	p	O	O
14	.	O	O
15	Val204Asp	O	S-Chemical
16	)	O	O
17	causes	O	O
18	loss	O	O
19	of	O	O
20	activity	O	S-Disease
21	and	O	O
22	prolonged	O	O
23	apnea	S-Disease	O
24	with	O	O
25	suxamethonium	S-Chemical	S-Chemical
26	.	O	O

0	Butyrylcholinesterase	B-Disease	S-Chemical
1	deficiency	E-Disease	S-Disease
2	is	O	O
3	characterized	O	O
4	by	O	O
5	prolonged	O	O
6	apnea	S-Disease	O
7	after	O	O
8	the	O	O
9	use	O	O
10	of	O	O
11	muscle	O	B-Disease
12	relaxants	O	E-Disease
13	(	O	O
14	suxamethonium	S-Chemical	S-Chemical
15	or	O	O
16	mivacurium	S-Chemical	S-Chemical
17	)	O	O
18	in	O	O
19	patients	O	O
20	who	O	O
21	have	O	O
22	mutations	O	O
23	in	O	O
24	the	O	O
25	BCHE	O	S-Chemical
26	gene	O	O
27	.	O	O

0	Here	O	O
1	,	O	O
2	we	O	O
3	report	O	O
4	a	O	O
5	case	O	O
6	of	O	O
7	prolonged	O	O
8	neuromuscular	O	S-Disease
9	block	O	O
10	after	O	O
11	administration	O	O
12	of	O	O
13	suxamethonium	S-Chemical	S-Chemical
14	leading	O	O
15	to	O	O
16	the	O	O
17	discovery	O	O
18	of	O	O
19	a	O	O
20	novel	O	O
21	BCHE	O	S-Chemical
22	variant	O	O
23	(	O	O
24	c	O	O
25	.	O	O
26	695T	O	O
27	>	O	O
28	A	O	O
29	,	O	O
30	p	O	O
31	.	O	O
32	Val204Asp	O	B-Chemical
33	)	O	O
34	.	O	O

0	Low	O	O
1	activity	O	O
2	of	O	O
3	patient	O	O
4	plasma	O	O
5	butyrylcholinesterase	O	S-Chemical
6	with	O	O
7	butyrylthiocholine	S-Chemical	S-Chemical
8	(	O	O
9	BTC	S-Chemical	S-Chemical
10	)	O	O
11	and	O	O
12	benzoylcholine	S-Chemical	S-Chemical
13	,	O	O
14	and	O	O
15	values	O	O
16	of	O	O
17	dibucaine	S-Chemical	S-Chemical
18	and	O	O
19	fluoride	S-Chemical	S-Chemical
20	numbers	O	O
21	fit	O	O
22	with	O	O
23	heterozygous	O	O
24	atypical	O	O
25	silent	O	O
26	genotype	O	O
27	.	O	O

0	Kinetic	O	O
1	analysis	O	O
2	showed	O	O
3	that	O	O
4	the	O	O
5	p	O	O
6	.	O	O
7	Val204Asp	O	S-Disease
8	/	O	O
9	p	O	O
10	.	O	O
11	Asp70Gly	O	S-Chemical
12	-	O	O
13	p	O	O
14	.	O	O
15	Ala539Thr	O	S-Chemical
16	BChE	O	S-Chemical
17	displays	O	O
18	a	O	O
19	pure	O	O
20	Michaelian	O	S-Chemical
21	behavior	O	O
22	with	O	O
23	BTC	S-Chemical	S-Chemical
24	as	O	O
25	the	O	O
26	substrate	O	O
27	.	O	O

0	Both	O	O
1	catalytic	O	O
2	parameters	O	O
3	Km	O	O
4	=	O	O
5	265	O	O
6	uM	O	O
7	for	O	O
8	BTC	S-Chemical	S-Disease
9	,	O	O
10	two	O	O
11	times	O	O
12	higher	O	O
13	than	O	O
14	that	O	O
15	of	O	O
16	the	O	O
17	atypical	O	O
18	enzyme	O	O
19	,	O	O
20	and	O	O
21	a	O	O
22	low	O	O
23	Vmax	O	S-Disease
24	are	O	O
25	consistent	O	O
26	with	O	O
27	the	O	O
28	absence	O	O
29	of	O	O
30	activity	O	O
31	against	O	O
32	suxamethonium	S-Chemical	S-Chemical
33	.	O	O

0	Molecular	O	O
1	dynamic	O	O
2	(	O	O
3	MD	O	O
4	)	O	O
5	simulations	O	O
6	showed	O	O
7	that	O	O
8	the	O	O
9	overall	O	O
10	effect	O	O
11	of	O	O
12	the	O	O
13	mutation	O	O
14	p	O	O
15	.	O	O
16	Val204Asp	O	S-Chemical
17	is	O	O
18	disruption	O	O
19	of	O	O
20	hydrogen	S-Chemical	O
21	bonding	O	O
22	between	O	O
23	Gln223	O	B-Chemical
24	and	O	O
25	Glu441	O	S-Chemical
26	,	O	O
27	leading	O	O
28	Ser198	O	B-Chemical
29	and	O	O
30	His438	O	S-Chemical
31	to	O	O
32	move	O	O
33	away	O	O
34	from	O	O
35	each	O	O
36	other	O	O
37	with	O	O
38	subsequent	O	O
39	disruption	O	O
40	of	O	O
41	the	O	O
42	catalytic	O	O
43	triad	O	O
44	functionality	O	O
45	regardless	O	O
46	of	O	O
47	the	O	O
48	type	O	O
49	of	O	O
50	substrate	O	O
51	.	O	O

0	Delayed	O	O
1	anemia	S-Disease	O
2	after	O	O
3	treatment	O	O
4	with	O	O
5	injectable	O	O
6	artesunate	S-Chemical	S-Disease
7	in	O	O
8	the	O	O
9	Democratic	O	O
10	Republic	O	S-Chemical
11	of	O	O
12	the	O	S-Chemical
13	Congo	O	O
14	:	O	O
15	a	O	O
16	manageable	O	O
17	issue	O	O
18	.	O	O

0	Cases	O	O
1	of	O	O
2	delayed	O	O
3	hemolytic	B-Disease	O
4	anemia	E-Disease	E-Disease
5	have	O	O
6	been	O	O
7	described	O	O
8	after	O	O
9	treatment	O	O
10	with	O	O
11	injectable	O	O
12	artesunate	S-Chemical	S-Disease
13	,	O	O
14	the	O	O
15	current	O	O
16	World	O	B-Disease
17	Health	O	I-Disease
18	Organization	O	S-Chemical
19	(	O	O
20	WHO	O	S-Chemical
21	)	O	O
22	-	O	O
23	recommended	O	O
24	first	O	O
25	-	O	O
26	line	O	O
27	drug	O	O
28	for	O	O
29	the	O	O
30	treatment	O	O
31	of	O	O
32	severe	O	O
33	malaria	S-Disease	S-Disease
34	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	350	O	O
4	patients	O	O
5	(	O	O
6	215	O	O
7	[	O	O
8	61	O	O
9	.	O	O
10	4	O	O
11	%	O	O
12	]	O	O
13	<	O	O
14	5	O	O
15	years	O	O
16	of	O	O
17	age	O	O
18	and	O	O
19	135	O	O
20	[	O	O
21	38	O	O
22	.	O	O
23	6	O	O
24	%	O	O
25	]	O	O
26	>	O	O
27	5	O	O
28	years	O	O
29	of	O	O
30	age	O	O
31	)	O	O
32	were	O	O
33	followed	O	O
34	-	O	O
35	up	O	O
36	after	O	O
37	treatment	O	O
38	with	O	O
39	injectable	O	O
40	artesunate	S-Chemical	O
41	for	O	O
42	severe	O	O
43	malaria	S-Disease	S-Disease
44	in	O	O
45	hospitals	O	O
46	and	O	O
47	health	O	O
48	centers	O	O
49	of	O	O
50	the	O	O
51	Democratic	O	S-Chemical
52	Republic	O	O
53	of	O	S-Chemical
54	the	O	O
55	Congo	O	O
56	.	O	O

0	All	O	O
1	cases	O	O
2	of	O	O
3	delayed	O	O
4	anemia	S-Disease	S-Disease
5	were	O	O
6	clinically	O	O
7	manageable	O	O
8	and	O	O
9	resolved	O	O
10	within	O	O
11	one	O	O
12	month	O	O
13	.	O	O

0	Regulation	O	O
1	of	O	O
2	signal	O	O
3	transducer	O	O
4	and	O	O
5	activator	O	O
6	of	O	O
7	transcription	O	O
8	3	O	O
9	and	O	O
10	apoptotic	O	O
11	pathways	O	O
12	by	O	O
13	betaine	S-Chemical	S-Chemical
14	attenuates	O	O
15	isoproterenol	S-Chemical	S-Chemical
16	-	O	O
17	induced	O	O
18	acute	O	B-Disease
19	myocardial	B-Disease	B-Disease
20	injury	E-Disease	E-Disease
21	in	O	O
22	rats	O	O
23	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	was	O	O
4	designed	O	O
5	to	O	O
6	investigate	O	O
7	the	O	O
8	cardioprotective	O	O
9	effects	O	O
10	of	O	O
11	betaine	S-Chemical	S-Chemical
12	on	O	O
13	acute	O	B-Disease
14	myocardial	B-Disease	B-Disease
15	ischemia	E-Disease	E-Disease
16	induced	O	O
17	experimentally	O	O
18	in	O	O
19	rats	O	O
20	focusing	O	O
21	on	O	O
22	regulation	O	O
23	of	O	O
24	signal	O	O
25	transducer	O	O
26	and	O	O
27	activator	O	O
28	of	O	O
29	transcription	O	O
30	3	O	O
31	(	O	O
32	STAT3	O	S-Chemical
33	)	O	O
34	and	O	O
35	apoptotic	O	O
36	pathways	O	O
37	as	O	O
38	the	O	O
39	potential	O	O
40	mechanism	O	O
41	underlying	O	O
42	the	O	O
43	drug	O	O
44	effect	O	O
45	.	O	O

0	Male	O	O
1	Sprague	O	O
2	Dawley	O	O
3	rats	O	O
4	were	O	O
5	treated	O	O
6	with	O	O
7	betaine	S-Chemical	S-Chemical
8	(	O	O
9	100	O	O
10	,	O	O
11	200	O	O
12	,	O	O
13	and	O	O
14	400	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	)	O	O
19	orally	O	O
20	for	O	O
21	40	O	O
22	days	O	O
23	.	O	O

0	Acute	O	O
1	myocardial	B-Disease	B-Disease
2	ischemic	I-Disease	E-Disease
3	injury	E-Disease	E-Disease
4	was	O	O
5	induced	O	O
6	in	O	O
7	rats	O	O
8	by	O	O
9	subcutaneous	O	O
10	injection	O	O
11	of	O	O
12	isoproterenol	S-Chemical	S-Chemical
13	(	O	O
14	85	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	)	O	O
19	,	O	O
20	for	O	O
21	two	O	O
22	consecutive	O	O
23	days	O	O
24	.	O	O

0	Oral	O	O
1	administration	O	O
2	of	O	O
3	betaine	S-Chemical	S-Chemical
4	(	O	O
5	200	O	O
6	and	O	O
7	400	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	)	O	O
12	significantly	O	O
13	reduced	O	O
14	the	O	O
15	level	O	O
16	of	O	O
17	cardiac	O	B-Disease
18	marker	O	O
19	enzyme	O	O
20	in	O	O
21	the	O	O
22	serum	O	O
23	and	O	O
24	prevented	O	O
25	left	O	O
26	ventricular	B-Disease	B-Disease
27	remodeling	E-Disease	E-Disease
28	.	O	O

0	Western	O	O
1	blot	O	O
2	analysis	O	O
3	showed	O	O
4	that	O	O
5	isoproterenol	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	phosphorylation	O	O
9	of	O	O
10	STAT3	O	B-Chemical
11	was	O	O
12	maintained	O	O
13	or	O	O
14	further	O	O
15	enhanced	O	O
16	by	O	O
17	betaine	S-Chemical	S-Chemical
18	treatment	O	O
19	in	O	O
20	myocardium	O	S-Chemical
21	.	O	O

0	Furthermore	O	O
1	,	O	O
2	betaine	S-Chemical	S-Chemical
3	(	O	O
4	200	O	O
5	and	O	O
6	400	O	O
7	mg	O	O
8	/	O	O
9	kg	O	O
10	)	O	O
11	treatment	O	O
12	increased	O	O
13	the	O	O
14	ventricular	O	O
15	expression	O	O
16	of	O	O
17	Bcl	O	S-Chemical
18	-	O	E-Chemical
19	2	O	O
20	and	O	O
21	reduced	O	O
22	the	O	O
23	level	O	O
24	of	O	O
25	Bax	O	S-Chemical
26	,	O	O
27	therefore	O	O
28	causing	O	O
29	a	O	O
30	significant	O	O
31	increase	O	O
32	in	O	O
33	the	O	O
34	ratio	O	O
35	of	O	O
36	Bcl	O	S-Chemical
37	-	O	O
38	2	O	O
39	/	O	O
40	Bax	O	O
41	.	O	O

0	The	O	O
1	protective	O	O
2	role	O	O
3	of	O	O
4	betaine	S-Chemical	S-Chemical
5	on	O	O
6	myocardial	B-Disease	B-Disease
7	damage	E-Disease	E-Disease
8	was	O	O
9	further	O	O
10	confirmed	O	O
11	by	O	O
12	histopathological	O	O
13	examination	O	O
14	.	O	O

0	In	O	O
1	summary	O	O
2	,	O	O
3	our	O	O
4	results	O	O
5	showed	O	O
6	that	O	O
7	betaine	S-Chemical	S-Chemical
8	pretreatment	O	O
9	attenuated	O	O
10	isoproterenol	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	acute	O	B-Disease
14	myocardial	B-Disease	I-Disease
15	ischemia	E-Disease	E-Disease
16	via	O	O
17	the	O	O
18	regulation	O	O
19	of	O	O
20	STAT3	O	S-Chemical
21	and	O	O
22	apoptotic	O	O
23	pathways	O	O
24	.	O	O

0	Quetiapine	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	neutropenia	S-Disease	S-Disease
4	in	O	O
5	a	O	O
6	bipolar	S-Disease	O
7	patient	O	O
8	with	O	O
9	hepatocellular	B-Disease	B-Disease
10	carcinoma	E-Disease	E-Disease
11	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	Quetiapine	S-Chemical	S-Chemical
3	is	O	O
4	a	O	O
5	dibenzothiazepine	O	S-Chemical
6	derivative	O	O
7	,	O	O
8	similar	O	O
9	to	O	O
10	clozapine	S-Chemical	S-Chemical
11	,	O	O
12	which	O	O
13	has	O	O
14	the	O	O
15	highest	O	O
16	risk	O	O
17	of	O	O
18	causing	O	O
19	blood	B-Disease	B-Disease
20	dyscrasias	E-Disease	E-Disease
21	,	O	O
22	especially	O	O
23	neutropenia	S-Disease	S-Disease
24	.	O	O

0	There	O	O
1	are	O	O
2	some	O	O
3	case	O	O
4	reports	O	O
5	about	O	O
6	this	O	O
7	side	O	O
8	effect	O	O
9	of	O	O
10	quetiapine	S-Chemical	S-Chemical
11	,	O	O
12	but	O	O
13	possible	O	O
14	risk	O	O
15	factors	O	O
16	are	O	O
17	seldom	O	O
18	discussed	O	O
19	and	O	O
20	identified	O	O
21	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	a	O	O
4	patient	O	O
5	with	O	O
6	hepatocellular	B-Disease	B-Disease
7	carcinoma	E-Disease	E-Disease
8	that	O	O
9	developed	O	O
10	neutropenia	S-Disease	S-Disease
11	after	O	O
12	treatment	O	O
13	with	O	O
14	quetiapine	S-Chemical	S-Chemical
15	is	O	O
16	described	O	O
17	here	O	O
18	.	O	O

0	CASE	O	O
1	REPORT	O	O
2	:	O	O
3	A	O	O
4	62	O	O
5	-	O	O
6	year	O	O
7	-	O	O
8	old	O	O
9	Taiwanese	O	S-Chemical
10	widow	O	O
11	with	O	O
12	bipolar	B-Disease	B-Disease
13	disorder	E-Disease	E-Disease
14	was	O	O
15	diagnosed	O	O
16	with	O	O
17	hepatocellular	B-Disease	B-Disease
18	carcinoma	E-Disease	I-Disease
19	at	O	O
20	age	O	O
21	60	O	O
22	.	O	O

0	She	O	O
1	developed	O	O
2	leucopenia	S-Disease	S-Disease
3	after	O	O
4	being	O	O
5	treated	O	O
6	with	O	O
7	quetiapine	S-Chemical	S-Chemical
8	.	O	O

0	After	O	O
1	quetiapine	S-Chemical	S-Chemical
2	was	O	O
3	discontinued	O	O
4	,	O	O
5	her	O	O
6	white	O	O
7	blood	O	O
8	cell	O	O
9	count	O	O
10	returned	O	O
11	to	O	O
12	normal	O	O
13	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Although	O	O
3	neutropenia	S-Disease	S-Disease
4	is	O	O
5	not	O	O
6	a	O	O
7	common	O	O
8	side	O	O
9	effect	O	O
10	of	O	O
11	quetiapine	S-Chemical	S-Chemical
12	,	O	O
13	physicians	O	O
14	should	O	O
15	be	O	O
16	cautious	O	O
17	about	O	O
18	its	O	O
19	presentation	O	O
20	and	O	O
21	associated	O	O
22	risk	O	O
23	factors	O	O
24	.	O	O

0	Hepatic	B-Disease	S-Chemical
1	dysfunction	E-Disease	S-Disease
2	may	O	O
3	be	O	O
4	one	O	O
5	of	O	O
6	the	O	O
7	possible	O	O
8	risk	O	O
9	factors	O	O
10	,	O	O
11	and	O	O
12	concomitant	O	O
13	fever	S-Disease	S-Disease
14	may	O	O
15	be	O	O
16	a	O	O
17	diagnostic	O	O
18	marker	O	O
19	for	O	O
20	adverse	O	O
21	reaction	O	O
22	to	O	O
23	quetiapine	S-Chemical	S-Chemical
24	.	O	O

0	Lateral	O	O
1	antebrachial	O	O
2	cutaneous	O	I-Disease
3	neuropathy	S-Disease	S-Disease
4	after	O	O
5	steroid	S-Chemical	S-Chemical
6	injection	O	O
7	at	O	O
8	lateral	O	O
9	epicondyle	O	E-Disease
10	.	O	O

0	BACKGROUND	O	O
1	AND	O	O
2	OBJECTIVES	O	O
3	:	O	O
4	This	O	O
5	report	O	O
6	aimed	O	O
7	to	O	O
8	present	O	O
9	a	O	O
10	case	O	O
11	of	O	O
12	lateral	O	O
13	antebrachial	O	I-Disease
14	cutaneous	O	I-Disease
15	neuropathy	S-Disease	E-Disease
16	(	O	O
17	LACNP	O	S-Disease
18	)	O	O
19	that	O	O
20	occurred	O	O
21	after	O	O
22	a	O	O
23	steroid	S-Chemical	S-Chemical
24	injection	O	O
25	in	O	O
26	the	O	O
27	lateral	O	O
28	epicondyle	O	S-Disease
29	to	O	O
30	treat	O	O
31	lateral	B-Disease	B-Disease
32	epicondylitis	E-Disease	E-Disease
33	in	O	O
34	a	O	O
35	40	O	O
36	-	O	O
37	year	O	O
38	-	O	O
39	old	O	O
40	woman	O	O
41	.	O	O

0	MATERIAL	O	O
1	AND	O	O
2	METHOD	O	O
3	:	O	O
4	A	O	O
5	40	O	O
6	-	O	O
7	year	O	O
8	-	O	O
9	old	O	O
10	woman	O	O
11	presented	O	O
12	with	O	O
13	decreased	O	O
14	sensation	O	S-Disease
15	and	O	O
16	paresthesia	S-Disease	S-Disease
17	over	O	O
18	her	O	O
19	right	O	O
20	lateral	O	O
21	forearm	O	O
22	;	O	O
23	the	O	O
24	paresthesia	S-Disease	O
25	had	O	O
26	occurred	O	O
27	after	O	O
28	a	O	O
29	steroid	S-Chemical	S-Chemical
30	injection	O	O
31	in	O	O
32	the	O	O
33	right	O	O
34	lateral	O	O
35	epicondyle	O	S-Disease
36	3	O	O
37	months	O	O
38	before	O	O
39	.	O	O

0	Her	O	O
1	sensation	O	O
2	of	O	O
3	light	O	O
4	touch	O	O
5	and	O	O
6	pain	S-Disease	O
7	was	O	O
8	diminished	O	O
9	over	O	O
10	the	O	O
11	lateral	O	O
12	side	O	O
13	of	O	O
14	the	O	O
15	right	O	O
16	forearm	O	O
17	and	O	O
18	wrist	O	O
19	area	O	O
20	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	This	O	O
3	report	O	O
4	describes	O	O
5	the	O	O
6	case	O	O
7	of	O	O
8	a	O	O
9	woman	O	O
10	with	O	O
11	LACNP	O	S-Disease
12	that	O	O
13	developed	O	O
14	after	O	O
15	a	O	O
16	steroid	S-Chemical	S-Chemical
17	injection	O	O
18	for	O	O
19	the	O	O
20	treatment	O	O
21	of	O	O
22	lateral	B-Disease	B-Disease
23	epicondylitis	E-Disease	E-Disease
24	.	O	O

0	Curcumin	S-Chemical	S-Chemical
1	prevents	O	O
2	maleate	S-Chemical	O
3	-	O	O
4	induced	O	O
5	nephrotoxicity	S-Disease	S-Disease
6	:	O	O
7	relation	O	O
8	to	O	O
9	hemodynamic	O	O
10	alterations	O	O
11	,	O	O
12	oxidative	O	O
13	stress	O	O
14	,	O	O
15	mitochondrial	O	B-Disease
16	oxygen	S-Chemical	I-Disease
17	consumption	O	E-Disease
18	and	O	O
19	activity	O	O
20	of	O	O
21	respiratory	O	B-Disease
22	complex	O	E-Disease
23	I	O	E-Disease
24	.	O	O

0	The	O	O
1	potential	O	O
2	protective	O	O
3	effect	O	O
4	of	O	O
5	the	O	O
6	dietary	O	O
7	antioxidant	O	O
8	curcumin	S-Chemical	S-Chemical
9	(	O	O
10	120	O	O
11	mg	O	O
12	/	O	O
13	Kg	O	O
14	/	O	O
15	day	O	O
16	for	O	O
17	6	O	O
18	days	O	O
19	)	O	O
20	against	O	O
21	the	O	O
22	renal	B-Disease	B-Disease
23	injury	E-Disease	E-Disease
24	induced	O	O
25	by	O	O
26	maleate	S-Chemical	O
27	was	O	O
28	evaluated	O	O
29	.	O	O

0	Tubular	O	O
1	proteinuria	S-Disease	S-Disease
2	and	O	O
3	oxidative	O	O
4	stress	O	O
5	were	O	O
6	induced	O	O
7	by	O	O
8	a	O	O
9	single	O	O
10	injection	O	O
11	of	O	O
12	maleate	S-Chemical	S-Chemical
13	(	O	O
14	400	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	)	O	O
19	in	O	O
20	rats	O	O
21	.	O	O

0	Maleate	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	renal	B-Disease	B-Disease
4	injury	E-Disease	E-Disease
5	included	O	O
6	increase	O	O
7	in	O	O
8	renal	O	I-Disease
9	vascular	O	I-Disease
10	resistance	O	E-Disease
11	and	O	O
12	in	O	O
13	the	O	O
14	urinary	O	O
15	excretion	O	O
16	of	O	O
17	total	O	O
18	protein	O	O
19	,	O	O
20	glucose	S-Chemical	S-Disease
21	,	O	O
22	sodium	S-Chemical	S-Disease
23	,	O	O
24	neutrophil	O	S-Disease
25	gelatinase	O	E-Chemical
26	-	O	O
27	associated	O	O
28	lipocalin	O	S-Chemical
29	(	O	O
30	NGAL	O	S-Chemical
31	)	O	O
32	and	O	O
33	N	O	B-Chemical
34	-	O	O
35	acetyl	O	E-Chemical
36	b	O	I-Chemical
37	-	O	O
38	D	O	I-Chemical
39	-	O	I-Chemical
40	glucosaminidase	O	E-Chemical
41	(	O	O
42	NAG	O	S-Chemical
43	)	O	O
44	,	O	O
45	upregulation	O	O
46	of	O	O
47	kidney	B-Disease	B-Disease
48	injury	E-Disease	E-Disease
49	molecule	O	E-Disease
50	(	O	O
51	KIM	O	B-Chemical
52	)	O	E-Chemical
53	-	O	E-Chemical
54	1	O	E-Chemical
55	,	O	O
56	decrease	O	O
57	in	O	O
58	renal	O	I-Disease
59	blood	O	I-Disease
60	flow	O	E-Disease
61	and	O	O
62	claudin	O	S-Chemical
63	-	O	E-Chemical
64	2	O	E-Chemical
65	expression	O	O
66	besides	O	O
67	of	O	O
68	necrosis	S-Disease	S-Disease
69	and	O	O
70	apoptosis	O	S-Disease
71	of	O	O
72	tubular	O	B-Disease
73	cells	O	E-Disease
74	on	O	O
75	24	O	O
76	h	O	O
77	.	O	O

0	Maleate	S-Chemical	S-Chemical
1	induced	O	O
2	cell	O	O
3	damage	O	O
4	and	O	O
5	reactive	O	O
6	oxygen	S-Chemical	I-Disease
7	species	O	O
8	(	O	O
9	ROS	O	S-Disease
10	)	O	O
11	production	O	O
12	in	O	O
13	LLC	O	B-Chemical
14	-	O	O
15	PK1	O	E-Chemical
16	cells	O	O
17	in	O	O
18	culture	O	O
19	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	maleate	S-Chemical	S-Chemical
4	treatment	O	O
5	reduced	O	O
6	oxygen	S-Chemical	S-Disease
7	consumption	O	O
8	in	O	O
9	ADP	S-Chemical	S-Chemical
10	-	O	O
11	stimulated	O	O
12	mitochondria	O	S-Disease
13	and	O	O
14	diminished	O	O
15	respiratory	O	B-Disease
16	control	O	I-Disease
17	index	O	O
18	when	O	O
19	using	O	O
20	malate	S-Chemical	B-Chemical
21	/	O	I-Chemical
22	glutamate	S-Chemical	E-Chemical
23	as	O	O
24	substrate	O	O
25	.	O	O

0	All	O	O
1	the	O	O
2	above	O	O
3	-	O	O
4	described	O	O
5	alterations	O	O
6	were	O	O
7	prevented	O	O
8	by	O	O
9	curcumin	S-Chemical	S-Chemical
10	.	O	O

0	It	O	O
1	is	O	O
2	concluded	O	O
3	that	O	O
4	curcumin	S-Chemical	S-Chemical
5	is	O	O
6	able	O	O
7	to	O	O
8	attenuate	O	O
9	in	O	O
10	vivo	O	O
11	maleate	S-Chemical	S-Disease
12	-	O	O
13	induced	O	O
14	nephropathy	S-Disease	S-Disease
15	and	O	O
16	in	O	O
17	vitro	O	O
18	cell	O	O
19	damage	O	E-Disease
20	.	O	O

0	The	O	O
1	in	O	O
2	vivo	O	O
3	protection	O	O
4	was	O	O
5	associated	O	O
6	to	O	O
7	the	O	O
8	prevention	O	O
9	of	O	O
10	oxidative	O	O
11	stress	O	O
12	and	O	O
13	preservation	O	O
14	of	O	O
15	mitochondrial	O	B-Disease
16	oxygen	S-Chemical	I-Disease
17	consumption	O	E-Disease
18	and	O	O
19	activity	O	O
20	of	O	O
21	respiratory	O	B-Disease
22	complex	O	E-Disease
23	I	O	E-Disease
24	,	O	O
25	and	O	O
26	the	O	O
27	in	O	O
28	vitro	O	O
29	protection	O	O
30	was	O	O
31	associated	O	O
32	to	O	O
33	the	O	O
34	prevention	O	O
35	of	O	O
36	ROS	O	S-Disease
37	production	O	O
38	.	O	O

0	Anticonvulsant	O	O
1	actions	O	O
2	of	O	O
3	MK	B-Chemical	B-Chemical
4	-	I-Chemical	E-Chemical
5	801	E-Chemical	E-Chemical
6	on	O	O
7	the	O	O
8	lithium	S-Chemical	S-Chemical
9	-	O	O
10	pilocarpine	S-Chemical	E-Chemical
11	model	O	O
12	of	O	O
13	status	B-Disease	B-Disease
14	epilepticus	E-Disease	E-Disease
15	in	O	O
16	rats	O	O
17	.	O	O

0	MK	B-Chemical	B-Chemical
1	-	I-Chemical	E-Chemical
2	801	E-Chemical	E-Chemical
3	,	O	O
4	a	O	O
5	noncompetitive	O	O
6	N	B-Chemical	B-Chemical
7	-	I-Chemical	I-Chemical
8	methyl	I-Chemical	E-Chemical
9	-	I-Chemical	I-Chemical
10	D	I-Chemical	I-Chemical
11	-	I-Chemical	I-Chemical
12	aspartate	E-Chemical	E-Chemical
13	(	O	O
14	NMDA	S-Chemical	O
15	)	O	O
16	receptor	O	O
17	antagonist	O	O
18	,	O	O
19	was	O	O
20	tested	O	O
21	for	O	O
22	anticonvulsant	O	O
23	effects	O	O
24	in	O	O
25	rats	O	O
26	using	O	O
27	two	O	O
28	seizure	S-Disease	O
29	models	O	O
30	,	O	O
31	coadministration	O	O
32	of	O	O
33	lithium	S-Chemical	S-Chemical
34	and	O	O
35	pilocarpine	S-Chemical	S-Chemical
36	and	O	O
37	administration	O	O
38	of	O	O
39	a	O	O
40	high	O	O
41	dose	O	O
42	of	O	O
43	pilocarpine	S-Chemical	S-Chemical
44	alone	O	O
45	.	O	O

0	First	O	O
1	,	O	O
2	pretreatment	O	O
3	with	O	O
4	MK	B-Chemical	B-Chemical
5	-	I-Chemical	E-Chemical
6	801	E-Chemical	E-Chemical
7	produced	O	O
8	an	O	O
9	effective	O	O
10	and	O	O
11	dose	O	O
12	-	O	O
13	dependent	O	O
14	anticonvulsant	O	O
15	action	O	O
16	with	O	O
17	the	O	O
18	lithium	S-Chemical	S-Chemical
19	-	O	O
20	pilocarpine	S-Chemical	S-Chemical
21	model	O	O
22	but	O	O
23	not	O	O
24	with	O	O
25	rats	O	O
26	treated	O	O
27	with	O	O
28	pilocarpine	S-Chemical	S-Chemical
29	alone	O	O
30	,	O	O
31	suggesting	O	O
32	that	O	O
33	different	O	O
34	biochemical	O	O
35	mechanisms	O	O
36	control	O	O
37	seizures	S-Disease	S-Disease
38	in	O	O
39	these	O	O
40	two	O	O
41	models	O	O
42	.	O	O

0	Second	O	O
1	,	O	O
2	the	O	O
3	anticonvulsant	O	O
4	effect	O	O
5	of	O	O
6	MK	B-Chemical	B-Chemical
7	-	I-Chemical	E-Chemical
8	801	E-Chemical	E-Chemical
9	in	O	O
10	the	O	O
11	lithium	S-Chemical	S-Chemical
12	-	O	O
13	pilocarpine	S-Chemical	E-Chemical
14	model	O	O
15	only	O	O
16	occurred	O	O
17	after	O	O
18	initial	O	O
19	periods	O	O
20	of	O	O
21	seizure	S-Disease	S-Disease
22	activity	O	O
23	.	O	O

0	This	O	O
1	observation	O	O
2	is	O	O
3	suggested	O	O
4	to	O	O
5	be	O	O
6	an	O	O
7	in	O	O
8	vivo	O	O
9	demonstration	O	O
10	of	O	O
11	the	O	O
12	conclusion	O	O
13	derived	O	O
14	from	O	O
15	in	O	O
16	vitro	O	O
17	experiments	O	O
18	that	O	O
19	MK	B-Chemical	B-Chemical
20	-	I-Chemical	I-Chemical
21	801	E-Chemical	E-Chemical
22	binding	O	O
23	requires	O	O
24	agonist	O	O
25	-	O	O
26	induced	O	O
27	opening	O	O
28	of	O	O
29	the	O	O
30	channel	O	O
31	sites	O	O
32	of	O	O
33	the	O	O
34	NMDA	S-Chemical	O
35	receptor	O	O
36	.	O	O

0	Third	O	O
1	,	O	O
2	although	O	O
3	it	O	O
4	is	O	O
5	relatively	O	O
6	easy	O	O
7	to	O	O
8	block	O	O
9	seizures	S-Disease	S-Disease
10	induced	O	O
11	by	O	O
12	lithium	S-Chemical	S-Chemical
13	and	O	O
14	pilocarpine	S-Chemical	S-Chemical
15	by	O	O
16	administration	O	O
17	of	O	O
18	anticonvulsants	O	O
19	prior	O	O
20	to	O	O
21	pilocarpine	S-Chemical	S-Chemical
22	,	O	O
23	it	O	O
24	is	O	O
25	more	O	O
26	difficult	O	O
27	to	O	O
28	terminate	O	O
29	ongoing	O	O
30	status	B-Disease	O
31	epilepticus	E-Disease	S-Disease
32	and	O	O
33	block	O	O
34	the	O	O
35	lethality	O	O
36	of	O	O
37	the	O	O
38	seizures	S-Disease	S-Disease
39	.	O	O

0	Administration	O	O
1	of	O	O
2	MK	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	801	E-Chemical	E-Chemical
5	30	O	O
6	or	O	O
7	60	O	O
8	min	O	O
9	after	O	O
10	pilocarpine	S-Chemical	S-Chemical
11	,	O	O
12	i	O	O
13	.	O	O
14	e	O	O
15	.	O	O
16	,	O	O
17	during	O	O
18	status	B-Disease	O
19	epilepticus	E-Disease	E-Disease
20	,	O	O
21	gradually	O	O
22	reduced	O	O
23	electrical	O	B-Disease
24	and	O	O
25	behavioral	O	B-Disease
26	seizure	S-Disease	B-Disease
27	activity	O	E-Disease
28	and	O	O
29	greatly	O	O
30	enhanced	O	O
31	the	O	O
32	survival	O	O
33	rate	O	O
34	.	O	O

0	These	O	O
1	results	O	O
2	suggest	O	O
3	that	O	O
4	activation	O	O
5	of	O	O
6	NMDA	S-Chemical	S-Disease
7	receptors	O	O
8	plays	O	O
9	an	O	O
10	important	O	O
11	role	O	O
12	in	O	O
13	status	B-Disease	B-Disease
14	epilepticus	E-Disease	E-Disease
15	and	O	O
16	brain	B-Disease	B-Disease
17	damage	E-Disease	E-Disease
18	in	O	O
19	the	O	O
20	lithium	S-Chemical	S-Chemical
21	-	O	O
22	pilocarpine	S-Chemical	S-Chemical
23	model	O	O
24	.	O	O

0	This	O	O
1	was	O	O
2	further	O	O
3	supported	O	O
4	by	O	O
5	results	O	O
6	showing	O	O
7	that	O	O
8	nonconvulsive	O	O
9	doses	O	O
10	of	O	O
11	NMDA	S-Chemical	S-Chemical
12	and	O	O
13	pilocarpine	S-Chemical	S-Chemical
14	were	O	O
15	synergistic	O	O
16	,	O	O
17	resulting	O	O
18	in	O	O
19	status	B-Disease	O
20	epilepticus	E-Disease	E-Disease
21	and	O	O
22	subsequent	O	O
23	mortality	O	O
24	.	O	O

0	Continuous	O	O
1	infusion	O	O
2	tobramycin	S-Chemical	S-Chemical
3	combined	O	O
4	with	O	O
5	carbenicillin	S-Chemical	S-Chemical
6	for	O	O
7	infections	S-Disease	S-Disease
8	in	O	O
9	cancer	S-Disease	S-Disease
10	patients	O	O
11	.	O	O

0	The	O	O
1	cure	O	O
2	rate	O	O
3	of	O	O
4	infections	S-Disease	S-Disease
5	in	O	O
6	cancer	S-Disease	S-Disease
7	patients	O	O
8	is	O	O
9	adversely	O	O
10	affected	O	O
11	by	O	O
12	neutropenia	S-Disease	S-Disease
13	(	O	O
14	less	O	O
15	than	O	O
16	1	O	O
17	,	O	O
18	000	O	O
19	/	O	O
20	mm3	O	O
21	)	O	O
22	.	O	O

0	In	O	O
1	particular	O	O
2	,	O	O
3	patients	O	O
4	with	O	O
5	severe	O	O
6	neutropenia	S-Disease	S-Disease
7	(	O	O
8	less	O	O
9	than	O	O
10	100	O	O
11	/	O	O
12	mm3	O	O
13	)	O	O
14	have	O	O
15	shown	O	O
16	a	O	O
17	poor	O	O
18	response	O	O
19	to	O	O
20	antibiotics	O	O
21	.	O	O

0	To	O	O
1	overcome	O	O
2	the	O	O
3	adverse	O	O
4	effects	O	O
5	of	O	O
6	neutropenia	S-Disease	S-Chemical
7	,	O	O
8	tobramycin	S-Chemical	S-Chemical
9	was	O	O
10	given	O	O
11	by	O	O
12	continuous	O	O
13	infusion	O	O
14	and	O	O
15	combined	O	O
16	with	O	O
17	intermittent	O	O
18	carbenicillin	S-Chemical	S-Chemical
19	.	O	O

0	Tobramycin	S-Chemical	S-Chemical
1	was	O	O
2	given	O	O
3	to	O	O
4	a	O	O
5	total	O	O
6	daily	O	O
7	dose	O	O
8	of	O	O
9	300	O	O
10	mg	O	O
11	/	O	O
12	m2	O	O
13	and	O	O
14	carbenicillin	S-Chemical	S-Chemical
15	was	O	O
16	given	O	O
17	at	O	O
18	a	O	O
19	dose	O	O
20	of	O	O
21	5	O	O
22	gm	O	O
23	every	O	O
24	four	O	O
25	hours	O	O
26	.	O	O

0	There	O	O
1	were	O	O
2	125	O	O
3	infectious	O	O
4	episodes	O	O
5	in	O	O
6	116	O	O
7	cancer	S-Disease	S-Disease
8	patients	O	O
9	receiving	O	O
10	myelosuppressive	O	S-Disease
11	chemotherapy	O	O
12	.	O	O

0	Pneumonia	S-Disease	S-Chemical
1	was	O	O
2	the	O	O
3	most	O	O
4	common	O	O
5	infection	S-Disease	S-Disease
6	and	O	O
7	61	O	O
8	%	O	O
9	of	O	O
10	59	O	O
11	episodes	O	O
12	were	O	O
13	cured	O	O
14	.	O	O

0	Gram	O	O
1	-	O	O
2	negative	O	O
3	bacilli	O	S-Disease
4	were	O	O
5	the	O	O
6	most	O	O
7	common	O	O
8	causative	O	O
9	organisms	O	O
10	and	O	O
11	69	O	O
12	%	O	O
13	of	O	O
14	these	O	O
15	infections	S-Disease	S-Disease
16	were	O	O
17	cured	O	O
18	.	O	O

0	The	O	O
1	most	O	O
2	common	O	O
3	pathogen	O	O
4	was	O	O
5	Klebsiella	O	B-Disease
6	pneumoniae	S-Disease	E-Disease
7	and	O	O
8	this	O	O
9	,	O	O
10	together	O	O
11	with	O	O
12	Escherichia	O	B-Disease
13	coli	O	E-Disease
14	and	O	O
15	Pseudomonas	O	B-Disease
16	aeruginosa	O	E-Disease
17	,	O	O
18	accounted	O	O
19	for	O	O
20	74	O	O
21	%	O	O
22	of	O	O
23	all	O	O
24	gram	B-Disease	O
25	-	I-Disease	O
26	negative	I-Disease	O
27	bacillary	I-Disease	S-Disease
28	infections	E-Disease	S-Disease
29	.	O	O

0	Response	O	O
1	was	O	O
2	not	O	O
3	influenced	O	O
4	by	O	O
5	the	O	O
6	initial	O	O
7	neutrophil	O	S-Disease
8	count	O	O
9	,	O	O
10	with	O	O
11	a	O	O
12	62	O	O
13	%	O	O
14	cure	O	O
15	rate	O	O
16	for	O	O
17	39	O	O
18	episodes	O	O
19	associated	O	O
20	with	O	O
21	severe	O	O
22	neutropenia	S-Disease	S-Disease
23	.	O	O

0	Azotemia	S-Disease	S-Chemical
1	was	O	O
2	the	O	O
3	major	O	O
4	side	O	O
5	effect	O	O
6	recognized	O	O
7	,	O	O
8	and	O	O
9	it	O	O
10	occurred	O	O
11	in	O	O
12	11	O	O
13	%	O	O
14	of	O	O
15	episodes	O	O
16	.	O	O

0	Major	O	O
1	azotemia	S-Disease	O
2	(	O	O
3	serum	O	O
4	creatinine	S-Chemical	S-Chemical
5	greater	O	O
6	than	O	O
7	2	O	O
8	.	O	O
9	5	O	O
10	mg	O	O
11	/	O	O
12	dl	O	O
13	or	O	O
14	BUN	O	O
15	greater	O	O
16	than	O	O
17	50	O	O
18	mg	O	O
19	/	O	O
20	dl	O	O
21	)	O	O
22	occurred	O	O
23	in	O	O
24	only	O	O
25	2	O	O
26	%	O	O
27	.	O	O

0	Azotemia	S-Disease	S-Chemical
1	was	O	O
2	not	O	O
3	related	O	O
4	to	O	O
5	duration	O	O
6	of	O	O
7	therapy	O	O
8	or	O	O
9	serum	O	O
10	tobramycin	S-Chemical	S-Chemical
11	concentration	O	O
12	.	O	O

0	This	O	O
1	antibiotic	O	O
2	regimen	O	O
3	showed	O	O
4	both	O	O
5	therapeutic	O	O
6	efficacy	O	O
7	and	O	O
8	acceptable	O	O
9	renal	B-Disease	B-Disease
10	toxicity	E-Disease	E-Disease
11	for	O	O
12	these	O	O
13	patients	O	O
14	.	O	O

0	Incidence	O	O
1	of	O	O
2	solid	O	O
3	tumours	S-Disease	O
4	among	O	O
5	pesticide	O	O
6	applicators	O	O
7	exposed	O	O
8	to	O	O
9	the	O	O
10	organophosphate	S-Chemical	S-Chemical
11	insecticide	O	O
12	diazinon	S-Chemical	S-Chemical
13	in	O	O
14	the	O	O
15	Agricultural	O	B-Disease
16	Health	O	I-Disease
17	Study	O	E-Disease
18	:	O	O
19	an	O	O
20	updated	O	O
21	analysis	O	O
22	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	Diazinon	S-Chemical	S-Chemical
3	,	O	O
4	a	O	O
5	common	O	O
6	organophosphate	S-Chemical	S-Chemical
7	insecticide	O	O
8	with	O	O
9	genotoxic	O	O
10	properties	O	O
11	,	O	O
12	was	O	O
13	previously	O	O
14	associated	O	O
15	with	O	O
16	lung	B-Disease	B-Disease
17	cancer	E-Disease	E-Disease
18	in	O	O
19	the	O	O
20	Agricultural	O	B-Disease
21	Health	O	I-Disease
22	Study	O	E-Disease
23	(	O	O
24	AHS	O	S-Chemical
25	)	O	O
26	cohort	O	O
27	,	O	O
28	but	O	O
29	few	O	O
30	other	O	O
31	epidemiological	O	O
32	studies	O	O
33	have	O	O
34	examined	O	O
35	diazinon	S-Chemical	S-Chemical
36	-	O	O
37	associated	O	O
38	cancer	S-Disease	S-Disease
39	risk	O	O
40	.	O	O

0	We	O	O
1	used	O	O
2	updated	O	O
3	diazinon	S-Chemical	S-Chemical
4	exposure	O	O
5	and	O	O
6	cancer	S-Disease	S-Disease
7	incidence	O	O
8	information	O	O
9	to	O	O
10	evaluate	O	O
11	solid	O	O
12	tumour	S-Disease	I-Disease
13	risk	O	O
14	in	O	O
15	the	O	O
16	AHS	O	S-Chemical
17	.	O	O

0	METHODS	O	O
1	:	O	O
2	Male	O	O
3	pesticide	O	O
4	applicators	O	O
5	in	O	O
6	Iowa	O	S-Chemical
7	and	O	O
8	North	O	O
9	Carolina	O	O
10	reported	O	O
11	lifetime	O	O
12	diazinon	S-Chemical	S-Chemical
13	use	O	O
14	at	O	O
15	enrolment	O	O
16	(	O	O
17	1993	O	O
18	-	O	O
19	1997	O	O
20	)	O	O
21	and	O	O
22	follow	O	O
23	-	O	O
24	up	O	O
25	(	O	O
26	1998	O	O
27	-	O	O
28	2005	O	O
29	)	O	O
30	;	O	O
31	cancer	S-Disease	S-Disease
32	incidence	O	O
33	was	O	O
34	assessed	O	O
35	through	O	O
36	2010	O	O
37	(	O	O
38	North	O	O
39	Carolina	O	O
40	)	O	O
41	/	O	O
42	2011	O	O
43	(	O	O
44	Iowa	O	S-Chemical
45	)	O	O
46	.	O	O

0	Among	O	O
1	applicators	O	O
2	with	O	O
3	usage	O	O
4	information	O	O
5	sufficient	O	O
6	to	O	O
7	evaluate	O	O
8	exposure	O	O
9	-	O	O
10	response	O	O
11	patterns	O	O
12	,	O	O
13	we	O	O
14	used	O	O
15	Poisson	O	S-Chemical
16	regression	O	O
17	to	O	O
18	estimate	O	O
19	adjusted	O	O
20	rate	O	O
21	ratios	O	O
22	(	O	O
23	RRs	O	O
24	)	O	O
25	and	O	O
26	95	O	O
27	%	O	O
28	CI	O	S-Chemical
29	for	O	O
30	cancer	S-Disease	S-Disease
31	sites	O	O
32	with	O	O
33	>	O	O
34	10	O	O
35	exposed	O	O
36	cases	O	O
37	for	O	O
38	both	O	O
39	lifetime	O	O
40	(	O	O
41	LT	O	O
42	)	O	O
43	exposure	O	O
44	days	O	O
45	and	O	O
46	intensity	O	O
47	-	O	O
48	weighted	O	O
49	(	O	O
50	IW	O	O
51	)	O	O
52	lifetime	O	O
53	exposure	O	O
54	days	O	O
55	(	O	O
56	accounting	O	O
57	for	O	O
58	factors	O	O
59	impacting	O	O
60	exposure	O	O
61	)	O	O
62	.	O	O

0	RESULTS	O	O
1	:	O	O
2	We	O	O
3	observed	O	O
4	elevated	O	O
5	lung	B-Disease	B-Disease
6	cancer	E-Disease	E-Disease
7	risks	O	O
8	(	O	O
9	N	O	O
10	=	O	O
11	283	O	O
12	)	O	O
13	among	O	O
14	applicators	O	O
15	with	O	O
16	the	O	O
17	greatest	O	O
18	number	O	O
19	of	O	O
20	LT	O	S-Disease
21	(	O	O
22	RR	O	O
23	=	O	O
24	1	O	O
25	.	O	O
26	60	O	O
27	;	O	O
28	95	O	O
29	%	O	O
30	CI	O	S-Disease
31	1	O	O
32	.	O	O
33	11	O	O
34	to	O	O
35	2	O	O
36	.	O	O
37	31	O	O
38	;	O	O
39	Ptrend	O	S-Disease
40	=	O	O
41	0	O	O
42	.	O	O
43	02	O	O
44	)	O	O
45	and	O	O
46	IW	O	O
47	days	O	O
48	of	O	O
49	diazinon	S-Chemical	S-Chemical
50	use	O	O
51	(	O	O
52	RR	O	O
53	=	O	O
54	1	O	O
55	.	O	O
56	41	O	O
57	;	O	O
58	95	O	O
59	%	O	O
60	CI	O	S-Chemical
61	0	O	O
62	.	O	O
63	98	O	O
64	to	O	O
65	2	O	O
66	.	O	O
67	04	O	O
68	;	O	O
69	Ptrend	O	S-Chemical
70	=	O	O
71	0	O	O
72	.	O	O
73	08	O	O
74	)	O	O
75	.	O	O

0	Kidney	B-Disease	B-Disease
1	cancer	E-Disease	E-Disease
2	(	O	O
3	N	O	O
4	=	O	O
5	94	O	O
6	)	O	O
7	risks	O	O
8	were	O	O
9	non	O	O
10	-	O	O
11	significantly	O	O
12	elevated	O	O
13	(	O	O
14	RRLT	O	O
15	days	O	O
16	=	O	O
17	1	O	O
18	.	O	O
19	77	O	O
20	;	O	O
21	95	O	O
22	%	O	O
23	CI	O	S-Chemical
24	0	O	O
25	.	O	O
26	90	O	O
27	to	O	O
28	3	O	O
29	.	O	O
30	51	O	O
31	;	O	O
32	Ptrend	O	S-Chemical
33	=	O	O
34	0	O	O
35	.	O	O
36	09	O	O
37	;	O	O
38	RRIW	O	O
39	days	O	O
40	1	O	O
41	.	O	O
42	37	O	O
43	;	O	O
44	95	O	O
45	%	O	O
46	CI	O	O
47	0	O	O
48	.	O	O
49	64	O	O
50	to	O	O
51	2	O	O
52	.	O	O
53	92	O	O
54	;	O	O
55	Ptrend	O	S-Chemical
56	=	O	O
57	0	O	O
58	.	O	O
59	50	O	O
60	)	O	O
61	,	O	O
62	as	O	O
63	were	O	O
64	risks	O	O
65	for	O	O
66	aggressive	O	O
67	prostate	B-Disease	B-Disease
68	cancer	E-Disease	E-Disease
69	(	O	O
70	N	O	B-Chemical
71	=	O	O
72	656	O	E-Chemical
73	)	O	O
74	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Our	O	O
3	updated	O	O
4	evaluation	O	O
5	of	O	O
6	diazinon	S-Chemical	S-Chemical
7	provides	O	O
8	additional	O	O
9	evidence	O	O
10	of	O	O
11	an	O	O
12	association	O	O
13	with	O	O
14	lung	B-Disease	B-Disease
15	cancer	E-Disease	E-Disease
16	risk	O	O
17	.	O	O

0	Newly	O	O
1	identified	O	O
2	links	O	O
3	to	O	O
4	kidney	B-Disease	B-Disease
5	cancer	E-Disease	E-Disease
6	and	O	O
7	associations	O	O
8	with	O	O
9	aggressive	O	O
10	prostate	B-Disease	B-Disease
11	cancer	E-Disease	E-Disease
12	require	O	O
13	further	O	O
14	evaluation	O	O
15	.	O	O

0	Associations	O	O
1	of	O	O
2	Ozone	S-Chemical	S-Chemical
3	and	O	O
4	PM2	O	S-Disease
5	.	O	O
6	5	O	O
7	Concentrations	O	O
8	With	O	O
9	Parkinson	B-Disease	B-Disease
10	'	I-Disease	I-Disease
11	s	I-Disease	I-Disease
12	Disease	E-Disease	E-Disease
13	Among	O	O
14	Participants	O	O
15	in	O	O
16	the	O	O
17	Agricultural	O	B-Disease
18	Health	O	I-Disease
19	Study	O	E-Disease
20	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	This	O	O
3	study	O	O
4	describes	O	O
5	associations	O	O
6	of	O	O
7	ozone	S-Chemical	S-Disease
8	and	O	O
9	fine	O	O
10	particulate	B-Chemical	O
11	matter	E-Chemical	O
12	with	O	O
13	Parkinson	B-Disease	B-Disease
14	'	I-Disease	I-Disease
15	s	I-Disease	I-Disease
16	disease	E-Disease	E-Disease
17	observed	O	O
18	among	O	O
19	farmers	O	O
20	in	O	O
21	North	O	O
22	Carolina	O	O
23	and	O	O
24	Iowa	O	S-Chemical
25	.	O	O

0	METHODS	O	O
1	:	O	O
2	We	O	O
3	used	O	O
4	logistic	O	O
5	regression	O	O
6	to	O	O
7	determine	O	O
8	the	O	O
9	associations	O	O
10	of	O	O
11	these	O	O
12	pollutants	O	O
13	with	O	O
14	self	O	O
15	-	O	O
16	reported	O	O
17	,	O	O
18	doctor	O	O
19	-	O	O
20	diagnosed	O	O
21	Parkinson	B-Disease	B-Disease
22	'	I-Disease	I-Disease
23	s	I-Disease	I-Disease
24	disease	E-Disease	E-Disease
25	.	O	O

0	RESULTS	O	O
1	:	O	O
2	We	O	O
3	observed	O	O
4	positive	O	O
5	associations	O	O
6	of	O	O
7	Parkinson	B-Disease	B-Disease
8	'	I-Disease	I-Disease
9	s	I-Disease	I-Disease
10	disease	E-Disease	E-Disease
11	with	O	O
12	ozone	S-Chemical	S-Disease
13	(	O	O
14	odds	O	O
15	ratio	O	O
16	=	O	O
17	1	O	O
18	.	O	O
19	39	O	O
20	;	O	O
21	95	O	O
22	%	O	O
23	CI	O	S-Chemical
24	:	O	O
25	0	O	O
26	.	O	O
27	98	O	O
28	to	O	O
29	1	O	O
30	.	O	O
31	98	O	O
32	)	O	O
33	and	O	O
34	fine	O	O
35	particulate	B-Chemical	O
36	matter	E-Chemical	O
37	(	O	O
38	odds	O	O
39	ratio	O	O
40	=	O	O
41	1	O	O
42	.	O	O
43	34	O	O
44	;	O	O
45	95	O	O
46	%	O	O
47	CI	O	O
48	:	O	O
49	0	O	O
50	.	O	O
51	93	O	O
52	to	O	O
53	1	O	O
54	.	O	O
55	93	O	O
56	)	O	O
57	in	O	O
58	North	O	O
59	Carolina	O	O
60	but	O	O
61	not	O	O
62	in	O	O
63	Iowa	O	S-Chemical
64	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	The	O	O
3	plausibility	O	O
4	of	O	O
5	an	O	O
6	effect	O	O
7	of	O	O
8	ambient	O	O
9	concentrations	O	O
10	of	O	O
11	these	O	O
12	pollutants	O	O
13	on	O	O
14	Parkinson	B-Disease	B-Disease
15	'	I-Disease	I-Disease
16	s	I-Disease	I-Disease
17	disease	E-Disease	E-Disease
18	risk	O	O
19	is	O	O
20	supported	O	O
21	by	O	O
22	experimental	O	O
23	data	O	O
24	demonstrating	O	O
25	damage	O	O
26	to	O	O
27	dopaminergic	O	O
28	neurons	O	O
29	at	O	O
30	relevant	O	O
31	concentrations	O	O
32	.	O	O

0	Low	O	O
1	functional	O	O
2	programming	O	O
3	of	O	O
4	renal	O	O
5	AT2R	O	E-Chemical
6	mediates	O	O
7	the	O	O
8	developmental	O	O
9	origin	O	O
10	of	O	O
11	glomerulosclerosis	S-Disease	S-Chemical
12	in	O	O
13	adult	O	O
14	offspring	O	O
15	induced	O	O
16	by	O	O
17	prenatal	O	O
18	caffeine	S-Chemical	S-Chemical
19	exposure	O	O
20	.	O	O

0	UNASSIGNED	O	O
1	:	O	O
2	Our	O	O
3	previous	O	O
4	study	O	O
5	has	O	O
6	indicated	O	O
7	that	O	O
8	prenatal	O	O
9	caffeine	S-Chemical	S-Chemical
10	exposure	O	O
11	(	O	O
12	PCE	O	S-Disease
13	)	O	O
14	could	O	O
15	induce	O	O
16	intrauterine	B-Disease	O
17	growth	I-Disease	I-Disease
18	retardation	E-Disease	E-Disease
19	(	O	O
20	IUGR	S-Disease	S-Disease
21	)	O	O
22	of	O	O
23	offspring	O	O
24	.	O	O

0	Recent	O	O
1	research	O	O
2	suggested	O	O
3	that	O	O
4	IUGR	S-Disease	S-Chemical
5	is	O	O
6	a	O	O
7	risk	O	O
8	factor	O	O
9	for	O	O
10	glomerulosclerosis	S-Disease	S-Disease
11	.	O	O

0	However	O	O
1	,	O	O
2	whether	O	O
3	PCE	O	S-Chemical
4	could	O	O
5	induce	O	O
6	glomerulosclerosis	S-Disease	S-Chemical
7	and	O	O
8	its	O	O
9	underlying	O	O
10	mechanisms	O	O
11	remain	O	O
12	unknown	O	O
13	.	O	O

0	This	O	O
1	study	O	O
2	aimed	O	O
3	to	O	O
4	demonstrate	O	O
5	the	O	O
6	induction	O	O
7	to	O	O
8	glomerulosclerosis	S-Disease	S-Chemical
9	in	O	O
10	adult	O	O
11	offspring	O	O
12	by	O	O
13	PCE	O	S-Disease
14	and	O	O
15	its	O	O
16	intrauterine	O	O
17	programming	O	O
18	mechanisms	O	O
19	.	O	O

0	A	O	O
1	rat	O	O
2	model	O	O
3	of	O	O
4	IUGR	S-Disease	S-Chemical
5	was	O	O
6	established	O	O
7	by	O	O
8	PCE	O	O
9	,	O	O
10	male	O	O
11	fetuses	O	O
12	and	O	O
13	adult	O	O
14	offspring	O	O
15	at	O	O
16	the	O	O
17	age	O	O
18	of	O	O
19	postnatal	O	O
20	week	O	O
21	24	O	O
22	were	O	O
23	euthanized	O	O
24	.	O	O

0	The	O	O
1	results	O	O
2	revealed	O	O
3	that	O	O
4	the	O	O
5	adult	O	O
6	offspring	O	O
7	kidneys	O	O
8	in	O	O
9	the	O	O
10	PCE	O	O
11	group	O	O
12	exhibited	O	O
13	glomerulosclerosis	S-Disease	S-Disease
14	as	O	O
15	well	O	O
16	as	O	O
17	interstitial	B-Disease	O
18	fibrosis	E-Disease	E-Disease
19	,	O	O
20	accompanied	O	O
21	by	O	O
22	elevated	O	O
23	levels	O	O
24	of	O	O
25	serum	O	O
26	creatinine	S-Chemical	S-Chemical
27	and	O	O
28	urine	O	O
29	protein	O	O
30	.	O	O

0	Renal	O	O
1	angiotensin	B-Chemical	O
2	II	E-Chemical	O
3	receptor	O	O
4	type	O	O
5	2	O	O
6	(	O	O
7	AT2R	O	S-Disease
8	)	O	O
9	gene	O	O
10	expression	O	O
11	in	O	O
12	adult	O	O
13	offspring	O	O
14	was	O	O
15	reduced	O	O
16	by	O	O
17	PCE	O	O
18	,	O	O
19	whereas	O	O
20	the	O	O
21	renal	O	B-Disease
22	angiotensin	B-Chemical	I-Disease
23	II	E-Chemical	I-Disease
24	receptor	O	O
25	type	O	O
26	1a	O	O
27	(	O	O
28	AT1aR	O	O
29	)	O	O
30	/	O	O
31	AT2R	O	O
32	expression	O	O
33	ratio	O	O
34	was	O	O
35	increased	O	O
36	.	O	O

0	Moreover	O	O
1	,	O	O
2	AT2R	O	O
3	gene	O	O
4	and	O	O
5	protein	O	O
6	expressions	O	O
7	in	O	O
8	fetal	O	O
9	kidneys	O	O
10	were	O	O
11	inhibited	O	O
12	by	O	O
13	PCE	O	S-Disease
14	,	O	O
15	associated	O	O
16	with	O	O
17	the	O	O
18	repression	O	O
19	of	O	O
20	the	O	O
21	gene	O	O
22	expression	O	O
23	of	O	O
24	glial	O	O
25	-	O	O
26	cell	O	O
27	-	O	O
28	line	O	O
29	-	O	O
30	derived	O	O
31	neurotrophic	O	O
32	factor	O	O
33	(	O	O
34	GDNF	O	S-Disease
35	)	O	O
36	/	O	O
37	tyrosine	S-Chemical	S-Disease
38	kinase	O	O
39	receptor	O	O
40	(	O	O
41	c	O	B-Chemical
42	-	O	I-Chemical
43	Ret	O	E-Chemical
44	)	O	O
45	signaling	O	O
46	pathway	O	O
47	.	O	O

0	These	O	O
1	results	O	O
2	demonstrated	O	O
3	that	O	O
4	PCE	O	S-Chemical
5	could	O	O
6	induce	O	O
7	dysplasia	B-Disease	S-Disease
8	of	I-Disease	O
9	fetal	I-Disease	O
10	kidneys	E-Disease	O
11	as	O	O
12	well	O	O
13	as	O	O
14	glomerulosclerosis	S-Disease	S-Disease
15	of	O	O
16	adult	O	O
17	offspring	O	O
18	,	O	O
19	and	O	O
20	the	O	O
21	low	O	O
22	functional	O	O
23	programming	O	O
24	of	O	O
25	renal	O	B-Disease
26	AT2R	O	I-Disease
27	might	O	O
28	mediate	O	O
29	the	O	O
30	developmental	O	O
31	origin	O	O
32	of	O	O
33	adult	O	O
34	glomerulosclerosis	S-Disease	S-Disease
35	.	O	O

0	1	B-Chemical	O
1	,	I-Chemical	O
2	3	I-Chemical	O
3	-	I-Chemical	O
4	Butadiene	E-Chemical	S-Chemical
5	,	O	O
6	CML	S-Disease	S-Chemical
7	and	O	O
8	the	O	O
9	t	O	O
10	(	O	O
11	9	O	O
12	:	O	O
13	22	O	O
14	)	O	O
15	translocation	O	O
16	:	O	O
17	A	O	O
18	reality	O	O
19	check	O	O
20	.	O	O

0	UNASSIGNED	O	O
1	:	O	O
2	Epidemiological	O	O
3	studies	O	O
4	of	O	O
5	1	B-Chemical	S-Chemical
6	,	I-Chemical	O
7	3	I-Chemical	I-Chemical
8	-	I-Chemical	I-Chemical
9	butadiene	E-Chemical	S-Chemical
10	have	O	O
11	suggest	O	O
12	that	O	O
13	exposures	O	O
14	to	O	O
15	humans	O	O
16	are	O	O
17	associated	O	O
18	with	O	O
19	chronic	B-Disease	B-Disease
20	myeloid	I-Disease	I-Disease
21	leukemia	E-Disease	E-Disease
22	(	O	O
23	CML	S-Disease	S-Chemical
24	)	O	O
25	.	O	O

0	CML	S-Disease	S-Chemical
1	has	O	O
2	a	O	O
3	well	O	O
4	-	O	O
5	documented	O	O
6	association	O	O
7	with	O	O
8	ionizing	O	B-Disease
9	radiation	O	E-Disease
10	,	O	O
11	but	O	O
12	reports	O	O
13	of	O	O
14	associations	O	O
15	with	O	O
16	chemical	O	O
17	exposures	O	O
18	have	O	O
19	been	O	O
20	questioned	O	O
21	.	O	O

0	Ionizing	O	O
1	radiation	O	O
2	is	O	O
3	capable	O	O
4	of	O	O
5	inducing	O	O
6	the	O	O
7	requisite	O	O
8	CML	S-Disease	S-Chemical
9	-	O	O
10	associated	O	O
11	t	O	O
12	(	O	O
13	9	O	O
14	:	O	O
15	22	O	O
16	)	O	O
17	translocation	O	O
18	(	O	O
19	Philadelphia	B-Disease	S-Chemical
20	chromosome	E-Disease	O
21	)	O	O
22	in	O	O
23	appropriate	O	O
24	cells	O	O
25	in	O	O
26	vitro	O	O
27	but	O	O
28	,	O	O
29	thus	O	O
30	far	O	O
31	,	O	O
32	chemicals	O	O
33	have	O	O
34	not	O	O
35	shown	O	O
36	this	O	O
37	capacity	O	O
38	.	O	O

0	We	O	O
1	have	O	O
2	proposed	O	O
3	that	O	O
4	1	B-Chemical	S-Chemical
5	,	I-Chemical	O
6	3	I-Chemical	I-Chemical
7	-	I-Chemical	I-Chemical
8	butadiene	E-Chemical	S-Chemical
9	metabolites	O	O
10	be	O	O
11	so	O	O
12	tested	O	O
13	as	O	O
14	a	O	O
15	reality	O	O
16	check	O	O
17	on	O	O
18	the	O	O
19	epidemiological	O	O
20	reports	O	O
21	.	O	O

0	Conditions	O	O
1	that	O	O
2	will	O	O
3	be	O	O
4	required	O	O
5	for	O	O
6	studies	O	O
7	of	O	O
8	1	B-Chemical	B-Chemical
9	,	I-Chemical	I-Chemical
10	3	I-Chemical	I-Chemical
11	-	I-Chemical	I-Chemical
12	butadiene	E-Chemical	S-Chemical
13	are	O	O
14	discussed	O	O
15	.	O	O

0	Cancer	S-Disease	S-Disease
1	incidence	O	O
2	and	O	O
3	metolachlor	S-Chemical	S-Chemical
4	use	O	O
5	in	O	O
6	the	O	O
7	Agricultural	O	B-Disease
8	Health	O	I-Disease
9	Study	O	E-Disease
10	:	O	O
11	An	O	O
12	update	O	O
13	.	O	O

0	UNASSIGNED	O	O
1	:	O	O
2	Metolachlor	S-Chemical	S-Chemical
3	,	O	O
4	a	O	O
5	widely	O	O
6	used	O	O
7	herbicide	O	O
8	,	O	O
9	is	O	O
10	classified	O	O
11	as	O	O
12	a	O	O
13	Group	O	O
14	C	O	O
15	carcinogen	O	O
16	by	O	O
17	the	O	O
18	U	O	O
19	.	O	O
20	S	O	O
21	.	O	O

0	Environmental	O	I-Disease
1	Protection	O	S-Disease
2	Agency	O	S-Chemical
3	based	O	O
4	on	O	O
5	increased	O	O
6	liver	B-Disease	O
7	neoplasms	E-Disease	S-Disease
8	in	O	O
9	female	O	O
10	rats	O	O
11	.	O	O

0	Epidemiologic	O	O
1	studies	O	O
2	of	O	O
3	the	O	O
4	health	O	O
5	effects	O	O
6	of	O	O
7	metolachlor	S-Chemical	S-Chemical
8	have	O	O
9	been	O	O
10	limited	O	O
11	.	O	O

0	We	O	O
1	evaluated	O	O
2	cancer	S-Disease	S-Disease
3	incidence	O	O
4	through	O	O
5	2010	O	O
6	/	O	O
7	2011	O	O
8	(	O	O
9	NC	O	S-Chemical
10	/	O	O
11	IA	O	E-Chemical
12	)	O	O
13	for	O	O
14	49	O	O
15	,	O	O
16	616	O	O
17	applicators	O	O
18	,	O	O
19	53	O	O
20	%	O	O
21	of	O	O
22	whom	O	O
23	reported	O	O
24	ever	O	O
25	using	O	O
26	metolachlor	S-Chemical	S-Chemical
27	.	O	O

0	We	O	O
1	used	O	O
2	Poisson	O	S-Chemical
3	regression	O	O
4	to	O	O
5	evaluate	O	O
6	relations	O	O
7	between	O	O
8	two	O	O
9	metrics	O	O
10	of	O	O
11	metolachlor	S-Chemical	S-Chemical
12	use	O	O
13	(	O	O
14	lifetime	O	O
15	days	O	O
16	,	O	O
17	intensity	O	O
18	-	O	O
19	weighted	O	O
20	lifetime	O	O
21	days	O	O
22	)	O	O
23	and	O	O
24	cancer	S-Disease	S-Disease
25	incidence	O	O
26	.	O	O

0	We	O	O
1	saw	O	O
2	no	O	O
3	association	O	O
4	between	O	O
5	metolachlor	S-Chemical	S-Chemical
6	use	O	O
7	and	O	O
8	incidence	O	O
9	of	O	O
10	all	O	O
11	cancers	S-Disease	S-Disease
12	combined	O	O
13	(	O	O
14	n	O	O
15	=	O	O
16	5	O	O
17	,	O	O
18	701	O	O
19	with	O	O
20	a	O	O
21	5	O	O
22	-	O	O
23	year	O	O
24	lag	O	O
25	)	O	O
26	or	O	O
27	most	O	O
28	site	O	O
29	-	O	O
30	specific	O	O
31	cancers	S-Disease	S-Disease
32	.	O	O

0	For	O	O
1	liver	B-Disease	B-Disease
2	cancer	E-Disease	E-Disease
3	,	O	O
4	in	O	O
5	analyses	O	O
6	restricted	O	O
7	to	O	O
8	exposed	O	O
9	workers	O	O
10	,	O	O
11	elevations	O	O
12	observed	O	O
13	at	O	O
14	higher	O	O
15	categories	O	O
16	of	O	O
17	use	O	O
18	were	O	O
19	not	O	O
20	statistically	O	O
21	significant	O	O
22	.	O	O

0	However	O	O
1	,	O	O
2	trends	O	O
3	for	O	O
4	both	O	O
5	lifetime	O	O
6	and	O	O
7	intensity	O	O
8	-	O	O
9	weighted	O	O
10	lifetime	O	O
11	days	O	O
12	of	O	O
13	metolachor	S-Chemical	S-Chemical
14	use	O	O
15	were	O	O
16	positive	O	O
17	and	O	O
18	statistically	O	O
19	significant	O	O
20	with	O	O
21	an	O	O
22	unexposed	O	O
23	reference	O	O
24	group	O	O
25	.	O	O

0	A	O	O
1	similar	O	O
2	pattern	O	O
3	was	O	O
4	observed	O	O
5	for	O	O
6	follicular	B-Disease	B-Disease
7	cell	I-Disease	I-Disease
8	lymphoma	E-Disease	E-Disease
9	,	O	O
10	but	O	O
11	no	O	O
12	other	O	O
13	lymphoma	S-Disease	S-Disease
14	subtypes	O	O
15	.	O	O

0	An	O	O
1	earlier	O	O
2	suggestion	O	O
3	of	O	O
4	increased	O	O
5	lung	B-Disease	B-Disease
6	cancer	E-Disease	E-Disease
7	risk	O	O
8	at	O	O
9	high	O	O
10	levels	O	O
11	of	O	O
12	metolachlor	S-Chemical	S-Chemical
13	use	O	O
14	in	O	O
15	this	O	O
16	cohort	O	O
17	was	O	O
18	not	O	O
19	confirmed	O	O
20	in	O	O
21	this	O	O
22	update	O	O
23	.	O	O

0	This	O	O
1	suggestion	O	O
2	of	O	O
3	an	O	O
4	association	O	O
5	between	O	O
6	metolachlor	S-Chemical	S-Chemical
7	and	O	O
8	liver	B-Disease	B-Disease
9	cancer	E-Disease	E-Disease
10	among	O	O
11	pesticide	O	O
12	applicators	O	O
13	is	O	O
14	a	O	O
15	novel	O	O
16	finding	O	O
17	and	O	O
18	echoes	O	O
19	observation	O	O
20	of	O	O
21	increased	O	O
22	liver	B-Disease	B-Disease
23	neoplasms	E-Disease	E-Disease
24	in	O	O
25	some	O	O
26	animal	O	O
27	studies	O	O
28	.	O	O

0	However	O	O
1	,	O	O
2	our	O	O
3	findings	O	O
4	for	O	O
5	both	O	O
6	liver	B-Disease	B-Disease
7	cancer	E-Disease	E-Disease
8	and	O	O
9	follicular	O	B-Disease
10	cell	O	I-Disease
11	lymphoma	S-Disease	E-Disease
12	warrant	O	O
13	follow	O	O
14	-	O	O
15	up	O	O
16	to	O	O
17	better	O	O
18	differentiate	O	O
19	effects	O	O
20	of	O	O
21	metolachlor	S-Chemical	S-Chemical
22	use	O	O
23	from	O	O
24	other	O	O
25	factors	O	O
26	.	O	O

0	Mechanisms	O	O
1	Underlying	O	O
2	Latent	O	O
3	Disease	O	I-Disease
4	Risk	O	O
5	Associated	O	O
6	with	O	O
7	Early	O	O
8	-	O	O
9	Life	O	O
10	Arsenic	S-Chemical	S-Disease
11	Exposure	O	O
12	:	O	O
13	Current	O	O
14	Research	O	O
15	Trends	O	O
16	and	O	O
17	Scientific	O	O
18	Gaps	O	O
19	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Millions	O	O
3	of	O	O
4	individuals	O	O
5	worldwide	O	O
6	,	O	O
7	particularly	O	O
8	those	O	O
9	living	O	O
10	in	O	O
11	rural	O	O
12	and	O	O
13	developing	O	O
14	areas	O	O
15	,	O	O
16	are	O	O
17	exposed	O	O
18	to	O	O
19	harmful	O	O
20	levels	O	O
21	of	O	O
22	inorganic	B-Chemical	S-Disease
23	arsenic	E-Chemical	S-Disease
24	(	O	O
25	iAs	S-Chemical	S-Chemical
26	)	O	O
27	in	O	O
28	their	O	O
29	drinking	O	O
30	water	O	O
31	.	O	O

0	Inorganic	B-Chemical	O
1	As	E-Chemical	O
2	exposure	O	O
3	during	O	O
4	key	O	O
5	developmental	O	O
6	periods	O	O
7	is	O	O
8	associated	O	O
9	with	O	O
10	a	O	O
11	variety	O	O
12	of	O	O
13	adverse	O	O
14	health	O	O
15	effects	O	O
16	including	O	O
17	those	O	O
18	that	O	O
19	are	O	O
20	evident	O	O
21	in	O	O
22	adulthood	O	O
23	.	O	O

0	There	O	O
1	is	O	O
2	considerable	O	O
3	interest	O	O
4	in	O	O
5	identifying	O	O
6	the	O	O
7	molecular	O	O
8	mechanisms	O	O
9	that	O	O
10	relate	O	O
11	early	O	O
12	-	O	O
13	life	O	O
14	iAs	S-Chemical	S-Chemical
15	exposure	O	O
16	to	O	O
17	the	O	O
18	development	O	O
19	of	O	O
20	these	O	O
21	latent	O	O
22	diseases	O	S-Disease
23	,	O	O
24	particularly	O	O
25	in	O	O
26	relationship	O	O
27	to	O	O
28	cancer	S-Disease	S-Disease
29	.	O	O

0	OBJECTIVES	O	O
1	:	O	O
2	This	O	O
3	work	O	O
4	summarizes	O	O
5	research	O	O
6	on	O	O
7	the	O	O
8	molecular	O	O
9	mechanisms	O	O
10	that	O	O
11	underlie	O	O
12	the	O	O
13	increased	O	O
14	risk	O	O
15	of	O	O
16	cancer	S-Disease	B-Disease
17	development	O	E-Disease
18	in	O	O
19	adulthood	O	O
20	that	O	O
21	is	O	O
22	associated	O	O
23	with	O	O
24	early	O	O
25	-	O	O
26	life	O	O
27	iAs	S-Chemical	S-Chemical
28	exposure	O	O
29	.	O	O

0	DISCUSSION	O	O
1	:	O	O
2	Epigenetic	O	O
3	reprogramming	O	O
4	that	O	O
5	imparts	O	O
6	functional	O	O
7	changes	O	O
8	in	O	O
9	gene	O	O
10	expression	O	O
11	,	O	O
12	the	O	O
13	development	O	O
14	of	O	O
15	cancer	S-Disease	B-Disease
16	stem	O	I-Disease
17	cells	O	E-Disease
18	,	O	O
19	and	O	O
20	immunomodulation	O	S-Disease
21	are	O	O
22	plausible	O	O
23	underlying	O	O
24	mechanisms	O	O
25	by	O	O
26	which	O	O
27	early	O	O
28	-	O	O
29	life	O	O
30	iAs	S-Chemical	S-Chemical
31	exposure	O	O
32	elicits	O	O
33	latent	O	O
34	carcinogenic	O	S-Disease
35	effects	O	O
36	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Evidence	O	O
3	is	O	O
4	mounting	O	O
5	that	O	O
6	relates	O	O
7	early	O	O
8	-	O	O
9	life	O	O
10	iAs	S-Chemical	S-Chemical
11	exposure	O	O
12	and	O	O
13	cancer	S-Disease	S-Disease
14	development	O	O
15	later	O	O
16	in	O	O
17	life	O	O
18	.	O	O

0	Nifedipine	S-Chemical	S-Chemical
1	induced	O	O
2	bradycardia	S-Disease	S-Disease
3	in	O	O
4	a	O	O
5	patient	O	O
6	with	O	O
7	autonomic	B-Disease	O
8	neuropathy	E-Disease	S-Disease
9	.	O	O

0	An	O	O
1	80	O	O
2	year	O	O
3	old	O	O
4	diabetic	S-Disease	O
5	male	O	O
6	with	O	O
7	evidence	O	O
8	of	O	O
9	peripheral	B-Disease	O
10	and	I-Disease	O
11	autonomic	I-Disease	O
12	neuropathy	E-Disease	S-Disease
13	was	O	O
14	admitted	O	O
15	with	O	O
16	chest	B-Disease	B-Disease
17	pain	E-Disease	E-Disease
18	.	O	O

0	He	O	O
1	was	O	O
2	found	O	O
3	to	O	O
4	have	O	O
5	atrial	B-Disease	B-Disease
6	flutter	E-Disease	E-Disease
7	at	O	O
8	a	O	O
9	ventricular	O	O
10	rate	O	O
11	of	O	O
12	70	O	O
13	/	O	O
14	min	O	O
15	which	O	O
16	slowed	O	O
17	down	O	O
18	to	O	O
19	30	O	O
20	-	O	O
21	40	O	O
22	/	O	O
23	min	O	O
24	when	O	O
25	nifedipine	S-Chemical	S-Chemical
26	(	O	O
27	60	O	O
28	mg	O	O
29	)	O	O
30	in	O	O
31	3	O	O
32	divided	O	O
33	doses	O	O
34	,	O	O
35	during	O	O
36	which	O	O
37	he	O	O
38	was	O	O
39	paced	O	O
40	at	O	O
41	a	O	O
42	rate	O	O
43	of	O	O
44	70	O	O
45	/	O	O
46	min	O	O
47	.	O	O

0	This	O	O
1	is	O	O
2	inconsistent	O	O
3	with	O	O
4	the	O	O
5	well	O	O
6	-	O	O
7	established	O	O
8	finding	O	O
9	that	O	O
10	nifedipine	S-Chemical	S-Chemical
11	induces	O	O
12	tachycardia	S-Disease	S-Disease
13	in	O	O
14	normally	O	O
15	innervated	O	O
16	hearts	O	O
17	.	O	O

0	However	O	O
1	,	O	O
2	in	O	O
3	hearts	O	O
4	deprived	O	O
5	of	O	O
6	compensatory	O	O
7	sympathetic	O	O
8	drive	O	O
9	,	O	O
10	it	O	O
11	may	O	O
12	lead	O	O
13	to	O	O
14	bradycardia	S-Disease	O
15	.	O	O

0	The	O	O
1	effect	O	O
2	of	O	O
3	haloperidol	S-Chemical	S-Chemical
4	in	O	O
5	cocaine	S-Chemical	S-Chemical
6	and	O	O
7	amphetamine	S-Chemical	S-Chemical
8	intoxication	O	E-Disease
9	.	O	O

0	The	O	O
1	effectiveness	O	O
2	of	O	O
3	haloperidol	S-Chemical	S-Chemical
4	pretreatment	O	O
5	in	O	O
6	preventing	O	O
7	the	O	O
8	toxic	O	O
9	effects	O	O
10	of	O	O
11	high	O	O
12	doses	O	O
13	of	O	O
14	amphetamine	S-Chemical	S-Chemical
15	and	O	O
16	cocaine	S-Chemical	S-Chemical
17	was	O	O
18	studied	O	O
19	in	O	O
20	rats	O	O
21	.	O	O

0	In	O	O
1	this	O	O
2	model	O	O
3	,	O	O
4	toxic	O	O
5	effects	O	O
6	were	O	O
7	induced	O	O
8	by	O	O
9	intraperitoneal	O	O
10	(	O	O
11	i	O	O
12	.	O	O
13	p	O	O
14	.	O	O
15	)	O	O
16	injection	O	O
17	of	O	O
18	amphetamine	S-Chemical	S-Chemical
19	75	O	O
20	mg	O	O
21	/	O	O
22	kg	O	O
23	(	O	O
24	100	O	O
25	%	O	O
26	death	O	O
27	rate	O	O
28	)	O	O
29	or	O	O
30	cocaine	S-Chemical	S-Chemical
31	70	O	O
32	mg	O	O
33	/	O	O
34	kg	O	O
35	(	O	O
36	82	O	O
37	%	O	O
38	death	O	O
39	rate	O	O
40	)	O	O
41	.	O	O

0	Haloperidol	S-Chemical	S-Chemical
1	failed	O	O
2	to	O	O
3	prevent	O	O
4	amphetamine	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	seizures	S-Disease	S-Disease
8	,	O	O
9	but	O	O
10	did	O	O
11	lower	O	O
12	the	O	O
13	mortality	O	O
14	rate	O	O
15	at	O	O
16	most	O	O
17	doses	O	O
18	tested	O	O
19	.	O	O

0	Haloperidol	S-Chemical	S-Chemical
1	decreased	O	O
2	the	O	O
3	incidence	O	O
4	of	O	O
5	cocaine	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	seizures	S-Disease	S-Disease
9	at	O	O
10	the	O	O
11	two	O	O
12	highest	O	O
13	doses	O	O
14	,	O	O
15	but	O	O
16	the	O	O
17	lowering	O	O
18	of	O	O
19	the	O	O
20	mortality	O	O
21	rate	O	O
22	did	O	O
23	not	O	O
24	reach	O	O
25	statistical	O	O
26	significance	O	O
27	at	O	O
28	any	O	O
29	dose	O	O
30	.	O	O

0	These	O	O
1	data	O	O
2	suggest	O	O
3	a	O	O
4	protective	O	O
5	role	O	O
6	for	O	O
7	the	O	O
8	central	O	O
9	dopamine	S-Chemical	S-Disease
10	blocker	O	O
11	haloperidol	S-Chemical	S-Chemical
12	against	O	O
13	death	O	O
14	from	O	O
15	high	O	O
16	-	O	O
17	dose	O	O
18	amphetamine	S-Chemical	S-Chemical
19	exposure	O	O
20	without	O	O
21	reducing	O	O
22	the	O	O
23	incidence	O	O
24	of	O	O
25	seizures	S-Disease	S-Disease
26	.	O	O

0	In	O	O
1	contrast	O	O
2	,	O	O
3	haloperidol	S-Chemical	S-Chemical
4	demonstrated	O	O
5	an	O	O
6	ability	O	O
7	to	O	O
8	reduce	O	O
9	cocaine	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	seizures	S-Disease	S-Disease
13	without	O	O
14	significantly	O	O
15	reducing	O	O
16	mortality	O	O
17	.	O	O

0	Autoradiographic	O	O
1	evidence	O	O
2	of	O	O
3	estrogen	S-Chemical	S-Chemical
4	binding	O	O
5	sites	O	O
6	in	O	O
7	nuclei	O	O
8	of	O	O
9	diethylstilbesterol	S-Chemical	S-Chemical
10	induced	O	O
11	hamster	O	B-Disease
12	renal	B-Disease	I-Disease
13	carcinomas	E-Disease	I-Disease
14	.	O	O

0	Estrogen	S-Chemical	O
1	binding	O	O
2	sites	O	O
3	were	O	O
4	demonstrated	O	O
5	by	O	O
6	autoradiography	O	O
7	in	O	O
8	one	O	O
9	transplantable	O	O
10	and	O	O
11	five	O	O
12	primary	O	O
13	diethylstilbesterol	S-Chemical	S-Chemical
14	induced	O	O
15	renal	B-Disease	B-Disease
16	carcinomas	E-Disease	E-Disease
17	in	O	O
18	three	O	O
19	hamsters	O	S-Disease
20	.	O	O

0	Radiolabelling	O	O
1	,	O	O
2	following	O	O
3	the	O	O
4	in	O	O
5	vivo	O	O
6	injection	O	O
7	of	O	O
8	3H	O	O
9	-	O	O
10	17	O	O
11	beta	O	O
12	estradiol	S-Chemical	S-Disease
13	,	O	O
14	was	O	O
15	increased	O	O
16	only	O	O
17	over	O	O
18	the	O	O
19	nuclei	O	O
20	of	O	O
21	tumor	S-Disease	S-Disease
22	cells	O	O
23	;	O	O
24	stereologic	O	O
25	analysis	O	O
26	revealed	O	O
27	a	O	O
28	4	O	O
29	.	O	O
30	5	O	O
31	-	O	O
32	to	O	O
33	6	O	O
34	.	O	O
35	7	O	O
36	-	O	O
37	times	O	O
38	higher	O	O
39	concentration	O	O
40	of	O	O
41	reduced	O	O
42	silver	S-Chemical	O
43	grains	O	O
44	over	O	O
45	nuclei	O	O
46	than	O	O
47	cytoplasm	O	S-Disease
48	of	O	O
49	these	O	O
50	cells	O	O
51	.	O	O

0	Despite	O	O
1	rapid	O	O
2	tubular	O	S-Disease
3	excretion	O	O
4	of	O	O
5	estradiol	S-Chemical	S-Chemical
6	which	O	O
7	peaked	O	O
8	in	O	O
9	less	O	O
10	than	O	O
11	1	O	O
12	h	O	O
13	,	O	O
14	the	O	O
15	normal	O	O
16	cells	O	O
17	did	O	O
18	not	O	O
19	appear	O	O
20	to	O	O
21	bind	O	O
22	the	O	O
23	ligand	O	O
24	.	O	O

0	This	O	O
1	is	O	O
2	the	O	O
3	first	O	O
4	published	O	O
5	report	O	O
6	documenting	O	O
7	the	O	O
8	preferential	O	O
9	in	O	O
10	vivo	O	O
11	binding	O	O
12	of	O	O
13	estrogen	S-Chemical	S-Chemical
14	to	O	O
15	nuclei	O	O
16	of	O	O
17	cells	O	O
18	in	O	O
19	estrogen	S-Chemical	S-Chemical
20	induced	O	O
21	hamster	O	B-Disease
22	renal	B-Disease	I-Disease
23	carcinomas	E-Disease	E-Disease
24	.	O	O

0	Bradycardia	S-Disease	S-Disease
1	due	O	O
2	to	O	O
3	biperiden	S-Chemical	S-Chemical
4	.	O	O

0	In	O	O
1	a	O	O
2	38	O	O
3	-	O	O
4	year	O	O
5	-	O	O
6	old	O	O
7	male	O	O
8	patient	O	O
9	suffering	O	O
10	from	O	O
11	a	O	O
12	severe	O	O
13	postzosteric	S-Disease	O
14	trigeminal	B-Disease	B-Disease
15	neuralgia	E-Disease	E-Disease
16	,	O	O
17	intravenous	O	O
18	application	O	O
19	of	O	O
20	10	O	O
21	mg	O	O
22	biperiden	B-Chemical	S-Chemical
23	lactate	E-Chemical	O
24	led	O	O
25	to	O	O
26	a	O	O
27	long	O	O
28	-	O	O
29	lasting	O	O
30	paradoxical	O	O
31	reaction	O	O
32	characterized	O	O
33	by	O	O
34	considerable	O	O
35	bradycardia	S-Disease	O
36	,	O	O
37	dysarthria	S-Disease	S-Disease
38	,	O	O
39	and	O	O
40	dysphagia	S-Disease	S-Disease
41	.	O	O

0	The	O	O
1	heart	O	O
2	rate	O	O
3	was	O	O
4	back	O	O
5	to	O	O
6	normal	O	O
7	within	O	O
8	12	O	O
9	hours	O	O
10	upon	O	O
11	administration	O	O
12	of	O	O
13	orciprenaline	S-Chemical	O
14	under	O	O
15	cardiac	O	B-Disease
16	monitoring	O	O
17	in	O	O
18	an	O	O
19	intensive	O	O
20	care	O	O
21	unit	O	O
22	.	O	O

0	Bradycardia	S-Disease	S-Disease
1	induced	O	O
2	by	O	O
3	biperiden	S-Chemical	S-Chemical
4	is	O	O
5	attributed	O	O
6	to	O	O
7	the	O	O
8	speed	O	O
9	of	O	O
10	injection	O	O
11	and	O	O
12	to	O	O
13	a	O	O
14	dose	O	O
15	-	O	O
16	related	O	O
17	dual	O	O
18	effect	O	O
19	of	O	O
20	atropine	S-Chemical	S-Chemical
21	-	O	O
22	like	O	O
23	drugs	O	O
24	on	O	O
25	muscarine	S-Chemical	S-Chemical
26	receptors	O	O
27	.	O	O

0	Deliberate	O	O
1	hypotension	S-Disease	S-Disease
2	induced	O	O
3	by	O	O
4	labetalol	S-Chemical	S-Chemical
5	with	O	O
6	halothane	S-Chemical	S-Chemical
7	,	O	O
8	enflurane	S-Chemical	S-Chemical
9	or	O	O
10	isoflurane	S-Chemical	S-Chemical
11	for	O	O
12	middle	O	O
13	-	O	O
14	ear	O	B-Disease
15	surgery	O	O
16	.	O	O

0	The	O	O
1	feasibility	O	O
2	of	O	O
3	using	O	O
4	labetalol	S-Chemical	S-Chemical
5	,	O	O
6	an	O	O
7	alpha	O	O
8	-	O	O
9	and	O	O
10	beta	O	O
11	-	O	O
12	adrenergic	O	O
13	blocking	O	O
14	agent	O	O
15	,	O	O
16	as	O	O
17	a	O	O
18	hypotensive	S-Disease	O
19	agent	O	O
20	in	O	O
21	combination	O	O
22	with	O	O
23	inhalation	O	O
24	anaesthetics	O	O
25	(	O	O
26	halothane	S-Chemical	S-Chemical
27	,	O	O
28	enflurane	S-Chemical	S-Chemical
29	or	O	O
30	isoflurane	S-Chemical	S-Chemical
31	)	O	O
32	was	O	O
33	studied	O	O
34	in	O	O
35	23	O	O
36	adult	O	O
37	patients	O	O
38	undergoing	O	O
39	middle	O	O
40	-	O	O
41	ear	O	O
42	surgery	O	O
43	.	O	O

0	The	O	O
1	mean	O	O
2	arterial	O	O
3	pressure	O	O
4	was	O	O
5	decreased	O	O
6	from	O	O
7	86	O	O
8	+	O	O
9	/	O	O
10	-	O	O
11	5	O	O
12	(	O	O
13	s	O	O
14	.	O	O
15	e	O	O
16	.	O	O
17	mean	O	O
18	)	O	O
19	mmHg	O	O
20	to	O	O
21	52	O	O
22	+	O	O
23	/	O	O
24	-	O	O
25	1	O	O
26	mmHg	O	O
27	(	O	O
28	11	O	O
29	.	O	O
30	5	O	O
31	+	O	O
32	/	O	O
33	-	O	O
34	0	O	O
35	.	O	O
36	7	O	O
37	to	O	O
38	6	O	O
39	.	O	O
40	9	O	O
41	+	O	O
42	/	O	O
43	-	O	O
44	0	O	O
45	.	O	O
46	1	O	O
47	kPa	O	O
48	)	O	O
49	for	O	O
50	98	O	O
51	+	O	O
52	/	O	O
53	-	O	O
54	10	O	O
55	min	O	O
56	in	O	O
57	the	O	O
58	halothane	S-Chemical	S-Chemical
59	(	O	O
60	H	S-Chemical	O
61	)	O	O
62	group	O	O
63	,	O	O
64	from	O	O
65	79	O	O
66	+	O	O
67	/	O	O
68	-	O	O
69	5	O	O
70	to	O	O
71	53	O	O
72	+	O	O
73	/	O	O
74	-	O	O
75	1	O	O
76	mmHg	O	O
77	(	O	O
78	10	O	O
79	.	O	O
80	5	O	O
81	+	O	O
82	/	O	O
83	-	O	O
84	0	O	O
85	.	O	O
86	7	O	O
87	to	O	O
88	7	O	O
89	.	O	O
90	1	O	O
91	+	O	O
92	/	O	O
93	-	O	O
94	0	O	O
95	.	O	O
96	1	O	O
97	kPa	O	O
98	)	O	O
99	for	O	O
100	129	O	O
101	+	O	O
102	/	O	O
103	-	O	O
104	11	O	O
105	min	O	O
106	in	O	O
107	the	O	O
108	enflurane	S-Chemical	S-Chemical
109	(	O	O
110	E	S-Chemical	O
111	)	O	O
112	group	O	O
113	,	O	O
114	and	O	O
115	from	O	O
116	80	O	O
117	+	O	O
118	/	O	O
119	-	O	O
120	4	O	O
121	to	O	O
122	49	O	O
123	+	O	O
124	/	O	O
125	-	O	O
126	1	O	O
127	mmHg	O	O
128	(	O	O
129	10	O	O
130	.	O	O
131	7	O	O
132	+	O	O
133	/	O	O
134	-	O	O
135	0	O	O
136	.	O	O
137	5	O	O
138	to	O	O
139	6	O	O
140	.	O	O
141	5	O	O
142	+	O	O
143	/	O	O
144	-	O	O
145	0	O	O
146	.	O	O
147	1	O	O
148	kPa	O	O
149	)	O	O
150	for	O	O
151	135	O	O
152	+	O	O
153	/	O	O
154	-	O	O
155	15	O	O
156	min	O	O
157	in	O	O
158	the	O	O
159	isoflurane	S-Chemical	S-Chemical
160	(	O	O
161	I	S-Chemical	O
162	)	O	O
163	group	O	O
164	.	O	O

0	The	O	O
1	mean	O	O
2	H	S-Chemical	O
3	concentration	O	O
4	during	O	O
5	hypotension	S-Disease	S-Disease
6	in	O	O
7	the	O	O
8	inspiratory	O	O
9	gas	O	O
10	was	O	O
11	0	O	O
12	.	O	O
13	7	O	O
14	+	O	O
15	/	O	O
16	-	O	O
17	0	O	O
18	.	O	O
19	1	O	O
20	vol	O	O
21	%	O	O
22	,	O	O
23	the	O	O
24	mean	O	O
25	E	S-Chemical	S-Disease
26	concentration	O	O
27	1	O	O
28	.	O	O
29	6	O	O
30	+	O	O
31	/	O	O
32	-	O	O
33	0	O	O
34	.	O	O
35	2	O	O
36	vol	O	O
37	%	O	O
38	,	O	O
39	and	O	O
40	the	O	O
41	mean	O	O
42	I	S-Chemical	O
43	concentration	O	O
44	1	O	O
45	.	O	O
46	0	O	O
47	+	O	O
48	/	O	O
49	-	O	O
50	0	O	O
51	.	O	O
52	1	O	O
53	vol	O	O
54	%	O	O
55	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	the	O	O
4	patients	O	O
5	received	O	O
6	fentanyl	S-Chemical	S-Chemical
7	and	O	O
8	d	B-Chemical	S-Chemical
9	-	I-Chemical	I-Chemical
10	tubocurarine	E-Chemical	E-Chemical
11	.	O	O

0	The	O	O
1	initial	O	O
2	dose	O	O
3	of	O	O
4	labetalol	S-Chemical	S-Chemical
5	for	O	O
6	lowering	O	O
7	blood	O	O
8	pressure	O	O
9	was	O	O
10	similar	O	O
11	,	O	O
12	0	O	O
13	.	O	O
14	52	O	O
15	-	O	O
16	0	O	O
17	.	O	O
18	59	O	O
19	mg	O	O
20	/	O	O
21	kg	O	O
22	,	O	O
23	in	O	O
24	all	O	O
25	the	O	O
26	groups	O	O
27	.	O	O

0	During	O	O
1	hypotension	S-Disease	S-Disease
2	,	O	O
3	the	O	O
4	heart	O	S-Disease
5	rate	O	O
6	was	O	O
7	stable	O	O
8	without	O	O
9	tachy	B-Disease	S-Disease
10	-	I-Disease	O
11	or	I-Disease	O
12	bradycardia	E-Disease	O
13	.	O	O

0	The	O	O
1	operating	O	O
2	conditions	O	O
3	regarding	O	O
4	bleeding	S-Disease	O
5	were	O	O
6	estimated	O	O
7	in	O	O
8	a	O	O
9	double	O	O
10	-	O	O
11	blind	O	O
12	manner	O	O
13	,	O	O
14	and	O	O
15	did	O	O
16	not	O	O
17	differ	O	O
18	significantly	O	O
19	between	O	O
20	the	O	O
21	groups	O	O
22	.	O	O

0	During	O	O
1	hypotension	S-Disease	S-Disease
2	,	O	O
3	the	O	O
4	serum	O	O
5	creatinine	S-Chemical	S-Chemical
6	concentration	O	O
7	rose	O	O
8	significantly	O	O
9	in	O	O
10	all	O	O
11	groups	O	O
12	from	O	O
13	the	O	O
14	values	O	O
15	before	O	O
16	hypotension	S-Disease	S-Disease
17	and	O	O
18	returned	O	O
19	postoperatively	O	O
20	to	O	O
21	the	O	O
22	initial	O	O
23	level	O	O
24	in	O	O
25	the	O	O
26	other	O	O
27	groups	O	O
28	,	O	O
29	except	O	O
30	the	O	O
31	isoflurane	S-Chemical	S-Chemical
32	group	O	O
33	.	O	O

0	After	O	O
1	hypotension	S-Disease	S-Disease
2	there	O	O
3	was	O	O
4	no	O	O
5	rebound	O	O
6	phenomenon	O	O
7	in	O	O
8	either	O	O
9	blood	O	O
10	pressure	O	E-Disease
11	or	O	O
12	heart	O	B-Disease
13	rate	O	E-Disease
14	.	O	O

0	These	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	labetalol	S-Chemical	S-Chemical
5	induces	O	O
6	easily	O	O
7	adjustable	O	O
8	hypotension	S-Disease	S-Disease
9	without	O	O
10	compensatory	O	O
11	tachycardia	S-Disease	S-Disease
12	and	O	O
13	rebound	O	O
14	hypertension	S-Disease	S-Disease
15	.	O	O

0	Convulsion	S-Disease	O
1	following	O	O
2	intravenous	O	O
3	fluorescein	S-Chemical	S-Chemical
4	angiography	O	O
5	.	O	O

0	Tonic	B-Disease	S-Chemical
1	-	I-Disease	O
2	clonic	I-Disease	O
3	seizures	E-Disease	S-Disease
4	followed	O	O
5	intravenous	O	O
6	fluorescein	S-Chemical	S-Chemical
7	injection	O	O
8	for	O	O
9	fundus	O	O
10	angiography	O	O
11	in	O	O
12	a	O	O
13	47	O	O
14	-	O	O
15	year	O	O
16	-	O	O
17	old	O	O
18	male	O	O
19	.	O	O

0	Despite	O	O
1	precautions	O	O
2	this	O	O
3	adverse	O	O
4	reaction	O	O
5	recurred	O	O
6	on	O	O
7	re	O	O
8	-	O	O
9	exposure	O	O
10	to	O	O
11	intravenous	O	O
12	fluorescein	S-Chemical	S-Chemical
13	.	O	O

0	Pharmacology	O	O
1	of	O	O
2	ACC	B-Chemical	B-Chemical
3	-	I-Chemical	I-Disease
4	9653	E-Chemical	E-Chemical
5	(	O	O
6	phenytoin	S-Chemical	S-Chemical
7	prodrug	O	O
8	)	O	O
9	.	O	O

0	ACC	B-Chemical	B-Chemical
1	-	I-Chemical	I-Chemical
2	9653	E-Chemical	E-Chemical
3	,	O	O
4	the	O	O
5	disodium	B-Chemical	S-Chemical
6	phosphate	I-Chemical	O
7	ester	E-Chemical	O
8	of	O	O
9	3	B-Chemical	B-Chemical
10	-	I-Chemical	I-Chemical
11	hydroxymethyl	I-Chemical	E-Chemical
12	-	I-Chemical	I-Chemical
13	5	I-Chemical	O
14	,	I-Chemical	I-Chemical
15	5	I-Chemical	O
16	-	I-Chemical	I-Chemical
17	diphenylhydantoin	E-Chemical	S-Chemical
18	,	O	O
19	is	O	O
20	a	O	O
21	prodrug	O	O
22	of	O	O
23	phenytoin	S-Chemical	S-Chemical
24	with	O	O
25	advantageous	O	O
26	physicochemical	O	O
27	properties	O	O
28	.	O	O

0	ACC	B-Chemical	B-Chemical
1	-	I-Chemical	I-Disease
2	9653	E-Chemical	E-Chemical
3	is	O	O
4	rapidly	O	O
5	converted	O	O
6	enzymatically	O	O
7	to	O	O
8	phenytoin	S-Chemical	S-Chemical
9	in	O	O
10	vivo	O	O
11	.	O	O

0	ACC	B-Chemical	B-Chemical
1	-	I-Chemical	I-Disease
2	9653	E-Chemical	E-Chemical
3	and	O	O
4	phenytoin	B-Chemical	B-Chemical
5	sodium	E-Chemical	E-Chemical
6	have	O	O
7	equivalent	O	O
8	anticonvulsant	O	O
9	activity	O	O
10	against	O	O
11	seizures	S-Disease	S-Disease
12	induced	O	O
13	by	O	O
14	maximal	O	O
15	electroshock	O	O
16	(	O	O
17	MES	O	S-Disease
18	)	O	O
19	in	O	O
20	mice	O	O
21	following	O	O
22	i	O	O
23	.	O	O
24	p	O	O
25	.	O	O
26	,	O	O
27	oral	O	O
28	,	O	O
29	or	O	O
30	i	O	O
31	.	O	O
32	v	O	O
33	.	O	O
34	administration	O	O
35	.	O	O

0	The	O	O
1	ED50	O	S-Disease
2	doses	O	O
3	were	O	O
4	16	O	O
5	mg	O	O
6	/	O	O
7	kg	O	O
8	for	O	O
9	i	O	O
10	.	O	O
11	v	O	O
12	.	O	O
13	ACC	B-Chemical	B-Disease
14	-	I-Chemical	I-Disease
15	9653	E-Chemical	E-Disease
16	and	O	O
17	8	O	O
18	mg	O	O
19	/	O	O
20	kg	O	O
21	for	O	O
22	i	O	O
23	.	O	O
24	v	O	O
25	.	O	O
26	phenytoin	B-Chemical	B-Chemical
27	sodium	E-Chemical	E-Disease
28	.	O	O

0	ACC	B-Chemical	B-Chemical
1	-	I-Chemical	I-Disease
2	9653	E-Chemical	E-Chemical
3	and	O	O
4	phenytoin	B-Chemical	S-Chemical
5	sodium	E-Chemical	E-Chemical
6	have	O	O
7	similar	O	O
8	antiarrhythmic	O	O
9	activity	O	O
10	against	O	O
11	ouabain	S-Chemical	S-Chemical
12	-	O	O
13	induced	O	O
14	ventricular	B-Disease	B-Disease
15	tachycardia	E-Disease	E-Disease
16	in	O	O
17	anesthetized	O	O
18	dogs	O	O
19	.	O	O

0	The	O	O
1	total	O	O
2	doses	O	O
3	of	O	O
4	ACC	B-Chemical	B-Chemical
5	-	I-Chemical	I-Disease
6	9653	E-Chemical	E-Chemical
7	or	O	O
8	phenytoin	B-Chemical	S-Chemical
9	sodium	E-Chemical	O
10	necessary	O	O
11	to	O	O
12	convert	O	O
13	the	O	O
14	arrhythmia	S-Disease	S-Disease
15	to	O	O
16	a	O	O
17	normal	O	O
18	sinus	O	B-Disease
19	rhythm	O	O
20	were	O	O
21	24	O	O
22	+	O	O
23	/	O	O
24	-	O	O
25	6	O	O
26	and	O	O
27	14	O	O
28	+	O	O
29	/	O	O
30	-	O	O
31	3	O	O
32	mg	O	O
33	/	O	O
34	kg	O	O
35	,	O	O
36	respectively	O	O
37	.	O	O

0	Only	O	O
1	phenytoin	B-Chemical	S-Chemical
2	sodium	E-Chemical	O
3	displayed	O	O
4	in	O	O
5	vitro	O	O
6	antiarrhythmic	O	O
7	activity	O	O
8	against	O	O
9	strophanthidin	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	arrhythmias	S-Disease	S-Disease
13	in	O	O
14	guinea	O	B-Disease
15	pig	O	I-Disease
16	right	O	I-Disease
17	atria	O	E-Disease
18	.	O	O

0	In	O	O
1	anesthetized	O	O
2	dogs	O	O
3	,	O	O
4	a	O	O
5	high	O	O
6	dose	O	O
7	of	O	O
8	ACC	B-Chemical	B-Chemical
9	-	I-Chemical	I-Disease
10	9653	E-Chemical	E-Chemical
11	(	O	O
12	31	O	O
13	mg	O	O
14	/	O	O
15	kg	O	O
16	)	O	O
17	was	O	O
18	infused	O	O
19	over	O	O
20	15	O	O
21	,	O	O
22	20	O	O
23	,	O	O
24	and	O	O
25	30	O	O
26	min	O	O
27	and	O	O
28	the	O	O
29	responses	O	O
30	were	O	O
31	compared	O	O
32	to	O	O
33	an	O	O
34	equimolar	O	O
35	dose	O	O
36	of	O	O
37	phenytoin	B-Chemical	S-Chemical
38	sodium	E-Chemical	O
39	(	O	O
40	21	O	O
41	mg	O	O
42	/	O	O
43	kg	O	O
44	)	O	O
45	.	O	O

0	The	O	O
1	ACC	B-Chemical	B-Chemical
2	-	I-Chemical	I-Disease
3	9653	E-Chemical	E-Chemical
4	and	O	O
5	phenytoin	B-Chemical	S-Chemical
6	sodium	E-Chemical	O
7	treatments	O	O
8	produced	O	O
9	similar	O	O
10	marked	O	O
11	reductions	O	O
12	in	O	O
13	diastolic	O	B-Disease
14	blood	O	I-Disease
15	pressure	O	E-Disease
16	and	O	O
17	contractile	O	O
18	force	O	O
19	(	O	O
20	LVdP	O	S-Disease
21	/	O	O
22	dt	O	O
23	)	O	O
24	.	O	O

0	The	O	O
1	maximum	O	O
2	effects	O	O
3	of	O	O
4	each	O	O
5	treatment	O	O
6	occurred	O	O
7	at	O	O
8	the	O	O
9	time	O	O
10	of	O	O
11	maximum	O	O
12	phenytoin	B-Chemical	B-Chemical
13	sodium	E-Chemical	E-Chemical
14	levels	O	O
15	.	O	O

0	Acute	O	O
1	toxicity	S-Disease	S-Disease
2	studies	O	O
3	of	O	O
4	ACC	B-Chemical	B-Chemical
5	-	I-Chemical	I-Disease
6	9653	E-Chemical	E-Chemical
7	and	O	O
8	phenytoin	B-Chemical	S-Chemical
9	sodium	E-Chemical	E-Chemical
10	were	O	O
11	carried	O	O
12	out	O	O
13	in	O	O
14	mice	O	O
15	,	O	O
16	rats	O	O
17	,	O	O
18	rabbits	O	O
19	,	O	O
20	and	O	O
21	dogs	O	O
22	by	O	O
23	i	O	O
24	.	O	O
25	v	O	O
26	.	O	O
27	,	O	O
28	i	O	O
29	.	O	O
30	m	O	O
31	.	O	O
32	,	O	O
33	and	O	O
34	i	O	O
35	.	O	O
36	p	O	O
37	.	O	O
38	routes	O	O
39	of	O	O
40	administration	O	O
41	.	O	O

0	Importantly	O	O
1	,	O	O
2	the	O	O
3	local	O	O
4	irritation	O	O
5	of	O	O
6	ACC	B-Chemical	B-Chemical
7	-	I-Chemical	I-Disease
8	9653	E-Chemical	E-Chemical
9	was	O	O
10	markedly	O	O
11	less	O	O
12	than	O	O
13	phenytoin	B-Chemical	S-Chemical
14	sodium	E-Chemical	O
15	following	O	O
16	i	O	O
17	.	O	O
18	m	O	O
19	.	O	O
20	administration	O	O
21	.	O	O
22	(	O	O
23	ABSTRACT	O	S-Disease
24	TRUNCATED	O	O
25	AT	O	O
26	250	O	O
27	WORDS	O	O
28	)	O	O

0	Tachyphylaxis	O	O
1	to	O	O
2	systemic	O	O
3	but	O	O
4	not	O	O
5	to	O	O
6	airway	O	B-Disease
7	responses	O	O
8	during	O	O
9	prolonged	O	O
10	therapy	O	O
11	with	O	O
12	high	O	O
13	dose	O	O
14	inhaled	O	O
15	salbutamol	S-Chemical	S-Chemical
16	in	O	O
17	asthmatics	S-Disease	O
18	.	O	O

0	High	O	O
1	doses	O	O
2	of	O	O
3	inhaled	O	O
4	salbutamol	S-Chemical	S-Chemical
5	produce	O	O
6	substantial	O	O
7	improvements	O	O
8	in	O	O
9	airway	O	B-Disease
10	response	O	O
11	in	O	O
12	patients	O	O
13	with	O	O
14	asthma	S-Disease	S-Disease
15	,	O	O
16	and	O	O
17	are	O	O
18	associated	O	O
19	with	O	O
20	dose	O	O
21	-	O	O
22	dependent	O	O
23	systemic	O	O
24	beta	O	B-Disease
25	-	O	O
26	adrenoceptor	O	E-Chemical
27	responses	O	O
28	.	O	O

0	The	O	O
1	purpose	O	O
2	of	O	O
3	the	O	O
4	present	O	O
5	study	O	O
6	was	O	O
7	to	O	O
8	investigate	O	O
9	whether	O	O
10	tachyphylaxis	O	S-Disease
11	occurs	O	O
12	during	O	O
13	prolonged	O	O
14	treatment	O	O
15	with	O	O
16	high	O	O
17	dose	O	O
18	inhaled	O	O
19	salbutamol	S-Chemical	S-Chemical
20	.	O	O

0	Twelve	O	O
1	asthmatic	S-Disease	O
2	patients	O	O
3	(	O	O
4	FEV1	O	S-Chemical
5	,	O	O
6	81	O	O
7	+	O	O
8	/	O	O
9	-	O	O
10	4	O	O
11	%	O	O
12	predicted	O	O
13	)	O	O
14	,	O	O
15	requiring	O	O
16	only	O	O
17	occasional	O	O
18	inhaled	O	O
19	beta	O	O
20	-	O	O
21	agonists	O	O
22	as	O	O
23	their	O	O
24	sole	O	O
25	therapy	O	O
26	,	O	O
27	were	O	O
28	given	O	O
29	a	O	O
30	14	O	O
31	-	O	O
32	day	O	O
33	treatment	O	O
34	with	O	O
35	high	O	O
36	dose	O	O
37	inhaled	O	O
38	salbutamol	S-Chemical	S-Chemical
39	(	O	O
40	HDS	O	S-Disease
41	)	O	O
42	,	O	O
43	4	O	O
44	,	O	O
45	000	O	O
46	micrograms	O	O
47	daily	O	O
48	,	O	O
49	low	O	O
50	dose	O	O
51	inhaled	O	O
52	salbutamol	S-Chemical	S-Chemical
53	(	O	O
54	LDS	O	O
55	)	O	O
56	,	O	O
57	800	O	O
58	micrograms	O	O
59	daily	O	O
60	,	O	O
61	or	O	O
62	placebo	O	S-Disease
63	(	O	O
64	PI	O	S-Disease
65	)	O	O
66	by	O	O
67	metered	O	O
68	-	O	O
69	dose	O	O
70	inhaler	O	O
71	in	O	O
72	a	O	O
73	double	O	O
74	-	O	O
75	blind	O	O
76	,	O	O
77	randomized	O	O
78	crossover	O	O
79	design	O	O
80	.	O	O

0	During	O	O
1	the	O	O
2	14	O	O
3	-	O	O
4	day	O	O
5	run	O	O
6	-	O	O
7	in	O	O
8	and	O	O
9	during	O	O
10	washout	O	O
11	periods	O	O
12	,	O	O
13	inhaled	O	O
14	beta	O	O
15	-	O	O
16	agonists	O	O
17	were	O	O
18	withheld	O	O
19	and	O	O
20	ipratropium	B-Chemical	B-Chemical
21	bromide	E-Chemical	E-Chemical
22	was	O	O
23	substituted	O	O
24	for	O	O
25	rescue	O	O
26	purposes	O	O
27	.	O	O

0	At	O	O
1	the	O	O
2	end	O	O
3	of	O	O
4	each	O	O
5	14	O	O
6	-	O	O
7	day	O	O
8	treatment	O	O
9	,	O	O
10	a	O	O
11	dose	O	O
12	-	O	O
13	response	O	O
14	curve	O	O
15	(	O	O
16	DRC	O	S-Disease
17	)	O	O
18	was	O	O
19	performed	O	O
20	,	O	O
21	and	O	O
22	airway	O	S-Disease
23	(	O	O
24	FEV1	O	S-Disease
25	,	O	O
26	FEF25	O	S-Disease
27	-	O	O
28	75	O	O
29	)	O	O
30	chronotropic	O	S-Disease
31	(	O	O
32	HR	O	O
33	)	O	O
34	,	O	O
35	tremor	S-Disease	S-Disease
36	,	O	O
37	and	O	O
38	metabolic	O	O
39	(	O	O
40	K	S-Chemical	S-Disease
41	,	O	O
42	Glu	S-Chemical	S-Chemical
43	)	O	O
44	responses	O	O
45	were	O	O
46	measured	O	O
47	at	O	O
48	each	O	O
49	step	O	O
50	(	O	O
51	from	O	O
52	100	O	O
53	to	O	O
54	4	O	O
55	,	O	O
56	000	O	O
57	micrograms	O	O
58	)	O	O
59	.	O	O

0	DRC	O	O
1	for	O	O
2	HR	O	O
3	(	O	O
4	p	O	O
5	less	O	O
6	than	O	O
7	0	O	O
8	.	O	O
9	001	O	O
10	)	O	O
11	,	O	O
12	K	S-Chemical	O
13	(	O	O
14	p	O	O
15	less	O	O
16	than	O	O
17	0	O	O
18	.	O	O
19	001	O	O
20	)	O	O
21	,	O	O
22	and	O	O
23	Glu	S-Chemical	S-Chemical
24	(	O	O
25	p	O	O
26	less	O	O
27	than	O	O
28	0	O	O
29	.	O	O
30	005	O	O
31	)	O	O
32	were	O	O
33	attenuated	O	O
34	after	O	O
35	treatment	O	O
36	with	O	O
37	HDS	O	S-Disease
38	compared	O	O
39	with	O	O
40	PI	O	O
41	.	O	O

0	There	O	O
1	were	O	O
2	also	O	O
3	differences	O	O
4	between	O	O
5	HDS	O	S-Disease
6	and	O	O
7	LDS	O	S-Disease
8	for	O	O
9	HR	O	O
10	(	O	O
11	p	O	O
12	less	O	O
13	than	O	O
14	0	O	O
15	.	O	O
16	001	O	O
17	)	O	O
18	and	O	O
19	Glu	S-Chemical	S-Chemical
20	(	O	O
21	p	O	O
22	less	O	O
23	than	O	O
24	0	O	O
25	.	O	O
26	05	O	O
27	)	O	O
28	responses	O	O
29	.	O	O

0	Frequency	O	O
1	and	O	O
2	severity	O	O
3	of	O	O
4	subjective	O	O
5	adverse	O	O
6	effects	O	O
7	were	O	O
8	also	O	O
9	reduced	O	O
10	after	O	O
11	HDS	O	S-Disease
12	:	O	O
13	tremor	S-Disease	S-Disease
14	(	O	O
15	p	O	O
16	less	O	O
17	than	O	O
18	0	O	O
19	.	O	O
20	001	O	O
21	)	O	O
22	,	O	O
23	palpitations	S-Disease	O
24	(	O	O
25	p	O	O
26	less	O	O
27	than	O	O
28	0	O	O
29	.	O	O
30	001	O	O
31	)	O	O
32	.	O	O
33	(	O	O
34	ABSTRACT	O	O
35	TRUNCATED	O	O
36	AT	O	O
37	250	O	O
38	WORDS	O	O
39	)	O	O

0	Phenytoin	S-Chemical	S-Chemical
1	induced	O	O
2	fatal	O	O
3	hepatic	B-Disease	S-Disease
4	injury	E-Disease	E-Disease
5	.	O	O

0	A	O	O
1	61	O	O
2	year	O	O
3	old	O	O
4	female	O	O
5	developed	O	O
6	fatal	O	O
7	hepatic	B-Disease	B-Disease
8	failure	E-Disease	E-Disease
9	after	O	O
10	phenytoin	S-Chemical	S-Chemical
11	administration	O	O
12	.	O	O

0	A	O	O
1	typical	O	O
2	multisystem	O	O
3	clinical	O	O
4	pattern	O	O
5	precedes	O	O
6	the	O	O
7	manifestations	O	O
8	of	O	O
9	hepatic	B-Disease	S-Disease
10	injury	E-Disease	E-Disease
11	.	O	O

0	The	O	O
1	hematologic	O	O
2	,	O	O
3	biochemical	O	O
4	and	O	O
5	pathologic	O	O
6	features	O	O
7	indicate	O	O
8	a	O	O
9	mixed	O	O
10	hepatocellular	B-Disease	B-Disease
11	damage	E-Disease	E-Disease
12	due	O	O
13	to	O	O
14	drug	B-Disease	O
15	hypersensitivity	E-Disease	S-Disease
16	.	O	O

0	In	O	O
1	a	O	O
2	patient	O	O
3	receiving	O	O
4	phenytoin	S-Chemical	S-Chemical
5	who	O	O
6	presents	O	O
7	a	O	O
8	viral	O	B-Disease
9	-	O	O
10	like	O	O
11	illness	O	E-Disease
12	,	O	O
13	early	O	O
14	recognition	O	O
15	and	O	O
16	discontinuation	O	O
17	of	O	O
18	the	O	O
19	drug	O	O
20	are	O	O
21	mandatory	O	O
22	.	O	O

0	Treatment	O	O
1	of	O	O
2	lethal	O	O
3	pertussis	B-Chemical	S-Disease
4	vaccine	E-Chemical	O
5	reaction	O	O
6	with	O	O
7	histamine	S-Chemical	S-Chemical
8	H1	O	O
9	antagonists	O	O
10	.	O	O

0	We	O	O
1	studied	O	O
2	mortality	O	O
3	after	O	O
4	pertussis	S-Disease	S-Disease
5	immunization	O	O
6	in	O	O
7	the	O	O
8	mouse	O	O
9	.	O	O

0	Without	O	O
1	treatment	O	O
2	,	O	O
3	73	O	O
4	of	O	O
5	92	O	O
6	animals	O	O
7	(	O	O
8	80	O	O
9	%	O	O
10	)	O	O
11	died	O	O
12	after	O	O
13	injection	O	O
14	of	O	O
15	bovine	O	B-Disease
16	serum	O	O
17	albumin	O	S-Disease
18	(	O	O
19	BSA	O	S-Disease
20	)	O	O
21	on	O	O
22	day	O	O
23	+	O	O
24	7	O	O
25	of	O	O
26	pertussis	S-Disease	S-Disease
27	immunization	O	O
28	.	O	O

0	After	O	O
1	pretreatment	O	O
2	with	O	O
3	3	O	O
4	mg	O	O
5	of	O	O
6	cyproheptadine	S-Chemical	S-Chemical
7	,	O	O
8	2	O	O
9	mg	O	O
10	mianserin	S-Chemical	S-Chemical
11	,	O	O
12	or	O	O
13	2	O	O
14	mg	O	O
15	chlorpheniramine	S-Chemical	S-Chemical
16	,	O	O
17	only	O	O
18	5	O	O
19	of	O	O
20	105	O	O
21	animals	O	O
22	(	O	O
23	5	O	O
24	%	O	O
25	)	O	O
26	died	O	O
27	after	O	O
28	receiving	O	O
29	BSA	O	S-Chemical
30	on	O	O
31	day	O	O
32	+	O	O
33	7	O	O
34	(	O	O
35	p	O	O
36	less	O	O
37	than	O	O
38	0	O	O
39	.	O	O
40	001	O	O
41	)	O	O
42	.	O	O

0	Blockade	O	O
1	of	O	O
2	histamine	S-Chemical	B-Chemical
3	H1	O	E-Chemical
4	receptors	O	O
5	may	O	O
6	reduce	O	O
7	mortality	O	O
8	in	O	O
9	pertussis	S-Disease	B-Disease
10	immunization	O	O
11	-	O	O
12	induced	O	O
13	encephalopathy	S-Disease	S-Disease
14	in	O	O
15	mice	O	O
16	.	O	O

0	Support	O	O
1	for	O	O
2	adrenaline	S-Chemical	S-Disease
3	-	O	O
4	hypertension	S-Disease	S-Disease
5	hypothesis	O	O
6	:	O	O
7	18	O	O
8	hour	O	O
9	pressor	O	S-Disease
10	effect	O	O
11	after	O	O
12	6	O	O
13	hours	O	O
14	adrenaline	S-Chemical	S-Disease
15	infusion	O	O
16	.	O	O

0	In	O	O
1	a	O	O
2	double	O	O
3	blind	O	O
4	,	O	O
5	crossover	O	O
6	study	O	O
7	6	O	O
8	h	O	O
9	infusions	O	O
10	of	O	O
11	adrenaline	S-Chemical	O
12	(	O	O
13	15	O	O
14	ng	O	O
15	/	O	O
16	kg	O	O
17	/	O	O
18	min	O	O
19	;	O	O
20	1	O	O
21	ng	O	O
22	=	O	O
23	5	O	O
24	.	O	O
25	458	O	O
26	pmol	O	S-Disease
27	)	O	O
28	,	O	O
29	noradrenaline	S-Chemical	S-Chemical
30	(	O	O
31	30	O	O
32	ng	O	O
33	/	O	O
34	kg	O	O
35	/	O	O
36	min	O	O
37	;	O	O
38	1	O	O
39	ng	O	O
40	=	O	O
41	5	O	O
42	.	O	O
43	911	O	O
44	pmol	O	O
45	)	O	O
46	,	O	O
47	and	O	O
48	a	O	O
49	5	O	O
50	%	O	O
51	dextrose	S-Chemical	O
52	solution	O	O
53	(	O	O
54	5	O	O
55	.	O	O
56	4	O	O
57	ml	O	O
58	/	O	O
59	h	O	O
60	)	O	O
61	,	O	O
62	were	O	O
63	given	O	O
64	to	O	O
65	ten	O	O
66	healthy	O	O
67	volunteers	O	O
68	in	O	O
69	random	O	O
70	order	O	O
71	2	O	O
72	weeks	O	O
73	apart	O	O
74	.	O	O

0	Adrenaline	S-Chemical	O
1	,	O	O
2	but	O	O
3	not	O	O
4	noradrenaline	S-Chemical	S-Chemical
5	,	O	O
6	caused	O	O
7	a	O	O
8	delayed	O	O
9	and	O	O
10	protracted	O	O
11	pressor	O	S-Disease
12	effect	O	O
13	.	O	O

0	Over	O	O
1	the	O	O
2	total	O	O
3	postinfusion	O	O
4	period	O	O
5	systolic	O	S-Disease
6	and	O	O
7	diastolic	O	B-Disease
8	arterial	O	E-Disease
9	pressure	O	O
10	were	O	O
11	6	O	O
12	(	O	O
13	SEM	O	O
14	2	O	O
15	)	O	O
16	%	O	O
17	and	O	O
18	7	O	O
19	(	O	O
20	2	O	O
21	)	O	O
22	%	O	O
23	,	O	O
24	respectively	O	O
25	,	O	O
26	higher	O	O
27	than	O	O
28	after	O	O
29	dextrose	S-Chemical	O
30	infusion	O	O
31	(	O	O
32	ANOVA	O	S-Chemical
33	,	O	O
34	p	O	O
35	less	O	O
36	than	O	O
37	0	O	O
38	.	O	O
39	001	O	O
40	)	O	O
41	.	O	O

0	Thus	O	O
1	,	O	O
2	"	O	O
3	stress	O	O
4	"	O	O
5	levels	O	O
6	of	O	O
7	adrenaline	S-Chemical	O
8	(	O	O
9	230	O	O
10	pg	O	O
11	/	O	O
12	ml	O	O
13	)	O	O
14	for	O	O
15	6	O	O
16	h	O	O
17	cause	O	O
18	a	O	O
19	delayed	O	O
20	and	O	O
21	protracted	O	O
22	pressor	O	S-Chemical
23	effect	O	O
24	.	O	O

0	These	O	O
1	findings	O	O
2	are	O	O
3	strong	O	O
4	support	O	O
5	for	O	O
6	the	O	O
7	adrenaline	S-Chemical	S-Chemical
8	-	O	O
9	hypertension	S-Disease	E-Disease
10	hypothesis	O	O
11	in	O	O
12	man	O	O
13	.	O	O

0	Effect	O	O
1	of	O	O
2	alkylxanthines	S-Chemical	S-Chemical
3	on	O	O
4	gentamicin	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	acute	B-Disease	B-Disease
8	renal	I-Disease	I-Disease
9	failure	E-Disease	E-Disease
10	in	O	O
11	the	O	O
12	rat	O	O
13	.	O	O

0	Adenosine	S-Chemical	S-Chemical
1	antagonists	O	O
2	have	O	O
3	been	O	O
4	previously	O	O
5	shown	O	O
6	to	O	O
7	be	O	O
8	of	O	O
9	benefit	O	O
10	in	O	O
11	some	O	O
12	ischaemic	S-Disease	O
13	and	O	O
14	nephrotoxic	S-Disease	O
15	models	O	O
16	of	O	O
17	acute	B-Disease	B-Disease
18	renal	I-Disease	I-Disease
19	failure	E-Disease	E-Disease
20	(	O	O
21	ARF	S-Disease	S-Disease
22	)	O	O
23	.	O	O

0	In	O	O
1	the	O	O
2	present	O	O
3	study	O	O
4	,	O	O
5	the	O	O
6	effects	O	O
7	of	O	O
8	three	O	O
9	alkylxanthines	S-Chemical	S-Chemical
10	with	O	O
11	different	O	O
12	potencies	O	O
13	as	O	O
14	adenosine	S-Chemical	S-Chemical
15	antagonists	O	O
16	8	B-Chemical	S-Chemical
17	-	I-Chemical	I-Chemical
18	phenyltheophylline	E-Chemical	S-Chemical
19	,	O	O
20	theophylline	S-Chemical	S-Chemical
21	and	O	O
22	enprofylline	S-Chemical	S-Disease
23	,	O	O
24	were	O	O
25	examined	O	O
26	in	O	O
27	rats	O	O
28	developing	O	O
29	acute	B-Disease	O
30	renal	I-Disease	I-Disease
31	failure	E-Disease	E-Disease
32	after	O	O
33	4	O	O
34	daily	O	O
35	injections	O	O
36	of	O	O
37	gentamicin	S-Chemical	S-Chemical
38	(	O	O
39	200	O	O
40	mg	O	O
41	kg	O	O
42	-	O	O
43	1	O	O
44	)	O	O
45	.	O	O

0	Renal	O	O
1	function	O	O
2	was	O	O
3	assessed	O	O
4	by	O	O
5	biochemical	O	O
6	(	O	O
7	plasma	O	O
8	urea	S-Chemical	S-Chemical
9	and	O	O
10	creatinine	S-Chemical	S-Chemical
11	)	O	O
12	,	O	O
13	functional	O	O
14	(	O	O
15	urine	O	O
16	analysis	O	O
17	and	O	O
18	[	O	O
19	3H	O	O
20	]	O	O
21	inulin	O	S-Chemical
22	and	O	O
23	[	O	O
24	14C	O	O
25	]	O	O
26	p	B-Chemical	S-Chemical
27	-	I-Chemical	O
28	aminohippuric	I-Chemical	E-Chemical
29	acid	E-Chemical	O
30	clearances	O	O
31	)	O	O
32	and	O	O
33	morphological	O	O
34	(	O	O
35	degree	O	O
36	of	O	O
37	necrosis	S-Disease	O
38	)	O	O
39	indices	O	O
40	.	O	O

0	However	O	O
1	,	O	O
2	any	O	O
3	improvement	O	O
4	produced	O	O
5	by	O	O
6	drug	O	O
7	treatment	O	O
8	was	O	O
9	largely	O	O
10	a	O	O
11	result	O	O
12	of	O	O
13	a	O	O
14	beneficial	O	O
15	effect	O	O
16	exerted	O	O
17	by	O	O
18	its	O	O
19	vehicle	O	O
20	(	O	O
21	polyethylene	B-Chemical	B-Chemical
22	glycol	E-Chemical	S-Chemical
23	and	O	O
24	NaOH	S-Chemical	S-Chemical
25	)	O	O
26	.	O	O

0	The	O	O
1	lack	O	O
2	of	O	O
3	any	O	O
4	consistent	O	O
5	protective	O	O
6	effect	O	O
7	noted	O	O
8	with	O	O
9	the	O	O
10	alkylxanthines	S-Chemical	S-Chemical
11	tested	O	O
12	in	O	O
13	the	O	O
14	present	O	O
15	study	O	O
16	indicates	O	O
17	that	O	O
18	adenosine	S-Chemical	S-Chemical
19	plays	O	O
20	little	O	O
21	,	O	O
22	if	O	O
23	any	O	O
24	,	O	O
25	pathophysiological	O	O
26	role	O	O
27	in	O	O
28	gentamicin	S-Chemical	S-Chemical
29	-	O	O
30	induced	O	O
31	ARF	S-Disease	O
32	.	O	O

0	Adverse	O	O
1	ocular	O	B-Disease
2	reactions	O	E-Disease
3	possibly	O	O
4	associated	O	O
5	with	O	O
6	isotretinoin	S-Chemical	S-Chemical
7	.	O	O

0	A	O	O
1	total	O	O
2	of	O	O
3	261	O	O
4	adverse	O	O
5	ocular	O	I-Disease
6	reactions	O	E-Disease
7	occurred	O	O
8	in	O	O
9	237	O	O
10	patients	O	O
11	who	O	O
12	received	O	O
13	isotretinoin	S-Chemical	S-Chemical
14	,	O	O
15	a	O	O
16	commonly	O	O
17	used	O	O
18	drug	O	O
19	in	O	O
20	the	O	O
21	treatment	O	O
22	of	O	O
23	severe	O	O
24	cystic	O	S-Chemical
25	acne	S-Disease	S-Disease
26	.	O	O

0	Blepharoconjunctivitis	S-Disease	S-Chemical
1	,	O	O
2	subjective	O	O
3	complaints	O	O
4	of	O	O
5	dry	B-Disease	O
6	eyes	E-Disease	O
7	,	O	O
8	blurred	B-Disease	O
9	vision	E-Disease	O
10	,	O	O
11	contact	O	B-Disease
12	lens	O	E-Disease
13	intolerance	O	E-Disease
14	,	O	O
15	and	O	O
16	photodermatitis	S-Disease	S-Disease
17	are	O	O
18	reversible	O	O
19	side	O	O
20	effects	O	O
21	.	O	O

0	More	O	O
1	serious	O	O
2	ocular	O	B-Disease
3	adverse	O	O
4	reactions	O	O
5	include	O	O
6	papilledema	S-Disease	S-Disease
7	,	O	O
8	pseudotumor	B-Disease	B-Disease
9	cerebri	E-Disease	S-Disease
10	,	O	O
11	and	O	O
12	white	O	O
13	or	O	O
14	gray	O	O
15	subepithelial	O	O
16	corneal	B-Disease	B-Disease
17	opacities	E-Disease	E-Disease
18	;	O	O
19	all	O	O
20	of	O	O
21	these	O	O
22	are	O	O
23	reversible	O	O
24	if	O	O
25	the	O	O
26	drug	O	O
27	is	O	O
28	discontinued	O	O
29	.	O	O

0	Isotretinoin	S-Chemical	S-Chemical
1	is	O	O
2	contraindicated	O	O
3	in	O	O
4	pregnancy	O	O
5	because	O	O
6	of	O	O
7	the	O	O
8	many	O	O
9	reported	O	O
10	congenital	B-Disease	O
11	abnormalities	E-Disease	E-Disease
12	after	O	O
13	maternal	O	O
14	use	O	O
15	(	O	O
16	including	O	O
17	microphthalmos	S-Disease	S-Disease
18	,	O	O
19	orbital	O	B-Disease
20	hypertelorism	S-Disease	E-Disease
21	,	O	O
22	and	O	O
23	optic	B-Disease	B-Disease
24	nerve	I-Disease	I-Disease
25	hypoplasia	E-Disease	E-Disease
26	)	O	O
27	.	O	O

0	Procaterol	S-Chemical	O
1	and	O	O
2	terbutaline	S-Chemical	S-Chemical
3	in	O	O
4	bronchial	B-Disease	S-Disease
5	asthma	E-Disease	S-Disease
6	.	O	O

0	Procaterol	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	new	O	O
4	beta	O	O
5	-	O	O
6	2	O	O
7	adrenoceptor	O	S-Disease
8	stimulant	O	O
9	,	O	O
10	was	O	O
11	studied	O	O
12	in	O	O
13	a	O	O
14	double	O	O
15	-	O	O
16	blind	O	O
17	,	O	O
18	placebo	O	O
19	-	O	O
20	controlled	O	O
21	,	O	O
22	cross	O	O
23	-	O	O
24	over	O	O
25	trial	O	O
26	in	O	O
27	patients	O	O
28	with	O	O
29	bronchial	B-Disease	S-Disease
30	asthma	E-Disease	S-Disease
31	.	O	O

0	Oral	O	O
1	procaterol	S-Chemical	O
2	50	O	O
3	micrograms	O	O
4	b	O	O
5	.	O	O
6	d	O	O
7	.	O	O
8	,	O	O
9	procaterol	S-Chemical	O
10	100	O	O
11	micrograms	O	O
12	b	O	O
13	.	O	O
14	d	O	O
15	.	O	O
16	,	O	O
17	and	O	O
18	terbutaline	S-Chemical	S-Chemical
19	5	O	O
20	mg	O	O
21	t	O	O
22	.	O	O
23	i	O	O
24	.	O	O
25	d	O	O
26	.	O	O
27	,	O	O
28	were	O	O
29	compared	O	O
30	when	O	O
31	given	O	O
32	randomly	O	O
33	in	O	O
34	1	O	O
35	-	O	O
36	week	O	O
37	treatment	O	O
38	periods	O	O
39	.	O	O

0	The	O	O
1	best	O	O
2	clinical	O	O
3	effect	O	O
4	was	O	O
5	found	O	O
6	with	O	O
7	terbutaline	S-Chemical	S-Chemical
8	.	O	O

0	Both	O	O
1	anti	O	O
2	-	O	O
3	asthmatic	S-Disease	S-Disease
4	and	O	O
5	tremorgenic	S-Disease	S-Disease
6	effects	O	O
7	of	O	O
8	procaterol	S-Chemical	S-Chemical
9	were	O	O
10	dose	O	O
11	-	O	O
12	related	O	O
13	.	O	O

0	Procaterol	S-Chemical	S-Chemical
1	appeared	O	O
2	effective	O	O
3	in	O	O
4	the	O	O
5	doses	O	O
6	tested	O	O
7	,	O	O
8	and	O	O
9	a	O	O
10	twice	O	O
11	daily	O	O
12	regimen	O	O
13	would	O	O
14	appear	O	O
15	to	O	O
16	be	O	O
17	suitable	O	O
18	with	O	O
19	this	O	O
20	drug	O	O
21	.	O	O

0	Subacute	O	O
1	effects	O	O
2	of	O	O
3	propranolol	S-Chemical	S-Chemical
4	and	O	O
5	B	O	O
6	24	O	O
7	/	O	O
8	76	O	O
9	on	O	O
10	isoproterenol	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	rat	O	O
14	heart	B-Disease	I-Disease
15	hypertrophy	E-Disease	E-Disease
16	in	O	O
17	correlation	O	O
18	with	O	O
19	blood	O	O
20	pressure	O	O
21	.	O	O

0	We	O	O
1	compared	O	O
2	the	O	O
3	potential	O	O
4	beta	O	O
5	-	O	O
6	receptor	O	O
7	blocker	O	O
8	,	O	O
9	B	O	O
10	24	O	O
11	/	O	O
12	76	O	O
13	i	O	O
14	.	O	O
15	e	O	O
16	.	O	O
17	1	O	O
18	-	O	O
19	(	O	O
20	2	O	O
21	,	O	O
22	4	O	O
23	-	O	O
24	dichlorophenoxy	O	E-Chemical
25	)	O	O
26	-	O	O
27	3	O	O
28	[	O	O
29	2	O	O
30	-	O	I-Chemical
31	3	O	O
32	,	O	O
33	4	O	O
34	-	O	I-Chemical
35	dimethoxyphenyl	O	O
36	)	O	O
37	ethanolamino	O	S-Chemical
38	]	O	O
39	-	O	O
40	prop	O	O
41	an	O	O
42	-	O	I-Chemical
43	2	O	O
44	-	O	I-Chemical
45	ol	O	O
46	,	O	O
47	which	O	O
48	is	O	O
49	characterized	O	O
50	by	O	O
51	beta	O	O
52	1	O	E-Chemical
53	-	O	O
54	adrenoceptor	O	E-Chemical
55	blocking	O	O
56	and	O	O
57	beta	O	B-Chemical
58	2	O	E-Chemical
59	-	O	I-Chemical
60	adrenoceptor	O	E-Chemical
61	stimulating	O	O
62	properties	O	O
63	with	O	O
64	propranolol	S-Chemical	S-Chemical
65	.	O	O

0	The	O	O
1	studies	O	O
2	were	O	O
3	performed	O	O
4	using	O	O
5	an	O	O
6	experimental	O	O
7	model	O	O
8	of	O	O
9	isoproterenol	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	heart	B-Disease	B-Disease
13	hypertrophy	E-Disease	E-Disease
14	in	O	O
15	rats	O	O
16	.	O	O

0	A	O	O
1	correlation	O	O
2	of	O	O
3	the	O	O
4	blood	O	O
5	pressure	O	O
6	was	O	O
7	neither	O	O
8	found	O	O
9	in	O	O
10	the	O	O
11	development	O	O
12	nor	O	O
13	in	O	O
14	the	O	O
15	attempt	O	O
16	to	O	O
17	suppress	O	O
18	the	O	O
19	development	O	O
20	of	O	O
21	heart	B-Disease	B-Disease
22	hypertrophy	E-Disease	E-Disease
23	with	O	O
24	the	O	O
25	two	O	O
26	beta	O	O
27	-	O	O
28	receptor	O	O
29	blockers	O	O
30	.	O	O

0	Both	O	O
1	beta	O	S-Disease
2	-	O	O
3	blockers	O	O
4	influenced	O	O
5	the	O	O
6	development	O	O
7	of	O	O
8	hypertrophy	S-Disease	S-Disease
9	to	O	O
10	a	O	O
11	different	O	O
12	,	O	O
13	but	O	O
14	not	O	O
15	reproducible	O	O
16	extent	O	O
17	.	O	O

0	It	O	O
1	was	O	O
2	possible	O	O
3	to	O	O
4	suppress	O	O
5	the	O	O
6	increased	O	O
7	ornithine	S-Chemical	S-Disease
8	decarboxylase	O	O
9	activity	O	O
10	with	O	O
11	both	O	O
12	beta	O	O
13	-	O	O
14	blockers	O	O
15	in	O	O
16	hypertrophied	B-Disease	S-Disease
17	hearts	E-Disease	O
18	,	O	O
19	but	O	O
20	there	O	O
21	was	O	O
22	no	O	O
23	effect	O	O
24	on	O	O
25	the	O	O
26	heart	O	O
27	mass	O	O
28	.	O	O

0	Neither	O	O
1	propranolol	S-Chemical	S-Chemical
2	nor	O	O
3	B	O	S-Disease
4	24	O	O
5	/	O	O
6	76	O	O
7	could	O	O
8	stop	O	O
9	the	O	O
10	changes	O	O
11	in	O	O
12	the	O	O
13	characteristic	O	O
14	myosin	O	S-Chemical
15	isoenzyme	O	O
16	pattern	O	O
17	of	O	O
18	the	O	O
19	hypertrophied	S-Disease	O
20	rat	O	O
21	heart	O	O
22	.	O	O

0	Thus	O	O
1	,	O	O
2	the	O	O
3	investigations	O	O
4	did	O	O
5	not	O	O
6	provide	O	O
7	any	O	O
8	evidence	O	O
9	that	O	O
10	the	O	O
11	beta	O	O
12	-	O	O
13	receptor	O	O
14	blockers	O	O
15	propranolol	S-Chemical	S-Chemical
16	and	O	O
17	B	O	S-Disease
18	24	O	O
19	/	O	O
20	76	O	O
21	have	O	O
22	the	O	O
23	potency	O	O
24	to	O	O
25	prevent	O	O
26	isoproterenol	S-Chemical	S-Chemical
27	from	O	O
28	producing	O	O
29	heart	B-Disease	B-Disease
30	hypertrophy	E-Disease	E-Disease
31	.	O	O

0	Increased	O	O
1	anxiogenic	O	O
2	effects	O	O
3	of	O	O
4	caffeine	S-Chemical	S-Chemical
5	in	O	O
6	panic	B-Disease	B-Disease
7	disorders	E-Disease	E-Disease
8	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	oral	O	O
4	administration	O	O
5	of	O	O
6	caffeine	S-Chemical	S-Chemical
7	(	O	O
8	10	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	)	O	O
13	on	O	O
14	behavioral	O	O
15	ratings	O	O
16	,	O	O
17	somatic	O	O
18	symptoms	O	O
19	,	O	O
20	blood	O	O
21	pressure	O	O
22	and	O	O
23	plasma	O	O
24	levels	O	O
25	of	O	O
26	3	B-Chemical	B-Chemical
27	-	I-Chemical	I-Chemical
28	methoxy	I-Chemical	S-Chemical
29	-	I-Chemical	I-Chemical
30	4	I-Chemical	I-Chemical
31	-	I-Chemical	I-Chemical
32	hydroxyphenethyleneglycol	E-Chemical	S-Chemical
33	(	O	O
34	MHPG	S-Chemical	S-Chemical
35	)	O	O
36	and	O	O
37	cortisol	S-Chemical	S-Chemical
38	were	O	O
39	determined	O	O
40	in	O	O
41	17	O	O
42	healthy	O	O
43	subjects	O	O
44	and	O	O
45	21	O	O
46	patients	O	O
47	meeting	O	O
48	DSM	O	S-Disease
49	-	O	I-Disease
50	III	O	O
51	criteria	O	O
52	for	O	O
53	agoraphobia	S-Disease	O
54	with	O	O
55	panic	B-Disease	B-Disease
56	attacks	E-Disease	E-Disease
57	or	O	O
58	panic	B-Disease	B-Disease
59	disorder	E-Disease	E-Disease
60	.	O	O

0	Caffeine	S-Chemical	S-Chemical
1	produced	O	O
2	significantly	O	O
3	greater	O	O
4	increases	O	O
5	in	O	O
6	subject	O	O
7	-	O	O
8	rated	O	O
9	anxiety	S-Disease	S-Disease
10	,	O	O
11	nervousness	O	S-Disease
12	,	O	O
13	fear	O	O
14	,	O	O
15	nausea	S-Disease	S-Disease
16	,	O	O
17	palpitations	S-Disease	O
18	,	O	O
19	restlessness	S-Disease	S-Disease
20	,	O	O
21	and	O	O
22	tremors	S-Disease	S-Disease
23	in	O	O
24	the	O	O
25	patients	O	O
26	compared	O	O
27	with	O	O
28	healthy	O	O
29	subjects	O	O
30	.	O	O

0	In	O	O
1	the	O	O
2	patients	O	O
3	,	O	O
4	but	O	O
5	not	O	O
6	the	O	O
7	healthy	O	O
8	subjects	O	O
9	,	O	O
10	these	O	O
11	symptoms	O	O
12	were	O	O
13	significantly	O	O
14	correlated	O	O
15	with	O	O
16	plasma	O	O
17	caffeine	S-Chemical	E-Chemical
18	levels	O	O
19	.	O	O

0	Seventy	O	O
1	-	O	O
2	one	O	O
3	percent	O	O
4	of	O	O
5	the	O	O
6	patients	O	O
7	reported	O	O
8	that	O	O
9	the	O	O
10	behavioral	O	O
11	effects	O	O
12	of	O	O
13	caffeine	S-Chemical	S-Chemical
14	were	O	O
15	similar	O	O
16	to	O	O
17	those	O	O
18	experienced	O	O
19	during	O	O
20	panic	B-Disease	B-Disease
21	attacks	E-Disease	E-Disease
22	.	O	O

0	Caffeine	S-Chemical	S-Chemical
1	did	O	O
2	not	O	O
3	alter	O	O
4	plasma	O	O
5	MHPG	S-Chemical	S-Disease
6	levels	O	O
7	in	O	O
8	either	O	O
9	the	O	O
10	healthy	O	O
11	subjects	O	O
12	or	O	O
13	patients	O	O
14	.	O	O

0	Caffeine	S-Chemical	S-Chemical
1	increased	O	O
2	plasma	O	O
3	cortisol	S-Chemical	S-Chemical
4	levels	O	O
5	equally	O	O
6	in	O	O
7	the	O	O
8	patient	O	O
9	and	O	O
10	healthy	O	O
11	groups	O	O
12	.	O	O

0	Because	O	O
1	caffeine	S-Chemical	S-Chemical
2	is	O	O
3	an	O	O
4	adenosine	S-Chemical	S-Chemical
5	receptor	O	O
6	antagonist	O	O
7	,	O	O
8	these	O	O
9	results	O	O
10	suggest	O	O
11	that	O	O
12	some	O	O
13	panic	B-Disease	B-Disease
14	disorder	E-Disease	E-Disease
15	patients	O	O
16	may	O	O
17	have	O	O
18	abnormalities	B-Disease	O
19	in	I-Disease	O
20	neuronal	I-Disease	B-Disease
21	systems	E-Disease	E-Disease
22	involving	O	O
23	adenosine	S-Chemical	S-Chemical
24	.	O	O

0	Patients	O	O
1	with	O	O
2	anxiety	B-Disease	B-Disease
3	disorders	E-Disease	E-Disease
4	may	O	O
5	benefit	O	O
6	by	O	O
7	avoiding	O	O
8	caffeine	S-Chemical	S-Chemical
9	-	O	O
10	containing	O	O
11	foods	O	O
12	and	O	O
13	beverages	O	O
14	.	O	O

0	Comparison	O	O
1	of	O	O
2	the	O	O
3	effect	O	O
4	of	O	O
5	oxitropium	B-Chemical	B-Chemical
6	bromide	E-Chemical	E-Chemical
7	and	O	O
8	of	O	O
9	slow	O	O
10	-	O	O
11	release	O	O
12	theophylline	S-Chemical	S-Disease
13	on	O	O
14	nocturnal	O	O
15	asthma	S-Disease	S-Disease
16	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	a	O	O
4	new	O	O
5	inhaled	O	O
6	antimuscarinic	O	O
7	drug	O	O
8	,	O	O
9	oxitropium	B-Chemical	B-Chemical
10	bromide	E-Chemical	E-Chemical
11	,	O	O
12	and	O	O
13	of	O	O
14	a	O	O
15	slow	O	O
16	-	O	O
17	release	O	O
18	theophylline	S-Chemical	S-Disease
19	preparation	O	O
20	upon	O	O
21	nocturnal	O	O
22	asthma	S-Disease	S-Disease
23	were	O	O
24	compared	O	O
25	in	O	O
26	a	O	O
27	placebo	O	O
28	-	O	O
29	controlled	O	O
30	double	O	O
31	-	O	O
32	blind	O	O
33	study	O	O
34	.	O	O

0	Two	O	O
1	samples	O	O
2	were	O	O
3	studied	O	O
4	:	O	O
5	12	O	O
6	patients	O	O
7	received	O	O
8	oxitropium	S-Chemical	S-Chemical
9	at	O	O
10	600	O	O
11	micrograms	O	O
12	(	O	O
13	6	O	O
14	subjects	O	O
15	)	O	O
16	or	O	O
17	at	O	O
18	400	O	O
19	micrograms	O	O
20	t	O	O
21	.	O	O
22	i	O	O
23	.	O	O
24	d	O	O
25	.	O	O

0	(	O	O
1	6	O	O
2	subjects	O	O
3	)	O	O
4	whereas	O	O
5	11	O	O
6	received	O	O
7	theophylline	S-Chemical	S-Disease
8	at	O	O
9	300	O	O
10	mg	O	O
11	b	O	O
12	.	O	O
13	i	O	O
14	.	O	O
15	d	O	O
16	.	O	O

0	No	O	O
1	significant	O	O
2	difference	O	O
3	was	O	O
4	noticed	O	O
5	between	O	O
6	results	O	O
7	obtained	O	O
8	with	O	O
9	either	O	O
10	active	O	O
11	drug	O	O
12	,	O	O
13	as	O	O
14	well	O	O
15	as	O	O
16	with	O	O
17	either	O	O
18	dosage	O	O
19	of	O	O
20	oxitropium	S-Chemical	S-Chemical
21	.	O	O

0	No	O	O
1	subject	O	O
2	reported	O	O
3	side	O	O
4	effects	O	O
5	of	O	O
6	oxitropium	S-Chemical	S-Chemical
7	,	O	O
8	as	O	O
9	compared	O	O
10	to	O	O
11	three	O	O
12	subjects	O	O
13	reporting	O	O
14	nausea	S-Disease	S-Disease
15	,	O	O
16	vomiting	S-Disease	S-Disease
17	and	O	O
18	tremors	S-Disease	S-Disease
19	after	O	O
20	theophylline	S-Chemical	S-Chemical
21	.	O	O

0	Oxitropium	S-Chemical	S-Chemical
1	proves	O	O
2	to	O	O
3	be	O	O
4	a	O	O
5	valuable	O	O
6	alternative	O	O
7	to	O	O
8	theophylline	S-Chemical	S-Chemical
9	in	O	O
10	nocturnal	O	O
11	asthma	S-Disease	S-Disease
12	,	O	O
13	since	O	O
14	it	O	O
15	is	O	O
16	equally	O	O
17	potent	O	O
18	,	O	O
19	safer	O	O
20	and	O	O
21	does	O	O
22	not	O	O
23	require	O	O
24	the	O	O
25	titration	O	O
26	of	O	O
27	dosage	O	O
28	.	O	O

0	Penicillin	S-Chemical	S-Chemical
1	anaphylaxis	S-Disease	O
2	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	oral	O	O
4	penicillin	S-Chemical	S-Chemical
5	anaphylaxis	S-Disease	S-Disease
6	is	O	O
7	described	O	O
8	,	O	O
9	and	O	O
10	the	O	O
11	terminology	O	O
12	,	O	O
13	occurrence	O	O
14	,	O	O
15	clinical	O	O
16	manifestations	O	O
17	,	O	O
18	pathogenesis	O	O
19	,	O	O
20	prevention	O	O
21	,	O	O
22	and	O	O
23	treatment	O	O
24	of	O	O
25	anaphylaxis	S-Disease	S-Disease
26	are	O	O
27	reviewed	O	O
28	.	O	O

0	Emergency	O	O
1	physicians	O	O
2	should	O	O
3	be	O	O
4	aware	O	O
5	of	O	O
6	oral	O	O
7	penicillin	S-Chemical	S-Chemical
8	anaphylaxis	S-Disease	S-Disease
9	in	O	O
10	order	O	O
11	to	O	O
12	prevent	O	O
13	its	O	O
14	occurrence	O	O
15	by	O	O
16	prescribing	O	O
17	the	O	O
18	antibiotic	O	O
19	judiciously	O	O
20	and	O	O
21	knowledgeably	O	O
22	and	O	O
23	to	O	O
24	offer	O	O
25	optimal	O	O
26	medical	O	O
27	therapy	O	O
28	once	O	O
29	this	O	O
30	life	O	O
31	-	O	O
32	threatening	O	O
33	reaction	O	O
34	has	O	O
35	begun	O	O
36	.	O	O

0	Reversible	O	O
1	valproic	B-Chemical	S-Disease
2	acid	E-Chemical	E-Chemical
3	-	O	O
4	induced	O	O
5	dementia	S-Disease	S-Disease
6	:	O	O
7	a	O	O
8	case	O	O
9	report	O	O
10	.	O	O

0	Reversible	O	O
1	valproic	B-Chemical	O
2	acid	E-Chemical	E-Chemical
3	-	O	O
4	induced	O	O
5	dementia	S-Disease	S-Disease
6	was	O	O
7	documented	O	O
8	in	O	O
9	a	O	O
10	21	O	O
11	-	O	O
12	year	O	O
13	-	O	O
14	old	O	O
15	man	O	O
16	with	O	O
17	epilepsy	S-Disease	S-Disease
18	who	O	O
19	had	O	O
20	a	O	O
21	3	O	O
22	-	O	O
23	year	O	O
24	history	O	O
25	of	O	O
26	insidious	O	O
27	progressive	O	O
28	decline	O	O
29	in	O	O
30	global	O	O
31	cognitive	O	B-Disease
32	abilities	O	E-Disease
33	documented	O	O
34	by	O	O
35	serial	O	O
36	neuropsychological	O	O
37	studies	O	O
38	.	O	O

0	Possible	O	O
1	pathophysiological	O	O
2	mechanisms	O	O
3	which	O	O
4	may	O	O
5	have	O	O
6	been	O	O
7	operative	O	O
8	in	O	O
9	this	O	O
10	case	O	O
11	include	O	O
12	:	O	O
13	a	O	O
14	direct	O	O
15	central	O	O
16	nervous	O	I-Disease
17	system	O	E-Disease
18	(	O	O
19	CNS	O	S-Disease
20	)	O	O
21	toxic	O	O
22	effect	O	O
23	of	O	O
24	valproic	B-Chemical	S-Chemical
25	acid	E-Chemical	O
26	;	O	O
27	a	O	O
28	paradoxical	O	O
29	epileptogenic	O	O
30	effect	O	O
31	secondary	O	O
32	to	O	O
33	the	O	O
34	drug	O	O
35	;	O	O
36	and	O	O
37	an	O	O
38	indirect	O	O
39	CNS	O	S-Disease
40	toxic	O	O
41	effect	O	O
42	mediated	O	O
43	through	O	O
44	valproic	B-Chemical	S-Disease
45	acid	E-Chemical	S-Disease
46	-	O	O
47	induced	O	O
48	hyperammonemia	S-Disease	S-Disease
49	.	O	O

0	Reversal	O	O
1	of	O	O
2	scopolamine	S-Chemical	S-Chemical
3	-	O	O
4	induced	O	O
5	amnesia	S-Disease	S-Disease
6	of	O	O
7	passive	O	O
8	avoidance	O	O
9	by	O	O
10	pre	O	O
11	-	O	O
12	and	O	O
13	post	O	O
14	-	O	O
15	training	O	O
16	naloxone	S-Chemical	S-Disease
17	.	O	O

0	In	O	O
1	a	O	O
2	series	O	O
3	of	O	O
4	five	O	O
5	experiments	O	O
6	,	O	O
7	the	O	O
8	modulating	O	O
9	role	O	O
10	of	O	O
11	naloxone	S-Chemical	S-Chemical
12	on	O	O
13	a	O	O
14	scopolamine	S-Chemical	S-Disease
15	-	O	O
16	induced	O	O
17	retention	B-Disease	O
18	deficit	E-Disease	O
19	in	O	O
20	a	O	O
21	passive	O	O
22	avoidance	O	O
23	paradigm	O	O
24	was	O	O
25	investigated	O	O
26	in	O	O
27	mice	O	O
28	.	O	O

0	Scopolamine	S-Chemical	S-Chemical
1	,	O	O
2	but	O	O
3	not	O	O
4	methyl	B-Chemical	S-Chemical
5	scopolamine	E-Chemical	E-Chemical
6	(	O	O
7	1	O	O
8	and	O	O
9	3	O	O
10	mg	O	O
11	/	O	O
12	kg	O	O
13	)	O	O
14	,	O	O
15	induced	O	O
16	an	O	O
17	amnesia	S-Disease	S-Disease
18	as	O	O
19	measured	O	O
20	by	O	O
21	latency	O	O
22	and	O	O
23	duration	O	O
24	parameters	O	O
25	.	O	O

0	Naloxone	S-Chemical	S-Chemical
1	(	O	O
2	0	O	O
3	.	O	O
4	3	O	O
5	,	O	O
6	1	O	O
7	,	O	O
8	3	O	O
9	,	O	O
10	and	O	O
11	10	O	O
12	mg	O	O
13	/	O	O
14	kg	O	O
15	)	O	O
16	injected	O	O
17	prior	O	O
18	to	O	O
19	training	O	O
20	attenuated	O	O
21	the	O	O
22	retention	B-Disease	O
23	deficit	E-Disease	O
24	with	O	O
25	a	O	O
26	peak	O	O
27	of	O	O
28	activity	O	O
29	at	O	O
30	3	O	O
31	mg	O	O
32	/	O	O
33	kg	O	O
34	.	O	O

0	The	O	O
1	effect	O	O
2	of	O	O
3	naloxone	S-Chemical	S-Chemical
4	could	O	O
5	be	O	O
6	antagonized	O	O
7	with	O	O
8	morphine	S-Chemical	S-Chemical
9	(	O	O
10	1	O	O
11	,	O	O
12	3	O	O
13	,	O	O
14	and	O	O
15	10	O	O
16	mg	O	O
17	/	O	O
18	kg	O	O
19	)	O	O
20	,	O	O
21	demonstrating	O	O
22	the	O	O
23	opioid	O	S-Chemical
24	specificity	O	O
25	of	O	O
26	the	O	O
27	naloxone	S-Chemical	S-Chemical
28	effect	O	O
29	.	O	O

0	Post	O	O
1	-	O	O
2	training	O	O
3	administration	O	O
4	of	O	O
5	naloxone	S-Chemical	S-Chemical
6	(	O	O
7	3	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	)	O	O
12	as	O	O
13	a	O	O
14	single	O	O
15	or	O	O
16	as	O	O
17	a	O	O
18	split	O	O
19	dose	O	O
20	also	O	O
21	attenuated	O	O
22	the	O	O
23	scopolamine	S-Chemical	S-Disease
24	-	O	O
25	induced	O	O
26	amnesia	S-Disease	S-Disease
27	.	O	O

0	Control	O	O
1	experiments	O	O
2	indicated	O	O
3	that	O	O
4	neither	O	O
5	an	O	O
6	increase	O	O
7	in	O	O
8	pain	S-Disease	S-Disease
9	sensitivity	O	O
10	(	O	O
11	pre	O	O
12	-	O	O
13	training	O	O
14	naloxone	S-Chemical	S-Chemical
15	)	O	O
16	nor	O	O
17	an	O	O
18	induced	O	O
19	aversive	O	O
20	state	O	O
21	(	O	O
22	post	O	O
23	-	O	O
24	training	O	O
25	naloxone	S-Chemical	S-Disease
26	)	O	O
27	appear	O	O
28	to	O	O
29	be	O	O
30	responsible	O	O
31	for	O	O
32	the	O	O
33	influence	O	O
34	of	O	O
35	naloxone	S-Chemical	S-Chemical
36	on	O	O
37	the	O	O
38	scopolamine	S-Chemical	S-Disease
39	-	O	O
40	induced	O	O
41	retention	B-Disease	S-Disease
42	deficit	E-Disease	O
43	.	O	O

0	Electron	O	O
1	microscopic	O	O
2	investigations	O	O
3	of	O	O
4	the	O	O
5	cyclophosphamide	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	lesions	B-Disease	O
9	of	I-Disease	O
10	the	I-Disease	O
11	urinary	I-Disease	O
12	bladder	E-Disease	O
13	of	O	O
14	the	O	O
15	rat	O	O
16	and	O	O
17	their	O	O
18	prevention	O	O
19	by	O	O
20	mesna	S-Chemical	S-Chemical
21	.	O	O

0	Fully	O	O
1	developed	O	O
2	cyclophosphamide	S-Chemical	S-Chemical
3	-	O	O
4	induced	O	O
5	cystitis	S-Disease	S-Disease
6	is	O	O
7	characterized	O	O
8	by	O	O
9	nearly	O	O
10	complete	O	O
11	detachment	O	O
12	of	O	O
13	the	O	O
14	urothelium	O	S-Disease
15	,	O	O
16	severe	O	O
17	submucosal	O	O
18	edema	S-Disease	S-Disease
19	owing	O	O
20	to	O	O
21	damage	O	O
22	to	O	O
23	the	O	O
24	microvascular	O	O
25	bed	O	O
26	and	O	O
27	focal	O	O
28	muscle	O	B-Disease
29	necroses	S-Disease	E-Disease
30	.	O	O

0	The	O	O
1	initial	O	O
2	response	O	O
3	to	O	O
4	the	O	O
5	primary	O	O
6	attack	O	O
7	by	O	O
8	the	O	O
9	cyclophosphamide	S-Chemical	S-Chemical
10	metabolites	O	O
11	seems	O	O
12	to	O	O
13	be	O	O
14	fragmentation	O	O
15	of	O	O
16	the	O	O
17	luminal	S-Chemical	O
18	membrane	O	E-Disease
19	.	O	O

0	Subsequent	O	O
1	breaks	O	O
2	in	O	O
3	the	O	O
4	lateral	O	O
5	cell	O	O
6	membranes	O	O
7	of	O	O
8	the	O	O
9	superficial	O	O
10	cells	O	O
11	and	O	O
12	in	O	O
13	all	O	O
14	the	O	O
15	plasma	O	O
16	membranes	O	O
17	of	O	O
18	the	O	O
19	intermediate	O	O
20	and	O	O
21	basal	O	O
22	cells	O	O
23	,	O	O
24	intercellular	O	O
25	and	O	O
26	intracellular	O	O
27	edema	S-Disease	S-Disease
28	and	O	O
29	disintegration	O	O
30	of	O	O
31	the	O	O
32	desmosomes	O	S-Disease
33	and	O	O
34	hemidesmosomes	O	S-Disease
35	lead	O	O
36	to	O	O
37	progressive	O	O
38	degeneration	O	O
39	and	O	O
40	detachment	O	O
41	of	O	O
42	the	O	O
43	epithelial	O	O
44	cells	O	O
45	with	O	O
46	exposure	O	O
47	and	O	O
48	splitting	O	O
49	of	O	O
50	the	O	O
51	basal	O	O
52	membrane	O	O
53	.	O	O

0	These	O	O
1	changes	O	O
2	can	O	O
3	be	O	O
4	effectively	O	O
5	prevented	O	O
6	by	O	O
7	mesna	S-Chemical	S-Chemical
8	.	O	O

0	Increase	O	O
1	in	O	O
2	intragastric	O	O
3	pressure	O	O
4	during	O	O
5	suxamethonium	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	muscle	B-Disease	B-Disease
9	fasciculations	E-Disease	E-Disease
10	in	O	O
11	children	O	O
12	:	O	O
13	inhibition	O	O
14	by	O	O
15	alfentanil	S-Chemical	S-Chemical
16	.	O	O

0	Changes	O	O
1	in	O	O
2	intragastric	O	O
3	pressure	O	O
4	after	O	O
5	the	O	O
6	administration	O	O
7	of	O	O
8	suxamethonium	S-Chemical	S-Chemical
9	1	O	O
10	.	O	O
11	5	O	O
12	mg	O	O
13	kg	O	O
14	-	O	O
15	1	O	O
16	i	O	O
17	.	O	O
18	v	O	O
19	.	O	O
20	were	O	O
21	studied	O	O
22	in	O	O
23	32	O	O
24	children	O	O
25	(	O	O
26	mean	O	O
27	age	O	O
28	6	O	O
29	.	O	O
30	9	O	O
31	yr	O	O
32	)	O	O
33	pretreated	O	O
34	with	O	O
35	either	O	O
36	physiological	O	O
37	saline	O	S-Disease
38	or	O	O
39	alfentanil	S-Chemical	S-Chemical
40	50	O	O
41	micrograms	O	O
42	kg	O	O
43	-	O	O
44	1	O	O
45	.	O	O

0	Anaesthesia	O	O
1	was	O	O
2	induced	O	O
3	with	O	O
4	thiopentone	S-Chemical	S-Chemical
5	5	O	O
6	mg	O	O
7	kg	O	O
8	-	O	O
9	1	O	O
10	.	O	O

0	The	O	O
1	incidence	O	O
2	and	O	O
3	intensity	O	O
4	of	O	O
5	muscle	B-Disease	O
6	fasciculations	E-Disease	O
7	caused	O	O
8	by	O	O
9	suxamethonium	S-Chemical	S-Chemical
10	were	O	O
11	significantly	O	O
12	greater	O	O
13	in	O	O
14	the	O	O
15	control	O	O
16	than	O	O
17	in	O	O
18	the	O	O
19	alfentanil	S-Chemical	S-Chemical
20	group	O	O
21	.	O	O

0	The	O	O
1	intragastric	O	O
2	pressure	O	O
3	during	O	O
4	muscle	B-Disease	O
5	fasciculations	E-Disease	O
6	was	O	O
7	significantly	O	O
8	higher	O	O
9	in	O	O
10	the	O	O
11	control	O	O
12	group	O	O
13	(	O	O
14	16	O	O
15	+	O	O
16	/	O	O
17	-	O	O
18	0	O	O
19	.	O	O
20	7	O	O
21	(	O	O
22	SEM	O	O
23	)	O	O
24	cm	O	O
25	H2O	S-Chemical	O
26	)	O	O
27	than	O	O
28	in	O	O
29	the	O	O
30	alfentanil	S-Chemical	S-Chemical
31	group	O	O
32	(	O	O
33	7	O	O
34	.	O	O
35	7	O	O
36	+	O	O
37	/	O	O
38	-	O	O
39	1	O	O
40	.	O	O
41	5	O	O
42	(	O	O
43	SEM	O	O
44	)	O	O
45	cm	O	O
46	H2O	S-Chemical	O
47	)	O	O
48	.	O	O

0	The	O	O
1	increase	O	O
2	in	O	O
3	intragastric	O	O
4	pressure	O	O
5	was	O	O
6	directly	O	O
7	related	O	O
8	to	O	O
9	the	O	O
10	intensity	O	O
11	of	O	O
12	muscle	B-Disease	O
13	fasciculations	E-Disease	E-Disease
14	(	O	O
15	regression	O	O
16	line	O	O
17	:	O	O
18	y	O	O
19	=	O	O
20	0	O	O
21	.	O	O
22	5	O	O
23	+	O	O
24	4	O	O
25	.	O	O
26	78x	O	O
27	with	O	O
28	r	O	O
29	of	O	O
30	0	O	O
31	.	O	O
32	78	O	O
33	)	O	O
34	.	O	O

0	It	O	O
1	is	O	O
2	concluded	O	O
3	that	O	O
4	intragastric	O	O
5	pressure	O	O
6	increases	O	O
7	significantly	O	O
8	during	O	O
9	muscle	B-Disease	O
10	fasciculations	E-Disease	E-Disease
11	caused	O	O
12	by	O	O
13	suxamethonium	S-Chemical	S-Chemical
14	in	O	O
15	healthy	O	O
16	children	O	O
17	.	O	O

0	Alfentanil	S-Chemical	S-Chemical
1	50	O	O
2	micrograms	O	O
3	kg	O	O
4	-	O	O
5	1	O	O
6	effectively	O	O
7	inhibits	O	O
8	the	O	O
9	incidence	O	O
10	and	O	O
11	intensity	O	O
12	of	O	O
13	suxamethonium	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	muscle	B-Disease	O
17	fasciculations	E-Disease	S-Disease
18	;	O	O
19	moreover	O	O
20	,	O	O
21	intragastric	O	O
22	pressure	O	O
23	remains	O	O
24	at	O	O
25	its	O	O
26	control	O	O
27	value	O	O
28	.	O	O

0	Acute	O	O
1	insulin	O	S-Disease
2	treatment	O	O
3	normalizes	O	O
4	the	O	O
5	resistance	O	O
6	to	O	O
7	the	O	O
8	cardiotoxic	S-Disease	S-Disease
9	effect	O	O
10	of	O	O
11	isoproterenol	S-Chemical	S-Chemical
12	in	O	O
13	streptozotocin	S-Chemical	S-Chemical
14	diabetic	S-Disease	E-Disease
15	rats	O	O
16	.	O	O

0	A	O	O
1	morphometric	O	O
2	study	O	O
3	of	O	O
4	isoproterenol	S-Chemical	S-Chemical
5	induced	O	O
6	myocardial	O	B-Disease
7	fibrosis	S-Disease	E-Disease
8	.	O	O

0	The	O	O
1	acute	O	O
2	effect	O	O
3	of	O	O
4	insulin	O	S-Chemical
5	treatment	O	O
6	on	O	O
7	the	O	O
8	earlier	O	O
9	reported	O	O
10	protective	O	O
11	effect	O	O
12	of	O	O
13	streptozotocin	S-Chemical	B-Disease
14	diabetes	S-Disease	E-Disease
15	against	O	O
16	the	O	O
17	cardiotoxic	S-Disease	O
18	effect	O	O
19	of	O	O
20	high	O	O
21	doses	O	O
22	of	O	O
23	isoproterenol	S-Chemical	S-Chemical
24	(	O	O
25	ISO	S-Chemical	S-Disease
26	)	O	O
27	was	O	O
28	investigated	O	O
29	in	O	O
30	rats	O	O
31	.	O	O

0	Thirty	O	O
1	to	O	O
2	135	O	O
3	min	O	O
4	after	O	O
5	the	O	O
6	injection	O	O
7	of	O	O
8	crystalline	O	O
9	insulin	O	O
10	,	O	O
11	ISO	S-Chemical	S-Disease
12	was	O	O
13	given	O	O
14	subcutaneously	O	O
15	and	O	O
16	when	O	O
17	ISO	S-Chemical	S-Chemical
18	induced	O	O
19	fibrosis	S-Disease	S-Disease
20	in	O	O
21	the	O	O
22	myocardium	O	S-Disease
23	was	O	O
24	morphometrically	O	O
25	analyzed	O	O
26	7	O	O
27	days	O	O
28	later	O	O
29	,	O	O
30	a	O	O
31	highly	O	O
32	significant	O	O
33	correlation	O	O
34	(	O	O
35	r	O	O
36	=	O	O
37	0	O	O
38	.	O	O
39	83	O	O
40	,	O	O
41	2	O	O
42	p	O	O
43	=	O	O
44	0	O	O
45	.	O	O
46	006	O	O
47	)	O	O
48	to	O	O
49	the	O	O
50	slope	O	O
51	of	O	O
52	the	O	O
53	fall	O	O
54	in	O	O
55	blood	O	O
56	glucose	S-Chemical	S-Disease
57	after	O	O
58	insulin	O	S-Disease
59	treatment	O	O
60	appeared	O	O
61	.	O	O

0	The	O	O
1	myocardial	O	S-Disease
2	content	O	O
3	of	O	O
4	catecholamines	S-Chemical	S-Chemical
5	was	O	O
6	estimated	O	O
7	in	O	O
8	these	O	O
9	8	O	O
10	day	O	O
11	diabetic	S-Disease	O
12	rats	O	O
13	.	O	O

0	The	O	O
1	norepinephrine	S-Chemical	S-Chemical
2	content	O	O
3	was	O	O
4	significantly	O	O
5	increased	O	O
6	while	O	O
7	epinephrine	S-Chemical	S-Chemical
8	remained	O	O
9	unchanged	O	O
10	.	O	O

0	An	O	O
1	enhanced	O	O
2	sympathetic	O	B-Disease
3	nervous	O	I-Disease
4	system	O	I-Disease
5	activity	O	E-Disease
6	with	O	O
7	a	O	O
8	consequent	O	O
9	down	O	O
10	regulation	O	O
11	of	O	O
12	the	O	O
13	myocardial	O	B-Disease
14	beta	O	I-Disease
15	-	O	O
16	adrenergic	O	E-Disease
17	receptors	O	O
18	could	O	O
19	,	O	O
20	therefore	O	O
21	,	O	O
22	explain	O	O
23	this	O	O
24	catecholamine	S-Chemical	S-Disease
25	resistance	O	O
26	.	O	O

0	The	O	O
1	rapid	O	O
2	reversion	O	O
3	after	O	O
4	insulin	O	O
5	treatment	O	O
6	excludes	O	O
7	the	O	O
8	possibility	O	O
9	that	O	O
10	streptozotocin	S-Chemical	S-Chemical
11	in	O	O
12	itself	O	O
13	causes	O	O
14	the	O	O
15	ISO	S-Chemical	B-Disease
16	resistance	O	E-Disease
17	and	O	O
18	points	O	O
19	towards	O	O
20	a	O	O
21	direct	O	O
22	insulin	O	S-Chemical
23	effect	O	O
24	on	O	O
25	myocardial	O	B-Disease
26	catecholamine	S-Chemical	E-Disease
27	sensitivity	O	E-Disease
28	in	O	O
29	diabetic	S-Disease	S-Disease
30	rats	O	O
31	.	O	O

0	The	O	O
1	phenomenon	O	O
2	described	O	O
3	might	O	O
4	elucidate	O	O
5	pathogenetic	O	O
6	mechanisms	O	O
7	behind	O	O
8	toxic	O	B-Disease
9	myocardial	O	B-Disease
10	cell	O	E-Disease
11	degeneration	O	E-Disease
12	and	O	O
13	may	O	O
14	possibly	O	O
15	have	O	O
16	relevance	O	O
17	for	O	O
18	acute	O	B-Disease
19	cardiovascular	O	I-Disease
20	complications	O	E-Disease
21	in	O	O
22	diabetic	S-Disease	S-Disease
23	patients	O	O
24	.	O	O

0	Differential	O	O
1	effects	O	O
2	of	O	O
3	non	O	O
4	-	O	O
5	steroidal	O	S-Chemical
6	anti	O	O
7	-	O	O
8	inflammatory	O	S-Disease
9	drugs	O	O
10	on	O	O
11	seizures	S-Disease	S-Disease
12	produced	O	O
13	by	O	O
14	pilocarpine	S-Chemical	S-Chemical
15	in	O	O
16	rats	O	O
17	.	O	O

0	The	O	O
1	muscarinic	O	S-Chemical
2	cholinergic	O	S-Disease
3	agonist	O	O
4	pilocarpine	S-Chemical	S-Chemical
5	induces	O	O
6	in	O	O
7	rats	O	O
8	seizures	S-Disease	S-Disease
9	and	O	O
10	status	B-Disease	O
11	epilepticus	E-Disease	E-Disease
12	followed	O	O
13	by	O	O
14	widespread	O	O
15	damage	O	O
16	to	O	O
17	the	O	O
18	forebrain	O	O
19	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	was	O	O
4	designed	O	O
5	to	O	O
6	investigate	O	O
7	the	O	O
8	effect	O	O
9	of	O	O
10	5	O	O
11	non	O	O
12	-	O	O
13	steroidal	O	S-Chemical
14	anti	O	O
15	-	O	O
16	inflammatory	O	S-Disease
17	drugs	O	O
18	,	O	O
19	sodium	B-Chemical	S-Chemical
20	salicylate	E-Chemical	E-Chemical
21	,	O	O
22	phenylbutazone	S-Chemical	S-Chemical
23	,	O	O
24	indomethacin	S-Chemical	S-Chemical
25	,	O	O
26	ibuprofen	S-Chemical	S-Chemical
27	and	O	O
28	mefenamic	B-Chemical	S-Chemical
29	acid	E-Chemical	E-Chemical
30	,	O	O
31	on	O	O
32	seizures	S-Disease	S-Disease
33	produced	O	O
34	by	O	O
35	pilocarpine	S-Chemical	S-Chemical
36	.	O	O

0	Pretreatment	O	O
1	of	O	O
2	rats	O	O
3	with	O	O
4	sodium	B-Chemical	S-Disease
5	salicylate	E-Chemical	S-Chemical
6	,	O	O
7	ED50	O	S-Chemical
8	103	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	(	O	O
13	60	O	O
14	-	O	O
15	174	O	O
16	)	O	O
17	,	O	O
18	and	O	O
19	phenylbutazone	S-Chemical	S-Chemical
20	,	O	O
21	59	O	O
22	mg	O	O
23	/	O	O
24	kg	O	O
25	(	O	O
26	50	O	O
27	-	O	O
28	70	O	O
29	)	O	O
30	converted	O	O
31	the	O	O
32	non	O	O
33	-	O	O
34	convulsant	O	O
35	dose	O	O
36	of	O	O
37	pilocarpine	S-Chemical	S-Chemical
38	,	O	O
39	200	O	O
40	mg	O	O
41	/	O	O
42	kg	O	O
43	,	O	O
44	to	O	O
45	a	O	O
46	convulsant	O	O
47	one	O	O
48	.	O	O

0	Indomethacin	S-Chemical	S-Chemical
1	,	O	O
2	1	O	O
3	-	O	O
4	10	O	O
5	mg	O	O
6	/	O	O
7	kg	O	O
8	,	O	O
9	and	O	O
10	ibuprofen	S-Chemical	S-Chemical
11	,	O	O
12	10	O	O
13	-	O	O
14	100	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	,	O	O
19	failed	O	O
20	to	O	O
21	modulate	O	O
22	seizures	S-Disease	S-Disease
23	produced	O	O
24	by	O	O
25	pilocarpine	S-Chemical	S-Chemical
26	.	O	O

0	Mefenamic	B-Chemical	S-Chemical
1	acid	E-Chemical	O
2	,	O	O
3	26	O	O
4	(	O	O
5	22	O	O
6	-	O	O
7	30	O	O
8	)	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	,	O	O
13	prevented	O	O
14	seizures	S-Disease	S-Disease
15	and	O	O
16	protected	O	O
17	rats	O	O
18	from	O	O
19	seizure	S-Disease	B-Disease
20	-	O	O
21	related	O	O
22	brain	B-Disease	B-Disease
23	damage	E-Disease	E-Disease
24	induced	O	O
25	by	O	O
26	pilocarpine	S-Chemical	S-Chemical
27	,	O	O
28	380	O	O
29	mg	O	O
30	/	O	O
31	kg	O	O
32	.	O	O

0	These	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	non	O	O
5	-	O	O
6	steroidal	O	S-Chemical
7	anti	O	O
8	-	O	O
9	inflammatory	O	E-Disease
10	drugs	O	O
11	differentially	O	O
12	modulate	O	O
13	the	O	O
14	threshold	O	O
15	for	O	O
16	pilocarpine	S-Chemical	S-Chemical
17	-	O	O
18	induced	O	O
19	seizures	S-Disease	S-Disease
20	.	O	O

0	Acute	B-Disease	O
1	neurologic	I-Disease	O
2	dysfunction	E-Disease	S-Disease
3	after	O	O
4	high	O	O
5	-	O	O
6	dose	O	O
7	etoposide	S-Chemical	S-Chemical
8	therapy	O	O
9	for	O	O
10	malignant	B-Disease	B-Disease
11	glioma	E-Disease	E-Disease
12	.	O	O

0	Etoposide	S-Chemical	S-Chemical
1	(	O	O
2	VP	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	16	I-Chemical	E-Chemical
5	-	I-Chemical	E-Chemical
6	213	E-Chemical	E-Chemical
7	)	O	O
8	has	O	O
9	been	O	O
10	used	O	O
11	in	O	O
12	the	O	O
13	treatment	O	O
14	of	O	O
15	many	O	O
16	solid	O	B-Disease
17	tumors	S-Disease	E-Disease
18	and	O	O
19	hematologic	B-Disease	O
20	malignancies	E-Disease	S-Disease
21	.	O	O

0	When	O	O
1	used	O	O
2	in	O	O
3	high	O	O
4	doses	O	O
5	and	O	O
6	in	O	O
7	conjunction	O	O
8	with	O	O
9	autologous	O	O
10	bone	O	B-Disease
11	marrow	O	I-Disease
12	transplantation	O	E-Disease
13	,	O	O
14	this	O	O
15	agent	O	O
16	has	O	O
17	activity	O	O
18	against	O	O
19	several	O	O
20	treatment	O	O
21	-	O	O
22	resistant	O	O
23	cancers	S-Disease	S-Disease
24	including	O	O
25	malignant	B-Disease	B-Disease
26	glioma	E-Disease	S-Disease
27	.	O	O

0	In	O	O
1	six	O	O
2	of	O	O
3	eight	O	O
4	patients	O	O
5	(	O	O
6	75	O	O
7	%	O	O
8	)	O	O
9	who	O	O
10	we	O	O
11	treated	O	O
12	for	O	O
13	recurrent	O	O
14	or	O	O
15	resistant	O	O
16	glioma	S-Disease	S-Chemical
17	,	O	O
18	sudden	O	O
19	severe	O	O
20	neurologic	B-Disease	O
21	deterioration	E-Disease	O
22	occurred	O	O
23	.	O	O

0	This	O	O
1	developed	O	O
2	a	O	O
3	median	O	O
4	of	O	O
5	9	O	O
6	days	O	O
7	after	O	O
8	initiation	O	O
9	of	O	O
10	high	O	O
11	-	O	O
12	dose	O	O
13	etoposide	S-Chemical	S-Chemical
14	therapy	O	O
15	.	O	O

0	Significant	O	O
1	clinical	O	O
2	manifestations	O	O
3	have	O	O
4	included	O	O
5	confusion	S-Disease	O
6	,	O	O
7	papilledema	S-Disease	S-Disease
8	,	O	O
9	somnolence	S-Disease	O
10	,	O	O
11	exacerbation	O	O
12	of	O	O
13	motor	B-Disease	B-Disease
14	deficits	E-Disease	E-Disease
15	,	O	O
16	and	O	O
17	sharp	O	O
18	increase	O	B-Disease
19	in	O	O
20	seizure	S-Disease	B-Disease
21	activity	O	E-Disease
22	.	O	O

0	These	O	O
1	abnormalities	O	O
2	resolved	O	O
3	rapidly	O	O
4	after	O	O
5	initiation	O	O
6	of	O	O
7	high	O	O
8	-	O	O
9	dose	O	O
10	intravenous	O	O
11	dexamethasone	S-Chemical	S-Chemical
12	therapy	O	O
13	.	O	O

0	In	O	O
1	all	O	O
2	patients	O	O
3	,	O	O
4	computerized	O	O
5	tomographic	O	O
6	(	O	O
7	CT	O	O
8	)	O	O
9	brain	O	O
10	scans	O	O
11	demonstrated	O	O
12	stability	O	O
13	in	O	O
14	tumor	S-Disease	S-Disease
15	size	O	O
16	and	O	O
17	peritumor	O	S-Disease
18	edema	S-Disease	S-Disease
19	when	O	O
20	compared	O	O
21	with	O	O
22	pretransplant	O	O
23	scans	O	O
24	.	O	O

0	This	O	O
1	complication	O	O
2	appears	O	O
3	to	O	O
4	represent	O	O
5	a	O	O
6	significant	O	O
7	new	O	O
8	toxicity	S-Disease	S-Disease
9	of	O	O
10	high	O	O
11	-	O	O
12	dose	O	O
13	etoposide	S-Chemical	S-Chemical
14	therapy	O	O
15	for	O	O
16	malignant	B-Disease	B-Disease
17	glioma	E-Disease	E-Disease
18	.	O	O

0	Progressive	O	O
1	bile	B-Disease	B-Disease
2	duct	I-Disease	I-Disease
3	injury	E-Disease	E-Disease
4	after	O	O
5	thiabendazole	S-Chemical	S-Chemical
6	administration	O	O
7	.	O	O

0	A	O	O
1	27	O	O
2	-	O	O
3	yr	O	O
4	-	O	O
5	old	O	O
6	man	O	O
7	developed	O	O
8	jaundice	S-Disease	O
9	2	O	O
10	wk	O	O
11	after	O	O
12	exposure	O	O
13	to	O	O
14	thiabendazole	S-Chemical	S-Chemical
15	.	O	O

0	Cholestasis	S-Disease	S-Chemical
1	persisted	O	O
2	for	O	O
3	3	O	O
4	yr	O	O
5	,	O	O
6	at	O	O
7	which	O	O
8	time	O	O
9	a	O	O
10	liver	O	B-Disease
11	transplant	O	O
12	was	O	O
13	performed	O	O
14	.	O	O

0	Prominent	O	O
1	fibrosis	S-Disease	S-Disease
2	and	O	O
3	hepatocellular	O	S-Disease
4	regeneration	O	S-Disease
5	were	O	O
6	also	O	O
7	present	O	O
8	;	O	O
9	however	O	O
10	,	O	O
11	the	O	O
12	lobular	O	O
13	architecture	O	O
14	was	O	O
15	preserved	O	O
16	.	O	O

0	This	O	O
1	case	O	O
2	represents	O	O
3	an	O	O
4	example	O	O
5	of	O	O
6	"	O	O
7	idiosyncratic	O	O
8	"	O	O
9	drug	B-Disease	O
10	-	I-Disease	O
11	induced	I-Disease	O
12	liver	I-Disease	B-Disease
13	damage	E-Disease	E-Disease
14	in	O	O
15	which	O	O
16	the	O	O
17	primary	O	O
18	target	O	O
19	of	O	O
20	injury	O	O
21	is	O	O
22	the	O	O
23	bile	O	B-Disease
24	duct	O	E-Disease
25	.	O	O

0	An	O	O
1	autoimmune	O	O
2	pathogenesis	O	O
3	of	O	O
4	the	O	O
5	bile	B-Disease	B-Disease
6	duct	I-Disease	I-Disease
7	destruction	E-Disease	E-Disease
8	is	O	O
9	suggested	O	O
10	.	O	O

0	Differential	O	O
1	effects	O	O
2	of	O	O
3	1	B-Chemical	B-Chemical
4	,	I-Chemical	I-Chemical
5	4	I-Chemical	I-Chemical
6	-	I-Chemical	I-Chemical
7	dihydropyridine	E-Chemical	I-Chemical
8	calcium	B-Chemical	I-Disease
9	channel	I-Chemical	E-Disease
10	blockers	E-Chemical	E-Disease
11	:	O	O
12	therapeutic	O	O
13	implications	O	O
14	.	O	O

0	Increasing	O	O
1	recognition	O	O
2	of	O	O
3	the	O	O
4	importance	O	O
5	of	O	O
6	calcium	S-Chemical	S-Disease
7	in	O	O
8	the	O	O
9	pathogenesis	O	O
10	of	O	O
11	cardiovascular	B-Disease	B-Disease
12	disease	E-Disease	E-Disease
13	has	O	O
14	stimulated	O	O
15	research	O	O
16	into	O	O
17	the	O	O
18	use	O	O
19	of	O	O
20	calcium	B-Chemical	B-Disease
21	channel	I-Chemical	I-Disease
22	blocking	I-Chemical	O
23	agents	E-Chemical	O
24	for	O	O
25	treatment	O	O
26	of	O	O
27	a	O	O
28	variety	O	O
29	of	O	O
30	cardiovascular	B-Disease	B-Disease
31	diseases	E-Disease	E-Disease
32	.	O	O

0	Clinical	O	O
1	applications	O	O
2	of	O	O
3	calcium	B-Chemical	B-Disease
4	channel	I-Chemical	O
5	blockers	E-Chemical	O
6	parallel	O	O
7	their	O	O
8	tissue	O	O
9	selectivity	O	O
10	.	O	O

0	In	O	O
1	contrast	O	O
2	to	O	O
3	verapamil	S-Chemical	S-Chemical
4	and	O	O
5	diltiazem	S-Chemical	S-Chemical
6	,	O	O
7	which	O	O
8	are	O	O
9	roughly	O	O
10	equipotent	O	O
11	in	O	O
12	their	O	O
13	actions	O	O
14	on	O	O
15	the	O	O
16	heart	O	B-Disease
17	and	O	O
18	vascular	O	B-Disease
19	smooth	O	I-Disease
20	muscle	O	E-Disease
21	,	O	O
22	the	O	O
23	dihydropyridine	S-Chemical	S-Chemical
24	calcium	B-Chemical	I-Disease
25	channel	I-Chemical	O
26	blockers	E-Chemical	O
27	are	O	O
28	a	O	O
29	group	O	O
30	of	O	O
31	potent	O	O
32	peripheral	O	O
33	vasodilator	O	O
34	agents	O	O
35	that	O	O
36	exert	O	O
37	minimal	O	O
38	electrophysiologic	O	O
39	effects	O	O
40	on	O	O
41	cardiac	O	B-Disease
42	nodal	O	E-Disease
43	or	O	O
44	conduction	O	S-Disease
45	tissue	O	O
46	.	O	O

0	As	O	O
1	the	O	O
2	first	O	O
3	dihydropyridine	S-Chemical	S-Chemical
4	available	O	O
5	for	O	O
6	use	O	O
7	in	O	O
8	the	O	O
9	United	O	O
10	States	O	O
11	,	O	O
12	nifedipine	S-Chemical	S-Chemical
13	controls	O	O
14	angina	S-Disease	S-Disease
15	and	O	O
16	hypertension	S-Disease	S-Disease
17	with	O	O
18	minimal	O	O
19	depression	O	S-Disease
20	of	O	O
21	cardiac	O	B-Disease
22	function	O	E-Disease
23	.	O	O

0	Additional	O	O
1	members	O	O
2	of	O	O
3	this	O	O
4	group	O	O
5	of	O	O
6	calcium	B-Chemical	B-Disease
7	channel	I-Chemical	O
8	blockers	E-Chemical	O
9	have	O	O
10	been	O	O
11	studied	O	O
12	for	O	O
13	a	O	O
14	variety	O	O
15	of	O	O
16	indications	O	O
17	for	O	O
18	which	O	O
19	they	O	O
20	may	O	O
21	offer	O	O
22	advantages	O	O
23	over	O	O
24	current	O	O
25	therapy	O	O
26	.	O	O

0	Once	O	O
1	or	O	O
2	twice	O	O
3	daily	O	O
4	dosage	O	O
5	possible	O	O
6	with	O	O
7	nitrendipine	S-Chemical	S-Chemical
8	and	O	O
9	nisoldipine	S-Chemical	S-Chemical
10	offers	O	O
11	a	O	O
12	convenient	O	O
13	administration	O	O
14	schedule	O	O
15	,	O	O
16	which	O	O
17	encourages	O	O
18	patient	O	O
19	compliance	O	O
20	in	O	O
21	long	O	O
22	-	O	O
23	term	O	O
24	therapy	O	O
25	of	O	O
26	hypertension	S-Disease	S-Disease
27	.	O	O

0	The	O	O
1	coronary	O	S-Disease
2	vasodilating	O	O
3	properties	O	O
4	of	O	O
5	nisoldipine	S-Chemical	S-Chemical
6	have	O	O
7	led	O	O
8	to	O	O
9	the	O	O
10	investigation	O	O
11	of	O	O
12	this	O	O
13	agent	O	O
14	for	O	O
15	use	O	O
16	in	O	O
17	angina	S-Disease	S-Disease
18	.	O	O

0	Selectivity	O	O
1	for	O	O
2	the	O	O
3	cerebrovascular	O	S-Disease
4	bed	O	O
5	makes	O	O
6	nimodipine	S-Chemical	S-Chemical
7	potentially	O	O
8	useful	O	O
9	in	O	O
10	the	O	O
11	treatment	O	O
12	of	O	O
13	subarachnoid	B-Disease	S-Disease
14	hemorrhage	E-Disease	S-Disease
15	,	O	O
16	migraine	B-Disease	B-Disease
17	headache	E-Disease	E-Disease
18	,	O	O
19	dementia	S-Disease	S-Disease
20	,	O	O
21	and	O	O
22	stroke	S-Disease	S-Disease
23	.	O	O

0	In	O	O
1	general	O	O
2	,	O	O
3	the	O	O
4	dihydropyridine	S-Chemical	S-Chemical
5	calcium	B-Chemical	I-Disease
6	channel	I-Chemical	O
7	blockers	E-Chemical	O
8	are	O	O
9	usually	O	O
10	well	O	O
11	tolerated	O	O
12	,	O	O
13	with	O	O
14	headache	S-Disease	S-Disease
15	,	O	O
16	facial	O	B-Disease
17	flushing	S-Disease	E-Disease
18	,	O	O
19	palpitations	S-Disease	O
20	,	O	O
21	edema	S-Disease	S-Disease
22	,	O	O
23	nausea	S-Disease	S-Disease
24	,	O	O
25	anorexia	S-Disease	S-Disease
26	,	O	O
27	and	O	O
28	dizziness	S-Disease	O
29	being	O	O
30	the	O	O
31	more	O	O
32	common	O	O
33	adverse	O	O
34	effects	O	O
35	.	O	O

0	The	O	O
1	enhancement	O	O
2	of	O	O
3	aminonucleoside	S-Chemical	S-Chemical
4	nephrosis	S-Disease	S-Disease
5	by	O	O
6	the	O	O
7	co	O	O
8	-	O	O
9	administration	O	O
10	of	O	O
11	protamine	O	S-Chemical
12	.	O	O

0	An	O	O
1	experimental	O	O
2	model	O	O
3	of	O	O
4	focal	B-Disease	O
5	segmental	I-Disease	O
6	glomerular	I-Disease	I-Disease
7	sclerosis	E-Disease	E-Disease
8	(	O	O
9	FSGS	S-Disease	S-Disease
10	)	O	O
11	was	O	O
12	developed	O	O
13	in	O	O
14	rats	O	O
15	by	O	O
16	the	O	O
17	combined	O	O
18	administration	O	O
19	of	O	O
20	puromycin	B-Chemical	S-Chemical
21	-	I-Chemical	O
22	aminonucleoside	E-Chemical	S-Chemical
23	(	O	O
24	AMNS	S-Chemical	S-Chemical
25	)	O	O
26	and	O	O
27	protamine	B-Chemical	S-Chemical
28	sulfate	E-Chemical	E-Chemical
29	(	O	O
30	PS	S-Chemical	S-Disease
31	)	O	O
32	.	O	O

0	Male	O	O
1	Sprague	O	O
2	-	O	O
3	Dawley	O	O
4	rats	O	O
5	,	O	O
6	uninephrectomized	O	O
7	three	O	O
8	weeks	O	O
9	before	O	O
10	,	O	O
11	received	O	O
12	daily	O	O
13	injections	O	O
14	of	O	O
15	subcutaneous	O	O
16	AMNS	S-Chemical	S-Chemical
17	(	O	O
18	1	O	O
19	mg	O	O
20	/	O	O
21	100	O	O
22	g	O	O
23	body	O	O
24	wt	O	O
25	)	O	O
26	and	O	O
27	intravenous	O	O
28	PS	S-Chemical	O
29	(	O	O
30	2	O	O
31	separated	O	O
32	doses	O	O
33	of	O	O
34	2	O	O
35	.	O	O
36	5	O	O
37	mg	O	O
38	/	O	O
39	100	O	O
40	g	O	O
41	body	O	O
42	wt	O	O
43	)	O	O
44	for	O	O
45	four	O	O
46	days	O	O
47	.	O	O

0	They	O	O
1	developed	O	O
2	nephrotic	B-Disease	S-Disease
3	syndrome	E-Disease	S-Disease
4	and	O	O
5	finally	O	O
6	renal	B-Disease	B-Disease
7	failure	E-Disease	E-Disease
8	.	O	O

0	The	O	O
1	time	O	O
2	-	O	O
3	course	O	O
4	curve	O	O
5	of	O	O
6	creatinine	S-Chemical	S-Chemical
7	clearance	O	O
8	dropped	O	O
9	and	O	O
10	showed	O	O
11	significant	O	O
12	difference	O	O
13	(	O	O
14	P	O	O
15	less	O	O
16	than	O	O
17	0	O	O
18	.	O	O
19	01	O	O
20	)	O	O
21	from	O	O
22	that	O	O
23	of	O	O
24	each	O	O
25	control	O	O
26	group	O	O
27	,	O	O
28	such	O	O
29	as	O	O
30	,	O	O
31	AMNS	S-Chemical	S-Chemical
32	alone	O	O
33	,	O	O
34	PS	S-Chemical	S-Chemical
35	alone	O	O
36	or	O	O
37	saline	O	S-Chemical
38	injected	O	O
39	.	O	O

0	Their	O	O
1	glomeruli	O	S-Disease
2	showed	O	O
3	changes	O	O
4	of	O	O
5	progressive	O	O
6	FSGS	S-Disease	S-Disease
7	.	O	O

0	The	O	O
1	ultrastructural	O	O
2	studies	O	O
3	in	O	O
4	the	O	O
5	initial	O	O
6	stage	O	O
7	revealed	O	O
8	significant	O	O
9	lack	O	O
10	of	O	O
11	particles	O	O
12	of	O	O
13	perfused	O	O
14	ruthenium	S-Chemical	S-Disease
15	red	O	O
16	on	O	O
17	the	O	O
18	lamina	O	O
19	rara	O	O
20	externa	O	O
21	and	O	O
22	marked	O	O
23	changes	O	O
24	in	O	O
25	epithelial	O	O
26	cell	O	O
27	cytoplasm	O	E-Disease
28	.	O	O

0	Therefore	O	O
1	,	O	O
2	it	O	O
3	is	O	O
4	suggested	O	O
5	that	O	O
6	the	O	O
7	administration	O	O
8	of	O	O
9	PS	S-Chemical	S-Disease
10	enhances	O	O
11	the	O	O
12	toxicity	S-Disease	S-Disease
13	of	O	O
14	AMNS	S-Chemical	S-Chemical
15	on	O	O
16	the	O	O
17	glomerulus	O	S-Disease
18	and	O	O
19	readily	O	O
20	produces	O	O
21	progressive	O	O
22	FSGS	S-Disease	S-Disease
23	in	O	O
24	rats	O	O
25	resulting	O	O
26	in	O	O
27	the	O	O
28	end	B-Disease	O
29	-	I-Disease	O
30	stage	I-Disease	O
31	renal	I-Disease	B-Disease
32	disease	E-Disease	E-Disease
33	.	O	O

0	Theophylline	S-Chemical	O
1	neurotoxicity	S-Disease	S-Disease
2	in	O	O
3	pregnant	O	O
4	rats	O	O
5	.	O	O

0	The	O	O
1	purpose	O	O
2	of	O	O
3	this	O	O
4	investigation	O	O
5	was	O	O
6	to	O	O
7	determine	O	O
8	whether	O	O
9	the	O	O
10	neurotoxicity	S-Disease	O
11	of	O	O
12	theophylline	S-Chemical	S-Chemical
13	is	O	O
14	altered	O	O
15	in	O	O
16	advanced	O	O
17	pregnancy	O	O
18	.	O	O

0	Sprague	O	O
1	-	O	O
2	Dawley	O	O
3	rats	O	O
4	that	O	O
5	were	O	O
6	20	O	O
7	days	O	O
8	pregnant	O	O
9	and	O	O
10	nonpregnant	O	O
11	rats	O	O
12	of	O	O
13	the	O	O
14	same	O	O
15	age	O	O
16	and	O	O
17	strain	O	O
18	received	O	O
19	infusions	O	O
20	of	O	O
21	aminophylline	S-Chemical	S-Chemical
22	until	O	O
23	onset	O	O
24	of	O	O
25	maximal	O	O
26	seizures	S-Disease	S-Disease
27	which	O	O
28	occurred	O	O
29	after	O	O
30	28	O	O
31	and	O	O
32	30	O	O
33	minutes	O	O
34	respectively	O	O
35	.	O	O

0	Theophylline	S-Chemical	S-Chemical
1	concentrations	O	O
2	at	O	O
3	this	O	O
4	endpoint	O	O
5	in	O	O
6	serum	O	O
7	(	O	O
8	total	O	O
9	)	O	O
10	and	O	O
11	CSF	O	S-Chemical
12	were	O	O
13	similar	O	O
14	but	O	O
15	serum	O	O
16	(	O	O
17	free	O	O
18	)	O	O
19	and	O	O
20	brain	O	O
21	concentrations	O	O
22	were	O	O
23	slightly	O	O
24	different	O	O
25	in	O	O
26	pregnant	O	O
27	rats	O	O
28	.	O	O

0	Theophylline	S-Chemical	O
1	serum	O	O
2	protein	O	O
3	binding	O	O
4	determined	O	O
5	by	O	O
6	equilibrium	O	O
7	dialysis	O	S-Disease
8	was	O	O
9	lower	O	O
10	in	O	O
11	pregnant	O	O
12	rats	O	O
13	.	O	O

0	Fetal	O	O
1	serum	O	O
2	concentrations	O	O
3	at	O	O
4	onset	O	O
5	of	O	O
6	seizures	S-Disease	S-Disease
7	in	O	O
8	the	O	O
9	mother	O	O
10	were	O	O
11	similar	O	O
12	to	O	O
13	maternal	O	O
14	brain	O	O
15	and	O	O
16	CSF	O	S-Chemical
17	concentrations	O	O
18	and	O	O
19	correlated	O	O
20	significantly	O	O
21	with	O	O
22	the	O	O
23	former	O	O
24	.	O	O

0	It	O	O
1	is	O	O
2	concluded	O	O
3	that	O	O
4	advanced	O	O
5	pregnancy	O	O
6	has	O	O
7	a	O	O
8	negligible	O	O
9	effect	O	O
10	on	O	O
11	the	O	O
12	neurotoxic	S-Disease	O
13	response	O	O
14	to	O	O
15	theophylline	S-Chemical	S-Chemical
16	in	O	O
17	rats	O	O
18	.	O	O

0	Hyperkalemia	S-Disease	S-Disease
1	induced	O	O
2	by	O	O
3	indomethacin	S-Chemical	S-Chemical
4	and	O	O
5	naproxen	S-Chemical	S-Chemical
6	and	O	O
7	reversed	O	O
8	by	O	O
9	fludrocortisone	S-Chemical	S-Chemical
10	.	O	O

0	We	O	O
1	have	O	O
2	described	O	O
3	a	O	O
4	patient	O	O
5	with	O	O
6	severe	O	O
7	rheumatoid	B-Disease	B-Disease
8	arthritis	E-Disease	S-Disease
9	and	O	O
10	a	O	O
11	history	O	O
12	of	O	O
13	mefenamic	B-Chemical	B-Disease
14	acid	E-Chemical	I-Disease
15	nephropathy	S-Disease	E-Disease
16	in	O	O
17	whom	O	O
18	hyperkalemia	S-Disease	S-Disease
19	and	O	O
20	inappropriate	O	O
21	hypoaldosteronism	S-Disease	S-Disease
22	were	O	O
23	caused	O	O
24	by	O	O
25	both	O	O
26	indomethacin	S-Chemical	S-Chemical
27	and	O	O
28	naproxen	S-Chemical	S-Chemical
29	,	O	O
30	without	O	O
31	major	O	O
32	decline	O	O
33	in	O	O
34	renal	O	I-Disease
35	function	O	E-Disease
36	.	O	O

0	It	O	O
1	is	O	O
2	likely	O	O
3	that	O	O
4	preexisting	O	O
5	renal	B-Disease	B-Disease
6	disease	E-Disease	E-Disease
7	predisposed	O	O
8	this	O	O
9	patient	O	O
10	to	O	O
11	type	B-Disease	O
12	IV	I-Disease	O
13	renal	I-Disease	B-Disease
14	tubular	I-Disease	I-Disease
15	acidosis	E-Disease	I-Disease
16	with	O	O
17	prostaglandin	S-Chemical	S-Chemical
18	synthetase	O	O
19	inhibitors	O	O
20	.	O	O

0	Because	O	O
1	he	O	O
2	was	O	O
3	unable	O	O
4	to	O	O
5	discontinue	O	O
6	nonsteroidal	O	O
7	anti	O	O
8	-	O	O
9	inflammatory	O	S-Disease
10	drug	O	O
11	therapy	O	O
12	,	O	O
13	fludrocortisone	S-Chemical	S-Chemical
14	was	O	O
15	added	O	O
16	,	O	O
17	correcting	O	O
18	the	O	O
19	hyperkalemia	S-Disease	S-Disease
20	and	O	O
21	allowing	O	O
22	indomethacin	S-Chemical	S-Chemical
23	therapy	O	O
24	to	O	O
25	be	O	O
26	continued	O	O
27	safely	O	O
28	.	O	O

0	Hypotension	S-Disease	O
1	as	O	O
2	a	O	O
3	manifestation	O	O
4	of	O	O
5	cardiotoxicity	S-Disease	S-Disease
6	in	O	O
7	three	O	O
8	patients	O	O
9	receiving	O	O
10	cisplatin	S-Chemical	S-Chemical
11	and	O	O
12	5	B-Chemical	S-Chemical
13	-	I-Chemical	I-Chemical
14	fluorouracil	E-Chemical	S-Disease
15	.	O	O

0	Cardiac	O	O
1	symptoms	O	O
2	,	O	O
3	including	O	O
4	hypotension	S-Disease	S-Disease
5	,	O	O
6	developed	O	O
7	in	O	O
8	three	O	O
9	patients	O	O
10	with	O	O
11	advanced	O	O
12	colorectal	B-Disease	B-Disease
13	carcinoma	E-Disease	E-Disease
14	while	O	O
15	being	O	O
16	treated	O	O
17	with	O	O
18	cisplatin	S-Chemical	S-Chemical
19	(	O	O
20	CDDP	S-Chemical	S-Chemical
21	)	O	O
22	and	O	O
23	5	B-Chemical	B-Chemical
24	-	I-Chemical	I-Chemical
25	fluorouracil	E-Chemical	S-Chemical
26	(	O	O
27	5	B-Chemical	O
28	-	I-Chemical	I-Chemical
29	FU	E-Chemical	S-Disease
30	)	O	O
31	.	O	O

0	In	O	O
1	two	O	O
2	patients	O	O
3	,	O	O
4	hypotension	S-Disease	S-Disease
5	was	O	O
6	associated	O	O
7	with	O	O
8	severe	O	O
9	left	B-Disease	B-Disease
10	ventricular	I-Disease	I-Disease
11	dysfunction	E-Disease	E-Disease
12	.	O	O

0	The	O	O
1	presentation	O	O
2	and	O	O
3	cardiac	O	O
4	evaluation	O	O
5	(	O	O
6	hemodynamic	O	O
7	,	O	O
8	echocardiographic	O	O
9	,	O	O
10	and	O	O
11	scintigraphic	O	O
12	)	O	O
13	of	O	O
14	these	O	O
15	patients	O	O
16	suggest	O	O
17	new	O	O
18	manifestations	O	O
19	of	O	O
20	5	B-Chemical	O
21	-	I-Chemical	O
22	FU	E-Chemical	O
23	cardiotoxicity	S-Disease	S-Disease
24	that	O	O
25	may	O	O
26	be	O	O
27	influenced	O	O
28	by	O	O
29	CDDP	S-Chemical	S-Chemical
30	.	O	O

0	Fatal	O	O
1	aplastic	B-Disease	O
2	anemia	E-Disease	E-Disease
3	in	O	O
4	a	O	O
5	patient	O	O
6	treated	O	O
7	with	O	O
8	carbamazepine	S-Chemical	S-Chemical
9	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	fatal	O	O
4	aplastic	B-Disease	O
5	anemia	E-Disease	E-Disease
6	due	O	O
7	to	O	O
8	carbamazepine	S-Chemical	S-Chemical
9	treatment	O	O
10	in	O	O
11	an	O	O
12	epileptic	S-Disease	O
13	woman	O	O
14	is	O	O
15	reported	O	O
16	.	O	O

0	Despite	O	O
1	concerns	O	O
2	of	O	O
3	fatal	O	O
4	bone	B-Disease	B-Disease
5	marrow	I-Disease	I-Disease
6	toxicity	E-Disease	S-Disease
7	due	O	O
8	to	O	O
9	carbamazepine	S-Chemical	S-Chemical
10	,	O	O
11	this	O	O
12	is	O	O
13	only	O	O
14	the	O	O
15	fourth	O	O
16	documented	O	O
17	and	O	O
18	published	O	O
19	report	O	O
20	.	O	O

0	Carbamazepine	S-Chemical	S-Chemical
1	is	O	O
2	a	O	O
3	safe	O	O
4	drug	O	O
5	,	O	O
6	but	O	O
7	physicians	O	O
8	and	O	O
9	patients	O	O
10	should	O	O
11	be	O	O
12	aware	O	O
13	of	O	O
14	the	O	O
15	exceedingly	O	O
16	rare	O	O
17	but	O	O
18	potentially	O	O
19	fatal	O	O
20	side	O	O
21	effects	O	O
22	,	O	O
23	better	O	O
24	prevented	O	O
25	by	O	O
26	clinical	O	O
27	than	O	O
28	by	O	O
29	laboratory	O	O
30	monitoring	O	O
31	.	O	O

0	Participation	O	O
1	of	O	O
2	a	O	O
3	bulbospinal	O	S-Disease
4	serotonergic	O	S-Disease
5	pathway	O	O
6	in	O	O
7	the	O	O
8	rat	O	O
9	brain	O	O
10	in	O	O
11	clonidine	S-Chemical	S-Chemical
12	-	O	O
13	induced	O	O
14	hypotension	S-Disease	S-Disease
15	and	O	O
16	bradycardia	S-Disease	S-Disease
17	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	microinjection	O	O
4	of	O	O
5	clonidine	S-Chemical	S-Chemical
6	(	O	O
7	1	O	O
8	-	O	O
9	10	O	O
10	micrograms	O	O
11	in	O	O
12	1	O	O
13	microliter	O	O
14	)	O	O
15	into	O	O
16	a	O	O
17	region	O	O
18	adjacent	O	O
19	to	O	O
20	the	O	O
21	ventrolateral	O	O
22	surface	O	O
23	of	O	O
24	the	O	O
25	medulla	O	O
26	oblongata	O	O
27	on	O	O
28	cardiovascular	O	O
29	function	O	O
30	were	O	O
31	assessed	O	O
32	in	O	O
33	urethane	S-Chemical	O
34	-	O	O
35	anesthetized	O	O
36	rats	O	O
37	.	O	O

0	Intramedullary	O	O
1	administration	O	O
2	of	O	O
3	clonidine	S-Chemical	S-Chemical
4	,	O	O
5	but	O	O
6	not	O	O
7	saline	O	S-Chemical
8	vehicle	O	O
9	,	O	O
10	caused	O	O
11	a	O	O
12	dose	O	O
13	-	O	O
14	dependent	O	O
15	decrease	O	O
16	in	O	O
17	both	O	O
18	the	O	O
19	mean	O	O
20	arterial	O	B-Disease
21	pressure	O	E-Disease
22	and	O	O
23	the	O	O
24	heart	O	B-Disease
25	rate	O	E-Disease
26	.	O	O

0	The	O	O
1	clonidine	S-Chemical	S-Chemical
2	-	O	O
3	induced	O	O
4	hypotension	S-Disease	S-Disease
5	was	O	O
6	antagonized	O	O
7	by	O	O
8	prior	O	O
9	spinal	O	B-Disease
10	transection	O	E-Disease
11	,	O	O
12	but	O	O
13	not	O	O
14	bilateral	O	O
15	vagotomy	O	S-Disease
16	.	O	O

0	On	O	O
1	the	O	O
2	other	O	O
3	hand	O	O
4	,	O	O
5	the	O	O
6	clonidine	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	bradycardia	S-Disease	O
10	was	O	O
11	antagonized	O	O
12	by	O	O
13	prior	O	O
14	bilateral	O	O
15	vagotomy	O	S-Disease
16	,	O	O
17	but	O	O
18	not	O	O
19	spinal	O	B-Disease
20	transection	O	E-Disease
21	.	O	O

0	Furthermore	O	O
1	,	O	O
2	selective	O	O
3	destruction	O	O
4	of	O	O
5	the	O	O
6	spinal	O	O
7	5	B-Chemical	E-Chemical
8	-	I-Chemical	O
9	HT	E-Chemical	O
10	nerves	O	O
11	,	O	O
12	produced	O	O
13	by	O	O
14	bilateral	O	O
15	spinal	O	O
16	injection	O	O
17	of	O	O
18	5	B-Chemical	O
19	,	I-Chemical	O
20	7	I-Chemical	I-Chemical
21	-	I-Chemical	I-Chemical
22	dihydroxytryptamine	E-Chemical	S-Chemical
23	,	O	O
24	reduced	O	O
25	the	O	O
26	magnitude	O	O
27	of	O	O
28	the	O	O
29	vasodepressor	O	O
30	or	O	O
31	the	O	O
32	bradycardiac	S-Disease	O
33	responses	O	O
34	to	O	O
35	clonidine	S-Chemical	S-Chemical
36	microinjected	O	O
37	into	O	O
38	the	O	O
39	area	O	O
40	near	O	O
41	the	O	O
42	ventrolateral	O	O
43	surface	O	O
44	of	O	O
45	the	O	O
46	medulla	O	O
47	oblongata	O	E-Chemical
48	in	O	O
49	rats	O	O
50	.	O	O

0	The	O	O
1	data	O	O
2	indicate	O	O
3	that	O	O
4	a	O	O
5	bulbospinal	O	S-Disease
6	serotonergic	O	S-Disease
7	pathway	O	O
8	is	O	O
9	involved	O	O
10	in	O	O
11	development	O	O
12	of	O	O
13	clonidine	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	hypotension	S-Disease	S-Disease
17	and	O	O
18	bradycardia	S-Disease	O
19	.	O	O

0	The	O	O
1	induced	O	O
2	hypotension	S-Disease	S-Disease
3	is	O	O
4	brought	O	O
5	about	O	O
6	by	O	O
7	a	O	O
8	decrease	O	O
9	in	O	O
10	sympathetic	O	B-Disease
11	efferent	O	E-Disease
12	activity	O	E-Disease
13	,	O	O
14	whereas	O	O
15	the	O	O
16	induced	O	O
17	bradycardia	S-Disease	S-Disease
18	was	O	O
19	due	O	O
20	to	O	O
21	an	O	O
22	increase	O	O
23	in	O	O
24	vagal	O	O
25	efferent	O	O
26	activity	O	O
27	.	O	O

0	Hypertension	S-Disease	S-Disease
1	in	O	O
2	neuroblastoma	S-Disease	S-Disease
3	induced	O	O
4	by	O	O
5	imipramine	S-Chemical	S-Chemical
6	.	O	O

0	Hypertension	S-Disease	S-Disease
1	is	O	O
2	a	O	O
3	well	O	O
4	-	O	O
5	known	O	O
6	finding	O	O
7	in	O	O
8	some	O	O
9	patients	O	O
10	with	O	O
11	neuroblastoma	S-Disease	B-Disease
12	.	O	O

0	However	O	O
1	,	O	O
2	it	O	O
3	has	O	O
4	not	O	O
5	previously	O	O
6	been	O	O
7	described	O	O
8	in	O	O
9	association	O	O
10	with	O	O
11	the	O	O
12	use	O	O
13	of	O	O
14	Imipramine	S-Chemical	S-Chemical
15	.	O	O

0	We	O	O
1	report	O	O
2	the	O	O
3	occurrence	O	O
4	of	O	O
5	severe	O	O
6	hypertension	S-Disease	S-Disease
7	(	O	O
8	blood	O	O
9	pressure	O	O
10	190	O	O
11	/	O	O
12	160	O	O
13	)	O	O
14	in	O	O
15	a	O	O
16	4	O	O
17	-	O	O
18	year	O	O
19	-	O	O
20	old	O	O
21	girl	O	O
22	with	O	O
23	neuroblastoma	S-Disease	B-Disease
24	who	O	O
25	was	O	O
26	given	O	O
27	Imipramine	S-Chemical	S-Chemical
28	to	O	O
29	control	O	O
30	a	O	O
31	behavior	B-Disease	B-Disease
32	disorder	E-Disease	E-Disease
33	.	O	O

0	It	O	O
1	was	O	O
2	determined	O	O
3	later	O	O
4	that	O	O
5	this	O	O
6	patient	O	O
7	'	O	O
8	s	O	O
9	tumor	S-Disease	S-Disease
10	was	O	O
11	recurring	O	O
12	at	O	O
13	the	O	O
14	time	O	O
15	of	O	O
16	her	O	O
17	hypertensive	S-Disease	S-Disease
18	episode	O	O
19	.	O	O

0	Since	O	O
1	she	O	O
2	had	O	O
3	no	O	O
4	blood	O	O
5	pressure	O	O
6	elevation	O	O
7	at	O	O
8	initial	O	O
9	diagnosis	O	O
10	and	O	O
11	none	O	O
12	following	O	O
13	discontinuation	O	O
14	of	O	O
15	the	O	O
16	Imipramine	S-Chemical	S-Chemical
17	(	O	O
18	when	O	O
19	she	O	O
20	was	O	O
21	in	O	O
22	florid	O	S-Disease
23	relapse	O	O
24	)	O	O
25	,	O	O
26	we	O	O
27	believe	O	O
28	that	O	O
29	this	O	O
30	drug	O	O
31	rather	O	O
32	than	O	O
33	her	O	O
34	underlying	O	O
35	disease	O	S-Disease
36	alone	O	O
37	caused	O	O
38	her	O	O
39	hypertension	S-Disease	S-Disease
40	.	O	O

0	The	O	O
1	mechanism	O	O
2	for	O	O
3	this	O	O
4	reaction	O	O
5	is	O	O
6	believed	O	O
7	to	O	O
8	be	O	O
9	increased	O	O
10	levels	O	O
11	of	O	O
12	vasoactive	O	O
13	catecholamines	S-Chemical	S-Disease
14	due	O	O
15	to	O	O
16	interference	O	O
17	of	O	O
18	their	O	O
19	physiologic	O	O
20	inactivation	O	O
21	by	O	O
22	Imipramine	S-Chemical	S-Chemical
23	.	O	O

0	From	O	O
1	this	O	O
2	experience	O	O
3	,	O	O
4	we	O	O
5	urge	O	O
6	extreme	O	O
7	caution	O	O
8	in	O	O
9	the	O	O
10	use	O	O
11	of	O	O
12	tricyclic	O	S-Chemical
13	antidepressants	O	O
14	in	O	O
15	children	O	O
16	with	O	O
17	active	O	O
18	neuroblastoma	S-Disease	B-Disease
19	.	O	O

0	Rechallenge	O	O
1	of	O	O
2	patients	O	O
3	who	O	O
4	developed	O	O
5	oral	B-Disease	O
6	candidiasis	E-Disease	O
7	or	O	O
8	hoarseness	S-Disease	O
9	with	O	O
10	beclomethasone	B-Chemical	S-Chemical
11	dipropionate	E-Chemical	S-Disease
12	.	O	O

0	Of	O	O
1	158	O	O
2	asthmatic	S-Disease	O
3	patients	O	O
4	who	O	O
5	were	O	O
6	placed	O	O
7	on	O	O
8	inhaled	O	O
9	beclomethasone	S-Chemical	S-Chemical
10	,	O	O
11	15	O	O
12	(	O	O
13	9	O	O
14	.	O	O
15	5	O	O
16	%	O	O
17	)	O	O
18	developed	O	O
19	either	O	O
20	hoarseness	S-Disease	O
21	(	O	O
22	8	O	O
23	)	O	O
24	,	O	O
25	oral	O	O
26	thrush	S-Disease	S-Disease
27	(	O	O
28	6	O	O
29	)	O	O
30	,	O	O
31	or	O	O
32	both	O	O
33	(	O	O
34	1	O	O
35	)	O	O
36	.	O	O

0	When	O	O
1	their	O	O
2	adverse	O	O
3	reactions	O	O
4	subsided	O	O
5	,	O	O
6	seven	O	O
7	of	O	O
8	these	O	O
9	15	O	O
10	patients	O	O
11	were	O	O
12	rechallenged	O	O
13	with	O	O
14	inhaled	O	S-Disease
15	beclomethasone	S-Chemical	S-Chemical
16	.	O	O

0	These	O	O
1	included	O	O
2	five	O	O
3	cases	O	O
4	who	O	O
5	developed	O	O
6	hoarseness	S-Disease	O
7	and	O	O
8	three	O	O
9	who	O	O
10	developed	O	O
11	Candidiasis	S-Disease	S-Chemical
12	.	O	O

0	Oral	O	O
1	thrush	S-Disease	S-Disease
2	did	O	O
3	not	O	O
4	recur	O	O
5	,	O	O
6	but	O	O
7	60	O	O
8	%	O	O
9	(	O	O
10	3	O	O
11	/	O	O
12	5	O	O
13	)	O	O
14	of	O	O
15	patients	O	O
16	with	O	O
17	hoarseness	S-Disease	O
18	had	O	O
19	recurrence	O	O
20	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	patients	O	O
4	may	O	O
5	be	O	O
6	restarted	O	O
7	on	O	O
8	inhaled	O	S-Disease
9	beclomethasone	S-Chemical	S-Chemical
10	when	O	O
11	clinically	O	O
12	indicated	O	O
13	;	O	O
14	however	O	O
15	,	O	O
16	because	O	O
17	of	O	O
18	the	O	O
19	high	O	O
20	recurrence	O	O
21	rate	O	O
22	,	O	O
23	patients	O	O
24	who	O	O
25	develop	O	O
26	hoarseness	S-Disease	O
27	should	O	O
28	not	O	O
29	be	O	O
30	re	O	O
31	-	O	O
32	challenged	O	O
33	.	O	O

0	Concomitant	O	O
1	use	O	O
2	of	O	O
3	oral	O	O
4	prednisone	S-Chemical	O
5	and	O	O
6	topical	O	O
7	beclomethasone	S-Chemical	S-Chemical
8	may	O	O
9	increase	O	O
10	the	O	O
11	risk	O	O
12	of	O	O
13	developing	O	O
14	hoarseness	S-Disease	S-Disease
15	or	O	O
16	candidiasis	S-Disease	O
17	.	O	O

0	Cyclophosphamide	S-Chemical	S-Chemical
1	cardiotoxicity	S-Disease	O
2	:	O	O
3	an	O	O
4	analysis	O	O
5	of	O	O
6	dosing	O	O
7	as	O	O
8	a	O	O
9	risk	O	O
10	factor	O	O
11	.	O	O

0	Patients	O	O
1	who	O	O
2	undergo	O	O
3	bone	O	B-Disease
4	marrow	O	O
5	transplantation	O	O
6	are	O	O
7	generally	O	O
8	immunosuppressed	O	O
9	with	O	O
10	a	O	O
11	dose	O	O
12	of	O	O
13	cyclophosphamide	S-Chemical	S-Chemical
14	(	O	O
15	CYA	S-Chemical	S-Chemical
16	)	O	O
17	which	O	O
18	is	O	O
19	usually	O	O
20	calculated	O	O
21	based	O	O
22	on	O	O
23	the	O	O
24	patient	O	O
25	'	O	O
26	s	O	O
27	weight	O	O
28	.	O	O

0	At	O	O
1	these	O	O
2	high	O	O
3	doses	O	O
4	of	O	O
5	CYA	S-Chemical	S-Chemical
6	,	O	O
7	serious	O	O
8	cardiotoxicity	S-Disease	S-Disease
9	may	O	O
10	occur	O	O
11	,	O	O
12	but	O	O
13	definitive	O	O
14	risk	O	O
15	factors	O	O
16	for	O	O
17	the	O	O
18	development	O	O
19	of	O	O
20	such	O	O
21	cardiotoxicity	S-Disease	S-Disease
22	have	O	O
23	not	O	O
24	been	O	O
25	described	O	O
26	.	O	O

0	Since	O	O
1	chemotherapeutic	O	S-Disease
2	agent	O	O
3	toxicity	S-Disease	S-Disease
4	generally	O	O
5	correlates	O	O
6	with	O	O
7	dose	O	O
8	per	O	O
9	body	O	O
10	surface	O	O
11	area	O	O
12	,	O	O
13	we	O	O
14	retrospectively	O	O
15	calculated	O	O
16	the	O	O
17	dose	O	O
18	of	O	O
19	CYA	S-Chemical	S-Chemical
20	in	O	O
21	patients	O	O
22	transplanted	O	O
23	at	O	O
24	our	O	O
25	institution	O	O
26	to	O	O
27	determine	O	O
28	whether	O	O
29	the	O	O
30	incidence	O	O
31	of	O	O
32	CYA	S-Chemical	S-Chemical
33	cardiotoxicity	S-Disease	S-Disease
34	correlated	O	O
35	with	O	O
36	the	O	O
37	dose	O	O
38	per	O	O
39	body	O	O
40	surface	O	O
41	area	O	O
42	.	O	O

0	Eighty	O	O
1	patients	O	O
2	who	O	O
3	were	O	O
4	to	O	O
5	receive	O	O
6	CYA	S-Chemical	S-Chemical
7	50	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	/	O	O
12	d	O	O
13	for	O	O
14	four	O	O
15	days	O	O
16	as	O	O
17	preparation	O	O
18	for	O	O
19	marrow	O	B-Disease
20	grafting	O	E-Disease
21	underwent	O	O
22	a	O	O
23	total	O	O
24	of	O	O
25	84	O	O
26	transplants	O	O
27	for	O	O
28	aplastic	B-Disease	O
29	anemia	E-Disease	E-Disease
30	,	O	O
31	Wiskott	B-Disease	B-Chemical
32	-	I-Disease	I-Disease
33	Aldrich	I-Disease	I-Disease
34	syndrome	E-Disease	E-Disease
35	,	O	O
36	or	O	O
37	severe	B-Disease	O
38	combined	I-Disease	O
39	immunodeficiency	I-Disease	B-Disease
40	syndrome	E-Disease	E-Disease
41	.	O	O

0	Fourteen	O	O
1	of	O	O
2	84	O	O
3	(	O	O
4	17	O	O
5	%	O	O
6	)	O	O
7	patients	O	O
8	had	O	O
9	symptoms	O	O
10	and	O	O
11	signs	O	O
12	consistent	O	O
13	with	O	O
14	CYA	S-Chemical	B-Chemical
15	cardiotoxicity	S-Disease	E-Disease
16	within	O	O
17	ten	O	O
18	days	O	O
19	of	O	O
20	receiving	O	O
21	1	O	O
22	to	O	O
23	4	O	O
24	doses	O	O
25	of	O	O
26	CYA	S-Chemical	S-Chemical
27	.	O	O

0	Six	O	O
1	of	O	O
2	the	O	O
3	14	O	O
4	patients	O	O
5	died	O	O
6	with	O	O
7	congestive	B-Disease	O
8	heart	I-Disease	B-Disease
9	failure	E-Disease	E-Disease
10	.	O	O

0	The	O	O
1	dose	O	O
2	of	O	O
3	CYA	S-Chemical	S-Chemical
4	per	O	O
5	body	O	O
6	surface	O	O
7	area	O	O
8	was	O	O
9	calculated	O	O
10	for	O	O
11	all	O	O
12	patients	O	O
13	and	O	O
14	the	O	O
15	patients	O	O
16	were	O	O
17	divided	O	O
18	into	O	O
19	two	O	O
20	groups	O	O
21	based	O	O
22	on	O	O
23	daily	O	O
24	CYA	S-Chemical	S-Chemical
25	dose	O	O
26	:	O	O
27	Group	O	O
28	1	O	O
29	,	O	O
30	CYA	S-Chemical	S-Chemical
31	less	O	O
32	than	O	O
33	or	O	O
34	equal	O	O
35	to	O	O
36	1	O	O
37	.	O	O
38	55	O	O
39	g	O	O
40	/	O	O
41	m2	O	O
42	/	O	O
43	d	O	O
44	;	O	O
45	Group	O	O
46	2	O	O
47	,	O	O
48	CYA	S-Chemical	S-Chemical
49	greater	O	O
50	than	O	O
51	1	O	O
52	.	O	O
53	55	O	O
54	g	O	O
55	/	O	O
56	m2	O	O
57	/	O	O
58	d	O	O
59	.	O	O

0	Cardiotoxicity	S-Disease	O
1	that	O	O
2	was	O	O
3	thought	O	O
4	to	O	O
5	be	O	O
6	related	O	O
7	to	O	O
8	CYA	S-Chemical	S-Chemical
9	occurred	O	O
10	in	O	O
11	1	O	O
12	/	O	O
13	32	O	O
14	(	O	O
15	3	O	O
16	%	O	O
17	)	O	O
18	of	O	O
19	patients	O	O
20	in	O	O
21	Group	O	O
22	1	O	E-Disease
23	and	O	O
24	in	O	O
25	13	O	O
26	/	O	O
27	52	O	O
28	(	O	O
29	25	O	O
30	%	O	O
31	)	O	O
32	patients	O	O
33	in	O	O
34	Group	O	O
35	2	O	O
36	(	O	O
37	P	O	O
38	less	O	O
39	than	O	O
40	0	O	O
41	.	O	O
42	025	O	O
43	)	O	O
44	.	O	O

0	Congestive	B-Disease	O
1	heart	I-Disease	I-Disease
2	failure	E-Disease	E-Disease
3	caused	O	O
4	or	O	O
5	contributed	O	O
6	to	O	O
7	death	O	O
8	in	O	O
9	0	O	O
10	/	O	O
11	32	O	O
12	patients	O	O
13	in	O	O
14	Group	O	O
15	1	O	O
16	v	O	O
17	6	O	O
18	/	O	O
19	52	O	O
20	(	O	O
21	12	O	O
22	%	O	O
23	)	O	O
24	of	O	O
25	patients	O	O
26	in	O	O
27	Group	O	O
28	2	O	O
29	(	O	O
30	P	O	O
31	less	O	O
32	than	O	O
33	0	O	O
34	.	O	O
35	25	O	O
36	)	O	O
37	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	the	O	O
4	CYA	S-Chemical	S-Chemical
5	cardiotoxicity	S-Disease	O
6	correlates	O	O
7	with	O	O
8	CYA	S-Chemical	S-Chemical
9	dosage	O	O
10	as	O	O
11	calculated	O	O
12	by	O	O
13	body	O	O
14	surface	O	O
15	area	O	O
16	,	O	O
17	and	O	O
18	that	O	O
19	patients	O	O
20	with	O	O
21	aplastic	B-Disease	O
22	anemia	E-Disease	E-Disease
23	and	O	O
24	immunodeficiencies	S-Disease	O
25	can	O	O
26	be	O	O
27	effectively	O	O
28	prepared	O	O
29	for	O	O
30	bone	O	B-Disease
31	marrow	O	I-Disease
32	grafting	O	O
33	at	O	O
34	a	O	O
35	CYA	S-Chemical	O
36	dose	O	O
37	of	O	O
38	1	O	O
39	.	O	O
40	55	O	O
41	g	O	O
42	/	O	O
43	m2	O	O
44	/	O	O
45	d	O	O
46	for	O	O
47	four	O	O
48	days	O	O
49	with	O	O
50	a	O	O
51	lower	O	O
52	incidence	O	O
53	of	O	O
54	cardiotoxicity	S-Disease	S-Disease
55	than	O	O
56	patients	O	O
57	whose	O	O
58	CYA	S-Chemical	S-Chemical
59	dosage	O	O
60	is	O	O
61	calculated	O	O
62	based	O	O
63	on	O	O
64	weight	O	O
65	.	O	O

0	This	O	O
1	study	O	O
2	reaffirms	O	O
3	the	O	O
4	principle	O	O
5	that	O	O
6	drug	O	O
7	toxicity	S-Disease	S-Disease
8	correlates	O	O
9	with	O	O
10	dose	O	O
11	per	O	O
12	body	O	O
13	surface	O	O
14	area	O	O
15	.	O	O

0	Studies	O	O
1	of	O	O
2	risk	O	O
3	factors	O	O
4	for	O	O
5	aminoglycoside	S-Chemical	S-Chemical
6	nephrotoxicity	S-Disease	S-Disease
7	.	O	O

0	The	O	O
1	epidemiology	O	O
2	of	O	O
3	aminoglycoside	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	nephrotoxicity	S-Disease	S-Disease
7	is	O	O
8	not	O	O
9	fully	O	O
10	understood	O	O
11	.	O	O

0	Experimental	O	O
1	studies	O	O
2	in	O	O
3	healthy	O	O
4	human	O	O
5	volunteers	O	O
6	indicate	O	O
7	aminoglycosides	S-Chemical	S-Chemical
8	cause	O	O
9	proximal	O	O
10	tubular	O	B-Disease
11	damage	O	E-Disease
12	in	O	O
13	most	O	O
14	patients	O	O
15	,	O	O
16	but	O	O
17	rarely	O	O
18	,	O	O
19	if	O	O
20	ever	O	O
21	,	O	O
22	cause	O	O
23	glomerular	B-Disease	S-Disease
24	or	I-Disease	O
25	tubular	I-Disease	B-Disease
26	dysfunction	E-Disease	E-Disease
27	.	O	O

0	Clinical	O	O
1	trials	O	O
2	of	O	O
3	aminoglycosides	S-Chemical	S-Chemical
4	in	O	O
5	seriously	O	O
6	ill	O	O
7	patients	O	O
8	indicate	O	O
9	that	O	O
10	the	O	O
11	relative	O	O
12	risk	O	O
13	for	O	O
14	developing	O	O
15	acute	B-Disease	B-Disease
16	renal	I-Disease	I-Disease
17	failure	E-Disease	E-Disease
18	during	O	O
19	therapy	O	O
20	ranges	O	O
21	from	O	O
22	8	O	O
23	to	O	O
24	10	O	O
25	and	O	O
26	that	O	O
27	the	O	O
28	attributable	O	O
29	risk	O	O
30	is	O	O
31	70	O	O
32	%	O	O
33	to	O	O
34	80	O	O
35	%	O	O
36	.	O	O

0	Further	O	O
1	analysis	O	O
2	of	O	O
3	these	O	O
4	data	O	O
5	suggests	O	O
6	that	O	O
7	the	O	O
8	duration	O	O
9	of	O	O
10	therapy	O	O
11	,	O	O
12	plasma	O	O
13	aminoglycoside	S-Chemical	S-Chemical
14	levels	O	O
15	,	O	O
16	liver	B-Disease	B-Disease
17	disease	E-Disease	E-Disease
18	,	O	O
19	advanced	O	O
20	age	O	O
21	,	O	O
22	high	O	O
23	initial	O	O
24	estimated	O	O
25	creatinine	S-Chemical	S-Chemical
26	clearance	O	S-Disease
27	and	O	O
28	,	O	O
29	possibly	O	O
30	,	O	O
31	female	O	O
32	gender	O	O
33	all	O	O
34	increase	O	O
35	the	O	O
36	risk	O	O
37	for	O	O
38	nephrotoxicity	S-Disease	S-Disease
39	.	O	O

0	Other	O	O
1	causes	O	O
2	of	O	O
3	acute	B-Disease	B-Disease
4	renal	I-Disease	I-Disease
5	failure	E-Disease	E-Disease
6	,	O	O
7	such	O	O
8	as	O	O
9	shock	S-Disease	S-Disease
10	,	O	O
11	appear	O	O
12	to	O	O
13	have	O	O
14	an	O	O
15	additive	O	O
16	effect	O	O
17	.	O	O

0	These	O	O
1	models	O	O
2	may	O	O
3	also	O	O
4	be	O	O
5	useful	O	O
6	in	O	O
7	developing	O	O
8	insights	O	O
9	into	O	O
10	the	O	O
11	pathophysiology	O	O
12	of	O	O
13	aminoglycoside	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	nephrotoxicity	S-Disease	S-Disease
17	.	O	O

0	The	O	O
1	effect	O	O
2	of	O	O
3	clonidine	S-Chemical	S-Chemical
4	,	O	O
5	naphazoline	S-Chemical	S-Chemical
6	and	O	O
7	xylometazoline	S-Chemical	S-Chemical
8	on	O	O
9	analgesia	O	O
10	induced	O	O
11	by	O	O
12	morphine	S-Chemical	S-Chemical
13	,	O	O
14	codeine	S-Chemical	S-Chemical
15	,	O	O
16	fentanyl	S-Chemical	S-Chemical
17	and	O	O
18	pentazocine	S-Chemical	S-Chemical
19	,	O	O
20	and	O	O
21	on	O	O
22	cataleptic	S-Disease	O
23	effect	O	O
24	of	O	O
25	morphine	S-Chemical	S-Chemical
26	,	O	O
27	codine	S-Chemical	S-Chemical
28	and	O	O
29	fentanyl	S-Chemical	S-Chemical
30	was	O	O
31	studied	O	O
32	in	O	O
33	rats	O	O
34	.	O	O

0	The	O	O
1	biochemical	O	O
2	assays	O	O
3	on	O	O
4	the	O	O
5	influence	O	O
6	of	O	O
7	four	O	O
8	analgesics	O	O
9	on	O	O
10	the	O	O
11	brain	O	O
12	concentration	O	O
13	and	O	O
14	turnover	O	S-Disease
15	of	O	O
16	noradrenaline	S-Chemical	S-Disease
17	(	O	O
18	NA	S-Chemical	S-Chemical
19	)	O	O
20	were	O	O
21	also	O	O
22	performed	O	O
23	.	O	O

0	It	O	O
1	was	O	O
2	found	O	O
3	that	O	O
4	three	O	O
5	drugs	O	O
6	stimulating	O	O
7	central	O	O
8	NA	S-Chemical	S-Disease
9	receptors	O	O
10	failed	O	O
11	to	O	O
12	affect	O	O
13	the	O	O
14	analgesic	O	O
15	ED50	O	S-Disease
16	of	O	O
17	all	O	O
18	antinociceptive	O	O
19	agents	O	O
20	and	O	O
21	they	O	O
22	enhanced	O	O
23	catalepsy	S-Disease	S-Disease
24	induced	O	O
25	by	O	O
26	morphine	S-Chemical	S-Chemical
27	and	O	O
28	fentanyl	S-Chemical	S-Chemical
29	.	O	O

0	Codeine	S-Chemical	S-Chemical
1	catalepsy	S-Disease	E-Chemical
2	was	O	O
3	increased	O	O
4	by	O	O
5	clonidine	S-Chemical	S-Chemical
6	and	O	O
7	decreased	O	O
8	by	O	O
9	naphazoline	S-Chemical	S-Chemical
10	and	O	O
11	xylometazoline	S-Chemical	S-Chemical
12	.	O	O

0	The	O	O
1	brain	O	O
2	concentration	O	O
3	of	O	O
4	NA	S-Chemical	S-Chemical
5	was	O	O
6	not	O	O
7	changed	O	O
8	by	O	O
9	morphine	S-Chemical	S-Chemical
10	and	O	O
11	fentanyl	S-Chemical	S-Chemical
12	,	O	O
13	but	O	O
14	one	O	O
15	of	O	O
16	the	O	O
17	doses	O	O
18	of	O	O
19	codeine	S-Chemical	S-Chemical
20	(	O	O
21	45	O	O
22	mg	O	O
23	/	O	O
24	kg	O	O
25	)	O	O
26	slightly	O	O
27	enhanced	O	O
28	it	O	O
29	.	O	O

0	Pentazocine	S-Chemical	S-Chemical
1	dose	O	O
2	-	O	O
3	dependently	O	O
4	decreased	O	O
5	the	O	O
6	brain	O	O
7	level	O	O
8	of	O	O
9	NA	S-Chemical	S-Chemical
10	.	O	O

0	The	O	O
1	rate	O	O
2	of	O	O
3	NA	S-Chemical	S-Chemical
4	turnover	O	O
5	was	O	O
6	not	O	O
7	altered	O	O
8	by	O	O
9	analgesics	O	O
10	except	O	O
11	for	O	O
12	the	O	O
13	higher	O	O
14	dose	O	O
15	of	O	O
16	fentanyl	S-Chemical	S-Chemical
17	(	O	O
18	0	O	O
19	.	O	O
20	2	O	O
21	mg	O	O
22	/	O	O
23	kg	O	O
24	)	O	O
25	following	O	O
26	which	O	O
27	the	O	O
28	disappearance	O	O
29	of	O	O
30	NA	S-Chemical	S-Chemical
31	from	O	O
32	the	O	O
33	brain	O	O
34	was	O	O
35	diminished	O	O
36	.	O	O

0	It	O	O
1	is	O	O
2	suggested	O	O
3	that	O	O
4	in	O	O
5	rats	O	O
6	the	O	O
7	brain	O	O
8	NA	S-Chemical	S-Chemical
9	plays	O	O
10	a	O	O
11	less	O	O
12	important	O	O
13	function	O	O
14	than	O	O
15	the	O	O
16	other	O	O
17	monoamines	S-Chemical	S-Chemical
18	in	O	O
19	the	O	O
20	behavioural	O	O
21	activity	O	O
22	of	O	O
23	potent	O	O
24	analgesics	O	O
25	.	O	O

0	Flurothyl	S-Chemical	S-Disease
1	seizure	S-Disease	S-Disease
2	thresholds	O	O
3	in	O	O
4	mice	O	O
5	treated	O	O
6	neonatally	O	O
7	with	O	O
8	a	O	O
9	single	O	O
10	injection	O	O
11	of	O	O
12	monosodium	B-Chemical	B-Chemical
13	glutamate	E-Chemical	E-Chemical
14	(	O	O
15	MSG	S-Chemical	S-Chemical
16	)	O	O
17	:	O	O
18	evaluation	O	O
19	of	O	O
20	experimental	O	O
21	parameters	O	O
22	in	O	O
23	flurothyl	S-Chemical	B-Chemical
24	seizure	S-Disease	S-Disease
25	testing	O	O
26	.	O	O

0	Monosodium	B-Chemical	B-Chemical
1	glutamate	E-Chemical	E-Chemical
2	(	O	O
3	MSG	S-Chemical	S-Chemical
4	)	O	O
5	administration	O	O
6	to	O	O
7	neonatal	O	O
8	rodents	O	O
9	produces	O	O
10	convulsions	S-Disease	O
11	and	O	O
12	results	O	O
13	in	O	O
14	numerous	O	O
15	biochemical	O	O
16	and	O	O
17	behavioral	O	O
18	deficits	O	O
19	.	O	O

0	These	O	O
1	studies	O	O
2	were	O	O
3	undertaken	O	O
4	to	O	O
5	determine	O	O
6	if	O	O
7	neonatal	O	O
8	administration	O	O
9	of	O	O
10	MSG	S-Chemical	S-Chemical
11	produced	O	O
12	permanent	O	O
13	alterations	O	O
14	in	O	O
15	seizure	S-Disease	S-Disease
16	susceptibility	O	O
17	,	O	O
18	since	O	O
19	previous	O	O
20	investigations	O	O
21	were	O	O
22	inconclusive	O	O
23	.	O	O

0	A	O	O
1	flurothyl	S-Chemical	S-Chemical
2	ether	S-Chemical	E-Chemical
3	seizure	S-Disease	O
4	screening	O	O
5	technique	O	O
6	was	O	O
7	used	O	O
8	to	O	O
9	evaluate	O	O
10	seizure	S-Disease	S-Disease
11	susceptibility	O	O
12	in	O	O
13	adult	O	O
14	mice	O	O
15	that	O	O
16	received	O	O
17	neonatal	O	O
18	injections	O	O
19	of	O	O
20	MSG	S-Chemical	S-Chemical
21	(	O	O
22	4	O	O
23	mg	O	O
24	/	O	O
25	g	O	O
26	and	O	O
27	1	O	O
28	mg	O	O
29	/	O	O
30	g	O	O
31	)	O	O
32	.	O	O

0	MSG	S-Chemical	S-Chemical
1	treatment	O	O
2	resulted	O	O
3	in	O	O
4	significant	O	O
5	reductions	O	O
6	in	O	O
7	whole	O	O
8	brain	O	O
9	weight	O	O
10	but	O	O
11	did	O	O
12	not	O	O
13	alter	O	O
14	seizure	S-Disease	S-Disease
15	threshold	O	O
16	.	O	O

0	A	O	O
1	naloxone	S-Chemical	S-Chemical
2	(	O	O
3	5	O	O
4	mg	O	O
5	/	O	O
6	kg	O	O
7	)	O	O
8	challenge	O	O
9	was	O	O
10	also	O	O
11	ineffective	O	O
12	in	O	O
13	altering	O	O
14	the	O	O
15	seizure	S-Disease	O
16	thresholds	O	O
17	of	O	O
18	either	O	O
19	control	O	O
20	of	O	O
21	MSG	S-Chemical	S-Chemical
22	-	O	O
23	treated	O	O
24	mice	O	O
25	.	O	O

0	Flurothyl	S-Chemical	S-Chemical
1	ether	S-Chemical	E-Chemical
2	produced	O	O
3	hypothermia	S-Disease	S-Disease
4	which	O	O
5	was	O	O
6	correlated	O	O
7	with	O	O
8	the	O	O
9	duration	O	O
10	of	O	O
11	flurothyl	S-Chemical	S-Disease
12	exposure	O	E-Disease
13	;	O	O
14	however	O	O
15	,	O	O
16	the	O	O
17	relationship	O	O
18	of	O	O
19	hypothermia	S-Disease	S-Disease
20	to	O	O
21	seizure	S-Disease	S-Disease
22	induction	O	O
23	was	O	O
24	unclear	O	O
25	.	O	O

0	Flurothyl	S-Chemical	O
1	seizure	S-Disease	S-Disease
2	testing	O	O
3	proved	O	O
4	to	O	O
5	be	O	O
6	a	O	O
7	rapid	O	O
8	and	O	O
9	reliable	O	O
10	technique	O	O
11	with	O	O
12	which	O	O
13	to	O	O
14	evaluate	O	O
15	seizure	S-Disease	S-Disease
16	susceptibility	O	O
17	.	O	O

0	Susceptibility	O	O
1	to	O	O
2	seizures	S-Disease	S-Disease
3	produced	O	O
4	by	O	O
5	pilocarpine	S-Chemical	S-Chemical
6	in	O	O
7	rats	O	O
8	after	O	O
9	microinjection	O	O
10	of	O	O
11	isoniazid	S-Chemical	S-Chemical
12	or	O	O
13	gamma	B-Chemical	B-Chemical
14	-	I-Chemical	I-Chemical
15	vinyl	I-Chemical	E-Chemical
16	-	I-Chemical	I-Chemical
17	GABA	E-Chemical	E-Chemical
18	into	O	O
19	the	O	O
20	substantia	O	O
21	nigra	O	S-Disease
22	.	O	O

0	Pilocarpine	S-Chemical	S-Chemical
1	,	O	O
2	given	O	O
3	intraperitoneally	O	O
4	to	O	O
5	rats	O	O
6	,	O	O
7	reproduces	O	O
8	the	O	O
9	neuropathological	O	O
10	sequelae	O	O
11	of	O	O
12	temporal	B-Disease	B-Disease
13	lobe	I-Disease	E-Disease
14	epilepsy	E-Disease	E-Disease
15	and	O	O
16	provides	O	O
17	a	O	O
18	relevant	O	O
19	animal	O	O
20	model	O	O
21	for	O	O
22	studying	O	O
23	mechanisms	O	O
24	of	O	O
25	buildup	O	O
26	of	O	O
27	convulsive	S-Disease	O
28	activity	O	O
29	and	O	O
30	pathways	O	O
31	operative	O	O
32	in	O	O
33	the	O	O
34	generalization	O	O
35	and	O	O
36	propagation	O	O
37	of	O	O
38	seizures	S-Disease	S-Disease
39	within	O	O
40	the	O	O
41	forebrain	O	O
42	.	O	O

0	In	O	O
1	the	O	O
2	present	O	O
3	study	O	O
4	,	O	O
5	the	O	O
6	effects	O	O
7	of	O	O
8	manipulating	O	O
9	the	O	O
10	activity	O	O
11	of	O	O
12	the	O	O
13	gamma	B-Chemical	S-Chemical
14	-	I-Chemical	O
15	aminobutyric	I-Chemical	E-Chemical
16	acid	E-Chemical	E-Disease
17	(	O	O
18	GABA	S-Chemical	S-Chemical
19	)	O	O
20	-	O	O
21	mediated	O	O
22	synaptic	O	O
23	inhibition	O	O
24	within	O	O
25	the	O	O
26	substantia	O	O
27	nigra	O	S-Disease
28	on	O	O
29	seizures	S-Disease	S-Disease
30	produced	O	O
31	by	O	O
32	pilocarpine	S-Chemical	S-Chemical
33	in	O	O
34	rats	O	O
35	,	O	O
36	were	O	O
37	investigated	O	O
38	.	O	O

0	In	O	O
1	animals	O	O
2	pretreated	O	O
3	with	O	O
4	microinjections	O	O
5	of	O	O
6	isoniazid	S-Chemical	S-Chemical
7	,	O	O
8	150	O	O
9	micrograms	O	O
10	,	O	O
11	an	O	O
12	inhibitor	O	O
13	of	O	O
14	activity	O	O
15	of	O	O
16	the	O	O
17	GABA	S-Chemical	S-Chemical
18	-	O	O
19	synthesizing	O	O
20	enzyme	O	O
21	,	O	O
22	L	B-Chemical	B-Chemical
23	-	I-Chemical	I-Chemical
24	glutamic	I-Chemical	E-Chemical
25	acid	E-Chemical	O
26	decarboxylase	O	O
27	,	O	O
28	into	O	O
29	the	O	O
30	substantia	O	O
31	nigra	O	O
32	pars	O	O
33	reticulata	O	O
34	(	O	O
35	SNR	O	S-Disease
36	)	O	O
37	,	O	O
38	bilaterally	O	O
39	,	O	O
40	non	O	O
41	-	O	O
42	convulsant	O	O
43	doses	O	O
44	of	O	O
45	pilocarpine	S-Chemical	S-Chemical
46	,	O	O
47	100	O	O
48	and	O	O
49	200	O	O
50	mg	O	O
51	/	O	O
52	kg	O	O
53	,	O	O
54	resulted	O	O
55	in	O	O
56	severe	O	O
57	motor	O	B-Disease
58	limbic	O	I-Disease
59	seizures	S-Disease	E-Disease
60	and	O	O
61	status	B-Disease	B-Disease
62	epilepticus	E-Disease	E-Disease
63	.	O	O

0	Electroencephalographic	O	O
1	and	O	O
2	behavioral	O	O
3	monitoring	O	O
4	revealed	O	O
5	a	O	O
6	profound	O	O
7	reduction	O	O
8	of	O	O
9	the	O	O
10	threshold	O	O
11	for	O	O
12	pilocarpine	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	convulsions	S-Disease	S-Disease
16	.	O	O

0	Morphological	O	O
1	analysis	O	O
2	of	O	O
3	frontal	O	O
4	forebrain	O	O
5	sections	O	O
6	with	O	O
7	light	O	O
8	microscopy	O	O
9	revealed	O	O
10	seizure	S-Disease	B-Disease
11	-	O	O
12	related	O	O
13	damage	O	O
14	to	O	O
15	the	O	O
16	hippocampal	O	B-Disease
17	formation	O	E-Disease
18	,	O	O
19	thalamus	O	S-Disease
20	,	O	O
21	amygdala	O	S-Disease
22	,	O	O
23	olfactory	O	O
24	cortex	O	O
25	,	O	O
26	substantia	O	O
27	nigra	O	S-Disease
28	and	O	O
29	neocortex	O	S-Disease
30	,	O	O
31	which	O	O
32	is	O	O
33	typically	O	O
34	observed	O	O
35	with	O	O
36	pilocarpine	S-Chemical	S-Chemical
37	in	O	O
38	doses	O	O
39	exceeding	O	O
40	350	O	O
41	mg	O	O
42	/	O	O
43	kg	O	O
44	.	O	O

0	Bilateral	O	O
1	intrastriatal	O	O
2	injections	O	O
3	of	O	O
4	isoniazid	S-Chemical	S-Chemical
5	did	O	O
6	not	O	O
7	augment	O	O
8	seizures	S-Disease	S-Disease
9	produced	O	O
10	by	O	O
11	pilocarpine	S-Chemical	S-Chemical
12	,	O	O
13	200	O	O
14	mg	O	O
15	/	O	O
16	kg	O	O
17	.	O	O

0	Application	O	O
1	of	O	O
2	an	O	O
3	irreversible	O	O
4	inhibitor	O	O
5	of	O	O
6	GABA	S-Chemical	S-Chemical
7	transaminase	O	O
8	,	O	O
9	gamma	B-Chemical	B-Chemical
10	-	I-Chemical	I-Chemical
11	vinyl	I-Chemical	I-Chemical
12	-	I-Chemical	I-Chemical
13	GABA	E-Chemical	E-Chemical
14	(	O	O
15	D	B-Chemical	S-Disease
16	,	I-Chemical	O
17	L	I-Chemical	O
18	-	I-Chemical	I-Chemical
19	4	I-Chemical	O
20	-	I-Chemical	I-Chemical
21	amino	I-Chemical	I-Chemical
22	-	I-Chemical	I-Chemical
23	hex	I-Chemical	E-Chemical
24	-	I-Chemical	I-Chemical
25	5	I-Chemical	E-Chemical
26	-	I-Chemical	I-Chemical
27	enoic	I-Chemical	E-Chemical
28	acid	E-Chemical	O
29	)	O	O
30	,	O	O
31	5	O	O
32	micrograms	O	O
33	,	O	O
34	into	O	O
35	the	O	O
36	SNR	O	S-Chemical
37	,	O	O
38	bilaterally	O	O
39	,	O	O
40	suppressed	O	O
41	the	O	O
42	appearance	O	O
43	of	O	O
44	electrographic	O	O
45	and	O	O
46	behavioral	O	O
47	seizures	S-Disease	S-Disease
48	produced	O	O
49	by	O	O
50	pilocarpine	S-Chemical	B-Chemical
51	,	O	O
52	380	O	O
53	mg	O	O
54	/	O	O
55	kg	O	O
56	.	O	O

0	This	O	O
1	treatment	O	O
2	was	O	O
3	also	O	O
4	sufficient	O	O
5	to	O	O
6	protect	O	O
7	animals	O	O
8	from	O	O
9	the	O	O
10	occurrence	O	O
11	of	O	O
12	brain	B-Disease	B-Disease
13	damage	E-Disease	E-Disease
14	.	O	O

0	Microinjections	O	O
1	of	O	O
2	gamma	B-Chemical	B-Chemical
3	-	I-Chemical	I-Disease
4	vinyl	I-Chemical	I-Chemical
5	-	I-Chemical	I-Disease
6	GABA	E-Chemical	E-Chemical
7	,	O	O
8	5	O	O
9	micrograms	O	O
10	,	O	O
11	into	O	O
12	the	O	O
13	dorsal	O	O
14	striatum	O	E-Disease
15	,	O	O
16	bilaterally	O	O
17	,	O	O
18	failed	O	O
19	to	O	O
20	prevent	O	O
21	the	O	O
22	development	O	O
23	of	O	O
24	convulsions	S-Disease	O
25	produced	O	O
26	by	O	O
27	pilocarpine	S-Chemical	S-Chemical
28	,	O	O
29	380	O	O
30	mg	O	O
31	/	O	O
32	kg	O	O
33	.	O	O

0	The	O	O
1	results	O	O
2	demonstrate	O	O
3	that	O	O
4	the	O	O
5	threshold	O	O
6	for	O	O
7	pilocarpine	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	seizures	S-Disease	S-Disease
11	in	O	O
12	rats	O	O
13	is	O	O
14	subjected	O	O
15	to	O	O
16	the	O	O
17	regulation	O	O
18	of	O	O
19	the	O	O
20	GABA	S-Chemical	S-Chemical
21	-	O	O
22	mediated	O	O
23	synaptic	O	O
24	inhibition	O	O
25	within	O	O
26	the	O	O
27	substantia	O	O
28	nigra	O	S-Disease
29	.	O	O

0	Human	O	O
1	and	O	O
2	canine	O	B-Disease
3	ventricular	O	I-Disease
4	vasoactive	O	I-Disease
5	intestinal	O	O
6	polypeptide	O	E-Disease
7	:	O	O
8	decrease	O	O
9	with	O	I-Disease
10	heart	B-Disease	B-Disease
11	failure	E-Disease	E-Disease
12	.	O	O

0	Myocardial	O	S-Disease
1	levels	O	O
2	of	O	O
3	VIP	O	S-Disease
4	were	O	O
5	assayed	O	O
6	before	O	O
7	and	O	O
8	after	O	O
9	the	O	O
10	development	O	O
11	of	O	O
12	heart	B-Disease	B-Disease
13	failure	E-Disease	E-Disease
14	in	O	O
15	two	O	O
16	canine	O	O
17	models	O	O
18	.	O	O

0	In	O	O
1	the	O	O
2	first	O	O
3	,	O	O
4	cobalt	S-Chemical	B-Chemical
5	cardiomyopathy	S-Disease	E-Chemical
6	was	O	O
7	induced	O	O
8	in	O	O
9	eight	O	O
10	dogs	O	O
11	;	O	O
12	VIP	O	S-Disease
13	(	O	O
14	by	O	O
15	radioimmunoassay	O	S-Disease
16	)	O	O
17	decreased	O	O
18	from	O	O
19	35	O	O
20	+	O	O
21	/	O	O
22	-	O	O
23	11	O	O
24	pg	O	O
25	/	O	O
26	mg	O	O
27	protein	O	O
28	(	O	O
29	mean	O	O
30	+	O	O
31	/	O	O
32	-	O	O
33	SD	O	O
34	)	O	O
35	to	O	O
36	5	O	O
37	+	O	O
38	/	O	O
39	-	O	O
40	4	O	O
41	pg	O	O
42	/	O	O
43	mg	O	O
44	protein	O	O
45	(	O	O
46	P	O	O
47	less	O	O
48	than	O	O
49	0	O	O
50	.	O	O
51	05	O	O
52	)	O	O
53	.	O	O

0	In	O	O
1	six	O	O
2	dogs	O	O
3	with	O	O
4	doxorubicin	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	heart	B-Disease	B-Disease
8	failure	E-Disease	E-Disease
9	,	O	O
10	VIP	O	S-Disease
11	decreased	O	O
12	from	O	O
13	31	O	O
14	+	O	O
15	/	O	O
16	-	O	O
17	7	O	O
18	to	O	O
19	11	O	O
20	+	O	O
21	/	O	O
22	-	O	O
23	4	O	O
24	pg	O	O
25	/	O	O
26	mg	O	O
27	protein	O	O
28	(	O	O
29	P	O	O
30	less	O	O
31	than	O	O
32	0	O	O
33	.	O	O
34	05	O	O
35	)	O	O
36	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	VIP	O	S-Disease
4	content	O	O
5	of	O	O
6	left	O	O
7	ventricular	O	O
8	muscle	O	O
9	of	O	O
10	resected	O	O
11	failing	O	B-Disease
12	hearts	O	E-Disease
13	in	O	O
14	10	O	O
15	patients	O	O
16	receiving	O	O
17	a	O	O
18	heart	O	B-Disease
19	transplant	O	O
20	was	O	O
21	compared	O	O
22	with	O	O
23	the	O	O
24	papillary	O	O
25	muscles	O	E-Disease
26	in	O	O
27	14	O	O
28	patients	O	O
29	(	O	O
30	five	O	O
31	with	O	O
32	rheumatic	B-Disease	B-Disease
33	disease	E-Disease	E-Disease
34	,	O	O
35	nine	O	O
36	with	O	O
37	myxomatous	B-Disease	S-Disease
38	degeneration	E-Disease	O
39	)	O	O
40	receiving	O	O
41	mitral	O	B-Disease
42	valve	O	E-Disease
43	prostheses	O	O
44	.	O	O

0	The	O	O
1	lowest	O	O
2	myocardial	O	B-Disease
3	VIP	O	E-Disease
4	concentration	O	O
5	was	O	O
6	found	O	O
7	in	O	O
8	the	O	O
9	hearts	O	O
10	of	O	O
11	patients	O	O
12	with	O	O
13	coronary	B-Disease	B-Disease
14	disease	E-Disease	E-Disease
15	(	O	O
16	one	O	O
17	patient	O	O
18	receiving	O	O
19	a	O	O
20	transplant	O	O
21	and	O	O
22	three	O	O
23	receiving	O	O
24	mitral	O	O
25	prostheses	O	O
26	)	O	O
27	(	O	O
28	6	O	O
29	.	O	O
30	3	O	O
31	+	O	O
32	/	O	O
33	-	O	O
34	1	O	O
35	.	O	O
36	9	O	O
37	pg	O	O
38	/	O	O
39	mg	O	O
40	protein	O	O
41	)	O	O
42	.	O	O

0	The	O	O
1	hearts	O	O
2	without	O	O
3	coronary	B-Disease	B-Disease
4	artery	I-Disease	I-Disease
5	disease	E-Disease	E-Disease
6	(	O	O
7	average	O	O
8	ejection	O	O
9	fraction	O	O
10	of	O	O
11	this	O	O
12	group	O	O
13	62	O	O
14	%	O	O
15	+	O	O
16	/	O	O
17	-	O	O
18	10	O	O
19	%	O	O
20	)	O	O
21	had	O	O
22	a	O	O
23	VIP	O	O
24	concentration	O	O
25	of	O	O
26	14	O	O
27	.	O	O
28	1	O	O
29	+	O	O
30	/	O	O
31	-	O	O
32	7	O	O
33	.	O	O
34	9	O	O
35	pg	O	O
36	/	O	O
37	mg	O	O
38	protein	O	O
39	,	O	O
40	and	O	O
41	this	O	O
42	was	O	O
43	greater	O	O
44	than	O	O
45	in	O	O
46	hearts	O	O
47	of	O	O
48	the	O	O
49	patients	O	O
50	with	O	O
51	coronary	B-Disease	B-Disease
52	disease	E-Disease	E-Disease
53	and	O	O
54	the	O	O
55	hearts	O	O
56	of	O	O
57	patients	O	O
58	receiving	O	O
59	a	O	O
60	transplant	O	O
61	(	O	O
62	P	O	S-Disease
63	less	O	O
64	than	O	O
65	0	O	O
66	.	O	O
67	05	O	O
68	)	O	O
69	.	O	O

0	Myocardial	O	S-Chemical
1	catecholamines	S-Chemical	E-Chemical
2	were	O	O
3	also	O	O
4	determined	O	O
5	in	O	O
6	14	O	O
7	subjects	O	O
8	;	O	O
9	a	O	O
10	weak	O	O
11	correlation	O	O
12	(	O	O
13	r	O	O
14	=	O	O
15	0	O	O
16	.	O	O
17	57	O	O
18	,	O	O
19	P	O	O
20	less	O	O
21	than	O	O
22	0	O	O
23	.	O	O
24	05	O	O
25	)	O	O
26	between	O	O
27	the	O	O
28	tissue	O	O
29	concentrations	O	O
30	of	O	O
31	VIP	O	S-Disease
32	and	O	O
33	norepinephrine	S-Chemical	S-Chemical
34	was	O	O
35	noted	O	O
36	.	O	O
37	(	O	O
38	ABSTRACT	O	S-Disease
39	TRUNCATED	O	O
40	AT	O	O
41	250	O	O
42	WORDS	O	S-Disease
43	)	O	O

0	Non	O	O
1	-	O	O
2	invasive	O	O
3	detection	O	O
4	of	O	O
5	coronary	B-Disease	B-Disease
6	artery	I-Disease	I-Disease
7	disease	E-Disease	E-Disease
8	by	O	O
9	body	O	O
10	surface	O	O
11	electrocardiographic	O	O
12	mapping	O	O
13	after	O	O
14	dipyridamole	S-Chemical	S-Chemical
15	infusion	O	O
16	.	O	O

0	Electrocardiographic	O	O
1	changes	O	O
2	after	O	O
3	dipyridamole	S-Chemical	S-Chemical
4	infusion	O	O
5	(	O	O
6	0	O	O
7	.	O	O
8	568	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	/	O	O
13	4	O	O
14	min	O	O
15	)	O	O
16	were	O	O
17	studied	O	O
18	in	O	O
19	41	O	O
20	patients	O	O
21	with	O	O
22	coronary	B-Disease	B-Disease
23	artery	I-Disease	I-Disease
24	disease	E-Disease	E-Disease
25	and	O	O
26	compared	O	O
27	with	O	O
28	those	O	O
29	after	O	O
30	submaximal	O	O
31	treadmill	O	O
32	exercise	O	O
33	by	O	O
34	use	O	O
35	of	O	O
36	the	O	O
37	body	O	O
38	surface	O	O
39	mapping	O	O
40	technique	O	O
41	.	O	O

0	Patients	O	O
1	were	O	O
2	divided	O	O
3	into	O	O
4	three	O	O
5	groups	O	O
6	;	O	O
7	19	O	O
8	patients	O	O
9	without	O	O
10	myocardial	B-Disease	B-Disease
11	infarction	E-Disease	E-Disease
12	(	O	O
13	non	O	O
14	-	O	O
15	MI	S-Disease	S-Disease
16	group	O	O
17	)	O	O
18	,	O	O
19	14	O	O
20	with	O	O
21	anterior	B-Disease	O
22	infarction	E-Disease	E-Disease
23	(	O	O
24	ANT	B-Disease	S-Chemical
25	-	I-Disease	I-Disease
26	MI	E-Disease	S-Disease
27	)	O	O
28	and	O	O
29	eight	O	O
30	with	O	O
31	inferior	B-Disease	O
32	infarction	E-Disease	O
33	(	O	O
34	INF	B-Disease	S-Disease
35	-	I-Disease	I-Disease
36	MI	E-Disease	S-Disease
37	)	O	O
38	.	O	O

0	After	O	O
1	dipyridamole	S-Chemical	S-Chemical
2	,	O	O
3	ischemic	S-Disease	S-Disease
4	ST	O	B-Disease
5	-	O	O
6	segment	O	I-Disease
7	depression	S-Disease	S-Disease
8	(	O	O
9	0	O	O
10	.	O	O
11	05	O	O
12	mV	O	O
13	or	O	O
14	more	O	O
15	)	O	O
16	was	O	O
17	observed	O	O
18	in	O	O
19	84	O	O
20	%	O	O
21	of	O	O
22	the	O	O
23	non	O	O
24	-	O	O
25	MI	S-Disease	S-Disease
26	group	O	O
27	,	O	O
28	29	O	O
29	%	O	O
30	of	O	O
31	the	O	O
32	ANT	B-Disease	S-Chemical
33	-	I-Disease	O
34	MI	E-Disease	S-Disease
35	group	O	O
36	,	O	O
37	63	O	O
38	%	O	O
39	of	O	O
40	the	O	O
41	INF	B-Disease	S-Disease
42	-	I-Disease	O
43	MI	E-Disease	O
44	group	O	O
45	and	O	O
46	61	O	O
47	%	O	O
48	of	O	O
49	the	O	O
50	total	O	O
51	population	O	O
52	.	O	O

0	Exercise	O	O
1	-	O	O
2	induced	O	O
3	ST	O	B-Disease
4	depression	S-Disease	E-Disease
5	was	O	O
6	observed	O	O
7	in	O	O
8	84	O	O
9	%	O	O
10	of	O	O
11	the	O	O
12	non	O	O
13	-	O	O
14	MI	S-Disease	S-Disease
15	group	O	O
16	,	O	O
17	43	O	O
18	%	O	O
19	of	O	O
20	the	O	O
21	ANT	B-Disease	S-Chemical
22	-	I-Disease	O
23	MI	E-Disease	S-Disease
24	group	O	O
25	,	O	O
26	38	O	O
27	%	O	O
28	of	O	O
29	the	O	O
30	INF	B-Disease	S-Disease
31	-	I-Disease	O
32	MI	E-Disease	S-Disease
33	group	O	O
34	and	O	O
35	61	O	O
36	%	O	O
37	of	O	O
38	the	O	O
39	total	O	O
40	.	O	O

0	For	O	O
1	individual	O	O
2	patients	O	O
3	,	O	O
4	there	O	O
5	were	O	O
6	no	O	O
7	obvious	O	O
8	differences	O	O
9	between	O	O
10	the	O	O
11	body	O	O
12	surface	O	O
13	distribution	O	O
14	of	O	O
15	ST	O	B-Disease
16	depression	S-Disease	E-Disease
17	in	O	O
18	both	O	O
19	tests	O	O
20	.	O	O

0	The	O	O
1	increase	O	O
2	in	O	O
3	pressure	O	O
4	rate	O	O
5	product	O	O
6	after	O	O
7	dipyridamole	S-Chemical	S-Chemical
8	was	O	O
9	significantly	O	O
10	less	O	O
11	than	O	O
12	that	O	O
13	during	O	O
14	the	O	O
15	treadmill	O	O
16	exercise	O	O
17	.	O	O

0	The	O	O
1	data	O	O
2	suggest	O	O
3	that	O	O
4	the	O	O
5	dipyridamole	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	myocardial	B-Disease	B-Disease
9	ischemia	E-Disease	E-Disease
10	is	O	O
11	caused	O	O
12	by	O	O
13	the	O	O
14	inhomogenous	O	O
15	distribution	O	O
16	of	O	O
17	myocardial	O	B-Disease
18	blood	O	I-Disease
19	flow	O	E-Disease
20	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	the	O	O
4	dipyridamole	S-Chemical	S-Chemical
5	ECG	O	S-Disease
6	test	O	O
7	is	O	O
8	as	O	O
9	useful	O	O
10	as	O	O
11	the	O	O
12	exercise	O	O
13	ECG	O	S-Disease
14	test	O	O
15	for	O	O
16	the	O	O
17	assessment	O	O
18	of	O	O
19	coronary	B-Disease	B-Disease
20	artery	I-Disease	I-Disease
21	disease	E-Disease	E-Disease
22	.	O	O

0	Bradycardia	S-Disease	S-Disease
1	after	O	O
2	high	O	O
3	-	O	O
4	dose	O	O
5	intravenous	O	O
6	methylprednisolone	S-Chemical	S-Chemical
7	therapy	O	O
8	.	O	O

0	In	O	O
1	5	O	O
2	consecutive	O	O
3	patients	O	O
4	with	O	O
5	rheumatoid	B-Disease	S-Disease
6	arthritis	E-Disease	S-Disease
7	who	O	O
8	received	O	O
9	intravenous	O	O
10	high	O	O
11	-	O	O
12	dose	O	O
13	methylprednisolone	S-Chemical	S-Chemical
14	(	O	O
15	MP	S-Chemical	O
16	)	O	O
17	therapy	O	O
18	(	O	O
19	1	O	O
20	g	O	O
21	daily	O	O
22	for	O	O
23	2	O	O
24	or	O	O
25	3	O	O
26	consecutive	O	O
27	days	O	O
28	)	O	O
29	,	O	O
30	a	O	O
31	decline	O	O
32	in	O	O
33	pulse	O	O
34	rate	O	O
35	was	O	O
36	observed	O	O
37	,	O	O
38	most	O	O
39	pronounced	O	O
40	on	O	O
41	day	O	O
42	4	O	O
43	.	O	O

0	In	O	O
1	one	O	O
2	of	O	O
3	the	O	O
4	5	O	O
5	patients	O	O
6	the	O	O
7	bradycardia	S-Disease	S-Disease
8	was	O	O
9	associated	O	O
10	with	O	O
11	complaints	O	O
12	of	O	O
13	substernal	O	O
14	pressure	O	E-Disease
15	.	O	O

0	Electrocardiographic	O	O
1	registrations	O	O
2	showed	O	O
3	sinus	B-Disease	B-Disease
4	bradycardia	E-Disease	E-Disease
5	in	O	O
6	all	O	O
7	cases	O	O
8	.	O	O

0	Careful	O	O
1	observation	O	O
2	of	O	O
3	patients	O	O
4	receiving	O	O
5	high	O	O
6	-	O	O
7	dose	O	O
8	MP	S-Chemical	S-Disease
9	is	O	O
10	recommended	O	O
11	.	O	O

0	High	O	O
1	-	O	O
2	dose	O	O
3	MP	S-Chemical	S-Chemical
4	may	O	O
5	be	O	O
6	contraindicated	O	O
7	in	O	O
8	patients	O	O
9	with	O	O
10	known	O	O
11	heart	B-Disease	B-Disease
12	disease	E-Disease	E-Disease
13	.	O	O

0	Two	O	O
1	cases	O	O
2	of	O	O
3	downbeat	B-Disease	O
4	nystagmus	E-Disease	S-Disease
5	and	O	O
6	oscillopsia	S-Disease	S-Disease
7	associated	O	O
8	with	O	O
9	carbamazepine	S-Chemical	S-Chemical
10	.	O	O

0	Downbeat	B-Disease	O
1	nystagmus	E-Disease	S-Disease
2	is	O	O
3	often	O	O
4	associated	O	O
5	with	O	O
6	structural	O	O
7	lesions	O	E-Disease
8	at	O	O
9	the	O	O
10	craniocervical	O	B-Disease
11	junction	O	E-Disease
12	,	O	O
13	but	O	O
14	has	O	O
15	occasionally	O	O
16	been	O	O
17	reported	O	O
18	as	O	O
19	a	O	O
20	manifestation	O	O
21	of	O	O
22	metabolic	O	B-Disease
23	imbalance	O	E-Disease
24	or	O	O
25	drug	O	O
26	intoxication	O	S-Disease
27	.	O	O

0	We	O	O
1	recorded	O	O
2	the	O	O
3	eye	O	O
4	movements	O	O
5	of	O	O
6	two	O	O
7	patients	O	O
8	with	O	O
9	reversible	O	O
10	downbeat	B-Disease	O
11	nystagmus	E-Disease	S-Disease
12	related	O	O
13	to	O	O
14	carbamazepine	S-Chemical	S-Chemical
15	therapy	O	O
16	.	O	O

0	The	O	O
1	nystagmus	S-Disease	S-Disease
2	of	O	O
3	both	O	O
4	patients	O	O
5	resolved	O	O
6	after	O	O
7	reduction	O	O
8	of	O	O
9	the	O	O
10	serum	O	O
11	carbamazepine	S-Chemical	S-Chemical
12	levels	O	O
13	.	O	O

0	In	O	O
1	patients	O	O
2	with	O	O
3	downbeat	B-Disease	O
4	nystagmus	E-Disease	S-Disease
5	who	O	O
6	are	O	O
7	taking	O	O
8	anticonvulsant	O	O
9	medications	O	O
10	,	O	O
11	consideration	O	O
12	should	O	O
13	be	O	O
14	given	O	O
15	to	O	O
16	reduction	O	O
17	in	O	O
18	dose	O	O
19	before	O	O
20	further	O	O
21	investigation	O	O
22	is	O	O
23	undertaken	O	O
24	.	O	O

0	Improvement	O	O
1	by	O	O
2	denopamine	S-Chemical	S-Chemical
3	(	O	O
4	TA	B-Chemical	S-Chemical
5	-	I-Chemical	O
6	064	E-Chemical	E-Chemical
7	)	O	O
8	of	O	O
9	pentobarbital	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	cardiac	B-Disease	B-Disease
13	failure	E-Disease	E-Disease
14	in	O	O
15	the	O	O
16	dog	O	O
17	heart	O	I-Disease
18	-	O	O
19	lung	O	E-Disease
20	preparation	O	O
21	.	O	O

0	The	O	O
1	efficacy	O	O
2	of	O	O
3	denopamine	S-Chemical	S-Chemical
4	,	O	O
5	an	O	O
6	orally	O	O
7	active	O	O
8	beta	O	O
9	1	O	I-Chemical
10	-	O	O
11	adrenoceptor	O	E-Chemical
12	agonist	O	O
13	,	O	O
14	in	O	O
15	improving	O	O
16	cardiac	B-Disease	B-Disease
17	failure	E-Disease	E-Disease
18	was	O	O
19	assessed	O	O
20	in	O	O
21	dog	O	O
22	heart	O	I-Disease
23	-	O	O
24	lung	O	E-Disease
25	preparations	O	O
26	.	O	O

0	Cardiac	O	O
1	functions	O	O
2	depressed	O	O
3	by	O	O
4	pentobarbital	S-Chemical	S-Chemical
5	(	O	O
6	118	O	O
7	+	O	O
8	/	O	O
9	-	O	O
10	28	O	O
11	mg	O	O
12	;	O	O
13	mean	O	O
14	value	O	O
15	+	O	O
16	/	O	O
17	-	O	O
18	SD	O	O
19	)	O	O
20	such	O	O
21	that	O	O
22	cardiac	O	B-Disease
23	output	O	E-Disease
24	and	O	O
25	maximum	O	O
26	rate	O	O
27	of	O	O
28	rise	O	O
29	of	O	O
30	left	O	O
31	ventricular	O	O
32	pressure	O	O
33	(	O	O
34	LV	O	O
35	dP	O	O
36	/	O	O
37	dt	O	O
38	max	O	O
39	)	O	O
40	had	O	O
41	been	O	O
42	reduced	O	O
43	by	O	O
44	about	O	O
45	35	O	O
46	%	O	O
47	and	O	O
48	26	O	O
49	%	O	O
50	of	O	O
51	the	O	O
52	respective	O	O
53	controls	O	O
54	were	O	O
55	improved	O	O
56	by	O	O
57	denopamine	S-Chemical	S-Chemical
58	(	O	O
59	10	O	O
60	-	O	O
61	300	O	O
62	micrograms	O	O
63	)	O	O
64	in	O	O
65	a	O	O
66	dose	O	O
67	-	O	O
68	dependent	O	O
69	manner	O	O
70	.	O	O

0	With	O	O
1	100	O	O
2	micrograms	O	O
3	denopamine	S-Chemical	S-Chemical
4	,	O	O
5	almost	O	O
6	complete	O	O
7	restoration	O	O
8	of	O	O
9	cardiac	O	S-Disease
10	performance	O	O
11	was	O	O
12	attained	O	O
13	,	O	O
14	associated	O	O
15	with	O	O
16	a	O	O
17	slight	O	O
18	increase	O	O
19	in	O	O
20	heart	O	S-Disease
21	rate	O	E-Disease
22	.	O	O

0	No	O	O
1	arrhythmias	S-Disease	O
2	were	O	O
3	induced	O	O
4	by	O	O
5	these	O	O
6	doses	O	O
7	of	O	O
8	denopamine	S-Chemical	S-Chemical
9	.	O	O

0	The	O	O
1	results	O	O
2	warrant	O	O
3	clinical	O	O
4	trials	O	O
5	of	O	O
6	denopamine	S-Chemical	S-Chemical
7	in	O	O
8	the	O	O
9	treatment	O	O
10	of	O	O
11	cardiac	B-Disease	B-Disease
12	failure	E-Disease	E-Disease
13	.	O	O

0	Clonazepam	S-Chemical	S-Chemical
1	monotherapy	O	O
2	for	O	O
3	epilepsy	S-Disease	S-Disease
4	in	O	O
5	childhood	O	O
6	.	O	O

0	Sixty	O	O
1	patients	O	O
2	(	O	O
3	age	O	O
4	-	O	O
5	range	O	O
6	one	O	O
7	month	O	O
8	to	O	O
9	14	O	O
10	years	O	O
11	)	O	O
12	with	O	O
13	other	O	O
14	types	O	O
15	of	O	O
16	epilepsy	S-Disease	S-Disease
17	than	O	O
18	infantile	B-Disease	B-Disease
19	spasms	E-Disease	E-Disease
20	were	O	O
21	treated	O	O
22	with	O	O
23	clonazepam	S-Chemical	S-Chemical
24	.	O	O

0	Disappearance	O	O
1	of	O	O
2	seizures	S-Disease	S-Disease
3	and	O	O
4	normalization	O	O
5	of	O	O
6	abnormal	O	O
7	EEG	O	S-Disease
8	with	O	O
9	disappearance	O	O
10	of	O	O
11	seizures	S-Disease	S-Disease
12	were	O	O
13	recognized	O	O
14	in	O	O
15	77	O	O
16	%	O	O
17	and	O	O
18	50	O	O
19	%	O	O
20	,	O	O
21	respectively	O	O
22	.	O	O

0	Seizures	S-Disease	O
1	disappeared	O	O
2	in	O	O
3	71	O	O
4	%	O	O
5	of	O	O
6	the	O	O
7	patients	O	O
8	with	O	O
9	generalized	O	O
10	seizures	S-Disease	S-Disease
11	and	O	O
12	89	O	O
13	%	O	O
14	of	O	O
15	partial	O	O
16	seizures	S-Disease	S-Disease
17	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	side	O	O
4	effects	O	O
5	such	O	O
6	as	O	O
7	drowsiness	S-Disease	S-Disease
8	and	O	O
9	ataxia	S-Disease	S-Disease
10	was	O	O
11	only	O	O
12	5	O	O
13	%	O	O
14	.	O	O

0	Postmarketing	O	O
1	study	O	O
2	of	O	O
3	timolol	S-Chemical	S-Chemical
4	-	O	I-Chemical
5	hydrochlorothiazide	S-Chemical	E-Chemical
6	antihypertensive	O	O
7	therapy	O	O
8	.	O	O

0	A	O	O
1	postmarketing	O	O
2	surveillance	O	O
3	study	O	O
4	was	O	O
5	conducted	O	O
6	to	O	O
7	determine	O	O
8	the	O	O
9	safety	O	O
10	and	O	O
11	efficacy	O	O
12	of	O	O
13	a	O	O
14	fixed	O	O
15	-	O	O
16	ratio	O	O
17	combination	O	O
18	containing	O	O
19	10	O	O
20	mg	O	O
21	of	O	O
22	timolol	B-Chemical	B-Chemical
23	maleate	E-Chemical	E-Chemical
24	and	O	O
25	25	O	O
26	mg	O	O
27	of	O	O
28	hydrochlorothiazide	S-Chemical	S-Chemical
29	,	O	O
30	administered	O	O
31	twice	O	O
32	daily	O	O
33	for	O	O
34	one	O	O
35	month	O	O
36	to	O	O
37	hypertensive	S-Disease	S-Disease
38	patients	O	O
39	.	O	O

0	Mean	O	O
1	systolic	O	O
2	blood	O	O
3	pressure	O	O
4	decreased	O	O
5	25	O	O
6	mmHg	O	O
7	and	O	O
8	mean	O	O
9	diastolic	O	B-Disease
10	blood	O	I-Disease
11	pressure	O	E-Disease
12	declined	O	O
13	15	O	O
14	mmHg	O	O
15	after	O	O
16	one	O	O
17	month	O	O
18	of	O	O
19	timolol	S-Chemical	S-Chemical
20	-	O	O
21	hydrochlorothiazide	S-Chemical	S-Chemical
22	therapy	O	O
23	(	O	O
24	P	O	O
25	less	O	O
26	than	O	O
27	0	O	O
28	.	O	O
29	01	O	O
30	,	O	O
31	both	O	O
32	comparisons	O	O
33	)	O	O
34	.	O	O

0	The	O	O
1	antihypertensive	O	O
2	effect	O	O
3	of	O	O
4	the	O	O
5	drug	O	O
6	was	O	O
7	greater	O	O
8	in	O	O
9	patients	O	O
10	with	O	O
11	more	O	O
12	severe	O	O
13	hypertension	S-Disease	S-Disease
14	.	O	O

0	Overall	O	O
1	,	O	O
2	1	O	O
3	,	O	O
4	453	O	O
5	patients	O	O
6	experienced	O	O
7	a	O	O
8	total	O	O
9	of	O	O
10	2	O	O
11	,	O	O
12	658	O	O
13	adverse	O	O
14	events	O	O
15	,	O	O
16	the	O	O
17	most	O	O
18	common	O	O
19	being	O	O
20	fatigue	S-Disease	S-Disease
21	,	O	O
22	dizziness	S-Disease	O
23	,	O	O
24	and	O	O
25	weakness	S-Disease	S-Disease
26	.	O	O

0	Salicylate	S-Chemical	S-Disease
1	nephropathy	S-Disease	S-Disease
2	in	O	O
3	the	O	O
4	Gunn	O	O
5	rat	O	O
6	:	O	O
7	potential	O	O
8	role	O	O
9	of	O	O
10	prostaglandins	S-Chemical	S-Disease
11	.	O	O

0	We	O	O
1	examined	O	O
2	the	O	O
3	potential	O	O
4	role	O	O
5	of	O	O
6	prostaglandins	S-Chemical	S-Disease
7	in	O	O
8	the	O	O
9	development	O	O
10	of	O	O
11	analgesic	O	B-Disease
12	nephropathy	S-Disease	E-Disease
13	in	O	O
14	the	O	O
15	Gunn	O	S-Disease
16	strain	O	O
17	of	O	O
18	rat	O	O
19	.	O	O

0	The	O	O
1	homozygous	O	O
2	Gunn	O	O
3	rats	O	O
4	have	O	O
5	unconjugated	O	O
6	hyperbilirubinemia	S-Disease	S-Disease
7	due	O	O
8	to	O	O
9	the	O	O
10	absence	O	O
11	of	O	O
12	glucuronyl	S-Chemical	S-Chemical
13	transferase	O	E-Chemical
14	,	O	O
15	leading	O	O
16	to	O	O
17	marked	O	O
18	bilirubin	S-Chemical	S-Chemical
19	deposition	O	O
20	in	O	O
21	renal	O	B-Disease
22	medulla	O	E-Disease
23	and	O	O
24	papilla	O	O
25	.	O	O

0	These	O	O
1	rats	O	O
2	are	O	O
3	also	O	O
4	highly	O	O
5	susceptible	O	O
6	to	O	O
7	develop	O	O
8	papillary	B-Disease	B-Disease
9	necrosis	E-Disease	E-Disease
10	with	O	O
11	analgesic	O	S-Disease
12	administration	O	O
13	.	O	O

0	Four	O	O
1	groups	O	O
2	of	O	O
3	rats	O	O
4	(	O	O
5	n	O	O
6	=	O	O
7	7	O	O
8	)	O	O
9	were	O	O
10	studied	O	O
11	:	O	O
12	jj	O	O
13	and	O	O
14	jJ	O	O
15	rats	O	O
16	treated	O	O
17	either	O	O
18	with	O	O
19	aspirin	S-Chemical	S-Chemical
20	300	O	O
21	mg	O	O
22	/	O	O
23	kg	O	O
24	every	O	O
25	other	O	O
26	day	O	O
27	or	O	O
28	sham	O	O
29	-	O	O
30	treated	O	O
31	.	O	O

0	After	O	O
1	one	O	O
2	week	O	O
3	,	O	O
4	slices	O	O
5	of	O	O
6	cortex	O	O
7	,	O	O
8	outer	O	O
9	and	O	O
10	inner	O	O
11	medulla	O	O
12	from	O	O
13	one	O	O
14	kidney	O	O
15	were	O	O
16	incubated	O	O
17	in	O	O
18	buffer	O	O
19	and	O	O
20	prostaglandin	S-Chemical	O
21	synthesis	O	O
22	was	O	O
23	determined	O	O
24	by	O	O
25	radioimmunoassay	O	O
26	.	O	O

0	A	O	O
1	marked	O	O
2	corticomedullary	O	S-Disease
3	gradient	O	O
4	of	O	O
5	prostaglandin	S-Chemical	S-Disease
6	synthesis	O	O
7	was	O	O
8	observed	O	O
9	in	O	O
10	all	O	O
11	groups	O	O
12	.	O	O

0	PGE2	S-Chemical	S-Chemical
1	synthesis	O	O
2	was	O	O
3	significantly	O	O
4	higher	O	O
5	in	O	O
6	outer	O	O
7	medulla	O	O
8	,	O	O
9	but	O	O
10	not	O	O
11	cortex	O	O
12	or	O	O
13	inner	O	O
14	medulla	O	O
15	,	O	O
16	of	O	O
17	jj	O	O
18	(	O	O
19	38	O	O
20	+	O	O
21	/	O	O
22	-	O	O
23	6	O	O
24	ng	O	O
25	/	O	O
26	mg	O	O
27	prot	O	O
28	)	O	O
29	than	O	O
30	jJ	O	O
31	rats	O	O
32	(	O	O
33	15	O	O
34	+	O	O
35	/	O	O
36	-	O	O
37	3	O	O
38	)	O	O
39	(	O	O
40	p	O	O
41	less	O	O
42	than	O	O
43	0	O	O
44	.	O	O
45	01	O	O
46	)	O	O
47	.	O	O

0	Aspirin	S-Chemical	O
1	treatment	O	O
2	reduced	O	O
3	PGE2	S-Chemical	S-Chemical
4	synthesis	O	O
5	in	O	O
6	all	O	O
7	regions	O	O
8	,	O	O
9	but	O	O
10	outer	O	O
11	medullary	O	O
12	PGE2	S-Chemical	S-Chemical
13	remained	O	O
14	higher	O	O
15	in	O	O
16	jj	O	O
17	(	O	O
18	18	O	O
19	+	O	O
20	/	O	O
21	-	O	O
22	3	O	O
23	)	O	O
24	than	O	O
25	jJ	O	O
26	rats	O	O
27	(	O	O
28	9	O	O
29	+	O	O
30	/	O	O
31	-	O	O
32	2	O	O
33	)	O	O
34	(	O	O
35	p	O	O
36	less	O	O
37	than	O	O
38	0	O	O
39	.	O	O
40	05	O	O
41	)	O	O
42	.	O	O

0	PGF2	B-Chemical	S-Chemical
1	alpha	E-Chemical	O
2	was	O	O
3	also	O	O
4	significantly	O	O
5	higher	O	O
6	in	O	O
7	the	O	O
8	outer	O	O
9	medulla	O	O
10	of	O	O
11	jj	O	O
12	rats	O	O
13	with	O	O
14	and	O	O
15	without	O	O
16	aspirin	S-Chemical	S-Chemical
17	administration	O	O
18	(	O	O
19	p	O	O
20	less	O	O
21	than	O	O
22	0	O	O
23	.	O	O
24	05	O	O
25	)	O	O
26	.	O	O

0	The	O	O
1	changes	O	O
2	in	O	O
3	renal	O	B-Disease
4	prostaglandin	S-Chemical	E-Disease
5	synthesis	O	O
6	were	O	O
7	accompanied	O	O
8	by	O	O
9	evidence	O	O
10	of	O	O
11	renal	B-Disease	B-Disease
12	damage	E-Disease	E-Disease
13	in	O	O
14	aspirin	S-Chemical	S-Chemical
15	-	O	O
16	treated	O	O
17	jj	O	S-Disease
18	but	O	O
19	not	O	O
20	jJ	O	S-Disease
21	rats	O	O
22	as	O	O
23	evidenced	O	O
24	by	O	O
25	:	O	O
26	increased	O	O
27	incidence	O	O
28	and	O	O
29	severity	O	O
30	of	O	O
31	hematuria	S-Disease	O
32	(	O	O
33	p	O	O
34	less	O	O
35	than	O	O
36	0	O	O
37	.	O	O
38	01	O	O
39	)	O	O
40	;	O	O
41	increased	O	O
42	serum	O	O
43	creatinine	S-Chemical	S-Chemical
44	(	O	O
45	p	O	O
46	less	O	O
47	than	O	O
48	0	O	O
49	.	O	O
50	05	O	O
51	)	O	O
52	;	O	O
53	and	O	O
54	increase	O	O
55	in	O	O
56	outer	O	O
57	medullary	O	O
58	histopathologic	O	S-Disease
59	lesions	O	S-Disease
60	(	O	O
61	p	O	O
62	less	O	O
63	than	O	O
64	0	O	O
65	.	O	O
66	005	O	O
67	compared	O	O
68	to	O	O
69	either	O	O
70	sham	O	S-Disease
71	-	O	O
72	treated	O	O
73	jj	O	S-Disease
74	or	O	O
75	aspirin	S-Chemical	S-Chemical
76	-	O	O
77	treated	O	O
78	jJ	O	S-Disease
79	)	O	O
80	.	O	O

0	These	O	O
1	results	O	O
2	suggest	O	O
3	that	O	O
4	enhanced	O	O
5	prostaglandin	S-Chemical	S-Chemical
6	synthesis	O	O
7	contributes	O	O
8	to	O	O
9	maintenance	O	O
10	of	O	O
11	renal	O	B-Disease
12	function	O	E-Disease
13	and	O	O
14	morphological	O	O
15	integrity	O	O
16	,	O	O
17	and	O	O
18	that	O	O
19	inhibition	O	O
20	of	O	O
21	prostaglandin	S-Chemical	S-Disease
22	synthesis	O	O
23	may	O	O
24	lead	O	O
25	to	O	O
26	pathological	B-Disease	O
27	renal	I-Disease	B-Disease
28	medullary	I-Disease	E-Disease
29	lesions	E-Disease	E-Disease
30	and	O	O
31	deterioration	B-Disease	O
32	of	I-Disease	O
33	renal	I-Disease	B-Disease
34	function	E-Disease	E-Disease
35	.	O	O

0	Prophylactic	O	O
1	lidocaine	S-Chemical	S-Disease
2	in	O	O
3	the	O	O
4	early	O	O
5	phase	O	O
6	of	O	O
7	suspected	O	O
8	myocardial	B-Disease	B-Disease
9	infarction	E-Disease	E-Disease
10	.	O	O

0	Four	O	O
1	hundred	O	O
2	two	O	O
3	patients	O	O
4	with	O	O
5	suspected	O	O
6	myocardial	B-Disease	B-Disease
7	infarction	E-Disease	E-Disease
8	seen	O	O
9	within	O	O
10	6	O	O
11	hours	O	O
12	of	O	O
13	the	O	O
14	onset	O	O
15	of	O	O
16	symptoms	O	O
17	entered	O	O
18	a	O	O
19	double	O	O
20	-	O	O
21	blind	O	O
22	randomized	O	O
23	trial	O	O
24	of	O	O
25	lidocaine	S-Chemical	S-Disease
26	vs	O	O
27	placebo	O	S-Disease
28	.	O	O

0	During	O	O
1	the	O	O
2	1	O	O
3	hour	O	O
4	after	O	O
5	administration	O	O
6	of	O	O
7	the	O	O
8	drug	O	O
9	the	O	O
10	incidence	O	O
11	of	O	O
12	ventricular	B-Disease	B-Disease
13	fibrillation	E-Disease	E-Disease
14	or	O	O
15	sustained	O	O
16	ventricular	B-Disease	B-Disease
17	tachycardia	E-Disease	E-Disease
18	among	O	O
19	the	O	O
20	204	O	O
21	patients	O	O
22	with	O	O
23	acute	O	B-Disease
24	myocardial	B-Disease	B-Disease
25	infarction	E-Disease	E-Disease
26	was	O	O
27	low	O	O
28	,	O	O
29	1	O	O
30	.	O	O
31	5	O	O
32	%	O	O
33	.	O	O

0	Lidocaine	S-Chemical	S-Chemical
1	,	O	O
2	given	O	O
3	in	O	O
4	a	O	O
5	300	O	O
6	mg	O	O
7	dose	O	O
8	intramuscularly	O	O
9	followed	O	O
10	by	O	O
11	100	O	O
12	mg	O	O
13	intravenously	O	O
14	,	O	O
15	did	O	O
16	not	O	O
17	prevent	O	O
18	sustained	O	O
19	ventricular	B-Disease	B-Disease
20	tachycardia	E-Disease	E-Disease
21	,	O	O
22	although	O	O
23	there	O	O
24	was	O	O
25	a	O	O
26	significant	O	O
27	reduction	O	O
28	in	O	O
29	the	O	O
30	number	O	O
31	of	O	O
32	patients	O	O
33	with	O	O
34	warning	O	O
35	arrhythmias	S-Disease	O
36	between	O	O
37	15	O	O
38	and	O	O
39	45	O	O
40	minutes	O	O
41	after	O	O
42	the	O	O
43	administration	O	O
44	of	O	O
45	lidocaine	S-Chemical	S-Chemical
46	(	O	O
47	p	O	O
48	less	O	O
49	than	O	O
50	0	O	O
51	.	O	O
52	05	O	O
53	)	O	O
54	.	O	O

0	The	O	O
1	average	O	O
2	plasma	O	O
3	lidocaine	S-Chemical	S-Disease
4	level	O	O
5	10	O	O
6	minutes	O	O
7	after	O	O
8	administration	O	O
9	for	O	O
10	patients	O	O
11	without	O	O
12	a	O	O
13	myocardial	B-Disease	B-Disease
14	infarction	E-Disease	E-Disease
15	was	O	O
16	significantly	O	O
17	higher	O	O
18	than	O	O
19	that	O	O
20	for	O	O
21	patients	O	O
22	with	O	O
23	an	O	O
24	acute	O	B-Disease
25	infarction	S-Disease	E-Disease
26	.	O	O

0	The	O	O
1	mean	O	O
2	plasma	O	O
3	lidocaine	S-Chemical	S-Disease
4	level	O	O
5	of	O	O
6	patients	O	O
7	on	O	O
8	beta	O	S-Disease
9	-	O	O
10	blocking	O	O
11	agents	O	O
12	was	O	O
13	no	O	O
14	different	O	O
15	from	O	O
16	that	O	O
17	in	O	O
18	patients	O	O
19	not	O	O
20	on	O	O
21	beta	O	B-Disease
22	blocking	O	O
23	agents	O	O
24	.	O	O

0	During	O	O
1	the	O	O
2	1	O	O
3	-	O	O
4	hour	O	O
5	study	O	O
6	period	O	O
7	,	O	O
8	the	O	O
9	incidence	O	O
10	of	O	O
11	central	O	B-Disease
12	nervous	O	I-Disease
13	system	O	E-Disease
14	side	O	O
15	effects	O	O
16	was	O	O
17	significantly	O	O
18	greater	O	O
19	in	O	O
20	the	O	O
21	lidocaine	S-Chemical	S-Disease
22	group	O	O
23	,	O	O
24	hypotension	S-Disease	S-Disease
25	occurred	O	O
26	in	O	O
27	11	O	O
28	patients	O	O
29	,	O	O
30	nine	O	O
31	of	O	O
32	whom	O	O
33	had	O	O
34	received	O	O
35	lidocaine	S-Chemical	S-Chemical
36	,	O	O
37	and	O	O
38	four	O	O
39	patients	O	O
40	died	O	O
41	from	O	O
42	asystole	S-Disease	S-Chemical
43	,	O	O
44	three	O	O
45	of	O	O
46	whom	O	O
47	had	O	O
48	had	O	O
49	lidocaine	S-Chemical	S-Disease
50	.	O	O

0	We	O	O
1	cannot	O	O
2	advocate	O	O
3	the	O	O
4	administration	O	O
5	of	O	O
6	lidocaine	S-Chemical	S-Chemical
7	prophylactically	O	O
8	in	O	O
9	the	O	O
10	early	O	O
11	hours	O	O
12	of	O	O
13	suspected	O	O
14	myocardial	B-Disease	B-Disease
15	infarction	E-Disease	E-Disease
16	.	O	O

0	Evidence	O	O
1	for	O	O
2	a	O	O
3	cholinergic	O	S-Chemical
4	role	O	O
5	in	O	O
6	haloperidol	S-Chemical	S-Chemical
7	-	O	O
8	induced	O	O
9	catalepsy	S-Disease	S-Disease
10	.	O	O

0	Experiments	O	O
1	in	O	O
2	mice	O	O
3	tested	O	O
4	previous	O	O
5	evidence	O	O
6	that	O	O
7	activation	O	O
8	of	O	O
9	cholinergic	O	B-Disease
10	systems	O	E-Disease
11	promotes	O	O
12	catalepsy	S-Disease	S-Disease
13	and	O	O
14	that	O	O
15	cholinergic	O	S-Chemical
16	mechanisms	O	O
17	need	O	O
18	to	O	O
19	be	O	O
20	intact	O	O
21	for	O	O
22	full	O	O
23	expression	O	O
24	of	O	O
25	neuroleptic	S-Chemical	S-Disease
26	-	O	O
27	induced	O	O
28	catalepsy	S-Disease	S-Disease
29	.	O	O

0	Large	O	O
1	doses	O	O
2	of	O	O
3	the	O	O
4	cholinomimetic	O	S-Chemical
5	,	O	O
6	pilocarpine	S-Chemical	S-Chemical
7	,	O	O
8	could	O	O
9	induce	O	O
10	catalepsy	S-Disease	S-Disease
11	when	O	O
12	peripheral	O	O
13	cholinergic	O	B-Disease
14	receptors	O	E-Disease
15	were	O	O
16	blocked	O	O
17	.	O	O

0	Low	O	O
1	doses	O	O
2	of	O	O
3	pilocarpine	S-Chemical	S-Chemical
4	caused	O	O
5	a	O	O
6	pronounced	O	O
7	enhancement	O	O
8	of	O	O
9	the	O	O
10	catalepsy	S-Disease	S-Disease
11	that	O	O
12	was	O	O
13	induced	O	O
14	by	O	O
15	the	O	O
16	dopaminergic	O	O
17	blocker	O	S-Disease
18	,	O	O
19	haloperidol	S-Chemical	S-Chemical
20	.	O	O

0	A	O	O
1	muscarinic	O	S-Chemical
2	receptor	O	O
3	blocker	O	O
4	,	O	O
5	atropine	S-Chemical	S-Chemical
6	,	O	O
7	disrupted	O	O
8	haloperidol	S-Chemical	S-Chemical
9	-	O	O
10	induced	O	O
11	catalepsy	S-Disease	S-Disease
12	.	O	O

0	Intracranial	O	O
1	injection	O	O
2	of	O	O
3	an	O	O
4	acetylcholine	S-Chemical	S-Chemical
5	-	O	O
6	synthesis	O	O
7	inhibitor	O	O
8	,	O	O
9	hemicholinium	S-Chemical	S-Chemical
10	,	O	O
11	prevented	O	O
12	the	O	O
13	catalepsy	S-Disease	S-Disease
14	that	O	O
15	is	O	O
16	usually	O	O
17	induced	O	O
18	by	O	O
19	haloperidol	S-Chemical	S-Chemical
20	.	O	O

0	These	O	O
1	findings	O	O
2	suggest	O	O
3	the	O	O
4	hypothesis	O	O
5	that	O	O
6	the	O	O
7	catalepsy	S-Disease	S-Disease
8	that	O	O
9	is	O	O
10	produced	O	O
11	by	O	O
12	neuroleptics	S-Chemical	S-Disease
13	such	O	O
14	as	O	O
15	haloperidol	S-Chemical	S-Chemical
16	is	O	O
17	actually	O	O
18	mediated	O	O
19	by	O	O
20	intrinsic	O	O
21	central	O	O
22	cholinergic	O	I-Disease
23	systems	O	E-Disease
24	.	O	O

0	Alternatively	O	O
1	,	O	O
2	activation	O	O
3	of	O	O
4	central	O	O
5	cholinergic	O	I-Disease
6	systems	O	E-Disease
7	could	O	O
8	promote	O	O
9	catalepsy	S-Disease	S-Disease
10	by	O	O
11	suppression	O	O
12	of	O	O
13	dopaminergic	O	S-Disease
14	systems	O	O
15	.	O	O

0	Cardiovascular	B-Disease	O
1	dysfunction	E-Disease	E-Disease
2	and	O	O
3	hypersensitivity	S-Disease	S-Disease
4	to	O	O
5	sodium	B-Chemical	B-Chemical
6	pentobarbital	E-Chemical	E-Chemical
7	induced	O	O
8	by	O	O
9	chronic	O	B-Disease
10	barium	B-Chemical	I-Disease
11	chloride	E-Chemical	E-Disease
12	ingestion	O	E-Disease
13	.	O	O

0	Barium	S-Chemical	S-Chemical
1	-	O	O
2	supplemented	O	O
3	Long	O	S-Chemical
4	-	O	O
5	Evans	O	O
6	hooded	O	O
7	rats	O	O
8	were	O	O
9	characterized	O	O
10	by	O	O
11	a	O	O
12	persistent	O	O
13	hypertension	S-Disease	S-Disease
14	that	O	O
15	was	O	O
16	evident	O	O
17	after	O	O
18	1	O	O
19	month	O	O
20	of	O	O
21	barium	S-Chemical	S-Chemical
22	(	O	O
23	100	O	O
24	micrograms	O	O
25	/	O	O
26	ml	O	O
27	mineral	O	O
28	fortified	O	O
29	water	O	O
30	)	O	O
31	treatment	O	O
32	.	O	O

0	Analysis	O	O
1	of	O	O
2	in	O	O
3	vivo	O	O
4	myocardial	O	B-Disease
5	excitability	O	O
6	,	O	O
7	contractility	O	S-Disease
8	,	O	O
9	and	O	O
10	metabolic	O	S-Disease
11	characteristics	O	O
12	at	O	O
13	16	O	O
14	months	O	O
15	revealed	O	O
16	other	O	O
17	significant	O	O
18	barium	S-Chemical	S-Disease
19	-	O	O
20	induced	O	O
21	disturbances	B-Disease	S-Disease
22	within	I-Disease	O
23	the	I-Disease	O
24	cardiovascular	I-Disease	B-Disease
25	system	E-Disease	E-Disease
26	.	O	O

0	The	O	O
1	most	O	O
2	distinctive	O	O
3	aspect	O	O
4	of	O	O
5	the	O	O
6	barium	S-Chemical	S-Chemical
7	effect	O	O
8	was	O	O
9	a	O	O
10	demonstrated	O	O
11	hypersensitivity	S-Disease	O
12	of	O	O
13	the	O	O
14	cardiovascular	O	B-Disease
15	system	O	O
16	to	O	O
17	sodium	B-Chemical	B-Chemical
18	pentobarbital	E-Chemical	E-Chemical
19	.	O	O

0	Under	O	O
1	barbiturate	S-Chemical	O
2	anesthesia	O	O
3	,	O	O
4	virtually	O	O
5	all	O	O
6	of	O	O
7	the	O	O
8	myocardial	O	B-Disease
9	contractile	O	E-Disease
10	indices	O	O
11	were	O	O
12	depressed	O	O
13	significantly	O	O
14	in	O	O
15	barium	S-Chemical	S-Chemical
16	-	O	O
17	exposed	O	O
18	rats	O	O
19	relative	O	O
20	to	O	O
21	the	O	O
22	corresponding	O	O
23	control	O	O
24	-	O	O
25	fed	O	O
26	rats	O	O
27	.	O	O

0	The	O	O
1	lack	O	O
2	of	O	O
3	a	O	O
4	similar	O	O
5	response	O	O
6	to	O	O
7	ketamine	S-Chemical	S-Chemical
8	and	O	O
9	xylazine	S-Chemical	S-Chemical
10	anesthesia	O	O
11	revealed	O	O
12	that	O	O
13	the	O	O
14	cardiovascular	O	O
15	actions	O	O
16	of	O	O
17	sodium	B-Chemical	B-Chemical
18	pentobarbital	E-Chemical	E-Chemical
19	in	O	O
20	barium	S-Chemical	S-Chemical
21	-	O	O
22	treated	O	O
23	rats	O	O
24	were	O	O
25	linked	O	O
26	specifically	O	O
27	to	O	O
28	this	O	O
29	anesthetic	O	O
30	,	O	O
31	and	O	O
32	were	O	O
33	not	O	O
34	representative	O	O
35	of	O	O
36	a	O	O
37	generalized	O	O
38	anesthetic	O	O
39	response	O	O
40	.	O	O

0	Other	O	O
1	myocardial	O	B-Disease
2	pathophysiologic	O	O
3	and	O	O
4	metabolic	O	B-Disease
5	changes	O	E-Disease
6	induced	O	O
7	by	O	O
8	barium	S-Chemical	S-Chemical
9	were	O	O
10	manifest	O	O
11	,	O	O
12	irrespective	O	O
13	of	O	O
14	the	O	O
15	anesthetic	O	O
16	employed	O	O
17	.	O	O

0	The	O	O
1	contractile	O	O
2	element	O	O
3	shortening	O	O
4	velocity	O	O
5	of	O	O
6	the	O	O
7	cardiac	O	B-Disease
8	muscle	O	I-Disease
9	fibers	O	O
10	was	O	O
11	significantly	O	O
12	slower	O	O
13	in	O	O
14	both	O	O
15	groups	O	O
16	of	O	O
17	barium	S-Chemical	S-Chemical
18	-	O	O
19	treated	O	O
20	rats	O	O
21	relative	O	O
22	to	O	O
23	the	O	O
24	control	O	O
25	groups	O	O
26	,	O	O
27	irrespective	O	O
28	of	O	O
29	the	O	O
30	anesthetic	O	O
31	regimen	O	O
32	.	O	O

0	Similarly	O	O
1	,	O	O
2	significant	O	O
3	disturbances	O	O
4	in	O	O
5	myocardial	O	B-Disease
6	energy	O	I-Disease
7	metabolism	O	E-Disease
8	were	O	O
9	detected	O	O
10	in	O	O
11	the	O	O
12	barium	S-Chemical	S-Chemical
13	-	O	O
14	exposed	O	O
15	rats	O	O
16	which	O	O
17	were	O	O
18	consistent	O	O
19	with	O	O
20	the	O	O
21	reduced	O	O
22	contractile	O	O
23	element	O	O
24	shortening	O	O
25	velocity	O	O
26	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	the	O	O
4	excitability	O	O
5	of	O	O
6	the	O	O
7	cardiac	O	B-Disease
8	conduction	O	E-Disease
9	system	O	E-Disease
10	was	O	O
11	depressed	O	O
12	preferentially	O	O
13	in	O	O
14	the	O	O
15	atrioventricular	O	O
16	nodal	O	E-Disease
17	region	O	O
18	of	O	O
19	hearts	O	O
20	from	O	O
21	barium	S-Chemical	B-Disease
22	-	O	O
23	exposed	O	O
24	rats	O	O
25	.	O	O

0	Overall	O	O
1	,	O	O
2	the	O	O
3	altered	O	O
4	cardiac	O	B-Disease
5	contractility	O	E-Disease
6	and	O	O
7	excitability	O	O
8	characteristics	O	O
9	,	O	O
10	the	O	O
11	myocardial	O	B-Disease
12	metabolic	B-Disease	I-Disease
13	disturbances	E-Disease	E-Disease
14	,	O	O
15	and	O	O
16	the	O	O
17	hypersensitivity	S-Disease	O
18	of	O	O
19	the	O	O
20	cardiovascular	O	B-Disease
21	system	O	E-Disease
22	to	O	O
23	sodium	B-Chemical	B-Chemical
24	pentobarbital	E-Chemical	E-Chemical
25	suggest	O	O
26	the	O	O
27	existence	O	O
28	of	O	O
29	a	O	O
30	heretofore	O	O
31	undescribed	O	O
32	cardiomyopathic	B-Disease	O
33	disorder	E-Disease	S-Disease
34	induced	O	O
35	by	O	O
36	chronic	O	B-Disease
37	barium	S-Chemical	I-Disease
38	exposure	O	E-Disease
39	.	O	O

0	These	O	O
1	experimental	O	O
2	findings	O	O
3	represent	O	O
4	the	O	O
5	first	O	O
6	indication	O	O
7	that	O	O
8	life	O	O
9	-	O	O
10	long	O	O
11	barium	S-Chemical	B-Disease
12	ingestion	O	E-Disease
13	may	O	O
14	have	O	O
15	significant	O	O
16	adverse	O	O
17	effects	O	O
18	on	O	O
19	the	O	O
20	mammalian	O	B-Disease
21	cardiovascular	O	I-Disease
22	system	O	E-Disease
23	.	O	O

0	Propranolol	S-Chemical	O
1	antagonism	O	O
2	of	O	O
3	phenylpropanolamine	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	hypertension	S-Disease	S-Disease
7	.	O	O

0	Phenylpropanolamine	S-Chemical	S-Chemical
1	(	O	O
2	PPA	S-Chemical	S-Chemical
3	)	O	O
4	overdose	S-Disease	O
5	can	O	O
6	cause	O	O
7	severe	O	O
8	hypertension	S-Disease	S-Disease
9	,	O	O
10	intracerebral	B-Disease	O
11	hemorrhage	E-Disease	S-Disease
12	,	O	O
13	and	O	O
14	death	O	O
15	.	O	O

0	We	O	O
1	studied	O	O
2	the	O	O
3	efficacy	O	O
4	and	O	O
5	safety	O	O
6	of	O	O
7	propranolol	S-Chemical	S-Chemical
8	in	O	O
9	the	O	O
10	treatment	O	O
11	of	O	O
12	PPA	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	hypertension	S-Disease	S-Disease
16	.	O	O

0	Subjects	O	O
1	received	O	O
2	propranolol	S-Chemical	S-Chemical
3	either	O	O
4	by	O	O
5	mouth	O	O
6	for	O	O
7	48	O	O
8	hours	O	O
9	before	O	O
10	PPA	S-Chemical	S-Chemical
11	or	O	O
12	as	O	O
13	a	O	O
14	rapid	O	O
15	intravenous	O	O
16	infusion	O	O
17	after	O	O
18	PPA	S-Chemical	S-Chemical
19	.	O	O

0	PPA	S-Chemical	S-Chemical
1	,	O	O
2	75	O	O
3	mg	O	O
4	alone	O	O
5	,	O	O
6	increased	O	O
7	blood	O	O
8	pressure	O	O
9	(	O	O
10	31	O	O
11	+	O	O
12	/	O	O
13	-	O	O
14	14	O	O
15	mm	O	O
16	Hg	O	O
17	systolic	O	S-Disease
18	,	O	O
19	20	O	O
20	+	O	O
21	/	O	O
22	-	O	O
23	5	O	O
24	mm	O	O
25	Hg	O	O
26	diastolic	O	S-Disease
27	)	O	O
28	,	O	O
29	and	O	O
30	propranolol	S-Chemical	S-Chemical
31	pretreatment	O	O
32	antagonized	O	O
33	this	O	O
34	increase	O	O
35	(	O	O
36	12	O	O
37	+	O	O
38	/	O	O
39	-	O	O
40	10	O	O
41	mm	O	O
42	Hg	O	O
43	systolic	O	O
44	,	O	O
45	10	O	O
46	+	O	O
47	/	O	O
48	-	O	O
49	7	O	O
50	mm	O	O
51	Hg	O	O
52	diastolic	O	S-Disease
53	)	O	O
54	.	O	O

0	Intravenous	O	O
1	propranolol	S-Chemical	S-Chemical
2	after	O	O
3	PPA	S-Chemical	S-Chemical
4	also	O	O
5	decreased	O	O
6	blood	O	O
7	pressure	O	O
8	.	O	O

0	Left	O	O
1	ventricular	O	O
2	function	O	O
3	(	O	O
4	assessed	O	O
5	by	O	O
6	echocardiography	O	O
7	)	O	O
8	showed	O	O
9	that	O	O
10	PPA	S-Chemical	S-Chemical
11	increased	O	O
12	the	O	O
13	stroke	S-Disease	S-Disease
14	volume	O	O
15	30	O	O
16	%	O	O
17	(	O	O
18	from	O	O
19	62	O	O
20	.	O	O
21	5	O	O
22	+	O	O
23	/	O	O
24	-	O	O
25	20	O	O
26	.	O	O
27	9	O	O
28	to	O	O
29	80	O	O
30	.	O	O
31	8	O	O
32	+	O	O
33	/	O	O
34	-	O	O
35	22	O	O
36	.	O	O
37	4	O	O
38	ml	O	O
39	)	O	O
40	,	O	O
41	the	O	O
42	ejection	O	O
43	fraction	O	O
44	9	O	O
45	%	O	O
46	(	O	O
47	from	O	O
48	64	O	O
49	%	O	O
50	+	O	O
51	/	O	O
52	-	O	O
53	10	O	O
54	%	O	O
55	to	O	O
56	70	O	O
57	%	O	O
58	+	O	O
59	/	O	O
60	-	O	O
61	7	O	O
62	%	O	O
63	)	O	O
64	,	O	O
65	and	O	O
66	cardiac	O	S-Disease
67	output	O	O
68	14	O	O
69	%	O	O
70	(	O	O
71	from	O	O
72	3	O	O
73	.	O	O
74	6	O	O
75	+	O	O
76	/	O	O
77	-	O	O
78	0	O	O
79	.	O	O
80	6	O	O
81	to	O	O
82	4	O	O
83	.	O	O
84	1	O	O
85	+	O	O
86	/	O	O
87	-	O	O
88	1	O	O
89	.	O	O
90	0	O	O
91	L	O	O
92	/	O	O
93	min	O	O
94	)	O	O
95	.	O	O

0	Intravenous	O	O
1	propranolol	S-Chemical	S-Chemical
2	reversed	O	O
3	these	O	O
4	effects	O	O
5	.	O	O

0	Systemic	O	O
1	vascular	O	B-Disease
2	resistance	O	E-Disease
3	was	O	O
4	increased	O	O
5	by	O	O
6	PPA	S-Chemical	S-Chemical
7	28	O	O
8	%	O	O
9	(	O	O
10	from	O	O
11	1710	O	O
12	+	O	O
13	/	O	O
14	-	O	O
15	200	O	O
16	to	O	O
17	2190	O	O
18	+	O	O
19	/	O	O
20	-	O	O
21	700	O	O
22	dyne	O	O
23	X	O	O
24	sec	O	O
25	/	O	O
26	cm5	O	O
27	)	O	O
28	and	O	O
29	was	O	O
30	further	O	O
31	increased	O	O
32	by	O	O
33	propranolol	S-Chemical	S-Chemical
34	22	O	O
35	%	O	O
36	(	O	O
37	to	O	O
38	2660	O	O
39	+	O	O
40	/	O	O
41	-	O	O
42	1200	O	O
43	dyne	O	O
44	X	O	O
45	sec	O	O
46	/	O	O
47	cm5	O	O
48	)	O	O
49	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	PPA	S-Chemical	S-Chemical
4	increases	O	O
5	blood	O	O
6	pressure	O	O
7	by	O	O
8	increasing	O	O
9	systemic	O	O
10	vascular	O	I-Disease
11	resistance	O	E-Disease
12	and	O	O
13	cardiac	O	B-Disease
14	output	O	E-Disease
15	,	O	O
16	and	O	O
17	that	O	O
18	propranolol	S-Chemical	S-Chemical
19	antagonizes	O	O
20	this	O	O
21	increase	O	O
22	by	O	O
23	reversing	O	O
24	the	O	O
25	effect	O	O
26	of	O	O
27	PPA	S-Chemical	S-Chemical
28	on	O	O
29	cardiac	O	S-Disease
30	output	O	O
31	.	O	O

0	That	O	O
1	propranolol	S-Chemical	S-Chemical
2	antagonizes	O	O
3	the	O	O
4	pressor	O	S-Chemical
5	effect	O	O
6	of	O	O
7	PPA	S-Chemical	S-Chemical
8	is	O	O
9	in	O	O
10	contrast	O	O
11	to	O	O
12	the	O	O
13	interaction	O	O
14	in	O	O
15	which	O	O
16	propranolol	S-Chemical	S-Chemical
17	enhances	O	O
18	the	O	O
19	pressor	O	S-Disease
20	effect	O	O
21	of	O	O
22	norepinephrine	S-Chemical	S-Chemical
23	.	O	O

0	This	O	O
1	is	O	O
2	probably	O	O
3	because	O	O
4	PPA	S-Chemical	S-Chemical
5	has	O	O
6	less	O	O
7	beta	O	O
8	2	O	O
9	activity	O	O
10	than	O	O
11	does	O	O
12	norepinephrine	S-Chemical	S-Chemical
13	.	O	O

0	Mesangial	O	O
1	function	O	O
2	and	O	O
3	glomerular	B-Disease	B-Disease
4	sclerosis	E-Disease	E-Disease
5	in	O	O
6	rats	O	O
7	with	O	O
8	aminonucleoside	S-Chemical	S-Chemical
9	nephrosis	S-Disease	S-Disease
10	.	O	O

0	The	O	O
1	possible	O	O
2	relationship	O	O
3	between	O	O
4	mesangial	B-Disease	B-Disease
5	dysfunction	E-Disease	E-Disease
6	and	O	O
7	development	O	O
8	of	O	O
9	glomerular	B-Disease	B-Disease
10	sclerosis	E-Disease	E-Disease
11	was	O	O
12	studied	O	O
13	in	O	O
14	the	O	O
15	puromycin	B-Chemical	S-Chemical
16	aminonucleoside	E-Chemical	E-Chemical
17	(	O	O
18	PAN	S-Chemical	S-Chemical
19	)	O	O
20	model	O	O
21	.	O	O

0	Five	O	O
1	male	O	O
2	Wistar	O	O
3	rats	O	O
4	received	O	O
5	repeated	O	O
6	subcutaneous	O	O
7	PAN	S-Chemical	S-Disease
8	injections	O	O
9	;	O	O
10	five	O	O
11	controls	O	O
12	received	O	O
13	saline	O	S-Chemical
14	only	O	O
15	.	O	O

0	After	O	O
1	4	O	O
2	weeks	O	O
3	the	O	O
4	PAN	S-Chemical	S-Chemical
5	rats	O	O
6	were	O	O
7	severely	O	O
8	proteinuric	S-Disease	S-Disease
9	(	O	O
10	190	O	O
11	+	O	O
12	/	O	O
13	-	O	O
14	80	O	O
15	mg	O	O
16	/	O	O
17	24	O	O
18	hr	O	O
19	)	O	O
20	,	O	O
21	and	O	O
22	all	O	O
23	rats	O	O
24	were	O	O
25	given	O	O
26	colloidal	O	S-Chemical
27	carbon	S-Chemical	O
28	(	O	O
29	CC	O	O
30	)	O	O
31	intravenously	O	O
32	.	O	O

0	At	O	O
1	5	O	O
2	months	O	O
3	glomerular	B-Disease	O
4	sclerosis	E-Disease	E-Disease
5	was	O	O
6	found	O	O
7	in	O	O
8	7	O	O
9	.	O	O
10	6	O	O
11	+	O	O
12	/	O	O
13	-	O	O
14	3	O	O
15	.	O	O
16	4	O	O
17	%	O	O
18	of	O	O
19	the	O	O
20	glomeruli	O	O
21	of	O	O
22	PAN	S-Chemical	S-Chemical
23	rats	O	O
24	;	O	O
25	glomeruli	O	S-Chemical
26	of	O	O
27	the	O	O
28	controls	O	O
29	were	O	O
30	normal	O	O
31	.	O	O

0	Glomeruli	O	O
1	of	O	O
2	PAN	S-Chemical	O
3	rats	O	O
4	contained	O	O
5	significantly	O	O
6	more	O	O
7	CC	O	O
8	than	O	O
9	glomeruli	O	S-Disease
10	of	O	O
11	controls	O	O
12	.	O	O

0	Glomeruli	O	S-Chemical
1	with	O	O
2	sclerosis	S-Disease	S-Disease
3	contained	O	O
4	significantly	O	O
5	more	O	O
6	CC	O	S-Disease
7	than	O	O
8	non	O	O
9	-	O	O
10	sclerotic	O	O
11	glomeruli	O	S-Disease
12	in	O	O
13	the	O	O
14	same	O	O
15	kidneys	O	O
16	.	O	O

0	Since	O	O
1	mesangial	O	B-Disease
2	CC	O	S-Disease
3	clearance	O	O
4	from	O	O
5	the	O	O
6	mesangium	O	S-Disease
7	did	O	O
8	not	O	O
9	change	O	O
10	during	O	O
11	chronic	O	B-Disease
12	PAN	S-Chemical	E-Disease
13	treatment	O	O
14	,	O	O
15	we	O	O
16	conclude	O	O
17	that	O	O
18	this	O	O
19	preferential	O	O
20	CC	O	S-Disease
21	localization	O	O
22	within	O	O
23	the	O	O
24	lesions	O	S-Disease
25	is	O	O
26	caused	O	O
27	by	O	O
28	an	O	O
29	increased	O	O
30	CC	O	S-Chemical
31	uptake	O	O
32	shortly	O	O
33	after	O	O
34	injection	O	O
35	in	O	O
36	apparent	O	O
37	vulnerable	O	O
38	areas	O	O
39	where	O	O
40	sclerosis	S-Disease	S-Disease
41	will	O	O
42	develop	O	O
43	subsequently	O	O
44	.	O	O

0	Cluster	O	O
1	analysis	O	O
2	showed	O	O
3	a	O	O
4	random	O	O
5	distribution	O	O
6	of	O	O
7	lesions	O	S-Disease
8	in	O	O
9	the	O	O
10	PAN	S-Chemical	B-Chemical
11	glomeruli	O	E-Chemical
12	in	O	O
13	concordance	O	O
14	with	O	O
15	the	O	O
16	random	O	O
17	localization	O	O
18	of	O	O
19	mesangial	O	S-Disease
20	areas	O	E-Disease
21	with	O	O
22	dysfunction	O	S-Disease
23	in	O	O
24	this	O	O
25	model	O	O
26	.	O	O

0	Similar	O	O
1	to	O	O
2	the	O	O
3	remnant	O	O
4	kidney	O	O
5	model	O	O
6	in	O	O
7	PAN	S-Chemical	B-Disease
8	nephrosis	S-Disease	E-Disease
9	the	O	O
10	development	O	O
11	of	O	O
12	glomerular	B-Disease	B-Disease
13	sclerosis	E-Disease	I-Disease
14	may	O	O
15	be	O	O
16	related	O	O
17	to	O	O
18	"	O	O
19	mesangial	O	S-Disease
20	overloading	O	E-Disease
21	.	O	O
22	"	O	O

0	Relationship	O	O
1	between	O	O
2	nicotine	S-Chemical	S-Chemical
3	-	O	O
4	induced	O	O
5	seizures	S-Disease	S-Disease
6	and	O	O
7	hippocampal	O	B-Disease
8	nicotinic	O	I-Disease
9	receptors	O	O
10	.	O	O

0	Using	O	O
1	mice	O	O
2	derived	O	O
3	from	O	O
4	a	O	O
5	classical	O	O
6	F2	O	S-Chemical
7	and	O	O
8	backcross	O	O
9	genetic	O	O
10	design	O	O
11	,	O	O
12	a	O	O
13	relationship	O	O
14	between	O	O
15	nicotine	S-Chemical	S-Chemical
16	-	O	O
17	induced	O	O
18	seizures	S-Disease	S-Disease
19	and	O	O
20	alpha	O	B-Disease
21	-	O	O
22	bungarotoxin	O	E-Chemical
23	nicotinic	O	O
24	receptor	O	O
25	concentration	O	O
26	was	O	O
27	found	O	O
28	.	O	O

0	Mice	O	O
1	sensitive	O	O
2	to	O	O
3	the	O	O
4	convulsant	O	O
5	effects	O	O
6	of	O	O
7	nicotine	S-Chemical	S-Chemical
8	had	O	O
9	greater	O	O
10	alpha	O	S-Chemical
11	-	O	O
12	bungarotoxin	O	S-Disease
13	binding	O	O
14	in	O	O
15	the	O	O
16	hippocampus	O	S-Disease
17	than	O	O
18	seizure	S-Disease	S-Disease
19	insensitive	O	O
20	mice	O	O
21	.	O	O

0	The	O	O
1	binding	O	O
2	sites	O	O
3	from	O	O
4	seizure	S-Disease	O
5	sensitive	O	O
6	and	O	O
7	resistant	O	O
8	mice	O	O
9	were	O	O
10	equally	O	O
11	affected	O	O
12	by	O	O
13	treatment	O	O
14	with	O	O
15	dithiothreitol	S-Chemical	S-Chemical
16	,	O	O
17	trypsin	O	S-Chemical
18	or	O	O
19	heat	O	O
20	.	O	O

0	Thus	O	O
1	it	O	O
2	appears	O	O
3	that	O	O
4	the	O	O
5	difference	O	O
6	between	O	O
7	seizure	S-Disease	S-Disease
8	sensitive	O	O
9	and	O	O
10	insensitive	O	O
11	animals	O	O
12	may	O	O
13	be	O	O
14	due	O	O
15	to	O	O
16	a	O	O
17	difference	O	O
18	in	O	O
19	hippocampal	O	B-Disease
20	nicotinic	O	I-Disease
21	receptor	O	S-Disease
22	concentration	O	O
23	as	O	O
24	measured	O	O
25	with	O	O
26	alpha	O	S-Chemical
27	-	O	O
28	bungarotoxin	O	S-Chemical
29	binding	O	O
30	.	O	O

0	The	O	O
1	role	O	O
2	of	O	O
3	p	B-Chemical	S-Chemical
4	-	I-Chemical	O
5	aminophenol	E-Chemical	S-Chemical
6	in	O	O
7	acetaminophen	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	nephrotoxicity	S-Disease	S-Disease
11	:	O	O
12	effect	O	O
13	of	O	O
14	bis	B-Chemical	S-Chemical
15	(	I-Chemical	O
16	p	I-Chemical	S-Chemical
17	-	I-Chemical	I-Chemical
18	nitrophenyl	I-Chemical	E-Chemical
19	)	I-Chemical	O
20	phosphate	E-Chemical	S-Disease
21	on	O	O
22	acetaminophen	S-Chemical	S-Chemical
23	and	O	O
24	p	B-Chemical	S-Chemical
25	-	I-Chemical	O
26	aminophenol	E-Chemical	S-Chemical
27	nephrotoxicity	S-Disease	S-Disease
28	and	O	O
29	metabolism	O	O
30	in	O	O
31	Fischer	O	B-Chemical
32	344	O	O
33	rats	O	O
34	.	O	O

0	Acetaminophen	S-Chemical	S-Chemical
1	(	O	O
2	APAP	S-Chemical	S-Disease
3	)	O	O
4	produces	O	O
5	proximal	O	O
6	tubular	B-Disease	B-Disease
7	necrosis	E-Disease	I-Disease
8	in	O	O
9	Fischer	O	B-Chemical
10	344	O	E-Chemical
11	(	O	O
12	F344	O	S-Chemical
13	)	O	O
14	rats	O	O
15	.	O	O

0	Recently	O	O
1	,	O	O
2	p	B-Chemical	S-Chemical
3	-	I-Chemical	B-Chemical
4	aminophenol	E-Chemical	E-Chemical
5	(	O	O
6	PAP	S-Chemical	S-Disease
7	)	O	O
8	,	O	O
9	a	O	O
10	known	O	O
11	potent	O	O
12	nephrotoxicant	O	O
13	,	O	O
14	was	O	O
15	identified	O	O
16	as	O	O
17	a	O	O
18	metabolite	O	O
19	of	O	O
20	APAP	S-Chemical	S-Chemical
21	in	O	O
22	F344	O	B-Chemical
23	rats	O	O
24	.	O	O

0	The	O	O
1	purpose	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	determine	O	O
8	if	O	O
9	PAP	S-Chemical	S-Chemical
10	formation	O	O
11	is	O	O
12	a	O	O
13	requisite	O	O
14	step	O	O
15	in	O	O
16	APAP	S-Chemical	S-Disease
17	-	O	O
18	induced	O	O
19	nephrotoxicity	S-Disease	S-Disease
20	.	O	O

0	Therefore	O	O
1	,	O	O
2	the	O	O
3	effect	O	O
4	of	O	O
5	bis	B-Chemical	S-Chemical
6	(	I-Chemical	O
7	p	I-Chemical	S-Chemical
8	-	I-Chemical	I-Chemical
9	nitrophenyl	I-Chemical	E-Chemical
10	)	I-Chemical	O
11	phosphate	E-Chemical	E-Chemical
12	(	O	O
13	BNPP	S-Chemical	S-Disease
14	)	O	O
15	,	O	O
16	an	O	O
17	acylamidase	O	O
18	inhibitor	O	O
19	,	O	O
20	on	O	O
21	APAP	S-Chemical	S-Chemical
22	and	O	O
23	PAP	S-Chemical	S-Chemical
24	nephrotoxicity	S-Disease	S-Disease
25	and	O	O
26	metabolism	O	O
27	was	O	O
28	determined	O	O
29	.	O	O

0	BNPP	S-Chemical	S-Chemical
1	(	O	O
2	1	O	O
3	to	O	O
4	8	O	O
5	mM	O	O
6	)	O	O
7	reduced	O	O
8	APAP	S-Chemical	S-Disease
9	deacetylation	O	O
10	and	O	O
11	covalent	O	O
12	binding	O	O
13	in	O	O
14	F344	O	B-Chemical
15	renal	O	I-Disease
16	cortical	O	I-Disease
17	homogenates	O	O
18	in	O	O
19	a	O	O
20	concentration	O	O
21	-	O	O
22	dependent	O	O
23	manner	O	O
24	.	O	O

0	Pretreatment	O	O
1	of	O	O
2	animals	O	O
3	with	O	O
4	BNPP	S-Chemical	S-Disease
5	prior	O	O
6	to	O	O
7	APAP	S-Chemical	S-Disease
8	or	O	O
9	PAP	S-Chemical	S-Disease
10	administration	O	O
11	resulted	O	O
12	in	O	O
13	marked	O	O
14	reduction	O	O
15	of	O	O
16	APAP	S-Chemical	S-Disease
17	(	O	O
18	900	O	O
19	mg	O	O
20	/	O	O
21	kg	O	O
22	)	O	O
23	nephrotoxicity	S-Disease	S-Disease
24	but	O	O
25	not	O	O
26	PAP	S-Chemical	S-Chemical
27	nephrotoxicity	S-Disease	S-Disease
28	.	O	O

0	This	O	O
1	result	O	O
2	was	O	O
3	not	O	O
4	due	O	O
5	to	O	O
6	altered	O	O
7	disposition	O	O
8	of	O	O
9	either	O	O
10	APAP	S-Chemical	S-Chemical
11	or	O	O
12	acetylated	O	S-Chemical
13	metabolites	O	O
14	in	O	O
15	plasma	O	O
16	or	O	O
17	renal	O	B-Disease
18	cortical	O	E-Disease
19	and	O	O
20	hepatic	O	S-Disease
21	tissue	O	O
22	.	O	O

0	Rather	O	O
1	,	O	O
2	BNPP	S-Chemical	S-Chemical
3	pretreatment	O	O
4	reduced	O	O
5	the	O	O
6	fraction	O	O
7	of	O	O
8	APAP	S-Chemical	S-Chemical
9	excreted	O	O
10	as	O	O
11	PAP	S-Chemical	S-Chemical
12	by	O	O
13	64	O	O
14	and	O	O
15	75	O	O
16	%	O	O
17	after	O	O
18	APAP	S-Chemical	S-Disease
19	doses	O	O
20	of	O	O
21	750	O	O
22	and	O	O
23	900	O	O
24	mg	O	O
25	/	O	O
26	kg	O	O
27	.	O	O

0	BNPP	S-Chemical	S-Chemical
1	did	O	O
2	not	O	O
3	alter	O	O
4	the	O	O
5	excretion	O	O
6	of	O	O
7	APAP	S-Chemical	S-Chemical
8	or	O	O
9	any	O	O
10	of	O	O
11	its	O	O
12	non	O	O
13	-	O	O
14	deacetylated	O	O
15	metabolites	O	O
16	nor	O	O
17	did	O	O
18	BNPP	S-Chemical	S-Chemical
19	alter	O	O
20	excretion	O	O
21	of	O	O
22	PAP	S-Chemical	S-Chemical
23	or	O	O
24	its	O	O
25	metabolites	O	O
26	after	O	O
27	PAP	S-Chemical	S-Chemical
28	doses	O	O
29	of	O	O
30	150	O	O
31	and	O	O
32	300	O	O
33	mg	O	O
34	/	O	O
35	kg	O	O
36	.	O	O

0	Therefore	O	O
1	,	O	O
2	the	O	O
3	BNPP	S-Chemical	O
4	-	O	O
5	induced	O	O
6	reduction	O	O
7	in	O	O
8	APAP	S-Chemical	S-Disease
9	-	O	O
10	induced	O	O
11	nephrotoxicity	S-Disease	S-Disease
12	appears	O	O
13	to	O	O
14	be	O	O
15	due	O	O
16	to	O	O
17	inhibition	O	O
18	of	O	O
19	APAP	S-Chemical	S-Chemical
20	deacetylation	O	S-Disease
21	.	O	O

0	It	O	O
1	is	O	O
2	concluded	O	O
3	that	O	O
4	PAP	S-Chemical	S-Chemical
5	formation	O	O
6	,	O	O
7	in	O	O
8	vivo	O	O
9	,	O	O
10	accounts	O	O
11	,	O	O
12	at	O	O
13	least	O	O
14	in	O	O
15	part	O	O
16	,	O	O
17	for	O	O
18	APAP	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	renal	B-Disease	I-Disease
22	tubular	I-Disease	I-Disease
23	necrosis	E-Disease	I-Disease
24	.	O	O

0	Morphine	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	seizures	S-Disease	S-Disease
4	in	O	O
5	newborn	O	O
6	infants	O	O
7	.	O	O

0	Two	O	O
1	neonates	O	O
2	suffered	O	O
3	from	O	O
4	generalized	O	O
5	seizures	S-Disease	S-Disease
6	during	O	O
7	the	O	O
8	course	O	O
9	of	O	O
10	intravenous	O	O
11	morphine	B-Chemical	B-Chemical
12	sulfate	E-Chemical	E-Chemical
13	for	O	O
14	post	O	O
15	-	O	O
16	operative	O	O
17	analgesia	O	O
18	.	O	O

0	They	O	O
1	received	O	O
2	morphine	S-Chemical	O
3	in	O	O
4	doses	O	O
5	of	O	O
6	32	O	O
7	micrograms	O	O
8	/	O	O
9	kg	O	O
10	/	O	O
11	hr	O	O
12	and	O	O
13	40	O	O
14	micrograms	O	O
15	/	O	O
16	kg	O	O
17	/	O	O
18	hr	O	O
19	larger	O	O
20	than	O	O
21	a	O	O
22	group	O	O
23	of	O	O
24	10	O	O
25	neonates	O	O
26	who	O	O
27	received	O	O
28	6	O	O
29	-	O	O
30	24	O	O
31	micrograms	O	O
32	/	O	O
33	kg	O	O
34	/	O	O
35	hr	O	O
36	and	O	O
37	had	O	O
38	no	O	O
39	seizures	S-Disease	S-Disease
40	.	O	O

0	Plasma	O	O
1	concentrations	O	O
2	of	O	O
3	morphine	S-Chemical	S-Chemical
4	in	O	O
5	these	O	O
6	neonates	O	O
7	was	O	O
8	excessive	O	O
9	(	O	O
10	60	O	O
11	and	O	O
12	90	O	O
13	mg	O	O
14	/	O	O
15	ml	O	O
16	)	O	O
17	.	O	O

0	Other	O	O
1	known	O	O
2	reasons	O	O
3	for	O	O
4	seizures	S-Disease	S-Disease
5	were	O	O
6	ruled	O	O
7	out	O	O
8	and	O	O
9	the	O	O
10	convulsions	S-Disease	O
11	stopped	O	O
12	a	O	O
13	few	O	O
14	hours	O	O
15	after	O	O
16	cessation	O	O
17	of	O	O
18	morphine	S-Chemical	S-Chemical
19	and	O	O
20	did	O	O
21	not	O	O
22	reoccur	O	O
23	in	O	O
24	the	O	O
25	subsequent	O	O
26	8	O	O
27	months	O	O
28	.	O	O

0	It	O	O
1	is	O	O
2	suggested	O	O
3	that	O	O
4	post	O	O
5	-	O	O
6	operative	O	O
7	intravenous	O	O
8	morphine	S-Chemical	S-Disease
9	should	O	O
10	not	O	O
11	exceed	O	O
12	20	O	O
13	micrograms	O	O
14	/	O	O
15	kg	O	O
16	/	O	O
17	ml	O	O
18	in	O	O
19	neonates	O	O
20	.	O	O

0	Indomethacin	S-Chemical	S-Chemical
1	induced	O	O
2	hypotension	S-Disease	S-Disease
3	in	O	O
4	sodium	S-Chemical	O
5	and	O	O
6	volume	O	O
7	depleted	O	O
8	rats	O	O
9	.	O	O

0	After	O	O
1	a	O	O
2	single	O	O
3	oral	O	O
4	dose	O	O
5	of	O	O
6	4	O	O
7	mg	O	O
8	/	O	O
9	kg	O	O
10	indomethacin	S-Chemical	O
11	(	O	O
12	IDM	S-Chemical	S-Disease
13	)	O	O
14	to	O	O
15	sodium	S-Chemical	O
16	and	O	O
17	volume	O	O
18	depleted	O	O
19	rats	O	O
20	plasma	O	O
21	renin	O	B-Disease
22	activity	O	E-Disease
23	(	O	O
24	PRA	O	S-Disease
25	)	O	O
26	and	O	O
27	systolic	O	S-Disease
28	blood	O	O
29	pressure	O	O
30	fell	O	O
31	significantly	O	O
32	within	O	O
33	four	O	O
34	hours	O	O
35	.	O	O

0	In	O	O
1	sodium	S-Chemical	O
2	repleted	O	O
3	animals	O	O
4	indomethacin	S-Chemical	S-Chemical
5	did	O	O
6	not	O	O
7	change	O	O
8	systolic	O	O
9	blood	O	O
10	pressure	O	O
11	(	O	O
12	BP	O	S-Disease
13	)	O	O
14	although	O	O
15	plasma	O	O
16	renin	O	E-Chemical
17	activity	O	O
18	was	O	O
19	decreased	O	O
20	.	O	O

0	Thus	O	O
1	,	O	O
2	indomethacin	S-Chemical	S-Chemical
3	by	O	O
4	inhibition	O	O
5	of	O	O
6	prostaglandin	S-Chemical	S-Disease
7	synthesis	O	O
8	may	O	O
9	diminish	O	O
10	the	O	O
11	blood	O	O
12	pressure	O	O
13	maintaining	O	O
14	effect	O	O
15	of	O	O
16	the	O	O
17	stimulated	O	O
18	renin	O	S-Chemical
19	-	O	I-Disease
20	angiotensin	S-Chemical	O
21	system	O	O
22	in	O	O
23	sodium	S-Chemical	O
24	and	O	O
25	volume	O	O
26	depletion	O	O
27	.	O	O

0	On	O	O
1	the	O	O
2	antiarrhythmic	O	O
3	activity	O	O
4	of	O	O
5	one	O	O
6	N	O	O
7	-	O	O
8	substituted	O	O
9	piperazine	S-Chemical	S-Chemical
10	derivative	O	O
11	of	O	O
12	trans	B-Chemical	B-Chemical
13	-	I-Chemical	I-Chemical
14	2	I-Chemical	I-Chemical
15	-	I-Chemical	I-Chemical
16	amino	I-Chemical	I-Chemical
17	-	I-Chemical	I-Chemical
18	3	I-Chemical	I-Chemical
19	-	I-Chemical	I-Chemical
20	hydroxy	I-Chemical	E-Chemical
21	-	I-Chemical	I-Chemical
22	1	I-Chemical	I-Chemical
23	,	I-Chemical	O
24	2	I-Chemical	O
25	,	I-Chemical	O
26	3	I-Chemical	I-Chemical
27	,	I-Chemical	O
28	4	I-Chemical	I-Chemical
29	-	I-Chemical	I-Chemical
30	tetrahydroanaphthalene	E-Chemical	E-Chemical
31	.	O	O

0	The	O	O
1	antiarrhythmic	O	O
2	activity	O	O
3	of	O	O
4	the	O	O
5	compound	O	O
6	N	B-Chemical	B-Chemical
7	-	I-Chemical	I-Chemical
8	(	I-Chemical	O
9	trans	I-Chemical	O
10	-	I-Chemical	I-Chemical
11	3	I-Chemical	O
12	-	I-Chemical	I-Chemical
13	hydroxy	I-Chemical	E-Chemical
14	-	I-Chemical	O
15	1	I-Chemical	O
16	,	I-Chemical	O
17	2	I-Chemical	O
18	,	I-Chemical	I-Chemical
19	3	I-Chemical	O
20	,	I-Chemical	O
21	4	I-Chemical	O
22	-	I-Chemical	I-Chemical
23	tetrahydro	I-Chemical	E-Chemical
24	-	I-Chemical	I-Chemical
25	2	I-Chemical	O
26	-	I-Chemical	I-Chemical
27	naphthyl	I-Chemical	S-Chemical
28	)	I-Chemical	O
29	-	I-Chemical	O
30	N	I-Chemical	O
31	-	I-Chemical	I-Chemical
32	(	I-Chemical	O
33	3	I-Chemical	O
34	-	I-Chemical	I-Chemical
35	oxo	I-Chemical	O
36	-	I-Chemical	I-Chemical
37	3	I-Chemical	O
38	-	I-Chemical	I-Chemical
39	phenyl	I-Chemical	O
40	-	I-Chemical	I-Chemical
41	2	I-Chemical	O
42	-	I-Chemical	O
43	methylpropyl	I-Chemical	S-Chemical
44	)	I-Chemical	O
45	-	I-Chemical	O
46	piperazine	I-Chemical	S-Chemical
47	hydrochloride	E-Chemical	E-Chemical
48	,	O	O
49	referred	O	O
50	to	O	O
51	as	O	O
52	P11	S-Chemical	S-Chemical
53	,	O	O
54	is	O	O
55	studied	O	O
56	on	O	O
57	anaesthesized	O	O
58	cats	O	O
59	and	O	O
60	Wistar	O	S-Disease
61	albino	O	S-Disease
62	rats	O	O
63	,	O	O
64	as	O	O
65	well	O	O
66	as	O	O
67	on	O	O
68	non	O	O
69	-	O	O
70	anaesthesized	O	O
71	rabbits	O	O
72	.	O	O

0	Four	O	O
1	types	O	O
2	of	O	O
3	experimental	O	O
4	arrhythmia	S-Disease	S-Disease
5	are	O	O
6	used	O	O
7	-	O	O
8	-	O	O
9	with	O	O
10	BaCl2	S-Chemical	S-Chemical
11	,	O	O
12	with	O	O
13	chloroform	S-Chemical	S-Chemical
14	-	O	O
15	adrenaline	S-Chemical	O
16	,	O	O
17	with	O	O
18	strophantine	B-Chemical	O
19	G	E-Chemical	S-Disease
20	and	O	O
21	with	O	O
22	aconitine	S-Chemical	S-Chemical
23	.	O	O

0	The	O	O
1	compound	O	O
2	P11	S-Chemical	S-Chemical
3	is	O	O
4	introduced	O	O
5	in	O	O
6	doses	O	O
7	of	O	O
8	0	O	O
9	.	O	O
10	25	O	O
11	and	O	O
12	0	O	O
13	.	O	O
14	50	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	intravenously	O	O
19	and	O	O
20	10	O	O
21	mg	O	O
22	/	O	O
23	kg	O	O
24	orally	O	O
25	.	O	O

0	The	O	O
1	compound	O	O
2	manifests	O	O
3	antiarrhythmic	O	O
4	activity	O	O
5	in	O	O
6	all	O	O
7	models	O	O
8	of	O	O
9	experimental	O	O
10	arrhythmia	S-Disease	S-Disease
11	used	O	O
12	,	O	O
13	causing	O	O
14	greatest	O	O
15	inhibition	O	O
16	on	O	O
17	the	O	O
18	arrhythmia	S-Disease	O
19	induced	O	O
20	by	O	O
21	chloroform	S-Chemical	S-Chemical
22	-	O	O
23	adrenaline	S-Chemical	O
24	(	O	O
25	in	O	O
26	90	O	O
27	per	O	O
28	cent	O	O
29	)	O	O
30	and	O	O
31	with	O	O
32	BaCl2	S-Chemical	B-Chemical
33	(	O	O
34	in	O	O
35	84	O	O
36	per	O	O
37	cent	O	O
38	)	O	O
39	.	O	O

0	Recurrent	O	O
1	subarachnoid	B-Disease	O
2	hemorrhage	E-Disease	O
3	associated	O	O
4	with	O	O
5	aminocaproic	B-Chemical	S-Chemical
6	acid	E-Chemical	O
7	therapy	O	O
8	and	O	O
9	acute	B-Disease	B-Disease
10	renal	I-Disease	I-Disease
11	artery	I-Disease	I-Disease
12	thrombosis	E-Disease	E-Disease
13	.	O	O

0	Epsilon	B-Chemical	B-Chemical
1	aminocaproic	I-Chemical	E-Chemical
2	acid	E-Chemical	E-Disease
3	(	O	O
4	EACA	S-Chemical	S-Chemical
5	)	O	O
6	has	O	O
7	been	O	O
8	used	O	O
9	to	O	O
10	prevent	O	O
11	rebleeding	O	O
12	in	O	O
13	patients	O	O
14	with	O	O
15	subarachnoid	B-Disease	S-Disease
16	hemorrhage	E-Disease	S-Disease
17	(	O	O
18	SAH	S-Disease	S-Chemical
19	)	O	O
20	.	O	O

0	Although	O	O
1	this	O	O
2	agent	O	O
3	does	O	O
4	decrease	O	O
5	the	O	O
6	frequency	O	O
7	of	O	O
8	rebleeding	O	O
9	,	O	O
10	several	O	O
11	reports	O	O
12	have	O	O
13	described	O	O
14	thrombotic	S-Disease	O
15	complications	O	O
16	of	O	O
17	EACA	S-Chemical	S-Chemical
18	therapy	O	O
19	.	O	O

0	These	O	O
1	complications	O	O
2	have	O	O
3	included	O	O
4	clinical	O	O
5	deterioration	O	O
6	and	O	O
7	intracranial	B-Disease	O
8	vascular	I-Disease	I-Disease
9	thrombosis	E-Disease	E-Disease
10	in	O	O
11	patients	O	O
12	with	O	O
13	SAH	S-Disease	S-Chemical
14	,	O	O
15	arteriolar	O	S-Disease
16	and	O	O
17	capillary	O	B-Disease
18	fibrin	O	I-Disease
19	thrombi	S-Disease	E-Disease
20	in	O	O
21	patients	O	O
22	with	O	O
23	fibrinolytic	O	S-Disease
24	syndromes	O	S-Disease
25	treated	O	O
26	with	O	O
27	EACA	S-Chemical	S-Disease
28	,	O	O
29	or	O	O
30	other	O	O
31	thromboembolic	B-Disease	O
32	phenomena	E-Disease	O
33	.	O	O

0	Since	O	O
1	intravascular	O	O
2	fibrin	O	B-Disease
3	thrombi	S-Disease	E-Disease
4	are	O	O
5	often	O	O
6	observed	O	O
7	in	O	O
8	patients	O	O
9	with	O	O
10	fibrinolytic	O	B-Disease
11	disorders	O	E-Disease
12	,	O	O
13	EACA	S-Chemical	S-Chemical
14	should	O	O
15	not	O	O
16	be	O	O
17	implicated	O	O
18	in	O	O
19	the	O	O
20	pathogenesis	O	O
21	of	O	O
22	fibrin	O	S-Chemical
23	thrombi	S-Disease	E-Disease
24	in	O	O
25	patients	O	O
26	with	O	O
27	disseminated	B-Disease	O
28	intravascular	I-Disease	O
29	coagulation	E-Disease	O
30	or	O	O
31	other	O	O
32	"	O	O
33	consumption	B-Disease	O
34	coagulopathies	E-Disease	O
35	.	O	O
36	"	O	O
37	This	O	O
38	report	O	O
39	describes	O	O
40	subtotal	O	O
41	infarction	S-Disease	O
42	of	O	O
43	the	O	O
44	kidney	O	O
45	due	O	O
46	to	O	O
47	thrombosis	B-Disease	S-Disease
48	of	I-Disease	O
49	a	I-Disease	O
50	normal	I-Disease	O
51	renal	I-Disease	I-Disease
52	artery	E-Disease	E-Disease
53	.	O	O

0	This	O	O
1	occlusion	O	O
2	occurred	O	O
3	after	O	O
4	EACA	S-Chemical	S-Chemical
5	therapy	O	O
6	in	O	O
7	a	O	O
8	patient	O	O
9	with	O	O
10	SAH	S-Disease	S-Chemical
11	and	O	O
12	histopathological	O	O
13	documentation	O	O
14	of	O	O
15	recurrent	O	O
16	SAH	S-Disease	S-Disease
17	.	O	O

0	The	O	O
1	corresponding	O	O
2	clinical	O	O
3	event	O	O
4	was	O	O
5	characterized	O	O
6	by	O	O
7	marked	O	O
8	hypertension	S-Disease	S-Disease
9	and	O	O
10	abrupt	O	O
11	neurological	O	O
12	deterioration	O	O
13	.	O	O

0	Effect	O	O
1	of	O	O
2	vincristine	B-Chemical	B-Chemical
3	sulfate	E-Chemical	E-Chemical
4	on	O	O
5	Pseudomonas	B-Disease	B-Disease
6	infections	E-Disease	E-Disease
7	in	O	O
8	monkeys	O	O
9	.	O	O

0	Leukocytosis	S-Disease	S-Chemical
1	was	O	O
2	observed	O	O
3	in	O	O
4	all	O	O
5	monkeys	O	O
6	.	O	O

0	Intravenous	O	O
1	or	O	O
2	intratracheal	O	O
3	inoculation	O	O
4	of	O	O
5	2	O	O
6	.	O	O
7	0	O	O
8	to	O	O
9	2	O	O
10	.	O	O
11	5	O	O
12	mg	O	O
13	of	O	O
14	vincristine	B-Chemical	B-Chemical
15	sulfate	E-Chemical	E-Chemical
16	was	O	O
17	followed	O	O
18	by	O	O
19	leukopenia	S-Disease	S-Disease
20	in	O	O
21	4	O	O
22	to	O	O
23	5	O	O
24	days	O	O
25	.	O	O

0	Intravenous	O	O
1	inoculation	O	O
2	of	O	O
3	4	O	O
4	.	O	O
5	2	O	O
6	x	O	O
7	10	O	O
8	(	O	O
9	10	O	O
10	)	O	O
11	to	O	O
12	7	O	O
13	.	O	O
14	8	O	O
15	x	O	O
16	10	O	O
17	(	O	O
18	10	O	O
19	)	O	O
20	pyocin	O	S-Chemical
21	type	O	O
22	6	O	O
23	Pseudomonas	O	S-Disease
24	organisms	O	O
25	in	O	O
26	monkeys	O	O
27	given	O	O
28	vincristine	B-Chemical	B-Chemical
29	sulfate	E-Chemical	E-Chemical
30	4	O	O
31	days	O	O
32	previously	O	O
33	resulted	O	O
34	in	O	O
35	fatal	O	O
36	infection	S-Disease	S-Disease
37	in	O	O
38	11	O	O
39	of	O	O
40	14	O	O
41	monkeys	O	O
42	,	O	O
43	whereas	O	O
44	none	O	O
45	of	O	O
46	four	O	O
47	receiving	O	O
48	Pseudomonas	O	S-Chemical
49	alone	O	O
50	died	O	O
51	.	O	O

0	These	O	O
1	studies	O	O
2	suggest	O	O
3	that	O	O
4	an	O	O
5	antimetabolite	O	O
6	-	O	O
7	induced	O	O
8	leukopenia	S-Disease	S-Disease
9	predisposes	O	O
10	to	O	O
11	severe	O	O
12	Pseudomonas	O	B-Disease
13	sepsis	S-Disease	E-Disease
14	and	O	O
15	that	O	O
16	such	O	O
17	monkeys	O	O
18	may	O	O
19	serve	O	O
20	as	O	O
21	a	O	O
22	biological	O	O
23	model	O	O
24	for	O	O
25	study	O	O
26	of	O	O
27	comparative	O	O
28	efficacy	O	O
29	of	O	O
30	antimicrobial	O	O
31	agents	O	O
32	.	O	O

0	Modification	O	O
1	by	O	O
2	propranolol	S-Chemical	S-Chemical
3	of	O	O
4	cardiovascular	O	O
5	effects	O	O
6	of	O	O
7	induced	O	O
8	hypoglycaemia	S-Disease	S-Disease
9	.	O	O

0	The	O	O
1	cardiovascular	O	O
2	effects	O	O
3	of	O	O
4	hypoglycaemia	S-Disease	S-Disease
5	,	O	O
6	with	O	O
7	and	O	O
8	without	O	O
9	beta	O	O
10	-	O	O
11	blockade	O	O
12	,	O	O
13	were	O	O
14	compared	O	O
15	in	O	O
16	fourteen	O	O
17	healthy	O	O
18	men	O	O
19	.	O	O

0	Eight	O	O
1	received	O	O
2	insulin	O	S-Disease
3	alone	O	O
4	,	O	O
5	and	O	O
6	eight	O	O
7	,	O	O
8	including	O	O
9	two	O	O
10	of	O	O
11	the	O	O
12	original	O	O
13	insulin	O	S-Chemical
14	-	O	O
15	only	O	O
16	group	O	O
17	,	O	O
18	were	O	O
19	given	O	O
20	propranolol	S-Chemical	S-Chemical
21	and	O	O
22	insulin	O	S-Chemical
23	.	O	O

0	In	O	O
1	the	O	O
2	insulin	O	S-Chemical
3	-	O	O
4	group	O	O
5	the	O	O
6	period	O	O
7	of	O	O
8	hypoglycaemia	S-Disease	S-Disease
9	was	O	O
10	associated	O	O
11	with	O	O
12	an	O	O
13	increase	O	O
14	in	O	I-Disease
15	heart	O	S-Disease
16	-	O	I-Disease
17	rate	O	E-Disease
18	and	O	O
19	a	O	O
20	fall	O	O
21	in	O	O
22	diastolic	O	B-Disease
23	blood	O	I-Disease
24	-	O	I-Disease
25	pressure	O	E-Disease
26	.	O	O

0	In	O	O
1	the	O	O
2	propranolol	S-Chemical	S-Chemical
3	-	O	O
4	insulin	O	S-Disease
5	group	O	O
6	there	O	O
7	was	O	O
8	a	O	O
9	significant	O	O
10	fall	O	O
11	in	O	O
12	heart	O	S-Disease
13	-	O	O
14	rate	O	E-Disease
15	in	O	O
16	most	O	O
17	subjects	O	O
18	and	O	O
19	an	O	O
20	increase	O	O
21	in	O	O
22	diastolic	O	B-Disease
23	pressure	O	E-Disease
24	.	O	O

0	Typical	O	O
1	S	O	B-Chemical
2	-	O	O
3	T	O	O
4	/	O	O
5	T	O	O
6	changes	O	O
7	occurred	O	O
8	in	O	O
9	the	O	O
10	insulin	O	S-Chemical
11	-	O	O
12	group	O	O
13	but	O	O
14	in	O	O
15	none	O	O
16	of	O	O
17	the	O	O
18	propranolol	S-Chemical	S-Chemical
19	-	O	O
20	insulin	O	E-Chemical
21	group	O	O
22	.	O	O

0	Hypertension	S-Disease	S-Disease
1	in	O	O
2	diabetics	S-Disease	S-Disease
3	prone	O	O
4	to	O	O
5	hypoglycaemia	S-Disease	S-Disease
6	attacks	O	S-Disease
7	should	O	O
8	not	O	O
9	be	O	O
10	treated	O	O
11	with	O	O
12	beta	O	S-Disease
13	-	O	O
14	blockers	O	O
15	because	O	O
16	these	O	O
17	drugs	O	O
18	may	O	O
19	cause	O	O
20	a	O	O
21	sharp	O	O
22	rise	O	O
23	in	O	O
24	blood	O	O
25	-	O	O
26	pressure	O	O
27	in	O	O
28	such	O	O
29	patients	O	O
30	.	O	O

0	Long	O	O
1	-	O	O
2	term	O	O
3	propranolol	S-Chemical	S-Chemical
4	therapy	O	O
5	in	O	O
6	pregnancy	O	O
7	:	O	O
8	maternal	O	O
9	and	O	O
10	fetal	O	O
11	outcome	O	O
12	.	O	O

0	Propranolol	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	beta	O	O
4	-	O	O
5	adrenergic	O	O
6	blocking	O	O
7	agent	O	O
8	,	O	O
9	has	O	O
10	found	O	O
11	an	O	O
12	important	O	O
13	position	O	O
14	in	O	O
15	the	O	O
16	practice	O	O
17	of	O	O
18	medicine	O	O
19	.	O	O

0	Ten	O	O
1	patients	O	O
2	and	O	O
3	12	O	O
4	pregnancies	O	O
5	are	O	O
6	reported	O	O
7	where	O	O
8	chronic	O	B-Chemical
9	propranolol	S-Chemical	E-Chemical
10	has	O	O
11	been	O	O
12	administered	O	O
13	.	O	O

0	Five	O	O
1	patients	O	O
2	with	O	O
3	serial	O	O
4	pregnancies	O	O
5	with	O	O
6	and	O	O
7	without	O	O
8	propranolol	S-Chemical	S-Chemical
9	therapy	O	O
10	are	O	O
11	also	O	O
12	examined	O	O
13	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	previously	O	O
4	reported	O	O
5	hypoglycemia	S-Disease	S-Disease
6	,	O	O
7	hyperbilirubinemia	S-Disease	S-Disease
8	,	O	O
9	polycythemia	S-Disease	S-Disease
10	,	O	O
11	neonatal	B-Disease	S-Disease
12	apnea	E-Disease	S-Disease
13	,	O	O
14	and	O	O
15	bradycardia	S-Disease	S-Disease
16	are	O	O
17	not	O	O
18	invariable	O	O
19	and	O	O
20	cannot	O	O
21	be	O	O
22	statistically	O	O
23	correlated	O	O
24	with	O	O
25	chronic	O	S-Disease
26	propranolol	S-Chemical	S-Chemical
27	therapy	O	O
28	.	O	O

0	Growth	B-Disease	S-Disease
1	retardation	E-Disease	O
2	,	O	O
3	however	O	O
4	,	O	O
5	appears	O	O
6	to	O	O
7	be	O	O
8	significant	O	O
9	in	O	O
10	both	O	O
11	of	O	O
12	our	O	O
13	series	O	O
14	.	O	O

0	Central	O	O
1	excitatory	O	O
2	actions	O	O
3	of	O	O
4	flurazepam	S-Chemical	S-Chemical
5	.	O	O

0	Toxic	O	O
1	actions	O	O
2	of	O	O
3	flurazepam	S-Chemical	S-Chemical
4	(	O	O
5	FZP	S-Chemical	S-Chemical
6	)	O	O
7	were	O	O
8	studied	O	O
9	in	O	O
10	cats	O	O
11	,	O	O
12	mice	O	O
13	and	O	O
14	rats	O	O
15	.	O	O

0	High	O	O
1	doses	O	O
2	caused	O	O
3	an	O	O
4	apparent	O	O
5	central	O	O
6	excitation	O	O
7	,	O	O
8	most	O	O
9	clearly	O	O
10	seen	O	O
11	as	O	O
12	clonic	O	S-Disease
13	convulsions	S-Disease	S-Disease
14	,	O	O
15	superimposed	O	O
16	on	O	O
17	general	O	O
18	depression	S-Disease	S-Disease
19	.	O	O

0	Following	O	O
1	a	O	O
2	lethal	O	O
3	dose	O	O
4	,	O	O
5	death	O	O
6	was	O	O
7	always	O	O
8	associated	O	O
9	with	O	O
10	convulsions	S-Disease	O
11	.	O	O

0	Comparing	O	O
1	the	O	O
2	relative	O	O
3	sensitivity	O	O
4	to	O	O
5	central	O	O
6	depression	S-Disease	E-Disease
7	and	O	O
8	excitation	O	O
9	revealed	O	O
10	that	O	O
11	rats	O	O
12	were	O	O
13	least	O	O
14	likely	O	O
15	to	O	O
16	have	O	O
17	convulsions	S-Disease	O
18	at	O	O
19	doses	O	O
20	that	O	O
21	did	O	O
22	not	O	O
23	first	O	O
24	cause	O	O
25	loss	B-Disease	O
26	of	I-Disease	O
27	consciousness	E-Disease	O
28	,	O	O
29	while	O	O
30	cats	O	O
31	most	O	O
32	clearly	O	O
33	showed	O	O
34	marked	O	O
35	central	O	O
36	excitatory	O	O
37	actions	O	O
38	.	O	O

0	Signs	O	O
1	of	O	O
2	FZP	S-Chemical	S-Chemical
3	toxocity	S-Disease	O
4	in	O	O
5	cats	O	O
6	included	O	O
7	excessive	O	O
8	salivation	S-Disease	S-Disease
9	,	O	O
10	extreme	O	O
11	apprehensive	O	O
12	behavior	O	O
13	,	O	O
14	retching	O	O
15	,	O	O
16	muscle	B-Disease	B-Disease
17	tremors	E-Disease	E-Disease
18	and	O	O
19	convulsions	S-Disease	O
20	.	O	O

0	An	O	O
1	interaction	O	O
2	between	O	O
3	FZP	S-Chemical	S-Chemical
4	and	O	O
5	pentylenetetrazol	S-Chemical	S-Chemical
6	(	O	O
7	PTZ	S-Chemical	S-Chemical
8	)	O	O
9	was	O	O
10	shown	O	O
11	by	O	O
12	pretreating	O	O
13	mice	O	O
14	with	O	O
15	FZP	S-Chemical	S-Chemical
16	before	O	O
17	PTZ	S-Chemical	S-Chemical
18	challenge	O	O
19	.	O	O

0	As	O	O
1	a	O	O
2	function	O	O
3	of	O	O
4	dose	O	O
5	,	O	O
6	FZP	S-Chemical	S-Chemical
7	first	O	O
8	protected	O	O
9	against	O	O
10	convulsions	S-Disease	O
11	and	O	O
12	death	O	O
13	.	O	O

0	At	O	O
1	higher	O	O
2	doses	O	O
3	,	O	O
4	however	O	O
5	,	O	O
6	convulsions	S-Disease	O
7	again	O	O
8	emerged	O	O
9	.	O	O

0	These	O	O
1	doses	O	O
2	of	O	O
3	FZP	S-Chemical	S-Chemical
4	were	O	O
5	lower	O	O
6	than	O	O
7	those	O	O
8	that	O	O
9	would	O	O
10	alone	O	O
11	cause	O	O
12	convulsions	S-Disease	S-Disease
13	.	O	O

0	These	O	O
1	results	O	O
2	may	O	O
3	be	O	O
4	relevant	O	O
5	to	O	O
6	the	O	O
7	use	O	O
8	of	O	O
9	FZP	S-Chemical	S-Chemical
10	in	O	O
11	clinical	O	O
12	situations	O	O
13	in	O	O
14	which	O	O
15	there	O	O
16	is	O	O
17	increased	O	O
18	neural	O	O
19	excitability	O	O
20	,	O	O
21	such	O	O
22	as	O	O
23	epilepsy	S-Disease	O
24	or	O	O
25	sedative	O	O
26	-	O	O
27	hypnotic	O	S-Disease
28	drug	O	O
29	withdrawal	O	O
30	.	O	O

0	Use	O	O
1	of	O	O
2	propranolol	S-Chemical	S-Chemical
3	in	O	O
4	the	O	O
5	treatment	O	O
6	of	O	O
7	idiopathic	B-Disease	B-Disease
8	orthostatic	I-Disease	O
9	hypotension	E-Disease	E-Disease
10	.	O	O

0	Five	O	O
1	patients	O	O
2	with	O	O
3	idiopathic	B-Disease	O
4	orthostatic	I-Disease	O
5	hypotension	E-Disease	S-Disease
6	who	O	O
7	had	O	O
8	physiologic	O	O
9	and	O	O
10	biochemical	O	O
11	evidence	O	O
12	of	O	O
13	severe	O	O
14	autonomic	O	O
15	dysfunction	O	S-Disease
16	were	O	O
17	included	O	O
18	in	O	O
19	the	O	O
20	study	O	O
21	.	O	O

0	They	O	O
1	all	O	O
2	exhibited	O	O
3	markedly	O	O
4	reduced	O	O
5	plasma	O	O
6	catecholamines	S-Chemical	S-Disease
7	and	O	O
8	plasma	O	O
9	renin	O	B-Disease
10	activity	O	E-Disease
11	in	O	O
12	both	O	O
13	recumbent	O	O
14	and	O	O
15	upright	O	O
16	positions	O	O
17	and	O	O
18	had	O	O
19	marked	O	O
20	hypersensitivity	S-Disease	O
21	to	O	O
22	the	O	O
23	pressor	O	O
24	effects	O	O
25	of	O	O
26	infused	O	O
27	norepinephrine	S-Chemical	S-Chemical
28	.	O	O

0	Treatment	O	O
1	with	O	O
2	propanolol	S-Chemical	S-Chemical
3	administered	O	O
4	intravenously	O	O
5	(	O	O
6	1	O	O
7	-	O	O
8	5	O	O
9	mg	O	O
10	)	O	O
11	produced	O	O
12	increases	O	O
13	in	O	O
14	supine	O	S-Chemical
15	and	O	O
16	upright	O	O
17	blood	O	O
18	pressure	O	O
19	in	O	O
20	4	O	O
21	of	O	O
22	the	O	O
23	5	O	O
24	individuals	O	O
25	with	O	O
26	rises	O	O
27	ranging	O	O
28	from	O	O
29	11	O	O
30	/	O	O
31	6	O	O
32	to	O	O
33	22	O	O
34	/	O	O
35	11	O	O
36	mmHg	O	O
37	.	O	O

0	Chronic	O	O
1	oral	O	O
2	administration	O	O
3	of	O	O
4	propranolol	S-Chemical	S-Chemical
5	(	O	O
6	40	O	O
7	-	O	O
8	160	O	O
9	mg	O	O
10	/	O	O
11	day	O	O
12	)	O	O
13	also	O	O
14	elevated	O	O
15	the	O	O
16	blood	O	O
17	pressures	O	O
18	of	O	O
19	these	O	O
20	individuals	O	O
21	with	O	O
22	increases	O	O
23	in	O	O
24	the	O	O
25	order	O	O
26	of	O	O
27	20	O	O
28	-	O	O
29	35	O	O
30	/	O	O
31	15	O	O
32	-	O	O
33	25	O	O
34	mmg	O	O
35	being	O	O
36	observed	O	O
37	.	O	O

0	In	O	O
1	1	O	O
2	patient	O	O
3	,	O	O
4	marked	O	O
5	hypertension	S-Disease	S-Disease
6	was	O	O
7	induced	O	O
8	by	O	O
9	propranolol	S-Chemical	S-Chemical
10	and	O	O
11	the	O	O
12	drug	O	O
13	had	O	O
14	to	O	O
15	be	O	O
16	withdrawn	O	O
17	.	O	O

0	Hemodynamic	O	O
1	measurements	O	O
2	in	O	O
3	1	O	O
4	of	O	O
5	the	O	O
6	patients	O	O
7	demonstrated	O	O
8	an	O	O
9	increase	O	O
10	in	O	O
11	total	O	O
12	peripheral	O	B-Disease
13	resistance	O	E-Disease
14	and	O	O
15	essentially	O	O
16	no	O	O
17	change	O	O
18	in	O	O
19	cardiac	O	B-Disease
20	output	O	E-Disease
21	following	O	O
22	propranolol	S-Chemical	S-Chemical
23	therapy	O	O
24	.	O	O

0	The	O	O
1	studies	O	O
2	suggest	O	O
3	that	O	O
4	propranolol	S-Chemical	S-Chemical
5	is	O	O
6	a	O	O
7	useful	O	O
8	drug	O	O
9	in	O	O
10	selected	O	O
11	patients	O	O
12	with	O	O
13	severe	O	O
14	idiopathic	B-Disease	S-Disease
15	orthostatic	I-Disease	I-Disease
16	hypotension	E-Disease	S-Disease
17	.	O	O

0	Total	O	O
1	intravenous	O	O
2	anesthesia	O	O
3	with	O	O
4	etomidate	S-Chemical	S-Chemical
5	.	O	O

0	An	O	O
1	investigation	O	O
2	was	O	O
3	undertaken	O	O
4	to	O	O
5	determine	O	O
6	the	O	O
7	dosage	O	O
8	of	O	O
9	etomidate	S-Chemical	S-Chemical
10	required	O	O
11	to	O	O
12	maintain	O	O
13	sleep	O	O
14	in	O	O
15	adults	O	O
16	undergoing	O	O
17	surgery	O	O
18	under	O	O
19	regional	O	O
20	local	O	O
21	anesthesia	O	O
22	.	O	O

0	Premedication	O	O
1	of	O	O
2	diazepam	S-Chemical	S-Chemical
3	10	O	O
4	mg	O	O
5	and	O	O
6	atropine	S-Chemical	S-Chemical
7	0	O	O
8	.	O	O
9	5	O	O
10	mg	O	O
11	was	O	O
12	given	O	O
13	,	O	O
14	and	O	O
15	sleep	O	O
16	was	O	O
17	induced	O	O
18	and	O	O
19	maintained	O	O
20	by	O	O
21	intermittent	O	O
22	intravenous	O	O
23	injections	O	O
24	of	O	O
25	etomidate	S-Chemical	S-Chemical
26	0	O	O
27	.	O	O
28	1	O	O
29	/	O	O
30	mg	O	O
31	/	O	O
32	kg	O	O
33	,	O	O
34	given	O	O
35	whenever	O	O
36	the	O	O
37	patient	O	O
38	would	O	O
39	open	O	O
40	his	O	O
41	eyes	O	O
42	on	O	O
43	request	O	O
44	.	O	O

0	A	O	O
1	mean	O	O
2	overall	O	O
3	dose	O	O
4	of	O	O
5	etomidate	S-Chemical	S-Chemical
6	17	O	O
7	.	O	O
8	4	O	O
9	microgram	O	O
10	/	O	O
11	kg	O	O
12	/	O	O
13	min	O	O
14	.	O	O
15	was	O	O
16	required	O	O
17	to	O	O
18	maintain	O	O
19	sleep	O	O
20	,	O	O
21	but	O	O
22	great	O	O
23	individual	O	O
24	variation	O	O
25	occurred	O	O
26	,	O	O
27	with	O	O
28	older	O	O
29	patients	O	O
30	requiring	O	O
31	less	O	O
32	drug	O	O
33	.	O	O

0	The	O	O
1	investigation	O	O
2	was	O	O
3	discontinued	O	O
4	after	O	O
5	18	O	O
6	patients	O	O
7	because	O	O
8	of	O	O
9	the	O	O
10	frequency	O	O
11	and	O	O
12	intensity	O	O
13	of	O	O
14	side	O	O
15	-	O	O
16	effects	O	O
17	,	O	O
18	particularly	O	O
19	pain	S-Disease	S-Disease
20	and	O	O
21	myoclonia	S-Disease	S-Disease
22	,	O	O
23	which	O	O
24	caused	O	O
25	the	O	O
26	technique	O	O
27	to	O	O
28	be	O	O
29	abandoned	O	O
30	in	O	O
31	two	O	O
32	cases	O	O
33	.	O	O

0	It	O	O
1	is	O	O
2	considered	O	O
3	unlikely	O	O
4	that	O	O
5	etomidate	S-Chemical	S-Chemical
6	will	O	O
7	prove	O	O
8	to	O	O
9	be	O	O
10	the	O	O
11	hypnotic	O	O
12	of	O	O
13	choice	O	O
14	for	O	O
15	a	O	O
16	totally	O	O
17	intravenous	O	O
18	anesthetic	O	O
19	technique	O	O
20	in	O	O
21	adults	O	O
22	because	O	O
23	of	O	O
24	the	O	O
25	high	O	O
26	incidence	O	O
27	of	O	O
28	myoclonia	S-Disease	S-Chemical
29	after	O	O
30	prolonged	O	O
31	administration	O	O
32	.	O	O

0	We	O	O
1	compared	O	O
2	the	O	O
3	effects	O	O
4	of	O	O
5	single	O	O
6	doses	O	O
7	of	O	O
8	50	O	O
9	mg	O	O
10	atenolol	S-Chemical	S-Chemical
11	(	O	O
12	cardioselective	O	S-Disease
13	)	O	O
14	,	O	O
15	40	O	O
16	mg	O	O
17	propranolol	S-Chemical	S-Chemical
18	(	O	O
19	nonselective	O	O
20	)	O	O
21	,	O	O
22	and	O	O
23	placebo	O	S-Disease
24	on	O	O
25	both	O	O
26	exercise	O	O
27	-	O	O
28	and	O	O
29	isoproterenol	S-Chemical	S-Chemical
30	-	O	O
31	induced	O	O
32	tachycardia	S-Disease	S-Disease
33	in	O	O
34	two	O	O
35	experiments	O	O
36	involving	O	O
37	nine	O	O
38	normal	O	O
39	subjects	O	O
40	.	O	O

0	Maximal	O	O
1	exercise	O	O
2	heart	O	S-Disease
3	rate	O	O
4	was	O	O
5	reduced	O	O
6	from	O	O
7	187	O	O
8	+	O	O
9	/	O	O
10	-	O	O
11	4	O	O
12	(	O	O
13	SEM	O	S-Disease
14	)	O	O
15	after	O	O
16	placebo	O	O
17	to	O	O
18	146	O	O
19	+	O	O
20	/	O	O
21	-	O	O
22	7	O	O
23	bpm	O	O
24	after	O	O
25	atenolol	S-Chemical	S-Chemical
26	and	O	O
27	138	O	O
28	+	O	O
29	/	O	O
30	-	O	O
31	6	O	O
32	bpm	O	O
33	after	O	O
34	propranolol	S-Chemical	S-Chemical
35	,	O	O
36	but	O	O
37	there	O	O
38	were	O	O
39	no	O	O
40	differences	O	O
41	between	O	O
42	the	O	O
43	drugs	O	O
44	.	O	O

0	The	O	O
1	effects	O	O
2	on	O	O
3	isoproterenol	S-Chemical	S-Chemical
4	tachycardia	S-Disease	S-Disease
5	were	O	O
6	determined	O	O
7	before	O	O
8	and	O	O
9	after	O	O
10	atropine	S-Chemical	S-Chemical
11	(	O	O
12	0	O	O
13	.	O	O
14	04	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	IV	O	O
19	)	O	O
20	.	O	O

0	Isoproterenol	S-Chemical	S-Chemical
1	sensitivity	O	O
2	was	O	O
3	determined	O	O
4	as	O	O
5	the	O	O
6	intravenous	O	O
7	dose	O	O
8	that	O	O
9	increased	O	O
10	heart	O	O
11	rate	O	O
12	by	O	O
13	25	O	O
14	bpm	O	O
15	(	O	O
16	CD25	O	S-Chemical
17	)	O	O
18	and	O	O
19	this	O	O
20	was	O	O
21	increased	O	O
22	from	O	O
23	1	O	O
24	.	O	O
25	8	O	O
26	+	O	O
27	/	O	O
28	-	O	O
29	0	O	O
30	.	O	O
31	3	O	O
32	micrograms	O	O
33	after	O	O
34	placebo	O	O
35	to	O	O
36	38	O	O
37	.	O	O
38	9	O	O
39	+	O	O
40	/	O	O
41	-	O	O
42	8	O	O
43	.	O	O
44	3	O	O
45	micrograms	O	O
46	after	O	O
47	propranolol	S-Chemical	S-Chemical
48	and	O	O
49	8	O	O
50	.	O	O
51	3	O	O
52	+	O	O
53	/	O	O
54	-	O	O
55	1	O	O
56	.	O	O
57	7	O	O
58	micrograms	O	O
59	after	O	O
60	atenolol	S-Chemical	S-Chemical
61	.	O	O

0	After	O	O
1	atropine	S-Chemical	O
2	the	O	O
3	CD25	O	S-Chemical
4	was	O	O
5	unchanged	O	O
6	after	O	O
7	placebo	O	O
8	(	O	O
9	2	O	O
10	.	O	O
11	3	O	O
12	+	O	O
13	/	O	O
14	-	O	O
15	0	O	O
16	.	O	O
17	3	O	O
18	micrograms	O	O
19	)	O	O
20	and	O	O
21	atenolol	S-Chemical	S-Chemical
22	(	O	O
23	7	O	O
24	.	O	O
25	7	O	O
26	+	O	O
27	/	O	O
28	-	O	O
29	1	O	O
30	.	O	O
31	3	O	O
32	micrograms	O	O
33	)	O	O
34	;	O	O
35	it	O	O
36	was	O	O
37	reduced	O	O
38	after	O	O
39	propranolol	S-Chemical	S-Chemical
40	(	O	O
41	24	O	O
42	.	O	O
43	8	O	O
44	+	O	O
45	/	O	O
46	-	O	O
47	5	O	O
48	.	O	O
49	0	O	O
50	micrograms	O	O
51	)	O	O
52	,	O	O
53	but	O	O
54	remained	O	O
55	different	O	O
56	from	O	O
57	atenolol	S-Chemical	S-Chemical
58	.	O	O

0	This	O	O
1	change	O	O
2	with	O	O
3	propranolol	S-Chemical	S-Chemical
4	sensitivity	O	O
5	was	O	O
6	calculated	O	O
7	as	O	O
8	the	O	O
9	apparent	O	O
10	Ka	O	S-Disease
11	,	O	O
12	this	O	O
13	was	O	O
14	unchanged	O	O
15	by	O	O
16	atropine	S-Chemical	S-Chemical
17	(	O	O
18	11	O	O
19	.	O	O
20	7	O	O
21	+	O	O
22	/	O	O
23	-	O	O
24	2	O	O
25	.	O	O
26	1	O	O
27	and	O	O
28	10	O	O
29	.	O	O
30	1	O	O
31	+	O	O
32	/	O	O
33	-	O	O
34	2	O	O
35	.	O	O
36	5	O	O
37	ml	O	O
38	/	O	O
39	ng	O	O
40	)	O	O
41	.	O	O

0	These	O	O
1	data	O	O
2	are	O	O
3	consistent	O	O
4	with	O	O
5	the	O	O
6	hypothesis	O	O
7	that	O	O
8	exercise	O	S-Disease
9	-	O	O
10	induced	O	O
11	tachycardia	S-Disease	S-Disease
12	results	O	O
13	largely	O	O
14	from	O	O
15	beta	O	B-Disease
16	1	O	O
17	-	O	O
18	receptor	O	O
19	activation	O	O
20	that	O	O
21	is	O	O
22	blocked	O	O
23	by	O	O
24	both	O	O
25	cardioselective	O	O
26	and	O	O
27	nonselective	O	O
28	drugs	O	O
29	,	O	O
30	whereas	O	O
31	isoproterenol	S-Chemical	S-Chemical
32	activates	O	O
33	both	O	O
34	beta	O	O
35	1	O	O
36	-	O	O
37	and	O	O
38	beta	O	O
39	2	O	O
40	-	O	O
41	receptors	O	O
42	so	O	O
43	that	O	O
44	after	O	O
45	cardioselective	O	O
46	blockade	O	O
47	there	O	O
48	remains	O	O
49	a	O	O
50	beta	O	O
51	2	O	O
52	-	O	O
53	component	O	O
54	that	O	O
55	can	O	O
56	be	O	O
57	blocked	O	O
58	with	O	O
59	a	O	O
60	nonselective	O	O
61	drug	O	O
62	.	O	O

0	Hormones	O	O
1	and	O	O
2	risk	O	O
3	of	O	O
4	breast	B-Disease	B-Disease
5	cancer	E-Disease	E-Disease
6	.	O	O

0	It	O	O
1	was	O	O
2	hypothesized	O	O
3	that	O	O
4	progestins	S-Chemical	S-Disease
5	could	O	O
6	equilibrate	O	O
7	the	O	O
8	effects	O	O
9	of	O	O
10	the	O	O
11	estrogenic	O	S-Disease
12	stimulation	O	O
13	on	O	O
14	the	O	O
15	mammary	O	O
16	and	O	O
17	endometrial	O	O
18	target	O	O
19	tissues	O	O
20	of	O	O
21	women	O	O
22	on	O	O
23	hormonal	O	O
24	replacement	O	O
25	therapy	O	O
26	.	O	O

0	The	O	O
1	treatment	O	O
2	schedule	O	O
3	consisted	O	O
4	of	O	O
5	conjugated	B-Chemical	O
6	estrogens	E-Chemical	S-Chemical
7	(	O	O
8	Premarin	S-Chemical	S-Chemical
9	)	O	O
10	1	O	O
11	.	O	O
12	25	O	O
13	mg	O	O
14	/	O	O
15	day	O	O
16	for	O	O
17	21	O	O
18	days	O	O
19	and	O	O
20	Medroxyprogesterone	B-Chemical	S-Chemical
21	acetate	E-Chemical	S-Chemical
22	10	O	O
23	mg	O	O
24	/	O	O
25	day	O	O
26	for	O	O
27	10	O	O
28	days	O	O
29	in	O	O
30	each	O	O
31	month	O	O
32	.	O	O

0	Mastodynia	S-Disease	S-Disease
1	was	O	O
2	reported	O	O
3	by	O	O
4	21	O	O
5	patients	O	O
6	,	O	O
7	and	O	O
8	physical	O	O
9	examination	O	O
10	revealed	O	O
11	a	O	O
12	light	O	O
13	increase	O	O
14	in	O	O
15	breast	O	B-Disease
16	firmness	O	E-Disease
17	in	O	O
18	12	O	O
19	women	O	O
20	and	O	O
21	a	O	O
22	moderate	O	O
23	increase	O	O
24	in	O	O
25	breast	O	B-Disease
26	nodularity	O	E-Disease
27	in	O	O
28	2	O	O
29	women	O	O
30	.	O	O

0	Themography	O	O
1	confirmed	O	O
2	the	O	O
3	existence	O	O
4	of	O	O
5	an	O	O
6	excessive	O	O
7	breast	O	B-Disease
8	stimulation	O	O
9	in	O	O
10	1	O	O
11	women	O	O
12	who	O	O
13	complained	O	O
14	of	O	O
15	moderate	O	O
16	mastodynia	S-Disease	S-Disease
17	and	O	O
18	in	O	O
19	5	O	O
20	of	O	O
21	the	O	O
22	7	O	O
23	women	O	O
24	who	O	O
25	complained	O	O
26	of	O	O
27	severe	O	O
28	mastodynia	S-Disease	S-Disease
29	.	O	O

0	Normalization	O	O
1	was	O	O
2	obtained	O	O
3	by	O	O
4	halving	O	O
5	the	O	O
6	estrogen	S-Chemical	S-Chemical
7	dose	O	O
8	.	O	O

0	Early	O	O
1	infections	S-Disease	O
2	in	O	O
3	kidney	O	O
4	,	O	O
5	heart	O	O
6	,	O	O
7	and	O	O
8	liver	O	O
9	transplant	O	E-Disease
10	recipients	O	O
11	on	O	O
12	cyclosporine	S-Chemical	S-Chemical
13	.	O	O

0	Eighty	O	O
1	-	O	O
2	one	O	O
3	renal	O	O
4	,	O	O
5	seventeen	O	O
6	heart	O	O
7	,	O	O
8	and	O	O
9	twenty	O	O
10	-	O	O
11	four	O	O
12	liver	O	B-Disease
13	transplant	O	E-Disease
14	patients	O	O
15	were	O	O
16	followed	O	O
17	for	O	O
18	infection	S-Disease	S-Disease
19	.	O	O

0	Seventeen	O	O
1	renal	O	O
2	patients	O	O
3	received	O	O
4	azathioprine	S-Chemical	S-Chemical
5	(	O	O
6	Aza	S-Chemical	S-Chemical
7	)	O	O
8	and	O	O
9	prednisone	S-Chemical	O
10	as	O	O
11	part	O	O
12	of	O	O
13	a	O	O
14	randomized	O	O
15	trial	O	O
16	of	O	O
17	immunosuppression	O	S-Disease
18	with	O	O
19	21	O	O
20	cyclosporine	S-Chemical	S-Chemical
21	-	O	O
22	and	O	O
23	-	O	O
24	prednisone	S-Chemical	O
25	-	O	O
26	treated	O	O
27	renal	O	B-Disease
28	transplant	O	E-Disease
29	patients	O	O
30	.	O	O

0	All	O	O
1	others	O	O
2	received	O	O
3	cyclosporine	S-Chemical	S-Chemical
4	and	O	O
5	prednisone	S-Chemical	O
6	.	O	O

0	The	O	O
1	randomized	O	O
2	Aza	S-Chemical	S-Chemical
3	patients	O	O
4	had	O	O
5	more	O	O
6	overall	O	O
7	infections	S-Disease	S-Disease
8	(	O	O
9	P	O	S-Disease
10	less	O	O
11	than	O	O
12	0	O	O
13	.	O	O
14	05	O	O
15	)	O	O
16	and	O	O
17	more	O	O
18	nonviral	O	O
19	infections	S-Disease	S-Disease
20	(	O	O
21	P	O	S-Disease
22	less	O	O
23	than	O	O
24	0	O	O
25	.	O	O
26	02	O	O
27	)	O	O
28	than	O	O
29	the	O	O
30	randomized	O	O
31	cyclosporine	S-Chemical	S-Chemical
32	patients	O	O
33	.	O	O

0	Heart	O	O
1	and	O	O
2	liver	O	O
3	patients	O	O
4	had	O	O
5	more	O	O
6	infections	S-Disease	O
7	than	O	O
8	cyclosporine	S-Chemical	S-Chemical
9	renal	O	I-Disease
10	patients	O	O
11	but	O	O
12	fewer	O	O
13	infections	S-Disease	S-Disease
14	than	O	O
15	the	O	O
16	Aza	S-Chemical	B-Disease
17	renal	O	E-Disease
18	patients	O	O
19	.	O	O

0	There	O	O
1	were	O	O
2	no	O	O
3	infectious	O	O
4	deaths	O	O
5	in	O	O
6	renal	O	O
7	transplant	O	E-Disease
8	patients	O	O
9	on	O	O
10	cyclosporine	S-Chemical	S-Chemical
11	or	O	O
12	Aza	S-Chemical	S-Chemical
13	,	O	O
14	but	O	O
15	infection	S-Disease	S-Disease
16	played	O	O
17	a	O	O
18	major	O	O
19	role	O	O
20	in	O	O
21	3	O	O
22	out	O	O
23	of	O	O
24	6	O	O
25	cardiac	O	B-Disease
26	transplant	O	E-Disease
27	deaths	O	O
28	and	O	O
29	in	O	O
30	8	O	O
31	out	O	O
32	of	O	O
33	9	O	O
34	liver	O	O
35	transplant	O	E-Disease
36	deaths	O	O
37	.	O	O

0	Renal	O	O
1	patients	O	O
2	on	O	O
3	cyclosporine	S-Chemical	S-Chemical
4	had	O	O
5	the	O	O
6	fewest	O	O
7	bacteremias	S-Disease	S-Disease
8	.	O	O

0	Analysis	O	O
1	of	O	O
2	site	O	O
3	of	O	O
4	infection	S-Disease	O
5	showed	O	O
6	a	O	O
7	preponderance	O	O
8	of	O	O
9	abdominal	B-Disease	B-Disease
10	infections	E-Disease	E-Disease
11	in	O	O
12	liver	O	O
13	patients	O	O
14	,	O	O
15	intrathoracic	O	O
16	infections	S-Disease	S-Disease
17	in	O	O
18	heart	O	S-Disease
19	patients	O	O
20	,	O	O
21	and	O	O
22	urinary	B-Disease	B-Disease
23	tract	I-Disease	I-Disease
24	infections	E-Disease	E-Disease
25	in	O	O
26	renal	O	O
27	patients	O	O
28	.	O	O

0	Pulmonary	O	O
1	infections	S-Disease	S-Disease
2	were	O	O
3	less	O	O
4	common	O	O
5	in	O	O
6	cyclosporine	S-Chemical	S-Chemical
7	-	O	O
8	treated	O	O
9	renal	O	S-Disease
10	patients	O	O
11	than	O	O
12	in	O	O
13	Aza	S-Chemical	S-Chemical
14	-	O	O
15	treated	O	O
16	patients	O	O
17	(	O	O
18	P	O	S-Disease
19	less	O	O
20	than	O	O
21	0	O	O
22	.	O	O
23	05	O	O
24	)	O	O
25	.	O	O

0	Aza	S-Chemical	S-Chemical
1	patients	O	O
2	had	O	O
3	significantly	O	O
4	more	O	O
5	staphylococcal	B-Disease	S-Disease
6	infections	E-Disease	S-Disease
7	than	O	O
8	all	O	O
9	other	O	O
10	transplant	O	O
11	groups	O	O
12	(	O	O
13	P	O	S-Disease
14	less	O	O
15	than	O	O
16	0	O	O
17	.	O	O
18	005	O	O
19	)	O	O
20	,	O	O
21	and	O	O
22	systemic	O	O
23	fungal	B-Disease	O
24	infections	E-Disease	S-Disease
25	occurred	O	O
26	only	O	O
27	in	O	O
28	the	O	O
29	liver	O	B-Disease
30	transplant	O	O
31	group	O	O
32	.	O	O

0	Cytomegalovirus	O	S-Chemical
1	(	O	O
2	CMV	O	S-Chemical
3	)	O	O
4	shedding	O	O
5	or	O	O
6	serological	O	O
7	rises	O	O
8	in	O	O
9	antibody	O	B-Disease
10	titer	O	E-Disease
11	,	O	O
12	or	O	O
13	both	O	O
14	occurred	O	O
15	in	O	O
16	78	O	O
17	%	O	O
18	of	O	O
19	cyclosporine	S-Chemical	S-Chemical
20	patients	O	O
21	and	O	O
22	76	O	O
23	%	O	O
24	of	O	O
25	Aza	S-Chemical	S-Chemical
26	patients	O	O
27	.	O	O

0	Of	O	O
1	the	O	O
2	cyclosporine	S-Chemical	S-Chemical
3	patients	O	O
4	,	O	O
5	15	O	O
6	%	O	O
7	had	O	O
8	symptoms	O	O
9	related	O	O
10	to	O	O
11	CMV	B-Disease	B-Disease
12	infection	E-Disease	E-Disease
13	.	O	O

0	Serological	O	O
1	evidence	O	O
2	for	O	O
3	Epstein	B-Disease	B-Chemical
4	Barr	I-Disease	I-Disease
5	Virus	I-Disease	I-Disease
6	infection	E-Disease	S-Disease
7	was	O	O
8	found	O	O
9	in	O	O
10	20	O	O
11	%	O	O
12	of	O	O
13	65	O	O
14	cyclosporine	S-Chemical	S-Chemical
15	patients	O	O
16	studied	O	O
17	.	O	O

0	Three	O	O
1	had	O	O
2	associated	O	O
3	symptoms	O	O
4	,	O	O
5	and	O	O
6	one	O	O
7	developed	O	O
8	a	O	O
9	lymphoma	S-Disease	S-Disease
10	.	O	O

0	Structure	O	O
1	-	O	O
2	activity	O	O
3	and	O	O
4	dose	O	O
5	-	O	O
6	effect	O	O
7	relationships	O	O
8	of	O	O
9	the	O	O
10	antagonism	O	O
11	of	O	O
12	picrotoxin	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	seizures	S-Disease	S-Disease
16	by	O	O
17	cholecystokinin	S-Chemical	S-Chemical
18	,	O	O
19	fragments	O	O
20	and	O	O
21	analogues	O	O
22	of	O	O
23	cholecystokinin	S-Chemical	S-Chemical
24	in	O	O
25	mice	O	O
26	.	O	O

0	Intraperitoneal	O	O
1	administration	O	O
2	of	O	O
3	cholecystokinin	B-Chemical	S-Chemical
4	octapeptide	E-Chemical	O
5	sulphate	O	E-Chemical
6	ester	O	O
7	(	O	O
8	CCK	B-Chemical	B-Chemical
9	-	I-Chemical	I-Chemical
10	8	E-Chemical	E-Chemical
11	-	O	O
12	SE	O	O
13	)	O	O
14	and	O	O
15	nonsulphated	O	O
16	cholecystokinin	B-Chemical	S-Chemical
17	octapeptide	E-Chemical	O
18	(	O	O
19	CCK	B-Chemical	S-Chemical
20	-	I-Chemical	O
21	8	E-Chemical	O
22	-	O	O
23	NS	O	O
24	)	O	O
25	enhanced	O	O
26	the	O	O
27	latency	O	O
28	of	O	O
29	seizures	S-Disease	S-Disease
30	induced	O	O
31	by	O	O
32	picrotoxin	S-Chemical	S-Chemical
33	in	O	O
34	mice	O	O
35	.	O	O

0	The	O	O
1	analogues	O	O
2	CCK	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	8	E-Chemical	E-Chemical
5	-	O	O
6	SE	O	O
7	and	O	O
8	CCK	B-Chemical	B-Chemical
9	-	I-Chemical	I-Chemical
10	8	E-Chemical	E-Chemical
11	-	O	O
12	NS	O	O
13	(	O	O
14	dose	O	O
15	range	O	O
16	0	O	O
17	.	O	O
18	2	O	O
19	-	O	O
20	6	O	O
21	.	O	O
22	4	O	O
23	mumol	O	S-Chemical
24	/	O	O
25	kg	O	O
26	)	O	O
27	and	O	O
28	caerulein	S-Chemical	S-Chemical
29	dose	O	O
30	range	O	O
31	0	O	O
32	.	O	O
33	1	O	O
34	-	O	O
35	0	O	O
36	.	O	O
37	8	O	O
38	mumol	O	S-Chemical
39	/	O	O
40	kg	O	O
41	)	O	O
42	showed	O	O
43	bell	O	O
44	-	O	O
45	shaped	O	O
46	dose	O	O
47	-	O	O
48	effect	O	O
49	curves	O	O
50	,	O	O
51	with	O	O
52	the	O	O
53	greatest	O	O
54	maximum	O	O
55	inhibition	O	O
56	for	O	O
57	CCK	B-Chemical	B-Chemical
58	-	I-Chemical	I-Chemical
59	8	E-Chemical	E-Chemical
60	-	O	I-Chemical
61	NS	O	E-Chemical
62	.	O	O

0	The	O	O
1	peptide	O	O
2	CCK	O	S-Disease
3	-	O	E-Chemical
4	5	O	E-Chemical
5	-	O	O
6	8	O	O
7	had	O	O
8	weak	O	O
9	anticonvulsant	O	O
10	activity	O	O
11	in	O	O
12	comparison	O	O
13	to	O	O
14	the	O	O
15	octapeptides	O	S-Chemical
16	,	O	O
17	3	O	O
18	.	O	O
19	2	O	O
20	mumol	O	S-Chemical
21	/	O	O
22	kg	O	O
23	and	O	O
24	larger	O	O
25	doses	O	O
26	of	O	O
27	the	O	O
28	reference	O	O
29	drug	O	O
30	,	O	O
31	diazepam	S-Chemical	S-Chemical
32	,	O	O
33	totally	O	O
34	prevented	O	O
35	picrotoxin	S-Chemical	S-Disease
36	-	O	O
37	induced	O	O
38	seizures	S-Disease	S-Disease
39	and	O	O
40	mortality	O	O
41	.	O	O

0	The	O	O
1	maximum	O	O
2	effect	O	O
3	of	O	O
4	the	O	O
5	peptides	O	O
6	tested	O	O
7	was	O	O
8	less	O	O
9	than	O	O
10	that	O	O
11	of	O	O
12	diazepam	S-Chemical	S-Chemical
13	.	O	O

0	Experiments	O	O
1	with	O	O
2	analogues	O	O
3	and	O	O
4	derivatives	O	O
5	of	O	O
6	CCK	O	B-Chemical
7	-	O	E-Chemical
8	5	O	E-Chemical
9	-	O	E-Chemical
10	8	O	O
11	demonstrated	O	O
12	that	O	O
13	the	O	O
14	effectiveness	O	O
15	of	O	O
16	the	O	O
17	beta	O	S-Chemical
18	-	O	O
19	alanyl	O	E-Chemical
20	derivatives	O	O
21	of	O	O
22	CCK	O	B-Chemical
23	-	O	E-Chemical
24	5	O	E-Chemical
25	-	O	I-Chemical
26	8	O	O
27	were	O	O
28	enhanced	O	O
29	and	O	O
30	that	O	O
31	they	O	O
32	were	O	O
33	equipotent	O	O
34	with	O	O
35	CCK	B-Chemical	B-Chemical
36	-	I-Chemical	I-Chemical
37	8	E-Chemical	E-Chemical
38	-	O	I-Chemical
39	SE	O	O
40	.	O	O

0	Of	O	O
1	the	O	O
2	CCK	O	B-Chemical
3	-	O	O
4	2	O	O
5	-	O	O
6	8	O	O
7	analogues	O	O
8	,	O	O
9	Ser	O	S-Chemical
10	(	O	O
11	SO3H	O	S-Chemical
12	)	O	O
13	7	O	S-Chemical
14	-	O	O
15	Ac	O	S-Chemical
16	-	O	O
17	CCK	O	E-Chemical
18	-	O	O
19	2	O	E-Chemical
20	-	O	O
21	8	O	O
22	-	O	O
23	SE	O	O
24	and	O	O
25	Thr	O	O
26	(	O	O
27	SO3H	O	S-Chemical
28	)	O	O
29	7	O	O
30	-	O	O
31	Ac	O	S-Chemical
32	-	O	O
33	CCK	O	S-Disease
34	-	O	O
35	2	O	O
36	-	O	O
37	8	O	O
38	-	O	O
39	SE	O	O
40	and	O	O
41	Hyp	O	S-Disease
42	(	O	O
43	SO3H	O	S-Chemical
44	)	O	O
45	-	O	O
46	Ac	O	B-Chemical
47	-	O	O
48	CCK	O	S-Disease
49	-	O	O
50	2	O	E-Chemical
51	-	O	O
52	8	O	E-Chemical
53	-	O	O
54	SE	O	O
55	were	O	O
56	slightly	O	O
57	more	O	O
58	active	O	O
59	than	O	O
60	CCK	B-Chemical	B-Chemical
61	-	I-Chemical	O
62	8	E-Chemical	E-Chemical
63	-	O	I-Chemical
64	SE	O	O
65	.	O	O

0	Vasopressin	S-Chemical	S-Chemical
1	as	O	O
2	a	O	O
3	possible	O	O
4	contributor	O	O
5	to	O	O
6	hypertension	S-Disease	S-Disease
7	.	O	O

0	The	O	O
1	role	O	O
2	of	O	O
3	vasopressin	S-Chemical	S-Chemical
4	as	O	O
5	a	O	O
6	pressor	O	O
7	agent	O	O
8	to	O	O
9	the	O	O
10	hypertensive	S-Disease	O
11	process	O	O
12	was	O	O
13	examined	O	O
14	.	O	O

0	Vasopressin	S-Chemical	S-Chemical
1	plays	O	O
2	a	O	O
3	major	O	O
4	role	O	O
5	in	O	O
6	the	O	O
7	pathogenesis	O	O
8	of	O	O
9	DOCA	S-Chemical	S-Chemical
10	-	O	O
11	salt	O	O
12	hypertension	S-Disease	S-Disease
13	,	O	O
14	since	O	O
15	the	O	O
16	elevation	O	O
17	of	O	O
18	blood	O	O
19	pressure	O	E-Disease
20	was	O	O
21	not	O	O
22	substantial	O	O
23	in	O	O
24	the	O	O
25	rats	O	O
26	with	O	O
27	lithium	S-Chemical	S-Chemical
28	-	O	O
29	treated	O	O
30	diabetes	B-Disease	B-Disease
31	insipidus	E-Disease	E-Disease
32	after	O	O
33	DOCA	S-Chemical	S-Chemical
34	-	O	O
35	salt	O	O
36	treatment	O	O
37	.	O	O

0	Administration	O	O
1	of	O	O
2	DDAVP	S-Chemical	S-Chemical
3	which	O	O
4	has	O	O
5	antidiuretic	O	O
6	action	O	O
7	but	O	O
8	minimal	O	O
9	vasopressor	O	S-Disease
10	effect	O	O
11	failed	O	O
12	to	O	O
13	increase	O	O
14	blood	O	O
15	pressure	O	O
16	to	O	O
17	the	O	O
18	levels	O	O
19	observed	O	O
20	after	O	O
21	administration	O	O
22	of	O	O
23	AVP	O	S-Chemical
24	.	O	O

0	Furthermore	O	O
1	,	O	O
2	the	O	O
3	pressor	O	O
4	action	O	O
5	of	O	O
6	vasopressin	S-Chemical	S-Chemical
7	appears	O	O
8	to	O	O
9	be	O	O
10	important	O	O
11	in	O	O
12	the	O	O
13	development	O	O
14	of	O	O
15	this	O	O
16	model	O	O
17	of	O	O
18	hypertension	S-Disease	S-Disease
19	,	O	O
20	since	O	O
21	the	O	O
22	enhanced	O	O
23	pressor	O	S-Disease
24	responsiveness	O	O
25	to	O	O
26	the	O	O
27	hormone	O	S-Disease
28	was	O	O
29	observed	O	O
30	in	O	O
31	the	O	O
32	initial	O	O
33	stage	O	O
34	of	O	O
35	hypertension	S-Disease	S-Disease
36	.	O	O

0	Increased	O	O
1	secretion	O	O
2	of	O	O
3	vasopressin	S-Chemical	S-Chemical
4	from	O	O
5	neurohypophysis	O	S-Disease
6	also	O	O
7	promotes	O	O
8	the	O	O
9	function	O	O
10	of	O	O
11	the	O	O
12	hormone	O	S-Disease
13	as	O	O
14	a	O	O
15	pathogenetic	O	O
16	factor	O	O
17	in	O	O
18	hypertension	S-Disease	S-Disease
19	.	O	O

0	An	O	O
1	unproportional	O	O
2	release	O	O
3	of	O	O
4	vasopressin	S-Chemical	S-Chemical
5	compared	O	O
6	to	O	O
7	plasma	O	O
8	osmolality	O	S-Disease
9	may	O	O
10	be	O	O
11	induced	O	O
12	by	O	O
13	the	O	O
14	absence	O	O
15	of	O	O
16	an	O	O
17	adjusting	O	O
18	control	O	O
19	of	O	O
20	angiotensin	S-Chemical	B-Disease
21	II	O	E-Disease
22	forming	O	O
23	and	O	O
24	receptor	O	O
25	binding	O	O
26	capacity	O	O
27	for	O	O
28	sodium	S-Chemical	B-Disease
29	balance	O	E-Disease
30	in	O	O
31	the	O	O
32	brain	O	O
33	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	role	O	O
4	of	O	O
5	vasopressin	S-Chemical	S-Chemical
6	remains	O	O
7	to	O	O
8	be	O	O
9	determined	O	O
10	in	O	O
11	human	O	O
12	essential	O	O
13	hypertension	S-Disease	S-Disease
14	.	O	O

0	Toxic	B-Disease	O
1	hepatitis	E-Disease	S-Disease
2	induced	O	O
3	by	O	O
4	disulfiram	S-Chemical	S-Chemical
5	in	O	O
6	a	O	O
7	non	O	O
8	-	O	O
9	alcoholic	O	O
10	.	O	O

0	A	O	O
1	reversible	O	O
2	toxic	B-Disease	B-Disease
3	liver	I-Disease	B-Disease
4	damage	E-Disease	E-Disease
5	was	O	O
6	observed	O	O
7	in	O	O
8	a	O	O
9	non	O	O
10	-	O	O
11	alcoholic	O	O
12	woman	O	O
13	treated	O	O
14	with	O	O
15	disulfiram	S-Chemical	S-Chemical
16	.	O	O

0	Atrial	B-Disease	O
1	thrombosis	E-Disease	E-Disease
2	involving	O	O
3	the	O	O
4	heart	O	O
5	of	O	O
6	F	O	B-Chemical
7	-	O	E-Chemical
8	344	O	O
9	rats	O	O
10	ingesting	O	O
11	quinacrine	B-Chemical	B-Chemical
12	hydrochloride	E-Chemical	E-Chemical
13	.	O	O

0	Quinacrine	B-Chemical	B-Chemical
1	hydrochloride	E-Chemical	E-Chemical
2	is	O	O
3	toxic	O	O
4	for	O	O
5	the	O	O
6	heart	O	O
7	of	O	O
8	F	O	B-Chemical
9	-	O	E-Chemical
10	344	O	O
11	rats	O	O
12	.	O	O

0	Rats	O	O
1	treated	O	O
2	with	O	O
3	500	O	O
4	ppm	O	O
5	quinacrine	B-Chemical	B-Chemical
6	hydrochloride	E-Chemical	E-Chemical
7	in	O	O
8	the	O	O
9	diet	O	O
10	all	O	O
11	developed	O	O
12	a	O	O
13	high	O	O
14	incidence	O	O
15	of	O	O
16	left	O	B-Disease
17	atrial	B-Disease	I-Disease
18	thrombosis	E-Disease	E-Disease
19	.	O	O

0	The	O	O
1	lesion	O	O
2	was	O	O
3	associated	O	O
4	with	O	O
5	cardiac	B-Disease	B-Disease
6	hypertrophy	E-Disease	E-Disease
7	and	O	O
8	dilatation	O	S-Disease
9	and	O	O
10	focal	O	O
11	myocardial	B-Disease	B-Disease
12	degeneration	E-Disease	E-Disease
13	.	O	O

0	Rats	O	O
1	died	O	O
2	from	O	O
3	cardiac	B-Disease	B-Disease
4	hypertrophy	E-Disease	E-Disease
5	with	O	O
6	severe	O	O
7	acute	O	B-Disease
8	and	O	O
9	chronic	O	B-Disease
10	congestion	O	I-Disease
11	of	O	I-Disease
12	the	O	I-Disease
13	lungs	O	E-Disease
14	,	O	O
15	liver	O	O
16	,	O	O
17	and	O	O
18	other	O	O
19	organs	O	O
20	.	O	O

0	Seventy	O	O
1	percent	O	O
2	of	O	O
3	rats	O	O
4	given	O	O
5	250	O	O
6	ppm	O	O
7	quinacrine	B-Chemical	B-Chemical
8	hydrochloride	E-Chemical	E-Chemical
9	and	O	O
10	1	O	O
11	,	O	O
12	000	O	O
13	ppm	O	O
14	sodium	B-Chemical	O
15	nitrite	E-Chemical	E-Chemical
16	simultaneously	O	O
17	in	O	O
18	the	O	O
19	diet	O	O
20	had	O	O
21	thrombosis	S-Disease	O
22	of	O	O
23	the	O	O
24	atria	O	S-Disease
25	of	O	O
26	the	O	O
27	heart	O	O
28	,	O	O
29	while	O	O
30	untreated	O	O
31	control	O	O
32	rats	O	O
33	in	O	O
34	this	O	O
35	laboratory	O	O
36	did	O	O
37	not	O	O
38	have	O	O
39	atrial	B-Disease	S-Disease
40	thrombosis	E-Disease	E-Disease
41	.	O	O

0	Sodium	B-Chemical	S-Chemical
1	nitrite	E-Chemical	E-Chemical
2	in	O	O
3	combination	O	O
4	with	O	O
5	quinacrine	B-Chemical	B-Chemical
6	hydrochloride	E-Chemical	E-Chemical
7	appeared	O	O
8	to	O	O
9	have	O	O
10	no	O	O
11	additional	O	O
12	effect	O	O
13	.	O	O

0	Alternating	B-Disease	O
1	sinus	I-Disease	S-Disease
2	rhythm	E-Disease	O
3	and	O	O
4	intermittent	O	O
5	sinoatrial	B-Disease	B-Disease
6	block	E-Disease	E-Disease
7	induced	O	O
8	by	O	O
9	propranolol	S-Chemical	S-Chemical
10	.	O	O

0	Alternating	B-Disease	O
1	sinus	I-Disease	S-Disease
2	rhythm	E-Disease	O
3	and	O	O
4	intermittent	O	O
5	sinoatrial	B-Disease	S-Disease
6	(	I-Disease	O
7	S	I-Disease	B-Chemical
8	-	I-Disease	I-Chemical
9	A	I-Disease	E-Chemical
10	)	I-Disease	O
11	block	E-Disease	O
12	was	O	O
13	observed	O	O
14	in	O	O
15	a	O	O
16	57	O	O
17	-	O	O
18	year	O	O
19	-	O	O
20	old	O	O
21	woman	O	O
22	,	O	O
23	under	O	O
24	treatment	O	O
25	for	O	O
26	angina	S-Disease	S-Disease
27	with	O	O
28	80	O	O
29	mg	O	O
30	propranolol	S-Chemical	S-Chemical
31	daily	O	O
32	.	O	O

0	Following	O	O
1	these	O	O
2	basic	O	O
3	sinus	O	O
4	cycles	O	O
5	,	O	O
6	alternating	B-Disease	O
7	rhythm	E-Disease	O
8	started	O	O
9	with	O	O
10	the	O	O
11	longer	O	O
12	P	O	O
13	-	O	O
14	P	O	O
15	interval	O	O
16	.	O	O

0	In	O	O
1	one	O	O
2	recording	O	O
3	a	O	O
4	short	O	O
5	period	O	O
6	of	O	O
7	regular	O	O
8	sinus	O	S-Disease
9	rhythm	O	O
10	with	O	O
11	intermittent	O	O
12	2	O	O
13	/	O	O
14	1	O	O
15	S	B-Disease	O
16	-	I-Disease	O
17	A	I-Disease	O
18	block	E-Disease	O
19	was	O	O
20	observed	O	O
21	.	O	O

0	Atropine	S-Chemical	S-Chemical
1	1	O	O
2	mg	O	O
3	given	O	O
4	intravenously	O	O
5	resulted	O	O
6	in	O	O
7	shortening	O	O
8	of	O	O
9	all	O	O
10	P	O	O
11	-	O	O
12	P	O	O
13	intervals	O	O
14	without	O	O
15	changing	O	O
16	the	O	O
17	rhythm	O	O
18	.	O	O

0	The	O	O
1	abnormal	O	O
2	rhythm	O	O
3	disappeared	O	O
4	with	O	O
5	the	O	O
6	withdrawal	O	O
7	of	O	O
8	propranolol	S-Chemical	S-Chemical
9	and	O	O
10	when	O	O
11	the	O	O
12	drug	O	O
13	was	O	O
14	restarted	O	O
15	a	O	O
16	2	O	O
17	/	O	O
18	1	O	O
19	S	B-Disease	O
20	-	I-Disease	O
21	A	I-Disease	O
22	block	E-Disease	O
23	was	O	O
24	seen	O	O
25	.	O	O

0	This	O	O
1	was	O	O
2	accepted	O	O
3	as	O	O
4	evidence	O	O
5	for	O	O
6	propranolol	S-Chemical	S-Chemical
7	being	O	O
8	the	O	O
9	cause	O	O
10	of	O	O
11	this	O	O
12	conduction	B-Disease	B-Disease
13	disorder	E-Disease	E-Disease
14	.	O	O

0	Antitumor	O	O
1	effect	O	O
2	,	O	O
3	cardiotoxicity	S-Disease	S-Disease
4	,	O	O
5	and	O	O
6	nephrotoxicity	S-Disease	S-Disease
7	of	O	O
8	doxorubicin	S-Chemical	S-Chemical
9	in	O	O
10	the	O	O
11	IgM	O	S-Chemical
12	solid	O	O
13	immunocytoma	S-Disease	O
14	-	O	O
15	bearing	O	O
16	LOU	O	S-Disease
17	/	O	O
18	M	O	O
19	/	O	O
20	WSL	O	O
21	rat	O	O
22	.	O	O

0	Antitumor	O	O
1	activity	O	O
2	,	O	O
3	cardiotoxicity	S-Disease	S-Disease
4	,	O	O
5	and	O	O
6	nephrotoxicity	S-Disease	S-Disease
7	induced	O	O
8	by	O	O
9	doxorubicin	S-Chemical	S-Chemical
10	were	O	O
11	studied	O	O
12	in	O	O
13	LOU	O	O
14	/	O	O
15	M	O	O
16	/	O	O
17	WSL	O	O
18	inbred	O	O
19	rats	O	O
20	each	O	O
21	bearing	O	O
22	a	O	O
23	transplantable	O	O
24	solid	O	O
25	IgM	O	S-Chemical
26	immunocytoma	S-Disease	O
27	.	O	O

0	Animals	O	O
1	with	O	O
2	a	O	O
3	tumor	S-Disease	S-Disease
4	(	O	O
5	diameter	O	O
6	,	O	O
7	15	O	O
8	.	O	O
9	8	O	O
10	+	O	O
11	/	O	O
12	-	O	O
13	3	O	O
14	.	O	O
15	3	O	O
16	mm	O	O
17	)	O	O
18	were	O	O
19	treated	O	O
20	with	O	O
21	iv	O	O
22	injections	O	O
23	of	O	O
24	doxorubicin	S-Chemical	S-Chemical
25	on	O	O
26	5	O	O
27	consecutive	O	O
28	days	O	O
29	,	O	O
30	followed	O	O
31	by	O	O
32	1	O	O
33	weekly	O	O
34	injection	O	O
35	for	O	O
36	7	O	O
37	weeks	O	O
38	(	O	O
39	dose	O	O
40	range	O	O
41	,	O	O
42	0	O	O
43	.	O	O
44	015	O	O
45	-	O	O
46	4	O	O
47	.	O	O
48	0	O	O
49	mg	O	O
50	/	O	O
51	kg	O	O
52	body	O	O
53	wt	O	O
54	)	O	O
55	.	O	O

0	Tumor	S-Disease	O
1	regression	O	O
2	was	O	O
3	observed	O	O
4	with	O	O
5	0	O	O
6	.	O	O
7	5	O	O
8	mg	O	O
9	doxorubicin	S-Chemical	S-Chemical
10	/	O	O
11	kg	O	O
12	.	O	O

0	Complete	O	O
1	disappearance	O	O
2	of	O	O
3	the	O	O
4	tumor	S-Disease	S-Disease
5	was	O	O
6	induced	O	O
7	with	O	O
8	1	O	O
9	.	O	O
10	0	O	O
11	mg	O	O
12	doxorubicin	S-Chemical	S-Chemical
13	/	O	O
14	kg	O	O
15	.	O	O

0	Histologic	O	O
1	evidence	O	O
2	of	O	O
3	cardiotoxicity	S-Disease	S-Disease
4	scored	O	O
5	as	O	O
6	grade	O	O
7	III	O	O
8	was	O	O
9	only	O	O
10	observed	O	O
11	at	O	O
12	a	O	O
13	dose	O	O
14	of	O	O
15	1	O	O
16	.	O	O
17	0	O	O
18	mg	O	O
19	doxorubicin	S-Chemical	S-Chemical
20	/	O	O
21	kg	O	O
22	.	O	O

0	Light	O	O
1	microscopic	O	O
2	evidence	O	O
3	of	O	O
4	renal	B-Disease	B-Disease
5	damage	E-Disease	E-Disease
6	was	O	O
7	seen	O	O
8	above	O	O
9	a	O	O
10	dose	O	O
11	of	O	O
12	0	O	O
13	.	O	O
14	5	O	O
15	mg	O	O
16	doxorubicin	S-Chemical	S-Chemical
17	/	O	O
18	kg	O	O
19	,	O	O
20	which	O	O
21	resulted	O	O
22	in	O	O
23	albuminuria	S-Disease	S-Chemical
24	and	O	O
25	very	O	O
26	low	O	O
27	serum	O	O
28	albumin	O	S-Chemical
29	levels	O	O
30	.	O	O

0	In	O	O
1	the	O	O
2	group	O	O
3	that	O	O
4	received	O	O
5	1	O	O
6	.	O	O
7	0	O	O
8	mg	O	O
9	doxorubicin	S-Chemical	S-Chemical
10	/	O	O
11	kg	O	O
12	,	O	O
13	the	O	O
14	serum	O	O
15	albumin	O	S-Chemical
16	level	O	O
17	decreased	O	O
18	from	O	O
19	33	O	O
20	.	O	O
21	6	O	O
22	+	O	O
23	/	O	O
24	-	O	O
25	4	O	O
26	.	O	O
27	1	O	O
28	to	O	O
29	1	O	O
30	.	O	O
31	5	O	O
32	+	O	O
33	/	O	O
34	-	O	O
35	0	O	O
36	.	O	O
37	5	O	O
38	g	O	O
39	/	O	O
40	liter	O	O
41	.	O	O

0	Ascites	S-Disease	O
1	and	O	O
2	hydrothorax	S-Disease	S-Disease
3	were	O	O
4	observed	O	O
5	simultaneously	O	O
6	.	O	O

0	The	O	O
1	same	O	O
2	experiments	O	O
3	were	O	O
4	performed	O	O
5	with	O	O
6	non	O	O
7	-	O	O
8	tumor	S-Disease	S-Disease
9	-	O	O
10	bearing	O	O
11	rats	O	O
12	,	O	O
13	in	O	O
14	which	O	O
15	no	O	O
16	major	O	O
17	differences	O	O
18	were	O	O
19	observed	O	O
20	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	antitumor	O	O
4	activity	O	O
5	,	O	O
6	cardiotoxicity	S-Disease	S-Disease
7	,	O	O
8	and	O	O
9	nephrotoxicity	S-Disease	S-Disease
10	were	O	O
11	studied	O	O
12	simultaneously	O	O
13	in	O	O
14	the	O	O
15	same	O	O
16	LOU	O	O
17	/	O	O
18	M	O	O
19	/	O	O
20	WSL	O	O
21	rat	O	O
22	.	O	O

0	Albuminuria	S-Disease	S-Chemical
1	due	O	O
2	to	O	O
3	renal	B-Disease	B-Disease
4	damage	E-Disease	E-Disease
5	led	O	O
6	to	O	O
7	extremely	O	O
8	low	O	O
9	serum	O	O
10	albumin	O	S-Chemical
11	levels	O	O
12	,	O	O
13	so	O	O
14	ascites	S-Disease	S-Disease
15	and	O	O
16	hydrothorax	S-Disease	S-Disease
17	were	O	O
18	not	O	O
19	necessarily	O	O
20	a	O	O
21	consequence	O	O
22	of	O	O
23	the	O	O
24	observed	O	O
25	cardiomyopathy	S-Disease	S-Disease
26	.	O	O

0	Intraoperative	O	O
1	bradycardia	S-Disease	O
2	and	O	O
3	hypotension	S-Disease	S-Disease
4	associated	O	O
5	with	O	O
6	timolol	S-Chemical	S-Chemical
7	and	O	O
8	pilocarpine	S-Chemical	S-Chemical
9	eye	O	O
10	drops	O	E-Disease
11	.	O	O

0	A	O	O
1	69	O	O
2	-	O	O
3	yr	O	O
4	-	O	O
5	old	O	O
6	man	O	O
7	,	O	O
8	who	O	O
9	was	O	O
10	concurrently	O	O
11	being	O	O
12	treated	O	O
13	with	O	O
14	pilocarpine	B-Chemical	S-Chemical
15	nitrate	E-Chemical	O
16	and	O	O
17	timolol	B-Chemical	S-Chemical
18	maleate	E-Chemical	E-Chemical
19	eye	O	O
20	drops	O	O
21	,	O	O
22	developed	O	O
23	a	O	O
24	bradycardia	S-Disease	O
25	and	O	O
26	became	O	O
27	hypotensive	S-Disease	O
28	during	O	O
29	halothane	S-Chemical	S-Chemical
30	anaesthesia	O	O
31	.	O	O

0	Both	O	O
1	timolol	S-Chemical	S-Chemical
2	and	O	O
3	pilocarpine	S-Chemical	S-Chemical
4	were	O	O
5	subsequently	O	O
6	identified	O	O
7	in	O	O
8	a	O	O
9	24	O	O
10	-	O	O
11	h	O	O
12	collection	O	O
13	of	O	O
14	urine	O	O
15	.	O	O

0	Timolol	S-Chemical	S-Chemical
1	(	O	O
2	but	O	O
3	not	O	O
4	pilocarpine	S-Chemical	S-Chemical
5	)	O	O
6	was	O	O
7	detected	O	O
8	in	O	O
9	a	O	O
10	sample	O	O
11	of	O	O
12	plasma	O	O
13	removed	O	O
14	during	O	O
15	surgery	O	O
16	;	O	O
17	the	O	O
18	plasma	O	O
19	concentration	O	O
20	of	O	O
21	timolol	S-Chemical	S-Chemical
22	(	O	O
23	2	O	O
24	.	O	O
25	6	O	O
26	ng	O	O
27	ml	O	O
28	-	O	O
29	1	O	O
30	)	O	O
31	was	O	O
32	consistent	O	O
33	with	O	O
34	partial	O	O
35	beta	O	O
36	-	O	O
37	adrenoceptor	O	S-Chemical
38	blockade	O	O
39	.	O	O

0	It	O	O
1	is	O	O
2	postulated	O	O
3	that	O	O
4	this	O	O
5	action	O	O
6	may	O	O
7	have	O	O
8	been	O	O
9	enhanced	O	O
10	during	O	O
11	halothane	S-Chemical	B-Disease
12	anaesthesia	O	E-Disease
13	with	O	O
14	resultant	O	O
15	bradycardia	S-Disease	O
16	and	O	O
17	hypotension	S-Disease	S-Disease
18	.	O	O

0	Pilocarpine	S-Chemical	S-Chemical
1	may	O	O
2	have	O	O
3	had	O	O
4	a	O	O
5	contributory	O	O
6	effect	O	O
7	.	O	O

0	Succinylcholine	S-Chemical	B-Chemical
1	apnoea	S-Disease	E-Chemical
2	:	O	O
3	attempted	O	O
4	reversal	O	O
5	with	O	O
6	anticholinesterases	O	O
7	.	O	O

0	Anticholinesterases	O	O
1	were	O	O
2	administered	O	O
3	in	O	O
4	an	O	O
5	attempt	O	O
6	to	O	O
7	antagonize	O	O
8	prolonged	O	O
9	neuromuscular	B-Disease	S-Disease
10	blockade	E-Disease	O
11	following	O	O
12	the	O	O
13	administration	O	O
14	of	O	O
15	succinylcholine	S-Chemical	S-Chemical
16	in	O	O
17	a	O	O
18	patient	O	O
19	later	O	O
20	found	O	O
21	to	O	O
22	be	O	O
23	homozygous	O	O
24	for	O	O
25	atypical	O	O
26	plasma	O	O
27	cholinesterase	O	S-Chemical
28	.	O	O

0	Edrophonium	S-Chemical	S-Chemical
1	10	O	O
2	mg	O	O
3	,	O	O
4	given	O	O
5	74	O	O
6	min	O	O
7	after	O	O
8	succinylcholine	S-Chemical	S-Chemical
9	,	O	O
10	when	O	O
11	train	O	O
12	-	O	O
13	of	O	O
14	-	O	O
15	four	O	O
16	stimulation	O	O
17	was	O	O
18	characteristic	O	O
19	of	O	O
20	phase	O	O
21	II	O	O
22	block	O	O
23	,	O	O
24	produced	O	O
25	partial	O	O
26	antagonism	O	O
27	which	O	O
28	was	O	O
29	not	O	O
30	sustained	O	O
31	.	O	O

0	Repeated	O	O
1	doses	O	O
2	of	O	O
3	edrophonium	S-Chemical	S-Chemical
4	to	O	O
5	70	O	O
6	mg	O	O
7	and	O	O
8	neostigmine	S-Chemical	S-Chemical
9	to	O	O
10	2	O	O
11	.	O	O
12	5	O	O
13	mg	O	O
14	did	O	O
15	not	O	O
16	antagonize	O	O
17	or	O	O
18	augment	O	O
19	the	O	O
20	block	O	O
21	.	O	O

0	Spontaneous	O	O
1	respiration	O	O
2	recommenced	O	O
3	200	O	O
4	min	O	O
5	after	O	O
6	succinylcholine	S-Chemical	S-Chemical
7	administration	O	O
8	.	O	O

0	It	O	O
1	is	O	O
2	concluded	O	O
3	that	O	O
4	anticholinesterases	O	O
5	are	O	O
6	only	O	O
7	partially	O	O
8	effective	O	O
9	in	O	O
10	restoring	O	O
11	neuromuscular	O	B-Disease
12	function	O	E-Disease
13	in	O	O
14	succinylcholine	S-Chemical	S-Chemical
15	apnoea	S-Disease	E-Chemical
16	despite	O	O
17	muscle	O	B-Disease
18	twitch	O	I-Disease
19	activity	O	S-Disease
20	typical	O	O
21	of	O	O
22	phase	O	O
23	II	O	O
24	block	O	O
25	.	O	O

0	Effect	O	O
1	of	O	O
2	doxorubicin	S-Chemical	S-Chemical
3	on	O	O
4	[	B-Chemical	O
5	omega	I-Chemical	B-Chemical
6	-	I-Chemical	I-Chemical
7	I	I-Chemical	E-Chemical
8	-	I-Chemical	I-Chemical
9	131	I-Chemical	E-Chemical
10	]	I-Chemical	O
11	heptadecanoic	I-Chemical	S-Chemical
12	acid	E-Chemical	O
13	myocardial	O	B-Disease
14	scintigraphy	O	E-Disease
15	and	O	O
16	echocardiography	O	O
17	in	O	O
18	dogs	O	O
19	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	serial	O	O
4	treatment	O	O
5	with	O	O
6	doxorubicin	S-Chemical	S-Chemical
7	on	O	O
8	dynamic	O	O
9	myocardial	O	B-Disease
10	scintigraphy	O	E-Disease
11	with	O	O
12	[	B-Chemical	O
13	omega	I-Chemical	S-Chemical
14	-	I-Chemical	I-Disease
15	I	I-Chemical	E-Chemical
16	-	I-Chemical	I-Chemical
17	131	I-Chemical	E-Chemical
18	]	I-Chemical	O
19	heptadecanoic	I-Chemical	S-Chemical
20	acid	E-Chemical	E-Disease
21	(	O	O
22	I	B-Chemical	S-Disease
23	-	I-Chemical	O
24	131	I-Chemical	O
25	HA	E-Chemical	O
26	)	O	O
27	,	O	O
28	and	O	O
29	on	O	O
30	global	O	O
31	left	O	O
32	-	O	O
33	ventricular	O	S-Disease
34	function	O	O
35	determined	O	O
36	echocardiographically	O	O
37	,	O	O
38	were	O	O
39	studied	O	O
40	in	O	O
41	a	O	O
42	group	O	O
43	of	O	O
44	nine	O	O
45	mongrel	O	O
46	dogs	O	O
47	.	O	O

0	Total	O	O
1	extractable	O	O
2	myocardial	O	B-Disease
3	lipid	O	E-Disease
4	was	O	O
5	compared	O	O
6	postmortem	O	O
7	between	O	O
8	a	O	O
9	group	O	O
10	of	O	O
11	control	O	O
12	dogs	O	O
13	and	O	O
14	doxorubicin	S-Chemical	S-Chemical
15	-	O	O
16	treated	O	O
17	dogs	O	O
18	.	O	O

0	A	O	O
1	significant	O	O
2	and	O	O
3	then	O	O
4	progressive	O	O
5	fall	O	O
6	in	O	O
7	global	O	O
8	LV	O	S-Disease
9	function	O	O
10	was	O	O
11	observed	O	O
12	at	O	O
13	a	O	O
14	cumulative	O	O
15	doxorubicin	S-Chemical	S-Chemical
16	dose	O	O
17	of	O	O
18	4	O	O
19	mg	O	O
20	/	O	O
21	kg	O	O
22	.	O	O

0	A	O	O
1	significant	O	O
2	increase	O	O
3	in	O	O
4	the	O	O
5	myocardial	O	B-Disease
6	t1	O	E-Disease
7	/	O	O
8	2	O	O
9	of	O	O
10	the	O	O
11	I	B-Chemical	B-Chemical
12	-	I-Chemical	I-Chemical
13	131	I-Chemical	O
14	HA	E-Chemical	O
15	was	O	O
16	observed	O	O
17	only	O	O
18	at	O	O
19	a	O	O
20	higher	O	O
21	cumulative	O	O
22	dose	O	O
23	,	O	O
24	10	O	O
25	mg	O	O
26	/	O	O
27	kg	O	O
28	.	O	O

0	No	O	O
1	significant	O	O
2	alteration	O	O
3	in	O	O
4	total	O	O
5	extractable	O	O
6	myocardial	O	B-Disease
7	lipids	O	E-Disease
8	was	O	O
9	observed	O	O
10	between	O	O
11	control	O	O
12	dogs	O	O
13	and	O	O
14	those	O	O
15	treated	O	O
16	with	O	O
17	doxorubicin	S-Chemical	S-Chemical
18	.	O	O

0	Our	O	O
1	findings	O	O
2	suggest	O	O
3	that	O	O
4	the	O	O
5	changes	O	O
6	leading	O	O
7	to	O	O
8	an	O	O
9	alteration	O	O
10	of	O	O
11	myocardial	O	S-Disease
12	dynamic	O	O
13	imaging	O	O
14	with	O	O
15	I	B-Chemical	B-Chemical
16	-	I-Chemical	E-Chemical
17	131	I-Chemical	O
18	HA	E-Chemical	O
19	are	O	O
20	not	O	O
21	the	O	O
22	initiating	O	O
23	factor	O	O
24	in	O	O
25	doxorubicin	S-Chemical	S-Chemical
26	cardiotoxicity	S-Disease	S-Disease
27	.	O	O

0	Hemodynamics	O	O
1	and	O	O
2	myocardial	O	B-Disease
3	metabolism	O	E-Disease
4	under	O	O
5	deliberate	O	O
6	hypotension	S-Disease	S-Disease
7	.	O	O

0	Coronary	O	O
1	blood	O	I-Disease
2	flow	O	O
3	,	O	O
4	cardiac	O	S-Disease
5	work	O	O
6	and	O	O
7	metabolism	O	O
8	were	O	O
9	studied	O	O
10	in	O	O
11	dogs	O	O
12	under	O	O
13	sodium	B-Chemical	B-Chemical
14	nitroprusside	E-Chemical	E-Chemical
15	(	O	O
16	SNP	S-Chemical	S-Disease
17	)	O	O
18	and	O	O
19	trimetaphan	S-Chemical	S-Chemical
20	(	O	O
21	TMP	S-Chemical	S-Disease
22	)	O	O
23	deliberate	O	O
24	hypotension	S-Disease	S-Disease
25	(	O	O
26	20	O	O
27	%	O	O
28	and	O	O
29	40	O	O
30	%	O	O
31	mean	O	O
32	pressure	O	O
33	decrease	O	O
34	from	O	O
35	baseline	O	O
36	)	O	O
37	.	O	O

0	Regarding	O	O
1	the	O	O
2	effects	O	O
3	of	O	O
4	drug	O	O
5	-	O	O
6	induced	O	O
7	hypotension	S-Disease	S-Disease
8	on	O	O
9	coronary	O	B-Disease
10	blood	O	I-Disease
11	flow	O	E-Disease
12	,	O	O
13	aortic	O	S-Disease
14	and	O	O
15	coronary	O	B-Disease
16	sinus	O	I-Disease
17	metabolic	O	E-Disease
18	data	O	O
19	(	O	O
20	pH	O	O
21	,	O	O
22	pO2	O	S-Disease
23	,	O	O
24	pCO2	O	S-Disease
25	)	O	O
26	we	O	O
27	could	O	O
28	confirm	O	O
29	that	O	O
30	nitroprusside	S-Chemical	S-Chemical
31	hypotension	S-Disease	S-Disease
32	could	O	O
33	be	O	O
34	safely	O	O
35	used	O	O
36	to	O	O
37	30	O	O
38	%	O	O
39	mean	O	O
40	blood	O	O
41	pressure	O	O
42	decrease	O	O
43	from	O	O
44	control	O	O
45	,	O	O
46	trimetaphan	S-Chemical	S-Chemical
47	hypotension	S-Disease	S-Disease
48	to	O	O
49	20	O	O
50	%	O	O
51	mean	O	O
52	blood	O	O
53	pressure	O	O
54	decrease	O	O
55	.	O	O

0	Cardiac	O	O
1	work	O	O
2	was	O	O
3	significantly	O	O
4	reduced	O	O
5	during	O	O
6	SNP	S-Chemical	S-Chemical
7	hypotension	S-Disease	S-Disease
8	.	O	O

0	Myocardial	O	B-Disease
1	O2	S-Chemical	B-Chemical
2	consumption	O	E-Disease
3	and	O	O
4	O2	S-Chemical	B-Chemical
5	availability	O	O
6	were	O	O
7	directly	O	O
8	dependent	O	O
9	on	O	O
10	the	O	O
11	coronary	O	B-Disease
12	perfusion	O	E-Disease
13	.	O	O

0	Evidence	O	O
1	for	O	O
2	a	O	O
3	selective	O	O
4	brain	O	O
5	noradrenergic	O	E-Disease
6	involvement	O	O
7	in	O	O
8	the	O	O
9	locomotor	O	B-Disease
10	stimulant	O	O
11	effects	O	O
12	of	O	O
13	amphetamine	S-Chemical	S-Chemical
14	in	O	O
15	the	O	O
16	rat	O	O
17	.	O	O

0	Male	O	O
1	rats	O	O
2	received	O	O
3	the	O	O
4	noradrenaline	S-Chemical	S-Disease
5	neurotoxin	O	S-Disease
6	DSP4	S-Chemical	S-Chemical
7	(	O	O
8	50	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	)	O	O
13	7	O	O
14	days	O	O
15	prior	O	O
16	to	O	O
17	injection	O	O
18	of	O	O
19	D	B-Chemical	S-Chemical
20	-	I-Chemical	I-Chemical
21	amphetamine	E-Chemical	E-Chemical
22	(	O	O
23	10	O	O
24	or	O	O
25	40	O	O
26	mumol	O	S-Disease
27	/	O	O
28	kg	O	O
29	i	O	O
30	.	O	O
31	p	O	O
32	.	O	O
33	)	O	O
34	.	O	O

0	The	O	O
1	hyperactivity	S-Disease	S-Disease
2	induced	O	O
3	by	O	O
4	D	B-Chemical	S-Chemical
5	-	I-Chemical	I-Chemical
6	amphetamine	E-Chemical	E-Chemical
7	(	O	O
8	10	O	O
9	mumol	O	S-Chemical
10	/	O	O
11	kg	O	O
12	)	O	O
13	was	O	O
14	significantly	O	O
15	reduced	O	O
16	by	O	O
17	DSP4	S-Chemical	S-Chemical
18	pretreatment	O	O
19	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	increased	O	O
4	rearings	O	O
5	and	O	O
6	the	O	O
7	amphetamine	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	stereotypies	S-Disease	S-Disease
11	were	O	O
12	not	O	O
13	blocked	O	O
14	by	O	O
15	pretreatment	O	O
16	with	O	O
17	DSP4	S-Chemical	S-Chemical
18	.	O	O

0	The	O	O
1	reduction	O	O
2	of	O	O
3	amphetamine	S-Chemical	S-Chemical
4	hyperactivity	S-Disease	S-Disease
5	induced	O	O
6	by	O	O
7	DSP4	S-Chemical	S-Chemical
8	was	O	O
9	blocked	O	O
10	by	O	O
11	pretreatment	O	O
12	with	O	O
13	the	O	O
14	noradrenaline	S-Chemical	S-Chemical
15	-	O	O
16	uptake	O	O
17	blocking	O	O
18	agent	O	O
19	,	O	O
20	desipramine	S-Chemical	S-Chemical
21	,	O	O
22	which	O	O
23	prevents	O	O
24	the	O	O
25	neurotoxic	S-Disease	O
26	action	O	O
27	of	O	O
28	DSP4	S-Chemical	S-Chemical
29	.	O	O

0	The	O	O
1	present	O	O
2	results	O	O
3	suggest	O	O
4	a	O	O
5	selective	O	O
6	involvement	O	O
7	of	O	O
8	central	O	O
9	noradrenergic	O	I-Disease
10	neurones	O	E-Disease
11	in	O	O
12	the	O	O
13	locomotor	O	B-Disease
14	stimulant	O	O
15	effect	O	O
16	of	O	O
17	amphetamine	S-Chemical	S-Chemical
18	in	O	O
19	the	O	O
20	rat	O	O
21	.	O	O

0	Accelerated	B-Disease	O
1	junctional	I-Disease	O
2	rhythms	E-Disease	O
3	during	O	O
4	oral	O	O
5	verapamil	S-Chemical	S-Disease
6	therapy	O	O
7	.	O	O

0	This	O	O
1	study	O	O
2	examined	O	O
3	the	O	O
4	frequency	O	O
5	of	O	O
6	atrioventricular	O	S-Disease
7	(	O	O
8	AV	O	S-Disease
9	)	O	O
10	dissociation	O	O
11	and	O	O
12	accelerated	B-Disease	O
13	junctional	I-Disease	O
14	rhythms	E-Disease	O
15	in	O	O
16	59	O	O
17	patients	O	O
18	receiving	O	O
19	oral	O	O
20	verapamil	S-Chemical	S-Disease
21	.	O	O

0	Accelerated	B-Disease	O
1	junctional	I-Disease	O
2	rhythms	E-Disease	O
3	and	O	O
4	AV	O	S-Chemical
5	dissociation	O	O
6	were	O	O
7	frequent	O	O
8	in	O	O
9	patients	O	O
10	with	O	O
11	supraventricular	B-Disease	O
12	tachyarrhythmias	E-Disease	E-Disease
13	,	O	O
14	particularly	O	O
15	AV	O	S-Chemical
16	nodal	O	O
17	reentry	O	O
18	.	O	O

0	Verapamil	S-Chemical	S-Chemical
1	administration	O	O
2	to	O	O
3	these	O	O
4	patients	O	O
5	led	O	O
6	to	O	O
7	an	O	O
8	asymptomatic	O	O
9	increase	O	B-Disease
10	in	O	O
11	activity	O	E-Disease
12	of	O	O
13	these	O	O
14	junctional	O	B-Disease
15	pacemakers	O	E-Disease
16	.	O	O

0	In	O	O
1	patients	O	O
2	with	O	O
3	various	O	O
4	chest	B-Disease	B-Disease
5	pain	E-Disease	I-Disease
6	syndromes	O	E-Disease
7	,	O	O
8	verapamil	S-Chemical	S-Chemical
9	neither	O	O
10	increased	O	O
11	the	O	O
12	frequency	O	O
13	of	O	O
14	junctional	O	O
15	rhythms	O	O
16	nor	O	O
17	suppressed	O	O
18	their	O	O
19	role	O	O
20	as	O	O
21	escape	O	O
22	rhythms	O	O
23	under	O	O
24	physiologically	O	O
25	appropriate	O	O
26	circumstances	O	O
27	.	O	O

0	Interstrain	O	O
1	variation	O	O
2	in	O	O
3	acute	O	B-Disease
4	toxic	O	E-Disease
5	response	O	O
6	to	O	O
7	caffeine	S-Chemical	S-Chemical
8	among	O	O
9	inbred	O	O
10	mice	O	O
11	.	O	O

0	Acute	O	O
1	toxic	O	O
2	dosage	O	O
3	-	O	O
4	dependent	O	O
5	behavioral	O	O
6	effects	O	O
7	of	O	O
8	caffeine	S-Chemical	S-Chemical
9	were	O	O
10	compared	O	O
11	in	O	O
12	adult	O	O
13	males	O	O
14	from	O	O
15	seven	O	O
16	inbred	O	O
17	mouse	O	O
18	strains	O	O
19	(	O	O
20	A	O	S-Disease
21	/	O	O
22	J	O	O
23	,	O	O
24	BALB	O	O
25	/	O	O
26	cJ	O	E-Chemical
27	,	O	O
28	CBA	O	S-Disease
29	/	O	O
30	J	O	O
31	,	O	O
32	C3H	O	B-Chemical
33	/	O	O
34	HeJ	O	E-Chemical
35	,	O	O
36	C57BL	O	B-Chemical
37	/	O	O
38	6J	O	O
39	,	O	O
40	DBA	O	S-Disease
41	/	O	I-Disease
42	2J	O	E-Chemical
43	,	O	O
44	SWR	O	S-Disease
45	/	O	O
46	J	O	O
47	)	O	O
48	.	O	O

0	C57BL	O	S-Chemical
1	/	O	O
2	6J	O	O
3	,	O	O
4	chosen	O	O
5	as	O	O
6	a	O	O
7	"	O	O
8	prototypic	O	O
9	"	O	O
10	mouse	O	O
11	strain	O	O
12	,	O	O
13	was	O	O
14	used	O	O
15	to	O	O
16	determine	O	O
17	behavioral	O	O
18	responses	O	O
19	to	O	O
20	a	O	O
21	broad	O	O
22	range	O	O
23	(	O	O
24	5	O	O
25	-	O	O
26	500	O	O
27	mg	O	O
28	/	O	O
29	kg	O	O
30	)	O	O
31	of	O	O
32	caffeine	S-Chemical	S-Chemical
33	doses	O	O
34	.	O	O

0	Five	O	O
1	phenotypic	O	O
2	characteristics	O	O
3	-	O	O
4	-	O	O
5	locomotor	O	S-Disease
6	activity	O	E-Disease
7	,	O	O
8	righting	O	O
9	ability	O	O
10	,	O	O
11	clonic	B-Disease	B-Disease
12	seizure	E-Disease	E-Disease
13	induction	O	O
14	,	O	O
15	stress	O	O
16	-	O	O
17	induced	O	O
18	lethality	O	S-Disease
19	,	O	O
20	death	O	S-Disease
21	without	O	O
22	external	O	O
23	stress	O	S-Disease
24	-	O	O
25	-	O	O
26	were	O	O
27	scored	O	O
28	at	O	O
29	various	O	O
30	caffeine	S-Chemical	S-Chemical
31	doses	O	O
32	in	O	O
33	drug	O	O
34	-	O	O
35	naive	O	O
36	animals	O	O
37	under	O	O
38	empirically	O	O
39	optimized	O	O
40	,	O	O
41	rigidly	O	O
42	constant	O	O
43	experimental	O	O
44	conditions	O	O
45	.	O	O

0	Mice	O	O
1	(	O	O
2	n	O	O
3	=	O	O
4	12	O	O
5	for	O	O
6	each	O	O
7	point	O	O
8	)	O	O
9	received	O	O
10	single	O	O
11	IP	O	O
12	injections	O	O
13	of	O	O
14	a	O	O
15	fixed	O	O
16	volume	O	O
17	/	O	O
18	g	O	O
19	body	O	O
20	weight	O	O
21	of	O	O
22	physiological	O	O
23	saline	O	S-Disease
24	carrier	O	O
25	with	O	O
26	or	O	O
27	without	O	O
28	caffeine	S-Chemical	S-Chemical
29	in	O	O
30	doses	O	O
31	ranging	O	O
32	from	O	O
33	125	O	O
34	-	O	O
35	500	O	O
36	mg	O	O
37	/	O	O
38	kg	O	O
39	.	O	O

0	In	O	O
1	the	O	O
2	same	O	O
3	animals	O	O
4	the	O	O
5	occurrence	O	O
6	of	O	O
7	clonic	B-Disease	B-Disease
8	seizures	E-Disease	E-Disease
9	was	O	O
10	scored	O	O
11	as	O	O
12	to	O	O
13	time	O	O
14	of	O	O
15	onset	O	O
16	and	O	O
17	severity	O	O
18	for	O	O
19	20	O	O
20	min	O	O
21	after	O	O
22	drug	O	O
23	administration	O	O
24	.	O	O

0	When	O	O
1	these	O	O
2	proceeded	O	O
3	to	O	O
4	tonic	B-Disease	B-Disease
5	seizures	E-Disease	E-Disease
6	,	O	O
7	death	O	O
8	occurred	O	O
9	in	O	O
10	less	O	O
11	than	O	O
12	20	O	O
13	min	O	O
14	.	O	O

0	Animals	O	O
1	surviving	O	O
2	for	O	O
3	20	O	O
4	min	O	O
5	were	O	O
6	immediately	O	O
7	stressed	O	O
8	by	O	O
9	a	O	O
10	swim	O	O
11	test	O	O
12	in	O	O
13	25	O	O
14	degrees	O	O
15	C	O	O
16	water	O	O
17	,	O	O
18	and	O	O
19	death	O	O
20	-	O	O
21	producing	O	O
22	tonic	B-Disease	B-Disease
23	seizures	E-Disease	E-Disease
24	were	O	O
25	scored	O	O
26	for	O	O
27	2	O	O
28	min	O	O
29	.	O	O

0	In	O	O
1	other	O	O
2	animals	O	O
3	locomotor	O	B-Disease
4	activity	O	E-Disease
5	was	O	O
6	measured	O	O
7	15	O	O
8	or	O	O
9	60	O	O
10	min	O	O
11	after	O	O
12	caffeine	S-Chemical	S-Chemical
13	administration	O	O
14	.	O	O

0	By	O	O
1	any	O	O
2	single	O	O
3	behavioral	O	O
4	criterion	O	O
5	or	O	O
6	a	O	O
7	combination	O	O
8	of	O	O
9	these	O	O
10	criteria	O	O
11	,	O	O
12	marked	O	O
13	differences	O	O
14	in	O	O
15	response	O	O
16	to	O	O
17	toxic	O	O
18	caffeine	S-Chemical	S-Chemical
19	doses	O	O
20	were	O	O
21	observed	O	O
22	between	O	O
23	strains	O	O
24	.	O	O

0	These	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	behavioral	O	O
5	toxicity	S-Disease	S-Disease
6	testing	O	O
7	of	O	O
8	alkylxanthines	S-Chemical	S-Chemical
9	in	O	O
10	a	O	O
11	single	O	O
12	mouse	O	O
13	strain	O	O
14	may	O	O
15	be	O	O
16	misleading	O	O
17	and	O	O
18	suggest	O	O
19	that	O	O
20	toxic	O	O
21	responses	O	O
22	of	O	O
23	the	O	O
24	central	O	I-Disease
25	nervous	O	I-Disease
26	system	O	E-Disease
27	to	O	O
28	this	O	O
29	class	O	O
30	of	O	O
31	compounds	O	O
32	are	O	O
33	genetically	O	O
34	influenced	O	O
35	in	O	O
36	mammals	O	O
37	.	O	O

0	Treatment	O	O
1	of	O	O
2	ovarian	B-Disease	B-Disease
3	cancer	E-Disease	E-Disease
4	with	O	O
5	a	O	O
6	combination	O	O
7	of	O	O
8	cis	B-Chemical	S-Chemical
9	-	I-Chemical	O
10	platinum	E-Chemical	S-Chemical
11	,	O	O
12	adriamycin	S-Chemical	S-Chemical
13	,	O	O
14	cyclophosphamide	S-Chemical	S-Chemical
15	and	O	O
16	hexamethylmelamine	S-Chemical	S-Chemical
17	.	O	O

0	During	O	O
1	the	O	O
2	last	O	O
3	2	O	O
4	1	O	O
5	/	O	O
6	2	O	O
7	years	O	O
8	,	O	O
9	38	O	O
10	patients	O	O
11	with	O	O
12	ovarian	B-Disease	B-Disease
13	cancer	E-Disease	E-Disease
14	were	O	O
15	treated	O	O
16	with	O	O
17	a	O	O
18	combination	O	O
19	of	O	O
20	cisplatinum	S-Chemical	S-Chemical
21	(	O	O
22	CPDD	S-Chemical	S-Disease
23	)	O	O
24	,	O	O
25	50	O	O
26	mg	O	O
27	/	O	O
28	m2	O	O
29	,	O	O
30	adriamycin	S-Chemical	S-Chemical
31	,	O	O
32	30	O	O
33	mg	O	O
34	/	O	O
35	m2	O	O
36	,	O	O
37	cyclophosphamide	S-Chemical	S-Chemical
38	,	O	O
39	300	O	O
40	mg	O	O
41	/	O	O
42	m2	O	O
43	,	O	O
44	on	O	O
45	day	O	O
46	1	O	O
47	;	O	O
48	and	O	O
49	hexamethylmelamine	S-Chemical	S-Chemical
50	(	O	O
51	HMM	S-Chemical	S-Disease
52	)	O	O
53	,	O	O
54	6	O	O
55	mg	O	O
56	/	O	O
57	kg	O	O
58	daily	O	O
59	,	O	O
60	for	O	O
61	14	O	O
62	days	O	O
63	.	O	O

0	14	O	O
1	of	O	O
2	the	O	O
3	38	O	O
4	patients	O	O
5	were	O	O
6	previously	O	O
7	treated	O	O
8	with	O	O
9	chemotherapy	O	O
10	,	O	O
11	1	O	O
12	with	O	O
13	radiation	O	O
14	,	O	O
15	6	O	O
16	with	O	O
17	both	O	O
18	chemotherapy	O	O
19	and	O	O
20	radiation	O	O
21	,	O	O
22	and	O	O
23	17	O	O
24	did	O	O
25	not	O	O
26	have	O	O
27	any	O	O
28	treatment	O	O
29	before	O	O
30	CPDD	S-Chemical	B-Chemical
31	combination	O	O
32	.	O	O

0	Hematologic	B-Disease	S-Disease
1	toxicity	E-Disease	S-Disease
2	was	O	O
3	moderate	O	O
4	and	O	O
5	with	O	O
6	reversible	O	O
7	anemia	S-Disease	O
8	developing	O	O
9	in	O	O
10	71	O	O
11	%	O	O
12	of	O	O
13	patients	O	O
14	.	O	O

0	Gastrointestinal	O	B-Disease
1	side	O	O
2	effects	O	O
3	from	O	O
4	CPDD	S-Chemical	S-Disease
5	were	O	O
6	universal	O	O
7	.	O	O

0	HMM	S-Chemical	B-Chemical
1	gastrointestinal	B-Disease	I-Disease
2	toxicity	E-Disease	E-Disease
3	necessitated	O	O
4	discontinuation	O	O
5	of	O	O
6	the	O	O
7	drug	O	O
8	in	O	O
9	5	O	O
10	patients	O	O
11	.	O	O

0	Severe	O	O
1	nephrotoxicity	S-Disease	S-Disease
2	was	O	O
3	observed	O	O
4	in	O	O
5	2	O	O
6	patients	O	O
7	but	O	O
8	was	O	O
9	reversible	O	O
10	.	O	O

0	Nontraumatic	O	O
1	dissecting	B-Disease	O
2	aneurysm	E-Disease	O
3	of	O	O
4	the	O	O
5	basilar	O	B-Disease
6	artery	O	E-Disease
7	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	nontraumatic	O	O
4	dissecting	B-Disease	O
5	aneurysm	E-Disease	S-Disease
6	of	O	O
7	the	O	O
8	basilar	O	B-Disease
9	artery	O	E-Disease
10	in	O	O
11	association	O	O
12	with	O	O
13	hypertension	S-Disease	S-Disease
14	,	O	O
15	smoke	O	S-Disease
16	,	O	O
17	and	O	O
18	oral	B-Chemical	O
19	contraceptives	E-Chemical	O
20	is	O	O
21	reported	O	O
22	in	O	O
23	a	O	O
24	young	O	O
25	female	O	O
26	patient	O	O
27	with	O	O
28	a	O	O
29	locked	B-Disease	B-Disease
30	-	I-Disease	O
31	in	I-Disease	O
32	syndrome	E-Disease	S-Disease
33	.	O	O

0	A	O	O
1	method	O	O
2	for	O	O
3	the	O	O
4	measurement	O	O
5	of	O	O
6	tremor	S-Disease	S-Disease
7	,	O	O
8	and	O	O
9	a	O	O
10	comparison	O	O
11	of	O	O
12	the	O	O
13	effects	O	O
14	of	O	O
15	tocolytic	O	S-Disease
16	beta	O	S-Disease
17	-	O	I-Disease
18	mimetics	O	S-Disease
19	.	O	O

0	A	O	O
1	method	O	O
2	permitting	O	O
3	measurement	O	O
4	of	O	O
5	finger	O	O
6	tremor	S-Disease	S-Disease
7	as	O	O
8	a	O	O
9	displacement	O	O
10	-	O	O
11	time	O	O
12	curve	O	O
13	is	O	O
14	described	O	O
15	,	O	O
16	using	O	O
17	a	O	O
18	test	O	O
19	system	O	O
20	with	O	O
21	simple	O	O
22	amplitude	O	O
23	calibration	O	O
24	.	O	O

0	By	O	O
1	means	O	O
2	of	O	O
3	a	O	O
4	computer	O	O
5	program	O	O
6	,	O	O
7	periods	O	O
8	and	O	O
9	amplitudes	O	O
10	of	O	O
11	tremor	S-Disease	S-Disease
12	oscillations	O	O
13	were	O	O
14	calculated	O	O
15	and	O	O
16	classified	O	O
17	.	O	O

0	The	O	O
1	actions	O	O
2	of	O	O
3	fenoterol	B-Chemical	S-Chemical
4	-	I-Chemical	O
5	hydrobromide	E-Chemical	E-Chemical
6	,	O	O
7	ritodrin	B-Chemical	S-Chemical
8	-	I-Chemical	O
9	HCl	E-Chemical	S-Disease
10	and	O	O
11	placebo	O	S-Disease
12	given	O	O
13	to	O	O
14	10	O	O
15	healthy	O	O
16	subjects	O	O
17	by	O	O
18	intravenous	O	O
19	infusion	O	O
20	in	O	O
21	a	O	O
22	double	O	O
23	-	O	O
24	blind	O	O
25	crossover	O	O
26	study	O	O
27	were	O	O
28	tested	O	O
29	by	O	O
30	this	O	O
31	method	O	O
32	.	O	O

0	At	O	O
1	therapeutic	O	O
2	doses	O	O
3	both	O	O
4	substances	O	O
5	raised	O	O
6	the	O	O
7	mean	O	O
8	tremor	S-Disease	S-Disease
9	amplitude	O	O
10	to	O	O
11	about	O	O
12	three	O	O
13	times	O	O
14	the	O	O
15	control	O	O
16	level	O	O
17	.	O	O

0	After	O	O
1	the	O	O
2	end	O	O
3	of	O	O
4	fenoterol	B-Chemical	S-Chemical
5	-	I-Chemical	O
6	hydrobromide	E-Chemical	E-Chemical
7	infusion	O	O
8	,	O	O
9	tremor	S-Disease	S-Disease
10	amplitudes	O	O
11	decreased	O	O
12	significantly	O	O
13	faster	O	O
14	than	O	O
15	those	O	O
16	following	O	O
17	ritodrin	B-Chemical	S-Chemical
18	-	I-Chemical	O
19	HCl	E-Chemical	E-Chemical
20	infusion	O	O
21	.	O	O

0	Propylthiouracil	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	hepatic	B-Disease	S-Disease
4	damage	E-Disease	E-Disease
5	.	O	O

0	Two	O	O
1	cases	O	O
2	of	O	O
3	propylthiouracil	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	liver	B-Disease	B-Disease
7	damage	E-Disease	E-Disease
8	have	O	O
9	been	O	O
10	observed	O	O
11	.	O	O

0	The	O	O
1	first	O	O
2	case	O	O
3	is	O	O
4	of	O	O
5	an	O	O
6	acute	O	O
7	type	O	O
8	of	O	O
9	damage	O	O
10	,	O	O
11	proven	O	O
12	by	O	O
13	rechallenge	O	O
14	;	O	O
15	the	O	O
16	second	O	O
17	presents	O	O
18	a	O	O
19	clinical	O	O
20	and	O	O
21	histologic	O	O
22	picture	O	O
23	resembling	O	O
24	chronic	B-Disease	B-Disease
25	active	I-Disease	I-Disease
26	hepatitis	E-Disease	E-Disease
27	,	O	O
28	with	O	O
29	spontaneous	O	O
30	remission	O	O
31	.	O	O

0	Studies	O	O
1	on	O	O
2	the	O	O
3	bradycardia	S-Disease	O
4	induced	O	O
5	by	O	O
6	bepridil	S-Chemical	S-Chemical
7	.	O	O

0	Bepridil	S-Chemical	S-Chemical
1	,	O	O
2	a	O	O
3	novel	O	O
4	active	O	O
5	compound	O	O
6	for	O	O
7	prophylactic	O	O
8	treatment	O	O
9	of	O	O
10	anginal	B-Disease	O
11	attacks	E-Disease	S-Disease
12	,	O	O
13	induced	O	O
14	persistent	O	O
15	bradycardia	S-Disease	O
16	and	O	O
17	a	O	O
18	non	O	O
19	-	O	O
20	specific	O	O
21	anti	O	O
22	-	O	O
23	tachycardial	S-Disease	S-Disease
24	effect	O	O
25	,	O	O
26	the	O	O
27	mechanisms	O	O
28	of	O	O
29	which	O	O
30	were	O	O
31	investigated	O	O
32	in	O	O
33	vitro	O	O
34	and	O	O
35	in	O	O
36	vivo	O	O
37	.	O	O

0	In	O	O
1	vitro	O	O
2	perfusion	O	O
3	of	O	O
4	bepridil	S-Chemical	S-Chemical
5	in	O	O
6	the	O	O
7	life	O	O
8	-	O	O
9	support	O	O
10	medium	O	O
11	for	O	O
12	isolated	O	O
13	sino	O	B-Disease
14	-	O	O
15	atrial	O	I-Disease
16	tissue	O	O
17	from	O	O
18	rabbit	O	O
19	heart	O	O
20	,	O	O
21	caused	O	O
22	a	O	O
23	reduction	O	O
24	in	O	O
25	action	O	O
26	potential	O	O
27	(	O	O
28	AP	O	O
29	)	O	O
30	spike	O	O
31	frequency	O	O
32	(	O	O
33	recorded	O	O
34	by	O	O
35	KCl	S-Chemical	S-Chemical
36	microelectrodes	O	O
37	)	O	O
38	starting	O	O
39	at	O	O
40	doses	O	O
41	of	O	O
42	5	O	O
43	X	O	O
44	10	O	O
45	(	O	O
46	-	O	O
47	6	O	O
48	)	O	O
49	M	O	O
50	.	O	O

0	Bepridil	S-Chemical	S-Chemical
1	at	O	O
2	a	O	O
3	dose	O	O
4	of	O	O
5	5	O	O
6	X	O	O
7	10	O	O
8	(	O	O
9	-	O	O
10	6	O	O
11	)	O	O
12	M	O	O
13	,	O	O
14	induced	O	O
15	a	O	O
16	concomitant	O	O
17	reduction	O	O
18	in	O	O
19	AP	O	S-Disease
20	amplitude	O	O
21	(	O	O
22	falling	O	O
23	from	O	O
24	71	O	O
25	+	O	O
26	/	O	O
27	-	O	O
28	8	O	O
29	mV	O	O
30	to	O	O
31	47	O	O
32	+	O	O
33	/	O	O
34	-	O	O
35	6	O	O
36	mV	O	O
37	)	O	O
38	,	O	O
39	maximum	O	O
40	systolic	O	O
41	depolarization	O	O
42	velocity	O	O
43	(	O	O
44	phase	O	O
45	0	O	O
46	)	O	O
47	which	O	O
48	fell	O	O
49	from	O	O
50	1	O	O
51	.	O	O
52	85	O	O
53	+	O	O
54	/	O	O
55	-	O	O
56	0	O	O
57	.	O	O
58	35	O	O
59	V	O	O
60	/	O	O
61	s	O	O
62	to	O	O
63	0	O	O
64	.	O	O
65	84	O	O
66	+	O	O
67	/	O	O
68	-	O	O
69	0	O	O
70	.	O	O
71	28	O	O
72	V	O	O
73	/	O	O
74	s	O	O
75	,	O	O
76	together	O	O
77	with	O	O
78	maximum	O	O
79	diastolic	O	S-Disease
80	depolarization	O	O
81	velocity	O	O
82	(	O	O
83	phase	O	O
84	4	O	O
85	)	O	O
86	which	O	O
87	fell	O	O
88	from	O	O
89	38	O	O
90	+	O	O
91	/	O	O
92	-	O	O
93	3	O	O
94	mV	O	O
95	/	O	O
96	s	O	O
97	to	O	O
98	24	O	O
99	+	O	O
100	/	O	O
101	-	O	O
102	5	O	O
103	mV	O	O
104	/	O	O
105	s	O	O
106	.	O	O

0	In	O	O
1	vivo	O	O
2	injection	O	O
3	of	O	O
4	bepridil	S-Chemical	S-Chemical
5	at	O	O
6	a	O	O
7	dose	O	O
8	of	O	O
9	5	O	O
10	mg	O	O
11	/	O	O
12	kg	O	O
13	(	O	O
14	i	O	O
15	.	O	O
16	v	O	O
17	.	O	O
18	)	O	O
19	into	O	O
20	6	O	O
21	anaesthetized	O	O
22	dogs	O	O
23	which	O	O
24	had	O	O
25	undergone	O	O
26	ablation	O	O
27	of	O	O
28	all	O	O
29	the	O	O
30	extrinsic	O	O
31	cardiac	O	S-Disease
32	afferent	O	O
33	nerve	O	O
34	supply	O	O
35	,	O	O
36	together	O	O
37	with	O	O
38	a	O	O
39	bilateral	O	O
40	medullo	O	O
41	-	O	O
42	adrenalectomy	O	S-Disease
43	,	O	O
44	caused	O	O
45	a	O	O
46	marked	O	O
47	reduction	O	O
48	in	O	O
49	heart	O	O
50	rate	O	O
51	which	O	O
52	fell	O	O
53	from	O	O
54	98	O	O
55	.	O	O
56	7	O	O
57	+	O	O
58	/	O	O
59	-	O	O
60	4	O	O
61	.	O	O
62	2	O	O
63	beats	O	O
64	/	O	O
65	min	O	O
66	to	O	O
67	76	O	O
68	+	O	O
69	/	O	O
70	-	O	O
71	5	O	O
72	.	O	O
73	3	O	O
74	beats	O	O
75	/	O	O
76	min	O	O
77	sustained	O	O
78	for	O	O
79	more	O	O
80	than	O	O
81	45	O	O
82	min	O	O
83	.	O	O

0	It	O	O
1	is	O	O
2	concluded	O	O
3	that	O	O
4	bepridil	S-Chemical	S-Chemical
5	reduces	O	O
6	heart	O	S-Disease
7	rate	O	O
8	by	O	O
9	acting	O	O
10	directly	O	O
11	on	O	O
12	the	O	O
13	sinus	O	B-Disease
14	node	O	O
15	.	O	O

0	This	O	O
1	effect	O	O
2	,	O	O
3	which	O	O
4	results	O	O
5	in	O	O
6	a	O	O
7	flattening	O	O
8	of	O	O
9	the	O	O
10	phase	O	O
11	0	O	O
12	and	O	O
13	phase	O	O
14	4	O	O
15	slope	O	O
16	,	O	O
17	together	O	O
18	with	O	O
19	a	O	O
20	longer	O	O
21	AP	O	O
22	duration	O	O
23	,	O	O
24	may	O	O
25	be	O	O
26	due	O	O
27	to	O	O
28	an	O	O
29	increase	O	O
30	in	O	O
31	the	O	O
32	time	O	O
33	constants	O	O
34	of	O	O
35	slow	O	O
36	inward	O	O
37	ionic	O	S-Disease
38	currents	O	O
39	(	O	O
40	already	O	O
41	demonstrated	O	O
42	elsewhere	O	O
43	)	O	O
44	,	O	O
45	but	O	O
46	also	O	O
47	to	O	O
48	an	O	O
49	increased	O	O
50	time	O	O
51	constant	O	O
52	for	O	O
53	deactivation	O	O
54	of	O	O
55	the	O	O
56	outward	O	O
57	potassium	S-Chemical	O
58	current	O	O
59	(	O	O
60	Ip	O	S-Chemical
61	)	O	O
62	.	O	O

0	Hepatitis	S-Disease	S-Disease
1	and	O	O
2	renal	B-Disease	B-Disease
3	tubular	I-Disease	I-Disease
4	acidosis	E-Disease	I-Disease
5	after	O	O
6	anesthesia	O	O
7	with	O	O
8	methoxyflurane	S-Chemical	S-Chemical
9	.	O	O

0	A	O	O
1	69	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	man	O	O
7	operated	O	O
8	for	O	O
9	acute	B-Disease	B-Disease
10	cholecystitis	E-Disease	E-Disease
11	under	O	O
12	methoxyflurane	S-Chemical	S-Chemical
13	anesthesia	O	O
14	developed	O	O
15	postoperatively	O	O
16	a	O	O
17	hepatic	B-Disease	S-Disease
18	insufficiency	I-Disease	B-Disease
19	syndrome	E-Disease	E-Disease
20	and	O	O
21	renal	B-Disease	B-Disease
22	tubular	I-Disease	I-Disease
23	acidosis	E-Disease	E-Disease
24	.	O	O

0	Massive	O	O
1	bleeding	S-Disease	O
2	appeared	O	O
3	during	O	O
4	surgery	O	O
5	which	O	O
6	lasted	O	O
7	for	O	O
8	six	O	O
9	hours	O	O
10	.	O	O

0	Pituitary	O	O
1	response	O	O
2	to	O	O
3	luteinizing	O	B-Disease
4	hormone	O	E-Disease
5	-	O	O
6	releasing	O	O
7	hormone	O	E-Disease
8	during	O	O
9	haloperidol	S-Chemical	S-Chemical
10	-	O	O
11	induced	O	O
12	hyperprolactinemia	S-Disease	S-Disease
13	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	a	O	O
4	6	O	O
5	-	O	O
6	hour	O	O
7	infusion	O	O
8	with	O	O
9	haloperidol	S-Chemical	S-Chemical
10	on	O	O
11	serum	O	O
12	prolactin	O	S-Chemical
13	and	O	O
14	luteinizing	O	B-Disease
15	hormone	O	E-Disease
16	(	O	O
17	LH	O	S-Chemical
18	)	O	O
19	levels	O	O
20	was	O	O
21	studied	O	O
22	in	O	O
23	a	O	O
24	group	O	O
25	of	O	O
26	male	O	O
27	subjects	O	O
28	.	O	O

0	Control	O	O
1	patients	O	O
2	received	O	O
3	infusions	O	O
4	of	O	O
5	0	O	O
6	.	O	O
7	9	O	O
8	%	O	O
9	NaCl	S-Chemical	S-Chemical
10	solution	O	O
11	.	O	O

0	During	O	O
1	the	O	O
2	course	O	O
3	of	O	O
4	haloperidol	S-Chemical	S-Chemical
5	infusions	O	O
6	,	O	O
7	significant	O	O
8	hyperprolactinemia	S-Disease	S-Disease
9	was	O	O
10	found	O	O
11	,	O	O
12	together	O	O
13	with	O	O
14	an	O	O
15	abolished	O	O
16	pituitary	O	B-Disease
17	response	O	O
18	to	O	O
19	LH	O	B-Chemical
20	-	O	I-Chemical
21	RH	O	E-Chemical
22	,	O	O
23	as	O	O
24	compared	O	O
25	with	O	O
26	responses	O	O
27	of	O	O
28	control	O	O
29	subjects	O	O
30	.	O	O

0	Antirifampicin	O	O
1	antibodies	O	O
2	in	O	O
3	acute	O	B-Disease
4	rifampicin	S-Chemical	E-Disease
5	-	O	O
6	associated	O	O
7	renal	B-Disease	B-Disease
8	failure	E-Disease	E-Disease
9	.	O	O

0	5	O	O
1	patients	O	O
2	with	O	O
3	acute	B-Disease	B-Disease
4	renal	I-Disease	I-Disease
5	failure	E-Disease	E-Disease
6	(	O	O
7	3	O	O
8	with	O	O
9	thrombopenia	S-Disease	S-Disease
10	and	O	O
11	hemolysis	S-Disease	S-Disease
12	)	O	O
13	induced	O	O
14	by	O	O
15	the	O	O
16	reintroduction	O	O
17	of	O	O
18	rifampicin	S-Chemical	S-Chemical
19	are	O	O
20	described	O	O
21	.	O	O

0	Antibodies	O	O
1	suggested	O	O
2	to	O	O
3	be	O	O
4	of	O	O
5	the	O	O
6	IgM	O	S-Chemical
7	class	O	O
8	were	O	O
9	detected	O	O
10	in	O	O
11	all	O	O
12	3	O	O
13	patients	O	O
14	with	O	O
15	hematological	B-Disease	O
16	disorders	E-Disease	E-Disease
17	.	O	O

0	The	O	O
1	pattern	O	O
2	of	O	O
3	non	O	O
4	-	O	O
5	specific	O	O
6	acute	B-Disease	B-Disease
7	tubular	I-Disease	I-Disease
8	necrosis	E-Disease	E-Disease
9	found	O	O
10	in	O	O
11	the	O	O
12	2	O	O
13	biopsied	O	O
14	patients	O	O
15	,	O	O
16	indistinguishable	O	O
17	from	O	O
18	that	O	O
19	of	O	O
20	ischemic	O	S-Disease
21	origin	O	O
22	,	O	O
23	raised	O	O
24	the	O	O
25	possibility	O	O
26	of	O	O
27	a	O	O
28	vascular	O	S-Disease
29	-	O	O
30	mediated	O	O
31	damage	O	O
32	.	O	O

0	Cardiovascular	O	O
1	effects	O	O
2	of	O	O
3	hypotension	S-Disease	S-Disease
4	induced	O	O
5	by	O	O
6	adenosine	B-Chemical	B-Chemical
7	triphosphate	E-Chemical	E-Chemical
8	and	O	O
9	sodium	B-Chemical	B-Chemical
10	nitroprusside	E-Chemical	E-Chemical
11	on	O	O
12	dogs	O	O
13	with	O	O
14	denervated	O	O
15	hearts	O	O
16	.	O	O

0	Adenosine	B-Chemical	S-Chemical
1	triphosphate	E-Chemical	E-Chemical
2	(	O	O
3	ATP	S-Chemical	O
4	)	O	O
5	and	O	O
6	sodium	B-Chemical	B-Chemical
7	nitroprusside	E-Chemical	E-Chemical
8	(	O	O
9	SNP	S-Chemical	S-Disease
10	)	O	O
11	are	O	O
12	administered	O	O
13	to	O	O
14	patients	O	O
15	to	O	O
16	induce	O	O
17	and	O	O
18	control	O	O
19	hypotension	S-Disease	S-Disease
20	during	O	O
21	anesthesia	O	O
22	.	O	O

0	SNP	S-Chemical	S-Chemical
1	is	O	O
2	authorized	O	O
3	for	O	O
4	clinical	O	O
5	use	O	O
6	in	O	O
7	USA	O	S-Chemical
8	and	O	O
9	UK	O	O
10	,	O	O
11	and	O	O
12	ATP	S-Chemical	S-Chemical
13	is	O	O
14	clinically	O	O
15	used	O	O
16	in	O	O
17	other	O	O
18	countries	O	O
19	such	O	O
20	as	O	O
21	Japan	O	S-Chemical
22	.	O	O

0	ATP	S-Chemical	S-Disease
1	(	O	O
2	10	O	O
3	dogs	O	O
4	)	O	O
5	or	O	O
6	SNP	S-Chemical	S-Disease
7	(	O	O
8	10	O	O
9	dogs	O	O
10	)	O	O
11	was	O	O
12	administered	O	O
13	to	O	O
14	reduce	O	O
15	mean	O	O
16	arterial	O	B-Disease
17	pressure	O	E-Disease
18	by	O	O
19	30	O	O
20	%	O	O
21	to	O	O
22	70	O	O
23	%	O	O
24	of	O	O
25	control	O	O
26	.	O	O

0	Before	O	O
1	,	O	O
2	during	O	O
3	and	O	O
4	after	O	O
5	induced	O	O
6	hypotension	S-Disease	S-Disease
7	,	O	O
8	we	O	O
9	measured	O	O
10	major	O	O
11	cardiovascular	O	O
12	parameters	O	O
13	.	O	O

0	Hypotension	S-Disease	O
1	induced	O	O
2	by	O	O
3	ATP	S-Chemical	S-Chemical
4	was	O	O
5	accompanied	O	O
6	by	O	O
7	significant	O	O
8	decreases	O	O
9	in	O	O
10	mean	O	O
11	pulmonary	O	B-Disease
12	arterial	O	E-Disease
13	pressure	O	E-Disease
14	(	O	O
15	p	O	O
16	less	O	O
17	than	O	O
18	0	O	O
19	.	O	O
20	001	O	O
21	)	O	O
22	,	O	O
23	central	O	O
24	venous	O	B-Disease
25	pressure	O	O
26	(	O	O
27	p	O	O
28	less	O	O
29	than	O	O
30	0	O	O
31	.	O	O
32	001	O	O
33	)	O	O
34	,	O	O
35	left	O	O
36	ventricular	O	O
37	end	O	O
38	-	O	O
39	diastolic	O	S-Disease
40	pressure	O	O
41	(	O	O
42	p	O	O
43	less	O	O
44	than	O	O
45	0	O	O
46	.	O	O
47	001	O	O
48	)	O	O
49	,	O	O
50	total	O	O
51	peripheral	O	O
52	resistance	O	O
53	(	O	O
54	p	O	O
55	less	O	O
56	than	O	O
57	0	O	O
58	.	O	O
59	001	O	O
60	)	O	O
61	,	O	O
62	rate	O	O
63	pressure	O	O
64	product	O	O
65	(	O	O
66	p	O	O
67	less	O	O
68	than	O	O
69	0	O	O
70	.	O	O
71	001	O	O
72	)	O	O
73	,	O	O
74	total	O	O
75	body	O	O
76	oxygen	S-Chemical	O
77	consumption	O	O
78	(	O	O
79	p	O	O
80	less	O	O
81	than	O	O
82	0	O	O
83	.	O	O
84	05	O	O
85	)	O	O
86	,	O	O
87	and	O	O
88	heart	O	O
89	rate	O	O
90	(	O	O
91	p	O	O
92	less	O	O
93	than	O	O
94	0	O	O
95	.	O	O
96	001	O	O
97	)	O	O
98	;	O	O
99	all	O	O
100	these	O	O
101	variables	O	O
102	returned	O	O
103	normal	O	O
104	within	O	O
105	30	O	O
106	min	O	O
107	after	O	O
108	ATP	S-Chemical	S-Chemical
109	was	O	O
110	stopped	O	O
111	.	O	O

0	During	O	O
1	hypotension	S-Disease	S-Disease
2	produced	O	O
3	by	O	O
4	SNP	S-Chemical	S-Disease
5	similar	O	O
6	decreases	O	O
7	were	O	O
8	observed	O	O
9	in	O	O
10	mean	O	O
11	pulmonary	O	B-Disease
12	arterial	O	I-Disease
13	pressure	O	O
14	(	O	O
15	p	O	O
16	less	O	O
17	than	O	O
18	0	O	O
19	.	O	O
20	01	O	O
21	)	O	O
22	,	O	O
23	central	O	O
24	venous	O	I-Disease
25	pressure	O	O
26	(	O	O
27	p	O	O
28	less	O	O
29	than	O	O
30	0	O	O
31	.	O	O
32	001	O	O
33	)	O	O
34	,	O	O
35	left	O	O
36	ventricular	O	O
37	end	O	O
38	-	O	O
39	diastolic	O	S-Disease
40	pressure	O	O
41	(	O	O
42	p	O	O
43	less	O	O
44	than	O	O
45	0	O	O
46	.	O	O
47	01	O	O
48	)	O	O
49	,	O	O
50	total	O	O
51	peripheral	O	O
52	resistance	O	O
53	(	O	O
54	p	O	O
55	less	O	O
56	than	O	O
57	0	O	O
58	.	O	O
59	001	O	O
60	)	O	O
61	,	O	O
62	rate	O	O
63	pressure	O	O
64	product	O	O
65	(	O	O
66	p	O	O
67	less	O	O
68	than	O	O
69	0	O	O
70	.	O	O
71	001	O	O
72	)	O	O
73	,	O	O
74	and	O	O
75	oxygen	S-Chemical	S-Disease
76	content	O	O
77	difference	O	O
78	between	O	O
79	arterial	O	O
80	and	O	O
81	mixed	O	O
82	venous	O	S-Disease
83	blood	O	O
84	(	O	O
85	p	O	O
86	less	O	O
87	than	O	O
88	0	O	O
89	.	O	O
90	05	O	O
91	)	O	O
92	,	O	O
93	while	O	O
94	heart	O	S-Disease
95	rate	O	O
96	(	O	O
97	p	O	O
98	less	O	O
99	than	O	O
100	0	O	O
101	.	O	O
102	001	O	O
103	)	O	O
104	and	O	O
105	cardiac	O	S-Disease
106	output	O	O
107	(	O	O
108	p	O	O
109	less	O	O
110	than	O	O
111	0	O	O
112	.	O	O
113	05	O	O
114	)	O	O
115	were	O	O
116	increased	O	O
117	.	O	O

0	Recoveries	O	O
1	of	O	O
2	heart	O	S-Disease
3	rate	O	O
4	and	O	O
5	left	O	O
6	ventricular	O	O
7	end	O	O
8	-	O	O
9	diastolic	O	B-Disease
10	pressure	O	O
11	were	O	O
12	not	O	O
13	shown	O	O
14	within	O	O
15	60	O	O
16	min	O	O
17	after	O	O
18	SNP	S-Chemical	S-Disease
19	had	O	O
20	been	O	O
21	stopped	O	O
22	.	O	O

0	Both	O	O
1	ATP	S-Chemical	S-Chemical
2	and	O	O
3	SNP	S-Chemical	S-Chemical
4	should	O	O
5	act	O	O
6	on	O	O
7	the	O	O
8	pacemaker	O	O
9	tissue	O	O
10	of	O	O
11	the	O	O
12	heart	O	O
13	.	O	O

0	Comparative	O	O
1	study	O	O
2	:	O	O
3	Endografine	S-Chemical	S-Chemical
4	(	O	O
5	diatrizoate	S-Chemical	S-Chemical
6	)	O	O
7	,	O	O
8	Vasurix	B-Chemical	B-Chemical
9	polyvidone	E-Chemical	E-Chemical
10	(	O	O
11	acetrizoate	S-Chemical	S-Chemical
12	)	O	O
13	,	O	O
14	Dimer	B-Chemical	S-Chemical
15	-	I-Chemical	O
16	X	E-Chemical	E-Chemical
17	(	O	O
18	iocarmate	S-Chemical	S-Chemical
19	)	O	O
20	and	O	O
21	Hexabrix	S-Chemical	S-Chemical
22	(	O	O
23	ioxaglate	S-Chemical	S-Chemical
24	)	O	O
25	in	O	O
26	hysterosalpingography	O	S-Disease
27	.	O	O

0	Side	O	O
1	effects	O	O
2	of	O	O
3	hysterosalpingography	O	S-Disease
4	with	O	O
5	Dimer	B-Chemical	S-Chemical
6	-	I-Chemical	I-Chemical
7	X	E-Chemical	E-Chemical
8	,	O	O
9	Hexabrix	S-Chemical	S-Chemical
10	,	O	O
11	Vasurix	B-Chemical	B-Chemical
12	polyvidone	E-Chemical	E-Chemical
13	and	O	O
14	Endografine	S-Chemical	S-Chemical
15	in	O	O
16	142	O	O
17	consecutive	O	O
18	patients	O	O
19	,	O	O
20	receiving	O	O
21	one	O	O
22	of	O	O
23	the	O	O
24	four	O	O
25	tested	O	O
26	media	O	O
27	were	O	O
28	evaluated	O	O
29	from	O	O
30	replies	O	O
31	to	O	O
32	postal	O	O
33	questionnaires	O	O
34	.	O	O

0	The	O	O
1	Dimer	B-Chemical	S-Chemical
2	-	I-Chemical	O
3	X	E-Chemical	O
4	group	O	O
5	had	O	O
6	a	O	O
7	higher	O	O
8	incidence	O	O
9	of	O	O
10	nausea	S-Disease	S-Disease
11	and	O	O
12	dizziness	S-Disease	O
13	.	O	O

0	The	O	O
1	Endografine	S-Chemical	S-Chemical
2	group	O	O
3	had	O	O
4	a	O	O
5	higher	O	O
6	incidence	O	O
7	of	O	O
8	abdominal	B-Disease	O
9	pain	E-Disease	E-Disease
10	.	O	O

0	Hexabrix	S-Chemical	S-Chemical
1	and	O	O
2	Vasurix	B-Chemical	S-Chemical
3	polyvidone	E-Chemical	E-Chemical
4	are	O	O
5	considered	O	O
6	the	O	O
7	best	O	O
8	contrast	B-Chemical	O
9	media	E-Chemical	O
10	for	O	O
11	hysterosalpingography	O	S-Disease
12	and	O	O
13	perhaps	O	O
14	because	O	O
15	of	O	O
16	its	O	O
17	low	O	O
18	toxicity	S-Disease	S-Disease
19	Hexabrix	S-Chemical	S-Chemical
20	should	O	O
21	be	O	O
22	preferred	O	O
23	.	O	O

0	Post	O	O
1	-	O	O
2	suxamethonium	S-Chemical	S-Disease
3	pains	S-Disease	S-Disease
4	in	O	O
5	Nigerian	O	S-Chemical
6	surgical	O	O
7	patients	O	O
8	.	O	O

0	Contrary	O	O
1	to	O	O
2	an	O	O
3	earlier	O	O
4	report	O	O
5	by	O	O
6	Coxon	O	S-Chemical
7	,	O	O
8	scoline	S-Chemical	B-Disease
9	pain	S-Disease	E-Disease
10	occurs	O	O
11	in	O	O
12	African	O	B-Disease
13	negroes	O	E-Disease
14	.	O	O

0	About	O	O
1	62	O	O
2	%	O	O
3	of	O	O
4	the	O	O
5	out	O	O
6	-	O	O
7	patients	O	O
8	developed	O	O
9	scoline	S-Chemical	B-Disease
10	pain	S-Disease	S-Disease
11	as	O	O
12	compared	O	O
13	with	O	O
14	about	O	O
15	26	O	O
16	%	O	O
17	among	O	O
18	the	O	O
19	in	O	O
20	-	O	O
21	patients	O	O
22	.	O	O

0	The	O	O
1	abolition	O	O
2	of	O	O
3	muscle	O	O
4	fasciculations	S-Disease	O
5	(	O	O
6	by	O	O
7	0	O	O
8	.	O	O
9	075mg	O	O
10	/	O	O
11	kg	O	O
12	dose	O	O
13	of	O	O
14	Fazadinium	S-Chemical	S-Chemical
15	)	O	O
16	did	O	O
17	not	O	O
18	influence	O	O
19	the	O	O
20	occurrence	O	O
21	of	O	O
22	scoline	S-Chemical	B-Disease
23	pain	S-Disease	S-Disease
24	.	O	O

0	Neither	O	O
1	the	O	O
2	type	O	O
3	of	O	O
4	induction	O	O
5	agent	O	O
6	(	O	O
7	Althesin	S-Chemical	S-Chemical
8	or	O	O
9	Thiopentone	S-Chemical	S-Chemical
10	)	O	O
11	nor	O	O
12	the	O	O
13	salt	O	O
14	preparation	O	O
15	of	O	O
16	suxamethonium	S-Chemical	S-Chemical
17	used	O	O
18	(	O	O
19	chloride	S-Chemical	S-Chemical
20	or	O	O
21	bromide	S-Chemical	S-Chemical
22	)	O	O
23	,	O	O
24	affected	O	O
25	the	O	O
26	incidence	O	O
27	of	O	O
28	scoline	S-Chemical	S-Disease
29	pain	S-Disease	S-Disease
30	.	O	O

0	Invasive	O	O
1	carcinoma	B-Disease	S-Disease
2	of	I-Disease	O
3	the	I-Disease	O
4	renal	I-Disease	B-Disease
5	pelvis	E-Disease	E-Disease
6	following	O	O
7	cyclophosphamide	S-Chemical	S-Chemical
8	therapy	O	O
9	for	O	O
10	nonmalignant	O	O
11	disease	O	S-Disease
12	.	O	O

0	A	O	O
1	47	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	woman	O	O
7	with	O	O
8	right	O	O
9	hydroureteronephrosis	S-Disease	S-Disease
10	due	O	O
11	to	O	O
12	ureterovesical	O	B-Disease
13	junction	O	E-Disease
14	obstruction	O	E-Disease
15	had	O	O
16	gross	O	O
17	hematuria	S-Disease	O
18	after	O	O
19	being	O	O
20	treated	O	O
21	for	O	O
22	five	O	O
23	years	O	O
24	wtih	O	O
25	cyclophosphamide	S-Chemical	S-Chemical
26	for	O	O
27	cerebral	B-Disease	B-Disease
28	vasculitis	E-Disease	E-Disease
29	.	O	O

0	A	O	O
1	right	O	O
2	nephroureterectomy	O	S-Disease
3	was	O	O
4	required	O	O
5	for	O	O
6	control	O	O
7	of	O	O
8	bleeding	S-Disease	S-Disease
9	.	O	O

0	The	O	O
1	pathology	O	O
2	specimen	O	O
3	contained	O	O
4	clinically	O	O
5	occult	O	O
6	invasive	O	O
7	carcinoma	B-Disease	B-Disease
8	of	I-Disease	O
9	the	I-Disease	O
10	renal	I-Disease	B-Disease
11	pelvis	E-Disease	E-Disease
12	.	O	O

0	Although	O	O
1	the	O	O
2	ability	O	O
3	of	O	O
4	cyclophosphamide	S-Chemical	S-Chemical
5	to	O	O
6	cause	O	O
7	hemorrhagic	B-Disease	O
8	cystitis	E-Disease	S-Disease
9	and	O	O
10	urine	O	O
11	cytologic	O	S-Disease
12	abnormalities	O	O
13	indistinguishable	O	O
14	from	O	O
15	high	O	O
16	grade	O	O
17	carcinoma	S-Disease	S-Disease
18	is	O	O
19	well	O	O
20	known	O	O
21	,	O	O
22	it	O	O
23	is	O	O
24	less	O	O
25	widely	O	O
26	appreciated	O	O
27	that	O	O
28	it	O	O
29	is	O	O
30	also	O	O
31	associated	O	O
32	with	O	O
33	carcinoma	B-Disease	B-Chemical
34	of	I-Disease	O
35	the	I-Disease	O
36	urinary	I-Disease	B-Disease
37	tract	E-Disease	E-Disease
38	.	O	O

0	Twenty	O	O
1	carcinomas	B-Disease	S-Disease
2	of	I-Disease	O
3	the	I-Disease	O
4	urinary	I-Disease	O
5	bladder	E-Disease	E-Disease
6	and	O	O
7	one	O	O
8	carcinoma	B-Disease	S-Disease
9	of	I-Disease	O
10	the	I-Disease	O
11	prostate	E-Disease	O
12	have	O	O
13	been	O	O
14	reported	O	O
15	in	O	O
16	association	O	O
17	with	O	O
18	its	O	O
19	use	O	O
20	.	O	O

0	The	O	O
1	present	O	O
2	case	O	O
3	is	O	O
4	the	O	O
5	first	O	O
6	carcinoma	B-Disease	S-Disease
7	of	I-Disease	O
8	the	I-Disease	O
9	renal	I-Disease	B-Disease
10	pelvis	E-Disease	E-Disease
11	reported	O	O
12	in	O	O
13	association	O	O
14	with	O	O
15	cyclophosphamide	S-Chemical	S-Chemical
16	treatment	O	O
17	.	O	O

0	It	O	O
1	is	O	O
2	the	O	O
3	third	O	O
4	urinary	B-Disease	B-Disease
5	tract	I-Disease	I-Disease
6	cancer	E-Disease	E-Disease
7	reported	O	O
8	in	O	O
9	association	O	O
10	with	O	O
11	cyclophosphamide	S-Chemical	S-Chemical
12	treatment	O	O
13	for	O	O
14	nonmalignant	O	B-Disease
15	disease	O	E-Disease
16	.	O	O

0	The	O	O
1	association	O	O
2	of	O	O
3	the	O	O
4	tumor	S-Disease	S-Disease
5	with	O	O
6	preexisting	O	O
7	hydroureteronephrosis	S-Disease	S-Disease
8	suggests	O	O
9	that	O	O
10	stasis	O	O
11	prolonged	O	O
12	and	O	O
13	intensified	O	O
14	exposure	O	O
15	of	O	O
16	upper	O	B-Disease
17	urinary	O	I-Disease
18	tract	O	I-Disease
19	epithelium	O	E-Disease
20	to	O	O
21	cyclophosphamide	S-Chemical	S-Chemical
22	.	O	O

0	Patients	O	O
1	who	O	O
2	are	O	O
3	candidates	O	O
4	for	O	O
5	long	O	O
6	-	O	O
7	term	O	O
8	cyclophosphamide	S-Chemical	S-Chemical
9	treatment	O	O
10	should	O	O
11	be	O	O
12	routinely	O	O
13	evaluated	O	O
14	for	O	O
15	obstructive	B-Disease	O
16	uropathy	E-Disease	S-Disease
17	.	O	O

0	Medial	O	O
1	changes	O	O
2	in	O	O
3	arterial	O	B-Disease
4	spasm	S-Disease	E-Disease
5	induced	O	O
6	by	O	O
7	L	B-Chemical	B-Chemical
8	-	I-Chemical	I-Chemical
9	norepinephrine	E-Chemical	S-Chemical
10	.	O	O

0	In	O	O
1	the	O	O
2	media	O	O
3	of	O	O
4	the	O	O
5	saphenous	O	B-Disease
6	artery	O	E-Disease
7	and	O	O
8	its	O	O
9	distal	O	O
10	branch	O	O
11	,	O	O
12	vasoconstriction	O	S-Disease
13	induced	O	O
14	by	O	O
15	L	B-Chemical	B-Chemical
16	-	I-Chemical	I-Chemical
17	norepinephrine	E-Chemical	E-Chemical
18	produced	O	O
19	many	O	O
20	cell	O	O
21	-	O	O
22	to	O	I-Disease
23	-	O	O
24	cell	O	O
25	hernias	S-Disease	S-Disease
26	within	O	O
27	15	O	O
28	minutes	O	O
29	.	O	O

0	The	O	O
1	experimental	O	O
2	data	O	O
3	are	O	O
4	discussed	O	O
5	in	O	O
6	relation	O	O
7	to	O	O
8	medial	O	O
9	changes	O	O
10	observed	O	O
11	in	O	O
12	other	O	O
13	instances	O	O
14	of	O	O
15	arterial	O	B-Disease
16	spasm	S-Disease	E-Disease
17	.	O	O

0	Bilateral	O	O
1	retinal	B-Disease	O
2	artery	I-Disease	E-Disease
3	and	I-Disease	O
4	choriocapillaris	I-Disease	B-Disease
5	occlusion	E-Disease	E-Disease
6	following	O	O
7	the	O	O
8	injection	O	O
9	of	O	O
10	long	O	O
11	-	O	O
12	acting	O	O
13	corticosteroid	S-Chemical	S-Chemical
14	suspensions	O	O
15	in	O	O
16	combination	O	O
17	with	O	O
18	other	O	O
19	drugs	O	O
20	:	O	O
21	I	O	S-Disease
22	.	O	O

0	Two	O	O
1	well	O	O
2	-	O	O
3	documented	O	O
4	cases	O	O
5	of	O	O
6	bilateral	O	O
7	retinal	B-Disease	I-Disease
8	artery	I-Disease	E-Disease
9	and	I-Disease	O
10	choriocapillaris	I-Disease	S-Disease
11	occlusions	E-Disease	O
12	with	O	O
13	blindness	S-Disease	O
14	following	O	O
15	head	O	O
16	and	O	O
17	neck	O	O
18	soft	O	O
19	-	O	O
20	tissue	O	O
21	injection	O	O
22	with	O	O
23	methylprednisolone	B-Chemical	S-Chemical
24	acetate	E-Chemical	E-Chemical
25	in	O	O
26	combination	O	O
27	with	O	O
28	lidocaine	S-Chemical	S-Chemical
29	,	O	O
30	epinephrine	S-Chemical	S-Chemical
31	,	O	O
32	or	O	O
33	penicillin	S-Chemical	S-Chemical
34	are	O	O
35	reported	O	O
36	.	O	O

0	The	O	O
1	acute	O	O
2	observations	O	O
3	included	O	O
4	hazy	O	O
5	sensorium	O	O
6	,	O	O
7	superior	O	O
8	gaze	O	B-Disease
9	palsy	S-Disease	O
10	,	O	O
11	pupillary	B-Disease	B-Disease
12	abnormalities	E-Disease	E-Disease
13	,	O	O
14	and	O	O
15	conjunctival	O	O
16	hemorrhages	S-Disease	E-Disease
17	with	O	O
18	edema	S-Disease	S-Disease
19	.	O	O

0	Follow	O	O
1	-	O	O
2	up	O	O
3	changes	O	O
4	showed	O	O
5	marked	O	O
6	visual	B-Disease	B-Disease
7	loss	E-Disease	E-Disease
8	,	O	O
9	constricted	O	O
10	visual	O	O
11	fields	O	O
12	,	O	O
13	optic	O	B-Disease
14	nerve	O	I-Disease
15	pallor	O	E-Disease
16	,	O	O
17	vascular	O	B-Disease
18	attenuation	O	E-Disease
19	,	O	O
20	and	O	O
21	chorioretinal	B-Disease	B-Disease
22	atrophy	E-Disease	E-Disease
23	.	O	O

0	Abnormalities	O	O
1	of	O	O
2	the	O	O
3	pupil	O	O
4	and	O	O
5	visual	O	O
6	-	O	O
7	evoked	O	O
8	potential	O	O
9	in	O	O
10	quinine	S-Chemical	B-Disease
11	amblyopia	S-Disease	E-Disease
12	.	O	O

0	Total	O	O
1	blindness	S-Disease	O
2	with	O	O
3	a	O	O
4	transient	O	O
5	tonic	B-Disease	B-Disease
6	pupillary	E-Disease	E-Disease
7	response	O	O
8	,	O	O
9	denervation	O	O
10	supersensitivity	O	O
11	,	O	O
12	and	O	O
13	abnormal	O	O
14	visual	O	O
15	-	O	O
16	evoked	O	O
17	potentials	O	E-Disease
18	developed	O	O
19	in	O	O
20	a	O	O
21	54	O	O
22	-	O	O
23	year	O	O
24	-	O	O
25	old	O	O
26	man	O	O
27	after	O	O
28	the	O	O
29	use	O	O
30	of	O	O
31	quinine	B-Chemical	B-Chemical
32	sulfate	E-Chemical	I-Chemical
33	for	O	O
34	leg	B-Disease	O
35	cramps	E-Disease	E-Disease
36	.	O	O

0	A	O	O
1	transient	O	O
2	tonic	B-Disease	B-Disease
3	pupillary	E-Disease	E-Disease
4	response	O	O
5	,	O	O
6	denervation	O	O
7	supersensitivity	O	O
8	,	O	O
9	and	O	O
10	abnormal	O	O
11	visual	O	O
12	-	O	O
13	evoked	O	O
14	potentials	O	O
15	in	O	O
16	quinine	S-Chemical	B-Disease
17	toxicity	S-Disease	E-Disease
18	,	O	O
19	to	O	O
20	our	O	O
21	knowledge	O	O
22	,	O	O
23	have	O	O
24	not	O	O
25	been	O	O
26	previously	O	O
27	reported	O	O
28	.	O	O

0	Suxamethonium	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	jaw	B-Disease	O
4	stiffness	E-Disease	S-Disease
5	and	O	O
6	myalgia	S-Disease	S-Disease
7	associated	O	O
8	with	O	O
9	atypical	O	O
10	cholinesterase	O	S-Chemical
11	:	O	O
12	case	O	O
13	report	O	O
14	.	O	O

0	An	O	O
1	11	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	boy	O	O
7	was	O	O
8	given	O	O
9	halothane	S-Chemical	S-Chemical
10	,	O	O
11	nitrous	B-Chemical	S-Chemical
12	oxide	E-Chemical	E-Chemical
13	and	O	O
14	oxygen	S-Chemical	S-Disease
15	,	O	O
16	pancuronium	S-Chemical	S-Chemical
17	0	O	O
18	.	O	O
19	4	O	O
20	mg	O	O
21	and	O	O
22	suxamethonium	S-Chemical	S-Chemical
23	100	O	O
24	mg	O	O
25	for	O	O
26	induction	O	O
27	of	O	O
28	anaesthesia	O	O
29	.	O	O

0	In	O	O
1	response	O	O
2	to	O	O
3	this	O	O
4	a	O	O
5	marked	O	O
6	jaw	B-Disease	O
7	stiffness	E-Disease	O
8	occurred	O	O
9	which	O	O
10	lasted	O	O
11	for	O	O
12	two	O	O
13	minutes	O	O
14	and	O	O
15	the	O	O
16	anaesthesia	O	O
17	were	O	O
18	terminated	O	O
19	.	O	O

0	Four	O	O
1	hours	O	O
2	of	O	O
3	apnoea	S-Disease	S-Disease
4	ensued	O	O
5	and	O	O
6	he	O	O
7	suffered	O	O
8	generalized	O	O
9	severe	O	O
10	myalgia	S-Disease	S-Disease
11	lasting	O	O
12	for	O	O
13	one	O	O
14	week	O	O
15	.	O	O

0	He	O	O
1	was	O	O
2	found	O	O
3	to	O	O
4	have	O	O
5	atypical	O	O
6	plasma	O	O
7	cholinesterase	O	S-Disease
8	with	O	O
9	a	O	O
10	dibucaine	S-Chemical	S-Chemical
11	number	O	O
12	of	O	O
13	12	O	O
14	,	O	O
15	indicating	O	O
16	homozygocity	O	O
17	.	O	O

0	The	O	O
1	case	O	O
2	shows	O	O
3	that	O	O
4	prolonged	B-Disease	O
5	jaw	I-Disease	O
6	rigidity	E-Disease	O
7	and	O	O
8	myalgia	S-Disease	S-Disease
9	may	O	O
10	occur	O	O
11	after	O	O
12	suxamethonium	S-Chemical	S-Chemical
13	in	O	O
14	patients	O	O
15	with	O	O
16	atypical	O	O
17	cholinesterase	O	S-Chemical
18	despite	O	O
19	pretreatment	O	O
20	with	O	O
21	pancuronium	S-Chemical	S-Disease
22	.	O	O

0	Indomethacin	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	hyperkalemia	S-Disease	S-Disease
4	in	O	O
5	three	O	O
6	patients	O	O
7	with	O	O
8	gouty	B-Disease	B-Disease
9	arthritis	E-Disease	E-Disease
10	.	O	O

0	We	O	O
1	describe	O	O
2	three	O	O
3	patients	O	O
4	in	O	O
5	whom	O	O
6	severe	O	O
7	,	O	O
8	life	O	O
9	-	O	O
10	threatening	O	O
11	hyperkalemia	S-Disease	S-Disease
12	and	O	O
13	renal	B-Disease	B-Disease
14	insufficiency	E-Disease	E-Disease
15	developed	O	O
16	after	O	O
17	treatment	O	O
18	of	O	O
19	acute	O	B-Disease
20	gouty	B-Disease	I-Disease
21	arthritis	E-Disease	E-Disease
22	with	O	O
23	indomethacin	S-Chemical	S-Chemical
24	.	O	O

0	This	O	O
1	complication	O	O
2	may	O	O
3	result	O	O
4	from	O	O
5	an	O	O
6	inhibition	O	O
7	of	O	O
8	prostaglandin	S-Chemical	S-Chemical
9	synthesis	O	O
10	and	O	O
11	consequent	O	O
12	hyporeninemic	B-Disease	B-Disease
13	hypoaidosteronism	E-Disease	E-Disease
14	.	O	O

0	Careful	O	O
1	attention	O	O
2	to	O	O
3	renal	O	B-Disease
4	function	O	E-Disease
5	and	O	O
6	potassium	S-Chemical	B-Disease
7	balance	O	E-Disease
8	in	O	O
9	patients	O	O
10	receiving	O	O
11	indomethacin	S-Chemical	S-Chemical
12	or	O	O
13	other	O	O
14	nonsteroidal	O	O
15	anti	O	O
16	-	O	O
17	inflammatory	O	S-Disease
18	agents	O	O
19	,	O	O
20	particularly	O	O
21	in	O	O
22	those	O	O
23	patients	O	O
24	with	O	O
25	diabetes	B-Disease	B-Disease
26	mellitus	E-Disease	E-Disease
27	or	O	O
28	preexisting	O	O
29	renal	B-Disease	B-Disease
30	disease	E-Disease	E-Disease
31	,	O	O
32	will	O	O
33	help	O	O
34	prevent	O	O
35	this	O	O
36	potentially	O	O
37	serious	O	O
38	complication	O	O
39	.	O	O

0	Etomidate	S-Chemical	O
1	:	O	O
2	a	O	O
3	foreshortened	O	O
4	clinical	O	O
5	trial	O	O
6	.	O	O

0	A	O	O
1	clinical	O	O
2	evaluation	O	O
3	of	O	O
4	etomidate	S-Chemical	S-Chemical
5	for	O	O
6	outpatient	O	O
7	cystoscopy	O	S-Disease
8	was	O	O
9	embarked	O	O
10	upon	O	O
11	.	O	O

0	Unpremedicated	O	O
1	patients	O	O
2	were	O	O
3	given	O	O
4	fentanyl	S-Chemical	S-Chemical
5	1	O	O
6	microgram	O	O
7	/	O	O
8	kg	O	O
9	followed	O	O
10	by	O	O
11	etomidate	S-Chemical	S-Chemical
12	0	O	O
13	.	O	O
14	3	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	.	O	O

0	Anaesthesia	O	O
1	was	O	O
2	maintained	O	O
3	with	O	O
4	intermittent	O	O
5	etomidate	S-Chemical	S-Disease
6	in	O	O
7	2	O	O
8	-	O	O
9	4	O	O
10	mg	O	O
11	doses	O	O
12	.	O	O

0	Venous	O	S-Disease
1	pain	S-Disease	S-Disease
2	occurred	O	O
3	in	O	O
4	68	O	O
5	%	O	O
6	of	O	O
7	patients	O	O
8	and	O	O
9	50	O	O
10	%	O	O
11	had	O	O
12	redness	O	O
13	,	O	O
14	pain	S-Disease	S-Disease
15	or	O	O
16	swelling	S-Disease	O
17	related	O	O
18	to	O	O
19	the	O	O
20	injection	O	O
21	site	O	O
22	,	O	O
23	in	O	O
24	some	O	O
25	cases	O	O
26	lasting	O	O
27	up	O	O
28	to	O	O
29	three	O	O
30	weeks	O	O
31	after	O	O
32	anaesthesia	O	O
33	.	O	O

0	Skeletal	O	O
1	movements	O	O
2	occurred	O	O
3	in	O	O
4	50	O	O
5	%	O	O
6	of	O	O
7	patients	O	O
8	;	O	O
9	30	O	O
10	%	O	O
11	experienced	O	O
12	respiratory	B-Disease	B-Disease
13	upset	E-Disease	E-Disease
14	,	O	O
15	one	O	O
16	sufficiently	O	O
17	severe	O	O
18	to	O	O
19	necessitate	O	O
20	abandoning	O	O
21	the	O	O
22	technique	O	O
23	.	O	O

0	Nausea	S-Disease	O
1	and	O	O
2	vomiting	S-Disease	S-Disease
3	occurred	O	O
4	in	O	O
5	40	O	O
6	%	O	O
7	and	O	O
8	25	O	O
9	%	O	O
10	had	O	O
11	disturbing	O	O
12	emergence	O	O
13	psychoses	S-Disease	S-Disease
14	.	O	O

0	Levodopa	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	dyskinesias	S-Disease	S-Disease
4	are	O	O
5	improved	O	O
6	by	O	O
7	fluoxetine	S-Chemical	S-Chemical
8	.	O	O

0	We	O	O
1	evaluated	O	O
2	the	O	O
3	severity	O	O
4	of	O	O
5	motor	B-Disease	B-Disease
6	disability	E-Disease	E-Disease
7	and	O	O
8	dyskinesias	S-Disease	S-Disease
9	in	O	O
10	seven	O	O
11	levodopa	S-Chemical	S-Chemical
12	-	O	O
13	responsive	O	O
14	patients	O	O
15	with	O	O
16	Parkinson	B-Disease	B-Disease
17	'	I-Disease	I-Disease
18	s	I-Disease	I-Disease
19	disease	E-Disease	E-Disease
20	after	O	O
21	an	O	O
22	acute	O	O
23	challenge	O	O
24	with	O	O
25	the	O	O
26	mixed	O	O
27	dopamine	S-Chemical	S-Disease
28	agonist	O	O
29	,	O	O
30	apomorphine	S-Chemical	O
31	,	O	O
32	before	O	O
33	and	O	O
34	after	O	O
35	the	O	O
36	administration	O	O
37	of	O	O
38	fluoxetine	S-Chemical	S-Chemical
39	(	O	O
40	20	O	O
41	mg	O	O
42	twice	O	O
43	per	O	O
44	day	O	O
45	)	O	O
46	for	O	O
47	11	O	O
48	+	O	O
49	/	O	O
50	-	O	O
51	1	O	O
52	days	O	O
53	.	O	O

0	After	O	O
1	fluoxetine	S-Chemical	S-Chemical
2	treatment	O	O
3	,	O	O
4	there	O	O
5	was	O	O
6	a	O	O
7	significant	O	O
8	47	O	O
9	%	O	O
10	improvement	O	O
11	(	O	O
12	p	O	O
13	<	O	O
14	0	O	O
15	.	O	O
16	05	O	O
17	)	O	O
18	of	O	O
19	apomorphine	S-Chemical	S-Chemical
20	-	O	O
21	induced	O	O
22	dyskinesias	S-Disease	S-Disease
23	without	O	O
24	modification	O	O
25	of	O	O
26	parkinsonian	S-Disease	B-Disease
27	motor	B-Disease	B-Disease
28	disability	E-Disease	E-Disease
29	.	O	O

0	The	O	O
1	dyskinesias	S-Disease	S-Disease
2	were	O	O
3	reduced	O	O
4	predominantly	O	O
5	in	O	O
6	the	O	O
7	lower	O	O
8	limbs	O	O
9	during	O	O
10	the	O	O
11	onset	O	O
12	and	O	O
13	disappearance	O	O
14	of	O	O
15	dystonic	B-Disease	S-Disease
16	dyskinesias	E-Disease	S-Disease
17	(	O	O
18	onset	O	O
19	-	O	O
20	and	O	O
21	end	O	O
22	-	O	O
23	of	O	O
24	-	O	O
25	dose	O	O
26	dyskinesias	S-Disease	S-Disease
27	)	O	O
28	and	O	O
29	in	O	O
30	the	O	O
31	upper	O	O
32	limbs	O	O
33	during	O	O
34	choreic	B-Disease	S-Disease
35	mid	I-Disease	O
36	-	I-Disease	O
37	dose	I-Disease	O
38	dyskinesias	E-Disease	S-Disease
39	.	O	O

0	The	O	O
1	results	O	O
2	suggest	O	O
3	that	O	O
4	increased	O	O
5	brain	O	O
6	serotoninergic	O	E-Disease
7	transmission	O	O
8	with	O	O
9	fluoxetine	S-Chemical	S-Chemical
10	may	O	O
11	reduce	O	O
12	levodopa	S-Chemical	S-Chemical
13	-	O	O
14	or	O	O
15	dopamine	S-Chemical	O
16	agonist	O	O
17	-	O	O
18	induced	O	O
19	dyskinesias	S-Disease	S-Disease
20	without	O	O
21	aggravating	O	O
22	parkinsonian	S-Disease	S-Disease
23	motor	B-Disease	B-Disease
24	disability	E-Disease	E-Disease
25	.	O	O

0	A	O	O
1	large	O	O
2	population	O	O
3	-	O	O
4	based	O	O
5	follow	O	O
6	-	O	O
7	up	O	O
8	study	O	O
9	of	O	O
10	trimethoprim	B-Chemical	S-Chemical
11	-	I-Chemical	O
12	sulfamethoxazole	E-Chemical	S-Chemical
13	,	O	O
14	trimethoprim	S-Chemical	S-Chemical
15	,	O	O
16	and	O	O
17	cephalexin	S-Chemical	S-Chemical
18	for	O	O
19	uncommon	O	O
20	serious	O	O
21	drug	B-Disease	O
22	toxicity	E-Disease	S-Disease
23	.	O	O

0	We	O	O
1	conducted	O	O
2	a	O	O
3	population	O	O
4	-	O	O
5	based	O	O
6	45	O	O
7	-	O	O
8	day	O	O
9	follow	O	O
10	-	O	O
11	up	O	O
12	study	O	O
13	of	O	O
14	232	O	O
15	,	O	O
16	390	O	O
17	people	O	O
18	who	O	O
19	were	O	O
20	prescribed	O	O
21	trimethoprim	B-Chemical	S-Chemical
22	-	I-Chemical	O
23	sulfamethoxazole	E-Chemical	S-Chemical
24	(	O	O
25	TMP	B-Chemical	S-Chemical
26	-	I-Chemical	O
27	SMZ	E-Chemical	S-Disease
28	)	O	O
29	,	O	O
30	266	O	O
31	,	O	O
32	951	O	O
33	prescribed	O	O
34	trimethoprim	S-Chemical	S-Chemical
35	alone	O	O
36	,	O	O
37	and	O	O
38	196	O	O
39	,	O	O
40	397	O	O
41	prescribed	O	O
42	cephalexin	S-Chemical	S-Chemical
43	,	O	O
44	to	O	O
45	estimate	O	O
46	the	O	O
47	risk	O	O
48	of	O	O
49	serious	O	O
50	liver	B-Disease	O
51	,	I-Disease	O
52	blood	I-Disease	O
53	,	I-Disease	O
54	skin	I-Disease	O
55	,	I-Disease	O
56	and	I-Disease	O
57	renal	I-Disease	I-Disease
58	disorders	E-Disease	E-Disease
59	resulting	O	O
60	in	O	O
61	referral	O	O
62	or	O	O
63	hospitalization	O	O
64	associated	O	O
65	with	O	O
66	these	O	O
67	drugs	O	O
68	.	O	O

0	The	O	O
1	risk	O	O
2	of	O	O
3	clinically	O	O
4	important	O	O
5	idiopathic	O	B-Disease
6	liver	B-Disease	I-Disease
7	disease	E-Disease	E-Disease
8	was	O	O
9	similar	O	O
10	for	O	O
11	persons	O	O
12	prescribed	O	O
13	TMP	B-Chemical	B-Chemical
14	-	I-Chemical	I-Disease
15	SMZ	E-Chemical	E-Chemical
16	(	O	O
17	5	O	O
18	.	O	O
19	2	O	O
20	/	O	O
21	100	O	O
22	,	O	O
23	000	O	O
24	)	O	O
25	and	O	O
26	those	O	O
27	prescribed	O	O
28	trimethoprim	S-Chemical	S-Chemical
29	alone	O	O
30	(	O	O
31	3	O	O
32	.	O	O
33	8	O	O
34	/	O	O
35	100	O	O
36	,	O	O
37	000	O	O
38	)	O	O
39	.	O	O

0	The	O	O
1	risk	O	O
2	for	O	O
3	those	O	O
4	prescribed	O	O
5	cephalexin	S-Chemical	S-Chemical
6	was	O	O
7	somewhat	O	O
8	lower	O	O
9	(	O	O
10	2	O	O
11	.	O	O
12	0	O	O
13	/	O	O
14	100	O	O
15	,	O	O
16	000	O	O
17	)	O	O
18	.	O	O

0	Only	O	O
1	five	O	O
2	patients	O	O
3	experienced	O	O
4	blood	O	B-Disease
5	disorders	O	E-Disease
6	,	O	O
7	one	O	O
8	of	O	O
9	whom	O	O
10	was	O	O
11	exposed	O	O
12	to	O	O
13	TMP	B-Chemical	B-Chemical
14	-	I-Chemical	I-Disease
15	SMZ	E-Chemical	E-Chemical
16	;	O	O
17	of	O	O
18	seven	O	O
19	with	O	O
20	erythema	B-Disease	B-Disease
21	multiforme	E-Disease	E-Disease
22	and	O	O
23	Stevens	B-Disease	B-Disease
24	-	I-Disease	I-Disease
25	Johnson	I-Disease	I-Disease
26	syndrome	E-Disease	E-Disease
27	,	O	O
28	four	O	O
29	were	O	O
30	exposed	O	O
31	to	O	O
32	TMP	B-Chemical	S-Disease
33	-	I-Chemical	I-Disease
34	SMZ	E-Chemical	S-Disease
35	.	O	O

0	The	O	O
1	one	O	O
2	case	O	O
3	of	O	O
4	toxic	B-Disease	O
5	epidermal	I-Disease	O
6	necrolysis	E-Disease	S-Disease
7	occurred	O	O
8	in	O	O
9	a	O	O
10	patient	O	O
11	who	O	O
12	took	O	O
13	cephalexin	S-Chemical	S-Chemical
14	.	O	O

0	Finally	O	O
1	,	O	O
2	only	O	O
3	five	O	O
4	cases	O	O
5	of	O	O
6	acute	O	B-Disease
7	parenchymal	O	I-Disease
8	renal	B-Disease	I-Disease
9	disease	E-Disease	E-Disease
10	occurred	O	O
11	,	O	O
12	none	O	O
13	likely	O	O
14	to	O	O
15	be	O	O
16	caused	O	O
17	by	O	O
18	a	O	O
19	study	O	O
20	drug	O	O
21	.	O	O

0	Clinical	O	O
1	safety	O	O
2	of	O	O
3	lidocaine	S-Chemical	S-Chemical
4	in	O	O
5	patients	O	O
6	with	O	O
7	cocaine	S-Chemical	S-Chemical
8	-	O	O
9	associated	O	O
10	myocardial	B-Disease	B-Disease
11	infarction	E-Disease	E-Disease
12	.	O	O

0	STUDY	O	O
1	OBJECTIVE	O	O
2	:	O	O
3	To	O	O
4	evaluate	O	O
5	the	O	O
6	safety	O	O
7	of	O	O
8	lidocaine	S-Chemical	S-Chemical
9	in	O	O
10	the	O	O
11	setting	O	O
12	of	O	O
13	cocaine	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	myocardial	B-Disease	B-Disease
17	infarction	E-Disease	E-Disease
18	(	O	O
19	MI	S-Disease	S-Disease
20	)	O	O
21	.	O	O

0	PARTICIPANTS	O	O
1	:	O	O
2	Patients	O	O
3	with	O	O
4	cocaine	S-Chemical	S-Chemical
5	-	O	O
6	associated	O	O
7	MI	S-Disease	S-Disease
8	who	O	O
9	received	O	O
10	lidocaine	S-Chemical	S-Disease
11	in	O	O
12	the	O	O
13	emergency	O	O
14	department	O	O
15	.	O	O

0	RESULTS	O	O
1	:	O	O
2	Of	O	O
3	29	O	O
4	patients	O	O
5	who	O	O
6	received	O	O
7	lidocaine	S-Chemical	S-Disease
8	in	O	O
9	the	O	O
10	setting	O	O
11	of	O	O
12	cocaine	S-Chemical	S-Chemical
13	-	O	O
14	associated	O	O
15	MI	S-Disease	S-Chemical
16	,	O	O
17	no	O	O
18	patient	O	O
19	died	O	O
20	;	O	O
21	exhibited	O	O
22	bradydysrhythmias	S-Disease	O
23	,	O	O
24	ventricular	B-Disease	B-Disease
25	tachycardia	E-Disease	E-Disease
26	,	O	O
27	or	O	O
28	ventricular	B-Disease	B-Disease
29	fibrillation	E-Disease	E-Disease
30	;	O	O
31	or	O	O
32	experienced	O	O
33	seizures	S-Disease	S-Disease
34	after	O	O
35	administration	O	O
36	of	O	O
37	lidocaine	S-Chemical	S-Disease
38	(	O	O
39	95	O	O
40	%	O	O
41	confidence	O	O
42	interval	O	O
43	,	O	O
44	0	O	O
45	%	O	O
46	to	O	O
47	11	O	O
48	%	O	O
49	)	O	O
50	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Despite	O	O
3	theoretical	O	O
4	concerns	O	O
5	that	O	O
6	lidocaine	S-Chemical	S-Chemical
7	may	O	O
8	enhance	O	O
9	cocaine	S-Chemical	B-Disease
10	toxicity	S-Disease	E-Disease
11	,	O	O
12	the	O	O
13	use	O	O
14	of	O	O
15	lidocaine	S-Chemical	S-Chemical
16	in	O	O
17	patients	O	O
18	with	O	O
19	cocaine	S-Chemical	S-Chemical
20	-	O	O
21	associated	O	O
22	MI	S-Disease	S-Chemical
23	was	O	O
24	not	O	O
25	associated	O	O
26	with	O	O
27	significant	O	O
28	cardiovascular	B-Disease	B-Disease
29	or	I-Disease	O
30	central	I-Disease	B-Disease
31	nervous	I-Disease	I-Disease
32	system	I-Disease	I-Disease
33	toxicity	E-Disease	E-Disease
34	.	O	O

0	Experimental	O	O
1	progressive	O	O
2	muscular	B-Disease	B-Disease
3	dystrophy	E-Disease	E-Disease
4	and	O	O
5	its	O	O
6	treatment	O	O
7	with	O	O
8	high	O	O
9	doses	O	O
10	anabolizing	O	O
11	agents	O	O
12	.	O	O

0	We	O	O
1	are	O	O
2	still	O	O
3	a	O	O
4	long	O	O
5	way	O	O
6	from	O	O
7	discovering	O	O
8	an	O	O
9	unequivocal	O	O
10	pathogenetic	O	O
11	interpretation	O	O
12	of	O	O
13	progressive	O	B-Disease
14	muscular	B-Disease	I-Disease
15	dystrophy	E-Disease	E-Disease
16	in	O	O
17	man	O	O
18	.	O	O

0	Myopathy	S-Disease	S-Disease
1	due	O	O
2	to	O	O
3	lack	O	O
4	of	O	O
5	vitamin	B-Chemical	O
6	E	E-Chemical	O
7	and	O	O
8	myopathy	S-Disease	S-Disease
9	induced	O	O
10	by	O	O
11	certain	O	O
12	viruses	O	O
13	have	O	O
14	much	O	O
15	in	O	O
16	common	O	O
17	anatomically	O	O
18	and	O	O
19	pathologically	O	O
20	with	O	O
21	the	O	O
22	human	O	O
23	form	O	O
24	.	O	O

0	The	O	O
1	authors	O	O
2	induced	O	O
3	myodystrophy	S-Disease	S-Disease
4	in	O	O
5	the	O	O
6	rat	O	O
7	by	O	O
8	giving	O	O
9	it	O	O
10	a	O	O
11	diet	O	O
12	lacking	O	O
13	in	O	O
14	vitamin	B-Chemical	O
15	E	E-Chemical	O
16	.	O	O

0	The	O	O
1	pharmacological	O	O
2	characteristics	O	O
3	of	O	O
4	vitamin	B-Chemical	O
5	E	E-Chemical	O
6	and	O	O
7	the	O	O
8	degenerative	O	O
9	changes	O	O
10	brought	O	O
11	about	O	O
12	by	O	O
13	its	O	O
14	deficiency	O	S-Disease
15	,	O	O
16	especially	O	O
17	in	O	O
18	the	O	O
19	muscles	O	O
20	,	O	O
21	are	O	O
22	illustrated	O	O
23	.	O	O

0	It	O	O
1	is	O	O
2	thus	O	O
3	confirmed	O	O
4	that	O	O
5	the	O	O
6	histological	O	O
7	characteristics	O	O
8	of	O	O
9	myopathic	S-Disease	B-Disease
10	rat	O	B-Disease
11	muscle	O	E-Disease
12	induced	O	O
13	experimentally	O	O
14	are	O	O
15	extraordinarily	O	O
16	similar	O	O
17	to	O	O
18	those	O	O
19	of	O	O
20	human	O	B-Disease
21	myopathy	S-Disease	E-Disease
22	as	O	O
23	confirmed	O	O
24	during	O	O
25	biopsies	O	O
26	performed	O	O
27	at	O	O
28	the	O	O
29	Orthopaedic	O	O
30	Traumatological	O	E-Disease
31	Centre	O	O
32	,	O	O
33	Florence	O	S-Chemical
34	.	O	O

0	The	O	O
1	encouraging	O	O
2	results	O	O
3	obtained	O	O
4	in	O	O
5	various	O	O
6	authoratative	O	O
7	departments	O	O
8	in	O	O
9	myopathic	S-Disease	S-Disease
10	patients	O	O
11	by	O	O
12	using	O	O
13	anabolizing	O	O
14	steroids	S-Chemical	S-Chemical
15	have	O	O
16	encouraged	O	O
17	the	O	O
18	authors	O	O
19	to	O	O
20	investigate	O	O
21	the	O	O
22	beneficial	O	O
23	effects	O	O
24	of	O	O
25	one	O	O
26	anabolizing	O	O
27	agent	O	O
28	(	O	O
29	Dianabol	S-Chemical	S-Chemical
30	,	O	O
31	CIBA	S-Chemical	S-Chemical
32	)	O	O
33	at	O	O
34	high	O	O
35	doses	O	O
36	in	O	O
37	rats	O	O
38	rendered	O	O
39	myopathic	S-Disease	S-Disease
40	by	O	O
41	a	O	O
42	diet	O	O
43	deficient	O	O
44	in	O	O
45	vitamin	B-Chemical	O
46	E	E-Chemical	E-Disease
47	.	O	O

0	In	O	O
1	this	O	O
2	way	O	O
3	they	O	O
4	obtained	O	O
5	appreciable	O	O
6	changes	O	O
7	in	O	O
8	body	O	O
9	weight	O	O
10	(	O	O
11	increased	O	O
12	from	O	O
13	50	O	O
14	to	O	O
15	70	O	O
16	g	O	O
17	after	O	O
18	forty	O	O
19	days	O	O
20	at	O	O
21	a	O	O
22	dose	O	O
23	of	O	O
24	5	O	O
25	mg	O	O
26	per	O	O
27	day	O	O
28	of	O	O
29	anabolizing	O	O
30	agent	O	O
31	)	O	O
32	,	O	O
33	but	O	O
34	most	O	O
35	of	O	O
36	all	O	O
37	they	O	O
38	found	O	O
39	histological	O	O
40	changes	O	O
41	due	O	O
42	to	O	O
43	"	O	O
44	regenerative	O	O
45	"	O	O
46	changes	O	O
47	in	O	O
48	the	O	O
49	muscle	O	O
50	tissue	O	O
51	,	O	O
52	which	O	O
53	however	O	O
54	maintained	O	O
55	its	O	O
56	myopathic	S-Disease	S-Disease
57	characteristics	O	O
58	in	O	O
59	the	O	O
60	control	O	O
61	animals	O	O
62	that	O	O
63	were	O	O
64	not	O	O
65	treated	O	O
66	with	O	O
67	the	O	O
68	anabolizing	O	O
69	agent	O	O
70	.	O	O

0	The	O	O
1	authors	O	O
2	conclude	O	O
3	by	O	O
4	affirming	O	O
5	the	O	O
6	undoubted	O	O
7	efficacy	O	O
8	of	O	O
9	the	O	O
10	anabolizing	O	O
11	steroids	S-Chemical	S-Chemical
12	in	O	O
13	experimental	O	O
14	myopathic	B-Disease	B-Disease
15	disease	E-Disease	E-Disease
16	,	O	O
17	but	O	O
18	they	O	O
19	have	O	O
20	reservations	O	O
21	as	O	O
22	to	O	O
23	the	O	O
24	transfer	O	O
25	of	O	O
26	the	O	O
27	results	O	O
28	into	O	O
29	the	O	O
30	human	O	O
31	field	O	O
32	,	O	O
33	where	O	O
34	high	O	O
35	dosage	O	O
36	cannot	O	O
37	be	O	O
38	carried	O	O
39	out	O	O
40	continuously	O	O
41	because	O	O
42	of	O	O
43	the	O	O
44	effects	O	O
45	of	O	O
46	the	O	O
47	drug	O	O
48	on	O	O
49	virility	O	O
50	;	O	O
51	because	O	O
52	the	O	O
53	tissue	O	O
54	injury	O	O
55	too	O	O
56	often	O	O
57	occurs	O	O
58	at	O	O
59	an	O	O
60	irreversible	O	O
61	stage	O	O
62	vis	O	O
63	-	O	O
64	a	O	O
65	-	O	O
66	vis	O	O
67	the	O	O
68	"	O	O
69	regeneration	O	O
70	"	O	O
71	of	O	O
72	the	O	O
73	muscle	O	O
74	tissue	O	O
75	;	O	O
76	and	O	O
77	finally	O	O
78	because	O	O
79	the	O	O
80	dystrophic	O	S-Disease
81	injurious	O	O
82	agent	O	O
83	is	O	O
84	certainly	O	O
85	not	O	O
86	the	O	O
87	lack	O	O
88	of	O	O
89	vitamin	B-Chemical	B-Disease
90	E	E-Chemical	E-Disease
91	but	O	O
92	something	O	O
93	as	O	O
94	yet	O	O
95	unknown	O	O
96	.	O	O

0	Paclitaxel	S-Chemical	S-Chemical
1	3	O	O
2	-	O	O
3	hour	O	O
4	infusion	O	O
5	given	O	O
6	alone	O	O
7	and	O	O
8	combined	O	O
9	with	O	O
10	carboplatin	S-Chemical	S-Chemical
11	:	O	O
12	preliminary	O	O
13	results	O	O
14	of	O	O
15	dose	O	O
16	-	O	O
17	escalation	O	O
18	trials	O	O
19	.	O	O

0	Paclitaxel	S-Chemical	S-Chemical
1	(	O	O
2	Taxol	S-Chemical	S-Chemical
3	;	O	O
4	Bristol	O	I-Chemical
5	-	O	I-Disease
6	Myers	O	I-Disease
7	Squibb	O	S-Disease
8	Company	O	S-Chemical
9	,	O	O
10	Princeton	O	S-Chemical
11	,	O	O
12	NJ	O	S-Chemical
13	)	O	O
14	by	O	O
15	3	O	O
16	-	O	O
17	hour	O	O
18	infusion	O	O
19	was	O	O
20	combined	O	O
21	with	O	O
22	carboplatin	S-Chemical	S-Chemical
23	in	O	O
24	a	O	O
25	phase	O	O
26	I	O	O
27	/	O	O
28	II	O	O
29	study	O	O
30	directed	O	O
31	to	O	O
32	patients	O	O
33	with	O	O
34	non	B-Disease	O
35	-	I-Disease	O
36	small	I-Disease	I-Disease
37	cell	I-Disease	I-Disease
38	lung	I-Disease	I-Disease
39	cancer	E-Disease	E-Disease
40	.	O	O

0	Carboplatin	S-Chemical	S-Chemical
1	was	O	O
2	given	O	O
3	at	O	O
4	a	O	O
5	fixed	O	O
6	target	O	O
7	area	O	O
8	under	O	O
9	the	O	O
10	concentration	O	O
11	-	O	O
12	time	O	O
13	curve	O	O
14	of	O	O
15	6	O	O
16	.	O	O
17	0	O	O
18	by	O	O
19	the	O	O
20	Calvert	O	S-Chemical
21	formula	O	O
22	,	O	O
23	whereas	O	O
24	paclitaxel	S-Chemical	S-Chemical
25	was	O	O
26	escalated	O	O
27	in	O	O
28	patient	O	O
29	cohorts	O	O
30	from	O	O
31	150	O	O
32	mg	O	O
33	/	O	O
34	m2	O	O
35	(	O	O
36	dose	O	O
37	level	O	O
38	I	O	O
39	)	O	O
40	to	O	O
41	175	O	O
42	,	O	O
43	200	O	O
44	,	O	O
45	225	O	O
46	,	O	O
47	and	O	O
48	250	O	O
49	mg	O	O
50	/	O	O
51	m2	O	O
52	.	O	O

0	The	O	O
1	225	O	O
2	mg	O	O
3	/	O	O
4	m2	O	O
5	level	O	O
6	was	O	O
7	expanded	O	O
8	for	O	O
9	the	O	O
10	phase	O	O
11	II	O	O
12	study	O	O
13	since	O	O
14	the	O	O
15	highest	O	O
16	level	O	O
17	achieved	O	O
18	(	O	O
19	250	O	O
20	mg	O	O
21	/	O	O
22	m2	O	O
23	)	O	O
24	required	O	O
25	modification	O	O
26	because	O	O
27	of	O	O
28	nonhematologic	O	O
29	toxicities	S-Disease	S-Disease
30	(	O	O
31	arthralgia	S-Disease	S-Disease
32	and	O	O
33	sensory	B-Disease	B-Disease
34	neuropathy	E-Disease	E-Disease
35	)	O	O
36	.	O	O

0	Toxicities	S-Disease	O
1	were	O	O
2	compared	O	O
3	with	O	O
4	a	O	O
5	cohort	O	O
6	of	O	O
7	patients	O	O
8	in	O	O
9	a	O	O
10	phase	O	O
11	I	O	O
12	trial	O	O
13	of	O	O
14	paclitaxel	S-Chemical	S-Chemical
15	alone	O	O
16	at	O	O
17	identical	O	O
18	dose	O	O
19	levels	O	O
20	.	O	O

0	Carboplatin	S-Chemical	S-Chemical
1	did	O	O
2	not	O	O
3	appear	O	O
4	to	O	O
5	add	O	O
6	to	O	O
7	the	O	O
8	hematologic	B-Disease	O
9	toxicities	E-Disease	S-Disease
10	observed	O	O
11	,	O	O
12	and	O	O
13	the	O	O
14	paclitaxel	S-Chemical	S-Disease
15	/	O	O
16	carboplatin	S-Chemical	S-Chemical
17	combination	O	O
18	could	O	O
19	be	O	O
20	dosed	O	O
21	every	O	O
22	3	O	O
23	weeks	O	O
24	.	O	O

0	The	O	O
1	dose	O	O
2	-	O	O
3	dependent	O	O
4	effect	O	O
5	of	O	O
6	misoprostol	S-Chemical	S-Chemical
7	on	O	O
8	indomethacin	S-Chemical	S-Chemical
9	-	O	O
10	induced	O	O
11	renal	B-Disease	B-Disease
12	dysfunction	E-Disease	E-Disease
13	in	O	O
14	well	O	O
15	compensated	O	O
16	cirrhosis	S-Disease	S-Chemical
17	.	O	O

0	Misoprostol	S-Chemical	S-Chemical
1	(	O	O
2	200	O	O
3	micrograms	O	O
4	)	O	O
5	has	O	O
6	been	O	O
7	shown	O	O
8	to	O	O
9	acutely	O	O
10	counteract	O	O
11	the	O	O
12	indomethacin	S-Chemical	O
13	-	O	O
14	induced	O	O
15	renal	B-Disease	B-Disease
16	dysfunction	E-Disease	E-Disease
17	in	O	O
18	well	O	O
19	compensated	O	O
20	cirrhotic	S-Disease	S-Chemical
21	patients	O	O
22	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	determine	O	O
8	if	O	O
9	the	O	O
10	prophylactic	O	O
11	value	O	O
12	of	O	O
13	misoprostol	S-Chemical	S-Chemical
14	was	O	O
15	dose	O	O
16	-	O	O
17	dependent	O	O
18	.	O	O

0	Parameters	O	O
1	of	O	O
2	renal	O	O
3	hemodynamics	O	O
4	and	O	O
5	tubular	O	B-Disease
6	sodium	S-Chemical	E-Disease
7	and	O	O
8	water	O	O
9	handling	O	O
10	were	O	O
11	assessed	O	O
12	by	O	O
13	clearance	O	O
14	techniques	O	O
15	in	O	O
16	26	O	O
17	well	O	O
18	compensated	O	O
19	cirrhotic	S-Disease	S-Disease
20	patients	O	O
21	before	O	O
22	and	O	O
23	after	O	O
24	an	O	O
25	oral	O	O
26	combination	O	O
27	of	O	O
28	50	O	O
29	mg	O	O
30	of	O	O
31	indomethacin	S-Chemical	S-Chemical
32	and	O	O
33	various	O	O
34	doses	O	O
35	of	O	O
36	misoprostol	S-Chemical	S-Chemical
37	.	O	O

0	The	O	O
1	200	O	O
2	-	O	O
3	micrograms	O	O
4	dose	O	O
5	was	O	O
6	able	O	O
7	to	O	O
8	totally	O	O
9	abolish	O	O
10	the	O	O
11	deleterious	O	O
12	renal	O	O
13	effects	O	E-Disease
14	of	O	O
15	indomethacin	S-Chemical	S-Chemical
16	,	O	O
17	whereas	O	O
18	the	O	O
19	800	O	O
20	-	O	O
21	micrograms	O	O
22	dose	O	O
23	resulted	O	O
24	in	O	O
25	significant	O	O
26	worsening	O	O
27	of	O	O
28	renal	O	S-Disease
29	hemodynamics	O	E-Disease
30	and	O	O
31	sodium	S-Chemical	S-Disease
32	retention	O	O
33	.	O	O

0	These	O	O
1	results	O	O
2	suggest	O	O
3	that	O	O
4	the	O	O
5	renal	O	O
6	protective	O	O
7	effects	O	O
8	of	O	O
9	misoprostol	S-Chemical	S-Chemical
10	is	O	O
11	dose	O	O
12	-	O	O
13	dependent	O	O
14	.	O	O

0	However	O	O
1	,	O	O
2	until	O	O
3	this	O	O
4	apparent	O	O
5	ability	O	O
6	of	O	O
7	200	O	O
8	micrograms	O	O
9	of	O	O
10	misoprostol	S-Chemical	S-Chemical
11	to	O	O
12	prevent	O	O
13	the	O	O
14	adverse	O	O
15	effects	O	O
16	of	O	O
17	indomethacin	S-Chemical	S-Chemical
18	on	O	O
19	renal	O	I-Disease
20	function	O	E-Disease
21	is	O	O
22	confirmed	O	O
23	with	O	O
24	chronic	O	O
25	frequent	O	O
26	dosing	O	O
27	,	O	O
28	it	O	O
29	would	O	O
30	be	O	O
31	prudent	O	O
32	to	O	O
33	avoid	O	O
34	nonsteroidal	O	O
35	anti	O	O
36	-	O	O
37	inflammatory	O	S-Disease
38	therapy	O	O
39	in	O	O
40	patients	O	O
41	with	O	O
42	cirrhosis	S-Disease	S-Chemical
43	.	O	O

0	Increased	O	O
1	frequency	O	O
2	and	O	O
3	severity	O	O
4	of	O	O
5	angio	B-Disease	S-Disease
6	-	I-Disease	I-Disease
7	oedema	E-Disease	S-Disease
8	related	O	O
9	to	O	O
10	long	O	O
11	-	O	O
12	term	O	O
13	therapy	O	O
14	with	O	O
15	angiotensin	B-Chemical	O
16	-	I-Chemical	O
17	converting	I-Chemical	O
18	enzyme	I-Chemical	O
19	inhibitor	E-Chemical	O
20	in	O	O
21	two	O	O
22	patients	O	O
23	.	O	O

0	Adverse	O	O
1	reactions	O	O
2	to	O	O
3	drugs	O	O
4	are	O	O
5	well	O	O
6	recognized	O	O
7	as	O	O
8	a	O	O
9	cause	O	O
10	of	O	O
11	acute	O	B-Disease
12	or	O	O
13	chronic	O	B-Disease
14	urticaria	S-Disease	E-Disease
15	,	O	O
16	and	O	O
17	angio	B-Disease	S-Disease
18	-	I-Disease	I-Disease
19	oedema	E-Disease	E-Disease
20	.	O	O

0	Angiotensin	B-Chemical	S-Disease
1	-	I-Chemical	O
2	converting	I-Chemical	O
3	enzyme	I-Chemical	O
4	(	I-Chemical	O
5	ACE	I-Chemical	S-Chemical
6	)	I-Chemical	O
7	inhibitors	E-Chemical	O
8	,	O	O
9	used	O	O
10	to	O	O
11	treat	O	O
12	hypertension	S-Disease	S-Disease
13	and	O	O
14	congestive	B-Disease	O
15	heart	I-Disease	B-Disease
16	failure	E-Disease	E-Disease
17	,	O	O
18	were	O	O
19	introduced	O	O
20	in	O	O
21	Europe	O	S-Chemical
22	in	O	O
23	the	O	O
24	middle	O	O
25	of	O	O
26	the	O	O
27	eighties	O	O
28	,	O	O
29	and	O	O
30	the	O	O
31	use	O	O
32	of	O	O
33	these	O	O
34	drugs	O	O
35	has	O	O
36	increased	O	O
37	progressively	O	O
38	.	O	O

0	Soon	O	O
1	after	O	O
2	the	O	O
3	introduction	O	O
4	of	O	O
5	ACE	B-Chemical	S-Chemical
6	inhibitors	E-Chemical	O
7	,	O	O
8	acute	O	O
9	bouts	O	O
10	of	O	O
11	angio	B-Disease	S-Disease
12	-	I-Disease	I-Disease
13	oedema	E-Disease	E-Disease
14	were	O	O
15	reported	O	O
16	in	O	O
17	association	O	O
18	with	O	O
19	the	O	O
20	use	O	O
21	of	O	O
22	these	O	O
23	drugs	O	O
24	.	O	O

0	We	O	O
1	wish	O	O
2	to	O	O
3	draw	O	O
4	attention	O	O
5	to	O	O
6	the	O	O
7	possibility	O	O
8	of	O	O
9	adverse	O	O
10	reactions	O	O
11	to	O	O
12	ACE	B-Chemical	S-Chemical
13	inhibitors	E-Chemical	O
14	after	O	O
15	long	O	O
16	-	O	O
17	term	O	O
18	use	O	O
19	and	O	O
20	in	O	O
21	patients	O	O
22	with	O	O
23	pre	O	O
24	-	O	O
25	existing	O	O
26	angio	B-Disease	S-Disease
27	-	I-Disease	I-Disease
28	oedema	E-Disease	E-Disease
29	.	O	O

0	Myoclonus	S-Disease	S-Chemical
1	associated	O	O
2	with	O	O
3	lorazepam	S-Chemical	S-Chemical
4	therapy	O	O
5	in	O	O
6	very	O	O
7	-	O	O
8	low	O	O
9	-	O	O
10	birth	O	O
11	-	O	O
12	weight	O	O
13	infants	O	O
14	.	O	O

0	Lorazepam	S-Chemical	S-Chemical
1	is	O	O
2	being	O	O
3	used	O	O
4	with	O	O
5	increasing	O	O
6	frequency	O	O
7	as	O	O
8	a	O	O
9	sedative	O	O
10	in	O	O
11	the	O	O
12	newborn	O	O
13	and	O	O
14	the	O	O
15	young	O	O
16	infant	O	O
17	.	O	O

0	Concern	O	O
1	has	O	O
2	been	O	O
3	raised	O	O
4	with	O	O
5	regard	O	O
6	to	O	O
7	the	O	O
8	safety	O	O
9	of	O	O
10	lorazepam	S-Chemical	S-Chemical
11	in	O	O
12	this	O	O
13	age	O	O
14	group	O	O
15	,	O	O
16	especially	O	O
17	in	O	O
18	very	O	O
19	-	O	O
20	low	O	O
21	-	O	O
22	birth	O	O
23	-	O	O
24	weight	O	O
25	(	O	O
26	VLBW	O	O
27	;	O	O
28	<	O	O
29	1	O	O
30	,	O	O
31	500	O	O
32	g	O	O
33	)	O	O
34	infants	O	O
35	.	O	O

0	Three	O	O
1	young	O	O
2	infants	O	O
3	,	O	O
4	all	O	O
5	of	O	O
6	birth	O	O
7	weight	O	O
8	<	O	O
9	1	O	O
10	,	O	O
11	500	O	O
12	g	O	O
13	,	O	O
14	experienced	O	O
15	myoclonus	S-Disease	S-Disease
16	following	O	O
17	the	O	O
18	intravenous	O	O
19	administration	O	O
20	of	O	O
21	lorazepam	S-Chemical	S-Chemical
22	.	O	O

0	The	O	O
1	potential	O	O
2	neurotoxic	S-Disease	O
3	effects	O	O
4	of	O	O
5	the	O	O
6	drug	O	O
7	(	O	O
8	and	O	O
9	its	O	O
10	vehicle	O	O
11	)	O	O
12	in	O	O
13	this	O	O
14	population	O	O
15	are	O	O
16	discussed	O	O
17	.	O	O

0	Injectable	O	O
1	lorazepam	S-Chemical	S-Chemical
2	should	O	O
3	be	O	O
4	used	O	O
5	with	O	O
6	caution	O	O
7	in	O	O
8	VLBW	O	S-Disease
9	infants	O	O
10	.	O	O

0	Transvenous	O	O
1	right	O	O
2	ventricular	O	O
3	pacing	O	O
4	during	O	O
5	cardiopulmonary	O	O
6	resuscitation	O	O
7	of	O	O
8	pediatric	O	O
9	patients	O	O
10	with	O	O
11	acute	O	B-Disease
12	cardiomyopathy	S-Disease	I-Disease
13	.	O	O

0	We	O	O
1	describe	O	O
2	the	O	O
3	cardiopulmonary	O	O
4	resuscitation	O	O
5	efforts	O	O
6	on	O	O
7	five	O	O
8	patients	O	O
9	who	O	O
10	presented	O	O
11	in	O	O
12	acute	O	B-Disease
13	circulatory	B-Disease	I-Disease
14	failure	E-Disease	E-Disease
15	from	O	O
16	myocardial	B-Disease	B-Disease
17	dysfunction	E-Disease	E-Disease
18	.	O	O

0	Three	O	O
1	patients	O	O
2	had	O	O
3	acute	O	B-Disease
4	viral	O	B-Disease
5	myocarditis	S-Disease	E-Disease
6	,	O	O
7	one	O	O
8	had	O	O
9	a	O	O
10	carbamazepine	S-Chemical	S-Chemical
11	-	O	O
12	induced	O	O
13	acute	O	B-Disease
14	eosinophilic	B-Disease	I-Disease
15	myocarditis	E-Disease	E-Disease
16	,	O	O
17	and	O	O
18	one	O	O
19	had	O	O
20	cardiac	O	B-Disease
21	hemosiderosis	O	E-Disease
22	resulting	O	O
23	in	O	O
24	acute	O	O
25	cardiogenic	B-Disease	B-Disease
26	shock	E-Disease	E-Disease
27	.	O	O

0	An	O	O
1	introducer	O	O
2	sheath	O	O
3	,	O	O
4	a	O	O
5	pacemaker	O	O
6	,	O	O
7	and	O	O
8	sterile	O	O
9	pacing	O	O
10	wires	O	O
11	were	O	O
12	made	O	O
13	readily	O	O
14	available	O	O
15	for	O	O
16	the	O	O
17	patients	O	O
18	,	O	O
19	should	O	O
20	the	O	O
21	need	O	O
22	arise	O	O
23	to	O	O
24	terminate	O	O
25	resistant	O	O
26	cardiac	O	B-Disease
27	dysrhythmias	S-Disease	E-Disease
28	.	O	O

0	All	O	O
1	patients	O	O
2	developed	O	O
3	cardiocirculatory	O	O
4	arrest	O	O
5	associated	O	O
6	with	O	O
7	extreme	O	O
8	hypotension	S-Disease	S-Disease
9	and	O	O
10	dysrhythmias	S-Disease	S-Disease
11	within	O	O
12	the	O	O
13	first	O	O
14	48	O	O
15	hours	O	O
16	of	O	O
17	their	O	O
18	admission	O	O
19	to	O	O
20	the	O	O
21	pediatric	O	O
22	intensive	O	O
23	care	O	O
24	unit	O	O
25	(	O	O
26	PICU	O	S-Disease
27	)	O	O
28	.	O	O

0	These	O	O
1	patients	O	O
2	had	O	O
3	a	O	O
4	second	O	O
5	event	O	O
6	of	O	O
7	cardiac	B-Disease	B-Disease
8	arrest	E-Disease	E-Disease
9	,	O	O
10	resulting	O	O
11	in	O	O
12	death	O	O
13	,	O	O
14	within	O	O
15	10	O	O
16	to	O	O
17	60	O	O
18	minutes	O	O
19	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	cardiac	O	S-Disease
4	pacing	O	O
5	during	O	O
6	resuscitative	O	O
7	efforts	O	O
8	in	O	O
9	pediatric	O	O
10	patients	O	O
11	suffering	O	O
12	from	O	O
13	acute	O	B-Disease
14	myocardial	B-Disease	B-Disease
15	dysfunction	E-Disease	E-Disease
16	may	O	O
17	not	O	O
18	have	O	O
19	long	O	O
20	-	O	O
21	term	O	O
22	value	O	O
23	in	O	O
24	and	O	O
25	of	O	O
26	itself	O	O
27	;	O	O
28	however	O	O
29	,	O	O
30	if	O	O
31	temporary	O	O
32	hemodynamic	O	O
33	stability	O	O
34	is	O	O
35	achieved	O	O
36	by	O	O
37	this	O	O
38	procedure	O	O
39	,	O	O
40	it	O	O
41	may	O	O
42	provide	O	O
43	additional	O	O
44	time	O	O
45	needed	O	O
46	to	O	O
47	institute	O	O
48	other	O	O
49	therapeutic	O	O
50	modalities	O	O
51	.	O	O

0	Efficacy	O	O
1	and	O	O
2	safety	O	O
3	of	O	O
4	granisetron	S-Chemical	S-Chemical
5	,	O	O
6	a	O	O
7	selective	O	O
8	5	B-Chemical	O
9	-	I-Chemical	O
10	hydroxytryptamine	E-Chemical	O
11	-	O	O
12	3	O	O
13	receptor	O	O
14	antagonist	O	O
15	,	O	O
16	in	O	O
17	the	O	O
18	prevention	O	O
19	of	O	O
20	nausea	S-Disease	S-Disease
21	and	O	O
22	vomiting	S-Disease	S-Disease
23	induced	O	O
24	by	O	O
25	high	O	O
26	-	O	O
27	dose	O	O
28	cisplatin	S-Chemical	S-Chemical
29	.	O	O

0	PURPOSE	O	O
1	:	O	O
2	To	O	O
3	assess	O	O
4	the	O	O
5	antiemetic	O	O
6	effects	O	O
7	and	O	O
8	safety	O	O
9	profile	O	O
10	of	O	O
11	four	O	O
12	different	O	O
13	doses	O	O
14	of	O	O
15	granisetron	S-Chemical	S-Chemical
16	(	O	O
17	Kytril	S-Chemical	S-Chemical
18	;	O	O
19	SmithKline	O	B-Chemical
20	Beecham	O	I-Disease
21	Pharmaceuticals	O	S-Disease
22	,	O	O
23	Philadelphia	O	S-Chemical
24	,	O	O
25	PA	O	S-Chemical
26	)	O	O
27	when	O	O
28	administered	O	O
29	as	O	O
30	a	O	O
31	single	O	O
32	intravenous	O	O
33	(	O	O
34	IV	O	O
35	)	O	O
36	dose	O	O
37	for	O	O
38	prophylaxis	O	O
39	of	O	O
40	cisplatin	S-Chemical	S-Chemical
41	-	O	O
42	induced	O	O
43	nausea	S-Disease	S-Disease
44	and	O	O
45	vomiting	S-Disease	S-Disease
46	.	O	O

0	PATIENTS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	One	O	O
5	hundred	O	O
6	eighty	O	O
7	-	O	O
8	four	O	O
9	chemotherapy	O	O
10	-	O	O
11	naive	O	O
12	patients	O	O
13	receiving	O	O
14	high	O	O
15	-	O	O
16	dose	O	O
17	cisplatin	S-Chemical	S-Chemical
18	(	O	O
19	81	O	O
20	to	O	O
21	120	O	O
22	mg	O	O
23	/	O	O
24	m2	O	O
25	)	O	O
26	were	O	O
27	randomized	O	O
28	to	O	O
29	receive	O	O
30	one	O	O
31	of	O	O
32	four	O	O
33	granisetron	S-Chemical	O
34	doses	O	O
35	(	O	O
36	5	O	O
37	,	O	O
38	10	O	O
39	,	O	O
40	20	O	O
41	,	O	O
42	or	O	O
43	40	O	O
44	micrograms	O	O
45	/	O	O
46	kg	O	O
47	)	O	O
48	administered	O	O
49	before	O	O
50	chemotherapy	O	O
51	.	O	O

0	Patients	O	O
1	were	O	O
2	observed	O	O
3	on	O	O
4	an	O	O
5	inpatient	O	O
6	basis	O	O
7	for	O	O
8	18	O	O
9	to	O	O
10	24	O	O
11	hours	O	O
12	,	O	O
13	and	O	O
14	vital	O	O
15	signs	O	O
16	,	O	O
17	nausea	S-Disease	S-Disease
18	,	O	O
19	vomiting	S-Disease	S-Disease
20	,	O	O
21	retching	O	O
22	,	O	O
23	and	O	O
24	appetite	O	S-Disease
25	were	O	O
26	assessed	O	O
27	.	O	O

0	RESULTS	O	O
1	:	O	O
2	After	O	O
3	granisetron	S-Chemical	O
4	doses	O	O
5	of	O	O
6	5	O	O
7	,	O	O
8	10	O	O
9	,	O	O
10	20	O	O
11	,	O	O
12	and	O	O
13	40	O	O
14	micrograms	O	O
15	/	O	O
16	kg	O	O
17	,	O	O
18	a	O	O
19	major	O	O
20	response	O	O
21	(	O	O
22	<	O	O
23	or	O	O
24	=	O	O
25	two	O	O
26	vomiting	S-Disease	O
27	or	O	O
28	retching	O	O
29	episodes	O	O
30	,	O	O
31	and	O	O
32	no	O	O
33	antiemetic	O	O
34	rescue	O	O
35	)	O	O
36	was	O	O
37	recorded	O	O
38	in	O	O
39	23	O	O
40	%	O	O
41	,	O	O
42	57	O	O
43	%	O	O
44	,	O	O
45	58	O	O
46	%	O	O
47	,	O	O
48	and	O	O
49	60	O	O
50	%	O	O
51	of	O	O
52	patients	O	O
53	,	O	O
54	respectively	O	O
55	,	O	O
56	and	O	O
57	a	O	O
58	complete	O	O
59	response	O	O
60	(	O	O
61	no	O	O
62	vomiting	S-Disease	S-Disease
63	or	O	O
64	retching	O	O
65	,	O	O
66	and	O	O
67	no	O	O
68	antiemetic	O	O
69	rescue	O	O
70	)	O	O
71	in	O	O
72	18	O	O
73	%	O	O
74	,	O	O
75	41	O	O
76	%	O	O
77	,	O	O
78	40	O	O
79	%	O	O
80	,	O	O
81	and	O	O
82	47	O	O
83	%	O	O
84	of	O	O
85	patients	O	O
86	,	O	O
87	respectively	O	O
88	.	O	O

0	There	O	O
1	was	O	O
2	a	O	O
3	statistically	O	O
4	longer	O	O
5	time	O	O
6	to	O	O
7	first	O	O
8	episode	O	O
9	of	O	O
10	nausea	S-Disease	S-Disease
11	(	O	O
12	P	O	S-Disease
13	=	O	O
14	.	O	O
15	0015	O	O
16	)	O	O
17	and	O	O
18	vomiting	S-Disease	S-Disease
19	(	O	O
20	P	O	S-Disease
21	=	O	O
22	.	O	O
23	0001	O	O
24	)	O	O
25	,	O	O
26	and	O	O
27	fewer	O	O
28	patients	O	O
29	were	O	O
30	administered	O	O
31	additional	O	O
32	antiemetic	O	O
33	medication	O	O
34	in	O	O
35	the	O	O
36	10	O	O
37	-	O	O
38	micrograms	O	O
39	/	O	O
40	kg	O	O
41	dosing	O	O
42	groups	O	O
43	than	O	O
44	in	O	O
45	the	O	O
46	5	O	O
47	-	O	O
48	micrograms	O	O
49	/	O	O
50	kg	O	O
51	dosing	O	O
52	group	O	O
53	.	O	O

0	As	O	O
1	granisetron	S-Chemical	S-Chemical
2	dose	O	O
3	increased	O	O
4	,	O	O
5	appetite	O	S-Disease
6	return	O	O
7	increased	O	O
8	(	O	O
9	P	O	B-Chemical
10	=	O	O
11	.	O	O
12	040	O	O
13	)	O	O
14	.	O	O

0	Headache	S-Disease	S-Disease
1	was	O	O
2	the	O	O
3	most	O	O
4	frequently	O	O
5	reported	O	O
6	adverse	O	O
7	event	O	O
8	(	O	O
9	20	O	O
10	%	O	O
11	)	O	O
12	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	A	O	O
3	single	O	O
4	10	O	O
5	-	O	O
6	,	O	O
7	20	O	O
8	-	O	O
9	,	O	O
10	or	O	O
11	40	O	O
12	-	O	O
13	micrograms	O	O
14	/	O	O
15	kg	O	O
16	dose	O	O
17	of	O	O
18	granisetron	S-Chemical	S-Chemical
19	was	O	O
20	effective	O	O
21	in	O	O
22	controlling	O	O
23	vomiting	S-Disease	S-Disease
24	in	O	O
25	57	O	O
26	%	O	O
27	to	O	O
28	60	O	O
29	%	O	O
30	of	O	O
31	patients	O	O
32	who	O	O
33	received	O	O
34	cisplatin	S-Chemical	S-Chemical
35	at	O	O
36	doses	O	O
37	greater	O	O
38	than	O	O
39	81	O	O
40	mg	O	O
41	/	O	O
42	m2	O	O
43	and	O	O
44	totally	O	O
45	prevented	O	O
46	vomiting	S-Disease	S-Disease
47	in	O	O
48	40	O	O
49	%	O	O
50	to	O	O
51	47	O	O
52	%	O	O
53	of	O	O
54	patients	O	O
55	.	O	O

0	Granisetron	S-Chemical	S-Chemical
1	was	O	O
2	well	O	O
3	tolerated	O	O
4	at	O	O
5	all	O	O
6	doses	O	O
7	.	O	O

0	Adverse	O	O
1	interaction	O	O
2	between	O	O
3	clonidine	S-Chemical	S-Chemical
4	and	O	O
5	verapamil	S-Chemical	S-Chemical
6	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	report	O	O
4	two	O	O
5	cases	O	O
6	of	O	O
7	a	O	O
8	possible	O	O
9	adverse	O	O
10	interaction	O	O
11	between	O	O
12	clonidine	S-Chemical	S-Chemical
13	and	O	O
14	verapamil	S-Chemical	S-Chemical
15	resulting	O	O
16	in	O	O
17	atrioventricular	B-Disease	S-Disease
18	(	I-Disease	O
19	AV	I-Disease	S-Chemical
20	)	I-Disease	O
21	block	E-Disease	O
22	in	O	O
23	both	O	O
24	patients	O	O
25	and	O	O
26	severe	O	O
27	hypotension	S-Disease	S-Disease
28	in	O	O
29	one	O	O
30	patient	O	O
31	.	O	O

0	CASE	O	O
1	SUMMARIES	O	O
2	:	O	O
3	A	O	O
4	54	O	O
5	-	O	O
6	year	O	O
7	-	O	O
8	old	O	O
9	woman	O	O
10	with	O	O
11	hyperaldosteronism	S-Disease	S-Disease
12	was	O	O
13	treated	O	O
14	with	O	O
15	verapamil	S-Chemical	S-Chemical
16	480	O	O
17	mg	O	O
18	/	O	O
19	d	O	O
20	and	O	O
21	spironolactone	S-Chemical	S-Disease
22	100	O	O
23	mg	O	O
24	/	O	O
25	d	O	O
26	.	O	O

0	After	O	O
1	the	O	O
2	addition	O	O
3	of	O	O
4	a	O	O
5	minimal	O	O
6	dose	O	O
7	of	O	O
8	clonidine	S-Chemical	S-Chemical
9	(	O	O
10	0	O	O
11	.	O	O
12	15	O	O
13	mg	O	O
14	bid	O	O
15	)	O	O
16	,	O	O
17	she	O	O
18	developed	O	O
19	complete	O	O
20	AV	B-Disease	S-Chemical
21	block	E-Disease	O
22	and	O	O
23	severe	O	O
24	hypotension	S-Disease	S-Disease
25	,	O	O
26	which	O	O
27	resolved	O	O
28	upon	O	O
29	cessation	O	O
30	of	O	O
31	all	O	O
32	medications	O	O
33	.	O	O

0	A	O	O
1	65	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	woman	O	O
7	was	O	O
8	treated	O	O
9	with	O	O
10	extended	O	O
11	-	O	O
12	release	O	O
13	verapamil	S-Chemical	S-Chemical
14	240	O	O
15	mg	O	O
16	/	O	O
17	d	O	O
18	.	O	O

0	After	O	O
1	the	O	O
2	addition	O	O
3	of	O	O
4	clonidine	S-Chemical	S-Chemical
5	0	O	O
6	.	O	O
7	15	O	O
8	mg	O	O
9	bid	O	O
10	she	O	O
11	developed	O	O
12	complete	O	O
13	AV	B-Disease	S-Disease
14	block	E-Disease	O
15	,	O	O
16	which	O	O
17	resolved	O	O
18	after	O	O
19	all	O	O
20	therapy	O	O
21	was	O	O
22	stopped	O	O
23	.	O	O

0	DISCUSSION	O	O
1	:	O	O
2	An	O	O
3	adverse	O	O
4	interaction	O	O
5	between	O	O
6	clonidine	S-Chemical	S-Chemical
7	and	O	O
8	verapamil	S-Chemical	S-Chemical
9	has	O	O
10	not	O	O
11	been	O	O
12	reported	O	O
13	previously	O	O
14	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	Caution	O	S-Disease
3	is	O	O
4	recommended	O	O
5	in	O	O
6	combining	O	O
7	clonidine	S-Chemical	S-Chemical
8	and	O	O
9	verapamil	S-Chemical	S-Disease
10	therapy	O	O
11	,	O	O
12	even	O	O
13	in	O	O
14	patients	O	O
15	who	O	O
16	do	O	O
17	not	O	O
18	have	O	O
19	sinus	O	S-Disease
20	or	O	O
21	AV	O	B-Disease
22	node	O	O
23	dysfunction	O	E-Disease
24	.	O	O

0	Pharmacological	O	O
1	studies	O	O
2	on	O	O
3	a	O	O
4	new	O	O
5	dihydrothienopyridine	B-Chemical	S-Chemical
6	calcium	E-Chemical	S-Disease
7	antagonist	O	O
8	,	O	O
9	S	B-Chemical	B-Chemical
10	-	I-Chemical	O
11	312	I-Chemical	E-Chemical
12	-	I-Chemical	O
13	d	E-Chemical	O
14	.	O	O

0	S	B-Chemical	O
1	-	I-Chemical	O
2	312	E-Chemical	O
3	,	O	O
4	S	B-Chemical	O
5	-	I-Chemical	O
6	312	I-Chemical	O
7	-	I-Chemical	O
8	d	E-Chemical	O
9	,	O	O
10	but	O	O
11	not	O	O
12	S	B-Chemical	O
13	-	I-Chemical	O
14	312	I-Chemical	O
15	-	I-Chemical	O
16	l	E-Chemical	O
17	,	O	O
18	L	O	O
19	-	O	O
20	type	O	O
21	calcium	S-Chemical	O
22	channel	O	O
23	antagonists	O	O
24	,	O	O
25	showed	O	O
26	anticonvulsant	O	O
27	effects	O	O
28	on	O	O
29	the	O	O
30	audiogenic	B-Disease	O
31	tonic	I-Disease	S-Disease
32	convulsions	E-Disease	O
33	in	O	O
34	DBA	O	B-Chemical
35	/	O	I-Disease
36	2	O	E-Disease
37	mice	O	O
38	;	O	O
39	and	O	O
40	their	O	O
41	ED50	O	O
42	values	O	O
43	were	O	O
44	18	O	O
45	.	O	O
46	4	O	O
47	(	O	O
48	12	O	O
49	.	O	O
50	8	O	O
51	-	O	O
52	27	O	O
53	.	O	O
54	1	O	O
55	)	O	O
56	mg	O	O
57	/	O	O
58	kg	O	O
59	,	O	O
60	p	O	O
61	.	O	O
62	o	O	O
63	.	O	O
64	and	O	O
65	15	O	O
66	.	O	O
67	0	O	O
68	(	O	O
69	10	O	O
70	.	O	O
71	2	O	O
72	-	O	O
73	23	O	O
74	.	O	O
75	7	O	O
76	)	O	O
77	mg	O	O
78	/	O	O
79	kg	O	O
80	,	O	O
81	p	O	O
82	.	O	O
83	o	O	O
84	.	O	O
85	,	O	O
86	respectively	O	O
87	,	O	O
88	while	O	O
89	that	O	O
90	of	O	O
91	flunarizine	S-Chemical	S-Chemical
92	was	O	O
93	34	O	O
94	.	O	O
95	0	O	O
96	(	O	O
97	26	O	O
98	.	O	O
99	0	O	O
100	-	O	O
101	44	O	O
102	.	O	O
103	8	O	O
104	)	O	O
105	mg	O	O
106	/	O	O
107	kg	O	O
108	,	O	O
109	p	O	O
110	.	O	O
111	o	O	O
112	.	O	O

0	Although	O	O
1	moderate	O	O
2	anticonvulsant	O	O
3	effects	O	O
4	of	O	O
5	S	B-Chemical	B-Chemical
6	-	I-Chemical	B-Chemical
7	312	I-Chemical	E-Chemical
8	-	I-Chemical	E-Chemical
9	d	E-Chemical	O
10	in	O	O
11	higher	O	O
12	doses	O	O
13	were	O	O
14	observed	O	O
15	against	O	O
16	the	O	O
17	clonic	O	S-Disease
18	convulsions	S-Disease	S-Disease
19	induced	O	O
20	by	O	O
21	pentylenetetrazole	S-Chemical	S-Chemical
22	(	O	O
23	85	O	O
24	mg	O	O
25	/	O	O
26	kg	O	O
27	,	O	O
28	s	O	O
29	.	O	O
30	c	O	O
31	.	O	O
32	)	O	O
33	or	O	O
34	bemegride	S-Chemical	S-Chemical
35	(	O	O
36	40	O	O
37	mg	O	O
38	/	O	O
39	kg	O	O
40	,	O	O
41	s	O	O
42	.	O	O
43	c	O	O
44	.	O	O
45	)	O	O
46	,	O	O
47	no	O	O
48	effects	O	O
49	were	O	O
50	observed	O	O
51	in	O	O
52	convulsions	S-Disease	O
53	induced	O	O
54	by	O	O
55	N	B-Chemical	B-Chemical
56	-	I-Chemical	I-Chemical
57	methyl	I-Chemical	I-Chemical
58	-	I-Chemical	I-Chemical
59	D	I-Chemical	I-Chemical
60	-	I-Chemical	I-Chemical
61	aspartate	E-Chemical	E-Chemical
62	,	O	O
63	picrotoxin	S-Chemical	S-Chemical
64	,	O	O
65	or	O	O
66	electroshock	O	O
67	in	O	O
68	Slc	O	S-Chemical
69	:	O	O
70	ddY	O	S-Chemical
71	mice	O	O
72	.	O	O

0	S	B-Chemical	B-Chemical
1	-	I-Chemical	I-Chemical
2	312	I-Chemical	E-Chemical
3	-	I-Chemical	O
4	d	E-Chemical	O
5	may	O	O
6	be	O	O
7	useful	O	O
8	in	O	O
9	the	O	O
10	therapy	O	O
11	of	O	O
12	certain	O	O
13	types	O	O
14	of	O	O
15	human	O	B-Disease
16	epilepsy	S-Disease	E-Disease
17	.	O	O

0	Transmural	O	O
1	myocardial	B-Disease	B-Disease
2	infarction	E-Disease	E-Disease
3	with	O	O
4	sumatriptan	S-Chemical	S-Chemical
5	.	O	O

0	For	O	O
1	sumatriptan	S-Chemical	S-Chemical
2	,	O	O
3	tightness	O	O
4	in	O	O
5	the	O	O
6	chest	O	O
7	caused	O	O
8	by	O	O
9	an	O	O
10	unknown	O	O
11	mechanism	O	O
12	has	O	O
13	been	O	O
14	reported	O	O
15	in	O	O
16	3	O	O
17	-	O	O
18	5	O	O
19	%	O	O
20	of	O	O
21	users	O	O
22	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	47	O	O
4	-	O	O
5	year	O	O
6	-	O	O
7	old	O	O
8	woman	O	O
9	with	O	O
10	an	O	O
11	acute	O	B-Disease
12	myocardial	B-Disease	B-Disease
13	infarction	E-Disease	E-Disease
14	after	O	O
15	administration	O	O
16	of	O	O
17	sumatriptan	S-Chemical	S-Chemical
18	6	O	O
19	mg	O	O
20	subcutaneously	O	O
21	for	O	O
22	cluster	B-Disease	O
23	headache	E-Disease	O
24	.	O	O

0	The	O	O
1	patient	O	O
2	had	O	O
3	no	O	O
4	history	O	O
5	of	O	O
6	underlying	O	O
7	ischaemic	B-Disease	B-Disease
8	heart	I-Disease	I-Disease
9	disease	E-Disease	E-Disease
10	or	O	O
11	Prinzmetal	B-Disease	S-Chemical
12	'	I-Disease	I-Disease
13	s	I-Disease	I-Disease
14	angina	E-Disease	S-Disease
15	.	O	O

0	Flumazenil	S-Chemical	S-Chemical
1	induces	O	O
2	seizures	S-Disease	S-Disease
3	and	O	O
4	death	O	O
5	in	O	O
6	mixed	O	O
7	cocaine	S-Chemical	S-Chemical
8	-	O	O
9	diazepam	S-Chemical	E-Chemical
10	intoxications	O	E-Disease
11	.	O	O

0	STUDY	O	O
1	HYPOTHESIS	O	S-Disease
2	:	O	O
3	Administration	O	O
4	of	O	O
5	the	O	O
6	benzodiazepine	S-Chemical	S-Chemical
7	antagonist	O	O
8	flumazenil	S-Chemical	S-Chemical
9	may	O	O
10	unmask	O	O
11	seizures	S-Disease	S-Disease
12	in	O	O
13	mixed	O	O
14	cocaine	S-Chemical	S-Chemical
15	-	O	O
16	benzodiazepine	S-Chemical	S-Chemical
17	intoxication	O	S-Disease
18	.	O	O

0	DESIGN	O	O
1	:	O	O
2	Male	O	O
3	Sprague	O	O
4	-	O	O
5	Dawley	O	O
6	rats	O	O
7	received	O	O
8	100	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	cocaine	S-Chemical	S-Disease
13	IP	O	O
14	alone	O	O
15	,	O	O
16	5	O	O
17	mg	O	O
18	/	O	O
19	kg	O	O
20	diazepam	S-Chemical	S-Chemical
21	alone	O	O
22	,	O	O
23	or	O	O
24	a	O	O
25	combination	O	O
26	of	O	O
27	diazepam	S-Chemical	S-Chemical
28	and	O	O
29	cocaine	S-Chemical	S-Disease
30	.	O	O

0	Three	O	O
1	minutes	O	O
2	later	O	O
3	,	O	O
4	groups	O	O
5	were	O	O
6	challenged	O	O
7	with	O	O
8	vehicle	O	O
9	or	O	O
10	flumazenil	S-Chemical	S-Chemical
11	5	O	O
12	or	O	O
13	10	O	O
14	mg	O	O
15	/	O	O
16	kg	O	O
17	IP	O	O
18	.	O	O

0	Animal	O	O
1	behavior	O	O
2	,	O	O
3	seizures	S-Disease	S-Disease
4	(	O	O
5	time	O	O
6	to	O	O
7	and	O	O
8	incidence	O	O
9	)	O	O
10	,	O	O
11	death	O	O
12	(	O	O
13	time	O	O
14	to	O	O
15	and	O	O
16	incidence	O	O
17	)	O	O
18	,	O	O
19	and	O	O
20	cortical	O	O
21	EEG	O	S-Disease
22	tracings	O	O
23	were	O	O
24	recorded	O	O
25	.	O	O

0	INTERVENTIONS	O	O
1	:	O	O
2	Administration	O	O
3	of	O	O
4	flumazenil	S-Chemical	S-Chemical
5	to	O	O
6	animals	O	O
7	after	O	O
8	they	O	O
9	had	O	O
10	received	O	O
11	a	O	O
12	combination	O	O
13	dose	O	O
14	of	O	O
15	cocaine	S-Chemical	S-Chemical
16	and	O	O
17	diazepam	S-Chemical	S-Chemical
18	.	O	O

0	RESULTS	O	O
1	:	O	O
2	In	O	O
3	group	O	O
4	1	O	O
5	,	O	O
6	animals	O	O
7	received	O	O
8	cocaine	S-Chemical	S-Chemical
9	followed	O	O
10	by	O	O
11	vehicle	O	O
12	.	O	O

0	This	O	O
1	resulted	O	O
2	in	O	O
3	100	O	O
4	%	O	O
5	developing	O	O
6	seizures	S-Disease	S-Disease
7	and	O	O
8	death	O	O
9	.	O	O

0	Group	O	O
1	2	O	O
2	received	O	O
3	diazepam	S-Chemical	S-Chemical
4	alone	O	O
5	followed	O	O
6	by	O	O
7	vehicle	O	O
8	.	O	O

0	Group	O	O
1	3	O	O
2	received	O	O
3	diazepam	S-Chemical	S-Chemical
4	followed	O	O
5	by	O	O
6	5	O	O
7	mg	O	O
8	/	O	O
9	kg	O	O
10	flumazenil	S-Chemical	S-Chemical
11	.	O	O

0	Animals	O	O
1	became	O	O
2	somnolent	O	O
3	after	O	O
4	diazepam	S-Chemical	S-Chemical
5	and	O	O
6	then	O	O
7	active	O	O
8	after	O	O
9	flumazenil	S-Chemical	S-Chemical
10	administration	O	O
11	.	O	O

0	In	O	O
1	group	O	O
2	4	O	O
3	,	O	O
4	a	O	O
5	combination	O	O
6	of	O	O
7	cocaine	S-Chemical	S-Chemical
8	and	O	O
9	diazepam	S-Chemical	S-Chemical
10	was	O	O
11	administered	O	O
12	simultaneously	O	O
13	.	O	O

0	This	O	O
1	resulted	O	O
2	in	O	O
3	no	O	O
4	overt	O	O
5	or	O	O
6	EEG	O	S-Disease
7	-	O	O
8	detectable	O	O
9	seizures	S-Disease	S-Disease
10	and	O	O
11	a	O	O
12	50	O	O
13	%	O	O
14	incidence	O	O
15	of	O	O
16	death	O	O
17	.	O	O

0	Group	O	O
1	5	O	O
2	received	O	O
3	a	O	O
4	similar	O	O
5	combination	O	O
6	of	O	O
7	cocaine	S-Chemical	S-Chemical
8	and	O	O
9	diazepam	S-Chemical	S-Chemical
10	,	O	O
11	followed	O	O
12	later	O	O
13	by	O	O
14	5	O	O
15	mg	O	O
16	/	O	O
17	kg	O	O
18	flumazenil	S-Chemical	S-Chemical
19	.	O	O

0	This	O	O
1	resulted	O	O
2	in	O	O
3	an	O	O
4	increased	O	O
5	incidence	O	O
6	of	O	O
7	seizures	S-Disease	S-Disease
8	,	O	O
9	90	O	O
10	%	O	O
11	(	O	O
12	P	O	S-Disease
13	<	O	O
14	.	O	O
15	01	O	O
16	)	O	O
17	,	O	O
18	and	O	O
19	death	O	O
20	,	O	O
21	100	O	O
22	%	O	O
23	(	O	O
24	P	O	O
25	<	O	O
26	or	O	O
27	=	O	O
28	.	O	O
29	01	O	O
30	)	O	O
31	,	O	O
32	compared	O	O
33	with	O	O
34	group	O	O
35	4	O	O
36	.	O	O

0	Group	O	O
1	6	O	O
2	received	O	O
3	cocaine	S-Chemical	S-Chemical
4	and	O	O
5	diazepam	S-Chemical	S-Chemical
6	followed	O	O
7	by	O	O
8	10	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	flumazenil	S-Chemical	S-Chemical
13	.	O	O

0	This	O	O
1	also	O	O
2	resulted	O	O
3	in	O	O
4	an	O	O
5	increased	O	O
6	incidence	O	O
7	of	O	O
8	seizures	S-Disease	S-Disease
9	,	O	O
10	90	O	O
11	%	O	O
12	(	O	O
13	P	O	S-Disease
14	<	O	O
15	or	O	O
16	=	O	O
17	.	O	O
18	01	O	O
19	)	O	O
20	,	O	O
21	and	O	O
22	death	O	O
23	,	O	O
24	90	O	O
25	%	O	O
26	(	O	O
27	P	O	O
28	<	O	O
29	or	O	O
30	=	O	O
31	.	O	O
32	05	O	O
33	)	O	O
34	,	O	O
35	compared	O	O
36	with	O	O
37	group	O	O
38	4	O	O
39	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Flumazenil	S-Chemical	S-Chemical
3	can	O	O
4	unmask	O	O
5	seizures	S-Disease	S-Disease
6	and	O	O
7	increase	O	O
8	the	O	O
9	incidence	O	O
10	of	O	O
11	death	O	O
12	in	O	O
13	a	O	O
14	model	O	O
15	of	O	O
16	combined	O	O
17	cocaine	S-Chemical	S-Chemical
18	-	O	O
19	diazepam	S-Chemical	E-Chemical
20	intoxications	O	E-Disease
21	.	O	O

0	Mechanisms	O	O
1	for	O	O
2	protective	O	O
3	effects	O	O
4	of	O	O
5	free	O	O
6	radical	O	O
7	scavengers	O	O
8	on	O	O
9	gentamicin	S-Chemical	S-Chemical
10	-	O	O
11	mediated	O	O
12	nephropathy	S-Disease	S-Disease
13	in	O	O
14	rats	O	O
15	.	O	O

0	Studies	O	O
1	were	O	O
2	performed	O	O
3	to	O	O
4	examine	O	O
5	the	O	O
6	mechanisms	O	O
7	for	O	O
8	the	O	O
9	protective	O	O
10	effects	O	O
11	of	O	O
12	free	O	O
13	radical	O	O
14	scavengers	O	O
15	on	O	O
16	gentamicin	S-Chemical	S-Chemical
17	(	O	O
18	GM	S-Chemical	S-Chemical
19	)	O	E-Chemical
20	-	O	O
21	mediated	O	O
22	nephropathy	S-Disease	S-Disease
23	.	O	O

0	Administration	O	O
1	of	O	O
2	GM	S-Chemical	S-Chemical
3	at	O	O
4	40	O	O
5	mg	O	O
6	/	O	O
7	kg	O	O
8	sc	O	O
9	for	O	O
10	13	O	O
11	days	O	O
12	to	O	O
13	rats	O	O
14	induced	O	O
15	a	O	O
16	significant	O	O
17	reduction	O	B-Disease
18	in	O	I-Disease
19	renal	O	I-Disease
20	blood	O	I-Disease
21	flow	O	E-Disease
22	(	O	O
23	RBF	O	S-Disease
24	)	O	O
25	and	O	O
26	inulin	O	B-Disease
27	clearance	O	E-Disease
28	(	O	O
29	CIn	O	S-Chemical
30	)	O	O
31	as	O	O
32	well	O	O
33	as	O	O
34	marked	O	O
35	tubular	B-Disease	B-Disease
36	damage	E-Disease	E-Disease
37	.	O	O

0	A	O	O
1	significant	O	O
2	reduction	O	O
3	in	O	O
4	urinary	O	B-Disease
5	guanosine	B-Chemical	I-Chemical
6	3	I-Chemical	E-Chemical
7	'	I-Chemical	I-Chemical
8	,	I-Chemical	O
9	5	I-Chemical	I-Chemical
10	'	I-Chemical	I-Chemical
11	-	I-Chemical	O
12	cyclic	I-Chemical	I-Chemical
13	monophosphate	E-Chemical	O
14	(	O	O
15	cGMP	S-Chemical	S-Chemical
16	)	O	O
17	excretion	O	O
18	and	O	O
19	a	O	O
20	significant	O	O
21	increase	O	O
22	in	O	O
23	renal	O	I-Disease
24	cortical	O	I-Disease
25	renin	O	E-Disease
26	and	O	O
27	endothelin	O	O
28	-	O	E-Chemical
29	1	O	E-Disease
30	contents	O	O
31	were	O	O
32	also	O	O
33	observed	O	O
34	in	O	O
35	GM	S-Chemical	B-Chemical
36	-	O	O
37	mediated	O	O
38	nephropathy	S-Disease	S-Disease
39	.	O	O

0	Superoxide	S-Chemical	O
1	dismutase	O	O
2	(	O	O
3	SOD	O	S-Chemical
4	)	O	O
5	or	O	O
6	dimethylthiourea	S-Chemical	S-Chemical
7	(	O	O
8	DMTU	S-Chemical	S-Chemical
9	)	O	O
10	significantly	O	O
11	lessened	O	O
12	the	O	O
13	GM	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	decrement	O	O
17	in	O	O
18	CIn	O	S-Chemical
19	.	O	O

0	The	O	O
1	SOD	O	S-Chemical
2	-	O	O
3	induced	O	O
4	increase	O	O
5	in	O	O
6	glomerular	O	O
7	filtration	O	S-Disease
8	rate	O	O
9	was	O	O
10	associated	O	O
11	with	O	O
12	a	O	O
13	marked	O	O
14	improvement	O	O
15	in	O	O
16	RBF	O	S-Disease
17	,	O	O
18	an	O	O
19	increase	O	O
20	in	O	O
21	urinary	O	B-Disease
22	cGMP	S-Chemical	E-Disease
23	excretion	O	O
24	,	O	O
25	and	O	O
26	a	O	O
27	decrease	O	O
28	in	O	O
29	renal	O	I-Disease
30	renin	O	E-Chemical
31	and	O	O
32	endothelin	O	S-Disease
33	-	O	I-Disease
34	1	O	E-Disease
35	content	O	O
36	.	O	O

0	SOD	O	S-Chemical
1	did	O	O
2	not	O	O
3	attenuate	O	O
4	the	O	O
5	tubular	B-Disease	B-Disease
6	damage	E-Disease	E-Disease
7	.	O	O

0	In	O	O
1	contrast	O	O
2	,	O	O
3	DMTU	S-Chemical	S-Chemical
4	significantly	O	O
5	reduced	O	O
6	the	O	O
7	tubular	B-Disease	B-Disease
8	damage	E-Disease	E-Disease
9	and	O	O
10	lipid	O	B-Disease
11	peroxidation	O	E-Disease
12	,	O	O
13	but	O	O
14	it	O	O
15	did	O	O
16	not	O	O
17	affect	O	O
18	renal	O	B-Disease
19	hemodynamics	O	E-Disease
20	and	O	O
21	vasoactive	O	O
22	substances	O	O
23	.	O	O

0	Neither	O	O
1	SOD	O	S-Chemical
2	nor	O	O
3	DMTU	S-Chemical	S-Chemical
4	affected	O	O
5	the	O	O
6	renal	O	I-Disease
7	cortical	O	I-Disease
8	GM	S-Chemical	B-Disease
9	content	O	E-Disease
10	in	O	O
11	GM	S-Chemical	S-Chemical
12	-	O	O
13	treated	O	O
14	rats	O	O
15	.	O	O

0	These	O	O
1	results	O	O
2	suggest	O	O
3	that	O	O
4	1	O	O
5	)	O	O
6	both	O	O
7	SOD	O	S-Chemical
8	and	O	O
9	DMTU	S-Chemical	S-Chemical
10	have	O	O
11	protective	O	O
12	effects	O	O
13	on	O	O
14	GM	S-Chemical	S-Chemical
15	-	O	O
16	mediated	O	O
17	nephropathy	S-Disease	S-Disease
18	,	O	O
19	2	O	O
20	)	O	O
21	the	O	O
22	mechanisms	O	O
23	for	O	O
24	the	O	O
25	protective	O	O
26	effects	O	O
27	differ	O	O
28	for	O	O
29	SOD	O	S-Chemical
30	and	O	O
31	DMTU	S-Chemical	S-Chemical
32	,	O	O
33	and	O	O
34	3	O	O
35	)	O	O
36	superoxide	S-Chemical	O
37	anions	O	O
38	play	O	O
39	a	O	O
40	critical	O	O
41	role	O	O
42	in	O	O
43	GM	S-Chemical	S-Chemical
44	-	O	O
45	induced	O	O
46	renal	O	I-Disease
47	vasoconstriction	O	S-Disease
48	.	O	O

0	Cephalothin	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	immune	O	B-Disease
4	hemolytic	B-Disease	E-Disease
5	anemia	E-Disease	E-Disease
6	.	O	O

0	A	O	O
1	patient	O	O
2	with	O	O
3	renal	B-Disease	B-Disease
4	disease	E-Disease	E-Disease
5	developed	O	O
6	Coombs	O	S-Chemical
7	-	O	I-Disease
8	positive	O	I-Disease
9	hemolytic	B-Disease	O
10	anemia	E-Disease	E-Disease
11	while	O	O
12	receiving	O	O
13	cephalothin	S-Chemical	S-Chemical
14	therapy	O	O
15	.	O	O

0	An	O	O
1	anti	O	O
2	-	O	O
3	cephalothin	S-Chemical	S-Chemical
4	IgG	O	E-Chemical
5	antibody	O	O
6	was	O	O
7	detected	O	O
8	in	O	O
9	the	O	O
10	patient	O	O
11	'	O	O
12	s	O	O
13	serum	O	O
14	and	O	O
15	in	O	O
16	the	O	O
17	eluates	O	O
18	from	O	O
19	her	O	O
20	erythrocytes	O	S-Disease
21	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	nonimmunologic	O	O
4	binding	O	O
5	of	O	O
6	normal	O	O
7	and	O	O
8	patient	O	O
9	'	O	O
10	s	O	O
11	serum	O	O
12	proteins	O	O
13	to	O	O
14	her	O	O
15	own	O	O
16	and	O	O
17	cephalothin	S-Chemical	S-Chemical
18	-	O	O
19	coated	O	O
20	normal	O	O
21	red	O	O
22	cells	O	O
23	was	O	O
24	demonstrated	O	O
25	.	O	O

0	Skin	O	O
1	tests	O	O
2	and	O	O
3	in	O	O
4	vitro	O	O
5	lymphocyte	O	S-Disease
6	stimulation	O	O
7	revealed	O	O
8	that	O	O
9	the	O	O
10	patient	O	O
11	was	O	O
12	sensitized	O	O
13	to	O	O
14	cephalothin	S-Chemical	S-Chemical
15	and	O	O
16	also	O	O
17	to	O	O
18	ampicillin	S-Chemical	S-Chemical
19	.	O	O

0	Careful	O	O
1	investigation	O	O
2	of	O	O
3	drug	O	O
4	-	O	O
5	induced	O	O
6	hemolytic	B-Disease	O
7	anemias	E-Disease	S-Disease
8	reveals	O	O
9	the	O	O
10	complexity	O	O
11	of	O	O
12	the	O	O
13	immune	O	O
14	mechanisms	O	O
15	involved	O	O
16	.	O	O

0	Assessment	O	O
1	of	O	O
2	cardiomyocyte	O	O
3	DNA	O	O
4	synthesis	O	O
5	during	O	O
6	hypertrophy	S-Disease	S-Disease
7	in	O	O
8	adult	O	O
9	mice	O	O
10	.	O	O

0	The	O	O
1	ability	O	O
2	of	O	O
3	cardiomyocytes	O	O
4	to	O	O
5	synthesize	O	O
6	DNA	O	O
7	in	O	O
8	response	O	O
9	to	O	O
10	experimentally	O	O
11	induced	O	O
12	cardiac	B-Disease	B-Disease
13	hypertrophy	E-Disease	E-Disease
14	was	O	O
15	assessed	O	O
16	in	O	O
17	adult	O	O
18	mice	O	O
19	.	O	O

0	Isoproterenol	S-Chemical	S-Chemical
1	delivered	O	O
2	by	O	O
3	osmotic	O	O
4	minipump	O	O
5	implantation	O	O
6	in	O	O
7	adult	O	O
8	C3Heb	O	S-Chemical
9	/	O	O
10	FeJ	O	E-Chemical
11	mice	O	O
12	resulted	O	O
13	in	O	O
14	a	O	O
15	46	O	O
16	%	O	O
17	increase	O	O
18	in	O	O
19	heart	O	B-Disease
20	weight	O	E-Disease
21	and	O	O
22	a	O	O
23	19	O	O
24	.	O	O
25	3	O	O
26	%	O	O
27	increase	O	O
28	in	O	O
29	cardiomyocyte	O	S-Disease
30	area	O	O
31	.	O	O

0	No	O	O
1	DNA	O	O
2	synthesis	O	O
3	,	O	O
4	as	O	O
5	assessed	O	O
6	by	O	O
7	autoradiographic	O	O
8	analysis	O	O
9	of	O	O
10	isolated	O	O
11	cardiomyocytes	O	S-Disease
12	,	O	O
13	was	O	O
14	observed	O	O
15	in	O	O
16	control	O	O
17	or	O	O
18	hypertrophic	B-Disease	S-Disease
19	hearts	E-Disease	S-Disease
20	.	O	O

0	To	O	O
1	determine	O	O
2	whether	O	O
3	the	O	O
4	capacity	O	O
5	for	O	O
6	reactive	O	O
7	DNA	O	O
8	synthesis	O	O
9	was	O	O
10	also	O	O
11	subject	O	O
12	to	O	O
13	genetic	O	O
14	regulation	O	O
15	,	O	O
16	cardiac	B-Disease	B-Disease
17	hypertrophy	E-Disease	E-Disease
18	was	O	O
19	induced	O	O
20	in	O	O
21	the	O	O
22	strains	O	O
23	of	O	O
24	mice	O	O
25	comprising	O	O
26	the	O	O
27	extremes	O	O
28	of	O	O
29	the	O	O
30	nuclear	O	O
31	number	O	O
32	survey	O	O
33	.	O	O

0	These	O	O
1	data	O	O
2	indicate	O	O
3	that	O	O
4	adult	O	O
5	mouse	O	O
6	atrial	O	O
7	and	O	O
8	ventricular	O	O
9	cardiomyocytes	O	E-Disease
10	do	O	O
11	not	O	O
12	synthesize	O	O
13	DNA	O	O
14	in	O	O
15	response	O	O
16	to	O	O
17	isoproterenol	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	cardiac	B-Disease	B-Disease
21	hypertrophy	E-Disease	E-Disease
22	.	O	O

0	Central	O	O
1	cardiovascular	O	O
2	effects	O	O
3	of	O	O
4	AVP	S-Chemical	S-Chemical
5	and	O	O
6	ANP	O	S-Chemical
7	in	O	O
8	normotensive	O	O
9	and	O	O
10	spontaneously	O	O
11	hypertensive	S-Disease	O
12	rats	O	O
13	.	O	O

0	The	O	O
1	purpose	O	O
2	of	O	O
3	the	O	O
4	present	O	O
5	study	O	O
6	was	O	O
7	to	O	O
8	compare	O	O
9	influence	O	O
10	of	O	O
11	central	O	O
12	arginine	B-Chemical	B-Disease
13	vasopressin	E-Chemical	S-Disease
14	(	O	O
15	AVP	S-Chemical	S-Chemical
16	)	O	O
17	and	O	O
18	of	O	O
19	atrial	O	B-Disease
20	natriuretic	O	I-Disease
21	peptide	O	E-Disease
22	(	O	O
23	ANP	O	S-Chemical
24	)	O	O
25	on	O	O
26	control	O	O
27	of	O	O
28	arterial	O	B-Disease
29	blood	O	I-Disease
30	pressure	O	E-Disease
31	(	O	O
32	MAP	O	S-Disease
33	)	O	O
34	and	O	O
35	heart	O	O
36	rate	O	O
37	(	O	O
38	HR	O	O
39	)	O	O
40	in	O	O
41	normotensive	O	O
42	(	O	O
43	WKY	O	O
44	)	O	O
45	and	O	O
46	spontaneously	O	O
47	hypertensive	S-Disease	S-Disease
48	(	O	O
49	SHR	O	O
50	)	O	O
51	rats	O	O
52	.	O	O

0	MAP	O	S-Disease
1	and	O	O
2	HR	O	O
3	were	O	O
4	monitored	O	O
5	before	O	O
6	and	O	O
7	after	O	O
8	i	O	O
9	.	O	O
10	v	O	O
11	.	O	O
12	injections	O	O
13	of	O	O
14	either	O	O
15	vehicle	O	O
16	or	O	O
17	1	O	O
18	,	O	O
19	10	O	O
20	and	O	O
21	50	O	O
22	ng	O	O
23	of	O	O
24	AVP	S-Chemical	S-Chemical
25	and	O	O
26	25	O	O
27	,	O	O
28	125	O	O
29	and	O	O
30	500	O	O
31	ng	O	O
32	of	O	O
33	ANP	O	S-Disease
34	.	O	O

0	Sensitivity	O	O
1	of	O	O
2	cardiac	O	S-Disease
3	component	O	O
4	of	O	O
5	baroreflex	O	S-Disease
6	(	O	O
7	CCB	O	S-Disease
8	)	O	O
9	,	O	O
10	expressed	O	O
11	as	O	O
12	a	O	O
13	slope	O	O
14	of	O	O
15	the	O	O
16	regression	O	O
17	line	O	O
18	was	O	O
19	determined	O	O
20	from	O	O
21	relationships	O	O
22	between	O	O
23	systolic	O	S-Disease
24	arterial	O	S-Disease
25	pressure	O	O
26	(	O	O
27	SAP	O	S-Disease
28	)	O	O
29	and	O	O
30	HR	O	O
31	period	O	O
32	(	O	O
33	HRp	O	O
34	)	O	O
35	during	O	O
36	phenylephrine	S-Chemical	S-Chemical
37	(	O	O
38	Phe	S-Chemical	S-Chemical
39	)	O	O
40	-	O	O
41	induced	O	O
42	hypertension	S-Disease	S-Disease
43	and	O	O
44	sodium	B-Chemical	B-Chemical
45	nitroprusside	E-Chemical	E-Chemical
46	(	O	O
47	SN	S-Chemical	S-Chemical
48	)	O	O
49	-	O	O
50	induced	O	O
51	hypotension	S-Disease	S-Disease
52	.	O	O

0	CCB	O	O
1	was	O	O
2	measured	O	O
3	before	O	O
4	and	O	O
5	after	O	O
6	administration	O	O
7	of	O	O
8	either	O	O
9	vehicle	O	O
10	,	O	O
11	AVP	S-Chemical	S-Chemical
12	,	O	O
13	ANP	O	S-Chemical
14	,	O	O
15	or	O	O
16	both	O	O
17	peptides	O	O
18	together	O	O
19	.	O	O

0	Increases	O	O
1	of	O	O
2	MAP	O	S-Chemical
3	occurred	O	O
4	after	O	O
5	LV	O	O
6	administration	O	O
7	of	O	O
8	1	O	O
9	,	O	O
10	10	O	O
11	and	O	O
12	50	O	O
13	ng	O	O
14	of	O	O
15	AVP	S-Chemical	S-Chemical
16	in	O	O
17	WKY	O	O
18	and	O	O
19	of	O	O
20	10	O	O
21	and	O	O
22	50	O	O
23	ng	O	O
24	in	O	O
25	SHR	O	O
26	.	O	O

0	ANP	O	S-Chemical
1	did	O	O
2	not	O	O
3	cause	O	O
4	significant	O	O
5	changes	O	O
6	in	O	O
7	MAP	O	S-Disease
8	in	O	O
9	both	O	O
10	strains	O	O
11	as	O	O
12	compared	O	O
13	to	O	O
14	vehicle	O	O
15	,	O	O
16	but	O	O
17	it	O	O
18	abolished	O	O
19	AVP	S-Chemical	S-Chemical
20	-	O	O
21	induced	O	O
22	MAP	O	S-Disease
23	increase	O	S-Disease
24	in	O	O
25	WKY	O	S-Disease
26	and	O	O
27	SHR	O	S-Disease
28	.	O	O

0	CCB	O	S-Disease
1	was	O	O
2	reduced	O	O
3	in	O	O
4	WKY	O	S-Disease
5	and	O	O
6	SHR	O	O
7	after	O	O
8	LV	O	O
9	administration	O	O
10	of	O	O
11	AVP	S-Chemical	S-Chemical
12	during	O	O
13	SN	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	hypotension	S-Disease	S-Disease
17	.	O	O

0	In	O	O
1	SHR	O	O
2	but	O	O
3	not	O	O
4	in	O	O
5	WKY	O	O
6	administration	O	O
7	of	O	O
8	ANP	O	S-Chemical
9	,	O	O
10	AVP	S-Chemical	S-Chemical
11	and	O	O
12	ANP	O	S-Chemical
13	+	O	O
14	AVP	S-Chemical	S-Disease
15	decreased	O	O
16	CCB	O	O
17	during	O	O
18	Phe	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	MAP	O	S-Chemical
22	elevation	O	S-Disease
23	.	O	O

0	The	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	centrally	O	O
5	applied	O	O
6	AVP	S-Chemical	S-Chemical
7	and	O	O
8	ANP	O	S-Chemical
9	exert	O	O
10	differential	O	O
11	effects	O	O
12	on	O	O
13	blood	O	O
14	pressure	O	O
15	and	O	O
16	baroreflex	O	S-Disease
17	control	O	O
18	of	O	O
19	heart	O	B-Disease
20	rate	O	E-Disease
21	in	O	O
22	WKY	O	S-Disease
23	and	O	O
24	SHR	O	S-Disease
25	and	O	O
26	suggest	O	O
27	interaction	O	O
28	of	O	O
29	these	O	O
30	two	O	O
31	peptides	O	O
32	in	O	O
33	blood	O	O
34	pressure	O	O
35	regulation	O	O
36	at	O	O
37	the	O	O
38	level	O	O
39	of	O	O
40	central	O	B-Disease
41	nervous	O	I-Disease
42	system	O	E-Disease
43	.	O	O

0	Cutaneous	O	O
1	exposure	O	O
2	to	O	O
3	warfarin	S-Chemical	S-Chemical
4	-	O	O
5	like	O	O
6	anticoagulant	O	O
7	causing	O	O
8	an	O	O
9	intracerebral	B-Disease	O
10	hemorrhage	E-Disease	S-Disease
11	:	O	O
12	a	O	O
13	case	O	O
14	report	O	O
15	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	intercerebral	O	O
4	hematoma	S-Disease	O
5	due	O	O
6	to	O	O
7	warfarin	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	coagulopathy	S-Disease	S-Disease
11	is	O	O
12	presented	O	O
13	.	O	O

0	The	O	O
1	39	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	woman	O	O
7	had	O	O
8	spread	O	O
9	a	O	O
10	warfarin	S-Chemical	S-Chemical
11	-	O	O
12	type	O	O
13	rat	O	O
14	poison	O	O
15	around	O	O
16	her	O	O
17	house	O	O
18	weekly	O	O
19	using	O	O
20	her	O	O
21	bare	O	O
22	hands	O	O
23	,	O	O
24	with	O	O
25	no	O	O
26	washing	O	O
27	post	O	O
28	application	O	O
29	.	O	O

0	Percutaneous	O	O
1	absorption	O	O
2	of	O	O
3	warfarin	S-Chemical	S-Chemical
4	causing	O	O
5	coagulopathy	S-Disease	S-Disease
6	,	O	O
7	reported	O	O
8	three	O	O
9	times	O	O
10	in	O	O
11	the	O	O
12	past	O	O
13	,	O	O
14	is	O	O
15	a	O	O
16	significant	O	O
17	risk	O	O
18	if	O	O
19	protective	O	O
20	measures	O	O
21	,	O	O
22	such	O	O
23	as	O	O
24	gloves	O	O
25	,	O	O
26	are	O	O
27	not	O	O
28	used	O	O
29	.	O	O

0	An	O	O
1	adverse	O	O
2	drug	O	O
3	interaction	O	O
4	with	O	O
5	piroxicam	S-Chemical	S-Chemical
6	,	O	O
7	which	O	O
8	she	O	O
9	took	O	O
10	occasionally	O	O
11	,	O	O
12	may	O	O
13	have	O	O
14	exacerbated	O	O
15	the	O	O
16	coagulopathy	S-Disease	S-Disease
17	.	O	O

0	Pediatric	O	O
1	heart	O	B-Disease
2	transplantation	O	E-Disease
3	without	O	O
4	chronic	O	B-Disease
5	maintenance	O	I-Disease
6	steroids	S-Chemical	E-Chemical
7	.	O	O

0	Indications	O	O
1	for	O	O
2	transplantation	O	O
3	were	O	O
4	idiopathic	B-Disease	B-Disease
5	cardiomyopathy	E-Disease	E-Disease
6	(	O	O
7	52	O	O
8	%	O	O
9	)	O	O
10	,	O	O
11	congenital	B-Disease	O
12	heart	I-Disease	I-Disease
13	disease	E-Disease	E-Disease
14	(	O	O
15	35	O	O
16	%	O	O
17	)	O	O
18	with	O	O
19	and	O	O
20	without	O	O
21	prior	O	O
22	repair	O	O
23	(	O	O
24	71	O	O
25	%	O	O
26	and	O	O
27	29	O	O
28	%	O	O
29	,	O	O
30	respectively	O	O
31	)	O	O
32	,	O	O
33	hypertrophic	B-Disease	S-Disease
34	cardiomyopathy	E-Disease	S-Disease
35	(	O	O
36	5	O	O
37	%	O	O
38	)	O	O
39	,	O	O
40	valvular	B-Disease	O
41	heart	I-Disease	I-Disease
42	disease	E-Disease	E-Disease
43	(	O	O
44	3	O	O
45	%	O	O
46	)	O	O
47	,	O	O
48	and	O	O
49	doxorubicin	S-Chemical	S-Chemical
50	cardiomyopathy	S-Disease	S-Disease
51	(	O	O
52	5	O	O
53	%	O	O
54	)	O	O
55	.	O	O

0	Patients	O	O
1	were	O	O
2	managed	O	O
3	with	O	O
4	cyclosporine	S-Chemical	S-Chemical
5	and	O	O
6	azathioprine	S-Chemical	S-Chemical
7	.	O	O

0	Steroids	S-Chemical	S-Disease
1	were	O	O
2	given	O	O
3	to	O	O
4	39	O	O
5	%	O	O
6	of	O	O
7	patients	O	O
8	for	O	O
9	refractory	O	O
10	rejection	O	S-Disease
11	,	O	O
12	but	O	O
13	weaning	O	O
14	was	O	O
15	always	O	O
16	attempted	O	O
17	and	O	O
18	generally	O	O
19	successful	O	O
20	(	O	O
21	64	O	O
22	%	O	O
23	)	O	O
24	.	O	O

0	Five	O	O
1	patients	O	O
2	(	O	O
3	14	O	O
4	%	O	O
5	)	O	O
6	received	O	O
7	maintenance	O	B-Disease
8	steroids	S-Chemical	E-Chemical
9	.	O	O

0	There	O	O
1	have	O	O
2	been	O	O
3	no	O	O
4	deaths	O	O
5	related	O	O
6	to	O	O
7	rejection	O	O
8	or	O	O
9	infection	S-Disease	S-Disease
10	.	O	O

0	Freedom	O	O
1	from	O	O
2	serious	O	O
3	infections	S-Disease	S-Disease
4	was	O	O
5	83	O	O
6	%	O	O
7	at	O	O
8	1	O	O
9	month	O	O
10	and	O	O
11	65	O	O
12	%	O	O
13	at	O	O
14	1	O	O
15	year	O	O
16	.	O	O

0	Cytomegalovirus	B-Disease	B-Disease
1	infections	E-Disease	E-Disease
2	were	O	O
3	treated	O	O
4	successfully	O	O
5	with	O	O
6	ganciclovir	S-Chemical	S-Chemical
7	in	O	O
8	11	O	O
9	patients	O	O
10	.	O	O

0	Twenty	O	O
1	-	O	O
2	one	O	O
3	patients	O	O
4	(	O	O
5	60	O	O
6	%	O	O
7	)	O	O
8	have	O	O
9	undergone	O	O
10	annual	O	O
11	catheterizations	O	O
12	and	O	O
13	no	O	O
14	sign	O	O
15	of	O	O
16	graft	O	B-Disease
17	atherosclerosis	S-Disease	I-Disease
18	has	O	O
19	been	O	O
20	observed	O	O
21	.	O	O

0	Seizures	S-Disease	O
1	occurred	O	O
2	in	O	O
3	five	O	O
4	patients	O	O
5	(	O	O
6	14	O	O
7	%	O	O
8	)	O	O
9	and	O	O
10	hypertension	S-Disease	S-Disease
11	was	O	O
12	treated	O	O
13	in	O	O
14	10	O	O
15	patients	O	O
16	(	O	O
17	28	O	O
18	%	O	O
19	)	O	O
20	.	O	O

0	No	O	O
1	patient	O	O
2	was	O	O
3	disabled	O	O
4	and	O	O
5	no	O	O
6	lymphoproliferative	B-Disease	B-Disease
7	disorder	E-Disease	E-Disease
8	was	O	O
9	observed	O	O
10	.	O	O
11	(	O	O
12	ABSTRACT	O	O
13	TRUNCATED	O	O
14	AT	O	O
15	250	O	O
16	WORDS	O	O
17	)	O	O

0	Delirium	S-Disease	O
1	during	O	O
2	fluoxetine	S-Chemical	S-Chemical
3	treatment	O	O
4	.	O	O

0	Only	O	O
1	a	O	O
2	few	O	O
3	reports	O	O
4	exist	O	O
5	,	O	O
6	however	O	O
7	,	O	O
8	on	O	O
9	the	O	O
10	relationship	O	O
11	between	O	O
12	the	O	O
13	serum	O	O
14	concentrations	O	O
15	of	O	O
16	selective	O	O
17	serotonin	S-Chemical	S-Chemical
18	reuptake	O	O
19	inhibitors	O	O
20	(	O	O
21	SSRIs	O	S-Disease
22	)	O	O
23	and	O	O
24	their	O	O
25	toxic	O	O
26	effects	O	O
27	.	O	O

0	In	O	O
1	some	O	O
2	cases	O	O
3	,	O	O
4	a	O	O
5	high	O	O
6	serum	O	O
7	concentration	O	O
8	of	O	O
9	citalopram	S-Chemical	S-Chemical
10	(	O	O
11	>	O	O
12	600	O	O
13	nmol	O	O
14	/	O	O
15	L	O	O
16	)	O	O
17	in	O	O
18	elderly	O	O
19	patients	O	O
20	has	O	O
21	been	O	O
22	associated	O	O
23	with	O	O
24	increased	O	O
25	somnolence	S-Disease	S-Disease
26	and	O	O
27	movement	B-Disease	O
28	difficulties	E-Disease	O
29	.	O	O

0	Widespread	O	O
1	cognitive	B-Disease	B-Disease
2	disorders	E-Disease	E-Disease
3	,	O	O
4	such	O	O
5	as	O	O
6	delirium	S-Disease	S-Disease
7	,	O	O
8	have	O	O
9	not	O	O
10	been	O	O
11	previously	O	O
12	linked	O	O
13	with	O	O
14	high	O	O
15	blood	O	O
16	levels	O	O
17	of	O	O
18	SSRIs	O	S-Disease
19	.	O	O

0	In	O	O
1	this	O	O
2	report	O	O
3	,	O	O
4	we	O	O
5	describe	O	O
6	a	O	O
7	patient	O	O
8	with	O	O
9	acute	O	O
10	hyperkinetic	S-Disease	I-Disease
11	delirium	S-Disease	E-Disease
12	connected	O	O
13	with	O	O
14	a	O	O
15	high	O	O
16	serum	O	O
17	total	O	O
18	fluoxetine	S-Chemical	S-Chemical
19	(	O	O
20	fluoxetine	S-Chemical	S-Chemical
21	plus	O	O
22	desmethylfluoxetine	S-Chemical	S-Chemical
23	)	O	O
24	concentration	O	O
25	.	O	O

0	Pulmonary	B-Disease	O
1	edema	E-Disease	S-Disease
2	and	O	O
3	shock	S-Disease	O
4	after	O	O
5	high	O	O
6	-	O	O
7	dose	O	O
8	aracytine	B-Chemical	S-Chemical
9	-	I-Chemical	O
10	C	E-Chemical	O
11	for	O	O
12	lymphoma	S-Disease	S-Disease
13	;	O	O
14	possible	O	O
15	role	O	O
16	of	O	O
17	TNF	O	S-Disease
18	-	O	I-Disease
19	alpha	O	E-Disease
20	and	O	O
21	PAF	O	S-Disease
22	.	O	O

0	Four	O	O
1	out	O	O
2	of	O	O
3	23	O	O
4	consecutive	O	O
5	patients	O	O
6	treated	O	O
7	with	O	O
8	high	O	O
9	-	O	O
10	dose	O	O
11	Ara	B-Chemical	S-Chemical
12	-	I-Chemical	O
13	C	E-Chemical	E-Chemical
14	for	O	O
15	lymphomas	S-Disease	S-Disease
16	in	O	O
17	our	O	O
18	institution	O	O
19	developed	O	O
20	a	O	O
21	strikingly	O	O
22	similar	O	O
23	syndrome	O	S-Disease
24	during	O	O
25	the	O	O
26	perfusion	O	O
27	.	O	O

0	It	O	O
1	was	O	O
2	characterized	O	O
3	by	O	O
4	the	O	O
5	onset	O	O
6	of	O	O
7	fever	S-Disease	S-Disease
8	,	O	O
9	diarrhea	S-Disease	S-Disease
10	,	O	O
11	shock	S-Disease	S-Disease
12	,	O	O
13	pulmonary	B-Disease	B-Disease
14	edema	E-Disease	E-Disease
15	,	O	O
16	acute	B-Disease	B-Disease
17	renal	I-Disease	I-Disease
18	failure	E-Disease	E-Disease
19	,	O	O
20	metabolic	B-Disease	B-Disease
21	acidosis	E-Disease	I-Disease
22	,	O	O
23	weight	B-Disease	B-Disease
24	gain	E-Disease	E-Disease
25	and	O	O
26	leukocytosis	S-Disease	S-Disease
27	.	O	O

0	Thorough	O	O
1	bacteriological	O	O
2	screening	O	O
3	failed	O	O
4	to	O	O
5	provide	O	O
6	evidence	O	O
7	of	O	O
8	infection	S-Disease	S-Disease
9	.	O	O

0	Sequential	O	O
1	biological	O	O
2	assays	O	O
3	of	O	O
4	IL	O	B-Chemical
5	-	O	E-Chemical
6	1	O	E-Chemical
7	,	O	O
8	IL	O	B-Chemical
9	-	O	E-Chemical
10	2	O	E-Chemical
11	,	O	O
12	TNF	O	S-Disease
13	and	O	O
14	PAF	O	S-Disease
15	were	O	O
16	performed	O	O
17	during	O	O
18	Ara	B-Chemical	S-Chemical
19	-	I-Chemical	I-Disease
20	C	E-Chemical	E-Chemical
21	infusion	O	O
22	to	O	O
23	ten	O	O
24	patients	O	O
25	,	O	O
26	including	O	O
27	the	O	O
28	four	O	O
29	who	O	O
30	developed	O	O
31	the	O	O
32	syndrome	O	S-Disease
33	.	O	O

0	As	O	O
1	TNF	O	S-Chemical
2	and	O	O
3	PAF	O	S-Chemical
4	are	O	O
5	thought	O	O
6	to	O	O
7	be	O	O
8	involved	O	O
9	in	O	O
10	the	O	O
11	development	O	O
12	of	O	O
13	septic	O	B-Disease
14	shock	S-Disease	E-Disease
15	and	O	O
16	adult	B-Disease	B-Disease
17	respiratory	I-Disease	I-Disease
18	distress	I-Disease	I-Disease
19	syndrome	E-Disease	E-Disease
20	,	O	O
21	we	O	O
22	hypothesize	O	O
23	that	O	O
24	high	O	O
25	-	O	O
26	dose	O	O
27	Ara	B-Chemical	S-Chemical
28	-	I-Chemical	I-Chemical
29	C	E-Chemical	E-Chemical
30	may	O	O
31	be	O	O
32	associated	O	O
33	with	O	O
34	cytokine	O	S-Chemical
35	release	O	O
36	.	O	O

0	Protective	O	O
1	effect	O	O
2	of	O	O
3	clentiazem	S-Chemical	S-Chemical
4	against	O	O
5	epinephrine	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	cardiac	B-Disease	B-Disease
9	injury	E-Disease	E-Disease
10	in	O	O
11	rats	O	O
12	.	O	O

0	We	O	O
1	investigated	O	O
2	the	O	O
3	effects	O	O
4	of	O	O
5	clentiazem	S-Chemical	S-Chemical
6	,	O	O
7	a	O	O
8	1	B-Chemical	O
9	,	I-Chemical	O
10	5	I-Chemical	O
11	-	I-Chemical	O
12	benzothiazepine	E-Chemical	S-Chemical
13	calcium	S-Chemical	S-Disease
14	antagonist	O	O
15	,	O	O
16	on	O	O
17	epinephrine	S-Chemical	S-Chemical
18	-	O	O
19	induced	O	O
20	cardiomyopathy	S-Disease	S-Disease
21	in	O	O
22	rats	O	O
23	.	O	O

0	With	O	O
1	2	O	O
2	-	O	O
3	week	O	O
4	chronic	O	B-Disease
5	epinephrine	S-Chemical	E-Disease
6	infusion	O	O
7	,	O	O
8	16	O	O
9	of	O	O
10	30	O	O
11	rats	O	O
12	died	O	O
13	within	O	O
14	4	O	O
15	days	O	O
16	,	O	O
17	and	O	O
18	severe	O	O
19	ischemic	B-Disease	B-Disease
20	lesions	E-Disease	E-Disease
21	and	O	O
22	fibrosis	S-Disease	S-Disease
23	of	O	O
24	the	O	O
25	left	O	O
26	ventricles	O	S-Disease
27	were	O	O
28	observed	O	O
29	.	O	O

0	In	O	O
1	epinephrine	S-Chemical	S-Chemical
2	-	O	O
3	treated	O	O
4	rats	O	O
5	,	O	O
6	left	O	O
7	atrial	O	B-Disease
8	and	O	O
9	left	O	O
10	ventricular	O	O
11	papillary	O	I-Disease
12	muscle	O	O
13	contractile	O	E-Disease
14	responses	O	O
15	to	O	O
16	isoproterenol	S-Chemical	S-Chemical
17	were	O	O
18	reduced	O	O
19	,	O	O
20	but	O	O
21	responses	O	O
22	to	O	O
23	calcium	S-Chemical	S-Disease
24	were	O	O
25	normal	O	O
26	or	O	O
27	enhanced	O	O
28	compared	O	O
29	to	O	O
30	controls	O	O
31	.	O	O

0	Treatment	O	O
1	with	O	O
2	clentiazem	S-Chemical	S-Chemical
3	prevented	O	O
4	epinephrine	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	death	O	S-Disease
8	(	O	O
9	P	O	O
10	<	O	O
11	.	O	O
12	05	O	O
13	)	O	O
14	,	O	O
15	and	O	O
16	attenuated	O	O
17	the	O	O
18	ventricular	O	B-Disease
19	ischemic	B-Disease	E-Disease
20	lesions	E-Disease	E-Disease
21	and	O	O
22	fibrosis	S-Disease	S-Disease
23	,	O	O
24	in	O	O
25	a	O	O
26	dose	O	O
27	-	O	O
28	dependent	O	O
29	manner	O	O
30	.	O	O

0	Left	O	O
1	atrial	O	S-Disease
2	and	O	O
3	left	O	O
4	ventricular	O	O
5	papillary	O	I-Disease
6	muscle	O	I-Disease
7	contractile	O	E-Disease
8	responses	O	O
9	to	O	O
10	isoproterenol	S-Chemical	S-Chemical
11	were	O	O
12	reduced	O	O
13	compared	O	O
14	to	O	O
15	controls	O	O
16	in	O	O
17	groups	O	O
18	treated	O	O
19	with	O	O
20	clentiazem	S-Chemical	S-Chemical
21	alone	O	O
22	,	O	O
23	but	O	O
24	combined	O	O
25	with	O	O
26	epinephrine	S-Chemical	S-Chemical
27	,	O	O
28	clentiazem	S-Chemical	S-Chemical
29	restored	O	O
30	left	O	O
31	atrial	O	S-Disease
32	responses	O	O
33	and	O	O
34	enhanced	O	O
35	left	O	O
36	ventricular	O	I-Disease
37	papillary	O	S-Disease
38	responses	O	O
39	to	O	O
40	isoproterenol	S-Chemical	S-Chemical
41	.	O	O

0	On	O	O
1	the	O	O
2	other	O	O
3	hand	O	O
4	clentiazem	S-Chemical	S-Chemical
5	did	O	O
6	not	O	O
7	prevent	O	O
8	epinephrine	S-Chemical	S-Chemical
9	-	O	O
10	induced	O	O
11	down	O	O
12	-	O	O
13	regulation	O	O
14	of	O	O
15	alpha	O	O
16	and	O	O
17	beta	O	O
18	adrenoceptors	O	S-Disease
19	.	O	O

0	Interestingly	O	O
1	,	O	O
2	clentiazem	S-Chemical	S-Chemical
3	,	O	O
4	infused	O	O
5	alone	O	O
6	,	O	O
7	resulted	O	O
8	in	O	O
9	decreased	O	O
10	adrenergic	O	O
11	receptor	O	O
12	densities	O	O
13	in	O	O
14	the	O	O
15	left	O	O
16	ventricle	O	S-Disease
17	.	O	O

0	Clentiazem	S-Chemical	S-Chemical
1	also	O	O
2	did	O	O
3	not	O	O
4	prevent	O	O
5	the	O	O
6	enhanced	O	O
7	responses	O	O
8	to	O	O
9	calcium	S-Chemical	S-Disease
10	seen	O	O
11	in	O	O
12	the	O	O
13	epinephrine	S-Chemical	S-Disease
14	-	O	O
15	treated	O	O
16	animals	O	O
17	,	O	O
18	although	O	O
19	the	O	O
20	high	O	O
21	dose	O	O
22	of	O	O
23	clentiazem	S-Chemical	S-Chemical
24	partially	O	O
25	attenuated	O	O
26	the	O	O
27	maximal	O	O
28	response	O	O
29	to	O	O
30	calcium	S-Chemical	S-Disease
31	compared	O	O
32	to	O	O
33	epinephrine	S-Chemical	S-Chemical
34	-	O	O
35	treated	O	O
36	animals	O	O
37	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	clentiazem	S-Chemical	S-Chemical
4	attenuated	O	O
5	epinephrine	S-Chemical	S-Disease
6	-	O	O
7	induced	O	O
8	cardiac	B-Disease	B-Disease
9	injury	E-Disease	E-Disease
10	,	O	O
11	possibly	O	O
12	through	O	O
13	its	O	O
14	effect	O	O
15	on	O	O
16	the	O	O
17	adrenergic	O	O
18	pathway	O	O
19	.	O	O

0	Kaliuretic	O	S-Chemical
1	effect	O	O
2	of	O	O
3	L	B-Chemical	B-Chemical
4	-	I-Chemical	I-Chemical
5	dopa	E-Chemical	E-Chemical
6	treatment	O	O
7	in	O	O
8	parkinsonian	S-Disease	S-Disease
9	patients	O	O
10	.	O	O

0	Hypokalemia	S-Disease	S-Disease
1	,	O	O
2	sometimes	O	O
3	severe	O	O
4	,	O	O
5	was	O	O
6	observed	O	O
7	in	O	O
8	some	O	O
9	L	B-Chemical	S-Chemical
10	-	I-Chemical	I-Chemical
11	dopa	E-Chemical	E-Chemical
12	-	O	O
13	treated	O	O
14	parkinsonian	S-Disease	S-Disease
15	patients	O	O
16	.	O	O

0	The	O	O
1	influence	O	O
2	of	O	O
3	L	B-Chemical	B-Chemical
4	-	I-Chemical	I-Chemical
5	dopa	E-Chemical	E-Chemical
6	on	O	O
7	the	O	O
8	renal	O	B-Disease
9	excretion	O	O
10	of	O	O
11	potassium	S-Chemical	S-Disease
12	was	O	O
13	studied	O	O
14	in	O	O
15	3	O	O
16	patients	O	O
17	with	O	O
18	hypokalemia	S-Disease	S-Disease
19	and	O	O
20	in	O	O
21	5	O	O
22	normokalemic	O	O
23	patients	O	O
24	by	O	O
25	determination	O	O
26	of	O	O
27	renal	O	B-Disease
28	plasma	O	I-Disease
29	flow	O	E-Disease
30	,	O	O
31	glomerular	O	O
32	filtration	O	O
33	rate	O	O
34	,	O	O
35	plasma	O	O
36	concentration	O	O
37	of	O	O
38	potassium	S-Chemical	S-Disease
39	and	O	O
40	sodium	S-Chemical	O
41	as	O	O
42	well	O	O
43	as	O	O
44	urinary	O	O
45	excretion	O	O
46	of	O	O
47	potassium	S-Chemical	S-Disease
48	,	O	O
49	sodium	S-Chemical	S-Disease
50	and	O	O
51	aldosterone	S-Chemical	S-Chemical
52	.	O	O

0	L	B-Chemical	B-Chemical
1	-	I-Chemical	I-Chemical
2	Dopa	E-Chemical	E-Chemical
3	intake	O	O
4	was	O	O
5	found	O	O
6	to	O	O
7	cause	O	O
8	an	O	O
9	increased	O	O
10	excretion	O	O
11	of	O	O
12	potassium	S-Chemical	S-Disease
13	,	O	O
14	and	O	O
15	sometimes	O	O
16	also	O	O
17	of	O	O
18	sodium	S-Chemical	S-Disease
19	,	O	O
20	in	O	O
21	the	O	O
22	hypokalemic	O	S-Disease
23	but	O	O
24	not	O	O
25	in	O	O
26	the	O	O
27	normokalemic	O	O
28	patients	O	O
29	.	O	O

0	It	O	O
1	is	O	O
2	not	O	O
3	known	O	O
4	why	O	O
5	this	O	O
6	effect	O	O
7	occurred	O	O
8	in	O	O
9	some	O	O
10	individuals	O	O
11	but	O	O
12	not	O	O
13	in	O	O
14	others	O	O
15	,	O	O
16	but	O	O
17	our	O	O
18	results	O	O
19	indicate	O	O
20	a	O	O
21	correlation	O	O
22	between	O	O
23	aldosterone	S-Chemical	S-Chemical
24	production	O	O
25	and	O	O
26	this	O	O
27	renal	O	S-Disease
28	effect	O	O
29	of	O	O
30	L	B-Chemical	B-Chemical
31	-	I-Chemical	I-Chemical
32	dopa	E-Chemical	E-Chemical
33	.	O	O

0	Cocaine	S-Chemical	S-Chemical
1	induced	O	O
2	myocardial	B-Disease	B-Disease
3	ischemia	E-Disease	E-Disease
4	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	myocardial	B-Disease	B-Disease
6	ischemia	E-Disease	E-Disease
7	induced	O	O
8	by	O	O
9	cocaine	S-Chemical	S-Chemical
10	.	O	O

0	The	O	O
1	ischemia	S-Disease	S-Disease
2	probably	O	O
3	induced	O	O
4	by	O	O
5	coronary	B-Disease	B-Disease
6	artery	I-Disease	I-Disease
7	spasm	E-Disease	E-Disease
8	was	O	O
9	reversed	O	O
10	by	O	O
11	nitroglycerin	S-Chemical	S-Chemical
12	and	O	O
13	calcium	S-Chemical	B-Disease
14	blocking	O	O
15	agents	O	O
16	.	O	O

0	Doxorubicin	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	cardiotoxicity	S-Disease	S-Disease
4	monitored	O	O
5	by	O	O
6	ECG	O	S-Disease
7	in	O	O
8	freely	O	O
9	moving	O	O
10	mice	O	O
11	.	O	O

0	In	O	O
1	laboratory	O	O
2	animals	O	O
3	,	O	O
4	histology	O	O
5	is	O	O
6	most	O	O
7	commonly	O	O
8	used	O	O
9	to	O	O
10	study	O	O
11	doxorubicin	S-Chemical	S-Chemical
12	-	O	O
13	induced	O	O
14	cardiotoxicity	S-Disease	S-Disease
15	.	O	O

0	With	O	O
1	this	O	O
2	model	O	O
3	we	O	O
4	investigated	O	O
5	the	O	O
6	effect	O	O
7	of	O	O
8	chronic	O	B-Disease
9	doxorubicin	S-Chemical	E-Chemical
10	administration	O	O
11	on	O	O
12	the	O	O
13	ECG	O	O
14	of	O	O
15	freely	O	O
16	moving	O	O
17	BALB	O	S-Disease
18	/	O	O
19	c	O	O
20	mice	O	O
21	and	O	O
22	the	O	O
23	efficacy	O	O
24	of	O	O
25	ICRF	B-Chemical	B-Chemical
26	-	I-Chemical	E-Chemical
27	187	E-Chemical	E-Disease
28	as	O	O
29	a	O	O
30	protective	O	O
31	agent	O	O
32	.	O	O

0	The	O	O
1	ST	O	S-Disease
2	interval	O	O
3	significantly	O	O
4	widened	O	O
5	from	O	O
6	15	O	O
7	.	O	O
8	0	O	O
9	+	O	O
10	/	O	O
11	-	O	O
12	1	O	O
13	.	O	O
14	5	O	O
15	to	O	O
16	56	O	O
17	.	O	O
18	8	O	O
19	+	O	O
20	/	O	O
21	-	O	O
22	11	O	O
23	.	O	O
24	8	O	O
25	ms	O	O
26	in	O	O
27	week	O	O
28	10	O	O
29	(	O	O
30	7	O	O
31	weekly	O	O
32	doses	O	O
33	of	O	O
34	4	O	O
35	mg	O	O
36	/	O	O
37	kg	O	O
38	doxorubicin	S-Chemical	S-Chemical
39	given	O	O
40	i	O	O
41	.	O	O
42	v	O	O
43	.	O	O
44	plus	O	O
45	3	O	O
46	weeks	O	O
47	of	O	O
48	observation	O	O
49	)	O	O
50	.	O	O

0	After	O	O
1	sacrifice	O	O
2	the	O	O
3	hearts	O	O
4	of	O	O
5	doxorubicin	S-Chemical	S-Chemical
6	-	O	O
7	treated	O	O
8	animals	O	O
9	were	O	O
10	enlarged	O	O
11	and	O	O
12	the	O	O
13	atria	O	S-Disease
14	were	O	O
15	hypertrophic	S-Disease	S-Disease
16	.	O	O

0	As	O	O
1	this	O	O
2	schedule	O	O
3	exerted	O	O
4	more	O	O
5	toxicity	S-Disease	S-Disease
6	than	O	O
7	needed	O	O
8	to	O	O
9	investigate	O	O
10	protective	O	O
11	agents	O	O
12	,	O	O
13	the	O	O
14	protection	O	O
15	of	O	O
16	ICRF	B-Chemical	B-Chemical
17	-	I-Chemical	E-Chemical
18	187	E-Chemical	E-Disease
19	was	O	O
20	determined	O	O
21	using	O	O
22	a	O	O
23	dose	O	O
24	schedule	O	O
25	with	O	O
26	lower	O	O
27	general	O	O
28	toxicity	S-Disease	S-Disease
29	(	O	O
30	6	O	O
31	weekly	O	O
32	doses	O	O
33	of	O	O
34	4	O	O
35	mg	O	O
36	/	O	O
37	kg	O	O
38	doxorubicin	S-Chemical	S-Chemical
39	given	O	O
40	i	O	O
41	.	O	O
42	v	O	O
43	.	O	O
44	plus	O	O
45	2	O	O
46	weeks	O	O
47	of	O	O
48	observation	O	O
49	)	O	O
50	.	O	O

0	On	O	O
1	this	O	O
2	schedule	O	O
3	,	O	O
4	the	O	O
5	animals	O	O
6	'	O	O
7	hearts	O	O
8	appeared	O	O
9	normal	O	O
10	after	O	O
11	sacrifice	O	O
12	and	O	O
13	ICRF	B-Chemical	B-Chemical
14	-	I-Chemical	E-Chemical
15	187	E-Chemical	E-Disease
16	(	O	O
17	50	O	O
18	mg	O	O
19	/	O	O
20	kg	O	O
21	given	O	O
22	i	O	O
23	.	O	O
24	p	O	O
25	.	O	O
26	1	O	O
27	h	O	O
28	before	O	O
29	doxorubicin	S-Chemical	S-Chemical
30	)	O	O
31	provided	O	O
32	almost	O	O
33	full	O	O
34	protection	O	O
35	.	O	O

0	The	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	this	O	O
5	new	O	O
6	model	O	O
7	is	O	O
8	very	O	O
9	sensitive	O	O
10	and	O	O
11	enables	O	O
12	monitoring	O	O
13	of	O	O
14	the	O	O
15	development	O	O
16	of	O	O
17	cardiotoxicity	S-Disease	S-Disease
18	with	O	O
19	time	O	O
20	.	O	O

0	These	O	O
1	findings	O	O
2	result	O	O
3	in	O	O
4	a	O	O
5	model	O	O
6	that	O	O
7	allows	O	O
8	the	O	O
9	testing	O	O
10	of	O	O
11	protectors	O	O
12	against	O	O
13	doxorubicin	S-Chemical	S-Chemical
14	-	O	O
15	induced	O	O
16	cardiotoxicity	S-Disease	S-Disease
17	as	O	O
18	demonstrated	O	O
19	by	O	O
20	the	O	O
21	protection	O	O
22	provided	O	O
23	by	O	O
24	ICRF	B-Chemical	B-Chemical
25	-	I-Chemical	E-Chemical
26	187	E-Chemical	E-Disease
27	.	O	O

0	Epinephrine	S-Chemical	B-Disease
1	dysrhythmogenicity	O	E-Disease
2	is	O	O
3	not	O	O
4	enhanced	O	O
5	by	O	O
6	subtoxic	O	O
7	bupivacaine	S-Chemical	S-Chemical
8	in	O	O
9	dogs	O	O
10	.	O	O

0	Since	O	O
1	bupivacaine	S-Chemical	S-Chemical
2	and	O	O
3	epinephrine	S-Chemical	S-Chemical
4	may	O	O
5	both	O	O
6	precipitate	O	O
7	dysrhythmias	S-Disease	S-Disease
8	,	O	O
9	circulating	O	O
10	bupivacaine	S-Chemical	S-Chemical
11	during	O	O
12	regional	O	O
13	anesthesia	O	O
14	could	O	O
15	potentiate	O	O
16	dysrhythmogenic	O	S-Disease
17	effects	O	O
18	of	O	O
19	epinephrine	S-Chemical	S-Chemical
20	.	O	O

0	We	O	O
1	therefore	O	O
2	examined	O	O
3	whether	O	O
4	bupivacaine	S-Chemical	S-Chemical
5	alters	O	O
6	the	O	O
7	dysrhythmogenicity	O	S-Disease
8	of	O	O
9	subsequent	O	O
10	administration	O	O
11	of	O	O
12	epinephrine	S-Chemical	S-Chemical
13	in	O	O
14	conscious	O	O
15	,	O	O
16	healthy	O	O
17	dogs	O	O
18	and	O	O
19	in	O	O
20	anesthetized	O	O
21	dogs	O	O
22	with	O	O
23	myocardial	B-Disease	B-Disease
24	infarction	E-Disease	E-Disease
25	.	O	O

0	Forty	O	O
1	-	O	O
2	one	O	O
3	conscious	O	O
4	dogs	O	O
5	received	O	O
6	10	O	O
7	micrograms	O	O
8	.	O	O
9	kg	O	O
10	-	O	O
11	1	O	O
12	.	O	O
13	min	O	O
14	-	O	O
15	1	O	O
16	epinephrine	S-Chemical	S-Disease
17	.	O	O

0	Seventeen	O	O
1	animals	O	O
2	responded	O	O
3	with	O	O
4	ventricular	B-Disease	O
5	tachycardia	E-Disease	S-Disease
6	(	O	O
7	VT	S-Disease	O
8	)	O	O
9	within	O	O
10	3	O	O
11	min	O	O
12	.	O	O

0	After	O	O
1	3	O	O
2	h	O	O
3	,	O	O
4	these	O	O
5	responders	O	O
6	randomly	O	O
7	received	O	O
8	1	O	O
9	or	O	O
10	2	O	O
11	mg	O	O
12	/	O	O
13	kg	O	O
14	bupivacaine	S-Chemical	S-Chemical
15	or	O	O
16	saline	O	S-Disease
17	over	O	O
18	5	O	O
19	min	O	O
20	,	O	O
21	followed	O	O
22	by	O	O
23	10	O	O
24	micrograms	O	O
25	.	O	O
26	kg	O	O
27	-	O	O
28	1	O	O
29	.	O	O
30	min	O	O
31	-	O	O
32	1	O	O
33	epinephrine	S-Chemical	S-Disease
34	.	O	O

0	In	O	O
1	the	O	O
2	bupivacaine	S-Chemical	S-Chemical
3	groups	O	O
4	,	O	O
5	epinephrine	S-Chemical	S-Chemical
6	caused	O	O
7	fewer	O	O
8	prodysrhythmic	O	O
9	effects	O	O
10	than	O	O
11	without	O	O
12	bupivacaine	S-Chemical	S-Chemical
13	.	O	O

0	VT	S-Disease	O
1	appeared	O	O
2	in	O	O
3	fewer	O	O
4	dogs	O	O
5	and	O	O
6	at	O	O
7	a	O	O
8	later	O	O
9	time	O	O
10	,	O	O
11	and	O	O
12	there	O	O
13	were	O	O
14	more	O	O
15	sinoatrial	O	B-Disease
16	beats	O	O
17	and	O	O
18	less	O	O
19	ectopies	O	O
20	.	O	O

0	Epinephrine	S-Chemical	S-Chemical
1	shortened	O	O
2	QT	O	O
3	less	O	O
4	after	O	O
5	bupivacaine	S-Chemical	S-Chemical
6	than	O	O
7	in	O	O
8	control	O	O
9	animals	O	O
10	.	O	O

0	One	O	O
1	day	O	O
2	after	O	O
3	experimental	O	O
4	myocardial	B-Disease	B-Disease
5	infarction	E-Disease	E-Disease
6	,	O	O
7	six	O	O
8	additional	O	O
9	halothane	S-Chemical	S-Chemical
10	-	O	O
11	anesthetized	O	O
12	dogs	O	O
13	received	O	O
14	4	O	O
15	micrograms	O	O
16	.	O	O
17	kg	O	O
18	-	O	O
19	1	O	O
20	.	O	O
21	min	O	O
22	-	O	O
23	1	O	O
24	epinephrine	S-Chemical	S-Disease
25	until	O	O
26	VT	S-Disease	O
27	appeared	O	O
28	.	O	O

0	After	O	O
1	45	O	O
2	min	O	O
3	,	O	O
4	1	O	O
5	mg	O	O
6	/	O	O
7	kg	O	O
8	bupivacaine	S-Chemical	S-Chemical
9	was	O	O
10	injected	O	O
11	over	O	O
12	5	O	O
13	min	O	O
14	,	O	O
15	again	O	O
16	followed	O	O
17	by	O	O
18	4	O	O
19	micrograms	O	O
20	.	O	O
21	kg	O	O
22	-	O	O
23	1	O	O
24	.	O	O
25	min	O	O
26	-	O	O
27	1	O	O
28	epinephrine	S-Chemical	S-Chemical
29	.	O	O

0	In	O	O
1	these	O	O
2	dogs	O	O
3	,	O	O
4	the	O	O
5	prodysrhythmic	O	O
6	response	O	O
7	to	O	O
8	epinephrine	S-Chemical	S-Chemical
9	was	O	O
10	also	O	O
11	mitigated	O	O
12	by	O	O
13	preceding	O	O
14	bupivacaine	S-Chemical	S-Chemical
15	.	O	O

0	Bupivacaine	S-Chemical	S-Chemical
1	antagonizes	O	O
2	epinephrine	S-Chemical	B-Disease
3	dysrhythmogenicity	O	E-Disease
4	in	O	O
5	conscious	O	O
6	dogs	O	O
7	susceptible	O	O
8	to	O	O
9	VT	S-Disease	S-Disease
10	and	O	O
11	in	O	O
12	anesthetized	O	O
13	dogs	O	O
14	with	O	O
15	spontaneous	O	O
16	postinfarct	O	O
17	dysrhythmias	S-Disease	S-Disease
18	.	O	O

0	There	O	O
1	is	O	O
2	no	O	O
3	evidence	O	O
4	that	O	O
5	systemic	O	O
6	subtoxic	O	O
7	bupivacaine	S-Chemical	S-Chemical
8	administration	O	O
9	enhances	O	O
10	the	O	O
11	dysrhythmogenicity	O	S-Disease
12	of	O	O
13	subsequent	O	O
14	epinephrine	S-Chemical	S-Disease
15	.	O	O

0	Milk	B-Disease	S-Chemical
1	-	I-Disease	O
2	alkali	I-Disease	I-Disease
3	syndrome	E-Disease	S-Disease
4	induced	O	O
5	by	O	O
6	1	B-Chemical	O
7	,	I-Chemical	O
8	25	I-Chemical	O
9	(	I-Chemical	O
10	OH	I-Chemical	O
11	)	I-Chemical	O
12	2D	E-Chemical	O
13	in	O	O
14	a	O	O
15	patient	O	O
16	with	O	O
17	hypoparathyroidism	S-Disease	S-Disease
18	.	O	O

0	Milk	B-Disease	S-Chemical
1	-	I-Disease	O
2	alkali	I-Disease	I-Disease
3	syndrome	E-Disease	S-Disease
4	was	O	O
5	first	O	O
6	described	O	O
7	70	O	O
8	years	O	O
9	ago	O	O
10	in	O	O
11	the	O	O
12	context	O	O
13	of	O	O
14	the	O	O
15	treatment	O	O
16	of	O	O
17	peptic	B-Disease	B-Disease
18	ulcer	I-Disease	I-Disease
19	disease	E-Disease	E-Disease
20	with	O	O
21	large	O	O
22	amounts	O	O
23	of	O	O
24	calcium	S-Chemical	S-Disease
25	and	O	O
26	alkali	S-Chemical	S-Disease
27	.	O	O

0	Although	O	O
1	with	O	O
2	current	O	O
3	ulcer	S-Disease	O
4	therapy	O	O
5	(	O	O
6	H	O	O
7	-	O	I-Chemical
8	2	O	O
9	blockers	O	O
10	,	O	O
11	omeprazole	S-Chemical	S-Chemical
12	,	O	O
13	and	O	O
14	sucralfate	S-Chemical	S-Chemical
15	)	O	O
16	,	O	O
17	the	O	O
18	frequency	O	O
19	of	O	O
20	milk	B-Disease	B-Disease
21	-	I-Disease	O
22	alkali	I-Disease	I-Disease
23	syndrome	E-Disease	S-Disease
24	has	O	O
25	decreased	O	O
26	significantly	O	O
27	,	O	O
28	the	O	O
29	classic	O	O
30	triad	O	O
31	of	O	O
32	hypercalcemia	S-Disease	S-Disease
33	,	O	O
34	alkalosis	S-Disease	O
35	,	O	O
36	and	O	O
37	renal	B-Disease	S-Disease
38	impairment	E-Disease	S-Disease
39	remains	O	O
40	the	O	O
41	hallmark	O	O
42	of	O	O
43	the	O	O
44	syndrome	O	S-Disease
45	.	O	O

0	Milk	B-Disease	B-Chemical
1	-	I-Disease	O
2	alkali	I-Disease	I-Disease
3	syndrome	E-Disease	S-Disease
4	can	O	O
5	present	O	O
6	serious	O	O
7	and	O	O
8	occasionally	O	O
9	life	O	O
10	-	O	O
11	threatening	O	O
12	illness	O	S-Disease
13	unless	O	O
14	diagnosed	O	O
15	and	O	O
16	treated	O	O
17	appropriately	O	O
18	.	O	O

0	This	O	O
1	article	O	O
2	presents	O	O
3	a	O	O
4	patient	O	O
5	with	O	O
6	hypoparathyroidism	S-Disease	S-Disease
7	who	O	O
8	was	O	O
9	treated	O	O
10	with	O	O
11	calcium	B-Chemical	B-Chemical
12	carbonate	E-Chemical	E-Chemical
13	and	O	O
14	calcitriol	S-Chemical	S-Chemical
15	resulting	O	O
16	in	O	O
17	two	O	O
18	admissions	O	O
19	to	O	O
20	the	O	O
21	hospital	O	O
22	for	O	O
23	milk	B-Disease	B-Disease
24	-	I-Disease	O
25	alkali	I-Disease	S-Disease
26	syndrome	E-Disease	E-Disease
27	.	O	O

0	The	O	O
1	patient	O	O
2	was	O	O
3	successfully	O	O
4	treated	O	O
5	with	O	O
6	intravenous	O	O
7	pamidronate	S-Chemical	S-Chemical
8	on	O	O
9	his	O	O
10	first	O	O
11	admission	O	O
12	and	O	O
13	with	O	O
14	hydrocortisone	S-Chemical	S-Chemical
15	on	O	O
16	the	O	O
17	second	O	O
18	.	O	O

0	This	O	O
1	illustrates	O	O
2	intravenous	O	O
3	pamidronate	S-Chemical	S-Disease
4	as	O	O
5	a	O	O
6	valuable	O	O
7	therapeutic	O	O
8	tool	O	O
9	when	O	O
10	milk	B-Disease	B-Disease
11	-	I-Disease	O
12	alkali	I-Disease	I-Disease
13	syndrome	E-Disease	S-Disease
14	presents	O	O
15	as	O	O
16	hypercalcemic	B-Disease	S-Disease
17	emergency	E-Disease	O
18	.	O	O

0	Famotidine	S-Chemical	S-Chemical
1	-	O	O
2	associated	O	O
3	delirium	S-Disease	S-Disease
4	.	O	O

0	Famotidine	S-Chemical	S-Chemical
1	is	O	O
2	a	O	O
3	histamine	O	S-Chemical
4	H2	O	O
5	-	O	O
6	receptor	O	O
7	antagonist	O	O
8	used	O	O
9	in	O	O
10	inpatient	O	O
11	settings	O	O
12	for	O	O
13	prevention	O	O
14	of	O	O
15	stress	O	B-Disease
16	ulcers	S-Disease	E-Disease
17	and	O	O
18	is	O	O
19	showing	O	O
20	increasing	O	O
21	popularity	O	O
22	because	O	O
23	of	O	O
24	its	O	O
25	low	O	O
26	cost	O	O
27	.	O	O

0	Although	O	O
1	all	O	O
2	of	O	O
3	the	O	O
4	currently	O	O
5	available	O	O
6	H2	O	O
7	-	O	O
8	receptor	O	O
9	antagonists	O	O
10	have	O	O
11	shown	O	O
12	the	O	O
13	propensity	O	O
14	to	O	O
15	cause	O	O
16	delirium	S-Disease	S-Disease
17	,	O	O
18	only	O	O
19	two	O	O
20	previously	O	O
21	reported	O	O
22	cases	O	O
23	have	O	O
24	been	O	O
25	associated	O	O
26	with	O	O
27	famotidine	S-Chemical	S-Chemical
28	.	O	O

0	The	O	O
1	authors	O	O
2	report	O	O
3	on	O	O
4	six	O	O
5	cases	O	O
6	of	O	O
7	famotidine	S-Chemical	S-Chemical
8	-	O	O
9	associated	O	O
10	delirium	S-Disease	S-Disease
11	in	O	O
12	hospitalized	O	O
13	patients	O	O
14	who	O	O
15	cleared	O	O
16	completely	O	O
17	upon	O	O
18	removal	O	O
19	of	O	O
20	famotidine	S-Chemical	S-Chemical
21	.	O	O

0	The	O	O
1	pharmacokinetics	O	O
2	of	O	O
3	famotidine	S-Chemical	S-Chemical
4	are	O	O
5	reviewed	O	O
6	,	O	O
7	with	O	O
8	no	O	O
9	change	O	O
10	in	O	O
11	its	O	O
12	metabolism	O	O
13	in	O	O
14	the	O	O
15	elderly	O	O
16	population	O	O
17	seen	O	O
18	.	O	O

0	The	O	O
1	implications	O	O
2	of	O	O
3	using	O	O
4	famotidine	S-Chemical	S-Chemical
5	in	O	O
6	elderly	O	O
7	persons	O	O
8	are	O	O
9	discussed	O	O
10	.	O	O

0	Encephalopathy	S-Disease	S-Disease
1	during	O	O
2	amitriptyline	S-Chemical	S-Chemical
3	therapy	O	O
4	:	O	O
5	are	O	O
6	neuroleptic	B-Disease	B-Disease
7	malignant	I-Disease	I-Disease
8	syndrome	E-Disease	E-Disease
9	and	O	O
10	serotonin	B-Disease	B-Disease
11	syndrome	E-Disease	I-Disease
12	spectrum	O	I-Disease
13	disorders	O	E-Disease
14	?	O	O

0	This	O	O
1	report	O	O
2	describes	O	O
3	a	O	O
4	case	O	O
5	of	O	O
6	encephalopathy	S-Disease	S-Disease
7	developed	O	O
8	in	O	O
9	the	O	O
10	course	O	O
11	of	O	O
12	amitriptyline	S-Chemical	S-Chemical
13	therapy	O	O
14	,	O	O
15	during	O	O
16	a	O	O
17	remission	O	O
18	of	O	O
19	unipolar	B-Disease	B-Disease
20	depression	E-Disease	S-Disease
21	.	O	O

0	This	O	O
1	patient	O	O
2	could	O	O
3	have	O	O
4	been	O	O
5	diagnosed	O	O
6	as	O	O
7	having	O	O
8	either	O	O
9	neuroleptic	B-Disease	B-Disease
10	malignant	I-Disease	I-Disease
11	syndrome	E-Disease	E-Disease
12	(	O	O
13	NMS	S-Disease	S-Disease
14	)	O	O
15	or	O	O
16	serotonin	B-Disease	B-Disease
17	syndrome	E-Disease	E-Disease
18	(	O	O
19	SS	S-Disease	S-Disease
20	)	O	O
21	.	O	O

0	The	O	O
1	major	O	O
2	determinant	O	O
3	of	O	O
4	the	O	O
5	symptoms	O	O
6	may	O	O
7	have	O	O
8	been	O	O
9	dopamine	S-Chemical	B-Chemical
10	/	O	I-Chemical
11	serotonin	S-Chemical	E-Chemical
12	imbalance	O	E-Disease
13	in	O	O
14	the	O	O
15	central	O	B-Disease
16	nervous	O	I-Disease
17	system	O	E-Disease
18	.	O	O

0	The	O	O
1	NMS	S-Disease	S-Chemical
2	-	O	O
3	like	O	O
4	encephalopathy	S-Disease	S-Disease
5	that	O	O
6	develops	O	O
7	in	O	O
8	association	O	O
9	with	O	O
10	the	O	O
11	use	O	O
12	of	O	O
13	antidepressants	O	O
14	indicates	O	O
15	that	O	O
16	NMS	S-Disease	S-Chemical
17	and	O	O
18	SS	S-Disease	S-Disease
19	are	O	O
20	spectrum	O	O
21	disorders	O	E-Disease
22	induced	O	O
23	by	O	O
24	drugs	O	O
25	with	O	O
26	both	O	O
27	antidopaminergic	O	O
28	and	O	O
29	serotonergic	O	S-Disease
30	effects	O	O
31	.	O	O

0	Genetic	O	O
1	separation	O	O
2	of	O	O
3	tumor	S-Disease	S-Disease
4	growth	O	E-Disease
5	and	O	O
6	hemorrhagic	S-Disease	O
7	phenotypes	O	O
8	in	O	O
9	an	O	O
10	estrogen	S-Chemical	S-Disease
11	-	O	O
12	induced	O	O
13	tumor	S-Disease	S-Disease
14	.	O	O

0	Chronic	O	O
1	administration	O	O
2	of	O	O
3	estrogen	S-Chemical	S-Chemical
4	to	O	O
5	the	O	O
6	Fischer	O	B-Chemical
7	344	O	E-Chemical
8	(	O	O
9	F344	O	S-Chemical
10	)	O	O
11	rat	O	O
12	induces	O	O
13	growth	O	O
14	of	O	O
15	large	O	O
16	,	O	O
17	hemorrhagic	S-Disease	O
18	pituitary	B-Disease	I-Disease
19	tumors	E-Disease	E-Disease
20	.	O	O

0	Ten	O	O
1	weeks	O	O
2	of	O	O
3	diethylstilbestrol	S-Chemical	S-Chemical
4	(	O	O
5	DES	S-Chemical	S-Disease
6	)	O	O
7	treatment	O	O
8	caused	O	O
9	female	O	O
10	F344	O	S-Disease
11	rat	O	O
12	pituitaries	O	S-Disease
13	to	O	O
14	grow	O	O
15	to	O	O
16	an	O	O
17	average	O	O
18	of	O	O
19	109	O	O
20	.	O	O
21	2	O	O
22	+	O	O
23	/	O	O
24	-	O	O
25	6	O	O
26	.	O	O
27	3	O	O
28	mg	O	O
29	(	O	O
30	mean	O	O
31	+	O	O
32	/	O	O
33	-	O	O
34	SE	O	O
35	)	O	O
36	versus	O	O
37	11	O	O
38	.	O	O
39	3	O	O
40	+	O	O
41	/	O	O
42	-	O	O
43	1	O	O
44	.	O	O
45	4	O	O
46	mg	O	O
47	for	O	O
48	untreated	O	O
49	rats	O	O
50	,	O	O
51	and	O	O
52	to	O	O
53	become	O	O
54	highly	O	O
55	hemorrhagic	S-Disease	O
56	.	O	O

0	The	O	O
1	same	O	O
2	DES	S-Chemical	S-Disease
3	treatment	O	O
4	produced	O	O
5	no	O	O
6	significant	O	O
7	growth	O	O
8	(	O	O
9	8	O	O
10	.	O	O
11	9	O	O
12	+	O	O
13	/	O	O
14	-	O	O
15	0	O	O
16	.	O	O
17	5	O	O
18	mg	O	O
19	for	O	O
20	treated	O	O
21	females	O	O
22	versus	O	O
23	8	O	O
24	.	O	O
25	7	O	O
26	+	O	O
27	/	O	O
28	-	O	O
29	1	O	O
30	.	O	O
31	1	O	O
32	for	O	O
33	untreated	O	O
34	females	O	O
35	)	O	O
36	or	O	O
37	morphological	O	O
38	changes	O	O
39	in	O	O
40	Brown	O	O
41	Norway	O	E-Disease
42	(	O	O
43	BN	O	O
44	)	O	O
45	rat	O	O
46	pituitaries	O	S-Disease
47	.	O	O

0	An	O	O
1	F1	O	O
2	hybrid	O	O
3	of	O	O
4	F344	O	S-Chemical
5	and	O	O
6	BN	O	S-Disease
7	exhibited	O	O
8	significant	O	O
9	pituitary	O	B-Disease
10	growth	O	E-Disease
11	after	O	O
12	10	O	O
13	weeks	O	O
14	of	O	O
15	DES	S-Chemical	S-Disease
16	treatment	O	O
17	with	O	O
18	an	O	O
19	average	O	O
20	mass	O	O
21	of	O	O
22	26	O	O
23	.	O	O
24	3	O	O
25	+	O	O
26	/	O	O
27	-	O	O
28	0	O	O
29	.	O	O
30	7	O	O
31	mg	O	O
32	compared	O	O
33	with	O	O
34	8	O	O
35	.	O	O
36	6	O	O
37	+	O	O
38	/	O	O
39	-	O	O
40	0	O	O
41	.	O	O
42	9	O	O
43	mg	O	O
44	for	O	O
45	untreated	O	O
46	rats	O	O
47	.	O	O

0	Surprisingly	O	O
1	,	O	O
2	the	O	O
3	F1	O	O
4	hybrid	O	O
5	tumors	S-Disease	O
6	were	O	O
7	not	O	O
8	hemorrhagic	S-Disease	O
9	and	O	O
10	had	O	O
11	hemoglobin	O	O
12	content	O	O
13	and	O	O
14	outward	O	O
15	appearance	O	O
16	identical	O	O
17	to	O	O
18	that	O	O
19	of	O	O
20	BN	O	S-Chemical
21	.	O	O

0	However	O	O
1	,	O	O
2	while	O	O
3	DES	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	pituitary	O	B-Disease
7	growth	O	E-Disease
8	exhibited	O	O
9	quantitative	O	O
10	,	O	O
11	additive	O	O
12	inheritance	O	O
13	,	O	O
14	the	O	O
15	hemorrhagic	S-Disease	O
16	phenotype	O	O
17	exhibited	O	O
18	recessive	O	O
19	,	O	O
20	epistatic	O	O
21	inheritance	O	O
22	.	O	O

0	Only	O	O
1	5	O	O
2	of	O	O
3	the	O	O
4	160	O	O
5	F2	O	O
6	pituitaries	O	O
7	exhibited	O	O
8	the	O	O
9	hemorrhagic	S-Disease	O
10	phenotype	O	O
11	;	O	O
12	36	O	O
13	of	O	O
14	the	O	O
15	160	O	O
16	F2	O	S-Disease
17	pituitaries	O	S-Disease
18	were	O	O
19	in	O	O
20	the	O	O
21	F344	O	B-Chemical
22	range	O	O
23	of	O	O
24	mass	O	O
25	,	O	O
26	but	O	O
27	31	O	O
28	of	O	O
29	these	O	O
30	were	O	O
31	not	O	O
32	hemorrhagic	S-Disease	O
33	,	O	O
34	indicating	O	O
35	that	O	O
36	the	O	O
37	hemorrhagic	S-Disease	O
38	phenotype	O	O
39	is	O	O
40	not	O	O
41	merely	O	O
42	a	O	O
43	consequence	O	O
44	of	O	O
45	extensive	O	O
46	growth	O	O
47	.	O	O

0	The	O	O
1	hemorrhagic	S-Disease	O
2	F2	O	S-Disease
3	pituitaries	O	S-Disease
4	were	O	O
5	all	O	O
6	among	O	O
7	the	O	O
8	most	O	O
9	massive	O	O
10	,	O	O
11	indicating	O	O
12	that	O	O
13	some	O	O
14	of	O	O
15	the	O	O
16	genes	O	O
17	regulate	O	O
18	both	O	O
19	phenotypes	O	O
20	.	O	O

0	Increased	O	O
1	expression	O	O
2	of	O	O
3	neuronal	O	B-Disease
4	nitric	B-Chemical	I-Disease
5	oxide	E-Chemical	E-Chemical
6	synthase	O	O
7	in	O	O
8	bladder	O	O
9	afferent	O	O
10	pathways	O	O
11	following	O	O
12	chronic	O	B-Disease
13	bladder	B-Disease	I-Disease
14	irritation	E-Disease	E-Disease
15	.	O	O

0	Immunocytochemical	O	O
1	techniques	O	O
2	were	O	O
3	used	O	O
4	to	O	O
5	examine	O	O
6	alterations	O	O
7	in	O	O
8	the	O	O
9	expression	O	O
10	of	O	O
11	neuronal	O	B-Disease
12	nitric	B-Chemical	I-Disease
13	oxide	E-Chemical	E-Disease
14	synthase	O	O
15	(	O	O
16	NOS	O	S-Chemical
17	)	O	O
18	in	O	O
19	bladder	O	O
20	pathways	O	O
21	following	O	O
22	acute	O	O
23	and	O	O
24	chronic	O	B-Disease
25	irritation	B-Disease	E-Disease
26	of	I-Disease	O
27	the	I-Disease	O
28	urinary	I-Disease	B-Disease
29	tract	E-Disease	E-Disease
30	of	O	O
31	the	O	O
32	rat	O	O
33	.	O	O

0	Chemical	O	O
1	cystitis	S-Disease	S-Disease
2	was	O	O
3	induced	O	O
4	by	O	O
5	cyclophosphamide	S-Chemical	S-Chemical
6	(	O	O
7	CYP	S-Chemical	S-Chemical
8	)	O	O
9	which	O	O
10	is	O	O
11	metabolized	O	O
12	to	O	O
13	acrolein	S-Chemical	S-Chemical
14	,	O	O
15	an	O	O
16	irritant	O	O
17	eliminated	O	O
18	in	O	O
19	the	O	O
20	urine	O	O
21	.	O	O

0	Injection	O	O
1	of	O	O
2	CYP	S-Chemical	S-Chemical
3	(	O	O
4	n	O	O
5	=	O	O
6	10	O	O
7	,	O	O
8	75	O	O
9	mg	O	O
10	/	O	O
11	kg	O	O
12	,	O	O
13	i	O	O
14	.	O	O
15	p	O	O
16	.	O	O
17	)	O	O
18	2	O	O
19	hours	O	O
20	prior	O	O
21	to	O	O
22	perfusion	O	O
23	(	O	O
24	acute	O	O
25	treatment	O	O
26	)	O	O
27	of	O	O
28	the	O	O
29	animals	O	O
30	increased	O	O
31	Fos	O	B-Chemical
32	-	O	E-Chemical
33	immunoreactivity	O	O
34	(	O	O
35	IR	O	S-Disease
36	)	O	O
37	in	O	O
38	neurons	O	O
39	in	O	O
40	the	O	O
41	dorsal	O	O
42	commissure	O	O
43	,	O	O
44	dorsal	O	O
45	horn	O	O
46	,	O	O
47	and	O	O
48	autonomic	O	O
49	regions	O	O
50	of	O	O
51	spinal	O	O
52	segments	O	O
53	(	O	O
54	L1	O	B-Chemical
55	-	O	I-Chemical
56	L2	O	E-Chemical
57	and	O	O
58	L6	O	B-Chemical
59	-	O	I-Chemical
60	S1	O	E-Chemical
61	)	O	O
62	which	O	O
63	receive	O	O
64	afferent	O	O
65	inputs	O	O
66	from	O	O
67	the	O	O
68	bladder	O	O
69	,	O	O
70	urethra	O	S-Disease
71	,	O	O
72	and	O	O
73	ureter	O	S-Disease
74	.	O	O

0	Fos	O	S-Chemical
1	-	O	O
2	IR	O	E-Chemical
3	in	O	O
4	the	O	O
5	spinal	O	O
6	cord	O	O
7	was	O	O
8	not	O	O
9	changed	O	O
10	in	O	O
11	rats	O	O
12	receiving	O	O
13	chronic	O	B-Disease
14	CYP	S-Chemical	E-Disease
15	treatment	O	O
16	(	O	O
17	n	O	O
18	=	O	O
19	15	O	O
20	,	O	O
21	75	O	O
22	mg	O	O
23	/	O	O
24	kg	O	O
25	,	O	O
26	i	O	O
27	.	O	O
28	p	O	O
29	.	O	O
30	,	O	O
31	every	O	O
32	3rd	O	O
33	day	O	O
34	for	O	O
35	2	O	O
36	weeks	O	O
37	)	O	O
38	.	O	O

0	In	O	O
1	control	O	O
2	animals	O	O
3	and	O	O
4	in	O	O
5	animals	O	O
6	treated	O	O
7	acutely	O	O
8	with	O	O
9	CYP	S-Chemical	S-Chemical
10	,	O	O
11	only	O	O
12	small	O	O
13	numbers	O	O
14	of	O	O
15	NOS	O	O
16	-	O	O
17	IR	O	O
18	cells	O	O
19	(	O	O
20	0	O	O
21	.	O	O
22	5	O	O
23	-	O	O
24	0	O	O
25	.	O	O
26	7	O	O
27	cell	O	O
28	profiles	O	O
29	/	O	O
30	sections	O	O
31	)	O	O
32	were	O	O
33	detected	O	O
34	in	O	O
35	the	O	O
36	L6	O	O
37	-	O	O
38	S1	O	O
39	dorsal	O	O
40	root	O	O
41	ganglia	O	E-Disease
42	(	O	O
43	DRG	O	O
44	)	O	O
45	.	O	O

0	Chronic	O	O
1	CYP	S-Chemical	S-Chemical
2	administration	O	O
3	significantly	O	O
4	(	O	O
5	P	O	S-Disease
6	<	O	O
7	or	O	O
8	=	O	O
9	.	O	O
10	002	O	O
11	)	O	O
12	increased	O	O
13	bladder	O	S-Disease
14	weight	O	E-Disease
15	by	O	O
16	60	O	O
17	%	O	O
18	and	O	O
19	increased	O	O
20	(	O	O
21	7	O	O
22	-	O	O
23	to	O	O
24	11	O	O
25	-	O	O
26	fold	O	O
27	)	O	O
28	the	O	O
29	numbers	O	O
30	of	O	O
31	NOS	O	O
32	-	O	O
33	immunoreactive	O	O
34	(	O	O
35	IR	O	S-Disease
36	)	O	O
37	afferent	O	O
38	neurons	O	O
39	in	O	O
40	the	O	O
41	L6	O	S-Disease
42	-	O	O
43	S1	O	O
44	DRG	O	S-Disease
45	.	O	O

0	Bladder	O	O
1	afferent	O	O
2	cells	O	O
3	in	O	O
4	the	O	O
5	L6	O	S-Disease
6	-	O	O
7	S1	O	O
8	DRG	O	S-Disease
9	labeled	O	O
10	by	O	O
11	Fluorogold	O	S-Chemical
12	(	O	O
13	40	O	O
14	microliters	O	O
15	)	O	O
16	injected	O	O
17	into	O	O
18	the	O	O
19	bladder	O	O
20	wall	O	O
21	did	O	O
22	not	O	O
23	exhibit	O	O
24	NOS	O	O
25	-	O	O
26	IR	O	S-Disease
27	in	O	O
28	control	O	O
29	animals	O	O
30	;	O	O
31	however	O	O
32	,	O	O
33	following	O	O
34	chronic	O	O
35	CYP	S-Chemical	E-Chemical
36	administration	O	O
37	,	O	O
38	a	O	O
39	significant	O	O
40	percentage	O	O
41	of	O	O
42	bladder	O	O
43	afferent	O	O
44	neurons	O	O
45	were	O	O
46	NOS	O	O
47	-	O	O
48	IR	O	S-Disease
49	:	O	O
50	L6	O	S-Disease
51	(	O	O
52	19	O	O
53	.	O	O
54	8	O	O
55	+	O	O
56	/	O	O
57	-	O	O
58	4	O	O
59	.	O	O
60	6	O	O
61	%	O	O
62	)	O	O
63	and	O	O
64	S1	O	S-Disease
65	(	O	O
66	25	O	O
67	.	O	O
68	3	O	O
69	+	O	O
70	/	O	O
71	-	O	O
72	2	O	O
73	.	O	O
74	9	O	O
75	%	O	O
76	)	O	O
77	.	O	O

0	Effects	O	O
1	of	O	O
2	a	O	O
3	new	O	O
4	calcium	S-Chemical	S-Disease
5	antagonist	O	O
6	,	O	O
7	CD	B-Chemical	B-Chemical
8	-	I-Chemical	E-Chemical
9	832	E-Chemical	E-Chemical
10	,	O	O
11	on	O	O
12	isoproterenol	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	myocardial	B-Disease	B-Disease
16	ischemia	E-Disease	E-Disease
17	in	O	O
18	dogs	O	O
19	with	O	O
20	partial	O	O
21	coronary	B-Disease	B-Disease
22	stenosis	E-Disease	E-Disease
23	.	O	O

0	Effects	O	O
1	of	O	O
2	CD	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	832	E-Chemical	E-Chemical
5	on	O	O
6	isoproterenol	S-Chemical	S-Chemical
7	(	O	O
8	ISO	S-Chemical	S-Chemical
9	)	O	O
10	-	O	O
11	induced	O	O
12	myocardial	B-Disease	B-Disease
13	ischemia	E-Disease	E-Disease
14	were	O	O
15	studied	O	O
16	in	O	O
17	dogs	O	O
18	with	O	O
19	partial	O	O
20	coronary	B-Disease	B-Disease
21	stenosis	E-Disease	E-Disease
22	of	O	O
23	the	O	O
24	left	O	O
25	circumflex	O	B-Disease
26	coronary	O	I-Disease
27	artery	O	E-Disease
28	and	O	O
29	findings	O	O
30	were	O	O
31	compared	O	O
32	with	O	O
33	those	O	O
34	for	O	O
35	nifedipine	S-Chemical	B-Chemical
36	or	O	O
37	diltiazem	S-Chemical	B-Chemical
38	.	O	O

0	In	O	O
1	the	O	O
2	presence	O	O
3	of	O	O
4	coronary	B-Disease	B-Disease
5	artery	I-Disease	I-Disease
6	stenosis	E-Disease	E-Disease
7	,	O	O
8	3	O	O
9	-	O	O
10	min	O	O
11	periods	O	O
12	of	O	O
13	intracoronary	O	O
14	ISO	S-Chemical	S-Chemical
15	infusion	O	O
16	(	O	O
17	10	O	O
18	ng	O	O
19	/	O	O
20	kg	O	O
21	/	O	O
22	min	O	O
23	)	O	O
24	increased	O	O
25	heart	O	S-Disease
26	rate	O	O
27	and	O	O
28	maximal	O	O
29	rate	O	O
30	of	O	O
31	left	O	O
32	ventricular	O	B-Disease
33	pressure	O	E-Disease
34	rise	O	O
35	,	O	O
36	which	O	O
37	resulted	O	O
38	in	O	O
39	a	O	O
40	decrease	O	O
41	in	O	O
42	percentage	O	O
43	segmental	O	O
44	shortening	O	O
45	and	O	O
46	ST	O	S-Disease
47	-	O	O
48	segment	O	O
49	elevation	O	O
50	of	O	O
51	the	O	O
52	epicardial	O	O
53	electrocardiogram	O	O
54	.	O	O

0	After	O	O
1	the	O	O
2	control	O	O
3	ISO	S-Chemical	S-Disease
4	infusion	O	O
5	with	O	O
6	stenosis	S-Disease	S-Disease
7	was	O	O
8	performed	O	O
9	,	O	O
10	equihypotensive	O	O
11	doses	O	O
12	of	O	O
13	CD	B-Chemical	B-Chemical
14	-	I-Chemical	I-Chemical
15	832	E-Chemical	E-Chemical
16	(	O	O
17	3	O	O
18	and	O	O
19	10	O	O
20	micrograms	O	O
21	/	O	O
22	kg	O	O
23	/	O	O
24	min	O	O
25	,	O	O
26	n	O	O
27	=	O	O
28	7	O	O
29	)	O	O
30	,	O	O
31	nifedipine	S-Chemical	O
32	(	O	O
33	1	O	O
34	and	O	O
35	3	O	O
36	micrograms	O	O
37	/	O	O
38	kg	O	O
39	/	O	O
40	min	O	O
41	,	O	O
42	n	O	O
43	=	O	O
44	9	O	O
45	)	O	O
46	or	O	O
47	diltiazem	S-Chemical	S-Chemical
48	(	O	O
49	10	O	O
50	and	O	O
51	30	O	O
52	micrograms	O	O
53	/	O	O
54	kg	O	O
55	/	O	O
56	min	O	O
57	,	O	O
58	n	O	O
59	=	O	O
60	7	O	O
61	)	O	O
62	were	O	O
63	infused	O	O
64	5	O	O
65	min	O	O
66	before	O	O
67	and	O	O
68	during	O	O
69	the	O	O
70	second	O	O
71	and	O	O
72	third	O	O
73	ISO	S-Chemical	S-Chemical
74	infusion	O	O
75	.	O	O

0	Both	O	O
1	CD	B-Chemical	B-Chemical
2	-	I-Chemical	E-Chemical
3	832	E-Chemical	E-Chemical
4	and	O	O
5	diltiazem	S-Chemical	S-Chemical
6	,	O	O
7	but	O	O
8	not	O	O
9	nifedipine	S-Chemical	S-Chemical
10	,	O	O
11	significantly	O	O
12	reduced	O	O
13	the	O	O
14	increase	O	O
15	in	O	O
16	heart	O	S-Disease
17	rate	O	E-Disease
18	induced	O	O
19	by	O	O
20	ISO	S-Chemical	S-Disease
21	infusion	O	O
22	.	O	O

0	In	O	O
1	contrast	O	O
2	to	O	O
3	nifedipine	S-Chemical	S-Chemical
4	,	O	O
5	CD	B-Chemical	B-Chemical
6	-	I-Chemical	E-Chemical
7	832	E-Chemical	E-Chemical
8	(	O	O
9	10	O	O
10	micrograms	O	O
11	/	O	O
12	kg	O	O
13	/	O	O
14	min	O	O
15	)	O	O
16	prevented	O	O
17	the	O	O
18	decrease	O	O
19	in	O	O
20	percentage	O	O
21	segmental	O	O
22	shortening	O	O
23	from	O	O
24	32	O	O
25	+	O	O
26	/	O	O
27	-	O	O
28	12	O	O
29	%	O	O
30	to	O	O
31	115	O	O
32	+	O	O
33	/	O	O
34	-	O	O
35	26	O	O
36	%	O	O
37	of	O	O
38	the	O	O
39	control	O	O
40	value	O	O
41	(	O	O
42	P	O	O
43	<	O	O
44	.	O	O
45	01	O	O
46	)	O	O
47	and	O	O
48	ST	O	S-Disease
49	-	O	O
50	segment	O	O
51	elevation	O	O
52	from	O	O
53	5	O	O
54	.	O	O
55	6	O	O
56	+	O	O
57	/	O	O
58	-	O	O
59	1	O	O
60	.	O	O
61	0	O	O
62	mV	O	O
63	to	O	O
64	1	O	O
65	.	O	O
66	6	O	O
67	+	O	O
68	/	O	O
69	-	O	O
70	1	O	O
71	.	O	O
72	3	O	O
73	mV	O	O
74	(	O	O
75	P	O	O
76	<	O	O
77	.	O	O
78	01	O	O
79	)	O	O
80	at	O	O
81	3	O	O
82	min	O	O
83	after	O	O
84	ISO	S-Chemical	B-Chemical
85	infusion	O	O
86	with	O	O
87	stenosis	S-Disease	S-Disease
88	.	O	O

0	Diltiazem	S-Chemical	S-Chemical
1	(	O	O
2	30	O	O
3	micrograms	O	O
4	/	O	O
5	kg	O	O
6	/	O	O
7	min	O	O
8	)	O	O
9	also	O	O
10	prevented	O	O
11	the	O	O
12	decrease	O	O
13	in	O	O
14	percentage	O	O
15	segmental	O	O
16	shortening	O	O
17	from	O	O
18	34	O	O
19	+	O	O
20	/	O	O
21	-	O	O
22	14	O	O
23	%	O	O
24	to	O	O
25	63	O	O
26	+	O	O
27	/	O	O
28	-	O	O
29	18	O	O
30	%	O	O
31	of	O	O
32	the	O	O
33	control	O	O
34	value	O	O
35	(	O	O
36	P	O	O
37	<	O	O
38	.	O	O
39	05	O	O
40	)	O	O
41	and	O	O
42	ST	O	S-Disease
43	-	O	O
44	segment	O	O
45	elevation	O	O
46	from	O	O
47	4	O	O
48	.	O	O
49	7	O	O
50	+	O	O
51	/	O	O
52	-	O	O
53	0	O	O
54	.	O	O
55	7	O	O
56	mV	O	O
57	to	O	O
58	2	O	O
59	.	O	O
60	1	O	O
61	+	O	O
62	/	O	O
63	-	O	O
64	0	O	O
65	.	O	O
66	7	O	O
67	mV	O	O
68	(	O	O
69	P	O	O
70	<	O	O
71	.	O	O
72	01	O	O
73	)	O	O
74	at	O	O
75	3	O	O
76	min	O	O
77	after	O	O
78	ISO	S-Chemical	S-Chemical
79	infusion	O	O
80	with	O	O
81	stenosis	S-Disease	O
82	.	O	O

0	These	O	O
1	data	O	O
2	show	O	O
3	that	O	O
4	CD	B-Chemical	B-Chemical
5	-	I-Chemical	E-Chemical
6	832	E-Chemical	E-Chemical
7	improves	O	O
8	myocardial	B-Disease	B-Disease
9	ischemia	E-Disease	E-Disease
10	during	O	O
11	ISO	S-Chemical	S-Disease
12	infusion	O	O
13	with	O	O
14	stenosis	S-Disease	S-Disease
15	and	O	O
16	suggest	O	O
17	that	O	O
18	the	O	O
19	negative	O	O
20	chronotropic	O	S-Disease
21	property	O	O
22	of	O	O
23	CD	B-Chemical	B-Chemical
24	-	I-Chemical	E-Chemical
25	832	E-Chemical	E-Chemical
26	plays	O	O
27	a	O	O
28	major	O	O
29	role	O	O
30	in	O	O
31	the	O	O
32	beneficial	O	O
33	effects	O	O
34	of	O	O
35	CD	B-Chemical	B-Chemical
36	-	I-Chemical	E-Chemical
37	832	E-Chemical	E-Chemical
38	.	O	O

0	The	O	O
1	effect	O	O
2	of	O	O
3	recombinant	O	O
4	human	O	O
5	insulin	O	S-Chemical
6	-	O	O
7	like	O	O
8	growth	O	I-Disease
9	factor	O	E-Disease
10	-	O	O
11	I	O	E-Disease
12	on	O	O
13	chronic	O	B-Disease
14	puromycin	B-Chemical	I-Disease
15	aminonucleoside	E-Chemical	S-Disease
16	nephropathy	S-Disease	E-Disease
17	in	O	O
18	rats	O	O
19	.	O	O

0	We	O	O
1	recently	O	O
2	demonstrated	O	O
3	that	O	O
4	recombinant	O	O
5	hGH	O	S-Chemical
6	exacerbates	O	O
7	renal	O	B-Disease
8	functional	O	I-Disease
9	and	O	O
10	structural	O	O
11	injury	O	E-Disease
12	in	O	O
13	chronic	O	B-Disease
14	puromycin	B-Chemical	I-Disease
15	aminonucleoside	E-Chemical	E-Chemical
16	(	O	O
17	PAN	S-Chemical	S-Chemical
18	)	O	O
19	nephropathy	S-Disease	S-Disease
20	,	O	O
21	an	O	O
22	experimental	O	O
23	model	O	O
24	of	O	O
25	glomerular	B-Disease	B-Disease
26	disease	E-Disease	E-Disease
27	.	O	O

0	Therefore	O	O
1	,	O	O
2	we	O	O
3	examined	O	O
4	whether	O	O
5	recombinant	O	O
6	human	O	O
7	(	O	O
8	rh	O	O
9	)	O	O
10	IGF	O	S-Chemical
11	-	O	E-Chemical
12	I	O	E-Chemical
13	is	O	O
14	a	O	O
15	safer	O	O
16	alternative	O	O
17	for	O	O
18	the	O	O
19	treatment	O	O
20	of	O	O
21	growth	B-Disease	B-Disease
22	failure	E-Disease	E-Disease
23	in	O	O
24	rats	O	O
25	with	O	O
26	chronic	O	B-Disease
27	PAN	S-Chemical	I-Disease
28	nephropathy	S-Disease	E-Disease
29	.	O	O

0	The	O	O
1	glomerulopathy	S-Disease	S-Disease
2	was	O	O
3	induced	O	O
4	by	O	O
5	seven	O	O
6	serial	O	O
7	injections	O	O
8	of	O	O
9	PAN	S-Chemical	S-Chemical
10	over	O	O
11	12	O	O
12	wk	O	O
13	.	O	O

0	rhIGF	O	S-Chemical
1	-	O	O
2	I	O	E-Chemical
3	improved	O	O
4	weight	O	O
5	gain	O	O
6	by	O	O
7	14	O	O
8	%	O	O
9	(	O	O
10	p	O	O
11	<	O	O
12	0	O	O
13	.	O	O
14	05	O	O
15	)	O	O
16	,	O	O
17	without	O	O
18	altering	O	O
19	hematocrit	O	O
20	or	O	O
21	blood	O	O
22	pressure	O	E-Disease
23	in	O	O
24	rats	O	O
25	with	O	O
26	renal	B-Disease	B-Disease
27	disease	E-Disease	E-Disease
28	.	O	O

0	Urinary	O	O
1	protein	O	O
2	excretion	O	O
3	was	O	O
4	unaltered	O	O
5	by	O	O
6	rhIGF	O	S-Disease
7	-	O	O
8	I	O	O
9	treatment	O	O
10	in	O	O
11	rats	O	O
12	with	O	O
13	chronic	O	B-Disease
14	PAN	S-Chemical	I-Disease
15	nephropathy	S-Disease	E-Disease
16	.	O	O

0	After	O	O
1	12	O	O
2	wk	O	O
3	,	O	O
4	the	O	O
5	inulin	O	S-Chemical
6	clearance	O	O
7	was	O	O
8	higher	O	O
9	in	O	O
10	rhIGF	O	S-Disease
11	-	O	O
12	I	O	E-Chemical
13	-	O	O
14	treated	O	O
15	rats	O	O
16	,	O	O
17	0	O	O
18	.	O	O
19	48	O	O
20	+	O	O
21	/	O	O
22	-	O	O
23	0	O	O
24	.	O	O
25	08	O	O
26	versus	O	O
27	0	O	O
28	.	O	O
29	24	O	O
30	+	O	O
31	/	O	O
32	-	O	O
33	0	O	O
34	.	O	O
35	06	O	O
36	mL	O	O
37	/	O	O
38	min	O	O
39	/	O	O
40	100	O	O
41	g	O	O
42	of	O	O
43	body	O	O
44	weight	O	O
45	in	O	O
46	untreated	O	O
47	PAN	S-Chemical	B-Disease
48	nephropathy	S-Disease	E-Disease
49	animals	O	O
50	,	O	O
51	p	O	O
52	<	O	O
53	0	O	O
54	.	O	O
55	05	O	O
56	.	O	O

0	The	O	O
1	improvement	O	O
2	in	O	O
3	GFR	O	S-Disease
4	was	O	O
5	not	O	O
6	associated	O	O
7	with	O	O
8	enhanced	O	O
9	glomerular	B-Disease	B-Disease
10	hypertrophy	E-Disease	E-Disease
11	or	O	O
12	increased	O	O
13	segmental	O	B-Disease
14	glomerulosclerosis	S-Disease	I-Disease
15	,	O	O
16	tubulointerstitial	B-Disease	S-Disease
17	injury	E-Disease	S-Disease
18	,	O	O
19	or	O	O
20	renal	O	B-Disease
21	cortical	O	I-Disease
22	malondialdehyde	S-Chemical	E-Chemical
23	content	O	O
24	.	O	O

0	In	O	O
1	rats	O	O
2	with	O	O
3	PAN	S-Chemical	B-Disease
4	nephropathy	S-Disease	E-Disease
5	,	O	O
6	administration	O	O
7	of	O	O
8	rhIGF	O	S-Disease
9	-	O	I-Disease
10	I	O	S-Disease
11	increased	O	O
12	IGF	O	S-Disease
13	-	O	I-Disease
14	I	O	E-Chemical
15	and	O	O
16	GH	O	B-Disease
17	receptor	O	O
18	gene	O	O
19	expression	O	O
20	,	O	O
21	without	O	O
22	altering	O	O
23	the	O	O
24	steady	O	O
25	state	O	O
26	level	O	O
27	of	O	O
28	IGF	O	B-Chemical
29	-	O	I-Disease
30	I	O	I-Disease
31	receptor	O	O
32	mRNA	O	O
33	.	O	O

0	In	O	O
1	normal	O	O
2	rats	O	O
3	with	O	O
4	intact	O	O
5	kidneys	O	O
6	,	O	O
7	rhIGF	O	S-Disease
8	-	O	O
9	I	O	O
10	administration	O	O
11	(	O	O
12	n	O	O
13	=	O	O
14	4	O	O
15	)	O	O
16	did	O	O
17	not	O	O
18	alter	O	O
19	weight	O	O
20	gain	O	O
21	,	O	O
22	blood	O	O
23	pressure	O	O
24	,	O	O
25	proteinuria	S-Disease	S-Disease
26	,	O	O
27	GFR	O	S-Disease
28	,	O	O
29	glomerular	O	O
30	planar	O	O
31	area	O	O
32	,	O	O
33	renal	O	B-Disease
34	cortical	O	I-Disease
35	malondialdehyde	S-Chemical	S-Disease
36	content	O	O
37	,	O	O
38	or	O	O
39	glomerular	O	O
40	or	O	O
41	tubulointerstitial	B-Disease	S-Disease
42	damage	E-Disease	O
43	,	O	O
44	compared	O	O
45	with	O	O
46	untreated	O	O
47	animals	O	O
48	(	O	O
49	n	O	O
50	=	O	O
51	4	O	O
52	)	O	O
53	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	:	O	O
4	1	O	O
5	)	O	O
6	administration	O	O
7	of	O	O
8	rhIGF	O	S-Chemical
9	-	O	O
10	I	O	E-Chemical
11	improves	O	O
12	growth	O	O
13	and	O	O
14	GFR	O	S-Disease
15	in	O	O
16	rats	O	O
17	with	O	O
18	chronic	O	B-Disease
19	PAN	S-Chemical	I-Disease
20	nephropathy	S-Disease	E-Disease
21	and	O	O
22	2	O	O
23	)	O	O
24	unlike	O	O
25	rhGH	O	S-Chemical
26	,	O	O
27	long	O	O
28	-	O	O
29	term	O	O
30	use	O	O
31	of	O	O
32	rhIGF	O	S-Chemical
33	-	O	O
34	I	O	E-Chemical
35	does	O	O
36	not	O	O
37	worsen	O	O
38	renal	O	B-Disease
39	functional	O	O
40	and	O	O
41	structural	O	O
42	injury	O	E-Disease
43	in	O	O
44	this	O	O
45	disease	O	S-Disease
46	model	O	O
47	.	O	O

0	Nefiracetam	S-Chemical	S-Chemical
1	(	O	O
2	DM	B-Chemical	B-Chemical
3	-	I-Chemical	E-Chemical
4	9384	E-Chemical	E-Chemical
5	)	O	O
6	reverses	O	O
7	apomorphine	S-Chemical	O
8	-	O	O
9	induced	O	O
10	amnesia	S-Disease	S-Disease
11	of	O	O
12	a	O	O
13	passive	O	O
14	avoidance	O	O
15	response	O	O
16	:	O	O
17	delayed	O	O
18	emergence	O	O
19	of	O	O
20	the	O	O
21	memory	O	O
22	retention	O	O
23	effects	O	O
24	.	O	O

0	Nefiracetam	S-Chemical	S-Chemical
1	is	O	O
2	a	O	O
3	novel	O	O
4	pyrrolidone	S-Chemical	S-Chemical
5	derivative	O	O
6	which	O	O
7	attenuates	O	O
8	scopolamine	S-Chemical	S-Disease
9	-	O	O
10	induced	O	O
11	learning	B-Disease	O
12	and	I-Disease	O
13	post	I-Disease	O
14	-	I-Disease	O
15	training	I-Disease	O
16	consolidation	I-Disease	O
17	deficits	E-Disease	O
18	.	O	O

0	Given	O	O
1	that	O	O
2	apomorphine	S-Chemical	S-Chemical
3	inhibits	O	O
4	passive	O	O
5	avoidance	O	O
6	retention	O	O
7	when	O	O
8	given	O	O
9	during	O	O
10	training	O	O
11	or	O	O
12	in	O	O
13	a	O	O
14	defined	O	O
15	10	O	O
16	-	O	O
17	12h	O	O
18	post	O	O
19	-	O	O
20	training	O	O
21	period	O	O
22	,	O	O
23	we	O	O
24	evaluated	O	O
25	the	O	O
26	ability	O	O
27	of	O	O
28	nefiracetam	S-Chemical	S-Chemical
29	to	O	O
30	attenuate	O	O
31	amnesia	S-Disease	S-Disease
32	induced	O	O
33	by	O	O
34	dopaminergic	O	O
35	agonism	O	O
36	.	O	O

0	A	O	O
1	step	O	O
2	-	O	O
3	down	O	O
4	passive	O	O
5	avoidance	O	O
6	paradigm	O	O
7	was	O	O
8	employed	O	O
9	and	O	O
10	nefiracetam	S-Chemical	S-Chemical
11	(	O	O
12	3	O	O
13	mg	O	O
14	/	O	O
15	kg	O	O
16	)	O	O
17	and	O	O
18	apomorphine	S-Chemical	S-Chemical
19	(	O	O
20	0	O	O
21	.	O	O
22	5	O	O
23	mg	O	O
24	/	O	O
25	kg	O	O
26	)	O	O
27	were	O	O
28	given	O	O
29	alone	O	O
30	or	O	O
31	in	O	O
32	combination	O	O
33	during	O	O
34	training	O	O
35	and	O	O
36	at	O	O
37	the	O	O
38	10	O	O
39	-	O	O
40	12h	O	O
41	post	O	O
42	-	O	O
43	training	O	O
44	period	O	O
45	of	O	O
46	consolidation	O	O
47	.	O	O

0	Co	O	O
1	-	O	O
2	administration	O	O
3	of	O	O
4	nefiracetam	S-Chemical	S-Chemical
5	and	O	O
6	apomorphine	S-Chemical	S-Chemical
7	during	O	O
8	training	O	O
9	or	O	O
10	10h	O	O
11	thereafter	O	O
12	produced	O	O
13	no	O	O
14	significant	O	O
15	anti	O	O
16	-	O	O
17	amnesic	O	S-Disease
18	effect	O	O
19	.	O	O

0	However	O	O
1	,	O	O
2	administration	O	O
3	of	O	O
4	nefiracetam	S-Chemical	S-Chemical
5	during	O	O
6	training	O	O
7	completely	O	O
8	reversed	O	O
9	the	O	O
10	amnesia	S-Disease	S-Disease
11	induced	O	O
12	by	O	O
13	apomorphine	S-Chemical	S-Chemical
14	at	O	O
15	the	O	O
16	10h	O	O
17	post	O	O
18	-	O	O
19	training	O	O
20	time	O	O
21	and	O	O
22	the	O	O
23	converse	O	O
24	was	O	O
25	also	O	O
26	true	O	O
27	.	O	O

0	These	O	O
1	effects	O	O
2	were	O	O
3	not	O	O
4	mediated	O	O
5	by	O	O
6	a	O	O
7	dopaminergic	O	O
8	mechanism	O	O
9	as	O	O
10	nefiracetam	S-Chemical	S-Chemical
11	,	O	O
12	at	O	O
13	millimolar	O	O
14	concentrations	O	O
15	,	O	O
16	failed	O	O
17	to	O	O
18	displace	O	O
19	either	O	O
20	[	O	O
21	3H	O	O
22	]	O	O
23	SCH	B-Chemical	B-Chemical
24	23390	E-Chemical	E-Chemical
25	or	O	O
26	[	O	O
27	3H	O	O
28	]	O	O
29	spiperone	S-Chemical	S-Chemical
30	binding	O	O
31	from	O	O
32	D1	O	S-Chemical
33	or	O	O
34	D2	O	S-Disease
35	dopamine	S-Chemical	O
36	receptor	O	O
37	subtypes	O	O
38	,	O	O
39	respectively	O	O
40	.	O	O

0	It	O	O
1	is	O	O
2	suggested	O	O
3	that	O	O
4	nefiracetam	S-Chemical	S-Chemical
5	augments	O	O
6	molecular	O	O
7	processes	O	O
8	in	O	O
9	the	O	O
10	early	O	O
11	stages	O	O
12	of	O	O
13	events	O	O
14	which	O	O
15	ultimately	O	O
16	lead	O	O
17	to	O	O
18	consolidation	O	O
19	of	O	O
20	memory	O	O
21	.	O	O

0	Phenytoin	S-Chemical	S-Chemical
1	encephalopathy	S-Disease	S-Disease
2	as	O	O
3	probable	O	O
4	idiosyncratic	O	O
5	reaction	O	O
6	:	O	O
7	case	O	O
8	report	O	O
9	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	phenytoin	S-Chemical	S-Chemical
4	(	O	O
5	DPH	S-Chemical	S-Chemical
6	)	O	O
7	encephalopathy	S-Disease	S-Disease
8	with	O	O
9	increasing	O	O
10	seizures	S-Disease	S-Disease
11	and	O	O
12	EEG	O	B-Disease
13	and	O	O
14	mental	O	B-Disease
15	changes	O	E-Disease
16	is	O	O
17	described	O	O
18	.	O	O

0	Despite	O	O
1	adequate	O	O
2	oral	O	O
3	dosage	O	O
4	of	O	O
5	DPH	S-Chemical	S-Chemical
6	(	O	O
7	5	O	O
8	mg	O	O
9	/	O	O
10	kg	O	O
11	/	O	O
12	daily	O	O
13	)	O	O
14	the	O	O
15	plasma	O	O
16	level	O	O
17	was	O	O
18	very	O	O
19	low	O	O
20	(	O	O
21	2	O	O
22	.	O	O
23	8	O	O
24	microgramg	O	O
25	/	O	O
26	ml	O	O
27	)	O	O
28	.	O	O

0	The	O	O
1	encephalopathy	S-Disease	S-Disease
2	was	O	O
3	probably	O	O
4	an	O	O
5	idiosyncratic	O	O
6	and	O	O
7	not	O	O
8	toxic	O	O
9	or	O	O
10	allergic	O	B-Disease
11	reaction	O	E-Disease
12	.	O	O

0	In	O	O
1	fact	O	O
2	the	O	O
3	concentration	O	O
4	of	O	O
5	free	O	O
6	DPH	S-Chemical	S-Chemical
7	was	O	O
8	normal	O	O
9	,	O	O
10	the	O	O
11	patient	O	O
12	presented	O	O
13	a	O	O
14	retarded	O	O
15	morbilliform	O	B-Disease
16	rash	S-Disease	E-Disease
17	during	O	O
18	DPH	S-Chemical	S-Chemical
19	treatment	O	O
20	,	O	O
21	the	O	O
22	protidogram	O	O
23	was	O	O
24	normal	O	O
25	,	O	O
26	and	O	O
27	an	O	O
28	intradermic	O	O
29	DPH	S-Chemical	S-Chemical
30	injection	O	O
31	had	O	O
32	no	O	O
33	local	O	O
34	effect	O	O
35	.	O	O

0	The	O	O
1	authors	O	O
2	conclude	O	O
3	that	O	O
4	in	O	O
5	a	O	O
6	patient	O	O
7	starting	O	O
8	DPH	S-Chemical	S-Chemical
9	treatment	O	O
10	an	O	O
11	unexpected	O	O
12	increase	O	O
13	in	O	O
14	seizures	S-Disease	S-Disease
15	,	O	O
16	with	O	O
17	EEG	O	B-Disease
18	and	O	O
19	mental	O	O
20	changes	O	E-Disease
21	occurring	O	O
22	simultaneously	O	O
23	,	O	O
24	should	O	O
25	alert	O	O
26	the	O	O
27	physician	O	O
28	to	O	O
29	the	O	O
30	possible	O	O
31	need	O	O
32	for	O	O
33	eliminating	O	O
34	DPH	S-Chemical	S-Chemical
35	from	O	O
36	the	O	O
37	therapeutic	O	O
38	regimen	O	O
39	,	O	O
40	even	O	O
41	if	O	O
42	plasma	O	O
43	concentrations	O	O
44	are	O	O
45	low	O	O
46	.	O	O

0	Prevention	O	O
1	and	O	O
2	treatment	O	O
3	of	O	O
4	endometrial	B-Disease	B-Disease
5	disease	E-Disease	E-Disease
6	in	O	O
7	climacteric	O	S-Disease
8	women	O	O
9	receiving	O	O
10	oestrogen	S-Chemical	S-Chemical
11	therapy	O	O
12	.	O	O

0	The	O	O
1	treatment	O	O
2	regimens	O	O
3	are	O	O
4	described	O	O
5	in	O	O
6	74	O	O
7	patients	O	O
8	with	O	O
9	endometrial	B-Disease	B-Disease
10	disease	E-Disease	E-Disease
11	among	O	O
12	850	O	O
13	climacteric	O	S-Disease
14	women	O	O
15	receiving	O	O
16	oestrogen	S-Chemical	B-Disease
17	therapy	O	O
18	.	O	O

0	Cystic	O	B-Disease
1	hyperplasia	S-Disease	E-Disease
2	was	O	O
3	associated	O	O
4	with	O	O
5	unopposed	O	O
6	oestrogen	S-Chemical	S-Chemical
7	therapy	O	O
8	without	O	O
9	progestagen	S-Chemical	S-Disease
10	.	O	O

0	Two	O	O
1	courses	O	O
2	of	O	O
3	21	O	O
4	days	O	O
5	of	O	O
6	5	O	O
7	mg	O	O
8	norethisterone	S-Chemical	S-Chemical
9	daily	O	O
10	caused	O	O
11	reversion	O	O
12	to	O	O
13	normal	O	O
14	in	O	O
15	all	O	O
16	57	O	O
17	cases	O	O
18	of	O	O
19	cystic	O	B-Disease
20	hyperplasia	S-Disease	E-Disease
21	and	O	O
22	6	O	O
23	of	O	O
24	the	O	O
25	8	O	O
26	cases	O	O
27	of	O	O
28	atypical	O	B-Disease
29	hyperplasia	S-Disease	E-Disease
30	.	O	O

0	4	O	O
1	cases	O	O
2	of	O	O
3	endometrial	B-Disease	O
4	carcinoma	E-Disease	S-Disease
5	referred	O	O
6	from	O	O
7	elsewhere	O	O
8	demonstrated	O	O
9	the	O	O
10	problems	O	O
11	of	O	O
12	inappropriate	O	O
13	and	O	O
14	unsupervised	O	O
15	unopposed	O	O
16	oestrogen	S-Chemical	S-Chemical
17	therapy	O	O
18	and	O	O
19	the	O	O
20	difficulty	O	O
21	in	O	O
22	distinguishing	O	O
23	severe	O	O
24	hyperplasia	S-Disease	S-Disease
25	from	O	O
26	malignancy	S-Disease	S-Disease
27	.	O	O

0	Cyclical	O	O
1	low	O	O
2	-	O	O
3	dose	O	O
4	oestrogen	S-Chemical	S-Disease
5	therapy	O	O
6	with	O	O
7	7	O	O
8	-	O	O
9	-	O	O
10	13	O	O
11	days	O	O
12	of	O	O
13	progestagen	S-Chemical	S-Disease
14	does	O	O
15	not	O	O
16	seem	O	O
17	to	O	O
18	increase	O	O
19	the	O	O
20	risk	O	O
21	of	O	O
22	endometrial	B-Disease	O
23	hyperplasia	E-Disease	S-Disease
24	or	O	O
25	carcinoma	S-Disease	S-Disease
26	.	O	O

0	Effects	O	O
1	of	O	O
2	exercise	O	O
3	on	O	O
4	the	O	O
5	severity	O	O
6	of	O	O
7	isoproterenol	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	myocardial	B-Disease	B-Disease
11	infarction	E-Disease	E-Disease
12	.	O	O

0	The	O	O
1	effect	O	O
2	of	O	O
3	exercise	O	O
4	on	O	O
5	the	O	O
6	severity	O	O
7	of	O	O
8	isoproterenol	S-Chemical	S-Chemical
9	-	O	O
10	induced	O	O
11	myocardial	B-Disease	B-Disease
12	infarction	E-Disease	E-Disease
13	was	O	O
14	studied	O	O
15	in	O	O
16	male	O	O
17	rats	O	O
18	.	O	O

0	The	O	O
1	exercise	O	O
2	-	O	O
3	isoproterenol	S-Chemical	S-Chemical
4	(	O	O
5	E	O	S-Disease
6	-	O	E-Chemical
7	1	O	O
8	)	O	O
9	and	O	O
10	exercise	O	O
11	control	O	O
12	(	O	O
13	EC	O	O
14	)	O	O
15	groups	O	O
16	exercised	O	O
17	daily	O	O
18	for	O	O
19	thirty	O	O
20	days	O	O
21	on	O	O
22	a	O	O
23	treadmill	O	O
24	at	O	O
25	1	O	O
26	mph	O	O
27	,	O	O
28	2	O	O
29	%	O	O
30	grade	O	O
31	while	O	O
32	animals	O	O
33	of	O	O
34	the	O	O
35	sedentary	O	O
36	-	O	O
37	isoproterenol	S-Chemical	S-Chemical
38	(	O	O
39	S	O	O
40	-	O	O
41	I	O	O
42	)	O	O
43	group	O	O
44	remained	O	O
45	sedentary	O	O
46	.	O	O

0	Forty	O	O
1	-	O	O
2	eight	O	O
3	hours	O	O
4	after	O	O
5	the	O	O
6	final	O	O
7	exercise	O	O
8	period	O	O
9	,	O	O
10	S	O	B-Chemical
11	-	O	I-Chemical
12	I	O	O
13	and	O	O
14	E	O	S-Disease
15	-	O	I-Chemical
16	I	O	O
17	animals	O	O
18	received	O	O
19	a	O	O
20	single	O	O
21	subcutaneous	O	O
22	injection	O	O
23	of	O	O
24	isoproterenol	S-Chemical	S-Chemical
25	(	O	O
26	250	O	O
27	mg	O	O
28	/	O	O
29	kg	O	O
30	body	O	O
31	weight	O	O
32	)	O	O
33	.	O	O

0	Animals	O	O
1	of	O	O
2	the	O	O
3	S	O	O
4	-	O	O
5	I	O	O
6	group	O	O
7	exhibited	O	O
8	significantly	O	O
9	(	O	O
10	Pp	O	S-Chemical
11	less	O	O
12	than	O	O
13	0	O	O
14	.	O	O
15	05	O	O
16	)	O	O
17	greater	O	O
18	mortality	O	O
19	from	O	O
20	the	O	O
21	effects	O	O
22	of	O	O
23	isoproterenol	S-Chemical	S-Chemical
24	than	O	O
25	animals	O	O
26	of	O	O
27	the	O	O
28	E	O	O
29	-	O	O
30	I	O	O
31	group	O	O
32	.	O	O

0	Serum	O	O
1	CPK	O	S-Disease
2	activity	O	O
3	for	O	O
4	E	O	O
5	-	O	O
6	I	O	O
7	animals	O	O
8	was	O	O
9	significantly	O	O
10	(	O	O
11	p	O	O
12	less	O	O
13	than	O	O
14	0	O	O
15	.	O	O
16	05	O	O
17	)	O	O
18	greater	O	O
19	than	O	O
20	for	O	O
21	animals	O	O
22	in	O	O
23	the	O	O
24	S	O	S-Chemical
25	-	O	O
26	I	O	O
27	and	O	O
28	EC	O	O
29	groups	O	O
30	twenty	O	O
31	hours	O	O
32	following	O	O
33	isoproterenol	S-Chemical	S-Chemical
34	injection	O	O
35	.	O	O

0	No	O	O
1	statistically	O	O
2	significant	O	O
3	differences	O	O
4	were	O	O
5	observed	O	O
6	between	O	O
7	the	O	O
8	two	O	O
9	isoproterenol	S-Chemical	S-Chemical
10	treated	O	O
11	groups	O	O
12	for	O	O
13	severity	O	O
14	of	O	O
15	the	O	O
16	induced	O	O
17	lesions	O	S-Disease
18	,	O	O
19	changes	O	O
20	in	O	O
21	heart	O	B-Disease
22	weight	O	E-Disease
23	,	O	O
24	or	O	O
25	heart	O	B-Disease
26	weight	O	E-Disease
27	to	O	O
28	body	O	O
29	weight	O	O
30	ratios	O	O
31	.	O	O

0	The	O	O
1	results	O	O
2	indicated	O	O
3	that	O	O
4	exercise	O	O
5	reduced	O	O
6	the	O	O
7	mortality	O	O
8	associated	O	O
9	with	O	O
10	the	O	O
11	effects	O	O
12	of	O	O
13	large	O	O
14	dosages	O	O
15	of	O	O
16	isoproterenol	S-Chemical	S-Chemical
17	but	O	O
18	had	O	O
19	little	O	O
20	on	O	O
21	the	O	O
22	severity	O	O
23	of	O	O
24	the	O	O
25	infarction	S-Disease	O
26	.	O	O

0	Human	O	O
1	corticotropin	S-Chemical	S-Chemical
2	-	O	O
3	releasing	O	O
4	hormone	O	O
5	and	O	O
6	thyrotropin	S-Chemical	S-Chemical
7	-	O	I-Disease
8	releasing	O	I-Disease
9	hormone	O	S-Disease
10	modulate	O	O
11	the	O	O
12	hypercapnic	S-Disease	S-Disease
13	ventilatory	O	I-Disease
14	response	O	O
15	in	O	O
16	humans	O	O
17	.	O	O

0	Human	O	O
1	corticotropin	S-Chemical	S-Chemical
2	-	O	O
3	releasing	O	O
4	hormone	O	O
5	(	O	O
6	hCRH	O	S-Disease
7	)	O	O
8	and	O	O
9	thyrotropin	S-Chemical	S-Chemical
10	-	O	O
11	releasing	O	O
12	hormone	O	O
13	(	O	O
14	TRH	O	S-Disease
15	)	O	O
16	are	O	O
17	known	O	O
18	to	O	O
19	stimulate	O	O
20	ventilation	O	S-Disease
21	after	O	O
22	i	O	O
23	.	O	O
24	v	O	O
25	.	O	O
26	administration	O	O
27	in	O	O
28	humans	O	O
29	.	O	O

0	Two	O	O
1	subsequent	O	O
2	CO2	S-Chemical	S-Chemical
3	-	O	O
4	rebreathing	O	O
5	tests	O	O
6	were	O	O
7	performed	O	O
8	in	O	O
9	healthy	O	O
10	young	O	O
11	volunteers	O	O
12	.	O	O

0	During	O	O
1	the	O	O
2	first	O	O
3	test	O	O
4	0	O	O
5	.	O	O
6	9	O	O
7	%	O	O
8	NaCl	S-Chemical	S-Chemical
9	was	O	O
10	given	O	O
11	i	O	O
12	.	O	O
13	v	O	O
14	.	O	O
15	;	O	O
16	during	O	O
17	the	O	O
18	second	O	O
19	test	O	O
20	200	O	O
21	micrograms	O	O
22	of	O	O
23	hCRH	O	O
24	(	O	O
25	n	O	O
26	=	O	O
27	12	O	O
28	)	O	O
29	or	O	O
30	400	O	O
31	micrograms	O	O
32	of	O	O
33	TRH	O	O
34	(	O	O
35	n	O	O
36	=	O	O
37	6	O	O
38	)	O	O
39	was	O	O
40	administered	O	O
41	i	O	O
42	.	O	O
43	v	O	O
44	.	O	O
45	Nine	O	O
46	subjects	O	O
47	received	O	O
48	0	O	O
49	.	O	O
50	9	O	O
51	%	O	O
52	NaCl	S-Chemical	O
53	i	O	O
54	.	O	O
55	v	O	O
56	.	O	O
57	during	O	O
58	both	O	O
59	rebreathing	O	O
60	manoeuvres	O	O
61	.	O	O

0	The	O	O
1	CO2	S-Chemical	O
2	-	O	O
3	response	O	O
4	curves	O	O
5	for	O	O
6	the	O	O
7	two	O	O
8	tests	O	O
9	were	O	O
10	compared	O	O
11	within	O	O
12	the	O	O
13	same	O	O
14	subject	O	O
15	.	O	O

0	In	O	O
1	the	O	O
2	hCRH	O	O
3	group	O	O
4	a	O	O
5	marked	O	O
6	parallel	O	O
7	shift	O	O
8	of	O	O
9	the	O	O
10	CO2	S-Chemical	S-Chemical
11	-	O	O
12	response	O	O
13	curve	O	O
14	to	O	O
15	the	O	O
16	left	O	O
17	was	O	O
18	observed	O	O
19	after	O	O
20	hCRH	O	S-Disease
21	(	O	O
22	P	O	S-Disease
23	<	O	O
24	0	O	O
25	.	O	O
26	01	O	O
27	)	O	O
28	.	O	O

0	hCRH	O	S-Chemical
1	and	O	O
2	TRH	O	S-Disease
3	caused	O	O
4	a	O	O
5	reduction	O	O
6	in	O	O
7	the	O	O
8	CO2	S-Chemical	S-Disease
9	threshold	O	O
10	.	O	O

0	The	O	O
1	CO2	S-Chemical	S-Chemical
2	-	O	O
3	response	O	O
4	curves	O	O
5	in	O	O
6	the	O	O
7	control	O	O
8	group	O	O
9	were	O	O
10	nearly	O	O
11	identical	O	O
12	.	O	O

0	The	O	O
1	results	O	O
2	indicate	O	O
3	an	O	O
4	additive	O	O
5	effect	O	O
6	of	O	O
7	both	O	O
8	releasing	O	O
9	hormones	O	O
10	on	O	O
11	the	O	O
12	hypercapnic	S-Disease	O
13	ventilatory	O	O
14	response	O	O
15	in	O	O
16	humans	O	O
17	,	O	O
18	presumably	O	O
19	independent	O	O
20	of	O	O
21	central	O	O
22	chemosensitivity	O	O
23	.	O	O

0	Lamivudine	S-Chemical	S-Chemical
1	is	O	O
2	effective	O	O
3	in	O	O
4	suppressing	O	O
5	hepatitis	B-Disease	B-Disease
6	B	E-Disease	I-Disease
7	virus	O	E-Disease
8	DNA	O	O
9	in	O	O
10	Chinese	O	O
11	hepatitis	B-Chemical	B-Disease
12	B	I-Chemical	O
13	surface	I-Chemical	O
14	antigen	E-Chemical	O
15	carriers	O	O
16	:	O	O
17	a	O	O
18	placebo	O	O
19	-	O	O
20	controlled	O	O
21	trial	O	O
22	.	O	O

0	Lamivudine	S-Chemical	S-Chemical
1	is	O	O
2	a	O	O
3	novel	O	O
4	2	B-Chemical	B-Chemical
5	'	I-Chemical	I-Chemical
6	,	I-Chemical	O
7	3	I-Chemical	I-Chemical
8	'	I-Chemical	I-Chemical
9	-	I-Chemical	I-Chemical
10	dideoxy	I-Chemical	E-Chemical
11	cytosine	E-Chemical	S-Chemical
12	analogue	O	O
13	that	O	O
14	has	O	O
15	potent	O	O
16	inhibitory	O	O
17	effects	O	O
18	on	O	O
19	hepatitis	B-Disease	B-Disease
20	B	E-Disease	I-Disease
21	virus	O	E-Disease
22	replication	O	O
23	in	O	O
24	vitro	O	O
25	and	O	O
26	in	O	O
27	vivo	O	O
28	.	O	O

0	We	O	O
1	performed	O	O
2	a	O	O
3	single	O	O
4	-	O	O
5	blind	O	O
6	,	O	O
7	placebo	O	O
8	-	O	O
9	controlled	O	O
10	study	O	O
11	to	O	O
12	assess	O	O
13	its	O	O
14	effectiveness	O	O
15	and	O	O
16	safety	O	O
17	in	O	O
18	Chinese	O	O
19	hepatitis	B-Chemical	B-Disease
20	B	I-Chemical	I-Disease
21	surface	I-Chemical	O
22	antigen	E-Chemical	O
23	(	O	O
24	HBsAg	S-Chemical	O
25	)	O	O
26	carriers	O	O
27	.	O	O

0	Forty	O	O
1	-	O	O
2	two	O	O
3	Chinese	O	O
4	HBsAg	S-Chemical	O
5	carriers	O	O
6	were	O	O
7	randomized	O	O
8	to	O	O
9	receive	O	O
10	placebo	O	O
11	(	O	O
12	6	O	O
13	patients	O	O
14	)	O	O
15	or	O	O
16	lamivudine	S-Chemical	S-Chemical
17	orally	O	O
18	in	O	O
19	dosages	O	O
20	of	O	O
21	25	O	O
22	mg	O	O
23	,	O	O
24	100	O	O
25	mg	O	O
26	,	O	O
27	or	O	O
28	300	O	O
29	mg	O	O
30	daily	O	O
31	(	O	O
32	12	O	O
33	patients	O	O
34	for	O	O
35	each	O	O
36	dosage	O	O
37	)	O	O
38	.	O	O

0	All	O	O
1	36	O	O
2	patients	O	O
3	receiving	O	O
4	lamivudine	S-Chemical	S-Chemical
5	had	O	O
6	a	O	O
7	decrease	O	O
8	in	O	O
9	hepatitis	B-Disease	B-Disease
10	B	E-Disease	I-Disease
11	virus	O	E-Disease
12	(	O	O
13	HBV	O	O
14	)	O	O
15	DNA	O	O
16	values	O	O
17	of	O	O
18	>	O	O
19	90	O	O
20	%	O	O
21	(	O	O
22	P	O	O
23	<	O	O
24	.	O	O
25	001	O	O
26	compared	O	O
27	with	O	O
28	placebo	O	O
29	)	O	O
30	.	O	O

0	Although	O	O
1	25	O	O
2	mg	O	O
3	of	O	O
4	lamivudine	S-Chemical	S-Chemical
5	was	O	O
6	slightly	O	O
7	less	O	O
8	effective	O	O
9	than	O	O
10	100	O	O
11	mg	O	O
12	(	O	O
13	P	O	O
14	=	O	O
15	.	O	O
16	011	O	O
17	)	O	O
18	and	O	O
19	300	O	O
20	mg	O	O
21	(	O	O
22	P	O	O
23	=	O	O
24	.	O	O
25	005	O	O
26	)	O	O
27	,	O	O
28	it	O	O
29	still	O	O
30	induced	O	O
31	94	O	O
32	%	O	O
33	suppression	O	O
34	of	O	O
35	HBV	O	O
36	DNA	O	O
37	after	O	O
38	the	O	O
39	fourth	O	O
40	week	O	O
41	of	O	O
42	therapy	O	O
43	.	O	O

0	There	O	O
1	was	O	O
2	no	O	O
3	change	O	O
4	in	O	O
5	the	O	O
6	hepatitis	B-Disease	S-Disease
7	B	E-Disease	E-Disease
8	e	O	O
9	antigen	O	O
10	status	O	O
11	or	O	O
12	in	O	O
13	aminotransferase	O	S-Chemical
14	levels	O	O
15	.	O	O

0	In	O	O
1	conclusion	O	O
2	,	O	O
3	a	O	O
4	4	O	O
5	-	O	O
6	week	O	O
7	course	O	O
8	of	O	O
9	lamivudine	S-Chemical	S-Chemical
10	was	O	O
11	safe	O	O
12	and	O	O
13	effective	O	O
14	in	O	O
15	suppression	O	O
16	of	O	O
17	HBV	O	O
18	DNA	O	O
19	in	O	O
20	Chinese	O	O
21	HBsAg	S-Chemical	O
22	carriers	O	O
23	.	O	O

0	Studies	O	O
1	with	O	O
2	long	O	O
3	-	O	O
4	term	O	O
5	lamivudine	S-Chemical	S-Chemical
6	administration	O	O
7	should	O	O
8	be	O	O
9	performed	O	O
10	to	O	O
11	determine	O	O
12	if	O	O
13	prolonged	O	O
14	suppression	O	O
15	of	O	O
16	HBV	O	O
17	DNA	O	O
18	can	O	O
19	be	O	O
20	achieved	O	O
21	.	O	O

0	Population	O	O
1	-	O	O
2	based	O	O
3	study	O	O
4	of	O	O
5	risk	O	O
6	of	O	O
7	venous	B-Disease	B-Disease
8	thromboembolism	E-Disease	E-Disease
9	associated	O	O
10	with	O	O
11	various	O	O
12	oral	B-Chemical	O
13	contraceptives	E-Chemical	O
14	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	Four	O	O
3	studies	O	O
4	published	O	O
5	since	O	O
6	December	O	O
7	,	O	O
8	1995	O	O
9	,	O	O
10	reported	O	O
11	that	O	O
12	the	O	O
13	incidence	O	O
14	of	O	O
15	venous	B-Disease	B-Disease
16	thromboembolism	E-Disease	E-Disease
17	(	O	O
18	VTE	S-Disease	S-Chemical
19	)	O	O
20	was	O	O
21	higher	O	O
22	in	O	O
23	women	O	O
24	who	O	O
25	used	O	O
26	oral	B-Chemical	O
27	contraceptives	E-Chemical	O
28	(	O	O
29	OCs	S-Chemical	S-Chemical
30	)	O	O
31	containing	O	O
32	the	O	O
33	third	O	O
34	-	O	O
35	generation	O	O
36	progestagens	S-Chemical	O
37	gestodene	S-Chemical	S-Chemical
38	or	O	O
39	desogestrel	S-Chemical	S-Disease
40	than	O	O
41	in	O	O
42	users	O	O
43	of	O	O
44	OCs	S-Chemical	S-Chemical
45	containing	O	O
46	second	O	O
47	-	O	O
48	generation	O	O
49	progestagens	S-Chemical	O
50	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	our	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	re	O	O
8	-	O	O
9	examine	O	O
10	the	O	O
11	association	O	O
12	between	O	O
13	risk	O	O
14	of	O	O
15	VTE	S-Disease	S-Disease
16	and	O	O
17	OC	S-Chemical	S-Chemical
18	use	O	O
19	with	O	O
20	a	O	O
21	different	O	O
22	study	O	O
23	design	O	O
24	and	O	O
25	analysis	O	O
26	to	O	O
27	avoid	O	O
28	some	O	O
29	of	O	O
30	the	O	O
31	bias	O	O
32	and	O	O
33	confounding	O	O
34	of	O	O
35	the	O	O
36	earlier	O	O
37	studies	O	O
38	.	O	O

0	All	O	O
1	women	O	O
2	who	O	O
3	had	O	O
4	a	O	O
5	recorded	O	O
6	diagnosis	O	O
7	of	O	O
8	deep	B-Disease	O
9	-	I-Disease	O
10	vein	I-Disease	O
11	thrombosis	E-Disease	S-Disease
12	,	O	O
13	venous	B-Disease	B-Disease
14	thrombosis	E-Disease	E-Disease
15	not	O	O
16	otherwise	O	O
17	specified	O	O
18	,	O	O
19	or	O	O
20	pulmonary	O	B-Disease
21	embolus	O	E-Disease
22	during	O	O
23	the	O	O
24	study	O	O
25	period	O	O
26	,	O	O
27	and	O	O
28	who	O	O
29	had	O	O
30	been	O	O
31	treated	O	O
32	with	O	O
33	an	O	O
34	anticoagulant	O	O
35	were	O	O
36	identified	O	O
37	as	O	O
38	potential	O	O
39	cases	O	O
40	of	O	O
41	VTE	S-Disease	S-Disease
42	.	O	O

0	We	O	O
1	did	O	O
2	a	O	O
3	cohort	O	O
4	analysis	O	O
5	to	O	O
6	estimate	O	O
7	and	O	O
8	compare	O	O
9	incidence	O	O
10	of	O	O
11	VTE	S-Disease	S-Disease
12	in	O	O
13	users	O	O
14	of	O	O
15	the	O	O
16	main	O	O
17	OC	S-Chemical	S-Chemical
18	preparations	O	O
19	,	O	O
20	and	O	O
21	a	O	O
22	nested	O	O
23	case	O	O
24	-	O	O
25	control	O	O
26	study	O	O
27	to	O	O
28	calculate	O	O
29	the	O	O
30	odds	O	O
31	ratios	O	O
32	of	O	O
33	VTE	S-Disease	S-Disease
34	associated	O	O
35	with	O	O
36	use	O	O
37	of	O	O
38	different	O	O
39	types	O	O
40	of	O	O
41	OC	S-Chemical	S-Chemical
42	,	O	O
43	after	O	O
44	adjustment	O	O
45	for	O	O
46	potential	O	O
47	confounding	O	O
48	factors	O	O
49	.	O	O

0	In	O	O
1	the	O	O
2	case	O	O
3	-	O	O
4	control	O	O
5	study	O	O
6	,	O	O
7	we	O	O
8	matched	O	O
9	cases	O	O
10	to	O	O
11	controls	O	O
12	by	O	O
13	exact	O	O
14	year	O	O
15	of	O	O
16	birth	O	O
17	,	O	O
18	practice	O	O
19	,	O	O
20	and	O	O
21	current	O	O
22	use	O	O
23	of	O	O
24	OCs	S-Chemical	S-Chemical
25	.	O	O

0	We	O	O
1	used	O	O
2	a	O	O
3	multiple	O	O
4	logistic	O	O
5	regression	O	O
6	model	O	O
7	that	O	O
8	included	O	O
9	body	O	O
10	-	O	O
11	mass	O	I-Disease
12	index	O	O
13	,	O	O
14	number	O	O
15	of	O	O
16	cycles	O	O
17	,	O	O
18	change	O	O
19	in	O	O
20	type	O	O
21	of	O	O
22	OC	S-Chemical	S-Chemical
23	prescribed	O	O
24	within	O	O
25	3	O	O
26	months	O	O
27	of	O	O
28	the	O	O
29	event	O	O
30	,	O	O
31	previous	O	O
32	pregnancy	O	O
33	,	O	O
34	and	O	O
35	concurrent	O	O
36	disease	O	S-Disease
37	.	O	O

0	FINDINGS	O	O
1	:	O	O
2	85	O	O
3	women	O	O
4	met	O	O
5	the	O	O
6	inclusion	O	O
7	criteria	O	O
8	for	O	O
9	VTE	S-Disease	S-Disease
10	,	O	O
11	two	O	O
12	of	O	O
13	whom	O	O
14	were	O	O
15	users	O	O
16	of	O	O
17	progestagen	S-Chemical	S-Chemical
18	-	O	O
19	only	O	O
20	OCs	S-Chemical	S-Chemical
21	.	O	O

0	Of	O	O
1	the	O	O
2	83	O	O
3	cases	O	O
4	of	O	O
5	VTE	S-Disease	S-Disease
6	associated	O	O
7	with	O	O
8	use	O	O
9	of	O	O
10	combined	O	O
11	OCs	S-Chemical	S-Chemical
12	,	O	O
13	43	O	O
14	were	O	O
15	recorded	O	O
16	as	O	O
17	deep	B-Disease	O
18	-	I-Disease	O
19	vein	I-Disease	O
20	thrombosis	E-Disease	S-Disease
21	,	O	O
22	35	O	O
23	as	O	O
24	pulmonary	O	B-Disease
25	thrombosis	S-Disease	E-Disease
26	,	O	O
27	and	O	O
28	five	O	O
29	as	O	O
30	venous	B-Disease	B-Disease
31	thrombosis	E-Disease	E-Disease
32	not	O	O
33	otherwise	O	O
34	specified	O	O
35	.	O	O

0	The	O	O
1	crude	O	O
2	rate	O	O
3	of	O	O
4	VTE	S-Disease	O
5	per	O	O
6	10	O	O
7	,	O	O
8	000	O	O
9	woman	O	O
10	-	O	O
11	years	O	O
12	was	O	O
13	4	O	O
14	.	O	O
15	10	O	O
16	in	O	O
17	current	O	O
18	users	O	O
19	of	O	O
20	any	O	O
21	OC	S-Chemical	S-Chemical
22	,	O	O
23	3	O	O
24	.	O	O
25	10	O	O
26	in	O	O
27	users	O	O
28	of	O	O
29	second	O	O
30	-	O	O
31	generation	O	O
32	OCs	S-Chemical	S-Chemical
33	,	O	O
34	and	O	O
35	4	O	O
36	.	O	O
37	96	O	O
38	in	O	O
39	users	O	O
40	of	O	O
41	third	O	O
42	-	O	O
43	generation	O	O
44	preparations	O	O
45	.	O	O

0	After	O	O
1	adjustment	O	O
2	for	O	O
3	age	O	O
4	,	O	O
5	the	O	O
6	rate	O	O
7	ratio	O	O
8	of	O	O
9	VTE	S-Disease	O
10	in	O	O
11	users	O	O
12	of	O	O
13	third	O	O
14	-	O	O
15	generation	O	O
16	relative	O	O
17	to	O	O
18	second	O	O
19	-	O	O
20	generation	O	O
21	OCs	S-Chemical	S-Chemical
22	was	O	O
23	1	O	O
24	.	O	O
25	68	O	O
26	(	O	O
27	95	O	O
28	%	O	O
29	CI	O	S-Chemical
30	1	O	O
31	.	O	O
32	04	O	O
33	-	O	O
34	2	O	O
35	.	O	O
36	75	O	O
37	)	O	O
38	.	O	O

0	Logistic	O	O
1	regression	O	O
2	showed	O	O
3	no	O	O
4	significant	O	O
5	difference	O	O
6	in	O	O
7	the	O	O
8	risk	O	O
9	of	O	O
10	VTE	S-Disease	S-Disease
11	between	O	O
12	users	O	O
13	of	O	O
14	third	O	O
15	-	O	O
16	generation	O	O
17	and	O	O
18	second	O	O
19	-	O	O
20	generation	O	O
21	OCs	S-Chemical	S-Chemical
22	.	O	O

0	Among	O	O
1	users	O	O
2	of	O	O
3	third	O	O
4	-	O	O
5	generation	O	O
6	progestagens	S-Chemical	O
7	,	O	O
8	the	O	O
9	risk	O	O
10	of	O	O
11	VTE	S-Disease	S-Chemical
12	was	O	O
13	higher	O	O
14	in	O	O
15	users	O	O
16	of	O	O
17	desogestrel	S-Chemical	S-Chemical
18	with	O	O
19	20	O	O
20	g	O	O
21	ethinyloestradiol	S-Chemical	S-Chemical
22	than	O	O
23	in	O	O
24	users	O	O
25	of	O	O
26	gestodene	S-Chemical	S-Chemical
27	or	O	O
28	desogestrel	S-Chemical	S-Chemical
29	with	O	O
30	30	O	O
31	g	O	O
32	ethinyloestradiol	S-Chemical	S-Chemical
33	.	O	O

0	With	O	O
1	all	O	O
2	second	O	O
3	-	O	O
4	generation	O	O
5	OCs	S-Chemical	S-Chemical
6	as	O	O
7	the	O	O
8	reference	O	O
9	,	O	O
10	the	O	O
11	odds	O	O
12	ratios	O	O
13	for	O	O
14	VTE	S-Disease	S-Disease
15	were	O	O
16	3	O	O
17	.	O	O
18	49	O	O
19	(	O	O
20	1	O	O
21	.	O	O
22	21	O	O
23	-	O	O
24	10	O	O
25	.	O	O
26	12	O	O
27	)	O	O
28	for	O	O
29	desogestrel	S-Chemical	S-Disease
30	plus	O	O
31	20	O	O
32	g	O	O
33	ethinyloestradiol	S-Chemical	S-Chemical
34	and	O	O
35	1	O	O
36	.	O	O
37	18	O	O
38	(	O	O
39	0	O	O
40	.	O	O
41	66	O	O
42	-	O	O
43	2	O	O
44	.	O	O
45	17	O	O
46	)	O	O
47	for	O	O
48	the	O	O
49	other	O	O
50	third	O	O
51	-	O	O
52	generation	O	O
53	progestagens	S-Chemical	O
54	.	O	O

0	INTERPRETATION	O	O
1	:	O	O
2	The	O	O
3	previously	O	O
4	reported	O	O
5	increase	O	O
6	in	O	O
7	odds	O	O
8	ratio	O	O
9	associated	O	O
10	with	O	O
11	third	O	O
12	-	O	O
13	generation	O	O
14	OCs	S-Chemical	S-Chemical
15	when	O	O
16	compared	O	O
17	with	O	O
18	second	O	O
19	-	O	O
20	generation	O	O
21	products	O	O
22	is	O	O
23	likely	O	O
24	to	O	O
25	have	O	O
26	been	O	O
27	the	O	O
28	result	O	O
29	of	O	O
30	residual	O	O
31	confounding	O	O
32	by	O	O
33	age	O	O
34	.	O	O

0	The	O	O
1	increased	O	O
2	odds	O	O
3	ratio	O	O
4	associated	O	O
5	with	O	O
6	products	O	O
7	containing	O	O
8	20	O	O
9	micrograms	O	O
10	ethinyloestradiol	S-Chemical	S-Chemical
11	and	O	O
12	desogestrel	S-Chemical	S-Chemical
13	compared	O	O
14	with	O	O
15	the	O	O
16	30	O	O
17	micrograms	O	O
18	product	O	O
19	is	O	O
20	biologically	O	O
21	implausible	O	O
22	,	O	O
23	and	O	O
24	is	O	O
25	likely	O	O
26	to	O	O
27	be	O	O
28	the	O	O
29	result	O	O
30	of	O	O
31	preferential	O	O
32	prescribing	O	O
33	and	O	O
34	,	O	O
35	thus	O	O
36	,	O	O
37	confounding	O	O
38	.	O	O

0	MK	B-Chemical	B-Chemical
1	-	I-Chemical	E-Chemical
2	801	E-Chemical	E-Chemical
3	augments	O	O
4	pilocarpine	S-Chemical	S-Disease
5	-	O	O
6	induced	O	O
7	electrographic	O	O
8	seizure	S-Disease	S-Disease
9	but	O	O
10	protects	O	O
11	against	O	O
12	brain	B-Disease	B-Disease
13	damage	E-Disease	E-Disease
14	in	O	O
15	rats	O	O
16	.	O	O

0	The	O	O
1	authors	O	O
2	examined	O	O
3	the	O	O
4	anticonvulsant	O	O
5	effects	O	O
6	of	O	O
7	MK	B-Chemical	B-Chemical
8	-	I-Chemical	E-Chemical
9	801	E-Chemical	E-Chemical
10	on	O	O
11	the	O	O
12	pilocarpine	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	seizure	S-Disease	S-Disease
16	model	O	O
17	.	O	O

0	Intraperitoneal	O	O
1	injection	O	O
2	of	O	O
3	pilocarpine	S-Chemical	S-Chemical
4	(	O	O
5	400	O	O
6	mg	O	O
7	/	O	O
8	kg	O	O
9	)	O	O
10	induced	O	O
11	tonic	B-Disease	B-Disease
12	and	I-Disease	I-Disease
13	clonic	I-Disease	B-Disease
14	seizure	E-Disease	E-Disease
15	.	O	O

0	Scopolamine	S-Chemical	S-Chemical
1	(	O	O
2	10	O	O
3	mg	O	O
4	/	O	O
5	kg	O	O
6	)	O	O
7	and	O	O
8	pentobarbital	S-Chemical	S-Chemical
9	(	O	O
10	5	O	O
11	mg	O	O
12	/	O	O
13	kg	O	O
14	)	O	O
15	prevented	O	O
16	development	O	O
17	of	O	O
18	pilocarpine	S-Chemical	S-Chemical
19	-	O	O
20	induced	O	O
21	behavioral	O	B-Disease
22	seizure	S-Disease	E-Disease
23	but	O	O
24	MK	B-Chemical	B-Chemical
25	-	I-Chemical	E-Chemical
26	801	E-Chemical	E-Chemical
27	(	O	O
28	0	O	O
29	.	O	O
30	5	O	O
31	mg	O	O
32	/	O	O
33	kg	O	O
34	)	O	O
35	did	O	O
36	not	O	O
37	.	O	O

0	An	O	O
1	electrical	O	O
2	seizure	S-Disease	S-Disease
3	measured	O	O
4	with	O	O
5	hippocampal	O	S-Disease
6	EEG	O	S-Disease
7	appeared	O	O
8	in	O	O
9	the	O	O
10	pilocarpine	S-Chemical	S-Chemical
11	-	O	O
12	treated	O	O
13	group	O	O
14	.	O	O

0	Scopolamine	S-Chemical	S-Chemical
1	and	O	O
2	pentobarbital	S-Chemical	S-Chemical
3	blocked	O	O
4	the	O	O
5	pilocarpine	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	electrographic	O	B-Disease
9	seizure	S-Disease	E-Disease
10	,	O	O
11	MK	B-Chemical	B-Chemical
12	-	I-Chemical	E-Chemical
13	801	E-Chemical	E-Chemical
14	treatment	O	O
15	augmented	O	O
16	the	O	O
17	electrographic	O	O
18	seizure	S-Disease	S-Disease
19	induced	O	O
20	by	O	O
21	pilocarpine	S-Chemical	S-Chemical
22	.	O	O

0	Brain	B-Disease	O
1	damage	E-Disease	E-Disease
2	was	O	O
3	assessed	O	O
4	by	O	O
5	examining	O	O
6	the	O	O
7	hippocampus	O	S-Disease
8	microscopically	O	O
9	.	O	O

0	Pilocarpine	S-Chemical	S-Chemical
1	produced	O	O
2	neuronal	B-Disease	B-Disease
3	death	E-Disease	E-Disease
4	in	O	O
5	the	O	O
6	hippocampus	O	S-Disease
7	,	O	O
8	which	O	O
9	showed	O	O
10	pyknotic	O	S-Disease
11	changes	O	O
12	.	O	O

0	Pentobarbital	S-Chemical	S-Disease
1	,	O	O
2	scopolamine	S-Chemical	S-Chemical
3	and	O	O
4	MK	B-Chemical	B-Chemical
5	-	I-Chemical	E-Chemical
6	801	E-Chemical	E-Chemical
7	protected	O	O
8	the	O	O
9	brain	B-Disease	B-Disease
10	damage	E-Disease	E-Disease
11	by	O	O
12	pilocarpine	S-Chemical	S-Chemical
13	,	O	O
14	though	O	O
15	in	O	O
16	the	O	O
17	MK	B-Chemical	B-Chemical
18	-	I-Chemical	E-Chemical
19	801	E-Chemical	E-Chemical
20	-	O	O
21	treated	O	O
22	group	O	O
23	,	O	O
24	the	O	O
25	pyramidal	O	S-Disease
26	cells	O	O
27	of	O	O
28	hippocampus	O	S-Disease
29	appeared	O	O
30	darker	O	O
31	than	O	O
32	normal	O	O
33	.	O	O

0	These	O	O
1	results	O	O
2	indicate	O	O
3	that	O	O
4	status	B-Disease	O
5	epilepticus	E-Disease	S-Disease
6	induced	O	O
7	by	O	O
8	pilocarpine	S-Chemical	S-Chemical
9	is	O	O
10	initiated	O	O
11	by	O	O
12	cholinergic	O	B-Disease
13	overstimulation	O	E-Disease
14	and	O	O
15	propagated	O	O
16	by	O	O
17	glutamatergic	O	S-Chemical
18	transmission	O	O
19	,	O	O
20	the	O	O
21	elevation	O	O
22	of	O	O
23	which	O	O
24	may	O	O
25	cause	O	O
26	brain	B-Disease	B-Disease
27	damage	E-Disease	E-Disease
28	through	O	O
29	an	O	O
30	excitatory	O	O
31	NMDA	S-Chemical	O
32	receptor	O	O
33	-	O	O
34	mediated	O	O
35	mechanism	O	O
36	.	O	O

0	Paclitaxel	S-Chemical	S-Chemical
1	,	O	O
2	5	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	fluorouracil	E-Chemical	S-Chemical
5	,	O	O
6	and	O	O
7	folinic	B-Chemical	S-Chemical
8	acid	E-Chemical	S-Disease
9	in	O	O
10	metastatic	O	O
11	breast	B-Disease	B-Disease
12	cancer	E-Disease	E-Disease
13	:	O	O
14	BRE	O	B-Chemical
15	-	O	E-Chemical
16	26	O	E-Disease
17	,	O	O
18	a	O	O
19	phase	O	O
20	II	O	O
21	trial	O	O
22	.	O	O

0	5	B-Chemical	O
1	-	I-Chemical	O
2	Fluorouracil	E-Chemical	S-Chemical
3	plus	O	O
4	folinic	B-Chemical	S-Chemical
5	acid	E-Chemical	O
6	and	O	O
7	paclitaxel	S-Chemical	S-Chemical
8	(	O	O
9	Taxol	S-Chemical	S-Chemical
10	;	O	O
11	Bristol	O	I-Chemical
12	-	O	I-Disease
13	Myers	O	I-Disease
14	Squibb	O	S-Disease
15	Company	O	S-Chemical
16	,	O	O
17	Princeton	O	S-Chemical
18	,	O	O
19	NJ	O	S-Chemical
20	)	O	O
21	are	O	O
22	effective	O	O
23	salvage	O	O
24	therapies	O	O
25	for	O	O
26	metastatic	O	O
27	breast	B-Disease	I-Disease
28	cancer	E-Disease	E-Disease
29	patients	O	O
30	.	O	O

0	Paclitaxel	S-Chemical	S-Chemical
1	and	O	O
2	5	B-Chemical	S-Chemical
3	-	I-Chemical	I-Chemical
4	fluorouracil	E-Chemical	S-Chemical
5	have	O	O
6	additive	O	O
7	cytotoxicity	S-Disease	S-Disease
8	in	O	O
9	MCF	O	S-Disease
10	-	O	O
11	7	O	O
12	cell	O	O
13	lines	O	O
14	.	O	O

0	We	O	O
1	performed	O	O
2	a	O	O
3	phase	O	O
4	II	O	O
5	trial	O	O
6	of	O	O
7	paclitaxel	S-Chemical	S-Disease
8	175	O	O
9	mg	O	O
10	/	O	O
11	m2	O	O
12	over	O	O
13	3	O	O
14	hours	O	O
15	on	O	O
16	day	O	O
17	I	O	O
18	followed	O	O
19	by	O	O
20	folinic	B-Chemical	S-Chemical
21	acid	E-Chemical	E-Chemical
22	300	O	O
23	mg	O	O
24	over	O	O
25	1	O	O
26	hour	O	O
27	before	O	O
28	5	B-Chemical	O
29	-	I-Chemical	O
30	fluorouracil	E-Chemical	S-Chemical
31	350	O	O
32	mg	O	O
33	/	O	O
34	m2	O	O
35	on	O	O
36	days	O	O
37	1	O	O
38	to	O	O
39	3	O	O
40	every	O	O
41	28	O	O
42	days	O	O
43	(	O	O
44	TFL	O	O
45	)	O	O
46	in	O	O
47	women	O	O
48	with	O	O
49	metastatic	O	O
50	breast	B-Disease	B-Disease
51	cancer	E-Disease	E-Disease
52	.	O	O

0	Analysis	O	O
1	is	O	O
2	reported	O	O
3	on	O	O
4	37	O	O
5	patients	O	O
6	with	O	O
7	a	O	O
8	minimum	O	O
9	of	O	O
10	6	O	O
11	months	O	O
12	follow	O	O
13	-	O	O
14	up	O	O
15	who	O	O
16	received	O	O
17	a	O	O
18	total	O	O
19	of	O	O
20	192	O	O
21	cycles	O	O
22	of	O	O
23	TFL	O	S-Disease
24	:	O	O
25	nine	O	O
26	cycles	O	O
27	(	O	O
28	5	O	O
29	%	O	O
30	)	O	O
31	were	O	O
32	associated	O	O
33	with	O	O
34	grade	O	O
35	3	O	O
36	/	O	O
37	4	O	O
38	neutropenia	S-Disease	S-Disease
39	requiring	O	O
40	hospitalization	O	O
41	;	O	O
42	seven	O	O
43	(	O	O
44	4	O	O
45	%	O	O
46	)	O	O
47	cycles	O	O
48	in	O	O
49	two	O	O
50	patients	O	O
51	required	O	O
52	granulocyte	B-Chemical	O
53	colony	I-Chemical	O
54	-	I-Chemical	O
55	stimulating	I-Chemical	O
56	factor	E-Chemical	O
57	due	O	O
58	to	O	O
59	neutropenia	S-Disease	S-Disease
60	;	O	O
61	no	O	O
62	patient	O	O
63	required	O	O
64	platelet	O	S-Disease
65	transfusions	O	O
66	.	O	O

0	Grade	O	O
1	3	O	O
2	/	O	O
3	4	O	O
4	nonhematologic	O	O
5	toxicities	S-Disease	S-Disease
6	were	O	O
7	uncommon	O	O
8	.	O	O

0	Of	O	O
1	the	O	O
2	19	O	O
3	evaluable	O	O
4	patients	O	O
5	with	O	O
6	prior	O	O
7	doxorubicin	S-Chemical	S-Chemical
8	exposure	O	O
9	,	O	O
10	11	O	O
11	(	O	O
12	58	O	O
13	%	O	O
14	)	O	O
15	responded	O	O
16	compared	O	O
17	with	O	O
18	nine	O	O
19	of	O	O
20	15	O	O
21	(	O	O
22	60	O	O
23	%	O	O
24	)	O	O
25	without	O	O
26	prior	O	O
27	doxorubicin	S-Chemical	S-Chemical
28	.	O	O

0	Plasma	O	O
1	paclitaxel	S-Chemical	S-Disease
2	concentrations	O	O
3	were	O	O
4	measured	O	O
5	at	O	O
6	the	O	O
7	completion	O	O
8	of	O	O
9	paclitaxel	S-Chemical	S-Disease
10	infusion	O	O
11	and	O	O
12	at	O	O
13	24	O	O
14	hours	O	O
15	in	O	O
16	19	O	O
17	patients	O	O
18	.	O	O

0	TFL	O	S-Chemical
1	is	O	O
2	an	O	O
3	active	O	O
4	,	O	O
5	well	O	O
6	-	O	O
7	tolerated	O	O
8	regimen	O	O
9	in	O	O
10	metastatic	O	O
11	breast	B-Disease	I-Disease
12	cancer	E-Disease	E-Disease
13	.	O	O

0	Efficacy	O	O
1	and	O	O
2	proarrhythmia	S-Disease	S-Disease
3	with	O	O
4	the	O	O
5	use	O	O
6	of	O	O
7	d	B-Chemical	S-Chemical
8	,	I-Chemical	O
9	l	I-Chemical	S-Chemical
10	-	I-Chemical	O
11	sotalol	E-Chemical	S-Chemical
12	for	O	O
13	sustained	O	O
14	ventricular	B-Disease	B-Disease
15	tachyarrhythmias	E-Disease	E-Disease
16	.	O	O

0	This	O	O
1	study	O	O
2	prospectively	O	O
3	evaluated	O	O
4	the	O	O
5	clinical	O	O
6	efficacy	O	O
7	,	O	O
8	the	O	O
9	incidence	O	O
10	of	O	O
11	torsades	B-Disease	S-Disease
12	de	I-Disease	O
13	pointes	E-Disease	O
14	,	O	O
15	and	O	O
16	the	O	O
17	presumable	O	O
18	risk	O	O
19	factors	O	O
20	for	O	O
21	torsades	B-Disease	S-Disease
22	de	I-Disease	O
23	pointes	E-Disease	O
24	in	O	O
25	patients	O	O
26	treated	O	O
27	with	O	O
28	d	B-Chemical	S-Chemical
29	,	I-Chemical	O
30	l	I-Chemical	S-Chemical
31	-	I-Chemical	O
32	sotalol	E-Chemical	S-Chemical
33	for	O	O
34	sustained	O	O
35	ventricular	B-Disease	S-Disease
36	tachyarrhythmias	E-Disease	S-Disease
37	.	O	O

0	Eighty	O	O
1	-	O	O
2	one	O	O
3	consecutive	O	O
4	patients	O	O
5	(	O	O
6	54	O	O
7	with	O	O
8	coronary	B-Disease	B-Disease
9	artery	I-Disease	I-Disease
10	disease	E-Disease	E-Disease
11	,	O	O
12	and	O	O
13	20	O	O
14	with	O	O
15	dilated	B-Disease	O
16	cardiomyopathy	E-Disease	B-Disease
17	)	O	O
18	with	O	O
19	inducible	O	O
20	sustained	O	O
21	ventricular	B-Disease	B-Disease
22	tachycardia	E-Disease	E-Disease
23	or	O	O
24	ventricular	B-Disease	B-Disease
25	fibrillation	E-Disease	E-Disease
26	received	O	O
27	oral	O	O
28	d	B-Chemical	S-Disease
29	,	I-Chemical	O
30	l	I-Chemical	B-Chemical
31	-	I-Chemical	O
32	sotalol	E-Chemical	S-Chemical
33	to	O	O
34	prevent	O	O
35	induction	O	O
36	of	O	O
37	the	O	O
38	ventricular	B-Disease	B-Disease
39	tachyarrhythmia	E-Disease	E-Disease
40	.	O	O

0	During	O	O
1	oral	O	O
2	loading	O	O
3	with	O	O
4	d	B-Chemical	S-Chemical
5	,	I-Chemical	O
6	l	I-Chemical	S-Chemical
7	-	I-Chemical	I-Chemical
8	sotalol	E-Chemical	S-Chemical
9	,	O	O
10	continuous	O	O
11	electrocardiographic	O	O
12	(	O	O
13	ECG	O	S-Disease
14	)	O	O
15	monitoring	O	O
16	was	O	O
17	performed	O	O
18	.	O	O

0	Those	O	O
1	patients	O	O
2	in	O	O
3	whom	O	O
4	d	B-Chemical	S-Chemical
5	,	I-Chemical	O
6	l	I-Chemical	S-Chemical
7	-	I-Chemical	O
8	sotalol	E-Chemical	S-Chemical
9	prevented	O	O
10	induction	O	O
11	of	O	O
12	ventricular	B-Disease	B-Disease
13	tachycardia	E-Disease	E-Disease
14	or	O	O
15	ventricular	B-Disease	B-Disease
16	fibrillation	E-Disease	E-Disease
17	were	O	O
18	discharged	O	O
19	with	O	O
20	the	O	O
21	drug	O	O
22	and	O	O
23	followed	O	O
24	up	O	O
25	on	O	O
26	an	O	O
27	outpatient	O	O
28	basis	O	O
29	for	O	O
30	21	O	O
31	+	O	O
32	/	O	O
33	-	O	O
34	18	O	O
35	months	O	O
36	.	O	O

0	Induction	O	O
1	of	O	O
2	the	O	O
3	ventricular	B-Disease	S-Disease
4	tachyarrhythmia	E-Disease	E-Disease
5	was	O	O
6	prevented	O	O
7	by	O	O
8	oral	O	O
9	d	B-Chemical	S-Chemical
10	,	I-Chemical	O
11	l	I-Chemical	S-Chemical
12	-	I-Chemical	I-Chemical
13	sotalol	E-Chemical	E-Chemical
14	in	O	O
15	35	O	O
16	(	O	O
17	43	O	O
18	%	O	O
19	)	O	O
20	patients	O	O
21	;	O	O
22	the	O	O
23	ventricular	B-Disease	B-Disease
24	tachyarrhythmia	E-Disease	E-Disease
25	remained	O	O
26	inducible	O	O
27	in	O	O
28	40	O	O
29	(	O	O
30	49	O	O
31	%	O	O
32	)	O	O
33	patients	O	O
34	;	O	O
35	and	O	O
36	two	O	O
37	(	O	O
38	2	O	O
39	.	O	O
40	5	O	O
41	%	O	O
42	)	O	O
43	patients	O	O
44	did	O	O
45	not	O	O
46	tolerate	O	O
47	even	O	O
48	40	O	O
49	mg	O	O
50	of	O	O
51	d	B-Chemical	S-Disease
52	,	I-Chemical	O
53	l	I-Chemical	B-Chemical
54	-	I-Chemical	I-Chemical
55	sotalol	E-Chemical	E-Chemical
56	once	O	O
57	daily	O	O
58	.	O	O

0	Four	O	O
1	(	O	O
2	5	O	O
3	%	O	O
4	)	O	O
5	patients	O	O
6	had	O	O
7	from	O	O
8	torsades	B-Disease	S-Disease
9	de	I-Disease	O
10	pointes	E-Disease	O
11	during	O	O
12	the	O	O
13	initial	O	O
14	oral	O	O
15	treatment	O	O
16	with	O	O
17	d	B-Chemical	S-Chemical
18	,	I-Chemical	I-Chemical
19	l	I-Chemical	B-Chemical
20	-	I-Chemical	I-Chemical
21	sotalol	E-Chemical	E-Chemical
22	.	O	O

0	Neither	O	O
1	ECG	O	S-Chemical
2	[	O	O
3	sinus	O	O
4	-	O	O
5	cycle	O	O
6	length	O	O
7	(	O	O
8	SCL	O	S-Disease
9	)	O	O
10	,	O	O
11	QT	O	O
12	or	O	O
13	QTc	O	O
14	interval	O	O
15	,	O	O
16	or	O	O
17	U	O	S-Disease
18	wave	O	O
19	]	O	O
20	nor	O	O
21	clinical	O	O
22	parameters	O	O
23	identified	O	O
24	patients	O	O
25	at	O	O
26	risk	O	O
27	for	O	O
28	torsades	B-Disease	S-Disease
29	de	I-Disease	O
30	pointes	E-Disease	O
31	.	O	O

0	However	O	O
1	,	O	O
2	the	O	O
3	oral	O	O
4	dose	O	O
5	of	O	O
6	d	B-Chemical	S-Chemical
7	,	I-Chemical	O
8	l	I-Chemical	B-Chemical
9	-	I-Chemical	I-Chemical
10	sotalol	E-Chemical	S-Chemical
11	was	O	O
12	significantly	O	O
13	lower	O	O
14	in	O	O
15	patients	O	O
16	with	O	O
17	torsades	B-Disease	O
18	de	I-Disease	O
19	pointes	E-Disease	O
20	(	O	O
21	200	O	O
22	+	O	O
23	/	O	O
24	-	O	O
25	46	O	O
26	vs	O	O
27	.	O	O
28	328	O	O
29	+	O	O
30	/	O	O
31	-	O	O
32	53	O	O
33	mg	O	O
34	/	O	O
35	day	O	O
36	;	O	O
37	p	O	O
38	=	O	O
39	0	O	O
40	.	O	O
41	0017	O	O
42	)	O	O
43	.	O	O

0	Risk	O	O
1	factors	O	O
2	associated	O	O
3	with	O	O
4	the	O	O
5	development	O	O
6	of	O	O
7	torsades	B-Disease	S-Disease
8	de	I-Disease	O
9	pointes	E-Disease	O
10	were	O	O
11	the	O	O
12	appearance	O	O
13	of	O	O
14	an	O	O
15	U	O	S-Disease
16	wave	O	O
17	(	O	O
18	p	O	O
19	=	O	O
20	0	O	O
21	.	O	O
22	049	O	O
23	)	O	O
24	,	O	O
25	female	O	O
26	gender	O	O
27	(	O	O
28	p	O	O
29	=	O	O
30	0	O	O
31	.	O	O
32	015	O	O
33	)	O	O
34	,	O	O
35	and	O	O
36	significant	O	O
37	dose	O	O
38	-	O	O
39	corrected	O	O
40	changes	O	O
41	of	O	O
42	SCL	O	S-Disease
43	,	O	O
44	QT	O	O
45	interval	O	O
46	,	O	O
47	and	O	O
48	QTc	O	O
49	interval	O	O
50	(	O	O
51	p	O	O
52	<	O	O
53	0	O	O
54	.	O	O
55	05	O	O
56	)	O	O
57	.	O	O

0	During	O	O
1	follow	O	O
2	-	O	O
3	up	O	O
4	,	O	O
5	seven	O	O
6	(	O	O
7	20	O	O
8	%	O	O
9	)	O	O
10	patients	O	O
11	had	O	O
12	a	O	O
13	nonfatal	O	O
14	ventricular	B-Disease	S-Disease
15	tachycardia	E-Disease	S-Disease
16	recurrence	O	O
17	,	O	O
18	and	O	O
19	two	O	O
20	(	O	O
21	6	O	O
22	%	O	O
23	)	O	O
24	patients	O	O
25	died	O	O
26	suddenly	O	O
27	.	O	O

0	One	O	O
1	female	O	O
2	patient	O	O
3	with	O	O
4	stable	O	O
5	cardiac	B-Disease	B-Disease
6	disease	E-Disease	E-Disease
7	had	O	O
8	recurrent	O	O
9	torsades	B-Disease	O
10	de	I-Disease	O
11	pointes	E-Disease	O
12	after	O	O
13	2	O	O
14	years	O	O
15	of	O	O
16	successful	O	O
17	treatment	O	O
18	with	O	O
19	d	B-Chemical	S-Chemical
20	,	I-Chemical	I-Chemical
21	l	I-Chemical	E-Chemical
22	-	I-Chemical	I-Chemical
23	sotalol	E-Chemical	E-Chemical
24	.	O	O

0	Torsades	B-Disease	S-Disease
1	de	I-Disease	O
2	pointes	E-Disease	O
3	occurred	O	O
4	early	O	O
5	during	O	O
6	treatment	O	O
7	even	O	O
8	with	O	O
9	low	O	O
10	doses	O	O
11	of	O	O
12	oral	O	O
13	d	B-Chemical	S-Chemical
14	,	I-Chemical	O
15	l	I-Chemical	S-Chemical
16	-	I-Chemical	O
17	sotalol	E-Chemical	S-Chemical
18	.	O	O

0	Pronounced	O	O
1	changes	O	O
2	in	O	O
3	the	O	O
4	surface	O	O
5	ECG	O	S-Disease
6	(	O	O
7	cycle	O	O
8	length	O	O
9	,	O	O
10	QT	O	O
11	,	O	O
12	and	O	O
13	QTc	O	O
14	)	O	O
15	in	O	O
16	relation	O	O
17	to	O	O
18	the	O	O
19	dose	O	O
20	of	O	O
21	oral	O	O
22	d	B-Chemical	S-Chemical
23	,	I-Chemical	O
24	l	I-Chemical	S-Chemical
25	-	I-Chemical	O
26	sotalol	E-Chemical	S-Chemical
27	might	O	O
28	identify	O	O
29	a	O	O
30	subgroup	O	O
31	of	O	O
32	patients	O	O
33	with	O	O
34	an	O	O
35	increased	O	O
36	risk	O	O
37	for	O	O
38	torsades	B-Disease	S-Disease
39	de	I-Disease	O
40	pointes	E-Disease	O
41	.	O	O

0	Other	O	O
1	ECG	O	S-Disease
2	parameters	O	O
3	before	O	O
4	the	O	O
5	application	O	O
6	of	O	O
7	d	B-Chemical	B-Chemical
8	,	I-Chemical	I-Chemical
9	l	I-Chemical	B-Chemical
10	-	I-Chemical	I-Chemical
11	sotalol	E-Chemical	S-Chemical
12	did	O	O
13	not	O	O
14	identify	O	O
15	patients	O	O
16	at	O	O
17	increased	O	O
18	risk	O	O
19	for	O	O
20	torsades	B-Disease	S-Disease
21	de	I-Disease	O
22	pointes	E-Disease	O
23	.	O	O

0	Recurrence	O	O
1	rates	O	O
2	of	O	O
3	ventricular	B-Disease	B-Disease
4	tachyarrhythmias	E-Disease	E-Disease
5	are	O	O
6	high	O	O
7	despite	O	O
8	complete	O	O
9	suppression	O	O
10	of	O	O
11	the	O	O
12	arrhythmia	S-Disease	S-Disease
13	during	O	O
14	programmed	O	O
15	stimulation	O	O
16	.	O	O

0	Therefore	O	O
1	programmed	O	O
2	electrical	O	O
3	stimulation	O	O
4	in	O	O
5	the	O	O
6	case	O	O
7	of	O	O
8	d	B-Chemical	S-Chemical
9	,	I-Chemical	O
10	l	I-Chemical	B-Chemical
11	-	I-Chemical	I-Chemical
12	sotalol	E-Chemical	S-Chemical
13	seems	O	O
14	to	O	O
15	be	O	O
16	of	O	O
17	limited	O	O
18	prognostic	O	O
19	value	O	O
20	.	O	O

0	Chronic	O	O
1	hyperprolactinemia	S-Disease	S-Disease
2	and	O	O
3	changes	O	O
4	in	O	O
5	dopamine	S-Chemical	S-Disease
6	neurons	O	O
7	.	O	O

0	The	O	O
1	purpose	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	induce	O	O
8	hyperprolactinemia	S-Disease	S-Disease
9	in	O	O
10	rats	O	O
11	for	O	O
12	extended	O	O
13	periods	O	O
14	of	O	O
15	time	O	O
16	and	O	O
17	examine	O	O
18	its	O	O
19	effects	O	O
20	on	O	O
21	dopaminergic	O	O
22	systems	O	O
23	in	O	O
24	the	O	O
25	brain	O	O
26	.	O	O

0	Hyperprolactinemia	S-Disease	S-Disease
1	was	O	O
2	induced	O	O
3	by	O	O
4	treatment	O	O
5	with	O	O
6	haloperidol	S-Chemical	S-Chemical
7	,	O	O
8	a	O	O
9	dopamine	S-Chemical	O
10	receptor	O	O
11	antagonist	O	O
12	,	O	O
13	and	O	O
14	Palkovits	O	S-Chemical
15	'	O	O
16	microdissection	O	O
17	technique	O	O
18	in	O	O
19	combination	O	O
20	with	O	O
21	high	O	O
22	-	O	O
23	performance	O	O
24	liquid	O	O
25	chromatography	O	O
26	was	O	O
27	used	O	O
28	to	O	O
29	measure	O	O
30	neurotransmitter	O	S-Disease
31	concentrations	O	O
32	in	O	O
33	several	O	O
34	areas	O	O
35	of	O	O
36	the	O	O
37	brain	O	O
38	.	O	O

0	After	O	O
1	6	O	O
2	months	O	O
3	of	O	O
4	hyperprolactinemia	S-Disease	S-Disease
5	,	O	O
6	dopamine	S-Chemical	S-Chemical
7	(	O	O
8	DA	S-Chemical	S-Chemical
9	)	O	O
10	concentrations	O	O
11	in	O	O
12	the	O	O
13	median	O	O
14	eminence	O	O
15	(	O	O
16	ME	O	S-Disease
17	)	O	O
18	increased	O	O
19	by	O	O
20	84	O	O
21	%	O	O
22	over	O	O
23	the	O	O
24	control	O	O
25	group	O	O
26	.	O	O

0	Nine	O	O
1	months	O	O
2	of	O	O
3	hyperprolactinemia	S-Disease	S-Disease
4	produced	O	O
5	a	O	O
6	50	O	O
7	%	O	O
8	increase	O	O
9	in	O	O
10	DA	S-Chemical	S-Chemical
11	concentrations	O	O
12	in	O	O
13	the	O	O
14	ME	O	S-Disease
15	over	O	O
16	the	O	O
17	control	O	O
18	group	O	O
19	.	O	O

0	However	O	O
1	,	O	O
2	DA	S-Chemical	S-Chemical
3	response	O	O
4	was	O	O
5	lost	O	O
6	if	O	O
7	a	O	O
8	9	O	O
9	-	O	O
10	month	O	O
11	long	O	O
12	haloperidol	S-Chemical	S-Chemical
13	-	O	O
14	induced	O	O
15	hyperprolactinemia	S-Disease	S-Disease
16	was	O	O
17	followed	O	O
18	by	O	O
19	a	O	O
20	1	O	O
21	1	O	O
22	/	O	O
23	2	O	O
24	month	O	O
25	-	O	O
26	long	O	O
27	extremely	O	O
28	high	O	O
29	increase	O	O
30	in	O	O
31	serum	O	O
32	PRL	O	O
33	levels	O	O
34	produced	O	O
35	by	O	O
36	implantation	O	O
37	of	O	O
38	MMQ	O	S-Disease
39	cells	O	O
40	under	O	O
41	the	O	O
42	kidney	O	O
43	capsule	O	O
44	.	O	O

0	There	O	O
1	was	O	O
2	no	O	O
3	change	O	O
4	in	O	O
5	the	O	O
6	levels	O	O
7	of	O	O
8	DA	S-Chemical	S-Chemical
9	,	O	O
10	norepinephrine	S-Chemical	S-Chemical
11	(	O	O
12	NE	S-Chemical	O
13	)	O	O
14	,	O	O
15	serotonin	S-Chemical	S-Chemical
16	(	O	O
17	5	B-Chemical	O
18	-	I-Chemical	O
19	HT	E-Chemical	O
20	)	O	O
21	,	O	O
22	or	O	O
23	their	O	O
24	metabolites	O	O
25	in	O	O
26	the	O	O
27	arcuate	O	B-Disease
28	nucleus	O	O
29	(	O	O
30	AN	O	S-Disease
31	)	O	O
32	,	O	O
33	medial	O	O
34	preoptic	O	O
35	area	O	O
36	(	O	O
37	MPA	O	S-Chemical
38	)	O	O
39	,	O	O
40	caudate	O	S-Disease
41	putamen	O	S-Disease
42	(	O	O
43	CP	O	S-Disease
44	)	O	O
45	,	O	O
46	substantia	O	O
47	nigra	O	S-Disease
48	(	O	O
49	SN	O	S-Disease
50	)	O	O
51	,	O	O
52	and	O	O
53	zona	O	S-Disease
54	incerta	O	O
55	(	O	O
56	ZI	O	S-Disease
57	)	O	O
58	,	O	O
59	except	O	O
60	for	O	O
61	a	O	O
62	decrease	O	O
63	in	O	O
64	5	B-Chemical	B-Chemical
65	-	I-Chemical	I-Chemical
66	hydroxyindoleacetic	I-Chemical	E-Chemical
67	acid	E-Chemical	S-Disease
68	(	O	O
69	5	B-Chemical	S-Disease
70	-	I-Chemical	I-Chemical
71	HIAA	E-Chemical	O
72	)	O	O
73	in	O	O
74	the	O	O
75	AN	O	S-Disease
76	after	O	O
77	6	O	O
78	-	O	O
79	months	O	O
80	of	O	O
81	hyperprolactinemia	S-Disease	S-Disease
82	and	O	O
83	an	O	O
84	increase	O	O
85	in	O	O
86	DA	S-Chemical	S-Chemical
87	concentrations	O	O
88	in	O	O
89	the	O	O
90	AN	O	S-Disease
91	after	O	O
92	9	O	O
93	-	O	O
94	months	O	O
95	of	O	O
96	hyperprolactinemia	S-Disease	S-Disease
97	.	O	O

0	These	O	O
1	results	O	O
2	demonstrate	O	O
3	that	O	O
4	hyperprolactinemia	S-Disease	S-Disease
5	specifically	O	O
6	affects	O	O
7	TIDA	O	B-Disease
8	neurons	O	O
9	and	O	O
10	these	O	O
11	effects	O	O
12	vary	O	O
13	,	O	O
14	depending	O	O
15	on	O	O
16	the	O	O
17	duration	O	O
18	and	O	O
19	intensity	O	O
20	of	O	O
21	hyperprolactinemia	S-Disease	S-Disease
22	.	O	O

0	The	O	O
1	age	O	O
2	-	O	O
3	related	O	O
4	decrease	O	O
5	in	O	O
6	hypothalamic	O	S-Disease
7	dopamine	S-Chemical	S-Disease
8	function	O	E-Disease
9	may	O	O
10	be	O	O
11	associated	O	O
12	with	O	O
13	increases	O	S-Disease
14	in	O	I-Disease
15	PRL	O	S-Disease
16	secretion	O	E-Disease
17	.	O	O

0	Treatment	O	O
1	-	O	O
2	related	O	O
3	disseminated	O	O
4	necrotizing	O	O
5	leukoencephalopathy	S-Disease	S-Disease
6	with	O	O
7	characteristic	O	O
8	contrast	O	O
9	enhancement	O	O
10	of	O	O
11	the	O	O
12	white	O	O
13	matter	O	O
14	.	O	O

0	This	O	O
1	report	O	O
2	describes	O	O
3	unique	O	O
4	contrast	O	O
5	enhancement	O	O
6	of	O	O
7	the	O	O
8	white	O	O
9	matter	O	O
10	on	O	O
11	T1	O	O
12	-	O	O
13	weighted	O	O
14	magnetic	O	O
15	resonance	O	O
16	images	O	O
17	of	O	O
18	two	O	O
19	patients	O	O
20	with	O	O
21	disseminated	O	O
22	necrotizing	O	O
23	leukoencephalopathy	S-Disease	S-Disease
24	,	O	O
25	which	O	O
26	developed	O	O
27	from	O	O
28	acute	B-Disease	O
29	lymphoblastic	I-Disease	B-Disease
30	leukemia	E-Disease	E-Disease
31	treated	O	O
32	with	O	O
33	high	O	O
34	-	O	O
35	dose	O	O
36	methotrexate	S-Chemical	S-Chemical
37	.	O	O

0	Necropsy	O	O
1	of	O	O
2	the	O	O
3	first	O	O
4	case	O	O
5	revealed	O	O
6	loss	B-Disease	O
7	of	I-Disease	O
8	myelination	E-Disease	S-Disease
9	and	O	O
10	necrosis	S-Disease	B-Disease
11	of	O	I-Disease
12	the	O	O
13	white	O	O
14	matter	O	O
15	.	O	O

0	Possible	O	O
1	mechanisms	O	O
2	causing	O	O
3	such	O	O
4	a	O	O
5	leukoencephalopathy	S-Disease	S-Disease
6	are	O	O
7	discussed	O	O
8	.	O	O

0	Thrombotic	S-Disease	O
1	complications	O	O
2	in	O	O
3	acute	B-Disease	S-Disease
4	promyelocytic	I-Disease	I-Disease
5	leukemia	E-Disease	S-Disease
6	during	O	O
7	all	B-Chemical	O
8	-	I-Chemical	O
9	trans	I-Chemical	O
10	-	I-Chemical	O
11	retinoic	I-Chemical	B-Disease
12	acid	E-Chemical	E-Disease
13	therapy	O	O
14	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	acute	B-Disease	B-Disease
4	renal	I-Disease	I-Disease
5	failure	E-Disease	E-Disease
6	,	O	O
7	due	O	O
8	to	O	O
9	occlusion	B-Disease	O
10	of	I-Disease	O
11	renal	I-Disease	B-Disease
12	vessels	E-Disease	E-Disease
13	in	O	O
14	a	O	O
15	patient	O	O
16	with	O	O
17	acute	B-Disease	B-Disease
18	promyelocytic	I-Disease	I-Disease
19	leukemia	E-Disease	E-Disease
20	(	O	O
21	APL	S-Disease	S-Disease
22	)	O	O
23	treated	O	O
24	with	O	O
25	all	B-Chemical	B-Chemical
26	-	I-Chemical	O
27	trans	I-Chemical	I-Chemical
28	-	I-Chemical	I-Chemical
29	retinoic	I-Chemical	E-Chemical
30	acid	E-Chemical	E-Disease
31	(	O	O
32	ATRA	S-Chemical	S-Chemical
33	)	O	O
34	and	O	O
35	tranexamic	B-Chemical	S-Chemical
36	acid	E-Chemical	E-Chemical
37	has	O	O
38	been	O	O
39	described	O	O
40	recently	O	O
41	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	acute	B-Disease	B-Disease
6	renal	I-Disease	I-Disease
7	failure	E-Disease	E-Disease
8	in	O	O
9	an	O	O
10	APL	S-Disease	O
11	patient	O	O
12	treated	O	O
13	with	O	O
14	ATRA	S-Chemical	S-Disease
15	alone	O	O
16	.	O	O

0	This	O	O
1	case	O	O
2	further	O	O
3	supports	O	O
4	the	O	O
5	concern	O	O
6	about	O	O
7	thromboembolic	S-Disease	S-Disease
8	complications	O	O
9	associated	O	O
10	with	O	O
11	ATRA	S-Chemical	S-Chemical
12	therapy	O	O
13	in	O	O
14	APL	S-Disease	S-Disease
15	patients	O	O
16	.	O	O

0	The	O	O
1	patients	O	O
2	,	O	O
3	a	O	O
4	43	O	O
5	-	O	O
6	year	O	O
7	-	O	O
8	old	O	O
9	man	O	O
10	,	O	O
11	presented	O	O
12	all	O	O
13	the	O	O
14	signs	O	O
15	and	O	O
16	symptoms	O	O
17	of	O	O
18	APL	S-Disease	S-Disease
19	and	O	O
20	was	O	O
21	included	O	O
22	in	O	O
23	a	O	O
24	treatment	O	O
25	protocol	O	O
26	with	O	O
27	ATRA	S-Chemical	S-Disease
28	.	O	O

0	After	O	O
1	10	O	O
2	days	O	O
3	of	O	O
4	treatment	O	O
5	,	O	O
6	he	O	O
7	developed	O	O
8	acute	B-Disease	B-Disease
9	renal	I-Disease	I-Disease
10	failure	E-Disease	E-Disease
11	that	O	O
12	was	O	O
13	completely	O	O
14	reversible	O	O
15	after	O	O
16	complete	O	O
17	remission	O	O
18	of	O	O
19	APL	S-Disease	S-Disease
20	was	O	O
21	achieved	O	O
22	and	O	O
23	therapy	O	O
24	discontinued	O	O
25	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	ATRA	S-Chemical	S-Chemical
4	is	O	O
5	a	O	O
6	valid	O	O
7	therapeutic	O	O
8	choice	O	O
9	for	O	O
10	patients	O	O
11	with	O	O
12	APL	S-Disease	S-Disease
13	,	O	O
14	although	O	O
15	the	O	O
16	procoagulant	O	O
17	tendency	O	O
18	is	O	O
19	not	O	O
20	completely	O	O
21	corrected	O	O
22	.	O	O

0	Thrombotic	S-Disease	S-Disease
1	events	O	O
2	,	O	O
3	however	O	O
4	,	O	O
5	could	O	O
6	be	O	O
7	avoided	O	O
8	by	O	O
9	using	O	O
10	low	O	O
11	-	O	O
12	dose	O	O
13	heparin	S-Chemical	S-Chemical
14	.	O	O

0	Pupillary	O	O
1	changes	O	O
2	associated	O	O
3	with	O	O
4	the	O	O
5	development	O	O
6	of	O	O
7	stimulant	O	O
8	-	O	O
9	induced	O	O
10	mania	S-Disease	S-Disease
11	:	O	O
12	a	O	O
13	case	O	O
14	report	O	O
15	.	O	O

0	A	O	O
1	30	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	cocaine	S-Chemical	S-Chemical
7	-	O	O
8	dependent	O	O
9	man	O	O
10	who	O	O
11	was	O	O
12	a	O	O
13	subject	O	O
14	in	O	O
15	a	O	O
16	study	O	O
17	evaluating	O	O
18	the	O	O
19	anticraving	O	O
20	efficacy	O	O
21	of	O	O
22	the	O	O
23	stimulant	O	O
24	medication	O	O
25	diethylpropion	S-Chemical	S-Chemical
26	(	O	O
27	DEP	S-Chemical	S-Chemical
28	)	O	O
29	became	O	O
30	manic	S-Disease	O
31	during	O	O
32	his	O	O
33	second	O	O
34	week	O	O
35	on	O	O
36	the	O	O
37	study	O	O
38	drug	O	O
39	.	O	O

0	Pupillometric	O	O
1	changes	O	O
2	while	O	O
3	on	O	O
4	DEP	S-Chemical	S-Chemical
5	,	O	O
6	especially	O	O
7	changes	O	O
8	in	O	O
9	the	O	O
10	total	O	O
11	power	O	O
12	of	O	O
13	pupillary	B-Disease	S-Disease
14	oscillation	E-Disease	E-Disease
15	,	O	O
16	were	O	O
17	dramatically	O	O
18	different	O	O
19	than	O	O
20	those	O	O
21	observed	O	O
22	in	O	O
23	the	O	O
24	eight	O	O
25	other	O	O
26	study	O	O
27	subjects	O	O
28	who	O	O
29	did	O	O
30	not	O	O
31	become	O	O
32	manic	S-Disease	O
33	.	O	O

0	The	O	O
1	large	O	O
2	changes	O	O
3	in	O	O
4	total	O	O
5	power	O	O
6	of	O	O
7	pupillary	B-Disease	S-Disease
8	oscillation	E-Disease	O
9	occurred	O	O
10	a	O	O
11	few	O	O
12	days	O	O
13	before	O	O
14	the	O	O
15	patient	O	O
16	became	O	O
17	fully	O	O
18	manic	S-Disease	O
19	.	O	O

0	Such	O	O
1	medication	O	O
2	-	O	O
3	associated	O	O
4	changes	O	O
5	in	O	O
6	the	O	O
7	total	O	O
8	power	O	O
9	of	O	O
10	pupillary	B-Disease	B-Disease
11	oscillation	E-Disease	E-Disease
12	might	O	O
13	be	O	O
14	of	O	O
15	utility	O	O
16	in	O	O
17	identifying	O	O
18	persons	O	O
19	at	O	O
20	risk	O	O
21	for	O	O
22	manic	S-Disease	B-Disease
23	-	O	O
24	like	O	O
25	adverse	O	O
26	effects	O	O
27	during	O	O
28	the	O	O
29	medical	O	O
30	use	O	O
31	of	O	O
32	psychomotor	O	S-Disease
33	stimulants	O	O
34	or	O	O
35	sympathomimetic	O	O
36	agents	O	O
37	.	O	O

0	Fetal	O	O
1	risks	O	O
2	due	O	O
3	to	O	O
4	warfarin	S-Chemical	S-Chemical
5	therapy	O	O
6	during	O	O
7	pregnancy	O	O
8	.	O	O

0	Two	O	O
1	mothers	O	O
2	with	O	O
3	heart	O	B-Disease
4	valve	O	E-Disease
5	prosthesis	O	O
6	were	O	O
7	treated	O	O
8	with	O	O
9	warfarin	S-Chemical	S-Chemical
10	during	O	O
11	pregnancy	O	O
12	.	O	O

0	In	O	O
1	the	O	O
2	first	O	O
3	case	O	O
4	a	O	O
5	caesarean	O	S-Disease
6	section	O	O
7	was	O	O
8	done	O	O
9	one	O	O
10	week	O	O
11	after	O	O
12	replacement	O	O
13	of	O	O
14	warfarin	S-Chemical	S-Chemical
15	with	O	O
16	heparin	S-Chemical	S-Chemical
17	.	O	O

0	The	O	O
1	baby	O	O
2	died	O	O
3	of	O	O
4	cerebral	B-Disease	O
5	and	I-Disease	O
6	pulmonary	I-Disease	B-Disease
7	hemorrhage	E-Disease	E-Disease
8	.	O	O

0	The	O	O
1	baby	O	O
2	showed	O	O
3	warfarin	S-Chemical	S-Chemical
4	-	O	O
5	induced	O	O
6	embryopathy	S-Disease	S-Disease
7	with	O	O
8	nasal	B-Disease	B-Disease
9	hypoplasia	E-Disease	E-Disease
10	and	O	O
11	stippled	B-Disease	O
12	epiphyses	E-Disease	S-Disease
13	(	O	O
14	chondrodysplasia	B-Disease	B-Disease
15	punctata	E-Disease	E-Disease
16	)	O	O
17	.	O	O

0	Nasal	B-Disease	O
1	hypoplasia	E-Disease	S-Disease
2	with	O	O
3	or	O	O
4	without	O	O
5	stippled	B-Disease	O
6	epiphyses	E-Disease	S-Disease
7	has	O	O
8	now	O	O
9	been	O	O
10	reported	O	O
11	in	O	O
12	11	O	O
13	infants	O	O
14	born	O	O
15	to	O	O
16	mothers	O	O
17	treated	O	O
18	with	O	O
19	warfarin	S-Chemical	S-Chemical
20	during	O	O
21	the	O	O
22	first	O	O
23	trimester	O	O
24	,	O	O
25	and	O	O
26	a	O	O
27	causal	O	O
28	association	O	O
29	is	O	O
30	probable	O	O
31	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	We	O	O
3	wanted	O	O
4	to	O	O
5	test	O	O
6	whether	O	O
7	assessment	O	O
8	of	O	O
9	both	O	O
10	a	O	O
11	central	O	O
12	pain	S-Disease	S-Disease
13	-	O	O
14	related	O	O
15	signal	O	O
16	(	O	O
17	chemo	O	S-Disease
18	-	O	O
19	somatosensory	O	S-Disease
20	evoked	O	O
21	potential	O	O
22	,	O	O
23	CSSEP	O	S-Disease
24	)	O	O
25	and	O	O
26	a	O	O
27	concomitantly	O	O
28	recorded	O	O
29	peripheral	O	O
30	signal	O	O
31	(	O	O
32	negative	O	O
33	mucosal	O	O
34	potential	O	O
35	,	O	O
36	NMP	O	S-Disease
37	)	O	O
38	allows	O	O
39	for	O	O
40	separation	O	O
41	of	O	O
42	central	O	O
43	and	O	O
44	peripheral	O	O
45	effects	O	O
46	of	O	O
47	NSAIDs	O	S-Disease
48	.	O	O

0	For	O	O
1	this	O	O
2	purpose	O	O
3	,	O	O
4	experimental	O	O
5	conditions	O	O
6	were	O	O
7	created	O	O
8	in	O	O
9	which	O	O
10	NSAIDs	O	S-Chemical
11	had	O	O
12	previously	O	O
13	been	O	O
14	observed	O	O
15	to	O	O
16	produce	O	O
17	effects	O	O
18	on	O	O
19	phasic	O	B-Disease
20	and	O	O
21	tonic	O	B-Disease
22	pain	S-Disease	E-Disease
23	by	O	O
24	either	O	O
25	central	O	O
26	or	O	O
27	peripheral	O	O
28	mechanisms	O	O
29	.	O	O

0	METHODS	O	O
1	:	O	O
2	According	O	O
3	to	O	O
4	a	O	O
5	double	O	O
6	-	O	O
7	blind	O	O
8	,	O	O
9	randomised	O	O
10	,	O	O
11	controlled	O	O
12	,	O	O
13	threefold	O	O
14	cross	O	O
15	-	O	O
16	over	O	O
17	design	O	O
18	,	O	O
19	18	O	O
20	healthy	O	O
21	subjects	O	O
22	(	O	O
23	11	O	O
24	males	O	O
25	,	O	O
26	7	O	O
27	females	O	O
28	;	O	O
29	mean	O	O
30	age	O	O
31	26	O	O
32	years	O	O
33	)	O	O
34	received	O	O
35	either	O	O
36	placebo	O	O
37	,	O	O
38	400	O	O
39	mg	O	O
40	ibuprofen	S-Chemical	O
41	,	O	O
42	or	O	O
43	800	O	O
44	mg	O	O
45	ibuprofen	S-Chemical	S-Chemical
46	.	O	O

0	Phasic	O	O
1	pain	S-Disease	S-Disease
2	was	O	O
3	applied	O	O
4	by	O	O
5	means	O	O
6	of	O	O
7	short	O	O
8	pulses	O	O
9	of	O	O
10	CO2	S-Chemical	S-Chemical
11	to	O	O
12	the	O	O
13	nasal	O	O
14	mucosa	O	O
15	(	O	O
16	stimulus	O	O
17	duration	O	O
18	500	O	O
19	ms	O	O
20	,	O	O
21	interval	O	O
22	approximately	O	O
23	60	O	O
24	s	O	O
25	)	O	O
26	,	O	O
27	and	O	O
28	tonic	O	B-Disease
29	pain	S-Disease	E-Disease
30	was	O	O
31	induced	O	O
32	in	O	O
33	the	O	O
34	nasal	O	O
35	cavity	O	E-Disease
36	by	O	O
37	means	O	O
38	of	O	O
39	dry	O	O
40	air	O	O
41	of	O	O
42	controlled	O	O
43	temperature	O	O
44	,	O	O
45	humidity	O	O
46	and	O	O
47	flow	O	O
48	rate	O	O
49	(	O	O
50	22	O	O
51	degrees	O	O
52	C	O	O
53	,	O	O
54	0	O	O
55	%	O	O
56	relative	O	O
57	humidity	O	O
58	,	O	O
59	145	O	O
60	ml	O	O
61	.	O	O
62	s	O	O
63	-	O	O
64	1	O	O
65	)	O	O
66	.	O	O

0	Both	O	O
1	CSSEPs	O	S-Disease
2	as	O	O
3	central	O	O
4	and	O	O
5	NMPs	O	S-Disease
6	as	O	O
7	peripheral	O	O
8	correlates	O	O
9	of	O	O
10	pain	S-Disease	S-Disease
11	were	O	O
12	obtained	O	O
13	in	O	O
14	response	O	O
15	to	O	O
16	the	O	O
17	CO2	S-Chemical	S-Chemical
18	stimuli	O	O
19	.	O	O

0	Additionally	O	O
1	,	O	O
2	the	O	O
3	subjects	O	O
4	rated	O	O
5	the	O	O
6	intensity	O	O
7	of	O	O
8	both	O	O
9	phasic	O	S-Disease
10	and	O	O
11	tonic	O	B-Disease
12	pain	S-Disease	E-Disease
13	by	O	O
14	means	O	O
15	of	O	O
16	visual	O	O
17	analogue	O	O
18	scales	O	O
19	.	O	O

0	RESULTS	O	O
1	:	O	O
2	As	O	O
3	described	O	O
4	earlier	O	O
5	,	O	O
6	administration	O	O
7	of	O	O
8	ibuprofen	S-Chemical	S-Chemical
9	was	O	O
10	followed	O	O
11	by	O	O
12	a	O	O
13	decrease	O	O
14	in	O	O
15	tonic	O	B-Disease
16	pain	S-Disease	E-Disease
17	but	O	O
18	-	O	O
19	relative	O	O
20	to	O	O
21	placebo	O	S-Disease
22	-	O	O
23	an	O	O
24	increase	O	O
25	in	O	O
26	correlates	O	O
27	of	O	O
28	phasic	O	S-Disease
29	pain	S-Disease	E-Disease
30	,	O	O
31	indicating	O	O
32	a	O	O
33	specific	O	O
34	effect	O	O
35	of	O	O
36	ibuprofen	S-Chemical	S-Chemical
37	on	O	O
38	the	O	O
39	interaction	O	O
40	between	O	O
41	the	O	O
42	pain	S-Disease	O
43	stimuli	O	O
44	under	O	O
45	these	O	O
46	special	O	O
47	experimental	O	O
48	conditions	O	O
49	.	O	O

0	The	O	O
1	major	O	O
2	advantage	O	O
3	of	O	O
4	this	O	O
5	pain	S-Disease	O
6	model	O	O
7	is	O	O
8	the	O	O
9	possibility	O	O
10	of	O	O
11	obtaining	O	O
12	peripheral	O	O
13	pain	S-Disease	I-Disease
14	-	O	O
15	related	O	O
16	activity	O	E-Disease
17	directly	O	O
18	using	O	O
19	a	O	O
20	non	O	O
21	-	O	O
22	invasive	O	O
23	technique	O	O
24	in	O	O
25	humans	O	O
26	.	O	O

0	Effect	O	O
1	of	O	O
2	D	B-Chemical	B-Chemical
3	-	I-Chemical	I-Chemical
4	Glucarates	E-Chemical	E-Chemical
5	on	O	O
6	basic	O	O
7	antibiotic	O	O
8	-	O	O
9	induced	O	O
10	renal	B-Disease	B-Disease
11	damage	E-Disease	E-Disease
12	in	O	O
13	rats	O	O
14	.	O	O

0	Dehydrated	S-Disease	O
1	rats	O	O
2	regularly	O	O
3	develop	O	O
4	acute	B-Disease	B-Disease
5	renal	I-Disease	I-Disease
6	failure	E-Disease	E-Disease
7	following	O	O
8	single	O	O
9	injection	O	O
10	of	O	O
11	aminoglycoside	S-Chemical	S-Chemical
12	antibiotics	O	O
13	combined	O	O
14	with	O	O
15	dextran	O	S-Chemical
16	or	O	O
17	of	O	O
18	antibiotics	O	O
19	only	O	O
20	.	O	O

0	Oral	O	O
1	administration	O	O
2	of	O	O
3	2	B-Chemical	O
4	,	I-Chemical	O
5	5	I-Chemical	I-Chemical
6	-	I-Chemical	I-Chemical
7	di	I-Chemical	I-Chemical
8	-	I-Chemical	I-Chemical
9	O	I-Chemical	I-Chemical
10	-	I-Chemical	I-Chemical
11	acetyl	I-Chemical	E-Chemical
12	-	I-Chemical	I-Chemical
13	D	I-Chemical	I-Chemical
14	-	I-Chemical	I-Chemical
15	glucaro	I-Chemical	I-Chemical
16	-	I-Chemical	I-Chemical
17	1	I-Chemical	O
18	,	I-Chemical	O
19	4	I-Chemical	I-Chemical
20	-	I-Chemical	I-Chemical
21	6	I-Chemical	O
22	,	I-Chemical	O
23	3	I-Chemical	I-Chemical
24	-	I-Chemical	I-Chemical
25	dilactone	E-Chemical	E-Chemical
26	protected	O	O
27	rats	O	O
28	against	O	O
29	renal	B-Disease	B-Disease
30	failure	E-Disease	E-Disease
31	induced	O	O
32	by	O	O
33	kanamycin	S-Chemical	S-Chemical
34	-	O	O
35	dextran	O	S-Chemical
36	.	O	O

0	The	O	O
1	protective	O	O
2	effect	O	O
3	was	O	O
4	prevalent	O	O
5	among	O	O
6	D	B-Chemical	S-Chemical
7	-	I-Chemical	I-Chemical
8	glucarates	E-Chemical	E-Chemical
9	,	O	O
10	and	O	O
11	also	O	O
12	to	O	O
13	other	O	O
14	saccharic	B-Chemical	S-Chemical
15	acid	E-Chemical	O
16	,	O	O
17	hexauronic	B-Chemical	S-Chemical
18	acids	E-Chemical	E-Disease
19	and	O	O
20	hexaaldonic	B-Chemical	S-Chemical
21	acids	E-Chemical	O
22	,	O	O
23	although	O	O
24	to	O	O
25	a	O	O
26	lesser	O	O
27	degree	O	O
28	,	O	O
29	but	O	O
30	not	O	O
31	to	O	O
32	a	O	O
33	hexaaldose	O	S-Disease
34	,	O	O
35	sugar	B-Chemical	O
36	alcohols	E-Chemical	O
37	,	O	O
38	substances	O	O
39	inthe	O	O
40	TCA	S-Chemical	S-Disease
41	cycle	O	O
42	and	O	O
43	other	O	O
44	acidic	O	O
45	compounds	O	O
46	.	O	O

0	D	B-Chemical	B-Chemical
1	-	I-Chemical	I-Chemical
2	Glucarates	E-Chemical	E-Chemical
3	were	O	O
4	effective	O	O
5	against	O	O
6	renal	B-Disease	B-Disease
7	damage	E-Disease	E-Disease
8	induced	O	O
9	by	O	O
10	peptide	O	S-Chemical
11	antibiotics	O	O
12	as	O	O
13	well	O	O
14	as	O	O
15	various	O	O
16	aminoglycoside	S-Chemical	S-Chemical
17	antibitocis	O	O
18	.	O	O

0	Dose	O	O
1	-	O	O
2	responses	O	O
3	were	O	O
4	observed	O	O
5	in	O	O
6	the	O	O
7	protective	O	O
8	effect	O	O
9	of	O	O
10	D	B-Chemical	B-Chemical
11	-	I-Chemical	I-Chemical
12	Glucarates	E-Chemical	E-Chemical
13	.	O	O

0	With	O	O
1	a	O	O
2	D	B-Chemical	S-Chemical
3	-	I-Chemical	S-Chemical
4	glucarate	E-Chemical	E-Chemical
5	of	O	O
6	a	O	O
7	fixed	O	O
8	size	O	O
9	of	O	O
10	dose	O	O
11	,	O	O
12	approximately	O	O
13	the	O	O
14	same	O	O
15	degree	O	O
16	of	O	O
17	protection	O	O
18	was	O	O
19	obtained	O	O
20	against	O	O
21	renal	B-Disease	B-Disease
22	damages	E-Disease	E-Disease
23	induced	O	O
24	by	O	O
25	different	O	O
26	basic	O	O
27	antibiotics	O	O
28	despite	O	O
29	large	O	O
30	disparities	O	O
31	in	O	O
32	administration	O	O
33	doses	O	O
34	of	O	O
35	different	O	O
36	antibiotics	O	O
37	.	O	O

0	D	B-Chemical	B-Chemical
1	-	I-Chemical	I-Chemical
2	Glucarates	E-Chemical	E-Chemical
3	had	O	O
4	the	O	O
5	ability	O	O
6	to	O	O
7	prevent	O	O
8	renal	B-Disease	B-Disease
9	damage	E-Disease	E-Disease
10	but	O	O
11	not	O	O
12	to	O	O
13	cure	O	O
14	it	O	O
15	.	O	O

0	Rats	O	O
1	excreted	O	O
2	acidic	O	O
3	urine	O	O
4	when	O	O
5	they	O	O
6	were	O	O
7	spared	O	O
8	from	O	O
9	renal	B-Disease	B-Disease
10	lesions	E-Disease	E-Disease
11	by	O	O
12	monosaccharides	S-Chemical	S-Chemical
13	.	O	O

0	The	O	O
1	reduction	O	O
2	effect	O	O
3	of	O	O
4	D	B-Chemical	S-Chemical
5	-	I-Chemical	I-Chemical
6	glucarates	E-Chemical	E-Chemical
7	against	O	O
8	nephrotoxicity	S-Disease	S-Disease
9	of	O	O
10	basic	O	O
11	antibiotics	O	O
12	was	O	O
13	discussed	O	O
14	.	O	O

0	Acute	O	O
1	severe	O	O
2	depression	S-Disease	S-Disease
3	following	O	O
4	peri	O	O
5	-	O	O
6	operative	O	O
7	ondansetron	S-Chemical	S-Disease
8	.	O	O

0	A	O	O
1	41	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	woman	O	O
7	with	O	O
8	a	O	O
9	strong	O	O
10	history	O	O
11	of	O	O
12	postoperative	B-Disease	O
13	nausea	I-Disease	S-Disease
14	and	I-Disease	O
15	vomiting	E-Disease	S-Disease
16	presented	O	O
17	for	O	O
18	abdominal	O	O
19	hysterectomy	O	E-Disease
20	3	O	O
21	months	O	O
22	after	O	O
23	a	O	O
24	previous	O	O
25	anaesthetic	O	O
26	where	O	O
27	ondansetron	S-Chemical	S-Chemical
28	prophylaxis	O	O
29	had	O	O
30	been	O	O
31	used	O	O
32	.	O	O

0	She	O	O
1	had	O	O
2	developed	O	O
3	a	O	O
4	severe	O	O
5	acute	O	B-Disease
6	major	B-Disease	I-Disease
7	depression	I-Disease	I-Disease
8	disorder	E-Disease	E-Disease
9	almost	O	O
10	immediately	O	O
11	thereafter	O	O
12	,	O	O
13	possibly	O	O
14	related	O	O
15	to	O	O
16	the	O	O
17	use	O	O
18	of	O	O
19	a	O	O
20	serotonin	S-Chemical	S-Chemical
21	antagonist	O	O
22	.	O	O

0	Nine	O	O
1	years	O	O
2	before	O	O
3	she	O	O
4	had	O	O
5	experienced	O	O
6	a	O	O
7	self	O	O
8	-	O	O
9	limited	O	O
10	puerperal	O	S-Disease
11	depressive	B-Disease	I-Disease
12	episode	E-Disease	O
13	.	O	O

0	Anaesthesia	O	O
1	with	O	O
2	a	O	O
3	propofol	S-Chemical	S-Chemical
4	infusion	O	O
5	and	O	O
6	avoidance	O	O
7	of	O	O
8	serotonin	S-Chemical	S-Chemical
9	antagonists	O	O
10	provided	O	O
11	a	O	O
12	nausea	S-Disease	S-Disease
13	-	O	O
14	free	O	O
15	postoperative	O	O
16	course	O	O
17	without	O	O
18	exacerbation	O	O
19	of	O	O
20	the	O	O
21	depression	B-Disease	B-Disease
22	disorder	E-Disease	E-Disease
23	.	O	O

0	Hypertensive	S-Disease	O
1	response	O	O
2	during	O	O
3	dobutamine	S-Chemical	S-Chemical
4	stress	O	O
5	echocardiography	O	O
6	.	O	O

0	Among	O	O
1	3	O	O
2	,	O	O
3	129	O	O
4	dobutamine	S-Chemical	S-Chemical
5	stress	O	O
6	echocardiographic	O	O
7	studies	O	O
8	,	O	O
9	a	O	O
10	hypertensive	S-Disease	O
11	response	O	O
12	,	O	O
13	defined	O	O
14	as	O	O
15	systolic	O	O
16	blood	O	I-Disease
17	pressure	O	O
18	(	O	O
19	BP	O	S-Disease
20	)	O	O
21	>	O	O
22	or	O	O
23	=	O	O
24	220	O	O
25	mm	O	O
26	Hg	O	O
27	and	O	O
28	/	O	O
29	or	O	O
30	diastolic	O	S-Disease
31	BP	O	S-Disease
32	>	O	O
33	or	O	O
34	=	O	O
35	110	O	O
36	mm	O	O
37	Hg	O	O
38	,	O	O
39	occurred	O	O
40	in	O	O
41	30	O	O
42	patients	O	O
43	(	O	O
44	1	O	O
45	%	O	O
46	)	O	O
47	.	O	O

0	Patients	O	O
1	with	O	O
2	this	O	O
3	response	O	O
4	more	O	O
5	often	O	O
6	had	O	O
7	a	O	O
8	history	O	O
9	of	O	O
10	hypertension	S-Disease	S-Disease
11	and	O	O
12	had	O	O
13	higher	O	O
14	resting	O	O
15	systolic	O	I-Disease
16	and	O	O
17	diastolic	O	B-Disease
18	BP	O	E-Disease
19	before	O	O
20	dobutamine	S-Chemical	S-Chemical
21	infusion	O	O
22	.	O	O

0	Continuously	O	O
1	nebulized	O	O
2	albuterol	S-Chemical	S-Chemical
3	in	O	O
4	severe	O	O
5	exacerbations	O	O
6	of	O	O
7	asthma	S-Disease	S-Disease
8	in	O	O
9	adults	O	O
10	:	O	O
11	a	O	O
12	case	O	O
13	-	O	O
14	controlled	O	O
15	study	O	O
16	.	O	O

0	A	O	O
1	retrospective	O	O
2	,	O	O
3	case	O	O
4	-	O	O
5	controlled	O	O
6	analysis	O	O
7	comparing	O	O
8	patients	O	O
9	admitted	O	O
10	to	O	O
11	a	O	O
12	medical	O	O
13	intensive	O	O
14	care	O	O
15	unit	O	O
16	with	O	O
17	severe	O	O
18	exacerbations	O	O
19	of	O	O
20	asthma	S-Disease	S-Disease
21	who	O	O
22	received	O	O
23	continuously	O	O
24	nebulized	O	O
25	albuterol	S-Chemical	S-Chemical
26	(	O	O
27	CNA	O	S-Chemical
28	)	O	O
29	versus	O	O
30	intermittent	O	O
31	albuterol	S-Chemical	S-Chemical
32	(	O	O
33	INA	O	S-Chemical
34	)	O	O
35	treatments	O	O
36	is	O	O
37	reported	O	O
38	.	O	O

0	Forty	O	O
1	matched	O	O
2	pairs	O	O
3	of	O	O
4	patients	O	O
5	with	O	O
6	asthma	S-Disease	S-Disease
7	are	O	O
8	compared	O	O
9	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	cardiac	B-Disease	B-Disease
4	dysrhythmias	E-Disease	E-Disease
5	was	O	O
6	similar	O	O
7	between	O	O
8	groups	O	O
9	.	O	O

0	Symptomatic	O	O
1	hypokalemia	S-Disease	S-Disease
2	did	O	O
3	not	O	O
4	occur	O	O
5	.	O	O

0	Paraplegia	S-Disease	O
1	following	O	O
2	intrathecal	O	O
3	methotrexate	S-Chemical	S-Chemical
4	:	O	O
5	report	O	O
6	of	O	O
7	a	O	O
8	case	O	O
9	and	O	O
10	review	O	O
11	of	O	O
12	the	O	O
13	literature	O	O
14	.	O	O

0	A	O	O
1	patient	O	O
2	who	O	O
3	developed	O	O
4	paraplegia	S-Disease	S-Disease
5	following	O	O
6	the	O	O
7	intrathecal	O	O
8	instillation	O	O
9	of	O	O
10	methotrexate	S-Chemical	S-Chemical
11	is	O	O
12	discribed	O	O
13	.	O	O

0	The	O	O
1	following	O	O
2	factors	O	O
3	appear	O	O
4	to	O	O
5	predispose	O	O
6	to	O	O
7	the	O	O
8	development	O	O
9	of	O	O
10	this	O	O
11	complication	O	O
12	:	O	O
13	abnormal	O	O
14	cerebrospinal	O	S-Disease
15	dynamics	O	O
16	related	O	O
17	to	O	O
18	the	O	O
19	presence	O	O
20	of	O	O
21	central	B-Disease	B-Disease
22	nervous	I-Disease	I-Disease
23	system	I-Disease	I-Disease
24	leukemia	E-Disease	S-Disease
25	,	O	O
26	and	O	O
27	epidural	O	O
28	cerebrospinal	O	I-Disease
29	leakage	O	E-Disease
30	;	O	O
31	elevated	O	O
32	cerebrospinal	O	B-Disease
33	fluid	O	O
34	methothexate	S-Chemical	S-Disease
35	concentration	O	O
36	related	O	O
37	to	O	O
38	abnormal	O	O
39	cerebrospinal	O	S-Disease
40	fluid	O	E-Disease
41	dynamics	O	O
42	and	O	O
43	to	O	O
44	inappropriately	O	O
45	high	O	O
46	methotrexate	S-Chemical	S-Chemical
47	doses	O	O
48	based	O	O
49	on	O	O
50	body	O	O
51	surface	O	O
52	area	O	O
53	calculations	O	O
54	in	O	O
55	older	O	O
56	children	O	O
57	and	O	O
58	adults	O	O
59	;	O	O
60	the	O	O
61	presence	O	O
62	of	O	O
63	neurotoxic	S-Disease	S-Disease
64	preservatives	O	O
65	in	O	O
66	commercially	O	O
67	available	O	O
68	methotrexate	S-Chemical	S-Chemical
69	preparations	O	O
70	and	O	O
71	diluents	O	S-Disease
72	;	O	O
73	and	O	O
74	the	O	O
75	use	O	O
76	of	O	O
77	methotrexate	S-Chemical	S-Chemical
78	diluents	O	O
79	of	O	O
80	unphysiologic	O	O
81	pH	O	O
82	,	O	O
83	ionic	O	S-Disease
84	content	O	S-Disease
85	and	O	O
86	osmolarity	O	S-Disease
87	.	O	O

0	The	O	O
1	role	O	O
2	of	O	O
3	methotrexate	S-Chemical	S-Chemical
4	contaminants	O	O
5	,	O	O
6	local	O	O
7	folate	B-Disease	S-Chemical
8	deficiency	E-Disease	E-Disease
9	,	O	O
10	and	O	O
11	cranial	O	S-Disease
12	irradiation	O	O
13	in	O	O
14	the	O	O
15	pathogenesis	O	O
16	of	O	O
17	intrathecal	O	O
18	methotrexate	S-Chemical	B-Disease
19	toxicity	S-Disease	E-Disease
20	is	O	O
21	unclear	O	O
22	.	O	O

0	The	O	O
1	incidence	O	O
2	of	O	O
3	neurotoxicity	S-Disease	S-Disease
4	may	O	O
5	be	O	O
6	reduced	O	O
7	by	O	O
8	employing	O	O
9	lower	O	O
10	doses	O	O
11	of	O	O
12	methotrexate	S-Chemical	S-Chemical
13	in	O	O
14	the	O	O
15	presence	O	O
16	of	O	O
17	central	B-Disease	B-Disease
18	nervous	I-Disease	I-Disease
19	system	I-Disease	I-Disease
20	leukemia	E-Disease	E-Disease
21	,	O	O
22	in	O	O
23	older	O	O
24	children	O	O
25	and	O	O
26	adults	O	O
27	,	O	O
28	and	O	O
29	in	O	O
30	the	O	O
31	presence	O	O
32	of	O	O
33	epidural	O	O
34	leakage	O	E-Disease
35	.	O	O

0	Only	O	O
1	preservative	O	O
2	-	O	O
3	free	O	O
4	methotrexate	S-Chemical	S-Chemical
5	in	O	O
6	Elliott	O	S-Disease
7	'	O	I-Disease
8	s	O	O
9	B	O	O
10	Solution	O	O
11	at	O	O
12	a	O	O
13	concentration	O	O
14	of	O	O
15	not	O	O
16	more	O	O
17	than	O	O
18	1	O	O
19	mg	O	O
20	/	O	O
21	ml	O	O
22	should	O	O
23	be	O	O
24	used	O	O
25	for	O	O
26	intrathecal	O	O
27	administration	O	O
28	.	O	O

0	Periodic	O	O
1	monitoring	O	O
2	of	O	O
3	cerebruspinal	O	S-Chemical
4	fluid	O	O
5	methotrexate	S-Chemical	S-Chemical
6	levels	O	O
7	may	O	O
8	be	O	O
9	predictive	O	O
10	of	O	O
11	the	O	O
12	development	O	O
13	of	O	O
14	serious	O	O
15	neurotoxicity	S-Disease	S-Disease
16	.	O	O

0	Hyperosmolar	B-Disease	O
1	nonketotic	I-Disease	O
2	coma	E-Disease	S-Disease
3	precipitated	O	O
4	by	O	O
5	lithium	S-Chemical	S-Chemical
6	-	O	O
7	induced	O	O
8	nephrogenic	B-Disease	B-Disease
9	diabetes	I-Disease	B-Disease
10	insipidus	E-Disease	E-Disease
11	.	O	O

0	A	O	O
1	45	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	man	O	O
7	,	O	O
8	with	O	O
9	a	O	O
10	10	O	O
11	-	O	O
12	year	O	O
13	history	O	O
14	of	O	O
15	manic	B-Disease	B-Disease
16	depression	E-Disease	E-Disease
17	treated	O	O
18	with	O	O
19	lithium	S-Chemical	S-Disease
20	,	O	O
21	was	O	O
22	admitted	O	O
23	with	O	O
24	hyperosmolar	B-Disease	S-Disease
25	,	I-Disease	O
26	nonketotic	I-Disease	O
27	coma	E-Disease	S-Disease
28	.	O	O

0	He	O	O
1	gave	O	O
2	a	O	O
3	five	O	O
4	-	O	O
5	year	O	O
6	history	O	O
7	of	O	O
8	polyuria	S-Disease	S-Disease
9	and	O	O
10	polydipsia	S-Disease	S-Disease
11	,	O	O
12	during	O	O
13	which	O	O
14	time	O	O
15	urinalysis	O	S-Disease
16	had	O	O
17	been	O	O
18	negative	O	O
19	for	O	O
20	glucose	S-Chemical	S-Disease
21	.	O	O

0	After	O	O
1	recovery	O	O
2	from	O	O
3	hyperglycaemia	S-Disease	S-Disease
4	,	O	O
5	he	O	O
6	remained	O	O
7	polyuric	S-Disease	S-Chemical
8	despite	O	O
9	normal	O	O
10	blood	O	B-Disease
11	glucose	S-Chemical	E-Disease
12	concentrations	O	O
13	;	O	O
14	water	O	O
15	deprivation	O	O
16	testing	O	O
17	indicated	O	O
18	nephrogenic	B-Disease	B-Disease
19	diabetes	I-Disease	B-Disease
20	insipidus	E-Disease	E-Disease
21	,	O	O
22	likely	O	O
23	to	O	O
24	be	O	O
25	lithium	S-Chemical	S-Chemical
26	-	O	O
27	induced	O	O
28	.	O	O

0	We	O	O
1	hypothesize	O	O
2	that	O	O
3	when	O	O
4	this	O	O
5	man	O	O
6	developed	O	O
7	type	B-Disease	B-Disease
8	2	I-Disease	O
9	diabetes	E-Disease	S-Disease
10	,	O	O
11	chronic	O	B-Disease
12	polyuria	S-Disease	E-Disease
13	due	O	O
14	to	O	O
15	nephrogenic	B-Disease	B-Disease
16	diabetes	I-Disease	B-Disease
17	insipidus	E-Disease	E-Disease
18	was	O	O
19	sufficient	O	O
20	to	O	O
21	precipitate	O	O
22	hyperosmolar	O	S-Disease
23	dehydration	S-Disease	O
24	.	O	O

0	Effects	O	O
1	of	O	O
2	the	O	O
3	intracoronary	O	O
4	infusion	O	O
5	of	O	O
6	cocaine	S-Chemical	S-Chemical
7	on	O	O
8	left	O	O
9	ventricular	O	O
10	systolic	O	S-Disease
11	and	O	O
12	diastolic	O	B-Disease
13	function	O	E-Disease
14	in	O	O
15	humans	O	O
16	.	O	O

0	BACKGROUND	O	O
1	:	O	O
2	In	O	O
3	dogs	O	O
4	,	O	O
5	a	O	O
6	large	O	O
7	amount	O	O
8	of	O	O
9	intravenous	O	O
10	cocaine	S-Chemical	S-Chemical
11	causes	O	O
12	a	O	O
13	profound	O	O
14	deterioration	B-Disease	O
15	of	I-Disease	O
16	left	I-Disease	O
17	ventricular	I-Disease	S-Disease
18	(	I-Disease	O
19	LV	I-Disease	S-Disease
20	)	I-Disease	O
21	systolic	I-Disease	S-Disease
22	function	E-Disease	O
23	and	O	O
24	an	O	O
25	increase	O	O
26	in	O	O
27	LV	O	O
28	end	O	O
29	-	O	O
30	diastolic	O	S-Disease
31	pressure	O	O
32	.	O	O

0	This	O	O
1	study	O	O
2	was	O	O
3	done	O	O
4	to	O	O
5	assess	O	O
6	the	O	O
7	influence	O	O
8	of	O	O
9	a	O	O
10	high	O	O
11	intracoronary	O	O
12	cocaine	S-Chemical	S-Chemical
13	concentration	O	O
14	on	O	O
15	LV	O	B-Disease
16	systolic	O	E-Disease
17	and	O	O
18	diastolic	O	B-Disease
19	function	O	E-Disease
20	in	O	O
21	humans	O	O
22	.	O	O

0	METHODS	O	O
1	AND	O	O
2	RESULTS	O	O
3	:	O	O
4	In	O	O
5	20	O	O
6	patients	O	O
7	(	O	O
8	14	O	O
9	men	O	O
10	and	O	O
11	6	O	O
12	women	O	O
13	aged	O	O
14	39	O	O
15	to	O	O
16	72	O	O
17	years	O	O
18	)	O	O
19	referred	O	O
20	for	O	O
21	cardiac	O	B-Disease
22	catheterization	O	E-Disease
23	for	O	O
24	the	O	O
25	evaluation	O	O
26	of	O	O
27	chest	B-Disease	O
28	pain	E-Disease	S-Disease
29	,	O	O
30	we	O	O
31	measured	O	O
32	heart	O	O
33	rate	O	O
34	,	O	O
35	systemic	O	O
36	arterial	O	S-Disease
37	pressure	O	O
38	,	O	O
39	LV	O	O
40	pressure	O	O
41	and	O	O
42	its	O	O
43	first	O	O
44	derivative	O	O
45	(	O	O
46	dP	O	O
47	/	O	O
48	dt	O	O
49	)	O	O
50	,	O	O
51	and	O	O
52	LV	O	O
53	volumes	O	O
54	and	O	O
55	ejection	O	O
56	fraction	O	O
57	before	O	O
58	and	O	O
59	during	O	O
60	the	O	O
61	final	O	O
62	2	O	O
63	to	O	O
64	3	O	O
65	minutes	O	O
66	of	O	O
67	a	O	O
68	15	O	O
69	-	O	O
70	minute	O	O
71	intracoronary	O	O
72	infusion	O	O
73	of	O	O
74	saline	O	S-Chemical
75	(	O	O
76	n	O	O
77	=	O	O
78	10	O	O
79	,	O	O
80	control	O	O
81	subjects	O	O
82	)	O	O
83	or	O	O
84	cocaine	B-Chemical	B-Chemical
85	hydrochloride	E-Chemical	E-Chemical
86	1	O	O
87	mg	O	O
88	/	O	O
89	min	O	O
90	(	O	O
91	n	O	O
92	=	O	O
93	10	O	O
94	)	O	O
95	.	O	O

0	With	O	O
1	cocaine	S-Chemical	S-Chemical
2	,	O	O
3	the	O	O
4	drug	O	O
5	concentration	O	O
6	in	O	O
7	blood	O	O
8	obtained	O	O
9	from	O	O
10	the	O	O
11	coronary	O	B-Disease
12	sinus	O	E-Disease
13	was	O	O
14	3	O	O
15	.	O	O
16	0	O	O
17	+	O	O
18	/	O	O
19	-	O	O
20	0	O	O
21	.	O	O
22	4	O	O
23	(	O	O
24	mean	O	O
25	+	O	O
26	/	O	O
27	-	O	O
28	SD	O	O
29	)	O	O
30	mg	O	O
31	/	O	O
32	L	O	O
33	,	O	O
34	similar	O	O
35	in	O	O
36	magnitude	O	O
37	to	O	O
38	the	O	O
39	blood	O	O
40	cocaine	S-Chemical	S-Chemical
41	concentration	O	O
42	reported	O	O
43	in	O	O
44	abusers	O	O
45	dying	O	O
46	of	O	O
47	cocaine	S-Chemical	B-Disease
48	intoxication	O	E-Disease
49	.	O	O

0	Cocaine	S-Chemical	S-Chemical
1	induced	O	O
2	no	O	O
3	significant	O	O
4	change	O	O
5	in	O	O
6	heart	O	S-Disease
7	rate	O	O
8	,	O	O
9	LV	O	O
10	dP	O	O
11	/	O	O
12	dt	O	O
13	(	O	O
14	positive	O	O
15	or	O	O
16	negative	O	O
17	)	O	O
18	,	O	O
19	or	O	O
20	LV	O	S-Disease
21	end	O	O
22	-	O	O
23	diastolic	O	S-Disease
24	volume	O	O
25	,	O	O
26	but	O	O
27	it	O	O
28	caused	O	O
29	an	O	O
30	increase	O	O
31	in	O	O
32	systolic	O	S-Disease
33	and	O	O
34	mean	O	O
35	arterial	O	O
36	pressures	O	O
37	,	O	O
38	LV	O	O
39	end	O	O
40	-	O	O
41	diastolic	O	S-Disease
42	pressure	O	O
43	,	O	O
44	and	O	O
45	LV	O	O
46	end	O	O
47	-	O	O
48	systolic	O	O
49	volume	O	O
50	,	O	O
51	as	O	O
52	well	O	O
53	as	O	O
54	a	O	O
55	decrease	O	O
56	in	O	O
57	LV	O	S-Disease
58	ejection	O	O
59	fraction	O	O
60	.	O	O

0	CONCLUSIONS	O	O
1	:	O	O
2	In	O	O
3	humans	O	O
4	,	O	O
5	the	O	O
6	intracoronary	O	O
7	infusion	O	O
8	of	O	O
9	cocaine	S-Chemical	S-Chemical
10	sufficient	O	O
11	in	O	O
12	amount	O	O
13	to	O	O
14	achieve	O	O
15	a	O	O
16	high	O	O
17	drug	O	O
18	concentration	O	O
19	in	O	O
20	coronary	O	B-Disease
21	sinus	O	I-Disease
22	blood	O	E-Disease
23	causes	O	O
24	a	O	O
25	deterioration	B-Disease	O
26	of	I-Disease	O
27	LV	I-Disease	S-Disease
28	systolic	I-Disease	S-Disease
29	and	I-Disease	O
30	diastolic	I-Disease	S-Disease
31	performance	E-Disease	O
32	.	O	O

0	Ascending	O	O
1	dose	O	O
2	tolerance	O	O
3	study	O	O
4	of	O	O
5	intramuscular	O	O
6	carbetocin	S-Chemical	S-Chemical
7	administered	O	O
8	after	O	O
9	normal	O	O
10	vaginal	O	O
11	birth	O	O
12	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	To	O	O
3	determine	O	O
4	the	O	O
5	maximum	O	O
6	tolerated	O	O
7	dose	O	O
8	(	O	O
9	MTD	O	O
10	)	O	O
11	of	O	O
12	carbetocin	S-Chemical	S-Chemical
13	(	O	O
14	a	O	O
15	long	O	O
16	-	O	O
17	acting	O	O
18	synthetic	O	O
19	analogue	O	O
20	of	O	O
21	oxytocin	S-Chemical	S-Chemical
22	)	O	O
23	,	O	O
24	when	O	O
25	administered	O	O
26	immediately	O	O
27	after	O	O
28	vaginal	O	O
29	delivery	O	O
30	at	O	O
31	term	O	O
32	.	O	O

0	MATERIALS	O	O
1	AND	O	O
2	METHODS	O	O
3	:	O	O
4	Carbetocin	S-Chemical	S-Chemical
5	was	O	O
6	given	O	O
7	as	O	O
8	an	O	O
9	intramuscular	O	O
10	injection	O	O
11	immediately	O	O
12	after	O	O
13	the	O	O
14	birth	O	O
15	of	O	O
16	the	O	O
17	infant	O	O
18	in	O	O
19	45	O	O
20	healthy	O	O
21	women	O	O
22	with	O	O
23	normal	O	O
24	singleton	O	O
25	pregnancies	O	O
26	who	O	O
27	delivered	O	O
28	vaginally	O	O
29	at	O	O
30	term	O	O
31	.	O	O

0	Dosage	O	O
1	groups	O	O
2	of	O	O
3	15	O	O
4	,	O	O
5	30	O	O
6	,	O	O
7	50	O	O
8	,	O	O
9	75	O	O
10	,	O	O
11	100	O	O
12	,	O	O
13	125	O	O
14	,	O	O
15	150	O	O
16	,	O	O
17	175	O	O
18	or	O	O
19	200	O	O
20	microg	O	O
21	carbetocin	S-Chemical	S-Chemical
22	were	O	O
23	assigned	O	O
24	to	O	O
25	blocks	O	O
26	of	O	O
27	three	O	O
28	women	O	O
29	according	O	O
30	to	O	O
31	the	O	O
32	continual	O	O
33	reassessment	O	O
34	method	O	O
35	(	O	O
36	CRM	O	S-Disease
37	)	O	O
38	.	O	O

0	Recorded	O	O
1	were	O	O
2	dose	O	O
3	-	O	O
4	limiting	O	O
5	adverse	O	O
6	events	O	O
7	:	O	O
8	hyper	B-Disease	S-Disease
9	-	I-Disease	O
10	or	I-Disease	O
11	hypotension	E-Disease	S-Disease
12	(	O	O
13	three	O	O
14	)	O	O
15	,	O	O
16	severe	O	O
17	abdominal	B-Disease	O
18	pain	E-Disease	S-Disease
19	(	O	O
20	0	O	O
21	)	O	O
22	,	O	O
23	vomiting	S-Disease	S-Disease
24	(	O	O
25	0	O	O
26	)	O	O
27	and	O	O
28	retained	B-Disease	O
29	placenta	E-Disease	S-Disease
30	(	O	O
31	four	O	O
32	)	O	O
33	.	O	O

0	Serious	O	O
1	adverse	O	O
2	events	O	O
3	occurred	O	O
4	in	O	O
5	seven	O	O
6	women	O	O
7	:	O	O
8	six	O	O
9	cases	O	O
10	with	O	O
11	blood	B-Disease	B-Disease
12	loss	E-Disease	E-Disease
13	>	O	O
14	or	O	O
15	=	O	O
16	1000	O	O
17	ml	O	O
18	,	O	O
19	four	O	O
20	cases	O	O
21	of	O	O
22	manual	O	O
23	placenta	O	S-Disease
24	removal	O	O
25	,	O	O
26	five	O	O
27	cases	O	O
28	of	O	O
29	additional	O	O
30	oxytocics	O	S-Chemical
31	administration	O	O
32	and	O	O
33	five	O	O
34	cases	O	O
35	of	O	O
36	blood	O	O
37	transfusion	O	O
38	.	O	O

0	Maximum	O	O
1	blood	B-Disease	O
2	loss	E-Disease	E-Disease
3	was	O	O
4	greatest	O	O
5	at	O	O
6	the	O	O
7	upper	O	O
8	and	O	O
9	lower	O	O
10	dose	O	O
11	levels	O	O
12	,	O	O
13	and	O	O
14	lowest	O	O
15	in	O	O
16	the	O	O
17	70	O	O
18	-	O	O
19	125	O	O
20	microg	O	O
21	dose	O	O
22	range	O	O
23	.	O	O

0	Four	O	O
1	out	O	O
2	of	O	O
3	six	O	O
4	cases	O	O
5	with	O	O
6	blood	B-Disease	O
7	loss	E-Disease	E-Disease
8	>	O	O
9	or	O	O
10	=	O	O
11	1000	O	O
12	ml	O	O
13	occurred	O	O
14	in	O	O
15	the	O	O
16	200	O	O
17	microg	O	O
18	group	O	O
19	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	The	O	O
3	MTD	O	O
4	was	O	O
5	calculated	O	O
6	to	O	O
7	be	O	O
8	at	O	O
9	200	O	O
10	microg	O	O
11	carbetocin	S-Chemical	S-Chemical
12	.	O	O

0	Heparin	S-Chemical	S-Chemical
1	-	O	O
2	induced	O	O
3	thrombocytopenia	S-Disease	S-Disease
4	,	O	O
5	paradoxical	O	O
6	thromboembolism	S-Disease	S-Disease
7	,	O	O
8	and	O	O
9	other	O	O
10	side	O	O
11	effects	O	O
12	of	O	O
13	heparin	S-Chemical	S-Chemical
14	therapy	O	O
15	.	O	O

0	Although	O	O
1	several	O	O
2	new	O	O
3	anticoagulant	O	O
4	drugs	O	O
5	are	O	O
6	in	O	O
7	development	O	O
8	,	O	O
9	heparin	S-Chemical	S-Chemical
10	remains	O	O
11	the	O	O
12	drug	O	O
13	of	O	O
14	choice	O	O
15	for	O	O
16	most	O	O
17	anticoagulation	O	O
18	needs	O	O
19	.	O	O

0	The	O	O
1	clinical	O	O
2	effects	O	O
3	of	O	O
4	heparin	S-Chemical	S-Chemical
5	are	O	O
6	meritorious	O	O
7	,	O	O
8	but	O	O
9	side	O	O
10	effects	O	O
11	do	O	O
12	exist	O	O
13	.	O	O

0	Important	O	O
1	untoward	O	O
2	effects	O	O
3	of	O	O
4	heparin	S-Chemical	S-Chemical
5	therapy	O	O
6	including	O	O
7	heparin	S-Chemical	S-Chemical
8	-	O	O
9	induced	O	O
10	thrombocytopenia	S-Disease	S-Disease
11	,	O	O
12	heparin	S-Chemical	S-Chemical
13	-	O	O
14	associated	O	O
15	osteoporosis	S-Disease	S-Disease
16	,	O	O
17	eosinophilia	S-Disease	S-Disease
18	,	O	O
19	skin	B-Disease	B-Disease
20	reactions	E-Disease	E-Disease
21	,	O	O
22	allergic	B-Disease	B-Disease
23	reactions	E-Disease	E-Disease
24	other	O	O
25	than	O	O
26	thrombocytopenia	S-Disease	S-Disease
27	and	O	O
28	alopecia	S-Disease	S-Disease
29	will	O	O
30	be	O	O
31	discussed	O	O
32	in	O	O
33	this	O	O
34	article	O	O
35	.	O	O

0	Nonopaque	O	O
1	crystal	O	O
2	deposition	O	O
3	causing	O	O
4	ureteric	B-Disease	B-Disease
5	obstruction	E-Disease	E-Disease
6	in	O	O
7	patients	O	O
8	with	O	O
9	HIV	O	S-Chemical
10	undergoing	O	O
11	indinavir	S-Chemical	O
12	therapy	O	O
13	.	O	O

0	OBJECTIVE	O	O
1	:	O	O
2	We	O	O
3	describe	O	O
4	the	O	O
5	unique	O	O
6	CT	O	O
7	features	O	O
8	of	O	O
9	ureteric	B-Disease	S-Disease
10	calculi	E-Disease	S-Chemical
11	in	O	O
12	six	O	O
13	HIV	B-Disease	B-Disease
14	-	I-Disease	I-Disease
15	infected	E-Disease	E-Disease
16	patients	O	O
17	receiving	O	O
18	indinavir	S-Chemical	S-Chemical
19	,	O	O
20	the	O	O
21	most	O	O
22	commonly	O	O
23	used	O	O
24	HIV	O	B-Disease
25	protease	O	E-Disease
26	inhibitor	O	O
27	,	O	O
28	which	O	O
29	is	O	O
30	associated	O	O
31	with	O	O
32	an	O	O
33	increased	O	O
34	incidence	O	O
35	of	O	O
36	urolithiasis	S-Disease	B-Chemical
37	.	O	O

0	CONCLUSION	O	O
1	:	O	O
2	Ureteric	B-Disease	B-Disease
3	obstruction	E-Disease	E-Disease
4	caused	O	O
5	by	O	O
6	precipitated	O	O
7	indinavir	S-Chemical	S-Chemical
8	crystals	O	O
9	may	O	O
10	be	O	O
11	difficult	O	O
12	to	O	O
13	diagnose	O	O
14	with	O	O
15	unenhanced	O	O
16	CT	O	S-Disease
17	.	O	O

0	Images	O	O
1	may	O	O
2	need	O	O
3	to	O	O
4	be	O	O
5	obtained	O	O
6	using	O	O
7	i	O	O
8	.	O	O
9	v	O	O
10	.	O	O
11	contrast	O	O
12	material	O	O
13	to	O	O
14	enable	O	O
15	diagnosis	O	O
16	of	O	O
17	ureteric	B-Disease	B-Disease
18	stones	I-Disease	E-Disease
19	or	I-Disease	O
20	obstruction	E-Disease	S-Disease
21	in	O	O
22	patients	O	O
23	with	O	O
24	HIV	B-Disease	B-Disease
25	infection	E-Disease	E-Disease
26	who	O	O
27	receive	O	O
28	indinavir	S-Chemical	S-Chemical
29	therapy	O	O
30	.	O	O

0	Ischemic	B-Disease	B-Disease
1	colitis	E-Disease	E-Disease
2	and	O	O
3	sumatriptan	S-Chemical	S-Chemical
4	use	O	O
5	.	O	O

0	Sumatriptan	B-Chemical	S-Chemical
1	succinate	E-Chemical	E-Chemical
2	,	O	O
3	a	O	O
4	serotonin	S-Chemical	S-Chemical
5	-	O	O
6	1	O	O
7	(	O	O
8	5	B-Chemical	O
9	-	I-Chemical	O
10	hydroxytryptamine	E-Chemical	O
11	-	O	O
12	1	O	O
13	)	O	O
14	receptor	O	O
15	agonist	O	O
16	,	O	O
17	is	O	O
18	an	O	O
19	antimigraine	O	O
20	drug	O	O
21	that	O	O
22	is	O	O
23	reported	O	O
24	to	O	O
25	act	O	O
26	by	O	O
27	selectively	O	O
28	constricting	O	O
29	intracranial	O	O
30	arteries	O	O
31	.	O	O

0	Cases	O	O
1	have	O	O
2	been	O	O
3	published	O	O
4	of	O	O
5	coronary	B-Disease	B-Disease
6	vasospasm	E-Disease	E-Disease
7	,	O	O
8	myocardial	B-Disease	B-Disease
9	ischemia	E-Disease	E-Disease
10	,	O	O
11	and	O	O
12	myocardial	B-Disease	B-Disease
13	infarction	E-Disease	E-Disease
14	occurring	O	O
15	after	O	O
16	sumatriptan	S-Chemical	S-Chemical
17	use	O	O
18	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	the	O	O
4	development	O	O
5	of	O	O
6	8	O	O
7	serious	O	O
8	cases	O	O
9	of	O	O
10	ischemic	B-Disease	B-Disease
11	colitis	E-Disease	E-Disease
12	in	O	O
13	patients	O	O
14	with	O	O
15	migraine	S-Disease	S-Disease
16	treated	O	O
17	with	O	O
18	sumatriptan	S-Chemical	S-Chemical
19	.	O	O

0	51	O	O
1	patients	O	O
2	with	O	O
3	medically	O	O
4	refractory	O	O
5	Parkinson	B-Disease	B-Disease
6	'	I-Disease	I-Disease
7	s	I-Disease	I-Disease
8	disease	E-Disease	E-Disease
9	underwent	O	O
10	stereotactic	O	O
11	posteromedial	O	S-Disease
12	pallidotomy	O	S-Disease
13	between	O	O
14	August	O	O
15	1993	O	O
16	and	O	O
17	February	O	O
18	1997	O	O
19	for	O	O
20	treatment	O	O
21	of	O	O
22	bradykinesia	S-Disease	S-Disease
23	,	O	O
24	rigidity	S-Disease	O
25	,	O	O
26	and	O	O
27	L	B-Chemical	B-Chemical
28	-	I-Chemical	I-Chemical
29	DOPA	E-Chemical	E-Chemical
30	-	O	O
31	induced	O	O
32	dyskinesias	S-Disease	S-Disease
33	.	O	O

0	Clinical	O	O
1	assessment	O	O
2	as	O	O
3	well	O	O
4	as	O	O
5	blinded	O	O
6	ratings	O	O
7	of	O	O
8	Unified	O	O
9	Parkinson	B-Disease	I-Disease
10	'	I-Disease	I-Disease
11	s	I-Disease	I-Disease
12	Disease	E-Disease	E-Disease
13	Rating	O	O
14	Scale	O	O
15	(	O	O
16	UPDRS	O	S-Disease
17	)	O	O
18	scores	O	O
19	were	O	O
20	carried	O	O
21	out	O	O
22	pre	O	O
23	-	O	O
24	and	O	O
25	postoperatively	O	O
26	.	O	O

0	85	O	O
1	percent	O	O
2	of	O	O
3	patients	O	O
4	with	O	O
5	dyskinesias	S-Disease	S-Disease
6	were	O	O
7	relieved	O	O
8	of	O	O
9	symptoms	O	O
10	,	O	O
11	regardless	O	O
12	of	O	O
13	whether	O	O
14	the	O	O
15	pallidotomies	O	O
16	were	O	O
17	performed	O	O
18	with	O	O
19	the	O	O
20	Gamma	O	B-Disease
21	Knife	O	E-Disease
22	or	O	O
23	radiofrequency	O	O
24	methods	O	O
25	.	O	O

0	About	O	O
1	2	O	O
2	/	O	O
3	3	O	O
4	of	O	O
5	the	O	O
6	patients	O	O
7	in	O	O
8	both	O	O
9	Gamma	O	B-Chemical
10	Knife	O	E-Chemical
11	and	O	O
12	radiofrequency	O	O
13	groups	O	O
14	showed	O	O
15	improvements	O	O
16	in	O	O
17	bradykinesia	S-Disease	S-Disease
18	and	O	O
19	rigidity	S-Disease	S-Disease
20	,	O	O
21	although	O	O
22	when	O	O
23	considered	O	O
24	as	O	O
25	a	O	O
26	group	O	O
27	neither	O	O
28	the	O	O
29	Gamma	O	B-Disease
30	Knife	O	E-Disease
31	nor	O	O
32	the	O	O
33	radiofrequency	O	O
34	group	O	O
35	showed	O	O
36	statistically	O	O
37	significant	O	O
38	improvements	O	O
39	in	O	O
40	UPDRS	O	O
41	scores	O	O
42	.	O	O

0	One	O	O
1	patient	O	O
2	in	O	O
3	the	O	O
4	Gamma	O	B-Disease
5	Knife	O	E-Disease
6	group	O	O
7	(	O	O
8	3	O	O
9	.	O	O
10	4	O	O
11	%	O	O
12	)	O	O
13	developed	O	O
14	a	O	O
15	homonymous	B-Disease	O
16	hemianopsia	E-Disease	O
17	9	O	O
18	months	O	O
19	following	O	O
20	treatment	O	O
21	and	O	O
22	5	O	O
23	patients	O	O
24	(	O	O
25	27	O	O
26	.	O	O
27	7	O	O
28	%	O	O
29	)	O	O
30	in	O	O
31	the	O	O
32	radiofrequency	O	O
33	group	O	O
34	became	O	O
35	transiently	O	O
36	confused	O	O
37	postoperatively	O	O
38	.	O	O

0	Gamma	O	O
1	Knife	O	O
2	pallidotomy	O	O
3	is	O	O
4	as	O	O
5	effective	O	O
6	as	O	O
7	radiofrequency	O	O
8	pallidotomy	O	S-Disease
9	in	O	O
10	controlling	O	O
11	certain	O	O
12	of	O	O
13	the	O	O
14	symptoms	O	O
15	of	O	O
16	Parkinson	B-Disease	B-Disease
17	'	I-Disease	I-Disease
18	s	I-Disease	I-Disease
19	disease	E-Disease	E-Disease
20	.	O	O

0	It	O	O
1	may	O	O
2	be	O	O
3	the	O	O
4	only	O	O
5	practical	O	O
6	technique	O	O
7	available	O	O
8	in	O	O
9	certain	O	O
10	patients	O	O
11	,	O	O
12	such	O	O
13	as	O	O
14	those	O	O
15	who	O	O
16	take	O	O
17	anticoagulants	O	O
18	,	O	O
19	have	O	O
20	bleeding	S-Disease	B-Disease
21	diatheses	O	E-Disease
22	or	O	O
23	serious	O	O
24	systemic	O	O
25	medical	O	O
26	illnesses	O	E-Disease
27	.	O	O

0	Centrally	O	O
1	mediated	O	O
2	cardiovascular	O	O
3	effects	O	O
4	of	O	O
5	intracisternal	O	O
6	application	O	O
7	of	O	O
8	carbachol	S-Chemical	S-Chemical
9	in	O	O
10	anesthetized	O	O
11	rats	O	O
12	.	O	O

0	The	O	O
1	pressor	O	O
2	response	O	O
3	to	O	O
4	the	O	O
5	intracisternal	O	O
6	(	O	O
7	i	O	O
8	.	O	O
9	c	O	O
10	.	O	O
11	)	O	O
12	injection	O	O
13	of	O	O
14	carbachol	S-Chemical	S-Chemical
15	(	O	O
16	1	O	O
17	mug	O	O
18	)	O	O
19	in	O	O
20	anesthetized	O	O
21	rats	O	O
22	was	O	O
23	analyzed	O	O
24	.	O	O

0	This	O	O
1	response	O	O
2	was	O	O
3	significantly	O	O
4	reduced	O	O
5	by	O	O
6	the	O	O
7	intravenous	O	O
8	(	O	O
9	i	O	O
10	.	O	O
11	v	O	O
12	.	O	O
13	)	O	O
14	injection	O	O
15	of	O	O
16	guanethidine	S-Chemical	S-Chemical
17	(	O	O
18	5	O	O
19	mg	O	O
20	)	O	O
21	,	O	O
22	hexamethonium	S-Chemical	S-Chemical
23	(	O	O
24	10	O	O
25	mg	O	O
26	)	O	O
27	or	O	O
28	phentolamine	S-Chemical	O
29	(	O	O
30	5	O	O
31	mg	O	O
32	)	O	O
33	,	O	O
34	and	O	O
35	conversely	O	O
36	,	O	O
37	potentiated	O	O
38	by	O	O
39	i	O	O
40	.	O	O
41	v	O	O
42	.	O	O
43	desmethylimipramine	S-Chemical	S-Chemical
44	(	O	O
45	0	O	O
46	.	O	O
47	3	O	O
48	mg	O	O
49	)	O	O
50	,	O	O
51	while	O	O
52	propranolol	S-Chemical	S-Chemical
53	(	O	O
54	0	O	O
55	.	O	O
56	5	O	O
57	mg	O	O
58	)	O	O
59	i	O	O
60	.	O	O
61	v	O	O
62	.	O	O
63	selectively	O	O
64	inhibited	O	O
65	the	O	O
66	enlargement	B-Disease	O
67	of	I-Disease	O
68	pulse	I-Disease	O
69	pressure	E-Disease	O
70	and	O	O
71	the	O	O
72	tachycardia	S-Disease	S-Disease
73	following	O	O
74	i	O	O
75	.	O	O
76	c	O	O
77	.	O	O
78	carbachol	S-Chemical	S-Chemical
79	(	O	O
80	1	O	O
81	mug	O	O
82	)	O	O
83	.	O	O

0	On	O	O
1	the	O	O
2	other	O	O
3	hand	O	O
4	,	O	O
5	the	O	O
6	pressor	O	O
7	response	O	O
8	to	O	O
9	i	O	O
10	.	O	O
11	c	O	O
12	.	O	O
13	carbachol	S-Chemical	S-Chemical
14	(	O	O
15	1	O	O
16	mug	O	O
17	)	O	O
18	was	O	O
19	almost	O	O
20	completely	O	O
21	blocked	O	O
22	by	O	O
23	i	O	O
24	.	O	O
25	c	O	O
26	.	O	O
27	atropine	S-Chemical	S-Chemical
28	(	O	O
29	3	O	O
30	mug	O	O
31	)	O	O
32	or	O	O
33	hexamethonium	S-Chemical	S-Chemical
34	(	O	O
35	500	O	O
36	mug	O	O
37	)	O	O
38	,	O	O
39	and	O	O
40	significantly	O	O
41	reduced	O	O
42	by	O	O
43	i	O	O
44	.	O	O
45	c	O	O
46	.	O	O
47	chlorpromazine	S-Chemical	S-Chemical
48	(	O	O
49	50	O	O
50	mug	O	O
51	)	O	O
52	but	O	O
53	significantly	O	O
54	potentiated	O	O
55	by	O	O
56	i	O	O
57	.	O	O
58	c	O	O
59	.	O	O
60	desmethylimipramine	S-Chemical	S-Chemical
61	(	O	O
62	30	O	O
63	mug	O	O
64	)	O	O
65	.	O	O

0	The	O	O
1	pressor	O	O
2	response	O	O
3	to	O	O
4	i	O	O
5	.	O	O
6	c	O	O
7	.	O	O
8	carbachol	S-Chemical	S-Chemical
9	(	O	O
10	1	O	O
11	mug	O	O
12	)	O	O
13	remained	O	O
14	unchanged	O	O
15	after	O	O
16	sectioning	O	O
17	of	O	O
18	the	O	O
19	bilateral	O	O
20	cervical	O	B-Disease
21	vagal	O	O
22	nerves	O	O
23	but	O	O
24	disappeared	O	O
25	after	O	O
26	sectioning	O	O
27	of	O	O
28	the	O	O
29	spinal	O	O
30	cord	O	O
31	(	O	O
32	C7	O	B-Chemical
33	-	O	O
34	C8	O	B-Chemical
35	)	O	O
36	.	O	O

0	From	O	O
1	the	O	O
2	above	O	O
3	result	O	O
4	it	O	O
5	is	O	O
6	suggested	O	O
7	that	O	O
8	the	O	O
9	pressor	O	O
10	response	O	O
11	to	O	O
12	i	O	O
13	.	O	O
14	c	O	O
15	.	O	O
16	carbachol	S-Chemical	S-Chemical
17	ortral	O	O
18	and	O	O
19	peripheral	O	O
20	adrenergic	O	O
21	mechanisms	O	O
22	,	O	O
23	and	O	O
24	that	O	O
25	the	O	O
26	sympathetic	O	O
27	trunk	O	E-Disease
28	is	O	O
29	the	O	O
30	main	O	O
31	pathway	O	O
32	.	O	O

0	Neuroleptic	B-Disease	O
1	malignant	I-Disease	I-Disease
2	syndrome	E-Disease	S-Disease
3	and	O	O
4	methylphenidate	S-Chemical	S-Chemical
5	.	O	O

0	A	O	O
1	1	O	O
2	-	O	O
3	year	O	O
4	-	O	O
5	old	O	O
6	female	O	O
7	presented	O	O
8	with	O	O
9	neuroleptic	B-Disease	B-Disease
10	malignant	I-Disease	I-Disease
11	syndrome	E-Disease	E-Disease
12	probably	O	O
13	caused	O	O
14	by	O	O
15	methylphenidate	S-Chemical	S-Chemical
16	.	O	O

0	She	O	O
1	had	O	O
2	defects	O	O
3	in	O	O
4	the	O	O
5	supratentorial	O	O
6	brain	O	O
7	including	O	O
8	the	O	O
9	basal	O	B-Disease
10	ganglia	O	E-Disease
11	and	O	O
12	the	O	O
13	striatum	O	S-Disease
14	(	O	O
15	multicystic	B-Disease	O
16	encephalomalacia	E-Disease	S-Disease
17	)	O	O
18	due	O	O
19	to	O	O
20	severe	O	O
21	perinatal	O	O
22	hypoxic	B-Disease	S-Disease
23	-	I-Disease	O
24	ischemic	I-Disease	S-Disease
25	encephalopathy	E-Disease	S-Disease
26	,	O	O
27	which	O	O
28	was	O	O
29	considered	O	O
30	to	O	O
31	be	O	O
32	a	O	O
33	possible	O	O
34	predisposing	O	O
35	factor	O	O
36	causing	O	O
37	neuroleptic	B-Disease	B-Disease
38	malignant	I-Disease	E-Disease
39	syndrome	E-Disease	E-Disease
40	.	O	O

0	However	O	O
1	,	O	O
2	methylphenidate	S-Chemical	S-Chemical
3	is	O	O
4	a	O	O
5	dopamine	S-Chemical	O
6	agonist	O	O
7	via	O	O
8	the	O	O
9	inhibition	O	O
10	of	O	O
11	uptake	O	O
12	of	O	O
13	dopamine	S-Chemical	S-Chemical
14	,	O	O
15	and	O	O
16	therefore	O	O
17	dopaminergic	O	O
18	systems	O	O
19	in	O	O
20	the	O	O
21	brainstem	O	O
22	(	O	O
23	mainly	O	O
24	the	O	O
25	midbrain	O	S-Disease
26	)	O	O
27	and	O	O
28	the	O	O
29	spinal	O	B-Disease
30	cord	O	E-Disease
31	were	O	O
32	unlikely	O	O
33	to	O	O
34	participate	O	O
35	in	O	O
36	the	O	O
37	onset	O	O
38	of	O	O
39	this	O	O
40	syndrome	O	S-Disease
41	.	O	O

0	A	O	O
1	relative	O	O
2	gamma	B-Chemical	B-Disease
3	-	I-Chemical	O
4	aminobutyric	I-Chemical	I-Disease
5	acid	E-Chemical	I-Disease
6	-	O	O
7	ergic	O	B-Disease
8	deficiency	O	E-Disease
9	might	O	O
10	occur	O	O
11	because	O	O
12	diazepam	S-Chemical	S-Chemical
13	,	O	O
14	a	O	O
15	gamma	B-Chemical	S-Chemical
16	-	I-Chemical	O
17	aminobutyric	I-Chemical	I-Chemical
18	acid	E-Chemical	E-Chemical
19	-	O	O
20	mimetic	O	S-Disease
21	agent	O	O
22	,	O	O
23	was	O	O
24	strikingly	O	O
25	effective	O	O
26	.	O	O

0	This	O	O
1	is	O	O
2	the	O	O
3	first	O	O
4	reported	O	O
5	patient	O	O
6	with	O	O
7	neuroleptic	B-Disease	B-Disease
8	malignant	I-Disease	I-Disease
9	syndrome	E-Disease	E-Disease
10	probably	O	O
11	caused	O	O
12	by	O	O
13	methylphenidate	S-Chemical	S-Chemical
14	.	O	O

0	Differential	O	O
1	effects	O	O
2	of	O	O
3	17alpha	B-Chemical	S-Chemical
4	-	I-Chemical	O
5	ethinylestradiol	E-Chemical	S-Chemical
6	on	O	O
7	the	O	O
8	neutral	O	O
9	and	O	O
10	acidic	O	O
11	pathways	O	O
12	of	O	O
13	bile	B-Chemical	S-Chemical
14	salt	E-Chemical	O
15	synthesis	O	O
16	in	O	O
17	the	O	O
18	rat	O	O
19	.	O	O

0	Effects	O	O
1	of	O	O
2	17alpha	B-Chemical	S-Chemical
3	-	I-Chemical	O
4	ethinylestradiol	E-Chemical	S-Chemical
5	(	O	O
6	EE	S-Chemical	S-Chemical
7	)	O	O
8	on	O	O
9	the	O	O
10	neutral	O	O
11	and	O	O
12	acidic	O	O
13	biosynthetic	O	O
14	pathways	O	O
15	of	O	O
16	bile	B-Chemical	S-Chemical
17	salt	E-Chemical	O
18	(	O	O
19	BS	S-Chemical	S-Chemical
20	)	O	O
21	synthesis	O	O
22	were	O	O
23	evaluated	O	O
24	in	O	O
25	rats	O	O
26	with	O	O
27	an	O	O
28	intact	O	O
29	enterohepatic	O	O
30	circulation	O	E-Disease
31	and	O	O
32	in	O	O
33	rats	O	O
34	with	O	O
35	long	O	O
36	-	O	O
37	term	O	O
38	bile	O	S-Chemical
39	diversion	O	O
40	to	O	O
41	induce	O	O
42	BS	S-Chemical	S-Disease
43	synthesis	O	O
44	.	O	O

0	For	O	O
1	this	O	O
2	purpose	O	O
3	,	O	O
4	bile	B-Chemical	S-Chemical
5	salt	E-Chemical	O
6	pool	O	O
7	composition	O	O
8	,	O	O
9	synthesis	O	O
10	of	O	O
11	individual	O	O
12	BS	S-Chemical	S-Chemical
13	in	O	O
14	vivo	O	O
15	,	O	O
16	hepatic	O	O
17	activities	O	O
18	,	O	O
19	and	O	O
20	expression	O	O
21	levels	O	O
22	of	O	O
23	cholesterol	S-Chemical	B-Chemical
24	7alpha	O	E-Chemical
25	-	O	O
26	hydroxylase	O	E-Chemical
27	(	O	O
28	CYP7A	O	B-Chemical
29	)	O	O
30	,	O	O
31	and	O	O
32	sterol	S-Chemical	B-Chemical
33	27	O	E-Chemical
34	-	O	O
35	hydroxylase	O	E-Chemical
36	(	O	O
37	CYP27	O	B-Chemical
38	)	O	O
39	,	O	O
40	as	O	O
41	well	O	O
42	as	O	O
43	of	O	O
44	other	O	O
45	enzymes	O	O
46	involved	O	O
47	in	O	O
48	BS	S-Chemical	S-Disease
49	synthesis	O	O
50	,	O	O
51	were	O	O
52	analyzed	O	O
53	in	O	O
54	rats	O	O
55	treated	O	O
56	with	O	O
57	EE	S-Chemical	S-Chemical
58	(	O	O
59	5	O	O
60	mg	O	O
61	/	O	O
62	kg	O	O
63	,	O	O
64	3	O	O
65	days	O	O
66	)	O	O
67	or	O	O
68	its	O	O
69	vehicle	O	O
70	.	O	O

0	BS	S-Chemical	S-Disease
1	pool	O	O
2	size	O	O
3	was	O	O
4	decreased	O	O
5	by	O	O
6	27	O	O
7	%	O	O
8	but	O	O
9	total	O	O
10	BS	S-Chemical	S-Chemical
11	synthesis	O	O
12	was	O	O
13	not	O	O
14	affected	O	O
15	by	O	O
16	EE	S-Chemical	S-Chemical
17	in	O	O
18	intact	O	O
19	rats	O	O
20	.	O	O

0	Synthesis	O	O
1	of	O	O
2	cholate	S-Chemical	S-Chemical
3	was	O	O
4	reduced	O	O
5	by	O	O
6	68	O	O
7	%	O	O
8	in	O	O
9	EE	S-Chemical	S-Chemical
10	-	O	O
11	treated	O	O
12	rats	O	O
13	,	O	O
14	while	O	O
15	that	O	O
16	of	O	O
17	chenodeoxycholate	S-Chemical	S-Chemical
18	was	O	O
19	increased	O	O
20	by	O	O
21	60	O	O
22	%	O	O
23	.	O	O

0	The	O	O
1	recently	O	O
2	identified	O	O
3	Delta22	O	S-Chemical
4	-	O	O
5	isomer	O	O
6	of	O	O
7	beta	O	S-Chemical
8	-	O	O
9	muricholate	O	S-Chemical
10	contributed	O	O
11	for	O	O
12	5	O	O
13	.	O	O
14	4	O	O
15	%	O	O
16	and	O	O
17	18	O	O
18	.	O	O
19	3	O	O
20	%	O	O
21	(	O	O
22	P	O	O
23	<	O	O
24	0	O	O
25	.	O	O
26	01	O	O
27	)	O	O
28	to	O	O
29	the	O	O
30	pool	O	O
31	in	O	O
32	control	O	O
33	and	O	O
34	EE	S-Chemical	S-Chemical
35	-	O	O
36	treated	O	O
37	rats	O	O
38	,	O	O
39	respectively	O	O
40	,	O	O
41	but	O	O
42	could	O	O
43	not	O	O
44	be	O	O
45	detected	O	O
46	in	O	O
47	bile	O	S-Chemical
48	after	O	O
49	exhaustion	O	O
50	of	O	O
51	the	O	O
52	pool	O	O
53	.	O	O

0	A	O	O
1	clear	O	O
2	reduction	O	O
3	of	O	O
4	BS	S-Chemical	S-Chemical
5	synthesis	O	O
6	was	O	O
7	found	O	O
8	in	O	O
9	bile	O	S-Chemical
10	-	O	O
11	diverted	O	O
12	rats	O	O
13	treated	O	O
14	with	O	O
15	EE	S-Chemical	S-Chemical
16	,	O	O
17	yet	O	O
18	biliary	O	B-Disease
19	BS	S-Chemical	S-Disease
20	composition	O	O
21	was	O	O
22	only	O	O
23	minimally	O	O
24	affected	O	O
25	.	O	O

0	Activity	O	O
1	of	O	O
2	CYP7A	O	B-Chemical
3	was	O	O
4	decreased	O	O
5	by	O	O
6	EE	S-Chemical	S-Chemical
7	in	O	O
8	both	O	O
9	intact	O	O
10	and	O	O
11	bile	O	O
12	-	O	O
13	diverted	O	O
14	rats	O	O
15	,	O	O
16	whereas	O	O
17	the	O	O
18	activity	O	O
19	of	O	O
20	the	O	O
21	CYP27	O	B-Chemical
22	was	O	O
23	not	O	O
24	affected	O	O
25	.	O	O

0	Hepatic	O	S-Chemical
1	mRNA	O	O
2	levels	O	O
3	of	O	O
4	CYP7A	O	S-Chemical
5	were	O	O
6	significantly	O	O
7	reduced	O	O
8	by	O	O
9	EE	S-Chemical	S-Chemical
10	in	O	O
11	bile	O	S-Disease
12	-	O	O
13	diverted	O	O
14	rats	O	O
15	only	O	O
16	;	O	O
17	CYP27	O	S-Chemical
18	mRNA	O	O
19	levels	O	O
20	were	O	O
21	not	O	O
22	affected	O	O
23	by	O	O
24	EE	S-Chemical	S-Chemical
25	.	O	O

0	In	O	O
1	addition	O	O
2	,	O	O
3	mRNA	O	O
4	levels	O	O
5	of	O	O
6	sterol	S-Chemical	B-Chemical
7	12alpha	O	E-Chemical
8	-	O	I-Chemical
9	hydroxylase	O	E-Chemical
10	and	O	O
11	lithocholate	O	S-Chemical
12	6beta	O	B-Chemical
13	-	O	I-Chemical
14	hydroxylase	O	E-Chemical
15	were	O	O
16	increased	O	O
17	by	O	O
18	bile	O	S-Chemical
19	diversion	O	O
20	and	O	O
21	suppressed	O	O
22	by	O	O
23	EE	S-Chemical	S-Chemical
24	.	O	O

0	This	O	O
1	study	O	O
2	shows	O	O
3	that	O	O
4	17alpha	B-Chemical	S-Chemical
5	-	I-Chemical	O
6	ethinylestradiol	E-Chemical	S-Chemical
7	(	O	O
8	EE	S-Chemical	S-Chemical
9	)	O	O
10	-	O	O
11	induced	O	O
12	intrahepatic	B-Disease	O
13	cholestasis	E-Disease	S-Disease
14	in	O	O
15	rats	O	O
16	is	O	O
17	associated	O	O
18	with	O	O
19	selective	O	O
20	inhibition	O	O
21	of	O	O
22	the	O	O
23	neutral	O	O
24	pathway	O	O
25	of	O	O
26	bile	B-Chemical	S-Chemical
27	salt	E-Chemical	O
28	(	O	O
29	BS	S-Chemical	S-Disease
30	)	O	O
31	synthesis	O	O
32	.	O	O

0	Simultaneous	O	O
1	impairment	O	O
2	of	O	O
3	other	O	O
4	enzymes	O	O
5	in	O	O
6	the	O	O
7	BS	S-Chemical	S-Disease
8	biosynthetic	O	O
9	pathways	O	O
10	may	O	O
11	contribute	O	O
12	to	O	O
13	overall	O	O
14	effects	O	O
15	of	O	O
16	EE	S-Chemical	S-Chemical
17	on	O	O
18	BS	S-Chemical	S-Disease
19	synthesis	O	O
20	.	O	O

0	Glibenclamide	S-Chemical	S-Chemical
1	-	O	O
2	sensitive	O	O
3	hypotension	S-Disease	S-Disease
4	produced	O	O
5	by	O	O
6	helodermin	S-Chemical	S-Chemical
7	assessed	O	O
8	in	O	O
9	the	O	O
10	rat	O	O
11	.	O	O

0	The	O	O
1	effects	O	O
2	of	O	O
3	helodermin	S-Chemical	S-Chemical
4	,	O	O
5	a	O	O
6	basic	O	O
7	35	O	O
8	-	O	O
9	amino	B-Chemical	O
10	acid	E-Chemical	O
11	peptide	O	O
12	isolated	O	O
13	from	O	O
14	the	O	O
15	venom	O	O
16	of	O	O
17	a	O	O
18	lizard	O	O
19	salivary	O	O
20	gland	O	O
21	,	O	O
22	on	O	O
23	arterial	O	O
24	blood	O	I-Disease
25	pressure	O	E-Disease
26	and	O	O
27	heart	O	S-Disease
28	rate	O	O
29	were	O	O
30	examined	O	O
31	in	O	O
32	the	O	O
33	rat	O	O
34	,	O	O
35	focusing	O	O
36	on	O	O
37	the	O	O
38	possibility	O	O
39	that	O	O
40	activation	O	O
41	of	O	O
42	ATP	S-Chemical	O
43	sensitive	O	O
44	K	S-Chemical	O
45	+	O	O
46	(	O	O
47	K	S-Chemical	O
48	(	O	O
49	ATP	S-Chemical	O
50	)	O	O
51	)	O	O
52	channels	O	O
53	is	O	O
54	involved	O	O
55	in	O	O
56	the	O	O
57	responses	O	O
58	.	O	O

0	Helodermin	S-Chemical	S-Chemical
1	produced	O	O
2	hypotension	S-Disease	S-Disease
3	in	O	O
4	a	O	O
5	dose	O	O
6	-	O	O
7	dependent	O	O
8	manner	O	O
9	with	O	O
10	approximately	O	O
11	similar	O	O
12	potency	O	O
13	and	O	O
14	duration	O	O
15	to	O	O
16	VIP	O	S-Disease
17	.	O	O

0	Hypotension	S-Disease	S-Disease
1	induced	O	O
2	by	O	O
3	both	O	O
4	peptides	O	O
5	was	O	O
6	significantly	O	O
7	attenuated	O	O
8	by	O	O
9	glibenclamide	S-Chemical	S-Chemical
10	,	O	O
11	which	O	O
12	abolished	O	O
13	a	O	O
14	levcromakalim	S-Chemical	S-Chemical
15	-	O	O
16	produced	O	O
17	decrease	O	O
18	in	O	O
19	arterial	O	B-Disease
20	blood	O	I-Disease
21	pressure	O	E-Disease
22	.	O	O

0	Oxyhemoglobin	O	S-Chemical
1	did	O	O
2	not	O	O
3	affect	O	O
4	helodermin	S-Chemical	S-Chemical
5	-	O	O
6	induced	O	O
7	hypotension	S-Disease	S-Disease
8	,	O	O
9	whereas	O	O
10	it	O	O
11	shortened	O	O
12	the	O	O
13	duration	O	O
14	of	O	O
15	acetylcholine	S-Chemical	S-Chemical
16	(	O	O
17	ACh	S-Chemical	S-Chemical
18	)	O	O
19	-	O	O
20	produced	O	O
21	hypotension	S-Disease	S-Disease
22	.	O	O

0	These	O	O
1	findings	O	O
2	suggest	O	O
3	that	O	O
4	helodermin	S-Chemical	S-Chemical
5	-	O	O
6	produced	O	O
7	hypotension	S-Disease	S-Disease
8	is	O	O
9	partly	O	O
10	attributable	O	O
11	to	O	O
12	the	O	O
13	activation	O	O
14	of	O	O
15	glibenclamide	S-Chemical	S-Chemical
16	-	O	O
17	sensitive	O	O
18	K	S-Chemical	B-Disease
19	+	O	O
20	channels	O	O
21	(	O	O
22	K	S-Chemical	O
23	(	O	O
24	ATP	S-Chemical	O
25	)	O	O
26	channels	O	O
27	)	O	O
28	,	O	O
29	which	O	O
30	presumably	O	O
31	exist	O	O
32	on	O	O
33	arterial	O	B-Disease
34	smooth	O	I-Disease
35	muscle	O	I-Disease
36	cells	O	O
37	.	O	O

0	EDRF	O	S-Chemical
1	(	O	O
2	endothelium	O	O
3	-	O	O
4	derived	O	O
5	relaxing	O	O
6	factor	O	O
7	)	O	O
8	/	O	O
9	nitric	B-Chemical	O
10	oxide	E-Chemical	E-Disease
11	does	O	O
12	not	O	O
13	seem	O	O
14	to	O	O
15	play	O	O
16	an	O	O
17	important	O	O
18	role	O	O
19	in	O	O
20	the	O	O
21	peptide	O	O
22	-	O	O
23	produced	O	O
24	hypotension	S-Disease	S-Disease
25	.	O	O

0	Long	O	O
1	-	O	O
2	term	O	O
3	efficacy	O	O
4	and	O	O
5	adverse	O	O
6	event	O	O
7	of	O	O
8	nifedipine	S-Chemical	S-Chemical
9	sustained	O	O
10	-	O	O
11	release	O	O
12	tablets	O	O
13	for	O	O
14	cyclosporin	B-Chemical	B-Chemical
15	A	E-Chemical	E-Chemical
16	-	O	O
17	induced	O	O
18	hypertension	S-Disease	S-Disease
19	in	O	O
20	patients	O	O
21	with	O	O
22	psoriasis	S-Disease	S-Disease
23	.	O	O

0	Thirteen	O	O
1	psoriatic	S-Disease	S-Disease
2	patients	O	O
3	with	O	O
4	hypertension	S-Disease	S-Disease
5	during	O	O
6	the	O	O
7	course	O	O
8	of	O	O
9	cyclosporin	B-Chemical	S-Chemical
10	A	E-Chemical	O
11	therapy	O	O
12	were	O	O
13	treated	O	O
14	for	O	O
15	25	O	O
16	months	O	O
17	with	O	O
18	a	O	O
19	calcium	S-Chemical	B-Disease
20	channel	O	E-Disease
21	blocker	O	E-Disease
22	,	O	O
23	sustained	O	O
24	-	O	O
25	release	O	O
26	nifedipine	S-Chemical	S-Chemical
27	,	O	O
28	to	O	O
29	study	O	O
30	the	O	O
31	clinical	O	O
32	antihypertensive	O	O
33	effects	O	O
34	and	O	O
35	adverse	O	O
36	events	O	O
37	during	O	O
38	treatment	O	O
39	with	O	O
40	both	O	O
41	drugs	O	O
42	.	O	O

0	Seven	O	O
1	of	O	O
2	the	O	O
3	13	O	O
4	patients	O	O
5	had	O	O
6	exhibited	O	O
7	a	O	O
8	subclinical	O	O
9	hypertensive	S-Disease	S-Disease
10	state	O	O
11	before	O	O
12	cyclosporin	B-Chemical	S-Chemical
13	A	E-Chemical	E-Disease
14	therapy	O	O
15	.	O	O

0	Both	O	O
1	systolic	O	O
2	and	O	O
3	diastolic	O	S-Disease
4	blood	O	O
5	pressures	O	O
6	of	O	O
7	these	O	O
8	13	O	O
9	patients	O	O
10	were	O	O
11	decreased	O	O
12	significantly	O	O
13	after	O	O
14	4	O	O
15	weeks	O	O
16	of	O	O
17	nifedipine	S-Chemical	S-Chemical
18	therapy	O	O
19	,	O	O
20	and	O	O
21	blood	O	O
22	pressure	O	O
23	was	O	O
24	maintained	O	O
25	within	O	O
26	the	O	O
27	normal	O	O
28	range	O	O
29	thereafter	O	O
30	for	O	O
31	25	O	O
32	months	O	O
33	.	O	O

0	The	O	O
1	adverse	O	O
2	events	O	O
3	during	O	O
4	combined	O	O
5	therapy	O	O
6	with	O	O
7	cyclosporin	B-Chemical	B-Chemical
8	A	E-Chemical	E-Chemical
9	and	O	O
10	nifedipine	S-Chemical	S-Chemical
11	included	O	O
12	an	O	O
13	increase	O	B-Disease
14	in	O	O
15	blood	B-Chemical	B-Disease
16	urea	I-Chemical	I-Disease
17	nitrogen	E-Chemical	I-Disease
18	levels	O	E-Disease
19	in	O	O
20	9	O	O
21	of	O	O
22	the	O	O
23	13	O	O
24	patients	O	O
25	and	O	O
26	development	O	O
27	of	O	O
28	gingival	B-Disease	B-Disease
29	hyperplasia	E-Disease	E-Disease
30	in	O	O
31	2	O	O
32	of	O	O
33	the	O	O
34	13	O	O
35	patients	O	O
36	.	O	O

0	Our	O	O
1	findings	O	O
2	indicate	O	O
3	that	O	O
4	sustained	O	O
5	-	O	O
6	release	O	O
7	nifedipine	S-Chemical	S-Chemical
8	is	O	O
9	useful	O	O
10	for	O	O
11	hypertensive	S-Disease	B-Disease
12	psoriatic	S-Disease	E-Disease
13	patients	O	O
14	under	O	O
15	long	O	O
16	-	O	O
17	term	O	O
18	treatment	O	O
19	with	O	O
20	cyclosporin	B-Chemical	S-Chemical
21	A	E-Chemical	E-Disease
22	,	O	O
23	but	O	O
24	that	O	O
25	these	O	O
26	patients	O	O
27	should	O	O
28	be	O	O
29	monitored	O	O
30	for	O	O
31	gingival	B-Disease	B-Disease
32	hyperplasia	E-Disease	E-Disease
33	.	O	O

